PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Minkler, M; Fuller-Thomson, E; Guralnik, JM				Minkler, Meredith; Fuller-Thomson, Esme; Guralnik, Jack M.			Gradient of disability across the socioeconomic spectrum in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SELF-REPORT; HEALTH; INEQUALITIES; PERFORMANCE; DISPARITIES; DETERMINANTS; AGE	BACKGROUND: Although the relationship between extreme poverty and poor health among older adults has long been recognized, less attention has been devoted to investigating whether a gradient in disability exists in the United States among persons with middle-class and upper-class incomes. We attempted to determine whether a gradient in functional limitation exists across the full spectrum of income among persons 55 years of age or older. METHODS: We obtained data from the Census 2000 Supplementary Survey, which used the methods and questionnaire of the American Community Survey, a nationally representative survey of 890,698 households with a response rate of 95 percent. Our sample included 149,000 men and 186,675 women who were at least 55 years of age, of whom 32,680 men and 48,111 women reported having a functional limitation (a long-lasting condition that substantially limited one or more basic physical activities, such as climbing stairs or lifting). RESULTS: A social-class gradient was observed for both men and women between the ages of 55 and 84, a gradient that held true even at the upper rungs of the socioeconomic ladder. For example, in comparison to persons between the ages of 55 and 64 who lived at 700 percent of the poverty line or above, persons of the same age but below the poverty line had six times the odds of reporting a functional limitation. With increasing income, the odds ratio declined. A significant gradient was present up to, but not beyond, the age of 85 years. CONCLUSIONS: Our findings suggest that functional limitation in Americans between the ages of 55 and 84 years is inversely related to social class across the full spectrum of the socioeconomic gradient.	Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada; NIA, Dept Demog & Biometry, Lab Epidmeiol, Bethesda, MD 20892 USA	University of California System; University of California Berkeley; University of Toronto; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Minkler, M (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, 316 Warren Hall, Berkeley, CA 94720 USA.	mink@berkeley.edu			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Breeze E, 2001, AM J PUBLIC HEALTH, V91, P277, DOI 10.2105/AJPH.91.2.277; BULATAO RA, 2004, UNDERSTANDING RACE E; *BUR CENS, 2000, AM COMM SURV US DAT; *BUR CENS, 2002, 63RV BUR CENS; *BUR CENS, 2004, MIDDL INT MIGR SER 1; *BUR CENS, 2002, 2 BUR CENS; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; CRESS ME, 1995, J AM GERIATR SOC, V43, P93, DOI 10.1111/j.1532-5415.1995.tb06372.x; DALAKER J, 2001, CURRENT POPULATION S; Department of Health Human Services Washington DC. Healthy People 2010 (Group) and United States Government Printing Office., 2000, HLTH PEOPL 2010; Eichner J, 2005, HEALTH AFFAIR, V24, P365, DOI 10.1377/hlthaff.24.2.365; FRANK JW, 1994, DAEDALUS, V123, P1; HARRINGTON C, 2004, NURSING FACILITIES S; HOUSE JS, 1994, J HEALTH SOC BEHAV, V35, P213, DOI 10.2307/2137277; House JS, 2002, J HEALTH SOC BEHAV, V43, P125, DOI 10.2307/3090192; Institute of Medicine, 1991, DIS AM NAT AG PREV; Isaacs SL, 2004, NEW ENGL J MED, V351, P1137, DOI 10.1056/NEJMsb040329; Kempen GIJM, 1996, J GERONTOL B-PSYCHOL, V51, pP254, DOI 10.1093/geronb/51B.5.P254; Kington RS, 1997, AM J PUBLIC HEALTH, V87, P805, DOI 10.2105/AJPH.87.5.805; Kitagawa EM., 1973, DIFFERENTIAL MORTALI; Lantz PM, 2001, SOC SCI MED, V53, P29, DOI 10.1016/S0277-9536(00)00319-1; Manton KG, 2001, P NATL ACAD SCI USA, V98, P6354, DOI 10.1073/pnas.111152298; Marmot MG, 2003, PERSPECT BIOL MED, V46, pS9, DOI 10.1353/pbm.2003.0056; McDonough P, 1999, J HEALTH SOC BEHAV, V40, P17, DOI 10.2307/2676376; *NAT CTR HLTH STAT, 1999, 1999 NAT NURS HOM SU; PAPPAS G, 1993, NEW ENGL J MED, V329, P1139; SAGER MA, 1992, J AM GERIATR SOC, V40, P457, DOI 10.1111/j.1532-5415.1992.tb02011.x; SATARIANO WA, 2005, SOCIAL EPIDEMIOLOGY; Schoeni RF, 2005, AM J PUBLIC HEALTH, V95, P2065, DOI 10.2105/AJPH.2004.048744; Siegrist J, 2004, SOC SCI MED, V58, P1463, DOI 10.1016/S0277-9536(03)00349-6	31	191	193	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					695	703		10.1056/NEJMsa044316	http://dx.doi.org/10.1056/NEJMsa044316			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	074AN	16914705				2023-01-03	WOS:000239784500008
J	Poehling, KA; Edwards, KM; Weinberg, GA; Szilagyi, P; Staat, MA; Iwane, MK; Bridges, CB; Grijalva, CG; Zhu, YW; Bernstein, DI; Herrera, G; Erdman, D; Hall, CB; Seither, R; Griffin, MR				Poehling, Katherine A.; Edwards, Kathryn M.; Weinberg, Geoffrey A.; Szilagyi, Peter; Staat, Mary Allen; Iwane, Marika K.; Bridges, Carolyn B.; Grijalva, Carlos G.; Zhu, Yuwei; Bernstein, David I.; Herrera, Guillermo; Erdman, Dean; Hall, Caroline B.; Seither, Ranee; Griffin, Marie R.		New Vaccine Surveillance Netw	The underrecognized burden of influenza in young children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OUTPATIENT VISITS; RAPID DIAGNOSIS; HOSPITALIZATIONS; INFECTIONS; INFANTS; IMPACT; VIRUS; MANAGEMENT; EMERGENCY; RATES	Background The disease burden of influenza infection among children is not well established. We conducted a population-based surveillance of medical visits associated with laboratory-confirmed influenza. Methods Eligible children were younger than five years of age, resided in three U.S. counties, and had a medical visit for an acute respiratory tract infection or fever. Nasal and throat swabs were tested for the influenza virus by viral culture and polymerase-chain-reaction assay. Epidemiologic data were collected from parental surveys and chart reviews. Children who were hospitalized were enrolled prospectively from 2000 through 2004. Population-based rates of hospitalizations associated with influenza were calculated. Children who were seen in selected pediatric clinics and emergency departments during two influenza seasons (2002-2003 and 2003-2004) were systematically enrolled. The rates of visits to clinics and emergency departments associated with influenza were estimated. Results The average annual rate of hospitalization associated with influenza was 0.9 per 1000 children. The estimated burden of outpatient visits associated with influenza was 50 clinic visits and 6 emergency department visits per 1000 children during the 2002-2003 season and 95 clinic visits and 27 emergency department visits per 1000 children during the 2003-2004 season. Few children who had laboratory-confirmed influenza were given a diagnosis of influenza by the treating physician in the inpatient (28 percent) or outpatient (17 percent) settings. Conclusions Among young children, outpatient visits associated with influenza were 10 to 250 times as common as hospitalizations. Few influenza infections were recognized clinically.	Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Prevent Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Strong Childrens Res Ctr, Rochester, NY 14642 USA; Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Infect Dis, Cincinnati, OH USA; Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Rochester; University of Rochester; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Centers for Disease Control & Prevention - USA	Poehling, KA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.		Weinberg, Geoffrey A./W-7510-2019	Weinberg, Geoffrey A./0000-0002-3900-379X; Grijalva, Carlos/0000-0002-2329-7797	NIAID NIH HHS [K23 AI065805] Funding Source: Medline; NCIRD CDC HHS [1 U01 IP000022] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI065805] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCIRD CDC HHS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; Bonner AB, 2003, PEDIATRICS, V112, P363, DOI 10.1542/peds.112.2.363; Brown LD, 2001, STAT SCI, V16, P101, DOI 10.1214/ss/1009213286; Casella G., 2002, STAT INFERENCE, V2; *CDCP, FLU ACT REP SURV MET; Center for Disease Control and Prevention, NAT IMM SURV NIS; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P547; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499; Griffin Marie R, 2004, Pediatr Infect Dis J, V23, pS188, DOI 10.1097/01.inf.0000144660.53024.64; Grijalva CG, 2006, EMERG INFECT DIS, V12, P103; Hemingway CO, 2004, PEDIATRICS, V114, P948, DOI 10.1542/peds.2003-0509-F; Homer CJ, 1996, PEDIATRICS, V98, P18; Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; Mac Donald R, 1999, AM J PREV MED, V16, P173, DOI 10.1016/S0749-3797(98)00159-7; Meltzer MI, 2005, VACCINE, V23, P1004, DOI 10.1016/j.vaccine.2004.07.040; MULLOOLY JP, 1982, AM J PUBLIC HEALTH, V72, P1008, DOI 10.2105/AJPH.72.9.1008; National Center for Health Statistics, NAT AMB MED CAR SURV; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Neuzil KM, 2002, J INFECT DIS, V185, P147, DOI 10.1086/338363; O'Brien MA, 2004, PEDIATRICS, V113, P585, DOI 10.1542/peds.113.3.585; Perrin JM, 1996, ARCH PEDIAT ADOL MED, V150, P479, DOI 10.1001/archpedi.1996.02170300033007; Poehling KA, 2002, PEDIATRICS, V110, P83, DOI 10.1542/peds.110.1.83; Sharma V, 2002, ARCH PEDIAT ADOL MED, V156, P41, DOI 10.1001/archpedi.156.1.41; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Weinberg GA, 2004, J INFECT DIS, V189, P706, DOI 10.1086/381456; 2003, SURVEY DATA REFERENC	29	665	700	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 6	2006	355	1					31	40		10.1056/NEJMoa054869	http://dx.doi.org/10.1056/NEJMoa054869			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	060DT	16822994	Bronze			2023-01-03	WOS:000238783200005
J	Darnill, S; Gamage, B				Darnill, Stephanie; Gamage, Bernadette			The patient's journey: palliative care - a parent's view	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Paediat Palliat Care, Lifeforce Team, London NW1 0PE, England		Gamage, B (corresponding author), Paediat Palliat Care, Lifeforce Team, London NW1 0PE, England.	bernigamage@hotmail.com							0	7	8	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 24	2006	332	7556					1494	1495		10.1136/bmj.332.7556.1494	http://dx.doi.org/10.1136/bmj.332.7556.1494			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	060RV	16793812	Green Published			2023-01-03	WOS:000238820200020
J	Deeks, SG				Deeks, Steven G.			Antiretroviral treatment of HIV infected adults	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RECOMMENDATIONS; LAMIVUDINE; THERAPY; ZIDOVUDINE; EFAVIRENZ; INDINAVIR; DISEASE		Univ Calif San Francisco, San Francisco, CA 94110 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	Deeks, SG (corresponding author), Univ Calif San Francisco, San Francisco, CA 94110 USA.	sdeeks@php.ucsf.edu						Bacchetti P, 2005, JAIDS-J ACQ IMM DEF, V40, P121, DOI 10.1097/01.qai.0000182230.47819.aa; Cane P, 2005, BMJ-BRIT MED J, V331, P1368, DOI 10.1136/bmj.38665.534595.55; Carr A, 2002, JAMA-J AM MED ASSOC, V288, P207, DOI 10.1001/jama.288.2.207; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195; Deeks SG, 2003, LANCET, V362, P2002, DOI 10.1016/S0140-6736(03)15022-2; *DHHS, 2006, GUID US ANT AG HIV I; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Gazzard B, 2005, HIV MED, V6, P1, DOI 10.1111/j.1468-1293.2005.0311b.x; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Johnson Victoria A, 2005, Top HIV Med, V13, P125; Lawrence J, 2003, NEW ENGL J MED, V349, P837, DOI 10.1056/NEJMoa035103; Opravil M, 2002, J INFECT DIS, V185, P1251, DOI 10.1086/340312; Schambelan M, 2002, JAIDS-J ACQ IMM DEF, V31, P257, DOI 10.1097/00126334-200211010-00001; *SMART STUD, 2006, 13 C RETR OPP INF 5; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; Vandamme AM, 2004, ANTIVIR THER, V9, P829; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; Wensing AMJ, 2005, J INFECT DIS, V192, P958, DOI 10.1086/432916; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	25	35	42	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 24	2006	332	7556					1489	1493		10.1136/bmj.332.7556.1489	http://dx.doi.org/10.1136/bmj.332.7556.1489			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	060RV	16793811	Green Published			2023-01-03	WOS:000238820200019
J	Allen, SA				Allen, SA			Dining with Wilkey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Allen, Scott/D-2403-2015	Allen, Scott/0000-0001-8815-4714					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	2006	295	22					2583	2584		10.1001/jama.295.22.2583	http://dx.doi.org/10.1001/jama.295.22.2583			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	052HI	16772612				2023-01-03	WOS:000238224000001
J	Ong, MEH; Ornato, JP; Edwards, DP; Dhindsa, HS; Best, AM; Ines, CS; Hickey, S; Clark, B; Williams, DC; Powell, RG; Overton, JL; Peberdy, MA				Ong, Marcus Eng Hock; Ornato, Joseph P.; Edwards, David P.; Dhindsa, Harinder S.; Best, Al M.; Ines, Caesar S.; Hickey, Scott; Clark, Bryan; Williams, Dean C.; Powell, Robert G.; Overton, Jerry L.; Peberdy, Mary Ann			Use of an automated, load-distributing band chest compression device for out-of-hospital cardiac arrest resuscitation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMERICAN-HEART-ASSOCIATION; PROLONGED CARDIOPULMONARY-RESUSCITATION; INTERNATIONAL LIAISON COMMITTEE; CORONARY PERFUSION-PRESSURE; HEALTH-CARE PROFESSIONALS; VENTRICULAR-FIBRILLATION; STROKE-FOUNDATION; TASK-FORCE; RECOMMENDED GUIDELINES; MYOCARDIAL PERFUSION	Context Only 1% to 8% of adults with out-of-hospital cardiac arrest survive to hospital discharge. Objective To compare resuscitation outcomes before and after an urban emergency medical services ( EMS) system switched from manual cardiopulmonary resuscitation ( CPR) to load-distributing band ( LDB) CPR. Design, Setting, and Patients A phased, observational cohort evaluation with intention-to-treat analysis of 783 adults with out-of-hospital, nontraumatic cardiac arrest. A total of 499 patients were included in the manual CPR phase ( January 1, 2001, to March 31, 2003) and 284 patients in the LDB-CPR phase ( December 20, 2003, to March 31, 2005); of these patients, the LDB device was applied in 210 patients. Intervention Urban EMS system change from manual CPR to LDB-CPR. Main Outcome Measures Return of spontaneous circulation ( ROSC), with secondary outcome measures of survival to hospital admission and hospital discharge, and neurological outcome at discharge. Results Patients in the manual CPR and LDB-CPR phases were comparable except for a faster response time interval ( mean difference, 26 seconds) and more EMS-witnessed arrests ( 18.7% vs 12.6%) with LDB. Rates for ROSC and survival were increased with LDB-CPR compared with manual CPR ( for ROSC, 34.5%; 95% confidence interval [ CI], 29.2%-40.3% vs 20.2%; 95% CI, 16.9%-24.0%; adjusted odds ratio [ OR], 1.94; 95% CI, 1.38-2.72; for survival to hospital admission, 20.9%; 95% CI, 16.6%-26.1% vs 11.1%; 95% CI, 8.6%-14.2%; adjusted OR, 1.88; 95% CI, 1.23-2.86; and for survival to hospital discharge, 9.7%; 95% CI, 6.7%-13.8% vs 2.9%; 95% CI, 1.7%-4.8%; adjusted OR, 2.27; 95% CI, 1.11-4.77). In secondary analysis of the 210 patients in whom the LDB device was applied, 38 patients ( 18.1%) survived to hospital admission ( 95% CI, 13.4%-23.9%) and 12 patients ( 5.7%) survived to hospital discharge ( 95% CI, 3.0%9.3%). Among patients in the manual CPR and LDB-CPR groups who survived to hospital discharge, there was no significant difference between groups in Cerebral Performance Category ( P=. 36) or Overall Performance Category ( P=. 40). The number needed to treat for the adjusted outcome survival to discharge was 15 ( 95% CI, 9-33). Conclusion Compared with resuscitation using manual CPR, a resuscitation strategy using LDB-CPR on EMS ambulances is associated with improved survival to hospital discharge in adults with out-of-hospital nontraumatic cardiac arrest.	Virginia Commonwealth Univ, Dept Epidemiol & Community Hlth, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23284 USA; Virginia Commonwealth Univ Hlth Syst, Dept Emergency Med, Richmond, VA USA; Virginia Commonwealth Univ Hlth Syst, Dept Internal Med, Div Cardiol, Richmond, VA USA; Virginia Commonwealth Univ Hlth Syst, Dept Emergency Med, Richmond, VA USA; Virginia Commonwealth Univ Hlth Syst, Virginia Commonwealth Univ Reanimat Engn & Shock, Richmond, VA USA; Richmond Ambulance Author, Richmond, VA USA; Chippenham & Johnston Willis Hosp, Dept Emergency Med, Richmond, VA USA; Richmond Community Hosp, Dept Emergency Med, Richmond, VA USA; St Marys Hosp, Dept Emergency Med, Richmond, VA USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Ornato, JP (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Emergency Med, 1250E Marshall St,2nd Floor, Richmond, VA 23298 USA.	ornato@aol.com	Best, Al/F-6425-2012	Best, Al/0000-0002-6300-3925				Abella BS, 2005, CIRCULATION, V111, P428, DOI 10.1161/01.CIR.0000153811.84257.59; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BECKER LB, 1993, ANN EMERG MED, V22, P86, DOI 10.1016/S0196-0644(05)80257-4; Caffrey SL, 2002, NEW ENGL J MED, V347, P1242, DOI 10.1056/NEJMoa020932; Casner Michael, 2005, Prehosp Emerg Care, V9, P61, DOI 10.1080/10903120590891714; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; Eftestol T, 2004, CIRCULATION, V110, P10, DOI 10.1161/01.CIR.0000133323.15565.75; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; HALPERIN HR, 1993, NEW ENGL J MED, V329, P762, DOI 10.1056/NEJM199309093291104; Halperin HR, 2002, CIRCULATION, V106, P538; HALPERIN HR, 1986, CIRCULATION, V74, P1407, DOI 10.1161/01.CIR.74.6.1407; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; KERN KB, 1988, RESUSCITATION, V16, P241, DOI 10.1016/0300-9572(88)90111-6; Kern KB, 2000, BAILLIERE CLIN ANAES, V14, P591; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; MCDONALD JL, 1983, ANN EMERG MED, V12, P144; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; OMATO JP, 2003, RESUSCITATION, V56, P135; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; RALSTON SH, 1984, ANN EMERG MED, V13, P79, DOI 10.1016/S0196-0644(84)80566-1; SANDERS AB, 1985, AM J EMERG MED, V3, P11, DOI 10.1016/0735-6757(85)90003-8; SANDERS AB, 1984, CRIT CARE MED, V12, P871, DOI 10.1097/00003246-198410000-00007; Timerman S, 2004, RESUSCITATION, V61, P273, DOI 10.1016/j.resuscitation.2004.01.025; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Weisfeldt ML, 2002, JAMA-J AM MED ASSOC, V288, P3035, DOI 10.1001/jama.288.23.3035; White RD, 1998, RESUSCITATION, V39, P145, DOI 10.1016/S0300-9572(98)00135-X; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389; WOLFE JA, 1988, J THORAC CARDIOV SUR, V95, P523; Zheng ZJ, 2001, CIRCULATION, V104, P2158, DOI 10.1161/hc4301.098254	36	164	180	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	2006	295	22					2629	2637		10.1001/jama.295.22.2629	http://dx.doi.org/10.1001/jama.295.22.2629			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	052HI	16772626	Bronze			2023-01-03	WOS:000238224000025
J	Birkhead, J; Weston, C; Lowe, D				Birkhead, John; Weston, Clive; Lowe, Derek		MINAP Steering Grp	Impact of specialty of admitting physician and type of hospital on care and outcome for myocardial infarction in England and Wales during 2004-5: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE CORONARY SYNDROMES; ELDERLY-PATIENTS; MANAGEMENT	Objective To examine process of care and outcome for patients admitted with acute myocardial infarction to hospitals in England and Wales in relation to type of consultant care and type of hospital. Design Observational study of 88 782 patients admitted with myocardial infarction during 2004-5, using records from the national audit of myocardial infarction project (MINAP) database. Outcome measures Use of reperfusion treatment and secondary prevention drugs, use of angiography, and 90 day mortality of patients admitted under the care of cardiologists and non-cardiologists in hospitals with and without facilities for coronary intervention. Findings 36% of patients were admitted under the care of a cardiologist and 20% to a hospital with coronary interventional facilities. Patients admitted under cardiologists had fewer comorbidities than other patients and were more likely to have reperfusion treatment (12 266/14 433 (85%) v 13 682/17 064 (80%)) and appropriate secondary prevention drugs. Overall, 27 431/79 374 (35%) of patients had angiography. Relatively more patients admitted to interventional hospitals (8167/14 661; 56%) than to other hospitals had angiography (19 264/64 713; 30%). The adjusted risk of death by 90 days for patients treated in interventional compared with non-interventional hospitals was 0.93 (95% confidence interval 0.82 to 1.06). The adjusted risk of death at 90 days for patients admitted under cardiologists compared with non-cardiologists was 0.86 (0.81 to 0.91). Conclusions Patients cared for by cardiologists had less comorbidity than other patients. They were more likely to receive proved treatments and angiography, and they had a lower adjusted 90 day mortality. Large differences existed in the use of angiography between interventional and non-interventional hospitals. These findings show wide variations in the management and outcome of patients with myocardial infarction in England and Wales.	Royal Coll Physicians, Clin Effectiveness & Evaluat Unit, London NW1 4LE, England; Northampton Gen Hosp, Northampton NN1 5BD, England; Singleton Hosp, Swansea SA2 8QA, W Glam, Wales	Royal College of Physicians; Singleton Hospital	Birkhead, J (corresponding author), Royal Coll Physicians, Clin Effectiveness & Evaluat Unit, London NW1 4LE, England.	john.birkhead@btinternet.com		Weston, Clive/0000-0002-8995-8199				Ayanian JZ, 1997, ARCH INTERN MED, V157, P2570, DOI 10.1001/archinte.157.22.2570; Bach RG, 2004, ANN INTERN MED, V141, P186, DOI 10.7326/0003-4819-141-3-200408030-00007; Bertrand ME, 2002, EUR HEART J, V23, P1809, DOI 10.1053/euhj.2002.3385; Birkhead JS, 2004, HEART, V90, P1004, DOI 10.1136/hrt.2004.034470; BIRKHEAD JS, 2001, BASELINE SURVEY FACI; Birkhead JS, 2002, J CLIN EXCELLENCE, V4, P379; Block P, 2003, EUR HEART J, V24, P299, DOI 10.1016/S0195-668X(02)00474-8; BRAUNWALD E, ACC AHA 2002 GUIDELI; British Cardiac Soc Guidelines Med, 2001, HEART, V85, P133; Chen J, 2000, AM J MED, V108, P460, DOI 10.1016/S0002-9343(00)00331-4; Department of Health, 1997, NEW NHS MOD DEP; Fox KAA, 2002, LANCET, V360, P743, DOI 10.1016/S0140-6736(02)09894-X; Frances CD, 1999, ARCH INTERN MED, V159, P1429, DOI 10.1001/archinte.159.13.1429; Go AS, 2000, AM J MED, V108, P216, DOI 10.1016/S0002-9343(99)00430-1; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Kaul P, 2004, CIRCULATION, V110, P1754, DOI 10.1161/01.CIR.0000142671.06167.91; LEON DA, 1993, LANCET, V342, P479, DOI 10.1016/0140-6736(93)91599-H; Rickards A, 1999, HEART, V82, P18; *ROYAL COLL PHYS, MINAP DAT SET; Van de Werf F, 2005, BRIT MED J, V330, P441, DOI 10.1136/bmj.38335.390718.82; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8	21	60	60	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 3	2006	332	7553					1306	1308B		10.1136/bmj.38849.440914.AE	http://dx.doi.org/10.1136/bmj.38849.440914.AE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	051YG	16705004	Green Published, Bronze			2023-01-03	WOS:000238197000021
J	Ferner, RE; McDowell, SE				Ferner, R. E.; McDowell, Sarah E.			How NICE may be outflanked	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PHARMACEUTICAL-INDUSTRY; MONOCLONAL-ANTIBODY; METASTATIC BREAST; ASSOCIATION; GUIDANCE; DRUGS		City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Ferner, RE (corresponding author), City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England.	r.e.lerner@bham.ac.uk	McDowell, Sarah/G-9230-2011	McDowell, Sarah/0000-0003-0979-3679; Ferner, Robin/0000-0003-3769-1346				*AB INT, NICE GUID IMPL TRACK; *ACT ALZH DRUGS AL, DRUG TREATM WHICH HE; *ALZH DIS INT, NICE GUID DEM DRUGS; *ALZH SOC, DRUGS TREATM ALZH DI; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Bhandari M, 2004, CAN MED ASSOC J, V170, P477; *BREAKTHR BREAST C, BREAKTHR COMM AM ROG; *BREAKTHR BREAST C, OUR PARTN; *BREAST CANC CAR, FULL SUPP LIST; *DEP HLTH, 2005, HEW FAST TRACKS CANC; *DIAB UK, GUID PUBL US INH INS; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; Ferner RE, 1996, BRIT MED J, V313, P1157, DOI 10.1136/bmj.313.7066.1157; Foot B, 2004, J PUBLIC HEALTH, V26, P52, DOI 10.1093/pubmed/fdh112; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; *HC, QUEST OR WRITT ANSW; *HC HLTH COMM, 2005, 4 HOUS COMM HLTH COM; *HELP AG, THANK YOU; Herxheimer A, 2003, BRIT MED J, V326, P1208, DOI 10.1136/bmj.326.7400.1208; HEWITT P, 2005, COMMUNICATION   1025; *HLTH SOC CAR INF, 2004, HOSP PRESCR; JEFFRIES M, 2005, PHARM MARKETING; Kjaergard LL, 2002, BMJ-BRIT MED J, V325, P249, DOI 10.1136/bmj.325.7358.249; *LINK PHARM, NIC POIS DEN BRAIN T; Maynard A, 2006, BMJ-BRIT MED J, V332, P906, DOI 10.1136/bmj.332.7546.906; Moynihan R, 2002, BRIT MED J, V324, P886, DOI 10.1136/bmj.324.7342.886; *NAT OST SOC, NAT OST SOC CRIT NIC; *NICE, CLIN EFF COST UT PHO; *NICE, DRAFT SCOP MAC DEG A; *NICE, DEV NICE TECHN APPR; OLIVER S, 1995, MAIL SUNDAY LON 0924, P1; *PAT VIEW, 2004, HLTH SOC CAMP NEWS; *PFIZ LTD, SAD DAY PAT NICE DEC; Raftery J, 2006, BRIT MED J, V332, P1266, DOI 10.1136/bmj.332.7552.1266; RAYNER C, 2005, DAILY MAIL LOND 1006, P6; REVILL J, 2005, OBSERVER        0313, P2; Sheldon TA, 2004, BRIT MED J, V329, P999, DOI 10.1136/bmj.329.7473.999; *SHIR PLC, NICE REQ DAT SUBGR A; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SPINK J, 2001, COMMUNIQUE; STEVEN S, 2001, MAIL SUNDAY     0812, P51; STUTTAFORD T, 2006, TIMES           0130, P11; WOMEN FIGHTING HERCE; 2001, MANCHESTER EVEN 0825, P1; 2001, EXPRESS         0316, P4; GENENTECH STUDY PUBL; 2001, MANCHESTER EVEN 1018, P2; 2001, MANCHESTER EVEN 0825, P2; SHROPSHIRE 6	50	36	36	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 27	2006	332	7552					1268	1271		10.1136/bmj.332.7552.1268	http://dx.doi.org/10.1136/bmj.332.7552.1268			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	048ZC	16735342	Green Published			2023-01-03	WOS:000237984100025
J	Ben-Maimon, CS; Garnick, R				Ben-Maimon, CS; Garnick, R			Biogenerics at the crossroads	NATURE BIOTECHNOLOGY			English	Editorial Material								Two executives-one from a leading generics manufacturer, the other from a leading brand manufacturer-argue the pros and cons of implementing an abbreviated US regulatory framework for the approval of biogeneric products.	Barr Pharmaceut, Woodcliff Lake, NJ 07677 USA		Ben-Maimon, CS (corresponding author), Barr Pharmaceut, 400 Chestnut Ridge Rd, Woodcliff Lake, NJ 07677 USA.	amanno@barrlabs.com							0	13	14	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2006	24	3					268	269		10.1038/nbt0306-268a	http://dx.doi.org/10.1038/nbt0306-268a			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	019WQ	16525381	Bronze			2023-01-03	WOS:000235868600018
J	Gazzard, B				Gazzard, B			Antiretroviral therapy for HIV: medical miracles do happen	LANCET			English	Editorial Material									Chelsea & Westminster Hosp, Dept HIV, London SW10 9NH, England	Imperial College London	Gazzard, B (corresponding author), Chelsea & Westminster Hosp, Dept HIV, London SW10 9NH, England.	eileen.witney@chelwest.nhs.uk						Beck EJ, 2004, AIDS, V18, P2411; Havlir D V, 1998, AIDS, V12 Suppl A, pS165; Keenan PA, 2005, POSTGRAD MED, V117, P47, DOI 10.3810/pgm.2005.03.1600; Ruxin J, 2005, LANCET, V365, P618, DOI 10.1016/S0140-6736(05)70806-0; SELIGMANN M, 1994, LANCET, V343, P871; Sterne JAC, 2005, LANCET, V366, P378, DOI 10.1016/S0140-6736(05)67022-5	6	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 30	2005	366	9483					346	347		10.1016/S0140-6736(05)67002-X	http://dx.doi.org/10.1016/S0140-6736(05)67002-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	950IB	16054922				2023-01-03	WOS:000230849700005
J	Padma, TV				Padma, TV			Ayurveda	NATURE			English	Article																			0	29	29	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 28	2005	436	7050					486	486		10.1038/436486a	http://dx.doi.org/10.1038/436486a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	949LE	16049472				2023-01-03	WOS:000230788800041
J	Johnson, MS; Klein, JD; Loveland-Cherry, C; Moyer, VA; Ockene, JK; Petitti, DB; Siu, AL; Teutsch, SM; Yawn, BP				Johnson, MS; Klein, JD; Loveland-Cherry, C; Moyer, VA; Ockene, JK; Petitti, DB; Siu, AL; Teutsch, SM; Yawn, BP		US Preventive Serv Task Force	Hormone therapy for the prevention of chronic conditions in postmenopausal women: Recommendations from the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Article							CONJUGATED EQUINE ESTROGENS; RANDOMIZED CONTROLLED-TRIAL; HEALTH INITIATIVE MEMORY; REPLACEMENT THERAPY; BREAST-CANCER; ESTROGEN/PROGESTIN REPLACEMENT; PLUS PROGESTIN; OVARIAN-CANCER; FOLLOW-UP; RISK	This statement summarizes the U.S. Preventive Services Task Force recommendations on hormone therapy for the prevention of chronic conditions in postmenopausal women and the supporting scientific evidence, and updates the Task Force's 2002 recommendations on hormone replacement therapy. The updated statement is based on the results of the Women's Health Initiative randomized, controlled trial, as well as the information in the 2002 summary of the evidence on this topic, which is available on the USPSTF Web site (www.preventiveservices.ahrq.gov).	US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA	Agency for Healthcare Research & Quality	Johnson, MS (corresponding author), US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA.							Abramson B, 2004, CAN MED ASSOC J, V170, P1388, DOI 10.1053/cmaj.1030755; *ACOG TASK FORC HO, 2004, OBSTET GYNECOL S, V104, pS1; *AM CANC SOC, CANC FACTS FIG 2004; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Berg AO, 2002, ANN INTERN MED, V137, P526, DOI 10.7326/0003-4819-137-6-200209170-00014; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; HUMPHREY L, 2002, SYSTEMATIC EVIDENCE; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; LEBLANC E, 2002, SYSTEMATIC EVIDENCE; Linfante A, 2004, CIRCULATION, V110, P664; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; Miller J, 2002, SYSTEMATIC EVIDENCE, V11; North American Menopause Society, 2004, Menopause, V11, P589; Persson I, 1996, INT J CANCER, V67, P327, DOI 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.3.CO;2-J; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sellers TA, 1997, ANN INTERN MED, V127, P973, DOI 10.7326/0003-4819-127-11-199712010-00004; Sheridan SL, 2004, AM J PREV MED, V26, P56, DOI 10.1016/j.amepre.2003.09.011; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Wathen CN, 2004, CAN MED ASSOC J, V170, P1535, DOI 10.1503/cmaj.1030756	30	96	97	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2005	142	10					855	860		10.7326/0003-4819-142-10-200505170-00011	http://dx.doi.org/10.7326/0003-4819-142-10-200505170-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926CE	15897536				2023-01-03	WOS:000229099600007
J	Dong, JH; Yang, GY; Mchaourab, HS				Dong, JH; Yang, GY; Mchaourab, HS			Structural basis of energy transduction in the transport cycle of MsbA	SCIENCE			English	Article							RESISTANCE P-GLYCOPROTEIN; BINDING CASSETTE TRANSPORTERS; MULTIDRUG-RESISTANCE; ABC TRANSPORTERS; ATP-BINDING; ESCHERICHIA-COLI; TRANSMEMBRANE DOMAINS; CROSS-LINKING; MECHANISM; CONFORMATION	We used site-directed spin-labeling and electron paramagnetic resonance spectroscopy to characterize the conformational motion that couples energy expenditure to substrate translocation in the multidrug transporter MsbA. In liposomes, ligand-free MsbA samples conformations that depart from the crystal structures, including looser packing and water penetration along the periplasmic side. Adenosine triphosphate (ATP) binding closes the substrate chamber to the cytoplasm while increasing hydration at the periplasmic side, consistent with an alternating access model. Accentuated by ATP hydrolysis, the changes in the chamber dielectric environment and its geometry provide the likely driving force for flipping amphipathic substrates and a potential exit pathway. These results establish the structural dynamic basis of the power stroke in multidrug-resistant ATP-binding cassette (MDR ABC) transporters.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Mchaourab, HS (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.	hassane.mchaourab@vanderbilt.edu		Dong, Jinhui/0000-0003-4542-7756				Buchaklian AH, 2004, BIOCHEMISTRY-US, V43, P8600, DOI 10.1021/bi0497751; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Dong J.-K., UNPUB; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Higgins CF, 2001, SCIENCE, V293, P1782, DOI 10.1126/science.1065588; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Higgins CF, 1997, SEMIN CANCER BIOL, V8, P135, DOI 10.1006/scbi.1997.0067; Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8; Loo TW, 2004, BIOCHEMISTRY-US, V43, P12081, DOI 10.1021/bi049045t; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; MITCHELL P, 1990, RES MICROBIOL, V141, P286, DOI 10.1016/0923-2508(90)90002-8; MITCHELL P, 1957, NATURE, V180, P134, DOI 10.1038/180134a0; Nikaido H, 1998, METHOD ENZYMOL, V292, P3; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Poelarends GJ, 2002, J BIOL CHEM, V277, P42891, DOI 10.1074/jbc.M206508200; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Seigneuret M, 2003, J BIOL CHEM, V278, P30115, DOI 10.1074/jbc.M302443200; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; van Veen HW, 1998, ADV EXP MED BIOL, V456, P145; van Veen HW, 1998, BBA-BIOENERGETICS, V1365, P31, DOI 10.1016/S0005-2728(98)00039-5; van Veen HW, 2001, RES MICROBIOL, V152, P365, DOI 10.1016/S0923-2508(01)01208-6; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	32	128	133	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	2005	308	5724					1023	1028		10.1126/science.1106592	http://dx.doi.org/10.1126/science.1106592			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927JR	15890883				2023-01-03	WOS:000229190700047
J	Walsh, B; Steiner, A; Pickering, RM; Ward-Basu, J				Walsh, B; Steiner, A; Pickering, RM; Ward-Basu, J			Economic evaluation of nurse led intermediate care versus standard acute care for post-acute medical patients: cost minimisation analysis of data from a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							INPATIENT UNIT	Objective To undertake an economic evaluation of nurse led intermediate care compared with standard hospital care for post-acute medical patients. Design Cost minimisation analysis from an NHS perspective, comprising secondary care, primary care, and community care, using data from a pragmatic randomised controlled trial. Setting Nurse led unit and acute general medical wards in large, urban, UK teaching hospital. Participants 238 patients. Outcome measure Costs to acute hospital trusts and to the NHS over six months. Results On an intention to treat basis, nurse led care was associated with higher costs during the initial admission period (nurse led care 7892 pound ($14 970; E11 503), standard care 4810 pound, difference 3082 pound (95% confidence interval 1161 pound to 5002 pound)) pound. During the readmission period, costs were similar (nurse led care 1444 pound, standard care 1879 pound, difference - 435 pound, - 1406 pound to 536 pound) pound. Total costs at six months were significantly higher (nurse led care 10 529 pound, standard care 7819 pound, difference 2710 pound, 518 pound to 4903 pound). Sensitivity analyses suggested that the trend for nurse led care to be more expensive was maintained even with substantial cost reductions, although differences were no longer significant. Conclusion Acute hospitals may not be cost effective settings for nurse led intermediate care. Both inpatient and total costs were significantly higher for nurse led care than for standard care of post-acute medical patients, suggesting that this model of care should not be pursued unless clinical or organisational benefits justify the increased investment.	Univ Southampton, Sch Nursing & Midwifery, Southampton SO17 1BJ, Hants, England; Univ Southampton, Dept Geriatr Med, Southampton SO9 5NH, Hants, England; Southampton Gen Hosp, Med Stat Grp, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England; Southampton Gen Hosp, Dept Geriatr Med, Elderly Care Res Unit, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton; University of Southampton; University of Southampton	Walsh, B (corresponding author), Univ Southampton, Sch Nursing & Midwifery, Southampton SO17 1BJ, Hants, England.	b.m.walsh@soton.ac.uk		Walsh, Bronagh/0000-0003-1008-0545				Coast J, 1998, BRIT MED J, V316, P1802, DOI 10.1136/bmj.316.7147.1802; *DEP HLTH, 2001, HLTH SERV CIRC 2001; *DEP HLTH, 2000, NHS PLAN; Department of Health, 2001, NAT SERV FRAM OLD PE; Department of Health, 2000, SHAP FUT NHS LONG TE; Griffiths P, 2001, AGE AGEING, V30, P483, DOI 10.1093/ageing/30.6.483; Griffiths P, 2000, INT J NURS STUD, V37, P153, DOI 10.1016/S0020-7489(99)00061-9; GRIFFITHS P, 1995, EVALUATING NURSE LED; NETTEN A, 1999, UNIT COSTS COMMUNITY; PEARSON A, 1992, NURSING BEDS EVALUAT; Stein RL, 2004, J PALESTINE STUD, V33, P5, DOI 10.1525/jps.2004.33.4.005; Steiner A, 2001, AGE AGEING, V30, P433, DOI 10.1093/ageing/30.6.433; Steiner A, 2001, BRIT MED J, V322, P453, DOI 10.1136/bmj.322.7284.453; Walsh B, 2003, INT J NURS STUD, V40, P307, DOI 10.1016/S0020-7489(02)00091-3; Wiles R, 2001, J ADV NURS, V34, P813, DOI 10.1046/j.1365-2648.2001.01812.x	15	24	24	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 26	2005	330	7493					699	702		10.1136/bmj.38397.633588.8F	http://dx.doi.org/10.1136/bmj.38397.633588.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	912IT	15757959	Green Published, Bronze			2023-01-03	WOS:000228071900015
J	Sabatine, MS; Cannon, CP; Gibson, CM; Lopez-Sendon, JL; Montalescot, G; Theroux, P; Claeys, MJ; Cools, F; Hill, KA; Skene, AM; McCabe, CH; Braunwald, E; Braunwald, E; Cannon, C; Sabatine, M; McCabe, C; McCagg, A; Job, B; Gaudin, C; Thizon-de Gaulle, I; Blumenthal, M; Saini, R; Delaet, I; Townes, L; Anhalt, D; van Holder, K; Skene, A; Hill, K; Braunwald, E; Cannon, C; Sabatine, M; McCabe, C; Job, B; Gaudin, C; Thizon-de Gaulle, I; Blumenthal, M; Saini, R; Delaet, I; Townes, L; Skene, A; Ardissino, D; Aylward, P; Bertrand, M; Bode, C; Budaj, A; Claeys, M; Dellborg, M; Ferreira, R; Gershlick, A; Huber, K; Keltai, M; Kleiman, N; Lewis, B; Lopez-Sendon, J; Marx, J; Montalescot, G; Nicolau, J; Ongen, Z; Paolasso, E; Pons, JL; Ruda, M; Theroux, P; Van de Werf, F; Verheugt, F; Wilcox, R; Zeymer, U; Braunwald, E; Cannon, C; Sabatine, M; Gibson, M; McCabe, C; McCagg, A; Job, B; Gaudin, C; Thizon-de Gaulle, I; Blumenthal, M; Saini, R; Froehlich, J; Delaet, I; Townes, L; Anhalt, D; van Holder, K; Pieters, A; Skene, A; Hill, K; Charlesworth, A; Goulder, M; Stead, S; Wiviott, S; Aroesty, J; Berger, C; Garcia, L; Greer, D; Leeman, D; Lyle, H; Philippides, G; Schwamm, L; Gibson, M; Marble, S; Aroesty, J; Buros, J; Ciaglo, L; Kirtane, A; Shui, A; Wilson, A; Scirica, B; Morrow, D; Giugliano, R; Wiviott, S; Morrow, D; Ridker, P; Rifai, N; Sabatine, M; Kucherlapati, R; Kwiatkowski, D; Stone, P; Maccallum, G; Lucier, M; Garriga, A; Anderson, J; Fox, K; Kelsey, S; Batalla, A; Areses, ELD; Fiol, M; Bethencourt, A; Lozano, I; Figueras, J; Cortes, JG; Jimenez, AG; Fernandez, AR; Montero, IF; Casasnovas, J; Aso, FO; de Blas, RC; Audicana, J; Errazti, IE; Montero, JS; Rohlfs, I; Pinero, C; Rodriguez, MM; Alvarez, LV; Belras, AC; Barros, S; Fernandez, JD; Tobaruela, A; Bonneau, A; Soulat, L; Lambert, Y; Caussanel, J; Livareck, B; Ramaut, C; Ricome, J; Lapostolle, F; Beruben, A; Thieleux, F; Martelli, J; Martelet, M; Mouallem, J; Ahmed, F; Galley, D; Alhabaj, S; Doucos, D; Bearez, E; Spetebroodt, S; Gully, C; Dujardin, J; Averland, B; Emmonot, B; Pollet, D; Vallet, P; Mossaz, R; Marquand, A; Kermarrec, A; Le Lay, C; Douillet, R; Olliver, L; Matas, O; Kassam, S; Halperin, F; Parsons, P; Bovak, B; Hart, B; Sussex, B; Newman, S; Gosselin, G; David, M; Sidhar, K; Wiseman, D; Lefkowitz, C; Thornley, M; Bhargava, R; McCullum, A; Grandmond, D; Carignan, D; Kouz, S; Roy, M; Polasek, P; Stedham, V; Lai, K; Paquette, B; Raco, D; Sayles, M; Sridhar, K; Wiseman, D; Tremblay, B; Darveau, C; Sussex, B; Newman, S; Senaratne, M; Holland, M; Bata, I; Hulan, M; Constance, C; Pouliot, S; Gossard, D; Day, L; Glanz, A; Vilag, C; Hui, W; Kvill, L; Dion, D; Morisette, A; Sandrin, F; Mitges, S; Cools, F; Vanhagendoren, S; De Meester, A; Marcovitch, O; Allaf, E; Gits, F; Verrostte, J; Thoeng, J; Quinonez, M; Appeltants, H; D'Hooghe, G; Eycken, M; Swennen, I; Hollanders, G; Michael, E; Decroly, P; Rombaut, E; Carlaire, D; Vermander, D; Marenne, SF; Gavray, C; Michel, P; Poth, A; Paquay, J; Lutasu, S; Dirk, D; Vermeulen, J; Govaerts, E; Boldueva, S; Sherenkov, A; Ruda, M; Kostenko, V; Tereschenko, S; Zalevsky, G; Boyarkin, M; Tankhilevitch, B; Glezer, M; Gratsiansky, N; Shlyakhto, E; Sidorenko, B; Zadiontchenko, V; Perepech, N; Gruzdev, A; Chernov, S; Pollock, B; Andresen, D; Hoffmann, S; Andresen, D; Arntz, H; Klein, H; Neuss, H; Wilhelms, E; Henzgen, R; Kuckuck, H; Darius, H; Hausdorf, C; Ochs, H; Olbrich, H; Willenbrock, R; Hepp, A; Wucherpfennig, P; Wiechmann, H; Schmidtendorf, H; Kohler, B; Sehnert, W; Ueberreiter, A; Uebis, R; Stockmann, M; Rommele, U; Meissner, A; Schneider, L; Adgey, J; McAllister, T; McEneaney, D; Mackin, A; Sulke, N; Dixon, R; Wilcox, R; Congreave, S; Flapan, A; Flint, L; Purvis, J; McCorkell, G; Stubbs, P; Steer, C; McKkee, P; Senior, R; Chester, L; Levy, T; Kennard, S; Bishop, A; Hlaing, S; de Belder, M; Cunningham, N; Gilbert, T; Young, J; Henderson, R; Falcon-Lang, D; Gershlick, A; Fairbrother, K; Rosenfeld, T; Atar, S; Lewis, B; Yuval, R; Meisel, S; Alony, I; Rozenman, Y; Logrineuko, S; Goldhammer, E; Harel, S; David, D; Erez, N; Jafari, J; Tubul, O; Marmor, A; Pritulo, L; Caspi, A; Roitberg, N; Kaluski, E; Amar, R; Tzivoni, D; Rojanski, A; Yedid-Am, S; Keren, A; Datiashvily, L; Saraiva, JK; Garcia, CT; Markman, M; Chaves, A; Vaz, RC; Dutra, O; Coelho, OR; Sciampaglia, R; da Cunha, CP; de Brito, MR; Lotufo, P; Ribeiro, E; Cicogna, A; Michalaros, YL; Ornellas, CE; Santos, SCD; Rosatelli, P; Pimentel, W; Grudzinski, M; Guimaraes, F; Gustavo, C; Moreira, M; Gosmao, J; Hertzberger, D; Schut, A; van der Zwaan, C; Havenaar, H; van Wijngaarden, J; Verheij, H; Wajon, E; Bosschaart, M; Oomen, A; Daniels, M; Coppes, A; Vergeught, F; Dieker, H; Jochemsen, D; Fijlstra, I; Leenders, C; Gelder, T; Janicke, D; Bass, J; Hamroff, G; Keeler, K; Chandra, M; Van Hoose, B; Minor, S; Mock, P; Chandra, M; Olliges, M; Unwala, A; Fisher, C; French, W; Barillas, O; Chandna, H; Holly, D; Chandna, H; Holly, D; Grewal, G; Gurnsey, L; Mehta, P; Cruse, A; Perlman, R; Palazzo, D; Puma, J; Payne, C; Torres, J; Patten, L; Lefkovic, L; Viswanathan, N; Rees, A; Yoches, A; Rodriguez-Ospina, L; Santos, J; Chohan, A; Kemp, A; Perlman, R; Palazzo, D; Weiss, R; Brennan, B; Aude, Y; Harrison, P; Brogan, G; Ayan, J; Cragg, D; Murawka, A; Garg, M; McKelvy, J; Hulyalkar, A; Kuchenrither, C; Jackson, S; Whitaker, J; Richardson, J; Vicari, R; Howard, M; Aude, Y; Harrison, P; Chadow, H; Hauptman, R; Gelormini, J; Giambra, T; Lakkis, N; Jiang, S; Hernandez, I; Vazquez, A; Rosas, EL; Lawrenz, JC; Bustamante, F; Martinez, CA; Alcocer, MA; Hernandez, EG; Dogre, CW; Bustillos, MDB; Alvarado, R; Ramirez, MC; Hinojosa, P; Rivera, OO; Pons, JL; Carrillo, J; Velasco, JA; Quintana, F; Petersen, F; Palomera, R; Ibarra, M; Sanchez, CJ; Delgado, L; Bayram, E; Machado, GM; Berli, MA; Vinuela, JC; Allall, O; Fuentealba, V; Reguero, M; Covelli, G; San Martin, E; Francia, E; Gadaleta, F; Haehnel, M; Iglesias, R; Blumberg, S; de Lima, AA; Henquin, R; Estrada, JN; de Arenaza, D; Fernandez, R; Abud, M; Becker, C; Milesi, R; Schamuck, R; Doyharzabal, JM; Caime, DG; Teresa, LC; Kuschnir, E; Sgammini, H; Sgammini, J; David, J; Sosa, CH; Redcozub, E; Avalos, V; Nul, D; Ramos, S; Castro, PT; Rodriguez, A; Sosa, C; Lopez, JG; Novo, F; Diez, F; Piraino, R; Godoy, G; Weller, C; Pomposiello, J; Sanchez, A; Karlsson, J; Collberg, K; Malmqvist, K; Cedergren, E; Dellborg, M; Coops, G; Kallryd, A; Laudon, P; Bandh, S; Andersson, C; Soome, S; Classon, H; Lugnegard, J; Ahlmark, H; Risenfors, M; Ortgren, L; Fjelstad, B; Osberg, S; Frisell, J; Sandstrom, M; Silvestri, O; Sasso, A; Rolli, A; Paoli, G; Chiarella, F; Olivotte, L; Doronzo, B; Coppolino, A; Pivoccari, G; Pesaresi, A; Ambrosio, G; Del Pinto, M; De Luca, I; Laico, M; De Ferrari, G; Baldini, E; Guiducci, U; Tortorella, G; Romano, M; Villani, R; Casazza, F; Capozi, A; Moretti, L; Del Pinto, M; Perelli, S; Sinagra, G; Maras, P; Porcu, M; Scorcu, G; Proietti, F; Severi, S; Gessek, J; Pawlowicz, L; Szelemej, R; Gorski, M; Janion, M; Sielski, J; Kleinrok, A; Rodzik, J; Hiczkiewicz, J; Pasler, MM; Soltsiak, M; Gorny, J; Huber, K; Jordanova, N; Heigert, M; Kopp, K; Frank, H; Laggner, A; Schreiber, W; Weihs, W; Drexel, MH; Doubell, A; Burgess, L; Bennett, J; Snyders, F; Ebrahim, I; Bobak, C; Marx, J; deBeer, M; Schmidt, S; Cyster, H; van der Berg, P; Groenewald, W; Herbst, L; Britz, A; Snyman, M; Schonken, M; Badenhorst, J; Blomerus, P; Mpe, M; Bobak, C; Mynhardt, J; Groenewald, C; van Dyk, C; Meiring, J; Steingo, L; Glaeser, L; Whelan, A; Tulloch, G; Gunalingham, B; Conway, B; Soward, A; Hales, S; Lefkovits, J; Sallaberger, M; Owesby, D; Kesby, J; Amerena, J; Fogarty, K; Chew, D; Austin, M; Kovaricek, S; Banham, N; Tulloch, G; Jobbagy, L; Dinnyes, J; Lippai, J; Oze, B; Szakal, I; Bartal, G; Foldi, A; Foley, D; McGrath, F; Meany, B; Geraghty, M; Daly, K; Henessey, S; Mulvihill, N; Schilling, C; Kearney, P; Kelly, P; Kearney, P; Kelly, P; Ongen, Z; Vura, A; Kozan, O; Ozaydin, E; Kultursay, H; Kayikcioglu, M; Degertekin, M; Mutlu, B; Monteiro, F; Ferreira, D; Carrageta, M				Sabatine, MS; Cannon, CP; Gibson, CM; Lopez-Sendon, JL; Montalescot, G; Theroux, P; Claeys, MJ; Cools, F; Hill, KA; Skene, AM; McCabe, CH; Braunwald, E; Braunwald, E; Cannon, C; Sabatine, M; McCabe, C; McCagg, A; Job, B; Gaudin, C; Thizon-de Gaulle, I; Blumenthal, M; Saini, R; Delaet, I; Townes, L; Anhalt, D; van Holder, K; Skene, A; Hill, K; Braunwald, E; Cannon, C; Sabatine, M; McCabe, C; Job, B; Gaudin, C; Thizon-de Gaulle, I; Blumenthal, M; Saini, R; Delaet, I; Townes, L; Skene, A; Ardissino, D; Aylward, P; Bertrand, M; Bode, C; Budaj, A; Claeys, M; Dellborg, M; Ferreira, R; Gershlick, A; Huber, K; Keltai, M; Kleiman, N; Lewis, B; Lopez-Sendon, J; Marx, J; Montalescot, G; Nicolau, J; Ongen, Z; Paolasso, E; Pons, JL; Ruda, M; Theroux, P; Van de Werf, F; Verheugt, F; Wilcox, R; Zeymer, U; Braunwald, E; Cannon, C; Sabatine, M; Gibson, M; McCabe, C; McCagg, A; Job, B; Gaudin, C; Thizon-de Gaulle, I; Blumenthal, M; Saini, R; Froehlich, J; Delaet, I; Townes, L; Anhalt, D; van Holder, K; Pieters, A; Skene, A; Hill, K; Charlesworth, A; Goulder, M; Stead, S; Wiviott, S; Aroesty, J; Berger, C; Garcia, L; Greer, D; Leeman, D; Lyle, H; Philippides, G; Schwamm, L; Gibson, M; Marble, S; Aroesty, J; Buros, J; Ciaglo, L; Kirtane, A; Shui, A; Wilson, A; Scirica, B; Morrow, D; Giugliano, R; Wiviott, S; Morrow, D; Ridker, P; Rifai, N; Sabatine, M; Kucherlapati, R; Kwiatkowski, D; Stone, P; Maccallum, G; Lucier, M; Garriga, A; Anderson, J; Fox, K; Kelsey, S; Batalla, A; Areses, ELD; Fiol, M; Bethencourt, A; Lozano, I; Figueras, J; Cortes, JG; Jimenez, AG; Fernandez, AR; Montero, IF; Casasnovas, J; Aso, FO; de Blas, RC; Audicana, J; Errazti, IE; Montero, JS; Rohlfs, I; Pinero, C; Rodriguez, MM; Alvarez, LV; Belras, AC; Barros, S; Fernandez, JD; Tobaruela, A; Bonneau, A; Soulat, L; Lambert, Y; Caussanel, J; Livareck, B; Ramaut, C; Ricome, J; Lapostolle, F; Beruben, A; Thieleux, F; Martelli, J; Martelet, M; Mouallem, J; Ahmed, F; Galley, D; Alhabaj, S; Doucos, D; Bearez, E; Spetebroodt, S; Gully, C; Dujardin, J; Averland, B; Emmonot, B; Pollet, D; Vallet, P; Mossaz, R; Marquand, A; Kermarrec, A; Le Lay, C; Douillet, R; Olliver, L; Matas, O; Kassam, S; Halperin, F; Parsons, P; Bovak, B; Hart, B; Sussex, B; Newman, S; Gosselin, G; David, M; Sidhar, K; Wiseman, D; Lefkowitz, C; Thornley, M; Bhargava, R; McCullum, A; Grandmond, D; Carignan, D; Kouz, S; Roy, M; Polasek, P; Stedham, V; Lai, K; Paquette, B; Raco, D; Sayles, M; Sridhar, K; Wiseman, D; Tremblay, B; Darveau, C; Sussex, B; Newman, S; Senaratne, M; Holland, M; Bata, I; Hulan, M; Constance, C; Pouliot, S; Gossard, D; Day, L; Glanz, A; Vilag, C; Hui, W; Kvill, L; Dion, D; Morisette, A; Sandrin, F; Mitges, S; Cools, F; Vanhagendoren, S; De Meester, A; Marcovitch, O; Allaf, E; Gits, F; Verrostte, J; Thoeng, J; Quinonez, M; Appeltants, H; D'Hooghe, G; Eycken, M; Swennen, I; Hollanders, G; Michael, E; Decroly, P; Rombaut, E; Carlaire, D; Vermander, D; Marenne, SF; Gavray, C; Michel, P; Poth, A; Paquay, J; Lutasu, S; Dirk, D; Vermeulen, J; Govaerts, E; Boldueva, S; Sherenkov, A; Ruda, M; Kostenko, V; Tereschenko, S; Zalevsky, G; Boyarkin, M; Tankhilevitch, B; Glezer, M; Gratsiansky, N; Shlyakhto, E; Sidorenko, B; Zadiontchenko, V; Perepech, N; Gruzdev, A; Chernov, S; Pollock, B; Andresen, D; Hoffmann, S; Andresen, D; Arntz, H; Klein, H; Neuss, H; Wilhelms, E; Henzgen, R; Kuckuck, H; Darius, H; Hausdorf, C; Ochs, H; Olbrich, H; Willenbrock, R; Hepp, A; Wucherpfennig, P; Wiechmann, H; Schmidtendorf, H; Kohler, B; Sehnert, W; Ueberreiter, A; Uebis, R; Stockmann, M; Rommele, U; Meissner, A; Schneider, L; Adgey, J; McAllister, T; McEneaney, D; Mackin, A; Sulke, N; Dixon, R; Wilcox, R; Congreave, S; Flapan, A; Flint, L; Purvis, J; McCorkell, G; Stubbs, P; Steer, C; McKkee, P; Senior, R; Chester, L; Levy, T; Kennard, S; Bishop, A; Hlaing, S; de Belder, M; Cunningham, N; Gilbert, T; Young, J; Henderson, R; Falcon-Lang, D; Gershlick, A; Fairbrother, K; Rosenfeld, T; Atar, S; Lewis, B; Yuval, R; Meisel, S; Alony, I; Rozenman, Y; Logrineuko, S; Goldhammer, E; Harel, S; David, D; Erez, N; Jafari, J; Tubul, O; Marmor, A; Pritulo, L; Caspi, A; Roitberg, N; Kaluski, E; Amar, R; Tzivoni, D; Rojanski, A; Yedid-Am, S; Keren, A; Datiashvily, L; Saraiva, JK; Garcia, CT; Markman, M; Chaves, A; Vaz, RC; Dutra, O; Coelho, OR; Sciampaglia, R; da Cunha, CP; de Brito, MR; Lotufo, P; Ribeiro, E; Cicogna, A; Michalaros, YL; Ornellas, CE; Santos, SCD; Rosatelli, P; Pimentel, W; Grudzinski, M; Guimaraes, F; Gustavo, C; Moreira, M; Gosmao, J; Hertzberger, D; Schut, A; van der Zwaan, C; Havenaar, H; van Wijngaarden, J; Verheij, H; Wajon, E; Bosschaart, M; Oomen, A; Daniels, M; Coppes, A; Vergeught, F; Dieker, H; Jochemsen, D; Fijlstra, I; Leenders, C; Gelder, T; Janicke, D; Bass, J; Hamroff, G; Keeler, K; Chandra, M; Van Hoose, B; Minor, S; Mock, P; Chandra, M; Olliges, M; Unwala, A; Fisher, C; French, W; Barillas, O; Chandna, H; Holly, D; Chandna, H; Holly, D; Grewal, G; Gurnsey, L; Mehta, P; Cruse, A; Perlman, R; Palazzo, D; Puma, J; Payne, C; Torres, J; Patten, L; Lefkovic, L; Viswanathan, N; Rees, A; Yoches, A; Rodriguez-Ospina, L; Santos, J; Chohan, A; Kemp, A; Perlman, R; Palazzo, D; Weiss, R; Brennan, B; Aude, Y; Harrison, P; Brogan, G; Ayan, J; Cragg, D; Murawka, A; Garg, M; McKelvy, J; Hulyalkar, A; Kuchenrither, C; Jackson, S; Whitaker, J; Richardson, J; Vicari, R; Howard, M; Aude, Y; Harrison, P; Chadow, H; Hauptman, R; Gelormini, J; Giambra, T; Lakkis, N; Jiang, S; Hernandez, I; Vazquez, A; Rosas, EL; Lawrenz, JC; Bustamante, F; Martinez, CA; Alcocer, MA; Hernandez, EG; Dogre, CW; Bustillos, MDB; Alvarado, R; Ramirez, MC; Hinojosa, P; Rivera, OO; Pons, JL; Carrillo, J; Velasco, JA; Quintana, F; Petersen, F; Palomera, R; Ibarra, M; Sanchez, CJ; Delgado, L; Bayram, E; Machado, GM; Berli, MA; Vinuela, JC; Allall, O; Fuentealba, V; Reguero, M; Covelli, G; San Martin, E; Francia, E; Gadaleta, F; Haehnel, M; Iglesias, R; Blumberg, S; de Lima, AA; Henquin, R; Estrada, JN; de Arenaza, D; Fernandez, R; Abud, M; Becker, C; Milesi, R; Schamuck, R; Doyharzabal, JM; Caime, DG; Teresa, LC; Kuschnir, E; Sgammini, H; Sgammini, J; David, J; Sosa, CH; Redcozub, E; Avalos, V; Nul, D; Ramos, S; Castro, PT; Rodriguez, A; Sosa, C; Lopez, JG; Novo, F; Diez, F; Piraino, R; Godoy, G; Weller, C; Pomposiello, J; Sanchez, A; Karlsson, J; Collberg, K; Malmqvist, K; Cedergren, E; Dellborg, M; Coops, G; Kallryd, A; Laudon, P; Bandh, S; Andersson, C; Soome, S; Classon, H; Lugnegard, J; Ahlmark, H; Risenfors, M; Ortgren, L; Fjelstad, B; Osberg, S; Frisell, J; Sandstrom, M; Silvestri, O; Sasso, A; Rolli, A; Paoli, G; Chiarella, F; Olivotte, L; Doronzo, B; Coppolino, A; Pivoccari, G; Pesaresi, A; Ambrosio, G; Del Pinto, M; De Luca, I; Laico, M; De Ferrari, G; Baldini, E; Guiducci, U; Tortorella, G; Romano, M; Villani, R; Casazza, F; Capozi, A; Moretti, L; Del Pinto, M; Perelli, S; Sinagra, G; Maras, P; Porcu, M; Scorcu, G; Proietti, F; Severi, S; Gessek, J; Pawlowicz, L; Szelemej, R; Gorski, M; Janion, M; Sielski, J; Kleinrok, A; Rodzik, J; Hiczkiewicz, J; Pasler, MM; Soltsiak, M; Gorny, J; Huber, K; Jordanova, N; Heigert, M; Kopp, K; Frank, H; Laggner, A; Schreiber, W; Weihs, W; Drexel, MH; Doubell, A; Burgess, L; Bennett, J; Snyders, F; Ebrahim, I; Bobak, C; Marx, J; deBeer, M; Schmidt, S; Cyster, H; van der Berg, P; Groenewald, W; Herbst, L; Britz, A; Snyman, M; Schonken, M; Badenhorst, J; Blomerus, P; Mpe, M; Bobak, C; Mynhardt, J; Groenewald, C; van Dyk, C; Meiring, J; Steingo, L; Glaeser, L; Whelan, A; Tulloch, G; Gunalingham, B; Conway, B; Soward, A; Hales, S; Lefkovits, J; Sallaberger, M; Owesby, D; Kesby, J; Amerena, J; Fogarty, K; Chew, D; Austin, M; Kovaricek, S; Banham, N; Tulloch, G; Jobbagy, L; Dinnyes, J; Lippai, J; Oze, B; Szakal, I; Bartal, G; Foldi, A; Foley, D; McGrath, F; Meany, B; Geraghty, M; Daly, K; Henessey, S; Mulvihill, N; Schilling, C; Kearney, P; Kelly, P; Kearney, P; Kelly, P; Ongen, Z; Vura, A; Kozan, O; Ozaydin, E; Kultursay, H; Kayikcioglu, M; Degertekin, M; Mutlu, B; Monteiro, F; Ferreira, D; Carrageta, M		CLARITY-TIMI 28 Investigators	Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REPERFUSION THERAPY; PLASMINOGEN-ACTIVATOR; FOLLOW-UP; THROMBOLYSIS; TIMI; HEPARIN; REOCCLUSION; RATIONALE; DESIGN	BACKGROUND: A substantial proportion of patients receiving fibrinolytic therapy for myocardial infarction with ST-segment elevation have inadequate reperfusion or reocclusion of the infarct-related artery, leading to an increased risk of complications and death. METHODS: We enrolled 3491 patients, 18 to 75 years of age, who presented within 12 hours after the onset of an ST-elevation myocardial infarction and randomly assigned them to receive clopidogrel (300-mg loading dose, followed by 75 mg once daily) or placebo. Patients received a fibrinolytic agent, aspirin, and when appropriate, heparin (dispensed according to body weight) and were scheduled to undergo angiography 48 to 192 hours after the start of study medication. The primary efficacy end point was a composite of an occluded infarct-related artery (defined by a Thrombolysis in Myocardial Infarction flow grade of 0 or 1) on angiography or death or recurrent myocardial infarction before angiography. RESULTS: The rates of the primary efficacy end point were 21.7 percent in the placebo group and 15.0 percent in the clopidogrel group, representing an absolute reduction of 6.7 percentage points in the rate and a 36 percent reduction in the odds of the end point with clopidogrel therapy (95 percent confidence interval, 24 to 47 percent; P<0.001). By 30 days, clopidogrel therapy reduced the odds of the composite end point of death from cardiovascular causes, recurrent myocardial infarction, or recurrent ischemia leading to the need for urgent revascularization by 20 percent (from 14.1 to 11.6 percent, P=0.03). The rates of major bleeding and intracranial hemorrhage were similar in the two groups. CONCLUSIONS: In patients 75 years of age or younger who have myocardial infarction with ST-segment elevation and who receive aspirin and a standard fibrinolytic regimen, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications.	Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Hosp Univ Gregorio Maranon, Madrid, Spain; Hop La Pitie Salpetriere, Inst Cardiol, Paris, France; Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; Univ Antwerp Hosp, Dept Cardiol, Edegem, Belgium; Acad Ziekenhuis Klina, Brasschaat, Belgium; Nottingham Clin Res Grp, Nottingham, England	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; General University Gregorio Maranon Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite de Montreal; University of Antwerp	Sabatine, MS (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	msabatine@partners.org	Verheugt, F.W.A./H-8105-2014; saini, renu/GRR-2088-2022; Sinagra, Gianfranco/AAE-3943-2020; Ongen, Zeki/AAD-1179-2021; Sabatine, Marc/AAJ-6751-2020; Kucherlapati, Raju/ABC-8807-2021; Lotufo, Paulo/A-9843-2008; Lenguas, José Antonio Casasnovas/F-4038-2010; Gibson, C. Michael/AAE-8212-2019; Boldueva, Svetlana/AAH-3862-2019; Nicolau, Jose C/E-1487-2012; Lima, Thaísa/AAG-6483-2021; Ardissino, Diego/AAC-4041-2022; Cannon, Christopher P/AAY-7644-2020; Wiviott, Stephen/HIK-2534-2022; Lopez de Sa, Esteban/AAY-2627-2021; Fiol, Miguel/F-6793-2016; KAYIKCIOGLU, Meral/AAH-6687-2020; Meisel, Simcha/AAH-8985-2021; Claeys, Marc/ABH-8781-2020; Kaluski, Edo/Q-1972-2019; Ambrosio, Giuseppe/C-6596-2013	Sabatine, Marc/0000-0002-0691-3359; Lotufo, Paulo/0000-0002-4856-8450; Lenguas, José Antonio Casasnovas/0000-0002-9887-2629; Boldueva, Svetlana/0000-0002-1898-084X; Nicolau, Jose C/0000-0002-9680-3689; Cannon, Christopher P/0000-0003-4596-2791; Lopez de Sa, Esteban/0000-0002-3504-6901; Fiol, Miguel/0000-0002-5370-1391; Kaluski, Edo/0000-0002-1400-3988; Ambrosio, Giuseppe/0000-0002-9677-980X; Budaj, Andrzej/0000-0002-6395-2098; MELCHOR, LORENZO/0000-0002-8685-268X; Claeys, Marc/0000-0002-6628-9543; Aylward, Philip/0000-0002-5358-8552; Chew, Derek/0000-0003-3593-296X	NHLBI NIH HHS [R01 HL072879] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072879] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; Antman Elliott M., 2004, J Am Coll Cardiol, V44, pE1, DOI 10.1016/j.jacc.2004.07.014; Antman EM, 2005, AM HEART J, V149, P217, DOI 10.1016/j.ahj.2004.08.038; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; BOVILL EG, 1991, ANN INTERN MED, V115, P256, DOI 10.7326/0003-4819-115-4-256; BRAUNWALD E, 1993, NEW ENGL J MED, V329, P1650, DOI 10.1056/NEJM199311253292211; Cannon CP, 1997, AM J CARDIOL, V80, P696, DOI 10.1016/S0002-9149(97)00497-9; *CLOP UNST ANG PRE, 2001, NEW ENGL J MED, V345, P1716; *CLOP UNST ANG PRE, 2001, NEW ENGL J MED, V345, P1506; DALEN JE, 1988, AM J CARDIOL, V62, P179, DOI 10.1016/0002-9149(88)90208-1; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gibson CM, 2000, CIRCULATION, V101, P125, DOI 10.1161/01.CIR.101.2.125; Giugliano RP, 2001, AM HEART J, V141, P742, DOI 10.1067/mhj.2001.114975; Herbert JM, 1998, THROMB HAEMOSTASIS, V80, P512; Liu LS, 2000, J CARDIOVASC RISK, V7, P435; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; MUELLER HS, 1995, J AM COLL CARDIOL, V26, P900, DOI 10.1016/0735-1097(95)00270-1; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; Patrono C, 2004, CHEST, V126, p234S, DOI 10.1378/chest.126.3_suppl.234S; Quinn MJ, 1999, CIRCULATION, V100, P1667, DOI 10.1161/01.CIR.100.15.1667; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Sabatine MS, 2005, AM HEART J, V149, P227, DOI 10.1016/j.ahj.2004.11.006; Steinhubl SR, 2003, JAMA-J AM MED ASSOC, V289, P987; The GUSTO Angiographic Investigators, 1994, NEW ENGL J MED, V330, P516; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2001, LANCET, V357, P1905; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 2001, LANCET, V358, P605; YASUDA T, 1990, J AM COLL CARDIOL, V16, P1728, DOI 10.1016/0735-1097(90)90327-L; Yusuf S, 2001, NEW ENGL J MED, V345, P494	33	1357	1492	0	70	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1179	1189		10.1056/NEJMoa050522	http://dx.doi.org/10.1056/NEJMoa050522			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15758000				2023-01-03	WOS:000227832300004
J	Escobar-Morreale, HF; Botella-Carretero, JI; Gomez-Bueno, M; Galan, JM; Barrios, V; Sancho, J				Escobar-Morreale, HF; Botella-Carretero, JI; Gomez-Bueno, M; Galan, JM; Barrios, V; Sancho, J			Thyroid hormone replacement therapy in primary hypothyroidism: A Randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone	ANNALS OF INTERNAL MEDICINE			English	Article							NOTTINGHAM HEALTH PROFILE; QUALITY-OF-LIFE; SPANISH VERSION; THYROIDECTOMIZED RATS; TRIIODOTHYRONINE; LEVOTHYROXINE; BIOAVAILABILITY; QUESTIONNAIRE; EUTHYROIDISM; CARCINOMA	Background: Substituting part of the dose of L-thyroxine with small but supraphysiologic doses of liothyronine in hypothyroid patients has yielded conflicting results. Objective: To evaluate combinations of L-thyroxine plus liothyronine in hypothyroid patients that match the proportions present in normal secretions of the human thyroid gland. Design: Randomized, double-blind, crossover trial. Setting: Academic research hospital. Participants: 28 women with overt primary hypothyroidism. Intervention: Crossover trial comparing treatment with L-thyroxine, 100 mu g/d (standard treatment), versus treatment with L-thyroxine, 75 mu g/d, plus liothyronine, 5 mu g/d (combination treatment), for 8-week periods. All patients also received L-thyroxine, 87.5 mu g/d, plus liothyronine, 7.5 mu g/d (add-on combination treatment), for a final 8-week add-on period. Measurements: Primary outcomes included serum thyroid hormone levels, results of quality-of-life and psychometric tests, and patients' preference. Multiple biological thyroid hormone end points were studied as secondary outcomes. Results: Compared with standard treatment, combination treatment led to lower free thyroxine levels (decrease, 3.9 pmol/L [95% CI, 2.5 to 5.3 pmol/L]), slightly higher serum levels of thyroid-stimulating hormone (increase, 0.62 mU/L [CI, 0.01 to 1.23 mU/L]), and unchanged free triiodothyronine levels. No improvement was observed in the other primary and secondary end points after combination treatment, with the exception of the Digit Span Test, in which the mean backward score and the mean total score increased slightly (0.6 digit [CI, 0.1 to 1.0 digit] and 0.8 digit [CI, 0.2 to 1.4 digits], respectively). The add-on combination treatment resulted in overreplacement. Levels of thyroidstimulating hormone decreased by 0.85 mU/L (CI, 0.27 to 1.43 mU/L and serum free triiodothyronine levels increased by 0.8 pmol/L (CI, 0.1 to 1.5 pmol/L compared with standard treatment; 10 patients had levels of thyroid-stimulating hormone that were below the normal range. Twelve patients preferred combination treatment, 6 patients preferred the add-on combination treatment, 2 patients preferred standard treatment, and 6 patients had no preference (P = 0.015). Limitations: Treatment with L-thyroxine, 87.5 mu g/d, plus liothyronine, 7.5 mu g/d, was an add-on regimen and was not randomized. Conclusions: Physiologic combinations of L-thyroxine plus liothyronine do not offer any objective advantage over L-thyroxine alone, yet patients prefer combination treatment.	Hosp Ramon & Cajal, Dept Endocrinol, E-28034 Madrid, Spain	Hospital Universitario Ramon y Cajal	Escobar-Morreale, HF (corresponding author), Hosp Ramon & Cajal, Dept Endocrinol, Carretera Colmenar Km 91, E-28034 Madrid, Spain.	hescobarm.hrc@salud.madrid.org	Botella-Carretero, Jose I./DGQ-8720-2022; Escobar-Morreale, Héctor F/G-5468-2010; Sancho, Juan J/H-1771-2013; SANCHO-INSENSER, JUAN-JOSE/AAH-8777-2021	Escobar-Morreale, Héctor F/0000-0002-6890-1644; Gomez-Bueno, Manuel/0000-0002-9764-7518; Botella-Carretero, Jose I./0000-0002-6425-2747				Alonso J, 1998, MED CLIN-BARCELONA, V111, P410; ALONSO J, 1990, AM J PUBLIC HEALTH, V80, P704, DOI 10.2105/AJPH.80.6.704; ALONSO J, 1994, QUAL LIFE RES, V3, P385, DOI 10.1007/BF00435390; Botella-Carretero JI, 2004, ENDOCR-RELAT CANCER, V11, P345, DOI 10.1677/erc.0.0110345; Botella-Carretero JI, 2003, ENDOCR-RELAT CANCER, V10, P601, DOI 10.1677/erc.0.0100601; Bullinger M, 1998, J CLIN EPIDEMIOL, V51, P913, DOI 10.1016/S0895-4356(98)00082-1; Bunevicius R, 2000, INT J NEUROPSYCHOPH, V3, P167, DOI 10.1017/S1461145700001826; Bunevicius R, 2002, ENDOCRINE, V18, P129, DOI 10.1385/ENDO:18:2:129; Bunevicius R, 1999, NEW ENGL J MED, V340, P424, DOI 10.1056/NEJM199902113400603; Celesia G G, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P53; Clyde PW, 2003, JAMA-J AM MED ASSOC, V290, P2952, DOI 10.1001/jama.290.22.2952; Cooper DS, 2003, JAMA-J AM MED ASSOC, V290, P3002, DOI 10.1001/jama.290.22.3002; DEESCOBAR GM, 1976, REGULATION THYROID F, V1, P109; Escobar-Morreale HF, 1999, BIOCHIMIE, V81, P453, DOI 10.1016/S0300-9084(99)80095-9; EscobarMorreale HF, 1996, ENDOCRINOLOGY, V137, P2490, DOI 10.1210/en.137.6.2490; EscobarMorreale HF, 1995, J CLIN INVEST, V96, P2828, DOI 10.1172/JCI118353; FISH LH, 1987, NEW ENGL J MED, V316, P764, DOI 10.1056/NEJM198703263161302; FLEISS JL, 1986, CROSSOVER STUDY, P263; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Hennemann G, 2004, THYROID, V14, P271, DOI 10.1089/105072504323030924; KAPLAN E, 1991, WAIS R NI NEUROPSYCH; Kaplan MM, 2003, J CLIN ENDOCR METAB, V88, P4540, DOI 10.1210/jc.2003-031436; Ladenson PW, 2002, CLIN ENDOCRINOL, V57, P575, DOI 10.1046/j.1365-2265.2002.01682.x; LEBOFF MS, 1982, METABOLISM, V31, P900, DOI 10.1016/0026-0495(82)90179-2; McNair D.M., 1992, POMS MANUAL PROFILE; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PILO A, 1990, AM J PHYSIOL, V258, pE715, DOI 10.1152/ajpendo.1990.258.4.E715; Pratt H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P69; Saravanan P, 2002, CLIN ENDOCRINOL, V57, P577, DOI 10.1046/j.1365-2265.2002.01654.x; Sawka AM, 2003, J CLIN ENDOCR METAB, V88, P4551, DOI 10.1210/jc.2003-030139; Siegmund W, 2004, CLIN ENDOCRINOL, V60, P750, DOI 10.1111/j.1365-2265.2004.02050.x; SMITH RN, 1970, BRIT MED J, V4, P145, DOI 10.1136/bmj.4.5728.145; Toft AD, 1999, NEW ENGL J MED, V340, P469, DOI 10.1056/NEJM199902113400611; Tudor G, 1994, Stat Methods Med Res, V3, P345, DOI 10.1177/096228029400300404; Utiger RD, 1995, ENDOCRINOLOGY, P752; Walsh JP, 2003, J CLIN ENDOCR METAB, V88, P4543, DOI 10.1210/jc.2003-030249; Wechsler D., 1981, WAIS R MANUAL WECHSL; Wechsler D, 2003, WAIS 3 ESCALA INTELI; Weintraub S., 1985, PRINCIPLES BEHAV NEU, P71; Zulewski H, 1997, J CLIN ENDOCR METAB, V82, P771, DOI 10.1210/jc.82.3.771	40	110	115	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	2005	142	6					412	424		10.7326/0003-4819-142-6-200503150-00007	http://dx.doi.org/10.7326/0003-4819-142-6-200503150-00007			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906DQ	15767619				2023-01-03	WOS:000227621100003
J	Muss, HB; Woolf, S; Berry, D; Cirrincione, C; Weiss, RB; Budman, D; Wood, WC; Henderson, IC; Hudis, C; Winer, E; Cohen, H; Wheeler, J; Norton, L				Muss, HB; Woolf, S; Berry, D; Cirrincione, C; Weiss, RB; Budman, D; Wood, WC; Henderson, IC; Hudis, C; Winer, E; Cohen, H; Wheeler, J; Norton, L		Canc Leukemia Grp B	Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED-TRIAL; ELDERLY-PATIENTS; DOSE-INTENSITY; CYCLOPHOSPHAMIDE; METHOTREXATE; TOXICITY; AGE; FLUOROURACIL; THERAPY; COMORBIDITY	Context Adjuvant chemotherapy improves survival for patients with local-regional breast cancer, but healthy older patients at high risk of recurrence are frequently not offered adjuvant chemotherapy, and the benefit of adjuvant chemotherapy in older patients is uncertain. Objective To compare the benefits and toxic effects of adjuvant chemotherapy among breast cancer patients in age groups of 50 years or younger, 51 to 64 years, and 65 years or older. Design and Setting Retrospective review of data from 4 randomized trials that accrued patients from academic and community medical centers between 1975 and 1999. Median follow-up for all patients was 9.6 years. All trials randomized patients to different regimens, doses, schedules, and durations of chemotherapy and all had a treatment arm with doses or schedules that were regarded to be "high" and potentially more toxic. Patients A total of 6487 women with lymph node-positive breast cancer; 542 (8%) patients were 65 years or older and 159 (2 %) were 70 years or older. Main Outcome Measure Comparison of disease-free survival, overall survival, and treatment-related mortality among different age groups. Results Multivariate analysis showed that smaller tumor size, fewer positive lymph nodes, more chemotherapy, and tamoxifen use were all significantly (P<.001) related to longer disease-free and overall survival. There was no association between age and disease-free survival. Overall survival was significantly (P<.001) worse for patients aged 65 or older because of death from causes other than breast cancer. Thirty-three deaths (0.5% of all patients) were attributed to treatment, and older women had higher treatment-related mortality. Older women and younger women derived Similar reductions in breast cancer mortality and recurrence from regimens containing more chemotherapy. Conclusion Age alone should not be a contraindication to the use of optimal chemotherapy regimens in older women who are in good general health.	Univ Vermont, Vermont Canc Ctr, Fletcher Allen Hlth Care, Burlington, VT 05401 USA; Canc & Leukemia Grp B Stat Ctr, Durham, NC USA; Duke Univ, Med Ctr, Durham, NC USA; Vet Adm Med Ctr, Durham, NC USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Georgetown Univ, Med Ctr, Washington, DC 20007 USA; NYU, N Shore Univ Hosp, Manhasset, NY USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Emory Univ, Sch Med, Atlanta, GA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of Vermont; University of Vermont Medical Center; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; UTMD Anderson Cancer Center; Georgetown University; New York University; Northwell Health; North Shore University Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Emory University; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center	Muss, HB (corresponding author), Univ Vermont, Vermont Canc Ctr, Fletcher Allen Hlth Care, UHC Campus,St Joseph 3400,1 S Prospect St, Burlington, VT 05401 USA.	hyman.muss@uvm.edu	Hudis, Clifford/AAW-9482-2021	Hudis, Clifford/0000-0001-7144-8791; Norton, Larry/0000-0003-3701-9250	NATIONAL CANCER INSTITUTE [U10CA060247, U10CA060138, U10CA016450, U10CA047555, U10CA045389, U10CA037135, U10CA008025, U10CA047559, U10CA074811, U10CA004326, U10CA047577, U10CA035279, U10CA035421, U10CA011028, U10CA007968, U10CA031946, U10CA045564, U10CA045808, U10CA077597, U10CA077298, U10CA026806, U10CA011789, U10CA031983, U10CA031809, U10CA025224, U10CA045374, U10CA033601, U10CA012046, U10CA021060, U10CA052784, U10CA041287, U10CA003927, U10CA054697, U10CA012011, U10CA077406, U10CA012449, U10CA035091, U10CA077651, U10CA032291, U10CA032102, U10CA002599, U10CA047642, U10CA004457, U10CA047545, U10CA021115, U10CA045418] Funding Source: NIH RePORTER; NCI NIH HHS [CA02599, CA03927, CA04326, CA04457, CA07968, CA08025, CA11028, CA11789, CA12011, CA12046, CA12449, CA16450, CA21060, CA21115, CA25224, CA26806, CA31809, CA31946, CA31983, CA32102, CA32291, CA33601, CA35091, CA35279, CA35421, CA37135, CA41287, CA45374, CA45389, CA45418, CA45564, CA45808, CA47515, CA47545, CA47555, CA47559, CA47577, CA47642, CA52784, CA54697, CA60138, CA60247, CA71323, CA74811, CA77298, CA77406, CA77440, CA77597, CA77651] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 1998, LANCET, V352, P930; *AM JOINT COMM CAN, 1997, CANC STAG MAN; BEGG CB, 1980, CANCER CLIN TRIALS, V3, P369; BONNETERRE JM, 2002, P AN M AM SOC CLIN, V21, pA39; Budman DR, 1998, J NATL CANCER I, V90, P1205, DOI 10.1093/jnci/90.16.1205; CHRISTMAN K, 1992, JAMA-J AM MED ASSOC, V268, P57, DOI 10.1001/jama.268.1.57; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Clarke M, 1998, LANCET, V351, P1451; Crivellari D, 2000, J CLIN ONCOL, V18, P1412, DOI 10.1200/JCO.2000.18.7.1412; Dees EC, 2000, CANCER INVEST, V18, P521, DOI 10.3109/07357900009012191; DESCH CE, 1993, J CLIN ONCOL, V11, P777, DOI 10.1200/JCO.1993.11.4.777; Du XLL, 2003, ANN INTERN MED, V138, P90, DOI 10.7326/0003-4819-138-2-200301210-00009; Du XLL, 2002, J CLIN ONCOL, V20, P4636, DOI 10.1200/JCO.2002.05.088; Extermann M, 2000, J CLIN ONCOL, V18, P1709, DOI 10.1200/JCO.2000.18.8.1709; GELMAN RS, 1984, J CLIN ONCOL, V2, P1404, DOI 10.1200/JCO.1984.2.12.1404; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Holmes CE, 2003, CA-CANCER J CLIN, V53, P227, DOI 10.3322/canjclin.53.4.227; Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706; Ibrahim NK, 1996, ARCH INTERN MED, V156, P882, DOI 10.1001/archinte.156.8.882; Kemeny MM, 2003, J CLIN ONCOL, V21, P2268, DOI 10.1200/JCO.2003.09.124; Kimmick GG, 2001, ONCOLOGY-NY, V15, P280; Levine MN, 1998, J CLIN ONCOL, V16, P2651, DOI 10.1200/JCO.1998.16.8.2651; Lichtman SM, 2000, ONCOLOGY-NY, V14, P1743; Lyman GH, 2003, J CLIN ONCOL, V21, P4524, DOI 10.1200/JCO.2003.05.002; Perloff M, 1996, J CLIN ONCOL, V14, P1589, DOI 10.1200/JCO.1996.14.5.1589; SATARIANO WA, 1994, ANN INTERN MED, V120, P104, DOI 10.7326/0003-4819-120-2-199401150-00002; Sateren WB, 2002, J CLIN ONCOL, V20, P2109, DOI 10.1200/JCO.2002.08.056; Thor AD, 1998, JNCI-J NATL CANCER I, V90, P1346, DOI 10.1093/jnci/90.18.1346; Weiss RB, 2003, J CLIN ONCOL, V21, P1825, DOI 10.1200/JCO.2003.09.006; Yancik R, 2000, HEMATOL ONCOL CLIN N, V14, P17, DOI 10.1016/S0889-8588(05)70275-6; Yancik R, 2001, JAMA-J AM MED ASSOC, V285, P885, DOI 10.1001/jama.285.7.885	31	308	314	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	2005	293	9					1073	1081		10.1001/jama.293.9.1073	http://dx.doi.org/10.1001/jama.293.9.1073			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901LY	15741529				2023-01-03	WOS:000227285200017
J	Morrison, LJ; Visentin, LM; Kiss, A; Theriault, R; Eby, D; Vermeulen, M; Sherbino, J; Verbeek, PR				Morrison, Laurie J.; Visentin, Laura M.; Kiss, Alex; Theriault, Rob; Eby, Don; Vermeulen, Marian; Sherbino, Jonathan; Verbeek, P. Richard		TOR Investigators	Validation of a rule for termination of resuscitation in out-of-hospital cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the National-Association-of-Emergency-Medical-Services-Physicians	JAN   20, 2006	Tucson, AZ	Natl Assoc Emergency Med Serv Physicians			AMERICAN-HEART-ASSOCIATION; CLINICAL-PREDICTION RULES; CARDIOPULMONARY-RESUSCITATION; LIFE-SUPPORT; METHODOLOGICAL STANDARDS; EMERGENCY; FUTILITY; CARE; GUIDELINES	BACKGROUND: We prospectively evaluated a clinical prediction rule to be used by emergency medical technicians (EMTs) trained in the use of an automated external defibrillator for the termination of basic life support resuscitative efforts during out-of-hospital cardiac arrest. The rule recommends termination when there is no return of spontaneous circulation, no shocks are administered, and the arrest is not witnessed by emergency medical-services personnel. Otherwise, the rule recommends transportation to the hospital, in accordance with routine practice. METHODS: The study included 24 emergency medical systems in Ontario, Canada. All patients 18 years of age or older who had an arrest of presumed cardiac cause and who were treated by EMTs trained in the use of an automated external defibrillator were included. The patients were treated according to standard guidelines. Characteristics of diagnostic tests for the prediction rule were calculated. These characteristics include sensitivity, specificity, and positive and negative predictive values. RESULTS: Follow-up data were obtained for all 1240 patients. Of 776 patients with cardiac arrest for whom the rule recommended termination, 4 survived (0.5 percent). The rule had a specificity of 90.2 percent for recommending transport of survivors to the emergency department and had a positive predictive value for death of 99.5 percent when termination was recommended. Implementation of this rule would result in a decrease in the rate of transportation from 100 percent of patients to 37.4 percent. The addition of other criteria (a response interval greater than eight minutes or a cardiac arrest not witnessed by a bystander) would further improve both the specificity and positive predictive value of the rule but would result in the transportation of a larger proportion of patients. CONCLUSIONS: The use of a clinical prediction rule for the termination of resuscitation may help clinicians decide whether to terminate basic life support resuscitative efforts in patients having an out-of-hospital cardiac arrest.	Sunnybrook & Womens Coll Hlth Sci Ctr, Prehosp & Transport Med Res Program, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Res Design & Biostat, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Sunnybrook Osler Ctr Prehosp Care, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Univ Toronto, Dept Med, Div Emergency Med, Toronto, ON, Canada; Inst Clin & Evaluat Studies, Toronto, ON, Canada; Owen Sound Hosp, Grey Bruce Hlth Serv, Grey Bruce Huron Paramed Base Hosp Program, Owen Sound, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto	Morrison, LJ (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Prehosp & Transport Med Res Program, Toronto, ON, Canada.		Morrison, Laurie Jean/A-6325-2012	Morrison, Laurie Jean/0000-0001-8369-9774				Ardagh M, 2000, J MED ETHICS, V26, P396, DOI 10.1136/jme.26.5.396; Bailey E D, 2000, Prehosp Emerg Care, V4, P190, DOI 10.1080/10903120090941498; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; BONNIN MJ, 1989, ANN EMERG MED, V18, P507, DOI 10.1016/S0196-0644(89)80834-0; Cheung M, 2001, CJEM, V3, P19; Clawson J J, 1997, Prehosp Disaster Med, V12, P274; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; Delbridge TR, 1996, ANN EMERG MED, V27, P649, DOI 10.1016/S0196-0644(96)70170-1; Eckstein M, 2005, ACAD EMERG MED, V12, P65, DOI 10.1197/j.aem.2004.07.020; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; FINLAY I, 1991, BRIT MED J, V302, P1524, DOI 10.1136/bmj.302.6791.1524; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; Helft PR, 2000, NEW ENGL J MED, V343, P293, DOI 10.1056/NEJM200007273430411; Hick JL, 1998, ANN EMERG MED, V32, P19, DOI 10.1016/S0196-0644(98)70094-0; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; JECKER NS, 1993, ARCH INTERN MED, V153, P2195, DOI 10.1001/archinte.153.19.2195; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; Mayfield T, 1998, JEMS, V23, P50; Morrison Laurie J, 2005, Prehosp Emerg Care, V9, P14, DOI 10.1080/10903120590891679; Morrison LJ, 2003, ACAD EMERG MED, V10, P633, DOI 10.1197/aemj.10.6.633; *NAT ASS EMS DIR, 1994, DO NUT RES DNR PROGR; Pepe P E, 2001, Prehosp Emerg Care, V5, P79, DOI 10.1080/10903120190940399; Petrie D A, 2001, CJEM, V3, P186; Safar PBN, 1988, CARDIOPULMONARY CERE; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SMITH JP, 1985, ANN EMERG MED, V14, P1093; Stiell IG, 1999, ANN EMERG MED, V34, P256, DOI 10.1016/S0196-0644(99)70241-6; Suchard JR, 1999, J EMERG MED, V17, P801, DOI 10.1016/S0736-4679(99)00086-4; VANDERHOEVEN JG, 1993, ANN EMERG MED, V22, P1659, DOI 10.1016/S0196-0644(05)81303-4; Verbeek PR, 2002, ACAD EMERG MED, V9, P671, DOI 10.1197/aemj.9.7.671; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; 2000, CIRCULATION S1, V102, P12; 2005, CIRCULATION S4, V112, pR1; 2000, CIRCULATION S1, V102, P60	39	223	224	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					478	487		10.1056/NEJMoa052620	http://dx.doi.org/10.1056/NEJMoa052620			10	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885551				2023-01-03	WOS:000239432500007
J	Falagas, ME; Zarkadoulia, EA; Samonis, G				Falagas, Matthew E.; Zarkadoulia, Effie A.; Samonis, George			Arab science in the golden age (750-1258 CE) and today	FASEB JOURNAL			English	Editorial Material									Alfa Inst Biomed Sci, Maroussi 15123, Greece; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Univ Crete, Sch Med, Dept Med, Iraklion, Crete, Greece	Alfa Institute Of Biomedical Sciences; Tufts University; University of Crete	Falagas, ME (corresponding author), Alfa Inst Biomed Sci, 9 Neapoleos St, Maroussi 15123, Greece.	m.falagas@aibs.gr						Bliziotis IA, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-16; HADDAD FS, 1993, B SOC LIBAN HIST MED, V1, P21; HADDAD FS, 1993, B SOC LIBAN HIST MED, V3, P74; HEAD HA, HIST ISLAMIC SCI, V2; *HOR MANN AC MIDDL, SCI CULT MED ISL C 1; *HOR MANN AC MIDDL, SCI CULT MED ISL C 4; *NAT LIB MED, 1998, ISL CULT MED ARTS; *OSW CIT SCH DISTR, GOLD AG ISL; Shaban SF, 2003, SAUDI MED J, V24, P294; Soteriades ES, 2005, BRIT MED J, V331, P192, DOI 10.1136/bmj.331.7510.192; SYED IB, ISLAMIC MED; Tadmouri GO, 2004, SAUDI MED J, V25, P7; *WORLD BANK, 2004, WORLD DEV IND 2002; Zetterstrom R, 2002, ACTA PAEDIATR, V91, P1020, DOI 10.1080/080352502760311467; ISLAM ISLAMIC HIST A	15	25	25	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1581	1586		10.1096/fj.06-0803ufm	http://dx.doi.org/10.1096/fj.06-0803ufm			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873881				2023-01-03	WOS:000240266600003
J	Donley-Hayes, K				Donley-Hayes, Karen			At face value	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											No Org, W Farmington, OH 44491 USA.	kdonley@bright.net							0	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	2006	295	23					2701	2702		10.1001/jama.295.23.2701	http://dx.doi.org/10.1001/jama.295.23.2701			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	054OZ	16788117				2023-01-03	WOS:000238389700001
J	Chan, AW; Upshur, R; Singh, JA; Ghersi, D; Chapuis, F; Altman, DG				Chan, AW; Upshur, R; Singh, JA; Ghersi, D; Chapuis, F; Altman, DG			Research protocols - Waiving confidentiality for the greater good	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RESEARCH ETHICS COMMITTEES; CLINICAL-RESEARCH; RANDOMIZED-TRIALS; PUBLICATION BIAS; FOLLOW-UP; FATE	Research protocols are usually kept confidential to protect intellectual and commercial interests. But secrecy can also hide deviations that affect the validity of results and threaten the integrity of medical research.	Canadian Inst Hlth Res, Randomized Controlled Trials Unit, Toronto, ON, Canada; Univ Toronto, Primary Care Res Unit, Toronto, ON, Canada; Ctr AIDS Program Res, Bioeth & Hlth Law Programme, Durban, South Africa; Univ Sydney, Natl Hlth & Med Res Council Clin Trials Ctr, Sydney, NSW 2006, Australia; Univ Lyon 1, Hosp Civils Lyon, Clin Epidemiol Unit, F-69365 Lyon, France; Canc Res UK, Oxford, England; NHS Ctr Stat Med, Oxford, England	Institute for Work & Health; University of Toronto; University of Sydney; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Cancer Research UK	Chan, AW (corresponding author), Canadian Inst Hlth Res, Randomized Controlled Trials Unit, Toronto, ON, Canada.	anwen.chan@utoronto.ca	Singh, Jerome Amir/ABG-1573-2021	Upshur, Ross/0000-0003-1128-0557				Academy of Medical Sciences, 2006, PERS DAT PUBL GOOD U; Chan AW, 2004, CAN MED ASSOC J, V171, P735, DOI 10.1503/cmaj.1041086; CHAN MHW, 1991, PHASE TRANSITION   S, V2, P1; *COMM NAT INF LIB, LOI 78 17 6 JAN 1978; Curfman GD, 2005, NEW ENGL J MED, V353, P2813, DOI 10.1056/NEJMe058314; DEANGELIS CD, 2005, JAMA; Decullier E, 2005, BMJ-BRIT MED J, V331, P19, DOI 10.1136/bmj.38488.385995.8F; *DEP HLTH, 2001, GOV ARR NHS RES ETH; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; EASTERBROOK PJ, 1992, J ROY SOC MED, V85, P71; Ghersi D, 2004, LANCET ONCOL, V5, P325, DOI 10.1016/S1470-2045(04)01473-1; GIAMMONA M, 1983, CLIN RES, V31, P572; GLASZIOU P, 2000, BRIT MED J, V328, P121; Gotzsche PC, 2006, JAMA-J AM MED ASSOC, V295, P1645, DOI 10.1001/jama.295.14.1645; Hahn S, 2002, J EVAL CLIN PRACT, V8, P353, DOI 10.1046/j.1365-2753.2002.00314.x; International Conference on Harmonisation of technical requirements for pharmaceuticals for human use (ICH), 1996, GUID GOOD CLIN PRACT; Jones G, 2004, BRIT MED J, V329, P1360, DOI 10.1136/bmj.329.7479.1360; Krleza-Jeric K, 2005, BMJ-BRIT MED J, V330, P956, DOI 10.1136/bmj.330.7497.956; LIN WT, 2000, J ASSOC INF SYST, V1, P1; Mann H, 2002, LANCET, V360, P406, DOI 10.1016/S0140-6736(02)09613-7; Marshall E, 2004, SCIENCE, V304, P1576, DOI 10.1126/science.304.5677.1576; McCabe S, 2005, PLOS MED, V2, P169, DOI 10.1371/journal.pmed.0020049; *MED RES COUNC, 2000, PERS INF MED RES; *MED RES COUNC CAN, 2003, TRIC POL STAT ETH CO; MILLER ED, 2001, J HOPKINS NEWS INFOR; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; MURRAY GD, 2001, BRIT MED J, V32, P1461; *NAT HLTH MED RES, 1999, NAT STAT ETH COND 1; *NAT LTH MED RES C, 1999, NAT STAT ETH COND 2; *NIH, PRIV BOARDS HIPAA PI; Pildal J, 2005, BMJ-BRIT MED J, V330, P1049, DOI 10.1136/bmj.38414.422650.8F; RELMAN AS, 1990, NEW ENGL J MED, V323, P1355; Savulescu J, 1996, BMJ-BRIT MED J, V313, P1390, DOI 10.1136/bmj.313.7069.1390; Soares HP, 2004, BRIT MED J, V328, P22, DOI 10.1136/bmj.328.7430.22; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; WEIJER C, 1995, CAN MED ASSOC J, V152, P1973	36	36	36	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 6	2006	332	7549					1086	1089		10.1136/bmj.332.7549.1086	http://dx.doi.org/10.1136/bmj.332.7549.1086			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	042HI	16675819	Green Published			2023-01-03	WOS:000237518400024
J	Stebbing, J; Sanitt, A; Nelson, M; Powles, T; Gazzard, B; Bower, M				Stebbing, J; Sanitt, A; Nelson, M; Powles, T; Gazzard, B; Bower, M			A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy	LANCET			English	Article							ADULT HIV-INFECTION; CLINICAL-TRIALS; DNA-SEQUENCES; TAT PROTEIN; HERPESVIRUS; REGRESSION; IMMUNODEFICIENCY; MODELS; RECOMMENDATIONS; QUANTIFICATION	Background AIDS-associated Kaposi's sarcoma remains common in individuals with HIV-1 infection in the era of highly active antiretroviral therapy (HAART). We developed a simple model for predicting mortality on the basis of clinical characteristics present at the time of diagnosis of Kaposi's sarcoma. Methods Of 5873 individuals with HIV-1 infection, 326 (6%) developed Kaposi's sarcoma; for 262 (80%) this was their first AIDS-defining illness. We did univariate and multivariate Cox regression analyses to identify covariates predictive of overall survival and validated our model with an independent data set of 446 patients with Kaposi's sarcoma. Results in the primary model, we developed a prognostic score from 0 to 15 starting at 10. Having Kaposi's sarcoma as the AIDS-defining illness (-3 points) and increasing CD4 count (-1 point for every complete 100 cells per mm(3)) improved prognosis; age of 50 years or older (2 points) and having another AIDS-associated illness at the same time (3 points) conveyed a poorer prognosis. In individuals with prognostic scores of 0, 5, 10, and 15, probability of survival at 1-year was 0.993, 0.967, 0.834, and 0.378, and at 5 years was 0.984, 0.918, 0.631, and 0.084, respectively. Increasing prognostic score by 1 increased I-year death hazard ratio by 40% (95% Cl 28-53%; bootstrapped hazard ratio 1.39, 1.25-1.51). The index had concordance of 76.8% (71.7-82.3). Interpretation We identified four prognostic factors that can be used to obtain an accurate prognostic index at diagnosis of AIDS-associated Kaposi's sarcoma. This index is widely applicable and can be used to guide therapeutic options.	Chelsea & Westminster Hosp, Dept Oncol, London SW10 9NH, England; Chelsea & Westminster Hosp, Dept HIV Med, London SW10 9NH, England	Imperial College London; Imperial College London	Stebbing, J (corresponding author), Chelsea & Westminster Hosp, Dept Oncol, London SW10 9NH, England.	justinstebbing@gmail.com; m.bower@imperial.ac.uk		Sanitt, Adam/0000-0003-2349-283X; Bower, Mark/0000-0002-4077-6351; Stebbing, Justin/0000-0002-1117-6947				ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823; Bourboulia D, 2004, AIDS, V18, P485, DOI 10.1097/00002030-200402200-00015; Bower M, 2005, ANN INTERN MED, V143, P265, DOI 10.7326/0003-4819-143-4-200508160-00007; Bower M, 2005, J CLIN ONCOL, V23, P5224, DOI 10.1200/JCO.2005.14.597; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; COX DR, 1972, J R STAT SOC B, V34, P187; Efron B., 1986, STAT SCI, P54; Engels EA, 2003, AIDS, V17, P1847, DOI 10.1097/00002030-200308150-00015; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Fleming TR, 2000, BIOMETRICS, V56, P971, DOI 10.1111/j.0006-341X.2000.0971.x; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; FRIEDMANKIEN AE, 1982, ANN INTERN MED, V96, P693, DOI 10.7326/0003-4819-96-6-693; Gill R, 1982, Experientia Suppl, V41, P187; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; Holkova B, 2001, J CLIN ONCOL, V19, P3848, DOI 10.1200/JCO.2001.19.18.3848; Hothorn T, 2003, COMPUT STAT DATA AN, V43, P121, DOI 10.1016/S0167-9473(02)00225-6; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOCH R, 1982, VERH K INN MED WIESB; Krown SE, 2004, J CLIN ONCOL, V22, P399, DOI 10.1200/JCO.2004.08.064; Krown SE, 1997, J CLIN ONCOL, V15, P3085, DOI 10.1200/JCO.1997.15.9.3085; KROWN SE, 1989, J CLIN ONCOL, V7, P1201, DOI 10.1200/JCO.1989.7.9.1201; Linton PJ, 2004, NAT IMMUNOL, V5, P133, DOI 10.1038/ni1033; Marcelin AG, 2004, AIDS RES HUM RETROV, V20, P704, DOI 10.1089/0889222041524689; Mariotti M, 2006, J CELL BIOCHEM, V98, P301, DOI 10.1002/jcb.20770; Nasti G, 2005, J CLIN ONCOL, V23, P2433, DOI 10.1200/JCO.2005.05.790; Nasti G, 2003, CANCER-AM CANCER SOC, V98, P2440, DOI 10.1002/cncr.11816; Nasti G, 2003, J CLIN ONCOL, V21, P2876, DOI 10.1200/JCO.2003.10.162; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Portsmouth S, 2003, AIDS, V17, pF17, DOI 10.1097/00002030-200307250-00001; Pozniak A, 2003, HIV Med, V4 Suppl 1, P1; Quinlivan EB, 2002, J INFECT DIS, V185, P1736, DOI 10.1086/340652; Reitz MS, 1999, J NATL CANCER I, V91, P1453, DOI 10.1093/jnci/91.17.1453; Royston P, 2000, STAT MED, V19, P1831, DOI 10.1002/1097-0258(20000730)19:14<1831::AID-SIM502>3.0.CO;2-1; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Sgadari C, 2002, NAT MED, V8, P225, DOI 10.1038/nm0302-225; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Solal-Celigny P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Spano J P, 2000, HIV Med, V1, P232, DOI 10.1046/j.1468-1293.2000.00034.x; Stebbing J, 2006, ANN ONCOL, V17, P503, DOI 10.1093/annonc/mdj091; Stebbing J, 2004, J CLIN ONCOL, V22, P2177, DOI 10.1200/JCO.2004.11.097; Stebbing J, 2004, TRENDS MOL MED, V10, P187, DOI 10.1016/j.molmed.2004.02.006; Stebbing J, 2003, J ANTIMICROB CHEMOTH, V51, P1095, DOI 10.1093/jac/dkg199; Sterne JAC, 2005, LANCET, V366, P378, DOI 10.1016/S0140-6736(05)67022-5; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Venables W., 2013, MODERN APPL STAT S, V53, P86; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	56	67	71	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 6	2006	367	9521					1495	1502		10.1016/S0140-6736(06)68649-2	http://dx.doi.org/10.1016/S0140-6736(06)68649-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	039RJ	16679162				2023-01-03	WOS:000237324200029
J	Herrera, S				Herrera, S			Price controls: preparing for the unthinkable	NATURE BIOTECHNOLOGY			English	Editorial Material								The momentum in the United States to impose price controls is growing. Stephan Herrera lists some of the reasons why.										*DHHS, STAT AG POP INTR; HARRIS GG, 2005, NY TIMES        0616; HEFFLER S, 2005, US HLTH SPENDING PRO; *KAIS FAM FDN, 2005, PRESCR DRUG TRENDS; National Association of Chain Drug Stores, IND FACTS GLANC; 2005, FORTUNE         0418; 2006, JP MORG 24 ANN HEALT; 2006, WORLD EC FOR DAV SWI	8	3	3	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2006	24	3					257	260		10.1038/nbt0306-257	http://dx.doi.org/10.1038/nbt0306-257			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	019WQ	16525374				2023-01-03	WOS:000235868600014
J	Bomback, A				Bomback, A			Errands	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												abomback@unch.unc.edu	Bomback, Andrew/A-8063-2009						0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2006	295	7					731	733		10.1001/jama.295.7.731	http://dx.doi.org/10.1001/jama.295.7.731			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011YZ	16478890				2023-01-03	WOS:000235306700001
J	Bent, S; Kane, C; Shinohara, K; Neuhaus, J; Hudes, ES; Goldberg, H; Avins, AL				Bent, S; Kane, C; Shinohara, K; Neuhaus, J; Hudes, ES; Goldberg, H; Avins, AL			Saw palmetto for benign prostatic hyperplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; SERENOA-REPENS; FINASTERIDE; EFFICACY; MEN; DOXAZOSIN; EXTRACT; TRIAL	BACKGROUND: Saw palmetto is used by over 2 million men in the United States for the treatment of benign prostatic hyperplasia and is commonly recommended as an alternative to drugs approved by the Food and Drug Administration. METHODS: In this double-blind trial, we randomly assigned 225 men over the age of 49 years who had moderate-to-severe symptoms of benign prostatic hyperplasia to one year of treatment with saw palmetto extract (160 mg twice a day) or placebo. The primary outcome measures were changes in the scores on the American Urological Association Symptom Index (AUASI) and the maximal urinary flow rate. Secondary outcome measures included changes in prostate size, residual urinary volume after voiding, quality of life, laboratory values, and the rate of reported adverse effects. RESULTS: There was no significant difference between the saw palmetto and placebo groups in the change in AUASI scores (mean difference, 0.04 point; 95 percent confidence interval, -0.93 to 1.01), maximal urinary flow rate (mean difference, 0.43 ml per minute; 95 percent confidence interval, -0.52 to 1.38), prostate size, residual volume after voiding, quality of life, or serum prostate-specific antigen levels during the one-year study. The incidence of side effects was similar in the two groups. CONCLUSIONS: In this study, saw palmetto did not improve symptoms or objective measures of benign prostatic hyperplasia.	San Francisco VA Med Ctr, Dept Med, Gen Internal Med Sect, San Francisco, CA 94121 USA; San Francisco VA Med Ctr, Urol Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, Osher Ctr Integrat Med, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Family Practice, San Francisco, CA 94143 USA; Kaiser Permanente No Calif, Oakland, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente	Bent, S (corresponding author), San Francisco VA Med Ctr, Dept Med, Gen Internal Med Sect, 111-A1,4150 Clement St, San Francisco, CA 94121 USA.	bent@itsa.ucsf.edu			NCCIH NIH HHS [1 K08 ATO1338-01] Funding Source: Medline; NIDDK NIH HHS [1 R01 DK56199-01] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K08AT001338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056199] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM UR ASS ED RES, 2003, AM UR ASS GUID MAN B; Barnes Patricia M, 2004, Adv Data, P1; BARRY MJ, 1995, J UROLOGY, V154, P1770, DOI 10.1016/S0022-5347(01)66780-6; Bauer H W, 1999, MMW Fortschr Med, V141, P62; Boccafoschi C, 1983, UROLOGIA, V50, P1257; Boyle P, 1996, UROLOGY, V48, P398, DOI 10.1016/S0090-4295(96)00353-6; BRAECKMAN J, 1997, EUR J CLIN RES, V9, P247; CARBIN BE, 1990, BRIT J UROL, V66, P639, DOI 10.1111/j.1464-410X.1990.tb07199.x; CHAMPAULT G, 1984, BRIT J CLIN PHARMACO, V18, P461, DOI 10.1111/j.1365-2125.1984.tb02491.x; CUKIER J, 1985, CR THER PHARM CLIN, V4, P15; DESCOTES JL, 1995, CLIN DRUG INVEST, V9, P291, DOI 10.2165/00044011-199509050-00007; Emili E, 1983, UROLOGIA, V50, P1042; *EXP COMM, 2002, DSB DIET S BOT, V28, P425; FOWLER FJ, 1993, EUR UROL, V24, P24; FUGHBERMAN A, 2003, 5 MINUTE HERB DIET S; GABRIC V, 1987, THERAPIEWOCHE, V37, P1775; Gerber GS, 2001, UROLOGY, V58, P960, DOI 10.1016/S0090-4295(01)01442-X; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; LOBELENZ J, 1992, THERAPEUTIKON, V6, P34; Lowe FC, 1996, UROLOGY, V48, P12, DOI 10.1016/S0090-4295(96)00077-5; MANDRESSI A, 1983, UROLOGIA, V50, P752; Marks LS, 2000, J UROLOGY, V163, P1451, DOI 10.1016/S0022-5347(05)67641-0; Mattei F. M., 1990, TW UROL NEPHROL, V2, P346; McConnell JD, 1998, NEW ENGL J MED, V338, P557, DOI 10.1056/NEJM199802263380901; McConnell JD, 2003, NEW ENGL J MED, V349, P2387, DOI 10.1056/NEJMoa030656; McCulloch C.E., 2001, GEN LINEAR MIXED MOD; Metzker H, 1996, UROLOGE B, V36, P292, DOI DOI 10.1007/S001310050033; Niederprum H J, 1994, Phytomedicine, V1, P127, DOI 10.1016/S0944-7113(11)80030-9; Roehrborn CG, 1996, UROLOGY, V48, P406, DOI 10.1016/S0090-4295(96)00208-7; Rotblatt M, 2002, EVIDENCE BASED HERBA; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Ryan P, 2000, RALLOC STATA MODULE; SMITH HR, 1986, BRIT J UROL, V58, P36, DOI 10.1111/j.1464-410X.1986.tb05424.x; *STAT CORP, 2003, STAT STAT SOFTW; Tasca A, 1985, Minerva Urol Nefrol, V37, P87; ULBRICHT CE, 2005, NATURAL STANDARD HER, P651; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Willetts KE, 2003, BJU INT, V92, P267, DOI 10.1046/j.1464-410X.2003.04316.x; Wilt T, 2002, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001423	39	246	257	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					557	566		10.1056/NEJMoa053085	http://dx.doi.org/10.1056/NEJMoa053085			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467543	Green Published			2023-01-03	WOS:000235177500005
J	Armstrong, DK; Bundy, B; Wenzel, L; Huang, HQ; Baergen, R; Lele, S; Copeland, LJ; Walker, JL; Burger, RA				Armstrong, DK; Bundy, B; Wenzel, L; Huang, HQ; Baergen, R; Lele, S; Copeland, LJ; Walker, JL; Burger, RA		Gynecologic Oncology Grp	Intraperitoneal cisplatin and paclitaxel in ovarian cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STAGE-III OVARIAN; GYNECOLOGIC-ONCOLOGY-GROUP; THERAPY; CHEMOTHERAPY; CARBOPLATIN; CARCINOMA; TRIAL; CYCLOPHOSPHAMIDE; INTERGROUP	BACKGROUND: Standard chemotherapy for newly diagnosed ovarian cancer is a platinum-taxane combination. The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel in patients with stage III ovarian cancer. METHODS: We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm to receive 135 mg of intravenous paclitaxel per square meter of body-surface area over a 24-hour period followed by either 75 mg of intravenous cisplatin per square meter on day 2 (intravenous-therapy group) or 100 mg of intraperitoneal cisplatin per square meter on day 2 and 60 mg of intraperitoneal paclitaxel per square meter on day 8 (intraperitoneal-therapy group). Treatment was given every three weeks for six cycles. Quality of life was assessed. RESULTS: Of 429 patients who underwent randomization, 415 were eligible. Grade 3 and 4 pain, fatigue, and hematologic, gastrointestinal, metabolic, and neurologic toxic effects were more common in the intraperitoneal-therapy group than in the intravenous-therapy group (P lessthan/equal 0.001). Only 42 percent of the patients in the intraperitoneal-therapy group completed six cycles of the assigned therapy, but the median duration of progression-free survival in the intravenous-therapy and intraperitoneal-therapy groups was 18.3 and 23.8 months, respectively (P=0.05 by the log-rank test). The median duration of overall survival in the intravenous-therapy and intraperitoneal-therapy groups was 49.7 and 65.6 months, respectively (P=0.03 by the log-rank test). Quality of life was significantly worse in the intraperitoneal-therapy group before cycle 4 and three to six weeks after treatment but not one year after treatment. CONCLUSIONS: As compared with intravenous paclitaxel plus cisplatin, intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel improves survival in patients with optimally debulked stage III ovarian cancer.	Gynecol Oncol Grp, Adm Off, Stat & Data Ctr, Philadelphia, PA 19103 USA; Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Univ Calif Irvine, Div Gynecol Oncol, Irvine, CA USA; Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, New York, NY USA; Ohio State Univ, Columbus, OH 43210 USA; Univ Oklahoma, Oklahoma City, OK USA	Johns Hopkins University; Johns Hopkins Medicine; Roswell Park Cancer Institute; University of California System; University of California Irvine; Cornell University; NewYork-Presbyterian Hospital; University System of Ohio; Ohio State University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Armstrong, DK (corresponding author), Gynecol Oncol Grp, Adm Off, Stat & Data Ctr, 4 Penn Ctr,1600 JFK Blvd,Ste 1020, Philadelphia, PA 19103 USA.				NCI NIH HHS [CA 37517, CA 27469] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA037517, U10CA027469] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts DS, 1996, NEW ENGL J MED, V335, P1950, DOI 10.1056/NEJM199612263352603; Alberts DS, 2002, J CLIN ONCOL, V20, P3944, DOI 10.1200/JCO.2002.20.19.3944; Basen-Engquist K, 2001, J CLIN ONCOL, V19, P1809, DOI 10.1200/JCO.2001.19.6.1809; Bristow RE, 2002, J CLIN ONCOL, V20, P1248, DOI 10.1200/JCO.20.5.1248; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; COX DR, 1972, J R STAT SOC B, V34, P187; FRANCIS P, 1995, J CLIN ONCOL, V13, P2961, DOI 10.1200/JCO.1995.13.12.2961; Fujiwara K, 2003, GYNECOL ONCOL, V91, P662, DOI 10.1016/j.ygyno.2003.09.006; Fujiwara K, 2003, GYNECOL ONCOL, V90, P637, DOI 10.1016/S0090-8258(03)00377-9; Greer BE, 2005, GYNECOL ONCOL, V99, P71, DOI 10.1016/j.ygyno.2005.05.012; Hollander M., 1999, NONPARAMETRIC STAT M; Jemal A, 2005, CA-CANCER J CLIN, V55, P259; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Markman M, 2001, J CLIN ONCOL, V19, P1001, DOI 10.1200/JCO.2001.19.4.1001; MCGUIRE WP, 1995, J CLIN ONCOL, V13, P1589, DOI 10.1200/JCO.1995.13.7.1589; McGuire WP, 2001, J CLIN ONCOL, V19, P921, DOI 10.1200/JCO.2001.19.4.921; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; Ozols RF, 1999, ANN ONCOL, V10, P59, DOI 10.1023/A:1008363519331; Rothenberg ML, 2003, J CLIN ONCOL, V21, P1313, DOI 10.1200/JCO.2003.07.031; SCHNEIDER JG, 1994, OBSTET GYN CLIN N AM, V21, P195; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Thigpen T, 2004, NEW ENGL J MED, V351, P2544, DOI 10.1056/NEJMe048292; Walker JL, 2006, GYNECOL ONCOL, V100, P27, DOI 10.1016/j.ygyno.2005.11.013; Wenzel LB, 2005, J CLIN ONCOL, V23, p754S; WENZEL LB, 2004, P AN M AM SOC CLIN, V23, P454	28	2000	2079	1	135	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 5	2006	354	1					34	43		10.1056/NEJMoa052985	http://dx.doi.org/10.1056/NEJMoa052985			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	998ZO	16394300	Bronze			2023-01-03	WOS:000234358600006
J	Curley, MAQ; Hibberd, PL; Fineman, LD; Wypij, D; Shih, MC; Thompson, J; Grant, MJC; Barr, FE; Cvijanovich, NZ; Sorce, L; Luckett, PM; Matthay, MA; Arnold, JH				Curley, MAQ; Hibberd, PL; Fineman, LD; Wypij, D; Shih, MC; Thompson, J; Grant, MJC; Barr, FE; Cvijanovich, NZ; Sorce, L; Luckett, PM; Matthay, MA; Arnold, JH			Effect of prone positioning on clinical outcomes in children with acute lung injury - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS-SYNDROME; PEDIATRIC INTENSIVE-CARE; HIGH TIDAL VOLUME; OXYGENATION; FAILURE; INFANTS; VENTILATION; PRESSURES; MECHANICS; PULMONARY	Context In uncontrolled clinical studies, prone positioning appeared to be safe and to improve oxygenation in pediatric patients with acute lung injury. However, the effect of prone positioning on clinical outcomes in children is not known. Objective To test the hypothesis that at the end of 28 days infants and children with acute lung injury treated with prone positioning would have more ventilator-free days than those treated with supine positioning. Design, Setting, and Patients Multicenter, randomized, controlled clinical trial conducted from August 28, 2001, to April 23, 2004, of 102 pediatric. patients from 7 US pediatric intensive care units aged 2 weeks to 18 years who were treated with supine vs prone positioning. Randomization was concealed and group assignment was not blinded. Intervention Patients were randomized to either supine or prone positioning within 48 hours of meeting acute lung injury criteria, with those patients in the prone group being positioned within 4 hours of randomization and remaining prone for 20 hours each day during the acute phase of their illness for a maximum of 7 days, after which they were positioned supine. Both groups were treated using lung protective ventilator and sedation protocols, extubation readiness testing, and hemodynamic, nutrition, and skin care guidelines. Main Outcome Measure Ventilator-free days to day 28. Results The trial was stopped at the planned interim analysis on the basis of the pre-specified futility stopping rule. There were no differences in the number of ventilator-free days between the 2 groups (mean [SD], 15.8 [8.5] supine vs 15.6 [8.6] prone; mean difference, -0.2 days; 95% Cl, -3.6 to 3.2; P=.91). After controlling for age, Pediatric Risk of Mortality III score, direct vs indirect acute lung injury, and mode of mechanical ventilation at enrollment, the adjusted difference in ventilator-free days was 0.3 days (95% Cl, -3.0 to 3.5; P=.87). There were no differences in the secondary end points, including proportion alive and ventilator-free on day 28 (P=.45), mortality from all causes (P>.99), the time to recovery of lung injury (P=.78), organ-failure-free days (P=.88), and cognitive impairment (P=.16) or overall functional health (P=.12) at hospital discharge or on day 28. Conclusion Prone positioning does not significantly reduce ventilator-free days or improve other clinical outcomes in pediatric patients with acute lung injury.	Childrens Hosp, Med Surg Intens Care Unit, Boston, MA 02115 USA; Tufts New England Med Ctr, Boston, MA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Primary Childrens Med Ctr, Salt Lake City, UT 84103 USA; Vanderbilt Childrens Hosp, Nashville, TN USA; Childrens Hosp Oakland, Oakland, CA USA; Childrens Mem Hosp, Chicago, IL 60614 USA; Childrens Med Ctr, Dallas, TX 75235 USA	Harvard University; Boston Children's Hospital; Tufts Medical Center; University of California System; University of California San Francisco; Vanderbilt University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Ann & Robert H. Lurie Children's Hospital of Chicago	Curley, MAQ (corresponding author), Childrens Hosp, Med Surg Intens Care Unit, 300 Longwood Ave, Boston, MA 02115 USA.	martha.curley@childrens.harvard.edu	Curley, Martha A/F-3579-2016	Curley, Martha A/0000-0001-5228-6694; Sorce, Lauren/0000-0002-5460-0664; Wypij, David/0000-0001-8367-8711; Hibberd, Patricia/0000-0002-7455-8117	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR005336] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00054, M01 RR000064, RR00064, M01 RR000054] Funding Source: Medline; NINR NIH HHS [R01 NR005336, R01NR05336] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Broccard AF, 1997, CRIT CARE MED, V25, P16, DOI 10.1097/00003246-199701000-00007; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; BRYAN AC, 1974, AM REV RESPIR DIS, V110, P143; Casado-Flores J, 2002, INTENS CARE MED, V28, P1792, DOI 10.1007/s00134-002-1527-8; Chatte G, 1997, AM J RESP CRIT CARE, V155, P473, DOI 10.1164/ajrccm.155.2.9032181; Curley M A, 1999, Am J Crit Care, V8, P397; Curley M A, 1998, Am J Crit Care, V7, P335; Curley MAQ, 2000, CHEST, V118, P156, DOI 10.1378/chest.118.1.156; Curley Martha A Q, 2005, Pediatr Crit Care Med, V6, pS150, DOI 10.1097/01.PCC.0000161582.63265.B6; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fridrich P, 1996, ANESTH ANALG, V83, P1206, DOI 10.1097/00000539-199612000-00013; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031; Guerin C, 2004, JAMA-J AM MED ASSOC, V292, P2379, DOI 10.1001/jama.292.19.2379; LAMM WJE, 1994, AM J RESP CRIT CARE, V150, P184, DOI 10.1164/ajrccm.150.1.8025748; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; MURDOCH IA, 1994, ACTA PAEDIATR, V83, P1043, DOI 10.1111/j.1651-2227.1994.tb12981.x; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; *NAT PRESS ULC ADV, 1989, DECUBITUS, V2, P24; *NPUAP, STAG 1 ASS DARKL PIG; Numa AH, 1997, AM J RESP CRIT CARE, V156, P1185, DOI 10.1164/ajrccm.156.4.9601042; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PAPASTAMELOS C, 1995, J APPL PHYSIOL, V78, P179, DOI 10.1152/jappl.1995.78.1.179; Pelosi P, 1998, AM J RESP CRIT CARE, V157, P387, DOI 10.1164/ajrccm.157.2.97-04023; Plotz FB, 2004, INTENS CARE MED, V30, P1865, DOI 10.1007/s00134-004-2363-9; Pollack MM, 1997, J PEDIATR-US, V131, P575, DOI 10.1016/S0022-3476(97)70065-9; Randolph AG, 2003, AM J RESP CRIT CARE, V167, P1334, DOI 10.1164/rccm.200210-1175OC; Randolph AG, 2002, JAMA-J AM MED ASSOC, V288, P2561, DOI 10.1001/jama.288.20.2561; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Spragg RG, 2004, NEW ENGL J MED, V351, P884, DOI 10.1056/NEJMoa033181; Taylor RW, 2004, JAMA-J AM MED ASSOC, V291, P1603, DOI 10.1001/jama.291.13.1603; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806	35	200	224	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	2005	294	2					229	237		10.1001/jama.294.2.229	http://dx.doi.org/10.1001/jama.294.2.229			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	944DO	16014597	Green Accepted			2023-01-03	WOS:000230406100027
J	Moldrup, C				Moldrup, C			No cure, no pay	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICINE		Danish Univ Pharmaceut Sci, Dept Social Pharm, DK-2100 Copenhagen, Denmark	University of Copenhagen	Moldrup, C (corresponding author), Danish Univ Pharmaceut Sci, Dept Social Pharm, Univ Pk 2, DK-2100 Copenhagen, Denmark.	cm@dfuni.dk						ANDERSON P, 1995, MED POST        0515; ANGELL M, 2004, NEW YORK REV, V51; [Anonymous], MED NEWS TODAY; Califano J A Jr, 1985, Health Matrix, V3, P32; DIMASI JA, 1995, CLIN PHARMACOL THER, V58, P1, DOI 10.1016/0009-9236(95)90066-7; Floyd EJ, 2003, J HEALTHC MANAG, V48, P233, DOI 10.1097/00115514-200307000-00007; GILBERT J, 2003, BUSINESS MED REP, V21; GRUND J, 2005, JYLLANDSPOSTEN  0303; *I RAT PHARM, WHAT IS RAT PHARM; Kalow Werner, 1963, PHARMACOGENETICS HER; Lee TH, 2004, NEW ENGL J MED, V350, P211, DOI 10.1056/NEJMp038215; Matthews M, 2004, MT SINAI J MED, V71, P225; *MERCK, PROD HIGHL; Moldrup Claus, 2001, Community Genet, V4, P204, DOI 10.1159/000064194; *NOV, 140 90 IN; *NOV, BP MON BACK GUAR; Silverstein K, 1999, NATION, V269, P13; Swick HM, 1998, ACAD MED, V73, P751, DOI 10.1097/00001888-199807000-00010; TONKS A, 1994, BRIT MED J, V309, P1252, DOI 10.1136/bmj.309.6964.1252a; 1998, DOCTORS GUIDE    NOV	20	16	16	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	2005	330	7502					1262	1264		10.1136/bmj.330.7502.1262	http://dx.doi.org/10.1136/bmj.330.7502.1262			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930WX	15920131	Green Published			2023-01-03	WOS:000229448900029
J	Marin, JM; Carrizo, SJ; Vicente, E; Agusti, AGN				Marin, JM; Carrizo, SJ; Vicente, E; Agusti, AGN			Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study	LANCET			English	Article							CORONARY-ARTERY-DISEASE; ISCHEMIC-HEART-DISEASE; CONTROLLED-TRIALS; CEREBRAL-INFARCTION; RISK-FACTORS; FOLLOW-UP; MORTALITY; POPULATION; HEALTH; HYPERTENSION	Background The effect of obstructive sleep apnoea-hypopnoea as a cardiovascular risk factor and the potential protective effect of its treatment with continuous positive airway pressure (CPAP) is unclear. We did an observational study to compare incidence of fatal and non-fatal cardiovascular events in simple snorers, patients with untreated obstructive sleep apnoea-hypopnoea, patients treated with CPAP, and healthy men recruited from the general population. Methods We recruited men with obstructive sleep apnoea-hypopnoea or simple snorers from a sleep clinic, and a population-based sample of healthy men, matched for age and body-mass index with the patients with untreated severe obstructive sleep apnoea-hypopnoea. The presence and severity of the disorder was determined with full polysonmography, and the apnoea-hypopnoea index (AHI) was calculated as the average number of apnoeas and hypopnoeas per hour of sleep. Participants were followed-up at least once per year for a mean of 10.1 years (SD 1.6) and CPAP compliance was checked with the built-in meter. Endpoints were fatal cardiovascular events (death from myocardial infarction or stroke) and non-fatal cardiovascular events (non-fatal myocardial infarction, non-fatal stroke, coronary artery bypass surgery, and percutaneous transluminal coronary angiography). Findings 264 healthy men, 377 simple snorers, 403 with untreated mild-moderate obstructive sleep apnoea-hypopnoea, 235 with untreated severe disease, and 372 with the disease and treated with CPAP were included in the analysis. Patients with untreated severe disease had a higher incidence of fatal cardiovascular events (1.06 per 100 person-years) and non-fatal cardiovascular events (2.13 per 100 person-years) than did untreated patients with mild-moderate disease (0.55, p=0.02 and 0.89, p<0.0001), simple snorers (0.34, p=0.0006 and 0.58, p<0.0001), patients treated with CPAP (0.35, p=0.0008 and 0.64, p<0.0001), and healthy participants (0.3, p=0.0012 and 0.45, p<0.0001). Multivariate analysis, adjusted for potential confounders, showed that untreated severe obstructive sleep apnoea-hypopnoea significantly increased the risk of fatal (odds ratio 2.87, 95%Cl 1.17-7.51) and non-fatal (3.17, 1.12-7.51) cardiovascular events compared with healthy participants. Interpretation In men, severe obstructive sleep apnoea-hypopnoea significantly increases the risk of fatal and non-fatal cardiovascular events. CPAP treatment reduces this risk.	Hosp Univ Miguel Servet, Resp Serv, Zaragoza, Spain; IUNICS, Hosp Univ Son Dureta, Resp Serv, Palma de Mallorca, Spain	Miguel Servet University Hospital; Hospital Universitari Son Espases; Hospital Universitari Son Dureta; Universitat de les Illes Balears	Marin, JM (corresponding author), Hosp Univ Miguel Servet, Serv Neurol, Isabel la Catolica, Zaragoza 50006, Spain.	jmmarint@unizar.es	CARRIZO SIERRA, SANTIAGO/AAO-1780-2021; Garcia-Navarro, Alvar Agusti/F-4474-2015; Lavu, Madhav/A-9409-2013	Garcia-Navarro, Alvar Agusti/0000-0003-3271-3788; Marin Trigo, Jose Maria/0000-0001-9096-2294				AncoliIsrael S, 1996, SLEEP, V19, P277, DOI 10.1093/sleep/19.4.277; [Anonymous], 1983, PROP MULT MON TRENDS; Ballester E, 1999, AM J RESP CRIT CARE, V159, P495, DOI 10.1164/ajrccm.159.2.9804061; Barbe F, 1998, AM J RESP CRIT CARE, V158, P18, DOI 10.1164/ajrccm.158.1.9709135; Bassetti C, 1996, NEUROLOGY, V47, P1167, DOI 10.1212/WNL.47.5.1167; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; BOBINSKY G, 1995, CHEST, V108, P625; Brooks D, 1997, J CLIN INVEST, V99, P106, DOI 10.1172/JCI119120; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; COX DR, 1972, J R STAT SOC B, V34, P187; Duran J, 2001, AM J RESP CRIT CARE, V163, P685, DOI 10.1164/ajrccm.163.3.2005065; Farre R, 1999, LANCET, V353, P1154, DOI 10.1016/S0140-6736(99)01056-9; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GONZALEZROTHI RJ, 1988, CHEST, V94, P531, DOI 10.1378/chest.94.3.531; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; HEDNER JA, 1992, AM REV RESPIR DIS, V146, P1240, DOI 10.1164/ajrccm/146.5_Pt_1.1240; Hu FB, 2000, J AM COLL CARDIOL, V35, P308, DOI 10.1016/S0735-1097(99)00540-9; Imadojemu VA, 2002, AM J RESP CRIT CARE, V165, P950, DOI 10.1164/ajrccm.165.7.2102003; Iranzo A, 2002, NEUROLOGY, V58, P911, DOI 10.1212/WNL.58.6.911; Jenkinson C, 1999, LANCET, V353, P2100, DOI 10.1016/S0140-6736(98)10532-9; JENNUM P, 1995, CHEST, V108, P138, DOI 10.1378/chest.108.1.138; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; Kannel WB, 1971, FRAMINGHAM STUDY EPI; Karlawish JHT, 2001, AM J RESP CRIT CARE, V163, P809, DOI 10.1164/ajrccm.163.4.ed0201d; Kato M, 2000, CIRCULATION, V102, P2607; KOSKENVUO M, 1987, BRIT MED J, V294, P16, DOI 10.1136/bmj.294.6563.16; LAVIE P, 1995, SLEEP, V18, P149, DOI 10.1093/sleep/18.3.149; Lindberg E, 1998, THORAX, V53, P631, DOI 10.1136/thx.53.8.631; Loube DI, 1999, CHEST, V115, P863, DOI 10.1378/chest.115.3.863; Marin JM, 1997, INT J EPIDEMIOL, V26, P381, DOI 10.1093/ije/26.2.381; Milleron O, 2004, EUR HEART J, V25, P728, DOI 10.1016/j.ehj.2004.02.008; Montserrat J M, 1998, Arch Bronconeumol, V34, P204; Montserrat JM, 2001, AM J RESP CRIT CARE, V164, P608, DOI 10.1164/ajrccm.164.4.2006034; MOORE T, 2001, AM J RESP CRIT CARE, V164, P1910; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; OLSON LG, 1995, AM J RESP CRIT CARE, V152, P717, DOI 10.1164/ajrccm.152.2.7633732; PALOMAKI H, 1991, STROKE, V22, P1021, DOI 10.1161/01.STR.22.8.1021; Parra O, 2000, AM J RESP CRIT CARE, V161, P375, DOI 10.1164/ajrccm.161.2.9903139; PARTINEN M, 1988, CHEST, V94, P1200, DOI 10.1378/chest.94.6.1200; PARTINEN M, 1985, LANCET, V2, P1325; Peker Y, 2000, AM J RESP CRIT CARE, V162, P81, DOI 10.1164/ajrccm.162.1.9905035; Peker Y, 2002, AM J RESP CRIT CARE, V166, P159, DOI 10.1164/rccm.2105124; RECHTSCHAFEN A, 1968, MANUAL STANDADIZED T; Sanner BM, 2000, EUR RESPIR J, V16, P648, DOI 10.1034/j.1399-3003.2000.16d14.x; SCHMIDTNOWARA WW, 1990, ARCH INTERN MED, V150, P597, DOI 10.1001/archinte.150.3.597; Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008; WALKER AE, 1981, STROKE S1, V12; WILKOX I, 1993, SLEEP, V16, P539; Wright J, 1998, THORAX, V53, P410, DOI 10.1136/thx.53.5.410; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	51	3181	3327	5	171	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 19	2005	365	9464					1046	1053		10.1016/S0140-6736(05)71141-7	http://dx.doi.org/10.1016/S0140-6736(05)71141-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	907QB	15781100				2023-01-03	WOS:000227731800029
J	Schmidt, C				Schmidt, Charlie			Profile: Una Ryan	NATURE BIOTECHNOLOGY			English	Biographical-Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2006	24	8					881	881		10.1038/nbt0806-881	http://dx.doi.org/10.1038/nbt0806-881			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	072VY	16900115				2023-01-03	WOS:000239702300008
J	Straus, SE; Chesney, MA				Straus, Stephen E.; Chesney, Margaret A.			In defense of NCCAM	SCIENCE			English	Editorial Material							OSTEOARTHRITIS; KNEE		NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Chesney, MA (corresponding author), NIH, Natl Ctr Complementary & Alternat Med, Bldg 10, Bethesda, MD 20892 USA.	chesneym@mail.nih.gov						BARNES PM, 2004, 343 CDCP; Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006; Clegg DO, 2006, NEW ENGL J MED, V354, P795, DOI 10.1056/NEJMoa052771; *COMM US COMPL ALT, 2005, COMPL ALT MED US; Marcus DM, 2006, SCIENCE, V313, P301, DOI 10.1126/science.1126978; Markowitz JS, 2003, JAMA-J AM MED ASSOC, V290, P1500, DOI 10.1001/jama.290.11.1500; *NCCAM US DEP HHS, 2005, EXP HOR HLTH CAR STR; Sampson W, 2005, NEW ENGL J MED, V353, P337, DOI 10.1056/NEJMp058130; Shekelle P, 2003, AHRQ PUBLICATION, V03-E023; Zubieta JK, 2006, BRAIN BEHAV IMMUN, V20, P15, DOI 10.1016/j.bbi.2005.08.006	10	10	10	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 21	2006	313	5785					303	304		10.1126/science.1131608	http://dx.doi.org/10.1126/science.1131608			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	065IV	16857924	Green Submitted			2023-01-03	WOS:000239154300026
J	Whitcomb, DC				Whitcomb, DC			Acute pancreatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE NECROTIZING PANCREATITIS; RISK-FACTOR; PARENTERAL-NUTRITION; COMPUTED-TOMOGRAPHY; PROGNOSTIC FACTORS; EARLY PREDICTION; APACHE-II; MANAGEMENT; SEVERITY; ASPIRATION		Univ Pittsburgh, Presbyterian Med Ctr, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Whitcomb, DC (corresponding author), Univ Pittsburgh, Presbyterian Med Ctr, Div Gastroenterol Hepatol & Nutr, Mezzanine Level 2,C Wing,200 Lothrop St, Pittsburgh, PA 15213 USA.	whitcomb@pitt.edu						ALOMRAN M, 2003, COCHRANE DB SYST REV, V1; [Anonymous], 2002, NIH Consens State Sci Statements, V19, P1; Arvanitakis M, 2004, GASTROENTEROLOGY, V126, P715, DOI 10.1053/j.gastro.2003.12.006; Ayub K, 2004, COCHRANE DB SYST REV, V4; Baillargeon JD, 1998, AM J GASTROENTEROL, V93, P2130; BALTHAZAR EJ, 1990, RADIOLOGY, V174, P331, DOI 10.1148/radiology.174.2.2296641; Banks PA, 1995, INT J PANCREATOL, V18, P265; Baron TH, 2002, GASTROINTEST ENDOSC, V56, P7, DOI 10.1067/mge.2002.125106; Bassi C, 2003, COCHRANE DB SYST REV; Batiste Marcelo C, 2002, Nutr Clin Care, V5, P115, DOI 10.1046/j.1523-5408.2002.t01-1-00005.x; BLAMEY SL, 1984, GUT, V25, P1340, DOI 10.1136/gut.25.12.1340; BRADLEY EL, 1993, ARCH SURG-CHICAGO, V128, P586; DeFrances C.J., 2005, ADV DATA VITAL HLTH; Draganov P, 2005, GASTROENTEROLOGY, V128, P756, DOI 10.1053/j.gastro.2005.01.037; Gastineau DA, 2001, TRANSFUSION, V41, P4, DOI 10.1046/j.1537-2995.2001.41010004.x; Jacobson BC, 2005, GASTROINTEST ENDOSC, V61, P363, DOI 10.1016/S0016-5107(04)02779-8; Johnson CD, 2001, GUT, V48, P62, DOI 10.1136/gut.48.1.62; Kemppainen E, 1997, GUT, V41, P690, DOI 10.1136/gut.41.5.690; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kozarek RA, 1998, GASTROINTEST ENDOSC, V47, pAB33; Lankisch PG, 2002, PANCREAS, V25, P411, DOI 10.1097/00006676-200211000-00015; LARVIN M, 1989, LANCET, V2, P201; Levy P, 2005, PANCREATOLOGY, V5, P450, DOI 10.1159/000086547; Marik PE, 2004, BMJ-BRIT MED J, V328, P1407, DOI 10.1136/bmj.38118.593900.55; Martinez J, 2004, PANCREATOLOGY, V4, P42, DOI 10.1159/000077025; Mayerle J, 2005, NAT CLIN PRACT GASTR, V2, P473, DOI 10.1038/ncpgasthep0293; Mayumi Toshihiko, 2002, J Hepatobiliary Pancreat Surg, V9, P413, DOI 10.1007/s005340200051; McArthur KE, 1996, ALIMENT PHARM THERAP, V10, P23; McClave Stephen A, 2002, Semin Gastrointest Dis, V13, P154; McKay CJ, 2004, BRIT J SURG, V91, P1243, DOI 10.1002/bjs.4750; Meier R, 2002, CLIN NUTR, V21, P173, DOI 10.1054/clnu.2002.0543; MORINVILLE V, 2005, GASTROENTEROL HEPATO, V1, P195; Nathens AB, 2004, CRIT CARE MED, V32, P2524, DOI 10.1097/01.CCM.0000148222.09869.92; Nathens Avery B, 2004, Proc Am Thorac Soc, V1, P289; Neoptolemos JP, 2000, LANCET, V355, P1955, DOI 10.1016/S0140-6736(00)02327-8; *NIH, 1998, NIH PUBL; Nordback I, 2001, J GASTROINTEST SURG, V5, P113, DOI 10.1016/S1091-255X(01)80021-4; Papachristou GI, 2005, CLIN GASTROENTEROL H, V3, P475, DOI 10.1016/S1542-3565(05)00163-1; Papachristou GI, 2004, GASTROENTEROL CLIN N, V33, P871, DOI 10.1016/j.gtc.2004.07.004; PEDERZOLI P, 1993, SURG GYNECOL OBSTET, V176, P480; RANSON JHC, 1976, SURG GYNECOL OBSTET, V143, P209; RANSON JHC, 1982, AM J GASTROENTEROL, V77, P633; Rau B, 1998, BRIT J SURG, V85, P179; Robert JH, 2002, WORLD J SURG, V26, P612, DOI 10.1007/s00268-001-0278-y; Romagnuolo J, 2005, GASTROINTEST ENDOSC, V61, P86, DOI 10.1016/S0016-5107(04)02472-1; Somogyi L, 2001, GASTROENTEROLOGY, V120, P708, DOI 10.1053/gast.2001.22333; STEINBERG WM, 1987, GASTROENTEROLOGY, V93, P1420, DOI 10.1016/0016-5085(87)90275-7; TENNER S, 1994, AM J GASTROENTEROL, V89, P1863; Uhl W, 2003, PANCREATOLOGY, V3, DOI 10.1159/000067684; Venneman NG, 2005, AM J GASTROENTEROL, V100, P2540, DOI 10.1111/j.1572-0241.2005.00317.x; Whitcomb DC, 2004, GUT, V53, P1710, DOI 10.1136/gut.2003.015511; WHITCOMB DC, 2004, PEDIAT GASTROINTESTI, P1584; Windsor ACJ, 1998, GUT, V42, P431, DOI 10.1136/gut.42.3.431; Working Party of the British Society of Gastroenterology, 2005, GUT, V54, P1, DOI DOI 10.1136/GUT.2004.047126	54	518	565	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2006	354	20					2142	2150		10.1056/NEJMcp054958	http://dx.doi.org/10.1056/NEJMcp054958			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	043BX	16707751				2023-01-03	WOS:000237575400008
J	Jiang, Y; Yan, YB; Zhou, HM				Jiang, Y; Yan, YB; Zhou, HM			Polyvinylpyrrolidone 40 assists the refolding of bovine carbonic anhydrase B by accelerating the refolding of the first molten globule intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE; PROTEIN AGGREGATION; THERMAL-STABILITY; MOLECULAR-WEIGHT; GROWTH-HORMONE; FOLDING AIDS; MECHANISM; DETERGENT; STABILIZATION; DENATURATION	Protecting proteins from aggregation is one of the most important issues in both protein science and protein engineering. In this research, the mechanism of enhancing the refolding of guanidine hydrochloride-denatured carbonic anhydrase B by polyvinylpyrrolidone 40 (PVP40) was studied by both kinetic and equilibrium refolding experiments. The reactivation and refolding kinetics indicated that the rate constant of refolding the first refolding intermediate (I-1) to the second one (I-2) is promoted by the addition of PVP. Fluorescence quenching studies further indicated that PVP could bind to the aggregation-prone species I-1, resulting in the protection of the exposed hydrophobic surface, a minimization of the protein surface, and more importantly, an increase of the refolding rate of I-1. These properties were quite different from those of poly(ethylene glycol) (PEG), which has been shown to have a strong and stoichiometric binding to I-1 and does not interfere with the refolding pathway. Unlike PEG, the binding of PVP to I-1 does not block the aggregation pathway directly but decreases the energy barrier for I-1 to refold to I-2 and thus reduces the accumulation of I-1. These results suggested that PVP works by a quite different mechanism from those well established ones in chaperones and chemical promoters. PVP is more like a folding catalyst rather than a chemical chaperone. The distinct mechanism of enhancing protein aggregation by PVP is expected to facilitate the attempt to develop new chemical compounds as well as new strategies to protect proteins from aggregation.	Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, Minist Educ, Prot Sci Lab, Beijing 100084, Peoples R China	Tsinghua University; Tsinghua University; Tsinghua University	Yan, YB (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.	ybyan@tsinghua.edu.cn; zhm-dbs@tsinghua.edu.cn	Yan, Yong-Bin/A-4282-2008	Yan, Yong-Bin/0000-0002-8565-3558				Bolen D W, 2001, Methods Mol Biol, V168, P17; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHARMAN SA, 1993, PHARM RES-DORDR, V10, P954, DOI 10.1023/A:1018994102218; Chi EY, 2003, PHARM RES-DORDR, V20, P1325, DOI 10.1023/A:1025771421906; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; CLELAND JL, 1992, J BIOL CHEM, V267, P3147; CLELAND JL, 1992, BIOTECHNOL PROGR, V8, P97, DOI 10.1021/bp00014a002; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CLELAND JL, 1992, J BIOL CHEM, V267, P13327; CLELAND JL, 1991, ACS SYM SER, V470, P169; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; FIELDS GB, 1992, J PHYS CHEM-US, V96, P3974, DOI 10.1021/j100189a013; Finke JM, 2000, BIOCHEMISTRY-US, V39, P575, DOI 10.1021/bi991518m; GOMBOTZ WR, 1994, PHARMACEUT RES, V11, P624, DOI 10.1023/A:1018903624373; HARRISON RAP, 1988, BIOCHEM J, V252, P875, DOI 10.1042/bj2520875; Jackson C., 1989, J APPL POLYM SCI APP, V43, P99; Jonasson P, 1997, BIOCHEMISTRY-US, V36, P5142, DOI 10.1021/bi961882a; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kurganov BI, 2002, BIOCHEMISTRY-MOSCOW+, V67, P409, DOI 10.1023/A:1015277805345; LEE LLY, 1987, BIOCHEMISTRY-US, V26, P7813, DOI 10.1021/bi00398a042; Li S, 2001, INT J BIOCHEM CELL B, V33, P279, DOI 10.1016/S1357-2725(01)00003-6; LILJAS A, 1972, NATURE-NEW BIOL, V235, P131, DOI 10.1038/newbio235131a0; Maa YF, 1998, J PHARM SCI, V87, P152, DOI 10.1021/js970308x; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; Meng FG, 2004, BIOPHYS J, V87, P2247, DOI 10.1529/biophysj.104.044784; Meng FG, 2001, INT J BIOCHEM CELL B, V33, P701, DOI 10.1016/S1357-2725(01)00048-6; Ou WB, 2002, INT J BIOCHEM CELL B, V34, P136, DOI 10.1016/S1357-2725(01)00113-3; Ou WB, 2001, EUR J BIOCHEM, V268, P5901, DOI 10.1046/j.0014-2956.2001.02539.x; Pan JC, 2004, PROTEIN SCI, V13, P1892, DOI 10.1110/ps.03464804; PESCE AJ, 1971, FLUORESCENCE SPECTRO, P20; POCKER Y, 1967, BIOCHEMISTRY-US, V6, P668, DOI 10.1021/bi00855a005; POLSON A, 1964, BIOCHIM BIOPHYS ACTA, V82, P463, DOI 10.1016/0304-4165(64)90438-6; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Ptitsyn Oleg B., 1992, P243; Randolph Theodore W, 2002, Pharm Biotechnol, V13, P159; RAVIN HA, 1952, NEW ENGL J MED, V247, P921, DOI 10.1056/NEJM195212112472403; Remmele RL, 1998, PHARMACEUT RES, V15, P200; RODIONOVA NA, 1989, MOL BIOL+, V23, P528; Rozema D, 1996, BIOCHEMISTRY-US, V35, P15760, DOI 10.1021/bi961638j; ROZEMA D, 1995, J AM CHEM SOC, V117, P2373, DOI 10.1021/ja00113a036; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; SEMISOTNOV GV, 1990, J MOL BIOL, V213, P561, DOI 10.1016/S0022-2836(05)80215-3; Singh R, 2005, J BIOL CHEM, V280, P11035, DOI 10.1074/jbc.M410716200; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; STEIN PJ, 1978, J BIOL CHEM, V253, P8016; TANDON S, 1986, J BIOL CHEM, V261, P5615; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; TOWNSEND M W, 1988, Journal of Parenteral Science and Technology, V42, P190; Tycko R, 2004, CURR OPIN STRUC BIOL, V14, P96, DOI 10.1016/j.sbi.2003.12.002; Uversky VN, 1996, J MOL BIOL, V255, P215, DOI 10.1006/jmbi.1996.0018; VANGELDER P, 1994, EUR J BIOCHEM, V226, P783; VRKLJAN M, 1994, PHARMACEUT RES, V11, P1004, DOI 10.1023/A:1018935420680; WETLAUFER DB, 1995, PROTEIN SCI, V4, P1535, DOI 10.1002/pro.5560040811; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	55	77	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9058	9065		10.1074/jbc.M507874200	http://dx.doi.org/10.1074/jbc.M507874200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16459336	hybrid			2023-01-03	WOS:000236404700010
J	McKee, MG; Layman, JM; Cashion, MP; Long, TE				McKee, MG; Layman, JM; Cashion, MP; Long, TE			Phospholipid nonwoven electrospun membranes	SCIENCE			English	Article							FIBER FORMATION; SURFACE-MORPHOLOGY; MOLECULAR-WEIGHT; POLYMER; NANOFIBERS; MONOLAYER; MICELLES; BEHAVIOR	Nonwoven fibrous membranes were formed from electrospinning lecithin solutions in a single processing step. As the concentration of lecithin increased, the micellar morphology evolved from spherical to cylindrical, and at higher concentrations the cylindrical micelles overlapped and entangled in a fashion similar to polymers in semi-dilute or concentrated solutions. At concentrations above the onset of entanglements of the wormlike micelles, electrospun fibers were fabricated with diameters on the order of 1 to 5 micrometers. The electrospun phospholipid fibers offer the potential for direct fabrication of biologically based, high-surface-area membranes without the use of multiple synthetic steps, complicated electrospinning designs, or postprocessing surface treatments.	Virginia Tech, Dept Chem, MII, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	Long, TE (corresponding author), Virginia Tech, Dept Chem, MII, Blacksburg, VA 24061 USA.	telong@vt.edu						Bai SJ, 2002, J POLYM SCI POL PHYS, V40, P1760, DOI 10.1002/polb.10229; CAPPELAERE E, 1995, COLLOID SURFACE A, V104, P353, DOI 10.1016/0927-7757(95)03332-2; Casper CL, 2004, MACROMOLECULES, V37, P573, DOI 10.1021/ma0351975; CHAPMAN D, 1993, LANGMUIR, V9, P39, DOI 10.1021/la00025a012; Cirkel PA, 1998, LANGMUIR, V14, P7095, DOI 10.1021/la971326x; Deitzel JM, 2001, POLYMER, V42, P261, DOI 10.1016/S0032-3861(01)00336-6; FENDLER JH, 1984, SCIENCE, V223, P888, DOI 10.1126/science.223.4639.888; Fong H, 1999, POLYMER, V40, P4585, DOI 10.1016/S0032-3861(99)00068-3; Fridrikh SV, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.144502; Gupta P, 2005, POLYMER, V46, P4799, DOI 10.1016/j.polymer.2005.04.021; He P, 2005, BIOMACROMOLECULES, V6, P2455, DOI 10.1021/bm050338r; Kanamaru M, 2002, POLYMER, V43, P3925, DOI 10.1016/S0032-3861(02)00218-5; Kim HK, 2005, BIOMATERIALS, V26, P3435, DOI 10.1016/j.biomaterials.2004.09.066; Kim K, 2004, LANGMUIR, V20, P5396, DOI 10.1021/la049959g; Korematsu A, 2002, BIOMATERIALS, V23, P263, DOI 10.1016/S0142-9612(01)00104-1; Lee KH, 2003, POLYMER, V44, P4029, DOI 10.1016/S0032-3861(03)00345-8; Li D, 2004, ADV MATER, V16, P1151, DOI 10.1002/adma.200400719; Magid LJ, 1998, J PHYS CHEM B, V102, P4064, DOI 10.1021/jp9730961; McKee MG, 2004, POLYMER, V45, P8705, DOI 10.1016/j.polymer.2004.10.049; McKee MG, 2004, MACROMOLECULES, V37, P1760, DOI 10.1021/ma035689h; McKee MG, 2005, MACROMOLECULES, V38, P6015, DOI 10.1021/ma050667b; Megelski S, 2002, MACROMOLECULES, V35, P8456, DOI 10.1021/ma020444a; Mezzasalma SA, 2000, LANGMUIR, V16, P10564, DOI 10.1021/la000860t; Morimoto N, 2002, BIOMATERIALS, V23, P4881, DOI 10.1016/S0142-9612(02)00246-6; NAKAI S, 1978, MAKROMOL CHEM, V179, P2349; Pratt C. W., 2004, ESSENTIAL BIOCH, V3rd; Regalado EJ, 1999, MACROMOLECULES, V32, P8580, DOI 10.1021/ma990999e; Reneker DH, 1996, NANOTECHNOLOGY, V7, P216, DOI 10.1088/0957-4484/7/3/009; Rubinstein M, 2001, MACROMOLECULES, V34, P1058, DOI 10.1021/ma0013049; SCHURTENBERGER P, 1990, J PHYS CHEM-US, V94, P3695, DOI 10.1021/j100372a062; SHCHIPUNOV YA, 1995, MAT SCI ENG C-BIOMIM, V3, P43, DOI 10.1016/0928-4931(95)00102-6; Shenoy SL, 2005, POLYMER, V46, P3372, DOI 10.1016/j.polymer.2005.03.011; Ye SH, 2003, BIOMATERIALS, V24, P4143, DOI 10.1016/S0142-9612(03)00296-5	33	239	254	4	224	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					353	355		10.1126/science.1119790	http://dx.doi.org/10.1126/science.1119790			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424332				2023-01-03	WOS:000234938500036
J	Barber, GN				Barber, GN			VSV-tumor selective replication and protein translation	ONCOGENE			English	Review						VSV; translation; oncolytic; virus; interferon; cancer	VESICULAR STOMATITIS-VIRUS; NUCLEOTIDE EXCHANGE FACTOR; CAP-DEPENDENT TRANSLATION; MESSENGER-RNA TRANSLATION; INITIATION-FACTOR EIF2B; MATRIX PROTEIN; MALIGNANT-TRANSFORMATION; TARGETED DISRUPTION; CATALYTIC DOMAIN; INNATE IMMUNITY	The emergence of vesicular stomatatis virus ( VSV) as a potent antitumor agent has made a dissection of the molecular determinants of host-cell permissiveness to this virus an important objective. Such insight would not only enable the intelligent design of future generations of recombinant VSV vectors to combat disease, but may also resolve general features of cellular transformation that may be exploited by this virus, and perhaps other oncolytic viruses. The defective pathways underlining the oncolytic activity of VSV remain to be fully determined but recent data indicates that flaws in innate immune responses, involving the interferon ( IFN) system, may commonly occur in tumor cells and thus play a large role in facilitating oncolysis. Aside from the IFN system, however, it is almost certain that other key cellular pathways may be similarly defective and therefore cooperatively contribute towards mediating rapid oncolytic virus activity. Recent data have indicated that defects in cancer cell translational regulation could be one area that may be exploited by VSV. Certainly, all viruses require cellular protein synthesis pathways to facilitate their replication and many have devised numerous mechanisms to ensure that viral mRNAs become translated at the expense of the host. Using VSV as a model, this review will discuss some of the recent developments in the fields of innate immunity and translational regulation that may help explain mechanisms of viral oncolysis.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami	Barber, GN (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, Sylvester Comprehens Canc Ctr, Room 511,Papanicolaou Bldg,1550 NW 10th St M710, Miami, FL 33136 USA.	gbarber@med.miami.edu						Abbott CM, 2004, TRENDS BIOCHEM SCI, V29, P25, DOI 10.1016/j.tibs.2003.11.006; Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Balachandran S, 2000, IUBMB LIFE, V50, P135, DOI 10.1080/15216540050212169; Ball LA, 1999, J VIROL, V73, P4705, DOI 10.1128/JVI.73.6.4705-4712.1999; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Barber GN, 2004, VIRAL IMMUNOL, V17, P516, DOI 10.1089/vim.2004.17.516; Barber GN, 2000, SEMIN CANCER BIOL, V10, P103, DOI 10.1006/scbi.2000.0313; Bergman I, 2003, VIROLOGY, V316, P337, DOI 10.1016/j.virol.2003.07.010; Bergmann M, 2001, CANCER RES, V61, P8188; BI ZB, 1995, J VIROL, V69, P6466, DOI 10.1128/JVI.69.10.6466-6472.1995; Biederer C, 2002, J MOL MED-JMM, V80, P163, DOI 10.1007/s00109-001-0295-1; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Boehme KW, 2004, J VIROL, V78, P7867, DOI 10.1128/JVI.78.15.7867-7873.2004; Carneiro FA, 2002, J VIROL, V76, P3756, DOI 10.1128/JVI.76.8.3756-3764.2002; Chiocca EA, 2002, NAT REV CANCER, V2, P938, DOI 10.1038/nrc948; Clemens MJ, 2001, PROG MOLEC, V27, P57; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Connor JH, 2005, J BIOL CHEM, V280, P13512, DOI 10.1074/jbc.M501156200; Connor JH, 2002, J VIROL, V76, P10177, DOI 10.1128/JVI.76.20.10177-10187.2002; DEMATTOS C, 2001, RHABDOVIRIDAE VIRUSE; Desforges M, 2001, VIRUS RES, V76, P87, DOI 10.1016/S0168-1702(01)00251-9; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Ebert O, 2004, CANCER RES, V64, P3265, DOI 10.1158/0008-5472.CAN-03-3753; Enninga J, 2002, SCIENCE, V295, P1523, DOI 10.1126/science.1067861; Faria PA, 2005, MOL CELL, V17, P93, DOI 10.1016/j.molcel.2004.11.023; Fernandez M, 2002, J VIROL, V76, P895, DOI 10.1128/JVI.76.2.895-904.2002; Gomez E, 2002, EMBO J, V21, P5292, DOI 10.1093/emboj/cdf515; HAMMON WMD, 1963, J NATL CANCER I, V31, P329; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hii SI, 2004, INT J CANCER, V109, P329, DOI 10.1002/ijc.11714; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kimball S R, 2001, Prog Mol Subcell Biol, V26, P155; Kimball SR, 1998, J BIOL CHEM, V273, P3039, DOI 10.1074/jbc.273.5.3039; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Lamberti A, 2004, AMINO ACIDS, V26, P443, DOI 10.1007/s00726-004-0088-2; Leegwater PAJ, 2001, NAT GENET, V29, P383, DOI 10.1038/ng764; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LODISH HF, 1980, J VIROL, V36, P719, DOI 10.1128/JVI.36.3.719-733.1980; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Merrick WC, 2004, GENE, V332, P1, DOI 10.1016/j.gene.2004.02.051; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Obuchi M, 2003, J VIROL, V77, P8843, DOI 10.1128/JVI.77.16.8843-8856.2003; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; Pasare C, 2003, CURR OPIN IMMUNOL, V15, P677, DOI 10.1016/j.coi.2003.09.002; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Petersen JM, 2000, MOL CELL BIOL, V20, P8590, DOI 10.1128/MCB.20.22.8590-8601.2000; Pitha PM, 2000, SEMIN CANCER BIOL, V10, P69, DOI 10.1006/scbi.2000.0309; PLAKHOV IV, 1995, VIROLOGY, V209, P257, DOI 10.1006/viro.1995.1252; Porosnicu M, 2003, CANCER RES, V63, P8366; Proud C G, 2001, Prog Mol Subcell Biol, V26, P95; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Roberts A, 1998, J VIROL, V72, P4704, DOI 10.1128/JVI.72.6.4704-4711.1998; Roberts A, 1999, J VIROL, V73, P3723, DOI 10.1128/JVI.73.5.3723-3732.1999; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rose JKWMA., 2001, RHABDOVIRIDAE VIRUSE; Rose NF, 2000, J VIROL, V74, P10903, DOI 10.1128/JVI.74.23.10903-10910.2000; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Schnell MJ, 1996, J VIROL, V70, P2318, DOI 10.1128/JVI.70.4.2318-2323.1996; Schnell MJ, 1997, CELL, V90, P849, DOI 10.1016/S0092-8674(00)80350-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310; Thomsen AR, 1997, INT IMMUNOL, V9, P1757, DOI 10.1093/intimm/9.11.1757; Tough DF, 2004, LEUKEMIA LYMPHOMA, V45, P257, DOI 10.1080/1042819031000149368; van den Pol AN, 2002, J VIROL, V76, P1309, DOI 10.1128/JVI.76.3.1309-1327.2002; Varghese S, 2002, CANCER GENE THER, V9, P967, DOI 10.1038/sj.cgt.7700537; von Kobbe C, 2000, MOL CELL, V6, P1243, DOI 10.1016/S1097-2765(00)00120-9; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wang XM, 2001, EMBO J, V20, P4349, DOI 10.1093/emboj/20.16.4349; Williams DD, 2001, J BIOL CHEM, V276, P24697, DOI 10.1074/jbc.M011788200; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200	92	119	127	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7710	7719		10.1038/sj.onc.1209042	http://dx.doi.org/10.1038/sj.onc.1209042			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299531				2023-01-03	WOS:000233372600007
J	Thorsdottir, I				Thorsdottir, I			Supplement and stimulation for stunted children	LANCET			English	Editorial Material							NUTRITIONAL SUPPLEMENTATION; EARLY-CHILDHOOD; PSYCHOSOCIAL STIMULATION; GROWTH; COGNITION; BENEFITS		Landspitali Univ Hosp, Unit Nutr Res, IS-101 Reykjavik, Iceland; Univ Iceland, Landspitali, IS-101 Reykjavik, Iceland	Landspitali National University Hospital; University of Iceland	Thorsdottir, I (corresponding author), Landspitali Univ Hosp, Unit Nutr Res, IS-101 Reykjavik, Iceland.	ingathor@landspitali.is	Thorsdottir, Inga/M-3260-2015	Thorsdottir, Inga/0000-0002-2946-287X				Berkman DS, 2002, LANCET, V359, P564, DOI 10.1016/S0140-6736(02)07744-9; Daniels MC, 2004, J NUTR, V134, P1439, DOI 10.1093/jn/134.6.1439; Glewwe P, 2001, J PUBLIC ECON, V81, P345, DOI 10.1016/S0047-2727(00)00118-3; GRANTHAMMCGREGOR SM, 1991, LANCET, V338, P1, DOI 10.1016/0140-6736(91)90001-6; Mendez MA, 1999, J NUTR, V129, P1555, DOI 10.1093/jn/129.8.1555; Pollitt E, 1997, AM J CLIN NUTR, V66, P1357, DOI 10.1093/ajcn/66.6.1357; Pollitt E, 1993, Monogr Soc Res Child Dev, V58, P1; *UN SYST STAND COM, 2004, 5 UN SYST STAND COMM; Walker SP, 1996, J NUTR, V126, P3017, DOI 10.1093/jn/126.12.3017; Walker SP, 2005, LANCET, V366, P1804, DOI 10.1016/S0140-6736(05)67574-5; Walker SP, 2000, J PEDIATR-US, V137, P36, DOI 10.1067/mpd.2000.106227	11	1	1	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 19	2005	366	9499					1756	1758		10.1016/S0140-6736(05)67538-1	http://dx.doi.org/10.1016/S0140-6736(05)67538-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	987KQ	16298203				2023-01-03	WOS:000233517200006
J	Herron, BJ; Liddell, RA; Parker, A; Grant, S; Kinne, J; Fisher, JK; Siracusa, LD				Herron, BJ; Liddell, RA; Parker, A; Grant, S; Kinne, J; Fisher, JK; Siracusa, LD			A mutation in stratifin is responsible for the repeated epilation (Er) phenotype in mice	NATURE GENETICS			English	Article							14-3-3-SIGMA; CANCER; MUTANT; MOUSE	Stratifin (Sfn, also called 14-3-3 sigma) is highly expressed in differentiating epidermis and mediates cell cycle arrest. Sfn is repressed in cancer, but its function during development is uncharacterized. We identified an insertion mutation in the gene Sfn in repeated epilation (Er) mutant mice by positional cloning. Er/+ mice expressed a truncated Sfn protein, which probably contributes to the defects in Er/Er and Er/+ epidermis and to cancer development in Er/+ mice.	New York State Dept Hlth, Wadsworth Ctr, Genom Inst, Albany, NY 12180 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	State University of New York (SUNY) System; Wadsworth Center; Jefferson University	Herron, BJ (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Genom Inst, 465 Jordan Rd, Albany, NY 12180 USA.	bherron@wadsworth.org						Benzinger A, 2005, MOL CELL PROTEOMICS, V4, P785, DOI 10.1074/mcp.M500021-MCP200; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; FISHER C, 1987, J CELL BIOL, V105, P1807, DOI 10.1083/jcb.105.4.1807; GUENET JL, 1994, HDB MOUSE MUTATION S, P399; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hunsicker PR, 1960, MOUSE NEWSLETT, V23, P58; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; LUTZNER MA, 1985, JNCI-J NATL CANCER I, V75, P161; O'Shaughnessy RFL, 2004, INT J DEV BIOL, V48, P171, DOI 10.1387/ijdb.15272382; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Wilker EW, 2005, J BIOL CHEM, V280, P18891, DOI 10.1074/jbc.M500982200; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349	12	59	59	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2005	37	11					1210	1212		10.1038/ng1652	http://dx.doi.org/10.1038/ng1652			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	980VB	16200063				2023-01-03	WOS:000233045200019
J	Ahmed, S				Ahmed, S			Tie it and trust	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									YSM IV, New Haven, CT 06520 USA		Ahmed, S (corresponding author), YSM IV, New Haven, CT 06520 USA.	shobi.ahmed@yale.edu							0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2005	294	15					1873	1874		10.1001/jama.294.15.1873	http://dx.doi.org/10.1001/jama.294.15.1873			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974OZ	16234487				2023-01-03	WOS:000232602600001
J	Henderson, GS				Henderson, GS			Hurricane Katrina - Finding supplies	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ochsner Clin Fdn, New Orleans, LA 70121 USA	Ochsner Health System	Henderson, GS (corresponding author), Ochsner Clin Fdn, New Orleans, LA 70121 USA.								0	5	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1542	1542		10.1056/NEJMp058230	http://dx.doi.org/10.1056/NEJMp058230			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221771				2023-01-03	WOS:000232486000002
J	Sachedina, A				Sachedina, A			End-of-life: the Islamic view	LANCET			English	Editorial Material									Univ Virginia, Dept Religious Studies, Charlottesville, VA 22904 USA	University of Virginia	Sachedina, A (corresponding author), Univ Virginia, Dept Religious Studies, POB 400126, Charlottesville, VA 22904 USA.	aas@cms.mail.virginia.edu						AHMAD B, 1965, KITAB ALMAHASIN, P123; *ALQ ALTH BISH MAW, 1990, MAJALLA ALBUHUTH ALF, V4, P159; HABIBI H, 2001, MARGI MAGHZI DIDGAHI; HAYYAN AA, 1992, ALMUQABASAT, P132; MUHAMMAD B, 1979, JAMI ALSAHIHI KITAB, P373; RISPLERCHAIM V, 1993, ISLAMIC MED ETHICS 2, P63; Sachedina A., 1995, ENCY BIOETHICS, P1289	7	113	114	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					774	779		10.1016/S0140-6736(05)67183-8	http://dx.doi.org/10.1016/S0140-6736(05)67183-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	958UV	16125596				2023-01-03	WOS:000231474600035
J	Osterberg, L; Blaschke, T				Osterberg, L; Blaschke, T			Drug therapy - Adherence to medication	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AIDS CLINICAL-TRIALS; ANTIRETROVIRAL MEDICATION; TREATMENT NONADHERENCE; REPORTED ADHERENCE; PATIENT COMPLIANCE; PHARMACY RECORDS; STATIN THERAPY; HEART-FAILURE; SELF-REPORT; PREDICTORS		VA Palo Alto Hlth Care Syst, Div Gen Med, Palo Alto, CA 94304 USA; Stanford Univ, Med Ctr, Div Clin Pharmacol, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Osterberg, L (corresponding author), VA Palo Alto Hlth Care Syst, Div Gen Med, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	larso@stanford.edu		Blaschke, Terrence/0000-0001-5307-2620				Alcoba M, 2003, JAIDS-J ACQ IMM DEF, V33, P253, DOI 10.1097/00126334-200306010-00022; Ammassari A, 2002, JAIDS, V31, pS123, DOI 10.1097/00126334-200212153-00007; Balkrishnan R, 1998, CLIN THER, V20, P764, DOI 10.1016/S0149-2918(98)80139-2; Benner JS, 2002, JAMA-J AM MED ASSOC, V288, P455, DOI 10.1001/jama.288.4.455; BERG JS, 1993, ANN PHARMACOTHER, V27, pS1; Bhanji NH, 2004, EUR NEUROPSYCHOPHARM, V14, P87, DOI 10.1016/S0924-977X(03)00109-3; Black HR, 1999, AM J HYPERTENS, V12, p225S; Blaiss M, 2004, CLIN THER, V26, P1876, DOI 10.1016/j.clinthera.2004.11.003; Bouvy ML, 2003, J CARD FAIL, V9, P404, DOI 10.1054/S1071-9164(03)00130-1; Brackis-Cott Elizabeth, 2003, J Pediatr Health Care, V17, P252, DOI 10.1016/S0891-5245(02)88313-4; Burnier M, 2001, J HYPERTENS, V19, P335, DOI 10.1097/00004872-200102000-00022; Burnier M, 2000, BLOOD PRESS MONIT, V5, pS31, DOI 10.1097/00126097-200005001-00006; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773; Christensen DB, 1997, MED CARE, V35, P1164, DOI 10.1097/00005650-199711000-00008; Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016/S0149-2918(01)80109-0; Colom Francesc, 2000, Journal of Clinical Psychiatry, V61, P549; Cramer J, 2003, VALUE HEALTH, V6, P566, DOI 10.1046/j.1524-4733.2003.65269.x; Cramer J., 1991, PATIENT COMPLIANCE M, P387; CRAMER JA, 1990, ARCH INTERN MED, V150, P1509, DOI 10.1001/archinte.150.7.1509; Cramer JA, 1998, PSYCHIATR SERV, V49, P196, DOI 10.1176/ps.49.2.196; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V262, P1472; CRAMER JA, 1995, NEUROLOGY, V45, pS25; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; Crespo-Fierro M, 1997, J Assoc Nurses AIDS Care, V8, P43, DOI 10.1016/S1055-3290(97)80012-X; DIMATTEO MR, 1993, HEALTH PSYCHOL, V12, P93, DOI 10.1037/0278-6133.12.2.93; Dunbar PJ, 2003, J AM MED INFORM ASSN, V10, P11, DOI 10.1197/jamia.M1047; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; Elliott WJ, 2000, POSTGRAD MED, V107, P29, DOI 10.3810/pgm.2000.03.940; Ellis JJ, 2004, J GEN INTERN MED, V19, P638, DOI 10.1111/j.1525-1497.2004.30516.x; EPSTEIN LH, 1981, J APPL BEHAV ANAL, V14, P365, DOI 10.1901/jaba.1981.14-365; Farley J, 2003, JAIDS-J ACQ IMM DEF, V33, P211, DOI 10.1097/00126334-200306010-00016; Farris KB, 2004, CAN FAM PHYSICIAN, V50, P998; FEINSTEIN AR, 1990, ARCH INTERN MED, V150, P1377, DOI 10.1001/archinte.150.7.1377; Feldman R, 1998, CAN J PUBLIC HEALTH, V89, pI16, DOI 10.1007/BF03404494; FESTA RS, 1992, J PEDIATR-US, V120, P807, DOI 10.1016/S0022-3476(05)80256-2; FRIEDMAN IM, 1986, J ADOLESCENT HEALTH, V7, P12, DOI 10.1016/S0197-0070(86)80088-2; FRIEDMAN IM, 1987, J ADOLESCENT HEALTH, V8, P52, DOI 10.1016/0197-0070(87)90246-4; Fulmer T T, 1999, J Gerontol Nurs, V25, P6; GILLIS LS, 1987, S AFR MED J, V72, P602; Golin CE, 2002, J GEN INTERN MED, V17, P756, DOI 10.1046/j.1525-1497.2002.11214.x; Golin CE, 1996, DIABETES CARE, V19, P1153, DOI 10.2337/diacare.19.10.1153; GREENANFOWLER E, 1987, ARCH PHYS MED REHAB, V68, P846; GREENBERG RN, 1984, CLIN THER, V6, P592; Haynes R B, 2002, Cochrane Database Syst Rev, pCD000011; Haynes RB, 2002, JAMA-J AM MED ASSOC, V288, P2880, DOI 10.1001/jama.288.22.2880; HAYNES RB, 1980, HYPERTENSION, V2, P757, DOI 10.1161/01.HYP.2.6.757; Hoffman L, 2003, AM J MANAG CARE, V9, P70; HORWITZ RI, 1993, ARCH INTERN MED, V153, P1863, DOI 10.1001/archinte.153.16.1863; Ickovics JR, 1997, J CLIN EPIDEMIOL, V50, P385, DOI 10.1016/S0895-4356(97)00041-3; Ickovics JR, 2002, ANTIVIR THER, V7, P185; Ickovics JR, 2002, AIDS CARE, V14, P309, DOI 10.1080/09540120220123685; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; JAY S, 1984, J ADOLESCENT HEALTH, V5, P124, DOI 10.1016/S0197-0070(84)80012-1; KASS MA, 1984, ARCH OPHTHALMOL-CHIC, V102, P1550; Kastrissios H, 1998, AIDS, V12, P2305, DOI 10.1097/00002030-199817000-00012; Lacro JP, 2002, J CLIN PSYCHIAT, V63, P892, DOI 10.4088/JCP.v63n1007; LaRosa J C, 2000, Curr Atheroscler Rep, V2, P1, DOI 10.1007/s11883-000-0086-0; Lau HS, 1997, J CLIN EPIDEMIOL, V50, P619, DOI 10.1016/S0895-4356(97)00040-1; Levy G, 2000, CLIN PHARMACOL THER, V68, P586, DOI 10.1067/mcp.2000.110976; Liu H, 2002, ANN INTERN MED, V136, P175, DOI 10.7326/0003-4819-134-10-200105150-00011; Liu HH, 2001, ANN INTERN MED, V134, P968, DOI 10.7326/0003-4819-134-10-200105150-00011; Loghmain-Adham M, 2003, AM J MANAG CARE, V9, P155; Love RC, 2002, AM J HEALTH-SYST PH, V59, pS10, DOI 10.1093/ajhp/59.suppl_8.S10; MAGRAB PR, 1977, J APPL BEHAV ANAL, V10, P573, DOI 10.1901/jaba.1977.10-573; Maro EE, 1997, E AFR MED J, V74, P539; McDonnell PJ, 2002, ANN PHARMACOTHER, V36, P1331, DOI 10.1345/aph.1A333; Michaud PA, 2004, ARCH DIS CHILD, V89, P943, DOI 10.1136/adc.2003.045377; Miller LG, 2002, J GEN INTERN MED, V17, P1, DOI 10.1046/j.1525-1497.2002.09004.x; Misdrahi D, 2002, ENCEPHALE, V28, P266; Mitchell P B, 1994, Aust Fam Physician, V23, P1771; Mitchell PB, 1994, AUST FAM PHYSICIAN, V23, P1776; Molassiotis A, 2003, AIDS CARE, V15, P125, DOI 10.1080/0954012021000039833; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Mundt JC, 2001, DEPRESS ANXIETY, V13, P1, DOI 10.1002/1520-6394(2001)13:1<1::AID-DA1>3.0.CO;2-S; Murphy DA, 2003, ARCH PEDIAT ADOL MED, V157, P249, DOI 10.1001/archpedi.157.3.249; Murri R, 2004, J GEN INTERN MED, V19, P1104, DOI 10.1111/j.1525-1497.2004.30248.x; Nemeroff CB, 2003, J CLIN PSYCHIAT, V64, P25; NORELL SE, 1981, AM J OPHTHALMOL, V92, P727, DOI 10.1016/S0002-9394(14)74670-7; Nose M, 2003, BRIT J PSYCHIAT, V183, P197, DOI 10.1192/bjp.183.3.197; Ofman JJ, 2004, AM J MED, V117, P182, DOI 10.1016/j.amjmed.2004.03.018; Okuno J, 2001, EUR J CLIN PHARMACOL, V57, P589, DOI 10.1007/s002280100347; OSTERBERG LG, 2005, HYPERTENSION COMPANI, P848, DOI DOI 10.1016/B978-0-7216-0258-5.50131-9; Paes AHP, 1997, DIABETES CARE, V20, P1512, DOI 10.2337/diacare.20.10.1512; Paterson DL, 2002, JAIDS, V31, pS103, DOI 10.1097/00126334-200212153-00003; Patton K, 1997, AM J MANAG C, V3, P1693; Pekkala E, 2002, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002831; Perkins DO, 2002, J CLIN PSYCHIAT, V63, P1121, DOI 10.4088/JCP.v63n1206; PULLAR T, 1989, CLIN PHARMACOL THER, V46, P163, DOI 10.1038/clpt.1989.121; Ran MS, 2003, SOC PSYCH PSYCH EPID, V38, P69, DOI 10.1007/s00127-003-0601-z; RAPOFF MA, 1984, ARCH PHYS MED REHAB, V65, P267; RAPOFF MA, 1989, ARTHRITIS CARE RES S, V2, P40; Rigsby MO, 2000, J GEN INTERN MED, V15, P841, DOI 10.1046/j.1525-1497.2000.00127.x; Rodgers P T, 1998, Manag Care Interface, V11, P67; RODGERS PT, 1998, MANAG CARE INTERFACE, V11, P75; Rosenheck R, 2000, J CLIN PSYCHIAT, V61, P382, DOI 10.4088/JCP.v61n0511; ROSS FM, 1991, SOC SCI MED, V32, P89, DOI 10.1016/0277-9536(91)90132-V; RUDD P, 1988, AM J HYPERTENS, V1, P309, DOI 10.1093/ajh/1.3.309; Sabate E, 2003, ADHERENCE LONG TERM; Safren SA, 2001, BEHAV RES THER, V39, P1151, DOI 10.1016/S0005-7967(00)00091-7; Schiff GD, 2003, AM J MED, V114, P625, DOI 10.1016/S0002-9343(03)00132-3; Schroeder K, 2004, ARCH INTERN MED, V164, P722, DOI 10.1001/archinte.164.7.722; Senst BL, 2001, AM J HEALTH-SYST PH, V58, P1126, DOI 10.1093/ajhp/58.12.1126; Sewitch MJ, 2003, AM J GASTROENTEROL, V98, P1535, DOI 10.1016/S0002-9270(03)00304-6; Shon KH, 2002, YONSEI MED J, V43, P579, DOI 10.3349/ymj.2002.43.5.579; Simoni Jane M, 2003, Top HIV Med, V11, P185; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8; SPILKER B, 1991, PATIENT COMPLIANCE M, P37; Steiner JF, 2000, ANN INTERN MED, V132, P926, DOI 10.7326/0003-4819-132-11-200006060-00026; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; Stilley CS, 2004, ANN BEHAV MED, V27, P117, DOI 10.1207/s15324796abm2702_6; Stone VE, 2001, J ACQ IMMUN DEF SYND, V28, P124, DOI 10.1097/00042560-200110010-00003; Stuart B, 1999, HEALTH AFFAIR, V18, P201, DOI 10.1377/hlthaff.18.2.201; TEBBI CK, 1993, CANCER, V71, P3441, DOI 10.1002/1097-0142(19930515)71:10+<3441::AID-CNCR2820711751>3.0.CO;2-P; TEBBI CK, 1986, CANCER, V58, P1179, DOI 10.1002/1097-0142(19860901)58:5<1179::AID-CNCR2820580534>3.0.CO;2-E; Tucker CM, 2002, PEDIATR NEPHROL, V17, P251, DOI 10.1007/s00467-001-0806-x; Tuldra A, 2000, J ACQ IMMUN DEF SYND, V25, P221, DOI 10.1097/00126334-200011010-00003; Turner BJ, 2001, ANN INTERN MED, V134, P1004, DOI 10.7326/0003-4819-134-10-200105150-00015; Urquhart J, 2002, BRIT J CLIN PHARMACO, V54, P212, DOI 10.1046/j.1365-2125.2002.01629.x; Urquhart J, 1997, CLIN PHARMACOKINET, V32, P345, DOI 10.2165/00003088-199732050-00001; Van Servellen G, 2002, AIDS PATIENT CARE ST, V16, P269, DOI 10.1089/10872910260066705; Vergouwen A C M, 2002, Ned Tijdschr Geneeskd, V146, P204; Vrijens B, 1997, CONTROL CLIN TRIALS, V18, P187, DOI 10.1016/S0197-2456(96)00235-8; Waeber B, 1999, J HYPERTENS, V17, P1041, DOI 10.1097/00004872-199917070-00022; Wagner JH, 2001, J CLIN EPIDEMIOL, V54, pS91, DOI 10.1016/S0895-4356(01)00450-4; Walsh JC, 2002, AIDS, V16, P269, DOI 10.1097/00002030-200201250-00017; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; Wilson J, 2005, AM J MANAG CARE, V11, pSP27; Zyczynski T M, 2000, Curr Hypertens Rep, V2, P510, DOI 10.1007/s11906-996-0034-7; Zygmunt A, 2002, AM J PSYCHIAT, V159, P1653, DOI 10.1176/appi.ajp.159.10.1653	131	5446	5654	19	487	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 4	2005	353	5					487	497		10.1056/NEJMra050100	http://dx.doi.org/10.1056/NEJMra050100			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	951OB	16079372				2023-01-03	WOS:000230939000008
J	Mann, J				Mann, J			The Indo-Mediterranean diet revisited	LANCET			English	Editorial Material							DISEASE		Univ Otago, Dept Human Nutr, Dunedin, New Zealand; Univ Otago, Dept Med, Dunedin, New Zealand	University of Otago; University of Otago	Mann, J (corresponding author), Univ Otago, Dept Human Nutr, Dunedin, New Zealand.	jim.mann@stonebow.otago.ac.nz						Berry EM, 2005, LANCET, V366, P366, DOI 10.1016/S0140-6736(05)67015-8; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; Soman CR, 2005, LANCET, V366, P365, DOI 10.1016/S0140-6736(05)67014-6; Trichopoulou A, 2005, BMJ-BRIT MED J, V330, P991, DOI 10.1136/bmj.38415.644155.8F	6	12	12	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 30	2005	366	9483					353	354		10.1016/S0140-6736(05)67005-5	http://dx.doi.org/10.1016/S0140-6736(05)67005-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	950IB	16054926				2023-01-03	WOS:000230849700009
J	Sengupta, S; Eavarone, D; Capila, I; Zhao, GL; Watson, N; Kiziltepe, T; Sasisekharan, R				Sengupta, S; Eavarone, D; Capila, I; Zhao, GL; Watson, N; Kiziltepe, T; Sasisekharan, R			Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system	NATURE			English	Article							ANGIOGENESIS INHIBITORS; ANTIANGIOGENIC THERAPY; HYPOXIA; VASCULATURE; GROWTH	In the continuing search for effective treatments for cancer, the emerging model is the combination of traditional chemotherapy with anti-angiogenesis agents(1) that inhibit blood vessel growth. However, the implementation of this strategy has faced two major obstacles. First, the long-term shutdown of tumour blood vessels by the anti-angiogenesis agent can prevent the tumour from receiving a therapeutic concentration of the chemotherapy agent. Second, inhibiting blood supply drives the intra-tumoural accumulation of hypoxia-inducible factor-1 alpha (HIF1-alpha); overexpression of HIF1-alpha is correlated with increased tumour invasiveness and resistance to chemotherapy(2-5). Here we report the disease-driven engineering of a drug delivery system, a 'nanocell', which overcomes these barriers unique to solid tumours. The nanocell comprises a nuclear nanoparticle within an extranuclear pegylated-lipid envelope, and is preferentially taken up by the tumour. The nanocell enables a temporal release of two drugs: the outer envelope first releases an anti-angiogenesis agent, causing a vascular shutdown; the inner nanoparticle, which is trapped inside the tumour, then releases a chemotherapy agent. This focal release within a tumour results in improved therapeutic index with reduced toxicity. The technology can be extended to additional agents, so as to target multiple signalling pathways or distinct tumour compartments, enabling the model of an 'integrative' approach in cancer therapy.	MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Sasisekharan, R (corresponding author), MIT, Biol Engn Div, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	rams@MIT.edu						Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Blagosklonny MV, 2004, CANCER CELL, V5, P13, DOI 10.1016/S1535-6108(03)00336-2; Chabner B.A, 1996, GOODMAN GILMANS PHAR; Hanahan D, 2000, J CLIN INVEST, V105, P1045, DOI 10.1172/JCI9872; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Kieran MW, 2003, NAT MED, V9, P1104, DOI 10.1038/nm0903-1104a; MIKLOS AG, 1994, BIOMATERIALS, V15, P55; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Rofstad EK, 2002, CANCER RES, V62, P1847; Semenza GL, 2000, J CLIN INVEST, V106, P809, DOI 10.1172/JCI11223; Sengupta S, 2004, FASEB J, V18, P1565, DOI 10.1096/fj.04-1934fje; Tong RT, 2004, CANCER RES, V64, P3731, DOI 10.1158/0008-5472.CAN-04-0074; Tozer GM, 2002, INT J EXP PATHOL, V83, P21, DOI 10.1046/j.1365-2613.2002.00211.x; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Yoo HS, 1999, PHARMACEUT RES, V16, P1114, DOI 10.1023/A:1018908421434; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; YUAN F, 1995, CANCER RES, V55, P3752	21	763	814	10	344	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 28	2005	436	7050					568	572		10.1038/nature03794	http://dx.doi.org/10.1038/nature03794			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	949LE	16049491				2023-01-03	WOS:000230788800064
J	DuPont, HL; Jiang, ZD; Okhuysen, PC; Ericsson, CD; de la Cabada, FJ; Ke, S; DuPont, MW; Martinez-Sandoval, F				DuPont, HL; Jiang, ZD; Okhuysen, PC; Ericsson, CD; de la Cabada, FJ; Ke, S; DuPont, MW; Martinez-Sandoval, F			A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea	ANNALS OF INTERNAL MEDICINE			English	Article							IRRITABLE-BOWEL-SYNDROME; ESCHERICHIA-COLI; BACTERIAL GASTROENTERITIS; SUSCEPTIBILITY; THERAPY; ENTEROPATHOGENS; TRIMETHOPRIM; PROPHYLAXIS; EMERGENCE; RIFAMYCIN	Background: Travelers' diarrhea causes substantial morbidity and postinfectious irritable bowel syndrome. Objective: To evaluate nonabsorbable rifaximin for prevention of travelers' diarrhea. Design: Randomized, double-blind, placebo-controlled clinical trial. Setting: Guadalajara, Mexico. Participants: U.S. students. Intervention: on arrival in Guadalajara, Mexico, 210 U.S. adults received rifaximin (200 mg/d, 200 mg twice daily, or 200 mg 3 times daily) or placebo for 2 weeks. Measurements: Participants were followed daily for 3 weeks for enteric disease and symptoms and daily for 5 weeks for drug side effects. Changes in intestinal coliform flora were studied. Results: Travelers' diarrhea developed in 14.74% of participants taking rifaximin and 53.70% of those taking placebo (rate ratio, 0.27 [95% CI, 0.17 to 0.43]). Rifaximin provided 72% and 77% protection against travelers' diarrhea and anti biotic-treated travelers' diarrhea, respectively (P < 0.001 for both), and all rifaximin doses were superior to placebo. in the groups that did not report travelers' diarrhea, rifaximin significantly reduced the occurrence of mild diarrhea (P = 0.02) and moderate and severe intestinal problems (P = 0.009 for pain or cramps; P = 0.02 for excessive gas). Rates of adverse events were comparable in the rifaximin and placebo groups. Minimal changes in coliform flora were found during rifaximin therapy. Limitations: Rifaximin safely prevented travelers' diarrhea in Mexico, where most cases are caused by diarrhea-producing Escherichia coli. A study is needed in Asia to determine whether rifaximin can prevent diarrhea caused by invasive bacterial pathogens. Conclusions: Rifaximin prevents travelers' diarrhea with minimal changes in fecal flora, and more liberal chemoprophylaxis against this disease should be considered. Future studies should evaluate whether rifaximin is effective in preventing postinfectious irritable bowel syndrome.	Univ Texas, Baylor Coll Med, St Lukes Episcopal Hosp, Houston, TX USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Hosp Gen Occidente Seguro Social, Guadalajara, Jalisco, Mexico; Univ Autonoma Guadalajara, Guadalajara, Jalisco, Mexico	Baylor College of Medicine; Saint Lukes Episcopal Hospital; University of Texas System; University of Texas System; UTMD Anderson Cancer Center; Universidad Autonoma de Guadalajara	DuPont, HL (corresponding author), 6720 Bertner Ave,MC 1-164, Houston, TX 77030 USA.	hdupont@sleh.com	DuPont, Herbert/AAH-6776-2021	Okhuysen, Pablo/0000-0002-1596-3411	NIAID NIH HHS [N01-AI-25465] Funding Source: Medline; NIDDK NIH HHS [DK 56338] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi JA, 2003, CLIN INFECT DIS, V37, P1165, DOI 10.1086/378746; Adachi JA, 2001, CLIN INFECT DIS, V32, P1706, DOI 10.1086/320756; ALEXANDER WJ, 1980, INFECT IMMUN, V28, P923; CORAZZA GR, 1988, J INT MED RES, V16, P312, DOI 10.1177/030006058801600410; DUPONT H, 1993, GASTROINTESTINAL DIS, V2, P1; DUPONT HL, 1982, REV INFECT DIS, V4, P533; DuPont HL, 2004, CLIN MICROBIOL INFEC, V10, P1009, DOI 10.1111/j.1469-0691.2004.00997.x; DUPONT HL, 1993, NEW ENGL J MED, V328, P1821, DOI 10.1056/NEJM199306243282507; DuPont HL, 2001, CLIN INFECT DIS, V33, P1807, DOI 10.1086/323814; DuPont HL, 1998, DIGESTION, V59, P708, DOI 10.1159/000007580; DUPONT HL, 1987, JAMA-J AM MED ASSOC, V257, P1347, DOI 10.1001/jama.257.10.1347; GILLIS JC, 1995, DRUGS, V49, P467, DOI 10.2165/00003495-199549030-00009; Gomi H, 2001, ANTIMICROB AGENTS CH, V45, P212, DOI 10.1128/AAC.45.1.212-216.2001; Hilton, 1997, J Travel Med, V4, P41, DOI 10.1111/j.1708-8305.1997.tb00772.x; HOOVER WW, 1993, DIAGN MICR INFEC DIS, V16, P111, DOI 10.1016/0732-8893(93)90004-Q; Ilnyckyj A, 2003, AM J GASTROENTEROL, V98, P596, DOI [10.1016/S0002-9270(02)06019-7, 10.1111/j.1572-0241.2003.07297.x]; Jiang ZD, 2000, ANTIMICROB AGENTS CH, V44, P2205, DOI 10.1128/AAC.44.8.2205-2206.2000; Jiang ZD, 2000, J INFECT DIS, V181, P779, DOI 10.1086/315272; Jiang ZD, 2002, J INFECT DIS, V185, P497, DOI 10.1086/338834; JOHNSON PC, 1986, ANTIMICROB AGENTS CH, V30, P671, DOI 10.1128/AAC.30.5.671; MERSON MH, 1976, NEW ENGL J MED, V294, P1299, DOI 10.1056/NEJM197606102942401; Miglio F, 1997, CURR MED RES OPIN, V13, P593, DOI 10.1185/03007999709113333; Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011; MURRAY BE, 1982, NEW ENGL J MED, V306, P130, DOI 10.1056/NEJM198201213060302; Okhuysen PC, 2004, AM J GASTROENTEROL, V99, P1774, DOI 10.1111/j.1572-0241.2004.30435.x; Parry SD, 2003, AM J GASTROENTEROL, V98, P327, DOI [10.1016/S0002-9270(02)05910-5, 10.1111/j.1572-0241.2003.07242.x]; Parry SD, 2003, AM J GASTROENTEROL, V98, P1970, DOI 10.1016/S0002-9270(03)00627-0; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; REVES RR, 1988, ARCH INTERN MED, V148, P2421, DOI 10.1001/archinte.148.11.2421; RIVA S, 1973, ANTIMICROB AGENTS CH, V3, P456, DOI 10.1128/AAC.3.4.456; SACK DA, 1978, NEW ENGL J MED, V298, P758, DOI 10.1056/NEJM197804062981402; Som R., 1996, PRACTICAL SAMPLING T, V2nd; Soro Ornella, 1997, Clin Microbiol Infect, V3, P147; Spiller RC, 2000, GUT, V47, P804, DOI 10.1136/gut.47.6.804; Spiller RC, 2002, GUT, V51, P759, DOI 10.1136/gut.51.6.759; Steffen R, 2003, AM J GASTROENTEROL, V98, P1073, DOI [10.1016/S0002-9270(02)06005-7, 10.1111/j.1572-0241.2003.07283.x]; STEFFEN R, 1986, ANTIMICROB AGENTS CH, V29, P625, DOI 10.1128/AAC.29.4.625; STRACCIARI JM, 1987, CHEMIOTERAPIA, V6, P82; TAYLOR D, 2004, AM SOC TROP MED HYG; TJOA WS, 1977, AM J EPIDEMIOL, V106, P61, DOI 10.1093/oxfordjournals.aje.a112433; von Sonnenburg F, 2000, LANCET, V356, P133, DOI 10.1016/S0140-6736(00)02451-X; VOSBECK K, 1979, REV INFECT DIS, V1, P845; WOOD LV, 1983, APPL ENVIRON MICROB, V46, P328, DOI 10.1128/AEM.46.2.328-332.1983; 1985, TRAV DIARRH NAT I HL; 1986, REV INFECT DIS S2, V8, pS109	45	153	164	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2005	142	10					805	812		10.7326/0003-4819-142-10-200505170-00005	http://dx.doi.org/10.7326/0003-4819-142-10-200505170-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926CE	15897530				2023-01-03	WOS:000229099600001
J	Murray, SA; Kendall, M; Boyd, K; Sheikh, A				Murray, SA; Kendall, M; Boyd, K; Sheikh, A			Illness trajectories and palliative care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PROSPECTIVE QUALITATIVE INTERVIEW; LUNG-CANCER; PEOPLE; LIFE; FAILURE; END		Univ Edinburgh, Gen Practice Sect, Div Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland	University of Edinburgh	Murray, SA (corresponding author), Univ Edinburgh, Gen Practice Sect, Div Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland.	Scott.Murray@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056; Boyd, Kirsty/0000-0002-5526-1078				Asbring P, 2004, QUAL HEALTH RES, V14, P226, DOI 10.1177/1049732303260682; BALLAM M, 2001, CUMULATIVE TRIVIA EX; BUCTOW S, 2001, PATIENT EDUC COUNS, V45, P181; Burke S O, 2000, Can J Nurs Res, V32, P19; CASSELL EJ, 1991, NATURE SUFFERING; Ellershaw JE, 2003, CARE DYING PATHWAY E; GLARE PA, 2004, OXFORD TXB PALLIATIV; Hardin SB, 2004, ARCH INTERN MED, V164, P1531, DOI 10.1001/archinte.164.14.1531; Higginson I J, 2000, J Palliat Med, V3, P287, DOI 10.1089/jpm.2000.3.287; Higgs R, 1999, J ROY COLL PHYS LOND, V33, P110; KITE S, 2001, PALLIATIVE MED, V15, P413; Lehman R, 2004, BRIT J GEN PRACT, V54, P892; Levenson JW, 2000, J AM GERIATR SOC, V48, pS101, DOI 10.1111/j.1532-5415.2000.tb03119.x; LUNNEY JR, 2003, JAMA-J AM MED ASSOC, V298, P2387; Lynn J, 2000, JAMA-J AM MED ASSOC, V284, P2508, DOI 10.1001/jama.284.19.2508; Lynn J, 2003, LIVING WELL END LIFE; McKinley RK, 2004, BRIT J GEN PRACT, V54, P909; Murray SA, 2004, PALLIATIVE MED, V18, P39, DOI 10.1191/0269216304pm837oa; Murray SA, 2002, BRIT MED J, V325, P929, DOI 10.1136/bmj.325.7370.929; Murtagh FEM, 2004, CLIN MED, V4, P39, DOI 10.7861/clinmedicine.4-1-39; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Thomas K., 2003, CARING DYING HOME CO; WILLIAMS R, 1992, SOC SCI MED, V34, P763, DOI 10.1016/0277-9536(92)90363-U; World Health Organization, 2004, PALL CAR SOL FACTS	24	834	842	4	54	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 30	2005	330	7498					1007	1011		10.1136/bmj.330.7498.1007	http://dx.doi.org/10.1136/bmj.330.7498.1007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923UP	15860828	Green Published, Green Submitted			2023-01-03	WOS:000228935100024
J	Frost, KR				Frost, KR			Ensuring the safety of HIV/AIDS generics	LANCET			English	Editorial Material									Amer Fdn AIDS Res, Global Initiat, New York, NY 10005 USA		Frost, KR (corresponding author), Amer Fdn AIDS Res, Global Initiat, New York, NY 10005 USA.	kevin.frost@amfar.org						ADELMAN C, 2004, WALL STREET J E 1209; *AM FDN AIDS RES, 2004, EXP AV HIV AIDS DRUG; BROWN D, 2004, WASHINGTON POST 0327, P3; BUCKLEY S, 2000, WASHINGTON POST 0917, P22; DSILVA J, 2004, EC TIMES NEW DE 1030; MASON A, 2004, SAN FRANCISCO C 1201, pB11; MCNEIL DG, 2005, NY TIMES        0126, pA9; SOLOMON J, 2004, OFFICIALS KNEW AIDS; VERJEE N, 2004, TIMES LOND      1120, P66; WHALEN J, 2004, WALL STREET J   1110, pB1	10	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1290	1291		10.1016/S0140-6736(05)61007-0	http://dx.doi.org/10.1016/S0140-6736(05)61007-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823366				2023-01-03	WOS:000228219600008
J	Sabin, CA; Hill, T; Lampe, F; Matthias, R; Bhagani, S; Gilson, R; Youle, MS; Johnson, MA; Fisher, M; Scullard, G; Easterbrook, P; Gazzard, B; Phillips, AN				Sabin, CA; Hill, T; Lampe, F; Matthias, R; Bhagani, S; Gilson, R; Youle, MS; Johnson, MA; Fisher, M; Scullard, G; Easterbrook, P; Gazzard, B; Phillips, AN		UK CHIC Study Grp	Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REGIMENS; AIDS	Objectives To investigate whether there is evidence that an increasing proportion of HIV infected patients is starting to experience increases in viral load and decreases in CD4 cell count that are consistent with exhaustion of available treatment options. Design Multicentre cohort study. Setting Six large HIV treatment centres in southeast England. Participants All individuals seen for care between. I January 1996 and 31 December 2002. Main outcome measures Exposure to individual antiretroviral drugs and drug classes, CD4 count, plasma HIV RNA burden. Results Information is available on 16 593 individuals (13 378 (80.6%) male patients, 10 340 (62.3%) infected via homosexual or bisexual sex, 4426 (26.7%) infected via heterosexual sex, median age 34 years). Overall, 10 207 of the 16 593 patients (61.5%) have been exposed to any antiretroviral therapy. This proportion increased from 41.2% of patients under follow up at the end of 1996 to 71.3% of those under follow up in 2002. The median CD4 count and HIV RNA burden of patients under follow up in each year changed from 270 cells/mm(3) and 4.34 log(10) copies/ml in 1996 to 408 cells/mm(3) and 1.89 log(10) copies/ml, respectively, in 2002. By 2002, 3060 (38%) of patients who had ever been treated with antiretroviral therapy had experienced all three main classes. Of these, around one quarter had evidence of "viral load failure" with all these three classes. Patients with three class failure were more likely to have an HIV RNA burden > 2.7 log(10) copies/ml and a CD4 count < 200 cells/mm(3). Conclusions The proportion of individuals with HfV infection in the United Kingdom who have been treated has increased gradually over time. A substantial proportion of these patients seem to be in danger of exhausting their options for antiretroviral treatment. New drugs with low toxicity, which are not associated with cross resistance to existing drugs, are urgently needed for such patients.	Royal Free & UC Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; Royal Free & UC Med Sch, UK CHIC Study, London NW3 2PF, England; MRC, Clin Trials Unit, UK CHIC Study, London NW1 2DA, England; Royal Free Hosp, Royal Free Ctr HIV Med, London NW3 2QG, England; Royal Free & UC Med Sch, Ctr Sexual Hlth & HIV Res, London WC1E 6AU, England; Brighton & Sussex Univ Hosp Trust, Dept HIV Med, Lawson Unit, Brighton BN2 5BE, E Sussex, England; St Marys NHS Trust, Dept GU Med & Communicable Dis, London W2 1NY, England; Guys Kings & St Thomas Sch Med, London SE5 9RT, England; Chelsea & Westminster Hosp, Kobler Ctr, London SW10 9NH, England	University of London; University College London; University of London; University College London; Medical Research Council Clinical Trials Unit; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; University of London; King's College London; Imperial College London	Sabin, CA (corresponding author), Royal Free & UC Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England.	c.sabin@pcps.ucl.ac.uk	Sabin, Caroline/C-2464-2008; Gilson, Richard J C/C-5123-2009; Lampe, Fiona/I-5826-2019; Phillips, Andrew N/B-4427-2008; Easterbrook, Philippa J/A-3937-2009	Sabin, Caroline/0000-0001-5173-2760; Lampe, Fiona/0000-0001-6851-5471; Phillips, Andrew N/0000-0003-2384-4807; Easterbrook, Philippa/0000-0002-2603-5418; Bhagani, Sanjay/0000-0003-2557-4337				Barry S M, 2002, HIV Med, V3, P129, DOI 10.1046/j.1468-1293.2002.00103.x; CHADBORN T, 2003, 9 ANN C BRIT HIV ASS; COLONNO R, 2003, 10 C RETR OPP INF BO; Easterbrook PJ, 2000, AIDS, V14, P561, DOI 10.1097/00002030-200003310-00012; Gulick RM, 2002, AIDS, V16, pS135, DOI 10.1097/00002030-200216004-00019; Kuritzkes DR, 2004, AIDS PATIENT CARE ST, V18, P259, DOI 10.1089/108729104323076007; LALEZARI J, 2000, 13 INT C AIDS DURB 9; Mocroft A, 2001, AIDS, V15, P201, DOI 10.1097/00002030-200101260-00009; Mocroft A, 2000, LANCET, V356, P291, DOI 10.1016/S0140-6736(00)02504-6; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paulsen D, 2002, AIDS RES HUM RETROV, V18, P1011, DOI 10.1089/08892220260235371; Phillips AN, 2002, J INFECT DIS, V186, P1086, DOI 10.1086/343801; *PUBL HLTH LAB SER, 2002, HIV AIDS UK 2001; Sabin C, 2004, HIV MED, V5, P115; SQUIRES KE, 2002, 42 INT C ANT AG CHEM; STASZEWSKI S, 2003, 10 C RETR OPP INF BO; *UK COLL GROUP HIV, IN PRESS AIDS	17	64	71	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 26	2005	330	7493					695	698B		10.1136/bmj.38369.669850.8F	http://dx.doi.org/10.1136/bmj.38369.669850.8F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912IT	15749728	Green Published, Green Submitted, Bronze, Green Accepted			2023-01-03	WOS:000228071900014
J	Tripp, J; Viner, R				Tripp, J; Viner, R			ABC of adolescence - Sexual health, contraception., and teenage pregnancy	BRITISH MEDICAL JOURNAL			English	Review									Univ Exeter, Exeter EX4 4QJ, Devon, England; UCL Hosp NHS Fdn Trust, London, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England	University of Exeter; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Tripp, J (corresponding author), Univ Exeter, Exeter EX4 4QJ, Devon, England.	rviner@ich.ucl.ac.uk	Viner, Russell M/A-1441-2009	Viner, Russell M/0000-0003-3047-2247				Rogstad KE, 2002, INT J STD AIDS, V13, P420, DOI 10.1258/095646202760029868; *SOC EXCL UN, 1999, TEEN PREGN REP; Toumbourou J., 2000, EVIDENCE BASED HLTH; *TRUST STUD AD, 2003, KEY DAT AD	4	59	63	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 12	2005	330	7491					590	593		10.1136/bmj.330.7491.590	http://dx.doi.org/10.1136/bmj.330.7491.590			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	906EC	15761001	Green Published			2023-01-03	WOS:000227622300022
J	Kiessling, AA				Kiessling, AA			Eggs alone - Human parthenotes: an ethical source of stem cells for therapies?	NATURE			English	Editorial Material									Harvard Inst Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kiessling, AA (corresponding author), Harvard Inst Med, 4 Blackfan Circle, Boston, MA 02115 USA.							Cibelli JB, 2002, SCIENCE, V295, P819, DOI 10.1126/science.1065637; KIESSLING AA, 2003, HUMAN EMBRYONIC STEM; Kiessling Ann A, 2004, Conn Law Rev, V36, P1051; Kono T, 2004, NATURE, V428, P860, DOI 10.1038/nature02402	4	18	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 10	2005	434	7030					145	145		10.1038/434145a	http://dx.doi.org/10.1038/434145a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904JU	15758976	Bronze			2023-01-03	WOS:000227494500022
J	Helms, B; Meijer, EW				Helms, Brett; Meijer, E. W.			Dendrimers at work	SCIENCE			English	Editorial Material							POLYAMIDOAMINE DENDRIMERS; DENDRITIC MACROMOLECULES; IN-VITRO; POLYMERS; TRANSFECTION; MOLECULES; DELIVERY		Eindhoven Univ Technol, Lab Macromol & Organ Chem, NL-5600 MB Eindhoven, Netherlands; Eindhoven Univ Technol, Dept Biomed Engn, NL-5600 MB Eindhoven, Netherlands	Eindhoven University of Technology; Eindhoven University of Technology	Meijer, EW (corresponding author), Eindhoven Univ Technol, Lab Macromol & Organ Chem, NL-5600 MB Eindhoven, Netherlands.	e.w.meijer@tue.nl	Meijer, E.W./K-7632-2013	Meijer, E.W./0000-0003-4126-7492; Helms, Brett/0000-0003-3925-4174				Altinier S, 2000, CLIN CHEM, V46, P991; De Brabander-van den Berg E.M.M., 1993, ANGEW CHEM INT EDIT, V105, P1370; Denkewalter R. G., 1981, U. S. Pat, Patent No. [4,289,872, 4289872, 4 289 872]; Flory PJ, 1941, J AM CHEM SOC, V63, P3083, DOI 10.1021/ja01856a061; Froehling P, 2004, J POLYM SCI POL CHEM, V42, P3110, DOI 10.1002/pola.20113; GRIES H, 1990, Patent No. 4957939; HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012; HAWKER CJ, 1990, J AM CHEM SOC, V112, P7638, DOI 10.1021/ja00177a027; Hudde T, 1999, GENE THER, V6, P939, DOI 10.1038/sj.gt.3300886; JANSEN JFGA, 1994, SCIENCE, V266, P1226, DOI 10.1126/science.266.5188.1226; Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207; Ma DG, 2002, APPL PHYS LETT, V81, P2285, DOI 10.1063/1.1507826; Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1; Mynar JL, 2006, J AM CHEM SOC, V128, P6334, DOI 10.1021/ja061735s; NEWKOME GR, 1985, J ORG CHEM, V50, P2003, DOI 10.1021/jo00211a052; Smith DK, 2006, CHEM COMMUN, P34, DOI 10.1039/b507416a; Tack F, 2006, J DRUG TARGET, V14, P69, DOI 10.1080/10611860600635665; Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630; TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117; Tomalia DA, 2006, U.S. Patents, Patent No. 7005124; Yin R., 2001, POLYM MAT SCI ENG, V84, P856; Zhou JH, 2006, CHEM COMMUN, P2362, DOI 10.1039/b601381c	22	180	184	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2006	313	5789					929	930		10.1126/science.1130639	http://dx.doi.org/10.1126/science.1130639			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917051				2023-01-03	WOS:000239817000031
J	Montaner, JSG; Hogg, R; Wood, E; Kerr, T; Tyndall, M; Levy, AR; Harrigan, PR				Montaner, Julio S. G.; Hogg, Robert; Wood, Evan; Kerr, Thomas; Tyndall, Mark; Levy, Adrian R.; Harrigan, P. Richard			The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL LOAD; HETEROSEXUAL TRANSMISSION; DRUG-RESISTANCE; INFECTED ADULTS; RISK-FACTORS; ZIDOVUDINE; NEVIRAPINE; LAMIVUDINE; EFAVIRENZ		Univ British Columbia, British Columbia Ctr Excellence HIV AIDS, Prov Hlth Care, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada	B.C. Centre for Excellence in HIV/AIDS; University of British Columbia; University of British Columbia; University of British Columbia	Montaner, JSG (corresponding author), Univ British Columbia, St Pauls Hosp, AIDS Res Program, Vancouver, BC V6Z 1Y6, Canada.	jmontaner@cfenet.ubc.ca	Harding, Richard/G-9729-2012; Montaner, Julio/K-7621-2012; Hogg, Robert S/B-2783-2012	Hogg, Robert S/0000-0003-3463-5488; Tyndall, Mark/0000-0003-4450-5679				Anema A, 2004, LANCET, V364, P1034, DOI 10.1016/S0140-6736(04)17053-0; Bicego G, 2003, SOC SCI MED, V56, P1235, DOI 10.1016/S0277-9536(02)00125-9; Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; CAMERON DW, 1989, LANCET, V2, P403; Cane P, 2005, BMJ-BRIT MED J, V331, P1368, DOI 10.1136/bmj.38665.534595.55; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Castilla J, 2005, JAIDS-J ACQ IMM DEF, V40, P96, DOI 10.1097/01.qai.0000157389.78374.45; Cote HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035; Cu-Uvin S, 2000, AIDS, V14, P415, DOI 10.1097/00002030-200003100-00015; Daar ES, 2005, AIDS RES HUM RETROV, V21, P343, DOI 10.1089/aid.2005.21.343; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; *DEP HHS, 2006, GUID US ANT AG HIV 1; Fang CT, 2004, J INFECT DIS, V190, P879, DOI 10.1086/422601; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Gayle Helene D, 2006, AIDS Res Ther, V3, P2, DOI 10.1186/1742-6405-3-2; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Guerrero A, 2005, ENFERM INFEC MICR CL, V23, P605, DOI 10.1016/S0213-005X(05)75040-0; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HAMMER SM, IN PRESS JAMA; HARDY AM, 1985, JAMA-J AM MED ASSOC, V253, P215, DOI 10.1001/jama.253.2.215; Hogg R, 2002, LANCET, V360, P1710, DOI 10.1016/S0140-6736(02)11722-3; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Hogg RS, 1998, AIDS, V12, P279, DOI 10.1097/00002030-199803000-00005; Hosseinipour M, 2002, CLIN INFECT DIS, V34, P1391, DOI 10.1086/340403; Karon JM, 2001, AM J PUBLIC HEALTH, V91, P1060, DOI 10.2105/AJPH.91.7.1060; Kerr T, 2004, LANCET, V364, P11, DOI 10.1016/S0140-6736(04)16610-5; KINGSLEY LA, 1987, LANCET, V1, P345; Kuritzkes D, 2003, NAT MED, V9, P1343, DOI 10.1038/nm1103-1343b; Law MG, 2001, AIDS, V15, P1287, DOI 10.1097/00002030-200107060-00011; Levy AR, 2006, LANCET INFECT DIS, V6, P171, DOI 10.1016/S1473-3099(06)70413-3; Markel H, 2005, NEW ENGL J MED, V353, P753, DOI 10.1056/NEJMp058146; MILLS E, IN PRESS JAMA; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Montaner JSG, 1998, AIDS, V12, P1398, DOI 10.1097/00002030-199811000-00028; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; MUSICCO M, 1994, ARCH INTERN MED, V154, P1971, DOI 10.1001/archinte.154.17.1971; Pillay D, 2004, ANTIVIR THER, V9, P695; PIOT P, 2005, SPEECH GIV LOND SCH; Pomerantz RJ, 1999, NEW ENGL J MED, V340, P1672, DOI 10.1056/NEJM199905273402110; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Routy JP, 2004, AIDS, V18, P2305, DOI 10.1097/00002030-200411190-00011; SCHECHTER MT, 1993, LANCET, V341, P658, DOI 10.1016/0140-6736(93)90421-C; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Strathdee SA, 1998, J ACQ IMMUN DEF SYND, V19, P61, DOI 10.1097/00042560-199809010-00010; Tovanabutra S, 2002, J ACQ IMMUN DEF SYND, V29, P275, DOI 10.1097/00126334-200203010-00008; *UNAIDS, 2005, FIN EXP RESP AIDS HI; UNAIDS, 2006, REP GLOB AIDS EP; *UNAIDS, 2005, RES NEEDS EXP RESP A; *USAID UNAIDS WHO, 2004, COV SEL SERV HIV AID; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; Velasco-Hernandez JX, 2002, LANCET INFECT DIS, V2, P487, DOI 10.1016/S1473-3099(02)00346-8; Vernazza PL, 1997, AIDS, V11, P1249, DOI 10.1097/00002030-199710000-00008; *WHO, EST PERC PEOPL ANT T; Wood E, 2005, LANCET INFECT DIS, V5, P407, DOI 10.1016/S1473-3099(05)70162-6; Wood E, 2002, AIDS, V16, P941, DOI 10.1097/00002030-200204120-00021; World Health Organization, 2005, PREV CHRON DIS VIT I, V34, P34; Yerly S, 2004, ANTIVIR THER, V9, P375; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; 2005, LANCET, V365, P1597; 2003, LANCET, V362, P179	65	381	385	2	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					531	536		10.1016/S0140-6736(06)69162-9	http://dx.doi.org/10.1016/S0140-6736(06)69162-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890841				2023-01-03	WOS:000239569000037
J	Gona, P; Van Dyke, RB; Williams, PL; Dankner, WM; Chernoff, MC; Nachman, SA; Seage, GR				Gona, Philimon; Van Dyke, Russell B.; Williams, Paige L.; Dankner, Wayne M.; Chernoff, Miriam C.; Nachman, Sharon A.; Seage, George R., III			Incidence of opportunistic and other infections in HIV-infected children in the HAART era	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; MORTALITY; RNA; INFANTS; DISEASE	Context Combination anti-retroviral therapy or highly active antiretroviral therapy (HAART) has resulted in a dramatic decline in the incidence of opportunistic and other infections in human immunodeficiency virus (HIV)-infected adults and children. Objectives To estimate the incidence of 29 targeted opportunistic and other infections occurring in the era of HAART-between January 1, 2001, and December 31, 2004-in HIV-infected infants, children, and adolescents followed up in Pediatric AIDS Clinical Trials Group (PACTG) 219C; to compare incidence rates in the HAART era to those of the pre-HAART era; and to test for linear trends over time in the HAART era. Design, Setting, and Participants Ongoing, multicenter, prospective cohort study designed to examine long-term outcomes in HIV-infected children. The study population included 2767 children enrolled between September 15, 2000, and December 31, 2004, with information entered in the database up to August 1, 2005, when data analysis was conducted. The pre-HAART era comparison population included 3331 children enrolled in 13 PACTG protocols from October 1988 to August 1998. Main Outcome Measures First occurrence of each of the 29 targeted infections. Results Seventy-five percent of the children were enrolled in 2000 and 2001, 90% acquired HIV perinatally, 52% were girls, and 59% were black. The median age was 8.2 years (range, 6-13 years). The median duration of follow-up was 3.4 years. Overall, 553 first episodes of a specific infection occurred among 395 (14%) of the study participants. The number of events for the 4 most common first-time infections and their incidence rates (IRs) per 100 person-years were 123 bacterial pneumonia (IR, 2.15; 95% confidence interval [CI], 1.79-2.56), 77 herpes zoster (IR, 1.11; 95% CI, 0.88-1.39), 57 dermatophyte infections (IR, 0.88; 0.67-1.14), and 52 oral candidiasis (IR, 0.93; 95% CI, 0.70-1.22). Incidence rates of first bacteremia, Pneumocystis jeroveci pneumonia, disseminated Mycobacterium avium complex, lymphoid interstitial pneumonitis, systemic fungal infection, cytomegalovirus retinitis, and tuberculosis were all less than 0.50 per 100 person-years. There were no statistically significant linear trends in incidence for any of the 29 infections over the 4 calendar years. However, infection rates were significantly lower than those reported in the PACTG in the pre-HAART era. The pre-HAART IRs were as follows: for bacterial pneumonia, IR, 11.1; 95% CI, 10.3-12.0; bacteremia, IR, 3.3; 95% CI, 2.9-3.8; herpes zoster, IR, 2.9; 95% CI, 2.6-3.3; disseminated M avium complex, IR, 1.8; 95% CI, 1.5-2.1; P jeroveci, IR, 1.3; 95% CI, 1.1-1.6; oral candidiasis, IR, 1.2; 95% CI, 1.0-1.5; cytomegalovirus retinitis, IR, 0.5; 95% CI, 0.3-0.6; and tuberculosis, IR, 0.2; 95% CI, 0.1-0.4. Conclusions Opportunistic infections and other related infections are uncommon in children in the HAART era, and infection rates continue to be lower than those reported in the pre-HAART era. Continued surveillance is important to assess the long-term effect of HAART on the occurrence of opportunistic and other related infections in children.	Boston Univ, Dept Math & Stat, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Boston Univ, Stat Consulting Unit, Boston, MA 02215 USA; Tulane Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70118 USA; Duke Univ, Dept Pediat, Durham, NC 27706 USA; SUNY Stony Brook, Dept Pediat, Stony Brook, NY 11794 USA	Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Tulane University; Duke University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Gona, P (corresponding author), Boston Univ, Dept Math & Stat, 111 Cummington St, Boston, MA 02215 USA.	philgona@math.bu.edu	Abrams, William R/A-5782-2008; Gona, Philimon/K-1477-2019		NIAID NIH HHS [5 U01 AI41110] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041110] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrams EJ, 2000, PEDIATR CLIN N AM, V47, P79, DOI 10.1016/S0031-3955(05)70196-6; Brogly S, 2005, JAMA-J AM MED ASSOC, V293, P2213, DOI 10.1001/jama.293.18.2213; *CDCP, PED HIV AIDS SURV L2; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; Dankner WM, 2001, PEDIATR INFECT DIS J, V20, P40, DOI 10.1097/00006454-200101000-00008; Dankner WM, 2003, MED MANAGEMENT AIDS; DUNN DT, 1995, AIDS, V9, pF7, DOI 10.1097/00002030-199509000-00001; Finkelstein DM, 1996, J ACQ IMMUN DEF SYND, V12, P38, DOI 10.1097/00042560-199605010-00006; Furrer Hansjakob, 2002, J HIV Ther, V7, P2; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Louie JK, 2002, J INFECT DIS, V186, P1023, DOI 10.1086/343862; Mofenson LM, 1997, J INFECT DIS, V175, P1029, DOI 10.1086/516441; Nachman S, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1847; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palumbo PE, 1998, JAMA-J AM MED ASSOC, V279, P756, DOI 10.1001/jama.279.10.756; Sharland M, 2004, HIV MED, V5, P61, DOI 10.1111/j.1468-1293.2004.00227.x; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Steketee RW, 1997, J INFECT DIS, V175, P707, DOI 10.1093/infdis/175.3.707; YLITALO N, IN PRESS ARCH PEDIAT	20	176	182	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	2006	296	3					292	300		10.1001/jama.296.3.292	http://dx.doi.org/10.1001/jama.296.3.292			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	064LA	16849662				2023-01-03	WOS:000239089900021
J	Rytter, MJH; Kjaeldgaard, AL; Bronnum-Hansen, H; Helweg-Larsen, K				Rytter, Maren Johanne Heilskov; Kjaeldgaard, Anne-Lene; Bronnum-Hansen, Henrik; Helweg-Larsen, Karin			Effects of armed conflict on access to emergency health care in Palestinian West Bank: systematic collection of data in emergency departments	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To assess the impact of restrictions in access to hospital services imposed on the civilian population during the armed conflict in the Palestinian territories occupied by Israel. Design Consecutive registration of demographic and medical data, with information about transportation time, delay in access to hospital, and course of hospital contact. Setting Three hospital emergency departments in Bethlehem and Nablus, in the occupied Palestinian West Bank, during one week in each hospital. Participants All patients seeking health care in the three hospitals during the study period. Results A total of 394 of the 2228 emergency department contacts reported being delayed at checkpoints or by detours on their way to the emergency department. Hospital admission was significantly more common for these patients: 32% (n = 125) compared with 13% (n = 205) among those who were not delayed. Conclusion 18% of the emergency department contacts were delayed because of the occupation. The higher hospital admission rate in this group suggests that restrictions in access to hospital services influence the severity of the medical conditions presented.	Natl Inst Publ Hlth, DK-1399 Copenhagen, Denmark		Helweg-Larsen, K (corresponding author), Natl Inst Publ Hlth, Oster Farimagsgade 5A, DK-1399 Copenhagen, Denmark.	khl@niph.dk	Rytter, Maren JH/G-3279-2016	Rytter, Maren JH/0000-0002-9490-9586; Bronnum-Hansen, Henrik/0000-0003-3513-7245				Bertini Catherine, 2002, MISSION REPORT; Krug EG, 2002, LANCET, V360, P1083, DOI 10.1016/S0140-6736(02)11133-0; LENIN Y, 2004, FORBIDDEN ROAD ISRAE	3	20	21	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 13	2006	332	7550					1122	1124		10.1136/bmj.38793.695081.AE	http://dx.doi.org/10.1136/bmj.38793.695081.AE			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	044OT	16585049	Green Published, Bronze			2023-01-03	WOS:000237682700016
J	Annas, GJ				Annas, GJ			Congress, controlled substances, and physician-assisted suicide - Elephants in mouseholes	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SCHIAVO,TERRI; CARE		Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; Annas GJ, 2005, NEW ENGL J MED, V353, P2291, DOI 10.1056/NEJMlim053151; Annas GJ, 2005, NEW ENGL J MED, V352, P1710, DOI 10.1056/NEJMlim050643; [Anonymous], 2001, FED REG; Berwick DM, 2006, JAMA-J AM MED ASSOC, V295, P324, DOI 10.1001/jama.295.3.324; Blendon RJ, 2005, ARCH INTERN MED, V165, P2580, DOI 10.1001/archinte.165.22.2580; Fins J. J, 2005, PALLIATIVE ETHICS CA; Johnson SH, 2005, J LAW MED ETHICS, V33, P741, DOI 10.1111/j.1748-720X.2005.tb00541.x; Quill TE, 2006, NEW ENGL J MED, V354, P1, DOI 10.1056/NEJMp058289	9	6	6	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					1079	1084		10.1056/NEJMlim060731	http://dx.doi.org/10.1056/NEJMlim060731			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	019FY	16525147	Green Published			2023-01-03	WOS:000235822200015
J	Heneghan, C; Alonso-Coello, P; Garcia-Alamino, JM; Perera, R; Meats, E; Glasziou, P				Heneghan, C; Alonso-Coello, P; Garcia-Alamino, JM; Perera, R; Meats, E; Glasziou, P			Self-monitoring of oral anticoagulation: a systematic review and meta-analysis	LANCET			English	Article							NONRHEUMATIC ATRIAL-FIBRILLATION; RANDOMIZED CONTROLLED-TRIAL; WARFARIN THERAPY; CLINICAL-TRIALS; STROKE PREVENTION; OLDER PATIENTS; DOSE WARFARIN; LOW-INTENSITY; MANAGEMENT; TRANSLATE	Background Near-patient testing has made self-monitoring of anticoagulation with warfarin feasible, and several trials have suggested that such monitoring might be equal to or better than standard monitoring. We did a systematic review and meta-analysis of all randomised controlled trials that assessed the effects of self-monitoring or self-management (self-testing and self-dosage) of anticoagulation compared with standard monitoring. Methods We searched the Cochrane Register of Controlled Trials, MEDLINE, EMBASE to April 2005, and contacted manufacturers and authors of relevant studies. Outcomes analysed were: major haemorrhage, thromboembolic events, death, tests in range, minor haemorrhage, frequency of testing, and feasibility of self-monitoring. Findings We identified 14 randomised trials of self-monitoring: pooled estimates showed significant reductions in thromboembolic events (odds ratio 0.45, 95% Cl 0.30-0.68), all-cause mortality (0.61, 0.38-0.98), and major haemorrhage (0.65, 0.42-0.99). Trials of combined self-monitoring and self-adjusted therapy showed significant reductions in thromboembolic events (0.27, 0.12-0.59) and death (0.37, 0.16-0.85), but not major haemorrhage (0.93, 0.42-2.05). No difference was noted in minor haemorrhage. 11 trials reported improvements in the mean proportion of international normalisation ratios in range. Interpretation Self-management improves the quality of oral anticoagulation. Patients capable of self-monitoring and self-adjusting therapy have fewer thromboembolic events and lower mortality than those who self-monitor alone. However, self-monitoring is not feasible for all patients, and requires identification and education of suitable candidates.	Univ Oxford, Dept Primary Hlth Care, Ctr Evidence Based Med, Oxford OX3 7LF, England; Hosp Sant Pau, Iberoamer Cochrane Ctr, Dept Clin Epidemiol & Publ Hlth, Barcelona, Spain	University of Oxford; Hospital of Santa Creu i Sant Pau	Heneghan, C (corresponding author), Univ Oxford, Dept Primary Hlth Care, Ctr Evidence Based Med, Rosemary Rue Bldg, Oxford OX3 7LF, England.	carl.heneghan@dphpc.ox.ac.uk	Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X; Perera, Rafael/0000-0003-2418-2091				Ansell J, 2005, INT J CARDIOL, V99, P37, DOI 10.1016/j.ijcard.2003.11.008; Ansell JE, 1999, JAMA-J AM MED ASSOC, V281, P182, DOI 10.1001/jama.281.2.182; Ansell JE, 1996, AM HEART J, V132, P1095, DOI 10.1016/S0002-8703(96)90040-X; BERNARDO A, 1992, THROMBOSIS EMBOLISM, P325; Beyth RJ, 2000, ANN INTERN MED, V133, P687, DOI 10.7326/0003-4819-133-9-200011070-00010; Blackshear JL, 1996, LANCET, V348, P633; Buckingham TA, 2002, CLIN CARDIOL, V25, P447, DOI 10.1002/clc.4960251003; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; Cromheecke ME, 2000, LANCET, V356, P97, DOI 10.1016/S0140-6736(00)02470-3; Dickersin K, 2002, EVAL HEALTH PROF, V25, P38, DOI 10.1177/0163278702025001004; Douketis J D, 2001, Am J Cardiovasc Drugs, V1, P245, DOI 10.2165/00129784-200101040-00003; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Fitzmaurice DA, 2002, J CLIN PATHOL, V55, P845, DOI 10.1136/jcp.55.11.845; Fitzmaurice DA, 2001, BRIT MED J, V323, P985, DOI 10.1136/bmj.323.7319.985; Gadisseur APA, 2003, ARCH INTERN MED, V163, P2639, DOI 10.1001/archinte.163.21.2639; Gardiner C, 2005, BRIT J HAEMATOL, V128, P242, DOI 10.1111/j.1365-2141.2004.05300.x; Go AS, 2003, JAMA-J AM MED ASSOC, V290, P2685, DOI 10.1001/jama.290.20.2685; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HOBBS F, 1996, BRIT MED J, V312, P577; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Horstkotte, 1998, J Thromb Thrombolysis, V5 Suppl 1, P19, DOI 10.1023/A:1013228718768; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kearon C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMoa035422; Khan TI, 2004, BRIT J HAEMATOL, V126, P557, DOI 10.1111/j.1365-2141.2004.05074.x; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; Kortke H, 2001, ANN THORAC SURG, V72, P44, DOI 10.1016/S0003-4975(01)02656-X; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; Menendez-Jandula B, 2005, ANN INTERN MED, V142, P1, DOI 10.7326/0003-4819-142-1-200501040-00006; Odegaard Kaja Johannson, 2004, Tidsskr Nor Laegeforen, V124, P2900; Sawicki PT, 1999, JAMA-J AM MED ASSOC, V281, P145, DOI 10.1001/jama.281.2.145; Sawicki PT, 2003, J INTERN MED, V254, P515, DOI 10.1046/j.1365-2796.2003.01215.x; Serra ODM, 2005, MED CLIN-BARCELONA, V124, P321, DOI 10.1157/13072418; Sidhu P, 2001, ANN THORAC SURG, V72, P1523, DOI 10.1016/S0003-4975(01)03049-1; Siebenhofer A, 2004, THROMB HAEMOSTASIS, V91, P225, DOI 10.1160/TH03-09-0598; Sunderji R, 2004, CAN J CARDIOL, V20, P1117; Taborski U, 1999, SEMIN THROMB HEMOST, V25, P43, DOI 10.1055/s-2007-996423; Voller H, 2001, EUR HEART J SUPPL, V3, pQ44, DOI 10.1016/S1520-765X(01)90042-2; WHITE RH, 1989, ANN INTERN MED, V111, P730, DOI 10.7326/0003-4819-111-9-730	42	308	320	1	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 4	2006	367	9508					404	411		10.1016/S0140-6736(06)68139-7	http://dx.doi.org/10.1016/S0140-6736(06)68139-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458764				2023-01-03	WOS:000235139400029
J	von Gunten, CF; Ryndes, T				von Gunten, CF; Ryndes, T			The academic hospice	ANNALS OF INTERNAL MEDICINE			English	Article							CARE	The academic hospice is a recent development in health care. Hospice programs and hospitals evolved from the same historical roots in Greek and Roman medicine. The academic hospital emerged as a place where patient care, education, and research are pursued as inextricable parts of the mission. The unique role of the academic medical center in health care is supported by the government, the medical profession, and the public. This article provides a perspective on the emergence of the academic hospice. Dr. Cicely Saunders, who died on 14 July 2005, founded the first such hospice in London, England, in 1967. The authors show that the philosophy of hospice care has the same historical roots as standard health care and describe those elements that distinguish academic hospice programs from other kinds of hospice programs. Finally, the authors note that demographic and economic challenges in the United States and elsewhere only increase the need for academic hospice programs.	San Diego Hospice & Palliat Care, San Diego, CA USA		von Gunten, CF (corresponding author), 4311 3rd Ave, San Diego, CA 92103 USA.	cvongunten@sdhospice.org			NCI NIH HHS [K05CA102582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K05CA102582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARING CD, 1971, UNDERSTANDING PHYS; DUNLOP RJ, 1998, HOSP BASED PALLIATIV, P1; Field MJ, 1997, APPROACHING DEATH IM; HINOHARA S, 1993, ANN INTERN MED, V118, P638, DOI 10.7326/0003-4819-118-8-199304150-00012; Kotlikoff LJ, 2004, COMING GENERATIONAL STORM: WHAT YOU NEED TO KNOW ABOUT AMERICA'S ECONOMIC FUTURE, P1; Kubler-Ross Elizabeth, 2011, DEATH DYING WHAT DYI; LORBER J, 1975, J HEALTH SOC BEHAV, V16, P213, DOI 10.2307/2137163; LYONS A, 1987, MED ILLUSTRATED HIST, P185; MOR V, 1988, HOSPICE EXPT, P6; *NAT HOSP ORG, 1979, HOSP STAND; ONEILL WM, 1992, J PAIN SYMPTOM MANAG, V7, P406, DOI 10.1016/0885-3924(92)90020-I; SAUNDERS CM, 1998, OXFORD TXB PALLIATIV, pR6; SAUNDERS CM, 2005, OXFORD TXB PALLIATIV, pR15; STARR P, 1982, SOCIAL TRANSFORMATIO, P362; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; TYLER B, 1997, QUEST DIE DIGNITY AN, P12; Wald F S, 1980, Nurs Outlook, V28, P173; WALSH TD, 1981, NEW ENGL J MED, V305, P1417	18	4	4	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2005	143	9					655	658		10.7326/0003-4819-143-9-200511010-00009	http://dx.doi.org/10.7326/0003-4819-143-9-200511010-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980PN	16263888				2023-01-03	WOS:000233030600005
J	Khan, J				Khan, J			Eye know it's red	LANCET			English	Editorial Material									Kings Coll Hosp London, Retinal Res Unit, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Khan, J (corresponding author), Kings Coll Hosp London, Retinal Res Unit, Normanby Bldg,Denmark Hill, London SE5 9RS, England.	jaheedkhan@yahoo.co.uk							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT-NOV	2005	366	9496					1583	1583		10.1016/S0140-6736(05)67630-1	http://dx.doi.org/10.1016/S0140-6736(05)67630-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257346				2023-01-03	WOS:000232984800028
J	Bajpai, AK; Park, JH; Moon, IJ; Kang, H; Lee, YH; Doh, KO; Suh, SI; Chang, BC; Park, JG				Bajpai, AK; Park, JH; Moon, IJ; Kang, H; Lee, YH; Doh, KO; Suh, SI; Chang, BC; Park, JG			Rapid blockade of telomerase activity and tumor cell growth by the DPL lipofection of ribbon antisense to hTR	ONCOGENE			English	Article						telomerase; hTR; ribbon antisense; DPL transfection	CATALYTIC SUBUNIT; IN-VITRO; MAMMALIAN TELOMERASE; INDUCED APOPTOSIS; RNA COMPONENT; INHIBITION; EXPRESSION; CANCER; OLIGONUCLEOTIDES; GENE	Ribbon antisense (RiAS) to the hTR RNA, a component of the telomerase complex, was employed to inhibit telomerase activity and cancer cell growth. The antisense molecule, hTR-RiAS, combined with enhanced cellular uptake was shown to effectively inhibit telomerase activity and cause rapid cell death in various cancer cell lines. When cancer cells were treated with hTR-RiAS, the level of hTR RNA was reduced by more than 90% accompanied with reduction in telomerase activity. When checked for cancer cell viability, cancer cell lines treated with hTR-RiAS using DNA+Peptide+Lipid complex showed 70-80% growth inhibition in 3 days. The reduced cell viability was due to apoptosis as the percentage of cells exhibiting the sub-G(0) arrest and DNA fragmentation increased after antisense treatment. Further, when subcutaneous tumors of a colon cancer cell line (SW480) were treated intratumorally with hTR-RiAS, tumor growth was markedly suppressed with almost total ablation of hTR RNA in the tumor tissue. Cells in the tumor tissue were also found to undergo apoptosis after hTR-RiAS treatment. These results suggest that hTR-RiAS is an effective anticancer reagent, with a potential for broad efficacy to diverse malignant tumors.	Keimyung Univ, Sch Med, Dongsan Med Ctr, Dept Med Genet Engn, Joongu, Daegu, South Korea; WelGENE Inc 71B4L, Dalseogu 704230, Daegu, South Korea; Keimyung Univ, Sch Med, Chron Dis Res Ctr, Taegu, South Korea; Keimyung Univ, Sch Med, Inst Med Sci, Taegu, South Korea	Keimyung University; Keimyung University; Keimyung University	Park, JG (corresponding author), Keimyung Univ, Sch Med, Dongsan Med Ctr, Dept Med Genet Engn, 194 Dongsadong, Joongu, Daegu, South Korea.	jonggu@kmu.ac.kr						Avilion AA, 1996, CANCER RES, V56, P645; Bisoffi M, 1998, EUR J CANCER, V34, P1242, DOI 10.1016/S0959-8049(98)00049-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holt SE, 1999, MOL CARCINOGEN, V25, P241, DOI 10.1002/(SICI)1098-2744(199908)25:4<241::AID-MC2>3.0.CO;2-9; Ishikawa T, 1999, CANCER LETT, V141, P187, DOI 10.1016/S0304-3835(99)00103-2; Kanazawa Y, 1996, BIOCHEM BIOPH RES CO, V225, P570, DOI 10.1006/bbrc.1996.1213; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Kondo Y, 2000, ONCOGENE, V19, P2205, DOI 10.1038/sj.onc.1203538; Kosciolek BA, 2003, MOL CANCER THER, V2, P209; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsuda M, 1996, MOL BIOL CELL, V7, P1095, DOI 10.1091/mbc.7.7.1095; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Moon IJ, 2000, BIOCHEM J, V346, P295, DOI 10.1042/0264-6021:3460295; Moon IJ, 2000, J BIOL CHEM, V275, P4647, DOI 10.1074/jbc.275.7.4647; Mukai S, 2000, CANCER RES, V60, P4461; Naka K, 1999, BIOCHEM BIOPH RES CO, V255, P753, DOI 10.1006/bbrc.1998.9938; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Ren JG, 2001, FEBS LETT, V488, P133, DOI 10.1016/S0014-5793(00)02397-8; Urquidi V, 2000, ANNU REV MED, V51, P65, DOI 10.1146/annurev.med.51.1.65; Wheeler CJ, 1996, P NATL ACAD SCI USA, V93, P11454, DOI 10.1073/pnas.93.21.11454; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x	34	7	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6492	6501		10.1038/sj.onc.1208731	http://dx.doi.org/10.1038/sj.onc.1208731			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16170384				2023-01-03	WOS:000232204100003
J	Wanner, C; Krane, V; Marz, W; Olschewski, M; Mann, JFE; Ruf, G; Ritz, E				Wanner, C; Krane, V; Marz, W; Olschewski, M; Mann, JFE; Ruf, G; Ritz, E		German Diabetes Dialysis Study Inv	Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOVASCULAR-DISEASE; CLINICAL-TRIALS; CHOLESTEROL; DEATH; MORTALITY; IMPACT	Background: Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined. Methods: We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined. Results: After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3 percent. During a median follow-up period of four years, 469 patients (37 percent) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95 percent confidence interval, 1.05 to 3.93; P=0.04). Atorvastatin reduced the rate of all cardiac events combined (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03, nominally significant) but not all cerebrovascular events combined (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) or total mortality (relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33). Conclusions: Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.	Univ Wurzburg, Dept Med, Div Nephrol, Wurzburg, Germany; Univ Gen Hosp, Clin Inst Med & Chem Lab Diagnost, Graz, Austria; Univ Hosp Freiburg, Dept Med Biometr & Stat, Freiburg, Germany; Schwabing Gen Hosp, Munich, Germany; Pfizer, Dept Clin Res, Karlsruhe, Germany; Heidelberg Univ, Dept Med, D-6900 Heidelberg, Germany	University of Wurzburg; University of Freiburg; Pfizer; Ruprecht Karls University Heidelberg	Wanner, C (corresponding author), Univ Hosp, Dept Med, Div Nephrol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	wanner_c@medizin.uni-wuerzburg.de	Mann, Johannes/AAI-8803-2020					Amann K, 1998, J AM SOC NEPHROL, V9, P1018; Armitage J, 2004, CURR OPIN LIPIDOL, V15, P439, DOI 10.1097/01.mol.0000137219.31407.16; Baigent C, 2000, LANCET, V356, P147, DOI 10.1016/S0140-6736(00)02456-9; Cheung BMY, 2004, BRIT J CLIN PHARMACO, V57, P640, DOI 10.1111/j.1365-2125.2003.02060.x; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Himmelfarb J, 2002, KIDNEY INT, V62, P1524, DOI 10.1046/j.1523-1755.2002.00600.x; Iseki K, 2002, KIDNEY INT, V61, P1887, DOI 10.1046/j.1523-1755.2002.00324.x; KOCH M, 1993, DIABETOLOGIA, V36, P1113, DOI 10.1007/BF02374508; Koch M, 1997, J AM SOC NEPHROL, V8, P1889; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Lins RL, 2003, NEPHROL DIAL TRANSPL, V18, P967, DOI 10.1093/ndt/gfg048; Mason NA, 2005, AM J KIDNEY DIS, V45, P119, DOI 10.1053/j.ajkd.2004.09.025; *NATI DIAB DIG KID, 2003, REN DAT SYST USRDS 2; NAUCK M, 1995, CLIN CHEM, V41, P1761; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PEDERSEN TR, 1994, LANCET, V344, P1383; Prichard SS, 2003, J AM SOC NEPHROL, V14, pS315, DOI 10.1097/01.ASN.0000081698.10331.83; Schulgen G, 2005, CONTEMP CLIN TRIALS, V26, P386, DOI 10.1016/j.cct.2005.01.010; Schwenger V, 2003, DEUT MED WOCHENSCHR, V128, P1216; Seliger SL, 2002, KIDNEY INT, V61, P297, DOI 10.1046/j.1523-1755.2002.00109.x; Takayama F, 1998, CELL MOL BIOL, V44, P1101; Tonelli M, 2004, CIRCULATION, V110, P1557, DOI 10.1161/01.CIR.0000143892.84582.60; TSCHOPE W, 1993, NEPHRON, V64, P354, DOI 10.1159/000187353; Wanner C, 1999, KIDNEY INT, V56, pS222, DOI 10.1046/j.1523-1755.1999.07158.x; Wanner C, 2004, KIDNEY BLOOD PRESS R, V27, P259, DOI 10.1159/000080241	29	1908	1969	1	78	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 21	2005	353	3					238	248		10.1056/NEJMoa043545	http://dx.doi.org/10.1056/NEJMoa043545			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	946YH	16034009	Bronze			2023-01-03	WOS:000230608700004
J	Dennis, CL				Dennis, CL			Psychosocial and psychological interventions for prevention of postnatal depression: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTPARTUM DEPRESSION	Objective To assess the effects of psychosocial and psychological interventions compared with usual antepartum, intrapartum, or postpartum care on the risk of postnatal depression. Data sources Medline, Embase, CINAHL, Cochrane central register of controlled trials, Cochrane pregnancy and childbirth group trials register, Cochrane depression, anxiety, and neurosis trials register, secondary references and review articles, and experts in the field. Study selection All published and unpublished randomised controlled trials of preventive psychosocial or psychological interventions in which the primary or secondary aim was a reduction in the risk of postnatal depression. All trials recruited pregnant women or new mothers less than six weeks postpartum. Eligible studies were abstracted, assessed for methodological quality, and pooled with relative risk for categorical data and weighted mean difference for continuous data. Results Fifteen trials with 7697 women were included. Although there was no overall statistically significant effect on the prevention of postnatal depression in the meta-analysis of all types of interventions (15 trials, n = 7697; relative risk 0.81, 95% confidence interval 0.65 to 1.02), these results suggest a potential reduction in postnatal depression. ne only intervention to have a clear preventive effect was intensive postpartum support provided by a health professional (0.68,0.55 to 0.84). Identifying women "at risk" assisted in the prevention of postnatal depression (0.67, 0.51 to 0.89). Interventions with only a postnatal component were more beneficial (0.76, 0.58 to 0.98) than interventions that incorporated an antenatal component. In addition, individually based interventions were more effective (0.76,0.59 to 1.00) than group based interventions (1.03, 0.65 to 1.63). Conclusions Diverse psychosocial or psychological interventions do not significantly reduce the number of women who develop postnatal depression. The most promising intervention is the provision of intensive, professionally based postpartum support.	Univ Toronto, Fac Nursing, Toronto, ON M5S 3H4, Canada	University of Toronto	Dennis, CL (corresponding author), Univ Toronto, Fac Nursing, 50 St George St, Toronto, ON M5S 3H4, Canada.	cindylee.dennis@utoronto.ca	Dennis, Cindy-Lee/ABA-2860-2020	Dennis, Cindy-Lee/0000-0002-0135-7242				Austin MP, 2003, ACTA PSYCHIAT SCAND, V107, P10, DOI 10.1034/j.1600-0447.2003.02024.x; Beck CT, 2001, NURS RES, V50, P275, DOI 10.1097/00006199-200109000-00004; Cooper PJ, 1997, ARCH DIS CHILD, V77, P97, DOI 10.1136/adc.77.2.97; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Dennis CL, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006309; Dennis CLE, 2004, CAN J PSYCHIAT, V49, P526, DOI 10.1177/070674370404900804; Dennis CLE, 2004, CAN J PSYCHIAT, V49, P467, DOI 10.1177/070674370404900708; Dennis CLE, 2004, J CLIN PSYCHIAT, V65, P1252, DOI 10.4088/JCP.v65n0915; Lumley J, 2004, INT J TECHNOL ASSESS, V20, P128, DOI 10.1017/S0266462304000911; OHara MW, 1996, INT REV PSYCHIATR, V8, P37, DOI 10.3109/09540269609037816	10	208	213	1	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	2005	331	7507					15	18		10.1136/bmj.331.7507.15	http://dx.doi.org/10.1136/bmj.331.7507.15			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	947TD	15994688	Green Published, Bronze			2023-01-03	WOS:000230668500015
J	Manasse, HR				Manasse, HR			Conscientious objection and the pharmacist	SCIENCE			English	Editorial Material									Amer Soc Hlth Syst Pharmacists, Bethesda, MD 20814 USA		Manasse, HR (corresponding author), Amer Soc Hlth Syst Pharmacists, Bethesda, MD 20814 USA.	evp@ashp.org						BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P389; Davey Monica, 2005, N Y Times Web, pA16	2	7	8	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1558	1559		10.1126/science.1114371	http://dx.doi.org/10.1126/science.1114371			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947160				2023-01-03	WOS:000229827000027
J	Pappas, G; Akritidis, N; Bosilkovski, M; Tsianos, E				Pappas, G; Akritidis, N; Bosilkovski, M; Tsianos, E			Medical progress: Brucellosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LINKED IMMUNOSORBENT-ASSAY; OUTER-MEMBRANE PROTEINS; PCR ASSAY; INTERFERON-GAMMA; RISK-FACTORS; WHOLE-BLOOD; B-ABORTUS; DIAGNOSIS; MELITENSIS; SERUM		Univ Hosp Ioannina, Dept Internal Med, Brucellosis Unit, Ioannina 45110, Greece	University Hospital Ioannina	Pappas, G (corresponding author), Univ Hosp Ioannina, Dept Internal Med, Brucellosis Unit, Ioannina 45110, Greece.	gpele@otenet.gr	Pappas, Georgios/A-1525-2008; Pappas, Georgios/AAQ-1893-2021	Pappas, Georgios/0000-0002-8425-6091				Ahmed K, 1999, AM J TROP MED HYG, V61, P425, DOI 10.4269/ajtmh.1999.61.425; Akritidis N, 2001, SCAND J GASTROENTERO, V36, P110, DOI 10.1080/00365520150218147; Al Dahouk Sascha, 2003, Clin Lab, V49, P487; Al Dahouk Sascha, 2003, Clin Lab, V49, P577; Al Shaalan Mohammed, 2002, International Journal of Infectious Diseases, V6, P182, DOI 10.1016/S1201-9712(02)90108-6; Almuneef M, 2003, J CHEMOTHERAPY, V15, P148, DOI 10.1179/joc.2003.15.2.148; Almuneef MA, 2004, EPIDEMIOL INFECT, V132, P533, DOI 10.1017/S0950268803001857; Araj G F, 1999, Clin Lab Sci, V12, P207; ARAJ GF, 1988, APMIS, V96, P171, DOI 10.1111/j.1699-0463.1988.tb05286.x; Arenas GN, 2000, INFECT IMMUN, V68, P4255, DOI 10.1128/IAI.68.7.4255-4263.2000; ARIZA J, 1992, CLIN INFECT DIS, V14, P131, DOI 10.1093/clinids/14.1.131; ARIZA J, 1995, CLIN INFECT DIS, V20, P1241, DOI 10.1093/clinids/20.5.1241; Ariza J, 2001, CLIN INFECT DIS, V32, P1024, DOI 10.1086/319608; ARIZA J, 1993, CLIN INFECT DIS, V16, P761, DOI 10.1093/clind/16.6.761; BAILY GG, 1992, J TROP MED HYG, V95, P271; Bannatyne RM, 1997, J CLIN MICROBIOL, V35, P2673, DOI 10.1128/JCM.35.10.2673-2674.1997; BERTOTTO A, 1993, EUR J IMMUNOL, V23, P1177, DOI 10.1002/eji.1830230531; Bodur H, 2003, SCAND J INFECT DIS, V35, P337, DOI 10.1080/00365540310008348; Bosilkovski M, 2004, INT J CLIN PRACT, V58, P1023, DOI 10.1111/j.1742-1241.2004.00208.x; Bravo MJ, 2003, EUR J IMMUNOGENET, V30, P433, DOI 10.1111/j.1365-2370.2003.00419.x; Bravo MJ, 2003, J RHEUMATOL, V30, P1051; Capasso L, 2002, J INFECTION, V45, P122, DOI 10.1053/jinf.2002.0996; Casao MA, 2003, CLIN MICROBIOL INFEC, V9, P301, DOI 10.1046/j.1469-0691.2003.00519.x; Celli J, 2003, J EXP MED, V198, P545, DOI 10.1084/jem.20030088; CERVANTES F, 1982, POSTGRAD MED J, V58, P346, DOI 10.1136/pgmj.58.680.346; Chang MH, 2003, EMERG INFECT DIS, V9, P556, DOI 10.3201/eid0905.020477; Cloeckaert A, 2002, VET MICROBIOL, V90, P229, DOI 10.1016/S0378-1135(02)00211-0; Colmenero JD, 1997, MEDICINE, V76, P139; COLMENERO JD, 1994, ANTIMICROB AGENTS CH, V38, P2798, DOI 10.1128/AAC.38.12.2798; Corbel MJ, 1997, EMERG INFECT DIS, V3, P213, DOI 10.3201/eid0302.970219; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; Demirdag K, 2003, FEMS IMMUNOL MED MIC, V39, P149, DOI 10.1016/S0928-8244(03)00207-4; DETILLEUX PG, 1991, AM J VET RES, V52, P1658; Dokuzoguz B, 2005, J INFECTION, V50, P41, DOI 10.1016/j.jinf.2004.02.005; Dornand J, 2002, VET MICROBIOL, V90, P383, DOI 10.1016/S0378-1135(02)00223-7; Ergonul O, 2004, J HOSP INFECT, V56, P223, DOI 10.1016/j.jhin.2003.12.020; EWALT DR, 1994, J VET DIAGN INVEST, V6, P448, DOI 10.1177/104063879400600408; FEKETE A, 1990, J APPL BACTERIOL, V69, P216, DOI 10.1111/j.1365-2672.1990.tb01512.x; Fosgate GT, 2002, EMERG INFECT DIS, V8, P877; Gorvel JP, 2002, VET MICROBIOL, V90, P281, DOI 10.1016/S0378-1135(02)00214-6; GOTUZZO E, 1986, J INFECT DIS, V153, P122, DOI 10.1093/infdis/153.1.122; Gross A, 2000, INFECT IMMUN, V68, P342, DOI 10.1128/IAI.68.1.342-351.2000; Guzman-Verri C, 2002, P NATL ACAD SCI USA, V99, P12375, DOI 10.1073/pnas.192439399; HADJICHRISTODOULOU C, 1994, EUR J CLIN MICROBIOL, V13, P129, DOI 10.1007/BF01982185; Jubier-Maurin V, 2001, INFECT IMMUN, V69, P4823, DOI 10.1128/IAI.69.8.4823-4830.2001; Karabay O, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-18; Kaufmann AF, 1997, EMERG INFECT DIS, V3, P83, DOI 10.3201/eid0302.970201; Khan MY, 2001, CLIN INFECT DIS, V32, P1172, DOI 10.1086/319758; Ko J, 2002, J IMMUNOL, V168, P2433, DOI 10.4049/jimmunol.168.5.2433; Ko JY, 2003, CLIN MICROBIOL REV, V16, P65, DOI 10.1128/CMR.16.1.65-78.2003; Lopez-Merino A, 2004, SCAND J INFECT DIS, V36, P636, DOI 10.1080/00365540410020767; LUBANI MM, 1989, PEDIATR INFECT DIS J, V8, P75; Matar GM, 1996, J CLIN MICROBIOL, V34, P477, DOI 10.1128/JCM.34.2.477-478.1996; McDonald R, 2001, MIL MED, V166, P237, DOI 10.1093/milmed/166.3.237; MCLEAN DR, 1992, CLIN INFECT DIS, V15, P582, DOI 10.1093/clind/15.4.582; Memish Z, 2000, J INFECTION, V40, P59, DOI 10.1053/jinf.1999.0586; Morata P, 2003, J CLIN MICROBIOL, V41, P144, DOI 10.1128/JCM.41.1.144-148.2003; Morata P, 1999, J CLIN MICROBIOL, V37, P4163, DOI 10.1128/JCM.37.12.4163-4166.1999; MORENO E, 1990, J BACTERIOL, V172, P3569, DOI 10.1128/jb.172.7.3569-3576.1990; Moreno E, 2002, VET MICROBIOL, V90, P209, DOI 10.1016/S0378-1135(02)00210-9; Moreno S, 1998, EUR J CLIN MICROBIOL, V17, P319, DOI 10.1007/BF01709454; Navarro E, 2004, EXPERT REV MOL DIAGN, V4, P115, DOI 10.1586/14737159.4.1.115; Navarro E, 2002, FEMS IMMUNOL MED MIC, V34, P147, DOI 10.1111/j.1574-695X.2002.tb00616.x; Navarro-Martinez A, 2001, CLIN INFECT DIS, V33, P2017, DOI 10.1086/324489; Nimri LF, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-5; Ottones F, 2000, J IMMUNOL, V165, P7133, DOI 10.4049/jimmunol.165.12.7133; Pappas G, 2005, EXPERT OPIN PHARMACO, V6, P201, DOI 10.1517/14656566.6.2.201; Pappas G, 2004, INT J ANTIMICROB AG, V24, P502, DOI 10.1016/j.ijantimicag.2004.05.003; Pappas G, 2004, AM J HEMATOL, V75, P139, DOI 10.1002/ajh.10473; Pappas G, 2003, CLIN INFECT DIS, V37, pE95, DOI 10.1086/378125; Paulsen IT, 2002, P NATL ACAD SCI USA, V99, P13148, DOI 10.1073/pnas.192319099; Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P2387; Probert WS, 2004, J CLIN MICROBIOL, V42, P1290, DOI 10.1128/JCM.42.3.1290-1293.2004; Queipo-Ortuno MI, 2005, CLIN INFECT DIS, V40, P260, DOI 10.1086/426818; Redkar R, 2001, MOL CELL PROBE, V15, P43, DOI 10.1006/mcpr.2000.0338; Reguera JM, 2003, EUR J CLIN MICROBIOL, V22, P647, DOI 10.1007/s10096-003-1026-z; RodriguezZapata M, 1997, INFECTION, V25, P187, DOI 10.1007/BF02113611; ROMERO C, 1995, J CLIN MICROBIOL, V33, P615, DOI 10.1128/JCM.33.3.615-617.1995; Ross HM, 1996, VET REC, V138, P647, DOI 10.1136/vr.138.26.647; SALMERON I, 1992, CLIN INFECT DIS, V15, P764, DOI 10.1093/clind/15.5.764; Sanchez DO, 2001, INFECT IMMUN, V69, P865, DOI 10.1128/IAI.69.2.865-868.2001; Schurig GG, 2002, VET MICROBIOL, V90, P479, DOI 10.1016/S0378-1135(02)00255-9; SHAKIR RA, 1987, BRAIN, V110, P213, DOI 10.1093/brain/110.1.213; Smart J.K., 1997, MED ASPECTS CHEM BIO, P9; Sohn AH, 2003, EMERG INFECT DIS, V9, P485, DOI 10.3201/eid0904.020576; Solera J, 1997, DRUGS, V53, P245, DOI 10.2165/00003495-199753020-00005; Solera J, 1999, CLIN INFECT DIS, V29, P1440, DOI 10.1086/313524; SOLERA J, 1994, MED CLIN-BARCELONA, V102, P731; Solera J, 1998, J INFECTION, V36, P85, DOI 10.1016/S0163-4453(98)93342-4; Solera J, 2001, CLIN INFECT DIS, V32, P506, DOI 10.1086/318503; Solera J, 2004, CLIN INFECT DIS, V39, P1776, DOI 10.1086/426024; Vrioni G, 2004, EUR J CLIN MICROBIOL, V23, P194, DOI 10.1007/s10096-003-1082-4; Yagupsky P, 1999, J CLIN MICROBIOL, V37, P3437, DOI 10.1128/JCM.37.11.3437-3442.1999; Yingst S, 2003, CRIT REV MICROBIOL, V29, P313, DOI 10.1080/713608012; Young EJ, 2000, CLIN INFECT DIS, V31, P904, DOI 10.1086/318129; YOUNG EJ, 1995, CLIN INFECT DIS, V21, P283, DOI 10.1093/clinids/21.2.283; YOUNG EJ, 1991, REV INFECT DIS, V13, P359; ZHAN YF, 1995, INFECT IMMUN, V63, P1387, DOI 10.1128/IAI.63.4.1387-1390.1995; ZHAN YF, 1993, INFECT IMMUN, V61, P4899, DOI 10.1128/IAI.61.11.4899-4901.1993	99	858	925	5	63	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2005	352	22					2325	2336		10.1056/NEJMra050570	http://dx.doi.org/10.1056/NEJMra050570			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930VY	15930423				2023-01-03	WOS:000229446400009
J	Gardner, CD; Coulston, A; Chatterjee, L; Rigby, A; Spiller, G; Farquhar, JW				Gardner, CD; Coulston, A; Chatterjee, L; Rigby, A; Spiller, G; Farquhar, JW			The effect of a plant-based diet on plasma lipids in hypercholesterolemic adults - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							SERUM-LIPIDS; LIPOPROTEIN CHOLESTEROL; NUTRITION COMMITTEE; MEDITERRANEAN DIET; PHYSICAL-ACTIVITY; FATTY-ACIDS; SOY PROTEIN; RISK; GUIDELINES; STATEMENT	Background: A variety of food combinations can be used to meet national U.S. guidelines for obtaining 30% of energy or less from total fat and 10% of energy or less from saturated fat. Objective: To contrast plasma lipid responses to 2 low-fat diet patterns. Design: Randomized clinical trial. Setting: 4-week outpatient feeding study with weight held constant. Participants: 120 adults 30 to 65 years of age with prestudy low-density lipoprotein (LDL) cholesterol concentrations of 3.3 to 4.8 mmol/L (130 to 190 mg/dL), body mass index less than 31 kg/m(2), estimated dietary saturated fat at least 10% of calories, and otherwise general good health. Measurements: Plasma lipid levels. Intervention: Two diets, the Low-Fat diet and the Low-Fat Plus diet, designed to be identical in total fat, saturated fat, protein, carbohydrate, and cholesterol content, consistent with former American Heart Association Step I guidelines. The Low-Fat diet was relatively typical of a low-fat U.S. diet. The Low-Fat Plus diet incorporated considerably more vegetables, legumes, and whole grains, consistent with the 2000 American Heart Association revised guidelines. Results: Four-week changes in the Low-Fat and Low-Fat Plus groups were -0.24 mmol/L (-9.2 mg/dL) versus -0.46 mmol/L (-17.6 mg/dL) for total cholesterol (P = 0.01) and -0.18 mmol/L (-7.0 mg/dL) versus -0.36 mmol/L (-13.8 mg/dL) for LDL cholesterol (P= 0.02); between-group differences were -0.22 mmol/L (-9 mg/dL) (95% Cl, -0.05 to -0.39 mmol/L [-2 to -15 mg/dL]) and -0.18 mmol/L (-7 mg/dL) (Cl, -0.04 to -0.32 mmol/L [-2 to -12 mg/dL]) for total and LDL cholesterol, respectively. The 2 diet groups did not differ significantly in high-density lipoprotein cholesterol and triglycericle levels. Limitations: 4-week duration. Conclusions: Previous national dietary guidelines primarily emphasized avoiding saturated fat and cholesterol; as a result, the guidelines probably underestimated the potential LDL cholesterol-lowering effect of diet. In this study, emphasis on including nutrient-dense plant-based foods, consistent with recently revised national guidelines, increased the total and LDL cholesterol-lowering effect of a low-fat diet.	Stanford Univ, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Stanford, CA 94305 USA; Hlth Sci Res Studies Ctr, Los Altos, CA USA	Stanford University; Stanford University	Gardner, CD (corresponding author), Hoover Pavil,N229,211 Quarry Rd, Stanford, CA 94305 USA.	cgardner@stanford.edu	Rigby, Alan/AFM-1194-2022	Rigby, Alan/0000-0001-8331-3907	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057386] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00070] Funding Source: Medline; NHLBI NIH HHS [R01 HL57386] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackermann RT, 2001, ARCH INTERN MED, V161, P813, DOI 10.1001/archinte.161.6.813; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Asztalos B, 2000, J LIPID RES, V41, P321; Byers T, 2002, CA-CANCER J CLIN, V52, P92, DOI 10.3322/canjclin.52.2.92; CHAIT A, 1993, CIRCULATION, V88, P3008, DOI 10.1161/01.CIR.88.6.3008; Crouse JR, 1999, ARCH INTERN MED, V159, P2070, DOI 10.1001/archinte.159.17.2070; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GARDNER CD, 1995, ARTERIOSCL THROM VAS, V15, P1917, DOI 10.1161/01.ATV.15.11.1917; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Jenkins DJA, 2003, JAMA-J AM MED ASSOC, V290, P502, DOI 10.1001/jama.290.4.502; Jenkins DJA, 1999, METABOLISM, V48, P809, DOI 10.1016/S0026-0495(99)90184-1; Katan MB, 1997, NEW ENGL J MED, V337, P563; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; Krauss RM, 2000, CIRCULATION, V102, P2284; KRISETHERTON PM, 1988, J AM DIET ASSOC, V88, P1373; Law M, 2000, BMJ-BRIT MED J, V320, P861, DOI 10.1136/bmj.320.7238.861; LEWIS B, 1981, LANCET, V2, P1310; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; RIPSIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317, DOI 10.1001/jama.267.24.3317; Sabate J, 2003, AM J CLIN NUTR, V77, P1379, DOI 10.1093/ajcn/77.6.1379; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; SAMPSON EJ, 1975, CLIN CHEM, V21, P1983; Schaefer EJ, 1996, AM J CLIN NUTR, V63, P234, DOI 10.1093/ajcn/63.2.234; Schaefer EJ, 1997, AM J CLIN NUTR, V65, P823, DOI 10.1093/ajcn/65.3.823; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; SPRECHER DL, 1993, ANN INTERN MED, V119, P545, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00001; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038	35	67	69	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 3	2005	142	9					725	733		10.7326/0003-4819-142-9-200505030-00007	http://dx.doi.org/10.7326/0003-4819-142-9-200505030-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	922GW	15867404				2023-01-03	WOS:000228825800001
J	Gautschi, OP; Zellweger, R				Gautschi, Oliver P.; Zellweger, Rene			Methicillin-resistant Staphylococcus aureus abscess after intramuscular steroid injection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Royal Perth Hosp, Perth, WA 6000, Australia	Royal Perth Hospital; University of Western Australia	Gautschi, OP (corresponding author), Royal Perth Hosp, Perth, WA 6000, Australia.								0	4	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					713	713		10.1056/NEJMicm062498	http://dx.doi.org/10.1056/NEJMicm062498			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074AN	16914707				2023-01-03	WOS:000239784500010
J	May, MT; Sterne, JAC; Costagliola, D; Sabin, CA; Phillips, AN; Justice, AC; Dabis, F; Gill, J; Lundgren, J; Hogg, RS; de Wolf, F; Fatkenheuer, G; Staszewski, S; Monforte, AD; Egger, M; Sterne, J; Weller, I; May, M; Beckthold, B; Yip, B; Dauer, B; Fusco, J; Lanoy, E; Rickenbach, M; Lavignolle, V; Sighem, A; Pereira, E; Pezzotti, P; Phillips, A; Sabin, C; Schmeisser, N				May, Margaret T.; Sterne, Jonathan A. C.; Costagliola, Dominique; Sabin, Caroline A.; Phillips, Andrew N.; Justice, Amy C.; Dabis, Francois; Gill, John; Lundgren, Jens; Hogg, Robert S.; de Wolf, Frank; Fatkenheuer, Gerd; Staszewski, Schlomo; Monforte, Antonella d'Arminio; Egger, Matthias; Sterne, Jonathan; Weller, Ian; May, Margaret; Beckthold, Brenda; Yip, Benita; Dauer, Brenda; Fusco, Jennifer; Lanoy, Emilie; Rickenbach, Martin; Lavignolle, Valerie; van Sighem, Ard; Pereira, Edwige; Pezzotti, Patrizio; Phillips, Andrew; Sabin, Caroline; Schmeisser, Norbert		ART Cohort Collaboration	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis	LANCET			English	Article							HIV-1-INFECTED PATIENTS; DISEASE PROGRESSION; INFECTED PATIENTS; TUBERCULOSIS; RISK; AIDS; ERA; TRANSMISSION; RESISTANCE; INITIATION	Background Highly active antiretroviral therapy (HAART) for the treatment of HIV infection was introduced a decade ago. We aimed to examine trends in the characteristics of patients starting HAART in Europe and North America, and their treatment response and short-term prognosis. Methods We analysed data from 22 217 treatment-naive HIV-1-infected adults who had started HAART and were followed up in one of 12 cohort studies. The probability of reaching 500 or less HIV-1 RNA copies per mL by 6 months, and the change in CD4 cell counts, were analysed for patients starting HAART in 1995-96, 1997, 1998, 1999, 2000, 2001, and 2002-03. The primary endpoints were the hazard ratios for AIDS and for death from all causes in the first year of HAART which were estimated using Cox regression. Results The proportion of heterosexually infected patients increased from 20% in 1995-96 to 47% in 2002-03, and the proportion of women from 16% to 32%. The median CD4 cell count when starting HAART increased from 170 cells per mu L in 1995-96 to 269 cells per mu L in 1998 but then decreased to around 200 cells per mu L. In 1995-96, 58% achieved HIV-1 RNA of 500 copies per mL or less by 6 months compared with 83% in 2002-03. Compared with 1998, adjusted hazard ratios for AIDS were 1.07 (95% CI 0.84-1.36) in 1995-96 and 1.35 (1.06-1.71) in 2002-03. Corresponding figures for death were 0.87 (0.56-1.36) and 0.96 (0.61-1.51). Interpretation Virological response after starting HAART improved over calendar years, but such improvement has not translated into a decrease in mortality.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	May, MT (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall,Whiteladies Rd, Bristol BS8 2PR, Avon, England.	m.t.may@bristol.ac.uk	Lundgren, Jens/AAE-6876-2019; DABIS, FRANCOIS/S-9298-2019; Phillips, Andrew N/B-4427-2008; Lanoy, Emilie/A-8541-2011; Dodsley, Maria/G-7083-2016; Sabin, Caroline/C-2464-2008; Costagliola, Dominique/H-5849-2011; Hogg, Robert S/B-2783-2012; PEZZOTTI, PATRIZIO/C-6480-2016; Sterne, Jonathan/Z-3106-2019; VALLET, Yannick/F-9979-2011; Gill, Michael John/G-7083-2016; May, Margaret/E-8099-2013	DABIS, FRANCOIS/0000-0002-1614-8857; Phillips, Andrew N/0000-0003-2384-4807; Lanoy, Emilie/0000-0002-4789-7770; Dodsley, Maria/0000-0001-7587-558X; Sabin, Caroline/0000-0001-5173-2760; Costagliola, Dominique/0000-0003-0765-0869; Hogg, Robert S/0000-0003-3463-5488; PEZZOTTI, PATRIZIO/0000-0002-0805-2927; Sterne, Jonathan/0000-0001-8496-6053; Gill, Michael John/0000-0002-8546-8790; May, Margaret/0000-0002-9733-1003	Medical Research Council [G0100221] Funding Source: Medline; MRC [G0100221] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], 1992, MMWR Recomm Rep, V41, P1; Barnes PF, 1999, AM J RESP CRIT CARE, V159, P1081, DOI 10.1164/ajrccm.159.4.9807153; Becker SL, 2001, J ACQ IMMUN DEF SYND, V26, P72, DOI 10.1097/00126334-200101010-00011; Binquet C, 2001, AM J EPIDEMIOL, V153, P386, DOI 10.1093/aje/153.4.386; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; Delgado J, 2003, ANTIVIR THER, V8, P471; DeSimone JA, 2000, ANN INTERN MED, V133, P447, DOI 10.7326/0003-4819-133-6-200009190-00013; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; Girardi E, 2000, AIDS, V14, P1985, DOI 10.1097/00002030-200009080-00015; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Hogg RS, 1999, CAN MED ASSOC J, V160, P659; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Lampe FC, 2006, ARCH INTERN MED, V166, P521, DOI 10.1001/archinte.166.5.521; Landon BE, 2005, ARCH INTERN MED, V165, P1133, DOI 10.1001/archinte.165.10.1133; Lewden C, 2005, INT J EPIDEMIOL, V34, P121, DOI 10.1093/ije/dyh307; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; Maggiolo F, 2003, ANTIVIR THER, V8, P339; Masquelier B, 2005, J MED VIROL, V76, P441, DOI 10.1002/jmv.20380; May M, 2005, J CLIN EPIDEMIOL, V58, P1033, DOI 10.1016/j.jclinepi.2005.02.015; May M, 2004, STAT MED, V23, P2375, DOI 10.1002/sim.1825; McLaughlin SI, 2003, INT J TUBERC LUNG D, V7, P665; Mocroft A, 1999, AIDS, V13, P1255, DOI 10.1097/00002030-199907090-00016; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Narita M, 1998, AM J RESP CRIT CARE, V158, P157, DOI 10.1164/ajrccm.158.1.9712001; Nieuwkerk PT, 2001, ARCH INTERN MED, V161, P1962, DOI 10.1001/archinte.161.16.1962; Nikolopoulos G, 2005, EUR J PUBLIC HEALTH, V15, P296, DOI 10.1093/eurpub/cki064; Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088; Sabin CA, 2006, AIDS, V20, P67, DOI 10.1097/01.aids.0000196178.73174.24; Staehelin C, 2003, AIDS, V17, P2237, DOI 10.1097/00002030-200310170-00012; Sterling TR, 2000, INT J TUBERC LUNG D, V4, P1066; Suligoi B, 2003, SCAND J INFECT DIS, V35, P12, DOI 10.1080/03008870310009588; Sullivan AK, 2005, BRIT MED J, V330, P1301, DOI 10.1136/bmj.38398.590602.E0; 2004, WKLY EPIDEMIOL REC, V79, P441	38	187	187	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					451	458						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890831				2023-01-03	WOS:000239569000027
J	Scharf, HP; Mansmann, U; Streitberger, K; Witte, S; Kramer, J; Maier, C; Trampisch, HJ; Victor, N				Scharf, Hanns-Peter; Mansmann, Ulrich; Streitberger, Konrad; Witte, Steffen; Kraemer, Juergen; Maier, Christoph; Trampisch, Hans-Joachim; Victor, Norbert			Acupuncture and knee osteoarthritis - A three-armed randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							ADJUNCTIVE THERAPY; ARTHRITIS; CRITERIA; VALIDATION; OUTCOMES; PATIENT; WOMAC; HIP	Background: Despite the popularity of acupuncture, evidence of its efficacy for reducing pain remains equivocal. Objective: To assess the efficacy and safety of traditional Chinese acupuncture (TCA) compared with sham acupuncture (needling at defined nonacupuncture points) and conservative therapy in patients with chronic pain due to osteoarthritis of the knee. Design: Randomized, controlled trial. Setting: 315 primary care practices staffed by 320 practitioners with at least 2 years' experience in acupuncture. Patients: 1007 patients who had had chronic pain for at least 6 months due to osteoarthritis of the knee (American College of Rheumatology [ACR] criteria and Kellgren-Lawrence score of 2 or 3). Interventions: Up to 6 physiotherapy sessions and as-needed anti-inflammatory drugs plus 10 sessions of TCA, 10 sessions of sham acupuncture, or 10 physician visits within 6 weeks. Patients could request up to 5 additional sessions or visits if the initial treatment was viewed as being partially successful. Measurements: Success rate, as defined by at least 36% improvement in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score at 26 weeks. Additional end points were WOMAC score and global patient assessment. Results: Success rates were 53.1% for TCA, 51.0% for sham acupuncture, and 29.1% for conservative therapy. Acupuncture groups had higher success rates than conservative therapy groups (relative risk for TCA compared with conservative therapy, 1.75 [95% Cl, 1.43 to 2.13]; relative risk for sham acupuncture compared with conservative therapy, 1.73 [CI, 1.42 to 2.11]). There was no difference between TCA and sham acupuncture (relative risk, 1.01 [Cl, 0.87 to 1.171). Limitations: There was no blinding between acupuncture and traditional therapy and no monitoring of acupuncture compliance with study protocol. In general, practitioner-patient contacts were less intense in the conservative therapy group than in the TCA and sham acupuncture groups. Conclusions: Compared with physiotherapy and as-needed antiinflammatory drugs, addition of either TCA or sham acupuncture led to greater improvement in WOMAC score at 26 weeks. No statistically significant difference was observed between TCA and sham acupuncture, suggesting that the observed differences could be due to placebo effects, differences in intensity of provider contact, or a physiologic effect of needling regardless of whether it is done according to TCA principles.	Heidelberg Univ, Heidelberg, Germany; Ruhr Univ Bochum, D-4630 Bochum, Germany	Ruprecht Karls University Heidelberg; Ruhr University Bochum	Victor, N (corresponding author), Heidelberg Univ, Bergheimer Str 58, Heidelberg, Germany.			Hans, Trampisch/0000-0001-9136-1079				ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Angst F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Berman BM, 1999, RHEUMATOLOGY, V38, P346, DOI 10.1093/rheumatology/38.4.346; Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006; CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x; Collins SL, 2001, PAIN, V91, P189, DOI 10.1016/S0304-3959(00)00435-8; Ezzo J, 2001, ARTHRITIS RHEUM, V44, P819, DOI 10.1002/1529-0131(200104)44:4<819::AID-ANR138>3.0.CO;2-P; FELSON DT, 1988, EPIDEMIOL REV, V10, P1; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1564, DOI 10.1002/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M; Felson DT, 2000, ANN INTERN MED, V133, P726, DOI 10.7326/0003-4819-133-9-200011070-00015; GOLDSMITH CH, 1993, J RHEUMATOL, V20, P561; *INT C HARM, 1998, CPMPICH36396 INT C H; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; KNUTSON K, 1994, ACTA ORTHOP SCAND, V65, P375, DOI 10.3109/17453679408995475; LACHIN JM, 1977, BIOMETRICS, V33, P315, DOI 10.2307/2529781; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.2307/2335748; Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104; Moerman DE, 2002, ANN INTERN MED, V136, P471, DOI 10.7326/0003-4819-136-6-200203190-00011; MOLSBERGER A, 1994, DER SCHMERZ, V8, P37; MOLSBERGER A, 2002, DTSCH ARZTEBLATT, V99, P1819; Puhl W, 2000, Z ORTHOP GRENZGEB, V138, P85, DOI 10.1055/s-2000-10120; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; SHAFFER JP, 1995, ANNU REV PSYCHOL, V46, P561, DOI 10.1146/annurev.ps.46.020195.003021; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Streitberger Konrad, 2004, BMC Complement Altern Med, V4, P6; Stucki G, 1996, Z RHEUMATOL, V55, P40; STUCKI G, 1995, CLIN EXP RHEUMATOL, V13, P349; STUX G, 2001, CLIN ACUPUNCTURE SCI, P171; Vas J, 2004, BMJ-BRIT MED J, V329, P1216, DOI 10.1136/bmj.38238.601447.3A; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7	34	256	290	0	38	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2006	145	1					12	20		10.7326/0003-4819-145-1-200607040-00005	http://dx.doi.org/10.7326/0003-4819-145-1-200607040-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	062IS	16818924				2023-01-03	WOS:000238938400002
J	Lindenauer, PK; Pekow, P; Gao, S; Crawford, AS; Gutierrez, B; Benjamin, EM				Lindenauer, Peter K.; Pekow, Penelope; Gao, Shan; Crawford, Allison S.; Gutierrez, Benjamin; Benjamin, Evan M.			Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease	ANNALS OF INTERNAL MEDICINE			English	Article							ELDERLY-PATIENTS; MANAGEMENT; OUTCOMES; DISPARITIES; APPRAISAL; PNEUMONIA	Background: Acute exacerbation of chronic obstructive pulmonary disease (COPD) is 1 of the 10 leading causes of hospitalization among adults in the United States. Objective: To evaluate the quality of care provided to patients hospitalized for acute exacerbations of COPD and to determine whether hospital or patient characteristics influence treatment. Design: Retrospective cohort study. Setting: 360 hospitals throughout the United States. Patients: 69 820 patients hospitalized for acute exacerbations of COPD. Measurements: Adherence to diagnosis and treatment recommendations contained in guidelines produced by the American College of Physicians and the American College of Chest Physicians; analyses of associations between hospital and patient characteristics and composite measures of performance. Results: Of the 69 820 patients, 66 276 (95%) underwent chest radiography, 63 715 (91%) received supplemental oxygen, 67 515 (97%) received bronchodilators, 59 240 (85%) received systemic steroids, and 59 053 (85%) were given antibiotics. In total, 45 800 (66%) received this entire set of recommended care processes. Numerous participants received tests or treatments that were not beneficial: 16 607 (24%) were treated with methylxanthine bronchodilators, 10 051 (14%) had sputum testing, 8354 (12%) underwent acute spirometry, 4299 (6%) had chest physiotherapy, and 1409 (2%) were treated with mucolytic medications. Overall, 31 519 patients (45%) received at least 1 of these non-recommended care elements, and 22 929 (33%) received ideal care, defined as all of the recommended care processes and none of the non-recommended ones. Individual hospital performance varied widely; whereas older patients and women were more likely to receive ideal care than their counterparts, a higher annual volume of admissions for COPD was not associated with improved hospital performance. Limitations: The study used administrative data, not chart review, and was limited to the inpatient management of COPD. Conclusions: The quality of care for patients hospitalized for acute exacerbations of COPD may be improved by increasing the use of systemic corticosteroid and antibiotic therapy, decreasing the use of unnecessary and potentially harmful treatments, and reducing variation in practice across hospitals.	Baystate Med Ctr, Div Healthcare Qual, Springfield, MA 01199 USA; Tufts Univ, Sch Med, Baystate Med Ctr, Springfield, MA 01199 USA; Univ Massachusetts, Amherst, MA 01003 USA; Premier Healthcare Informat, Charlotte, NC USA	Baystate Medical Center; Baystate Medical Center; Tufts University; University of Massachusetts System; University of Massachusetts Amherst	Lindenauer, PK (corresponding author), Baystate Med Ctr, Div Healthcare Qual, 759 Chestnut St,P-5928, Springfield, MA 01199 USA.	Peter.Lindenauer@bhs.org						Agency for Healthcare Research and Quality, HCUPNET HEALTHC COST; *AM THOR SOC EUR R, 2005, STAND DIAGN MAN PAT; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], AHRQ PUBL; Bach PB, 2001, ANN INTERN MED, V134, P600, DOI 10.7326/0003-4819-134-7-200104030-00016; Barnato AE, 2005, MED CARE, V43, P308, DOI 10.1097/01.mlr.0000156848.62086.06; Bratzler Dale W, 2004, J Okla State Med Assoc, V97, P227; *CTR MED SERV, MED PAY PERF DEM SHO; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fine JM, 2002, ARCH INTERN MED, V162, P827, DOI 10.1001/archinte.162.7.827; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; Gibson P G, 1998, J Qual Clin Pract, V18, P125; Global initiative for chronic obstructive lung disease (GOLD), 2016, GLOBAL STRATEGY DIAG; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Houck PM, 2004, ARCH INTERN MED, V164, P637, DOI 10.1001/archinte.164.6.637; Hoyert DL, 2005, NATL VITAL STAT REPO, V53; *I HEALTHC IMP R, BUNDL SAF; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; *JOINT COMM ACCR H, 2005, SPEC MAN NAT HOSP QU; McCrory DC, 2001, CHEST, V119, P1190, DOI 10.1378/chest.119.4.1190; Meehan TP, 2000, CHEST, V117, P1378, DOI 10.1378/chest.117.5.1378; Meehan TP, 1997, JAMA-J AM MED ASSOC, V278, P2080, DOI 10.1001/jama.278.23.2080; Meehan TP, 2001, AM J MED, V111, P203, DOI 10.1016/S0002-9343(01)00803-8; Moody A, 2004, THORAX, V59, P1; O'Donnell Denis E, 2003, Can Respir J, V10 Suppl A, p11A; Snow V, 2001, ANN INTERN MED, V134, P595, DOI 10.7326/0003-4819-134-7-200104030-00015; *US DEP HHS, HOSP COMP QUAL TOOOL	27	152	160	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 20	2006	144	12					894	903		10.7326/0003-4819-144-12-200606200-00006	http://dx.doi.org/10.7326/0003-4819-144-12-200606200-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	056WJ	16785478				2023-01-03	WOS:000238555500004
J	Nowis, D; Legat, M; Grzela, T; Niderla, J; Wilczek, E; Wilczynski, GM; Glodkowska, E; Mrowka, P; Issat, T; Dulak, J; Jozkowicz, A; Was, H; Adamek, M; Wrzosek, A; Nazarewski, S; Makowski, M; Stoklosa, T; Jakobisiak, M; Golab, J				Nowis, D.; Legat, M.; Grzela, T.; Niderla, J.; Wilczek, E.; Wilczynski, G. M.; Glodkowska, E.; Mrowka, P.; Issat, T.; Dulak, J.; Jozkowicz, A.; Was, H.; Adamek, M.; Wrzosek, A.; Nazarewski, S.; Makowski, M.; Stoklosa, T.; Jakobisiak, M.; Golab, J.			Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity	ONCOGENE			English	Article						photodynamic therapy; Photofrin; heme oxygenase; cancer	MANGANESE SUPEROXIDE-DISMUTASE; UP-REGULATION; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; GENE-EXPRESSION; CARBON-MONOXIDE; SINGLET OXYGEN; NITRIC-OXIDE; CANCER CELLS; APOPTOSIS	Photodynamic therapy is a promising antitumor treatment modality approved for the management of both early and advanced tumors. The mechanisms of its antitumor action include generation of singlet oxygen and reactive oxygen species that directly damage tumor cells and tumor vasculature. A number of mechanisms seem to be involved in the protective responses to PDT that include activation of transcription factors, heat shock proteins, antioxidant enzymes and antiapoptotic pathways. Elucidation of these mechanisms might result in the design of more effective combination strategies to improve the antitumor efficacy of PDT. Using DNA microarray analysis to identify stress-related genes induced by Photofrin-mediated PDT in colon adenocarcinoma C-26 cells, we observed a marked induction of heme oxygenase-1 (HO-1). Induction of HO-1 with hemin or stable transfection of C-26 with a plasmid vector encoding HO-1 increased resistance of tumor cells to PDT-mediated cytotoxicity. On the other hand, zinc (II) protoporphyrin IX, an HO-1 inhibitor, markedly augmented PDT-mediated cytotoxicity towards C-26 and human ovarian carcinoma MDAH2774 cells. Neither bilirubin, biliverdin nor carbon monoxide, direct products of HO-1 catalysed heme degradation, was responsible for cytoprotection. Importantly, desferrioxamine, a potent iron chelator significantly potentiated cytotoxic effects of PDT. Altogether our results indicate that HO-1 is involved in an important protective mechanism against PDT-mediated phototoxicity and administration of HO-1 inhibitors might be an effective way to potentiate antitumor effectiveness of PDT.	Warsaw Univ, Ctr Biostruct Res, Dept Immunol, PL-02097 Warsaw, Poland; Warsaw Univ, Ctr Biostruct Res, Dept Histol & Embryol, PL-02097 Warsaw, Poland; Warsaw Univ, Ctr Biostruct Res, Dept Pathol, PL-02097 Warsaw, Poland; Warsaw Univ, Dept Gen & Vasc Surg & Transplantat, PL-02097 Warsaw, Poland; Jagiellonian Univ, Fac Biotechnol, Dept Med Biotechnol, Krakow, Poland; Silesian Univ, Ctr Laser Diagnost & Therapy, Chair & Clin Internal Dis & Phys Med, Bytom, Poland; M Nencki Inst Expt Biol, Dept Muscle Biochem, PL-02093 Warsaw, Poland	University of Warsaw; University of Warsaw; University of Warsaw; University of Warsaw; Jagiellonian University; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Golab, J (corresponding author), Warsaw Univ, Ctr Biostruct Res, Dept Immunol, 1A Banacha Str,F Bldg, PL-02097 Warsaw, Poland.	jgolab@ib.amwaw.edu.pl	Nowis, Dominika/P-6866-2019; Issat, Tadeusz/AAE-4176-2019; Nowis, Dominika/P-1213-2017; Golab, Jakub/K-6974-2013; Wrzosek, Antoni/AAE-8070-2021; Glodkowska-Mrowka, Eliza/AAC-7294-2020; Nazarewski, Sławomir D./T-3998-2018; Glodkowska-Mrowka, Eliza/AAR-8503-2021; Wolinska, Ewa/AAE-4628-2021	Nowis, Dominika/0000-0003-2748-9523; Issat, Tadeusz/0000-0002-3647-3550; Nowis, Dominika/0000-0003-2748-9523; Golab, Jakub/0000-0002-2830-5100; Glodkowska-Mrowka, Eliza/0000-0002-5865-8425; Nazarewski, Sławomir D./0000-0003-1195-9252; Glodkowska-Mrowka, Eliza/0000-0002-5865-8425; Wolinska, Ewa/0000-0001-9592-1301; Was, Halina/0000-0003-2743-0337; Wrzosek, Antoni/0000-0001-6376-8816; Stoklosa, Tomasz/0000-0001-6918-5056; Wilczynski, Grzegorz/0000-0001-6667-0291				Abels C, 2004, PHOTOCH PHOTOBIO SCI, V3, P765, DOI 10.1039/b314241h; Almeida RD, 2004, BBA-REV CANCER, V1704, P59, DOI 10.1016/j.bbcan.2004.05.003; BACHOWSKI GJ, 1994, LIPIDS, V29, P449, DOI 10.1007/BF02578241; BALLA G, 1992, J BIOL CHEM, V267, P18148; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; BRESSOUD D, 1992, J PHOTOCH PHOTOBIO B, V14, P311, DOI 10.1016/1011-1344(92)85110-G; Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4; Cisowski J, 2005, BIOCHEM BIOPH RES CO, V326, P670, DOI 10.1016/j.bbrc.2004.11.083; Deshane J, 2005, ACTA BIOCHIM POL, V52, P273; Dolgachev V, 2005, BIOCHEM BIOPH RES CO, V332, P411, DOI 10.1016/j.bbrc.2005.04.141; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dulak J, 2002, ANTIOXID REDOX SIGN, V4, P229, DOI 10.1089/152308602753666280; Dulak J, 2003, ACTA BIOCHIM POL, V50, P31; Fang J, 2004, INT J CANCER, V109, P1, DOI 10.1002/ijc.11644; Ferrario A, 2000, CANCER RES, V60, P4066; Ferrario A, 2002, CANCER RES, V62, P3956; Frankel D, 2000, J CELL PHYSIOL, V185, P80, DOI 10.1002/1097-4652(200010)185:1<80::AID-JCP7>3.0.CO;2-W; Golab J, 2000, BRIT J CANCER, V82, P1485; Golab J, 2003, J BIOL CHEM, V278, P407, DOI 10.1074/jbc.M209125200; Golab J, 2002, CLIN CANCER RES, V8, P1265; Gomer CJ, 1996, CANCER RES, V56, P2355; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V53, P275, DOI 10.1111/j.1751-1097.1991.tb03934.x; Granville DJ, 2000, BLOOD, V95, P256; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Grune T, 2001, FREE RADICAL BIO MED, V30, P1243, DOI 10.1016/S0891-5849(01)00515-9; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Jalili A, 2004, CLIN CANCER RES, V10, P4498, DOI 10.1158/1078-0432.CCR-04-0367; Kapitulnik J, 2004, MOL PHARMACOL, V66, P773, DOI 10.1124/mol.104.002832; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kick G, 1996, BRIT J CANCER, V74, P30, DOI 10.1038/bjc.1996.311; Kliukiene R, 1997, BIOCHEM MOL BIOL INT, V41, P707; Koukourakis MI, 2001, CANCER RES, V61, P1830; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lin FB, 1996, CANCER RES, V56, P4636; LUNA MC, 1994, CANCER RES, V54, P1374; Makowski M, 2003, CLIN CANCER RES, V9, P5417; Mcbride G, 2002, J NATL CANCER I, V94, P1740; Minetti M, 1998, ARCH BIOCHEM BIOPHYS, V352, P165, DOI 10.1006/abbi.1998.0584; Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613; Nowis D, 2005, ACTA BIOCHIM POL, V52, P339; Oberdanner CB, 2005, PHOTOCHEM PHOTOBIOL, V81, P609, DOI 10.1562/2004-08-23-RN-284.1; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Rasch MH, 1997, PHOTOCHEM PHOTOBIOL, V66, P209, DOI 10.1111/j.1751-1097.1997.tb08645.x; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Sahoo SK, 2002, BIOCONJUGATE CHEM, V13, P1031, DOI 10.1021/bc020010k; Sharman WM, 2000, METHOD ENZYMOL, V319, P376; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Shiraishi F, 2001, ANAL BIOCHEM, V289, P303, DOI 10.1006/abio.2000.4965; Srivastava M, 2001, J BIOL CHEM, V276, P15481, DOI 10.1074/jbc.M006920200; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Tanaka S, 2003, BRIT J CANCER, V88, P902, DOI 10.1038/sj.bjc.6600830; Turkseven S, 2005, AM J PHYSIOL-HEART C, V289, pH701, DOI 10.1152/ajpheart.00024.2005; Verwanger T, 2002, INT J ONCOL, V21, P1353; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Wang HP, 2002, PHOTOCHEM PHOTOBIOL, V76, P98, DOI 10.1562/0031-8655(2002)076<0098:UROHPA>2.0.CO;2; Wild PJ, 2005, MOL CANCER THER, V4, P516, DOI 10.1158/1535-7163.MCT-04-0141; Woods JA, 2004, PHOTOCHEM PHOTOBIOL, V79, P105, DOI 10.1111/j.1751-1097.2004.tb09864.x; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Zhuang SG, 2003, PHOTOCHEM PHOTOBIOL, V78, P361, DOI 10.1562/0031-8655(2003)078<0361:SOAOPK>2.0.CO;2	61	152	155	2	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3365	3374		10.1038/sj.onc.1209378	http://dx.doi.org/10.1038/sj.onc.1209378			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16462769	Green Accepted			2023-01-03	WOS:000238448100002
J	Pritchard, KI; Shepherd, LE; O'Malley, FP; Andrulis, IL; Tu, DS; Bramwell, VH; Levine, MN				Pritchard, KI; Shepherd, LE; O'Malley, FP; Andrulis, IL; Tu, DS; Bramwell, VH; Levine, MN		Natl Canc Inst Canada Clin Trials	HER2 and responsiveness of breast cancer to adjuvant chemotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	38th Annual Meeting of the American-Society-of-Clinical-Oncology	MAY 18-21, 2002	ORLANDO, FL	Amer Soc Clin Oncol			II-ALPHA; PREMENOPAUSAL WOMEN; PREDICTIVE MARKERS; IN-SITU; HER-2/NEU OVEREXPRESSION; RANDOMIZED-TRIAL; NODE; CYCLOPHOSPHAMIDE; METHOTREXATE; FLUOROURACIL	Background: Amplification of the human epidermal growth factor receptor type 2 (HER2, also called HER2/neu) gene and overexpression of its product in breast-cancer cells may be associated with responsiveness to anthracycline-containing chemotherapy regimens. Methods: In the randomized, controlled Mammary.5 trial, we studied 639 formalin-fixed paraffin-embedded specimens obtained from 710 premenopausal women with node-positive breast cancer who had received either cyclophosphamide, epirubicin, and fluorouracil (CEF) or cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant chemotherapy. HER2 amplification or overexpression was evaluated with the use of fluorescence in situ hybridization, immunohistochemical analysis, and polymerase-chain-reaction analysis. Results: Amplification of HER2 was associated with a poor prognosis regardless of the type of treatment. In patients whose tumors showed amplification of HER2, CEF was superior to CMF when assessed on the basis of relapse-free survival (hazard ratio, 0.52; 95 percent confidence interval, 0.34 to 0.80; P=0.003) and overall survival (hazard ratio, 0.65; 95 percent confidence interval, 0.42 to 1.02; P=0.06). For women whose tumors lacked amplification of HER2, CEF did not improve relapse-free survival (hazard ratio for relapse, 0.91; 95 percent confidence interval, 0.71 to 1.18; P=0.49) or overall survival (hazard ratio for death, 1.06; 95 percent confidence interval, 0.83 to 1.44; P=0.68). The adjusted hazard ratio for the interaction between treatment and HER2 amplification was 1.96 for relapse-free survival (95 percent confidence interval, 1.15 to 3.36; P=0.01) and 2.04 for overall survival (95 percent confidence interval, 1.14 to 3.65; P=0.02). Conclusions: Amplification of HER2 in breast-cancer cells is associated with clinical responsiveness to anthracycline-containing chemotherapy. (cancer.gov number, NCI-V90-0027.).	Univ Toronto, Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada; Queens Univ, Kingston, ON, Canada; Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Mt Sinai Hosp, Fred A Litwin Ctr Canc Genet, Samuel Lunenfeld Res Inst, Toronto, ON, Canada; Univ Calgary, Dept Oncol, Calgary, AB, Canada; Tom Baker Canc Clin, Calgary, AB, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Queens University - Canada; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Calgary; Tom Baker Cancer Clinic; University of Calgary; McMaster University; McMaster University	Pritchard, KI (corresponding author), Univ Toronto, Toronto Sunnybrook Reg Canc Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	kathy.pritchard@sunnybrook.ca	Andrulis, Irene L./E-7267-2013; Pritchard, Kathleen I/I-2184-2014	Pritchard, Kathleen I/0000-0003-0758-9666				ALLRED DC, 1992, J CLIN ONCOL, V10, P599, DOI 10.1200/JCO.1992.10.4.599; ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; ARNOULD L, 2003, BREAST CANC RES TREA, V76, pA538; BONNETERRE J, 2003, P AN M AM SOC CLIN, V22, pA93; CARPENTER JT, 1994, P AN M AM SOC CLIN, V13, pA68; Clahsen PC, 1998, J CLIN ONCOL, V16, P470, DOI 10.1200/JCO.1998.16.2.470; DELAURENTIIS M, 2001, P AN M AM SOC CLIN, V20, pA133; DELMASTRO L, 2004, J CLIN ONCOL S, V22, pA571; DEPLACIDO S, 1995, BRIT J CANCER, V71, P1283, DOI 10.1038/bjc.1995.248; Di Leo A, 2002, CLIN CANCER RES, V8, P1107; Di Leo A, 2001, ANN ONCOL, V12, P1081, DOI 10.1023/A:1011669223035; DILEO A, 1999, P AN M AM SOC CLIN, V18, pA69; Dressler LG, 2005, J CLIN ONCOL, V23, P4287, DOI 10.1200/JCO.2005.11.012; FISHER B, 1990, J CLIN ONCOL, V8, P1483, DOI 10.1200/JCO.1990.8.9.1483; GOLDHIRSCH A, 1989, NEW ENGL J MED, V320, P491; GOLDHIRSCH A, 1988, NEW ENGL J MED, V319, P677; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; Isola J. J., 2000, Breast Cancer Research and Treatment, V64, P31; Jarvinen TAH, 1999, GENE CHROMOSOME CANC, V26, P142; Knoop AS, 2005, J CLIN ONCOL, V23, P7483, DOI 10.1200/JCO.2005.11.007; Konecny G, 2001, BREAST CANCER RES TR, V69, P53, DOI 10.1023/A:1012226006395; LANDIS JR, 1977, BIOMETRICS, V33, P671, DOI 10.2307/2529465; Latta EK, 2002, MODERN PATHOL, V15, P1318, DOI 10.1097/01.MP.0000038462.62634.B1; Levine MN, 2005, J CLIN ONCOL, V23, P5166, DOI 10.1200/JCO.2005.09.423; Levine MN, 1998, J CLIN ONCOL, V16, P2651, DOI 10.1200/JCO.1998.16.8.2651; LEVINE MN, 1993, EUR J CANCER, V29A, P37, DOI 10.1016/0959-8049(93)90573-X; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; MOLITERNI A, 1991, J CLIN ONCOL, V9, P1124, DOI 10.1200/JCO.1991.9.7.1124; Moliterni A, 2003, J CLIN ONCOL, V21, P458, DOI 10.1200/JCO.2003.04.021; Mueller RE, 2004, GENE CHROMOSOME CANC, V39, P288, DOI 10.1002/gcc.20008; O'Malley FP, 2001, AM J CLIN PATHOL, V115, P504; Paik S, 2000, J NATL CANCER I, V92, P1991, DOI 10.1093/jnci/92.24.1991; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Press MF, 2005, CLIN CANCER RES, V11, P6598, DOI 10.1158/1078-0432.CCR-05-0636; Press MF, 2005, J CLIN ONCOL, V23, p847S; PRITCHARD KI, 2002, P AN M AM SOC CLIN, V21, pA42; Ravdin P, 1998, P AN M AM SOC CLIN, V17, p97a; Rodenhuis S, 2003, NEW ENGL J MED, V349, P7, DOI 10.1056/NEJMoa022794; SLAMON D, 2005, 28 SAN ANT BREAST CA; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Thor AD, 1998, JNCI-J NATL CANCER I, V90, P1346, DOI 10.1093/jnci/90.18.1346; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; WOOD WC, 1994, NEW ENGL J MED, V331, P139	44	411	439	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2006	354	20					2103	2111		10.1056/NEJMoa054504	http://dx.doi.org/10.1056/NEJMoa054504			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	043BX	16707747				2023-01-03	WOS:000237575400004
J	Casarett, D; Kapo, J; Caplan, A				Casarett, D; Kapo, J; Caplan, A			Appropriate use of artificial nutrition and hydration - Fundamental principles and recommendations	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; ADJUVANT PARENTERAL-NUTRITION; NURSING-HOME RESIDENTS; ENTERAL NUTRITION; ADVANCED DEMENTIA; CARE; PREFERENCES; END; MANAGEMENT; PHYSICIANS											AHRONHEIM JC, 1990, LANCET, V335, P278, DOI 10.1016/0140-6736(90)90084-I; *AM AC HOSP PALL M, STAT US NUTR HYDR; *AM NURS ASS, 1992, ANA NURSING WOR 0402; [Anonymous], COMMUNICATION; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Beauchamp T. L., 2012, PRINCIPLES BIOMEDICA, VVII-a; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; BRENNAN MF, 1994, ANN SURG, V220, P436, DOI 10.1097/00000658-199410000-00003; Brett AS, 2001, ARCH INTERN MED, V161, P745, DOI 10.1001/archinte.161.5.745; Buchanan Allen E., 1989, DECIDING OTHERS ETHI; Callahan CM, 2000, J AM GERIATR SOC, V48, P1048, DOI 10.1111/j.1532-5415.2000.tb04779.x; CALLAHAN D, 1983, HASTINGS CENT REP, V13, P22, DOI 10.2307/3560573; Casarett David J, 2002, J Palliat Med, V5, P3, DOI 10.1089/10966210252784962; Casarett DJ, 2001, ANN INTERN MED, V135, P32, DOI 10.7326/0003-4819-135-1-200107030-00011; Centers for Medicare and Medicaid Services, NURS HOM COMP; CIOCON JO, 1988, ARCH INTERN MED, V148, P429, DOI 10.1001/archinte.148.2.429; *COMM UN STAT LAWS, 1993, NAT C COMM UN STAT L; *CTR MED MED SERV, DESCR RUG3 CLASS SYS; DALY JM, 1995, ANN SURG, V221, P327, DOI 10.1097/00000658-199504000-00002; DALY JM, 1984, AM J SURG, V148, P514, DOI 10.1016/0002-9610(84)90379-9; Dresser R, 2004, HASTINGS CENT REP, V34, P8, DOI 10.2307/3528413; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Ganzini L, 2003, NEW ENGL J MED, V349, P359, DOI 10.1056/NEJMsa035086; Gillick MR, 2000, NEW ENGL J MED, V342, P206, DOI 10.1056/NEJM200001203420312; Grubb A, 1996, LANCET, V348, P35, DOI 10.1016/S0140-6736(96)02030-2; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Happ MB, 2002, J AM GERIATR SOC, V50, P829, DOI 10.1046/j.1532-5415.2002.50207.x; Helman, 2000, CULTURE HLTH ILLNESS; HODGES MO, 1994, ARCH INTERN MED, V154, P1013, DOI 10.1001/archinte.154.9.1013; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; *HOSP PALL NURS AS, POS STAT ART NUTR HY; LANKEN PN, 1991, AM REV RESPIR DIS, V144, P726, DOI 10.1164/ajrccm/144.3_Pt_1.726; Lee JH, 1998, ARCH OTOLARYNGOL, V124, P871, DOI 10.1001/archotol.124.8.871; Lo B, 2002, NEW ENGL J MED, V346, P1489, DOI 10.1056/NEJM200205093461912; Martin CM, 2004, CAN MED ASSOC J, V170, P197, DOI 10.1503/cmaj.1040621; MAZZINI L, 1995, J NEUROL, V242, P695, DOI 10.1007/BF00866922; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Meier DE, 2001, ARCH INTERN MED, V161, P594, DOI 10.1001/archinte.161.4.594; Meisel A, 1995, AM J LAW MED, V21, P335; Meisel A, 2004, RIGHT DIE LAW END OF; MEISEL A, 1995, RIGHT TO DIE; Miller RG, 2001, AMYOTROPH LATERAL SC, V2, P3, DOI 10.1080/146608201300079355; Mitchell SL, 2003, JAMA-J AM MED ASSOC, V290, P73, DOI 10.1001/jama.290.1.73; Mitchell SL, 2003, J AM GERIATR SOC, V51, P129, DOI 10.1034/j.1601-5215.2002.51021.x; Mitchell SL, 2001, J AM GERIATR SOC, V49, P313, DOI 10.1046/j.1532-5415.2001.4930313.x; Mitchell SL, 1998, J GERONTOL A-BIOL, V53, pM207, DOI 10.1093/gerona/53A.3.M207; Mitchell Susan L, 2004, J Am Med Dir Assoc, V5, pS22, DOI 10.1097/00130535-200403001-00010; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; Morrison RS, 1998, ARCH INTERN MED, V158, P2493, DOI 10.1001/archinte.158.22.2493; Morrison RS, 2004, ARCH INTERN MED, V164, P2421, DOI 10.1001/archinte.164.22.2421; National Consensus Project for Quality Palliative Care, CLIN PRACT GUID QUAL; Odom SR, 2003, SURG ENDOSC, V17, P651, DOI 10.1007/s00464-002-8599-y; Pasman HRW, 2005, ARCH INTERN MED, V165, P1729, DOI 10.1001/archinte.165.15.1729; PATRICK DL, 1994, MED DECIS MAKING, V14, P9, DOI 10.1177/0272989X9401400102; POPP MB, 1981, SURGERY, V90, P195; Post SG, 2001, HASTINGS CENT REP, V31, P36, DOI 10.2307/3528732; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAK HLTH CAR DEC REP; Rabeneck L, 1997, LANCET, V349, P496, DOI 10.1016/S0140-6736(96)07369-2; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Scolapio JS, 1999, MAYO CLIN PROC, V74, P217, DOI 10.4065/74.3.217; Senkal M, 1999, ARCH SURG-CHICAGO, V134, P1309, DOI 10.1001/archsurg.134.12.1309; SHAMBERGER RC, 1984, SURGERY, V96, P1; Shannon TA, 2004, HASTINGS CENT REP, V34, P18, DOI 10.2307/3528689; Sieger CE, 2002, J AM GERIATR SOC, V50, P544, DOI 10.1046/j.1532-5415.2002.50124.x; *SOC CRIT CAR MED, 1990, CRIT CARE MED, V18, P1435; SPRUNG CL, 1992, CRIT CARE MED, V20, P320; Teno JM, 1997, J AM GERIATR SOC, V45, P939, DOI 10.1111/j.1532-5415.1997.tb02963.x; Tolle SW, 1998, J AM GERIATR SOC, V46, P1097, DOI 10.1111/j.1532-5415.1998.tb06647.x; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; Viola RA, 1997, J PALLIATIVE CARE, V13, P41, DOI 10.1177/082585979701300407; WANKLYN P, 1995, AGE AGEING, V24, P510, DOI 10.1093/ageing/24.6.510; Wenger NS, 2001, JAMA-J AM MED ASSOC, V285, P2880, DOI 10.1001/jama.285.22.2880; who, WHO DEF PALL CAR; YAMADA N, 1983, BRIT J SURG, V70, P267, DOI 10.1002/bjs.1800700508; 2005, PHYS ORDERS LIFE SUS	78	124	127	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	2005	353	24					2607	2612		10.1056/NEJMsb052907	http://dx.doi.org/10.1056/NEJMsb052907			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	993BA	16354899				2023-01-03	WOS:000233926500013
J	White, HD				White, HD			Adherence and outcomes: it's more than taking the pills	LANCET			English	Editorial Material							HEART-FAILURE; CONTROLLED-TRIAL; THERAPY; CARE; MORTALITY; PLACEBO; RISK		Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland 1001, New Zealand	Auckland City Hospital	White, HD (corresponding author), Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland 1001, New Zealand.	HarveyW@adhb.govt.nz						Benner JS, 2002, JAMA-J AM MED ASSOC, V288, P455, DOI 10.1001/jama.288.4.455; Bissell P, 2004, SOC SCI MED, V58, P851, DOI 10.1016/S0277-9536(03)00259-4; Blue L, 2001, BRIT MED J, V323, P715, DOI 10.1136/bmj.323.7315.715; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; Chapman RH, 2005, ARCH INTERN MED, V165, P1147, DOI 10.1001/archinte.165.10.1147; EKMAN I, 2005, PATIENT EDUC COUNS, DOI DOI 10.1016/JPEC.2005.04.005; Evangelista LS, 2000, AM J CARDIOL, V86, P1339, DOI 10.1016/S0002-9149(00)01238-8; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; Granger BB, 2005, LANCET, V366, P2005, DOI 10.1016/S0140-6736(05)67760-4; Haynes RB, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub2; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; Irvine J, 1999, PSYCHOSOM MED, V61, P566, DOI 10.1097/00006842-199907000-00023; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; Lavie Carl J, 2004, Am J Geriatr Cardiol, V13, P29; McDonald K, 2001, EUR J HEART FAIL, V3, P209, DOI 10.1016/S1388-9842(00)00134-3; Miller NH, 1997, CIRCULATION, V95, P1085; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Roe CM, 1999, AM HEART J, V138, P818, DOI 10.1016/S0002-8703(99)70005-0; van der Wal MHL, 2005, EUR J HEART FAIL, V7, P5, DOI 10.1016/j.ejheart.2004.04.007	19	31	32	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 10	2005	366	9502					1989	1991		10.1016/S0140-6736(05)67761-6	http://dx.doi.org/10.1016/S0140-6736(05)67761-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	991PW	16338439				2023-01-03	WOS:000233826900006
J	Fitzmaurice, DA; Murray, ET; McCahon, D; Holder, R; Raftery, JP; Hussain, S; Sandhar, H; Hobbs, FDR				Fitzmaurice, DA; Murray, ET; McCahon, D; Holder, R; Raftery, JP; Hussain, S; Sandhar, H; Hobbs, FDR			Self management of oral anticoagulation: randomised trial	BRITISH MEDICAL JOURNAL			English	Article							ATRIAL-FIBRILLATION; THERAPY; GUIDELINES	Objective To determine the clinical effectiveness of self management compared with routine care in patients on long term oral anticoagulants. Design Multicentre open randomised controlled trial. Setting Midlands region of the UK. Participants 617 patients aged over 18 and receiving warfarin randomised to intervention (n = 337) and routine care (n = 280) Front 2470 invited; 193/337 (57%) completed the 12 month intervention. Intervention Intervention patients used a point of care device to measure international normalised ratio twice a week mid a simple closing chart to interpret their dose of warfarin. Main outcome measure Percentage of time spent within the therapeutic range of international normalised ratio. Results No significant differences were found in percentage of time in the therapeutic range between self management and routine care (70% v 68%). Self managed patients with poor control before the study showed an improvement in control that was not seen in die routine care group. Nine patients (2.8/100 patient years) had serious adverse events in the self managed group, compared with seven (2.7/100 patient years) in the routine care arm (chi(2)(df = 1) = 0.02, P = 0.89). Conclusion With appropriate training, self management is safe and reliable for a sizeable proportion of patients receiving oral anticoagulation treatment. It may improve die time spent within the therapeutic range for patients with initially poor control.	Univ Birmingham, Dept Primary Care Gen Practice, Birmingham B15 2TT, W Midlands, England; Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of Birmingham; University of Birmingham	Fitzmaurice, DA (corresponding author), Univ Birmingham, Dept Primary Care Gen Practice, Birmingham B15 2TT, W Midlands, England.	d.a.fitzmaurice@bham.ac.uk		hobbs, richard/0000-0001-7976-7172				Ansell J, 2005, INT J CARDIOL, V99, P37, DOI 10.1016/j.ijcard.2003.11.008; BAGLIN T, 1994, CLIN LAB HAEMATOL, V16, P327; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; COLVIN BT, 1990, J CLIN PATHOL, V43, P177; Cromheecke ME, 2000, LANCET, V356, P97, DOI 10.1016/S0140-6736(00)02470-3; Fitzmaurice DA, 2002, J CLIN PATHOL, V55, P845, DOI 10.1136/jcp.55.11.845; Fitzmaurice DA, 2001, BRIT MED J, V323, P985, DOI 10.1136/bmj.323.7319.985; Gadisseur APA, 2003, ARCH INTERN MED, V163, P2639, DOI 10.1001/archinte.163.21.2639; Hasenkam JM, 1997, EUR J CARDIO-THORAC, V11, P935, DOI 10.1016/S1010-7940(97)01204-9; *IMS HLTH, 1999, MP990207 IMS HLTH; Menendez-Jandula B, 2005, ANN INTERN MED, V142, P1, DOI 10.7326/0003-4819-142-1-200501040-00006; Morsdorf S, 1999, SEMIN THROMB HEMOST, V25, P109, DOI 10.1055/s-2007-996433; Murray E, 2004, BRIT MED J, V328, P437, DOI 10.1136/bmj.328.7437.437; Murray ET, 1999, J CLIN PATHOL, V52, P842, DOI 10.1136/jcp.52.11.842; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Rose PE, 1996, J CLIN PATHOL, V49, P5, DOI 10.1136/jcp.49.1.5; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; Sawicki PT, 1999, JAMA-J AM MED ASSOC, V281, P145, DOI 10.1001/jama.281.2.145; Siebenhofer A, 2004, THROMB HAEMOSTASIS, V91, P225, DOI 10.1160/TH03-09-0598; SUDLOW CM, 1995, BRIT MED J, V311, P558, DOI 10.1136/bmj.311.7004.558; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; TAYLOR F, 1993, BRIT MED J, V307, P1493, DOI 10.1136/bmj.307.6917.1493	22	86	89	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 5	2005	331	7524					1057	1059		10.1136/bmj.38618.580903.AE	http://dx.doi.org/10.1136/bmj.38618.580903.AE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16216821	Green Published, Bronze			2023-01-03	WOS:000233211200020
J	Branthwaite, MA				Branthwaite, MA			Taking the final step: changing the law on euthanasia and physician assisted suicide - Time for change	BRITISH MEDICAL JOURNAL			English	Editorial Material							DEATH; NEED											Doyal L, 2001, BMJ-BRIT MED J, V323, P1079, DOI 10.1136/bmj.323.7321.1079; Grayling AC, 2005, BRIT MED J, V330, P799, DOI 10.1136/bmj.330.7495.799; Hemmings Philip, 2003, Nurs Times, V99, P20; *HOUS LORDS REP, 1994, SEL COMM MED ETH; Huxtable R, 2004, BRIT MED J, V328, P1088, DOI 10.1136/bmj.328.7448.1088; Kravitz RL, 2001, BRIT MED J, V323, P584, DOI 10.1136/bmj.323.7313.584; *OR DEP HUM SERV, 2005, 7 OR DEP HUM SERV OF; Smith R, 2000, BMJ-BRIT MED J, V320, P129, DOI 10.1136/bmj.320.7228.129; WISSELMANN B, 2005, BRIT MED J, V330, P1389	9	9	9	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	SEP 24	2005	331	7518					681	683		10.1136/bmj.331.7518.681	http://dx.doi.org/10.1136/bmj.331.7518.681			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970HH	16179704	Green Published			2023-01-03	WOS:000232295400021
J	Chen, B; Colgrave, ML; Daly, NL; Rosengren, KJ; Gustafson, KR; Craik, DJ				Chen, B; Colgrave, ML; Daly, NL; Rosengren, KJ; Gustafson, KR; Craik, DJ			Isolation and characterization of novel cyclotides from Viola hederaceae - Solution structure and anti-HIV activity of vhl-1, a leaf-specific expressed cyclotide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SULFOXIDE REDUCTASE; NMR STRUCTURE CALCULATION; SPIN COUPLING-CONSTANTS; CYSTINE KNOT MOTIF; KALATA B1; MACROCYCLIC PEPTIDES; PLANT CYCLOTIDES; CIRCULAR PROTEINS; DRUG DESIGN; SPECTROSCOPY	Based on a newly established sequencing strategy featured by its efficiency, simplicity, and easy manipulation, the sequences of four novel cyclotides (macrocyclic knotted proteins) isolated from an Australian plant Viola hederaceae were determined. The three-dimensional solution structure of V. hederaceae leaf cyclotide-1 ( vhl-1), a leaf-specific expressed 31-residue cyclotide, has been determined using two-dimensional H-1 NMR spectroscopy. vhl-1 adopts a compact and well defined structure including a distorted triple-stranded beta- sheet, a short 310 helical segment and several turns. It is stabilized by three disulfide bonds, which, together with backbone segments, form a cyclic cystine knot motif. The three-disulfide bonds are almost completely buried into the protein core, and the six cysteines contribute only 3.8% to the molecular surface. A pH titration experiment revealed that the folding of vhl-1 shows little pH dependence and allowed the pK(a) of 3.0 for Glu(3) and similar to 5.0 for Glu(14) to be determined. Met(7) was found to be oxidized in the native form, consistent with the fact that its side chain protrudes into the solvent, occupying 7.5% of the molecular surface. vhl-1 shows anti-HIV activity with an EC50 value of 0.87 mu m.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Chinese Acad Sci, Chengdu Inst Biol, Ctr Nat Prod, Chengdu 610041, Peoples R China; NCI, Mol Targets Dev Program, Ctr Canc Res, NIH, Ft Detrick, MD 21702 USA	University of Queensland; Chinese Academy of Sciences; Chengdu Institute of Biology, CAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chen, B (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Rosengren, K. Johan/P-4450-2016; Craik, David/B-1695-2010; Colgrave, Michelle/A-5710-2012; Daly, Norelle L/D-4302-2013	Rosengren, K. Johan/0000-0002-5007-8434; Craik, David/0000-0003-0007-6796; Colgrave, Michelle/0000-0001-8463-805X; Daly, Norelle L/0000-0002-4697-6602	NATIONAL CANCER INSTITUTE [Z01BC010469, ZICBC010469] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barry DG, 2004, STRUCTURE, V12, P85, DOI 10.1016/j.str.2003.11.019; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bokesch HR, 2001, J NAT PROD, V64, P249, DOI 10.1021/np000372l; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Ciorba MA, 1997, P NATL ACAD SCI USA, V94, P9932, DOI 10.1073/pnas.94.18.9932; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2001, TOXICON, V39, P1809, DOI 10.1016/S0041-0101(01)00129-5; Craik DJ, 2004, CURR PROTEIN PEPT SC, V5, P297, DOI 10.2174/1389203043379512; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Craik DJ, 2002, CURR OPIN DRUG DI DE, V5, P251; Daly NL, 2004, FEBS LETT, V574, P69, DOI 10.1016/j.febslet.2004.08.007; Daly NL, 1999, J MOL BIOL, V285, P333, DOI 10.1006/jmbi.1998.2276; DAVOODI J, 1995, EUR J BIOCHEM, V232, P839, DOI 10.1111/j.1432-1033.1995.tb20881.x; Dutton JL, 2004, J BIOL CHEM, V279, P46858, DOI 10.1074/jbc.M407421200; El Hassouni M, 1999, P NATL ACAD SCI USA, V96, P887, DOI 10.1073/pnas.96.3.887; Goransson U, 2003, J BIOL CHEM, V278, P48188, DOI 10.1074/jbc.M308771200; Goransson U, 2003, ANAL BIOCHEM, V318, P107, DOI 10.1016/S0003-2697(03)00114-3; Goransson U, 1999, J NAT PROD, V62, P283, DOI 10.1021/np9803878; GRAN L, 1973, LLOYDIA, V36, P207; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Gustafson KR, 2004, CURR PROTEIN PEPT SC, V5, P331, DOI 10.2174/1389203043379468; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Hallock YF, 2000, J ORG CHEM, V65, P124, DOI 10.1021/jo990952r; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; Jennings CV, 2005, BIOCHEMISTRY-US, V44, P851, DOI 10.1021/bi047837h; Koltay A, 2005, INT J PEPT RES THER, V11, P99, DOI 10.1007/s10989-004-1722-2; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Li H, 2004, PROTEINS, V55, P689, DOI 10.1002/prot.20032; Lindholm P, 2002, MOL CANCER THER, V1, P365; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; Schoepke T., 1993, SCI PHARM, V61, P145; SHRAGER RI, 1972, BIOCHEMISTRY-US, V11, P541, DOI 10.1021/bi00754a010; Skjeldal L, 2002, ARCH BIOCHEM BIOPHYS, V399, P142, DOI 10.1006/abbi.2002.2769; Svangard E, 2004, J NAT PROD, V67, P144, DOI 10.1021/np030101l; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; Trabi M, 2004, PLANT CELL, V16, P2204, DOI 10.1105/tpc.104.021790; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002	53	107	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22395	22405		10.1074/jbc.M501737200	http://dx.doi.org/10.1074/jbc.M501737200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824119	hybrid			2023-01-03	WOS:000229557900085
J	Simon, V; Ho, DD; Karim, QA				Simon, Viviana; Ho, David D.; Karim, Quarraisha Abdool			HIV/AIDS epidemiology, pathogenesis, prevention, and treatment	LANCET			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; ACTIVE ANTIRETROVIRAL THERAPY; SEXUALLY-TRANSMITTED-DISEASES; DRUG-RESISTANT HIV-1; CYCLE STRUCTURED INTERMITTENT; SINGLE-DOSE NEVIRAPINE; MESSENGER-RNA LEVELS; SCALING-UP TREATMENT; MALE CIRCUMCISION	The HIV-1 pandemic is a complex mix of diverse epidemics within and between countries and regions of the world, and is undoubtedly the defining public-health crisis of our time. Research has deepened our understanding of how the virus replicates, manipulates, and hides in an infected person. Although our understanding of pathogenesis and transmission dynamics has become more nuanced and prevention options have expanded, a cure or protective vaccine remains elusive. Antiretroviral treatment has transformed AIDS from an inevitably fatal condition to a chronic, manageable disease in some settings. This transformation has yet to be realised in those parts of the world that continue to bear a disproportionate burden of new HIV-1 infections and are most affected by increasing morbidity and mortality. This Seminar provides an update on epidemiology, pathogenesis, treatment, and prevention interventions pertinent to HIV-1.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA; Univ Kwazulu Natal, Ctr AIDS Programme Res S Africa, Durban, South Africa; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA	Rockefeller University; University of Kwazulu Natal; Columbia University	Simon, V (corresponding author), Mt Sinai Sch Med, Dept Med, Div Infect Dis, New York, NY 10029 USA.	viviana.simon@mssm.edu	Abdool Karim, Quarraisha/GVS-1160-2022; simon, viviana/A-9131-2008	Abdool Karim, Quarraisha/0000-0002-0985-477X; simon, viviana/0000-0002-6416-5096	FOGARTY INTERNATIONAL CENTER [D43TW000231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064001, U19AI051794] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW000231, D43 TW00231] Funding Source: Medline; NIAID NIH HHS [U19 AI051794, R01 AI064001-01A2, R01 AI064001-02, R01AI064001, R01 AI064001, 1 U19AI51794] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas UL, 2002, P NATL ACAD SCI USA, V99, P13377, DOI 10.1073/pnas.212518999; [Anonymous], 13 C RETR OPP INF DE; Aral SO, 2005, J INFECT DIS, V191, pS1, DOI 10.1086/425290; Aral SO, 1996, INT J STD AIDS, V7, P30, DOI 10.1258/0956462961917753; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Bachmann MO, 2006, AIDS CARE, V18, P109, DOI 10.1080/09540120500159334; Badri M, 2004, AIDS, V18, P1159, DOI 10.1097/00002030-200405210-00009; Bailey Robert C, 2005, AIDS Read, V15, P136; Balabanian K, 2004, J IMMUNOL, V173, P7150, DOI 10.4049/jimmunol.173.12.7150; BarreSinoussi F, 1996, LANCET, V348, P31, DOI 10.1016/S0140-6736(96)09058-7; Bassett IV, 2004, CLIN INFECT DIS, V39, P395, DOI 10.1086/422459; Berger A, 2005, J CLIN VIROL, V33, P43, DOI 10.1016/j.jcv.2004.09.025; Bieniasz PD, 2006, VIROLOGY, V344, P55, DOI 10.1016/j.virol.2005.09.044; Bieniasz PD, 2004, NAT IMMUNOL, V5, P1109, DOI 10.1038/ni1125; Blackard JT, 2002, CLIN INFECT DIS, V34, P1108, DOI 10.1086/339547; Bloom SS, 2002, SEX TRANSM INFECT, V78, P261, DOI 10.1136/sti.78.4.261; Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650; Briggs JAG, 2006, STRUCTURE, V14, P15, DOI 10.1016/j.str.2005.09.010; Buchbinder SP, 2005, JAIDS-J ACQ IMM DEF, V39, P82, DOI 10.1097/01.qai.0000134740.41585.f4; Calmy A, 2004, AIDS, V18, P2353; Calza L, 2004, J ANTIMICROB CHEMOTH, V53, P10, DOI 10.1093/jac/dkh013; Cantin R, 2005, J VIROL, V79, P6577, DOI 10.1128/JVI.79.11.6577-6587.2005; Carrington M, 1999, HUM MOL GENET, V8, P1939, DOI 10.1093/hmg/8.10.1939; Cates W, 2005, JAIDS-J ACQ IMM DEF, V38, pS8, DOI 10.1097/01.qai.0000167025.87783.31; Ceffa S, 2005, J BIOL REG HOMEOS AG, V19, P169; Centlivre M, 2006, AIDS, V20, P657, DOI 10.1097/01.aids.0000216365.38572.2f; Chaix ML, 2006, J INFECT DIS, V193, P482, DOI 10.1086/499966; Chan DJ, 2005, CURR HIV RES, V3, P223, DOI 10.2174/1570162054368075; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Cho SJ, 2006, J VIROL, V80, P2069, DOI 10.1128/JVI.80.4.2069-2072.2006; Chohan B, 2005, J VIROL, V79, P10701, DOI 10.1128/JVI.79.16.10701-10708.2005; Cicala C, 2002, P NATL ACAD SCI USA, V99, P9380, DOI 10.1073/pnas.142287999; Ciuffi A, 2005, NAT MED, V11, P1287, DOI 10.1038/nm1329; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Coffin J.M., 1997, RETROVIRUSES; Coffin JM, 1996, FIELDS VIROLOGY, P1767; Cohen J, 2003, SCIENCE, V299, P1290, DOI 10.1126/science.299.5611.1290; Cohen MS, 2005, J INFECT DIS, V191, P1391, DOI 10.1086/429414; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001; Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144; Cressey TR, 2005, JAIDS-J ACQ IMM DEF, V38, P283; Cullen BR, 2006, J VIROL, V80, P1067, DOI 10.1128/JVI.80.3.1067-1076.2006; De Boer RJ, 2003, J IMMUNOL, V170, P2479, DOI 10.4049/jimmunol.170.5.2479; Deeks SG, 2003, LANCET, V362, P2002, DOI 10.1016/S0140-6736(03)15022-2; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; Dhawan D, 2006, J INFECT DIS, V193, P36, DOI 10.1086/499163; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Duerr A, 2005, LANCET, V366, P261, DOI 10.1016/S0140-6736(05)66917-6; Duffy Lynne, 2005, J Transcult Nurs, V16, P23, DOI 10.1177/1043659604270962; Dybul M, 2003, J INFECT DIS, V188, P388, DOI 10.1086/376535; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Ekouevi Didier K, 2005, AIDS Read, V15, P479; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Eshleman Susan H., 2002, AIDS Reviews, V4, P59; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; FLYS TS, 2006, J ACQ IMMUN DEF SYND, DOI DOI 10.1097/01.QAI.0000221686.67810.20; Francis DP, 2003, AIDS, V17, P147, DOI 10.1097/00002030-200301240-00003; French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06; Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794; Garber DA, 2004, LANCET INFECT DIS, V4, P397, DOI 10.1016/S1473-3099(04)01056-4; Garenne M, 2006, PLOS MED, V3, P143, DOI 10.1371/journal.pmed.0030078; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Gottlieb GS, 2004, LANCET, V363, P619, DOI 10.1016/S0140-6736(04)15596-7; Gray RH, 2005, LANCET, V366, P1182, DOI 10.1016/S0140-6736(05)67481-8; Gray RH, 1998, LANCET, V351, P98, DOI 10.1016/S0140-6736(97)09381-1; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Greenwald Jeffrey L, 2006, Curr Infect Dis Rep, V8, P125, DOI 10.1007/s11908-006-0008-6; Gregson S, 2006, SCIENCE, V311, P664, DOI 10.1126/science.1121054; Grosskurth H, 2000, LANCET, V355, P1981, DOI 10.1016/S0140-6736(00)02336-9; Gupta R, 2004, J INFECT DIS, V190, P1374, DOI 10.1086/424519; Gupta R, 2004, LANCET, V363, P320, DOI 10.1016/S0140-6736(03)15394-9; Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706; Halperin DT, 2005, SEX TRANSM DIS, V32, P238, DOI 10.1097/01.olq.0000149782.47456.5b; Halperin DT, 2004, LANCET, V364, P4, DOI 10.1016/S0140-6736(04)16606-3; Harris RS, 2004, NAT REV IMMUNOL, V4, P868, DOI 10.1038/nri1489; Hayes R, 2006, SCIENCE, V311, P620, DOI 10.1126/science.1124072; Hillier SL, 2005, JAIDS-J ACQ IMM DEF, V39, P1, DOI 10.1097/01.qai.0000159671.25950.74; Hirschel B, 2001, Lancet Infect Dis, V1, P53, DOI 10.1016/S1473-3099(01)00022-6; *HO, 2004, SCAL ANT THER RES LT; Ho DD, 2002, CELL, V110, P135, DOI 10.1016/S0092-8674(02)00832-2; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Hosken NA, 2005, VACCINE, V23, P2395, DOI 10.1016/j.vaccine.2005.01.017; Huthoff H, 2005, VIROLOGY, V334, P147, DOI 10.1016/j.virol.2005.01.038; Inciardi JA, 2005, AIDS CARE, V17, pS1, DOI 10.1080/09540120500120435; Jamieson BD, 2006, VACCINE, V24, P3426, DOI 10.1016/j.vaccine.2006.02.023; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Jennings C, 2005, J CLIN MICROBIOL, V43, P5950, DOI 10.1128/JCM.43.12.5950-5956.2005; Jin X, 2005, J VIROL, V79, P11513, DOI 10.1128/JVI.79.17.11513-11516.2005; Kantor R, 2005, PLOS MED, V2, P325, DOI 10.1371/journal.pmed.0020112; KARIM QA, 1992, AIDS, V6, P1535, DOI 10.1097/00002030-199212000-00018; Karim QA, 2002, INT J EPIDEMIOL, V31, P37, DOI 10.1093/ije/31.1.37; KEELE BF, 2006, SCIENCE; Kieffer TL, 2005, J VIROL, V79, P1975, DOI 10.1128/JVI.79.3.1975-1980.2005; Kim JY, 2005, NEW ENGL J MED, V353, P2392, DOI 10.1056/NEJMe058261; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Korenromp EL, 2005, J INFECT DIS, V191, pS168, DOI 10.1086/425274; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; Kulkarni Prasad S., 2003, AIDS Reviews, V5, P87; LAEYENDECKER O, 2006, 13 C RETR OPP INF DE; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211; Lee EJ, 2005, J INFECT DIS, V192, P1260, DOI 10.1086/444424; Lehrman G, 2005, LANCET, V366, P549, DOI 10.1016/S0140-6736(05)67098-5; Levy NC, 2005, J URBAN HEALTH, V82, P498, DOI 10.1093/jurban/jti090; Libamba E, 2005, INT J TUBERC LUNG D, V9, P1062; Lombart JP, 2005, AIDS, V19, P1273, DOI 10.1097/01.aids.0000180098.58017.48; Lurie MN, 2003, SEX TRANSM DIS, V30, P149, DOI 10.1097/00007435-200302000-00011; Luzuriaga K, 2005, CLIN INFECT DIS, V40, P466; Magoni M, 2005, AIDS, V19, P433, DOI 10.1097/01.aids.0000161773.29029.c0; Mahalingam S, 2002, J LEUKOCYTE BIOL, V72, P429; Malcolm RK, 2005, J ANTIMICROB CHEMOTH, V56, P954, DOI 10.1093/jac/dki326; Mangeat B, 2005, HUM GENE THER, V16, P913, DOI 10.1089/hum.2005.16.913; Manzi M, 2005, TROP MED INT HEALTH, V10, P1242, DOI 10.1111/j.1365-3156.2005.01526.x; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; McCutchan FE, 2005, J VIROL, V79, P11693, DOI 10.1128/JVI.79.18.11693-11704.2005; McIntyre J, 2006, CURR OPIN INFECT DIS, V19, P33, DOI 10.1097/01.qco.0000200290.99790.72; Mehandru S, 2005, J ALLERGY CLIN IMMUN, V116, P419, DOI 10.1016/j.jaci.2005.05.040; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; Mocroft A, 2004, J ANTIMICROB CHEMOTH, V54, P10, DOI 10.1093/jac/dkh290; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mofenson LM, 2003, LANCET, V362, P1625, DOI 10.1016/S0140-6736(03)14825-8; Mohri H, 2001, J EXP MED, V194, P1277, DOI 10.1084/jem.194.9.1277; Myer L, 2005, J INFECT DIS, V192, P1372, DOI 10.1086/462427; Nagot N, 2005, JAIDS-J ACQ IMM DEF, V39, P632; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Newell ML, 2006, T ROY SOC TROP MED H, V100, P1, DOI 10.1016/j.trstmh.2005.05.012; Newell ML, 2003, JAIDS-J ACQ IMM DEF, V32, P380, DOI 10.1097/00126334-200304010-00006; NICOLOSI A, 1994, EPIDEMIOLOGY, V5, P570, DOI 10.1097/00001648-199411000-00003; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Nolan David, 2005, Sex Health, V2, P153, DOI 10.1071/SH04058; NUNN AJ, 1995, AIDS, V9, P503, DOI 10.1097/00002030-199509050-00013; Orrell Catherine, 2005, Curr HIV/AIDS Rep, V2, P171, DOI 10.1007/s11904-005-0012-8; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palmer S, 2006, P NATL ACAD SCI USA, V103, P7094, DOI 10.1073/pnas.0602033103; Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557; Parkin NT, 2004, ANTIVIR THER, V9, P3; Patterson BK, 2002, AM J PATHOL, V161, P867, DOI 10.1016/S0002-9440(10)64247-2; Perez-Caballero D, 2005, J VIROL, V79, P15567, DOI 10.1128/JVI.79.24.15567-15572.2005; Petersen-Mahrt SK, 2003, J BIOL CHEM, V278, P19583, DOI 10.1074/jbc.C300114200; Pettifor AE, 2005, AIDS, V19, P1525, DOI 10.1097/01.aids.0000183129.16830.06; Platt EJ, 2005, J VIROL, V79, P4347, DOI 10.1128/JVI.79.7.4347-4356.2005; Powers AE, 2006, AIDS, V20, P837, DOI 10.1097/01.aids.0000218547.39339.13; Price MA, 2004, J INFECT DIS, V190, P1448, DOI 10.1086/424470; Puro V, 2004, EUR J EPIDEMIOL, V19, P577, DOI 10.1023/B:EJEP.0000032349.57057.8a; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Quinn TC, 2005, SCIENCE, V308, P1582, DOI 10.1126/science.1112489; Ramratnam B, 1999, LANCET, V354, P1782, DOI 10.1016/S0140-6736(99)02035-8; Ray N, 2006, CURR TOP MICROBIOL, V303, P97, DOI 10.1007/978-3-540-33397-5_5; Read JS, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005479; Rennie S, 2006, B WORLD HEALTH ORGAN, V84, P52, DOI 10.2471/BLT.05.025536; Roberts DM, 2006, NATURE, V441, P239, DOI 10.1038/nature04721; Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182; Rollins N, 2004, JAIDS-J ACQ IMM DEF, V35, P188, DOI 10.1097/00126334-200402010-00014; Rottingen JA, 2001, SEX TRANSM DIS, V28, P579; Sawyer SL, 2004, PLOS BIOL, V2, P1278, DOI 10.1371/journal.pbio.0020275; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Schrofelbauer B, 2004, AIDS REV, V6, P34; Schwebke JR, 2005, J INFECT DIS, V192, P1315, DOI 10.1086/462430; Sharghi N, 2005, JAIDS-J ACQ IMM DEF, V40, P472, DOI 10.1097/01.qai.0000164246.49098.47; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Sheppard Haynes W., 2005, Current Drug Targets - Infectious Disorders, V5, P131, DOI 10.2174/1568005054201599; Shisana O, 2004, B WORLD HEALTH ORGAN, V82, P812; Siegfried N, 2005, LANCET INFECT DIS, V5, P165, DOI 10.1016/S1473-3099(05)01309-5; Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2; Simon V, 2003, NAT REV MICROBIOL, V1, P181, DOI 10.1038/nrmicro772; Simon V, 2005, PLOS PATHOG, V1, P20, DOI 10.1371/journal.ppat.0010006; Smith DM, 2005, J INFECT DIS, V192, P438, DOI 10.1086/431682; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; Spacek LA, 2006, JAIDS-J ACQ IMM DEF, V41, P607, DOI 10.1097/01.qai.0000214807.98465.a2; Steain Megan C, 2004, Sex Health, V1, P239, DOI 10.1071/SH04024; STEIN ZA, 1994, LANCET, V343, P362, DOI 10.1016/S0140-6736(94)91205-X; Stremlau M, 2006, P NATL ACAD SCI USA, V103, P5514, DOI 10.1073/pnas.0509996103; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Szabo R, 2000, BRIT MED J, V320, P1592, DOI 10.1136/bmj.320.7249.1592; Telenti A, 2006, FUTURE VIROL, V1, P55, DOI 10.2217/17460794.1.1.55; Thomson MM, 2005, AIDS REV, V7, P210; Tian CJ, 2006, J VIROL, V80, P3112, DOI 10.1128/JVI.80.6.3112-3115.2006; Toni TD, 2005, AIDS RES HUM RETROV, V21, P1031, DOI 10.1089/aid.2005.21.1031; Tuaillon E, 2004, JAIDS-J ACQ IMM DEF, V37, P1543, DOI 10.1097/00126334-200412150-00001; Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159; Turlure F, 2006, NUCLEIC ACIDS RES, V34, P1653, DOI 10.1093/nar/gkl052; UNAIDS, 2006 REP GLOB AIDS E; Uttayamakul S, 2005, J VIROL METHODS, V128, P128, DOI 10.1016/j.jviromet.2005.04.010; Valdez H, 2002, AIDS, V16, P1113, DOI 10.1097/00002030-200205240-00004; Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8; van der Kuyl AC, 2005, NEW ENGL J MED, V352, P2557, DOI 10.1056/NEJM200506163522420; van der Straten A, 2005, SEX TRANSM DIS, V32, P64, DOI 10.1097/01.olq.0000148301.90343.3a; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; Weber J, 2005, PLOS MED, V2, P392, DOI 10.1371/journal.pmed.0020142; Weller S, 2002, Cochrane Database Syst Rev, pCD003255; Welty TK, 2005, JAIDS-J ACQ IMM DEF, V40, P486, DOI 10.1097/01.qai.0000163196.36199.89; Wensing Annemarie M. J., 2003, AIDS Reviews, V5, P140; Winston A, 2005, HIV MED, V6, P191, DOI 10.1111/j.1468-1293.2005.00288.x; Wyatt CM, 2006, EXPERT OPIN DRUG SAF, V5, P275, DOI 10.1517/14740338.5.2.275; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Yerly S, 2004, AIDS, V18, P1413, DOI 10.1097/01.aids.0000131330.28762.0c; Ylisastigui L, 2004, AIDS, V18, P1101, DOI 10.1097/00002030-200405210-00003; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	207	314	342	1	100	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					489	504		10.1016/S0140-6736(06)69157-5	http://dx.doi.org/10.1016/S0140-6736(06)69157-5			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890836	Green Submitted, Green Accepted			2023-01-03	WOS:000239569000032
J	Jayaraman, KS				Jayaraman, K. S.			Break with tradition	NATURE			English	News Item																			0	3	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 27	2006	442	7101					342	343		10.1038/442342a	http://dx.doi.org/10.1038/442342a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	067CI	16871181				2023-01-03	WOS:000239278900010
J	Kemler, MA; de Vet, HCW; Barendse, GAM; van den Wildenberg, FAJM; van Kleef, M				Kemler, Marius A.; de Vet, Henrica C. W.; Barendse, Gerard A. M.; van den Wildenberg, Frans A. J. M.; van Kleef, Maarten			Spinal cord stimulation for chronic reflex sympathetic dystrophy - Five-year follow-up	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							SYNDROME TYPE-I; PAIN; IMPACT; TRIAL; LIFE		Acad Med Ctr, NL-1100 DD Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, NL-1007 MB Amsterdam, Netherlands; Maastricht Univ Hosp, NL-6202 AZ Maastricht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Maastricht University; Maastricht University Medical Centre (MUMC)	Kemler, MA (corresponding author), Acad Med Ctr, NL-1100 DD Amsterdam, Netherlands.	mvk@anaesth.azm.nl		Kemler, Marius/0000-0003-0306-1565				Kemler MA, 2000, J PAIN SYMPTOM MANAG, V20, P68, DOI 10.1016/S0885-3924(00)00170-6; Kemler MA, 2000, NEW ENGL J MED, V343, P618, DOI 10.1056/NEJM200008313430904; Kemler MA, 2004, ANN NEUROL, V55, P13, DOI 10.1002/ana.10996; Kemler MA, 2002, J PAIN SYMPTOM MANAG, V23, P433, DOI 10.1016/S0885-3924(02)00386-X; Kemler MA, 2001, ANESTHESIOLOGY, V95, P72, DOI 10.1097/00000542-200107000-00016	5	77	84	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	2006	354	22					2394	2396		10.1056/NEJMc055504	http://dx.doi.org/10.1056/NEJMc055504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	047ZZ	16738284	Bronze			2023-01-03	WOS:000237918500032
J	Garnick, R				Garnick, R			Counterpoint: Why biogenerics are a strawman	NATURE BIOTECHNOLOGY			English	Editorial Material									Genentech Inc, San Francisco, CA 94080 USA	Roche Holding; Genentech	Garnick, R (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	snyder.robin@gene.com							0	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2006	24	3					269	269		10.1038/nbt0306-269	http://dx.doi.org/10.1038/nbt0306-269			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	019WQ	16525383	Bronze			2023-01-03	WOS:000235868600019
J	Heyns, AD; Benjamin, RJ; Swanevelder, JPR; Laycock, ME; Pappalardo, BL; Crookes, RL; Wright, DJ; Busch, MP				Heyns, AD; Benjamin, RJ; Swanevelder, JPR; Laycock, ME; Pappalardo, BL; Crookes, RL; Wright, DJ; Busch, MP			Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMITTED VIRAL-INFECTIONS; FACING DONOR RECRUITMENT; RISK-FACTORS; UNITED-STATES; PERIOD MODEL; ZIMBABWE; EPIDEMIOLOGY; TRANSMISSION; PREVENTION	Context The South African National Blood Service collects more than 700000 units of blood annually from a population in which 11.4% is infected with human immunodeficiency virus 1 (HIV-1). The prevalence of HIV-1 in blood donations increased to 0.26% (1:385) in 1998, indicating that a significant number of window-period infective units were entering the blood supply (risk 3.4/100 000). Objectives To determine whether the implementation of anew donor selection policy and educational program introduced in 1999 was associated with reductions in the incidence and prevalence of HIV-1 in blood donations and the reduced transmission risk. Design We compared the prevalence of HIV-1 in 880534 blood donations collected from 1999 through 2000 with the 791639 blood donations collected from 2001 through 2002. We estimated the incidence of HIV-1 in 93 378 (1999-2000) and 67 231 (2001-2002) first-time donations and the residual risk for all donations in 2001-2002 using the less-sensitive enzyme-linked immunoassay and incidence-window period model. Setting All blood donors in the Inland region of the South African National Blood Service were analyzed. Intervention Donor clinics in high HIV prevalence areas were closed. Programs targeting repeat donors and youth were initiated and HIV risk behavior education programs were developed. Structured donor interviews and an enhanced donor self-exclusion questionnaire were institutionalized. Results The prevalence of HIV-1 in blood donations declined from 0.17% in 1999-2000 to 0.08% in 2001-2002 after the implementation of the new donor selection and education policy. The number of high-risk donations collected decreased from 2.6% to 1.7% (P<.001), and the likelihood of these donations being infected decreased from 4.8% to 3.25%. The likelihood of first-time donors being recently infected with HIV-1 decreased from 18% to 14% (P=.07) and respective incidence of high-risk donations collected decreased from 2.6% to 1.7%. Donations from the majority black population declined from 6.6% to 4.2% (P<.001). Analysis of HIV-1 incidence in 20012002 suggests a residual risk of collecting a window period infectious unit of 2.6/ 100 000. Conclusion The implementation of enhanced education and selection policies in South Africa was associated with decreased prevalence of HIV-1 in blood donations.	S African Natl Blood Serv, ZA-1715 Weltevreden Pk, South Africa; Harvard Univ, Joint Program Transfus Med, Boston, MA 02115 USA; Amer Red Cross Blood Serv, Dedham, MA USA; Blood Syst Res Inst, San Francisco, CA USA; Westat Corp, Rockville, MD USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Harvard University; American Red Cross; Vitalant; Vitalant Research Institute; Westat; University of California System; University of California San Francisco	Heyns, AD (corresponding author), S African Natl Blood Serv, Private Bag X14, ZA-1715 Weltevreden Pk, South Africa.	aheyns@inl.sanbs.org.za						Bateman C, 2005, SAMJ S AFR MED J, V95, P202; Busch MP, 2005, TRANSFUSION, V45, P254, DOI 10.1111/j.1537-2995.2004.04215.x; Connolly C, 2004, SAMJ S AFR MED J, V94, P776; de Coning D, 2004, VOX SANG, V87, P168, DOI 10.1111/j.1741-6892.2004.00478.x; deConing D, 2002, VOX SANG, V83, P237, DOI 10.1111/j.1423-0410.2002.tb05310.x; Dodd RY, 2002, TRANSFUSION, V42, P975, DOI 10.1046/j.1537-2995.2002.00174.x; Fang CT, 2003, VOX SANG, V85, P9, DOI 10.1046/j.1423-0410.2003.00311.x; Field SP, 2004, VOX SANG, V87, P19, DOI 10.1111/j.1741-6892.2004.00447.x; Glynn SA, 2000, JAMA-J AM MED ASSOC, V284, P229, DOI 10.1001/jama.284.2.229; Glynn SA, 2002, TRANSFUSION, V42, P966, DOI 10.1046/j.1537-2995.2002.00200.x; HEYNS A, 2005, SAFE BLOOD SUPPLIES; Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42; Kaplan JB, 2003, JAMA-J AM MED ASSOC, V289, P2709, DOI 10.1001/jama.289.20.2709; Kleinman S, 1997, TRANSFUS MED REV, V11, P155, DOI 10.1053/tmrv.1997.0110155; KUSTNER HGV, 1994, S AFR MED J, V84, P195; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; MCFARLAND W, 1995, J ACQ IMMUN DEF SYND, V9, P183; McFarland W, 1998, TRANSFUSION, V38, P279, DOI 10.1046/j.1537-2995.1998.38398222872.x; McFarland W, 1997, VOX SANG, V72, P85, DOI 10.1046/j.1423-0410.1997.7220085.x; McFarland W, 1997, AIDS, V11, pS97; MILLER RG, 1981, DELTA METHOD; Mvere D, 1996, LANCET, V347, P902, DOI 10.1016/S0140-6736(96)91382-3; *NAT DEP HLTH, NAT HIV SYPH ANT SER; Okware S, 2001, B WORLD HEALTH ORGAN, V79, P1113; *S AFR NAT BLOOD S, HAEM ANN REP BLOOD T; *S AFR NAT BLOOD S, DON SELF EXCL QUEST; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Statistics South Africa, 2005, MID POP EST S AFR 20; Stramer SL, 2000, TRANSFUSION, V40, P1165, DOI 10.1046/j.1537-2995.2000.40101165.x; Stramer SL, 2004, NEW ENGL J MED, V351, P760, DOI 10.1056/NEJMoa040085; *UNAIDS WHO, AIDS EP UPD 2003; *WHO, AID MEM NAT BLOOD PR	32	41	44	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2006	295	5					519	526		10.1001/jama.295.5.519	http://dx.doi.org/10.1001/jama.295.5.519			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	007SP	16449617	Bronze			2023-01-03	WOS:000234990300019
J	Carvalho, J; Farkas, A				Carvalho, J; Farkas, A			Essay - Rehabilitation through sport - pilot project with amputees in Angola	LANCET			English	Article									Int Paralymp Comm, D-53113 Bonn, Germany; Univ Lisbon, Fac Human Kinet, P-1699 Lisbon, Portugal	Universidade de Lisboa	Farkas, A (corresponding author), Int Paralymp Comm, Adenauerallee 212-214, D-53113 Bonn, Germany.	Amy.farkas@paralympic.org							0	1	1	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC	2005	366				SI		S5	S6		10.1016/S0140-6736(05)67821-X	http://dx.doi.org/10.1016/S0140-6736(05)67821-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	999FO	16360754				2023-01-03	WOS:000234374400004
J	Cohen, AJ				Cohen, AJ			Hurricane Katrina - Lethal levels	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ochsner Clin Fdn, New Orleans, LA 70121 USA	Ochsner Health System	Cohen, AJ (corresponding author), Ochsner Clin Fdn, New Orleans, LA 70121 USA.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1549	1549		10.1056/NEJMp058250	http://dx.doi.org/10.1056/NEJMp058250			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221775				2023-01-03	WOS:000232486000006
J	Lo, B; Rubenfeld, G				Lo, B; Rubenfeld, G			Palliative sedation in dying patients - "We turn to it when everything else hasn't worked"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; INTENSIVE-CARE-UNIT; OPIOID-RELATED MYOCLONUS; LIFE DECISION-MAKING; TERMINAL SEDATION; CANCER-PATIENTS; SUPREME-COURT; ILL PATIENTS; END; EUTHANASIA		Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Washington, Harborview Med Ctr, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98104 USA	University of California System; University of California San Francisco; Harborview Medical Center; University of Washington; University of Washington Seattle	Lo, B (corresponding author), Room C 126,521 Parnassus Ave, San Francisco, CA 94143 USA.	bernie@medicine.ucsf.edu			NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR005226] Funding Source: NIH RePORTER; NINR NIH HHS [R01NR005226] Funding Source: Medline	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Alpers A, 1999, ARCH FAM MED, V8, P200, DOI 10.1001/archfami.8.3.200; Back AL, 2005, JAMA-J AM MED ASSOC, V293, P1374, DOI 10.1001/jama.293.11.1374; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P206; BEAUCHAMP TL, 2001, PRINCIPLES BIOMEDICA, P128; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; Boyle J, 2004, THEOR MED BIOETH, V25, P51; Braun Ted C, 2003, J Palliat Med, V6, P345, DOI 10.1089/109662103322144655; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Cherny N I, 1994, J Palliat Care, V10, P31; Clarke EB, 2004, J CRIT CARE, V19, P108, DOI 10.1016/j.jcrc.2004.05.001; Cowan JD, 2001, SUPPORT CARE CANCER, V9, P403, DOI 10.1007/s005200100235; CURTIS J, 2001, MANAGING DEATH ICU T; Fainsinger RL, 2000, J PALLIAT CARE, V16, P5, DOI 10.1177/082585970001600202; Gillon R, 1999, BMJ-BRIT MED J, V318, P1431, DOI 10.1136/bmj.318.7196.1431; Gorsuch NM, 2000, HARVARD J LAW PUBL P, V23, P599; Green Kelly, 2003, Indiana Int Comp Law Rev, V13, P639; Hagen N, 1997, J PAIN SYMPTOM MANAG, V14, P51, DOI 10.1016/S0885-3924(97)00001-8; Hough CL, 2005, J CRIT CARE, V20, P20, DOI 10.1016/j.jcrc.2004.09.006; Jackson W Clay, 2002, Am J Hosp Palliat Care, V19, P81, DOI 10.1177/104990910201900202; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Jansen LA, 2002, ANN INTERN MED, V136, P845, DOI 10.7326/0003-4819-136-11-200206040-00014; Lanuke Kathryn, 2004, J Palliat Med, V7, P257, DOI 10.1089/109662104773709378; Li Denise, 2004, Crit Care Nurse, V24, P72; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Lo B, 2002, JAMA-J AM MED ASSOC, V287, P749, DOI 10.1001/jama.287.6.749; LO B, 2005, RESOLVING ETHICAL DI, P107; Lo Bernard, 2003, J Palliat Med, V6, P409, DOI 10.1089/109662103322144727; Lo Bernard, 2003, Palliat Support Care, V1, P3; McIntyre A, 2004, THEOR MED BIOETH, V25, P61, DOI 10.1023/B:META.0000025095.73394.34; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; Mercadante S, 1998, PAIN, V74, P5, DOI 10.1016/S0304-3959(97)00090-0; MERCADANTE S, 1995, ANESTH ANALG, V81, P1307, DOI 10.1097/00000539-199512000-00034; Mercadante S, 2001, SUPPORT CARE CANCER, V9, P205, DOI 10.1007/s005200000230; Morita T, 2004, PALLIATIVE MED, V18, P550, DOI 10.1191/0269216304pm911oa; Morita T, 2002, J PAIN SYMPTOM MANAG, V24, P447, DOI 10.1016/S0885-3924(02)00499-2; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Parker RA, 1999, JAMA-J AM MED ASSOC, V281, P1937, DOI 10.1001/jama.281.20.1937; President ' Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DEC FOR LIF SUST TRE, P73; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Rousseau Paul, 2003, J Palliat Med, V6, P425, DOI 10.1089/109662103322144745; Rousseau Paul, 2005, J Palliat Med, V8, P10, DOI 10.1089/jpm.2005.8.10; Rubenfeld GD, 2004, CRIT CARE CLIN, V20, P435, DOI 10.1016/j.ccc.2004.03.005; RUBENFELD GD, 2000, MANAGING DEATH ICU T; Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034; Sheldon Tony, 2005, BMJ, V330, P61, DOI 10.1136/bmj.330.7482.61; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; Sykes N, 2003, LANCET ONCOL, V4, P312, DOI 10.1016/S1470-2045(03)01079-9; Sykes N, 2003, ARCH INTERN MED, V163, P341, DOI 10.1001/archinte.163.3.341; Tannsjo T., 2004, TERMINAL SEDATION EU; Taylor Brigit R, 2005, J Palliat Med, V8, P144, DOI 10.1089/jpm.2005.8.144; Truog RD, 2001, CRIT CARE MED, V29, P2332, DOI 10.1097/00003246-200112000-00017; Truog RD, 2000, NEW ENGL J MED, V342, P508, DOI 10.1056/NEJM200002173420712; WARNOCK M, 1998, INTELLIGENT PERSONS, P27; Wilson Robin K, 2004, J Palliat Med, V7, P580, DOI 10.1089/1096621041838461; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	60	132	132	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	2005	294	14					1810	1816		10.1001/jama.294.14.1810	http://dx.doi.org/10.1001/jama.294.14.1810			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972RX	16219885				2023-01-03	WOS:000232472000021
J	Block, SD; Billings, JA				Block, SD; Billings, JA			Becoming a physician - Learning from dying	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Dana Farber Canc Inst, Div Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Block, SD (corresponding author), Dana Farber Canc Inst, Div Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.							GERTEIS M, 1993, PATIENTS EYES PROMOT; Hafferty F.W., 1991, VALLEY DEATH SOCIALI; Kubler-Ross Elisabeth, 1969, DEATH DYING	3	30	31	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1313	1315		10.1056/NEJMp048171	http://dx.doi.org/10.1056/NEJMp048171			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	968FB	16192474				2023-01-03	WOS:000232146200001
J	Lee, SJ; Ralston, HJP; Drey, EA; Partridge, JC; Rosen, MA				Lee, SJ; Ralston, HJP; Drey, EA; Partridge, JC; Rosen, MA			Fetal pain - A systematic multidisciplinary review of the evidence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LEGAL-ABORTION MORTALITY; VELOCITY WAVE-FORMS; PRETERM INFANTS; INVASIVE PROCEDURES; STRESS-RESPONSE; NEWBORN-INFANTS; UNITED-STATES; HUMAN BRAIN; HUMAN FETUS; ANESTHESIA	Context Proposed federal legislation would require physicians to inform women seeking abortions at 20 or more weeks after fertilization that the fetus feels pain and to offer anesthesia administered directly to the fetus. This article examines whether a fetus feels pain and if so, whether safe and effective techniques exist for providing direct fetal anesthesia or analgesia in the context of therapeutic procedures or abortion. Evidence Acquisition Systematic search of PubMed for English-language articles focusing on human studies related to fetal pain, anesthesia, and analgesia. included articles studied fetuses of less than 30 weeks' gestational age or specifically addressed fetal pain perception or nociception. Articles were reviewed for additional references. The search was performed without date limitations and was current as of June 6, 2005. Evidence Synthesis Pain perception requires conscious recognition or awareness of a noxious stimulus. Neither withdrawal reflexes nor hormonal stress responses to invasive procedures prove the existence of fetal pain, because they can be elicited by nonpainful stimuli and occur without conscious cortical processing. Fetal awareness of noxious stimuli requires functional thalamocortical connections. Thalamocortical fibers begin appearing between 23 to 30 weeks' gestational age, while electroencephalography suggests the capacity for functional pain perception in preterm neonates probably does not exist before 29 or 30 weeks. For fetal surgery, women may receive general anesthesia and/or analgesics intended for placental transfer, and parenteral opioids may be administered to the fetus under direct or sonographic visualization. In these circumstances, administration of anesthesia and analgesia serves purposes unrelated to reduction of fetal pain, including inhibition of fetal movement, prevention of fetal hormonal stress responses, and induction of uterine atony. Conclusions Evidence regarding the capacity for fetal pain is limited but indicates that fetal perception of pain is unlikely before the third trimester. Little or no evidence addresses the effectiveness of direct fetal anesthetic or analgesic techniques. Similarly, limited or no data exist on the safety of such techniques for pregnant women in the context of abortion. Anesthetic techniques currently used during fetal surgery are not directly applicable to abortion procedures.	Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn Integrat Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rosen, MA (corresponding author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, 513 Parnassus Ave, San Francisco, CA 94143 USA.	rosenm@anesthesia.ucsf.edu						ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, LANCET, V1, P62; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANDREWS K, 1994, PAIN, V56, P95, DOI 10.1016/0304-3959(94)90154-6; ASHWAL S, 1990, PEDIATR NEUROL, V6, P233, DOI 10.1016/0887-8994(90)90113-F; ATRASH HK, 1987, AM J OBSTET GYNECOL, V156, P605, DOI 10.1016/0002-9378(87)90061-5; ATRASH HK, 1988, AM J OBSTET GYNECOL, V158, P420, DOI 10.1016/0002-9378(88)90169-X; Barbas H, 2000, BRAIN RES BULL, V52, P319, DOI 10.1016/S0361-9230(99)00245-2; Bartlett LA, 2004, OBSTET GYNECOL, V103, P729, DOI 10.1097/01.AOG.0000116260.81570.60; Benatar D, 2001, BIOETHICS, V15, P57, DOI 10.1111/1467-8519.00212; Burgess JA, 1996, BIOETHICS, V10, P1, DOI 10.1111/j.1467-8519.1996.tb00100.x; Carrasco GA, 2003, EUR J PHARMACOL, V463, P235, DOI 10.1016/S0014-2999(03)01285-8; Cauldwell Charles B, 2002, Anesthesiol Clin North Am, V20, P211, DOI 10.1016/S0889-8537(03)00062-2; Clancy RR, 2003, CURRENT PRACTICE CLI, P160; Clyburn PA, 2004, ANAESTHESIA, V59, P1157, DOI 10.1111/j.1365-2044.2004.04060.x; Craig K. D., 2001, HDB PAIN ASSESSMENT, P153; CRAIG KD, 1993, PAIN, V52, P287, DOI 10.1016/0304-3959(93)90162-I; CRAIG KD, 1994, J PEDIATR PSYCHOL, V19, P305, DOI 10.1093/jpepsy/19.3.305; Derbyshire SWG, 1999, BIOETHICS, V13, P1, DOI 10.1111/1467-8519.00129; Derbyshire SWG, 2001, BIOETHICS, V15, P77, DOI 10.1111/1467-8519.00213; Fisch B. J., 1999, FISCH SPEHLMANNS EEG; Fisk NM, 2001, ANESTHESIOLOGY, V95, P828, DOI 10.1097/00000542-200110000-00008; Fitzgerald M, 2003, PAIN INFANTS CHILDRE, V2nd, P19; Franck LS, 1997, J PAIN SYMPTOM MANAG, V14, P343, DOI 10.1016/S0885-3924(97)00222-4; Gaiser RR, 1999, SEMIN PERINATOL, V23, P507, DOI 10.1016/S0146-0005(99)80029-9; GERDIN E, 1990, J PERINAT MED, V18, P305, DOI 10.1515/jpme.1990.18.4.305; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; Giannakoulopoulos X, 1999, PEDIATR RES, V45, P494, DOI 10.1203/00006450-199904010-00007; Glover V, 1999, BRIT J OBSTET GYNAEC, V106, P881, DOI 10.1111/j.1471-0528.1999.tb08424.x; Goubet N, 2001, J DEV BEHAV PEDIATR, V22, P418, DOI 10.1097/00004703-200112000-00009; GREGORY GA, 1983, ANESTH ANALG, V62, P9; Hadjistavropoulos HD, 1997, PAIN, V73, P319, DOI 10.1016/S0304-3959(97)00113-9; HARAM K, 1980, BRIT J OBSTET GYNAEC, V87, P506, DOI 10.1111/j.1471-0528.1980.tb04587.x; Henshaw K, 2003, PERSPECT SEX REPRO H, V35, P16; Hevner RF, 2000, J NEUROPATH EXP NEUR, V59, P385, DOI 10.1093/jnen/59.5.385; HRBEK A, 1973, ELECTROEN CLIN NEURO, V34, P225, DOI 10.1016/0013-4694(73)90249-6; Humphery T, 1964, PROGR BRAIN RES, V4, P93, DOI [10.1016/s0079-6123(08)61273-x, DOI 10.1016/S0079-6123(08)61273-X, 10.1016/S0079-6123]; *INT ASS STUD PAIN, 2004, IASP PAIN TERM; Jauniaux E, 1996, HUM REPROD, V11, P889; Johnston CC, 1996, DEV MED CHILD NEUROL, V38, P438; JOHNSTON CC, 1995, PAIN, V61, P471, DOI 10.1016/0304-3959(94)00213-X; Johnston CC, 1996, PEDIATRICS, V98, P925; KLIMACH VJ, 1988, DEV MED CHILD NEUROL, V30, P208; KONSTANTINIDOU AD, 1995, J COMP NEUROL, V354, P1, DOI 10.1002/cne.903540102; KOSTOVIC I, 1995, INT J PSYCHOPHYSIOL, V19, P85, DOI 10.1016/0167-8760(94)00081-O; Kostovic I, 2002, ANAT RECORD, V267, P1, DOI 10.1002/ar.10069; KOSTOVIC I, 1984, J NEUROSCI, V4, P25; KOSTOVIC I, 1983, J COMP NEUROL, V219, P431, DOI 10.1002/cne.902190405; KOSTOVIC I, 1990, J COMP NEUROL, V297, P441, DOI 10.1002/cne.902970309; KRMPOTICNEMANIC J, 1983, ACTA ANAT, V116, P69; LEHMANN KA, 1991, ACTA ANAESTH SCAND, V35, P221, DOI 10.1111/j.1399-6576.1991.tb03277.x; Lindh V, 1997, EARLY HUM DEV, V48, P131, DOI 10.1016/S0378-3782(96)01851-8; LOFTUS JR, 1995, ANESTHESIOLOGY, V83, P300, DOI 10.1097/00000542-199508000-00010; Missant C, 2004, Acta Anaesthesiol Belg, V55, P239; MRZLJAK L, 1988, J COMP NEUROL, V271, P355, DOI 10.1002/cne.902710306; Munnur U, 2004, CRIT CARE CLIN, V20, P617, DOI 10.1016/j.ccc.2004.05.011; Myers Laura B, 2004, Best Pract Res Clin Anaesthesiol, V18, P231, DOI 10.1016/j.bpa.2004.01.001; Myers LB, 2002, PAEDIATR ANAESTH, V12, P569, DOI 10.1046/j.1460-9592.2002.00840.x; Oberlander TF, 2002, PEDIATRICS, V110, P570, DOI 10.1542/peds.110.3.570; OKADO N, 1984, CLIN DEV MED, V94, P31; Pilon M, 1996, BRAIN INJURY, V10, P421, DOI 10.1080/026990596124287; POKELA ML, 1994, PEDIATRICS, V93, P379; Porter FL, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e13; RADUNOVIC N, 1993, AM J PERINAT, V10, P112, DOI 10.1055/s-2007-994640; RAYBURN W, 1989, AM J OBSTET GYNECOL, V161, P202, DOI 10.1016/0002-9378(89)90266-4; ROSEN MA, 1991, SEMIN PERINATOL, V15, P410; Rosen MA, 2001, YONSEI MED J, V42, P669, DOI 10.3349/ymj.2001.42.6.669; ROSEN MA, 1984, UNBORN PATIENT PRENA, P417; *ROYAL COLL OBST G, 2004, CONF ENQ MAT CHILD H; SCHENK VWD, 1968, BRAIN, V91, P497, DOI 10.1093/brain/91.3.497; SCHER MS, 1999, ELECTROENCEPHALOGRAP, P896; Schnitzler A, 2000, J CLIN NEUROPHYSIOL, V17, P592, DOI 10.1097/00004691-200011000-00005; SCHULZE S, 1988, SURGERY, V103, P321; Schwarz Uwe, 2003, Semin Pediatr Surg, V12, P196, DOI 10.1016/S1055-8586(03)00025-8; SEEDS JW, 1986, AM J OBSTET GYNECOL, V155, P818, DOI 10.1016/S0002-9378(86)80028-X; Sharbrough F. W., 1999, ELECTROENCEPHALOGRAP, P215; Smith RP, 2000, EUR J OBSTET GYN R B, V92, P161, DOI 10.1016/S0301-2115(00)00441-3; Strauss Lilo T., 2004, Morbidity and Mortality Weekly Report, V53, P1; Strigo IA, 2003, J NEUROPHYSIOL, V89, P3294, DOI 10.1152/jn.01048.2002; Strumper D, 2003, ANESTHESIOLOGY, V98, P1400, DOI 10.1097/00000542-200306000-00015; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; Taylor A, 2000, LANCET, V355, P120, DOI 10.1016/S0140-6736(99)02549-0; Teixeira JMA, 1999, AM J OBSTET GYNECOL, V181, P1018, DOI 10.1016/S0002-9378(99)70340-6; TORRES F, 1985, J CLIN NEUROPHYSIOL, V2, P89, DOI 10.1097/00004691-198504000-00001; Ulfig N, 2000, HISTOL HISTOPATHOL, V15, P771, DOI 10.14670/HH-15.771; Van De Velde M, 2005, ANESTH ANALG, V101, P251, DOI 10.1213/01.ANE.0000156566.62182.AB; VOGT BA, 1979, SCIENCE, V204, P205, DOI 10.1126/science.107587; Waxman SG, 1996, PROG BRAIN RES, V107, P595; White Michelle C, 2004, Best Pract Res Clin Anaesthesiol, V18, P205, DOI 10.1016/j.bpa.2003.12.011; WILLIAMS RH, 2003, WILLIAMS TXB ENDOCRI; WLADIMIROFF JW, 1987, OBSTET GYNECOL, V69, P705; WOO JSK, 1987, OBSTET GYNECOL, V70, P613; Xia Chuanxiong, 2002, J Huazhong Univ Sci Technolog Med Sci, V22, P84	93	212	223	0	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	2005	294	8					947	954		10.1001/jama.294.8.947	http://dx.doi.org/10.1001/jama.294.8.947			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	957JM	16118385	Bronze			2023-01-03	WOS:000231366100025
J	Gostin, LO				Gostin, LO			Medical marijuana, American federalism, and the Supreme Court	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Law Ctr, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Law Ctr, 600 New Jersey Law Ctr NW, Washington, DC 20001 USA.	gostin@georgetown.edu						GREENHOUSE L, 2005, NY TIMES        0710, P3; Institute of Medicine, 1999, MAR MED ASS SCI BAS; ISIKOFF M, 1988, WASHINGTON POST 0907; Kassirer JP, 1997, NEW ENGL J MED, V336, P366, DOI 10.1056/NEJM199701303360509; MADISON J, 1968, FEDERALIST PAPERS, P292; SATEL S, 2005, NY TIMES        0608, P3; Steinbrook R, 2004, NEW ENGL J MED, V351, P1380, DOI 10.1056/NEJMp048222; 2001, FED REG 20038, V66	8	10	10	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	2005	294	7					842	844		10.1001/jama.294.7.842	http://dx.doi.org/10.1001/jama.294.7.842			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955LI	16106011				2023-01-03	WOS:000231227000026
J	Holloway, RG; Benesch, CG; Burgin, WS; Zentner, JB				Holloway, RG; Benesch, CG; Burgin, WS; Zentner, JB			Prognosis and decision making in severe stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; OF-LIFE CARE; REQUIRING MECHANICAL VENTILATION; HEMISPHERIC ISCHEMIC-STROKE; LOCKED-IN SYNDROME; INTRACEREBRAL HEMORRHAGE; TREATMENT PREFERENCES; PALLIATIVE CARE; SERIOUSLY ILL; SUSTAINING TREATMENTS	Context An increasing number of deaths following severe stroke are due to terminal extubations. Variation in withdrawal-of-care practices suggests the possibility of unnecessary prolongation of suffering or of unwanted deaths. Objectives To review the available evidence on prognosis in mechanically ventilated stroke patients and to provide an overall framework to optimize decision making for clinicians, patients, and families. Data Sources Search of MEDLINE from 1980 through March 2005 for English-language articles addressing prognosis in mechanically ventilated stroke patients. From 689 articles identified, we selected 17 for further review. We also identified factors that influence, and decision-making biases that may result, in overuse or underuse of life-sustaining therapies, with a particular emphasis on mechanical ventilation. Evidence Synthesis Overall mortality among mechanically ventilated stroke patients is high, with a 30-day death rate approximating 58% (range in literature, 46%-75%). Although data are limited, among survivors as many as one third may have no or only slight disability, yet many others have severe disability. One can further refine prognosis according to knowledge of stroke syndromes, early patient characteristics, use of clinical prediction rules, and the need for continuing interventions. Factors influencing preferences for life-sustaining treatments include the severity and pattern of future clinical deficits, the probability of these deficits, and the burdens of treatments. Decision-making biases that may affect with drawal-of-treatment decisions include erroneous prognostic estimates, inappropriate methods of communicating evidence, misunderstanding patient values and expectations, and failing to appreciate the extent to which patients can physically and psychologically adapt. Conclusions Although prognosis among mechanically ventilated stroke patients is generally poor, a minority do survive without severe disability. Prognosis can be assessed according to clinical presentation and patient characteristics. There is an urgent need to better understand the marked variation in the care of these patients and to reliably measure and improve the patient-centeredness of such decisions.	Univ Rochester, Sch Med, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Community & Prevent Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Imaging Sci, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Ctr Palliat Care & Clin Eth, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Holloway, RG (corresponding author), Univ Rochester, Sch Med, Dept Neurol, 601 Elmwood Ave,Box 673, Rochester, NY 14642 USA.	robert_holloway@urmc.rochester.edu		Burgin, William/0000-0001-5376-8302				Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; AINSLIE N, 1994, ARCH INTERN MED, V154, P2225, DOI 10.1001/archinte.154.19.2225; Appelros P, 2003, STROKE, V34, P122, DOI 10.1161/01.STR.0000047852.05842.3C; Ariesen MJ, 2005, J NEUROL NEUROSUR PS, V76, P839, DOI 10.1136/jnnp.2004.048223; Back AL, 2005, JAMA-J AM MED ASSOC, V293, P1374, DOI 10.1001/jama.293.11.1374; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Berrouschot J, 2000, CRIT CARE MED, V28, P2956, DOI 10.1097/00003246-200008000-00045; Bestue M, 1999, NEUROLOGY, V52, P1922; BONITA R, 1988, STROKE, V19, P1497, DOI 10.1161/01.STR.19.12.1497; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; BURTIN P, 1994, INTENS CARE MED, V20, P32, DOI 10.1007/BF02425052; Bushnell CD, 1999, NEUROLOGY, V52, P1374, DOI 10.1212/WNL.52.7.1374; Carlet J, 2004, INTENS CARE MED, V30, P770, DOI 10.1007/s00134-004-2241-5; *CDC NCHS, 2001, TECHN APP VIT STAT U; CHRISTAKIS NA, 1995, AM J PUBLIC HEALTH, V85, P367, DOI 10.2105/AJPH.85.3.367; Clarke J, 2005, LANCET, V365, P764, DOI 10.1016/S0140-6736(05)17983-5; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; Coppola KM, 1999, DEATH STUD, V23, P617, DOI 10.1080/074811899200803; Counsell C, 2001, CEREBROVASC DIS, V12, P159, DOI 10.1159/000047699; Curtis JR, 2005, AM J RESP CRIT CARE, V171, P844, DOI 10.1164/rccm.200409-1267OC; Damschroder LJ, 2005, SOC SCI MED, V61, P267, DOI 10.1016/j.socscimed.2004.11.060; Dennis MS, 2003, CEREBROVASC DIS, V16, P9, DOI 10.1159/000069935; Diamond PT, 2003, DISABIL REHABIL, V25, P689, DOI 10.1080/0963828031000090470; Diringer MN, 2001, CRIT CARE MED, V29, P1792, DOI 10.1097/00003246-200109000-00023; Ditto PH, 1996, HEALTH PSYCHOL, V15, P332, DOI 10.1037/0278-6133.15.5.332; Doble JE, 2003, J HEAD TRAUMA REHAB, V18, P435, DOI 10.1097/00001199-200309000-00005; ElAd B, 1996, NEUROLOGY, V47, P657, DOI 10.1212/WNL.47.3.657; Elkins JS, 2003, STROKE, V34, P2109, DOI 10.1161/01.STR.0000085829.60324.DE; *EPEC TEAM, 1999, ED PHYS END OF LIF C; Epstein RM, 2004, JAMA-J AM MED ASSOC, V291, P2359, DOI 10.1001/jama.291.19.2359; Fanshawe M, 2002, ANAESTH INTENS CARE, V30, P628, DOI 10.1177/0310057X0203000515; Foerch C, 2004, J NEUROL NEUROSUR PS, V75, P988, DOI 10.1136/jnnp.2003.021014; Frankel MR, 2000, NEUROLOGY, V55, P952, DOI 10.1212/WNL.55.7.952; Frick S, 2003, CRIT CARE MED, V31, P456, DOI 10.1097/01.CCM.0000049945.69373.7C; Fried TR, 2003, ARCH INTERN MED, V163, P2073, DOI 10.1001/archinte.163.17.2073; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Goodlin SJ, 1999, JAMA-J AM MED ASSOC, V282, P2333, DOI 10.1001/jama.282.24.2333; Grant MD, 1998, JAMA-J AM MED ASSOC, V279, P1973, DOI 10.1001/jama.279.24.1973; GROTTA J, 1995, NEUROLOGY, V45, P640, DOI 10.1212/WNL.45.4.640; Gujjar AR, 1998, NEUROLOGY, V51, P447, DOI 10.1212/WNL.51.2.447; Hallenbeck J, 2005, JAMA-J AM MED ASSOC, V293, P2265, DOI 10.1001/jama.293.18.2265; Hamel Mary Beth, 1995, JAMA (Journal of the American Medical Association), V273, P1842, DOI 10.1001/jama.273.23.1842; Hankey GJ, 2003, CEREBROVASC DIS, V16, P14, DOI 10.1159/000069936; Hanson LC, 1996, ARCH INTERN MED, V156, P785, DOI 10.1001/archinte.156.7.785; Heinsius T, 1998, NEUROLOGY, V50, P341, DOI 10.1212/WNL.50.2.341; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Hinkka H, 2002, J MED ETHICS, V28, P109, DOI 10.1136/jme.28.2.109; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; JENNETT B, 1975, LANCET, V1, P480; Jorgensen HS, 1999, STROKE, V30, P2008, DOI 10.1161/01.STR.30.10.2008; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; Lamont EB, 2003, JAMA-J AM MED ASSOC, V290, P98, DOI 10.1001/jama.290.1.98; Leker RR, 2000, J NEUROL SCI, V176, P83, DOI 10.1016/S0022-510X(00)00316-6; Lessire H, 1996, INTENS CARE MED, V22, P174, DOI 10.1007/BF01720727; Magi E, 2000, Minerva Med, V91, P99; MAHONEY F I, 1965, Md State Med J, V14, P61; MALENKA DJ, 1993, J GEN INTERN MED, V8, P543, DOI 10.1007/BF02599636; Mayer SA, 2000, STROKE, V31, P2346, DOI 10.1161/01.STR.31.10.2346; Mayor SA, 1999, NEUROLOGY, V52, P1602, DOI 10.1212/WNL.52.8.1602; MAZUR DJ, 1993, J AM GERIATR SOC, V41, P223, DOI 10.1111/j.1532-5415.1993.tb06696.x; Mebane EW, 1999, J AM GERIATR SOC, V47, P579, DOI 10.1111/j.1532-5415.1999.tb02573.x; Meisel A, 2000, JAMA-J AM MED ASSOC, V284, P2495, DOI 10.1001/jama.284.19.2495; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; Navarrete-Navarro P, 2003, INTENS CARE MED, V29, P1237, DOI 10.1007/s00134-003-1755-6; Norero E, 2004, REV MED CHILE, V132, P11; *ORG PROC TRANSPL, DAT REP 2003; Patrick DL, 1997, ANN INTERN MED, V127, P509, DOI 10.7326/0003-4819-127-7-199710010-00002; Pearlman R A, 2000, J Palliat Med, V3, P37, DOI 10.1089/jpm.2000.3.37; Post PN, 2001, STROKE, V32, P1425, DOI 10.1161/01.STR.32.6.1425; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 2002, JAMA-J AM MED ASSOC, V288, P2732, DOI 10.1001/jama.288.21.2732; Rabinstein AA, 2004, CEREBROVASC DIS, V18, P325, DOI 10.1159/000080771; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; Roch A, 2003, CRIT CARE MED, V31, P2651, DOI 10.1097/01.CCM.0000094222.57803.B4; Rocker G, 2004, CRIT CARE MED, V32, P1149, DOI 10.1097/01.CCM.0000126402.51524.52; Santoli F, 2001, INTENS CARE MED, V27, P1141, DOI 10.1007/s001340100998; Schapira MM, 2001, MED DECIS MAKING, V21, P459, DOI 10.1177/02729890122062811; SCHIELKE E, 2005, J NEUROL         JUN; Sepucha KR, 2004, HLTH AFF S; Sheehy E, 2003, NEW ENGL J MED, V349, P667, DOI 10.1056/NEJMsa021271; Smith E, 2005, BMJ-BRIT MED J, V330, P406, DOI 10.1136/bmj.330.7488.406; Steiner T, 1997, STROKE, V28, P711, DOI 10.1161/01.STR.28.4.711; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Weimar C, 2002, J NEUROL, V249, P888, DOI 10.1007/s00415-002-0755-8; Weissman DE, 2004, JAMA-J AM MED ASSOC, V292, P1738, DOI 10.1001/jama.292.14.1738; Wennberg JE, 2004, BMJ-BRIT MED J, V328, P607, DOI 10.1136/bmj.328.7440.607; Wijdicks EFM, 1997, NEUROLOGY, V49, P1342, DOI 10.1212/WNL.49.5.1342; Wijdicks EFM, 1997, MAYO CLIN PROC, V72, P210, DOI 10.4065/72.3.210; Wijdicks EFM, 1996, STROKE, V27, P1301, DOI 10.1161/01.STR.27.8.1301; WUNSCH H, 2005, INTENSIVE CARE MED	92	94	95	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2005	294	6					725	733						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	953IA	16091575				2023-01-03	WOS:000231068600026
J	Beral, V; Bull, D; Reeves, G				Beral, V; Bull, D; Reeves, G		Million Women Study Collaborators	Endometrial cancer and hormone-replacement therapy in the Million Women Study	LANCET			English	Article							ESTROGEN REPLACEMENT; RISK; PROGESTIN	Background Postmenopausal women who use hormone-replacement therapy (HRT) containing oestrogen alone are at increased risk of endometrial cancer. To minimise this risk, many HRT users who have not had a hysterectomy use combined oestrogen-progestagen preparations or tibolone. Limited information is available on the incidence of endometrial cancer in users of these therapies. Methods 716 738 postmenopausal women in the UK without previous cancer or previous hysterectomy were recruited into the Million Women Study in 1996-2001, provided information about their use of HRT and other personal details, and were followed up for an average of 3.4 years, during which time 1320 incident endometrial cancers were diagnosed. Findings 320 953 women (45%) reported at recruitment that they had used HRT, among whom 69 577 (22%) last used continuous combined therapy (progestagen added daily to oestrogen), 145 486 (45%) last used cyclic combined therapy (progestagen added to oestrogen, usually for 10-14 days per month), 28 028 (9%) last used tibolone, and 14 204 (4%) last used oestrogen-only HRT. These HRT types had sharply contrasting effects on the overall risk of endometrial cancer (p<0.0001 for heterogeneity). Compared with never users of HRT, risk was: reduced with last use of continuous combined preparations (relative risk 0.71 [95% Cl 0.56-0.90]; p=0.005); increased with last use of tibolone (1.79 [1.43-2.25]; p<0.0001) and oestrogen only (1.45 [1.02-2.06]; p=0.04); and not significantly altered with last use of cyclic combined preparations (1.05 [0.91-1.22]; p=0.5). A woman's body-mass index significantly affected these associations, such that the adverse effects of tibolone and oestrogen-only HRT were greatest in non-obese women, and the beneficial effects of combined HRT were greatest in obese women. Interpretation Oestrogens and tibolone increase the risk of endometrial cancer. Progestagens counteract the adverse effect of oestrogens on the endometrium, the effect being greater the more days every month that they are added to oestrogen and the more obese that women are. However, combined oestrogen-progestagen HRT causes a greater increase in breast cancer than the other therapies do. Thus, when endometrial and breast cancers are added together, there is a greater increase in total cancer incidence with use of combined HRT, both continuous and cyclic, than with use of the other therapies.	Radcliffe Infirm, Mill Women Study Coordinating Ctr, Canc Res UK Epidemiol Unit, Oxford OX2 6HE, England	Cancer Research UK; Radcliffe Infirmary; University of Oxford	Beral, V (corresponding author), Radcliffe Infirm, Mill Women Study Coordinating Ctr, Canc Res UK Epidemiol Unit, Gibson Bldg,Woodstock Rd, Oxford OX2 6HE, England.	secretariat@millionwomenstudy.org						Abbott S, 2002, BJOG-INT J OBSTET GY, V109, P1319; Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; ARMITAGE M, 2004, MENOPAUSE HORMONE RE, P325; BAKKEN K, 2002, INT J CANCER, V112, P130; Banks E, 2001, J Epidemiol Biostat, V6, P357; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 2005, BJOG-INT J OBSTET GY, V112, P692, DOI 10.1111/j.1471-0528.2005.00541.x; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; BRINTON LA, 1993, OBSTET GYNECOL, V81, P265; de Vries CS, 2005, DRUG SAFETY, V28, P241, DOI 10.2165/00002018-200528030-00005; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Hill DA, 2000, AM J OBSTET GYNECOL, V183, P1456, DOI 10.1067/mob.2000.108081; *IARC, 1999, IARC MON EV CARC RIS, V72; JICK SS, 1993, EPIDEMIOLOGY, V4, P20, DOI 10.1097/00001648-199301000-00005; *JOINT FORM COMM, 1999, BRIT NAT FORM; KEY TJA, 1988, BRIT J CANCER, V57, P205, DOI 10.1038/bjc.1988.44; Lukanova A, 2004, INT J CANCER, V108, P425, DOI 10.1002/ijc.11529; *NAT STAT, 2003, CANC STAT REG CA MB1, V31; Newcomb PA, 2003, CANCER CAUSE CONTROL, V14, P195, DOI 10.1023/A:1023066304473; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; Pike MC, 1997, J NATL CANCER I, V89, P1110, DOI 10.1093/jnci/89.15.1110; SIITERI PK, 1987, AM J CLIN NUTR, V45, P277, DOI 10.1093/ajcn/45.1.277; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; Townsend PP., 1988, HLTH DEPRIVATION INE; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; Weiderpass E, 1999, J NATL CANCER I, V91, P1131, DOI 10.1093/jnci/91.13.1131; World Health Organization, 1998, INT CLASS DIS; Yazigi R, 2004, GYNECOL ONCOL, V93, P568, DOI 10.1016/j.ygyno.2004.02.003; Zeleniuch-Jacquotte A, 2001, BRIT J CANCER, V84, P975, DOI 10.1054/bjoc.2001.1704	29	441	465	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 30	2005	365	9470					1543	1551						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	921HL	15866308				2023-01-03	WOS:000228754800026
J	Bosset, JF; Collette, L; Calais, G; Mineur, L; Maingon, P; Radosevic-Jelic, L; Daban, A; Bardet, E; Beny, A; Ollier, J				Bosset, Jean-Francois; Collette, Laurence; Calais, Gilles; Mineur, Laurent; Maingon, Philippe; Radosevic-Jelic, Ljiljana; Daban, Alain; Bardet, Etienne; Beny, Alexander; Ollier, Jean-Claude		EORTC Radiotherapy Grp Trial 22921	Chemotherapy with preoperative radiotherapy in rectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TOTAL MESORECTAL EXCISION; RANDOMIZED-TRIAL; CARCINOMA; CHEMORADIOTHERAPY; FRACTIONATION; IRRADIATION; RECURRENCE; TOXICITY; PATTERNS; SURGERY	BACKGROUND: Preoperative radiotherapy is recommended for selected patients with rectal cancer. We evaluated the addition of chemotherapy to preoperative radiotherapy and the use of postoperative chemotherapy in the treatment of rectal cancer. METHODS: We randomly assigned patients with clinical stage T3 or T4 resectable rectal cancer to receive preoperative radiotherapy, preoperative chemoradiotherapy, preoperative radiotherapy and postoperative chemotherapy, or preoperative chemoradiotherapy and postoperative chemotherapy. Radiotherapy consisted of 45 Gy delivered over a period of 5 weeks. One course of chemotherapy consisted of 350 mg of fluorouracil per square meter of body-surface area per day and 20 mg of leucovorin per square meter per day, both given for 5 days. Two courses were combined with preoperative radiotherapy in the group receiving preoperative chemoradiotherapy and the group receiving preoperative chemoradiotherapy and postoperative chemotherapy; four courses were planned postoperatively in the group receiving preoperative radiotherapy and postoperative chemotherapy and the group receiving preoperative chemoradiotherapy and postoperative chemotherapy. The primary end point was overall survival. RESULTS: We enrolled 1011 patients in the trial. There was no significant difference in overall survival between the groups that received chemotherapy preoperatively (P=0.84) and those that received it postoperatively (P=0.12). The combined 5-year overall survival rate for all four groups was 65.2%. The 5-year cumulative incidence rates for local recurrences were 8.7%, 9.6%, and 7.6% in the groups that received chemotherapy preoperatively, postoperatively, or both, respectively, and 17.1% in the group that did not receive chemotherapy (P=0.002). The rate of adherence to preoperative chemotherapy was 82.0%, and to postoperative chemotherapy was 42.9%. CONCLUSIONS: In patients with rectal cancer who receive preoperative radiotherapy, adding fluorouracil-based chemotherapy preoperatively or postoperatively has no significant effect on survival. Chemotherapy, regardless of whether it is administered before or after surgery, confers a significant benefit with respect to local control.	Univ Franche Comte, Dept Radiat Therapy, F-25030 Besancon, France; European Org Res Treatment Canc, Ctr Data, Brussels, Belgium; Univ Tours, Dept Radiat Therapy, Tours, France; Clin Ste Catherine, Dept Radiat Therapy, Avignon, France; Canc Ctr Dijon, Dept Radiat Therapy, Dijon, France; Inst Oncol & Radiol, Belgrade, Serbia; Univ Poitiers, Dept Radiat Therapy, Poitiers, France; Canc Ctr Nantes, Dept Radiat Therapy, Nantes, France; Rambam Med Ctr, Dept Radiat Therapy, Haifa, Israel; Canc Ctr Strasbourg, Dept Surg, Strasbourg, France	Universite de Franche-Comte; European Organisation for Research & Treatment of Cancer; Universite de Tours; Institute for Oncology & Radiology of Serbia (IORS); Universite de Poitiers; Rambam Health Care Campus; Technion Israel Institute of Technology	Bosset, JF (corresponding author), Besancon Univ Hosp, Dept Radiotherapy, Blvd Fleming, F-25030 Besancon, France.	jean-francois.bosset@ufc-chu.univ-fcomte.fr		Collette, Laurence/0000-0003-2518-7281	NCI NIH HHS [2U10-CA11488-30, 2U10-CA11488-31, 2U10-CA11488-32, 2U10-CA11488-33, 2U10-CA11488-34, 2U10-CA11488-35, 2U10-CA11488-21, 2U10-CA11488-22, 2U10-CA11488-23, 2U10-CA11488-24, 2U10-CA11488-25, 2U10-CA11488-26, 2U10-CA11488-27, 2U10-CA11488-28, 2U10-CA11488-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARENDSEN GW, 1982, INT J RADIAT ONCOL, V8, P1981, DOI 10.1016/0360-3016(82)90459-X; Bosset JF, 2005, J CLIN ONCOL, V23, P5620, DOI 10.1200/JCO.2005.02.113; Bosset JF, 2004, EUR J CANCER, V40, P219, DOI 10.1016/j.ejca.2003.09.032; BOSSET JF, 1993, EUR J CANCER, V29A, P1406, DOI 10.1016/0959-8049(93)90012-5; CEDERMARK B, 1995, CANCER-AM CANCER SOC, V75, P2269, DOI 10.1002/1097-0142(19950501)75:9<2269::AID-CNCR2820750913>3.0.CO;2-I; CEDERMARK B, 1994, P AN M AM SOC CLIN, V13, P198; Chan I, 2006, J CLIN ONCOL, V24, P668, DOI 10.1200/JCO.2005.04.4875; DAHL O, 1990, CANCER-AM CANCER SOC, V66, P2286, DOI 10.1002/1097-0142(19901201)66:11<2286::AID-CNCR2820661106>3.0.CO;2-T; Dahlberg M, 1998, DIS COLON RECTUM, V41, P543, DOI 10.1007/BF02235256; GALANDIUK S, 1992, SURG GYNECOL OBSTET, V174, P27; GERARD A, 1988, ANN SURG, V208, P606, DOI 10.1097/00000658-198811000-00011; GOLDBERG PA, 1994, EUR J CANCER, V30A, P1602, DOI 10.1016/0959-8049(94)00312-S; Gray R, 2001, LANCET, V358, P1291; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI, P163; Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kouloulias VE, 2002, EUR J CANCER, V38, P1849, DOI 10.1016/S0959-8049(02)00174-0; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Marijnen CAM, 2004, RADIOTHER ONCOL, V73, pS127; MARSH PJ, 1994, DIS COLON RECTUM, V37, P1205, DOI 10.1007/BF02257783; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MINSKY BD, 1988, CANCER-AM CANCER SOC, V61, P1408, DOI 10.1002/1097-0142(19880401)61:7<1408::AID-CNCR2820610722>3.0.CO;2-A; MUSAT E, 2005, EJC SUPPL, V2, P171; NETO JAR, 1989, DIS COLON RECTUM, V32, P702, DOI 10.1007/BF02555778; Oates GD, 1996, LANCET, V348, P1605; Pahlman L, 1997, NEW ENGL J MED, V336, P1539; Pahlman L, 1997, NEW ENGL J MED, V336, P980; Peeters KCMJ, 2005, J CLIN ONCOL, V23, P6199, DOI 10.1200/JCO.2005.14.779; PHILLIPS RKS, 1984, BRIT J SURG, V71, P12, DOI 10.1002/bjs.1800710104; Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694; Sobin LH, 1987, TNM CLASSIFICATION M; TURESSON I, 1984, INT J RADIAT ONCOL, V10, P593, DOI 10.1016/0360-3016(84)90289-X	33	1970	2102	2	71	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	2006	355	11					1114	1123		10.1056/NEJMoa060829	http://dx.doi.org/10.1056/NEJMoa060829			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	083NJ	16971718				2023-01-03	WOS:000240462800006
J	Voss, C; Eyol, E; Frank, M; von der Lieth, CW; Berger, MR				Voss, Cristina; Eyol, Ergul; Frank, Martin; von der Lieth, Claus-W.; Berger, Martin R.			Identification and characterization of riproximin, a new type II ribosome-inactivating protein with antineoplastic activity from Ximenia americana	FASEB JOURNAL			English	Article						anticancer agent; plant protein; lectin; peroral activity; liver metastasis model	RAT-LIVER METASTASIS; RICIN-A-CHAIN; ENDOPLASMIC-RETICULUM; AVISCUMINE RVISCUMIN; CRYSTAL-STRUCTURE; SOLID TUMORS; CELL-LINES; PHASE-I; LECTIN; BINDING	The aim of this study was to identify and characterize the active component(s) of Ximenia americana plant material used to treat cancer in African traditional medicine. By a combination of preextraction, extraction, ion exchange and affinity chromatography, a mixture of two cytotoxic proteins was isolated. Using degenerated primers designed on the de novo sequence of two tryptic peptides from one of these proteins, a DNA fragment was amplified and the sequence obtained was used to determine the complete cDNA sequence by the RACE method. Sequence analysis and molecular modeling showed that the new protein, riproximin, belongs to the family of type II ribosome inactivating proteins. These results are in good agreement with the ability of riproximin to inhibit protein synthesis in a cell-free system, as well as with the cytotoxicity of riproximin, as demonstrated by its IC50 value of 0.5 pM in MCF7, 1.1 pM in HELA and 0.6 pM in CC531-lacZ cells. To assess the antineoplastic efficacy of the purified riproximin in vivo, the CC531-lacZ colorectal cancer rat metastasis model was used. Significant anticancer activity was found after administration of total dosages of 100 (perorally) and 10 (intraperitoneally) pmol riproximin/kg. These results suggest that riproximin has distinct potential for cancer treatment.	Deutsch Krebsforschungszentrum, Toxicol & Chemotherapy Unit, D-69120 Heidelberg, Germany; German Canc Res Ctr, Cent Spectroscop Dept, D-6900 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Berger, MR (corresponding author), Deutsch Krebsforschungszentrum, Toxicol & Chemotherapy Unit, E100,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.berger@dkfz.de		Frank, Martin/0000-0002-1006-6746				ADAM KP, 2000, ANAL BIOGENER ARZNEI, P470; Barbieri L, 2004, FEBS LETT, V563, P219, DOI 10.1016/S0014-5793(04)00286-8; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Battelli MG, 2004, MINI-REV MED CHEM, V4, P513, DOI 10.2174/1389557043403819; Battelli MG, 2004, CELL MOL LIFE SCI, V61, P1975, DOI 10.1007/s00018-004-4171-3; CITORES L, 2003, CELL MOL BIOL, P49; Deeks ED, 2002, BIOCHEMISTRY-US, V41, P3405, DOI 10.1021/bi011580v; Eck J, 1999, EUR J BIOCHEM, V264, P775, DOI 10.1046/j.1432-1327.1999.00638.x; Girbes T, 2003, CELL MOL BIOL, V49, P537; Girbes T, 1996, CELL MOL BIOL, V42, P461; Hartley MR, 2004, MINI-REV MED CHEM, V4, P487, DOI 10.2174/1389557043403828; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; KINTER M, 1952, PROTEIN SEQUENCING I, P81; Kinter M, 2000, PROTEIN SEQUENCING I, V1st, P152; Konstantinov SM, 1998, INT J CANCER, V77, P778, DOI 10.1002/(SICI)1097-0215(19980831)77:5<778::AID-IJC18>3.0.CO;2-Y; Krauspenhaar R, 1999, BIOCHEM BIOPH RES CO, V257, P418, DOI 10.1006/bbrc.1999.0470; Kreitman RJ, 2003, CURR OPIN MOL THER, V5, P44; Langer M, 1996, ANAL BIOCHEM, V243, P150, DOI 10.1006/abio.1996.0493; LIN JY, 1970, NATURE, V227, P292, DOI 10.1038/227292a0; Lord JM, 2003, BIOCHEM SOC T, V31, P1260; Lord Michael J., 2003, Toxicological Reviews, V22, P53, DOI 10.2165/00139709-200322010-00006; Marsden CJ, 2004, EUR J BIOCHEM, V271, P153, DOI 10.1046/j.1432-1033.2003.03914.x; Mishra V, 2005, J BIOL CHEM, V280, P20712, DOI 10.1074/jbc.M500735200; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Munoz R, 2001, CANCER LETT, V167, P163, DOI 10.1016/S0304-3835(01)00477-3; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; Pryme IF, 2004, CANCER DETECT PREV, V28, P52, DOI 10.1016/j.cdp.2003.10.003; Pusztai A, 1998, J NUTR BIOCHEM, V9, P31, DOI 10.1016/S0955-2863(97)00164-2; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P240, DOI 10.1002/prot.340100308; Saenger J, 2004, J CANCER RES CLIN, V130, P203, DOI 10.1007/s00432-003-0523-x; Schoffski P, 2005, EUR J CANCER, V41, P1431, DOI 10.1016/j.ejca.2005.03.019; Schoffski P, 2004, ANN ONCOL, V15, P1816, DOI 10.1093/annonc/mdh469; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Stirpe F, 2004, TOXICON, V44, P371, DOI 10.1016/j.toxicon.2004.05.004; VOSS C, 2005, TOXICOL APPL PHARM; Wittmer A, 1999, CLIN EXP METASTAS, V17, P369, DOI 10.1023/A:1006643831825	39	37	37	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1194	+		10.1096/fj.05-5231fje	http://dx.doi.org/10.1096/fj.05-5231fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16641197				2023-01-03	WOS:000240210300023
J	Krasner, CN; Roche, M; Horowitz, NS; Supko, JG; Lee, SI; Oliva, E; Harris, NL; Fuller, AF				Krasner, CN; Roche, M; Horowitz, NS; Supko, JG; Lee, SI; Oliva, E; Harris, NL; Fuller, AF			Case 11-2006: A 54-year-old woman with a mass in the pelvis - Mixed high-grade serous papillary and transitional-cell carcinoma of the fallopian tube, FIGO stage IIIC.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GYNECOLOGIC-ONCOLOGY-GROUP; EPITHELIAL OVARIAN-CANCER; PRIMARY CYTOREDUCTIVE SURGERY; INTRAPERITONEAL CISPLATIN; CLINICOPATHOLOGICAL ANALYSIS; RANDOMIZED-TRIAL; PACLITAXEL; CARBOPLATIN; SURVIVAL; WOMEN		Massachusetts Gen Hosp, Ctr Canc, Gillette Ctr Womens Canc, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc, Clin Pharmacol Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard University	Krasner, CN (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Gillette Ctr Womens Canc, Boston, MA 02114 USA.			Lee, Susanna I/0000-0003-2195-2943				Alberts DS, 1996, NEW ENGL J MED, V335, P1950, DOI 10.1056/NEJM199612263352603; AlvaradoCabrero I, 1997, INT J GYNECOL PATHOL, V16, P189, DOI 10.1097/00004347-199707000-00001; Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Bookman MA, 2003, INT J GYNECOL CANCER, V13, P735, DOI 10.1111/j.1525-1438.2003.13602.x; Brown DL, 2001, RADIOLOGY, V219, P213, DOI 10.1148/radiology.219.1.r01ap28213; BUCHSBAUM HJ, 1989, SURG GYNECOL OBSTET, V169, P226; Chi DS, 2001, GYNECOL ONCOL, V82, P532, DOI 10.1006/gyno.2001.6328; Colgan TJ, 2003, INT J GYNECOL PATHOL, V22, P109, DOI 10.1097/00004347-200304000-00001; DEDRICK RL, 1978, CANCER TREAT REP, V62, P1; Eisenkop SM, 1998, GYNECOL ONCOL, V69, P103, DOI 10.1006/gyno.1998.4955; EISENKOP SM, 1992, GYNECOL ONCOL, V47, P203, DOI 10.1016/0090-8258(92)90107-T; Elit L, 2002, GYNECOL ONCOL, V87, P260, DOI 10.1006/gyno.2002.6834; Fennelly D, 1997, J CLIN ONCOL, V15, P187, DOI 10.1200/JCO.1997.15.1.187; Fujiwara K, 2005, J CLIN ONCOL, V23, p465S; Georgiadis MS, 1997, CLIN CANCER RES, V3, P449; GIANNI L, 1995, J CLIN ONCOL, V13, P180, DOI 10.1200/JCO.1995.13.1.180; Goff BA, 2004, JAMA-J AM MED ASSOC, V291, P2705, DOI 10.1001/jama.291.22.2705; GREEN TH, 1962, CLIN OBSTET GYNECOL, V5, P886, DOI 10.1097/00003081-196209000-00022; GRIFFITHS CT, 1975, NATL CANCER I MONOGR, P101; HACKER NF, 1983, OBSTET GYNECOL, V61, P413; HELEWA ME, 1986, AM J OBSTET GYNECOL, V154, P282, DOI 10.1016/0002-9378(86)90656-3; HOSKINS WJ, 1994, AM J OBSTET GYNECOL, V170, P974, DOI 10.1016/S0002-9378(94)70090-7; HOSKINS WJ, 1992, GYNECOL ONCOL, V47, P159, DOI 10.1016/0090-8258(92)90100-W; HU CY, 1950, AM J OBSTET GYNECOL, V59, P58, DOI 10.1016/0002-9378(50)90341-3; Junor EJ, 1999, BRIT J OBSTET GYNAEC, V106, P1130, DOI 10.1111/j.1471-0528.1999.tb08137.x; Kawamoto S, 1999, RADIOGRAPHICS, V19, pS85, DOI 10.1148/radiographics.19.suppl_1.g99oc10s85; Le T, 1997, GYNECOL ONCOL, V67, P208, DOI 10.1006/gyno.1997.4839; Makhija S, 2001, GYNECOL ONCOL, V81, P77, DOI 10.1006/gyno.2000.6108; MALKASIAN GD, 1988, AM J OBSTET GYNECOL, V159, P341, DOI 10.1016/S0002-9378(88)80081-4; MARKMAN M, 1993, GYNECOL ONCOL, V50, P100, DOI 10.1006/gyno.1993.1171; Markman M, 2001, J CLIN ONCOL, V19, P1001, DOI 10.1200/JCO.2001.19.4.1001; MARKMAN M, 1991, J CLIN ONCOL, V9, P1801, DOI 10.1200/JCO.1991.9.10.1801; Markman M, 2003, LANCET ONCOL, V4, P277, DOI 10.1016/S1470-2045(03)01074-X; Markman M, 2003, J CLIN ONCOL, V21, P2460, DOI 10.1200/JCO.2003.07.013; MAYER AR, 1992, GYNECOL ONCOL, V47, P223, DOI 10.1016/0090-8258(92)90110-5; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Milojkovic Miodrag, 2004, Archives of Gynecology and Obstetrics, V269, P176, DOI 10.1007/s00404-002-0411-7; Narod SA, 2001, LANCET, V357, P1467, DOI 10.1016/S0140-6736(00)04642-0; Navani SS, 1996, GYNECOL ONCOL, V63, P371, DOI 10.1006/gyno.1996.0338; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; PFEIFFER P, 1990, GYNECOL ONCOL, V36, P306, DOI 10.1016/0090-8258(90)90131-4; Piccart MJ, 2000, JNCI-J NATL CANCER I, V92, P699, DOI 10.1093/jnci/92.9.699; Piek JMJ, 2001, LANCET, V358, P844, DOI 10.1016/S0140-6736(01)05992-X; PIVER MS, 1976, OBSTET GYNECOL, V48, P312; Puls LE, 1997, SOUTHERN MED J, V90, P1097; ROSEN A, 1993, BRIT J CANCER, V68, P605, DOI 10.1038/bjc.1993.394; Rosenblatt KA, 1996, CANCER EPIDEM BIOMAR, V5, P933; Sakuragi N, 2000, GYNECOL ONCOL, V79, P420, DOI 10.1006/gyno.2000.5979; Sengupta PS, 1999, BRIT J CANCER, V80, P444, DOI 10.1038/sj.bjc.6690376; STIVER W, 2005, CHEMOTHERAPY BIOTHER, P53; Szklaruk J, 2003, RADIOGRAPHICS, V23, P403, DOI 10.1148/rg.232025089; Vasey PA, 2004, JNCI-J NATL CANCER I, V96, P1682, DOI 10.1093/jnci/djh323; Walker JL, 2006, GYNECOL ONCOL, V100, P27, DOI 10.1016/j.ygyno.2005.11.013; Woodman C, 1997, BRIT J OBSTET GYNAEC, V104, P135, DOI 10.1111/j.1471-0528.1997.tb11032.x; WOOLAS R, 1994, INT J GYNECOL CANCER, V4, P384, DOI 10.1046/j.1525-1438.1994.04060384.x; WU PC, 1986, AM J OBSTET GYNECOL, V155, P1103, DOI 10.1016/0002-9378(86)90359-5; YOUNG RC, 1983, JAMA-J AM MED ASSOC, V250, P3072, DOI 10.1001/jama.250.22.3072	57	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	2006	354	15					1615	1625		10.1056/NEJMcpc069002	http://dx.doi.org/10.1056/NEJMcpc069002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	031WW	16611953				2023-01-03	WOS:000236736900012
J	Ledford, AS; Weinberg, RB; Cook, VR; Hantgan, RR; Shelness, GS				Ledford, AS; Weinberg, RB; Cook, VR; Hantgan, RR; Shelness, GS			Self-association and lipid binding properties of the lipoprotein initiating domain of apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; N-TERMINAL 17-PERCENT; INTERFACIAL PROPERTIES; SUBCELLULAR-LOCALIZATION; A-IV; SECRETION; MODEL; LIPOVITELLIN; SOLUBILIZATION; BIOSYNTHESIS	The amino-terminal 20.1% of apolipoprotein B (apoB20.1; residues 1-912) is sufficient to initiate and direct the formation of nascent apoB-containing lipoprotein particles. To investigate the mechanism of initial lipid acquisition by apoB, we examined the lipid binding and interfacial properties of a carboxyl-terminal His6-tagged form of apoB20.1 (apoB20.1H). ApoB20.1H was expressed in Sf9 cells and purified by nickel affinity chromatography. ApoB20.1H was produced in a folded state as characterized by formation of intramolecular disulfide bonds and resistance to chemical reduction. Dynamic light scattering in physiological buffer indicated that purified apoB20.1H formed multimers, which were readily dissociable upon the addition of nonionic detergent (0.1% Triton X-100). ApoB20.1H was incapable of binding dimyristoylphosphatidylcholine multilamellar vesicles, unless its multimeric structure was first disrupted by guanidine hydrochloride. However, apoB20.1H multimers spontaneously dissociated and bound to the interface of naked and phospholipid-coated triolein droplets. These data reveal that the initiating domain of apoB contains solvent-accessible hydrophobic sequences, which, in the absence of a hydrophobic lipid interface or detergent, engage in self-association. The high affinity of apoB20.1H for neutral lipid is consistent with the membrane binding and desorption model of apoB-containing lipoprotein assembly.	Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Shelness, GS (corresponding author), Wake Forest Univ, Sch Med, Dept Pathol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	gshelnes@wfubmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030897, R23HL030897, P01HL049373] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL030897-23, HL49373, R01 HL030897, HL30897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Burch WL, 2000, J BIOL CHEM, V275, P16267, DOI 10.1074/jbc.M000446200; Chu B., 1983, MEASUREMENT SUSPENDE, P81; Dashti N, 2002, BIOCHEMISTRY-US, V41, P6978, DOI 10.1021/bi011757l; DeLozier JA, 2001, J LIPID RES, V42, P399; GIBBONS GF, 1990, BIOCHEM J, V268, P1; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Gusarova V, 2003, J BIOL CHEM, V278, P48051, DOI 10.1074/jbc.M306898200; HAMILTON JA, 1983, J BIOL CHEM, V258, P2821; HAMILTON JA, 1981, P NATL ACAD SCI-BIOL, V78, P6878, DOI 10.1073/pnas.78.11.6878; Hamilton RL, 1998, J LIPID RES, V39, P1543; HANTGAN RR, 1993, BIOCHEMISTRY-US, V32, P3935, DOI 10.1021/bi00066a013; Harazono A, 2005, GLYCOBIOLOGY, V15, P447, DOI 10.1093/glycob/cwi033; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; Herscovitz H, 2001, J LIPID RES, V42, P51; Hockey KJ, 2001, J LIPID RES, V42, P211; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Hussain MM, 2005, CURR OPIN LIPIDOL, V16, P281, DOI 10.1097/01.mol.0000169347.53568.5a; Ingram MF, 1997, J BIOL CHEM, V272, P10279; Jiang ZG, 2005, BIOCHEMISTRY-US, V44, P1163, DOI 10.1021/bi048286y; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; Manchekar M, 2004, J BIOL CHEM, V279, P39757, DOI 10.1074/jbc.M406302200; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; McLachlin DT, 1996, PROTEIN EXPRES PURIF, V7, P275, DOI 10.1006/prep.1996.0039; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; Richardson PE, 2005, BIOPHYS J, V88, P2789, DOI 10.1529/biophysj.104.046235; Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; Segrest JP, 1999, J LIPID RES, V40, P1401; Segrest JP, 2001, J LIPID RES, V42, P1346; Shelness GS, 2005, CURR OPIN LIPIDOL, V16, P325, DOI 10.1097/01.mol.0000169353.12772.eb; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; Swift LL, 2003, J LIPID RES, V44, P1841, DOI 10.1194/jlr.M300276-JLR200; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; Thompson JR, 2002, BIOCHEMISTRY-US, V41, P9398, DOI 10.1021/bi025674w; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; Wang LB, 2004, J LIPID RES, V45, P1704, DOI 10.1194/jlr.M400106-JLR200; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200; Weinberg RB, 2000, J LIPID RES, V41, P1419; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96	50	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8871	8876		10.1074/jbc.M507657200	http://dx.doi.org/10.1074/jbc.M507657200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407215	hybrid			2023-01-03	WOS:000236247100067
J	Joensuu, H; Kellokumpu-Lehtinen, P; Bono, P; Alanko, T; Kataja, V; Asola, R; Utriainen, T; Kokko, R; Hemminki, A; Tarkkanen, M; Turpeenniemi-Hujanen, T; Jyrkkio, S; Flander, M; Helle, L; Ingalsuo, S; Johansson, K; Jaaskelainen, A; Pajunen, M; Rauhala, M; Kaleva-Kerola, J; Salminen, T; Leinonen, M; Elomaa, I; Isola, J				Joensuu, H; Kellokumpu-Lehtinen, P; Bono, P; Alanko, T; Kataja, V; Asola, R; Utriainen, T; Kokko, R; Hemminki, A; Tarkkanen, M; Turpeenniemi-Hujanen, T; Jyrkkio, S; Flander, M; Helle, L; Ingalsuo, S; Johansson, K; Jaaskelainen, A; Pajunen, M; Rauhala, M; Kaleva-Kerola, J; Salminen, T; Leinonen, M; Elomaa, I; Isola, J		FinHer Study Investigators	Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POOR-PROGNOSIS; CHEMOTHERAPY; PLUS; CYCLOPHOSPHAMIDE; AMPLIFICATION; COMBINATIONS; EPIRUBICIN; SURVIVAL; ONCOGENE; ANTIBODY	BACKGROUND: We compared docetaxel with vinorelbine for the adjuvant treatment of early breast cancer. Women with tumors that overexpressed HER2/neu were also assigned to receive concomitant treatment with trastuzumab or no such treatment. METHODS: We randomly assigned 1010 women with axillary-node-positive or high-risk node-negative cancer to receive three cycles of docetaxel or vinorelbine, followed by (in both groups) three cycles of fluorouracil, epirubicin, and cyclophosphamide. The 232 women whose tumors had an amplified HER2/neu gene were further assigned to receive or not to receive nine weekly trastuzumab infusions. The primary end point was recurrence-free survival. RESULTS: Recurrence-free survival at three years was better with docetaxel than with vinorelbine (91 percent vs. 86 percent; hazard ratio for recurrence or death, 0.58; 95 percent confidence interval, 0.40 to 0.85; P=0.005), but overall survival did not differ between the groups (P=0.15). Within the subgroup of patients who had HER2/neu-positive cancer, those who received trastuzumab had better three-year recurrence-free survival than those who did not receive the antibody (89 percent vs. 78 percent; hazard ratio for recurrence or death, 0.42; 95 percent confidence interval, 0.21 to 0.83; P=0.01). Docetaxel was associated with more adverse effects than was vinorelbine. Trastuzumab was not associated with decreased left ventricular ejection fraction or cardiac failure. CONCLUSIONS: Adjuvant treatment with docetaxel, as compared with vinorelbine, improves recurrence-free survival in women with early breast cancer. A short course of trastuzumab administered concomitantly with docetaxel or vinorelbine is effective in women with breast cancer who have an amplified HER2/neu gene.	Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland; Tampere Univ Hosp, Dept Oncol, Tampere, Finland; Univ Tampere, Inst Med Technol, Canc Biol Lab, FIN-33101 Tampere, Finland; Kuopio Univ Hosp, Dept Oncol, SF-70210 Kuopio, Finland; Satakunta Cent Hosp, Pori, Finland; Hameenlinna Cent Hosp, Hameenlinna, Finland; Oulu Univ Hosp, Dept Radiotherapy & Oncol, Oulu, Finland; Turku Univ, Cent Hosp, Dept Oncol, Turku, Finland; S Karelia Cent Hosp, Lappeenranta, Finland; Kotka Cent Hosp, Kotka, Finland; Vaasa Cent Hosp, Vaasa, Finland; Kokkola Cent Hosp, Kokkola, Finland; Jyvaskyla Cent Hosp, Jyvaskyla, Finland; Kajaani Cent Hosp, Kajaani, Finland; Kemi Cent Hosp, Kemi, Finland; 4Pharma, Turku, Finland; Univ Helsinki Hosp, Helsinki, Finland; Seinajoki Cent Hosp, Seinajoki, Finland; Joensuu Cent Hosp, Joensuu, Finland; Rovaniemi Cent Hosp, Rovaniemi, Finland	University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University Hospital; Tampere University; Kuopio University Hospital; University of Eastern Finland; Satakunta Central Hospital; University of Oulu; University of Turku; Vaasa Central Hospital; Central Finland Central Hospital; University of Helsinki; Helsinki University Central Hospital; Seinajoki Central Hospital	Joensuu, H (corresponding author), Univ Helsinki, Cent Hosp, Dept Oncol, Haartmaninkatu 4,POB 180, FIN-00029 Helsinki, Finland.			Joensuu, Heikki/0000-0003-0281-2507; Kataja, Vesa/0000-0003-4846-4843				Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Bonneterre J, 2005, J CLIN ONCOL, V23, P2686, DOI 10.1200/JCO.2005.05.059; Isola J, 2004, CLIN CANCER RES, V10, P4793, DOI 10.1158/1078-0432.CCR-0428-03; Jahanzeb Mohammad, 2003, Clin Breast Cancer, V4, P28, DOI 10.3816/CBC.2003.n.009; JOENSUU H, 2003, P AN M AM SOC CLIN, V22, pA19; Lundin J, 2003, BRIT MED J, V326, P29, DOI 10.1136/bmj.326.7379.29; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P739, DOI 10.1093/jnci/djh131; Perez EA, 2004, J CLIN ONCOL, V22, P3700, DOI 10.1200/JCO.2004.03.516; Perez EA, 2004, J CLIN ONCOL, V22, P322, DOI 10.1200/JCO.2004.01.120; Perez EA, 2005, J CLIN ONCOL, V23, p17S; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; Press MF, 1997, J CLIN ONCOL, V15, P2894, DOI 10.1200/JCO.1997.15.8.2894; RAVDIN PM, 1995, GENE, V159, P19, DOI 10.1016/0378-1119(94)00866-Q; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Untch M, 2004, EUR J CANCER, V40, P988, DOI 10.1016/j.ejca.2004.01.011	22	1119	1169	1	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					809	820		10.1056/NEJMoa053028	http://dx.doi.org/10.1056/NEJMoa053028			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495393				2023-01-03	WOS:000235456200005
J	Elkins, MR; Robinson, M; Rose, BR; Harbour, C; Moriarty, CP; Marks, GB; Belousova, EG; Xuan, W; Bye, PTP				Elkins, MR; Robinson, M; Rose, BR; Harbour, C; Moriarty, CP; Marks, GB; Belousova, EG; Xuan, W; Bye, PTP		NHSCF Study Grp	A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUCOCILIARY CLEARANCE; PULMONARY-FUNCTION; DISEASE; SPUTUM; LUNG; PATHOGENESIS; BACTERIA; DNASE; CARE	BACKGROUND: Inhaled hypertonic saline acutely increases mucociliary clearance and, in short-term trials, improves lung function in people with cystic fibrosis. We tested the safety and efficacy of inhaled hypertonic saline in a long-term trial. METHODS: In this double-blind, parallel-group trial, 164 patients with stable cystic fibrosis who were at least six years old were randomly assigned to inhale 4 ml of either 7 percent hypertonic saline or 0.9 percent (control) saline twice daily for 48 weeks, with quinine sulfate (0.25 mg per milliliter) added to each solution to mask the taste. A bronchodilator was given before each dose, and other standard therapies were continued during the trial. RESULTS: The primary outcome measure, the rate of change (slope) in lung function (reflected by the forced vital capacity [FVC], forced expiratory volume in one second [FEV(sub 1)], and forced expiratory flow at 25 to 75 percent of FVC [FEF(sub 25-75)]) during the 48 weeks of treatment, did not differ significantly between groups (P=0.79). However, the absolute difference in lung function between groups was significant (P=0.03) when averaged across all post-randomization visits in the 48-week treatment period. As compared with the control group, the hypertonic-saline group had significantly higher FVC (by 82 ml; 95 percent confidence interval, 12 to 153) and FEV(sub 1) (by 68 ml; 95 percent confidence interval, 3 to 132) values, but similar FEF(sub 25-75) values. The hypertonic-saline group also had significantly fewer pulmonary exacerbations (relative reduction, 56 percent; P=0.02) and a significantly higher percentage of patients without exacerbations (76 percent, as compared with 62 percent in the control group; P=0.03). Hypertonic saline was not associated with worsening bacterial infection or inflammation. CONCLUSIONS: Hypertonic saline preceded by a bronchodilator is an inexpensive, safe, and effective additional therapy for patients with cystic fibrosis.	Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; Univ Sydney, Dept Microbiol & Infect Dis, Sydney, NSW 2006, Australia; Woolcock Inst Med Res, Sydney, NSW, Australia	University of Sydney; University of Sydney; University of Sydney; University of Sydney; Woolcock Institute of Medical Research	Bye, PTP (corresponding author), Royal Prince Alfred Hosp, Dept Resp Med, Level 11 E Block,Missenden Rd, Camperdown, NSW 2050, Australia.	peterb@med.usyd.edu.au	Elkins, Mark/C-3240-2012; Marks, Guy B./F-5058-2013; Wainwright, Claire E/G-4218-2013	Marks, Guy B./0000-0002-8976-8053; Wainwright, Claire E/0000-0001-8389-3809; Elkins, Mark/0000-0002-2052-7366; mcdonald, vanessa/0000-0001-9890-3408				Ballmann Manfred, 2002, J Cyst Fibros, V1, P35, DOI 10.1016/S1569-1993(01)00009-1; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Cobos N, 2000, EUR J PEDIATR, V159, P176, DOI 10.1007/s004310050046; *CYST FIBR FDN, 1994, CLIN PRACT GUID CONC, P5; De Rse V, 2002, EUR RESPIR J, V19, P333, DOI 10.1183/09031936.02.00229202; Donaldson SH, 2006, NEW ENGL J MED, V354, P241, DOI 10.1056/NEJMoa043891; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; King M, 1997, AM J RESP CRIT CARE, V156, P173, DOI 10.1164/ajrccm.156.1.9512074; Koehler DR, 2004, AM J RESP CELL MOL, V31, P377, DOI 10.1165/rcmb.2004-0124TR; Liou TG, 2001, AM J EPIDEMIOL, V153, P345, DOI 10.1093/aje/153.4.345; Littell R.C., 1996, SAS SYSTEMS MIXED MO; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MORRIS JF, 1976, WESTERN J MED, V125, P110; Pocock S, 1996, CLIN TRIALS PRACTICA; POLGAR G, 1971, PULMONARY FUNCTION T, P254; Quittner AL, 2000, J PEDIATR PSYCHOL, V25, P403, DOI 10.1093/jpepsy/25.6.403; Ramsey BW, 1999, NEW ENGL J MED, V340, P23, DOI 10.1056/NEJM199901073400104; Robinson M, 1996, AM J RESP CRIT CARE, V153, P1503, DOI 10.1164/ajrccm.153.5.8630593; Robinson M, 1997, THORAX, V52, P900, DOI 10.1136/thx.52.10.900; Saiman L, 2003, JAMA-J AM MED ASSOC, V290, P1749, DOI 10.1001/jama.290.13.1749; SAS Institute, 1997, SAS STAT SOFTW CHANG; Sheppard David N., 1999, Physiological Reviews, V79, pS23; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Smith JJ, 1996, CELL, V87, pU25; Suri R, 2002, THORAX, V57, P841, DOI 10.1136/thorax.57.10.841; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wills PJ, 1997, J CLIN INVEST, V99, P9, DOI 10.1172/JCI119138; Wolter JM, 1999, CLIN DIAGN LAB IMMUN, V6, P260, DOI 10.1128/CDLI.6.2.260-265.1999; WONG K, 1984, J MED MICROBIOL, V17, P113, DOI 10.1099/00222615-17-2-113	32	601	637	0	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					229	240		10.1056/NEJMoa043900	http://dx.doi.org/10.1056/NEJMoa043900			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421364	Bronze			2023-01-03	WOS:000234661100003
J	Okie, S				Okie, S			Glimpses of Guantanamo - Medical ethics and the war on terror	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*DEP JUST IMM NAT, 1992, IMM ACT 1990 REP CRI, P3; Lewis Neil A, 2004, N Y Times Web, pA14; RUMSFELD D, 2003, COMMUNICATION   0416; WHITE J, 2005, WASHINGTON POST 0902, pA1	4	31	32	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 15	2005	353	24					2529	2534		10.1056/NEJMp058296	http://dx.doi.org/10.1056/NEJMp058296			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	993BA	16354888				2023-01-03	WOS:000233926500001
J	Dorff, EN				Dorff, EN			End-of-life: Jewish perspectives	LANCET			English	Editorial Material									Univ Judaism, Bel Air, CA 90077 USA		Dorff, EN (corresponding author), Univ Judaism, 15600 Mulholland Dr, Bel Air, CA 90077 USA.	edorff@uj.edu						ADDRESS RF, 1992, TIME PREPARE PRACTIC; BLEICH JD, 1981, JUDAISM HEALING, P162; BLEICH JD, 1995, CONTEMP HALAKHIC PRO, V4, P273; BLEICH JD, 1981, JUDAISM HEALING, P134; BLEICH JD, 1981, JUDAISM HEALING, P146; BLEICH JD, 1981, JUDAISM HEALING, P129; Dorff Elliot N., 1988, LIVING TREE ROOTS GR; Dorff Elliot N., 1998, MATTERS LIFE DEATH J, P176; DORFF EN, 1998, MATTERS LIFE DEATH J, P221; DORFF EN, 1998, MATTERS LIFE DEATH J, P14; DORFF EN, 1991, UNITED SYNAGOGUE REV, V44, P21; Ellenson David H., 1995, CONT JEWISH ETHICS M, P129; FELDMAN DM, 1986, HLTH MED JEWISH TRAD; FELDMAN DM, 1984, COMPENDIUM MED ETHIC; FREEHOF SB, 1960, REFORM RESPONSA, P130; FREEHOF SB, 1974, CONT REFORM RESPONSA, P216; GOLDFARB DC, 1976, CONSERVATIVE JUDAISM, V30, P10; GOLDMAN AJ, 1978, JUDAISM CONFRONTS CO, P223; JACOB W, 1983, AM REFORM RESPONSA, P273; Jakobovits I, 1975, JEWISH MED ETHICS; JAKOBOVITS Y, 1989, TRADITION, V24, P1; KLEIN I, 2000, LIFE DEATH RESPONSIB, P435; Klein I., 1975, RESPONSA HALAKHIC ST; *RABB ASS, 1990, P CONS RABB ASS, V52; REISNER AI, 2000, LIFE DEATH RESPONSBI, P233; ROSNER F, 1979, JEWISH BIOETHICS, P358; SIEGEL S, 1976, CONSERVATIVE JUDAISM, V30, P23	27	45	47	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 3	2005	366	9488					862	865		10.1016/S0140-6736(05)67219-4	http://dx.doi.org/10.1016/S0140-6736(05)67219-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	960XR	16139662				2023-01-03	WOS:000231627000032
J	Adams, GP; Weiner, LM				Adams, GP; Weiner, LM			Monoclonal antibody therapy of cancer	NATURE BIOTECHNOLOGY			English	Review							GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; CHRONIC LYMPHOCYTIC-LEUKEMIA; METASTATIC BREAST-CANCER; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; HUMANIZED ANTI-CD22 ANTIBODY; REFRACTORY LOW-GRADE; COLORECTAL-CANCER	The most significant recent advances in the application of monoclonal antibodies (mAbs) to oncology have been the introduction and approval of bevacizumab (Avastin), an anti-vascular endothelial growth factor antibody, and of cetuximab (Erbitux), an anti-epidermal growth factor antibody. In combination with standard chemotherapy regimens, bevacizumab significantly prolongs the survival of patients with metastatic cancers of the colorectum, breast and lung. Cetuximab, used alone or with salvage chemotherapy, produces clinically meaningful anti-tumor responses in patients with chemotherapy-refractory cancers of the colon and rectum. In addition, the anti-HER2/neu antibody trastuzumab ( Herceptin), in combination with standard adjuvant chemotherapy, has been shown to reduce relapses and prolong disease-free and overall survival in high-risk patients after definitive local therapy for breast cancer. These exciting recent results provide optimism for the development of mAbs that bind novel targets, exploit novel mechanisms of action or possess improved tumor targeting. Progress in the clinical use of radioimmunoconjugates remains hindered by complexity of administration, toxicity concerns and insufficiently selective tumor targeting.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Weiner, LM (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	louis.weiner@fccc.edu	Gascon, Pere/F-7905-2015; Adams, Gregory/ABE-8245-2020					ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Austin CD, 2004, MOL BIOL CELL, V15, P5268, DOI 10.1091/mbc.E04-07-0591; BADGER CC, 1987, PATHOL IMMUNOPATH R, V6, P419, DOI 10.1159/000157067; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; Baselga J, 2001, EUR J CANCER, V37, pS18, DOI 10.1016/S0959-8049(00)00404-4; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Behr TM, 2002, CANCER-AM CANCER SOC, V94, P1373, DOI 10.1002/cncr.10308; BERNSTEIN N, 1988, ANN ONCOL, V9, P995; Bowen AL, 1997, BRIT J HAEMATOL, V96, P617, DOI 10.1046/j.1365-2141.1997.d01-2061.x; Byrd JC, 1999, J CLIN ONCOL, V17, P791, DOI 10.1200/JCO.1999.17.3.791; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Chang SS, 1999, CANCER RES, V59, P3192; Cheng JD, 2005, MOL CANCER THER, V4, P351; Chong G, 2005, CLIN CANCER RES, V11, P4818, DOI 10.1158/1078-0432.CCR-04-2330; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Coiffier B, 2002, SEMIN ONCOL, V29, P30, DOI 10.1053/sonc.2002.30153; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Coiffier B, 1998, BLOOD, V92, P1927; Czuczman MS, 2005, J CLIN ONCOL, V23, P4390, DOI 10.1200/JCO.2005.09.018; Czuczman MS, 1999, J CLIN ONCOL, V17, P268, DOI 10.1200/JCO.1999.17.1.268; Davis TA, 1999, CLIN CANCER RES, V5, P611; Di Gaetano N, 2003, J IMMUNOL, V171, P1581, DOI 10.4049/jimmunol.171.3.1581; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1993, CANCER RES, V53, P4637; Foon KA, 2004, INT J RADIAT ONCOL, V58, P984, DOI 10.1016/j.ijrobp.2003.09.098; Francis RJ, 2002, BRIT J CANCER, V87, P600, DOI 10.1038/sj.bjc.6600517; Francisco JA, 1997, BLOOD, V89, P4493, DOI 10.1182/blood.V89.12.4493; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Funakoshi S, 1996, J IMMUNOTHER, V19, P93, DOI 10.1097/00002371-199603000-00002; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Gelderman KA, 2004, TRENDS IMMUNOL, V25, P158, DOI 10.1016/j.it.2004.01.008; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Golay J, 2001, BLOOD, V98, P3383, DOI 10.1182/blood.V98.12.3383; GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439; Gordon LI, 2004, CLIN LYMPHOMA, V5, P98, DOI 10.3816/CLM.2004.n.015; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; HAGA Y, 1994, INT J PANCREATOL, V15, P43; Hale G, 1998, BLOOD, V92, P4581, DOI 10.1182/blood.V92.12.4581.424k22_4581_4590; Hartung G, 2005, ONKOLOGIE, V28, P347, DOI 10.1159/000084595; Heijnen I A, 1997, Int Rev Immunol, V16, P29, DOI 10.3109/08830189709045702; Herbst RS, 2002, SEMIN ONCOL, V29, P27, DOI [10.1053/sonc.2002.31525, 10.1053/sonc.2002.33079]; Hirano F, 2005, CANCER RES, V65, P1089; Hoffmann T, 1997, ANTICANCER RES, V17, P4419; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; JANEWAY C, 1997, IMMUNOBIOLOGY, V3; Johns TG, 2004, J BIOL CHEM, V279, P30375, DOI 10.1074/jbc.M401218200; Juweid ME, 2000, J NUCL MED, V41, P93; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112; Kaminski MS, 2005, NEW ENGL J MED, V352, P441, DOI 10.1056/NEJMoa041511; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; KHAZAELI MB, 1994, J IMMUNOTHER, V15, P42, DOI 10.1097/00002371-199401000-00006; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kreitman RJ, 2001, NEW ENGL J MED, V345, P241, DOI 10.1056/NEJM200107263450402; Lee J, 1998, CANCER RES, V58, P1478; Leonard JP, 2003, J CLIN ONCOL, V21, P3051, DOI 10.1200/JCO.2003.01.082; Leonard JP, 2004, CLIN CANCER RES, V10, P5327, DOI 10.1158/1078-0432.CCR-04-0294; Leonard JP, 2002, SEMIN ONCOL, V29, P81, DOI 10.1053/sonc.2002.30149; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Lin MI, 2004, CANCER CELL, V6, P529, DOI 10.1016/S1535-6108(04)00340-X; LOO D, 2005, P AM ASSOC CANC RES, V46, P558; Lundin J, 2002, BLOOD, V100, P768, DOI 10.1182/blood-2002-01-0159; Lundin J, 1998, J CLIN ONCOL, V16, P3257, DOI 10.1200/JCO.1998.16.10.3257; Maloney DG, 1997, J CLIN ONCOL, V15, P3266, DOI 10.1200/JCO.1997.15.10.3266; Maloney DG, 1997, BLOOD, V90, P2188; May KF, 2002, CANCER RES, V62, P3459; Mayer A, 2004, BRIT J CANCER, V90, P2402, DOI 10.1038/sj.bjc.6601888; Mayer A, 2000, CLIN CANCER RES, V6, P1711; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Mendez MJ, 1997, NAT GENET, V15, P146, DOI 10.1038/ng0297-146; MEREDITH RF, 1991, J NUCL MED, V32, P1162; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Miller KD, 2001, ONCOLOGY-NY, V15, P38; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; Modjtahedi H, 1998, INT J CANCER, V75, P310, DOI 10.1002/(SICI)1097-0215(19980119)75:2<310::AID-IJC22>3.0.CO;2-F; MURPHY WJ, 1995, BLOOD, V86, P1946, DOI 10.1182/blood.V86.5.1946.bloodjournal8651946; NADLER LM, 1980, CANCER RES, V40, P3147; Naparstek E, 1999, EXP HEMATOL, V27, P1210, DOI 10.1016/S0301-472X(99)00052-1; Norton L, 1999, P AN M AM SOC CLIN, V18, p127a; Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P759, DOI 10.1093/jnci/djh133; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Piro LD, 1999, ANN ONCOL, V10, P655, DOI 10.1023/A:1008389119525; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Reardon DA, 2002, J CLIN ONCOL, V20, P1389, DOI 10.1200/JCO.2002.20.5.1389; Rizzieri DA, 2004, BLOOD, V104, P642, DOI 10.1182/blood-2003-12-4264; Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Sanderson K, 2005, J CLIN ONCOL, V23, P741, DOI 10.1200/JCO.2005.01.128; Santimaria M, 2003, CLIN CANCER RES, V9, P571; Scott AM, 2003, CLIN CANCER RES, V9, P1639; Scott AM, 2005, CLIN CANCER RES, V11, P4810, DOI 10.1158/1078-0432.CCR-04-2329; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; Shankar S, 2004, NUCL MED BIOL, V31, P909, DOI 10.1016/j.nucmedbio.2004.04.007; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Starling N, 2004, CURR OPIN ONCOL, V16, P385, DOI 10.1097/01.cco.0000128278.15371.e4; STEPLEWSKI Z, 1983, SCIENCE, V221, P865, DOI 10.1126/science.6879183; Sulica A, 2001, Int Rev Immunol, V20, P371, DOI 10.3109/08830180109054414; SUNADA H, 1990, J CELL PHYSIOL, V142, P284, DOI 10.1002/jcp.1041420210; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; SWISHER EM, 1991, BLOOD, V77, P1977; Tai YT, 2004, CANCER RES, V64, P2846, DOI 10.1158/0008-5472.CAN-03-3630; Teramoto T, 1996, CANCER, V77, P1639, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1639::AID-CNCR33>3.0.CO;2-Z; UCKUN FM, 1990, BLOOD, V76, P2449; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; van Mierlo GJD, 2002, P NATL ACAD SCI USA, V99, P5561, DOI 10.1073/pnas.082107699; Vanhoefer U, 2004, J CLIN ONCOL, V22, P175, DOI 10.1200/JCO.2004.05.114; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; VUIST WMJ, 1994, BLOOD, V83, P899; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Wong JYC, 2000, CLIN CANCER RES, V6, P3855; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141; Yang XD, 1999, CANCER RES, V59, P1236; Zhu Z, 2003, LEUKEMIA, V17, P604, DOI 10.1038/sj.leu.2402831	123	891	1046	10	354	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2005	23	9					1147	1157		10.1038/nbt1137	http://dx.doi.org/10.1038/nbt1137			11	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	963GA	16151408				2023-01-03	WOS:000231790600032
J	Seymour, B; O'Doherty, JP; Koltzenburg, M; Wiech, K; Frackowiak, R; Friston, KJ; Dolan, R				Seymour, B; O'Doherty, JP; Koltzenburg, M; Wiech, K; Frackowiak, R; Friston, KJ; Dolan, R			Opponent appetitive-aversive neural processes underlie predictive learning of pain relief	NATURE NEUROSCIENCE			English	Article							TEMPORAL DIFFERENCE MODELS; ACQUIRED MOTIVATION; NUCLEUS-ACCUMBENS; OPIOID ANALGESIA; VENTRAL STRIATUM; HUMAN BRAIN; REWARD; DOPAMINE; AMYGDALA; ANTICIPATION	Termination of a painful or unpleasant event can be rewarding. However, whether the brain treats relief in a similar way as it treats natural reward is unclear, and the neural processes that underlie its representation as a motivational goal remain poorly understood. We used fMRI ( functional magnetic resonance imaging) to investigate how humans learn to generate expectations of pain relief. Using a pavlovian conditioning procedure, we show that subjects experiencing prolonged experimentally induced pain can be conditioned to predict pain relief. This proceeds in a manner consistent with contemporary reward-learning theory ( average reward/loss reinforcement learning), reflected by neural activity in the amygdala and midbrain. Furthermore, these reward-like learning signals are mirrored by opposite aversion-like signals in lateral orbitofrontal cortex and anterior cingulate cortex. This dual coding has parallels to 'opponent process' theories in psychology and promotes a formal account of prediction and expectation during pain.	Wellcome Dept Imaging Neurosci, London WC1N 3BG, England; CALTECH, Div Humanities & Social Sci 228 77, Pasadena, CA 91125 USA; UCL, Inst Child Hlth, London WC1N 1EH, England; Fdn Santa Lucia, Neuroimaging Lab, I-00179 Rome, Italy	University of London; University College London; California Institute of Technology; University of London; University College London; IRCCS Santa Lucia	Seymour, B (corresponding author), Wellcome Dept Imaging Neurosci, 12 Queen Sq, London WC1N 3BG, England.	bseymour@fil.ion.ucl.ac.uk	Friston, Karl/D-9230-2011; Koltzenburg, Martin/C-1349-2008; Frackowiak, Richard S/I-1809-2013; Frackowiak, Richard/H-4383-2011; O'Doherty, John P/F-1204-2013	Friston, Karl/0000-0001-7984-8909; Koltzenburg, Martin/0000-0001-9181-5966; Frackowiak, Richard/0000-0002-3151-822X; Dolan, Ray/0000-0001-9356-761X; Seymour, Ben/0000-0003-1724-5832	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altier N, 1999, LIFE SCI, V65, P2269, DOI 10.1016/S0024-3205(99)00298-2; Barto A. G., 1995, MODELS INFORM PROCES, P215; Buchel C, 1998, NEUROIMAGE, V8, P140, DOI 10.1006/nimg.1998.0351; CABANAC M, 1971, SCIENCE, V173, P1103, DOI 10.1126/science.173.4002.1103; CAMERER C, IN PRESS J EC LIT; Craig ADB, 2003, TRENDS NEUROSCI, V26, P303, DOI 10.1016/S0166-2236(03)00123-1; Daw ND, 2002, NEURAL COMPUT, V14, P2567, DOI 10.1162/089976602760407973; Daw ND, 2002, NEURAL NETWORKS, V15, P603, DOI 10.1016/S0893-6080(02)00052-7; Dayan P, 2002, NEURON, V36, P285, DOI 10.1016/S0896-6273(02)00963-7; Dayan P, 2001, COMPUTATIONAL NEUROS; DICKENSON, 1979, MECH LEARNING MOTIVA, P203; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Fields HL, 2000, PROG BRAIN RES, V122, P245; Gadd CA, 2003, J NEUROSCI, V23, P8271, DOI 10.1523/jneurosci.23-23-08271.2003; Glascher J, 2005, NEURON, V47, P295, DOI 10.1016/j.neuron.2005.06.008; GROSSBERG S, 1984, BIOL PSYCHIAT, V19, P1075; Holland PC, 2004, CURR OPIN NEUROBIOL, V14, P148, DOI 10.1016/j.conb.2004.03.007; Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1; Jensen J, 2003, NEURON, V40, P1251, DOI 10.1016/S0896-6273(03)00724-4; Johansen JP, 2004, NAT NEUROSCI, V7, P398, DOI 10.1038/nn1207; Konorski J, 1967, INTEGRATIVE ACTIVITY; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; MAHADEVAN S, 1996, MACH LEARN, V22, P1; Markowitz H, 1952, J POLIT ECON, V60, P151, DOI 10.1086/257177; McClure SM, 2003, NEURON, V38, P339, DOI 10.1016/S0896-6273(03)00154-5; Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996; O'Doherty J, 2001, NAT NEUROSCI, V4, P95, DOI 10.1038/82959; O'Doherty JP, 2003, NEURON, V38, P329, DOI 10.1016/S0896-6273(03)00169-7; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Ploghaus A, 1999, SCIENCE, V284, P1979, DOI 10.1126/science.284.5422.1979; Price D. D., 1999, PSYCHOL MECH PAIN AN; Rogan MT, 2005, NEURON, V46, P309, DOI 10.1016/j.neuron.2005.02.017; Roitman MF, 2005, NEURON, V45, P587, DOI 10.1016/j.neuron.2004.12.055; Schull J., 1979, PSYCHOL LEARN MOTIV, V13, P57; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SCHWARTZ A, 1993, P 10 INT C MACH LEAR, P298; Setlow B, 2003, NEURON, V38, P625, DOI 10.1016/S0896-6273(03)00264-2; Seymour B, 2004, NATURE, V429, P664, DOI 10.1038/nature02581; Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720; Smith AJ, 2005, NEURAL COMPUT, V17, P361, DOI 10.1162/0899766053011546; SOLOMON RL, 1980, ACTA NEUROBIOL EXP, V40, P271; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; SOLOMON RL, 1980, AM PSYCHOL, V35, P691, DOI 10.1037/0003-066X.35.8.691; Stefanovic B, 2004, NEUROIMAGE, V22, P771, DOI 10.1016/j.neuroimage.2004.01.036; Sutton R.S., 1998, INTRO REINFORCEMENT, V135; Tanaka SC, 2004, NAT NEUROSCI, V7, P887, DOI 10.1038/nn1279; Tanimoto H, 2004, NATURE, V430, P983, DOI 10.1038/430983a; Ungless MA, 2004, SCIENCE, V303, P2040, DOI 10.1126/science.1093360; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Watkins LR, 1998, BEHAV NEUROSCI, V112, P360	50	306	309	0	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	SEP	2005	8	9					1234	1240		10.1038/nn1527	http://dx.doi.org/10.1038/nn1527			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	958YJ	16116445	Green Published			2023-01-03	WOS:000231483800024
J	Vandenbroucke, JP				Vandenbroucke, JP			Homoeopathy and "the growth of truth"	LANCET			English	Editorial Material							PHARMACEUTICAL-INDUSTRY; MEDICINE; TRIALS		Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Vandenbroucke, JP (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands.	j.p.vandenbroucke@lumc.nl	Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				[Anonymous], BR FOREIGN MED REV; Gould SJ, 2000, SCIENCE, V287, P253, DOI 10.1126/science.287.5451.253; Haack S., 1998, MANIFESTO PASSIONATE; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Melander H, 2003, BMJ-BRIT MED J, V326, P1171, DOI 10.1136/bmj.326.7400.1171; Osler W, 1906, Br Med J, V2, P1077; Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2; Topol EJ, 2005, JAMA-J AM MED ASSOC, V293, P366, DOI 10.1001/jama.293.3.366; Vandenbroucke JP, 1998, LANCET, V352, P2001, DOI 10.1016/S0140-6736(98)10208-8; Vandenbroucke JP, 1997, LANCET, V350, P824, DOI 10.1016/S0140-6736(97)22038-6; Vandenbroucke JP, 2001, ANN INTERN MED, V135, P507, DOI 10.7326/0003-4819-135-7-200110020-00010; Walton D, 1999, ONE SIDED ARGUMENTS	12	27	28	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					691	692		10.1016/S0140-6736(05)67151-6	http://dx.doi.org/10.1016/S0140-6736(05)67151-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125568				2023-01-03	WOS:000231474600004
J	Sisk, JE; Hebert, PL; Horowitz, CR; McLaughlin, MA; Wang, JJ; Chassin, MR				Sisk, Jane E.; Hebert, Paul L.; Horowitz, Carol R.; McLaughlin, Mary Ann; Wang, Jason J.; Chassin, Mark R.			Effects of nurse management on the quality of heart failure care in minority communities - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE MANAGEMENT; ELDERLY-PATIENTS; CLINICAL-TRIAL; HIGH-RISK; STRATEGIES; OUTCOMES; READMISSION; PERFORMANCE; IMPUTATION; SURVIVAL	Background: Despite therapies proven effective for heart failure with systolic dysfunction, the condition continues to cause substantial hospitalization, disability, and death, especially among African-American and other nonwhite populations. Objective: To compare the effects of a nurse-led intervention focused on specific management problems versus usual care among ethnically diverse patients with systolic dysfunction in ambulatory care practices. Design: Randomized effectiveness trial conducted from September 2000 to September 2002. Setting: The 4 hospitals in Harlem, New York. Patients: 406 adults (45.8% were non-Hispanic black adults, 32.5% were Hispanic adults, 46.3% were women, and 36.7% were >= 65 years of age) who met eligibility criteria: systolic dysfunction, English- or Spanish-language speakers, community-dwelling patients, and ambulatory care practice patients. Intervention: During a 12-month intervention, bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medicabons in discussions with patients' clinicians. Measurements: Hospitalizations (in 406 of 406 patients during follow-up) and self-reported functioning (in 286 of 406 patients during follow-up) at 12 months. Results: At 12 months, nurse management patients had had fewer hospitalizations (143 hospitalizations vs. 180 hospitalizations; adjusted difference, -0.13 hospitalization/ person-year [95% CI, -0.25 to -0.001 hospitalization/person-year]) than usual care patients. They also had better functioning: The Short Form-12 physical component score was 39.9 versus 36.3, respectively (difference, 3.6 [CI, 1.2 to 6.11), and the Minnesota Living with Heart Failure Questionnaire score was 38.6 versus 47.3, respectively (difference, -8.8 [CI, -15.3 to -2.2]). Through 12 months, 22 deaths occurred in each group and percentages of patients who were hospitalized at least once were similar in each group (30.5% of nurse management patients vs. 36.5% of control patients; adjusted difference, -7.1 percentage points [CI, -16.9 to 2.6 percentage points]). Limitations: Three nurses at 4 hospitals delivered interventions in this modest-sized trial, and 75% of the participants were from 1 site. It is not clear which aspects of the complex intervention accounted for the results. Conclusions: Nurse management can improve functioning and modestly lower hospitalizations in ethnically diverse ambulatory care patients who have heart failure with systolic dysfunction. Sustaining improved functioning may require continuing nurse contact.	Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Sisk, JE (corresponding author), Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, Room 3418,331 Toledo Rd, Hyattsville, MD 20782 USA.	jsisk@cdc.gov	Wang, Jason/AAG-8248-2019		AHRQ HHS [R01 HS010402, R01 HS 10402] Funding Source: Medline; NIMHD NIH HHS [P60 MD000270] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010402] Funding Source: NIH RePORTER; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P60MD000270] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		*AG HLTH CAR POL R, 1994, CONS GUID AG HLTH CA, V11; American Heart Association, 2005, HEART DIS STROKE STA; Ansari M, 2003, CIRCULATION, V107, P2799, DOI 10.1161/01.CIR.0000070952.08969.5B; Baker DW, 1999, PATIENT EDUC COUNS, V38, P33, DOI 10.1016/S0738-3991(98)00116-5; Benatar D, 2003, ARCH INTERN MED, V163, P347, DOI 10.1001/archinte.163.3.347; Bennett SJ, 2003, NURS RES, V52, P207, DOI 10.1097/00006199-200307000-00001; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BILLINGS J, 1993, FINDINGS AMBULATORY; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1389, DOI 10.1016/0895-4356(94)90083-3; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DeBusk RF, 2004, ANN INTERN MED, V141, P606, DOI 10.7326/0003-4819-141-8-200410190-00008; Diggle P., 2002, J R STAT SOC, DOI DOI 10.2307/2983303; Fonarow GC, 2004, CIRCULATION, V110, P3506, DOI 10.1161/01.CIR.0000151101.17629.20; Galbreath AD, 2004, CIRCULATION, V110, P3518, DOI 10.1161/01.CIR.0000148957.62328.89; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; Hogan JW, 2004, STAT MED, V23, P1455, DOI 10.1002/sim.1728; Horowitz CR, 2004, SOC SCI MED, V58, P631, DOI 10.1016/S0277-9536(03)00232-6; Hunt Sharon Ann, 2005, J Am Coll Cardiol, V46, pe1, DOI 10.1016/j.jacc.2005.08.022; *ISL PEER REV ORG, 1996, QUAL IMPR STUD CONG; Kasper EK, 2002, J AM COLL CARDIOL, V39, P471, DOI 10.1016/S0735-1097(01)01761-2; KONSTAM M, 1994, CLIN PRACTICE GUIDEL, V11; Kozak LJ, 2001, HEALTH AFFAIR, V20, P225, DOI 10.1377/hlthaff.20.2.225; Liu HH, 2005, HEALTH SERV RES, V40, P905, DOI 10.1111/j.1475-6773.2005.00391.x; McAlister FA, 2004, J AM COLL CARDIOL, V44, P810, DOI 10.1016/j.jacc.2004.05.055; Miller RH, 2002, HEALTH AFFAIR, V21, P63, DOI 10.1377/hlthaff.21.4.63; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Newman J, 1997, ARCH INTERN MED, V157, P1103; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Packer M, 1999, AM J CARDIOL, V83, p1A; Philbin EF, 1996, JOINT COMM J QUAL IM, V22, P721, DOI 10.1016/S1070-3241(16)30278-4; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Pugh LC., 2001, MEDSURG NURS, V10, P71; RETCHIN SM, 1991, AM J MED, V90, P236; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Stafford RS, 2003, HEALTH SERV RES, V38, P595, DOI 10.1111/1475-6773.00135; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Wagner EH, 2004, ANN INTERN MED, V141, P644, DOI 10.7326/0003-4819-141-8-200410190-00015; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; West JA, 1997, AM J CARDIOL, V79, P58, DOI 10.1016/S0002-9149(96)00676-5	40	112	114	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	2006	145	4					273	283		10.7326/0003-4819-145-4-200608150-00007	http://dx.doi.org/10.7326/0003-4819-145-4-200608150-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	075CC	16908918	Green Accepted			2023-01-03	WOS:000239858800005
J	Marcus, DM; Grollman, AP				Marcus, Donald M.; Grollman, Arthur P.			Review for NCCAM is overdue	SCIENCE			English	Editorial Material							ALTERNATIVE MEDICINE; CHELATION-THERAPY; HERBAL REMEDIES; HEART-DISEASE; HEALTH		Baylor Coll Med, Dept Med, Houston, TX 77030 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	Baylor College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Marcus, DM (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	dmarcus@bcm.tmc.edu						*AM HEART ASS, QUEST ANSW CHEL THER; Bent S, 2006, NEW ENGL J MED, V354, P557, DOI 10.1056/NEJMoa053085; Berman JD, 2004, ANNU REV MED, V55, P239, DOI 10.1146/annurev.med.55.091902.103657; Blendon RJ, 2001, ARCH INTERN MED, V161, P805, DOI 10.1001/archinte.161.6.805; BUDIANSKY S, 1995, US NEWS WORLD R 0717, P48; *COMM US COMPL ALT, 2005, COMPL ALT MED US, pCH9; Couzin J, 1998, SCIENCE, V282, P2175, DOI 10.1126/science.282.5397.2175; De Smet PAGM, 2004, CLIN PHARMACOL THER, V76, P1, DOI 10.1016/j.clpt.2004.03.005; Elvin-Lewis Memory, 2005, Adv Food Nutr Res, V50, P219, DOI 10.1016/S1043-4526(05)50007-X; Ernst E, 2000, AM HEART J, V140, P139, DOI 10.1067/mhj.2000.107548; Knudtson ML, 2002, JAMA-J AM MED ASSOC, V287, P481, DOI 10.1001/jama.287.4.481; KOLATA G, 2005, NY TIMES        0728; Markowitz JS, 2003, JAMA-J AM MED ASSOC, V290, P1500, DOI 10.1001/jama.290.11.1500; MARSHALL E, 1994, SCIENCE, V265, P2000, DOI 10.1126/science.8091220; Mervis J, 2006, SCIENCE, V311, P28, DOI 10.1126/science.311.5757.28; *NCCAM US DEP HHS, 2005, EXP HOR HLTH CAR STR; Sampson W, 2005, NEW ENGL J MED, V353, P337, DOI 10.1056/NEJMp058130; Seely Dugald M R, 2005, BMC Cardiovasc Disord, V5, P32, DOI 10.1186/1471-2261-5-32; Stokstad E, 2000, SCIENCE, V288, P1568, DOI 10.1126/science.288.5471.1568; Turner RB, 2005, NEW ENGL J MED, V353, P341, DOI 10.1056/NEJMoa044441; Villarruz MV, 2002, COCHRANE DB SYST REV, V4, DOI [10.1002/14651858.CD002785, DOI 10.1002/14651858.CD002785, DOI 10.1002/14651858]; Vogel G, 1997, SCIENCE, V278, P378, DOI 10.1126/science.278.5337.378; Young JH, 1998, B HIST MED, V72, P279, DOI 10.1353/bhm.1998.0110; 1992, WORKSH ALT MED CHANT	24	10	10	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 21	2006	313	5785					301	302		10.1126/science.1126978	http://dx.doi.org/10.1126/science.1126978			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	065IV	16857923				2023-01-03	WOS:000239154300025
J	Kerbel, RS				Kerbel, Robert S.			Antiangiogenic therapy: A universal chemosensitization strategy for cancer?	SCIENCE			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; METASTATIC BREAST-CANCER; METRONOMIC CHEMOTHERAPY; TUMOR ANGIOGENESIS; RANDOMIZED-TRIAL; CELLS; CYCLOPHOSPHAMIDE; CHEMORESISTANCE; NORMALIZATION; BEVACIZUMAB		Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med Biophys, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Kerbel, RS (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med Biophys, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	robert.kerbel@sri.utoronto.ca						ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bertolini F, 2003, CANCER RES, V63, P4342; Browder T, 2000, CANCER RES, V60, P1878; CANADY C, 2005, ONCOL NEWS INT, V14, P8; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Citron ML, 2004, CANCER INVEST, V22, P555, DOI 10.1081/CNV-200027134; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cohn DE, 2006, GYNECOL ONCOL, V102, P134, DOI 10.1016/j.ygyno.2006.01.030; Colleoni M, 2002, ANN ONCOL, V13, P73, DOI 10.1093/annonc/mdf013; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Emmenegger U, 2004, CANCER RES, V64, P3994, DOI 10.1158/0008-5472.CAN-04-0580; ESCUDIER B, 2005, 2005 ASCO ANN M P, V23, pS380; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Franco M, 2006, CANCER RES, V66, P3639, DOI 10.1158/0008-5472.CAN-05-3295; Furstenberger G, 2006, BRIT J CANCER, V94, P524, DOI 10.1038/sj.bjc.6602952; Giannoni DS, 2002, APPL LINGUIST, V23, P1, DOI 10.1093/applin/23.1.1; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Hudis Clifford A, 2005, Oncology (Williston Park), V19, P26; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Kieran MW, 2005, J PEDIAT HEMATOL ONC, V27, P573, DOI 10.1097/01.mph.0000183863.10792.d4; Kim JE, 2005, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2005/01/005; Kindler HL, 2005, J CLIN ONCOL, V23, P8033, DOI 10.1200/JCO.2005.01.9661; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Ma L, 2005, CANCER RES, V65, P5365, DOI 10.1158/0008-5472.CAN-04-3156; Marx J, 2005, SCIENCE, V308, P1248, DOI 10.1126/science.308.5726.1248; Miller KD, 2001, J CLIN ONCOL, V19, P1195, DOI 10.1200/JCO.2001.19.4.1195; MILLER KD, 2005, 41 ANN M AM SOC CLIN; Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574; Munoz R, 2006, CANCER RES, V66, P3386, DOI 10.1158/0008-5472.CAN-05-4411; Natori T, 2002, BIOCHEM BIOPH RES CO, V297, P1058, DOI 10.1016/S0006-291X(02)02335-5; Okazaki T, 2006, INT IMMUNOL, V18, P1, DOI 10.1093/intimm/dxh334; Pietras K, 2005, J CLIN ONCOL, V23, P939, DOI 10.1200/JCO.2005.07.093; SANDLER AB, 2005, 2005 ASCO ANN M P, V23, pS2; Schrag D, 2004, NEW ENGL J MED, V351, P317, DOI 10.1056/NEJMp048143; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023; Shaked Y, 2005, BLOOD, V106, P3058, DOI 10.1182/blood-2005-04-1422; Sweeney CJ, 2001, CANCER RES, V61, P3369; Tozer GM, 2005, NAT REV CANCER, V5, P423, DOI 10.1038/nrc1628; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Udagawa T, 2006, FASEB J, V20, P95, DOI 10.1096/fj.04-3669com; Vogelzang NJ, 2006, J CLIN ONCOL, V24, P1, DOI 10.1200/JCO.2005.03.7234; Wang JY, 2003, ANTI-CANCER DRUG, V14, P13, DOI 10.1097/00001813-200301000-00003; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327	53	397	419	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	2006	312	5777					1171	1175		10.1126/science.1125950	http://dx.doi.org/10.1126/science.1125950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048OW	16728631				2023-01-03	WOS:000237957400041
J	Feder, S; Matheny, RL; Loveless, RS; Rea, TD				Feder, S; Matheny, RL; Loveless, RS; Rea, TD			Withholding resuscitation: A new approach to prehospital end-of-life decisions	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIAC-ARREST	Background: Emergency medical services (EMS) personnel often are not permitted to honor requests to withhold resuscitation at the end of life, particularly if there is no written do-not-resuscitate (DNR) order. Objective: To determine whether EMS personnel from agencies implementing new guidelines would be more likely to withhold resuscitation from persons having out-of-hospital cardiac arrests than would personnel from agencies that did not implement the guidelines. Design: Observational study in which 16 of 35 local EMS agencies volunteered to implement new guidelines for withholding resuscitation. Setting: King County, Washington. Patients: 2770 patients with EMS-attended cardiac arrest. Intervention: New guidelines adopted by participating agencies permitted EMS personnel to withhold resuscitation if the patient had a terminal condition and if the patient, family, or caregivers indicated, in writing or verbally, that no resuscitation was desired. Measurements: Proportion of resuscitations withheld in agencies that implemented new guidelines compared with those that did not. Results: Emergency medical services personnel from agencies implementing new guidelines withheld resuscitation in 11.8% of patients (99 of 841 patients) having cardiac arrests, compared with an average of 5.3% (range, 4.2% to 5.9%) of patients (103 of 1929 patients) in 3 historical and contemporary control groups. Honoring verbal requests alone accounted for 53% of withheld resuscitations in the intervention group (52 of 99 patients) compared with an average of 8% (range, 7% to 9%) in the control groups (8 of 103 patients). Limitations: The study was not a randomized, controlled trial; individual agencies chose whether to implement the guidelines. Conclusions: Implementation of new guidelines was associated with an increase in the number of resuscitations withheld by EMS personnel. This increase was primarily due to honoring verbal requests.			Feder, S (corresponding author), King Cty Med 1,7064 S 220th St, Kent, WA 98032 USA.	sylvia_feder@kcfiremed.org						Becker Linda J, 2003, Prehosp Emerg Care, V7, P303, DOI 10.1080/10903120390936464; DULL SM, 1994, ANN EMERG MED, V23, P997, DOI 10.1016/S0196-0644(94)70093-1; Guru V, 1999, CAN MED ASSOC J, V161, P1251; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; Marco CA, 2003, J EMERG MED, V24, P101, DOI 10.1016/S0736-4679(02)00688-1; R Development Core Team, 2005, R LANG ENV STAT COMP; Rea TD, 2003, CIRCULATION, V107, P2780, DOI 10.1161/01.CIR.0000070950.17208.2A; Sabatino CP, 1999, J LAW MED ETHICS, V27, P297, DOI 10.1111/j.1748-720X.1999.tb01465.x; Silveira MJ, 2003, J AM GERIATR SOC, V51, P1435, DOI 10.1046/j.1532-5415.2003.51462.x	9	35	36	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2006	144	9					634	640		10.7326/0003-4819-144-9-200605020-00006	http://dx.doi.org/10.7326/0003-4819-144-9-200605020-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	039GJ	16670132				2023-01-03	WOS:000237293700002
J	Van den Berghe, G; Wilmer, A; Hermans, G; Meersseman, W; Wouters, PJ; Milants, I; Van Wijngaerden, E; Bobbaers, H; Bouillon, R				Van den Berghe, G; Wilmer, A; Hermans, G; Meersseman, W; Wouters, PJ; Milants, I; Van Wijngaerden, E; Bobbaers, H; Bouillon, R			Intensive insulin therapy in the medical ICU	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERVENTION SCORING SYSTEM; BLOOD-GLUCOSE CONTROL; CRITICALLY-ILL; MYOCARDIAL-INFARCTION; STRESS HYPERGLYCEMIA; MORTALITY; PROTECTS; CULTURES	BACKGROUND: Intensive insulin therapy reduces morbidity and mortality in patients in surgical intensive care units (ICUs), but its role in patients in medical ICUs is unknown. METHODS: In a prospective, randomized, controlled study of adult patients admitted to our medical ICU, we studied patients who were considered to need intensive care for at least three days. On admission, patients were randomly assigned to strict normalization of blood glucose levels (80 to 110 mg per deciliter [4.4 to 6.1 mmol per liter]) with the use of insulin infusion or to conventional therapy (insulin administered when the blood glucose level exceeded 215 mg per deciliter [12 mmol per liter], with the infusion tapered when the level fell below 180 mg per deciliter [10 mmol per liter]). There was a history of diabetes in 16.9 percent of the patients. RESULTS: In the intention-to-treat analysis of 1200 patients, intensive insulin therapy reduced blood glucose levels but did not significantly reduce in-hospital mortality (40.0 percent in the conventional-treatment group vs. 37.3 percent in the intensive-treatment group, P=0.33). However, morbidity was significantly reduced by the prevention of newly acquired kidney injury, accelerated weaning from mechanical ventilation, and accelerated discharge from the ICU and the hospital. Although length of stay in the ICU could not be predicted on admission, among 433 patients who stayed in the ICU for less than three days, mortality was greater among those receiving intensive insulin therapy. In contrast, among 767 patients who stayed in the ICU for three or more days, in-hospital mortality in the 386 who received intensive insulin therapy was reduced from 52.5 to 43.0 percent (P=0.009) and morbidity was also reduced. CONCLUSIONS: Intensive insulin therapy significantly reduced morbidity but not mortality among all patients in the medical ICU. Although the risk of subsequent death and disease was reduced in patients treated for three or more days, these patients could not be identified before therapy. Further studies are needed to confirm these preliminary data.	Catholic Univ Louvain, Dept Intens Care Med, B-3000 Louvain, Belgium; Catholic Univ Louvain, Dept Med Intens Care Med, B-3000 Louvain, Belgium; Catholic Univ Louvain, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; KU Leuven; Universite Catholique Louvain	Van den Berghe, G (corresponding author), Catholic Univ Louvain, Dept Intens Care Med, B-3000 Louvain, Belgium.	greta.vandenberghe@med.kuleuven.be	Hermans, Greet M/E-6234-2018; Van Wijngaerden, Eric/AAB-9187-2021; Van den Berghe, Greet/J-6788-2018; Wilmer, Alexander/H-7784-2018	Hermans, Greet M/0000-0001-5340-1500; Van Wijngaerden, Eric/0000-0001-8926-099X; Van den Berghe, Greet/0000-0002-5320-1362; Wilmer, Alexander/0000-0002-4176-3608				Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Cely CM, 2004, CHEST, V126, P879, DOI 10.1378/chest.126.3.879; Clement S, 2004, DIABETES CARE, V27, P553, DOI 10.2337/diacare.27.2.553; Clement S, 2004, DIABETES CARE, V27, P1255; Clement S, 2004, DIABETES CARE, V27, P856; Evans TW, 2001, NEW ENGL J MED, V345, P1417, DOI 10.1056/NEJM200111083451910; Furnary AP, 2003, J THORAC CARDIOV SUR, V125, P1007, DOI 10.1067/mtc.2003.181; Hansen TK, 2003, J CLIN ENDOCR METAB, V88, P1082, DOI 10.1210/jc.2002-021478; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Langouche L, 2005, J CLIN INVEST, V115, P2277, DOI 10.1172/JCI25385; Malmberg K, 2005, EUR HEART J, V26, P650, DOI 10.1093/eurheartj/ehi199; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Miranda DR, 1996, CRIT CARE MED, V24, P64, DOI 10.1097/00003246-199601000-00012; MIZOCK BA, 1995, AM J MED, V98, P75, DOI 10.1016/S0002-9343(99)80083-7; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Souba WW, 1997, NEW ENGL J MED, V336, P41, DOI 10.1056/NEJM199701023360107; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Van den Berghe G, 2003, CRIT CARE MED, V31, P359, DOI 10.1097/01.CCM.0000045568.12881.10; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2004, J CLIN INVEST, V114, P1187, DOI 10.1172/JCI200423506; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vanhorebeek I, 2005, LANCET, V365, P53, DOI 10.1016/S0140-6736(04)17665-4; Weekers F, 2003, ENDOCRINOLOGY, V144, P5329, DOI 10.1210/en.2003-0697; Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584; Weinstein MP, 1998, J CLIN MICROBIOL, V36, P2089, DOI 10.1128/JCM.36.7.2089-2092.1998	28	2377	2454	1	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					449	461		10.1056/NEJMoa052521	http://dx.doi.org/10.1056/NEJMoa052521			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008DC	16452557				2023-01-03	WOS:000235019400005
J	Shankaran, S; Laptook, AR; Ehrenkranz, RA; Tyson, JE; McDonald, SA; Donovan, EF; Fanaroff, AA; Poole, WK; Wright, LL; Higgins, RD; Finer, NN; Carlo, WA; Duara, S; Oh, W; Cotten, CM; Stevenson, DK; Stoll, BJ; Lemons, JA; Guillet, R; Jobe, AH				Shankaran, S; Laptook, AR; Ehrenkranz, RA; Tyson, JE; McDonald, SA; Donovan, EF; Fanaroff, AA; Poole, WK; Wright, LL; Higgins, RD; Finer, NN; Carlo, WA; Duara, S; Oh, W; Cotten, CM; Stevenson, DK; Stoll, BJ; Lemons, JA; Guillet, R; Jobe, AH		Natl Inst Child Hlth Human Dev Neo	Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL BLOOD-FLOW; POSTISCHEMIC HYPOTHERMIA; BRAIN TEMPERATURE; NEURONAL DAMAGE; SELECTIVE HEAD; POSTHYPOXIC HYPOTHERMIA; MODERATE HYPOTHERMIA; PERINATAL ASPHYXIA; MILD HYPOTHERMIA; CARDIAC-ARREST	BACKGROUND: Hypothermia is protective against brain injury after asphyxiation in animal models. However, the safety and effectiveness of hypothermia in term infants with encephalopathy is uncertain. METHODS: We conducted a randomized trial of hypothermia in infants with a gestational age of at least 36 weeks who were admitted to the hospital at or before six hours of age with either severe acidosis or perinatal complications and resuscitation at birth and who had moderate or severe encephalopathy. Infants were randomly assigned to usual care (control group) or whole-body cooling to an esophageal temperature of 33.5 degreesC for 72 hours, followed by slow rewarming (hypothermia group). Neurodevelopmental outcome was assessed at 18 to 22 months of age. The primary outcome was a combined end point of death or moderate or severe disability. RESULTS: Of 239 eligible infants, 102 were assigned to the hypothermia group and 106 to the control group. Adverse events were similar in the two groups during the 72 hours of cooling. Primary outcome data were available for 205 infants. Death or moderate or severe disability occurred in 45 of 102 infants (44 percent) in the hypothermia group and 64 of 103 infants (62 percent) in the control group (risk ratio, 0.72; 95 percent confidence interval, 0.54 to 0.95; P=0.01). Twenty-four infants (24 percent) in the hypothermia group and 38 (37 percent) in the control group died (risk ratio, 0.68; 95 percent confidence interval, 0.44 to 1.05; P=0.08). There was no increase in major disability among survivors; the rate of cerebral palsy was 15 of 77 (19 percent) in the hypothermia group as compared with 19 of 64 (30 percent) in the control group (risk ratio, 0.68; 95 percent confidence interval, 0.38 to 1.22; P=0.20). CONCLUSIONS: Whole-body hypothermia reduces the risk of death or disability in infants with moderate or severe hypoxic-ischemic encephalopathy.	Wayne State Univ, Div Neonatal Perinatal Med, Detroit, MI USA; Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA; Yale Univ, Sch Med, New Haven, CT USA; Univ Texas, Houston, TX USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA; Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; NICHHD, Bethesda, MD 20892 USA; Univ Calif San Diego, San Diego, CA 92103 USA; Univ Alabama, Birmingham, AL USA; Univ Miami, Dept Pediat, Miami, FL 33152 USA; Duke Univ, Med Ctr, Durham, NC USA; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; Emory Univ, Sch Med, Atlanta, GA USA; Indiana Univ, Sch Med, Indianapolis, IN USA; Univ Rochester, Rochester, NY USA	Wayne State University; Women & Infants Hospital Rhode Island; Yale University; University of Texas System; Research Triangle Institute; University System of Ohio; University of Cincinnati; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; University of Miami; Duke University; Stanford University; Emory University; Indiana University System; Indiana University-Purdue University Indianapolis; University of Rochester	Shankaran, S (corresponding author), Wayne State Univ, Childrens Hosp Michigan, Div Neonatal Perinatal Med, 3901 Beaubien Blvd,Rm 4H46, Detroit, MI 48201 USA.	sshankar@med.wayne.edu		McDonald, Scott/0000-0002-0054-1099; Shankaran, Seetha/0000-0001-5512-9571	NCRR NIH HHS [5 M01 RR00044, M01 RR 00125, M01 RR 00039, M01 RR 00750, M01 RR 08084, M01 RR 0039-43, M01 RR 00070] Funding Source: Medline; NICHD NIH HHS [U10 HD40498, U10 HD27871, U10 HD27856, U10 HD40461, U10 HD27853, U10 HD21397, U01 HD36790, U10 HD21373, U10 HD21385, U10 HD40492, U10 HD27851, U10 HD40689, U10 HD27904, U10 HD021385, U10 HD34216, U10 HD40521, U10 HD27880] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD027880, U10HD040689, U10HD027904, U10HD027871, U10HD040492, U10HD040461, U10HD027856, U10HD027851, U10HD021385, U10HD027853, U10HD034216, U10HD021373] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD021397, U10HD040521, U10HD040498, U01HD036790] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070, M01RR000125, M01RR000750, M01RR000039, M01RR008084, M01RR000044] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		al Naqeeb N, 1999, PEDIATRICS, V103, P1263, DOI 10.1542/peds.103.6.1263; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; BALDWIN WA, 1991, AM J PHYSIOL, V261, pH774, DOI 10.1152/ajpheart.1991.261.3.H774; Barkovich AJ, 1998, AM J NEURORADIOL, V19, P143; BAYLEY N, 1993, BAYLEY SCALES INFANT, V2; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CARROLL M, 1992, METAB BRAIN DIS, V7, P45, DOI 10.1007/BF01000440; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Gelman B, 1996, CRIT CARE MED, V24, P1009, DOI 10.1097/00003246-199606000-00022; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Gunn AJ, 1998, PEDIATRICS, V102, P1098, DOI 10.1542/peds.102.5.1098; HORN M, 1991, ACTA NEUROPATHOL, V81, P443, DOI 10.1007/BF00293466; Krageloh-Mann I, 2002, DEV MED CHILD NEUROL, V44, P477; KULUZ JW, 1993, AM J PHYSIOL, V265, pH824, DOI 10.1152/ajpheart.1993.265.3.H824; Laptook AR, 1997, PEDIATR RES, V42, P17, DOI 10.1203/00006450-199707000-00004; Laptook AR, 2001, PEDIATRICS, V108, P1103, DOI 10.1542/peds.108.5.1103; Nedelcu J, 2000, BRAIN PATHOL, V10, P61; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; ROBERTSON CMT, 1989, J PEDIATR-US, V114, P753, DOI 10.1016/S0022-3476(89)80132-5; Roland EP, 1998, ANN NEUROL, V44, P161, DOI 10.1002/ana.410440205; Shankaran S, 2002, PEDIATRICS, V110, P377, DOI 10.1542/peds.110.2.377; SHANKARAN S, 1991, EARLY HUM DEV, V25, P135, DOI 10.1016/0378-3782(91)90191-5; SIMBRUNER G, 1994, AM J PERINAT, V11, P137, DOI 10.1055/s-2007-994574; Thoresen M, 1997, NEUROREPORT, V8, P3359, DOI 10.1097/00001756-199710200-00033; Thoresen M, 1996, ARCH DIS CHILD-FETAL, V74, pF3, DOI 10.1136/fn.74.1.F3; Thoresen M, 2001, PEDIATR RES, V49, P594, DOI 10.1203/00006450-200104000-00024; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; Toet MC, 1999, ARCH DIS CHILD-FETAL, V81, pF19, DOI 10.1136/fn.81.1.F19; TOWFIGHI J, 1994, ACTA NEUROPATHOL, V87, P598; Wagner BP, 2002, PEDIATR RES, V51, P354, DOI 10.1203/00006450-200203000-00015; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454	35	1841	1913	2	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2005	353	15					1574	1584		10.1056/NEJMcps050929	http://dx.doi.org/10.1056/NEJMcps050929			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972XF	16221780				2023-01-03	WOS:000232486000011
J	Markwell, H				Markwell, H			End-of-life: a Catholic view	LANCET			English	Editorial Material									St Michaels Hosp, Ctr Clin Eth, Toronto, ON M6R 1B5, Canada; St Josephs Hlth Ctr, Toronto, ON M6R 1B5, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Joseph's Health Centre, Toronto; Western University (University of Western Ontario)	Markwell, H (corresponding author), St Michaels Hosp, Ctr Clin Eth, 30 Queensway, Toronto, ON M6R 1B5, Canada.	markwellh@smh.toronto.on.ca						BROCK I, 1997, DYING WELL PROSPECT, P59; *CATH HLTH ASS CAN, 2001, HLTH ETH GUID, P11; CRONIN DA, 1958, MORAL LAW REGARD ORD, P471; FLANNERY A, 1988, VATICAN COUNCIL 2 CO, P905; FLANNERY A, 1988, VATICAN COUNCIL 2 CO, P903; Katz J., 2002, SILENT WORLD DOCTOR; KELLY G, 1958, MEDICOMORAL PROBLEMS, P129; MAY WF, 1983, PHYSICIANS COVENANT, P109; MAY WF, 1994, HASTINGS CTR REP MAY; NOUWEN H, 1994, OUR GREATEST GIFT ME, P32; PELLEGRINO ED, 1997, HELPING HEALING RELI, P45; RAMSAY P, 1978, ETHICS EDGES LIFE; ROCHE J, 2000, FACING DEATH DISCOVE, P16; Singer PA, 2002, BMJ-BRIT MED J, V324, P1291, DOI 10.1136/bmj.324.7349.1291; Singer PA, 2001, BMC MED ETHICS, V2, P1, DOI DOI 10.1186/1472-6939-2-1; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; *VAT 2, SACR CONC, V22; WILDES KW, 1997, CHOOSING LIFE DIALOG; 1999, BMJ, P318	19	33	34	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 24	2005	366	9491					1132	1135		10.1016/S0140-6736(05)67425-9	http://dx.doi.org/10.1016/S0140-6736(05)67425-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	967TL	16182902				2023-01-03	WOS:000232114000032
J	Quon, BS; Firszt, R; Eisenberg, MJ				Quon, BS; Firszt, R; Eisenberg, MJ			A comparison of brand-name drug prices between Canadian-based Internet pharmacies and major US drug chain pharmacies	ANNALS OF INTERNAL MEDICINE			English	Article								Background: many Americans have been purchasing their medications from online Canadian pharmacies. Although it is commonly perceived that medications are less expensive in Canada than in the United States, little research has been done to quantify this difference. Objective: To compare the prices of retail brand-name medications between Canadian Internet pharmacies and major U.S. drug chain pharmacies with online pricing. Design: Cross-sectional study. Setting: 12 Canadian Internet pharmacies and 3 major online U.S. drug chain pharmacies. Measurements: The authors calculated the per unit and annual savings (in U.S. dollars) for an American if he or she were to buy the 44 brand-name medications most commonly purchased through the Internet from Canadian Internet pharmacies instead of from an online U.S. drug chain pharmacy. Results: Americans can save a mean of approximately 24% per unit of drug if they purchase their medications from Canadian Internet pharmacies instead of from major online U.S. drug chain pharmacies. Forty-one of the 44 brand-name medications examined were less expensive in Canada. The medications offering the largest mean yearly savings were Zyprexa (olanzapine) (Eli Lilly, Indianapolis, Indiana) ($1159), Actos (pioglitazone) (Eli Lilly, Indianapolis, Indiana) ($852), and Nexium (esomeprazole) (AstraZeneca, Wilmington, Delaware) ($772). Only 3 medications, all in the erectile dysfunction category, were more expensive in Canada. Limitations: Potential savings may vary because of temporal fluctuations in drug prices. Conclusions: Brand-name medications are often substantially less expensive when purchased from Canadian Internet pharmacies instead of from major online U.S. drug chain pharmacies.	McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Jewish Gen Hosp, Div Clin Epidemiol, Montreal, PQ H3T 1E2, Canada; Univ British Columbia, Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; Montreal Childrens Hosp, Vancouver, BC, Canada	McGill University; McGill University; University of British Columbia; St. Paul's Hospital; University of Saskatchewan; McGill University	Eisenberg, MJ (corresponding author), McGill Univ, Jewish Gen Hosp, Div Cardiol, 3755 Cote Ste Catherine Rd,Suite A-118, Montreal, PQ H3T 1E2, Canada.	meisenberg@epid.jgh.mcgill.ca						*CAN PHARM ASS, 2004, 2004 COMP PHARM SPEC; *CTR STUD SERV, 2004, CONSUMERS CHECKBOOK, V1, P64; DAVEY M, 2004, NY TIMES        0817, pA15; *HARR INT POLL, 2004, HARR INT SURV PRESCR; *HLTH CAN, ITS YOUR HLTH BUYING; *INT MARK SERV, 2003, MED CTR RET PRESCR G; Lybecker Kristina M, 2004, Manag Care, V13, P10; *NAT LEG ASS PRESC, 2003, DRUG PRIC COMP; *P DANG CONS INC, 2002, PDCI REP SER; *PAT MED PRIC REV, ANN REP 2003; *US HR, 1998, PRESCR DRUG PRIC 1 C; *US HR, 1998, PRESCR DRUG PRIC VER; Zuger A, 2003, NEW ENGL J MED, V349, P2188, DOI 10.1056/NEJMp038196; MEDICARE FREQUENTLY; NEW HAMPSHIRES MED C; 2004, DRUG STORE NEWS 0419	16	29	32	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 20	2005	143	6					397	403		10.7326/0003-4819-143-6-200509200-00004	http://dx.doi.org/10.7326/0003-4819-143-6-200509200-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967OG	16172438				2023-01-03	WOS:000232099900001
J	Engelhardt, HT; Iltis, AS				Engelhardt, HT; Iltis, AS			End-of-life: the traditional Christian view	LANCET			English	Editorial Material									Rice Univ, Dept Philosophy MS14, Houston, TX 77005 USA; St Louis Univ, Ctr Hlth Care Eth, St Louis, MO 63103 USA	Rice University; Saint Louis University	Engelhardt, HT (corresponding author), Rice Univ, Dept Philosophy MS14, 6100 Main St, Houston, TX 77005 USA.	htengelh@rice.edu						*BISH PA, 1992, ORIGINS, V21, P541; *BISH TX, 1990, ORIGINS, V20, P53; *CHRIST MED DENT A, ETH STAT PAT REF THE; CRONIN D, 1958, THESIS PONTIFICAL GR; *DIV CHURCH SOC, 1992, MESS END OF LIF DEC; ENGELHARDT HT, 1999, CHRIST BIOET, V4, P231; ENGELHARDT HT, 2000, FDN CHRISTIAN BIOETH, P369; HAMEL R, 1991, ACTIVE EUTHANASIA RE; HARAKAS SS, 1990, HLTH MED E ORTHODOX, P145; HOLIFIELD EB, 1986, HLTH MED METHODIST T, P85; KILNER J, 1992, LIFE LINE; MARTY ME, 1983, HLTH MED LUTHERAN TR, P157; MCCORMICK RA, 1984, HLTH MED CATHOLIC TR, P107; MEILAENDER G, 1984, HASTINGS CENT REP, P11; *MENN CHURCH CAN, 1995, LIF WORTH LIV ISS EU; *MO SYN LUTH CHURC, 1993, CHRIST CAR LIF END; PEEL R, 1988, HLTH MED CHRISTIAN S, P71; *PRESB CHURCH US, 1974, 1974 STAT, P199; SCHAFF P, 1994, NICENE POSTNICENE FA, V14, P549; SCHAFF P, 1994, NICENE POSTNICENE FA, V8, P78; SCHAFF P, 1994, NICENE POSTNICENE FA, V14, P613; SMITH DH, 1986, HLTH MED ANGLICAN TR, P45; Thomasma David C, 1998, Christ Bioeth, V4, P122, DOI 10.1076/chbi.4.2.122.6905; *UN UN GEN ASS, 1988, STAT EUTH; VAUX KL, 1984, HLTH MED REFORMED TR, P131; WAGNER M, 1962, ST BASIL LONG RULES, P330; Wildes KW, 1996, THEOL STUD, V57, P500, DOI 10.1177/004056399605700306; 1947, RITUALE ROMANUM, P103; 1989, DIVINE LITURGY, P281	29	41	42	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 17	2005	366	9490					1045	1049						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	965MZ	16168787				2023-01-03	WOS:000231955900040
J	Winch, PJ; Alam, MA; Akther, A; Afroz, D; Ali, NA; Ellis, AA; Baqui, AH; Darmstadt, GL; El Arifeen, S; Seraji, MHR				Winch, PJ; Alam, MA; Akther, A; Afroz, D; Ali, NA; Ellis, AA; Baqui, AH; Darmstadt, GL; El Arifeen, S; Seraji, MHR		Bangladesh PROJAHNMO Study Grp	Local understandings of vulnerability and protection during the neonatal period in Sylhet district, Bangladesh: a qualitative study	LANCET			English	Article							CARE-SEEKING; POPULAR THERAPEUTICS; CHILDHOOD DEATHS; RURAL BANGLADESH; PRETERM INFANTS; NEWBORN BABIES; SKIN BARRIER; HEALTH; INDIA; WOMEN	Background Understanding of local knowledge and practices relating to the newborn period, as locally defined, is needed in the development of interventions to reduce neonatal mortality. We describe the organisation of the neonatal period in Sylhet District, Bangladesh, the perceived threats to the well-being of neonates, and the ways in which families seek to protect them. Methods We did 39 in-depth, unstructured, qualitative interviews with mothers, fathers, and grandmothers of neonates, and traditional birth attendants. Data on neonatal knowledge and practices were also obtained from a household survey of 6050 women who had recently given birth. Findings Interviewees defined the neonatal period as the first 40 days of life (chollish din). Confinement of the mother and baby is most strongly observed before the noai ceremony on day 7 or 9, and involves restriction of movement outside the home, sleeping where the birth took place rather than in the mother's bedroom, and sleeping on a mat on the floor. Newborns are seen as vulnerable to cold air, cold food or drinks (either directly or indirectly through the mother), and to malevolent spirits or evil eye. Bathing, skin care, confinement, and dietary practices all aim to reduce exposure to cold, but some of these practices might increase the risk of hypothermia. Interpretation Although fatalism and cultural acceptance of high mortality have been cited as reasons for high levels of neonatal mortality, Sylheti families seek to protect newborns in several ways. These actions reflect a set of assumptions about the newborn period that differ from those of neonatal health specialists, and have implications for the design of interventions for neonatal care.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Social & Behav Intervent Program, Baltimore, MD 21205 USA; Project Adv Hlth Newborns & Mothers, Sylhet, Bangladesh; ICDDR B, Ctr Hlth & Populat Res, Dhaka, Bangladesh; Save Children USA, Saving Newborn Lives, Washington, DC USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; International Centre for Diarrhoeal Disease Research (ICDDR); Save the Children	Winch, PJ (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Social & Behav Intervent Program, Room E5030,615 N Wolfe St, Baltimore, MD 21205 USA.	pwinch@jhsph.edu	Darmstadt, Gary/AAU-7488-2020	Darmstadt, Gary/0000-0002-7522-5824; Arifeen, Shams/0000-0002-5372-5932; Alam, Neeloy Ashraful/0000-0001-7034-1095				Afsana K, 2000, DISCOURSING BIRTHING; Ahmed S, 2001, J TROP PEDIATRICS, V47, P98, DOI 10.1093/tropej/47.2.98; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; BANG AT, 1994, B WORLD HEALTH ORGAN, V72, P897; Baqui AH, 1998, B WORLD HEALTH ORGAN, V76, P161; Baqui AH, 2001, ACTA PAEDIATR, V90, P682, DOI 10.1080/080352501750258775; Bell C., 1997, RITUAL PERSPECTIVES; BERLAND J, 2000, CULTURE CREATION PRO, P157; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Carter A. T., 1982, CONCEPTS PERSON KINS, P118, DOI [10.1525/aa.1984.86.4.02a00190, DOI 10.1525/AA.1984.86.4.02A00190]; Cecil R., 1996, ANTHR PREGNANCY LOSS; COMAROFF J, 1977, MED ENCOUNTERS EXPER, P115; Cosminsky Sheila, 1994, ETHNOGRAPHY FERTILIT, P195; Darmstadt GL, 2005, LANCET, V365, P1039, DOI 10.1016/S0140-6736(05)74228-8; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Darmstadt GL, 2004, PEDIATR INFECT DIS J, V23, P719, DOI 10.1097/01.inf.0000133047.50836.6f; Darmstadt GL, 2002, ACTA PAEDIATR, V91, P546, DOI 10.1080/080352502753711678; Davis-Floyd Robbie, 1997, CHILDBIRTH AUTHORITA; de Souza ACT, 2000, SOC SCI MED, V51, P1675, DOI 10.1016/S0277-9536(00)00100-3; De Zoysa I, 1998, SOC SCI MED, V47, P2101, DOI 10.1016/S0277-9536(98)00275-5; DeLoache Judy, 2000, WORLD BABIES IMAGINE; Dundes L., 2003, MANNER BORN BIRTH RI; Fikree FF, 2005, SOC SCI MED, V60, P911, DOI 10.1016/j.socscimed.2004.06.034; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; GIDEON TEC, 1962, AM ANTHROPOL, V64, P1220; GOODBURN EA, 1995, STUD FAMILY PLANN, V26, P22, DOI 10.2307/2138048; Gottlieb Alma, 2004, AFTERLIFE IS WE COME; HART DV, 1965, SE ASIAN BIRTH CUSTO; Jeffery Patricia, 1993, KNOWLEDGE POWER PRAC, P7; Jeffery PM, 1985, CONTAMINATING STATES; JEFFERY PM, 1989, LABOUR PAINS LAOUR P; Kay Margarita Artschwager, 1982, ANTHR HUMAN BIRTH; KITZINGER S, 1994, ETHNOGRAPHY FERTILIT, P171; Knippenberg R, 2005, LANCET, V365, P1087, DOI 10.1016/S0140-6736(05)74233-1; LADERMAN C, 1987, SOC SCI MED, V25, P357, DOI 10.1016/0277-9536(87)90274-7; Laderman Carol, 1983, WIVES MIDWIVES CHILD; LAMBERT H, 1992, SOC SCI MED, V34, P1069, DOI 10.1016/0277-9536(92)90280-4; Lambert H, 1996, LANCET, V348, P1706, DOI 10.1016/S0140-6736(96)07135-8; Lambert Helen, 2000, CULTURES RELATEDNESS, P73; LANCHET T, 1984, WOMEN POLLUTION MARG; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lawn JE, 2004, LANCET, V364, P399, DOI 10.1016/S0140-6736(04)16783-4; LAYNE L.L., 2003, MOTHERHOOD LOST; MacCormack C.P., 1994, ETHNOGRAPHY FERTILIT; Mahon-Daly P, 2002, HEALTH PLACE, V8, P61, DOI 10.1016/S1353-8292(01)00026-0; MANDERSON L, 1981, SOC SCI MED-MED ANTH, V15, P509, DOI 10.1016/0160-7987(81)90025-9; Marsh David R, 2002, J Perinatol, V22, P572, DOI 10.1038/sj.jp.7210793; MCCLAIN CS, 1975, ANTHR Q, V40, P38; McGilvray Dennis B., 1994, ETHNOGRAPHY FERTILIT, P15; Niang C.I., 2004, FORMATIVE RES PERINE; NICHTER M, 1983, HUM ORGAN, V42, P235, DOI 10.17730/humo.42.3.43081445235366lk; NICHTER M, 1987, SOC SCI MED, V25, P377, DOI 10.1016/0277-9536(87)90276-0; REISSLAND N, 1987, SOC SCI MED, V25, P231, DOI 10.1016/0277-9536(87)90226-7; REISSLAND N, 1988, SOC SCI MED, V27, P461, DOI 10.1016/0277-9536(88)90369-3; Rice PL, 2000, MIDWIFERY, V16, P22, DOI 10.1054/midw.1999.0180; Rice PL, 2000, EARLY HUM DEV, V57, P189, DOI 10.1016/S0378-3782(99)00062-6; RICE PL, 1994, MED J AUSTRALIA, V160, P577, DOI 10.5694/j.1326-5377.1994.tb138351.x; Romney A. Kimball, 1963, 6 CULTURES STUDIES C, P541; Sesia PM, 1996, MED ANTHROPOL Q, V10, P121, DOI 10.1525/maq.1996.10.2.02a00020; Subbarayappa BV, 1997, LANCET, V350, P1841, DOI 10.1016/S0140-6736(97)04223-2; SUTRISNA B, 1993, LANCET, V342, P787, DOI 10.1016/0140-6736(93)91545-W; THOMPSON C, 1985, SOC SCI MED, V21, P701, DOI 10.1016/0277-9536(85)90210-2; Turner Victor, 1977, RITUAL PROCESS STRUC; Van Gennep A., 1960, RITES PASSAGE; VanHollen C, 2003, BIRTH ON THE THRESHOLD: CHILDBIRTH AND MODERNITY IN SOUTH INDIA, P1	65	136	136	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2005	366	9484					478	485		10.1016/S0140-6736(05)66836-5	http://dx.doi.org/10.1016/S0140-6736(05)66836-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	952RD	16084256				2023-01-03	WOS:000231022300029
J	McGinn, CG				McGinn, CG			Close calls with club drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mt Auburn Hosp, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Mount Auburn Hospital; Harvard University; Harvard Medical School	McGinn, CG (corresponding author), Mt Auburn Hosp, Cambridge, MA 02138 USA.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2671	2672		10.1056/NEJMp058107	http://dx.doi.org/10.1056/NEJMp058107			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987915				2023-01-03	WOS:000230133800003
J	Brogly, S; Williams, P; Seage, GR; Oleske, JM; Van Dyke, R; McIntosh, K				Brogly, S; Williams, P; Seage, GR; Oleske, JM; Van Dyke, R; McIntosh, K		PACTG 219C Team	Antiretroviral treatment in pediatric HIV infection in the United States - From clinical trials to clinical practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITOR INDINAVIR; RANDOMIZED CONTROLLED-TRIAL; COMBINATION THERAPY; TYPE-1 INFECTION; VIRAL LOAD; CHILDREN; ZIDOVUDINE; RITONAVIR; NEVIRAPINE	Context Antiretroviral therapy (ART) for pediatric human immunodeficiency virus (HIV) infection has evolved from simple nucleoside reverse transcriptase inhibitor (NRTI) regimens to complex combination therapies based largely on evidence from clinical trials. However, the integration of novel ART into the clinical care of pediatric HIV infection has not been examined. Objectives To describe changes in the treatment of pediatric HIV infection in the United States from 1987-2003, to assess concordance of initial regimens with US pediatric guidelines, and to identify predictors of the first regimen switch. Design, Setting, and Participants The study population included 766 perinatally HIV-infected children in the Pediatric AIDS Clinical Trials Group 219C cohort born before January 1, 2004, who had not participated in an ART clinical trial at 219C enrollment or during follow-up. Main Outcome Measures Proportion of children receiving specific ART regimens, proportion of children initiating ART according to pediatric guidelines, and time to first regimen switch (risk of switching). Results Single and dual NRTI regimens were used most frequently through 1997. In 1998, 2 years after protease inhibitors were approved for adult HIV infection and at the time pediatric guidelines were issued, regimens of highly active antiretroviral therapy including a protease inhibitor became most frequently used. From 1998-2003, 22% of children initiated ART with a regimen not recommended by pediatric guidelines. in multivariate regression, the risk of switching decreased with age at ART initiation (hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.94-0.99) and increased with year of initiation (HR, 1.28; 95% Cl, 1.23-1.33). The risk of switching was higher in children who started with 1 NRTI (HR, 8.05; 95% Cl, 5.80-11.18), 2 NRTIs (HR, 4.08; 95% Cl, 3.08-5.40), or an unconventional regimen (HR, 6.23; 95% Cl, 3.36-11.54) vs children who started with a protease inhibitor-containing regimen; and in children who initiated ART at CD4 T lymphocyte percentages less than 15 vs 15 or greater (HR, 2.90; 95% Cl, 1.03-8.13). Conclusions There was a short lag between the identification of novel ART and its adoption in the pediatric community. A variety of regimens were used, including some unorthodox therapies. Important predictors of first regimen switch were identified.	Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Med & Dent New Jersey, Dept Pediat, Newark, NJ 07103 USA; Tulane Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70118 USA; Childrens Hosp Boston, Div Infect Dis, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Rutgers State University New Brunswick; Rutgers State University Medical Center; Tulane University; Harvard University; Boston Children's Hospital	Brogly, S (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, 651 Huntington Ave,FXB-607, Boston, MA 02115 USA.	sbrogly@sdac.harvard.edu	Oleske, James M/C-1951-2016	Oleske, James M/0000-0003-2305-5605; Brogly, Susan/0000-0002-2339-3287	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041110] Funding Source: NIH RePORTER; NIAID NIH HHS [5 U01 AI41110] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bernardi S, 2000, EUR J PEDIATR, V159, P170, DOI 10.1007/s004310050045; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P1; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; CONNOR EM, 1993, PEDIATR INFECT DIS J, V12, P513, DOI 10.1097/00006454-199306000-00011; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; *DEP HLTH HUM SERV, GUID US ANT AG HIV I; Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1; Gandhi M, 2002, CLIN INFECT DIS, V35, P313, DOI 10.1086/341249; Giaquinto C, 2002, AIDS, V16, P97, DOI 10.1097/00002030-200201040-00012; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Kirstein LM, 2002, J ACQ IMMUN DEF SYND, V29, P495, DOI 10.1097/00126334-200204150-00010; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MCCONNELL M, 2002, 14 INT AIDS C JUL 7; Melvin AJ, 1997, PEDIATR INFECT DIS J, V16, P968, DOI 10.1097/00006454-199710000-00013; Mocroft A, 2001, AIDS, V15, P185, DOI 10.1097/00002030-200101260-00007; Mueller BU, 1998, PEDIATRICS, V102, P101, DOI 10.1542/peds.102.1.101; Nachman SA, 2000, JAMA-J AM MED ASSOC, V283, P492, DOI 10.1001/jama.283.4.492; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Rutstein RM, 1997, AIDS, V11, pF107, DOI 10.1097/00002030-199712000-00004; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583; Starr SE, 1999, NEW ENGL J MED, V341, P1874, DOI 10.1056/NEJM199912163412502; van Roon EN, 1999, J ACQ IMMUN DEF SYND, V20, P290, DOI 10.1097/00042560-199903010-00012; VANDYKE RB, 2002, PEDIATRICS, V109, P109; Wintergerst U, 1998, PEDIATR INFECT DIS J, V17, P495, DOI 10.1097/00006454-199806000-00012; Wiznia A, 2000, AIDS RES HUM RETROV, V16, P1113, DOI 10.1089/088922200414956; *WORK GROUP ANT TH, GUID US ANT AG PED H	30	47	48	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2005	293	18					2213	2220		10.1001/jama.293.18.2213	http://dx.doi.org/10.1001/jama.293.18.2213			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	924LU	15886376	Bronze			2023-01-03	WOS:000228981100022
J	Mehta, RH; Alexander, JH; Van de Werf, F; Armstrong, PW; Pieper, KS; Garg, J; Califf, RM; Granger, CB				Mehta, RH; Alexander, JH; Van de Werf, F; Armstrong, PW; Pieper, KS; Garg, J; Califf, RM; Granger, CB			Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; MEDICATION ERRORS; THROMBOLYSIS; TRIAL; PREDICTORS; MORTALITY; ALTEPLASE; BENEFITS; STROKE; AGENTS	Context Incorrect dosing of alteplase has been associated with worse clinical outcomes in patients. However, patients at high risk of adverse events are more prone to dosing errors, thus confounding this relationship. Objective To determine if the association between incorrect dosing of alteplase and adverse outcomes is related to cause and effect or to confounding. Design, Setting, and Patients Observational analysis in May 2004 of a double-blind, double-dummy trial of 16949 patients with ST-segment elevation myocardial infarction who were enrolled in the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) trial and were assigned to either a bolus of tenecteplase (with alteplase placebo bolus plus infusion) or a bolus of alteplase (with tenecteplase placebo plus infusion). Main Outcome Measures Thirty-day mortality, in-hospital stroke, and major bleeding associated with incorrect dosing of active alteplase compared with placebo alteplase. Results Incorrect dosing occurred in 4.9% of patients who received active alteplase and in 4.6% of patients who received alteplase placebo. Patients receiving incorrect doses of alteplase or alteplase placebo were more likely to be older, female, black, shorter, have lower body weight and systolic blood pressure, and have a higher Killip class at presentation. Thirty-day mortality was higher in patients who received an overdose (9.8%) or underdose (19.5%) of alteplase compared with those who received a correct dose (5.4%). The same pattern was present in patients who received an alteplase placebo (10.0% for overdose, 23.5% for underclose, and 5.4% for correct dose). Similar patterns were seen for in-hospital intracranial hemorrhage and major bleeding. The higher rates of adverse outcomes with incorrect dosing were largely accounted for by adjusting for baseline characteristics. Conclusions The relationship between incorrect dosing and patient outcome in ASSENT-2 is primarily due to confounding factors rather than incorrect dosing itself. These data highlight the need for caution when ascribing a causal relationship to associations between incorrect dosing and adverse outcomes.	Duke Univ, Med Ctr, Durham, NC 27710 USA; Duke Clin Res Inst, Durham, NC USA; Katholieke Univ Leuven Hosp, Dept Internal Med, Div Cardiol, Louvain, Belgium; Univ Alberta, Dept Internal Med, Div Cardiol, Edmonton, AB, Canada	Duke University; Duke University; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; University of Alberta	Granger, CB (corresponding author), Duke Univ, Med Ctr, Box 3409, Durham, NC 27710 USA.	grang001@mc.duke.edu	Granger, Christopher B/D-3458-2014; Alexander, John/GVS-7271-2022	Granger, Christopher B/0000-0002-0045-3291; Alexander, John/0000-0002-1444-2462; Armstrong, Paul/0000-0002-0460-3445; Van de Werf, Frans/0000-0001-9479-7767				Berkowitz SD, 1997, CIRCULATION, V95, P2508, DOI 10.1161/01.CIR.95.11.2508; Cannon CP, 2000, AM HEART J, V140, pS154, DOI 10.1067/mhj.2000.111605; Cannon CP, 2000, AM J CARDIOL, V85, p17C; COULTER SA, 2000, CIRCULATION S2, V102, P1590; Freedman JE, 2002, CIRCULATION, V106, P2623, DOI 10.1161/01.CIR.0000037748.19282.7D; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; GRANGER CB, 1994, CIRCULATION S1, V90, P1324; Gurwitz JH, 1998, ANN INTERN MED, V129, P597, DOI 10.7326/0003-4819-129-8-199810150-00002; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; Phillips DP, 1998, LANCET, V351, P643, DOI 10.1016/S0140-6736(98)24009-8; SMALLING RW, 1995, CIRCULATION, V91, P2725, DOI 10.1161/01.CIR.91.11.2725; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; VORCHHEIMER DA, 1997, CIRCULATION S1, V96, P1535	13	13	14	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2005	293	14					1746	1750		10.1001/jama.293.14.1746	http://dx.doi.org/10.1001/jama.293.14.1746			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915JS	15827313	Bronze			2023-01-03	WOS:000228301100028
J	[Anonymous]				[Anonymous]			Thrombolytic (fibrinolytic) drugs and progress in treating cardiovascular disease	FASEB JOURNAL			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; THERAPY											Albers GW, 2004, CHEST, V126, p483S, DOI 10.1378/chest.126.3_suppl.483S; FLETCHER AP, 1958, T ASSOC AM PHYSICIAN, V71, P287; Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507; Menon V, 2004, CHEST, V126, p549S, DOI 10.1378/chest.126.3_suppl.549S; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905	5	1	1	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					671	671		10.1096/fj.05-3896bkt	http://dx.doi.org/10.1096/fj.05-3896bkt			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791008				2023-01-03	WOS:000228865300042
J	Milne, F; Redman, C; Walker, J; Baker, P; Bradley, J; Cooper, C; de Swiet, M; Fletcher, G; Jokinen, M; Murphy, D; Nelson-Piercy, C; Osgood, V; Robson, S; Shennan, A; Tuffnell, A; Twaddle, S; Waugh, J				Milne, F; Redman, C; Walker, J; Baker, P; Bradley, J; Cooper, C; de Swiet, M; Fletcher, G; Jokinen, M; Murphy, D; Nelson-Piercy, C; Osgood, V; Robson, S; Shennan, A; Tuffnell, A; Twaddle, S; Waugh, J			The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community	BRITISH MEDICAL JOURNAL			English	Article							32 WEEKS GESTATION; CONTROLLED-TRIAL; RISK-FACTORS; HYPERTENSION; PREGNANCY; ECLAMPSIA; WOMEN; PROTEINURIA; MORBIDITY; PREDICT		Act Preeclampsia, Harrow HA1 4HZ, Middx, England; John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England; St Jamess Univ Hosp, Leeds LS9 7TF, W Yorkshire, England; St Marys Hosp, Manchester M13 0JH, Lancs, England; Stony Stratford Hlth Ctr, Stonedean Practice, Milton Keynes MK11 1YA, Bucks, England; Cuckoo Lane Practice, London W7 3EY, England; Queen Charlottes Matern Hosp, Imperial Coll London, London W12 0NN, England; Natl Childbirth Trust, London W3 6NH, England; Royal Coll Midwives, London W1G 9NH, England; Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ London Kings Coll, St Thomas Hosp, London SE1 7EH, England; St Marys Hosp, Portsmouth PO3 6AD, Hants, England; Royal Victoria Infirm, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Hosp Leicester NHS Trust, Leicester Royal Infirm, Leicester LE1 5WW, Leics, England	University of Oxford; Saint James's University Hospital; University of Leeds; University of Manchester; Imperial College London; University of Dundee; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Newcastle University - UK; University Hospitals of Leicester NHS Trust; University of Leicester	Milne, F (corresponding author), Act Preeclampsia, Harrow HA1 4HZ, Middx, England.	fionamilne@talk2l.com		Shennan, Andrew/0000-0001-5273-3132; Walker, James/0000-0002-8922-083X; Murphy, Deirdre/0000-0001-6074-6718				ABISAID D, 1995, AM J EPIDEMIOL, V142, P437, DOI 10.1093/oxfordjournals.aje.a117652; BANIAS BB, 1992, AM J PERINAT, V9, P357, DOI 10.1055/s-2007-999264; Barton JR, 2001, AM J OBSTET GYNECOL, V184, P979, DOI 10.1067/mob.2001.112905; Carroli G, 2001, LANCET, V357, P1565, DOI 10.1016/S0140-6736(00)04723-1; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; Duckitt K, 2005, BRIT MED J, V330, P565, DOI 10.1136/bmj.38380.674340.E0; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; Durnwald C, 2003, AM J OBSTET GYNECOL, V189, P848, DOI 10.1067/S0002-9378(03)00849-4; FERRAZZANI S, 1990, AM J OBSTET GYNECOL, V162, P366, DOI 10.1016/0002-9378(90)90387-M; Henderson J, 2000, J Health Serv Res Policy, V5, P69; Koike T, 2002, GYNECOL OBSTET INVES, V53, P22, DOI 10.1159/000049406; Martin JN, 1999, AM J OBSTET GYNECOL, V180, P1407, DOI 10.1016/S0002-9378(99)70026-8; *MAT CHILD HLTH RE, 1999, CONF ENQ STILLB DEAT; Maternal and Child Health Research Consortium, 2001, CONF ENQ STILLB DEAT; *NAT I CLIN EXC, 2004, 6 REP CONF ENQ MAT D; *NAT I CLIN EXC, 2001, 5 REP CONF ENQ MAT D; *NHS NAT I CLIN EX, GUID DEV PROC INF NA; North RA, 1999, BRIT J OBSTET GYNAEC, V106, P767, DOI 10.1111/j.1471-0528.1999.tb08396.x; Seshadri L, 1997, J REPROD MED, V42, P88; SIBAI BM, 1994, AM J OBSTET GYNECOL, V171, P818, DOI 10.1016/0002-9378(94)90104-X; Stamilio DM, 2000, AM J OBSTET GYNECOL, V182, P589, DOI 10.1067/mob.2000.103890; STETTLER RW, 1992, AM J OBSTET GYNECOL, V167, P1219; Waterstone M, 2001, BMJ-BRIT MED J, V322, P1089, DOI 10.1136/bmj.322.7294.1089; Witlin AG, 1999, AM J OBSTET GYNECOL, V180, P1322, DOI 10.1016/S0002-9378(99)70014-1	24	194	206	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 12	2005	330	7491					576	580		10.1136/bmj.330.7491.576	http://dx.doi.org/10.1136/bmj.330.7491.576			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906EC	15760998	Green Published, Bronze			2023-01-03	WOS:000227622300019
J	Billings, J; Dixon, J; Mijanovich, T; Wennberg, D				Billings, John; Dixon, Jennifer; Mijanovich, Tod; Wennberg, David			Case finding for patients at risk of readmission to hospital: development of algorithm to identify high risk patients	BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP	Objective To develop a method of identifying patients at high risk of readmission to hospital in the next 12 months for practical use by primary care trusts and general practices in the NHS in England. Data sources Data from hospital episode statistics showing all admissions in NHS trusts in England over five years, 1999-2000 to 2003-4; data from die 2001 census for England. Population All residents in England admitted to hospital in the previous four years with a subset of "reference" conditions for which improved management may help to prevent future admissions. Design Multivariate statistical analysis of routinely collected data to develop an algorithm to predict patients at highest risk of readmission in the next 12 months. The algorithm was developed by using a 10% sample of hospital episode statistics data for all of England for the period indicated. The coefficients for 21 most powerful (and statistically significant) variables were then applied against a second 10% test sample to validate the findings of the algorithm from the first sample. Results The key factors predicting subsequent admission included age, sex, ethnicity, number of previous admissions, and clinical condition. The algorithm produces a risk score (from 0 to 100) for each patient admitted with a reference condition. At a risk score threshold of 50, the algorithm identified 54.3% of patients admitted with a reference condition who would have an admission in the next 12 months; 34.7% of patients were "flagged" incorrectly (they would not have a subsequent admission). At risk score threshold levels of 70 and 80, the rate of incorrectly "flagged" patients dropped to 22.6% and 15.7%, but the algorithm found a lower percentage of patients who would be readmitted. The algorithm is made freely available to primary care trusts via a website. Conclusions A method of predicting individual patients at highest risk of readmission to hospital in the next 12 months has been developed, which has a reasonable level of sensitivity and specificity. Using various assumptions a "business case" has been modelled to demonstrate to primary care trusts and practices the potential costs and impact of an intervention using the algorithm to reduce hospital admissions.	NYU, Ctr Hlth & Publ Serv Res, New York, NY 10012 USA; Kings Fund, London W1G 0AN, England; Hlth Dialog Analyt Solut, Hlth Dialog Corp Headquarters, Boston, MA USA	New York University	Billings, J (corresponding author), NYU, Ctr Hlth & Publ Serv Res, 295 Lafayette St, New York, NY 10012 USA.	john.billings@nyu.edu						Department of Health, 2005, SUPP PEOPL LONG TERM; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Roland M, 2005, BRIT MED J, V330, P289, DOI 10.1136/bmj.330.7486.289	4	257	260	0	25	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 12	2006	333	7563					327	330		10.1136/bmj.38870.657917.AE	http://dx.doi.org/10.1136/bmj.38870.657917.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073VI	16815882	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000239770300015
J	Ding, M; Feng, RT; Wang, SY; Bowman, L; Lu, YJ; Qian, Y; Castranova, V; Jiang, BH; Shi, XL				Ding, Min; Feng, Rentian; Wang, Shiow Y.; Bowman, Linda; Lu, Yongju; Qian, Yong; Castranova, Vincent; Jiang, Bing-Hua; Shi, Xianglin			Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; FACTOR-KAPPA-B; NEOPLASTIC TRANSFORMATION; CANCER CHEMOPREVENTION; SIGNALING PATHWAYS; ANTHOCYANIN-RICH; MAP KINASES; INHIBITION; CYCLOOXYGENASE-2; TUMORIGENESIS	Epidemiological data suggest that consumption of fruits and vegetables has been associated with a lower incidence of cancer. Cyanidin-3- glucoside (C3G), a compound found in blackberry and other food products, was shown to possess chemopreventive and chemotherapeutic activity in the present study. In cultured JB6 cells, C3G was able to scavenge ultraviolet B-induced (OH)-O-center dot and O-2(center dot). radicals. In vivo studies indicated that C3G treatment decreased the number of non-malignant and malignant skin tumors per mouse induced by 12-O-tetradecanolyphorbol-13-acetate (TPA) in 7,12-dimethylbenz[a] anthracene-initiated mouse skin. Pretreatment of JB6 cells with C3G inhibited UVB- and TPA-induced transactivation of NF-kappa B and AP-1 and expression of cyclooxygenase-2 and tumor necrosis factor-alpha. These inhibitory effects appear to be mediated through the inhibition of MAPK activity. C3G also blocked TPAinduced neoplastic transformation in JB6 cells. In addition, C3G inhibited proliferation of a human lung carcinoma cell line, A549. Animal studies showed that C3G reduced the size of A549 tumor xenograft growth and significantly inhibited metastasis in nude mice. Mechanistic studies indicated that C3G inhibited migration and invasion of A549 tumor cells. These finding demonstrate for the first time that a purified compound of anthocyanin inhibits tumor promoter- induced carcinogenesis and tumor metastasis in vivo.	NIOSH, Pathol & Physiol Res Branch, Hlth Effect Lab Div, Morgantown, WV 26505 USA; USDA, Beltsville Agr Res Ctr, Fruit Lab, Beltsville, MD 20705 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); United States Department of Agriculture (USDA); West Virginia University	Ding, M (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effect Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.	mid5@cdc.gov	Shi, Xianglin/B-8588-2012	Jiang, Bing-Hua/0000-0003-4526-2031				Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; Afaq F, 2003, ONCOGENE, V22, P9254, DOI 10.1038/sj.onc.1207035; Afaq F, 2005, INT J CANCER, V113, P423, DOI 10.1002/ijc.20587; Aggarwal BB, 2003, ANTICANCER RES, V23, P363; [Anonymous], 1996, CA Cancer J Clin, V46, P325; Bagchi D, 2004, BIOCHEMISTRY-MOSCOW+, V69, P75, DOI 10.1023/B:BIRY.0000016355.19999.93; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Castonguay A, 1997, CARCINOGENESIS, V18, P491, DOI 10.1093/carcin/18.3.491; Chen T, 2006, CANCER RES, V66, P2853, DOI 10.1158/0008-5472.CAN-05-3279; Chung TW, 2004, FASEB J, V18, P1670, DOI 10.1096/fj.04-2126com; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Ding M, 2004, J BIOL CHEM, V279, P10670, DOI 10.1074/jbc.M311465200; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Gupta S, 2001, SKIN PHARMACOL APPL, V14, P373, DOI 10.1159/000056371; Hou DX, 2004, CARCINOGENESIS, V25, P29, DOI 10.1093/carcin/bgg184; Hou DX, 2003, CURR MOL MED, V3, P149, DOI 10.2174/1566524033361555; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KUNDU JK, 2004, MUTAT RES, V2, P555; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Li JJ, 1997, CANCER RES, V57, P3569; Lochter A, 1999, APMIS, V107, P128, DOI 10.1111/j.1699-0463.1999.tb01535.x; Lu YP, 2002, P NATL ACAD SCI USA, V99, P12455, DOI 10.1073/pnas.182429899; Ma Q, 2003, MOL PHARMACOL, V64, P211, DOI 10.1124/mol.64.2.211; Marrogi AJ, 2000, CLIN CANCER RES, V6, P4739; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; NAITO M, 1988, CARCINOGENESIS, V9, P639, DOI 10.1093/carcin/9.4.639; Nishino H, 2005, ONCOLOGY-BASEL, V69, P38, DOI 10.1159/000086631; Paik J, 2002, ADV EXP MED BIOL, V507, P503; Qian Y, 2003, J BIOL CHEM, V278, P16189, DOI 10.1074/jbc.M207517200; REDDY BS, 1987, CANCER RES, V47, P5340; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Rigas B, 2005, J PHARMACOL EXP THER, V314, P1, DOI 10.1124/jpet.104.080564; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Seifried HE, 2003, CANCER RES, V63, P4295; Singh B, 2005, INT J ONCOL, V26, P1393; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; SPANO IP, 2004, B CANC, V91, P109; Sturm MW, 2003, INT J CANCER, V107, P11, DOI 10.1002/ijc.11320; Subbaramaiah K, 2002, CANCER RES, V62, P2522; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Weidner Noel, 1996, P167; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zheng W, 2003, J AGR FOOD CHEM, V51, P502, DOI 10.1021/jf020728u	54	232	246	4	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17359	17368		10.1074/jbc.M600861200	http://dx.doi.org/10.1074/jbc.M600861200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16618699	Green Submitted, hybrid			2023-01-03	WOS:000238326300062
J	Deeks, SG				Deeks, Steven G.			The risk of treatment versus the risk of HIV replication	LANCET			English	Editorial Material							TREATMENT INTERRUPTION; ADULTS; TRIAL		San Francisco Gen Hosp, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center	Deeks, SG (corresponding author), San Francisco Gen Hosp, San Francisco, CA 94110 USA.	sdeeks@php.ucsf.edu						ANANWORANICH J, 2006, 13 C RETR OPP INF DE, P102; [Anonymous], 13 C RETR OPP INF DE; Cardiello PG, 2005, CLIN INFECT DIS, V40, P594, DOI 10.1086/427695; Danel C, 2006, LANCET, V367, P1981, DOI 10.1016/S0140-6736(06)68887-9; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Levy AR, 2006, LANCET INFECT DIS, V6, P171, DOI 10.1016/S1473-3099(06)70413-3; Maggiolo F, 2004, AIDS, V18, P439, DOI 10.1097/00002030-200402200-00010; Panel on Clinical Practices for the Treatment of HIV Infection and DHHS Guidelines, 2006, GUID US ANT AG HIV I	8	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 17	2006	367	9527					1955	1956		10.1016/S0140-6736(06)68857-0	http://dx.doi.org/10.1016/S0140-6736(06)68857-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	055ZC	16782465				2023-01-03	WOS:000238488900004
J	Trollope-Kumar, K; Guyatt, G				Trollope-Kumar, K; Guyatt, G			Syndromic approach for treatment of STIs: time for a change	LANCET			English	Editorial Material							SEXUALLY-TRANSMITTED INFECTIONS; VAGINAL DISCHARGE; LOW-PREVALENCE; WOMEN; MANAGEMENT		McMaster Univ, Dept Family Med, Hamilton, ON L8S 4L8, Canada; W End Clin, Hamilton, ON, Canada; McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada	McMaster University; McMaster University	Trollope-Kumar, K (corresponding author), McMaster Univ, Dept Family Med, Hamilton, ON L8S 4L8, Canada.	kumarak@mcmaster.ca						Bogaerts J, 1999, SEX TRANSM INFECT, V75, P437, DOI 10.1136/sti.75.6.437; Chalamilla G, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-22; Desai VK, 2003, SEX TRANSM INFECT, V79, P111, DOI 10.1136/sti.79.2.111; Hawkes S, 1999, LANCET, V354, P1776, DOI 10.1016/S0140-6736(99)02463-0; Hawkes S, 2002, SEX TRANSM INFECT, V78, pI31, DOI 10.1136/sti.78.suppl_1.i31; Koenig M., 1998, Reproductive Health Matters, V6, P84, DOI 10.1016/S0968-8080(98)90085-4; Patel V, 2005, INT J EPIDEMIOL, V34, P853, DOI 10.1093/ije/dyi072; Pepin J, 2004, SEX TRANSM INFECT, V80, P230, DOI 10.1136/sti.2003.007534; Trollope-Kumar K, 2001, TROP MED INT HEALTH, V6, P260, DOI 10.1046/j.1365-3156.2001.00699.x	9	12	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 29	2006	367	9520					1380	1381		10.1016/S0140-6736(06)68593-0	http://dx.doi.org/10.1016/S0140-6736(06)68593-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	038CI	16650635				2023-01-03	WOS:000237195600009
J	Bottle, A; Aylin, P				Bottle, A; Aylin, P			Mortality associated with delay in operation after hip fracture: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NECK	Objective To estimate the number of deaths and readmissions associated with delay in Operation after femoral fracture. Design Analysis of inpatient hospital episode statistics. Setting NHS hospital trusts in England with at least 100 admissions for fractured neck Of femur during the study period. Patients People aged >= 65 admitted from home with fractured neck of femur and discharged between April 2001 and March 2004. Main outcome measures In hospital mortality and emergency readmission within 28 days. Results There were 129 522 admissions for fractured neck Of femur in 151 trusts With 18 508 deaths in hospital (14.3%). Delay in operation was associated with all increased risk of death in hospital, which was reduced but persisted after adjustment for comorbidity. For all deaths in hospital, the odds ratio for more than one clay's delay relative to one day or less was 1.27 (95% confidence interval 1.23 to 1.32) after adjustment for comorbidity. The proportion with more than two days' delay ranged from 1.1% to 62.4% between trusts. If death rates in patients with at most one day's delay had been repeated throughout all 151 trusts in this study, there would have been all average of 581 (478 to 683) fewer total deaths per year (9.4% of the total). There was little evidence of all association between delay and emergency readmission. Conclusions Delay in operation is associated With all increased risk of death but nit readmission after a fractured neck of femur, even with adjustment for comorbidity, and there is wide variation between trusts.	Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, Dept Primary Care & Social Med, London W6 8RP, England	Imperial College London	Bottle, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, Dept Primary Care & Social Med, London W6 8RP, England.	robert.bottle@imperial.ac.uk	Aylin, Paul/A-1073-2014	Bottle, Alex/0000-0001-9978-2011; Aylin, Paul/0000-0003-4589-1743				Cooper C, 1996, OSTEOPOROSIS NEW PER, P1; COOPER G, 1996, OSTEOPOROSIS NEW PER, P1; Cree M, 2000, J AM GERIATR SOC, V48, P283, DOI 10.1111/j.1532-5415.2000.tb02647.x; *DEP ENV TRANSP RE, 2000, 31 DETR; FOX HJ, 1994, INJURY, V25, P297, DOI 10.1016/0020-1383(94)90239-9; Hansell A, 2001, J PUBLIC HEALTH MED, V23, P51, DOI 10.1093/pubmed/23.1.51; *HEALTHC COMM, PERF IND 2005; *HLTHC COMM, 2005, PERF IND; HOLMBERG S, 1987, CLIN ORTHOP RELAT R, P42; HOLT EM, 1994, INJURY, V25, P91, DOI 10.1016/0020-1383(94)90109-0; Lyons Anthony R., 1997, American Journal of Medicine, V103, p51S, DOI 10.1016/S0002-9343(97)90027-9; Lyons AR, 1997, AM J MED, V103, P51; McKee M, 1993, Qual Health Care, V2, P104, DOI 10.1136/qshc.2.2.104; Moran CG, 2005, J BONE JOINT SURG AM, V87A, P483, DOI 10.2106/JBJS.D.01796; ROGERS FB, 1995, J TRAUMA, V39, P261, DOI 10.1097/00005373-199508000-00012; *ROYAL COLL PHYS, 1989, FRACT NECK FEM PREV; Turner P, 1997, AUST NZ J SURG, V67, P126, DOI 10.1111/j.1445-2197.1997.tb01917.x; WOLFINGER RD, 1999, 287 SAS I	18	301	322	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 22	2006	332	7547					947	950		10.1136/bmj.38790.468519.55	http://dx.doi.org/10.1136/bmj.38790.468519.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	037JV	16554334	Green Published, Bronze			2023-01-03	WOS:000237143900017
J	Sharp, D				Sharp, D			Meloxicam to prevent rabies?	LANCET			English	Editorial Material							DICLOFENAC; VULTURES		The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							Agarwal N, 2004, TROP DOCT, V34, P76, DOI 10.1177/004947550403400205; Meteyer CU, 2005, J WILDLIFE DIS, V41, P707, DOI 10.7589/0090-3558-41.4.707; Pain DJ, 2003, CONSERV BIOL, V17, P661, DOI 10.1046/j.1523-1739.2003.01740.x; Shultz S, 2004, P ROY SOC B-BIOL SCI, V271, pS458, DOI 10.1098/rsbl.2004.0223; Sudarshan M. K., 2001, Journal of Communicable Diseases, V33, P245; Swan G, 2006, PLOS BIOL, V4, P395, DOI 10.1371/journal.pbio.0040066	6	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2006	367	9514					887	888		10.1016/S0140-6736(06)68361-X	http://dx.doi.org/10.1016/S0140-6736(06)68361-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	025CE	16546526				2023-01-03	WOS:000236242100010
J	Steffen, LM; Nettleton, JA				Steffen, LM; Nettleton, JA			Carbohydrates: how low can you go?	LANCET			English	Editorial Material							VEGETABLES; DISEASE; ATKINS; FRUIT; DIET; RISK		Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA	University of Minnesota System; University of Minnesota Twin Cities	Steffen, LM (corresponding author), Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA.	steffen@epi.umn.edu		Steffen, Lyn M/0000-0002-4053-6729				[Anonymous], 2005, US DIET GUID AM; Astrup A, 2004, LANCET, V364, P897, DOI 10.1016/S0140-6736(04)16986-9; Chen TY, 2006, LANCET, V367, P958, DOI 10.1016/S0140-6736(06)68394-3; Cummings S, 2002, J AM DIET ASSOC, V102, P1145, DOI 10.1016/S0002-8223(02)90255-5; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; FREEDMAN M, 2001, OBESITY REV S1, V9, P1, DOI DOI 10.1038/0BY.2001.113; Malin AS, 2003, INT J CANCER, V105, P413, DOI 10.1002/ijc.11088; Metges CC, 2000, J NUTR, V130, P886, DOI 10.1093/jn/130.4.886; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; Nutrition and Food Security Programme WHO Regional Office for Europe, 2003, FOOD BAS DIET GUID W; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Steffen LM, 2003, AM J CLIN NUTR, V78, P383, DOI 10.1093/ajcn/78.3.383; *USDA, MY PYR GOV STEPS HLT	13	9	10	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2006	367	9514					880	881		10.1016/S0140-6736(06)68357-8	http://dx.doi.org/10.1016/S0140-6736(06)68357-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	025CE	16546522				2023-01-03	WOS:000236242100006
J	Kashikar-Zuck, S				Kashikar-Zuck, S			Treatment of children with unexplained chronic pain	LANCET			English	Editorial Material							PRIMARY FIBROMYALGIA SYNDROME; RANDOMIZED CONTROLLED-TRIALS; FUNCTIONAL DISABILITY; PEDIATRIC PAIN; INTERVENTION; METAANALYSIS; DEPRESSION; THERAPY		Childrens Hosp, Med Ctr, Div Behav Med & Clin Psychol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Kashikar-Zuck, S (corresponding author), Childrens Hosp, Med Ctr, Div Behav Med & Clin Psychol, Cincinnati, OH 45229 USA.	Susmita.Kashikar-Zuck@cchmc.org						Chambers CT, 2003, PROG PAIN RES MANAG, V26, P99; Eccleston C, 2002, PAIN, V99, P157, DOI 10.1016/S0304-3959(02)00072-6; Gatchel RJ, 1996, PSYCHOL APPROACHES P; Kashikar-Zuck S, 2005, J RHEUMATOL, V32, P1594; Kashikar-Zuck S, 2001, CLIN J PAIN, V17, P341, DOI 10.1097/00002508-200112000-00009; Kashikar-Zuck S, 2002, J PAIN, V3, P412, DOI 10.1054/jpai.2002.126786; Konijnenberg AY, 2005, ARCH DIS CHILD, V90, P680, DOI 10.1136/adc.2004.056820; Morley S, 1999, PAIN, V80, P1, DOI 10.1016/S0304-3959(98)00255-3; Perquin CW, 2001, PAIN, V94, P205, DOI 10.1016/S0304-3959(01)00355-4; Robins PM, 2005, J PEDIATR PSYCHOL, V30, P397, DOI 10.1093/jpepsy/jsi063	10	24	24	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 4	2006	367	9508					380	382		10.1016/S0140-6736(06)68118-X	http://dx.doi.org/10.1016/S0140-6736(06)68118-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458749				2023-01-03	WOS:000235139400010
J	Quill, TE; Meier, DE				Quill, TE; Meier, DE			The big chill - Inserting the DEA into end-of-life care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PAIN MANAGEMENT		Univ Rochester, Sch Med, Ctr Palliat Care & Clin Eth, Rochester, NY 14627 USA; Mt Sinai Sch Med, Lilian & Benjamin Hertzberg Palliat Care Inst, New York, NY USA; Mt Sinai Sch Med, Ctr Adv Palliat Care, New York, NY USA	University of Rochester; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Quill, TE (corresponding author), Univ Rochester, Sch Med, Ctr Palliat Care & Clin Eth, Rochester, NY 14627 USA.							Drayer RA, 1999, J PAIN SYMPTOM MANAG, V17, P434, DOI 10.1016/S0885-3924(99)00022-6; Field MJ, 1997, APPROACHING DEATH IM; Gilson AM, 2005, HEALTH POLICY, V74, P192, DOI 10.1016/j.healthpol.2005.01.004; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; Tucker KL, 2004, PAIN MED, V5, P214, DOI 10.1111/j.1526-4637.2004.4029_2.x	5	21	22	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 5	2006	354	1					1	3		10.1056/NEJMp058289	http://dx.doi.org/10.1056/NEJMp058289			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	998ZO	16394295				2023-01-03	WOS:000234358600001
J	Howard, BV; Manson, JE; Stefanick, ML; Beresford, SA; Frank, G; Jones, BT; Rodabough, RJ; Snetselaar, L; Thomson, C; Tinker, L; Vitolins, M; Prentice, R				Howard, BV; Manson, JE; Stefanick, ML; Beresford, SA; Frank, G; Jones, BT; Rodabough, RJ; Snetselaar, L; Thomson, C; Tinker, L; Vitolins, M; Prentice, R			Low-fat dietary pattern and weight change over 7 years - The Women's Health Initiative Dietary Modification Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONGITUDINAL DATA-ANALYSIS; LOW-CARBOHYDRATE-DIET; RANDOMIZED-TRIAL; BODY-WEIGHT; NUTRITION; RISK; PREVENTION; GUIDELINES; CALORIE; CANCER	Context Obesity in the United States has increased dramatically during the past several decades. There is debate about optimum calorie balance for prevention of weight gain, and proponents of some low-carbohydrate diet regimens have suggested that the increasing obesity may be attributed, in part, to low-fat, high-carbohydrate diets. Objectives To report data on body weight in a long-term, low-fat diet trial for which the primary end points were breast and colorectal cancer and to examine the relationships between weight changes and changes in dietary components. Design, Setting, and Participants Randomized intervention trial of 48835 postmenopausal women in the United States who were of diverse backgrounds and ethnicities and participated in the Women's Health Initiative Dietary Modification Trial; 40% (19 541) were randomized to the intervention and 60% (29 294) to a control group. Study enrollment was between 1993 and 1998, and this analysis includes a mean follow-up of 7.5 years (through August 31, 2004). Interventions The intervention included group and individual sessions to promote a decrease in fat intake and increases in vegetable, fruit, and grain consumption and did not include weight loss or caloric restriction goals. The control group received diet-related education materials. Main Outcome Measure Change in body weight from baseline to follow-up. Results Women in the intervention group lost weight in the first year (mean of 2.2 kg, P<.001) and maintained lower weight than control women during an average 7.5 years of follow-up (difference, 1.9 kg, P<.001 at 1 year and 0.4 kg, P=.01 at 7.5 years). No tendency toward weight gain was observed in intervention group women overall or when stratified by age, ethnicity, or body mass index. Weight loss was greatest among women in either group who decreased their percentage of energy from fat. A similar but lesser trend was observed with increases in vegetable and fruit servings, and a nonsignificant trend toward weight loss occurred with increasing intake of fiber. Conclusion A low-fat eating pattern does not result in weight gain in postmenopausal women.	MedStar Res Inst, Washington, DC USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; Stanford Sch Med, Stanford, CA USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Calif Irvine, Orange, CA 92668 USA; Univ N Carolina, Sch Med & Publ Hlth, Durham, NC USA; Univ Iowa, Iowa City, IA USA; Univ Arizona, Dept Nutr Sci, Tucson, AZ USA; Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Stanford University; Fred Hutchinson Cancer Center; University of California System; University of California Irvine; University of North Carolina; University of Iowa; University of Arizona; Arizona Center Cancer Care; University of Arizona; Wake Forest University; Wake Forest Baptist Medical Center	Howard, BV (corresponding author), MedStar Res Inst, 6495 New Hampshire Ave,Suite 201, Hyattsville, MD 20783 USA.	Barbara.V.Howard@MedStar.net						Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Astrup A, 2002, P NUTR SOC, V61, P299, DOI 10.1079/PNS2002149; Atkins RC, 1998, ATKINS NEW DIET REVO; Bowen D, 2002, J AM DIET ASSOC, V102, P1631, DOI 10.1016/S0002-8223(02)90347-0; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Buchholz AC, 2004, AM J CLIN NUTR, V79, P899; Byers T, 2002, CA-CANCER J CLIN, V52, P92, DOI 10.3322/canjclin.52.2.92; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Franz MJ, 2002, DIABETES CARE, V25, P148, DOI 10.2337/diacare.25.1.148; Freedman MR, 2001, OBES RES, V9, p1S, DOI 10.1038/oby.2001.113; Hall WD, 2003, ETHNIC DIS, V13, P337; Krauss RM, 2000, CIRCULATION, V102, P2284; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; McManus K, 2001, INT J OBESITY, V25, P1503, DOI 10.1038/sj.ijo.0801796; *NAT CTR HLTH STAT, 2004, HLTH US; Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6; Ritenbaugh C, 2003, ANN EPIDEMIOL, V13, pS87, DOI 10.1016/S1047-2797(03)00044-9; ROBINS JM, 1994, J AM STAT ASSOC, V89, P846, DOI 10.2307/2290910; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; SEARS B, 1995, ZONE DIET DIETARY RO; STEWARD HL, 1995, SUGAR BUSTERS; Subar AF, 2003, AM J EPIDEMIOL, V158, P1, DOI 10.1093/aje/kwg092; Thomson CA, 2005, EUR J NUTR, V44, P18, DOI 10.1007/s00394-004-0487-x; Tinker Lesley Fels, 1996, P510; *USDA, 1995, HOM GARD B, V232; *USDA, 1990, HOM GARD B, V232; Wadden TA, 2004, OBES RES, V12, p151S, DOI 10.1038/oby.2004.282; Wang CY, 1999, BIOMETRICS, V55, P711, DOI 10.1111/j.0006-341X.1999.00711.x; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	32	303	308	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	2006	295	1					39	49		10.1001/jama.295.1.39	http://dx.doi.org/10.1001/jama.295.1.39			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	999HT	16391215	Bronze			2023-01-03	WOS:000234381100019
J	Petri, M; Kim, MY; Kalunian, KC; Grossman, J; Hahn, BH; Sammaritano, LR; Lockshin, M; Merrill, JT; Belmont, HM; Askanase, AD; McCune, WJ; Hearth-Holmes, M; Dooley, MA; Von Feldt, J; Friedman, A; Tan, M; Davis, J; Cronin, M; Diamond, B; Mackay, M; Sigler, L; Fillius, M; Rupel, A; Licciardi, F; Buyon, JP				Petri, M; Kim, MY; Kalunian, KC; Grossman, J; Hahn, BH; Sammaritano, LR; Lockshin, M; Merrill, JT; Belmont, HM; Askanase, AD; McCune, WJ; Hearth-Holmes, M; Dooley, MA; Von Feldt, J; Friedman, A; Tan, M; Davis, J; Cronin, M; Diamond, B; Mackay, M; Sigler, L; Fillius, M; Rupel, A; Licciardi, F; Buyon, JP		OC-SELENA Trial	Combined oral contraceptives in women with systemic lupus erythematosus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE-ACTIVITY; UNITED-STATES; ESTROGEN; THERAPY; CLASSIFICATION; OSTEOPOROSIS; FREQUENCY; TRIAL; RISK; SLE	BACKGROUND: Oral contraceptives are rarely prescribed for women with systemic lupus erythematosus, because of concern about potential negative side effects. In this double-blind, randomized, noninferiority trial, we prospectively evaluated the effect of oral contraceptives on lupus activity in premenopausal women with systemic lupus erythematosus. METHODS: A total of 183 women with inactive (76 percent) or stable active (24 percent) systemic lupus erythematosus at 15 U.S. sites were randomly assigned to receive either oral contraceptives (triphasic ethinyl estradiol at a dose of 35 microg plus norethindrone at a dose of 0.5 to 1 mg for 12 cycles of 28 days each; 91 women) or placebo (92 women) and were evaluated at months 1, 2, 3, 6, 9, and 12. Subjects were excluded if they had moderate or high levels of anticardiolipin antibodies, lupus anticoagulant, or a history of thrombosis. RESULTS: The primary end point, a severe lupus flare, occurred in 7 of 91 subjects receiving oral contraceptives (7.7 percent) as compared with 7 of 92 subjects receiving placebo (7.6 percent). The 12-month rates of severe flare were similar: 0.084 for the group receiving oral contraceptives and 0.087 for the placebo group (P=0.95; upper limit of the one-sided 95 percent confidence interval for this difference, 0.069, which is within the prespecified 9 percent margin for noninferiority). Rates of mild or moderate flares were 1.40 flares per person-year for subjects receiving oral contraceptives and 1.44 flares per person-year for subjects receiving placebo (relative risk, 0.98; P=0.86). In the group that was randomized to receive oral contraceptives, there was one deep venous thrombosis and one clotted graft; in the placebo group, there was one deep venous thrombosis, one ocular thrombosis, one superficial thrombophlebitis, and one death (after cessation of the trial). CONCLUSIONS: Our study indicates that oral contraceptives do not increase the risk of flare among women with systemic lupus erythematosus whose disease is stable.	NYU, Hosp Joint Dis, Sch Med, Dept Rheumatol, New York, NY 10003 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Hosp Special Surg, New York, NY 10021 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; NYU, Sch Med, Bellevue Hosp, New York, NY USA; Univ Michigan, Ann Arbor, MI 48109 USA; Louisiana State Univ, Hlth Sci Ctr, Shreveport, LA 71105 USA; Univ N Carolina, Chapel Hill, NC USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Texas, Houston, TX USA; Rheumatol Associates Long Isl, Port Jefferson Stn, NY USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; Johns Hopkins University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California Los Angeles; Oklahoma Medical Research Foundation; Bellevue Hospital Center; New York University; University of Michigan System; University of Michigan; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; University of Texas System; University of California System; University of California San Francisco; Medical College of Wisconsin	Buyon, JP (corresponding author), NYU, Hosp Joint Dis, Sch Med, Dept Rheumatol, Rm 1608,301 E 17th St, New York, NY 10003 USA.	jill.buyon@nyumc.org	Kalunian, Kenneth/L-4471-2019; Kalunian, Kenneth/AAK-6424-2020	Buyon, Jill/0000-0002-3852-7129; Kalunian, Kenneth/0000-0003-0261-3102; Licciardi, Frederick/0000-0002-2186-5981; Belmont, Howard/0000-0003-3389-2976	NCRR NIH HHS [M01-RR 00096, M01-RR 00052] Funding Source: Medline; NIAID NIH HHS [R01 AI062069] Funding Source: Medline; NIAMS NIH HHS [AR 43727, U01 AR42540] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI062069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043727, U01AR042540, R55AR043727] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Buyon J P, 1995, J Clin Rheumatol, V1, P205, DOI 10.1097/00124743-199508000-00002; Buyon JP, 2005, ANN INTERN MED, V142, P953, DOI 10.7326/0003-4819-142-12_Part_1-200506210-00004; Cooper GS, 2002, ARTHRITIS RHEUM, V46, P1830, DOI 10.1002/art.10365; FINE LG, 1981, ANN INTERN MED, V94, P667, DOI 10.7326/0003-4819-94-5-667; GALLAGHER JC, 1980, J CLIN ENDOCR METAB, V51, P1359, DOI 10.1210/jcem-51-6-1359; Grimaldi CM, 2002, J CLIN INVEST, V109, P1625, DOI 10.1172/JCI200214873; Hochberg MC, 1996, ARTHRITIS RHEUM-US, V39, P1791; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; JULKUNEN HA, 1991, SCAND J RHEUMATOL, V20, P427, DOI 10.3109/03009749109096822; JUNGERS P, 1982, ARTHRITIS RHEUM, V25, P618, DOI 10.1002/art.1780250603; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LAHITA RG, 1982, ARTHRITIS RHEUM, V25, P843, DOI 10.1002/art.1780250726; MASI AT, 1978, ARTHRITIS RHEUM-US, V21, P480, DOI 10.1002/art.1780210413; PACIFICI R, 1989, P NATL ACAD SCI USA, V86, P2398, DOI 10.1073/pnas.86.7.2398; Petri M, 1997, ARTHRITIS RHEUM, V40, P797, DOI 10.1002/art.1780400504; Petri M, 1995, Arthritis Care Res, V8, P137, DOI 10.1002/art.1790080305; Petri M, 1999, LUPUS, V8, P685, DOI 10.1191/096120399680411281; Ramsey-Goldman R, 1999, ARTHRITIS RHEUM, V42, P882, DOI 10.1002/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C; Rosenberg MJ, 1998, AM J OBSTET GYNECOL, V179, P577, DOI 10.1016/S0002-9378(98)70047-X; ROUBINIAN J, 1979, ARTHRITIS RHEUM, V22, P1162; SanchezGuerrero J, 1997, ARTHRITIS RHEUM, V40, P804, DOI 10.1002/art.1780400505; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TRUSSELL J, 1987, STUD FAMILY PLANN, V18, P237, DOI 10.2307/1966856	25	721	756	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	2005	353	24					2550	2558		10.1056/NEJMoa051135	http://dx.doi.org/10.1056/NEJMoa051135			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	993BA	16354891	Green Published, Bronze			2023-01-03	WOS:000233926500004
J	Fan, E; Needham, DM; Stewart, TE				Fan, E; Needham, DM; Stewart, TE			Ventilatory management of acute lung injury and acute respiratory distress syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							INHALED NITRIC-OXIDE; FREQUENCY OSCILLATORY VENTILATION; TIDAL VOLUME VENTILATION; QUALITY-OF-LIFE; MECHANICAL VENTILATION; PROTECTIVE-VENTILATION; RECRUITMENT MANEUVERS; SYNDROME ARDS; GAS-EXCHANGE; TRIAL	Context The acute lung injury and acute respiratory distress syndrome are critical illnesses associated with significant morbidity and mortality. Mechanical ventilation is the cornerstone of supportive therapy. However, despite several important advances, the optimal strategy for ventilation and adjunctive therapies for patients with acute lung injury and acute respiratory distress syndrome is still evolving. Evidence Acquisition To identify reports of invasive ventilatory and adjunctive therapies in adult patients with acute lung injury and acute respiratory distress syndrome, we performed a systematic English-language literature search of MEDLINE (19662005) using the Medical Subject Heading respiratory distress syndrome, adult, and related text words, with emphasis on randomized controlled trials and meta-analyses. EMBASE and the Cochrane Central Register of Controlled Trials were similarly searched. The search yielded 1357 potential articles of which 53 were relevant to the study objectives and considered in this review. Evidence Synthesis There is strong evidence to support the use of volume- and pressure-limited lung-protective ventilation in adult patients with acute lung injury and acute respiratory distress syndrome. The benefit of increased levels of positive end-expiratory pressure and recruitment maneuvers is uncertain and is being further evaluated in ongoing trials. Existing randomized controlled trials of alternative ventilation modes, such as high-frequency oscillation and adjunctive therapies, including inhaled nitric oxide and prone positioning demonstrate no significant survival advantage. However, they may have a role as rescue therapy for patients with acute respiratory distress syndrome with refractory life-threatening hypoxemia. Conclusions Volume- and pressure-limited ventilation strategies should be used in managing adult acute lung injury and acute respiratory distress syndrome patients. Further research is needed to identify barriers to widespread adoption of this strategy, as well as the role of alternative ventilation modes and adjunctive therapies.	Mt Sinai Hosp, Univ Hlth Network, Toronto, ON M5G 1X5, Canada; Univ Toronto, Interdepartmental Div Crit Care Med, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University Health Network Toronto; University of Toronto; University of Toronto; Johns Hopkins University	Stewart, TE (corresponding author), Mt Sinai Hosp, Univ Hlth Network, 600 Univ Ave,Suite 18-206, Toronto, ON M5G 1X5, Canada.	tstewart@mtsinai.on.ca			NHLBI NIH HHS [P050 HL 73994-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL073994] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; *AM THOR SOC, 1999, AM J RESP CRIT CARE, V160, P2118; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; ARDS Clinical Trials Network, 2003, CRIT CARE MED, V31, P2592, DOI 10.1097/01.CCM.0000090001.91640.45; ASHBAUGH DG, 1967, LANCET, V2, P319; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bollen CW, 2005, CRIT CARE, V9, pR430, DOI 10.1186/cc3737; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2002, AM J RESP CRIT CARE, V166, P1515, DOI 10.1164/ajrccm.166.11.340; BROWER RG, 2004, AM J RESP CRIT CARE, V169, pA17; BRYAN AC, 1974, AM REV RESPIR DIS, V110, P143; Cakar N, 2002, CRIT CARE MED, V30, P2103, DOI 10.1097/00003246-200209000-00025; Crimi Ettore, 2004, Best Pract Res Clin Anaesthesiol, V18, P477, DOI 10.1016/S1521-6896(03)00121-6; Davidson TA, 1999, JAMA-J AM MED ASSOC, V281, P354, DOI 10.1001/jama.281.4.354; Dellinger RP, 1998, CRIT CARE MED, V26, P15, DOI 10.1097/00003246-199801000-00011; Derdak S, 2002, AM J RESP CRIT CARE, V166, P801, DOI 10.1164/rccm.2108052; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1510, DOI 10.1164/rccm.200208-956OC; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2004, ANN INTERN MED, V141, P440, DOI 10.7326/0003-4819-141-6-200409210-00009; Fan Eddy, 2005, Crit Care Med, V33, pS182, DOI 10.1097/01.CCM.0000155927.54034.34; Ferguson ND, 2005, CRIT CARE MED, V33, P479, DOI 10.1097/01.CCM.0000155785.23200.9E; Ferguson ND, 2004, INTENS CARE MED, V30, P1111, DOI 10.1007/s00134-004-2163-2; Foti G, 2000, INTENS CARE MED, V26, P501, DOI 10.1007/s001340051196; Frutos-Vivar Fernando, 2004, Curr Opin Crit Care, V10, P1, DOI 10.1097/00075198-200402000-00001; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; Gattinoni L, 2001, AM J RESP CRIT CARE, V164, P1701, DOI 10.1164/ajrccm.164.9.2103121; Gattinoni L, 2005, INTENS CARE MED, V31, P776, DOI 10.1007/s00134-005-2627-z; Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031; Gattinoni L., 1987, INTENSIVE CRIT CARE, V6, P1; Guerin C, 2004, JAMA-J AM MED ASSOC, V292, P2379, DOI 10.1001/jama.292.19.2379; Habashi Nader M, 2005, Crit Care Med, V33, pS228, DOI 10.1097/01.CCM.0000155920.11893.37; Hager DN, 2005, AM J RESP CRIT CARE, V172, P1241, DOI 10.1164/rccm.200501-048CP; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Imai Yumiko, 2005, Crit Care Med, V33, pS129, DOI 10.1097/01.CCM.0000156793.05936.81; Kahn JM, 2005, CRIT CARE MED, V33, P766, DOI 10.1097/01.CCM.0000157786.41506.24; Kallet RH, 2005, CRIT CARE MED, V33, P925, DOI 10.1097/01.CCM.0000162382.59289.9C; Laffey JG, 2004, INTENS CARE MED, V30, P347, DOI 10.1007/s00134-003-2051-1; Lapinsky SE, 1999, INTENS CARE MED, V25, P1297, DOI 10.1007/s001340051061; Lapinsky SE, 2005, CRIT CARE, V9, P60, DOI 10.1186/cc2934; Levy MM, 2004, NEW ENGL J MED, V351, P389, DOI 10.1056/NEJMe048103; Lim SC, 2004, CRIT CARE MED, V32, P2371, DOI 10.1097/01.CCM.0000147445.73344.3A; Lundin S, 1999, INTENS CARE MED, V25, P911, DOI 10.1007/s001340050982; Mancebo J, 2003, INTENS CARE MED, V29, pS64; Marini JJ, 2004, CRIT CARE MED, V32, P250, DOI 10.1097/01.CCM.0000104946.66723.A8; Meade MO, 2001, AM J RESP CRIT CARE, V165, pA683; Medoff BD, 2005, NEW ENGL J MED, V352, P2425, DOI 10.1056/NEJMcpc059012; Mehta S, 2004, CHEST, V126, P518, DOI 10.1378/chest.126.2.518; MEHTA S, 2001, J APPL RES, V1, P73; Michael JR, 1998, AM J RESP CRIT CARE, V157, P1372, DOI 10.1164/ajrccm.157.5.96-10089; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; Moran JL, 2005, INTENS CARE MED, V31, P227, DOI 10.1007/s00134-004-2506-z; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Pelosi P, 1999, AM J RESP CRIT CARE, V159, P872, DOI 10.1164/ajrccm.159.3.9802090; Pelosi P, 2003, EUR RESPIR J, V22, p48S, DOI 10.1183/09031936.03.00420803; Pelosi P, 2002, EUR RESPIR J, V20, P1017, DOI 10.1183/09031936.02.00401702; Petrucci N, 2004, ANESTH ANALG, V99, P193, DOI 10.1213/01.ANE.0000118102.93688.97; PETTY TL, 1971, CHEST, V60, P233, DOI 10.1378/chest.60.3.233; Plotz FB, 2004, INTENS CARE MED, V30, P1865, DOI 10.1007/s00134-004-2363-9; Ritacca FV, 2003, CRIT CARE, V7, P385, DOI 10.1186/cc2182; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; Rubenfeld GD, 1999, CHEST, V116, P1347, DOI 10.1378/chest.116.5.1347; Rubenfeld GD, 2004, CRIT CARE MED, V32, P1289, DOI 10.1097/01.CCM.0000127266.39560.96; Rubenfeld GD, 2003, CRIT CARE MED, V31, pS276, DOI 10.1097/01.CCM.0000057904.62683.2B; Santos C, 2000, AM J RESP CRIT CARE, V161, P26, DOI 10.1164/ajrccm.161.1.9902084; SHAPIRO BA, 1980, CHEST, V77, P138, DOI 10.1378/chest.77.2.138; Slutsky AS, 1999, CHEST, V116, p9S, DOI 10.1378/chest.116.suppl_1.9S-a; Sokol J, 2003, ANESTH ANALG, V97, P989, DOI [10.1213/01.ANE.0000078819.48523.26, 10.1213/01.ANE.0000078819.45523.26]; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Taylor RW, 2004, JAMA-J AM MED ASSOC, V291, P1603, DOI 10.1001/jama.291.13.1603; Tremblay LN, 1998, P ASSOC AM PHYSICIAN, V110, P482; Troncy E, 1998, AM J RESP CRIT CARE, V157, P1483, DOI 10.1164/ajrccm.157.5.9707090; Weinert CR, 2003, AM J RESP CRIT CARE, V167, P1304, DOI 10.1164/rccm.200205-478OC; Young MP, 2004, CRIT CARE MED, V32, P1260, DOI 10.1097/01.CCM.0000127784.54727.56	79	131	142	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	2005	294	22					2889	2896		10.1001/jama.294.22.2889	http://dx.doi.org/10.1001/jama.294.22.2889			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	991PU	16352797	Bronze			2023-01-03	WOS:000233826700030
J	McCormick, F				McCormick, F			Future prospects for oncolytic therapy	ONCOGENE			English	Review						oncolytic viruses; adenovirus; targeted therapy; oncology	AGENTS; POTENT	Viruses have been engineered to replicate selectively in cancer cells, based on a number of innovative principles. Several of these viruses have entered clinical trials and have proven relatively safe, and have shown evidence of efficacy. However, further research is required to enable these agents to function systemically. This might involve attempts to suppress immune responses to virus antigens, and re-targeting of viruses to favor tumor infection and increased potency. When these barriers are overcome, oncolytic viruses could enter the mainstream of clinical oncology.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	McCormick, F (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94115 USA.	mccormick@cc.ucsf.edu						Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; Ko D, 2005, ONCOGENE, V24, P7763, DOI 10.1038/sj.onc.1209048; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; Nemunaitis J, 2002, CANCER GENE THER, V9, P987, DOI 10.1038/sj.cgt.7700547; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Reid T, 2001, GENE THER, V8, P1618, DOI 10.1038/sj.gt.3301512; Reid T, 2002, CANCER GENE THER, V9, P979, DOI 10.1038/sj.cgt.7700539; YU C, 2001, CANCER RES, V61, P5453	11	35	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2005	24	52					7817	7819		10.1038/sj.onc.1209064	http://dx.doi.org/10.1038/sj.onc.1209064			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299540	Bronze			2023-01-03	WOS:000233372600016
J	Kalivas, PW				Kalivas, PW			How do we determine which drug-induced neuroplastic changes are important?	NATURE NEUROSCIENCE			English	Editorial Material							SYNAPTIC PLASTICITY; DELTA-FOSB; ADDICTION; COCAINE; MOTIVATION; MECHANISMS; SENSITIZATION; PATHOLOGY; ABUSE	Although many drug-induced neural changes are known, progress has been slow in identifying the ones that actually mediate addiction. Identifying changes that are specific to particular elements of the transition from initial to habitual to relapsing drug use may be a fruitful strategy for pinpointing which forms of drug-induced plasticity are critical for addiction.	Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA	Medical University of South Carolina	Kalivas, PW (corresponding author), Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.	kalivasp@musc.edu						Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872; Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069; Baptista MAS, 2004, J NEUROSCI, V24, P4723, DOI 10.1523/JNEUROSCI.0176-04.2004; Canales JJ, 2005, NEUROBIOL LEARN MEM, V83, P93, DOI 10.1016/j.nlm.2004.10.006; Carlezon WA, 2002, TRENDS NEUROSCI, V25, P610, DOI 10.1016/S0166-2236(02)02289-0; Jones S, 2005, CURR OPIN PHARMACOL, V5, P20, DOI 10.1016/j.coph.2004.08.011; Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005; Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403; Kauer JA, 2004, ANNU REV PHYSIOL, V66, P447, DOI 10.1146/annurev.physiol.66.032102.112534; Keitz M., 2003, Neural Plasticity, V10, P121, DOI 10.1155/NP.2003.121; Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016; Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI 10.1016/j.neubiorev.2003.11.007; Lu L, 2005, NAT NEUROSCI, V8, P212, DOI 10.1038/nn1383; Mackler SA, 2000, J NEUROSCI, V20, P6210, DOI 10.1523/JNEUROSCI.20-16-06210.2000; McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143; Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698; Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237; SZUMLINSKI KK, 2005, NEUROPSYCHOPHAR 0914; Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975; Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406	20	54	55	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1097-6256			NAT NEUROSCI	Nat. Neurosci.	NOV	2005	8	11					1440	1441		10.1038/nn1105-1440	http://dx.doi.org/10.1038/nn1105-1440			2	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	979TB	16251984				2023-01-03	WOS:000232966600012
J	Aikins, AD				Aikins, AD			Healer shopping in Africa: new evidence from rural-urban qualitative study of Ghanaian diabetes experiences	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DISEASES; CARE	Objectives To provide counterevidence to existing literature on healer shopping in Africa through a systematic analysis of illness practices by Ghanaians with diabetes; to outline approaches towards improving patient centred health care and policy development regarding diabetes in Ghana. Design Longitudinal qualitative study with individual interviews, group interviews, and ethnographies. Settings Two urban towns (Accra, Tema) and two rural towns (Nkoranza and Kintampo) in Ghana. Participants 26 urban people and 41 rural people with diabetes with diverse profiles (sex, age, education, socioeconomic status, diabetes status). Results Six focus groups, 20 interviews, and three ethnographical studies were conducted to explore experiences and illness practices. Analysis identified four kinds of illness practice: biomedical management, spiritual action, cure seeking (passive and active), and medical inaction. Most participants privileged biomedicine over other health systems and emphasised biomedical management as ideal self care practice. However, the psychosocial impact of diabetes and the high cost of biomedical care drove cure seeking and medical inaction. Cure seeking constituted healer shopping between biomedicine, ethnomedicine, and faith healing; medical inaction constituted passive disengagement from medical management and active engagement with faith healing. Crucially, although spiritual causal theories of diabetes existed, they were secondary to dietary, lifestyle, and physiological theories and did not constitute the primary motivation for cure seeking. Cure seeking within unregulated ethnomedical systems and non-pharmacological faith healing systems exacerbated the complications of diabetes. Conclusions To minimise inappropriate healer shopping and maximise committed biomedical and regulated ethnomedical management for Ghanaians with diabetes, the greatest challenges lie in providing affordable pharmaceutical drugs, standardised ethnomedical drugs, recommended foods, and psychosocial support. For health systems, the greatest challenges lie in correcting structural deficiencies that impinge on biomedical practices, regulating ethnomedical diabetes treatment, and foregrounding faith healer practices within diabetes policy discussions.	Univ Cambridge, Fac Social & Polit Sci, Dept Social & Dev Psychol, Cambridge CB2 3RQ, England	University of Cambridge	Aikins, AD (corresponding author), Univ Cambridge, Fac Social & Polit Sci, Dept Social & Dev Psychol, Cambridge CB2 3RQ, England.	ada21@cam.ac.uk						Aikins AD, 2002, SOC SCI INFORM, V41, P625, DOI 10.1177/0539018402041004007; AIKINS AD, 2004, THESIS LONDON SCH EC; Aikins ADG, 2004, J HEALTH PSYCHOL, V9, P295, DOI 10.1177/1359105304040895; Aikins ADG, 2003, J HEALTH PSYCHOL, V8, P557, DOI 10.1177/13591053030085007; Amoah AGB, 2002, DIABETES RES CLIN PR, V56, P197, DOI 10.1016/S0168-8227(01)00374-6; Bediako K, 2000, AFR AFFAIRS, V99, P303, DOI 10.1093/afraf/99.395.303; De Jong J., 1991, TRADITIONAL MED SUBS; DEJONG J, 1909, TRADITIONAL MED SUBS; GASKELL G, 2000, QUALITATIVE RES TEXT, V39; *GOV GHAN MIN HLTH, 2001, HLTH NAT AN HLTH SEC; GREEN EC, 1992, SOC SCI MED, V35, P121, DOI 10.1016/0277-9536(92)90159-N; KIRBY JP, 1993, SOC SCI MED, V36, P237, DOI 10.1016/0277-9536(93)90007-Q; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; Krause M, 2003, J HEALTH PSYCHOL, V8, P599, DOI 10.1177/13591053030085010; KRIPPENDORFF K, 1980, CONTENT ANAL; KROEGER A, 1983, SOC SCI MED, V17, P147, DOI 10.1016/0277-9536(83)90248-4; *MON EV TEAM, 1998, FORM BAS RES DIAB ME; Moscovici S., 2001, SOCIAL REPRESENTATIO, P18; NKWI PN, 1994, J DIARRHOEAL DIS RES, V12, P35; NYAMWAYA D, 1987, SOC SCI MED, V25, P1277, DOI 10.1016/0277-9536(87)90126-2; OFEI F, 1996, SELF CARE BEHAV GHAN; OFEI F, 1996, UNPUB SELF CARE BEHA; Rekdal OB, 1999, MED ANTHROPOL Q, V13, P458, DOI 10.1525/maq.1999.13.4.458; ROSENTHAL K, 1995, SEMIN AVIAN EXOT PET, V4, P1; Ryan GW, 1998, SOC SCI MED, V46, P209, DOI 10.1016/S0277-9536(97)00151-2; SILVERMAN D, 2001, INTERPRETING QUALITA, V70; Unwin N, 2001, B WORLD HEALTH ORGAN, V79, P947; Valente TW, 1997, SOC SCI MED, V45, P677, DOI 10.1016/S0277-9536(96)00385-1	28	113	114	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2005	331	7519					737	742		10.1136/bmj.331.7519.737	http://dx.doi.org/10.1136/bmj.331.7519.737			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971XB	16195290	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000232417100020
J	Onwuteaka-Philipsen, BD; van der Heide, A; Muller, MT; Rurup, M; Rietjens, JAC; Georges, JJ; Vrakking, AM; Cuperus-Bosma, JM; van der Wal, G; van der Maas, PJ				Onwuteaka-Philipsen, BD; van der Heide, A; Muller, MT; Rurup, M; Rietjens, JAC; Georges, JJ; Vrakking, AM; Cuperus-Bosma, JM; van der Wal, G; van der Maas, PJ			Dutch experience of monitoring euthanasia	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; NETHERLANDS; ATTITUDES; DEATH		Vrije Univ Amsterdam Med Ctr, Inst Res Extramural Med, Dept Publ & Occupat Hlth, NL-1081 BT Amsterdam, Netherlands; Erasmus MC, Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Erasmus University Rotterdam; Erasmus MC	Onwuteaka-Philipsen, BD (corresponding author), Vrije Univ Amsterdam Med Ctr, Inst Res Extramural Med, Dept Publ & Occupat Hlth, NL-1081 BT Amsterdam, Netherlands.	b.philipsen@vumc.nl						*BOARD ROYAL DUTCH, 2003, CONC EUTH; Dyer Owen, 2003, BMJ, V327, P1186; Emanuel EJ, 2002, ARCH INTERN MED, V162, P142, DOI 10.1001/archinte.162.2.142; Forde R, 1997, SOC SCI MED, V45, P887, DOI 10.1016/S0277-9536(96)00430-3; Gordijn B, 2004, HEALTH CARE ANAL, V12, P195, DOI 10.1023/B:HCAN.0000044926.05523.ef; Hedberg K, 2003, NEW ENGL J MED, V348, P961, DOI 10.1056/NEJM200303063481022; Huxtable R, 2004, BRIT MED J, V328, P1088, DOI 10.1136/bmj.328.7448.1088; Kirschner R, 1998, Gesundheitswesen, V60, P247; Onwuteaka-Philipsen BD, 2003, LANCET, V362, P395, DOI 10.1016/S0140-6736(03)14029-9; *REG REV COMM EUTH, 2004, ANN REP 2003; Rietjens JAC, 2004, ANN INTERN MED, V141, P178, DOI 10.7326/0003-4819-141-3-200408030-00006; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; van der Wal G, 2003, MED DECISION MAKING; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; WATSON R, 2001, BRIT MED J, V323, P1024; Weide MCJVD, 2004, HEALTH POLICY, V69, P365, DOI 10.1016/j.healthpol.2004.04.010	17	24	25	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 24	2005	331	7518					691	693		10.1136/bmj.331.7518.691	http://dx.doi.org/10.1136/bmj.331.7518.691			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970HH	16179708	Green Published			2023-01-03	WOS:000232295400025
J	Zietman, AL; DeSilvio, ML; Slater, JD; Rossi, CJ; Miller, DW; Adams, JA; Shipley, WU				Zietman, AL; DeSilvio, ML; Slater, JD; Rossi, CJ; Miller, DW; Adams, JA; Shipley, WU			Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXTERNAL-BEAM RADIOTHERAPY; RADICAL PROSTATECTOMY; ANTIGEN LEVELS; CANCER; IRRADIATION; CARCINOMA; GY; ESCALATION; GUIDELINES; BIOPSY	Context Clinically localized prostate cancer is very prevalent among US men, but recurrence after treatment with conventional radiation therapy is common. Objective To evaluate the hypothesis that increasing the radiation dose delivered to men with clinically localized prostate cancer improves disease outcome. Design, Setting, and Patients Randomized controlled trial of 393 patients with stage T1b through T2b prostate cancer and prostate-specific antigen (PSA) levels less than 15 ng/mL randomized between January 1996 and December 1999 and treated at 2 US academic institutions. Median age was 67 years and median PSA level was 6.3 ng/mL. Median follow-up was 5.5 (range, 1.2-8.2) years. Intervention Patients were randomized to receive external beam radiation to a total dose of either 70.2 Gy (conventional dose) or 79.2 Gy (high dose). This was delivered using a combination of conformal photon and proton beams. Main Outcome Measure Increasing PSA level (ie, biochemical failure) 5 years after treatment. Results The proportions of men free from biochemical failure at 5 years were 61.4% (95% confidence interval, 54.6%-68.3%) for conventional-dose and 80.4% (95% confidence interval, 74.7%-86.1%) for high-dose therapy (P<.001), a 49% reduction in the risk of failure. The advantage to high-dose therapy was observed in both the low-risk and the higher-risk subgroups (risk reduction, 51% [P<.001] and 44% [P=.03], respectively). There has been no significant difference in overall survival rates between the treatment groups. Only 1% of patients receiving conventional-dose and 2% receiving high-dose radiation experienced acute urinary or rectal morbidity of Radiation Therapy Oncology Group (RTOG) grade 3 or greater. So far, only 2% and 1%, respectively, have experienced late morbidity of RTOG grade 3 or greater. Conclusions Men with clinically localized prostate cancer have a lower risk of biochemical failure if they receive high-dose rather than conventional-dose conformal radiation. This advantage was achieved without any associated increase in RTOG grade 3 acute or late urinary or rectal morbidity.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA; Loma Linda Univ, Med Ctr, Loma Linda, CA USA; Amer Coll Radiol, Philadelphia, PA USA; Radiat Therapy Oncol Grp, Philadelphia, PA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Loma Linda University; American College of Radiology; Radiation Therapy Oncology Group (RTOG)	Zietman, AL (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA.	azietman@partners.org			NCI NIH HHS [P01 CA21239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA021239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cooperberg MR, 2004, J UROLOGY, V171, P1393, DOI 10.1097/01.ju.0000107247.81471.06; Cox JD, 1999, J CLIN ONCOL, V17, P1155; Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035; Crook JM, 1997, CANCER, V79, P81, DOI 10.1002/(SICI)1097-0142(19970101)79:1<81::AID-CNCR12>3.3.CO;2-I; D'Amico AV, 2002, INT J RADIAT ONCOL, V54, P436, DOI 10.1016/S0360-3016(02)02940-1; DUGAN TC, 1991, J UROLOGY, V146, P1313, DOI 10.1016/S0022-5347(17)38077-1; Gottschalk AR, 2004, BRIT J CANCER, V90, P950, DOI 10.1038/sj.bjc.6601625; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Gretzer MB, 2002, J UROLOGY, V168, P1419, DOI 10.1016/S0022-5347(05)64464-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KUPELIAN P, 2002, INT J RADIAT ONCOL, V58, P25; Kupelian PA, 2004, INT J RADIAT ONCOL, V58, P25, DOI 10.1016/S0360-3016(03)00784-3; LAWTON CA, 1991, INT J RADIAT ONCOL, V21, P935, DOI 10.1016/0360-3016(91)90732-J; Lukka H., 2003, International Journal of Radiation Oncology Biology Physics, V57, pS126, DOI 10.1016/S0360-3016(03)00827-7; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Pollack A, 2000, J CLIN ONCOL, V18, P3904, DOI 10.1200/JCO.2000.18.23.3904; Pollack A, 2004, J UROLOGY, V171, P1132, DOI 10.1097/01.ju.0000111844.95024.74; Pollack A, 2002, INT J RADIAT ONCOL, V53, P1097, DOI 10.1016/S0360-3016(02)02829-8; Ryu JK, 2002, INT J RADIAT ONCOL, V54, P1036, DOI 10.1016/S0360-3016(02)03006-7; SHIPLEY WU, 1979, JAMA-J AM MED ASSOC, V241, P1912, DOI 10.1001/jama.241.18.1912; SHIPLEY WU, 1995, INT J RADIAT ONCOL, V32, P3, DOI 10.1016/0360-3016(95)00063-5; Slater JD, 1998, INT J RADIAT ONCOL, V42, P299, DOI 10.1016/S0360-3016(98)00225-9; Vicini FA, 1999, INT J RADIAT ONCOL, V45, P553, DOI 10.1016/S0360-3016(99)00235-7; Zelefsky MJ, 2004, INT J RADIAT ONCOL, V59, P1053, DOI 10.1016/j.ijrobp.2003.12.011; Zelefsky MJ, 2001, J UROLOGY, V166, P876, DOI 10.1016/S0022-5347(05)65855-7; Zelefsky MJ, 1998, INT J RADIAT ONCOL, V41, P491, DOI 10.1016/S0360-3016(98)00091-1; Zietman AL, 2004, J UROLOGY, V171, P210, DOI 10.1097/01.ju.0000100980.13364.a6	27	982	998	1	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	2005	294	10					1233	1239		10.1001/jama.294.10.1233	http://dx.doi.org/10.1001/jama.294.10.1233			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	963UI	16160131	Bronze			2023-01-03	WOS:000231831200020
J	Baxter, PJ				Baxter, PJ			Commentary: Evacuation decisions in chemical incidents benefit from expert health advice	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Cambridge, Dept Publ Hlth & Primary Care, Inst Publ Hlth, Cambridge CB2 2SR, England	University of Cambridge	Baxter, PJ (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Inst Publ Hlth, Cambridge CB2 2SR, England.	Pjb21@medschl.cam.ac.uk						BAXTER PJ, 1995, OCCUP ENVIRON MED, V52, P694, DOI 10.1136/oem.52.10.694; BAXTER PJ, 1990, INT C S SERIES, V155, P7; *DEP ENV FOOD RUR, 2005, GUID HAL HYDR HAL AM; *HLTH SAF EX, CONTR MAJ ACC HAZ CO; Kinra S, 2005, BMJ-BRIT MED J, V330, P1471, DOI 10.1136/bmj.330.7506.1471	5	2	2	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 25	2005	330	7506					1474	1475		10.1136/bmj.330.7506.1474	http://dx.doi.org/10.1136/bmj.330.7506.1474			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942NR	15976420	Green Published, Bronze			2023-01-03	WOS:000230289600016
J	Li, J; Laursen, TM; Precht, DH; Olsen, J; Mortensen, PB				Li, J; Laursen, TM; Precht, DH; Olsen, J; Mortensen, PB			Hospitalization for mental illness among parents after the death of a child	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE EVENTS; WOMEN; SCHIZOPHRENIA; BEREAVEMENT; DEPRESSION; SUICIDE; ONSET; RISK; PERSPECTIVE; DISORDERS	BACKGROUND: The loss of a child is considered one of the most stressful events in the life of a parent. We hypothesized that parental bereavement increases the risk of hospital admission for a psychiatric disorder, especially for affective disorders. METHODS: We studied a cohort of 1,082,503 persons identified from national registers in Denmark who were born between 1952 and 1999 and had at least one child under 18 years of age during the follow-up period, from 1970 to 1999. Parents who lost a child during follow-up were categorized as ``bereaved'' from the date of death of the child. RESULTS: As compared with parents who did not lose a child, parents who lost a child had an overall relative risk of a first psychiatric hospitalization for any disorder of 1.67 (95 percent confidence interval, 1.53 to 1.83). Bereaved mothers had a higher relative risk of being hospitalized for any psychiatric disorder than bereaved fathers (relative risks, 1.78 [95 percent confidence interval, 1.60 to 1.98] and 1.38 [95 percent confidence interval, 1.17 to 1.63], respectively; P value for interaction, 0.01). The relative risks of hospitalization specifically for affective disorders were 1.91 (95 percent confidence interval, 1.59 to 2.30) and 1.61 (95 percent confidence interval, 1.15 to 2.27) for bereaved mothers and fathers, respectively. Among mothers, the relative risk of being hospitalized for any psychiatric disorder was highest during the first year after the death of the child but remained significantly elevated five years or more after the death. CONCLUSIONS: The risk of psychiatric hospitalization was increased among parents, especially mothers, who lost a child.	Univ Aarhus, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, Aarhus, Denmark; Univ Aarhus, Natl Ctr Register Based Res, Aarhus, Denmark; Bispebjerg Hosp, Clin Unit Prevent Med & Hlth Promot, DK-2400 Copenhagen, Denmark	Aarhus University; Aarhus University; University of Copenhagen; Bispebjerg Hospital	Olsen, J (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Box 951772, Los Angeles, CA 90095 USA.	jo@ucla.edu	Mortensen, Preben B/D-2358-2015; li, jiong/L-6534-2014; Laursen, Thomas Munk/AFQ-8066-2022	Mortensen, Preben B/0000-0002-5230-9865; li, jiong/0000-0002-1716-8067; Laursen, Thomas Munk/0000-0001-6934-1784; li, jiong/0000-0003-1125-026X				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andersen P. K., 2012, STAT MODELS BASED CO; Bennedsen BE, 2001, ARCH GEN PSYCHIAT, V58, P674, DOI 10.1001/archpsyc.58.7.674; Brown GW, 1989, LIFE EVENTS ILLNESS; Chen JH, 1999, PSYCHOL MED, V29, P367, DOI 10.1017/S0033291798008137; CLARKE M, 1979, LANCET, V1, P916; CLAYTON PJ, 1974, ARCH GEN PSYCHIAT, V30, P747; Cleiren M.P., 1993, BEREAVEMENT ADAPTATI; FINLAYJONES R, 1981, PSYCHOL MED, V11, P803, DOI 10.1017/S0033291700041301; FROST NR, 1977, ARCH GEN PSYCHIAT, V34, P1172; HOYER G, 1993, ARCH GEN PSYCHIAT, V50, P134; HUDGENS RW, 1967, ARCH GEN PSYCHIAT, V16, P134; Jablensky AV, 2003, AM J PSYCHIAT, V160, P425, DOI 10.1176/appi.ajp.160.3.425; Johnson L, 2000, J AFFECT DISORDERS, V59, P139, DOI 10.1016/S0165-0327(99)00146-9; KENDLER KS, 1992, ARCH GEN PSYCHIAT, V49, P109; Kivela SL, 1998, INT J GERIATR PSYCH, V13, P527, DOI 10.1002/(SICI)1099-1166(199808)13:8<527::AID-GPS814>3.3.CO;2-#; Krupnick J.L., 1984, BEREAVEMENT REACTION, P99; LAIRD N, 1981, J AM STAT ASSOC, V76, P231, DOI 10.2307/2287816; Lewis G, 1998, BMJ-BRIT MED J, V317, P1283, DOI 10.1136/bmj.317.7168.1283; Li J, 2003, LANCET, V361, P363, DOI 10.1016/S0140-6736(03)12387-2; MALIG C, 1996, 66 IIVRS; Malkinson R, 1999, DEATH STUD, V23, P413, DOI 10.1080/074811899200939; Mortensen PB, 1999, NEW ENGL J MED, V340, P603, DOI 10.1056/NEJM199902253400803; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; PARKES CM, 1965, BRIT J MED PSYCHOL, V38, P1, DOI 10.1111/j.2044-8341.1965.tb00956.x; PAYKEL ES, 1969, ARCH GEN PSYCHIAT, V21, P753; Qin P, 2003, ARCH GEN PSYCHIAT, V60, P797, DOI 10.1001/archpsyc.60.8.797; Rosenzweig A, 1997, ANNU REV MED, V48, P421; Rubin SS., 2001, HDB BEREAVEMENT RES, P219; VANCE JC, 1991, MED J AUSTRALIA, V155, P292, DOI 10.5694/j.1326-5377.1991.tb142283.x	30	225	228	1	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1190	1196		10.1056/NEJMoa033160	http://dx.doi.org/10.1056/NEJMoa033160			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	909AW	15788495				2023-01-03	WOS:000227832300005
J	Verhagen, E; Sauer, PJJ				Verhagen, E; Sauer, PJJ			The Groningen protocol - Euthanasia in severely ill newborn	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LIFE		Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands	University of Groningen	Verhagen, E (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands.		Verhagen, Eduard/F-9784-2013	Verhagen, Eduard/0000-0001-9555-6922				Sauer PJJ, 2001, EUR J PEDIATR, V160, P364, DOI 10.1007/s004310100735; vanderHeide A, 1997, LANCET, V350, P251, DOI 10.1016/S0140-6736(97)02315-5; Verhagen A A E, 2005, Ned Tijdschr Geneeskd, V149, P183	3	218	224	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 10	2005	352	10					959	962		10.1056/NEJMp058026	http://dx.doi.org/10.1056/NEJMp058026			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904JC	15758003	Bronze			2023-01-03	WOS:000227491200001
J	Taylor, R				Taylor, Rosie			Revenge of the hymenoptera	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Taylor, R (corresponding author), The Lancet, London NW1 7BY, England.							Goetz J., 2003, P 12 IEEE INT WORKSH; POPPLE S, 1999, ACTA HORTIC, V495, P491; *UK PARL HOUS COMM, 2006, HANS UK PARL HOUS CO	3	0	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 22	2006	368	9532					272	272		10.1016/S0140-6736(06)69055-7	http://dx.doi.org/10.1016/S0140-6736(06)69055-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	067PF	16860684				2023-01-03	WOS:000239314400009
J	Aita, K; Kai, I				Aita, K; Kai, I			Withdrawal of care in Japan	LANCET			English	Editorial Material									Univ Tokyo, Sch Hlth Sci & Nursing, Dept Social Gerontol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Aita, K (corresponding author), Univ Tokyo, Sch Hlth Sci & Nursing, Dept Social Gerontol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	aitak-tky@umin.ac.jp	Kai, Ichiro/AAF-1970-2021	Kai, Ichiro/0000-0002-7883-7383				Akabayashi A, 2002, SOC SCI MED, V55, P517, DOI 10.1016/S0277-9536(01)00184-8; KAI I, 1993, SOC SCI MED, V36, P1151, DOI 10.1016/0277-9536(93)90235-V; KAI K, 2004, SEIBUNDO, P284; NAGAO N, 2005, SEIMEI RINRI, V15, P101; NAKAYAMA K, 2000, ANRAKUSHI SONGENSHI, P83; Otomo Eiichi, 2004, Nihon Ronen Igakkai Zasshi, V41, P483; Schreiner Andrea S, 2004, Int J Palliat Nurs, V10, P185; 2005, YOMIURI SHIMBUN 0519, P35; 2006, YOMIURI SHIMBUN 0325, P1; 2006, MAINICHI SHIMBU 0329, P1; 2005, CHUNICHI SHIMBU 0103, P1; 2006, MAINICHI SHIMBU 0325, P1; 2006, ASAHI SHIMBUN   0427, P22; 2005, ASAHI SHIMBUN   0326, P39; 2004, YOMIURI SHIMBUN 0514, P1; 2006, ASAHI SHIMBUN   0423, P34; 2006, ASAHI SHIMBUN   0325, P1; 2006, ASAHI SHIMBUN   0330, P39	18	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2006	368	9529					12	14		10.1016/S0140-6736(06)68946-0	http://dx.doi.org/10.1016/S0140-6736(06)68946-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	058TQ	16815362				2023-01-03	WOS:000238687900009
J	Hallstrom, A; Rea, TD; Sayre, MR; Christenson, J; Anton, AR; Mosesso, VN; Van Ottingham, L; Olsufka, M; Pennington, S; White, LJ; Yahn, S; Husar, J; Morris, MF; Cobb, LA				Hallstrom, Al; Rea, Thomas D.; Sayre, Michael R.; Christenson, James; Anton, Andy R.; Mosesso, Vince N., Jr.; Van Ottingham, Lois; Olsufka, Michele; Pennington, Sarah; White, Lynn J.; Yahn, Stephen; Husar, James; Morris, Mary F.; Cobb, Leonard A.			Manual chest compression vs use of an automated chest compression device during resuscitation following out-of-hospital cardiac arrest - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOPULMONARY-RESUSCITATION; VENTRICULAR-FIBRILLATION; PORCINE MODEL; QUALITY; DEFIBRILLATION; SURVIVORS; SIZE; TIME	Context High-quality cardiopulmonary resuscitation ( CPR) may improve both cardiac and brain resuscitation following cardiac arrest. Compared with manual chest compression, an automated load-distributing band ( LDB) chest compression device produces greater blood flow to vital organs and may improve resuscitation outcomes. Objective To compare resuscitation outcomes following out-of-hospital cardiac arrest when an automated LDB-CPR device was added to standard emergency medical services ( EMS) care with manual CPR. Design, Setting, and Patients Multicenter, randomized trial of patients experiencing out-of-hospital cardiac arrest in the United States and Canada. The a priori primary population was patients with cardiac arrest that was presumed to be of cardiac origin and that had occurred prior to the arrival of EMS personnel. Initial study enrollment varied by site, ranging from late July to mid November 2004; all sites halted study enrollment on March 31, 2005. Intervention Standard EMS care for cardiac arrest with an LDB-CPR device ( n= 554) or manual CPR ( n= 517). Main Outcome Measures The primary end point was survival to 4 hours after the 911 call. Secondary end points were survival to hospital discharge and neurological status among survivors. Results Following the first planned interim monitoring conducted by an independent data and safety monitoring board, study enrollment was terminated. No difference existed in the primary end point of survival to 4 hours between the manual CPR group and the LDB-CPR group overall ( N= 1071; 29.5% vs 28.5%; P=. 74) or among the primary study population ( n= 767; 24.7% vs 26.4%, respectively; P=. 62). However, among the primary population, survival to hospital discharge was 9.9% in the manual CPR group and 5.8% in the LDB-CPR group ( P=. 06, adjusted for covariates and clustering). A cerebral performance category of 1 or 2 at hospital discharge was recorded in 7.5% of patients in the manual CPR group and in 3.1% of the LDB-CPR group ( P=. 006). Conclusions Use of an automated LDB-CPR device as implemented in this study was associated with worse neurological outcomes and a trend toward worse survival than manual CPR. Device design or implementation strategies require further evaluation.	Univ Washington, Dept Biostat, Seattle, WA 98105 USA; Univ Washington, Dept Med, Seattle, WA USA; Ohio State Univ, Dept Emergency Med, Columbus, OH 43210 USA; British Columbia Ambulance Serv, Vancouver, BC, Canada; Calgary Emergency Med Serv, Calgary, AB, Canada; Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; St. Paul's Hospital; University of Saskatchewan	Hallstrom, A (corresponding author), Univ Washington, Dept Biostat, 1107 NE 45th St,Suite 505, Seattle, WA 98105 USA.	aph@u.washington.edu	Sayre, Michael R/E-8383-2017; White, Lynn/C-9399-2009	Sayre, Michael R/0000-0003-0322-3181; White, Lynn/0000-0003-2464-0304				Anderson Travis, 2003, Curr Opin Crit Care, V9, P194, DOI 10.1097/00075198-200306000-00004; Blackstone E, 2005, SCIENCE, V308, P518, DOI 10.1126/science.1108581; CAMPBELL JP, 1995, ANN EMERG MED, V26, P590, DOI 10.1016/S0196-0644(95)70009-9; Casner Michael, 2005, Prehosp Emerg Care, V9, P61, DOI 10.1080/10903120590891714; Chen YHJ, 2004, STAT MED, V23, P1023, DOI 10.1002/sim.1688; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; Connelly LB, 2003, CONTROL CLIN TRIALS, V24, P544, DOI 10.1016/S0197-2456(03)00093-X; *CYT SOFTW CO, 2003, E VERS 3 0 SOFTW DES; Ewy GA, 2005, CIRCULATION, V111, P2134, DOI 10.1161/01.CIR.0000162503.57657.FA; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; Hallstrom AP, 2005, RESUSCITATION, V65, P65, DOI 10.1016/j.resuscitation.2004.10.008; Halperin HR, 2002, CIRCULATION, V106, P538; Hart AP, 2005, J FORENSIC SCI, V50, P164; HERLITZ J, 1995, ANN EMERG MED, V25, P58, DOI 10.1016/S0196-0644(95)70356-X; HIGHTOWER D, 1995, ANN EMERG MED, V26, P300, DOI 10.1016/S0196-0644(95)70076-5; Huseyin TS, 2002, RESUSCITATION, V54, P57, DOI 10.1016/S0300-9572(02)00040-0; Ikeno F, 2006, RESUSCITATION, V68, P109, DOI 10.1016/j.resuscitation.2005.05.024; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; Lairet JR, 2005, ANN EMERG MED, V46, pS114; NIEMANN JT, 1992, NEW ENGL J MED, V327, P1075; ORNATO J, 2005, AM HEART ASS RES SCI; Rea TD, 2003, CIRCULATION, V107, P2780, DOI 10.1161/01.CIR.0000070950.17208.2A; Rogers WH, 1993, STATA TECHNICAL B RE, V13, P19; Steen S, 2003, RESUSCITATION, V58, P249, DOI 10.1016/S0300-9572(03)00265-X; Stiell I, 2003, CIRCULATION, V108, P1939, DOI 10.1161/01.CIR.0000095028.95929.B0; Timmerman S, 2003, PREHOSP EMERG CARE, V7, P162; Venables W.N., 2002, MODERN APPL STAT S; VUKMIR RB, SURVIVAL OUTCOME PRE; Weisfeldt ML, 2002, JAMA-J AM MED ASSOC, V288, P3035, DOI 10.1001/jama.288.23.3035; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x; Wooldridge J.M., 2002, ECONOMETRIC ANAL CRO; Yu T, 2002, CIRCULATION, V106, P368, DOI 10.1161/01.CIR.0000021429.22005.2E	37	274	290	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	2006	295	22					2620	2628		10.1001/jama.295.22.2620	http://dx.doi.org/10.1001/jama.295.22.2620			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	052HI	16772625	Bronze			2023-01-03	WOS:000238224000024
J	Harries, AD; Chimzizi, R; Zachariah, R				Harries, AD; Chimzizi, R; Zachariah, R			Safety, effectiveness, and outcomes of concomitant use of highly active antiretroviral therapy with drugs for tuberculosis in resource-poor settings	LANCET			English	Editorial Material									Minist Hlth, HIV Unit, Lilongwe, Malawi; London Sch Hyg & Trop Med, London WC1, England; Natl TB Control Programme, Community Hlth Sci Unit, Lilongwe, Malawi; Med Sans Frontieres, HIV TB Operat Res Unit, Brussels, Belgium	University of London; London School of Hygiene & Tropical Medicine; Doctors Without Borders	Harries, AD (corresponding author), Family Hlth Int, Malawi Country Off, Arwa House,3rd Floor,POB 30455, Lilongwe 3, Malawi.	adharries@malawi.net						Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; Breen RAM, 2005, AIDS, V19, P1201, DOI 10.1097/01.aids.0000176221.33237.67; Dean GL, 2002, AIDS, V16, P75, DOI 10.1097/00002030-200201040-00010; Kwara A, 2005, INT J TUBERC LUNG D, V9, P248; Lawn SD, 2005, LANCET INFECT DIS, V5, P361, DOI 10.1016/S1473-3099(05)70140-7; Manosuthi W, 2005, AIDS, V19, P1481, DOI 10.1097/01.aids.0000183630.27665.30; Pedral-Sampaio Diana B., 2004, Braz J Infect Dis, V8, P211, DOI 10.1590/S1413-86702004000300004; Sanne I, 2005, J INFECT DIS, V191, P825, DOI 10.1086/428093; Seyler C, 2005, AM J RESP CRIT CARE, V172, P123, DOI 10.1164/rccm.200410-1342OC	9	24	26	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2006	367	9514					944	945		10.1016/S0140-6736(06)68387-6	http://dx.doi.org/10.1016/S0140-6736(06)68387-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	025CE	16546545				2023-01-03	WOS:000236242100033
J	Puhan, MA; Suarez, A; Lo Cascio, C; Zahn, A; Heitz, M; Braendli, O				Puhan, MA; Suarez, A; Lo Cascio, C; Zahn, A; Heitz, M; Braendli, O			Didgeridoo playing as alternative treatment for obstructive sleep apnoea syndrome: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSITIVE AIRWAY PRESSURE; CONTROLLED CROSSOVER TRIAL; STIMULATION; HYPOPNEA; OUTCOMES	Objective To assess the effects of didgeridoo playing on daytime sleepiness and other outcomes related to sleep by reducing collapsibility of the upper airways in patients with moderate obstructive sleep apnoea syndrome and snoring. Design Randomised controlled trial. Setting Private practice of a didgeridoo instructor and a single centre for sleep medicine. Participants 25 patients aged > 18 years with an apnoea-hypopnoea index between 15 mid 30 and who complained about snoring. Interventions Didgeridoo lessons,and daily practice at home with standardised instruments for four months. Participants in the control group remained on the waiting list for lessons. Main outcome measure Daytime sleepiness (Epworth scale from 0 (no daytime sleepiness) to 24), sleep quality (Pittsburgh quality of sleep index from 0 (excellent sleep quality) to 21), partner rating of sleep disturbance (visual analogue scale from 0 (not disturbed) to 10), apnoea-hypopnoea index, and health related quality of life (SF-36). Results Participants in the didgeridoo group practised an average of 5.9 days a week (SD 0.86) for 25.3 minutes (SD 3.4). Compared with the control group in the didgeridoo group daytime sleepiness (difference - 3.0, 95% confidence interval - 5.7 to - 0.3, P = 0.03) and apnoea-hypopnoea index (difference - 6.2, - 12.3 to - 0.1, P = 0.05) improved significantly and partners reported less sleep disturbance (difference -2.8, -4.7 to -0.9, P < 0.01). There was no effect on the quality of sleep (difference -0.7, -2.1 to 0.6, P = 0.27). The combined analysis of sleep related outcomes showed a moderate to large effect of didgeridoo playing (difference between summary z scores -0.78 SD units, -1.27 to -0.28, P < 0.01). Changes in health related quality of life did not differ between groups. Conclusion Regular didgeridoo playing is an effective treatment alternative well accepted by patients with moderate obstructive sleep apnoea syndrome.	Zuercher Hoehenklin Wald, Sleep Lab, CH-8639 Faltigberg Wald, Switzerland; Univ Zurich, Horten Ctr, CH-8091 Zurich, Switzerland; Asate Alex Suarez, CH-9630 Wattwil, Switzerland; Lungenpraxis Morgental, Zurich, Switzerland	University of Zurich	Braendli, O (corresponding author), Zuercher Hoehenklin Wald, Sleep Lab, CH-8639 Faltigberg Wald, Switzerland.	otto.braendli@zhw.ch	Puhan, Milo/ABE-6298-2020	Puhan, Milo/0000-0003-4721-1879				BACKHAUS J, 2001, WORLD J BIOL PSYCHIA, pS374; Bloch KE, 1999, RESPIRATION, V66, P440, DOI 10.1159/000029408; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Caples SM, 2005, ANN INTERN MED, V142, P187, DOI 10.7326/0003-4819-142-3-200502010-00010; Duran J, 2001, AM J RESP CRIT CARE, V163, P685, DOI 10.1164/ajrccm.163.3.2005065; Engleman HM, 1999, AM J RESP CRIT CARE, V159, P461, DOI 10.1164/ajrccm.159.2.9803121; FURRERBOSCHUNG E, 1997, THESIS U ZURICH ZURI; FURRERBOSCHUNG E, 1997, THESIS U ZURICH; Kingshott RN, 2001, AM J RESP CRIT CARE, V163, P918, DOI 10.1164/ajrccm.163.4.2005036; Lewis KE, 2004, SLEEP, V27, P134, DOI 10.1093/sleep/27.1.134; Mann EA, 2002, LARYNGOSCOPE, V112, P351, DOI 10.1097/00005537-200202000-00027; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Pepin JL, 1999, AM J RESP CRIT CARE, V160, P1124, DOI 10.1164/ajrccm.160.4.9802027; Randerath WJ, 2004, SLEEP, V27, P254, DOI 10.1093/sleep/27.2.254; Schouten HJA, 2000, J CLIN EPIDEMIOL, V53, P1137, DOI 10.1016/S0895-4356(00)00238-9; SCHULZ H, 2005, KOMPENDIUM SCHLAFMED; Tarnopolsky A, 2005, NATURE, V436, P39, DOI 10.1038/43639a; Verse T, 2003, HNO, V51, P966, DOI 10.1007/s00106-003-0842-x; White J., 2002, COCHRANE DB SYST REV; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	21	134	139	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	2006	332	7536					266	268B		10.1136/bmj.38705.470590.55	http://dx.doi.org/10.1136/bmj.38705.470590.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16377643	Green Published, Bronze			2023-01-03	WOS:000235259000015
J	Ulmer, TS; Bax, A				Ulmer, TS; Bax, A			Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE DETERMINATION; MOLECULAR FRAGMENT REPLACEMENT; RESIDUAL DIPOLAR COUPLINGS; MODEL-FREE APPROACH; BIOLOGICAL MACROMOLECULES; SECONDARY STRUCTURE; ALZHEIMERS-DISEASE; BACKBONE DYNAMICS; GLOBULAR-PROTEINS; FIBRIL FORMATION	Three point mutations (A30P, E46K, and A53T) as well as gene triplication genetically link the 140-residue protein alpha-synuclein (aS) to the development of Parkinson disease. Here, the structure and dynamics of micelle-bound aS( A30P) and aS( A53T) are described and compared with wild-type aS, in addition to describing the aS-micelle interaction. A53T is sensed only by directly adjacent residues and leaves the backbone structure and dynamics indistinguishable from the wild type. A30P interrupts one helix turn (Val(26)-Ala(29)) and destabilizes the preceding one. A shift in helix register following A30P disturbs the canonical succession of polar and hydrophobic residues for at least two turns. The shortened helix-N adopts a slightly higher helical content and is less bent, indicating that strain was present in the micelle-bound helix. In the vicinity of the A30P-induced perturbations, the underlying micelle environment has rearranged, but nevertheless all aS variants maintain similar interrelationships with the micelle. Moreover, aS-micelle immersion correlates well with fast and slow aS backbone dynamics, allowing a rare insight into protein-micelle interplay.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bax, A (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Room B1-31,5 Mem Dr, Bethesda, MD 20892 USA.	tulmer@usc.edu; bax@nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029020] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Anderson CAF, 2002, STRUCTURE, V10, P175, DOI 10.1016/S0969-2126(02)00700-1; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bisaglia M, 2005, BIOCHEMISTRY-US, V44, P329, DOI 10.1021/bi048448q; Bouvignies G, 2005, J MAGN RESON, V173, P328, DOI 10.1016/j.jmr.2005.01.001; BRITO RMM, 1986, ANAL BIOCHEM, V152, P250, DOI 10.1016/0003-2697(86)90406-9; Bussell R, 2005, PROTEIN SCI, V14, P862, DOI 10.1110/ps.041255905; Bussell R, 2004, BIOCHEMISTRY-US, V43, P4810, DOI 10.1021/bi036135+; Cabin DE, 2002, J NEUROSCI, V22, P8797; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Choi W, 2004, FEBS LETT, V576, P363, DOI 10.1016/j.febslet.2004.09.038; Chou JJ, 2000, J BIOMOL NMR, V18, P101, DOI 10.1023/A:1008358318863; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Cole NB, 2005, J BIOL CHEM, V280, P9678, DOI 10.1074/jbc.M409946200; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Cordier F, 1999, J AM CHEM SOC, V121, P1601, DOI 10.1021/ja983945d; Cornilescu G, 2000, J AM CHEM SOC, V122, P10143, DOI 10.1021/ja0016194; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Delaglio F, 2000, J AM CHEM SOC, V122, P2142, DOI 10.1021/ja993603n; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deschamps M, 2005, J MAGN RESON, V172, P118, DOI 10.1016/j.jmr.2004.09.023; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fersht A., 1999, STRUCTURE MECH PROTE, DOI DOI 10.1142/10574; Garg G, 2005, J PHYS CHEM B, V109, P1340, DOI 10.1021/jp0472663; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Greenbaum EA, 2005, J BIOL CHEM, V280, P7800, DOI 10.1074/jbc.M411638200; Grishaev A, 2004, J AM CHEM SOC, V126, P7281, DOI 10.1021/ja0319994; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Jaroniec CP, 2004, J BIOMOL NMR, V30, P181, DOI 10.1023/B:JNMR.0000048946.71249.2f; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Karplus PA, 1996, PROTEIN SCI, V5, P1406, DOI 10.1002/pro.5560050719; Kontaxis G, 2005, METHOD ENZYMOL, V394, P42, DOI 10.1016/S0076-6879(05)94003-2; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kumar S, 1998, BIOPHYS J, V75, P1935, DOI 10.1016/S0006-3495(98)77634-9; Kuszewski J, 2000, J MAGN RESON, V146, P249, DOI 10.1006/jmre.2000.2142; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Meiler J, 2001, J AM CHEM SOC, V123, P6098, DOI 10.1021/ja010002z; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; Montserret R, 2000, BIOCHEMISTRY-US, V39, P8362, DOI 10.1021/bi000208x; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Norris EH, 2004, CURR TOP DEV BIOL, V60, P17; Nuscher B, 2004, J BIOL CHEM, V279, P21966, DOI 10.1074/jbc.M401076200; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Prieto J, 1997, J MOL BIOL, V274, P276, DOI 10.1006/jmbi.1997.1322; Ramakrishnan M, 2003, BIOCHEMISTRY-US, V42, P12919, DOI 10.1021/bi035048e; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; Sambrook J., 2001, MOL CLONING LAB MANU, V3; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tolman JR, 2001, J AM CHEM SOC, V123, P1416, DOI 10.1021/ja002500y; Tycko R, 2000, J AM CHEM SOC, V122, P9340, DOI 10.1021/ja002133q; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Ulmer TS, 2004, J MAGN RESON, V166, P190, DOI 10.1016/j.jmr.2003.10.012; Ulmer TS, 2003, J AM CHEM SOC, V125, P9179, DOI 10.1021/ja0350684; Vekrellis K, 2004, MOL NEUROBIOL, V30, P1, DOI 10.1385/MN:30:1:001; Weigelt J, 1998, J AM CHEM SOC, V120, P10778, DOI 10.1021/ja982649y; Wishart DS, 2001, METHOD ENZYMOL, V338, P3; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhu G, 2000, J MAGN RESON, V143, P423, DOI 10.1006/jmre.2000.2022	78	127	134	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43179	43187		10.1074/jbc.M507624200	http://dx.doi.org/10.1074/jbc.M507624200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16166095	hybrid			2023-01-03	WOS:000234200800084
J	George, RJD; Finlay, IG; Jeffrey, D				George, RJD; Finlay, IG; Jeffrey, D			Legalised euthanasia will violate the rights of vulnerable patients	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							LIFE DECISION-MAKING; ASSISTED SUICIDE; LAST WEEK; END; NETHERLANDS		Univ Coll, Ctr Bioeth & Philosophy Med, London UB1 3HW, England; House Lords, London SW1A 0PW, England; Assoc Palliat Med Great Britain & Ireland, Southampton SO17 1DL, Hants, England	University of London; University College London	George, RJD (corresponding author), Univ Coll, Ctr Bioeth & Philosophy Med, London UB1 3HW, England.	rob@palliativecare.org.uk						*BRIT MED ASS, 2005, ASS DYING; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; Groenewoud JH, 2000, NEW ENGL J MED, V342, P551, DOI 10.1056/NEJM200002243420805; Haverkate I, 2000, BRIT MED J, V321, P865, DOI 10.1136/bmj.321.7265.865; Jochemsen H, 1998, ISSUES LAW MED, V13, P447; Jochemsen H, 1999, J MED ETHICS, V25, P16, DOI 10.1136/jme.25.1.16; Sheldon T, 2000, BRIT MED J, V321, P1174; Sheldon T, 1999, BRIT MED J, V319, P75, DOI 10.1136/bmj.319.7202.75b; Sheldon T, 2001, BRIT MED J, V322, P509; Sykes N, 2003, ARCH INTERN MED, V163, P341, DOI 10.1001/archinte.163.3.341; Thorns A, 2000, LANCET, V356, P398, DOI 10.1016/S0140-6736(00)02534-4; vanThiel GJMW, 1997, BRIT MED J, V315, P88, DOI 10.1136/bmj.315.7100.88	12	30	30	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 24	2005	331	7518					684	685		10.1136/bmj.331.7518.684	http://dx.doi.org/10.1136/bmj.331.7518.684			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970HH	16179705	Green Published			2023-01-03	WOS:000232295400022
J	Keown, D				Keown, D			End of life: the Buddhist view	LANCET			English	Editorial Material									Univ London Goldsmiths Coll, London SE14 6NW, England	University of London; Goldsmiths University London	Keown, D (corresponding author), Univ London Goldsmiths Coll, London SE14 6NW, England.	d.keown@gold.ac.uk						FLORIDA RE, 1993, STUD RELIG-SCI RELIG, V22, P35, DOI 10.1177/000842989302200103; HARVEY P, 2001, BUDDHIST STUD REV, P183; HARVEY P, 2000, INTRO BUDDHIST ETHIC, P292; Hoffenberg R, 2001, BMJ-BRIT MED J, V323, P1478, DOI 10.1136/bmj.323.7327.1478; Keown D, 1998, J Law Relig, V13, P385, DOI 10.2307/1051472; KEOWN D, 2001, BUDDHISM BIOETHICS, P144; Keown Damien, 1999, BUDDHISM ABORTION, P199; LaFleur W. A., 2001, ETHICS WORLD RELIG, P271; OLDENBERG H, 1992, VINAYA PITAKAM; Potts Michael, 2000, BRAIN DEATH CASE BRA; RATANAKUL P, 2000, CONT BUDDHIST ETHICS, P169; TAKAKUSU J, 1975, SAMANTAPASADIKA; Youngner S., 1999, DEFINITION DEATH CON; Youngner SJ, 2001, J MED PHILOS, V26, P527, DOI 10.1076/jmep.26.5.527.3002	14	42	43	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 10	2005	366	9489					952	955		10.1016/S0140-6736(05)67323-0	http://dx.doi.org/10.1016/S0140-6736(05)67323-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	962YR	16154024				2023-01-03	WOS:000231770000035
J	Santaguida, PL; Helfand, M; Raina, P				Santaguida, PL; Helfand, M; Raina, P			Challenges in systematic reviews that evaluate drug efficacy or effectiveness	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIALS; ALZHEIMER-DISEASE; NETWORK METAANALYSIS; HEALTH-POLICY; HEPATITIS-C; COMBINATION; PROGRESSION; DEMENTIA; VALIDITY; THERAPY	Increasingly, consumers, clinicians, regulatory bodies, and insurers are using systematic reviews of drug interventions to select treatments and set policies. Although a systematic review cannot provide all the information a clinician needs to make an informed choice for therapy, it can help decision makers distinguish what claims about effectiveness are based on evidence, identify critical information gaps, describe features of the evidence that limit applicability in practice, and address whether drug effectiveness differs for particular subgroups of patients. To improve the relevance and validity of reviews of drug therapies, reviewers need to delineate clinically important subgroups, specific aims of therapy, and most important outcomes. They may need to find unpublished trials, studies other than direct comparator (head-to-head) trials, and additional details of published trials from pharmaceutical manufacturers and regulatory agencies. In this paper, we address ways to formulate questions relevant to specific clinical therapeutic aims; discuss types of studies to include in drug efficacy and effectiveness reviews and how to find them; and describe ways to assess applicability of studies to actual practice.	McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada; Portland VA Med Ctr, Portland, OR USA; Oregon Hlth & Sci Univ, Evidence Based Pract Ctr, Portland, OR USA	McMaster University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Oregon Health & Science University	Raina, P (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, DTC Room 306,1280 Main St W, Hamilton, ON L8S 4L8, Canada.							Baker Stuart G, 2002, BMC Med Res Methodol, V2, P13, DOI 10.1186/1471-2288-2-13; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Bowler JV, 1997, ARCH NEUROL-CHICAGO, V54, P697, DOI 10.1001/archneur.1997.00550180021007; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Chou R, 2005, ANN INTERN MED, V142, P1090, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00009; Chou R, 2004, ANN INTERN MED, V140, P465, DOI 10.7326/0003-4819-140-6-200403160-00014; Cochrane Collaboration, 2003, COCHR REV HDB VERS 4; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; EDDY DM, 1990, MED DECIS MAKING, V10, P15, DOI 10.1177/0272989X9001000104; Falck-Ytter Y, 2002, ANN INTERN MED, V136, P288, DOI 10.7326/0003-4819-136-4-200202190-00008; Fox DM, 2005, HEALTH AFFAIR, V24, P114, DOI 10.1377/hlthaff.24.1.114; Frackiewicz Editya J., 2002, ETHNICITY DRUG DEV T; Helfand M., 2005, DRUG CLASS REV TRIPT; Huster WJ, 1998, STAT MED, V17, P1829; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Kalow W, 1998, PHARMACOGENETICS, V8, P283; Khan A, 2002, INT J NEUROPSYCHOPH, V5, P193, DOI 10.1017/S1461145702002912; Leber P, 1997, ALZ DIS ASSOC DIS, V11, pS10; Leber P, 1997, ALZ DIS ASSOC DIS, V11, pS37; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201; McDermott MP, 2002, CONTROL CLIN TRIALS, V23, P635, DOI 10.1016/S0197-2456(02)00238-6; MULROW CD, 1999, AHCPR PUBLICATION; Phillips Carl V, 2004, BMC Med Res Methodol, V4, P20, DOI 10.1186/1471-2288-4-20; Psaty BM, 2002, JAMA-J AM MED ASSOC, V287, P1680, DOI 10.1001/jama.287.13.1680; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; SANTAGUIDA PS, 2004, AHRQ PUBLICATION; Shekelle P, 2003, AHRQ PUBLICATION, V03-E023; Snow V, 2002, ANN INTERN MED, V137, P840, DOI 10.7326/0003-4819-137-10-200211190-00014; Snow V, 2000, ANN INTERN MED, V132, P738, DOI 10.7326/0003-4819-132-9-200005020-00010; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; SONG F, 2000, HEALTH TECHNOL ASSES, V4, P10; STERN RG, 1994, AM J PSYCHIAT, V151, P390; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; WEINSHILBOUM R, 2003, NEW ENGL J MED, P41; Whitehouse PJ, 1998, ALZ DIS ASSOC DIS, V12, P281, DOI 10.1097/00002093-199812000-00007; Yazdanpanah Y, 2004, BMJ-BRIT MED J, V328, P249, DOI 10.1136/bmj.37995.435787.A6	38	22	22	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1066	1072		10.7326/0003-4819-142-12_Part_2-200506211-00006	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938CN	15968031				2023-01-03	WOS:000229977600006
J	Greenberger, MD; Vogelstein, R				Greenberger, MD; Vogelstein, R			Pharmacist refusals: A threat to women's health	SCIENCE			English	Editorial Material									Natl Womens Law Ctr, Washington, DC 20036 USA		Greenberger, MD (corresponding author), Natl Womens Law Ctr, Washington, DC 20036 USA.	riaser@nwlc.org						*AMWA, 2005, STAT AMWA SUPP PHARM; *APHA, 2003, POL STAT 2003 15; WINCKLER SC, 2004, UNPUB COMMUNICA 0701; 2005, N CAROLINA BOARD PHA, V26, P1; 2005, SUNDAY MIRROR   0227; 2005, FINANCIAL TIMES 0331	6	6	7	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1557	1558		10.1126/science.1114466	http://dx.doi.org/10.1126/science.1114466			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947159				2023-01-03	WOS:000229827000026
J	Reynolds, EE				Reynolds, EE			A 60-year-old woman trying to discontinue hormone replacement therapy, 2 years later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; ESTROGEN											Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Grady D, 2002, JAMA-J AM MED ASSOC, V287, P2130, DOI 10.1001/jama.287.16.2130; LENFANT C, 2000, PRELIMINARY TRENDS W; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2005	293	14					1780	1780		10.1001/jama.293.14.1780	http://dx.doi.org/10.1001/jama.293.14.1780			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915JS	15827318				2023-01-03	WOS:000228301100033
J	Provoost, V; Cools, F; Mortier, F; Bilsen, J; Ramet, J; Vandenplas, Y; Deliens, L				Provoost, V; Cools, F; Mortier, F; Bilsen, J; Ramet, J; Vandenplas, Y; Deliens, L		Neonatal Intensive Care Consortium	Medical end-of-life decisions in neonates and infants in Flanders	LANCET			English	Article							SELF-REPORTED PRACTICES; INTENSIVE-CARE; ATTITUDES; EUTHANASIA; NEWBORNS	Background Paediatricians are increasingly confronted with end-of-life decisions in critically ill neonates and infants. little is known about the frequency and characteristics of end-of-life decisions in this population, nor about the relation with clinical and patients' characteristics. Methods A death-certificate study was done for all deaths of neonates and infants in the whole of Flanders over a 12-month period (August, 1999, to July, 2000). We sent an anonymous questionnaire by mail to the attending physician for each of the 292 children who died under the age of 1 year. Information on patients was obtained from national registers. An attitude study was done for all physicians who attended at least one death during the study period. Findings 253 (87%) of the 292 questionnaires were returned, and 121 (69%) of the 175 physicians involved completed the attitude questions. An end-of-life decision was possible in 194 (77%; 95% CI 70.4-82.4) of the 253 deaths studied, and such a decision was made in 143 cases (57%; 48.9-64.0). Lethal drugs were administered in 15 cases among 117 early neonatal deaths and in two cases among 77 later deaths (13% vs 3%; p=0.018). The attitude study showed that 95 (79%; 70.1-85.5) of the 121 physicians thought that their professional duty sometimes includes the prevention of unnecessary suffering by hastening death and 69 (58%; 48.1-66.5) of 120 supported legalisation of life termination in some cases. Interpretation Death of neonates and infants is commonly preceded by an end-of-life decision. The type of decision varied substantially according to the age of the child. Most physicians favour legalisation of the use of lethal drugs in some cases.	Free Univ Brussels, End Life Care Res Grp, B-1090 Brussels, Belgium; Free Univ Brussels, Univ Hosp, Dept Paediat, Brussels, Belgium; Univ Ghent, Ctr Bioeth, B-9000 Ghent, Belgium; Vrije Univ Amsterdam Med Ctr, Dept Publ & Occupat Hlth, Inst Res Extramural Med, Amsterdam, Netherlands	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Ghent University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Deliens, L (corresponding author), Free Univ Brussels, End Life Care Res Grp, Laarbeeklaan 103, B-1090 Brussels, Belgium.	luc.deliens@vub.ac.be	Provoost, Veerle/H-4214-2011	Deliens, Luc/0000-0002-8158-2422; Cools, Filip/0000-0002-6581-7009; Mortier, Freddy/0000-0002-5390-3508				*BRIT MED ASS, 1999, WITHH WITHDR LIF PRO; Cantagrel S, 2000, ARCH PEDIATRIE, V7, P725, DOI 10.1016/S0929-693X(00)80152-9; Cook L A, 1996, J Perinatol, V16, P133; Cuttini M, 2000, LANCET, V355, P2112, DOI 10.1016/S0140-6736(00)02378-3; de Leeuw R, 2000, J PEDIATR-US, V137, P608, DOI 10.1067/mpd.2000.109144; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; DILLMAN DA, 1991, ANNU REV SOCIOL, V17, P225, DOI 10.1146/annurev.so.17.080191.001301; Doron MW, 1998, PEDIATRICS, V102, P574, DOI 10.1542/peds.102.3.574; DUFF RS, 1973, NEW ENGL J MED, V289, P890, DOI 10.1056/NEJM197310252891705; *EUR WORK GROUP, 2001, 7 SCI PUBL HLTH EUR; Garel M, 1997, ARCH PEDIATRIE, V4, P662, DOI 10.1016/S0929-693X(97)83370-2; HARRIS J, 1985, VALUE LIFE INTRO MED, P34; Kollee LAA, 1999, SEMIN PERINATOL, V23, P234, DOI 10.1016/S0146-0005(99)80068-8; McCallum DE, 2000, J PAIN SYMPTOM MANAG, V20, P417, DOI 10.1016/S0885-3924(00)00212-8; McHaffie HE, 1999, J MED ETHICS, V25, P440, DOI 10.1136/jme.25.6.440; McHugh-Strong CM, 2000, AM J PERINAT, V17, P27, DOI 10.1055/s-2000-7291; Norup M, 1998, ACTA PAEDIATR, V87, P896, DOI 10.1080/080352598750013707; Norup M, 1999, ACTA PAEDIATR, V88, P438, DOI 10.1080/08035259950169846; POWDERLY KE, 1999, ETHICS CRITICAL CARE, P475; Rebagliato M, 2000, JAMA-J AM MED ASSOC, V284, P2451, DOI 10.1001/jama.284.19.2451; Sklansky M, 2001, J MED ETHICS, V27, P5, DOI 10.1136/jme.27.1.5; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderHeide A, 1997, LANCET, V350, P251, DOI 10.1016/S0140-6736(97)02315-5	24	47	47	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2005	365	9467					1315	1320		10.1016/S0140-6736(05)61028-8	http://dx.doi.org/10.1016/S0140-6736(05)61028-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823381				2023-01-03	WOS:000228219600026
J	Morales, A; Paris, R; Villanueva, A; Llavuna, L; Garcia-Ruiz, C; Fernandez-Checa, JC				Morales, A.; Paris, R.; Villanueva, A.; Llavuna, L.; Garcia-Ruiz, C.; Fernandez-Checa, J. C.			Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo	ONCOGENE			English	Article						cancer therapy; ceramide; sphingosine-1-phosphate; mitochondria; apoptosis	MITOCHONDRIAL PERMEABILITY TRANSITION; DAUNORUBICIN-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; SPHINGOSINE 1-PHOSPHATE; GD3 GANGLIOSIDE; SPHINGOSINE-1-PHOSPHATE; GENERATION; KINASE; DEATH; NECROSIS	Ceramidases (CDases) play a key role in cancer therapy through enhanced conversion of ceramide into sphingosine 1-phosphate (S1P), but their involvement in hepatocarcinogenesis is unknown. Here, we report that daunorubicin (DNR) activated acid CDase post-transcriptionally in established human (HepG2 cells) or mouse (Hepa1c1c7) hepatoma cell lines as well as in primary cells from murine liver tumors, but not in cultured mouse hepatocytes. Acid CDase silencing by small interfering RNA (siRNA) or pharmacological inhibition with N-oleoylethanolamine (NOE) enhanced the ceramide to S1P balance compared to DNR alone, sensitizing hepatoma cells (HepG2, Hep-3B, SK-Hep and Hepa1c1c7) to DNR-induced cell death. DNR plus NOE or acid CDase siRNA-induced cell death was preceded by ultrastructural changes in mitochondria, stimulation of reactive oxygen species generation, release of Smac/DIABLO and cytochrome c and caspase-3 activation. In addition, in vivo siRNA treatment targeting acid CDase reduced tumor growth in liver tumor xenografts of HepG2 cells and enhanced DNR therapy. Thus, acid CDase promotes hepatocarcinogenesis and its antagonism may be a promising strategy in the treatment of liver cancer.	Hosp Clin Barcelona, Liver Unit, Inst Malalties Digest, Inst Invest Biomed August Pi & Sunyer,IDIBAPS, Barcelona 08036, Spain; IDIBELL, Inst Invest Bellvitge, Inst Catala Oncol, Lab Recerca Translac, Barcelona, Spain; CSIC, Inst Invest Biomed, Dept Expt Pathol, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB)	Fernandez-Checa, JC (corresponding author), Hosp Clin Barcelona, Liver Unit, Inst Malalties Digest, Inst Invest Biomed August Pi & Sunyer,IDIBAPS, C Villarroel 170, Barcelona 08036, Spain.	checa229@yahoo.com	Garcia-Ruiz, Carmen/L-8211-2014; Fernández-Checa, José Carlos/L-8342-2014; Morales, Albert/E-2988-2013	Garcia-Ruiz, Carmen/0000-0002-2652-6102; Fernández-Checa, José Carlos/0000-0003-3422-2990; Morales, Albert/0000-0001-8702-2269	NIAAA NIH HHS [P50 AA11999, 1R21 AA014135-01] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA014135, P50AA011999] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Colell Anna, 2001, FASEB Journal, V15, P1068; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gilot D, 2005, CARCINOGENESIS, V26, P2086, DOI 10.1093/carcin/bgi187; Gruber C, 2004, BIOCHEM PHARMACOL, V67, P1859, DOI 10.1016/j.bcp.2004.01.026; Hara S, 2004, CELL DEATH DIFFER, V11, P853, DOI 10.1038/sj.cdd.4401428; HASSLER DF, 1993, ADV LIPID RES, V26, P49; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Kawaguchi K, 2005, BIOCHEM BIOPH RES CO, V329, P370, DOI 10.1016/j.bbrc.2005.01.128; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Li CM, 1999, GENOMICS, V62, P223, DOI 10.1006/geno.1999.5940; Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Paris F, 2002, NAT MED, V8, P901, DOI 10.1038/nm0902-901; Paris R, 2002, J BIOL CHEM, V277, P49870, DOI 10.1074/jbc.M208303200; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Payne SG, 2002, FEBS LETT, V531, P54, DOI 10.1016/S0014-5793(02)03480-4; Prinetti A, 2006, BIOCHEM J, V395, P311, DOI 10.1042/BJ20051184; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Selzner M, 2001, CANCER RES, V61, P1233; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Suzuki E, 2004, P NATL ACAD SCI USA, V101, P14788, DOI 10.1073/pnas.0406536101; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533	46	83	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					905	916		10.1038/sj.onc.1209834	http://dx.doi.org/10.1038/sj.onc.1209834			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16862171				2023-01-03	WOS:000244063800011
J	Tang, JL				Tang, Jin-Ling			Research priorities in traditional Chinese medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CONTROLLED-TRIAL; EQUIPOISE		Chinese Univ Hong Kong, Hong Kong Cochrane Branch, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong	Tang, JL (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med,Sch Publ Hlth, Chinese Cochrane Ctr Hong Kong Branch, Shatin, Hong Kong, Peoples R China.	jltang@cuhk.edu.hk	Tang, Jin-Ling/AAJ-4090-2021; Tang, JL/G-1759-2013					[Anonymous], 2000, LANCET, V356, P2023; Dingwall R, 1992, RES HLTH CARE, P161; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Haynes RB, 1999, BRIT MED J, V319, P1632; HAYVEY AL, 1998, ADV DRUG DISCOVERY T, P1; Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202; HILL AB, 1952, NEW ENGL J MED, V247, P113, DOI 10.1056/NEJM195207242470401; KUHN TS, 1970, STRUCTURE SCI REVOLU, P77; Liang MX, 1998, PREDICAMENTS FUTURE, P1; Rapola JM, 1996, JAMA-J AM MED ASSOC, V275, P693, DOI 10.1001/jama.275.9.693; SHE JB, 1990, DIFFERENCES PERPLEXI; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E; Steele VE, 1998, HEMATOL ONCOL CLIN N, V12, P943, DOI 10.1016/S0889-8588(05)70035-6; Tang JL, 1999, BMJ-BRIT MED J, V319, P160, DOI 10.1136/bmj.319.7203.160; TIAO KY, 1997, PHILOS CONSIDERATION; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; WARREN KS, 1993, ANN NY ACAD SCI, V703, P1, DOI 10.1111/j.1749-6632.1993.tb26327.x; Weijer C, 2000, BMJ-BRIT MED J, V321, P756, DOI 10.1136/bmj.321.7263.756; World Health Organization, 2004, WORLD REP KNOWL BETT; WYNDER EL, 1994, AM J EPIDEMIOL, V139, P547, DOI 10.1093/oxfordjournals.aje.a117045; YUAN Z, 1997, RATIONAL THINKING DE, P36	21	39	45	7	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2006	333	7564					391	394		10.1136/bmj.333.7564.391	http://dx.doi.org/10.1136/bmj.333.7564.391			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	078OD	16916829	Green Published			2023-01-03	WOS:000240112200021
J	Huang, L; Quartin, A; Jones, D; Havlir, DV				Huang, Laurence; Quartin, Andew; Jones, Denis; Havlir, Diane V.			Intensive care of patients with HIV infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE RECONSTITUTION; ANTIRETROVIRAL THERAPY; MEDICINE ASSOCIATION; DISEASES-SOCIETY; RISK-FACTORS; HEPATITIS-B; MANAGEMENT; GUIDELINES; PATTERNS		Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, Ward 84, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Div Pulm & Crit Care Med, San Francisco, CA 94110 USA; Univ Miami, Miller Sch Med, Miami Vet Affairs Med Ctr, Div Pulm & Crit Care Med, Miami, FL 33152 USA; Univ Saskatchewan, Dept Med, Regina, SK, Canada	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of Miami; University of Saskatchewan	Huang, L (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, Ward 84, 995 Potrero Ave, San Francisco, CA 94110 USA.	lhuang@php.ucsf.edu	Huang, Laurence/AAE-1590-2019; Huang, Laurence/AAZ-7120-2021	Huang, Laurence/0000-0003-3888-2195	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL072117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027663, K24AI051982, U01AI027670, U01AI027675] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aberg JA, 2004, CLIN INFECT DIS, V39, P609, DOI 10.1086/423390; *AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Alberti A, 2005, J HEPATOL, V43, P1098, DOI 10.1016/j.jhep.2005.10.001; Alberti A, 2005, J HEPATOL, V42, P615, DOI 10.1016/j.jhep.2005.03.003; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Bulterys M, 2004, JAMA-J AM MED ASSOC, V292, P219, DOI 10.1001/jama.292.2.219; Casalino E, 2004, AIDS, V18, P1429, DOI 10.1097/01.aids.0000131301.55204.a7; Murillo-Zumbado Gustavo, 2021, Tecnología en Marcha, V34, P130, DOI [10.18845/tm.v34i4.5274, 10.1103/PhysRevE.106.055304]; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Dellinger RP, 2004, CRIT CARE MED, V32, P1448; DELORENZO LJ, 1987, CHEST, V91, P323, DOI 10.1378/chest.91.3.323; FEENEY C, 1995, CRIT CARE MED, V23, P1680, DOI 10.1097/00003246-199510000-00012; Franzetti F, 2006, INFECTION, V34, P9, DOI 10.1007/s15010-006-5007-x; Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010; FriisMoller N, 2004, NEW ENGL J MED, V350, P955; Goldsack NR, 2003, SEX TRANSM INFECT, V79, P337, DOI 10.1136/sti.79.4.337; Grinspoon S, 2005, NEW ENGL J MED, V352, P48, DOI 10.1056/NEJMra041811; Gupta SK, 2005, CLIN INFECT DIS, V40, P1559, DOI 10.1086/430257; Halpern SD, 2005, JAMA-J AM MED ASSOC, V294, P734, DOI 10.1001/jama.294.6.734; Heyland DK, 1996, INTENS CARE MED, V22, P1339, DOI 10.1007/BF01709548; Hirsch HH, 2004, CLIN INFECT DIS, V38, P1159, DOI 10.1086/383034; Hsue PY, 2004, CIRCULATION, V109, P316, DOI 10.1161/01.CIR.0000114520.38748.AA; Lawn SD, 2005, LANCET INFECT DIS, V5, P361, DOI 10.1016/S1473-3099(05)70140-7; LIN RY, 1993, CHEST, V104, P847, DOI 10.1378/chest.104.3.847; Mimoz O, 1998, INTENS CARE MED, V24, P1047, DOI 10.1007/s001340050714; Morris A, 2003, AIDS, V17, P73, DOI 10.1097/00002030-200301030-00010; Morris A, 2002, AM J RESP CRIT CARE, V166, P262, DOI 10.1164/rccm.2111025; Narasimhan M, 2004, CHEST, V125, P1800, DOI 10.1378/chest.125.5.1800; *NAT HIV AIDS CLIN, DOS FORM MOD REN HEP; Nickas G, 2000, ARCH INTERN MED, V160, P541, DOI 10.1001/archinte.160.4.541; Nunez M, 2005, LANCET INFECT DIS, V5, P374, DOI 10.1016/S1473-3099(05)70141-9; Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG HIV 1; Pastores SM, 1996, AM J MED SCI, V312, P229, DOI 10.1097/00000441-199611000-00008; Petrosillo N, 2005, CURR OPIN PULM MED, V11, P231, DOI 10.1097/01.mcp.0000156993.30376.67; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Roland ME, 2003, TRANSPLANTATION, V75, P425, DOI 10.1097/01.TP.0000046943.35335.18; American Medical Association, 2004, MMWR Recomm Rep, V53, P1; Tarling MM, 1997, INTENS CARE MED, V23, P256, DOI 10.1007/s001340050325; Trachiotis GD, 2003, ANN THORAC SURG, V76, P1114, DOI 10.1016/S0003-4975(02)04756-2; Vincent B, 2004, INTENS CARE MED, V30, P859, DOI 10.1007/s00134-004-2158-z; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; Wislez M, 2001, AM J RESP CRIT CARE, V164, P847, DOI 10.1164/ajrccm.164.5.2007034; 2005, MMWR MORB MORTAL WKL, V54, P311	43	95	105	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2006	355	2					173	181		10.1056/NEJMra050836	http://dx.doi.org/10.1056/NEJMra050836			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	062UP	16837681	Bronze			2023-01-03	WOS:000238970600009
J	Salazar, M; Rojo, AI; Velasco, D; de Sagarra, RM; Cuadrado, A				Salazar, Maria; Rojo, Ana I.; Velasco, Diego; de Sagarra, Rosa Maria; Cuadrado, Antonio			Glycogen synthase kinase-3 beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; SUBSTRATE ADAPTER PROTEIN; OXIDATIVE STRESS; HEME OXYGENASE-1; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL-3 KINASE/AKT; PROTEASOMAL DEGRADATION; INDUCIBLE EXPRESSION; NEGATIVE REGULATION; HEAT-SHOCK	The transcription factor Nrf2 ( nuclear factor E2-related factor 2) regulates the expression of antioxidant phase II genes and contributes to preserve redox homeostasis and cell viability in response to oxidant insults. Nrf2 should be coordinated with the canonical cell survival pathway represented by phosphatidylinositol 3-kinase (PI3K) and the Ser/Thr kinase Akt but so far the mechanistic connections remain undefined. Here we identify glycogen synthase kinase-3 beta (GSK-3 beta), which is inhibited by Akt-mediated phosphorylation, as the link between both processes. Using heme oxygenase-1 (HO-1) as a model phase II gene, we found that both PI3K and Akt increased mRNA and protein levels of this enzyme. Pharmacological inhibitors (LiCl and PDZD-8) and genetic variants of GSK-3 beta ( constitutively active and dominant negative mutants) indicated that PI3K/Akt activates and GSK-3 beta inhibits the antioxidant response elements of the ho1 promoter and pointed Nrf2 as directly involved in this process. Indeed, GSK-3 beta phosphorylated Nrf2 in vitro and in vivo. Immunocytochemistry and subcellular fractionation analyses demonstrated that the effect of GSK-3 beta-mediated phosphorylation of Nrf2 is to exclude this transcription factor from the nucleus. Nrf2 up-regulated the expression of HO-1, glutathione peroxidase, glutathione S-transferase A1, NAD(P)H: quinone oxidoreductase and glutamate-cysteine ligase and protected against hydrogen peroxide-induced glutathione depletion and cell death, whereas co-expression of active GSK-3 beta attenuated both phase II gene expression and oxidant protection. These results contribute to clarify the cross-talk between the survival signal elicited by PI3K/Akt and the antioxidant phase II cell response, and introduce GSK-3 beta as the key mediator of this regulation mechanism.	Univ Autonoma Madrid, Dept Bioquim, Fac Med, Madrid 28029, Spain; Univ Autonoma Madrid, Inst Invest Biomed, Fac Med, Madrid 28029, Spain	Autonomous University of Madrid; Autonomous University of Madrid	Cuadrado, A (corresponding author), Univ Autonoma Madrid, Dept Bioquim, Fac Med, Arzobispo Morcillo 4, Madrid 28029, Spain.	antonio.cuadrado@uam.es	Rojo, Ana I/AAA-5203-2019; Roa, Maria Salazar/I-1168-2015	Roa, Maria Salazar/0000-0001-6784-9541; Cuadrado, Antonio/0000-0002-4039-7140; Rojo, Ana I/0000-0002-0312-5867; Cuadrado, Antonio/0000-0002-3444-9012				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dennery PA, 2006, FREE RADICAL BIO MED, V40, P1, DOI 10.1016/j.freeradbiomed.2005.09.003; Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200; Dhakshinamoorthy S, 2002, ONCOGENE, V21, P5301, DOI 10.1038/sj.onc.1205642; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Kang KW, 2005, ANTIOXID REDOX SIGN, V7, P1664, DOI 10.1089/ars.2005.7.1664; Katsuoka F, 2005, MOL CELL BIOL, V25, P8044, DOI 10.1128/MCB.25.18.8044-8051.2005; KIM HP, 2005, ANN REV PHARM TOXICO; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Koh SH, 2004, NEUROTOXICOLOGY, V25, P793, DOI 10.1016/j.neuro.2004.02.001; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; LEGRAND C, 1992, J BIOTECHNOL, V25, P231, DOI 10.1016/0168-1656(92)90158-6; Li WG, 2005, J BIOL CHEM, V280, P28430, DOI 10.1074/jbc.M410601200; Maines MD, 2005, BIOCHEM BIOPH RES CO, V338, P568, DOI 10.1016/j.bbrc.2005.08.121; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Martin D, 2001, J NEUROCHEM, V78, P1000, DOI 10.1046/j.1471-4159.2001.00472.x; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; Minc E, 1999, J BIOL CHEM, V274, P503, DOI 10.1074/jbc.274.1.503; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moreira PI, 2005, ANN NY ACAD SCI, V1043, P545, DOI 10.1196/annals.1333.062; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; Sasaki C, 2001, NEUROL RES, V23, P588, DOI 10.1179/016164101101199054; Schafer M, 2004, BRAIN RES, V1005, P84, DOI 10.1016/j.brainres.2004.01.037; Sebastia J, 2003, CYTOM PART A, V51A, P16, DOI 10.1002/cyto.a.10003; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101; Suzuki H, 2003, J BIOL CHEM, V278, P49246, DOI 10.1074/jbc.M306764200; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Zhang DD, 2005, J BIOL CHEM, V280, P30091, DOI 10.1074/jbc.M501279200; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zielonka J, 2005, FREE RADICAL BIO MED, V39, P853, DOI 10.1016/j.freeradbiomed.2005.05.001; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	58	377	383	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14841	14851		10.1074/jbc.M513737200	http://dx.doi.org/10.1074/jbc.M513737200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551619	hybrid			2023-01-03	WOS:000237671300038
J	Freedman, SB; Adler, M; Seshadri, R; Powell, EC				Freedman, SB; Adler, M; Seshadri, R; Powell, EC			Oral ondansetron for gastroenteritis in a pediatric emergency department	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-TRIAL; CHILDREN; DEHYDRATION; PROCHLORPERAZINE; PROMETHAZINE; REHYDRATION; PARAMETERS; THERAPY; NAUSEA; SIGNS	BACKGROUND: Vomiting limits the success of oral rehydration in children with gastroenteritis. We conducted a double-blind trial to determine whether a single oral dose of ondansetron, an antiemetic, would improve outcomes in children with gastroenteritis. METHODS: We enrolled 215 children 6 months through 10 years of age who were treated in a pediatric emergency department for gastroenteritis and dehydration. After being randomly assigned to treatment with orally disintegrating ondansetron tablets or placebo, the children received oral-rehydration therapy according to a standardized protocol. The primary outcome was the proportion who vomited while receiving oral rehydration. The secondary outcomes were the number of episodes of vomiting and the proportions who were treated with intravenous rehydration or hospitalized. RESULTS: As compared with children who received placebo, children who received ondansetron were less likely to vomit (14 percent vs. 35 percent; relative risk, 0.40; 95 percent confidence interval, 0.26 to 0.61), vomited less often (mean number of episodes per child, 0.18 vs. 0.65; P<0.001), had greater oral intake (239 ml vs. 196 ml, P=0.001), and were less likely to be treated by intravenous rehydration (14 percent vs. 31 percent; relative risk, 0.46; 95 percent confidence interval, 0.26 to 0.79). Although the mean length of stay in the emergency department was reduced by 12 percent in the ondansetron group, as compared with the placebo group (P=0.02), the rates of hospitalization (4 percent and 5 percent, respectively; P=1.00) and of return visits to the emergency department (19 percent and 22 percent, P=0.73) did not differ significantly between groups. CONCLUSIONS: In children with gastroenteritis and dehydration, a single dose of oral ondansetron reduces vomiting and facilitates oral rehydration and may thus be well suited for use in the emergency department.	Univ Toronto, Hosp Sick Children, Div Pediat Emergency Med, Toronto, ON M5G 1X8, Canada; Childrens Mem Hosp, Childrens Mem Res Ctr, Div Pediat Emergency Med, Chicago, IL 60614 USA; Childrens Mem Hosp, Childrens Mem Res Ctr, Mary Ann & J Milburn Smith Child Hlth Res Program, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Freedman, SB (corresponding author), Univ Toronto, Hosp Sick Children, Div Pediat Emergency Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	stephen.freedman@sickkids.ca	; Freedman, Stephen/H-9102-2012	Adler, Mark/0000-0003-1857-8639; Freedman, Stephen/0000-0003-2319-6192; Powell, Elizabeth/0000-0003-3147-9889	NCRR NIH HHS [M01 RR-00048] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000048] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Behrman RE, 2004, NELSON TXB PEDIAT, V17th; Chan-Tack KM, 1999, SOUTHERN MED J, V92, P1017, DOI 10.1097/00007611-199910000-00015; DAVIGNON A, 1980, PEDIATR CARDIOL, V1, P123, DOI 10.1007/BF02083144; DeGrandi T, 1987, Pediatr Emerg Care, V3, P91, DOI 10.1097/00006565-198706000-00007; Drotts DL, 1999, ANN EMERG MED, V34, P469, DOI 10.1016/S0196-0644(99)80048-1; Duggan C, 1996, J PEDIATR GASTR NUTR, V22, P56, DOI 10.1097/00005176-199601000-00009; Ernst AA, 2000, ANN EMERG MED, V36, P89, DOI 10.1067/mem.2000.108652; Freedman SB, 2004, PEDIATR EMERG CARE, V20, P625, DOI 10.1097/01.pec.0000139748.61838.ad; Friedman L. M., 1998, FUNDAMENTALS CLIN TR; Frifdman JN, 2004, J PEDIATR-US, V145, P201, DOI 10.1016/j.jpeds.2004.05.035; GINSBURG CM, 1980, J PEDIATR-US, V96, P767, DOI 10.1016/S0022-3476(80)80764-5; Gorelick MH, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.5.e6; King Caleb K, 2003, MMWR Recomm Rep, V52, P1; LANG TA, 1997, REPORT STAT MED ANNO; Li STT, 2003, ARCH PEDIAT ADOL MED, V157, P475, DOI 10.1001/archpedi.157.5.475; MACKENZIE A, 1989, LANCET, V2, P605; McCullagh P., 1989, GEN LINEAR MODELS; MCMILLAN JA, 1999, OSKIS PEDIAT PRINCIP; Ozuah PO, 2002, PEDIATRICS, V109, P259, DOI 10.1542/peds.109.2.259; Ramsook C, 2002, ANN EMERG MED, V39, P397, DOI 10.1067/mem.2002.122706; Reeves JJ, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e62; REIS EC, 1994, PEDIATRICS, V93, P708; Rudolph CD, 2002, RUDOLPHS PEDIAT; Steiner MJ, 2004, JAMA-J AM MED ASSOC, V291, P2746, DOI 10.1001/jama.291.22.2746; Vega RM, 1997, PEDIATR EMERG CARE, V13, P179, DOI 10.1097/00006565-199706000-00001; World Health Organization, 2005, TREATM DIARRH MAN PH	26	157	162	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 20	2006	354	16					1698	1705		10.1056/NEJMoa055119	http://dx.doi.org/10.1056/NEJMoa055119			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	033ZP	16625009	Bronze			2023-01-03	WOS:000236893900006
J	Barsoum, RS				Barsoum, RS			Chronic kidney disease in the developing world	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cairo Univ, Cairo, Egypt	Egyptian Knowledge Bank (EKB); Cairo University	Barsoum, RS (corresponding author), Cairo Univ, Cairo, Egypt.			Barsoum, Rashad/0000-0003-1620-764X				Barsoum RS, 2002, ARTIF ORGANS, V26, P737, DOI 10.1046/j.1525-1594.2002.07061.x; BARSOUM RS, 2005, KIDNEY DIS DEV WORLD, P1; International Society of Nephrology, PROGR DET MAN CHRON; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047	4	313	337	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					997	999		10.1056/NEJMp058318	http://dx.doi.org/10.1056/NEJMp058318			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	019FY	16525136				2023-01-03	WOS:000235822200003
J	Chidambaram, JD; Alemayehu, W; Melese, M; Lakew, T; Yi, E; House, J; Cevallos, V; Zhou, ZX; Maxey, K; Lee, DC; Shapiro, BL; Srinivasan, M; Porco, T; Whitcher, JP; Gaynor, BD; Lietman, TM				Chidambaram, JD; Alemayehu, W; Melese, M; Lakew, T; Yi, E; House, J; Cevallos, V; Zhou, ZX; Maxey, K; Lee, DC; Shapiro, BL; Srinivasan, M; Porco, T; Whitcher, JP; Gaynor, BD; Lietman, TM			Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHLAMYDIA-TRACHOMATIS; DOSE AZITHROMYCIN; COMMUNITY; DISEASE; AREAS	Context The World Health Organization recommends mass antibiotic distributions in its strategy to eliminate blinding trachoma as a public health concern. Some hypothesize that a single distribution is sufficient to control the ocular strains of chlamydia that cause trachoma. Others believe infection will inevitably return and periodic treatments or other measures are essential. Objective To determine whether ocular chlamydial infection returns to the community up to 24 months after a single mass antibiotic distribution in a hyperendemic region of Ethiopia. Design, Setting, and Participants Longitudinal cohort study conducted March 2003 to March 2005 in the Gurage Zone of Ethiopia. Eight randomly selected villages were assessed for ocular chlamydial infection. Fifteen untreated villages were randomly chosen at 12 months to allow assessment of a secular trend. Intervention A single dose of oral azithromycin was offered to all residents of the 8 selected villages who were aged 1 year or older. Main Outcome Measure Prevalence of ocular chlamydial infection in all children aged 1 to 5 years from each intervention village prior to treatment and 2, 6, 12, 18, and 24 months after mass antibiotic treatment, and also in untreated villages enrolled at 12 months. Results Five hundred fifteen children were examined for ocular chlamydial infection at baseline. For the follow-up examinations, the mean participation rate was 83%. The mean prevalence of infection in children aged 1 to 5 years decreased from 43.5% (95% confidence interval [CI], 35.0%-52.0%) to 5.1% ( 95% CI, 1.1%-9.2%) after treatment. On average, infection returned gradually over 24 months to 11.3% ( 95% CI, 4.5%-18.1%; P = .001). In 7 of 8 villages, infection was higher at 24 months than at 2 months. In the remaining village, no infection could be identified at any point after treatment. Villages enrolled at 12 months had significantly fewer infections than those enrolled 12 months earlier, suggesting a secular trend ( P < .001). Conclusions Ocular chlamydial infection was not eliminated in children aged 1 to 5 years after a single mass azithromycin distribution; it slowly returned over 24 months, although not to baseline levels. Repeated treatments or other effective measures will be necessary for elimination.	Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Global Hlth, San Francisco, CA 94143 USA; Orbis Int, Addis Ababa, Ethiopia; Aravind Eye Hosp, Madural, India; Calif Dept Hlth Serv, Berkeley, CA 94704 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Department of Health Care Services	Lietman, TM (corresponding author), Univ Calif San Francisco, Francis I Proctor Fdn, Box 0412,513 Parnassus Ave,Med Sci S309, San Francisco, CA 94143 USA.	tom.lietman@ucsf.edu		Chidambaram, Jaya/0000-0001-5438-2858	NATIONAL EYE INSTITUTE [U10EY016214] Funding Source: NIH RePORTER; NEI NIH HHS [U10-EY016214] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bird M, 2003, J INFECT DIS, V187, P1669, DOI 10.1086/374743; Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X; Chidambaram JD, 2005, LANCET INFECT DIS, V5, P194, DOI 10.1016/S1473-3099(05)70032-3; Chidambaram JD, 2004, EMERG INFECT DIS, V10, P1895; Diamant J, 2001, Ophthalmic Epidemiol, V8, P109, DOI 10.1076/opep.8.2.109.4156; Dolin PJ, 1997, LANCET, V349, P1511, DOI 10.1016/S0140-6736(97)01355-X; Gaynor BD, 2003, EMERG INFECT DIS, V9, P596, DOI 10.3201/eid0905.020577; Gaynor Bruce D., 2002, International Ophthalmology Clinics, V42, P85; Hoechsmann A, 2001, Ophthalmic Epidemiol, V8, P145, DOI 10.1076/opep.8.2.145.4169; Jha H, 2002, CLIN INFECT DIS, V35, P765, DOI 10.1086/342298; Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451; Lietman TM, 2005, NEW ENGL J MED, V352, P414; Mariotti SP, 2004, NEW ENGL J MED, V351, P2004, DOI 10.1056/NEJMe048205; Melese M, 2004, JAMA-J AM MED ASSOC, V292, P721, DOI 10.1001/jama.292.6.721; Peeling RW, 1998, SEX TRANSM INFECT, V74, P66, DOI 10.1136/sti.74.1.66; Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844; Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5; Solomon AW, 2005, NEW ENGL J MED, V352, P414; Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979; VERRENGIA JB, ANTIBIOTIC DOSE MAY; Wang SA, 2005, J INFECT DIS, V191, P917, DOI 10.1086/428290; West ES, 2005, INVEST OPHTH VIS SCI, V46, P83, DOI 10.1167/iovs.04-0327; WHO, 2004, WHOPBDGET042; Zhang JZ, 2004, PEDIATR INFECT DIS J, V23, P217, DOI 10.1097/01.inf.0000115501.60397.a6	24	101	101	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2006	295	10					1142	1146		10.1001/jama.295.10.1142	http://dx.doi.org/10.1001/jama.295.10.1142			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019GB	16522834	Bronze, Green Accepted			2023-01-03	WOS:000235822500022
J	Wang, PS; Schneeweiss, S; Avorn, J; Fischer, MA; Mogun, H; Solomon, DH; Brookhart, MA				Wang, PS; Schneeweiss, S; Avorn, J; Fischer, MA; Mogun, H; Solomon, DH; Brookhart, MA			Risk of death in elderly users of conventional vs. atypical antipsychotic medications	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISPERIDONE; MORTALITY; EFFICACY	Background: Recently, the Food and Drug Administration (FDA) issued an advisory stating that atypical antipsychotic medications increase mortality among elderly patients. However, the advisory did not apply to conventional antipsychotic medications; the risk of death with these older agents is not known. Methods: We conducted a retrospective cohort study involving 22,890 patients 65 years of age or older who had drug insurance benefits in Pennsylvania and who began receiving a conventional or atypical antipsychotic medication between 1994 and 2003. Analyses of mortality rates and Cox proportional-hazards models were used to compare the risk of death within 180 days, less than 40 days, 40 to 79 days, and 80 to 180 days after the initiation of therapy with an antipsychotic medication. We controlled for potential confounding variables with the use of traditional multivariate Cox models, propensity-score adjustments, and an instrumental-variable analysis. Results: Conventional antipsychotic medications were associated with a significantly higher adjusted risk of death than were atypical antipsychotic medications at all intervals studied (lessthan/equal 180 days: relative risk, 1.37; 95 percent confidence interval, 1.27 to 1.49; <40 days: relative risk, 1.56; 95 percent confidence interval, 1.37 to 1.78; 40 to 79 days: relative risk, 1.37; 95 percent confidence interval, 1.19 to 1.59; and 80 to 180 days: relative risk, 1.27; 95 percent confidence interval, 1.14 to 1.41) and in all subgroups defined according to the presence or absence of dementia or nursing home residency. The greatest increases in risk occurred soon after therapy was initiated and with higher dosages of conventional antipsychotic medications. Increased risks associated with conventional as compared with atypical antipsychotic medications persisted in confirmatory analyses performed with the use of propensity-score adjustment and instrumental-variable estimation. Conclusions: If confirmed, these results suggest that conventional antipsychotic medications are at least as likely as atypical agents to increase the risk of death among elderly persons and that conventional drugs should not be used to replace atypical agents discontinued in response to the FDA warning.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Wang, PS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	pwang@rics.bwh.harvard.edu	Schneeweiss, Sebastian/C-2125-2013	Schneeweiss, Sebastian/0000-0003-2575-467X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069772] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH069772] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alexopoulos GS, 2004, J CLIN PSYCHIAT, V65, P5; Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; [Anonymous], 1989, PHYS CURR PROC TERM; Barak Y, 2002, J CLIN PSYCHOPHARM, V22, P115, DOI 10.1097/00004714-200204000-00003; Briesacher BA, 2005, ARCH INTERN MED, V165, P1280, DOI 10.1001/archinte.165.11.1280; BROOKHART MA, IN PRESS EPIDEMIOLOG; Chan YC, 1999, PHARMACOTHERAPY, V19, P811, DOI 10.1592/phco.19.10.811.31560; Colenda CC, 2002, AM J GERIAT PSYCHIAT, V10, P609; Department of Health and Human Services PHS, 1988, INT CLASS DIS; Dewa CS, 2002, CLIN THER, V24, P1466, DOI 10.1016/S0149-2918(02)80050-9; Dolder CR, 2002, AM J PSYCHIAT, V159, P514; Food and Drug Administration, FDA PUBL HLTH ADV DE; Giron MST, 2001, INT J GERIATR PSYCH, V16, P900, DOI 10.1002/gps.438; Kuehn BM, 2005, JAMA-J AM MED ASSOC, V293, P2462, DOI 10.1001/jama.293.20.2462; Lawlor BA, 2004, J CLIN PSYCHIAT, V65, P5; Maixner SM, 1999, J CLIN PSYCHIAT, V60, P29; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; Nasrallah HA, 2004, AM J GERIAT PSYCHIAT, V12, P437, DOI 10.1176/appi.ajgp.12.4.437; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; RJ Bowden, 1984, INSTRUMENTAL VARIABL; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Salzman C, 2005, CLIN GERIATRIC PSYCH; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; *SOC SEC ADM, 2004, SOC SEC ADM DEATH MA; STRONG C, 2005, NEUROPSYCHIATRY REV, V6, P1; Tariot PN, 1999, J CLIN PSYCHIAT, V60, P29; Wang PS, 2001, J AM GERIATR SOC, V49, P1685, DOI 10.1111/j.1532-5415.2001.49280.x; 1993, ST ANTHONYS DRG WORK	28	659	674	0	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 1	2005	353	22					2335	2341		10.1056/NEJMoa052827	http://dx.doi.org/10.1056/NEJMoa052827			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	988EO	16319382				2023-01-03	WOS:000233574600005
J	Nisoli, E; Tonello, C; Cardile, A; Cozzi, V; Bracale, R; Tedesco, L; Falcone, S; Valerio, A; Cantoni, O; Clementi, E; Moncada, S; Carruba, MO				Nisoli, E; Tonello, C; Cardile, A; Cozzi, V; Bracale, R; Tedesco, L; Falcone, S; Valerio, A; Cantoni, O; Clementi, E; Moncada, S; Carruba, MO			Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS	SCIENCE			English	Article							LIFE-SPAN EXTENSION; SACCHAROMYCES-CEREVISIAE; NITRIC-OXIDE; CELL-SURVIVAL; PPAR-GAMMA; MICE; METABOLISM; MAMMALS; WEIGHT; TISSUE	Calorie restriction extends life span in organisms ranging from yeast to mammals. Here, we report that Calorie restriction for either 3 or 12 months induced endothelial nitric oxide synthase (eNOS) expression and 3',5'-cyclic guanosine monophosphate formation in various tissues of male mice. This was accompanied by mitochondrial biogenesis, with increased oxygen consumption and adenosine triphosphate production, and an enhanced expression of sirtuin 1. These effects were strongly attenuated in eNOS null-mutant mice. Thus, nitric oxide plays a fundamental role in the processes induced by calorie restriction and may be involved in the extension of Life span in mammals.	Univ Milan, Luigi Sacco Hosp, Dept Preclin Sci, Integrated Labs Network, I-20157 Milan, Italy; Ist Auxol Italiano, I-20149 Milan, Italy; Eugenio Medea Sci Inst, I-23842 Bosisio Parini, Italy; Univ Urbino, Ist Farmacol & Farmacognosia, I-61029 Urbino, Italy; Osped San Raffaele, Dipartimento Biotecnol, Stem Cell Res Inst, I-20132 Milan, Italy; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of Milan; Luigi Sacco Hospital; IRCCS Istituto Auxologico Italiano; IRCCS Eugenio Medea; University of Urbino; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of London; University College London	Nisoli, E (corresponding author), Univ Milan, Luigi Sacco Hosp, Dept Preclin Sci, Integrated Labs Network, I-20157 Milan, Italy.	enzo.nisoli@unimi.it	Valerio, Alessandra/B-3413-2009; Nisoli, Enzo/D-6526-2014; Tedesco, Laura/HHZ-5493-2022; FALCONE, Sestina/F-6103-2014	Valerio, Alessandra/0000-0001-5844-2256; Nisoli, Enzo/0000-0002-6670-1630; FALCONE, Sestina/0000-0002-3574-0602; BRACALE, Renata/0000-0003-3650-7033; Carruba, Michele/0000-0003-4589-387X				Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Chin CH, 2004, GENE DEV, V18, P1970, DOI 10.1101/gad.1213104; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cook S, 2003, SWISS MED WKLY, V133, P360; Dere E, 2002, GENES BRAIN BEHAV, V1, P204, DOI 10.1034/j.1601-183X.2002.10402.x; Dessi-Fulgheri P, 1999, HYPERTENSION, V33, P658, DOI 10.1161/01.HYP.33.2.658; Fenster CP, 2004, FREE RADICAL BIO MED, V37, P695, DOI 10.1016/j.freeradbiomed.2004.05.021; GOODRICK CL, 1990, MECH AGEING DEV, V55, P69, DOI 10.1016/0047-6374(90)90107-Q; Higami Y, 2003, FASEB J, V17, P415, DOI 10.1096/fj.03-0678fje; Houthoofd K, 2002, EXP GERONTOL, V37, P1359, DOI 10.1016/S0531-5565(02)00172-9; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; Larrouy D, 1999, INT J OBESITY, V23, P1327, DOI 10.1038/sj.ijo.0801106; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; MASORO EJ, 1982, P NATL ACAD SCI-BIOL, V79, P4239, DOI 10.1073/pnas.79.13.4239; Miwa S, 2004, ANN NY ACAD SCI, V1019, P388, DOI 10.1196/annals.1297.069; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59	26	849	878	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	2005	310	5746					314	317		10.1126/science.1117728	http://dx.doi.org/10.1126/science.1117728			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975NV	16224023				2023-01-03	WOS:000232670100052
J	Holmberg, L; Tamini, R				Holmberg, L; Tamini, R			Reducing cancer drug doses in obese patients: dogma disputed	LANCET			English	Editorial Material							TREATMENT-RELATED TOXICITY; BODY-MASS INDEX; BREAST-CANCER; CHEMOTHERAPY; SUBGROUP; OUTCOMES; TRIALS		Univ Uppsala Hosp, Reg Oncol Ctr, S-75185 Uppsala, Sweden; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA	Uppsala University; Uppsala University Hospital; Harvard University; Brigham & Women's Hospital	Holmberg, L (corresponding author), Univ Uppsala Hosp, Reg Oncol Ctr, S-75185 Uppsala, Sweden.	lars.holmberg@akademiska.se						Chlebowski RT, 2002, J CLIN ONCOL, V20, P1128, DOI 10.1200/JCO.20.4.1128; CHLEBOWSKI RT, 2005, P ASCO, V10; Colleoni M, 2005, LANCET, V366, P1108, DOI 10.1016/S0140-6736(05)67110-3; Griggs JJ, 2005, ARCH INTERN MED, V165, P1267, DOI 10.1001/archinte.165.11.1267; Holmes MD, 2005, JAMA-J AM MED ASSOC, V293, P2479, DOI 10.1001/jama.293.20.2479; Madarnas Y, 2001, BREAST CANCER RES TR, V66, P123, DOI 10.1023/A:1010635328299; Meyerhardt JA, 2003, CANCER, V98, P484, DOI 10.1002/cncr.11544; Meyerhardt JA, 2004, J CLIN ONCOL, V22, P648, DOI 10.1200/JCO.2004.07.121; Popper K, 2003, ALL LIFE IS PROBLEM, P3; Rosenau F, 2004, CHEMBIOCHEM, V5, P153, DOI 10.1002/cbic.200300761; Rosner GL, 1996, J CLIN ONCOL, V14, P3000, DOI 10.1200/JCO.1996.14.11.3000; Rothwell PM, 2005, LANCET, V365, P176, DOI 10.1016/S0140-6736(05)17709-5; Schulz KF, 2005, LANCET, V365, P1657, DOI 10.1016/S0140-6736(05)66516-6	13	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 24	2005	366	9491					1056	1057		10.1016/S0140-6736(05)67111-5	http://dx.doi.org/10.1016/S0140-6736(05)67111-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967TL	16182880				2023-01-03	WOS:000232114000006
J	Ricaurte, GA; McCann, UD				Ricaurte, GA; McCann, UD			Recognition and management of complications of new recreational drug use	LANCET			English	Review							(ECSTASY)-INDUCED SEROTONIN NEUROTOXICITY; GAMMA-HYDROXYBUTYRATE; MDMA ECSTASY; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; CLUB DRUGS; KETAMINE; ABUSE; BUTYROLACTONE; FLUNITRAZEPAM; WITHDRAWAL	Use of illicit drugs in clubs and large dance parties (so-called raves) is a burgeoning cultural trend. Such recreational drug use is associated with several medical complications, both acute and longlasting. Although few, if any, of the drugs currently used in recreational venues are truly new, their patterns and context of use have changed (a great deal in some instances). For some of these substances, this cultural repackaging of the drug experience has resulted in various medical disorders that have previously gone undocumented. This review aims to help treating physicians recognise and manage complications associated with the use of new drugs in clubs, including methylenedioxymethamfetamine, ephedrine, gamma-hydroxybutyrate; gamma-butyrolactone, 1,4-butanediol, flunitrazepam, ketamine, and nitrites. We also alert researchers to specific toxic effects of club-drugs on which more basic information is needed.	Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Neurol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Psychiat, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Ricaurte, GA (corresponding author), Johns Hopkins Med Inst, Dept Neurol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	Ricaurte@jhmi.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009487, R01DA005707, R29DA005707, R01DA010217, R01DA013790] Funding Source: NIH RePORTER; NIDA NIH HHS [DA5707, DA13790, DA10217, DA00206, DA09487] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Andriamampandry C, 2003, FASEB J, V17, P1691, DOI 10.1096/fj.02-0846fje; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; Catalano MC, 2001, PSYCHOSOMATICS, V42, P83, DOI 10.1176/appi.psy.42.1.83; Curran HV, 2000, ADDICTION, V95, P575, DOI 10.1046/j.1360-0443.2000.9545759.x; de la Torre R, 2000, BRIT J CLIN PHARMACO, V49, P104, DOI 10.1046/j.1365-2125.2000.00121.x; Diehl JL, 2000, ANN MED INTERNE, V151, pA44; Doyon S, 2001, CURR OPIN PEDIATR, V13, P170, DOI 10.1097/00008480-200104000-00015; Druid H, 2001, FORENSIC SCI INT, V122, P136, DOI 10.1016/S0379-0738(01)00481-9; Dyer JE, 2001, ANN EMERG MED, V37, P147, DOI 10.1067/mem.2001.112985; *EMCDDA, STAT DRUGS PROBL EUR; FARRE M, 2001, DRUG ALCOHOL DEPEN S, V63, pS46; Galloway GP, 1997, ADDICTION, V92, P89, DOI 10.1111/j.1360-0443.1997.tb03640.x; Giannini A J, 2000, Am J Ther, V7, P389; Graeme KA, 2000, EMERG MED CLIN N AM, V18, P625, DOI 10.1016/S0733-8627(05)70150-4; GREEN AR, 1995, PSYCHOPHARMACOLOGY, V119, P247, DOI 10.1007/BF02246288; Green SM, 2000, ACAD EMERG MED, V7, P278, DOI 10.1111/j.1553-2712.2000.tb01076.x; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; Hartung TK, 2002, QJM-INT J MED, V95, P431, DOI 10.1093/qjmed/95.7.431; Henry JA, 1998, LANCET, V351, P1784, DOI 10.1016/S0140-6736(05)78744-4; HENRY JA, 1992, LANCET, V340, P384, DOI 10.1016/0140-6736(92)91469-O; Jansen KLR, 2001, J PSYCHOACTIVE DRUGS, V33, P151, DOI 10.1080/02791072.2001.10400480; Johnston L D., 2003, MONITORING FUTURE NA, VII; Johnston L. D., 2003, MONITORING FUTURE NA, V1; Jones AL, 1999, ALIMENT PHARM THER, V13, P129; Kalant H, 2001, CAN MED ASSOC J, V165, P917; Koesters SC, 2002, PEDIATR CLIN N AM, V49, P415, DOI 10.1016/S0031-3955(01)00012-8; Kraner JC, 2001, J ANAL TOXICOL, V25, P645, DOI 10.1093/jat/25.7.645; Mallick A, 1997, J ACCID EMERG MED, V14, P336; McCann UD, 2000, NEUROPSYCHOBIOLOGY, V42, P11, DOI 10.1159/000026665; Miotto K, 2001, AM J ADDICTION, V10, P232; NEWELL GR, 1985, AM J MED, V78, P811, DOI 10.1016/0002-9343(85)90288-8; Nicholson KL, 2001, DRUG ALCOHOL DEPEN, V63, P1, DOI 10.1016/S0376-8716(00)00191-5; OCONNOR B, 1994, BRIT J HOSP MED, V52, P507; OLNEY JW, 1995, NEUROPSYCHOPHARMACOL, V13, P335, DOI 10.1038/sj.npp.1380292; Pal HR, 2002, ANAESTH INTENS CARE, V30, P382, DOI 10.1177/0310057X0203000323; Reneman L, 2001, LANCET, V358, P1864, DOI 10.1016/S0140-6736(01)06888-X; Ricaurte GA, 2000, NEUROPSYCHOBIOLOGY, V42, P5, DOI 10.1159/000026664; RICAURTE GA, 1995, NEUROLOGY GEN MED, P631; Ricaurte George A., 2003, Science (Washington D C), V301, P1479; Romanelli F, 2004, PHARMACOTHERAPY, V24, P69, DOI 10.1592/phco.24.1.69.34801; Ropero-Miller JD, 1998, CLIN LAB MED, V18, P727; Samenuk D, 2002, MAYO CLIN PROC, V77, P12, DOI 10.4065/77.1.12; Schneir AB, 2001, J EMERG MED, V21, P31, DOI 10.1016/S0736-4679(01)00324-9; Shannon M, 2000, PEDIATR EMERG CARE, V16, P377, DOI 10.1097/00006565-200010000-00022; Shannon M, 2000, PEDIATR EMERG CARE, V16, P435, DOI 10.1097/00006565-200012000-00017; Simmons MM, 1998, ANN PHARMACOTHER, V32, P117, DOI 10.1345/aph.17027; Sivilotti MLA, 2001, ANN EMERG MED, V38, P660, DOI 10.1067/mem.2001.119454; Smith KM, 2002, AM J HEALTH-SYST PH, V59, P1067, DOI 10.1093/ajhp/59.11.1067; Traub SJ, 2002, J URBAN HEALTH, V79, P549, DOI 10.1093/jurban/79.4.549; Verbaten MN, 2003, HUM PSYCHOPHARM CLIN, V18, P281, DOI 10.1002/hup.482; Weinbroum AA, 1997, DRUG SAFETY, V17, P181, DOI 10.2165/00002018-199717030-00004; Weiner AL, 2000, J EMERG MED, V18, P447, DOI 10.1016/S0736-4679(00)00162-1; Williams A, 1997, NEPHROL DIAL TRANSPL, V12, P361, DOI 10.1093/ndt/12.2.361; Woods JH, 1997, J CLIN PSYCHOPHARM, V17, pS1, DOI 10.1097/00004714-199706001-00001; WRIGHT HH, 1988, SOUTHERN MED J, V81, P565, DOI 10.1097/00007611-198805000-00005; Zvosec DL, 2001, NEW ENGL J MED, V344, P87, DOI 10.1056/NEJM200101113440202	56	97	98	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2137	2145		10.1016/S0140-6736(05)66737-2	http://dx.doi.org/10.1016/S0140-6736(05)66737-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	936LZ	15964451				2023-01-03	WOS:000229858800031
J	Quill, TE				Quill, TE			Terri Schiavo - A tragedy compounded	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Rochester, Med Ctr, Ctr Palliat Care & Clin Eth, Rochester, NY 14642 USA	University of Rochester	Quill, TE (corresponding author), Univ Rochester, Med Ctr, Ctr Palliat Care & Clin Eth, Rochester, NY 14642 USA.							ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Ganzini L, 2003, NEW ENGL J MED, V349, P359, DOI 10.1056/NEJMsa035086; Gostin L, 1991, Law Med Health Care, V19, P9; JENNETT B, 2002, VEGETATIVE STATE MED; *MULT TASK FORC PV, 1995, NEW ENGL J MED, V333, P130	5	77	80	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 21	2005	352	16					1630	+		10.1056/NEJMp058062	http://dx.doi.org/10.1056/NEJMp058062			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	918CE	15784658				2023-01-03	WOS:000228515200002
J	Rosvold, EA; Tyssen, R				Rosvold, EA; Tyssen, R			Should physicians' self-prescribing be restricted by law?	LANCET			English	Editorial Material							MENTAL-HEALTH PROBLEMS; DOCTORS; CARE		Univ Oslo, Fac Med, Inst Gen Practice & Community Med, N-0318 Oslo, Norway; Univ Oslo, Fac Med, Dept Behav Sci Med, Inst Basic Med Sci, N-0318 Oslo, Norway	University of Oslo; University of Oslo	Rosvold, EA (corresponding author), Univ Oslo, Fac Med, Inst Gen Practice & Community Med, N-0318 Oslo, Norway.	e.o.rosvold@medisin.uio.no						Forsythe M, 1999, BRIT MED J, V319, P605, DOI 10.1136/bmj.319.7210.605; Fromme E, 2003, JAMA-J AM MED ASSOC, V290, P2048, DOI 10.1001/jama.290.15.2048; Garfinkel PE, 1997, CAN J PSYCHIAT, V42, P764, DOI 10.1177/070674379704200710; HUGHES PH, 1992, JAMA-J AM MED ASSOC, V267, P2333, DOI 10.1001/jama.267.17.2333; Ingstad B., 2001, ANTHROPOL MED, V8, P201, DOI [10.1080/13648470120101372, DOI 10.1080/13648470120101372, DOI 10.HTTP://DX.D0I.0RG/10.1080/13648470120101372]; Kay Margaret, 2005, Aust Fam Physician, V34, P94; LOTT DA, 2001, PSYCHIAT TIMES, V18; ROSVOLD EO, 2002, THESIS U OSLO OSLO N; Schneck SA, 1998, JAMA-J AM MED ASSOC, V280, P2039, DOI 10.1001/jama.280.23.2039; STOUDEMIRE A, 1983, ANN INTERN MED, V98, P654, DOI 10.7326/0003-4819-98-5-654; Toyry S, 2000, ARCH FAM MED, V9, P1079, DOI 10.1001/archfami.9.10.1079; Tyssen R, 2004, SOC PSYCH PSYCH EPID, V39, P989, DOI 10.1007/s00127-004-0831-8; Tyssen R, 2002, HARVARD REV PSYCHIAT, V10, P154, DOI 10.1080/10673220216218	13	15	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 16	2005	365	9468					1372	1374		10.1016/S0140-6736(05)66353-2	http://dx.doi.org/10.1016/S0140-6736(05)66353-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916QY	15836873				2023-01-03	WOS:000228401900009
J	Elden, H; Ladfors, L; Olsen, MF; Ostgaard, HC; Hagberg, H				Elden, H; Ladfors, L; Olsen, MF; Ostgaard, HC; Hagberg, H			Effects of acupuncture and stabilising exercises as adjunct to standard treatment in pregnant women with pelvic girdle pain: randomised single blind controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-BACK-PAIN	Objectives To compare the efficacy of standard treatment, standard treatment plus acupuncture, and standard treatment plus stabihsing exercises for pelvic girdle pain during pregnancy. Design Randomised single blind controlled trial. Settings East Hospital and 27 maternity care centres in Gothenburg, Sweden. Participants 386 pregnant women with pelvic girdle pain. Interventions Treatment for six weeks with standard treatment (n = 130), standard treatment plus acupuncture (n = 125), or standard treatment plus stabilising exercises (n = 11). Main outcome measures Primary outcome measure was pain (visual analogue scale); secondary outcome measure was assessment of severity of pelvic girdle pain by an independent examiner before and after treatment. Results After treatment the stabilising exercise group had less pain than the standard group in the morning (median difference = 9, 95% confidence interval 1.7 to 12.8; P = 0.0312) and in the evening (13, 2.7 to 17.5; P = 0.0245). The acupuncture group bad less pain in the evening than the stabilising exercise group (- 14, - 18.1 to - 3.3; P = 0.0130). The acupuncture group had less pain than the standard treatment group in the morning (12, 5.9 to 17.3; P < 0.001) and in the evening (27,13.3 to 29.5; P < 0.001). Attenuation of pelvic girdle pain as assessed by the independent examiner was greatest in the acupuncture group. Conclusion Acupuncture and stabilising exercises are efficient complements to standard treatment for the management of pelvic girdle pain during pregnancy. Acupuncture was superior to stabilising exercises in this study.	East Hosp, Sahlgrenska Acad, Inst Hlth Women & Children, Dept Obstet & Gynecol,Perinatal Ctr, S-41685 Gothenburg, Sweden; Sahlgrenska Hosp, Sahlgrenska Acad, Dept Occupat Therapy & Phys Therapy, Antenatal Unit, Gothenburg, Sweden; Molndal Cty Hosp, Sahlgrenska Acad, Dept Orthoped, Molndal, Sweden	University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; University of Gothenburg	Elden, H (corresponding author), East Hosp, Sahlgrenska Acad, Inst Hlth Women & Children, Dept Obstet & Gynecol,Perinatal Ctr, S-41685 Gothenburg, Sweden.	helen.elden@vgregion.se	Corteling, Shavonne/A-8424-2012	Elden, Helen/0000-0003-0000-0476; Ladfors, Lars/0000-0002-7512-2059; Hagberg, Henrik/0000-0003-3962-1448				Albert H, 2000, EUR SPINE J, V9, P161, DOI 10.1007/s005860050228; Albert HB, 2002, SPINE, V27, P2831, DOI 10.1097/00007632-200212150-00020; ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5; Bjorklund K, 2000, ACTA OBSTET GYN SCAN, V79, P24, DOI 10.1034/j.1600-0412.2000.079001024.x; Carlsson CPO, 2001, CLIN J PAIN, V17, P296, DOI 10.1097/00002508-200112000-00003; COAN RM, 1980, AM J CHINESE MED, V8, P181, DOI 10.1142/S0192415X80000141; Kristiansson P, 1996, SPINE, V21, P2337, DOI 10.1097/00007632-199610150-00006; Kvorning N, 2004, ACTA OBSTET GYN SCAN, V83, P246; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Ostgaard H C, 1994, Eur Spine J, V3, P258, DOI 10.1007/BF02226575; Ostgaard HC, 1996, SPINE, V21, P2777, DOI 10.1097/00007632-199612010-00013; OSTGAARD HC, 1994, SPINE, V19, P894; Ostgaard HC, 1997, SPINE, V22, P2945, DOI 10.1097/00007632-199712150-00018; Pool-Goudzwaard A. L., 1998, Man Ther, V3, P12, DOI 10.1054/math.1998.0311; Richardson CA, 2002, SPINE, V27, P399, DOI 10.1097/00007632-200202150-00015; RICHARDSON CA, 2000, MAN THER, V1, P2; Sihvonen T, 1998, ARCH PHYS MED REHAB, V79, P1210, DOI 10.1016/S0003-9993(98)90264-7; Stuge B, 2004, SPINE, V29, pE197, DOI 10.1097/00007632-200405150-00021; Stuge B, 2003, ACTA OBSTET GYN SCAN, V82, P983, DOI 10.1034/j.1600-0412.2003.00125.x; Wedenberg K, 2000, ACTA OBSTET GYN SCAN, V79, P331, DOI 10.1034/j.1600-0412.2000.079005331.x; Wu WH, 2004, EUR SPINE J, V13, P575, DOI 10.1007/s00586-003-0615-y; Young G L, 2002, Cochrane Database Syst Rev, pCD000121	22	110	118	1	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	2005	330	7494					761	764A		10.1136/bmj.38397.507014.E0	http://dx.doi.org/10.1136/bmj.38397.507014.E0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914JE	15778231	Green Published, Bronze			2023-01-03	WOS:000228222900022
J	Markowitz, AJ; McPhee, S				Markowitz, AJ; McPhee, S			Caring for the child with cancer at the close of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article														Markowitz, Amy/0000-0001-9314-2814				Hurwitz CA, 2004, JAMA-J AM MED ASSOC, V292, P2141, DOI 10.1001/jama.292.17.2141	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	2005	293	11					1382	1382		10.1001/jama.293.11.1382	http://dx.doi.org/10.1001/jama.293.11.1382			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	907EP	15769972				2023-01-03	WOS:000227698600027
J	Mills, EJ; Nachega, JB; Buchan, I; Orbinski, J; Attaran, A; Singh, S; Rachlis, B; Wu, P; Cooper, C; Thabane, L; Wilson, K; Guyatt, GH; Bangsberg, DR				Mills, Edward J.; Nachega, Jean B.; Buchan, Iain; Orbinski, James; Attaran, Amir; Singh, Sonal; Rachlis, Beth; Wu, Ping; Cooper, Curtis; Thabane, Lehana; Wilson, Kumanan; Guyatt, Gordon H.; Bangsberg, David R.			Adherence to antiretroviral therapy in sub-Saharan Africa and North America - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HIV-INFECTED PERSONS; QUALITY-OF-LIFE; MEDICATION ADHERENCE; SOUTH-AFRICA; PROTEASE INHIBITORS; REPORTED ADHERENCE; DRUG-RESISTANCE; HAART ADHERENCE; SUBSTANCE USE; VIRAL LOAD	Context Adherence to antiretroviral therapy is a powerful predictor of survival for individuals living with human immunodeficiency virus (HIV) and AIDS. Concerns about incomplete adherence among patients living in poverty have been an important consideration in expanding the access to antiretroviral therapy in sub-Saharan Africa. Objective To evaluate estimates of antiretroviral therapy adherence in sub-Saharan Africa and North America. Data Sources Eleven electronic databases were searched along with major conference abstract databases (inclusion dates: inception of database up until April 18, 2006) for all English-language articles and abstracts; and researchers and treatment advocacy groups were contacted. Study Selection and Data Abstraction To best reflect the general population, studies of mixed populations in both North America and Africa were selected. Studies evaluating specific populations such as men only, homeless individuals, or drug users, were excluded. The data were abstracted in duplicate on study adherence outcomes, thresholds used to determine adherence, and characteristics of the populations. A random-effects meta-analysis was performed in which heterogeneity was examined using multivariable random-effects logistic regression. A sensitivity analysis was performed using Bayesian methods. Data Synthesis Thirty-one studies from North America (28 full-text articles and 3 abstracts) and 27 studies (9 full-text articles and 18 abstracts) from sub-Saharan Africa were included. African studies represented 12 sub-Saharan countries. Of the North American studies, 71% used patient self-report to assess adherence; this was true of 66% of the African assessments. Studies reported similar thresholds for adherence monitoring (eg, 100%, > 95%, > 90%, > 80%). A pooled analysis of the North American studies (17 573 patients total) indicated a pooled estimate of 55% (95% confidence interval, 49%-62%; I-2, 98.6%) of the populations achieving adequate levels of adherence. Our pooled analysis of African studies (12 116 patients total) indicated a pooled estimate of 77% (95% confidence interval, 68%-85%; I-2, 98.4%). Study continent, adherence thresholds, and study quality were significant predictors of heterogeneity. Bayesian analysis was used as an alternative statistical method for combining adherence rates and provided similar findings. Conclusion Our findings indicate that favorable levels of adherence, much of which was assessed via patient self-report, can be achieved in sub-Saharan African settings and that adherence remains a concern in North America.	Ctr Int Hlth & Human Rights Studies, Toronto, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa; Univ Manchester, Sch Med, NW Inst Biohlth Informat, Manchester, Lancs, England; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Ottawa, Ctr Global Hlth, Ottawa, ON, Canada; Univ Ottawa, Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, MPH Program, Baltimore, MD USA; Wake Forest Univ, Dept Med, Winston Salem, NC 27109 USA; St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; London Sch Hyg & Trop Med, Dept Epidemiol, London WC1, England; Univ Calif San Francisco, San Francisco Gen Hosp, Epidemiol & Prevent Intervent Ctr, San Francisco, CA USA	McMaster University; University of Cape Town; University of Manchester; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Wake Forest University; B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of London; London School of Hygiene & Tropical Medicine; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Mills, EJ (corresponding author), Ctr Int Hlth & Human Rights Studies, 1255 Sheppard Ave E, N York, ON M2K 1E2, Canada.	emills@cihhrs.org	Franzeck, Fabian C/B-5055-2011; Buchan, Iain E/H-5767-2013; Singh, Sonal/A-4614-2008; Cooper, Curtis/M-9320-2019	Buchan, Iain E/0000-0003-3392-1650; Singh, Sonal/0000-0003-0912-941X; Nachega, Jean/0000-0002-2862-4443	NIAAA NIH HHS [AA015287] Funding Source: Medline; NIAID NIH HHS [AI005535901, AI27763] Funding Source: Medline; NIMH NIH HHS [R01 MH054907, MH54907] Funding Source: Medline; PHS HHS [K23A106858201] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K24AA015287] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Acri T, 2005, AIDS PATIENT CARE ST, V19, P167, DOI 10.1089/apc.2005.19.167; ADEDAYO A, 2005, 12 C RETR OPP INF FE; AKAM A, 2004, 15 INT AIDS C JUL 11; Akileswaran C, 2005, CLIN INFECT DIS, V41, P376, DOI 10.1086/431482; Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008; Attaran A, 2001, WASHINGTON POST 0615, pA33; Bangsberg DR, 2006, AIDS, V20, P140, DOI 10.1097/01.aids.0000196168.50303.31; Bangsberg DR, 2003, AIDS, V17, P1925, DOI 10.1097/00002030-200309050-00011; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Becker Stephen L, 2002, MedGenMed, V4, P21; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; BOILEU C, 2005, 12 C RETR OPP INF FE; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; BROWN S, 2004, 15 INT AIDS C JUL 11; BYAKIKA J, 2005, 12 C RETR OPP INF FE; Byakika-Tusiime J, 2005, INT J STD AIDS, V16, P38, DOI 10.1258/0956462052932548; Castillo E, 2004, AIDS CARE, V16, P446, DOI 10.1080/09540120410001683385; Cook RL, 2001, J GEN INTERN MED, V16, P83, DOI 10.1046/j.1525-1497.2001.00122.x; CRANE JT, 2006, AIDS BEHAV      0425; DANIEL O, 2004, 15 INT AIDS C JUL 11; DARDER M, 2004, 15 INT AIDS C JUL 11; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diamond C, 2005, JAIDS-J ACQ IMM DEF, V39, P211; EHOLIE E, 2004, 15 INT AIDS C JUL 11; Eldred LJ, 1998, J ACQ IMMUN DEF SYND, V18, P117, DOI 10.1097/00042560-199806010-00003; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Ferguson TF, 2002, AIDS CARE, V14, P607, DOI 10.1080/0954012021000005434; FERRIS D, 2004, 15 INT AIDS C JUL 11; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Gebo KA, 2003, J GEN INTERN MED, V18, P104, DOI 10.1046/j.1525-1497.2003.10801.x; Gifford AL, 2000, J ACQ IMMUN DEF SYND, V23, P386; Gill CJ, 2005, AIDS, V19, P1243, DOI 10.1097/01.aids.0000180094.04652.3b; Graney Marshall J, 2003, Tenn Med, V96, P73; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Heckman BD, 2004, AIDS CARE, V16, P219, DOI 10.1080/09540120410001641066; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hinkin CH, 2004, AIDS, V18, pS19, DOI 10.1097/00002030-200418001-00004; HOSSEINIPOUR MC, 2004, EJOURNAL INT AIDS SO; Idigbe EO, 2005, JAIDS-J ACQ IMM DEF, V40, P65, DOI 10.1097/01.qai.0000159516.39982.1b; Iliyasu Z, 2005, Niger J Med, V14, P290; Ingersoll KS, 2005, AIDS BEHAV, V9, P89, DOI 10.1007/s10461-005-1684-1; Jaynes E.T., 1976, FDN PROBABILITY THEO, P175, DOI DOI 10.1007/978-94-010-1436-6_6; Johnson MO, 2005, J PAIN SYMPTOM MANAG, V29, P193, DOI 10.1016/j.jpainsymman.2004.05.005; *JOINT UN PROGR HI, UN WORLD AIDS; Kalichman SC, 2005, HEALTH EDUC RES, V20, P24, DOI 10.1093/her/cyg106; KARCHER H, 2004, EJOURNAL INT AIDS SO; Laniece I, 2003, AIDS, V17, pS103, DOI 10.1097/00002030-200317003-00014; Laurent C, 2002, AIDS, V16, P1363, DOI 10.1097/00002030-200207050-00008; Laurent C, 2004, LANCET, V364, P29, DOI 10.1016/S0140-6736(04)16586-0; Levine AJ, 2005, AIDS BEHAV, V9, P355, DOI 10.1007/s10461-005-9009-y; Liechty CA, 2003, AIDS, V17, P1383, DOI 10.1097/00002030-200306130-00013; Liu HH, 2001, ANN INTERN MED, V134, P968, DOI 10.7326/0003-4819-134-10-200105150-00011; Mannheimer SB, 2005, AIDS CARE, V17, P10, DOI 10.1080/09540120412331305098; Meade MO, 2001, AM J RESP CRIT CARE, V163, P490, DOI 10.1164/ajrccm.163.2.2006067; MILLS E, 2005, ONT HIV TREATM NETW; Mohammed H, 2004, AIDS PATIENT CARE ST, V18, P289, DOI 10.1089/108729104323076025; MONTESSORI V, 2000, 7 C RETR OPP INF FEB; Moss AR, 2004, CLIN INFECT DIS, V39, P1190, DOI 10.1086/424008; MUGANZI A, 2004, 15 INT AIDS C JUL 11; NACHEGA J, 2005, 12 C RETR OPP INF FE; Nachega JB, 2005, JAIDS-J ACQ IMM DEF, V38, P196, DOI 10.1097/00126334-200502010-00011; Nachega JB, 2004, AIDS RES HUM RETROV, V20, P1053, DOI 10.1089/aid.2004.20.1053; NACHEGA JB, 2005, STAT SCI M RES IMPR; OKONGO B, 2004, 15 INT AIDS C JUL 11; OMES C, 2004, 15 INT AIDS C JUL 11; Orrell C, 2003, AIDS, V17, P1369, DOI 10.1097/00002030-200306130-00011; Orrell Catherine, 2005, Curr HIV/AIDS Rep, V2, P171, DOI 10.1007/s11904-005-0012-8; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Palepu A, 2003, JAIDS-J ACQ IMM DEF, V32, P522, DOI 10.1097/00126334-200304150-00009; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Penedo FJ, 2003, J PSYCHOSOM RES, V54, P271, DOI 10.1016/S0022-3999(02)00482-8; Power R, 2003, AIDS PATIENT CARE ST, V17, P245, DOI 10.1089/108729103321655890; RAMADHANI HO, 2006, 13 C RETR OPP INF FE; Robert C.P., 2004, TECHNOMETRICS, DOI DOI 10.2307/1270959; ROBERTSON K, 2006, 13 C RETR OPP INF FE; RUEDA S, 2005, ONT HIV TREATM NETW; Russell J, 2004, J ASSOC NURSE AIDS C, V15, P40, DOI 10.1177/1055329004269283; Samet JH, 2004, ALCOHOL CLIN EXP RES, V28, P572, DOI 10.1097/01.ALC.0000122103.74491.78; Schneider J, 2004, J GEN INTERN MED, V19, P1096, DOI 10.1111/j.1525-1497.2004.30418.x; Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908; SHIHAB H, 2004, 15 INT AIDS C JUL 11; Stuart A, 1994, KENDALLS ADV THEORY; TEMOSHOK L, 2004, 15 INT AIDS C JUL 11; Tesoriero J, 2003, JAIDS-J ACQ IMM DEF, V33, P484, DOI 10.1097/00126334-200308010-00009; TRAORE A, 2004, 15 INT AIDS C JUL 11; TU D, 2004, 15 INT AIDS C JUL 11; Tucker JS, 2003, AM J MED, V114, P573, DOI 10.1016/S0002-9343(03)00093-7; van Oosterhout JJ, 2005, TROP MED INT HEALTH, V10, P464, DOI 10.1111/j.1365-3156.2005.01409.x; Vist GE, 2005, BMJ-BRIT MED J, V330, P1175, DOI 10.1136/bmj.330.7501.1175; Wagner GJ, 2002, AIDS CARE, V14, P105, DOI 10.1080/09540120220097973; Weiser S, 2003, JAIDS-J ACQ IMM DEF, V34, P281, DOI 10.1097/00126334-200311010-00004; Weiss L, 2003, AIDS CARE, V15, P673, DOI 10.1080/09540120310001595159; *WHO WEB SIT, 3 5 IN COUNTR PROF; Wilson IB, 2001, J ACQ IMMUN DEF SYND, V28, P259, DOI 10.1097/00042560-200111010-00009; Wood E, 2003, CAN MED ASSOC J, V169, P656; Wood E, 2003, AIDS, V17, P711, DOI 10.1097/00002030-200303280-00009; Wood E, 2002, AIDS, V16, P2065, DOI 10.1097/00002030-200210180-00012; 2005, LANCET, V365, P1597	99	641	654	1	45	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2006	296	6					679	690		10.1001/jama.296.6.679	http://dx.doi.org/10.1001/jama.296.6.679			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071LN	16896111				2023-01-03	WOS:000239603800030
J	Simpson, SH; Eurich, DT; Majumdar, SR; Padwal, RS; Tsuyuki, RT; Varney, J; Johnson, JA				Simpson, Scot H.; Eurich, Dean T.; Majumdar, Sumit R.; Padwal, Rajdeep S.; Tsuyuki, Ross T.; Varney, Janice; Johnson, Jeffrey A.			A meta-analysis of the association between adherence to drug therapy and mortality	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; MYOCARDIAL-INFARCTION; PATIENT ADHERENCE; OUTCOMES; IMPACT; RECOMMENDATIONS; NONCOMPLIANCE; PROPHYLAXIS; MEDICATIONS; PREVENTION	Objective To evaluate the relation between adherence to drug therapy, including placebo, and mortality. Design Meta-analysis of observational Studies. Data sources Electronic databases, contact with investigators, and textbooks and reviews on adherence. Review methods Predefined criteria were used to select studies reporting mortality among participants with good and poor adherence to drug therapy. Data were extracted for disease, drug therapy groups, methods for measurement of adherence rate, definition for good adherence, and mortality. Results Data were available from 21 studies (46 847 participants), including eight studies with placebo arms (19 633 participants). Compared with poor adherence, good adherence was associated with lower mortality (odds ratio 0,56, 95% confidence interval 0.50 to 0.63). Good adherence to placebo was associated with lower mortality (0.56, 0.43 to 0.74), as was good adherence to beneficial drug therapy (0.55, 0.49 to 0.62). Good adherence to harmful drug therapy was associated with increased mortality (2.90,1.04 to 8.11). Conclusion Good adherence to drug therapy is associated with positive health Outcomes. Moreover, the observed association between good adherence to placebo and mortality supports the existence of die "healthy adherer" effect, whereby adherence to drug therapy may be a Surrogate marker for overall health), behaviour.	Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada; Inst Hlth Econ, Edmonton, AB, Canada; Univ Alberta, Fac Med & Dent, Dept Med, Div Internal Med, Edmonton, AB T6G 2M7, Canada; Univ Alberta, Fac Med & Dent, Dept Med, Div Cardiol, Edmonton, AB T6G 2M7, Canada; Univ Alberta, Fac Med & Dent, Dept Publ Hlth Sci, Edmonton, AB T6G 2M7, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta	Simpson, SH (corresponding author), Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.	ssimpson@pharmacy.ualberta.ca	Tsuyuki, Ross T/E-2462-2016; Padwal, Raj/G-6903-2016	Tsuyuki, Ross T/0000-0002-3724-598X; Johnson, Jeffrey/0000-0001-8290-2857; Simpson, Scot/0000-0002-9880-2129; Padwal, Raj/0000-0003-3541-2817				Boudes P, 1998, CONTROL CLIN TRIALS, V19, P257, DOI 10.1016/S0197-2456(98)00005-1; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; Ciechanowski PS, 2000, ARCH INTERN MED, V160, P3278, DOI 10.1001/archinte.160.21.3278; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cohn SE, 2002, CLIN INFECT DIS, V34, P1129, DOI 10.1086/339542; CONRAD P, 1985, SOC SCI MED, V20, P29, DOI 10.1016/0277-9536(85)90308-9; CORNFEIL.J, 1971, J AMER MED ASSOC, V217, P1676, DOI 10.1001/jama.217.12.1676; Cotter G, 2004, AM HEART J, V147, P293, DOI 10.1016/j.ahj.2003.07.011; Cramer JA, 2004, DIABETES CARE, V27, P1218, DOI 10.2337/diacare.27.5.1218; CZAJKOWSKI SM, 1990, HDB HLTH BEHAV CHANG, P515; de Olalla PG, 2002, J ACQ IMMUN DEF SYND, V30, P105, DOI 10.1097/00042560-200205010-00014; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DiMatteo MR, 2002, MED CARE, V40, P794, DOI 10.1097/01.MLR.0000024612.61915.2D; DiMatteo MR, 2004, MED CARE, V42, P200, DOI 10.1097/01.mlr.0000114908.90348.f9; Dobbels F, 2004, J HEART LUNG TRANSPL, V23, P1245, DOI 10.1016/j.healun.2003.09.016; DONOVAN JL, 1995, INT J TECHNOL ASSESS, V11, P443, DOI 10.1017/S0266462300008667; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; EFRON B, 1991, J AM STAT ASSOC, V86, P9, DOI 10.2307/2289707; Ellis S, 2000, CONTROL CLIN TRIALS, V21, p218S, DOI 10.1016/S0197-2456(00)00082-9; Fogarty L, 2002, PATIENT EDUC COUNS, V46, P93, DOI 10.1016/S0738-3991(01)00219-1; GALLAGHER EJ, 1993, JAMA-J AM MED ASSOC, V270, P742, DOI 10.1001/jama.270.6.742; GLYNN RJ, 1994, ARCH INTERN MED, V154, P2649, DOI 10.1001/archinte.1994.00420230032005; Grimwade K, 2005, AIDS, V19, P163, DOI 10.1097/00002030-200501280-00008; HAYNES RB, 1987, CONTROL CLIN TRIALS, V8, P12, DOI 10.1016/0197-2456(87)90021-3; HAYS RD, 1994, J BEHAV MED, V17, P347, DOI 10.1007/BF01858007; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; Howell N., 2004, PHARM J, V272, P23; Irvine J, 1999, PSYCHOSOM MED, V61, P566, DOI 10.1097/00006842-199907000-00023; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; McDermott MM, 1997, ARCH INTERN MED, V157, P1921, DOI 10.1001/archinte.157.17.1921; MEINERT CL, 1970, DIABETES, V19, P789; Miller NH, 1997, CIRCULATION, V95, P1085; Miura T, 2001, EUR J CLIN PHARMACOL, V57, P77, DOI 10.1007/s002280100272; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; MORRIS LS, 1992, J CLIN PHARM THER, V17, P283, DOI 10.1111/j.1365-2710.1992.tb01306.x; Myers LB, 1998, ADHERENCE TREATMENT; ObiasManno D, 1996, ANN EPIDEMIOL, V6, P93, DOI 10.1016/1047-2797(95)00134-4; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; REBOLLO FJS, 2004, AN MED INTERN, V21, P523; RUDD P, 1979, ARCH INTERN MED, V139, P627, DOI 10.1001/archinte.139.6.627; Shepherd J, 1997, EUR HEART J, V18, P1718; SHUMAKER SA, 1990, HDB HLTH BEHAV CHANG; Simoni Jane M, 2003, Top HIV Med, V11, P185; Spilker B., 1991, PATIENT COMPLIANCE M; Tobias A., 1999, STATA TECH B, V47, P15; Wei L, 2002, HEART, V88, P229, DOI 10.1136/heart.88.3.229; Wei L, 2004, PHARMACOEPIDEM DR S, V13, P761, DOI 10.1002/pds.963; WEINTRAUB M, 1981, CONTEMP PHARM PRACT, V4, P8; Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008	53	844	869	3	41	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2006	333	7557					15	18		10.1136/bmj.38875.675486.55	http://dx.doi.org/10.1136/bmj.38875.675486.55			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	062CT	16790458	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000238922900019
J	Choi, JM; Ahn, MH; Chae, WJ; Jung, YG; Park, JC; Song, HM; Kim, YE; Shin, JA; Park, CS; Park, JW; Park, TK; Lee, JH; Seo, BF; Kim, KD; Kim, ES; Lee, DH; Lee, SK; Lee, SK				Choi, Je-Min; Ahn, Mi-Hyun; Chae, Wook-Jin; Jung, Yung-Gook; Park, Jae-Chul; Song, Hyun-Mi; Kim, Young-Eun; Shin, Jung-Ah; Park, Choon-Sik; Park, Jung-Won; Park, Tae-Kwann; Lee, Jung-Hoon; Seo, Byung-Fhy; Kim, Kyun-Do; Kim, Eun-Sung; Lee, Dong-Ho; Lee, Seung-Kyou; Lee, Sang-Kyou			Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation	NATURE MEDICINE			English	Article							CD4(+) T-CELLS; AIRWAY HYPERRESPONSIVENESS; IN-VIVO; TYROSINE PHOSPHATASE; INHIBITORY RECEPTORS; MAMMALIAN-CELLS; ASTHMA; MOUSE; ACTIVATION; MODEL	CTLA-4 is a negative regulator of T-cell activation, and its inhibitory effects can be accomplished either by competition with CD28 or by transmitting negative signals through its intracellular domain. To utilize the cytoplasmic domain of CTLA-4 to suppress allergic inflammation, we fused it to a novel protein-transduction domain in the human transcriptional factor Hph-1. Transduction efficiency was verified in vitro and in vivo after ocular, intranasal and intradermal administration. After transduction into T cells, the Hph-1 ctCTLA-4 fusion protein inhibited the production of interleukin (IL)-2, and downregulated CD69 and CD25. Intranasal administration of Hph-1-ctCTLA-4 resulted in markedly reduced infiltration of inflammatory cells, secretion of T helper type 2 (T(H)2) cytokines, serum IgE levels and airway hyper-responsiveness in a mouse model of allergic airway inflammation. These results indicated that Hph-1-ctCTLA-4 constitutes an effective immunosuppressive protein drug for potential use in the treatment of allergic asthma, via nasal administration.	Yonsei Univ, Coll Engn, Dept Biotechnol, Seoul 120749, South Korea; Soonchunhyang Univ Hosp, Genome Res Ctr Allergy & Resp Dis, Puchon 420767, South Korea; Yonsei Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, Seoul 120749, South Korea; Soonchunhyang Univ Hosp, Dept Ophthalmol, Puchon 420767, South Korea; Chungnam Natl Univ Hosp, Dept Dermatol, Taejon 301721, South Korea; Amorepacific Co, R&D Ctr, Skin Res Inst, Yongin 449729, South Korea; ForHumanTech Co Ltd, Suwon, South Korea	Yonsei University; Soonchunhyang University; Soonchunhyang University Hospital; Yonsei University; Soonchunhyang University; Soonchunhyang University Hospital; Chungnam National University; Chungnam National University Hospital; Samsung	Lee, SK (corresponding author), Yonsei Univ, Coll Engn, Dept Biotechnol, Seoul 120749, South Korea.	sjrlee@yonsei.ac.kr		Park, Choon-Sik/0000-0003-2977-0255; Park, Tae Kwann/0000-0001-9689-4384; Choi, Je-Min/0000-0002-9482-710X; Park, Jung-Won/0000-0003-0249-8749				Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Busch R, 2004, J IMMUNOL METHODS, V286, P97, DOI 10.1016/j.jim.2003.12.012; Calvo CR, 1997, J EXP MED, V186, P1645, DOI 10.1084/jem.186.10.1645; Chikuma S, 2005, J IMMUNOL, V175, P177, DOI 10.4049/jimmunol.175.1.177; Guntermann C, 2002, J IMMUNOL, V168, P4420, DOI 10.4049/jimmunol.168.9.4420; Krautwald S, 2004, J BIOL CHEM, V279, P44005, DOI 10.1074/jbc.M401327200; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Myou S, 2003, J EXP MED, V198, P1573, DOI 10.1084/jem.20030298; Myou S, 2003, J IMMUNOL, V171, P4379, DOI 10.4049/jimmunol.171.8.4379; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; Oh SW, 2002, J IMMUNOL, V168, P1992, DOI 10.4049/jimmunol.168.4.1992; Park JW, 2004, AM J RESP CRIT CARE, V169, P726, DOI 10.1164/rccm.200307-1042OC; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Schneider H, 2000, BIOCHEM BIOPH RES CO, V269, P279, DOI 10.1006/bbrc.2000.2234; Schneider H, 2001, EUR J IMMUNOL, V31, P2042, DOI 10.1002/1521-4141(200107)31:7<2042::AID-IMMU2042>3.0.CO;2-D; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; TEFT WA, 2005, ANNU REV IMMUNOL; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; Veldhoen M, 2005, EUR J IMMUNOL, V35, P207, DOI 10.1002/eji.200425542; Vijayakrishnan L, 2004, IMMUNITY, V20, P563, DOI 10.1016/S1074-7613(04)00110-4; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Yi LA, 2004, INT IMMUNOL, V16, P539, DOI 10.1093/intimm/dxh055; Zhang JY, 1999, J IMMUNOL, V163, P3012	30	113	119	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2006	12	5					574	579		10.1038/nm1385	http://dx.doi.org/10.1038/nm1385			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16604087				2023-01-03	WOS:000238149100042
J	Gomes, B; Higginson, IJ				Gomes, B; Higginson, IJ			Factors influencing death at home in terminally ill patients with cancer: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PALLIATIVE-CARE; SOUTH-AUSTRALIA; HOSPICE CARE; PATIENTS DIE; BACK-PAIN; PLACE; LIFE; DETERMINANTS; END; PREDICTORS	Objectives To determine the relative influence of different factors on place of death in patients with cancer. Data sources Four electronic databases-Medline (1966-2004), PsycINFO (1972-2004), CINAHL (1982-2004), and ASSIA (1987-2004); previous contacts with key experts; hand search of six relevant journals. Review methods We generated a conceptual model, against which studies were analysed. Included studies had original data on risk factors for place of death among patients, > 80% of whom had cancer. Strength of evidence was assigned according to the quantity and quality of studies and consistency of findings. Odds ratios for home death were plotted for factors with high strength evidence. Results 58 studies were included, with over 1.5 million patients from 13 countries. There was high strength evidence for the effect of 17 factors on place of death, of which six were strongly associated with home death: patients' low functional status (odds ratios range 2.29-11.1), their preferences (2.19-8.38), home care (1.37-5.1) and its intensity (1.06-8.65), living with relatives (1.78-7.85), and extended family support (2.28-5.47). The risk factors covered all groups of the model: related to illness, the individual and the environment (healthcare input and social support), the latter found to be the most important. Conclusions The network of factors that influence where patients with cancer die is complicated. Future policies and clinical practice should focus on ways of empowering families and public education, as well as intensifying home care, risk assessment, and training practitioners in end of life care.	Kings Coll London, Dept Palliat Care Policy & Rehabil, Cicely Saunders Fdn, London SE5 9RJ, England	University of London; King's College London	Gomes, B (corresponding author), Kings Coll London, Dept Palliat Care Policy & Rehabil, Cicely Saunders Fdn, London SE5 9RJ, England.	barbara.gomes_da_silva@kcl.ac.uk	Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313; Gomes, Barbara/0000-0001-8149-1806				ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], GOLD STANDARDS FRAME; [Anonymous], 2005, MORT STAT; Auchincloss AH, 2001, J AGING HEALTH, V13, P329, DOI 10.1177/089826430101300302; BASS DM, 1985, OMEGA-J DEATH DYING, V16, P51; BASS DM, 1984, DEATH EDUC, V8, P199, DOI 10.1080/07481188408252460; Brazil Kevin, 2002, BMC Palliat Care, V1, P2, DOI 10.1186/1472-684X-1-2; Bronfenbrenner U, 1979, ECOLOGY HUMAN DEV EX; Bruera E, 2003, J PAIN SYMPTOM MANAG, V26, P637, DOI 10.1016/S0885-3924(03)00204-5; Bruera E, 2002, J CLIN ONCOL, V20, P2127, DOI 10.1200/JCO.2002.08.138; Burge F, 2003, CAN MED ASSOC J, V168, P265; Burge Frederick, 2003, J Palliat Med, V6, P911, DOI 10.1089/109662103322654794; Cantwell P, 2000, J PALLIATIVE CARE, V16, P23, DOI 10.1177/082585970001600105; CATALANFERNANDEZ JG, 1991, MED CARE, V29, P841, DOI 10.1097/00005650-199109000-00005; Chochinov HM, 2002, SOC SCI MED, V54, P433, DOI 10.1016/S0277-9536(01)00084-3; Chow E, 2001, CLIN ONCOL-UK, V13, P209, DOI 10.1007/s001740170078; Costantini M, 2000, PUBLIC HEALTH, V114, P15, DOI 10.1016/S0033-3506(00)00302-4; Costantini Massimo, 1993, Palliative Medicine, V7, P323; Dansky KH, 2001, TELEMED J E-HEALTH, V7, P225, DOI 10.1089/153056201316970920; DeConno F, 1996, EUR J CANCER, V32A, P1142, DOI 10.1016/0959-8049(96)00036-6; Ebell MH, 2004, J AM BOARD FAM PRACT, V17, P59, DOI 10.3122/jabfm.17.1.59; Ellershaw JE, 2003, CARE DYING PATHWAY E; Ferreira PH, 2002, J CLIN EPIDEMIOL, V55, P1126, DOI 10.1016/S0895-4356(02)00498-5; Flynn A, 1979, J Community Health, V5, P126, DOI 10.1007/BF01324014; Fukui S, 2004, CANCER-AM CANCER SOC, V101, P421, DOI 10.1002/cncr.20383; Fukui S, 2003, PALLIATIVE MED, V17, P445, DOI 10.1191/0269216303pm782oa; Gallo WT, 2001, J AM GERIATR SOC, V49, P771, DOI 10.1046/j.1532-5415.2001.49154.x; Gomes B, 2004, J ROY SOC MED, V97, P413, DOI 10.1258/jrsm.97.9.413; Gott M, 2004, PALLIATIVE MED, V18, P460, DOI 10.1191/0269216304pm889oa; Grande GE, 2003, J PALLIAT CARE, V19, P263, DOI 10.1177/082585970301900408; Grande GE, 1998, SOC SCI MED, V47, P565, DOI 10.1016/S0277-9536(98)00115-4; Gyllenhammar E, 2003, SUPPORT CARE CANCER, V11, P560, DOI 10.1007/s00520-003-0487-z; Higginson I J, 2000, J Palliat Med, V3, P287, DOI 10.1089/jpm.2000.3.287; Higginson IJ, 1999, J PUBLIC HEALTH MED, V21, P22, DOI 10.1093/pubmed/21.1.22; Higginson IJ, 2002, J CLIN ONCOL, V20, P3674, DOI 10.1200/JCO.2002.11.008; Hinton John, 1994, Palliative Medicine, V8, P197, DOI 10.1177/026921639400800303; Hoogendoorn WE, 2000, SPINE, V25, P2114, DOI 10.1097/00007632-200008150-00017; Hunt R, 1996, PALLIATIVE MED, V10, P5, DOI 10.1177/026921639601000103; HUNT R, 1993, AUST NZ J MED, V23, P245, DOI 10.1111/j.1445-5994.1993.tb01725.x; Izquierdo-Porrera AM, 2001, J PAIN SYMPTOM MANAG, V21, P481, DOI 10.1016/S0885-3924(01)00283-4; Jordhoy MS, 2000, LANCET, V356, P888, DOI 10.1016/S0140-6736(00)02678-7; Karlsen S, 1998, PALLIATIVE MED, V12, P279, DOI 10.1191/026921698673427657; KHAN K, 2001, UNDERTAKING SYSTEMAT; Koffman Jonathan, 2004, J Palliat Med, V7, P628, DOI 10.1089/jpm.2004.7.628; MACADAM M, 2004, HOME HLTH CARE MANAG, V16, P393; MANN WJ, 1993, CANCER, V71, P2876, DOI 10.1002/1097-0142(19930501)71:9<2876::AID-CNCR2820710932>3.0.CO;2-V; Martineau I, 2003, J APPL SOC PSYCHOL, V33, P1973, DOI 10.1111/j.1559-1816.2003.tb02089.x; MCCUSKER J, 1983, PUBLIC HEALTH REP, V98, P170; MCCUSKER J, 1988, PUBLIC HLTH REP, V98, P170; MOINPOUR CM, 1989, AM J PUBLIC HEALTH, V79, P1549, DOI 10.2105/AJPH.79.11.1549; Moos RH., 1977, COPING PHYS ILLNESS; MOR V, 1983, J HEALTH SOC BEHAV, V24, P375, DOI 10.2307/2136403; Munday DF, 2003, PALLIATIVE MED, V17, P308, DOI 10.1191/0269216303pm771oa; Murray MA, 2003, J PALLIATIVE CARE, V19, P176, DOI 10.1177/082585970301900305; Murray SA, 2004, BMJ-BRIT MED J, V329, P1056, DOI 10.1136/bmj.329.7474.1056; Pemberton Chris, 2003, Int J Palliat Nurs, V9, P439; RODER D, 1987, MED J AUSTRALIA, V147, P11, DOI 10.5694/j.1326-5377.1987.tb133227.x; Sachpazidis I, 2002, Biomed Tech (Berl), V47 Suppl 1 Pt 2, P970, DOI 10.1515/bmte.2002.47.s1b.970; STOREY L, 2003, CANC NURS PRACT, V2, P33; Takahashi T, 2001, INT J MED INFORM, V61, P131, DOI 10.1016/S1386-5056(01)00135-6; Tang ST, 2000, CANCER NURS, V23, P367, DOI 10.1097/00002820-200010000-00007; Tang ST, 2003, CANCER NURS, V26, P245, DOI 10.1097/00002820-200306000-00012; Tang ST, 2001, CANCER INVEST, V19, P165, DOI 10.1081/CNV-100000151; Tang ST, 2002, CANCER NURS, V25, P158, DOI 10.1097/00002820-200204000-00013; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; Weitzen S, 2003, MED CARE, V41, P323, DOI 10.1097/00005650-200302000-00013; West S, 2002, Evid Rep Technol Assess (Summ), P1; World Health Organization, PALL CAR SOL FACTS; Young NL, 2004, TELEMED J E-HEALTH, V10, P45, DOI 10.1089/153056204773644571	69	647	652	1	66	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2006	332	7540					515	518A		10.1136/bmj.38740.614954.55	http://dx.doi.org/10.1136/bmj.38740.614954.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	023WB	16467346	Green Published, Bronze			2023-01-03	WOS:000236155800014
J	Chelu, MG; Goonasekera, SA; Durham, WJ; Tang, W; Lueck, JD; Riehl, J; Pessah, IN; Zhang, PM; Bhattacharjee, MB; Dirksen, RT; Hamilton, SL				Chelu, Mihail G.; Goonasekera, Sanjeewa A.; Durham, William J.; Tang, Wei; Lueck, John D.; Riehl, Joyce; Pessah, Isaac N.; Zhang, Pumin; Bhattacharjee, Meenakshi B.; Dirksen, Robert T.; Hamilton, Susan L.			Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse	FASEB JOURNAL			English	Article									[Chelu, Mihail G.; Durham, William J.; Tang, Wei; Zhang, Pumin; Hamilton, Susan L.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Bhattacharjee, Meenakshi B.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Goonasekera, Sanjeewa A.; Lueck, John D.; Dirksen, Robert T.] Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; [Riehl, Joyce; Pessah, Isaac N.] Univ Calif Davis, Dept VM Mol Biosci, Davis, CA 95616 USA; [Riehl, Joyce; Pessah, Isaac N.] Univ Calif Davis, Ctr Childrens Environm Hlth & Dis Prevent, Davis, CA 95616 USA	Baylor College of Medicine; Baylor College of Medicine; University of Rochester; University of California System; University of California Davis; University of California System; University of California Davis	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.	susanh@bcm.tmc.edu	Chelu, Mihail/AAM-7426-2020; Pessah, Isaac N/K-7985-2017	Chelu, Mihail/0000-0001-9688-1604; Pessah, Isaac N/0000-0002-8149-588X; Hamilton, Susan/0000-0003-0241-9369; Lueck, John/0000-0002-1820-711X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044657, R01AR044657, R01AR044864, R01AR041802, R01AR046513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41802, AR46513, AR44864, AR44657] Funding Source: Medline; NIEHS NIH HHS [ES11269] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))			0	129	132	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					329	330		10.1096/fj.05-4497fje	http://dx.doi.org/10.1096/fj.05-4497fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16284304				2023-01-03	WOS:000207915000010
J	Brett, AS; Zuger, A				Brett, AS; Zuger, A			The run on Tamilflu - Should physicians prescribe on demand?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ S Carolina, Sch Med, Columbia, SC 29208 USA; St Lukes Roosevelt Hosp, New York, NY USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Mount Sinai St. Luke's; Mount Sinai West	Brett, AS (corresponding author), Univ S Carolina, Sch Med, Columbia, SC 29208 USA.							BROWN D, 2005, WASH POST       0417, pA1; *HARV VANG MED ASS, AV INFL BIRD FLU FRE; *INF DIS SOC AM, JOINT POS STAT INF D; Kass NE, 2001, AM J PUBLIC HEALTH, V91, P1776, DOI 10.2105/AJPH.91.11.1776; Lee TH, 2004, NEW ENGL J MED, V351, P2365, DOI 10.1056/NEJMp048328	5	19	22	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	2005	353	25					2636	2637		10.1056/NEJMp058290	http://dx.doi.org/10.1056/NEJMp058290			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995IQ	16371627				2023-01-03	WOS:000234094400002
J	Wills, BA; Dung, NM; Loan, HT; Tam, DTH; Thuy, TTN; Minh, LTT; Diet, TV; Hao, NT; Chau, NV; Stepniewska, K; White, NJ; Farrar, JJ				Wills, BA; Dung, NM; Loan, HT; Tam, DTH; Thuy, TTN; Minh, LTT; Diet, TV; Hao, NT; Chau, NV; Stepniewska, K; White, NJ; Farrar, JJ			Comparison of three fluid solutions for resuscitation in dengue shock syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLLOIDS; ALBUMIN; PLASMA	Background: Dengue shock syndrome is characterized by severe vascular leakage and disordered hemostasis and progresses to death in 1 to 5 percent of cases. Although volume replacement is recognized as the critical therapeutic intervention, World Health Organization management guidelines remain empirical rather than evidence-based. Methods: We performed a double-blind, randomized comparison of three fluids for initial resuscitation of Vietnamese children with dengue shock syndrome. We randomly assigned 383 children with moderately severe shock to receive Ringer's lactate, 6 percent dextran 70 (a colloid), or 6 percent hydroxyethyl starch (a colloid) and 129 children with severe shock to receive one of the colloids. The primary outcome measure was requirement for rescue colloid at any time after administration of the study fluid. Results: Only one patient died (< 0.2 percent mortality). The primary outcome measure - requirement for rescue colloid -- was similar for the different fluids in the two severity groups. The relative risk of requirement for rescue colloid was 1.08 (95 percent confidence interval, 0.78 to 1.47; P=0.65) among children with moderate shock who received Ringer's lactate as compared with either of the colloid solutions, 1.13 (95 percent confidence interval, 0.74 to 1.74; P=0.59) among children who received dextran as compared with starch in the group with severe shock, and 0.88 (95 percent confidence interval, 0.66 to 1.17; P=0.38) among children who received dextran as compared with starch in the combined analysis. Although treatment with Ringer's lactate resulted in less rapid improvement in the hematocrit and a marginally longer time to initial recovery than did treatment with either of the colloid solutions, there were no differences in all other measures of treatment response. Only minor differences in efficacy were detected between the two colloids, but significantly more recipients of dextran than of starch had adverse reactions. Bleeding manifestations, coagulation derangements, and severity of fluid overload were similar for all fluid-treatment groups. Conclusions: Initial resuscitation with Ringer's lactate is indicated for children with moderately severe dengue shock syndrome. Dextran 70 and 6 percent hydroxyethyl starch perform similarly in children with severe shock, but given the adverse reactions associated with the use of dextran, starch may be preferable for this group.	Univ Oxford, Clin Res Unit, Hosp Trop Dis, Ho Chi Minh City, Vietnam; Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England	University of Oxford; University of Oxford	Wills, BA (corresponding author), Univ Oxford, Clin Res Unit, Hosp Trop Dis, 190 Ben Ham Tu, Ho Chi Minh City, Vietnam.	bridgetw@hcm.vnn.vn	Farrar, Jeremy J./HGA-7610-2022; White, Nicholas J/I-4629-2012; White, Nick/AAC-6527-2019	White, Nick/0000-0002-1897-1978; Wills, Bridget/0000-0001-9086-8804; Farrar, Jeremy/0000-0002-2700-623X; Stepniewska, Kasia/0000-0002-1713-6209	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALDERSON P, 2000, COCHRANE DB SYST REV, V2; Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053; COHEN SN, 1966, J PEDIATR-US, V68, P448, DOI 10.1016/S0022-3476(66)80249-4; Dung NM, 1999, CLIN INFECT DIS, V29, P787, DOI 10.1086/520435; Finfer S, 2004, NEW ENGL J MED, V350, P2247; GRIFFEL MI, 1992, CRIT CARE CLIN, V8, P235, DOI 10.1016/S0749-0704(18)30249-5; Halstead Scott B., 1997, P23; HARALDSSON B, 1987, ACTA PHYSIOL SCAND, V129, P127, DOI 10.1111/j.1748-1716.1987.tb08047.x; HAUPT MT, 1992, CRIT CARE CLIN, V8, P341, DOI 10.1016/S0749-0704(18)30254-9; HUXLEY VH, 1991, AM J PHYSIOL, V260, pH1645, DOI 10.1152/ajpheart.1991.260.5.H1645; Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Nhan NT, 2001, CLIN INFECT DIS, V32, P204, DOI 10.1086/318479; Rigau-Perez JG, 1998, LANCET, V352, P971, DOI 10.1016/S0140-6736(97)12483-7; Schierhout G, 1998, BMJ-BRIT MED J, V316, P961, DOI 10.1136/bmj.316.7136.961; SCHNEEBERGER EE, 1990, AM J PHYSIOL, V258, pL89, DOI 10.1152/ajplung.1990.258.2.L89; Starling E H, 1896, J Physiol, V19, P312; Vink H, 2000, AM J PHYSIOL-HEART C, V278, pH285, DOI 10.1152/ajpheart.2000.278.1.H285; (WHO) WHO, 1997, DENG HAEM FEV DIAGN; Wills BA, 2004, J INFECT DIS, V190, P810, DOI 10.1086/422754; World Health Organization, 1975, TECHN GUID DIAGN TRE	21	283	302	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	2005	353	9					877	889		10.1056/NEJMoa044057	http://dx.doi.org/10.1056/NEJMoa044057			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	959WX	16135832	Bronze			2023-01-03	WOS:000231551100005
J	Okie, S				Okie, S			Medical marijuana and the Supreme Court	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Abrams DI, 2003, ANN INTERN MED, V139, P258, DOI 10.7326/0003-4819-139-4-200308190-00008; BINZ S, 2005, SAN FRANCISCO C 0624, pB4; Joy JE, 1999, MARIJUANA MED ASSESS	3	16	16	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2005	353	7					648	651		10.1056/NEJMp058165	http://dx.doi.org/10.1056/NEJMp058165			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955UW	16107619				2023-01-03	WOS:000231254100002
J	Witt, C; Brinkhaus, B; Jena, S; Linde, K; Streng, A; Wagenpfeil, S; Hummelsberger, J; Walther, HU; Melchart, D; Willich, SN				Witt, C; Brinkhaus, B; Jena, S; Linde, K; Streng, A; Wagenpfeil, S; Hummelsberger, J; Walther, HU; Melchart, D; Willich, SN			Acupuncture in patients with osteoarthritis of the knee: a randomised trial	LANCET			English	Article							CLINICAL-TRIALS; RECOMMENDATIONS; FOLLOW; HIP; THERAPY; DESIGN; WOMAC; PAIN	Background Acupuncture is widely used by patients with effectiveness. We investigated the efficacy of acupuncture acupuncture in patients with osteoarthritis of the knee. chronic pain although there is little evidence of its compared with minimal acupuncture and with no acupuncture in patients with osteoarthritis of the knee. Methods Patients with chronic osteoarthritis of the knee (Kellgren grade <= 2) were randomly assigned to acupuncture (n=150), minimal acupuncture (superficial needling at non-acupuncture points; n=76), or a waiting list control (n=74). Specialised physicians, in 28 outpatient centres, administered acupuncture and minimal acupuncture in 12 sessions over 8 weeks. Patients completed standard questionnaires at baseline and after 8 weeks, 26 weeks, and 52 weeks. The primary outcome was the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index at the end of week 8 (adjusted for baseline score). All main analyses were by intention to treat. Results 294 patients were enrolled from March 6, 2002, to January 17, 2003; eight patients were lost to follow-up after randomisation, but were included in the final analysis. The mean baseline-adjusted WOMAC index at week 8 was 26.9 (SE 1.4) in the acupuncture group, 35.8 (1.9) in the minimal acupuncture group, and 49.6 (2.0) in the waiting list group (treatment difference acupuncture vs minimal acupuncture -8.8, [95% Cl -13.5 to -4.2], p=0.0002; acupuncture vs waiting list -22.7 [-27.5 to -17.9], p<0.0001). After 52 weeks the difference between the acupuncture and minimal acupuncture groups was no longer significant (p=0.08). Interpretation After 8 weeks of treatment, pain and joint function are improved more with acupuncture than with minimal acupuncture or no acupuncture in patients with osteoarthritis of the knee. However, this benefit decreases over time.	Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-10098 Berlin, Germany; Charite Univ Med Ctr, Ctr Musculoskeletal Surg, D-10098 Berlin, Germany; Tech Univ Munich, Ctr Complementary Med, Dept Internal Med 2, D-8000 Munich, Germany; Tech Univ Munich, Inst Med Stat & Epidemiol, D-8000 Munich, Germany; Univ Zurich Hosp, Dept Internal Med, Div Complementary Med, Zurich, Switzerland; Soc Med Sinensis, Int Soc Chinese Med, Munich, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Munich; Technical University of Munich; University of Zurich; University Zurich Hospital	Witt, C (corresponding author), Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-10098 Berlin, Germany.	claudia.witt@charite.de	Brinkhaus, Benno/AAU-2428-2021; Witt, Claudia M./AAX-2370-2021; Streng, Andrea/AAR-4986-2020	Brinkhaus, Benno/0000-0001-6290-744X; Witt, Claudia M./0000-0002-5440-7805; Streng, Andrea/0000-0003-2377-7106; Linde, Klaus/0000-0002-2902-970X				Altman R, 1996, OSTEOARTHR CARTILAGE, V4, P217, DOI 10.1016/S1063-4584(05)80101-3; Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; Bellamy N, 1997, J RHEUMATOL, V24, P799; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Berman BM, 1999, RHEUMATOLOGY, V38, P346, DOI 10.1093/rheumatology/38.4.346; Brinkhaus B, 2003, FORSCH KOMP KLAS NAT, V10, P185, DOI 10.1159/000073474; BULLINGER M, 1998, SF36 FRAGEBOGEN GESU; CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x; Creamer P, 1997, LANCET, V350, P503, DOI 10.1016/S0140-6736(97)07226-7; Deadman P, 2001, MANUAL ACUPUNCTURE; DILLMANN U, 1994, SCHMERZ, P100; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ezzo J, 2001, ARTHRITIS RHEUM, V44, P819, DOI 10.1002/1529-0131(200104)44:4<819::AID-ANR138>3.0.CO;2-P; Geissner E, 1996, SCHMERZEMPFINDUNGSSK; Hautzinger M., 1993, ALLGEMEINE DEPRESSIO; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kessler S, 1998, CLIN RHEUMATOL, V17, P205, DOI 10.1007/BF01451048; Linde K, 2004, J ALTERN COMPLEM MED, V10, P379, DOI 10.1089/107555304323062374; Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104; MOLSBERGER A, 1994, DER SCHMERZ, V8, P37; Nagel B, 2002, SCHMERZ, V16, P263, DOI 10.1007/s00482-002-0162-1; PETROU P, 1988, SCAND J ACUPUNCT, V3, P112; Sangdee Chaichan, 2002, BMC Complement Altern Med, V2, P3, DOI 10.1186/1472-6882-2-3; Stucki G, 1996, Z RHEUMATOL, V55, P40; Takeda W, 1994, Arthritis Care Res, V7, P118, DOI 10.1002/art.1790070304; Tillu Abhay, 2002, Acupunct Med, V20, P19; Tramer MR, 2000, PAIN, V85, P169, DOI 10.1016/S0304-3959(99)00267-5; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; VINCENT C, 1995, J ROY SOC MED, V88, P199; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; WHITE AR, 2001, SURVEY ADVERSE EVENT, V1; Yamashita H, 2000, J ALTERN COMPLEM MED, V6, P345, DOI 10.1089/10755530050120718	32	412	440	2	109	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 9	2005	366	9480					136	143		10.1016/S0140-6736(05)66871-7	http://dx.doi.org/10.1016/S0140-6736(05)66871-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	943JH	16005336				2023-01-03	WOS:000230349200032
J	Assefi, NP; Sherman, KJ; Jacobsen, C; Goldberg, J; Smith, WR; Buchwald, D				Assefi, NP; Sherman, KJ; Jacobsen, C; Goldberg, J; Smith, WR; Buchwald, D			A Randomized clinical trial of acupuncture compared with sham acupuncture in Fibromyalgia	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC-FATIGUE-SYNDROME; GENERAL-POPULATION; PAIN; ELECTROACUPUNCTURE	Background: Fibromyalgia is a common chronic pain condition for which patients frequently use acupuncture. Objective: To determine whether acupuncture relieves pain in fibromyalgia. Design: Randomized, sham-controlled trial in which participants, data collection staff, and data analysts were blinded to treatment group. Setting: Private acupuncture offices in the greater Seattle, Washington, metropolitan area. Patients: 100 adults with fibromyalgia. Intervention: Twice-weekly treatment for 12 weeks with an acupuncture program that was specifically designed to treat fibromyalgia, or 1 of 3 sham acupuncture treatments: acupuncture for an unrelated condition, needle insertion at nonacupoint locations, or noninsertive simulated acupuncture. Measurements: The primary outcome was subjective pain as measured by a 10-cm visual analogue scale ranging from 0 (no pain) to 10 (worst pain ever). Measurements were obtained at baseline; 1, 4, 8, and 12 weeks of treatment; and 3 and 6 months after completion of treatment. Participant blinding and adverse effects were ascertained by self-report. The primary outcomes were evaluated by pooling the 3 sham-control groups and comparing them with the group that received acupuncture to treat fibromyalgia. Results: The mean subjective pain rating among patients who received acupuncture for fibromyalgia did not differ from that in the pooled sham acupuncture group (mean between-group difference, 0.5 cm [95% CI, -0.3 cm to 1.2 cm]). Participant blinding was adequate throughout the trial, and no serious adverse effects were noted. Limitations: A prescription of acupuncture at fixed points may differ from acupuncture administered in clinical settings, in which therapy is individualized and often combined with herbal supplementation and other adjunctive measures. A usual-care comparison group was not studied. Conclusion: Acupuncture was no better than sham acupuncture at relieving pain in fibromyalgia.	Univ Washington, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; Group Health Cooperative	Buchwald, D (corresponding author), Box 359780,1730 Minor Ave,Suite 1760, Seattle, WA 98101 USA.		Muler, Clemma/O-5595-2019	Muller, Clemma/0000-0001-5379-8747	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000003] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01AT00003] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Bombardier CH, 1996, MED CARE, V34, P924, DOI 10.1097/00005650-199609000-00005; Buchwald D, 1996, AM J MED, V101, P364, DOI 10.1016/S0002-9343(96)00234-3; CHEN XH, 1992, EUR J PHARMACOL, V211, P203; Cho ZH, 2002, J ALTERN COMPLEM MED, V8, P399, DOI 10.1089/107555302760253577; CHOU J, 1984, J PHARMACOL EXP THER, V230, P349; Crofford L J, 2001, Curr Rheumatol Rep, V3, P147, DOI 10.1007/s11926-001-0010-9; DELUZE C, 1992, BRIT MED J, V305, P1249, DOI 10.1136/bmj.305.6864.1249; Dimmock S, 1996, CLIN RHEUMATOL, V15, P478, DOI 10.1007/BF02229645; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; Goddard G, 2002, J OROFAC PAIN, V16, P71; Komaroff AL, 1996, AM J MED, V101, P281, DOI 10.1016/S0002-9343(96)00174-X; Le Bars D, 1992, Patol Fiziol Eksp Ter, P55; Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4; Lewith G T, 1996, J Altern Complement Med, V2, P79, DOI 10.1089/acm.1996.2.79; NOSEWORTHY JH, 1994, NEUROLOGY, V44, P16, DOI 10.1212/WNL.44.1.16; Park J, 1999, ACUPUNCT MED, V17, P110, DOI DOI 10.1136/AIM.17.2.110; PioroBoisset M, 1996, ARTHRIT CARE RES, V9, P13, DOI 10.1002/art.1790090105; Sherman KJ, 2002, J ALTERN COMPLEM MED, V8, P11, DOI 10.1089/107555302753507140; Shlay JC, 1998, JAMA-J AM MED ASSOC, V280, P1590, DOI 10.1001/jama.280.18.1590; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; STUX G, 2001, CLIN ACUPUNCTURE; Twisk JWR, 2003, APPL LONGITUDINAL DA; VINCENT C, 1995, J ROY SOC MED, V88, P199; WARE JE, 1994, SHORT FORM 36 PHYS M; WARE JE, 2000, SHORT FORM 36 HLTH S; WOLFE F, 1995, ARTHRITIS RHEUM-US, V38, P19, DOI 10.1002/art.1780380104; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; XINNONG C, 1999, CHINESE ACUPUNCTURE	28	147	169	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 5	2005	143	1					10	19		10.7326/0003-4819-143-1-200507050-00005	http://dx.doi.org/10.7326/0003-4819-143-1-200507050-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941XB	15998750				2023-01-03	WOS:000230246400002
J	Rossi, JJ				Rossi, JJ			Receptor-targeted siRNAs	NATURE BIOTECHNOLOGY			English	Editorial Material							GENE; RNAS; INHIBITION; DELIVERY	Protamine-antibody fragment fusions enable delivery of siRNAs to specific cells in mice.	City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Grad Sch Biol Sci, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Rossi, JJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Grad Sch Biol Sci, 1450 E Duarte Rd, Duarte, CA 91010 USA.	jrossi@bricoh.edu						Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Li XG, 2001, CANCER GENE THER, V8, P555, DOI 10.1038/sj.cgt.7700337; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121	10	13	19	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2005	23	6					682	684		10.1038/nbt0605-682	http://dx.doi.org/10.1038/nbt0605-682			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	933LA	15940237				2023-01-03	WOS:000229628700021
J	Manheimer, E; White, A; Berman, B; Forys, K; Ernst, E				Manheimer, E; White, A; Berman, B; Forys, K; Ernst, E			Meta-analysis: Acupuncture for low back pain	ANNALS OF INTERNAL MEDICINE			English	Review							CHINESE MEDICINE ACUPUNCTURISTS; ELECTRICAL NERVE-STIMULATION; RANDOMIZED CLINICAL-TRIAL; PLACEBO-CONTROLLED TRIAL; CHRONIC SPINAL PAIN; TERM-FOLLOW-UP; COMPARING ACUPUNCTURE; SYSTEMATIC REVIEWS; NECK PAIN; MANIPULATION	Background: Low back pain limits activity and is the second most frequent reason for physicians visits. Previous research shows widespread use of acupuncture for low back pain. Purpose: To assess acupuncture's effectiveness for treating low back pain. Data Sources: Randomized, controlled trials were identified through searches of MEDLINE, Cochrane Central, EMBASE, AMED, CINAHL, CISCOM, and GERA databases through August 2004. Additional data sources included previous reviews and personal contacts with colleagues. Study Selection: Randomized, controlled trials comparing needle acupuncture with sham acupuncture, other sham treatments, no additional treatment, or another active treatment for patients with low back pain. Data Extraction: Data were dually extracted for the outcomes of pain, functional status, overall improvement, return to work, and analgesic consumption. In addition, study quality was assessed. Data Synthesis: The 33 randomized, controlled trials that met inclusion criteria were subgrouped according to acute or chronic pain, style of acupuncture, and type of control group used. For the primary outcome of short-term relief of chronic pain, the meta-analyses showed that acupuncture is significantly more effective than sham treatment (standardized mean difference, 0.54 [95% CI, 0.35 to 0.73]; 7 trials) and no additional treatment (standardized mean difference, 0.69 [CI, 0.40 to 0.98]; 8 trials). For patients with acute low back pain, data are sparse and inconclusive. Data are also insufficient for drawing conclusions about acupuncture's short-term effectiveness compared with most other therapies. Limitations: The quantity and quality of the included trials varied. Conclusions: Acupuncture effectively relieves chronic low back pain. No evidence suggests that acupuncture is more effective than other active therapies.	Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21207 USA; Peninsula Med Sch, Plymouth, Devon, England	University System of Maryland; University of Maryland Baltimore; University of Plymouth	Manheimer, E (corresponding author), Univ Maryland, Sch Med, Ctr Integrat Med, 2200 Kernan Dr,Kernan Hosp Mans, Baltimore, MD 21207 USA.	emanheimer@compmed.umm.edu			National Center for Complementary & Integrative Health [R24AT001293] Funding Source: NIH RePORTER; NCCIH NIH HHS [R24 AT001293] Funding Source: Medline	National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		ALDERSON P, 2003, REV HDB 5; ALDERSON P, 2004, COCHRANS REV HDB 4 2; Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; Birch S., 1997, COMPLEM THER MED, V5, P8; BIRCH S, 2001, CLIN ACUPUNCT ORIENT, V2, P17; Brinkhaus B, 2003, FORSCH KOMP KLAS NAT, V10, P185, DOI 10.1159/000073474; Carlsson CPO, 2001, CLIN J PAIN, V17, P296, DOI 10.1097/00002508-200112000-00003; Cherkin Daniel C, 2002, J Am Board Fam Pract, V15, P463; Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011; Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081; COAN RM, 1980, AM J CHINESE MED, V8, P181, DOI 10.1142/S0192415X80000141; DASILVA GJB, 2004, ACUPUNCT MED, V22, P60; DUPLAN B, 1983, SEM HOP PARIS, V59, P3109; EDELIST G, 1976, CAN ANAESTH SOC J, V23, P303, DOI 10.1007/BF03005706; Ernst E, 1998, ARCH INTERN MED, V158, P2235, DOI 10.1001/archinte.158.20.2235; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; GALLACCHI G, 1981, SCHWEIZ MED WSCHR, V111, P1360; GARVEY TA, 1989, SPINE, V14, P962, DOI 10.1097/00007632-198909000-00008; GILES LG, 2003, SPINE, V502, P1502; Giles LGF, 2003, SPINE, V28, P1490, DOI 10.1097/00007632-200307150-00003; Giles LGF, 1999, J MANIP PHYSIOL THER, V22, P376, DOI 10.1016/S0161-4754(99)70082-5; Grant DJ, 1999, PAIN, V82, P9, DOI 10.1016/S0304-3959(99)00027-5; GUNN CC, 1980, SPINE, V5, P279, DOI 10.1097/00007632-198005000-00011; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hiroshi Tsukayama, 2002, CLIN ACUPUNCT ORIENT, V3, P105; Hogeboom CJ, 2001, COMPLEMENT THER MED, V9, P154, DOI 10.1054/ctim.2001.0457; ITO K, 2000, CONTROLLED COMP TRIA; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kalauokalani D, 2001, SPINE, V26, P1418, DOI 10.1097/00007632-200107010-00005; Kerr DP, 2003, CLIN J PAIN, V19, P364, DOI 10.1097/00002508-200311000-00004; Kittang G, 2001, Tidsskr Nor Laegeforen, V121, P1207; KUROSU Y, 1979, NIPPON GAN CHIRYO GA, V28, P31; Kvorning N, 2004, ACTA OBSTET GYN SCAN, V83, P246; LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304-3959(79)90049-6; LEHMANN TR, 1986, PAIN, V26, P277, DOI 10.1016/0304-3959(86)90057-6; Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4; Lewith G T, 1996, J Altern Complement Med, V2, P79, DOI 10.1089/acm.1996.2.79; Lopacz S, 1979, Neurol Neurochir Pol, V13, P405; MACDONALD AJR, 1983, ANN ROY COLL SURG, V65, P44; MAZIERES B, 1985, WORLD C RHEUM SYDN A, V100, pF53; MENDELSON G, 1983, AM J MED, V74, P49, DOI 10.1016/0002-9343(83)91117-8; Meng CF, 2003, RHEUMATOLOGY, V42, P1508, DOI 10.1093/rheumatology/keg405; Molsberger AF, 2002, PAIN, V99, P579, DOI 10.1016/S0304-3959(02)00269-5; NOBILI C, 1985, MINERVA RIFLESSOTERA, V2, P61; Sakai T., 2001, J JAPAN SOC ACUPUNCT, V51, P175; Sherman KJ, 2001, COMPLEMENT THER MED, V9, P146, DOI 10.1054/ctim.2001.0458; Smith LA, 2000, PAIN, V86, P119, DOI 10.1016/S0304-3959(00)00234-7; Thomas K J, 1999, Complement Ther Med, V7, P91, DOI 10.1016/S0965-2299(99)80087-9; THOMAS M, 1994, ACTA ANAESTH SCAND, V38, P63, DOI 10.1111/j.1399-6576.1994.tb03839.x; Tsukayama Hiroshi, 2002, Acupunct Med, V20, P175; Van Tulder M.W., 1999, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001351, 10.1002/14651858.CD001351]; vanTulder MW, 1997, SPINE, V22, P2323, DOI 10.1097/00007632-199710150-00001; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; Von Mencke M., 1989, AKUPUNKTUR, V5, P5; VONMENCKE M, 1988, AKUPUNKTUR, V4, P204; Wedenberg K, 2000, ACTA OBSTET GYN SCAN, V79, P331, DOI 10.1034/j.1600-0412.2000.079005331.x; Wolsko PM, 2003, SPINE, V28, P292, DOI 10.1097/00007632-200302010-00018; Yeung CKN, 2003, J ALTERN COMPLEM MED, V9, P479, DOI 10.1089/107555303322284767; Yokoyama M, 2004, ANESTH ANALG, V98, P1552, DOI 10.1213/01.ANE.0000112312.94043.DF; YUE SJ, 1978, ACUPUNCTURE ELECTRO, V3, P323; ZHANG DW, 2002, SHANGHAI J ACUPUCTUR, V21, P22; [张昭勇 Zhang Zhaoyong], 2002, [传感器技术, Sensor technology], V21, P15	63	281	292	3	58	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					651	663		10.7326/0003-4819-142-8-200504190-00014	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00014			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916TZ	15838072				2023-01-03	WOS:000228410400008
J	Crowther, CA; Haslam, RR; Hiller, JE; Doyle, LW; Robinson, JS				Crowther, Caroline A.; Haslam, Ross R.; Hiller, Janet E.; Doyle, Lex W.; Robinson, Jeffrey S.		ACTORDS Study Grp	Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial	LANCET			English	Article							WEEKLY COURSES; SINGLE COURSE; BIRTH; GLUCOCORTICOIDS; GROWTH	Background The efficacy and safety of repeat doses of prenatal corticosteroids remains uncertain. Our aim was to establish whether repeat prenatal corticosteroids given to women at risk of preterm. birth can reduce neonatal morbidity without harm. Methods In this hospital-based study, 982 women who remained at risk of preterm birth at less than 32 weeks' gestation, 7 or more days after receiving a first course of prenatal corticosteroids, were randomly assigned to receive a repeat intramuscular dose of either 11.4 mg betamethasone (as Celestone Chronodose), or saline placebo. This was repeated every week the woman remained undelivered, at less than 32 weeks' gestation, and at risk of preterm birth. Primary outcomes were occurrence and severity of neonatal respiratory distress syndrome, use and duration of oxygen and mechanical ventilation, and weight, length, and head circumference at birth and hospital discharge. Statistical analyses were on an intention to treat basis. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN48656428. Findings Fewer babies exposed to repeat corticosteroids had respiratory distress syndrome (33% vs 41%; relative risk 0.82,95% CI 0.71-0.95, p=0.01) and fewer had severe lung disease (12% vs 20%; relative risk 0.60,95% CI 0.46-0.79, P=0.0003) than those in the placebo group. in keeping with these benefits, babies exposed to repeat corticosteroids needed less oxygen therapy (p=0.03), and shorter duration of mechanical ventilation (p=0.01). Mean weight, length, and head circumference at birth and hospital discharge did not differ between treatment groups. Z-scores for weight (p=0.04) and head circumference (p=0.03) at birth were lower in the babies who received repeat corticosteroids although at the time of hospital discharge Z-scores did not differ between treatment groups (p=0.29 for weight, p=0.48 for head circumference). Interpretation Exposure to repeat doses of antenatal corticosteroids reduces neonatal morbidity. Pending long-term outcome results, the short-term benefits for the babies in our study support the use of repeat doses of corticosteroids in women who remain at risk of very preterm birth 7 or more days after an initial course.	Univ Adelaide, Discipline Obstet & Gynaecol, Adelaide, SA 5006, Australia; Univ Adelaide, Dept Publ Hlth, Adelaide, SA 5006, Australia; Womens & Childrens Hosp, Dept Neonatal Med, Adelaide, SA, Australia; Univ Melbourne, Royal Hosp Women, Dept Obstet & Gynaecol, Melbourne, Vic, Australia; Univ Melbourne, Royal Hosp Women, Dept Paediat, Melbourne, Vic, Australia	University of Adelaide; University of Adelaide; Womens & Childrens Hospital Australia; University of Melbourne; University of Melbourne	Crowther, CA (corresponding author), Univ Adelaide, Discipline Obstet & Gynaecol, Adelaide, SA 5006, Australia.	caroline.crowther@adelaide.edu.au	Pritchard, Margo A/G-5188-2010; Lawrence, Annemarie/I-4180-2013; Dodd, Jodie/Y-6849-2019; Hiller, Janet E./A-5633-2008; Flenady, Vicki Jane/O-9609-2014; Doyle, Lex/AAJ-5205-2021	Pritchard, Margo A/0000-0002-1058-9117; Lawrence, Annemarie/0000-0002-8736-4741; Dodd, Jodie/0000-0002-6363-4874; Hiller, Janet E./0000-0002-8532-4033; Flenady, Vicki Jane/0000-0001-8114-7677; Doyle, Lex/0000-0002-7667-7312				Aghajafari Fariba, 2002, J Obstet Gynaecol Can, V24, P321; Beeby PJ, 1996, J PAEDIATR CHILD H, V32, P512, DOI 10.1111/j.1440-1754.1996.tb00965.x; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; Brocklehurst P, 1999, BRIT J OBSTET GYNAEC, V106, P977, DOI 10.1111/j.1471-0528.1999.tb08440.x; Crowley P, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000065; CROWTHER CA, 1995, LANCET, V345, P877; CROWTHER CA, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003935; Dalziel SR, 2005, LANCET, V365, P1856, DOI 10.1016/S0140-6736(05)66617-2; Dunlop S A, 1997, J Matern Fetal Med, V6, P309; ESPLIN M, 2000, AM J OBSTET GYNECOL, V182; French NP, 2004, AM J OBSTET GYNECOL, V190, P588, DOI 10.1016/j.ajog.2003.12.016; French NP, 1999, AM J OBSTET GYNECOL, V180, P114, DOI 10.1016/S0002-9378(99)70160-2; Guinn DA, 2001, JAMA-J AM MED ASSOC, V286, P1581, DOI 10.1001/jama.286.13.1581; GUINN DA, 2000, AM J OBSTET GYNECOL, V182; Hasbargen U, 2001, EUR J PEDIATR, V160, P552, DOI 10.1007/s004310100804; Ikegami M, 1997, AM J RESP CRIT CARE, V156, P178, DOI 10.1164/ajrccm.156.1.9612036; Laws P, 2004, PERINATAL STAT SERIE; LIGGINS GC, 1972, PEDIATRICS, V50, P515; *MAT INF REPR HLTH, MULT COURS ANT CORT; McCullagh P, 1989, GEN LINEAR MODELS; McEvoy C, 2002, PEDIATRICS, V110, P280, DOI 10.1542/peds.110.2.280; McLaughlin KJ, 2003, AUST NZ J OBSTET GYN, V43, P101, DOI 10.1046/j.0004-8666.2003.00052.x; McLaughlin KJ, 2002, AUST NZ J OBSTET GYN, V42, P353, DOI 10.1111/j.0004-8666.2002.00353.x; PELTONIEMI OM, 2005, ESPR ABSTR; ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13; Smith GN, 2000, LANCET, V355, P251, DOI 10.1016/S0140-6736(99)00448-1; Thorp JA, 2001, AM J OBSTET GYNECOL, V185, pS87, DOI 10.1016/S0002-9378(01)80077-6; TSCHANZ SA, 1995, BIOL NEONATE, V68, P229; Wapner RJ, 2003, AM J OBSTET GYNECOL, V189, pS56, DOI 10.1016/j.ajog.2003.10.003; 2000, OBSTET GYNECOL, V98, P144, DOI DOI 10.1016/S0029-7844(01)01410-7	30	215	228	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 10	2006	367	9526					1913	1919		10.1016/S0140-6736(06)68846-6	http://dx.doi.org/10.1016/S0140-6736(06)68846-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	051XG	16765760				2023-01-03	WOS:000238194400030
J	Fallon, M; Hanks, G; Cherny, N				Fallon, M; Hanks, G; Cherny, N			ABC of palliative care - Principles of control of cancer pain	BRITISH MEDICAL JOURNAL			English	Editorial Material									Western Gen Hosp, Edinburgh Canc Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Bristol, Bristol BS8 1TH, Avon, England; Shaare Zedek Med Ctr, Jerusalem, Israel	University of Edinburgh; University of Bristol; Hebrew University of Jerusalem; Shaare Zedek Medical Center	Fallon, M (corresponding author), Western Gen Hosp, Edinburgh Canc Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.			Cherny, Nathan/0000-0003-1976-8952; Fallon, Marie/0000-0001-9214-0091					0	34	38	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 29	2006	332	7548					1022	1024		10.1136/bmj.332.7548.1022	http://dx.doi.org/10.1136/bmj.332.7548.1022			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	040TK	16644831	Green Submitted, Green Published			2023-01-03	WOS:000237403100024
J	Nishioka, NS; Lauwers, GY				Nishioka, NS; Lauwers, GY			Case 10-2006: A 66-year-old woman with Barrett's esophagus with high-grade dysplasia - Barrett's esophagus with high-grade dysplasia and intramucosal carcinoma with regression of dysplasia and regression of Barrett's esophagus after endoscopic mucosal resection and photodynamic therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PORFIMER SODIUM; FOLLOW-UP; CANCER; ADENOCARCINOMA; ABLATION; SURVEILLANCE; MULTICENTER; PROGRESSION; MANAGEMENT; EPITHELIUM		Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Nishioka, NS (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.		Jovani, Manol/AAF-5333-2020					Ban S, 2004, AM J SURG PATHOL, V28, P1466, DOI 10.1097/01.pas.0000141392.91677.7f; Buttar NS, 2001, GASTROINTEST ENDOSC, V54, P682, DOI 10.1067/mge.2001.119875; Ell C, 2000, GASTROENTEROLOGY, V118, P670, DOI 10.1016/S0016-5085(00)70136-3; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Goldblum JR, 2002, SEMIN DIAGN PATHOL, V19, P12, DOI 10.1053/sdia.2002.31767; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; Lightdale C J, 2000, Gastrointest Endosc Clin N Am, V10, P397; LIGHTDALE CJ, 1995, GASTROINTEST ENDOSC, V42, P507, DOI 10.1016/S0016-5107(95)70002-1; Mino-Kenudson M, 2005, AM J SURG PATHOL, V29, P680, DOI 10.1097/01.pas.0000154129.87219.fa; Overholt BF, 2005, GASTROINTEST ENDOSC, V62, P488, DOI 10.1016/j.gie.2005.06.047; Overholt BF, 1999, GASTROINTEST ENDOSC, V49, P1, DOI 10.1016/S0016-5107(99)70437-2; Provenzale D, 1999, AM J GASTROENTEROL, V94, P2043; Reid BJ, 2000, AM J GASTROENTEROL, V95, P1669, DOI 10.1111/j.1572-0241.2000.02196.x; Sampliner RE, 2002, AM J GASTROENTEROL, V97, P1888; Sampliner RE, 2001, GASTROINTEST ENDOSC, V53, P554, DOI 10.1067/mge.2001.114418; Schnell TG, 2001, GASTROENTEROLOGY, V120, P1607, DOI 10.1053/gast.2001.25065; Schulz H, 2000, GASTROINTEST ENDOSC, V51, P659, DOI 10.1016/S0016-5107(00)33002-4; Skacel M, 2000, AM J GASTROENTEROL, V95, P3383; Spechler SJ, 2002, NEW ENGL J MED, V346, P836, DOI 10.1056/NEJMcp012118; Weston AP, 2000, AM J GASTROENTEROL, V95, P1888; Wolfsen HC, 2002, MAYO CLIN PROC, V77, P1176, DOI 10.4065/77.11.1176; Wright TA, 1997, BRIT J SURG, V84, P760, DOI 10.1002/bjs.1800840606	22	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 30	2006	354	13					1403	1409		10.1056/NEJMcpc059007	http://dx.doi.org/10.1056/NEJMcpc059007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026KO	16571884				2023-01-03	WOS:000236338000011
J	Hawthorne, R; Lynch, JW				Hawthorne, R; Lynch, JW			A picrotoxin-specific conformational change in the glycine receptor M2-M3 loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL-LINING RESIDUES; NICOTINIC ACETYLCHOLINE-RECEPTOR; BETA-SUBUNIT; SURFACE ACCESSIBILITY; CHLORIDE CHANNELS; IDENTIFICATION; ACTIVATION; PORE; MECHANISM; BLOCK	The external loop linking the M2 and M3 transmembrane domains is crucial for coupling agonist binding to channel gating in the glycine receptor chloride channel (GlyR). A substituted cysteine accessibility scan previously showed that glycine activation increased the surface accessibility of 6 contiguous residues (Arg(271) Lys(276)) toward the N-terminal end of the homomeric alpha 1 GlyR M2 - M3 loop. In the present study we used a similar approach to determine whether the allosteric antagonist, picrotoxin, could impose conformational changes to this domain that cannot be induced by varying agonist concentrations alone. Picrotoxin slowed the reaction rate of a sulfhydryl-containing compound ( MTSET) with A272C, S273C, and L274C. Before interpreting this as a picrotoxin-specific conformational change, it was necessary to eliminate the possibility of steric competition between picrotoxin and MTSET. Accordingly, we showed that picrotoxin and the structurally unrelated blocker, bilobalide, were both trapped in the R271C GlyR in the closed state and that a point mutation to the pore-lining Thr(6') residue abolished inhibition by both compounds. We also demonstrated that the picrotoxin dissociation rate was linearly related to the channel open probability. These observations constitute a strong case for picrotoxin binding in the pore. We thus conclude that the picrotoxin-specific effects on the M2 - M3 loop are mediated allosterically. This suggests that the M2 - M3 loop responds differently to the occupation of different binding sites.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Queensland	Lynch, JW (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	j.lynch@uq.edu.au	Lynch, Joseph/C-8636-2009					AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; AUERBACH A, 2003, SCI STKE, pRE11; Barry PH, 2005, IEEE T NANOBIOSCI, V4, P70, DOI 10.1109/TNB.2004.842497; Beato M, 2002, J GEN PHYSIOL, V119, P443, DOI 10.1085/jgp.20028530; Chang YC, 2002, NAT NEUROSCI, V5, P1163, DOI 10.1038/nn926; Dibas MI, 2002, J BIOL CHEM, V277, P9112, DOI 10.1074/jbc.M111356200; Etter A, 1999, J NEUROCHEM, V72, P318, DOI 10.1111/jnc.1999.72.1.318; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; GURLEY D, 1995, RECEPTOR CHANNEL, V3, P13; Holmgren M, 1997, J GEN PHYSIOL, V109, P527, DOI 10.1085/jgp.109.5.527; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Ivic L, 2003, J BIOL CHEM, V278, P49279, DOI 10.1074/jbc.M304034200; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kash TL, 2004, BIOCHEM SOC T, V32, P540, DOI 10.1042/BST0320540; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kondratskaya EL, 2002, NEUROCHEM INT, V40, P647, DOI 10.1016/S0197-0186(01)00109-7; Legendre P, 1997, J NEUROPHYSIOL, V77, P2400, DOI 10.1152/jn.1997.77.5.2400; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; LYNCH JW, 1995, J BIOL CHEM, V270, P13799, DOI 10.1074/jbc.270.23.13799; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; MILLER C, 1987, BIOPHYS J, V52, P123, DOI 10.1016/S0006-3495(87)83196-X; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; Panicker S, 2004, J BIOL CHEM, V279, P28149, DOI 10.1074/jbc.M403545200; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Phillips LR, 2003, J GEN PHYSIOL, V122, P795, DOI 10.1085/jgp.200308953; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Qian HH, 2005, MOL PHARMACOL, V67, P470, DOI 10.1124/mol.104.003996; RUNDSTROM N, 1994, P NATL ACAD SCI USA, V91, P8950, DOI 10.1073/pnas.91.19.8950; Shan Q, 2002, J BIOL CHEM, V277, P44845, DOI 10.1074/jbc.M208647200; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; Unwin N, 2003, FEBS LETT, V555, P91, DOI 10.1016/S0014-5793(03)01084-6; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; WANG TL, 1995, P NATL ACAD SCI USA, V92, P11751, DOI 10.1073/pnas.92.25.11751; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; YOON KW, 1993, J PHYSIOL-LONDON, V464, P423, DOI 10.1113/jphysiol.1993.sp019643; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Zhorov BS, 2000, BIOPHYS J, V78, P1786, DOI 10.1016/S0006-3495(00)76729-4	44	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35836	35843		10.1074/jbc.M506645200	http://dx.doi.org/10.1074/jbc.M506645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109711	hybrid			2023-01-03	WOS:000232726900010
J	Lamming, DW; Latorre-Esteves, M; Medvedik, O; Wong, SN; Tsang, FA; Wang, C; Lin, SJ; Sinclair, DA				Lamming, DW; Latorre-Esteves, M; Medvedik, O; Wong, SN; Tsang, FA; Wang, C; Lin, SJ; Sinclair, DA			HST2 mediates SIR2-independent life-span extension by catorie restriction	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; DEACETYLASE ACTIVITY; PROTEIN SIR2; GENE FAMILY; YEAST; NAD; LONGEVITY; NICOTINAMIDE; REQUIREMENT	Calorie restriction (CR) extends the life span of numerous species, from yeast to rodents. Yeast Sir2 is a nicotinamide adenine dinucleotide (NAD+)dependent histone deacetylase that has been proposed to mediate the effects of CR. However, this hypothesis has been challenged by the observation that CR can extend yeast life span in the absence of Sir2. Here, we show that Sir2-independent life-span extension is mediated by Hst2, a Sir2 homolog that promotes the stability of repetitive ribosomal DNA, the same mechanism by which Sir2 extends life span. These findings demonstrate that the maintenance of DNA stability is critical for yeast life-span extension by CR and suggest that, in higher organisms, multiple members of the Sir2 family may regulate life span in response to diet.	Harvard Univ, Sch Med, Dept Pathol, Paul F Glenn Labs Biol Mech Aging, Boston, MA 02115 USA; Univ Calif Davis, Ctr Genet & Dev, Davis, CA 95616 USA; Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA	Harvard University; Harvard Medical School; University of California System; University of California Davis; University of California System; University of California Davis	Lin, SJ (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Paul F Glenn Labs Biol Mech Aging, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	slin@ucdavis.edu; david_sindair@hms.harvard.edu	Lamming, Dudley/O-7191-2015; Latorre-Esteves, Magda/GMW-6353-2022	Lamming, Dudley/0000-0002-0079-4467; Sinclair, David/0000-0002-9936-436X	NIA NIH HHS [R01 AG024351] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG024351] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Falcon AA, 2003, J BIOL CHEM, V278, P41607, DOI 10.1074/jbc.M307025200; Gallo CA, 2004, MOL CELL BIOL, V24, P1301, DOI 10.1128/MCB.24.3.1301-1312.2004; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Halme A, 2004, CELL, V116, P405, DOI 10.1016/S0092-8674(04)00118-7; Houthoofd K, 2003, EXP GERONTOL, V38, P947, DOI 10.1016/S0531-5565(03)00161-X; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jiang JC, 2002, EXP GERONTOL, V37, P1023, DOI 10.1016/S0531-5565(02)00064-5; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2005, MECH AGEING DEV, V126, P491, DOI 10.1016/j.mad.2004.10.007; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kobayashi T, 1998, GENE DEV, V12, P3821, DOI 10.1101/gad.12.24.3821; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	30	180	191	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	2005	309	5742					1861	1864		10.1126/science.1113611	http://dx.doi.org/10.1126/science.1113611			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	965ZN	16051752				2023-01-03	WOS:000231989500051
J	Shang, AJ; Huwiler-Muntener, K; Nartey, L; Juni, P; Dorig, S; Sterne, JA; Pewsner, D; Egger, M				Shang, AJ; Huwiler-Muntener, K; Nartey, L; Juni, P; Dorig, S; Sterne, JA; Pewsner, D; Egger, M			Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy	LANCET			English	Article							RANDOMIZED-TRIALS; METHODOLOGICAL QUALITY; SYSTEMATIC REVIEWS; HEALTH-CARE; METAANALYSIS; BIAS; HETEROGENEITY; COMPLEMENTARY; PUBLICATION; MEDICINE	Background Homoeopathy is widely used, but specific effects of homoeopathic remedies seem implausible. Bias in the conduct and reporting of trials is a possible explanation for positive findings of trials of both homoeopathy and conventional medicine. We analysed trials of homoeopathy and conventional medicine and estimated treatment effects in trials least likely to be affected by bias. Methods Placebo-controlled trials of homoeopathy were identified by a comprehensive literature search, which covered 19 electronic databases, reference lists of relevant papers, and contacts with experts. Trials in conventional medicine matched to homoeopathy trials for disorder and type of outcome were randomly selected from the Cochrane Controlled Trials Register (issue 1, 2003). Data were extracted in duplicate and outcomes coded so that odds ratios below 1 indicated benefit. Trials described as double-blind, with adequate randomisation, were assumed to be of higher methodological quality. Bias effects were examined in funnel plots and meta-regression models. Findings 110 homoeopathy trials and 110 matched conventional-medicine trials were analysed. The median study size was 65 participants (range ten to 1573). 21 homoeopathy trials (19%) and nine (8%) conventional-medicine trials were of higher quality. In both groups, smaller trials and those of lower quality showed more beneficial treatment effects than larger and higher-quality trials. When the analysis was restricted to large trials of higher quality, the odds ratio was 0.88 (95% CI 0.65-1.19) for homoeopathy (eight trials) and 0.58 (0.39-0.85) for conventional medicine (six trials). Interpretation Biases are present in placebo-controlled trials of both homoeopathy and conventional medicine. When account was taken for these biases in the analysis, there was weak evidence for a specific effect of homoeopathic remedies, but strong evidence for specific effects of conventional interventions. This finding is compatible with the notion that the clinical effects of homoeopathy are placebo effects.	Univ Bern, Dept Social & Prevent Med, Bern, Switzerland; Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol, Avon, England; Univ Zurich, Dept Pharmacol, Zurich, Switzerland; MediX Gen Practice Network, Practice Bruckfeld, Bern, Switzerland	University of Bern; University of Bristol; University of Zurich	Egger, M (corresponding author), Univ Bern, Dept Social & Prevent Med, Bern, Switzerland.	egger@ispm.unibe.ch	Sterne, Jonathan/Z-3106-2019; Juni, Peter/Q-8700-2016	Sterne, Jonathan/0000-0001-8496-6053; Juni, Peter/0000-0002-5985-0670; Egger, Matthias/0000-0001-7462-5132				ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; Dickersin K, 2002, EVAL HEALTH PROF, V25, P38, DOI 10.1177/0163278702025001004; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2000, BMJ-BRIT MED J, V321, P1133, DOI 10.1136/bmj.321.7269.1133; GOTZSCHE PC, 1993, LANCET, V341, P1533; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437; Jonas W., 1996, HEALING HOMEOPATHY; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kaptchuk TJ, 1998, ANN INTERN MED, V129, P1061, DOI 10.7326/0003-4819-129-12-199812150-00011; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; Linde K, 2001, INT J EPIDEMIOL, V30, P526, DOI 10.1093/ije/30.3.526; Linde K, 1999, J CLIN EPIDEMIOL, V52, P631, DOI 10.1016/S0895-4356(99)00048-7; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Morrison B, 2000, PERFUSION, V13, P132; Rennie D, 1999, JAMA-J AM MED ASSOC, V282, P1766, DOI 10.1001/jama.282.18.1766; Schulte J, 1999, Br Homeopath J, V88, P155, DOI 10.1054/homp.1999.0317; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 1996, LANCET, V348, P596, DOI 10.1016/S0140-6736(96)01201-9; SKRABANEK P, 1986, LANCET, V2, P1107; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8; Vandenbroucke JP, 1997, LANCET, V350, P824, DOI 10.1016/S0140-6736(97)22038-6; Vickers A, 1999, BRIT MED J, V319, P1115, DOI 10.1136/bmj.319.7217.1115	31	485	523	5	150	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2005	366	9487					726	732		10.1016/S0140-6736(05)67177-2	http://dx.doi.org/10.1016/S0140-6736(05)67177-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958UV	16125589				2023-01-03	WOS:000231474600028
J	Akhtar, S; Bradley, MJ; Quinton, DN; Burke, FD				Akhtar, S; Bradley, MJ; Quinton, DN; Burke, FD			Management and referral for trigger finger/thumb	BRITISH MEDICAL JOURNAL			English	Review							STENOSING TENOVAGINITIS; PERCUTANEOUS RELEASE; STEROID INJECTION; DIABETES-MELLITUS; A1 PULLEY; THUMB; FINGERS; CHILDREN; HAND; EFFICACY		Derbyshire Royal Infirm, Pulvertaft Hand Ctr, Derby DE1 2QY, England		Akhtar, S (corresponding author), 27 Belle Vue Ave, Leeds LS8 2NN, W Yorkshire, England.	sohailakhtar001@yahoo.co.uk						AMETEWEE K, 1983, HAND, V15, P103, DOI 10.1016/S0072-968X(83)80045-X; ANDERSON B, 1991, ARCH INTERN MED, V151, P153, DOI 10.1001/archinte.151.1.153; BAIN GI, 1995, J HAND SURG-AM, V20A, P781, DOI 10.1016/S0363-5023(05)80430-7; Benson LS, 1997, J HAND SURG-AM, V22A, P138, DOI 10.1016/S0363-5023(05)80194-7; BONNICI AV, 1988, J HAND SURG-BRIT EUR, V13B, P202, DOI 10.1016/0266-7681(88)90139-8; CHAMMAS M, 1995, J HAND SURG-AM, V20A, P109, DOI 10.1016/S0363-5023(05)80068-1; Cihantimur B, 1998, ACTA ORTHOP SCAND, V69, P167, DOI 10.3109/17453679809117620; CLARK DD, 1973, PLAST RECONSTR SURG, V51, P179, DOI 10.1097/00006534-197302000-00014; FAHEY JJ, 1954, J BONE JOINT SURG AM, V36-A, P1200, DOI 10.2106/00004623-195436060-00009; Gaffield JW, 2001, ANN PLAS SURG, V46, P352, DOI 10.1097/00000637-200103000-00037; GRIGGS SM, 1995, J HAND SURG-AM, V20A, P787, DOI 10.1016/S0363-5023(05)80432-0; HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P1720, DOI 10.2106/00004623-199411000-00018; KAMHIN M, 1983, HAND, V15, P218, DOI 10.1016/S0072-968X(83)80018-7; KOLINDSORENSEN V, 1970, ACTA ORTHOP SCAND, V41, P428, DOI 10.3109/17453677008991530; LAPIDUS PW, 1972, CLIN ORTHOP RELAT R, P87; LORTHIOIR J, 1958, J BONE JOINT SURG AM, V40, P793, DOI 10.2106/00004623-195840040-00003; Nemoto K, 1996, J HAND SURG-BRIT EUR, V21B, P416, DOI 10.1016/S0266-7681(05)80221-9; NEWPORT ML, 1990, J HAND SURG-AM, V15A, P748, DOI 10.1016/0363-5023(90)90149-L; Park BH, 2001, IEEE T PLASMA SCI, V29, P502, DOI 10.1109/27.928948; Patel MR, 1997, J HAND SURG-AM, V22A, P150, DOI 10.1016/S0363-5023(05)80196-0; PATEL MR, 1992, J HAND SURG-AM, V17A, P110, DOI 10.1016/0363-5023(92)90124-8; POPE DF, 1995, J HAND SURG-AM, V20A, P280, DOI 10.1016/S0363-5023(05)80026-7; Rodgers JA, 1998, ORTHOPEDICS, V21, P305; SAMPSON SP, 1991, J HAND SURG-AM, V16A, P714, DOI 10.1016/0363-5023(91)90200-U; SCHOFIELD CB, 1993, J HAND SURG-BRIT EUR, V18B, P247, DOI 10.1016/0266-7681(93)90120-5; SERADGE H, 1981, J HAND SURG-AM, V6, P54; Sherman PJ, 1996, J BONE JOINT SURG AM, V78A, P1753, DOI 10.2106/00004623-199611000-00019; Stahl S, 1997, J DIABETES COMPLICAT, V11, P287, DOI 10.1016/S1056-8727(96)00076-1; Strom L, 1977, J Med Soc N J, V74, P951; Tan AHC, 2002, J PEDIATR ORTHOP B, V11, P256, DOI 10.1097/00009957-200207000-00011; TARAS JS, 1995, J HAND SURG-AM, V20A, P276, DOI 10.1016/S0363-5023(05)80024-3; Taras JS, 1998, J HAND SURG-AM, V23A, P717, DOI 10.1016/S0363-5023(98)80060-9; THORPE AP, 1988, J HAND SURG-BRIT EUR, V13B, P199, DOI 10.1016/0266-7681(88)90138-6; Trezies AJH, 1998, J HAND SURG-BRIT EUR, V23B, P539, DOI 10.1016/S0266-7681(98)80142-3; Verdon ME, 1996, PRIMARY CARE, V23, P305, DOI 10.1016/S0095-4543(05)70278-5; Watanabe H, 2001, ARCH ORTHOP TRAUM SU, V121, P388, DOI 10.1007/s004020000249; Wilhelmi BJ, 2003, PLAST RECONSTR SURG, V112, P993, DOI 10.1097/01.PRS.0000076225.79854.F7; Wilhelmi BJ, 2001, PLAST RECONSTR SURG, V108, P908, DOI 10.1097/00006534-200109150-00014; YOSIPOVITCH G, 1990, J RHEUMATOL, V17, P951; YOUNG L, 1980, PLAST RECONSTR SURG, V65, P68, DOI 10.1097/00006534-198001000-00013	40	77	79	3	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 2	2005	331	7507					30	33		10.1136/bmj.331.7507.30	http://dx.doi.org/10.1136/bmj.331.7507.30			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947TD	15994689	Green Published			2023-01-03	WOS:000230668500019
J	Winton, T; Livingston, R; Johnson, D; Rigas, J; Johnston, M; Butts, C; Cormier, Y; Goss, G; Inculet, R; Vallieres, E; Fry, W; Bethune, D; Ayoub, J; Ding, K; Seymour, L; Graham, B; Tsao, MS; Gandara, D; Kesler, K; Demmy, T; Shepherd, F				Winton, T; Livingston, R; Johnson, D; Rigas, J; Johnston, M; Butts, C; Cormier, Y; Goss, G; Inculet, R; Vallieres, E; Fry, W; Bethune, D; Ayoub, J; Ding, K; Seymour, L; Graham, B; Tsao, MS; Gandara, D; Kesler, K; Demmy, T; Shepherd, F		Natl Canc Inst Canada Clin Trials Grp; Natl Canc Inst US Intergroup JBR 10	Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RAS GENE-MUTATIONS; QUALITY-OF-LIFE; STAGE-II; ADJUVANT CHEMOTHERAPY; SURVIVAL; TRIAL; THERAPY	Background We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer. Methods We randomly assigned patients with completely resected stage IB or stage II non-small-cell lung cancer to vinorelbine plus cisplatin or to observation. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimen. Results A total of 482 patients underwent randomization to vinorelbine plus cisplatin (242 patients) or observation (240); 45 percent of the patients had pathological stage IB disease and 55 percent had stage II, and all had an Eastern Cooperative Oncology Group performance status score of 0 or 1. In both groups, the median age was 61 years, 65 percent were men, and 53 percent had adenocarcinomas. Chemotherapy caused neutropenia in 88 percent of patients (including grade 3 febrile neutropenia in 7 percent) and death from toxic effects in two patients (0.8 percent). Nonhematologic toxic effects of chemotherapy were fatigue (81 percent of patients), nausea (80 percent), anorexia (55 percent), vomiting (48 percent), neuropathy (48 percent), and constipation (47 percent), but severe (grade 3 or greater) toxic effects were uncommon (<10 percent). Overall survival was significantly prolonged in the chemotherapy group as compared with the observation group (94 vs. 73 months; hazard ratio for death, 0.69; P=0.04), as was relapse-free survival (not reached vs. 46.7 months; hazard ratio for recurrence, 0.60; P<0.001). Five-year survival rates were 69 percent and 54 percent, respectively (P=0.03). Conclusions Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.	Natl Canc Inst Canada Clin Trials Grp, Kingston, ON, Canada; SW Oncol Grp, San Antonio, TX USA; Eastern Cooperat Oncol Grp, Boston, MA USA; Canc & Leukemia Grp B, Chicago, IL USA	Queens University - Canada; Canadian Cancer Trials Group; Southwest Oncology Group	Winton, T (corresponding author), Univ Alberta Hosp, Walter Mackenzie Hlth Sci Ctr 2D2 09, 8440 112th St, Edmonton, AB T6G 2B7, Canada.	twinton@cha.ab.ca	Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; Vallieres, Eric/0000-0003-1732-2658	NCI NIH HHS [CA04326, CA31946] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA004326, U10CA031946] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alam N, 2005, LUNG CANCER, V47, P385, DOI 10.1016/j.lungcan.2004.08.016; ALBERTI W, 1995, BRIT MED J, V311, P899; BEZIAK A, 2003, LUNG CANCER S4, V41, pS20; Bonomi P, 2000, J CLIN ONCOL, V18, P623, DOI 10.1200/JCO.2000.18.3.623; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Bunn PA, 1998, CLIN CANCER RES, V4, P1087; Burdett S, 1998, LANCET, V352, P257; COX DR, 1972, J R STAT SOC B, V34, P187; Cullen M, 2003, THORAX, V58, P352, DOI 10.1136/thorax.58.4.352; Giaccone G, 1998, J CLIN ONCOL, V16, P2133, DOI 10.1200/JCO.1998.16.6.2133; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keller SM, 2000, NEW ENGL J MED, V343, P1217, DOI 10.1056/NEJM200010263431703; Keller SM, 2002, LUNG CANCER, V37, P303, DOI 10.1016/S0169-5002(02)00103-4; Kelly K, 2001, J CLIN ONCOL, V19, P3210, DOI 10.1200/JCO.2001.19.13.3210; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; LECHEVALIER T, 1994, J CLIN ONCOL, V12, P360, DOI 10.1200/JCO.1994.12.2.360; MITSUDOMI T, 1991, CANCER RES, V51, P4999; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Ponn RB, 2005, GEN THORACIC SURG, V6, P1548; ROILA F, 1992, LANCET, V340, P96; ROSELL R, 1993, ONCOGENE, V8, P2407; Scagliotti GV, 2003, JNCI-J NATL CANCER I, V95, P1453, DOI 10.1093/jnci/djg059; SHEPHERD FA, 2002, THORACIC SURG, P859; Socinski MA, 2003, CHEST, V123, p226S, DOI 10.1378/chest.123.1_suppl.226S; Soria JC, 2002, ANN ONCOL, V13, P1515, DOI 10.1093/annonc/mdf331; Strauss GM, 2004, J CLIN ONCOL, V22, P7019; SUGIO K, 1992, CANCER RES, V52, P2903; Tsao MS, 1997, CLIN CANCER RES, V3, P1807; TSIATIS AA, 1984, BIOMETRICS, V40, P797, DOI 10.2307/2530924; Waller D, 2004, EUR J CARDIO-THORAC, V26, P173, DOI 10.1016/j.ejcts.2004.03.041; Zojwalla NJ, 2004, J CLIN ONCOL, V22, p633S	33	1410	1481	2	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2005	352	25					2589	2597		10.1056/NEJMoa043623	http://dx.doi.org/10.1056/NEJMoa043623			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937VJ	15972865				2023-01-03	WOS:000229953700006
J	Buyon, JP; Petri, MA; Kim, MY; Kalunian, KC; Grossman, J; Hahn, BH; Merrill, JT; Sammaritano, L; Lockshin, M; Alarcon, GS; Manzi, S; Belmont, HM; Askanase, AD; Sigler, L; Dooley, MA; Von Feldt, J; McCune, WJ; Friedman, A; Wachs, J; Cronin, M; Hearth-Holmes, M; Tan, M; Licciardi, F				Buyon, JP; Petri, MA; Kim, MY; Kalunian, KC; Grossman, J; Hahn, BH; Merrill, JT; Sammaritano, L; Lockshin, M; Alarcon, GS; Manzi, S; Belmont, HM; Askanase, AD; Sigler, L; Dooley, MA; Von Feldt, J; McCune, WJ; Friedman, A; Wachs, J; Cronin, M; Hearth-Holmes, M; Tan, M; Licciardi, F			The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; ORAL-CONTRACEPTIVE THERAPY; POSTMENOPAUSAL WOMEN; PLUS PROGESTIN; FOLLOW-UP; ACCELERATED ATHEROSCLEROSIS; PULMONARY-HYPERTENSION; CARDIOVASCULAR-DISEASE; RISK; SLE	Background: There is concern that exogenous female hormones may worsen disease activity in women with systemic lupus erythematosus (SLE). Objective: To evaluate the effect of hormone replacement therapy (HRT) on disease activity in postmenopausal women with SLE. Design: Randomized, double-blind, placebo-controlled nonin-feriority trial conducted from March 1996 to June 2002. Setting: 16 university-affiliated rheumatology clinics or practices in 11 U.S. states. Patients: 351 menopausal patients (mean age, 50 years) with inactive (81.5%) or stable-active (18.5%) SLE. Interventions: 12 months of treatment with active drug (0.625 mg of conjugated estrogen daily, plus 5 mg of medroxyprogesterone for 12 days per month) or placebo. The 12-month follow-up rate was 82% for the HRT group and 87% for the placebo group. Measurements: The primary end point was occurrence of a severe flare as defined by Safety of Estrogens in Lupus Erythem- atosus, National Assessment-Systemic Lupus Erythematosus Disease Activity Index composite. Results: Severe flare was rare in both treatment groups: The 12-month severe flare rate was 0.081 for the HRT group and 0.049 for the placebo group, yielding an estimated difference of 0.033 (P = 0.23). The upper limit of the 1-sided 95% Cl for the treatment difference was 0.078, within the prespecified margin of 9% for noninferiority. Mild to moderate flares were significantly increased in the HRT group: 1.14 flares/person-year for HRT and 0.86 flare/person-year for placebo (relative risk, 1.34; P = 0.01). The probability of any type of flare by 12 months was 0.64 for the HRT group and 0.51 for the placebo group (P = 0.01). In the HRT group, there were 1 death, 1 stroke, 2 cases of deep venous thrombosis, and 1 case of thrombosis in an arteriovenous graft; in the placebo group, 1 patient developed deep venous thrombosis. Limitations: Findings are not generalizable to women with high-titer anticardiolipin antibodies, lupus anticoagulant, or previous thrombosis. Conclusions: Adding a short course of HRT is associated with a small risk for increasing the natural flare rate of lupus. Most of these flares are mild to moderate. The benefits of HRT can be balanced against the risk for flare because HRT did not significantly increase the risk for severe flare compared with placebo.	NYU, Hosp Joint Dis, Sch Med, New York, NY 10003 USA; Johns Hopkins Univ, Baltimore, MD 21218 USA	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; Johns Hopkins University	Buyon, JP (corresponding author), NYU, Hosp Joint Dis, Sch Med, 550 1St Ave, New York, NY 10003 USA.	jill.buyon@nyumc.org	Kalunian, Kenneth/AAK-6424-2020; Kalunian, Kenneth/L-4471-2019	Belmont, Howard/0000-0003-3389-2976; Licciardi, Frederick/0000-0002-2186-5981; Buyon, Jill/0000-0002-3852-7129; Kalunian, Kenneth/0000-0003-0261-3102	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096, M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043727, U01AR042540, R55AR043727] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00052, M01 RR00096] Funding Source: Medline; NIAMS NIH HHS [U01 AR42540, AR 43727] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARCHER DF, 1994, OBSTET GYNECOL, V83, P686; ARDEN NK, 1994, LUPUS, V3, P11, DOI 10.1177/096120339400300104; Asanuma Y, 2003, NEW ENGL J MED, V349, P2407, DOI 10.1056/NEJMoa035611; Bagger YZ, 2004, BONE, V34, P728, DOI 10.1016/j.bone.2003.12.021; BARRETT C, 1986, BRIT J RHEUMATOL, V25, P300; Bastian Holly M., 1994, Arthritis and Rheumatism, V37, pS321; BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; CASTELOBRANCO C, 1995, J REPROD MED, V40, P556; CHAPEL TA, 1971, AM J OBSTET GYNECOL, V110, P366, DOI 10.1016/0002-9378(71)90730-7; Esdaile JM, 2001, ARTHRITIS RHEUM, V44, P2331, DOI 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I; FURUKAWA F, 1991, Journal of Dermatology (Tokyo), V18, P56; GAROVICH M, 1980, ARTHRITIS RHEUM, V23, P1396, DOI 10.1002/art.1780231213; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grimaldi CM, 2002, J CLIN INVEST, V109, P1625, DOI 10.1172/JCI200214873; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; HADIDA M, 1968, B SOC FR DERMATO SYP, V74, P616; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JUNGERS P, 1982, ARTHRITIS RHEUM, V25, P618, DOI 10.1002/art.1780250603; Kreidstein S, 1997, J RHEUMATOL, V24, P2149; LAHITA RG, 1982, ARTHRITIS RHEUM, V25, P843, DOI 10.1002/art.1780250726; LAHITA RG, 1979, ARTHRITIS RHEUM, V22, P1195, DOI 10.1002/art.1780221106; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Manzi S, 1997, AM J EPIDEMIOL, V145, P408; MASI AT, 1978, ARTHRITIS RHEUM-US, V21, P480, DOI 10.1002/art.1780210413; Meier CR, 1998, J RHEUMATOL, V25, P1515; MILLER MH, 1987, ANN RHEUM DIS, V46, P159, DOI 10.1136/ard.46.2.159; Mok CC, 1998, SCAND J RHEUMATOL, V27, P342, DOI 10.1080/03009749850154357; Naftolin F, 2004, FERTIL STERIL, V81, P1498, DOI 10.1016/j.fertnstert.2004.02.095; Peeva E, 2004, BIOMED PHARMACOTHER, V58, P310, DOI 10.1016/j.biopha.2004.04.007; Petri M, 1999, LUPUS, V8, P685, DOI 10.1191/096120399680411281; Petri M, 2000, RHEUM DIS CLIN N AM, V26, P199, DOI 10.1016/S0889-857X(05)70135-6; Pimstone B., 1966, S AFR MED J, V4, P62; Ramsey-Goldman R, 1999, ARTHRITIS RHEUM, V42, P882, DOI 10.1002/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C; Roman MJ, 2003, NEW ENGL J MED, V349, P2399, DOI 10.1056/NEJMoa035471; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; ROUBINIAN J, 1979, ARTHRITIS RHEUM, V22, P1162; Sanchez-Guerrero J, 2001, ARTHRITIS RHEUM, V44, pS263; SANCHEZGUERRERO J, 1995, ANN INTERN MED, V122, P430, DOI 10.7326/0003-4819-122-6-199503150-00005; Selzer F, 2001, HYPERTENSION, V37, P1075, DOI 10.1161/01.HYP.37.4.1075; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TODD GRG, 1985, ANN RHEUM DIS, V44, P266, DOI 10.1136/ard.44.4.266; TRAVERS RL, 1978, J RHEUMATOL, V5, P448; Wang DR, 1996, MOL BIOL REP, V23, P205, DOI 10.1007/BF00351170; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084	46	418	429	1	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	1				953	962		10.7326/0003-4819-142-12_Part_1-200506210-00004	http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937IN	15968009				2023-01-03	WOS:000229917900001
J	Trichopoulou, A				Trichopoulou, A		EPIC-Elderly Prospective Study Grp	Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; CANCER; CALIBRATION; DISEASE; RISK; MEN; AGE	Objective To examine whether adherence to the modified Mediterranean diet, in which unsaturates were substituted for monounsaturates, is associated with longer life expectancy among elderly Europeans. Design Multicentre, prospective cohort study. Setting Nine European countries (Denmark, France, Germany, Greece, Italy, the Netherlands, Spain, Sweden, United Kingdom). Participants 74 607 men and women, aged 60 or more, without coronary heart disease, stroke, or cancer at enrolment and with complete information about dietary intake and potentially confounding variables. Main outcome measures Extent of adherence to a modified Mediterranean diet using a scoring system on a 10 point scale, and death from any cause by time of occurrence, modelled through Cox regression. Results An increase in the modified Mediterranean diet score was associated with lower overall mortality, a two unit increment corresponding to a statistically significant reduction of 8% (95% confidence interval 3% to 12%). No statistically significant evidence of heterogeneity was found among countries in the association of the score with overall mortality even though the association was stronger in Greece and Spain. When dietary exposures were calibrated across countries, the reduction in mortality was 7% (1% to 12%). Conclusion The Mediterranean diet, modified so as to apply across Europe, was associated with increased survival among older people.	Univ Athens, Sch Med, Dept Hyg & Epidemiol, Athens 11527, Greece	Athens Medical School; National & Kapodistrian University of Athens	Trichopoulou, A (corresponding author), Univ Athens, Sch Med, Dept Hyg & Epidemiol, Athens 11527, Greece.	antonia@nut.uoa.gr	M, RODRIGUEZ-BARRANCO/H-4541-2012; van der Schouw, Yvonne T./F-8327-2014; Nagel, Gabriele/C-3635-2012; Orfanos, Philippos/AAL-2606-2021; TRICHOPOULOU, ANTONIA/ABF-8727-2021; Kesse-Guyot, Emmanuelle/K-4689-2012; Krogh, Vittorio/K-2628-2016; Clavel-Chapelon, Francoise/G-6733-2014	M, RODRIGUEZ-BARRANCO/0000-0002-9972-9779; van der Schouw, Yvonne T./0000-0002-4605-435X; Nagel, Gabriele/0000-0001-6185-8535; TRICHOPOULOU, ANTONIA/0000-0002-7204-6396; Krogh, Vittorio/0000-0003-0122-8624; Benetou, Vassiliki/0000-0002-0415-0386; Riboli, Elio/0000-0001-6795-6080; Masala, Giovanna/0000-0002-5758-9069; Navarro, Carmen/0000-0001-8896-7483; tumino, rosario/0000-0003-2666-414X; Spencer, Elizabeth/0000-0002-9079-8006; Overvad, Kim/0000-0001-6429-7921; Pera, Guillem/0000-0003-3188-7268; Orfanos, Philippos/0000-0002-9949-3137				BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; deGroot LCPGM, 1996, NUTR REV, V54, P211, DOI 10.1111/j.1753-4887.1996.tb03935.x; Deharveng G, 1999, EUR J CLIN NUTR, V53, P60, DOI 10.1038/sj.ejcn.1600677; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; *DEP HLTH, 2001, UK DEP HLTH REP HLTH, V41; *DEP HLTH, 1991, UK DEP HLTH REP HLTH, V41; Huijbregts P, 1997, BRIT MED J, V315, P13, DOI 10.1136/bmj.315.7099.13; Jacques PF, 2001, AM J CLIN NUTR, V73, P1, DOI 10.1093/ajcn/73.1.1; James W. P. T., 1990, HUMAN ENERGY REQUIRE; Kaaks R, 1997, INT J EPIDEMIOL, V26, pS15, DOI 10.1093/ije/26.suppl_1.S15; Keys A., 1980, MULTIVARIATE ANAL DE; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; Kumagai S, 1999, J Nutr Health Aging, V3, P29; Lasheras C, 2000, AM J CLIN NUTR, V71, P987; Margetts BM, 1997, INT J EPIDEMIOL, V26, pS1, DOI 10.1093/ije/26.suppl_1.S1; Osler M, 1997, INT J EPIDEMIOL, V26, P155, DOI 10.1093/ije/26.1.155; Riboli E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; Slimani N, 2002, PUBLIC HEALTH NUTR, V5, P1125, DOI 10.1079/PHN2002395; TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; WILLETT W, 1998, NUTR EPIDEMIOLOGY, P414; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC	25	540	552	0	46	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 30	2005	330	7498					991	995		10.1136/bmj.38415.644155.8F	http://dx.doi.org/10.1136/bmj.38415.644155.8F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923UP	15820966	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000228935100018
J	Sakhalkar, HS; Hanes, J; Fu, J; Benavides, U; Malgor, R; Borruso, CL; Kohn, LD; Kujiaka, DT; Goetz, DJ				Sakhalkar, HS; Hanes, J; Fu, J; Benavides, U; Malgor, R; Borruso, CL; Kohn, LD; Kujiaka, DT; Goetz, DJ			Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules	FASEB JOURNAL			English	Article						colitis; inflammation; endothelial cell adhesion molecules; biodegradable polymer; targeted drug delivery; microspheres	ACTIVATED ENDOTHELIAL-CELLS; INFLAMMATORY-BOWEL-DISEASE; E-SELECTIN IMMUNOCONJUGATE; TARGETED DRUG-DELIVERY; ULCERATIVE-COLITIS; CROHNS-DISEASE; P-SELECTIN; DEXAMETHASONE; NANOPARTICLES; EXPRESSION	The expression of certain endothelial cell adhesion molecules (ECAMs) is increased in the vasculature of the inflamed bowel (e.g., colitis), thereby providing an opportunity for targeted drug delivery. We recently demonstrated that biodegradable particles conjugated with ligands to ECAMs exhibit significant selective adhesion to ECAM expressing endothelium. In the present study, we used a murine model of colitis to determine whether poly(lactic acid)-poly(ethylene glycol) particles conjugated with a VCAM-I ligand (alpha-V) exhibit enhanced adhesion to colitic vasculature. In post-capillary venules of the colon, significantly more alpha-V particles accumulate in colitic mice relative to (i) control mice (i.e., selectivity) and (ii) particles bearing a control ligand (i.e., ligand efficiency). The selectivity and ligand efficiency of alpha-V particles were a function of the total number of particles infused. The highest selectivity observed within our test regime was 3, while ligand efficiency increased linearly with the number of particles injected to a value of 24. This work represents a significant step towards achieving a targeted drug delivery scheme for the treatment of inflammatory bowel disease and indicates that the efficiency of targeting is dependent on the dose regime.	Ohio Univ, Dept Chem Engn, Stocker Ctr 172, Athens, OH 45701 USA; Ohio Univ, Dept Biol Sci, Athens, OH 45701 USA; Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA; Ohio Univ, Dept Biomed Sci, Athens, OH 45701 USA; Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA	Ohio University; Ohio University; Ohio University; Ohio University; Johns Hopkins University	Goetz, DJ (corresponding author), Ohio Univ, Dept Chem Engn, Stocker Ctr 172, Athens, OH 45701 USA.	goetzd@ohio.edu			NIGMS NIH HHS [GM57640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM057640] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asgeirsdottir SA, 2003, BIOCHEM PHARMACOL, V65, P1729, DOI 10.1016/S0006-2952(03)00122-9; Caprilli R, 2002, ALIMENT PHARM THER, V16, P1579, DOI 10.1046/j.1365-2036.2002.01319.x; Chapman PT, 1996, ARTHRITIS RHEUM, V39, P1371, DOI 10.1002/art.1780390815; Chourasia MK, 2003, J PHARM PHARM SCI, V6, P33; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Dickerson JB, 2001, BIOTECHNOL BIOENG, V73, P500, DOI 10.1002/bit.1085; Eniola AO, 2002, BIOMATERIALS, V23, P2167, DOI 10.1016/S0142-9612(01)00349-0; Everts M, 2002, J IMMUNOL, V168, P883, DOI 10.4049/jimmunol.168.2.883; Everts M., 2001, DRUG TARGETING ORGAN, P171; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Fiocchi C, 1997, AM J PHYSIOL-GASTR L, V273, pG769, DOI 10.1152/ajpgi.1997.273.4.G769; Fu J, 2004, MACROMOLECULES, V37, P7174, DOI 10.1021/ma049853s; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; GRISHAM MB, 1999, INFLAMM BOWEL DIS, P55; Kirsner JB, 1999, ITAL J GASTROENTEROL, V31, P651; Kok RJ, 2002, PHARM RES-DORDR, V19, P1730, DOI 10.1023/A:1020769716288; Lamprecht A, 2001, J PHARMACOL EXP THER, V299, P775; Langer R, 1998, NATURE, V392, P5; MURTHY SNS, 1993, DIGEST DIS SCI, V38, P1722, DOI 10.1007/BF01303184; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Panes J, 1998, GASTROENTEROLOGY, V114, P1066, DOI 10.1016/S0016-5085(98)70328-2; Sakhalkar HS, 2003, P NATL ACAD SCI USA, V100, P15895, DOI 10.1073/pnas.2631433100; Salem AK, 2001, BIOMACROMOLECULES, V2, P575, DOI 10.1021/bm010030+; SCHURMANN GM, 1995, GUT, V36, P411, DOI 10.1136/gut.36.3.411; Shigematsu T, 2001, AM J PHYSIOL-GASTR L, V281, pG1309, DOI 10.1152/ajpgi.2001.281.5.G1309; Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4; Soriano A, 2000, LAB INVEST, V80, P1541, DOI 10.1038/labinvest.3780164; Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Wiewrodt R, 2002, BLOOD, V99, P912, DOI 10.1182/blood.V99.3.912; Xu CT, 2004, WORLD J GASTROENTERO, V10, P2311	31	38	39	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					792	+		10.1096/fj.04-2668fje	http://dx.doi.org/10.1096/fj.04-2668fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15764649				2023-01-03	WOS:000227901300016
J	Marsh, R				Marsh, R			Avian influenza - Preparing for the pandemic - Hard decisions will have to be made: view from intensive care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Northampton Gen Hosp NHS Trust, Northampton NN1 5BD, England		Marsh, R (corresponding author), Northampton Gen Hosp NHS Trust, Northampton NN1 5BD, England.	Richard.Marsh@ngh.nhs.uk						Beigel H, 2005, NEW ENGL J MED, V353, P1374, DOI 10.1056/NEJMra052211; *HLTH PROT AG, INFL PAND CONT PLAN; Rubinson L, 2005, CRIT CARE MED, V33, P2393, DOI 10.1097/01.CCM.0000173411.06574.D5; Scales DC, 2003, EMERG INFECT DIS, V9, P1205, DOI 10.3201/eid0910.030525	4	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2006	332	7544					790	791		10.1136/bmj.332.7544.790	http://dx.doi.org/10.1136/bmj.332.7544.790			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	032JA	16575088	Green Published			2023-01-03	WOS:000236769500032
J	Hanson, LC; Ersek, M				Hanson, LC; Ersek, M			Meeting palliative care needs in post-acute care settings - "To help them live until they die"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; NURSING-HOME RESIDENTS; HOSPICE ENROLLMENT; QUALITY-IMPROVEMENT; PAIN MANAGEMENT; END; FACILITIES; HOSPITALIZATION; PREFERENCES		Univ N Carolina, Div Geriatr Med, Pain & Symptom Care Program, Chapel Hill, NC 27599 USA; Univ Washington, Sch Nursing, Swedish Med Ctr, Pain & Palliat Care Res Dept, Seattle, WA 98195 USA; Univ Washington, Sch Nursing, Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA	University of North Carolina; University of North Carolina Chapel Hill; Swedish Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hanson, LC (corresponding author), Univ N Carolina, Div Geriatr Med, Pain & Symptom Care Program, CB 7550, Chapel Hill, NC 27599 USA.	lhanson@med.unc.edu		Ersek, Mary/0000-0002-0520-311X; Hanson, Laura/0000-0001-5120-6058				Baer WM, 2000, J AM GERIATR SOC, V48, P879, DOI 10.1111/j.1532-5415.2000.tb06883.x; Baier RR, 2004, J AM GERIATR SOC, V52, P1988, DOI 10.1111/j.1532-5415.2004.52553.x; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Boockvar K, 2004, ARCH INTERN MED, V164, P545, DOI 10.1001/archinte.164.5.545; Bradley EH, 1998, J AM GERIATR SOC, V46, P1235, DOI 10.1111/j.1532-5415.1998.tb04539.x; Brock D B, 1998, Hosp J, V13, P49; Casarett D, 2005, JAMA-J AM MED ASSOC, V294, P211, DOI 10.1001/jama.294.2.211; Castle N G, 1997, Hosp J, V12, P59; Castle NG, 2005, MED CARE, V43, P616, DOI 10.1097/01.mlr.0000163661.67170.b9; Chan J, 2002, GERONTOLOGIST, V42, P301; Dixon Sharon, 2002, Am J Hosp Palliat Care, V19, P187, DOI 10.1177/104990910201900310; Ersek Mary, 2005, J Palliat Med, V8, P556, DOI 10.1089/jpm.2005.8.556; Ersek Mary, 2003, J Palliat Med, V6, P45, DOI 10.1089/10966210360510118; FERRELL BA, 1995, ANN INTERN MED, V123, P681, DOI 10.7326/0003-4819-123-9-199511010-00007; Fried TR, 1999, ANN INTERN MED, V131, P109, DOI 10.7326/0003-4819-131-2-199907200-00006; Gillick M, 1999, J AM GERIATR SOC, V47, P227, DOI 10.1111/j.1532-5415.1999.tb04582.x; Hanson Laura C, 2002, J Palliat Med, V5, P117; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Hanson LC, 2005, J PALLIAT MED, V8, P1207, DOI 10.1089/jpm.2005.8.1207; HENDERSON ML, 2003, IMPROVING NURSING HO; Hickman SE, 2004, J AM GERIATR SOC, V52, P1424, DOI 10.1111/j.1532-5415.2004.52402.x; Horner JK, 2005, J PAIN SYMPTOM MANAG, V30, P271, DOI 10.1016/j.jpainsymman.2005.03.014; Keay Timothy J, 2003, J Palliat Med, V6, P205, DOI 10.1089/109662103764978452; Kovach CR, 1996, AM J ALZHEIMERS DIS, V11, P7, DOI DOI 10.1177/153331759601100402; Levin JR, 1999, J AM GERIATR SOC, V47, P82, DOI 10.1111/j.1532-5415.1999.tb01905.x; LINN MW, 1989, INT J AGING HUM DEV, V28, P305, DOI 10.2190/JA0E-9T0Y-H2K8-QBV6; Maccabee Joyce, 1994, Palliative Medicine, V8, P211, DOI 10.1177/026921639400800304; Marcantonio ER, 2005, J AM GERIATR SOC, V53, P963, DOI 10.1111/j.1532-5415.2005.53305.x; Mattimore TJ, 1997, J AM GERIATR SOC, V45, P818, DOI 10.1111/j.1532-5415.1997.tb01508.x; Miller SC, 2004, J PAIN SYMPTOM MANAG, V28, P537, DOI 10.1016/j.jpainsymman.2004.10.007; Miller SC, 2004, J AM GERIATR SOC, V52, P1284, DOI 10.1111/j.1532-5415.2004.52357.x; Miller SC, 2003, J PAIN SYMPTOM MANAG, V26, P791, DOI 10.1016/S0885-3924(03)00284-7; Miller SC, 2001, AM J MED, V111, P38, DOI 10.1016/S0002-9343(01)00747-1; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; Morrison RS, 2005, J AM GERIATR SOC, V53, P290, DOI 10.1111/j.1532-5415.2005.53116.x; Murtaugh CM, 2002, MED CARE, V40, P227; OMORI DM, 1991, ARCH INTERN MED, V151, P1562, DOI 10.1001/archinte.151.8.1562; Petrisek AC, 1999, GERONTOLOGIST, V39, P279, DOI 10.1093/geront/39.3.279; Reynolds Kimberly, 2002, J Palliat Med, V5, P895, DOI 10.1089/10966210260499087; Sloane PD, 2003, J AM GERIATR SOC, V51, P1587, DOI 10.1046/j.1532-5415.2003.51511.x; Tarzian Anita J, 2004, J Am Med Dir Assoc, V5, P82, DOI 10.1097/01.JAM.0000110648.46882.B3; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM, FACTS DYING; VOLICER L, 1986, JAMA-J AM MED ASSOC, V256, P2210, DOI 10.1001/jama.256.16.2210; VOLICER L, 1994, J AM GERIATR SOC, V42, P597, DOI 10.1111/j.1532-5415.1994.tb06856.x; Weissman DE, 2000, J PAIN SYMPTOM MANAG, V20, P35, DOI 10.1016/S0885-3924(00)00168-8; Wilson S A, 1998, J Palliat Med, V1, P21, DOI 10.1089/jpm.1998.1.21; Wilson SA, 1996, GERIATR NURS, V17, P6, DOI 10.1016/S0197-4572(96)80004-8; Zerzan J, 2000, JAMA-J AM MED ASSOC, V284, P2489, DOI 10.1001/jama.284.19.2489; Zimmerman Sheryl, 2003, J Am Med Dir Assoc, V4, P23, DOI 10.1016/S1525-8610(04)70260-1	50	30	30	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2006	295	6					681	+		10.1001/jama.295.6.681	http://dx.doi.org/10.1001/jama.295.6.681			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010DX	16467237				2023-01-03	WOS:000235168200028
J	Rubinfeld, B; Upadhyay, A; Clark, SL; Fong, SE; Smith, V; Koeppen, H; Ross, S; Polakis, P				Rubinfeld, B; Upadhyay, A; Clark, SL; Fong, SE; Smith, V; Koeppen, H; Ross, S; Polakis, P			Identification and immunotherapeutic targeting of antigens induced by chemotherapy	NATURE BIOTECHNOLOGY			English	Article							SQUAMOUS CARCINOMA-CELLS; NECK-CANCER PATIENTS; MICROARRAY ANALYSIS; CDNA MICROARRAY; E48; HEAD; THERAPY; ENZYME; GENES	Cancer cells differ from normal cells in their response to chemotherapy. We exploited this dissimilarity by identifying and targeting tumor-specific, cell-surface proteins whose expression is induced by the chemotherapeutic irinotecan (CPT-11; Camptosar). A cytotoxin-armed antibody reactive with one of these drug-induced surface proteins, the LY6D/E48 antigen, originally identified as the target of a monoclonal antibody reactive with squamous cell carcinomas, caused complete regression of colorectal tumor xenografts in mice treated with CPT-11, whereas either agent alone was less effective. These results suggest that a positive therapeutic index may be generated for other drug combinations by immunotherapeutic targeting of chemotherapy-induced antigens.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol & Translat Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Polakis, P (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	ppolakis@gene.com		Rubinfeld, Bonnee/0000-0001-9861-6775				Bevins CL, 2004, CURR OPIN GASTROEN, V20, P572, DOI 10.1097/00001574-200411000-00012; BRAKENHOFF RH, 1995, J CELL BIOL, V129, P1677, DOI 10.1083/jcb.129.6.1677; Brakenhoff RH, 1997, J IMMUNOL, V159, P4879; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; de Bree R, 2003, ORAL DIS, V9, P241; deBree R, 1997, BRIT J CANCER, V75, P1049, DOI 10.1038/bjc.1997.179; Doronina SO, 2003, NAT BIOTECHNOL, V21, P778, DOI 10.1038/nbt832; Eshel R, 2002, INT J CANCER, V98, P803, DOI 10.1002/ijc.10301; Eshel R, 2000, J BIOL CHEM, V275, P12833, DOI 10.1074/jbc.275.17.12833; Kudoh K, 2000, CANCER RES, V60, P4161; Li YW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-7; Macdonald JS, 2004, CANCER CHEMOTH PHARM, V54, pS4, DOI 10.1007/s00280-004-0880-4; Mehta K, 2004, MOL CANCER THER, V3, P345; Nieuwenhuis EJC, 2003, LAB INVEST, V83, P1233, DOI 10.1097/01.LAB.0000083532.46536.56; Oosterhoff D, 2003, MOL CANCER THER, V2, P765; Qin LF, 2002, LIFE SCI, V70, P1677, DOI 10.1016/S0024-3205(01)01554-5; QUAK JJ, 1990, AM J PATHOL, V136, P191; Taxman DJ, 2003, CANCER RES, V63, P5095; Tice DA, 2002, J BIOL CHEM, V277, P14329, DOI 10.1074/jbc.M200334200; Whiteside MA, 2004, ONCOGENE, V23, P744, DOI 10.1038/sj.onc.1207164; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Zhou Y, 2002, CANCER RES, V62, P1688	22	49	54	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2006	24	2					205	209		10.1038/nbt1185	http://dx.doi.org/10.1038/nbt1185			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	010XW	16444269				2023-01-03	WOS:000235232300038
J	Coast, J; Noble, S; Noble, A; Horrocks, S; Asim, O; Peters, TJ; Salisbury, C				Coast, J; Noble, S; Noble, A; Horrocks, S; Asim, O; Peters, TJ; Salisbury, C			Economic evaluation of a general practitioner with special interest led dermatology service in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OUTREACH CLINICS	Objective To carry out an economic evaluation of a general practitioner with special interest service for non-urgent skin problems compared with hospital outpatient care. Design Cost effectiveness analysis and cost consequences analysis alongside a randomised controlled trial. Setting General practitioner with special interest dermatology service covering 29 general practices in Bristol. Participants Adults referred to a hospital dermatology clinic who were potentially suitable for management by a general practitioner with special interest. Interventions Participants were randomised 2:1 to receive either care by general practitioner with special interest service or usual hospital outpatient care. Main outcome measures Costs to NHS, patients, and companions, and costs of lost production. Cost effectiveness, using the two primary outcomes of dermatology life quality index scores and improved patient perceived access, was assessed by incremental cost effectiveness ratios and cost effectiveness acceptability curves. Cost consequences are presented in relation to all costs and both primary and secondary outcomes from the trial. Results Costs to the NHS for patients attending the general practitioner with special interest service were 208 ($361; E308) compared with 118 pound for hospital outpatient care. Based on analysis with imputation of missing data, costs to patients and companions were 48 pound and 51 pound, respectively; costs of lost production were 27 pound and 34 pound, respectively. The incremental cost effectiveness ratios for general practitioner with special interest care over outpatient care were 540 pound per one point gain in the dermatology life quality index and 66 pound per 10 point change in the access scale. Conclusions The general practitioner with special interest service for dermatology is more costly than hospital Outpatient care, but this additional cost needs to be weighed against improved access and broadly similar health outcomes.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Bristol, Dept Community Based Med, Acad Unit Primary Hlth Care, Bristol BS6 6JL, Avon, England; Univ W England, Fac Hlth & Social Care, Bristol BS16 1DD, Avon, England; Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England; Univ Bristol, Dept Community Based Med, Acad Unit Primary Hlth Care, Bristol BS8 1AU, Avon, England	University of Bristol; University of Bristol; University of West England; University of Oxford; University of Bristol	Coast, J (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	j.coast@bham.ac.uk	Salisbury, Chris/C-6724-2008	Salisbury, Chris/0000-0002-4378-3960; Noble, Sian/0000-0002-8011-0722; Coast, Joanna/0000-0002-3537-5166; Peters, Tim/0000-0003-2881-4180				Black M, 1997, BRIT J GEN PRACT, V47, P558; Bond M, 2000, J EPIDEMIOL COMMUN H, V54, P149, DOI 10.1136/jech.54.2.149; Bowling A, 2001, BRIT J GEN PRACT, V51, P264; Coast J, 2004, BRIT MED J, V329, P1233, DOI 10.1136/bmj.329.7476.1233; Coast J, 2000, J Health Serv Res Policy, V5, P42; Curtis L, 2004, UNIT COSTS HLTH SOCI; *DEP HLTH, 2002, IMPL SCHEM GEN PRACT; *DEP HLTH, 2004, NAT TAR 2005 6; Department of Health, 2002, REF NHS FIN FLOWS IN; Kernick DP, 2003, BRIT J GEN PRACT, V53, P553; Nocon A, 2004, DIABETIC MED, V21, P32, DOI 10.1046/j.1464-5491.2003.01063.x; Powell John, 2002, J Health Serv Res Policy, V7, P177, DOI 10.1258/135581902760082490; Rosen R, 2003, BRIT MED J, V327, P460, DOI 10.1136/bmj.327.7413.460; Salisbury C, 2005, BMJ-BRIT MED J, V331, P1441, DOI 10.1136/bmj.38670.494734.7C	14	47	47	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 17	2005	331	7530					1444	1448		10.1136/bmj.38676.446910.7C	http://dx.doi.org/10.1136/bmj.38676.446910.7C			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	996EE	16339217	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000234156400023
J	O'Shea, CC				O'Shea, CC			Viruses: tools for tumor target discovery, and agents for oncolytic therapies - an introduction	ONCOGENE			English	Editorial Material						oncolytic; virus; cancer therapy; transformation	REPLICATION		Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	O'Shea, CC (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St,N315, San Francisco, CA 94115 USA.	coshea@cc.ucsf.edu						Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Barber GN, 2005, ONCOGENE, V24, P7710, DOI 10.1038/sj.onc.1209042; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Freeman-Cook LL, 2005, ONCOGENE, V24, P7756, DOI 10.1038/sj.onc.1209039; Ko D, 2005, ONCOGENE, V24, P7763, DOI 10.1038/sj.onc.1209048; Mathis JM, 2005, ONCOGENE, V24, P7775, DOI 10.1038/sj.onc.1209044; McCormick F, 2005, ONCOGENE, V24, P7817, DOI 10.1038/sj.onc.1209064; Mohr I, 2005, ONCOGENE, V24, P7697, DOI 10.1038/sj.onc.1209053; O'Shea CC, 2005, ONCOGENE, V24, P7640, DOI 10.1038/sj.onc.1209047; Shmulevitz M, 2005, ONCOGENE, V24, P7720, DOI 10.1038/sj.onc.1209041; Uren AG, 2005, ONCOGENE, V24, P7656, DOI 10.1038/sj.onc.1209043; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Working PK, 2005, ONCOGENE, V24, P7792, DOI 10.1038/sj.onc.1209045	15	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7636	7639		10.1038/sj.onc.1209035	http://dx.doi.org/10.1038/sj.onc.1209035			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299525				2023-01-03	WOS:000233372600001
J	Jefford, M; Savulescu, J; Thomson, J; Schofield, P; Mileshkin, L; Agalianos, E; Zalcberg, J				Jefford, M; Savulescu, J; Thomson, J; Schofield, P; Mileshkin, L; Agalianos, E; Zalcberg, J			Medical paternalism and expensive unsubsidised drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CANCER		Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Melbourne, Vic 8006, Australia; Univ Oxford, Oxford Uehiro Ctr Pract Eth, Oxford, England	Peter Maccallum Cancer Center; University of Oxford	Jefford, M (corresponding author), Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	Michael.Jefford@petermac.org		Jefford, Michael/0000-0002-8792-7807				*CANCERBACUP, CANCERBACUP DOSS DEL; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; Jefford M, 2002, LANCET ONCOL, V3, P629, DOI 10.1016/S1470-2045(02)00877-X; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Okie S, 2005, NEW ENGL J MED, V352, P1173, DOI 10.1056/NEJMp058029; OLIVER K, DRUG APPROVAL US PRO; Schrag D, 2004, NEW ENGL J MED, V351, P317, DOI 10.1056/NEJMp048143; Scott J A, 2005, Eur J Oncol Nurs, V9, P131, DOI 10.1016/j.ejon.2005.03.012; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SOUMERAI SB, 2004, HLTH AFF MILLWOOD, V239, P135; Tamblyn R, 2001, Can J Clin Pharmacol, V8 Suppl A, p39A; Uyl-De Groot CA, 2005, CURR OPIN ONCOL, V17, P392, DOI 10.1097/01.cco.0000168535.25330.6a; Vickers AJ, 2001, LANCET ONCOL, V2, P226, DOI 10.1016/S1470-2045(00)00293-X; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; Ziebland S, 2004, BMJ-BRIT MED J, V328, P564, DOI 10.1136/bmj.328.7439.564; [No title captured]	16	21	21	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	2005	331	7524					1075	1077		10.1136/bmj.331.7524.1075	http://dx.doi.org/10.1136/bmj.331.7524.1075			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16269497	Green Published			2023-01-03	WOS:000233211200034
J	Chou, R; Helfand, M				Chou, R; Helfand, M			Challenges in systematic reviews that assess treatment harms	ANNALS OF INTERNAL MEDICINE			English	Review							ADVERSE DRUG-REACTIONS; SEROTONIN REUPTAKE INHIBITORS; RANDOMIZED CONTROLLED-TRIALS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONFLICT-OF-INTEREST; HEALTH-CARE; CAUSALITY ASSESSMENT; BALANCING BENEFITS; GASTROINTESTINAL TOXICITY; METHODOLOGICAL QUALITY	An evidence synthesis of a medical intervention should assess the balance of benefits and harms. Investigators performing systematic reviews of harms face challenges in finding data, rating the quality of harms reporting, and synthesizing and displaying data from different sources. Systematic reviews of harms often rely primarily on published clinical trials. Identifying important harms of treatment and quantifying the risk associated with them, however, often require a broader range of data sources, including unpublished trials, observational studies, and unpublished information on published trials submitted to the U.S. Food and Drug Administration. Each source of data has some potential for yielding important information. Criteria for judging the quality of harms assessment and reporting are still in their early stages of development. Investigators conducting systematic reviews of harms should consider empirically validating the criteria they use to judge the validity of studies reporting harms. Synthesizing harms data from different sources requires careful consideration of internal validity, applicability, and sources of heterogeneity. This article highlights examples of approaches to methodologic issues associated with performing systematic reviews of harms from 96 Evidence-based Practice Center evidence reports.	Oregon Hlth & Sci Univ, Oregon Evidence Based Pract Ctr, Portland, OR 97201 USA; Portland VA Med Ctr, Portland, OR USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center	Chou, R (corresponding author), Oregon Hlth & Sci Univ, Oregon Evidence Based Pract Ctr, 3181 SW Sam Jackson Pk Rd,Mail Code BICC, Portland, OR 97201 USA.	chour@ohsu.edu		Chou, Roger/0000-0001-9889-8610				[Anonymous], 2001, UND SYST REV RES EFF; Arnaiz JA, 2001, EUR J CLIN PHARMACOL, V57, P89, DOI 10.1007/s002280100265; Aronson JK, 2003, BRIT MED J, V326, P1346, DOI 10.1136/bmj.326.7403.1346; Aronson JK, 2002, FUND CLIN PHARMACOL, V16, P49, DOI 10.1046/j.1472-8206.2002.00066.x; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; BEGAUD B, 1994, BRIT J CLIN PHARMACO, V38, P401, DOI 10.1111/j.1365-2125.1994.tb04373.x; BENICHOU C, 1993, J CLIN EPIDEMIOL, V46, P1331, DOI 10.1016/0895-4356(93)90102-7; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Berlin JA, 1999, JAMA-J AM MED ASSOC, V281, P830, DOI 10.1001/jama.281.9.830; Black N, 1999, WORLD J SURG, V23, P789, DOI 10.1007/s002689900581; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Bond R, 2003, STROKE, V34, P2290, DOI 10.1161/01.STR.0000087785.01407.CC; Britton A, 1998, HLTH TECHNOLOGY ASSE, V2, P1; Brown NJ, 1996, CLIN PHARMACOL THER, V60, P8, DOI 10.1016/S0009-9236(96)90161-7; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Cuervo LG, 2003, BMJ-BRIT MED J, V327, P65, DOI 10.1136/bmj.327.7406.65; Cuervo LG, 2004, BMJ-BRIT MED J, V329, P1, DOI 10.1136/bmj.329.7456.1; Dalziel K, 2005, HEALTH TECHNOL ASSES, V9, P1; DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6; Derry S, 2001, BMC Med Res Methodol, V1, P7, DOI 10.1186/1471-2288-1-7; Dickersin K, 2002, INT J EPIDEMIOL, V31, P6, DOI 10.1093/ije/31.1.6; Dieppe P, 2004, BMJ-BRIT MED J, V329, P31, DOI 10.1136/bmj.329.7456.31; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Edwards JE, 1999, J PAIN SYMPTOM MANAG, V18, P427, DOI 10.1016/S0885-3924(99)00093-7; Egger M, 1998, BRIT MED J, V316, P140; Egger M, 2003, Health Technol Assess, V7, P1; Ernst E, 2001, BRIT MED J, V323, P546, DOI 10.1136/bmj.323.7312.546; Etminan M, 2004, PHARMACOTHERAPY, V24, P1105, DOI 10.1592/phco.24.13.1105.38083; Etminan M, 2004, PHARMACOTHERAPY, V24, P964, DOI 10.1592/phco.24.11.964.36143; Ettinger B, 1998, AM J MANAG CARE, V4, P1377; Farrington CP, 2004, VACCINE, V22, P2064, DOI 10.1016/j.vaccine.2004.01.017; *FDA CTR DRUG EV R, FDA PUBL HLTH ADV CR; Fergusson D, 2005, BMJ-BRIT MED J, V330, P396, DOI 10.1136/bmj.330.7488.396; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; Glasziou P, 2004, BMJ-BRIT MED J, V328, P39, DOI 10.1136/bmj.328.7430.39; GOUDAS L, 2001, AHRQ PUBLICATION; Gunnell D, 2005, BMJ-BRIT MED J, V330, P385, DOI 10.1136/bmj.330.7488.385; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Hrachovec JB, 2001, JAMA-J AM MED ASSOC, V286, P2398, DOI 10.1001/jama.286.19.2398; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jefferson T, 2003, VACCINE, V21, P3954, DOI 10.1016/S0264-410X(03)00271-8; Jefferson T, 2003, VACCINE, V21, P2003, DOI 10.1016/S0264-410X(02)00770-3; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Kaufman DW, 2000, LANCET, V356, P1339, DOI 10.1016/S0140-6736(00)02826-9; Lasser KE, 2002, JAMA-J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215; LAU J, 2002, AHRQ PUBLICATION; Lawlor DA, 2004, LANCET, V363, P1724, DOI 10.1016/S0140-6736(04)16260-0; Lawlor DA, 2003, J CLIN EPIDEMIOL, V56, P155; LEE S, 2005, STAT REV; Lindbloom EJ, 2004, MED CARE, V42, P45, DOI 10.1097/01.mlr.0000119397.65643.d4; Loke YK, 2004, BRIT J CLIN PHARMACO, V57, P616, DOI 10.1111/j.0306-5251.2003.02055.x; LOKE YK, 2004, INCLUDING ADVERSE EF; Lucena MA, 2001, HEPATOLOGY, V33, P123, DOI 10.1053/jhep.2001.20645; Mann RD, 1998, BRIT J CLIN PHARMACO, V46, P195, DOI 10.1046/j.1365-2125.1998.00774.x; Maria VAJ, 1997, HEPATOLOGY, V26, P664, DOI 10.1002/hep.510260319; Martin RCG, 2002, ANN SURG, V235, P803, DOI 10.1097/00000658-200206000-00007; Martinez C, 2005, BRIT MED J, V330, P389, DOI 10.1136/bmj.330.7488.389; McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0; McIntosh Heather M, 2004, BMC Med Res Methodol, V4, P19, DOI 10.1186/1471-2288-4-19; McPherson K, 2004, BRIT MED J, V328, P518, DOI 10.1136/bmj.328.7438.518; MEENAN RT, 2002, AHRQ PUBLICATION, V48; MICHEL DJ, 1986, AM J HOSP PHARM, V43, P1709, DOI 10.1093/ajhp/43.7.1709; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moore SW, 2003, SOUTH MED J, V96, P1244, DOI 10.1097/01.SMJ.0000102285.48482.C9; MULROW C, 2000, AHRQ PUBLICATION; MULROW CD, 1988, AHCPR PUBLICATION; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Ofman JJ, 2002, J RHEUMATOL, V29, P804; Papanikolaou PN, 2004, AM J MED, V117, P582, DOI 10.1016/j.amjmed.2004.04.026; Papanikolaou PN, 2004, AM J PSYCHIAT, V161, P1692, DOI 10.1176/appi.ajp.161.9.1692; Petticrew M, 2003, BMJ-BRIT MED J, V326, P756, DOI 10.1136/bmj.326.7392.756; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Psaty BM, 1999, J AM GERIATR SOC, V47, P749, DOI 10.1111/j.1532-5415.1999.tb01603.x; Psaty BM, 2004, JAMA-J AM MED ASSOC, V292, P2622, DOI 10.1001/jama.292.21.2622; Ray JG, 2002, ARCH INTERN MED, V162, P249, DOI 10.1001/archinte.162.3.249; Ray WA, 2003, NEW ENGL J MED, V349, P1592, DOI 10.1056/NEJMp038145; Rosendaal FR, 2001, CURR CONTR TRIALS C, V2, P109; Ross SD, 2001, ARCH INTERN MED, V161, P1041, DOI 10.1001/archinte.161.8.1041; Rothwell PM, 1996, STROKE, V27, P260, DOI 10.1161/01.STR.27.2.260; Santaguida PL, 2005, ANN INTERN MED, V142, P1066, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00006; Saunders LD, 2003, WESTERN J NURS RES, V25, P223, DOI 10.1177/0193945902250039; Schunemann HJ, 2003, CAN MED ASSOC J, V169, P677; SHEKELLE P, AHRQ PUBLICATION; Shepherd J, 2004, AM J CARDIOL, V94, P882, DOI 10.1016/j.amjcard.2004.06.049; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x; Smith L A, 2001, BMC Med Res Methodol, V1, P1, DOI 10.1186/1471-2288-1-1; Stricker BHC, 2004, BRIT MED J, V329, P44, DOI 10.1136/bmj.329.7456.44; Strom BL, 2004, JAMA-J AM MED ASSOC, V292, P2643, DOI 10.1001/jama.292.21.2643; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Thase ME, 2001, BRIT J PSYCHIAT, V178, P234, DOI 10.1192/bjp.178.3.234; Vandenbroucke JP, 2004, BRIT MED J, V329, P2, DOI 10.1136/bmj.329.7456.2; Vandenbroucke JP, 2004, LANCET, V363, P1728, DOI 10.1016/S0140-6736(04)16261-2; VENNING GR, 1983, BRIT MED J, V286, P458, DOI 10.1136/bmj.286.6363.458; VENNING GR, 1982, BMJ-BRIT MED J, V284, P249, DOI 10.1136/bmj.284.6311.249; Wald NJ, 2003, BRIT MED J, V327, P616, DOI 10.1136/bmj.327.7415.616; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; WEST S, 2002, 47 RES TRIANGL I U N; Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1; WITTER J, MED REV 1; Wood L, 2004, DRUG SAFETY, V27, P871, DOI 10.2165/00002018-200427120-00004; Wright JM, 2001, JAMA-J AM MED ASSOC, V286, P2398	109	103	104	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1090	1099		10.7326/0003-4819-142-12_Part_2-200506211-00009	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938CN	15968034				2023-01-03	WOS:000229977600009
J	Gafter-Gvili, A; Fraser, A; Paul, M; Leibovici, L				Gafter-Gvili, A; Fraser, A; Paul, M; Leibovici, L			Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients	ANNALS OF INTERNAL MEDICINE			English	Review							BONE-MARROW TRANSPLANTATION; ACUTE NONLYMPHOCYTIC LEUKEMIA; PLACEBO-CONTROLLED TRIAL; TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS; HOSPITALIZED GRANULOCYTOPENIC PATIENTS; ORAL ANTIMICROBIAL PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; GRAM-POSITIVE PROPHYLAXIS; ANTI-MICROBIAL MODULATION; DOUBLE-BLIND	Background: Bacterial infections are a major cause of illness and death in patients who are neutropenic after chemotherapy treatment for cancer. Trials have shown the efficacy of antibiotic prophylaxis in decreasing the incidence of bacterial infections but not in reducing mortality rates. Purpose: To evaluate whether antibiotic prophylaxis in neutropenic patients reduces mortality and incidence of infection and to assess related adverse events. Data Sources: The Cochrane Cancer Network register of trials (2004), The Cochrane Library (issue 4, 2004), EMBASE (19802004), MEDLINE (1966-2004), and references of identified studies. Study Selection: Randomized, controlled trials comparing antibiotic prophylaxis with placebo or no intervention or another antibiotic in afebrile neutropenic patients. Data Extraction: Two reviewers independently appraised the quality of trials and extracted data. Data Synthesis: Ninety-five trials performed between 1973 and 2004 met inclusion criteria. Fifty-two trials addressed quinolone prophylaxis. Antibiotic prophylaxis significantly decreased the risk for death when compared with placebo or no treatment (relative risk, 0.67 [95% Cl, 0.55 to 0.81]). All prophylactic antibiotics were associated with an increased risk for adverse events (relative risk, 1.69 [Cl, 1.14 to 2.50]). Fluoroquinolone prophylaxis reduced the risk for all-cause mortality (relative risk, 0.52 [Cl, 0.35 to 0.77]), as well as infection-related mortality, fever, clinically documented infections, and microbiologically documented infections. Fluoroquinolone prophylaxis increased the risk for harboring bacilli resistant to the specific drug after treatment and adverse events, but these results were not statistically significant (relative risks, 1.69 [Cl, 0.73 to 3.92]) and 1.30 [Cl, 0.61 to 2.761, respectively). Limitations: Most trials involved patients with hematologic cancer. Data on all-cause mortality were missing in 10 of 50 trials comparing prophylaxis with no prophylaxis. Effect estimates were larger in trials of unclear methodologic quality compared with trials of adequate methodologic quality. Conclusions: Antibiotic prophylaxis for neutropenic patients undergoing cytotoxic therapy reduces mortality. Mortality was substantially reduced when analysis was limited to fluoroquinolones. Antibiotic prophylaxis, preferably with a fluoroquinolone, should be considered for neutropenic patients.	Rabin Med Ctr, Petah Tiqwa, Israel; Tel Aviv Univ, IL-69978 Tel Aviv, Israel	Rabin Medical Center; Tel Aviv University	Leibovici, L (corresponding author), Rabin Med Ctr, Petah Tiqwa, Israel.	leibovic@post.tau.ac.il		Fraser, Abigail/0000-0002-7741-9470				ARCHIMBAUD E, 1991, EUR J CANCER, V27, P174, DOI 10.1016/0277-5379(91)90481-R; ARNING M, 1990, J ANTIMICROB CHEMOTH, V26, P137, DOI 10.1093/jac/26.suppl_D.137; ATTAL M, 1991, J CLIN ONCOL, V9, P865, DOI 10.1200/JCO.1991.9.5.865; BARTOLONI A, 1989, J CHEMOTHERAPY, V1, P91, DOI 10.1080/1120009X.1989.11738871; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BENDER JF, 1979, ANTIMICROB AGENTS CH, V15, P455, DOI 10.1128/AAC.15.3.455; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BOW EJ, 1988, AM J MED, V84, P847, DOI 10.1016/0002-9343(88)90062-9; Bow EJ, 1996, ANN INTERN MED, V125, P183, DOI 10.7326/0003-4819-125-3-199608010-00004; BOW EJ, 1984, AM J MED, V76, P223, DOI 10.1016/0002-9343(84)90777-0; BRODSKY AL, 1993, MEDICINA-BUENOS AIRE, V53, P401; BROUN ER, 1994, ANTIMICROB AGENTS CH, V38, P576, DOI 10.1128/AAC.38.3.576; Carlson JW, 1997, GYNECOL ONCOL, V65, P325, DOI 10.1006/gyno.1997.4630; CASALI A, 1988, CHEMIOTERAPIA, V7, P327; Castagnola E, 2003, PEDIATR INFECT DIS J, V22, P359; CRUCIANI M, 1989, INFECTION, V17, P65, DOI 10.1007/BF01646878; Cruciani M, 1996, CLIN INFECT DIS, V23, P795, DOI 10.1093/clinids/23.4.795; Cruciani M, 2003, J CLIN ONCOL, V21, P4127, DOI 10.1200/JCO.2003.01.234; DANTONIO D, 1994, J ANTIMICROB CHEMOTH, V33, P837, DOI 10.1093/jac/33.4.837; DANTONIO D, 1992, DRUG EXP CLIN RES, V18, P141; DANTONIO D, 1991, CURR THER RES CLIN E, V50, P304; DEJONGH CA, 1983, J CLIN ONCOL, V1, P302, DOI 10.1200/JCO.1983.1.5.302; DEKKER AW, 1981, ANN INTERN MED, V95, P555, DOI 10.7326/0003-4819-95-5-555; DEKKER AW, 1987, ANN INTERN MED, V106, P7, DOI 10.7326/0003-4819-106-1-7; DELFAVERO A, 1991, ANN INTERN MED, V115, P7, DOI 10.7326/0003-4819-115-1-7; DONNELLY JP, 1992, EUR J CANCER, V28A, P873; Engels EA, 1998, J CLIN ONCOL, V16, P1179, DOI 10.1200/JCO.1998.16.3.1179; ENNO A, 1978, LANCET, V2, P395; ESTEY E, 1984, ARCH INTERN MED, V144, P1562, DOI 10.1001/archinte.144.8.1562; FANCI R, 1993, J CHEMOTHERAPY, V5, P119; Ford CD, 1998, ANTIMICROB AGENTS CH, V42, P1402, DOI 10.1128/AAC.42.6.1402; GAFTERGVILI A, 2003, COCHRANE DATABASE SY; Gentry C, 2002, AM J INFECT CONTROL, V30, P411, DOI 10.1067/mic.2002.124937; GLUCKMAN E, 1988, PATHOL BIOL, V36, P902; GLUCKMAN E, 1991, CHEMOTHERAPY, V37, P33, DOI 10.1159/000238904; Gomez-Martin C, 2000, J CLIN ONCOL, V18, P2126, DOI 10.1200/JCO.2000.18.10.2126; GOORIN AM, 1985, PEDIATR INFECT DIS J, V4, P265, DOI 10.1097/00006454-198505000-00012; GUALTIERI RJ, 1983, AM J MED, V74, P934, DOI 10.1016/0002-9343(83)90785-4; GUIOT HFL, 1983, J INFECT DIS, V147, P615, DOI 10.1093/infdis/147.4.615; GUIOT HFL, 1992, ANN HEMATOL, V64, P260, DOI 10.1007/BF01695467; GURWITH MJ, 1979, AM J MED, V66, P248, DOI 10.1016/0002-9343(79)90539-4; HARGADON MT, 1981, ANTIMICROB AGENTS CH, V20, P620, DOI 10.1128/AAC.20.5.620; HAROUSSEAU JL, 1987, PRESSE MED, V16, P1737; HARTLAPP JH, 1987, DRUGS, V34, P131, DOI 10.2165/00003495-198700341-00028; HENRY SA, 1984, AM J MED, V77, P663, DOI 10.1016/0002-9343(84)90359-0; Hidalgo M, 1997, ANTIMICROB AGENTS CH, V41, P1175, DOI 10.1128/AAC.41.5.1175; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; Hughes WT, 2002, CLIN INFECT DIS, V34, P730, DOI 10.1086/339215; INOUE M, 1983, DRUG EXP CLIN RES, V9, P35; JANSEN J, 1994, AM J MED, V96, P335, DOI 10.1016/0002-9343(94)90063-9; JEHN U, 1981, KLIN WOCHENSCHR, V59, P1093, DOI 10.1007/BF01746196; KARP JE, 1987, ANN INTERN MED, V106, P1, DOI 10.7326/0003-4819-106-1-1; KAUFFMAN CA, 1983, AM J MED, V74, P599, DOI 10.1016/0002-9343(83)91017-3; KERN W, 1991, INFECTION, V19, P73, DOI 10.1007/BF01645571; KERN WV, 1994, ANTIMICROB AGENTS CH, V38, P465, DOI 10.1128/AAC.38.3.465; KERN WV, 1994, ANTIMICROB AGENTS CH, V38, P681, DOI 10.1128/AAC.38.4.681; KLASTERSKY J, 1974, PATHOL BIOL, V22, P5; KOVATCH AL, 1985, PEDIATRICS, V76, P754; KRAMER BS, 1984, CANCER, V53, P329, DOI 10.1002/1097-0142(19840115)53:2<329::AID-CNCR2820530226>3.0.CO;2-X; KURRLE E, 1986, INFECTION, V14, P226, DOI 10.1007/BF01644268; KURRLE E, 1983, KLIN WOCHENSCHR, V61, P691, DOI 10.1007/BF01487614; LAMYA T, 1993, ACTA HAEMATOL-BASEL, V90, P109, DOI 10.1159/000204389; LANGE AB, 1984, ARCH INSECT BIOCHEM, V1, P231, DOI 10.1002/arch.940010306; Lee Dong Gun, 2002, Korean J Intern Med, V17, P38; LEIBOVICI L, 1992, EUR J CLIN MICROBIOL, V11, P782, DOI 10.1007/BF01960876; LEVINE AS, 1973, NEW ENGL J MED, V288, P477, DOI 10.1056/NEJM197303082881001; LEW MA, 1995, J CLIN ONCOL, V13, P239, DOI 10.1200/JCO.1995.13.1.239; LEW MA, 1991, TRANSPLANTATION, V51, P630, DOI 10.1097/00007890-199103000-00017; LIANG RHS, 1990, ANTIMICROB AGENTS CH, V34, P215, DOI 10.1128/AAC.34.2.215; Lucas KG, 1996, CANCER, V77, P791, DOI 10.1002/(SICI)1097-0142(19960215)77:4<791::AID-CNCR27>3.3.CO;2-B; MAICHE AG, 1993, EUR J CANCER, V29A, P1403, DOI 10.1016/0959-8049(93)90011-4; MALARME M, 1981, EUR J CANCER CLIN ON, V17, P1315, DOI 10.1016/0014-2964(81)90014-1; MARTINO P, 1984, AM J MED SCI, V287, P7, DOI 10.1097/00000441-198405000-00002; MASCHMEYER G, 1988, INFECTION, V16, P98, DOI 10.1007/BF01644312; Mocikova K, 1992, Vnitr Lek, V38, P166; Moreau P, 1995, BONE MARROW TRANSPL, V15, pS129; Moriuchi Y, 1990, Rinsho Ketsueki, V31, P1664; Murase T, 1995, Kansenshogaku Zasshi, V69, P28; NEMET D, 1989, Bone Marrow Transplantation, V4, P105; Nenova I S, 2001, Folia Med (Plovdiv), V43, P40; OPPENHEIM BA, 1989, BRIT MED J, V299, P294, DOI 10.1136/bmj.299.6694.294; ORLANDI E, 1990, HAEMATOLOGICA, V75, P296; PETERSEN FB, 1986, INFECTION, V14, P115, DOI 10.1007/BF01643474; PIGNON B, 1990, NOUV REV FR HEMATOL, V32, P249; PIZZO PA, 1983, J PEDIATR-US, V102, P125, DOI 10.1016/S0022-3476(83)80310-2; Prentice HG, 2001, BRIT J HAEMATOL, V115, P46, DOI 10.1046/j.1365-2141.2001.03034.x; ROTSTEIN C, 1997, CURR ONCOL S2, V4, pS2; Sampi K, 1992, Gan To Kagaku Ryoho, V19, P823; SCHIMPFF SC, 1986, AM J MED, V80, P13; SCHIMPFF SC, 1975, ANN INTERN MED, V82, P351, DOI 10.7326/0003-4819-82-3-351; SCHROEDER M, 1992, ONKOLOGIE, V15, P476; SLEIJFER DT, 1980, EUR J CANCER, V16, P859, DOI 10.1016/0014-2964(80)90140-1; STARKE ID, 1982, LANCET, V1, P5; TALBOT GH, 1993, ANTIMICROB AGENTS CH, V37, P474, DOI 10.1128/AAC.37.3.474; TEINTURIER C, 1995, PEDIATR HEMAT ONCOL, V12, P73, DOI 10.3109/08880019509029531; Thomas X, 2000, PRESSE MED, V29, P1745; Tjan-Heijnen VCG, 2001, ANN ONCOL, V12, P1359, DOI 10.1023/A:1012545507920; TSUTANI H, 1992, INTERNAL MED, V31, P319, DOI 10.2169/internalmedicine.31.319; VANEYS J, 1987, CANCER, V59, P19; WADE JC, 1981, NEW ENGL J MED, V304, P1057, DOI 10.1056/NEJM198104303041801; WADE JC, 1983, J INFECT DIS, V147, P624, DOI 10.1093/infdis/147.4.624; WADE JC, 1994, CLIN APPROACH INFECT; WALSH TJ, 1994, BAILLIERE CLIN INF D, V1, P469; WARD TT, 1993, CLIN INFECT DIS, V17, P323, DOI 10.1093/clinids/17.3.323; WATSON JG, 1982, LANCET, V1, P6; WEISER B, 1981, ANN INTERN MED, V95, P436, DOI 10.7326/0003-4819-95-4-436; WINSTON DJ, 1990, AM J MED, V88, P36, DOI 10.1016/0002-9343(90)90125-W; WINSTON DJ, 1986, AM J MED, V80, P884, DOI 10.1016/0002-9343(86)90633-9; YAMADA T, 1993, INTERNAL MED, V32, P710, DOI 10.2169/internalmedicine.32.710; YATES JW, 1973, CANCER, V32, P1490, DOI 10.1002/1097-0142(197312)32:6<1490::AID-CNCR2820320628>3.0.CO;2-6; YOUNG LS, 1994, CLIN APPROACH INFECT; ZINNER S, 1984, J INFECT DIS, V150, P372; ZINNER SH, 1994, JAMA-J AM MED ASSOC, V272, P1183, DOI 10.1001/jama.1994.03520150051036	114	317	339	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	1				979	995		10.7326/0003-4819-142-12_Part_1-200506210-00008	http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00008			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937IN	15968013				2023-01-03	WOS:000229917900005
J	Song, EW; Zhu, PC; Lee, SK; Chowdhury, D; Kussman, S; Dykxhoorn, DM; Feng, Y; Palliser, D; Weiner, DB; Shankar, P; Marasco, WA; Lieberman, J				Song, EW; Zhu, PC; Lee, SK; Chowdhury, D; Kussman, S; Dykxhoorn, DM; Feng, Y; Palliser, D; Weiner, DB; Shankar, P; Marasco, WA; Lieberman, J			Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors	NATURE BIOTECHNOLOGY			English	Article							HUMAN-BREAST-CANCER; HEPATITIS-B-VIRUS; FAS PROTECTS MICE; GENE-EXPRESSION; ADULT MICE; INHIBITION; SIRNAS; ACTIVATION; ONCOGENE; SURVIVAL	Delivery of small interfering RNAs (siRNAs) into cells is a key obstacle to their therapeutic application. We designed a protamine-antibody fusion protein to deliver siRNA to HIV-infected or envelope-transfected cells. The fusion protein (F105-P) was designed with the protamine coding sequence linked to the C terminus of the heavy chain Fab fragment of an HIV-1 envelope antibody. siRNAs bound to F105-P induced silencing only in cells expressing HIV-1 envelope. Additionally, siRNAs targeted against the HIV-1 capsid gene gag, inhibited HIV replication in hard-to-transfect, HIV-infected primary T cells. Intratumoral or intravenous injection of F105-P-complexed siRNAs into mice targeted HIV envelope-expressing B16 melanoma cells, but not normal tissue or envelope-negative B16 cells; injection of F105-P with siRNAs targeting c-myc, MDM2 and VEGF inhibited envelope-expressing subcutaneous B16 tumors. Furthermore, an ErbB2 single-chain antibody fused with protamine delivered siRNAs specifically into ErbB2-expressing cancer cells. This study demonstrates the potential for systemic, cell-type specific, antibody-mediated siRNA delivery.	Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Lieberman, J (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	lieberman@cbr.med.harvard.edu	Dykxhoorn, Derek M/D-1357-2015; Lieberman, Judy/A-2717-2015; Weiner, David B/H-8579-2014		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI056900] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 056900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164; Brody JR, 2004, AM J PATHOL, V164, P273, DOI 10.1016/S0002-9440(10)63117-3; CHEN SY, 1995, GENE THER, V2, P116; CHEN SY, 1994, P NATL ACAD SCI USA, V91, P5932, DOI 10.1073/pnas.91.13.5932; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Contreras JL, 2004, SURGERY, V136, P390, DOI 10.1016/j.surg.2004.05.015; Dykxhoorn DM, 2005, ANNU REV MED, V56, P401, DOI 10.1146/annurev.med.56.082103.104606; Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101; Hamar P, 2004, P NATL ACAD SCI USA, V101, P14883, DOI 10.1073/pnas.0406421101; HASSANI Z, 2004, J GENE MED; Hung L, 2004, FEBS LETT, V560, P210, DOI 10.1016/S0014-5793(04)00113-9; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604; Li XG, 2001, CANCER GENE THER, V8, P555, DOI 10.1038/sj.cgt.7700337; Massaro D, 2004, AM J PHYSIOL-LUNG C, V287, pL1066, DOI 10.1152/ajplung.00067.2004; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824; Minakuchi Y, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh093; Muthumani K, 2003, VIROLOGY, V314, P134, DOI 10.1016/S0042-6822(03)00459-8; Reich S, 2003, MOL VIS, V9, P210; Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Song EW, 2003, J VIROL, V77, P7174, DOI 10.1128/JVI.77.13.7174-7181.2003; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Sorensen DR, 2003, J MOL BIOL, V327, P761, DOI 10.1016/S0022-2836(03)00181-5; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200; Zhang Y, 2004, CLIN CANCER RES, V10, P3667, DOI 10.1158/1078-0432.CCR-03-0740	31	811	1009	8	182	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2005	23	6					709	717		10.1038/nbt1101	http://dx.doi.org/10.1038/nbt1101			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	933LA	15908939				2023-01-03	WOS:000229628700031
J	Miao, WM; Hu, LG; Scrivens, PJ; Batist, G				Miao, WM; Hu, LG; Scrivens, PJ; Batist, G			Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway - Direct cross-talk between phase I and II drug-metabolizing enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR AROMATIC-COMPOUNDS; GENE-EXPRESSION; INDUCIBLE EXPRESSION; AH RECEPTOR; NAD(P)H-QUINONE OXIDOREDUCTASE; CHEMOPREVENTIVE AGENTS; OXIDATIVE STRESS; SUBUNIT GENE; CANCER; IDENTIFICATION	The aryl hydrocarbon receptor (AHR) and NF-E2 p45-related factor (NRF2) are two distinct transcription factors involved in the regulation of drug-metabolizing enzymes. Increasing evidence from several studies implies that AHR and NRF2 have direct links, but the molecular mechanism remains unknown. In this work we demonstrate for the first time that Nrf2 gene transcription is directly modulated by AHR activation. DNA sequence analyses of the mouse Nrf2 promoter revealed one xenobiotic response element (XRE)-like element (XREL1) located at -712 and two additional XRE-like elements located at +755 (XREL2) and +850 (XREL3). Functional analysis using luciferase assay showed that XREL1, XREL2, and XREL3 are all inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment, with XREL2 being the most potent. The functionality of these XRE-like elements was further confirmed by mutagenesis and gel shift experiments. Finally, we used chromatin immuno-precipitation assay to show a direct binding of AHR to the Nrf2 promoter. Cells with silenced AHR expression using siRNA also lost NRF2 mRNA induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin. These new data position NRF2- antioxidant response element downstream in the AHR-XRE pathway. Moreover, direct regulation of NRF2 by AHR contributes to couple phase I and II enzymes into an integrated system facilitating more effective xenobiotic and carcinogen detoxification.	McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University	Batist, G (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	gbatist@onc.jgh.mcgill.ca						Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; DENISON MS, 1988, J BIOL CHEM, V263, P17221; Dyer KD, 2004, MAMM GENOME, V15, P126, DOI 10.1007/s00335-003-2304-x; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Kensler TW, 2003, NAT REV CANCER, V3, P321, DOI 10.1038/nrc1076; Klenova E, 2004, J NEUROSCI, V24, P5966, DOI 10.1523/JNEUROSCI.1150-04.2004; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Levi MS, 2001, CURR MED CHEM, V8, P1349, DOI 10.2174/0929867013372229; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lin CY, 2004, GENE, V334, P63, DOI 10.1016/j.gene.2004.03.016; Ma Q, 2004, BIOCHEM J, V377, P205, DOI 10.1042/BJ20031123; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Miao WM, 2004, BIOCHEM PHARMACOL, V67, P1897, DOI 10.1016/j.bcp.2004.02.009; Miao WM, 2003, MOL PHARMACOL, V64, P346, DOI 10.1124/mol.64.2.346; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Radjendirane V, 1999, BIOCHEM PHARMACOL, V58, P1649, DOI 10.1016/S0006-2952(99)00245-2; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Safe S, 2002, INT J ONCOL, V20, P1123; Sato A, 2004, J BIOCHEM, V135, P259, DOI 10.1093/jb/mvh031; Senft AP, 2002, FREE RADICAL BIO MED, V33, P1268, DOI 10.1016/S0891-5849(02)01014-6; Shen GX, 2004, J BIOL CHEM, V279, P23052, DOI 10.1074/jbc.M401368200; Sherratt PJ, 2004, METHOD ENZYMOL, V378, P286; Shertzer HG, 1998, BIOCHEM BIOPH RES CO, V253, P44, DOI 10.1006/bbrc.1998.9753; Sogawa K, 2004, BIOCHEM BIOPH RES CO, V318, P746, DOI 10.1016/j.bbrc.2004.04.090; Sudakin DL, 2003, J TOXICOL-CLIN TOXIC, V41, P195, DOI 10.1081/CLT-120019137; Vasiliou V, 1995, BIOCHEM PHARMACOL, V50, P2057, DOI 10.1016/0006-2952(95)02108-6; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang LY, 1998, J BIOL CHEM, V273, P5174, DOI 10.1074/jbc.273.9.5174; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	40	367	375	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20340	20348		10.1074/jbc.M412081200	http://dx.doi.org/10.1074/jbc.M412081200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790560	hybrid			2023-01-03	WOS:000229242000024
J	Berk, DR; Falkovitz-Halpern, MS; Hill, DW; Albin, C; Arrieta, A; Bork, JM; Cohan, D; Nilson, B; Petru, A; Ruiz, J; Weintrub, PS; Wenman, W; Maldonado, YA				Berk, DR; Falkovitz-Halpern, MS; Hill, DW; Albin, C; Arrieta, A; Bork, JM; Cohan, D; Nilson, B; Petru, A; Ruiz, J; Weintrub, PS; Wenman, W; Maldonado, YA		California Pediat HIV Study Grp	Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; PROTEASE INHIBITOR; 1-INFECTED INFANTS; COMBINATION THERAPY; DISEASE PROGRESSION; FOLLOW-UP; CHILDREN; ZIDOVUDINE	Context The effect of early antiretroviral therapy (ART) on the early progression of perinatal human immunodeficiency virus (HIV) infection is not well defined. Objective To examine early disease progression and survival in a population-based cohort with perinatal HIV infection in relation to year of birth and use of ART. Design, Setting, and Patients Retrospective study of temporal trends in early progression of perinatal HIV infection among 205 HIV-infected children in Northern California born between January 1, 1988, and December 31, 2001, and followed up through age 3 years. Main Outcome Measures Prevalence of and age at progression to a first US Centers for Disease Control and Prevention category C diagnosis relative to year of birth, type of ART, and age at initiation of therapy. Results Of 205 children, 134 (65%)received ART and/or Pneumocystis jiroveci pneumonia prophylaxis. By age 3 years, 81 (40%) progressed to a category C diagnosis, 41 (51%) of whom died. Untreated children were significantly more likely to progress to a category C diagnosis (62% [44/71] untreated vs 28% [37/134] treated children, P<.001); none of 23 infants who received triple ART progressed to category C. However, even without triple ART, very early mono/dual ART (by age 2 months vs 3-4 months) was associated with delayed and decreased progression to category C (P=.02). Of 33 children born between January 1, 1996, and December 31, 2001, only 7 (21%) progressed to category C (P=.02 compared with 1988-1995), 6 of 7 of whom received no therapy. More recent year of birth and more advanced therapy were associated with improved survival. Conclusions This population-based cohort demonstrated decreased early HIV progression and improved survival at age 3 years, associated with more advanced therapy. Although limited by small sample size, the findings suggest that very early treatment, even without triple ART, was associated with improved outcome.	Stanford Univ, Sch Med, Dept Pediat, Div Infect Dis, Stanford, CA 94305 USA; Santa Clara Valley Med Ctr, Dept Pediat, San Jose, CA 95128 USA; Childrens Hosp Orange Cty, Orange, CA 92668 USA; Loma Linda Univ, Childrens Hosp, Loma Linda, CA 92350 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco Gen Hosp, Bay Area Perinatal AIDS Ctr, San Francisco, CA USA; Univ Med Ctr, Specialty Serv, Fresno, CA USA; Calif Dept Hlth Serv, Off AIDS, Sacramento, CA USA; Childrens Hosp & Res Ctr Oakland, Oakland, CA USA; Univ Calif Davis, Sacramento, CA 95817 USA	Stanford University; Santa Clara Valley Medical Center; Childrens Hospital of Orange County; Children's Hospital Los Angeles; Loma Linda University; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; California Department of Health Care Services; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of California System; University of California Davis	Maldonado, YA (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Div Infect Dis, G312B ID,MC 5208, Stanford, CA 94305 USA.	bonniem@stanford.edu						Aboulker JP, 2004, AIDS, V18, P237, DOI [10.1097/01.aids.0000111388.02002.6b, 10.1097/00002030-200401230-00013]; Aboulker JP, 2001, ARCH DIS CHILD, V84, P230, DOI 10.1136/adc.84.3.230; Abrams EJ, 2003, AIDS, V17, P867, DOI 10.1097/00002030-200304110-00012; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; Barnett AA, 1996, LANCET, V347, P678; Blanche S, 1997, J ACQ IMMUN DEF SYND, V14, P442, DOI 10.1097/00042560-199704150-00008; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; Blazevic V, 2001, CLIN DIAGN LAB IMMUN, V8, P943, DOI 10.1128/CDLI.8.5.943-948.2001; *CAL DEP HLTH SERV, 2001, CAL CHILDB WOM COMP; Centers for Disease Control and Prevention, 2005, HIV AIDS SURV REP; Chougnet C, 2001, J INFECT DIS, V184, P201, DOI 10.1086/322006; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 1998, J PEDIATR-US, V132, P808, DOI 10.1016/S0022-3476(98)70308-7; de Martino M, 2000, JAMA-J AM MED ASSOC, V284, P190, DOI 10.1001/jama.284.2.190; DULIEGE AM, 1992, PEDIATR INFECT DIS J, V11, P630; Englund JA, 1997, NEW ENGL J MED, V336, P1704, DOI 10.1056/NEJM199706123362403; Faye A, 2004, CLIN INFECT DIS, V39, P1692, DOI 10.1086/425739; Faye A, 2002, PEDIATR INFECT DIS J, V21, P518, DOI 10.1097/00006454-200206000-00008; *FDA, 1990, ONCOLOGY HUNTINGT, V4, P96; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Hainaut M, 2000, EUR J PEDIATR, V159, P778, DOI 10.1007/PL00008346; Jankelevich S, 2001, J INFECT DIS, V183, P1116, DOI 10.1086/319274; *JOINT UN PROGR HI, 2003, AIDS EP UPD; Krogstad P, 1999, CLIN INFECT DIS, V28, P1109, DOI 10.1086/514759; LOBATO MN, 1995, J PEDIATR-US, V126, P710, DOI 10.1016/S0022-3476(95)70397-7; LOYAL JK, 2002, 14 INT AIDS C JUL 7; Luzuriaga K, 2000, J VIROL, V74, P6984, DOI 10.1128/JVI.74.15.6984-6991.2000; Luzuriaga K, 2004, NEW ENGL J MED, V350, P2471, DOI 10.1056/NEJMoa032706; Luzuriaga K, 1999, J VIROL, V73, P362, DOI 10.1128/JVI.73.1.362-367.1999; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; Magder LS, 2005, JAIDS-J ACQ IMM DEF, V38, P87, DOI 10.1097/00126334-200501010-00016; MALDONADO YA, 1995, J INFECT DIS, V171, P689, DOI 10.1093/infdis/171.3.689; Maldonado YA, 1998, PEDIATR INFECT DIS J, V17, P398, DOI 10.1097/00006454-199805000-00010; MAWHINNEY S, 1993, J ACQ IMMUN DEF SYND, V6, P1139; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; Mueller BU, 1998, PEDIATRICS, V101, P335, DOI 10.1542/peds.101.3.335; Nachman SA, 2000, JAMA-J AM MED ASSOC, V283, P492, DOI 10.1001/jama.283.4.492; Palumbo P, 2002, CLIN LAB MED, V22, P759, DOI 10.1016/S0272-2712(02)00010-0; Rich KC, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.1.e8; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; SANCHEZ JM, 2003, PEDIATR INFECT DIS J, V22, P863; Starr SE, 1999, NEW ENGL J MED, V341, P1874, DOI 10.1056/NEJM199912163412502; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P614, DOI 10.1001/jama.277.8.614; Sullivan JL, 2001, NEW ENGL J MED, V345, P1568, DOI 10.1056/NEJM200111223452111; *US PUBL HLTH SERV, 1995, MMWR-MORBID MORTAL W, V44, P1; Wade NA, 2004, JAIDS-J ACQ IMM DEF, V36, P1075, DOI 10.1097/00126334-200408150-00011; Walker AS, 2004, AIDS, V18, P1915, DOI 10.1097/00002030-200409240-00007; Wiznia A, 2000, AIDS RES HUM RETROV, V16, P1113, DOI 10.1089/088922200414956; *WORK GROUP ANT TH, 2004, GUID US ANT AG PED H; 1994, MMWR MORB MORTAL WKL, V43, P285	52	47	48	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2005	293	18					2221	2231		10.1001/jama.293.18.2221	http://dx.doi.org/10.1001/jama.293.18.2221			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	924LU	15886377				2023-01-03	WOS:000228981100023
J	Annas, GJ				Annas, GJ			"Culture of life'' politics at the bedside - The case of Terri Schiavo	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; ANNAS GJ, 1975, RIGHTS HOSP PATIENTS, P81; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; EISENBERG D, 2005, TIME            0404, P23; GOODNOUGH A, 2005, NY TIMES        0427, pA1; Kirkpatrick David D, 2005, N Y Times Web, pA18; *MULT TASK FORC PV, 1995, NEW ENGL J MED, V333, P130; Shannon TA, 2004, HASTINGS CENT REP, V34, P18, DOI 10.2307/3528689	8	95	97	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 21	2005	352	16					1710	1715		10.1056/NEJMlim050643	http://dx.doi.org/10.1056/NEJMlim050643			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	918CE	15784657	Green Published			2023-01-03	WOS:000228515200015
J	Fialova, D; Topinkova, E; Gambassi, G; Finne-Soveri, H; Jonsson, PV; Carpenter, I; Schroll, M; Onder, G; Sorbye, LW; Wagner, C; Reissigova, J; Bernabei, R				Fialova, D; Topinkova, E; Gambassi, G; Finne-Soveri, H; Jonsson, PV; Carpenter, I; Schroll, M; Onder, G; Sorbye, LW; Wagner, C; Reissigova, J; Bernabei, R		AdHOC Project Res Grp	Potentially inappropriate among elderly home medication use care patients in Europe	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINIMUM DATA SET; OLDER-ADULTS; EXPLICIT CRITERIA; CONSENSUS PANEL; COMMUNITY; POPULATION; RESIDENTS; POLYPHARMACY; INPATIENTS; PEOPLE	Context Criteria for potentially inappropriate medication use among elderly patients have been used in the past decade in large US epidemiological surveys to identify populations at risk and specifically target risk-management strategies. In contrast, in Europe little information is available about potentially inappropriate medication use and is based on small studies with uncertain generalizability. Objective To estimate the prevalence and associated factors of potentially inappropriate medication use among elderly home care patients in European countries. Design, Setting, and Participants Retrospective cross-sectional study of 2707 elderly patients receiving home care (mean [SDI age, 82.2 [7.2] years) representatively enrolled in metropolitan areas of the Czech Republic, Denmark, Finland, Iceland, Italy, the Netherlands, Norway, and the United Kingdom. Patients were prospectively assessed between September 2001 and January 2002 using the Minimum Data Set in Home Care instrument. Main Outcome Measures Prevalence of potentially inappropriate medication use was documented using all expert panels criteria for community-living elderly persons (Beers and McLeod). Patient-related characteristics independently associated with inappropriate medication use were identified with a multiple logistic regression model. Results Combining all 3 sets of criteria, we found that 19.8% of patients in the total sample used at least 1 inappropriate medication; using older 1997 criteria it was 9.8% to 10.9%. Substantial differences were documented between Eastern Europe (41.1% in the Czech Republic) and Western Europe (mean 15.8%, ranging from 5.8% in Denmark to 26.5% in Italy). Potentially inappropriate medication use was associated with patient's poor economic situation (adjusted relative risk [RR], 1.96; 95% confidence interval [CI], 1.58-2.36), polypharmacy (RR, 1.91; 95% Cl, 1.62-2.22), anxiolytic drug use (RR, 1.82; 95% Cl, 1.51-2.15), and depression (RR, 1.29; 95% Cl, 1.06-1.55). Negatively associated factors were age 85 years and older (RR, 0.78; 95% Cl, 0.65-0.92) and living alone (RR, 0.76; 95% Cl, 0.64-0.89). The odds of potentially inappropriate medication use significantly increased with the number of associated factors (P<.001). Conclusions Substantial differences in potentially inappropriate medication use exist between European countries and might be a consequence of different regulatory measures, clinical practices, or inequalities in socioeconomic background. Since financial resources and selected patient-related characteristics are associated with such prescribing, specific educational strategies and regulations should reflect these factors to improve prescribing quality in elderly individuals in Europe.	Charles Univ Prague, Dept Geriatr & Gerontol, Fac Med 1, Prague 12000 2, Czech Republic; Charles Univ Prague, Fac Pharm, Dept Social & Clin Pharm, CS-50165 Hradec Kralove, Czech Republic; Univ Cattolica Sacro Cuore, Ctr Med Invecchiamento, Rome, Italy; Natl Res & Dev Ctr Social Welf & Hlth, STATES CHESS, Helsinki, Finland; Univ Iceland, Landspitali Univ Hosp, Dept Geriatr, Reykjavik, Iceland; Univ Kent, Ctr Hlth Serv Studies, Canterbury, Kent, England; E Kent Hosp NHS Trust, Canterbury, Kent, England; Bispebjerg Hosp, DK-2400 Copenhagen, Denmark; Decon Coll, Oslo, Norway; Netherlands Inst Hlth Serv Res, NIVEL, Utrecht, Netherlands; AS CR, Inst Comp Sci, EuroMISE Ctr, Prague, Czech Republic	Charles University Prague; Charles University Prague; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Landspitali National University Hospital; University of Iceland; University of Kent; University of Copenhagen; Bispebjerg Hospital; Netherlands Institute for Health Services Research; Czech Academy of Sciences; Institute of Computer Science of the Czech Academy of Sciences	Fialova, D (corresponding author), Charles Univ Prague, Dept Geriatr & Gerontol, Fac Med 1, Londynska 15, Prague 12000 2, Czech Republic.	fickova@faf.cuni.cz	Reissigova, Jindra/B-3201-2014; Bernabei, Roberto/AAB-2704-2019; Topinkova, Eva/A-5076-2019	Bernabei, Roberto/0000-0002-9197-004X; Topinkova, Eva/0000-0002-6786-4116				ADAMS SR, 2002, 48325 HCFAOBRA MEDPA; Balogun SA, 2003, J AM GERIATR SOC, V51, pS103; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; *BRIT MED ASS ROYA, 2004, BRIT NAT FORM; Burrows AB, 2000, AGE AGEING, V29, P165, DOI 10.1093/ageing/29.2.165; Carpenter I, 2004, AGING CLIN EXP RES, V16, P259; Chutka DS, 2004, MAYO CLIN PROC, V79, P122, DOI 10.4065/79.1.122; Cohen JS, 2000, GERIATRICS-US, V55, P54; Curtis LH, 2004, ARCH INTERN MED, V164, P1621, DOI 10.1001/archinte.164.15.1621; *CZECH NAT FORM, 2003, PHARM BREV; Fick D, 2001, J MANAGE CARE PHARM, V7, P407, DOI [10.18553/jmcp.2001.7.5.407, DOI 10.18553/JMCP.2001.7.5.407]; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Giron MST, 2001, J AM GERIATR SOC, V49, P277, DOI 10.1046/j.1532-5415.2001.4930277.x; Goulding MR, 2004, ARCH INTERN MED, V164, P305, DOI 10.1001/archinte.164.3.305; Gray SL, 2003, ANN PHARMACOTHER, V37, P988, DOI 10.1345/aph.1C365; Hanlon JT, 2001, J AM GERIATR SOC, V49, P200, DOI 10.1046/j.1532-5415.2001.49042.x; Hanlon JT, 2004, ANN PHARMACOTHER, V38, P9, DOI 10.1345/aph.1D313; *IC NAT FORM, 2003, SERL 2002 2003; Landi F, 2000, MED CARE, V38, P1184, DOI 10.1097/00005650-200012000-00005; Lane CJ, 2004, J AM GERIATR SOC, V52, P861, DOI 10.1111/j.1532-5415.2004.52250.x; Lau DT, 2005, ARCH INTERN MED, V165, P68, DOI 10.1001/archinte.165.1.68; Linjakumpu T, 2002, INT J GERIATR PSYCH, V17, P874, DOI 10.1002/gps.712; Malik AB, 2003, J AM GERIATR SOC, V51, pS123; McLeod PJ, 1997, CAN MED ASSOC J, V156, P385; MCNUTT LA, 1994, J CLIN EPIDEMIOL, V47, P613, DOI 10.1016/0895-4356(94)90209-7; Morris JN, 1997, J AM GERIATR SOC, V45, P1017, DOI 10.1111/j.1532-5415.1997.tb02975.x; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; *NORW MED AG, NORW PHARM PROD COMP; Onder G, 2003, EUR J CLIN PHARMACOL, V59, P157, DOI 10.1007/s00228-003-0600-8; ONDER G, IN PRESS EUR J CLIN; Pitkala KH, 2002, ARCH INTERN MED, V162, P1707, DOI 10.1001/archinte.162.15.1707; Schmader KE, 2004, AM J MED, V116, P394, DOI 10.1016/j.amjmed.2003.10.031; STEWART RB, 1994, DRUG AGING, V4, P449, DOI 10.2165/00002512-199404060-00002; STUCK AE, 1994, ARCH INTERN MED, V154, P2195; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Tamblyn R, 2003, CAN MED ASSOC J, V169, P549; Thirstrup S, 2001, LANCET, V358, P1734, DOI 10.1016/S0140-6736(01)06760-5; Zhan Chunliu, 2001, JAMA (Journal of the American Medical Association), V286, P2823; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	41	482	503	5	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	2005	293	11					1348	1358		10.1001/jama.293.11.1348	http://dx.doi.org/10.1001/jama.293.11.1348			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	907EP	15769968	Bronze, Green Published			2023-01-03	WOS:000227698600023
J	Jacobs, T				Jacobs, T			Bugs or drugs, tortoises or hares?	NATURE BIOTECHNOLOGY			English	Editorial Material												tom@completegrowth.com							0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2005	23	3					293	293		10.1038/nbt0305-293	http://dx.doi.org/10.1038/nbt0305-293			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	906IW	15765079	Bronze			2023-01-03	WOS:000227635400012
J	Van der Borght, S; de Wit, TFR; Janssens, V; van der Loeff, MFS; Rijckborst, H; Lange, JMA				Van der Borght, Stefaan; de Wit, Tobias F. Rinke; Janssens, Vincent; van der Loeff, Maarten F. Schim; Rijckborst, Henk; Lange, Joep M. A.			HAART for the HIV-infected employees of large companies in Africa	LANCET			English	Editorial Material							ANTIRETROVIRAL THERAPY; AIDS; MORTALITY; COSTS		Heineken Int Hlth Affairs, NL-1017 HL Amsterdam, Netherlands; PharmAccess Fdn, Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Ctr Poverty Related Communicable Dis, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Van der Borght, S (corresponding author), Heineken Int Hlth Affairs, Vijzelstr 72, NL-1017 HL Amsterdam, Netherlands.	S.vanderBorght@heineken.com	de Wit, Tobias TF Rinke/A-1224-2013					Akileswaran C, 2005, CLIN INFECT DIS, V41, P376, DOI 10.1086/431482; BLOOM DE, 2006, BUISNESS HIV AIDS HL; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Byakika-Tusiime J, 2005, INT J STD AIDS, V16, P38, DOI 10.1258/0956462052932548; Dror DM., 2002, SOCIAL REINSURANCE N; Dybul Mark, 2002, MMWR Recomm Rep, V51, P1; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Kimball AM, 2005, LANCET, V365, P1213, DOI 10.1016/S0140-6736(05)74792-9; Lavalle C, 2000, ARCH MED RES, V31, P515, DOI 10.1016/S0188-4409(00)00097-7; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Marseille E, 2006, AIDS, V20, P907, DOI 10.1097/01.aids.0000218556.36661.47; Mocroft A, 2004, HIV MED, V5, P437, DOI 10.1111/j.1468-1293.2004.00250.x; Orrell Catherine, 2005, Curr HIV/AIDS Rep, V2, P171, DOI 10.1007/s11904-005-0012-8; Paul S, 2002, AIDS RES HUM RETROV, V18, P501, DOI 10.1089/088922202317406646; Piot P, 2004, SCIENCE, V304, P1909, DOI 10.1126/science.1101137; Stevens W, 2004, BMJ-BRIT MED J, V328, P280, DOI 10.1136/bmj.328.7434.280; Teixeira PR, 2004, AIDS, V18, pS5, DOI 10.1097/00002030-200406003-00002; Venter L, 2005, LANCET, V365, P1215, DOI 10.1016/S0140-6736(05)74793-0; Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0; *WORLD BANK, 1999, MILL DEV GOALS MDG; World Health Organization, 2003, SCAL ANT THER RES LT; 2001, BOSTON GLOBE    0607, pA8	22	16	16	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2006	368	9534					547	550		10.1016/S0140-6736(06)69165-4	http://dx.doi.org/10.1016/S0140-6736(06)69165-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890844				2023-01-03	WOS:000239569000040
J	McDonald, CJ				McDonald, CJ			Computerization can create safety hazards: A bar-coding near miss	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIAN ORDER ENTRY; ADVERSE DRUG EVENTS; MEDICATION ERRORS; INFORMATION-TECHNOLOGY; PATIENT SAFETY; HEALTH-CARE; SYSTEMS; RATES; HOSPITALS; INCREASE	Increasing numbers of hospitals are implementing bar-coding systems to prevent errors in patient identification. In the present case, a diabetic patient admitted to a teaching hospital was mistakenly given the bar-coded identification wristband of another patient who was admitted at the same time. When a laboratory result that documented the diabetic patient's severe hyperglycemia was entered into the other patient's electronic medical record, the latter patient seemed to have a very high glucose level and was almost given what could have been a fatal dose of insulin. This near miss shows that computer systems, although having the potential to improve safety, may create new kinds of errors if not accompanied by well-designed, well-implemented cross-check processes and a culture of safety. Moreover, computer systems may have the pernicious effect of weakening human vigilance, removing an important safety protection. Researchers should continue to study realworld implementation of computerized systems to understand their benefits and potential harms, and administrators and providers should seek ways to anticipate these harms and mitigate them.	Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	McDonald, CJ (corresponding author), Regenstrief Inst Hlth Care, 1050 Wishard Blvd, Indianapolis, IN 46202 USA.	cmcdonald@regenstrief.org			NATIONAL LIBRARY OF MEDICINE [G08LM008232] Funding Source: NIH RePORTER; NLM NIH HHS [G08 LM008232] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Ash JS, 2004, J AM MED INFORM ASSN, V11, P104, DOI 10.1197/jamia.M1471; Bates DW, 2000, BRIT MED J, V320, P788, DOI 10.1136/bmj.320.7237.788; Bierstock S, 2005, JAMA-J AM MED ASSOC, V294, P178, DOI 10.1001/jama.294.2.178-b; BREWIN B, 2004, COMP WORLD      0226; BRODER C, 2005, JCAHO DROPS BAR CODI; Dexter PR, 2001, NEW ENGL J MED, V345, P965, DOI 10.1056/NEJMsa010181; Dexter PR, 2004, JAMA-J AM MED ASSOC, V292, P2366, DOI 10.1001/jama.292.19.2366; Doolan DF, 2002, HEALTH AFFAIR, V21, P180, DOI 10.1377/hlthaff.21.4.180; Gallian JA, 1996, ACM COMPUT SURV, V28, P504, DOI 10.1145/243439.243457; Garg AX, 2005, JAMA-J AM MED ASSOC, V293, P1223, DOI 10.1001/jama.293.10.1223; Grannis SJ, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P305; GRUDIN JT, 2003, COGNITIVE ASPECTS SK, P121; Halamka J, 2005, NEW ENGL J MED, V353, P331, DOI 10.1056/NEJMp058077; Han YY, 2005, PEDIATRICS, V116, P1506, DOI 10.1542/peds.2005-1287; HICKS RW, 2004, MEDMARX 5 ANNIVERSAR; Horsky J, 2005, J AM MED INFORM ASSN, V12, P377, DOI 10.1197/jamia.M1740; *JOINT COMM ACCR H, 2005, HOSP NAT PAT SAF GOA; Keillor A, 2005, JAMA-J AM MED ASSOC, V294, P178, DOI 10.1001/jama.294.2.178-a; KLEMMER ET, 1962, J APPL PSYCHOL, V46, P401, DOI 10.1037/h0048461; Koppel R, 2005, J BIOMED INFORM, V38, P267, DOI 10.1016/j.jbi.2005.05.006; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; Larrabee Susanne, 2003, Jt Comm J Qual Saf, V29, P345; Lee SU, 2005, J BACK MUSCULOSKELET, V18, P15, DOI 10.3233/BMR-2005-181-203; Levick D, 2005, JAMA-J AM MED ASSOC, V294, P179, DOI 10.1001/jama.294.2.179-c; Linden JV, 2000, TRANSFUSION, V40, P1207, DOI 10.1046/j.1537-2995.2000.40101207.x; MacKay DJC, 1999, IEEE T INFORM THEORY, V45, P399, DOI 10.1109/18.748992; McDonald CJ, 2004, J AM MED INFORM ASSN, V11, P121, DOI 10.1197/jamia.M1488; Nebeker JR, 2005, ARCH INTERN MED, V165, P1111, DOI 10.1001/archinte.165.10.1111; Oren E, 2003, AM J HEALTH-SYST PH, V60, P1447, DOI 10.1093/ajhp/60.14.1447; Patterson ES, 2002, J AM MED INFORM ASSN, V9, P540, DOI 10.1197/jamia.M1061; PAVLIDIS T, 1990, COMPUTER, V23, P74, DOI 10.1109/2.55471; Phillips DP, 1998, LANCET, V351, P643, DOI 10.1016/S0140-6736(98)24009-8; Potts AL, 2004, PEDIATRICS, V113, P59, DOI 10.1542/peds.113.1.59; Rooney C, 1998, LANCET, V351, P1656, DOI 10.1016/S0140-6736(05)77710-2; ROSENTHAL M, 2003, CHECK WRISTBAND AHRQ; Shulman R, 2005, CRIT CARE, V9, pR516, DOI 10.1186/cc3793; STEIN R, 2004, WASHINGTON POST 1014; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; WAGNER NR, 1989, COMMUN ACM, V32, P106, DOI 10.1145/63238.63246; WALD H, 2005, AHRQ PUBLICATION; WANT R, 2004, QCM QUEUE, V2; Wright AA, 2005, NEW ENGL J MED, V353, P329, DOI 10.1056/NEJMp058101; CREDIT CARD VALIDATI; 2005, MMWR MORB MORTAL WKL, P33	44	92	92	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2006	144	7					510	516		10.7326/0003-4819-144-7-200604040-00010	http://dx.doi.org/10.7326/0003-4819-144-7-200604040-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	031DU	16585665				2023-01-03	WOS:000236685100006
J	Self, CH; Thompson, S				Self, CH; Thompson, S			How specific are therapeutic rnonoclonal antibodies?	LANCET			English	Editorial Material									Newcastle Univ, Sch Med, Sch Clin & Lab Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Self, CH (corresponding author), Newcastle Univ, Sch Med, Sch Clin & Lab Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	C.H.Self@ncl.ac.uk						Bodey B, 2000, CURR PHARM DESIGN, V6, P261, DOI 10.2174/1381612003401109; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Christiansen J, 2004, MOL CANCER THER, V3, P1493; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Levine MN, 2005, J CLIN ONCOL, V23, P7775, DOI 10.1200/JCO.2005.04.1558; Morrow KJ, 2005, GENET ENG NEWS, V25, P1; Schrama D, 2006, NAT REV DRUG DISCOV, V5, P147, DOI 10.1038/nrd1957; Self CH, 1996, NAT MED, V2, P817, DOI 10.1038/nm0796-817; Smith KA, 2004, J CLIN PATHOL, V57, P912, DOI 10.1136/jcp.2003.014407; Stockwin LH, 2003, EXPERT OPIN BIOL TH, V3, P1133, DOI 10.1517/14712598.3.7.1133; Thompson JF, 2001, ANN SURG ONCOL, V8, P564, DOI 10.1245/aso.2001.8.7.564	11	12	16	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	2006	367	9516					1038	1039		10.1016/S0140-6736(06)68396-7	http://dx.doi.org/10.1016/S0140-6736(06)68396-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	030ZF	16581388				2023-01-03	WOS:000236673200009
J	Jafar, TH				Jafar, TH			The growing burden of chronic kidney disease in Pakistan	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Aga Khan Univ, Clin Epidemiol Unit, Karachi, Pakistan	Aga Khan University	Jafar, TH (corresponding author), Aga Khan Univ, Clin Epidemiol Unit, Karachi, Pakistan.							Ahmad K, 2005, J HYPERTENS, V23, P1979, DOI 10.1097/01.hjh.0000187258.86824.00; Bhargava SK, 2004, NEW ENGL J MED, V350, P865, DOI 10.1056/NEJMoa035698; Jafar TH, 2005, J AM SOC NEPHROL, V16, P1413, DOI 10.1681/ASN.2004121100; Jafar TH, 2005, CIRCULATION, V111, P1291, DOI 10.1161/01.CIR.0000157699.87728.F1	4	70	71	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					995	997		10.1056/NEJMp058319	http://dx.doi.org/10.1056/NEJMp058319			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019FY	16525135	Green Published			2023-01-03	WOS:000235822200002
J	Foster, G				Foster, G			Children who live in communities affected by AIDS	LANCET			English	Editorial Material									Mutare Prov Hosp, Dept Paediat, Mutare, Zimbabwe		Foster, G (corresponding author), Mutare Prov Hosp, Dept Paediat, Box 30, Mutare, Zimbabwe.	gfoster@mweb.co.zw						Bauman L, 2005, GENERATION RISK GLOB; Birdthistle I., 2004, UNDERSTANDING NEEDS; Bonnel R., 2004, POVERTY REDUCTION ST; Forsyth BWC, 1996, ARCH PEDIAT ADOL MED, V150, P1015, DOI 10.1001/archpedi.1996.02170350017002; FOSTER G, RADAR COMMUNITY SAFE; Foster G., 2005, BOTTLENECKS DRIPFEED; Germann S., 2002, AIDS AFRICA, P664; Gilborn L.Z., 2001, MAKING DIFFERENCE CH; Heckman JJ, 1999, POLICIES FOSTER HUMA; Lindblade KA, 2003, TROP MED INT HEALTH, V8, P67, DOI 10.1046/j.1365-3156.2003.00987.x; Monasch R, 2004, AIDS, V18, pS55, DOI 10.1097/00002030-200406002-00007; Mutangadura G., 1999, REV HOUSEHOLD COMMUN; RICHTER L, IN PRESS STRENGTHENI; UNICEF, 2003, AFR ORPH GEN; *USAID UNICEF UNAI, CHILDR BRINK 2004 JO	15	31	32	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 25	2006	367	9511					700	701		10.1016/S0140-6736(06)68273-1	http://dx.doi.org/10.1016/S0140-6736(06)68273-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	016HR	16503473				2023-01-03	WOS:000235611800039
J	Havrda, DE; Omundsen, BA; Bender, W; Kirkpatrick, MA				Havrda, DE; Omundsen, BA; Bender, W; Kirkpatrick, MA			Impact of the Medicare modernization act on low-income persons	ANNALS OF INTERNAL MEDICINE			English	Article								Background: Low-income Medicare beneficiaries without prescription benefits have high out-of-pocket medication expenses that can discourage adherence to treatment regimens. The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 created a temporary drug discount card program and a prescription benefit with low-income provisions to assist with medication expenditures for eligible seniors. Objective: To determine the impact of the new drug discount card and prescription benefit on medication expenditures by low-income Medicare recipients who require pharmaceutical company assistance for obtaining medications. Design: Retrospective, nonrandomized evaluation. Setting: Family practice physicians' office in northern Virginia. Patients: 137 Medicare recipients without prescription coverage who received assistance from pharmaceutical companies for medications. Measurements: Patients were stratified into 3 categories according to income, household size, and the federal poverty line (FPL), as defined by the new Medicare act. Participants' long-term oral and inhaled medications, dosages, and instructions for use were obtained. The MMA criteria for low-income provisions were applied for the drug discount program and for the prescription benefit. Medication costs under the new Medicare benefits were compared with those incurred without assistance and with the use of pharmaceutical company programs for the cohort and FPL categories. Results: In all income categories, medication costs were lower after enrollment in all programs than those of patients without assistance. Compared with pharmaceutical company assistance, Medicare drug discount cards resulted in less savings for all income groups. For the prescription benefit, persons with incomes less than 135% of FPL had the greatest benefit because of low-income subsidies. Persons ineligible for low-income subsidies receiving the standard benefit had a smaller reduction in out-of-pocket costs and variable monthly expenditures; they realized a superior savings with pharmaceutical company assistance programs. Limitations: The generalizability of these findings is limited because the authors used a discount pharmacy to determine drug costs for persons receiving no assistance, could not determine asset criteria for the MMA drug benefit low-income subsidy, and used a selected Medicare population. Conclusions: in a low-income Medicare population without prescription coverage, pharmaceutical company programs offered considerable savings and were superior to the Medicare drug discount cards. For the Medicare prescription plan, the greatest savings was among those eligible for low-income subsidies. Month-to-month medication costs may vary substantially for persons ineligible for such subsidies, and pharmaceutical company assistance may be a better alternative.	Shenandoah Univ, Sch Pharm, Winchester 22601, Hants, England; Amherst Family Practice, Winchester, Hants, England		Havrda, DE (corresponding author), Shenandoah Univ, Sch Pharm, 1775 N Sector Court, Winchester 22601, Hants, England.	dhavrda@su.edu						ANTOS J, 2004, PRIV DISC PUBL SUBS, P1; BRYANT J, 2004, ASSESSMENT BENEFICIA, pA1; CAPLAN C, 2003, OUT POCKET SPENDING; *CTR MED MED SERV, 2004, CMS STUD CONF SIGN S; *CTR MED MED SERV, 2004, PHARM DEM PROGR STAT; *CTR MED MED SERV, 2005, MLN MATTERS, P1; Doherty RB, 2004, ANN INTERN MED, V141, P391, DOI 10.7326/0003-4819-141-5-200409070-00100; Duke KS, 2005, AM J HEALTH-SYST PH, V62, P726, DOI 10.1093/ajhp/62.7.726; Ellingsen P, 2004, DETAILED DESCRIPTION, p[1, 4]; GROSS DJ, 2004, TRENDS MANUFACTURER, P1; Health and Safety Executive, 2004, MED DRUG DISC CARDS, P1; MAYS J, 2004, ESTIMATES MEDICARE B, P1; *MED RIGHTS CTR, 2005, STAT PRESCR DRUG RX; *PENN DEP AG, 2004, PACE PHARM ASS CONTR, P1; *PRICEWATERHOUSC, 2004, IMP MED PRESCR DRUG, P1; RICE T, 2005, LOW INCOME SUBSIDIES, P1; RODGERS J, 2004, MEICARE PRESCRIPTION, P1; SAFRAN DG, 2002, PRESCRIPTION DRUG CO, pW253; 2004, FEDERAL REGISTER, V69, P7336; 2005, FEDERAL REGISER, V70, P4464	20	9	9	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 18	2005	143	8					600	608		10.7326/0003-4819-143-8-200510180-00011	http://dx.doi.org/10.7326/0003-4819-143-8-200510180-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	16230727				2023-01-03	WOS:000232674000011
J	Williams, BR				Williams, BR			Targeting specific cell types with silencing RNA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Williams, BR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101	1	17	18	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2005	353	13					1410	1411		10.1056/NEJMcibr052492	http://dx.doi.org/10.1056/NEJMcibr052492			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968FB	16192490				2023-01-03	WOS:000232146200018
J	Bloche, MG				Bloche, MG			Managing conflict at the end of life	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Georgetown Univ, Washington, DC 20057 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bloche, MG (corresponding author), Georgetown Univ, Washington, DC 20057 USA.							Bercovitch Jacob, 1989, MEDIATION RES PROCES; Bloche MG, 2002, STANFORD LAW REV, V55, P919, DOI 10.2307/1229676; Dubler N. N., 2004, BIOETHICS MEDIATION; Frey B.S., 1999, EC VALUES ORG, P437; LYNCH RN, 2005, COMMUNICATION   0228	5	32	33	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2371	2373		10.1056/NEJMp058104	http://dx.doi.org/10.1056/NEJMp058104			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944420				2023-01-03	WOS:000229638900001
J	Chan, O; Wilson, A; Walsh, M				Chan, O; Wilson, A; Walsh, M			ABC of emergency radiology - Major trauma	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Royal London Hosp, London E1 1BB, England	Barts Health NHS Trust; Royal London Hospital	Chan, O (corresponding author), Royal London Hosp, London E1 1BB, England.	zaideotto@blueyonder.co.uk							0	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 14	2005	330	7500					1136	1138		10.1136/bmj.330.7500.1136	http://dx.doi.org/10.1136/bmj.330.7500.1136			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927BH	15891230	Green Published			2023-01-03	WOS:000229166900024
J	Currie, GP; Devereux, GS; Lee, DKC; Ayres, JG				Currie, GP; Devereux, GS; Lee, DKC; Ayres, JG			Recent developments in asthma management	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED-TRIAL; ANTIIMMUNOGLOBULIN-E THERAPY; PLACEBO-CONTROLLED TRIAL; SMOOTH-MUSCLE-CELLS; DOUBLE-BLIND; AIRWAY HYPERRESPONSIVENESS; ALLERGIC-ASTHMA; FLUTICASONE; MONTELUKAST; SALMETEROL		Aberdeen Royal Infirm, Chest Clin C, Aberdeen AB25 2ZN, Scotland; Dept Environm & Occupat Med, Aberdeen AB25 2ZP, Scotland; Ipswich Hosp, Dept Resp Med, Ipswich IP4 5PD, Suffolk, England	University of Aberdeen; University of Aberdeen; Ipswich Hospital NHS Trust; Ipswich Hospital	Currie, GP (corresponding author), Aberdeen Royal Infirm, Chest Clin C, Aberdeen AB25 2ZN, Scotland.	graeme.currie@nhs.net		Currie, Graeme P/0000-0002-5711-9147				Anderson HR, 2005, BRIT MED J, V330, P117, DOI 10.1136/bmj.38316.729907.8F; Ayres JG, 2004, ALLERGY, V59, P701, DOI 10.1111/j.1398-9995.2004.00533.x; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bjermer L, 2003, BMJ-BRIT MED J, V327, P891, DOI 10.1136/bmj.327.7420.891; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Calder PC, 2002, P NUTR SOC, V61, P345, DOI 10.1079/PNS2002166; Camargo CA, 2003, AM J RESP CRIT CARE, V167, P528, DOI 10.1164/rccm.200208-802OC; Cooper S, 2003, THORAX, V58, P674, DOI 10.1136/thorax.58.8.674; Currie GP, 2003, AM J RESP CRIT CARE, V167, P1232, DOI 10.1164/rccm.200209-1116OC; Currie GP, 2003, CLIN EXP ALLERGY, V33, P783, DOI 10.1046/j.1365-2222.2003.01688.x; Currie GP, 2003, EUR J CLIN PHARMACOL, V59, P11, DOI 10.1007/s00228-003-0571-9; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; Fogarty A, 2003, CLIN EXP ALLERGY, V33, P1355, DOI 10.1046/j.1365-2222.2003.01777.x; Gibson PG, 2004, THORAX, V59, P94, DOI 10.1136/thorax.2003.011858; *GINA, NIH PUBL; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; HOLLOWAY E, 2001, COCHRANE DATABASE SY; Holt S, 2001, BRIT MED J, V323, P253, DOI 10.1136/bmj.323.7307.253; Ilowite J, 2004, ANN ALLERG ASTHMA IM, V92, P641, DOI 10.1016/S1081-1206(10)61430-5; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Pearson PJK, 2004, THORAX, V59, P652, DOI 10.1136/thx.2004.022616; Plant PK, 2003, THORAX, V58, P537, DOI 10.1136/thorax.58.6.537; Porter R S, 2001, Eur J Emerg Med, V8, P9, DOI 10.1097/00063110-200103000-00003; Powell RM, 2003, EXPERT OPIN THER TAR, V7, P485; RAM FS, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000993.PUB2; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Silverman RA, 2002, CHEST, V122, P489, DOI 10.1378/chest.122.2.489; Silverman RA, 2004, CHEST, V126, P1480, DOI 10.1378/chest.126.5.1480; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; WOODS RK, 2000, COCHRANE DB SYST REV; 2003, THORAX S1, V58, P1	39	13	14	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 12	2005	330	7491					585	589		10.1136/bmj.330.7491.585	http://dx.doi.org/10.1136/bmj.330.7491.585			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906EC	15761000	Green Published			2023-01-03	WOS:000227622300021
J	Dieppe, PA; Lohmander, LS				Dieppe, PA; Lohmander, LS			Pathogenesis and management of pain in osteoarthritis	LANCET			English	Review							RADIOGRAPHIC KNEE OSTEOARTHRITIS; BONE-MINERAL DENSITY; HAND OSTEOARTHRITIS; HIP OSTEOARTHRITIS; OSTEO-ARTHRITIS; MUSCULOSKELETAL DISORDERS; GENETIC CONTRIBUTION; JOINT REPLACEMENT; UNITED-STATES; BRISTOL OA500	The term osteoarthritis describes a common, age-related, heterogeneous group of disorders characterised pathologically by focal areas of loss of articular cartilage in synovial joints, associated with varying degrees of orsteophyte formation, subchondral bone change, and synovitis. joint damage is caused by a mixture of systemic factors that predispose to the disease, and local mechanical factors that dictate its distribution and severity. Various genetic abnormalities have been described, but most sporadic osteoarthritis probably depends on minor contributions from several genetic loci. Osteoarthritic joint damage may be associated with clinical problems, but the severity of joint disease is only weakly related to that of the clinical problem. For this reason the associations and pathogenesis of pain are in as much need of investigation as joint damage. Subchondral bone and synovium may be responsible for nociceptive stimuli, and peripheral neuronal sensitisation. is an important feature, and can result in normal activities (such as walking) causing pain. Central pain sensitisation can also occur, and psychosocial factors are important determinants of pain severity. We present a stepwise approach to the management of osteoarthritis.	Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England; Lund Univ, Dept Orthopaed, Inst Musculoskeletal Dis, Lund, Sweden	University of Bristol; Lund University	Dieppe, PA (corresponding author), Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Canynge Hall,Whiteladies Rd, Bristol BS8 2PR, Avon, England.	p.Dieppe@bristol.ac.uk	Lohmander, Stefan/I-8326-2012; Lohmander, Stefan/AAL-8314-2021	Lohmander, Stefan/0000-0002-5424-9448				Abramson SB, 2004, J RHEUMATOL, V31, P70, DOI 10.1097/BOR.0b013e328349c2b1; Aigner T, 2001, ARTHRITIS RHEUM-US, V44, P2777, DOI 10.1002/1529-0131(200112)44:12<2777::AID-ART465>3.0.CO;2-H; ALTMAN RD, 1991, SEMIN ARTHRITIS RHEU, V20, P40, DOI 10.1016/0049-0172(91)90026-V; Amin S, 2004, ARTHRITIS RHEUM, V50, pS142; Bajaj P, 2001, PAIN, V93, P107, DOI 10.1016/S0304-3959(01)00300-1; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bettica P, 2002, ARTHRITIS RHEUM, V46, P3178, DOI 10.1002/art.10630; Bischoff HA, 2003, OSTEOARTHRITIS, P381; BRADLEY LA, 2004, NOVART FDN SYMP, V260, P270; Bradley Laurence A, 2004, Novartis Found Symp, V260, P258; BRANDT KD, 1991, ARTHRITIS RHEUM, V34, P1381; Brooks P, 2003, B WORLD HEALTH ORGAN, V81, P689; Burr D, 2003, OSTEOARTHRITIS, P125; Chitnavis J, 1997, J BONE JOINT SURG BR, V79B, P660, DOI 10.1302/0301-620X.79B4.7437; Cooper C, 2000, ARTHRITIS RHEUM, V43, P995, DOI 10.1002/1529-0131(200005)43:5<995::AID-ANR6>3.0.CO;2-1; Creamer P, 1999, ARTHRIT CARE RES, V12, P3, DOI 10.1002/1529-0131(199902)12:1<3::AID-ART2>3.0.CO;2-K; Creamer P, 1996, J RHEUMATOL, V23, P1031; CROFT P, 1993, J RHEUMATOL, V20, P710; DAVIS MA, 1992, J RHEUMATOL, V19, P1943; DEKKER J, 1993, BEHAV RES THER, V31, P203, DOI 10.1016/0005-7967(93)90073-4; Dequeker J, 2003, AGING CLIN EXP RES, V15, P426, DOI 10.1007/BF03327364; Dieppe P, 2003, RHEUM DIS CLIN N AM, V29, P687, DOI 10.1016/S0889-857X(03)00054-1; DIEPPE P, 1993, ANN RHEUM DIS, V52, P557, DOI 10.1136/ard.52.8.557; Dieppe P, 2000, OSTEOARTHR CARTILAGE, V8, P63, DOI 10.1053/joca.1999.0272; Dieppe PA, 1997, OSTEOARTHR CARTILAGE, V5, P87, DOI 10.1016/S1063-4584(97)80002-7; Dixon T, 2004, ANN RHEUM DIS, V63, P825, DOI 10.1136/ard.2003.012724; DOHERTY M, 1983, LANCET, V2, P8; Ehrlich G E, 2001, Curr Rheumatol Rep, V3, P484, DOI 10.1007/s11926-001-0062-x; Elliott AM, 1999, LANCET, V354, P1248, DOI 10.1016/S0140-6736(99)03057-3; Englund M, 2004, ARTHRITIS RHEUM-US, V50, P2811, DOI 10.1002/art.20489; Englund M, 2004, ARTHRITIS RHEUM, V50, P469, DOI 10.1002/art.20035; Farrell M, 2000, J RHEUMATOL, V27, P441; Felson DT, 2003, ANN INTERN MED, V139, P330, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00008; Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016; Felson DT, 2000, ANN INTERN MED, V133, P726, DOI 10.7326/0003-4819-133-9-200011070-00015; Felson DT, 2004, RADIOL CLIN N AM, V42, P1, DOI 10.1016/S0033-8389(03)00161-1; Forster T, 2004, HUM GENET, V114, P391, DOI 10.1007/s00439-004-1083-0; Greenspan Adam, 2003, Semin Musculoskelet Radiol, V7, P155; HADLER N, 2003, OSTEOARTHRITIS, P189; Hannan MT, 2000, J RHEUMATOL, V27, P1513; HEINEGARD D, 2003, OSTEOARTHRITIS, P73; HOCHBERG MC, 1989, SEMIN ARTHRITIS RHEU, V18, P4, DOI 10.1016/0049-0172(89)90008-5; Hochberg MC, 2004, J RHEUMATOL, V31, P6; Hunter D, 2004, ARTHRITIS RHEUM, V50, pS141; HUNTER DJ, 2004, T ORTHOP RES SOC, V29, P284; Ingvarsson T, 2001, ARTHRITIS RHEUM-US, V44, P2548, DOI 10.1002/1529-0131(200111)44:11<2548::AID-ART435>3.0.CO;2-S; Ingvarsson T, 2000, ARTHRITIS RHEUM, V43, P2785, DOI 10.1002/1529-0131(200012)43:12<2785::AID-ANR19>3.0.CO;2-I; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; Kaila-Kangas L, 2004, SPINE, V29, P1823, DOI 10.1097/01.BRS.0000134572.46151.0A; Keefe FJ, 2004, PAIN, V110, P571, DOI 10.1016/j.pain.2004.03.028; KELLGREN JH, 1952, BRIT MED J, V1, P181, DOI 10.1136/bmj.1.4751.181; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kidd BL, 2003, NEUROREPORT, V14, P2189, DOI 10.1097/00001756-200312020-00011; Kidd BL, 2004, NOVART FDN SYMP, V260, P33; Kidd BL, 2004, NOVART FDN SYMP, V260, P277; Kidd Bruce L, 2004, Novartis Found Symp, V260, P122; Lanyon P, 2000, BRIT MED J, V321, P1179, DOI 10.1136/bmj.321.7270.1179; LAWRENCE JS, 1966, ANN RHEUM DIS, V25, P1; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; LICHTENBERG PA, 1986, J PSYCHOSOM RES, V30, P327, DOI 10.1016/0022-3999(86)90010-3; Lievense AM, 2002, RHEUMATOLOGY, V41, P1155, DOI 10.1093/rheumatology/41.10.1155; Linaker CH, 1999, BEST PRACT RES CL RH, V13, P197, DOI 10.1053/berh.1999.0016; LINDBERG H, 1986, CLIN ORTHOP RELAT R, V203, P273; Lohmander S, 2004, ARTHRITIS RHEUM, V50, pS140; Loughlin J, 1999, AM J HUM GENET, V65, P1795, DOI 10.1086/302685; Loughlin J, 2004, P NATL ACAD SCI USA, V101, P9757, DOI 10.1073/pnas.0403456101; Loughlin J, 2003, CURR OPIN PHARMACOL, V3, P295, DOI 10.1016/S1471-4892(03)00018-3; MacGregor AJ, 2000, ARTHRITIS RHEUM, V43, P2410, DOI 10.1002/1529-0131(200011)43:11<2410::AID-ANR6>3.0.CO;2-E; Mazzuca SA, 2004, J RHEUMATOL, V31, P329; MCALINDON T, 1989, ANN RHEUM DIS, V48, P531, DOI 10.1136/ard.48.7.531; MCALINDON TE, 1992, BRIT J RHEUMATOL, V31, P189; MCCRAE F, 1992, ANN RHEUM DIS, V51, P938, DOI 10.1136/ard.51.8.938; Melzack R, 2001, ANN NY ACAD SCI, V933, P157; Murray C. J. L., 1996, GLOBAL BURDEN DIS; O'Reilly SC, 1998, BRIT J RHEUMATOL, V37, P870; Paradowski Przemyslaw T, 2004, Health Qual Life Outcomes, V2, P38, DOI 10.1186/1477-7525-2-38; Peat G, 2001, ANN RHEUM DIS, V60, P91, DOI 10.1136/ard.60.2.91; PETERFY CG, 2003, OSTEOARTHRITIS, P433; Petersson IF, 1996, ANN RHEUM DIS, V55, P659, DOI 10.1136/ard.55.9.659; Picavet HSJ, 2004, ANN RHEUM DIS, V63, P723, DOI 10.1136/ard.2003.010769; Pritzker K. P. H, 2003, OSTEOARTHRITIS, P49; Quilty B, 2003, J RHEUMATOL, V30, P1311; Roos Ewa M, 2003, Health Qual Life Outcomes, V1, P64, DOI 10.1186/1477-7525-1-64; SAHLSTROM A, 1997, CLIN ORTHOP RELAT R, V340, P152; Sanders C, 2004, RHEUMATOLOGY, V43, P353, DOI 10.1093/rheumatology/keh044; SANDY JD, 2003, OSTEOARTHRITIS, P82; Schneider DL, 2002, J RHEUMATOL, V29, P1467; Scott D, 2004, CLIN EVID, V11, P1560; Sharma L, 2003, OSTEOARTHRITIS, V2, P177; Slemenda C, 1998, ARTHRITIS RHEUM, V41, P1951, DOI 10.1002/1529-0131(199811)41:11<1951::AID-ART9>3.0.CO;2-9; Smith AJP, 2004, GENES IMMUN, V5, P451, DOI 10.1038/sj.gene.6364107; Spector T D, 1993, Osteoarthritis Cartilage, V1, P203, DOI 10.1016/S1063-4584(05)80325-5; Spector TD, 1996, BRIT MED J, V312, P940; Stecher RM, 1941, AM J MED SCI, V201, P801, DOI 10.1097/00000441-194106000-00004; Stefansson SE, 2003, AM J HUM GENET, V72, P1448, DOI 10.1086/375556; Van den Berg W, 2003, OSTEOARTHRITIS, P147; Watson P J, 1993, Agents Actions Suppl, V39, P261; Watt IDM., 2003, OSTEOARTHRITIS 2, P211; WESTACOTT CI, 2003, OSTEOARTHRITIS, P133; *WORK BACKS SCOTL, YELL FLAGS; World Health Organization, 2003, BURD MUSC COND START; Zelzer E, 2003, NATURE, V423, P343, DOI 10.1038/nature01659; Zhang YQ, 2000, J RHEUMATOL, V27, P1032	103	738	767	3	137	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	2005	365	9463					965	973		10.1016/S0140-6736(05)71086-2	http://dx.doi.org/10.1016/S0140-6736(05)71086-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	905HS	15766999				2023-01-03	WOS:000227559800030
J	MacDonald, R; Das, A				MacDonald, Rhona; Das, Aditi			UK classification of drugs of abuse: an un-evidence-based mess	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England; Univ Manchester, Sch Med, Manchester, Lancs, England	University of Manchester	MacDonald, R (corresponding author), The Lancet, London NW1 7BY, England.							House of Commons Science and Technology Committee, 2006, 5 HOUS COMM SCI TECH; *UN OFF DRUGS CRIM, 2006, UN DRUGS CHIEF SOUND; 2006, RETHINK CANNABIS ED	3	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 12	2006	368	9535					559	561		10.1016/S0140-6736(06)69175-7	http://dx.doi.org/10.1016/S0140-6736(06)69175-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905003				2023-01-03	WOS:000239821000007
J	Ballard, RA; Truog, WE; Cnaan, A; Martin, RJ; Ballard, PL; Merrill, JD; Walsh, MC; Durand, DJ; Mayock, DE; Eichenwald, EC; Null, DR; Hudak, ML; Puri, AR; Golombek, SG; Courtney, SE; Stewart, DL; Welty, SE; Phibbs, RH; Hibbs, AM; Luan, XQ; Wadlinger, SR; Asselin, JM; Coburn, CE				Ballard, Roberta A.; Truog, William E.; Cnaan, Avital; Martin, Richard J.; Ballard, Philip L.; Merrill, Jeffrey D.; Walsh, Michele C.; Durand, David J.; Mayock, Dennis E.; Eichenwald, Eric C.; Null, Donald R.; Hudak, Mark L.; Puri, Asha R.; Golombek, Sergio G.; Courtney, Sherry E.; Stewart, Dan L.; Welty, Stephen E.; Phibbs, Roderic H.; Hibbs, Anna Maria; Luan, Xianqun; Wadlinger, Sandra R.; Asselin, Jeanette M.; Coburn, Christine E.		NO CLD Study Grp	Inhaled nitric oxide in preterm infants undergoing mechanical ventilation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERSISTENT PULMONARY-HYPERTENSION; PREMATURE-INFANTS; LUNG GROWTH; NEURODEVELOPMENTAL OUTCOMES; RESPIRATORY-FAILURE; THERAPY; DISEASE; EFFICACY; SAFETY; MODEL	Background: Bronchopulmonary dysplasia in premature infants is associated with prolonged hospitalization, as well as abnormal pulmonary and neurodevelopmental outcome. In animal models, inhaled nitric oxide improves both gas exchange and lung structural development, but the use of this therapy in infants at risk for bronchopulmonary dysplasia is controversial. Methods: We conducted a randomized, stratified, double-blind, placebo-controlled trial of inhaled nitric oxide at 21 centers involving infants with a birth weight of 1250 g or less who required ventilatory support between 7 and 21 days of age. Treated infants received decreasing concentrations of nitric oxide, beginning at 20 ppm, for a minimum of 24 days. The primary outcome was survival without bronchopulmonary dysplasia at 36 weeks of postmenstrual age. Results: Among 294 infants receiving nitric oxide and 288 receiving placebo birth weight (766 g and 759 g, respectively), gestational age (26 weeks in both groups), and other characteristics were similar. The rate of survival without bronchopulmonary dysplasia at 36 weeks of postmenstrual age was 43.9 percent in the group receiving nitric oxide and 36.8 percent in the placebo group (P=0.042). The infants who received inhaled nitric oxide were discharged sooner (P=0.04) and received supplemental oxygen therapy for a shorter time (P=0.006). There were no short-term safety concerns. Conclusions: Inhaled nitric oxide therapy improves the pulmonary outcome for premature infants who are at risk for bronchopulmonary dysplasia when it is started between 7 and 21 days of age and has no apparent short-term adverse effects. (ClinicalTrials.gov number, NCT00000548.)	Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Univ Missouri, Kansas City, MO 64110 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Childrens Hosp & Res Ctr, Oakland, CA USA; Univ Washington, Sch Med, Seattle, WA USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Utah, Med Ctr, Salt Lake City, UT USA; Univ Florida, Hlth Sci Ctr, Jacksonville, FL 32209 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; New York Med Coll, Valhalla, NY 10595 USA; Long Isl Jewish Hlth Syst, New Hyde Pk, NY USA; Univ Louisville, Sch Med, Louisville, KY 40292 USA; Ohio State Univ, Sch Med & Publ Hlth, Columbus, OH 43210 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Missouri System; University of Missouri Kansas City; Case Western Reserve University; University of Washington; University of Washington Seattle; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah; State University System of Florida; University of Florida; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; New York Medical College; Northwell Health; University of Louisville; University System of Ohio; Ohio State University; University of California System; University of California San Francisco	Ballard, RA (corresponding author), Childrens Hosp Philadelphia, 3535 Market St,Suite 1584, Philadelphia, PA 19104 USA.	ballard@email.chop.edu	Щербак, Геннадий/B-5738-2018; Golombek, Sergio G/A-7697-2008; Kavyrshina, Viktoria/N-1770-2018; Vorobev, Alexander/C-1918-2016; Truog, William/R-5576-2019; Welty, Stephen/AGS-7454-2022; Welty, Stephen/AAZ-4307-2021; Stewart, Dan/R-7130-2019; Ioda, Julia/P-1722-2015	Щербак, Геннадий/0000-0001-8462-6147; Kavyrshina, Viktoria/0000-0002-1762-2477; Vorobev, Alexander/0000-0002-7324-428X; Welty, Stephen/0000-0002-6321-8440; Durand, David/0000-0003-1181-0941; Ioda, Julia/0000-0002-7320-0666	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD026979] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064, M01RR000425, M01RR000080, M01RR001271, M01RR000240, M01RR000084] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056401, U01HL062514] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00425, M01-RR00240, M01-RR001271, M01-RR00064, M01-RR00080, M01-RR00084] Funding Source: Medline; NHLBI NIH HHS [U01-HL62514, P50-HL56401] Funding Source: Medline; NICHD NIH HHS [P30-HD26979, HD26979] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 2004, PEDIATRICS, V114, P1377; [Anonymous], 1997, NEW ENGL J MED, V337, P434; Ballard PL, 2006, PEDIATR RES, V59, P157, DOI 10.1203/01.pdr.0000190664.69081.f1; Ballard RA, 1998, NEW ENGL J MED, V338, P493, DOI 10.1056/NEJM199802193380802; Banks BA, 1999, PEDIATRICS, V103, P610, DOI 10.1542/peds.103.3.610; BERMAN W, 1986, J PEDIATR-US, V109, P45, DOI 10.1016/S0022-3476(86)80570-4; Bland RD, 2005, AM J RESP CRIT CARE, V172, P899, DOI 10.1164/rccm.200503-384OC; Bloche MG, 2004, NEW ENGL J MED, V351, P2035, DOI 10.1056/NEJMp048271; Clark PL, 2002, ARCH DIS CHILD-FETAL, V86, pF41, DOI 10.1136/fn.86.1.F41; Clark RH, 2000, NEW ENGL J MED, V342, P469, DOI 10.1056/NEJM200002173420704; Coalson Jacqueline J, 2003, Semin Neonatol, V8, P73, DOI 10.1016/S1084-2756(02)00193-8; Cotton RB, 2006, PEDIATR RES, V59, P142, DOI 10.1203/01.pdr.0000191815.60293.cc; *CYT, 2005, STATXACT 7 STAT SOFT; *CYT STAT SOFTW SE, 2003, EAST VERS 3 0 SOFTW; Field D, 2005, PEDIATRICS, V115, P926, DOI 10.1542/peds.2004-1209; Follmann D, 2003, BIOMETRICS, V59, P420, DOI 10.1111/1541-0420.00049; Hascoet JM, 2005, J PEDIATR-US, V146, P318, DOI 10.1016/j.jpeds.2004.10.019; Jennison C, 1999, GROUP SEQUENTIAL MET; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Kinsella JP, 2006, NEW ENGL J MED, V355, P354, DOI 10.1056/NEJMoa060442; Kinsella JP, 1999, LANCET, V354, P1061, DOI 10.1016/S0140-6736(99)03558-8; Laptook AR, 2005, PEDIATRICS, V115, P673, DOI 10.1542/peds.2004-0667; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lin YJ, 2005, PEDIATR RES, V58, P22, DOI 10.1203/01.PDR.0000163378.94837.3E; Marlow N, 2005, NEW ENGL J MED, V352, P9, DOI 10.1056/NEJMoa041367; Martin RJ, 2005, NEW ENGL J MED, V353, P82, DOI 10.1056/NEJMe058124; Martin RJ, 2002, SEMIN PERINATOL, V26, P432, DOI 10.1053/sper.2002.37311; McCurnin DC, 2005, AM J PHYSIOL-LUNG C, V288, pL450, DOI 10.1152/ajplung.00347.2004; Mestan KKL, 2005, NEW ENGL J MED, V353, P23, DOI 10.1056/NEJMoa043514; NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357, DOI 10.1056/NEJM196702162760701; Roberts JD, 1997, NEW ENGL J MED, V336, P605, DOI 10.1056/NEJM199702273360902; Schreiber MD, 2003, NEW ENGL J MED, V349, P2099, DOI 10.1056/NEJMoa031154; Stork E, 1997, NEW ENGL J MED, V336, P597; Tang JR, 2004, AM J PHYSIOL-LUNG C, V287, pL344, DOI 10.1152/ajplung.00291.2003; Van Meurs KP, 2005, NEW ENGL J MED, V353, P13, DOI 10.1056/NEJMoa043927; Walsh MC, 2004, PEDIATRICS, V114, P1305, DOI 10.1542/peds.2004-0204	36	334	350	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	2006	355	4					343	353		10.1056/NEJMoa061088	http://dx.doi.org/10.1056/NEJMoa061088			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	067DT	16870913				2023-01-03	WOS:000239282600003
J	Gostin, LO				Gostin, LO			Physician-assisted suicide - A legitimate medical practice?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Univ, Ctr Law & Publ Hlth, Washington, DC USA; Johns Hopkins Univ, Baltimore, MD USA	Georgetown University; Johns Hopkins University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Law Ctr NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						*AM MED ASS, 1993, COD MED ETH PHYS ASS; [Anonymous], 2001, FED REG, V66, P56; Bloche MG, 2006, NEW ENGL J MED, V354, P993, DOI 10.1056/NEJMp068019; Gostin LO, 1997, JAMA-J AM MED ASSOC, V278, P1523, DOI 10.1001/jama.278.18.1523; Gostin LO, 2005, JAMA-J AM MED ASSOC, V294, P842, DOI 10.1001/jama.294.7.842; Greenhouse Linda, 2006, NY TIMES, pA1; LANE C, 2006, WASH POST       0221, pA1; *OR DEP HUM SERV, 2006, 8 OR DEP HUM SERV; Pew Research Center, 2006, STRONG PUBL SUPP RIG; VOGEL N, 2005, LOS ANGELES TIM 0524, pA1	10	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2006	295	16					1941	1943		10.1001/jama.295.16.1941	http://dx.doi.org/10.1001/jama.295.16.1941			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	036GI	16639054				2023-01-03	WOS:000237059200030
J	Chen, YP; Shen, YY; Guo, X; Zhang, CS; Yang, WJ; Ma, ML; Liu, S; Zhang, MB; Wen, LP				Chen, YP; Shen, YY; Guo, X; Zhang, CS; Yang, WJ; Ma, ML; Liu, S; Zhang, MB; Wen, LP			Transdermal protein delivery by a coadministered peptide identified via phage display	NATURE BIOTECHNOLOGY			English	Article							DRUG-DELIVERY; PENETRATION ENHANCERS; SKIN PENETRATION; HAIR FOLLICLE	Efficient transdermal drug delivery of large hydrophilic drugs is challenging. Here we report that the short synthetic peptide, ACSSSPSKHCG, identified by in vivo phage display, facilitated efficient transdermal protein drug delivery through intact skin. Coadministration of the peptide and insulin to the abdominal skin of diabetic rats resulted in elevated systemic levels of insulin and suppressed serum glucose levels for at least 11 h. Significant systemic bioavailability of human growth hormone was also achieved when topically coadministered with the peptide. The transdermal-enhancing activity of the peptide was sequence specific and dose dependent, did not involve direct interaction with insulin and enabled penetration of insulin into hair follicles beyond a depth of 600 mu m. Time-lapse studies suggested that the peptide creates a transient opening in the skin barrier to enable macromolecular drugs to reach systemic circulation.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wen, LP (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	lpwen@ustc.edu.cn	liu, shu/G-7430-2014	Wen, Longping/0000-0003-0384-4578				Agarwal R, 2000, METHOD FIND EXP CLIN, V22, P129, DOI 10.1358/mf.2000.22.2.796082; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Duerr DM, 2004, J VIROL METHODS, V116, P177, DOI 10.1016/j.jviromet.2003.11.012; Frenkel D, 2002, P NATL ACAD SCI USA, V99, P5675, DOI 10.1073/pnas.072027199; Guy R. H., 2003, TRANSDERMAL DRUG DEL; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026; Karande P, 2005, P NATL ACAD SCI USA, V102, P4688, DOI 10.1073/pnas.0501176102; Karande P, 2004, NAT BIOTECHNOL, V22, P192, DOI 10.1038/nbt928; LAUER AC, 1995, PHARM RES-DORDR, V12, P179, DOI 10.1023/A:1016250422596; Lavon A, 2004, DRUG DISCOV TODAY, V9, P670, DOI 10.1016/S1359-6446(04)03170-8; LI LN, 1995, NAT MED, V1, P705, DOI 10.1038/nm0795-705; Lopes LB, 2005, PHARM RES-DORDR, V22, P750, DOI 10.1007/s11095-005-2591-x; Meidan VM, 1998, PHARMACEUT RES, V15, P85, DOI 10.1023/A:1011956905388; Montagna W, 1956, STRUCTURE FUNCTION S; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Prausnitz MR, 2004, ADV DRUG DELIVER REV, V56, P581, DOI 10.1016/j.addr.2003.10.023; Prausnitz MR, 2004, NAT REV DRUG DISCOV, V3, P115, DOI 10.1038/nrd1304; Purdon CH, 2004, CRIT REV THER DRUG, V21, P97, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i2.20; Rafii S, 2003, CANCER CELL, V4, P331, DOI 10.1016/S1535-6108(03)00278-2; ROLLAND A, 1993, PHARMACEUT RES, V10, P1738, DOI 10.1023/A:1018922114398; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; SCHEUPLEIN RJ, 1971, PHYSIOL REV, V51, P702, DOI 10.1152/physrev.1971.51.4.702; Schutze-Redelmeier MPM, 2004, VACCINE, V22, P1985, DOI 10.1016/j.vaccine.2003.10.028; Thomas BJ, 2004, DRUG DISCOV TODAY, V9, P697, DOI 10.1016/S1359-6446(04)03180-0; Uversky VN, 2003, J PHARM SCI, V92, P847, DOI 10.1002/jps.10355; Williams AC, 2004, ADV DRUG DELIVER REV, V56, P603, DOI 10.1016/j.addr.2003.10.025	30	160	190	7	98	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2006	24	4					455	460		10.1038/nbt1193	http://dx.doi.org/10.1038/nbt1193			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	032HU	16565728				2023-01-03	WOS:000236766300030
J	Bloche, MG				Bloche, MG			The supreme court and the purposes of medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Georgetown Univ, Washington, DC 20057 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA	Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bloche, MG (corresponding author), Georgetown Univ, Washington, DC 20057 USA.							BLOCHE MG, 2002, ETHICAL DIMENSIONS H, P133; HENDERSON JA, 1994, CORNELL LAW REV, V79, P1382	2	11	11	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					993	995		10.1056/NEJMp068019	http://dx.doi.org/10.1056/NEJMp068019			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	019FY	16525134				2023-01-03	WOS:000235822200001
J	Conroy, SP; Luxton, T; Dingwall, R; Harwood, RH; Gladman, JRF				Conroy, SP; Luxton, T; Dingwall, R; Harwood, RH; Gladman, JRF			Controversy - Cardiopulmonary resuscitation in continuing care settings: time for a rethink?	BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL CARDIAC-ARREST; FUNCTIONAL STATUS; NURSING-HOMES; SURVIVORS; CPR; LIFE; GUIDELINES; OUTCOMES; EXPERIENCE; MORTALITY		Univ Nottingham, Sch Med, Queens Med Ctr, Div Rehabil & Ageing, Nottingham NG7 2UH, England; Cambridge Univ Hosp, Cambridge CB1 3DF, England; Univ Nottingham, Inst Study Genet Biorisks & Soc, Nottingham NG7 2RD, England; City Hosp Nottingham, Nottingham NG5 1PB, England	University of Nottingham; University of Cambridge; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital	Conroy, SP (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Div Rehabil & Ageing, Nottingham NG7 2UH, England.	simon.conroy@nottingham.ac.uk	Conroy, Simon/B-8832-2009; Dingwall, Robert WJ/A-9348-2008; Gladman, John/M-7429-2015	Dingwall, Robert WJ/0000-0002-1588-3796; Conroy, Simon/0000-0002-4306-6064; Harwood, Rowan/0000-0002-4920-6718; Gladman, John/0000-0002-8506-7786				APPLEBAUM GE, 1990, J AM GERIATR SOC, V38, P197, DOI 10.1111/j.1532-5415.1990.tb03490.x; Ballew KA, 1995, RESUSCITATION, V30, P203, DOI 10.1016/0300-9572(95)00894-2; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BEER RJ, 1994, RESUSCITATION, V27, P189, DOI 10.1016/0300-9572(94)90032-9; Benkendorf R, 1997, Prehosp Emerg Care, V1, P68, DOI 10.1080/10903129708958790; BILSKY GS, 1992, AM J PHYS MED REHAB, V71, P232, DOI 10.1097/00002060-199208000-00006; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Bowker L, 1999, RESUSCITATION, V40, P89, DOI 10.1016/S0300-9572(99)00008-8; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; De Maio VJ, 2001, ANN EMERG MED, V37, P602, DOI 10.1067/mem.2001.114302; de Vos R, 1999, ARCH INTERN MED, V159, P249, DOI 10.1001/archinte.159.3.249; *DEP HLTH, 2003, NAT DEF PROGR BACKGR; deVreedeSwagemakers JJM, 1997, J AM COLL CARDIOL, V30, P1500, DOI 10.1016/S0735-1097(97)00355-0; Diggory P, 2003, RESUSCITATION, V56, P159, DOI 10.1016/S0300-9572(02)00349-0; Ebell MH, 1998, J GEN INTERN MED, V13, P805, DOI 10.1046/j.1525-1497.1998.00244.x; Fitz Gerald JD, 1997, ARCH INTERN MED, V157, P72, DOI 10.1001/archinte.157.1.72; Gjerdingen DK, 1999, ARCH FAM MED, V8, P421, DOI 10.1001/archfami.8.5.421; Graves JR, 1997, RESUSCITATION, V35, P117; Herlitz J, 2005, CORONARY ARTERY DIS, V16, P51, DOI 10.1097/00019501-200502000-00010; Herlitz J, 2004, HEART, V90, P1114, DOI 10.1136/hrt.2003.029348; Kim C, 2000, ARCH INTERN MED, V160, P3439, DOI 10.1001/archinte.160.22.3439; Leung L P, 2001, Prehosp Emerg Care, V5, P308, DOI 10.1080/10903120190939887; Lim HC, 2001, RESUSCITATION, V51, P123, DOI 10.1016/S0300-9572(01)00399-9; LONGSTRETH WT, 1983, ANN INTERN MED, V98, P588, DOI 10.7326/0003-4819-98-5-588; Nichol G, 1999, ACAD EMERG MED, V6, P95, DOI 10.1111/j.1553-2712.1999.tb01044.x; O'Keeffe ST, 2001, AGE AGEING, V30, P19, DOI 10.1093/ageing/30.1.19; OBRIEN LA, 1995, JAMA-J AM MED ASSOC, V274, P1775, DOI 10.1001/jama.274.22.1775; OKEEFFE S, 1994, RESUSCITATION, V28, P21, DOI 10.1016/0300-9572(94)90050-7; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Pell JP, 2000, EUR HEART J, V21, P239, DOI 10.1053/euhj.1999.1629; *RES COUNC, 2001, DEC REL CARD RES JOI; Rothera IC, 2002, PUBLIC HEALTH, V116, P160, DOI 10.1038/sj.ph.190032; Stratton SJ, 1998, ANN EMERG MED, V32, P448, DOI 10.1016/S0196-0644(98)70174-X; TRESCH DD, 1993, AM J MED, V95, P123, DOI 10.1016/0002-9343(93)90252-K; Valentin A, 1995, RESUSCITATION, V30, P217, DOI 10.1016/0300-9572(95)00898-5	35	26	26	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 25	2006	332	7539					479	482		10.1136/bmj.332.7539.479	http://dx.doi.org/10.1136/bmj.332.7539.479			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018VM	16497767	Green Published			2023-01-03	WOS:000235792900023
J	Srivastava, R				Srivastava, R			Doctors need doctors too	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												docranjana@gmail.com							0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2006	295	8					866	867		10.1001/jama.295.8.866	http://dx.doi.org/10.1001/jama.295.8.866			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014DO	16493091				2023-01-03	WOS:000235459200001
J	Canter, PH; Coon, JT; Ernst, E				Canter, PH; Coon, JT; Ernst, E			Cost effectiveness of complementary treatments in the United Kingdom: systematic review	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; BACK-PAIN; MANIPULATION		Univ Exeter & Plymouth, Peninsula Med Sch, Exeter EX2 4NT, Devon, England	University of Exeter	Canter, PH (corresponding author), Univ Exeter & Plymouth, Peninsula Med Sch, Exeter EX2 4NT, Devon, England.	peter.canter@pms.ac.uk	Coon, Jo Thompson/C-7923-2017	Coon, Jo Thompson/0000-0002-5161-0234				Burton AK, 2000, EUR SPINE J, V9, P202, DOI 10.1007/s005869900113; Manca A, 2004, BMJ-BRIT MED J, V329, P1381, DOI 10.1136/bmj.38282.607859.AE; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; Williams NH, 2004, FAM PRACT, V21, P643, DOI 10.1093/fampra/cmh612; Wonderling D, 2004, BMJ-BRIT MED J, V328, P747, DOI 10.1136/bmj.38033.896505.EB	5	23	24	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 15	2005	331	7521					880	881		10.1136/bmj.38625.575903.79	http://dx.doi.org/10.1136/bmj.38625.575903.79			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975SX	16223821	Bronze, Green Published			2023-01-03	WOS:000232683300022
J	Campbell, AJ; Robertson, MC; La Grow, SJ; Kerse, NM; Sanderson, GF; Jacobs, RJ; Sharp, DM; Hale, LA				Campbell, AJ; Robertson, MC; La Grow, SJ; Kerse, NM; Sanderson, GF; Jacobs, RJ; Sharp, DM; Hale, LA			Randomised controlled trial of prevention of falls in people aged >= 75 with severe visual impairment: the VIP trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOME EXERCISE PROGRAM; OLDER-PEOPLE; RISK-FACTORS; MULTIFACTORIAL INTERVENTION; ECONOMIC-EVALUATION	Objectives To assess the efficacy and cost effectiveness of a home safety programme and a home exercise programme to reduce falls and injuries in older people with low vision. Design Randomised controlled trial. Setting Dunedin and Auckland, New Zealand. Participants 391 women and men aged >= 75 with visual acuity of 6/24 or worse who were living in the community; 92% (361 of 391) completed one year of follow-up. Interventions Participants received a home safety assessment and modification programme delivered by an occupational therapist (n=100), an exercise programme prescribed at home by a physiotherapist plus vitamin D supplementation (n=97), both interventions (n=98), or social visits (n=96). Main outcome measures Numbers of falls and injuries resulting from falls, costs of implementing the home safety programme. Results Fewer falls occurred in people randomised to the home safety programme but not in those randomised to the exercise programme (incidence rate ratios 0.59 (95% confidence interval 0.42 to 0.83) and 1.15 (0.82 to 1.61), respectively). However, within the exercise programme, stricter adherence was associated with fewer falls (P = 0.001). A conservative analysis showed neither intervention was effective in reducing injuries from falls. Delivering the home safety programme cost $NZ650 (234; pound $432; 344) (at 2004 prices) per fall prevented. Conclusion The home safety programme reduced falls and was more cost effective than an exercise programme in this group of elderly people with poor vision. The Otago exercise programme with vitamin D supplementation was not effective in reducing falls or injuries in this group, possibly due to low levels of adherence.	Univ Otago Sch Med, Dept Med & Surg Sci, Dunedin, New Zealand; Massey Univ, Sch Hlth Sci, Palmerston North, New Zealand; Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand; Univ Auckland, Dept Optometry & Vis Sci, Auckland 1, New Zealand; Auckland Hosp, Auckland, New Zealand; Univ Otago, Sch Physiotherapy, Dunedin, New Zealand	University of Otago; Massey University; University of Auckland; University of Auckland; Auckland City Hospital; University of Otago	Campbell, AJ (corresponding author), Univ Otago Sch Med, Dept Med & Surg Sci, Dunedin, New Zealand.	john.campbell@stonebow.otago.ac.nz	Robertson, Mary Clare/A-3964-2009; Hale, Leigh Anne/AFD-2919-2022; Kerse, Ngaire/AFF-8119-2022	Jacobs, Robert/0000-0001-6709-1785				*ACC COMP CORP, 2003, OT EX PROGR PREV FAL; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/j.1532-5415.1993.tb06708.x; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; Campbell AJ, 1999, J AM GERIATR SOC, V47, P850, DOI 10.1111/j.1532-5415.1999.tb03843.x; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; CLEMSON L, 1997, HOME FALL HAZARDS GU; CLEMSON L, 1997, HOME FULL HAZARDS GU; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; *CROWN CO MON ADV, 1999, HOSP HLTH SERV PERF; Cumming RG, 1999, J AM GERIATR SOC, V47, P1397, DOI 10.1111/j.1532-5415.1999.tb01556.x; Drummond M.F., 2015, METHODS EC EVALUATIO, V4; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; Guideline for the prevention of falls in older persons, 2001, J AM GERIATR SOC, V49, P664, DOI DOI 10.1046/J.1532-5415.2001.49115.X; Harwood RH, 2005, BRIT J OPHTHALMOL, V89, P53, DOI 10.1136/bjo.2004.049478; Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x; LORD SR, 1991, J AM GERIATR SOC, V39, P1194, DOI 10.1111/j.1532-5415.1991.tb03574.x; Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x; McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; *NHS NAT I CLIN EX, 2004, FALLS ASS PREV FALLS; Nikolaus T, 2003, J AM GERIATR SOC, V51, P300, DOI 10.1046/j.1532-5415.2003.51102.x; Robertson MC, 2005, J GERONTOL A-BIOL, V60, P530, DOI 10.1093/gerona/60.4.530; Robertson MC, 2002, J AM GERIATR SOC, V50, P905, DOI 10.1046/j.1532-5415.2002.50218.x; Robertson MC, 2001, BRIT MED J, V322, P697, DOI 10.1136/bmj.322.7288.697; Robertson MC, 2001, BRIT MED J, V322, P701, DOI 10.1136/bmj.322.7288.701; Shaw FE, 2003, BRIT MED J, V326, P73, DOI 10.1136/bmj.326.7380.73; Tinetti ME, 1996, AM J EPIDEMIOL, V144, P389; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301	29	246	248	0	48	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	2005	331	7520					817	820A		10.1136/bmj.38601.447731.55	http://dx.doi.org/10.1136/bmj.38601.447731.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974BC	16183652	Green Published, Bronze			2023-01-03	WOS:000232565300022
J	Tannsjo, T				Tannsjo, T			Moral dimensions	BRITISH MEDICAL JOURNAL			English	Editorial Material									Stockholm Univ, Dept Philosophy, S-10691 Stockholm, Sweden	Stockholm University	Tannsjo, T (corresponding author), Stockholm Univ, Dept Philosophy, S-10691 Stockholm, Sweden.	torbjorn.tannsjo@philosophy.su.se		Tannsjo, Torbjorn/0000-0001-9670-4608					0	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	SEP 24	2005	331	7518					689	691		10.1136/bmj.331.7518.689	http://dx.doi.org/10.1136/bmj.331.7518.689			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970HH	16179707	Green Published			2023-01-03	WOS:000232295400024
J	Hernandez, PJ; Kelley, AE				Hernandez, PJ; Kelley, AE			Cracking addiction the second time around: Reconsolidation of drug-related memories	NEURON			English	Editorial Material							COCAINE-SEEKING BEHAVIOR; ACCUMBENS CORE; REACTIVATION; ACTIVATION; RETRIEVAL; BRAIN; SHELL	One of the greatest challenges in the understanding and treatment of addiction is cue-elicited relapse to drug use. The present findings of Miller and Marshall and Lee et al. reported in this issue of Neuron demonstrate that retrieved drug-related memories undergo reconsolidation and thus suggest that these maladaptive associations may be more labile than previously thought.	Univ Wisconsin, Madison Med Sch, Dept Psychiat, Madison, WI 53719 USA; Univ Wisconsin, Madison Med Sch, Neurosci Training Program, Madison, WI 53719 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Hernandez, PJ (corresponding author), Univ Wisconsin, Madison Med Sch, Dept Psychiat, 6001 Res Pk Blvd, Madison, WI 53719 USA.							Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11; Dudai Y, 2004, NEURON, V44, P93, DOI 10.1016/j.neuron.2004.09.003; Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040; Ikemoto S, 2005, J NEUROSCI, V25, P5061, DOI 10.1523/JNEUROSCI.0892-05.2005; Ito R, 2004, NAT NEUROSCI, V7, P389, DOI 10.1038/nn1217; Lattal KM, 2004, P NATL ACAD SCI USA, V101, P4667, DOI 10.1073/pnas.0306546101; Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007; Milekic MH, 2002, NEURON, V36, P521, DOI 10.1016/S0896-6273(02)00976-5; Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006; MISANIN JR, 1968, SCIENCE, V160, P554, DOI 10.1126/science.160.3827.554; Nader K, 2003, TRENDS NEUROSCI, V26, P65, DOI 10.1016/S0166-2236(02)00042-5; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; ROUTTENBERG A, 1979, FED PROC, V38, P2446; STEWART J, 1984, PSYCHOL REV, V91, P251, DOI 10.1037/0033-295X.91.2.251; Thomas KL, 2003, EUR J NEUROSCI, V17, P1964, DOI 10.1046/j.1460-9568.2003.02617.x; Valjent E, 2000, J NEUROSCI, V20, P8701; Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533	17	12	12	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	SEP 15	2005	47	6					772	775		10.1016/j.neuron.2005.09.001	http://dx.doi.org/10.1016/j.neuron.2005.09.001			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	967IN	16157269	Bronze			2023-01-03	WOS:000232085000002
J	Bucaneve, G; Micozzi, A; Menichetti, F; Martino, P; Dionisi, MS; Martinelli, G; Allione, B; D'Antonio, D; Buelli, M; Nosari, AM; Cilloni, D; Zuffa, E; Cantaffa, R; Specchia, G; Amadori, S; Fabbiano, F; Deliliers, GL; Lauria, F; Foa, R; Del Favero, A				Bucaneve, G; Micozzi, A; Menichetti, F; Martino, P; Dionisi, MS; Martinelli, G; Allione, B; D'Antonio, D; Buelli, M; Nosari, AM; Cilloni, D; Zuffa, E; Cantaffa, R; Specchia, G; Amadori, S; Fabbiano, F; Deliliers, GL; Lauria, F; Foa, R; Del Favero, A		GIMEMA Infection Program	Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESISTANT ESCHERICHIA-COLI; PLACEBO-CONTROLLED TRIAL; HEMATOLOGIC MALIGNANCIES; DOUBLE-BLIND; ANTIMICROBIAL THERAPY; EMPIRIC THERAPY; PROPHYLAXIS; NORFLOXACIN; FEVER; GRANULOCYTOPENIA	BACKGROUND: The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is controversial and is not a recommended intervention. METHODS: We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resolution of neutropenia. Patients were stratified according to their underlying disease (acute leukemia vs. solid tumor or lymphoma). RESULTS: An intention-to-treat analysis showed that fever was present for the duration of neutropenia in 65 percent of patients who received levofloxacin prophylaxis, as compared with 85 percent of those receiving placebo (243 of 375 vs. 308 of 363; relative risk, 0.76; absolute difference in risk, -20 percent; 95 percent confidence interval, -26 to -14 percent; P=0.001). The levofloxacin group had a lower rate of microbiologically documented infections (absolute difference in risk, -17 percent; 95 percent confidence interval, -24 to -10 percent; P<0.001), bacteremias (difference in risk, -16 percent; 95 percent confidence interval, -22 to -9 percent; P<0.001), and single-agent gram-negative bacteremias (difference in risk, -7 percent; 95 percent confidence interval, -10 to -2 percent; P<0.01) than did the placebo group. Mortality and tolerability were similar in the two groups. The effects of prophylaxis were also similar between patients with acute leukemia and those with solid tumors or lymphoma. CONCLUSIONS: Prophylactic treatment with levofloxacin is an effective and well-tolerated way of preventing febrile episodes and other relevant infection-related outcomes in patients with cancer and profound and protracted neutropenia. The long-term effect of this intervention on microbial resistance in the community is not known.	Univ Perugia, Monteluce Policlin, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Univ Roma La Sapienza, Rome, Italy; Osped Cisanello, Pisa, Italy; Ist Europeo Oncol, Milan, Italy; Osped Santi Antonio & Biagio, Alessandria, Italy; Osped Civile Santo Spirito, Pescara, Italy; Osped Riuniti Bergamo, I-24100 Bergamo, Italy; Osped Niguarda Ca Granda, Milan, Italy; Osped San Luigi, Orbassano, Italy; Osped Santa Maria delle Croci, Ravenna, Italy; Azienda Osped Pugliese Ciaccio, Catanzaro, Italy; Univ Bari, Bari, Italy; Osped SantEugenio, Rome, Italy; Azienda Osped Cervello, Palermo, Italy; Osped Maggiore, Ist Ricovero & Cura Carattere Sci, Milan, Italy; Policlin Scotte, Siena, Italy	University of Perugia; Sapienza University Rome; IRCCS European Institute of Oncology (IEO); Azienda Ospedaliera SS Antonio Biagio Cesare Arrigo; Ospedali Riuniti di Bergamo; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Universita degli Studi di Bari Aldo Moro; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Siena	Del Favero, A (corresponding author), Univ Perugia, Monteluce Policlin, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy.	delfa@unipg.it	Specchia, Giorgina/K-3084-2016	Specchia, Giorgina/0000-0002-2479-9529; Amadori, Sergio/0000-0002-2356-8681				BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BODEY GP, 1978, CANCER, V41, P1610, DOI 10.1002/1097-0142(197804)41:4<1610::AID-CNCR2820410452>3.0.CO;2-B; CARRATALA J, 1995, CLIN INFECT DIS, V20, P557, DOI 10.1093/clinids/20.3.557; Cometta AF, 1996, ANTIMICROB AGENTS CH, V40, P1108, DOI 10.1128/AAC.40.5.1108; Cruciani M, 1996, CLIN INFECT DIS, V23, P795, DOI 10.1093/clinids/23.4.795; Del Favero A, 2001, CLIN INFECT DIS, V33, P1295, DOI 10.1086/322646; DELFAVERO A, 1991, ANN INTERN MED, V115, P7, DOI 10.7326/0003-4819-115-1-7; Engels EA, 1998, J CLIN ONCOL, V16, P1179, DOI 10.1200/JCO.1998.16.3.1179; Freifeld A, 1999, NEW ENGL J MED, V341, P305, DOI 10.1056/NEJM199907293410501; Gaya H, 1975, Eur J Cancer, V11suppl, P1; Hughes WT, 2002, CLIN INFECT DIS, V34, P730, DOI 10.1086/339215; KARP JE, 1987, ANN INTERN MED, V106, P1, DOI 10.7326/0003-4819-106-1-1; KERN WV, 1994, ANTIMICROB AGENTS CH, V38, P681, DOI 10.1128/AAC.38.4.681; Kern WV, 1999, NEW ENGL J MED, V341, P312, DOI 10.1056/NEJM199907293410502; LEW MA, 1991, TRANSPLANTATION, V51, P630, DOI 10.1097/00007890-199103000-00017; Martino R, 1998, ACTA HAEMATOL-BASEL, V99, P206, DOI 10.1159/000040840; *PFN 2003, 2003, NUOV PRONT FARM NAZ; Reuter S, 2005, CLIN INFECT DIS, V40, P1087, DOI 10.1086/428732; SOMOLINOS N, 1992, J ANTIMICROB CHEMOTH, V30, P730, DOI 10.1093/jac/30.5.730; TALBOT GH, 1993, ANTIMICROB AGENTS CH, V37, P474, DOI 10.1128/AAC.37.3.474; Tascini Carlo, 1999, Clin Microbiol Infect, V5, P457, DOI 10.1111/j.1469-0691.1999.tb00175.x; Viscoli C, 2002, EUR J CANCER, V38, pS82, DOI 10.1016/S0959-8049(01)00461-0	22	414	436	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 8	2005	353	10					977	987		10.1056/NEJMoa044097	http://dx.doi.org/10.1056/NEJMoa044097			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	961YQ	16148283	Bronze			2023-01-03	WOS:000231698200003
J	Drummond, AER; Pearson, B; Lincoln, NB; Berman, P				Drummond, AER; Pearson, B; Lincoln, NB; Berman, P			Ten year follow-up of a randomised controlled trial of care in a stroke rehabilitation unit	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Queens Med Ctr, Div Ageing & Rehabil, Nottingham NG7 2UH, England; Derbyshire Royal Infirm, Derby DE1 2QY, England; Univ Nottingham, Inst Work Hlth & Org, Nottingham NG7 2RQ, England; City Hosp, Nottingham NG5 1PB, England	University of Nottingham; University of Nottingham; University of Nottingham	Drummond, AER (corresponding author), Queens Med Ctr, Div Ageing & Rehabil, Nottingham NG7 2UH, England.	Avril.Drummond@nottingham.ac.uk	Lincoln, Nadina B/B-9149-2009	Drummond, Avril/0000-0003-1220-8354				Collin C, 1988, Int Disabil Stud, V10, P61; Indredavik B, 1999, STROKE, V30, P1524, DOI 10.1161/01.STR.30.8.1524; Juby LC, 1996, CEREBROVASC DIS, V6, P106, DOI 10.1159/000108005; Lincoln NB, 2000, BMJ-BRIT MED J, V320, P549, DOI 10.1136/bmj.320.7234.549; *STROK UN TRIAL CO, 1997, BMJ-BRIT MED J, V814, P1151	5	27	28	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	2005	331	7515					491	492		10.1136/bmj.38537.679479.E0	http://dx.doi.org/10.1136/bmj.38537.679479.E0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	963RA	16093255	Bronze, Green Published			2023-01-03	WOS:000231820400018
J	Green, J; Young, J; Forster, A; Mallinder, K; Bogle, S; Lowson, K; Small, N				Green, J; Young, J; Forster, A; Mallinder, K; Bogle, S; Lowson, K; Small, N			Effects of locality based community hospital care on independence in older people needing rehabilitation: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE; OXFORDSHIRE; SCALE; BEDS	Objective To determine the effects on independence in older people needing rehabilitation in a locality based community hospital compared with care on a ward for elderly people in a district general hospital. Design Randomised controlled trial. Setting Care in a community hospital and district general hospital in Bradford, England. Participants 220 patients needing rehabilitation after an acute illness that required hospital admission. Interventions Patients were randomly allocated to a locality based community hospital or to remain within a department for the care of elderly people in a district general hospital. Main outcome measures Primary outcomes were Nottingham extended activities of daily living scale and general health questionnaire 28 (carer). Secondary outcomes were activities of daily living (Barthel index), Nottingham health profile, hospital anxiety and depression scale, mortality, destination after discharge, satisfaction with services, carer strain index, and carer's satisfaction with services. Results The median length of stay was 15 days for both the community hospital and the district general hospital groups (interquartile range: community hospital 9-25 days; district general hospital 9-24 days). Independence at six months was greater in the community hospital group (adjusted mean difference 5.30, 95% confidence interval 0.64 to 9.96). Results for the secondary outcome measures, including care satisfaction and measures of carer burden, were similar for both groups. Conclusions Care in a locality based community hospital is associated with greater independence for older people than care in wards for elderly people in a district general hospital.	St Lukes Hosp, Dept Hlth Care Elderly, Bradford BD5 0NA, W Yorkshire, England; Aysgarth Stat, Beaconsfield HP9 2AS, England; Univ York, York Hlth Econ Consortium, York YO10 5NH, N Yorkshire, England; Univ Bradford, Sch Hlth Studies, Bradford BD5 0BB, W Yorkshire, England	University of York - UK; University of Bradford	Green, J (corresponding author), St Lukes Hosp, Dept Hlth Care Elderly, Bradford BD5 0NA, W Yorkshire, England.	becarrd.1@bradfordhospitals.nhs.uk		young, john/0000-0003-4085-9306; Forster, Anne/0000-0001-7466-4414				BAKER JE, 1986, J EPIDEMIOL COMMUN H, V40, P117, DOI 10.1136/jech.40.2.117; BROOK RH, 1992, JAMA-J AM MED ASSOC, V268, P1321, DOI 10.1001/jama.268.10.1321; Collin C, 1988, Int Disabil Stud, V10, P61; Cook PJ, 1998, AGE AGEING, V27, P357, DOI 10.1093/ageing/27.3.357; *DEP HLTH, 2001, INT CAR; *DEP HLTH, 2000, CM48181; Department of Health, 2001, NAT SERV FRAM OLD PE; Department of Health, 2000, CM4818 DEP HLTH; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Harwood RH, 2002, DISABIL REHABIL, V24, P371, DOI 10.1080/09638280110101541; Hine C, 1996, J ROY SOC MED, V89, P681, DOI 10.1177/014107689608901207; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Hunt SM, 1986, MEASURING HLTH STATU; MAHONEY F I, 1965, Md State Med J, V14, P61; McCormack B, 1993, Qual Health Care, V2, P253, DOI 10.1136/qshc.2.4.253; Nouri FMLN., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; POUND P, 1993, J EPIDEMIOL COMMUN H, V47, P500, DOI 10.1136/jech.47.6.500; POUND P, 1994, CLIN REHABIL, V8, P7, DOI DOI 10.1177/026921559400800102; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Shepperd S, 2001, COCHRANE DB SYST REV, V2, DOI [10.1002/14651858.CD000356, DOI 10.1002/14651858.CD000356]; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; Young J, 2005, HEALTH SOC CARE COMM, V13, P307, DOI 10.1111/j.1365-2524.2005.00555.x; Young J, 2001, AGE AGEING, V30, P7, DOI 10.1093/ageing/30.suppl_3.7; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	24	40	42	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	2005	331	7512					317	320		10.1136/bmj.38498.387569.8F	http://dx.doi.org/10.1136/bmj.38498.387569.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	955WZ	15994660	Bronze, Green Published			2023-01-03	WOS:000231259800013
J	Wright, AA; Katz, IT				Wright, AA; Katz, IT			Bar coding for patient safety	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADVERSE DRUG EVENTS; HOSPITALIZED-PATIENTS		Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Wright, AA (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.		Wright, Alexi/T-5793-2019	Katz, Ingrid/0000-0002-3014-238X				Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; POON EG, 2005, SOC GEN INT MED 28 A; Rothschild JM, 2005, CRIT CARE MED, V33, P533, DOI 10.1097/01.ccm.0000155912.73313.cd	5	38	39	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	2005	353	4					329	331		10.1056/NEJMp058101	http://dx.doi.org/10.1056/NEJMp058101			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	949JW	16049205				2023-01-03	WOS:000230782800001
J	von Plessen, C; Aslaksen, A				von Plessen, C; Aslaksen, A			Improving the quality of palliative care for ambulatory patients with lung cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Problem Most patients with advanced lung cancer currently receive much of their health care, including chemotherapy, as outpatients. Patients have to deal with the complex and time consuming logistics of ambulatory cancer care. At the same time, members of staff often waste considerable time and energy in organisational aspects of care that could be better used in direct interaction with patients. Design Quality improvement study using direct observation and run and flow charts, and focus group meetings with patients and families regarding perceptions of the clinic and with staff regarding satisfaction with working conditions. Setting Thoracic oncology outpatient clinic at a Norwegian university hospital where patients receive chemotherapy and complementary palliative care. Key measures for improvement Waiting time and time wasted during consultations; calmer working situation at the clinic; satisfaction among patients. Strategies for change Rescheduled patients' appointments, automated retrieval of blood test results, systematic reporting in patients' files, design of an information leaflet, and refurnishing of the waiting area at the clinic. Effects of change Interventions resulted in increased satisfaction for patients and staff, reduced waiting time, and reduced variability of waiting time. Lessons learnt Direct observation, focus groups, questionnaires on patients' satisfaction, and measurement of process time were useful in systematically improving care in this outpatient clinic. The description of this experience can serve as an example for the improvement of a microsystem, particularly in other settings with similar problems.	Haukeland Univ Hosp, Dept Thorac Med, N-5021 Bergen, Norway; Haukeland Univ Hosp, Dept Radiol, N-5021 Bergen, Norway	University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital	von Plessen, C (corresponding author), Haukeland Univ Hosp, Dept Thorac Med, N-5021 Bergen, Norway.	christian.von.plessen@helse-bergen.no	von Plessen, Christian/AFZ-7617-2022	von Plessen, Christian/0000-0002-6134-6780				Batalden P B, 1997, Qual Manag Health Care, V5, P1; Benson RJ, 2001, CLIN ONCOL-UK, V13, P138; Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5; KLEINER A, 1994, 5 DISCIPLINE FIELDBO, P479; Lock Karen K, 2002, Can J Nurs Res, V34, P83; Mitchell Geoff, 2002, Aust Fam Physician, V31, P129; Nelson EC, 1998, ANN INTERN MED, V128, P460, DOI 10.7326/0003-4819-128-6-199803150-00007; Nelson EC, 1996, JOINT COMM J QUAL IM, V22, P243, DOI 10.1016/S1070-3241(16)30228-0; Nelson Eugene C, 2002, Jt Comm J Qual Improv, V28, P472; Newell S, 1999, EUR J CANCER CARE, V8, P73; Zimber J, 2001, MMW Fortschr Med, V143, P22	11	17	17	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	2005	330	7503					1309	1313		10.1136/bmj.330.7503.1309	http://dx.doi.org/10.1136/bmj.330.7503.1309			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TL	15933354	Green Published			2023-01-03	WOS:000229655700025
J	Young, AER; Chambers, TL				Young, AER; Chambers, TL			Standards for care of critically ill children with burns	LANCET			English	Editorial Material									N Bristol NHS Trust, S W Paediat Burn Serv, Bristol BS16 1LE, Avon, England; N Bristol NHS Trust, Dept Paediat, Bristol BS16 1LE, Avon, England	North Bristol NHS Trust; North Bristol NHS Trust	Young, AER (corresponding author), N Bristol NHS Trust, S W Paediat Burn Serv, Bristol BS16 1LE, Avon, England.	Amber.Young@north-bristol.swest.nhs.uk	Young, Amber/H-2988-2018	Young, Amber/0000-0001-7205-492X				*DEP HLTH NHS EX H, 1997, PAED INT CAR FRAM FU; Frame JD, 2003, LANCET, V361, P980, DOI 10.1016/S0140-6736(03)12840-1; Kennedy I., 2001, REPORT PUBLIC INQUIR; National Service framework for Children, 2004, YOUNG PEOPL MAT SERV; Pearson G, 1997, LANCET, V349, P1213, DOI 10.1016/S0140-6736(96)12396-5; Radcliffe J, 1998, BRIT MED J, V316, P1547	6	1	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1911	1913		10.1016/S0140-6736(05)66639-1	http://dx.doi.org/10.1016/S0140-6736(05)66639-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936407				2023-01-03	WOS:000229587800008
J	Linde, K; Streng, A; Jurgens, S; Hoppe, A; Brinkhaus, B; Witt, C; Wagenpfeil, S; Pfaffenrath, V; Hammes, MG; Weidenhammer, W; Willich, SN; Melchart, D				Linde, K; Streng, A; Jurgens, S; Hoppe, A; Brinkhaus, B; Witt, C; Wagenpfeil, S; Pfaffenrath, V; Hammes, MG; Weidenhammer, W; Willich, SN; Melchart, D			Acupuncture for patients with migraine - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC HEADACHE; PLACEBO; PROPHYLAXIS; PREVALENCE	Context Acupuncture is widely used to prevent migraine attacks, but the available evidence of its benefit is scarce. Objective To investigate the effectiveness of acupuncture compared with sham acupuncture and with no acupuncture in patients with migraine. Design, Setting, and Patients Three-group, randomized, controlled trial (April 2002-January 2003) involving 302 patients (88% women), mean (SD) age of 43 (11) years, with migraine headaches, based on International Headache Society criteria. Patients were treated at 18 outpatient centers in Germany. Interventions Acupuncture, sham acupuncture, or waiting list control. Acupuncture and sham acupuncture were administered by specialized physicians and consisted of 12 sessions per patient over 8 weeks. Patients completed headache diaries from 4 weeks before to 12 weeks after randomization and from week 21 to 24 after randomization. Main Outcome Measures Difference in headache days of moderate or severe intensity between the 4 weeks before and weeks 9 to 12 after randomization. Results Between baseline and weeks 9 to 12, the mean (SD) number of days with headache of moderate or severe intensity decreased by 2.2 (2.7) days from a baseline of 5.2 (2.5) days in the acupuncture group compared with a decrease to 2.2 (2.7) days from a baseline of 5.0 (2.4) days in the sham acupuncture group, and by 0.8 (2.0) days from a baseline if 5.4 (3.0) days in the waiting list group. No difference was detected between the Acupuncture and the sham acupuncture groups (0.0 days, 95% confidence interval, -0.7 to 0.7 days; P=.96) while there was a difference between the acupuncture group compared with the waiting list group (1.4 days; 95% confidence interval; 0.8-2.1 days; P<.001). The proportion of responders (reduction in headache days by at least 50%) was 51 % in the acupuncture group, 53% in the sham acupuncture group, and 15% in the waiting list group. Conclusion Acupuncture was no more effective than sham acupuncture in reducing migraine headaches although both interventions were more effective than a waiting list control.	Tech Univ Munich, Dept Internal Med 2, Ctr Complementary Med Res, D-80801 Munich, Germany; Tech Univ Munich, Inst Med Stat & Epidemiol, D-80801 Munich, Germany; Tech Univ Munich, Dept Neurol, D-80801 Munich, Germany; Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; Univ Zurich Hosp, Dept Internal Med, Div Complementary Med, Zurich, Switzerland	Technical University of Munich; Technical University of Munich; Technical University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Zurich; University Zurich Hospital	Linde, K (corresponding author), Tech Univ Munich, Dept Internal Med 2, Ctr Complementary Med Res, Kaiserstr 9, D-80801 Munich, Germany.	Klaus.Linde@lrz.tu-muenchen.de	Streng, Andrea/AAR-4986-2020; Brinkhaus, Benno/AAU-2428-2021; Witt, Claudia M./AAX-2370-2021	Streng, Andrea/0000-0003-2377-7106; Brinkhaus, Benno/0000-0001-6290-744X; Witt, Claudia M./0000-0002-5440-7805; Linde, Klaus/0000-0002-2902-970X				Allais G, 2002, HEADACHE, V42, P855, DOI 10.1046/j.1526-4610.2002.02203.x; Brandes JL, 2004, JAMA-J AM MED ASSOC, V291, P965, DOI 10.1001/jama.291.8.965; Bullinger M, 1998, SF 36 FRAGEBOGEN ZUM; Diener HC, 2002, CEPHALALGIA, V22, P209, DOI 10.1046/j.1468-2982.2002.t01-1-00309.x; DIENER HC, 1997, DTSCH ARZTEBL, V94, pC2277; Dillmann U, 1994, Schmerz, V8, P100, DOI 10.1007/BF02530415; Geissner E, 1996, SCHMERZEMPFINDUNGSSK; Gray RN, 1999, DRUG TREATMENTS PREV; HAUYZINGER M, 1993, ALLGEMEINE DEPRESSIO; HESSE J, 1994, J INTERN MED, V235, P451, DOI 10.1111/j.1365-2796.1994.tb01102.x; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Irnich D, 2002, SCHMERZ, V16, P93, DOI 10.1007/s004820100094; JENA S, 2004, FOCUS ALTERNATIVE S, V9, P17; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; MACHIN D, 1997, PINOL APY SAMPLE SIZ; Melchart D, 1999, CEPHALALGIA, V19, P779, DOI 10.1046/j.1468-2982.1999.1909779.x; Melchart D, 2003, FORSCH KOMP KLAS NAT, V10, P179, DOI 10.1159/000073473; Melchart Dieter, 2004, Z Arztl Fortbild Qualitatssich, V98, P471; MOLSBERGER A, 2002, DTSCH ARZTEBL, V99, pA1819; Nagel B, 2002, SCHMERZ, V16, P263, DOI 10.1007/s00482-002-0162-1; Sandkuhler J, 1996, PROG NEUROBIOL, V50, P49; STEWART WF, 1994, NEUROLOGY, V44, P17; Tfelt-Hansen P, 2000, CEPHALALGIA, V20, P765; Vickers AJ, 2004, BRIT MED J, V328, P744, DOI 10.1136/bmj.38029.421863.EB; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; Walach H, 2004, J ALTERN COMPLEM MED, V10, pS103; Welch KMA, 1997, CEPHALALGIA, V17, P1, DOI 10.1046/j.1468-2982.1997.1701001.x; Wonderling D, 2004, BMJ-BRIT MED J, V328, P747, DOI 10.1136/bmj.38033.896505.EB	30	424	490	8	116	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	2005	293	17					2118	2125		10.1001/jama.293.17.2118	http://dx.doi.org/10.1001/jama.293.17.2118			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	922AO	15870415	Bronze			2023-01-03	WOS:000228808200021
J	Chamberlain, P				Chamberlain, P			Death after withdrawal of nutrition and hydration	LANCET			English	Editorial Material							RIGHT-TO-DIE		John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England	University of Oxford	Chamberlain, P (corresponding author), John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.	paul.chamberlain@obs-gyn.ox.ac.uk						GOVE M, 2005, TIMES LONDON    0329, P18; *IR MED COUNC, 1995, IR MED COUNC STAT; JENNETT B, 2002, VEGETATIVE STATE MED; MURDOCH A, 1995, BRIT MED J, V311, P405; SHERWELL P, 2005, SUNDAY TELEGRAP 0327, P17; WALL M, 1995, LANCET, V346, P368, DOI 10.1016/S0140-6736(95)92243-1	6	9	9	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 23	2005	365	9469					1446	1447		10.1016/S0140-6736(05)66397-0	http://dx.doi.org/10.1016/S0140-6736(05)66397-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	919XT	15850616				2023-01-03	WOS:000228651600007
J	Srivastava, D; Ivey, KN				Srivastava, D; Ivey, KN			Potential of stem-cell-based therapies for heart disease	NATURE			English	Article							RANDOMIZED CONTROLLED-TRIAL; MYOCARDIAL REGENERATION; INFARCTED MYOCARDIUM; DIFFERENTIATION; EXPRESSION; SURVIVAL; FUSION; MIGRATION; MESODERM; REPAIR	The use of stem cells to generate replacement cells for damaged heart muscle, valves, vessels and conduction cells holds great potential. Recent identification of multipotent progenitor cells in the heart and improved understanding of developmental processes relevant to pluripotent embryonic stem cells may facilitate the generation of specific types of cell that can be used to treat human heart disease. Secreted factors from circulating progenitor cells that localize to sites of damage may also be useful for tissue protection or neovascularization. The exciting discoveries in basic science will require rigorous testing in animal models to determine those most worthy of future clinical trials.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Srivastava, D (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, 1650 Owens St, San Francisco, CA 94158 USA.	dsrivastava@Gladstone.ucsf.edu						*AM HEART ASS, 2004, HEART DIS STROK STAT, P11; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Brambrink T, 2006, P NATL ACAD SCI USA, V103, P933, DOI 10.1073/pnas.0510485103; Buckingham M, 2005, NAT REV GENET, V6, P826, DOI 10.1038/nrg1710; Cai CL, 2003, DEV CELL, V5, P877, DOI 10.1016/S1534-5807(03)00363-0; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; Ding S, 2004, NAT BIOTECHNOL, V22, P833, DOI 10.1038/nbt987; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Grant D S, 1999, Angiogenesis, V3, P125, DOI 10.1023/A:1009041911493; Janssens S, 2006, LANCET, V367, P113, DOI 10.1016/S0140-6736(05)67861-0; Kitajima S, 2000, DEVELOPMENT, V127, P3215; Kwon C, 2005, P NATL ACAD SCI USA, V102, P18986, DOI 10.1073/pnas.0509535102; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215; Leri A, 2005, PHYSIOL REV, V85, P1373, DOI 10.1152/physrev.00013.2005; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Martin CM, 2004, DEV BIOL, V265, P262, DOI 10.1016/j.ydbio.2003.09.028; Menasche P, 2003, J AM COLL CARDIOL, V41, P1078, DOI 10.1016/S0735-1097(03)00092-5; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pal R, 2006, STEM CELLS DEV, V15, P29, DOI 10.1089/scd.2006.15.29; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; Shim WSN, 2004, BIOCHEM BIOPH RES CO, V324, P481, DOI 10.1016/j.bbrc.2004.09.087; Silva WA, 2003, STEM CELLS, V21, P661, DOI 10.1634/stemcells.21-6-661; Urbanek K, 2005, CIRC RES, V97, P663, DOI 10.1161/01.RES.0000183733.53101.11; Wilson V, 1997, DEV BIOL, V192, P45, DOI 10.1006/dbio.1997.8701; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817; Zohlnhofer D, 2006, JAMA-J AM MED ASSOC, V295, P1003, DOI 10.1001/jama.295.9.1003	35	109	122	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2006	441	7097					1097	1099		10.1038/nature04961	http://dx.doi.org/10.1038/nature04961			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	057SM	16810246				2023-01-03	WOS:000238615500038
J	George, A; Tokars, JI; Clutterbuck, EJ; Bamford, KB; Pusey, C; Holmes, AH				George, Abraham; Tokars, Jerome I.; Clutterbuck, Elaine J.; Bamford, Kathleen B.; Pusey, Charles; Holmes, Alison H.			Quality improvement report - Reducing dialysis associated bacteraemia, and recommendations for surveillance in the United Kingdom: prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEMODIALYSIS; INFECTIONS; MORTALITY	Problem Bacteraemia in dialysis units accounts for major morbidity, mortality and antibiotic usage. Risk is much greater when lines rather than fistulas are used for haemodialysis. Surveillance is critical for infection control, but no standardised surveillance scheme exists in die United Kingdom. Design Prospective study in a London dialysis unit of the implementation and applicability of a dialysis associated bacteraemia surveillance scheme developed in the United States and its effect on bacteraemia, antibiotic usage, and admission. Setting Hammersmith Hospital dialysis unit, London, where 112 outpatients receive dialysis three times weekly. Between June 2002 and December 2004, 3418 patient months of data were collected. Key measures for improvement Successful adoption of the scheme and reductions in bacteraemia rates, antibiotic usage, and admission to hospital. Strategy for improvement Embedding the surveillance scheme in the unit's clinical activity. Effects of change Raised awareness of bacteraemia prevention, prudent antibiotic prescribing, and the need for improved provision of vascular access. The scheme required two hours a month of consultant time. Significant downward trends were seen in bacteraemia rates and antibiotic usage: mean rate ratios from quarter to quarter 0.90 (95% confidence interval 0.85 to 0.94) and 0.91 (0.87 to 0.96), respectively The rate of admission to hospital also showed a significant downward trend, with admissions directly connected to access related infection declining more rapidly: mean rate ratio Of Successive quarters 0.90 (0.84 to 0.96).The overall proportion of patients dialysed through catheters was significantly higher than in US outpatient centres (62.3% v 29.4%, P < 0.01). Study data were successfully, used in a business case to improve access provision. Lessons learnt Dialysis specific surveillance of bacteraemia is critical to infection control in dialysis units and improving quality of care. Such a scheme could be adopted across the United Kingdom.	Imperial Coll London, Dept Infect Dis, London W12 0NN, England; Hammersmith Hosp NHS Trust, Renal Unit, London, England; Ctr Dis Control & Prevent, Atlanta, GA USA	Imperial College London; Imperial College London; Centers for Disease Control & Prevention - USA	Holmes, AH (corresponding author), Imperial Coll London, Dept Infect Dis, London W12 0NN, England.	alison.holmes@imperial.ac.uk						[Anonymous], 2000, KDOQI CLIN PRACT GUI; [Anonymous], 2002, MMWR-MORBID MORTAL W, V51, P565; BLOEMBERGEN WE, 1995, J AM SOC NEPHROL, V6, P184; Briggs JD, 1997, NEPHROL DIAL TRANSPL, V12, P2251, DOI 10.1093/ndt/12.11.2251; CHURCHILL DN, 1992, AM J KIDNEY DIS, V19, P214, DOI 10.1016/S0272-6386(13)80002-9; Dhingra RK, 2001, KIDNEY INT, V60, P1443, DOI 10.1046/j.1523-1755.2001.00947.x; Duckworth G, 2005, BRIT MED J, V331, P976, DOI 10.1136/bmj.331.7523.976; DUCKWORTH G, 2005, BRIT MED J, V351, P976; GREENWOOD RN, 2002, KIDNEY INT, V61, P305; Hugonnet S, 2004, CURR OPIN INFECT DIS, V17, P329, DOI 10.1097/01.qco.0000136931.83167.d2; *NAT AUD OFF, 2004, IMPR PAT RAR RED RIS; *NIH, 2003, USRDS2003 DAT REP AT, P161; *NIT, 2003, USRDS2003 ANN DAT RE, P161; RADY AR, 1997, TRANSPLANT P, V29, P8724; Rayner HC, 2004, NEPHROL DIAL TRANSPL, V19, P108, DOI 10.1093/ndt/gfg483; *REN ASS, 2002, TREATM AD CHILDR REN; RODERICK PJ, 1994, BMJ-BRIT MED J, V300, P1111; SCHWAB SJ, 1988, AM J KIDNEY DIS, V11, P166, DOI 10.1016/S0272-6386(88)80206-3; Taylor G, 2002, INFECT CONT HOSP EP, V23, P716, DOI 10.1086/501999; Tokars JI, 2002, AM J INFECT CONTROL, V30, P288, DOI 10.1067/mic.2002.120904; *UK DEP HLTH, 2004, NAT SERV FRAM REN 1; *UK NAT AUD OFF, 2003, IMPR PAT CAR RED RIS; UNLEY AH, 1989, EPIDEMIOL INFECT, V103, P173; UTTLEY AHC, 1989, EPIDEMIOL INFECT, V103, P173, DOI 10.1017/S0950268800030478	24	35	38	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 17	2006	332	7555					1435	1437		10.1136/bmj.332.7555.1435	http://dx.doi.org/10.1136/bmj.332.7555.1435			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	056UO	16777887	Green Published			2023-01-03	WOS:000238550800034
J	Loeb, M; Carusone, SC; Goeree, R; Walter, SD; Brazil, K; Krueger, P; Simor, A; Moss, L; Marrie, T				Loeb, Mark; Carusone, Soo Chan; Goeree, Ron; Walter, Stephen D.; Brazil, Kevin; Krueger, Paul; Simor, Andrew; Moss, Lorraine; Marrie, Thomas			Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; TERM-CARE FACILITIES; RISK-FACTORS; INFECTIONS; OUTCOMES; SURVEILLANCE; DEFINITIONS; SURVIVAL; CLUSTER	Context Nursing home residents with pneumonia are frequently hospitalized. Such transfers may be associated with multiple hazards of hospitalization as well as economic costs. Objective To assess whether using a clinical pathway for on-site treatment of pneumonia and other lower respiratory tract infections in nursing homes could reduce hospital admissions, related complications, and costs. Design, Setting, and Participants A cluster randomized controlled trial of 680 residents aged 65 years or older in 22 nursing homes in Hamilton, Ontario, Canada. Nursing homes began enrollment between January 2, 2001, and April 18, 2002, with the last resident follow-up occurring July 4, 2005. Residents were eligible if they met a standardized definition of lower respiratory tract infection. Interventions Treatment in nursing homes according to a clinical pathway, which included use of oral antimicrobials, portable chest radiographs, oxygen saturation monitoring, rehydration, and close monitoring by a research nurse, or usual care. Main Outcome Measures Hospital admissions, length of hospital stay, mortality, health-related quality of life, functional status, and cost. Results Thirty-four (10%) of 327 residents in the clinical pathway group were hospitalized compared with 76 (22%) of 353 residents in the usual care group. Adjusting for clustering of residents in nursing homes, the weighted mean reduction in hospitalizations was 12% (95% confidence interval [CI], 5%-18%; P=.001). The mean number of hospital days per resident was 0.79 in the clinical pathway group vs 1.74 in the usual care group, with a weighted mean difference of 0.95 days per resident ( 95% CI, 0.34-1.55 days; P=.004). The mortality rate was 8% ( 24 deaths) in the clinical pathway group vs 9% ( 32 deaths) in the usual care group, with a weighted mean difference of 2.9% ( 95% CI, - 2.0% to 7.9%; P=.23). There were no significant differences between the groups in health-related quality of life or functional status. The clinical pathway resulted in an overall cost savings of US $1016 per resident ( 95% CI, $207$ 1824) treated. Conclusion Treating residents of nursing homes with pneumonia and other lower respiratory tract infections with a clinical pathway can result in comparable clinical outcomes, while reducing hospitalizations and health care costs.	McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Microbiol, Toronto, ON, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada	McMaster University; McMaster University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Alberta	Loeb, M (corresponding author), McMaster Univ, Dept Pathol, 1200 Main St W,MDCL 3200, Hamilton, ON L8N 3Z5, Canada.	loebm@mcmaster.ca	Walter, Stephen/AAB-5548-2022	Walter, Stephen/0000-0003-4157-8928; Chan Carusone, Soo/0000-0003-3977-0523				Allard JP, 2004, J AM GERIATR SOC, V52, P59, DOI 10.1111/j.1532-5415.2004.52011.x; BERGMAN H, 1991, J AM GERIATR SOC, V39, P1164, DOI 10.1111/j.1532-5415.1991.tb03568.x; Boockvar KS, 2005, J AM GERIATR SOC, V53, P590, DOI 10.1111/j.1532-5415.2005.53205.x; Centers for Medicare & Medicaid Services, PHYS FEE SCHED; Collin C, 1988, Int Disabil Stud, V10, P61; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Dasgupta M, 2000, J AM GERIATR SOC, V48, P795, DOI 10.1111/j.1532-5415.2000.tb04755.x; DEMPSEY CL, 1995, PHARMACOTHERAPY, V15, pS33; Ellis SE, 2003, J AM GERIATR SOC, V51, P761, DOI 10.1046/j.1365-2389.2003.51254.x; Fried TR, 1997, J AM GERIATR SOC, V45, P302, DOI 10.1111/j.1532-5415.1997.tb00944.x; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gill TM, 2004, JAMA-J AM MED ASSOC, V292, P2115, DOI 10.1001/jama.292.17.2115; Halm EA, 1998, JAMA-J AM MED ASSOC, V279, P1452, DOI 10.1001/jama.279.18.1452; HSIEH FY, 1988, STAT MED, V7, P1195, DOI 10.1002/sim.4780071113; JACKSON MM, 1992, AM J EPIDEMIOL, V135, P685, DOI 10.1093/oxfordjournals.aje.a116348; JONES A, 2002, VITAL HLTH STAT, V152, P1; KAYSERJONES JS, 1989, GERONTOLOGIST, V29, P502, DOI 10.1093/geront/29.4.502; KERR HD, 1991, J AM GERIATR SOC, V39, P132, DOI 10.1111/j.1532-5415.1991.tb01614.x; Kerry SM, 2001, STAT MED, V20, P377, DOI 10.1002/1097-0258(20010215)20:3<377::AID-SIM799>3.0.CO;2-N; Kruse RL, 2004, MED CARE, V42, P860, DOI 10.1097/01.mlr.0000135828.95415.b1; Loeb M, 1999, ARCH INTERN MED, V159, P2058, DOI 10.1001/archinte.159.17.2058; Loeb M, 2001, J GEN INTERN MED, V16, P376, DOI 10.1046/j.1525-1497.2001.016006376.x; Mandell L A, 2000, Can Respir J, V7, P371; Marrie TJ, 2002, INFECT CONT HOSP EP, V23, P159, DOI 10.1086/502030; Marrie TJ, 2000, JAMA-J AM MED ASSOC, V283, P749, DOI 10.1001/jama.283.6.749; MCGEER A, 1991, AM J INFECT CONTROL, V19, P1, DOI 10.1016/0196-6553(91)90154-5; Muder RR, 1998, AM J MED, V105, P319, DOI 10.1016/S0002-9343(98)00262-9; Muder RR, 1996, ARCH INTERN MED, V156, P2365, DOI 10.1001/archinte.156.20.2365; Naughton BJ, 2000, J AM GERIATR SOC, V48, P1292, DOI 10.1111/j.1532-5415.2000.tb02604.x; *OCCI, ONT CAS COST IN WEB; Samsa GP, 2005, CHEST, V128, P3246, DOI 10.1378/chest.128.5.3246; Scanlan A, 1996, MED CARE, V34, P837, DOI 10.1097/00005650-199608000-00010; *STAT CAN, RES CAR FAC SURV; TERESI JA, 1991, GERONTOLOGIST, V31, P795, DOI 10.1093/geront/31.6.795; Thompson R S, 1997, J Am Board Fam Pract, V10, P82; Wiener J, 1999, JAMA-J AM MED ASSOC, V281, P517, DOI 10.1001/jama.281.6.517; Wodchis WP, 2003, INT J TECHNOL ASSESS, V19, P490; WUNDERLICH GS, 2000, IMPROVING QUALITY LO	38	188	192	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	2006	295	21					2503	2510		10.1001/jama.295.21.2503	http://dx.doi.org/10.1001/jama.295.21.2503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	049ZQ	16757722	Bronze			2023-01-03	WOS:000238057300025
J	Zohlnhofer, D; Ott, I; Mehilli, J; Schoming, K; Michalk, F; Ibrahim, T; Meisetschlager, G; von Wedel, J; Bollwein, H; Seyfarth, M; Dirschinger, J; Schmitt, C; Schwaiger, M; Kastrati, A; Schomig, A				Zohlnhofer, D; Ott, I; Mehilli, J; Schoming, K; Michalk, F; Ibrahim, T; Meisetschlager, G; von Wedel, J; Bollwein, H; Seyfarth, M; Dirschinger, J; Schmitt, C; Schwaiger, M; Kastrati, A; Schomig, A		REVIVAL-2 Investigators	Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENDOTHELIAL PROGENITOR CELLS; PERIPHERAL-BLOOD; CARDIAC MYOCYTES; REPAIR; REGENERATION; GROWTH; HEART; NEOVASCULARIZATION; TRANSPLANTATION; RECOVERY	Context Experimental studies and early phase clinical trials suggest that transplantation of blood-derived or bone marrow - derived stem cells may improve cardiac regeneration and neovascularization after acute myocardial infarction. Granulocyte colony-stimulating factor (G-CSF) induces mobilization of bone marrow stem cells. Objective To assess the value of stem cell mobilization by G-CSF therapy in patients with acute myocardial infarction. Design, Setting, and Patients Randomized, double-blind, placebo-controlled trial of patients diagnosed with ST-segment elevation acute myocardial infarction who had successful reperfusion by percutaneous coronary intervention within 12 hours after onset of symptoms in Germany between February 24, 2004, and February 2, 2005. Interventions Patients were randomly assigned to receive subcutaneously either a daily dose of 10 mu g/kg of G-CSF or placebo for 5 days. Main Outcome Measures The primary end point was reduction of left ventricular infarct size according to technetium Tc 99m sestamibi scintigraphy performed at baseline and at 4 to 6 months after randomization. Secondary end points included improvement of left ventricular ejection fraction measured by magnetic resonance imaging and the incidence of angiographic restenosis. Results Of the 114 patients, 56 were assigned to receive treatment with G-CSF and 58 were assigned to receive placebo. Treatment with G-CSF produced a significant mobilization of stem cells. Between baseline and follow-up, left ventricular infarct size according to scintigraphy was reduced by a mean (SD) of 6.2% (9.1%) in the G-CSF group and 4.9% (8.9%) in the placebo group (P=. 56) and left ventricular ejection fraction was improved by 0.5% (3.8%) in the G-CSF group and 2.0% ( 4.9%) in the placebo group ( P=. 14). Angiographic restenosis occurred in 19 (35.2%) of 54 patients in the G-CSF group and in 17 (30.9%) of 55 patients in the placebo group ( P=. 79). The most common adverse event among patients assigned to G-CSF was mild to moderate bone pain and muscle discomfort. Conclusion Stem cell mobilization by G-CSF therapy in patients with acute myocardial infarction and successful mechanical reperfusion has no influence on infarct size, left ventricular function, or coronary restenosis. Clinical Trial Registration ClinicalTrials. gov Identifier: NCT00126100.	Tech Univ Munich, Deutsch Herzzentrum, D-80636 Munich, Germany; Tech Univ Munich, Med Klin 1, Klinikum Rechts Isar, D-80636 Munich, Germany; Tech Univ Munich, Nukl Med Klin & Poliklin Rechts Isar, D-80636 Munich, Germany	German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich	Schomig, A (corresponding author), Tech Univ Munich, Deutsch Herzzentrum, Lazarettstr 36, D-80636 Munich, Germany.	aschoemig@dhm.mhn.de	Mehilli, Julinda/F-2629-2016; , Kastrati/Y-2389-2019	schwaiger, markus/0000-0002-2305-7144				Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Barnett D, 2000, BRIT J HAEMATOL, V108, P784, DOI 10.1046/j.1365-2141.2000.01932.x; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Carion A, 2002, J HEMATOTH STEM CELL, V11, P491, DOI 10.1089/15258160260090951; Dimmeler S, 2005, J CLIN INVEST, V115, P572, DOI 10.1172/JCI200524283; Dlubek D, 2006, BONE MARROW TRANSPL, V37, P19, DOI 10.1038/sj.bmt.1705198; ELLIS SG, 1983, J AM COLL CARDIOL, V1, P1047, DOI 10.1016/S0735-1097(83)80107-7; Forrester JS, 2003, CIRCULATION, V108, P1139, DOI 10.1161/01.CIR.0000085305.82019.65; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; Heil M, 2004, CIRC RES, V94, P573, DOI 10.1161/01.RES.0000124603.46777.EB; Hill JM, 2005, J AM COLL CARDIOL, V46, P1643, DOI 10.1016/j.jacc.2005.01.067; Hubel K, 2003, ANN HEMATOL, V82, P207, DOI 10.1007/s00277-003-0628-y; Ince H, 2005, CIRCULATION, V112, P3097, DOI 10.1161/CIRCULATIONAHA.105.541433; Janssens S, 2006, LANCET, V367, P113, DOI 10.1016/S0140-6736(05)67861-0; Kajstura J, 2005, CIRC RES, V96, P127, DOI 10.1161/01.RES.0000151843.79801.60; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kastrati A, 2002, LANCET, V359, P920, DOI 10.1016/S0140-6736(02)08022-4; Kawamoto A, 2004, CIRCULATION, V110, P1398, DOI 10.1161/01.CIR.0000141563.71410.64; KLONER RA, 1989, AM J MED, V86, P14, DOI 10.1016/0002-9343(89)90005-3; KLONER RA, 1991, NEW ENGL J MED, V325, P1877, DOI 10.1056/NEJM199112263252610; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Krause DS, 1996, BLOOD, V87, P1; Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215; Leone AM, 2005, EUR HEART J, V26, P1196, DOI 10.1093/eurheartj/ehi164; Leri A, 2005, PHYSIOL REV, V85, P1373, DOI 10.1152/physrev.00013.2005; Massa M, 2005, BLOOD, V105, P199, DOI 10.1182/blood-2004-05-1831; Mathur A, 2004, LANCET, V364, P183, DOI 10.1016/S0140-6736(04)16632-4; Minatoguchi S, 2004, CIRCULATION, V109, P2572, DOI 10.1161/01.CIR.0000129770.93985.3E; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Ohki Y, 2005, FASEB J, V19, P2005, DOI 10.1096/fj.04-3496fje; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; PATEL B, 1988, ANN INTERN MED, V108, P626, DOI 10.7326/0003-4819-108-4-626; SCHACHINGER V, INTRACORONARY INFUSI; Schomig A, 2000, NEW ENGL J MED, V343, P385, DOI 10.1056/NEJM200008103430602; Schomig A, 2005, JAMA-J AM MED ASSOC, V293, P2865, DOI 10.1001/jama.293.23.2865; SCHOMIG K, IN PRESS EUR HEART J; Sesti C, 2005, J AM COLL CARDIOL, V46, P1662, DOI 10.1016/j.jacc.2005.08.012; SHEEHAN FH, 1985, CIRCULATION, V71, P1121, DOI 10.1161/01.CIR.71.6.1121; Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Sugano Y, 2005, CARDIOVASC RES, V65, P446, DOI 10.1016/j.cardiores.2004.10.008; Valgimigli M, 2005, EUR HEART J, V26, P1838, DOI 10.1093/eurheartj/ehi289; Wojakowski W, 2006, EUR HEART J, V27, P283, DOI 10.1093/eurheartj/ehi628; Wojakowski W, 2004, CIRCULATION, V110, P3213, DOI 10.1161/01.CIR.0000147609.39780.02; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9	48	340	359	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2006	295	9					1003	1010		10.1001/jama.295.9.1003	http://dx.doi.org/10.1001/jama.295.9.1003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016XJ	16507801	Bronze			2023-01-03	WOS:000235656600020
J	Smith, IE; Chua, S				Smith, IE; Chua, S			ABC of breast diseases - Medical treatment of early breast cancer. IV: neoadjuvant treatment	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Marsden Hosp, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Smith, IE (corresponding author), Royal Marsden Hosp, London SW3 6JJ, England.								0	12	12	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 28	2006	332	7535					223	224		10.1136/bmj.332.7535.223	http://dx.doi.org/10.1136/bmj.332.7535.223			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009BU	16439402	Green Published			2023-01-03	WOS:000235086900022
J	Romond, EH; Perez, EA; Bryant, J; Suman, VJ; Geyer, CE; Davidson, NE; Tan-Chiu, E; Martino, S; Paik, S; Kaufman, PA; Swain, SM; Pisansky, TM; Fehrenbacher, L; Kutteh, LA; Vogel, VG; Visscher, DW; Yothers, G; Jenkins, RB; Brown, AM; Dakhil, SR; Mamounas, EP; Lingle, WL; Klein, PM; Ingle, JN; Wolmark, N				Romond, EH; Perez, EA; Bryant, J; Suman, VJ; Geyer, CE; Davidson, NE; Tan-Chiu, E; Martino, S; Paik, S; Kaufman, PA; Swain, SM; Pisansky, TM; Fehrenbacher, L; Kutteh, LA; Vogel, VG; Visscher, DW; Yothers, G; Jenkins, RB; Brown, AM; Dakhil, SR; Mamounas, EP; Lingle, WL; Klein, PM; Ingle, JN; Wolmark, N			Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METASTASES; TRIAL; WOMEN; HER2	BACKGROUND: We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer. METHODS: The National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin and cyclophosphamide followed by paclitaxel every 3 weeks (group 1) with the same regimen plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel (group 2). The North Central Cancer Treatment Group trial N9831 compared three regimens: doxorubicin and cyclophosphamide followed by weekly paclitaxel (group A), the same regimen followed by 52 weeks of trastuzumab after paclitaxel (group B), and the same regimen plus 52 weeks of trastuzumab initiated concomitantly with paclitaxel (group C). The studies were amended to include a joint analysis comparing groups 1 and A (the control group) with groups 2 and C (the trastuzumab group). Group B was excluded because trastuzumab was not given concurrently with paclitaxel. RESULTS: By March 15, 2005, 394 events (recurrent, second primary cancer, or death before recurrence) had been reported, triggering the first scheduled interim analysis. Of these, 133 were in the trastuzumab group and 261 in the control group (hazard ratio, 0.48; P<0.0001). This result crossed the early stopping boundary. The absolute difference in disease-free survival between the trastuzumab group and the control group was 12 percent at three years. Trastuzumab therapy was associated with a 33 percent reduction in the risk of death (P=0.015). The three-year cumulative incidence of class III or IV congestive heart failure or death from cardiac causes in the trastuzumab group was 4.1 percent in trial B-31 and 2.9 percent in trial N9831. CONCLUSIONS: Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.	Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA; Univ Kentucky, Lexington, KY USA; N Cent Canc Treatment Grp, Rochester, MN USA; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; Mayo Clin, Rochester, MN USA; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; Canc Res Network, Plantation, FL USA; Angeles Clin & Res Inst, Santa Monica, CA USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA; NCI, Canc Therapeut Branch, Bethesda, MD 20892 USA; Kaiser Permanente Med Ctr No Calif, Vallejo, CA USA; Oncol Associates Cedar Rapids, Cedar Rapids, IA USA; Wichita Community Clin Oncol Program, Wichita, KS USA; Aultman Hlth Fdn, Canton, OH USA; Genentech Inc, San Francisco, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; University of Kentucky; Mayo Clinic; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Mayo Clinic; Allegheny General Hospital; Johns Hopkins University; Johns Hopkins Medicine; Angeles Clinic & Research Institute; Dartmouth College; Norris Cotton Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kaiser Permanente; Roche Holding; Genentech	Geyer, CE (corresponding author), Allegheny Canc Ctr, 5th Fl,320 E North Ave, Pittsburgh, PA 15212 USA.	cgeyer@wpahs.org	Geyer, Charles/AGY-0119-2022	Geyer, Charles/0000-0002-2379-5702; Paik, Soonmyung/0000-0001-9688-6480; Swain, Sandra/0000-0002-1320-3830; Yothers, Greg/0000-0002-7965-7333	NATIONAL CANCER INSTITUTE [U10CA037377, U10CA012027, U10CA069651, U10CA031946, U10CA025224, U10CA069974, U10CA021115, U10CA032102] Funding Source: NIH RePORTER; NCI NIH HHS [U10-CA-25224, U10-CA-12027, U10-CA-69974, U10-CA-69651, U10-CA-37377, U10-CA-32102, U10-CA-021115, U10-CA-31946] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albain KS, 2002, P AN M AM SOC CLIN, V21, p37a; Baum M, 2002, LANCET, V359, P2131; Baum M, 2002, LANCET, V360, P1520; Bendell JC, 2003, CANCER-AM CANCER SOC, V97, P2972, DOI 10.1002/cncr.11436; CHIU ET, IN PRESS J CLIN ONCO; Clayton AJ, 2004, BRIT J CANCER, V91, P639, DOI 10.1038/sj.bjc.6601970; EWER MS, 2002, P AN M AM SOC CLIN, V21, pA123; Lewis S, 2001, BMJ-BRIT MED J, V322, P1479, DOI 10.1136/bmj.322.7300.1479; Lin NU, 2004, J CLIN ONCOL, V22, P3608, DOI 10.1200/JCO.2004.01.175; Paik S, 2000, J NATL CANCER I, V92, P1991, DOI 10.1093/jnci/92.24.1991; PEREZ EA, HER2 TESTING LOCAL C; PICCARTGEBHART M, RANDOMIZED 3 GROUP M; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Seidman A, 2002, J CLIN ONCOL, V20, P1215, DOI 10.1200/JCO.20.5.1215; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124	17	4047	4235	12	365	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1673	1684		10.1056/NEJMoa052122	http://dx.doi.org/10.1056/NEJMoa052122			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975IC	16236738				2023-01-03	WOS:000232653200007
J	Jones, M; Onslow, M; Packman, A; Williams, S; Ormond, T; Schwarz, I; Gebski, V				Jones, M; Onslow, M; Packman, A; Williams, S; Ormond, T; Schwarz, I; Gebski, V			Randomised controlled trial of the Lidcombe programme of early stuttering intervention	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECOVERY; CHILDREN; IMPACT	Objectives To evaluate the efficacy of the Lidcombe programme of early Stuttering intervention by comparison to a control group. Design A pragmatic, open plan, parallel group, randomised controlled trial with blinded outcome assessment. Setting Two public speech clinics in New Zealand. Participants Stuttering preschool children who presented to the speech clinics for treatment. Inclusion criteria were age 3-6 years and frequency of stuttering of at least 2% syllables stuttered. Exclusion criteria were onset of stuttering during the six months before recruitment and treatment for stuttering during the previous 12 months. 54 participants were randomised: 29 to the Lidcombe programme arm and 25 to the control arm. 12 of the participants were girls. Intervention Lidcombe programme of early stuttering intervention. Main outcome measures Frequency of stuttering was measured as the proportion of syllables stuttered, from audiotaped recordings of participants' conversational speech outside the clinic. Parents in both arms of the trial collected speech samples in three different speaking situations before randomisation and at three, six, and nine months after randomisation. Results Analysis showed a highly significant difference (P = 0.003) at nine months after randomisation. The mean proportion of syllables stuttered at nine months after randomisation was 1.50% (SD 1.4) for the treatment arm and 3.9% (SD 3.5) for the control arm, giving an effect size of 2.3% of syllables stuttered (95% confidence interval 0.8 to 3.9). This effect size was more than double the minimum clinically worthwhile difference specified in the trial protocol. Conclusions The results provide evidence from a randomised controlled trial to support early intervention for stuttering. The Lidcombe programme is an efficacious treatment for stuttering in children of preschool age.	Univ Sydney, Stuttering Res Ctr, Lidcombe, NSW 2141, Australia; Univ Queensland, Princess Alexandra Hosp, Queensland Clin Trials Ctr, Woolloongabba, Qld 4102, Australia; Stuttering Treatment & Res Trust, Auckland 1001, New Zealand; Univ Canterbury, Dept Commun Disorders, Christchurch 8020, New Zealand; Univ Tennessee, Dept Speech Pathol & Audiol, Knoxville, TN 37996 USA; Univ Sydney, Clin Trials Ctr, Natl Hlth & Med Res Council, Camperdown, NSW 2050, Australia	University of Sydney; University of Queensland; University of Canterbury; University of Tennessee System; University of Tennessee Knoxville; University of Sydney	Onslow, M (corresponding author), Univ Sydney, Stuttering Res Ctr, Lidcombe, NSW 2141, Australia.	m.onslow@fhs.usyd.edu.au	; Jones, Mark/I-2720-2016	Packman, Ann/0000-0001-7378-326X; Jones, Mark/0000-0001-6858-9710; Onslow, Mark/0000-0003-2629-2390				Bloodstein O., 1995, HDB STUTTERING; Bonelli P, 2000, CLIN LINGUIST PHONET, V14, P427; CRAIG AR, 1991, J SPEECH HEAR RES, V34, P279, DOI 10.1044/jshr.3402.279; Davis S, 2002, J CHILD PSYCHOL PSYC, V43, P939, DOI 10.1111/1469-7610.00093; Harris V, 2002, J FLUENCY DISORD, V27, P203, DOI 10.1016/S0094-730X(02)00127-4; Hayhow R, 2002, J FLUENCY DISORD, V27, P1, DOI 10.1016/S0094-730X(01)00102-4; Jones M, 2000, J SPEECH LANG HEAR R, V43, P1440, DOI 10.1044/jslhr.4306.1440; King W, 2004, AFR AM REV, V38, P165, DOI 10.2307/1512246; Lincoln M, 1996, AM J SPEECH-LANG PAT, V5, P73, DOI [10.1044/1058-0360.0502.73, DOI 10.1044/1058-0360.0502.73]; Lincoln M., 1997, AM J SPEECH-LANG PAT, V6, P77, DOI [10.1044/1058-0360.0602.77, DOI 10.1044/1058-0360.0602.77]; Lincoln M., 1997, AM J SPEECH-LANG PAT, V6, P51, DOI [10.1044/1058-0360.0601.51, DOI 10.1044/1058-0360.0601.51]; ONSLOW M, 1994, J SPEECH HEAR RES, V37, P1244, DOI 10.1044/jshr.3706.1244; ONSLOW M, 1990, J SPEECH HEAR DISORD, V55, P405, DOI 10.1044/jshd.5503.405; Onslow M, 2003, LIDCOMBE PROGRAM EAR; ONSLOW M, 1999, HDB EARLY STUTTERING; ONSLOW M, 1996, BEHAV MANAGEMENT STU; ROSEMAN B, 1998, EASY DOES IT FLUENCY; SIGNORINI DF, 1993, STAT MED, V12, P2343, DOI 10.1002/sim.4780122410; VAIRI E, 1999, J SPEECH LANG HEAR R, V42, P1097; Woods S, 2002, INT J LANG COMM DIS, V37, P31, DOI 10.1080/13682820110096670; Yairi E, 1996, J COMMUN DISORD, V29, P51, DOI 10.1016/0021-9924(95)00051-8; Yairi E, 1999, J SPEECH LANG HEAR R, V42, P1097, DOI 10.1044/jslhr.4205.1097	22	138	140	0	43	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 24	2005	331	7518					659	661		10.1136/bmj.38520.451840.E0	http://dx.doi.org/10.1136/bmj.38520.451840.E0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970HH	16096286	Bronze, Green Published			2023-01-03	WOS:000232295400015
J	Nahin, RL				Nahin, RL			Identifying and pursuing research priorities at the National Center for Complementary and Alternative Medicine	FASEB JOURNAL			English	Article						disease burden; NCCAM funding; public health	OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC KIDNEY-DISEASE; UNITED-STATES; CARE EXPENDITURES; ECONOMIC BURDEN; ALZHEIMERS-DISEASE; PREVALENCE; COSTS; HEALTH; DISORDERS	As part of its planning process, the National Center for Complementary and Alternative Medicine ( NCCAM), a component of the National Institutes of Health, periodically evaluates how well it applies its criteria for setting research priorities. For its most recent evaluation, NCCAM compared funding levels in fiscal years 2000 and 2003 for 18 diseases with a substantial public health burden including Alzheimer's disease, arthritis, back pain, cancer, diabetes, coronary heart disease, HIV/ AIDS, migraine, and stroke, with 7 measures of disease burden: 1) prevalence, 2) mortality, 3) years of life lost ( YLL), 4) years lost to disability ( YLD), 5) disability- adjusted life years ( DALY's), 6) direct costs of illness ( COI), and 7) total COI. There is an increasing relationship between NCCAM research funding and disease burden over the 4- year study period that reflects funding of specific research initiatives. The strength of the individual correlations varied among measures, with the strongest correlations seen with total COI and the weakest seen with mortality. When applied with its other criteria, measures of disease burden aid identification and matching of NCCAM priorities with levels of support.	NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Nahin, RL (corresponding author), NIH, Natl Ctr Complementary & Alternat Med, 9000 Rockville Pike,Bldg 31,Room 2B-11, Bethesda, MD 20892 USA.	nahinr@mail.nih.gov		Nahin, Richard/0000-0002-3682-4816				ADAMS PF, 1995, VITAL HLTH STAT, V10, P193; Adelmann PK, 2003, ADM POLICY MENT HLTH, V31, P111, DOI 10.1023/B:APIH.0000003017.78877.56; *AG HEALTHC RES QU, 2004, 1996 EXP COND; *AM HEART ASS, 2004, AM HEART ASS HEART D; [Anonymous], 2001, JAMA, V285, P1571; Barnes Patricia M, 2004, Adv Data, P1; Bedir E, 2002, J AGR FOOD CHEM, V50, P3150, DOI 10.1021/jf011682s; Berman JD, 2004, ANNU REV MED, V55, P239, DOI 10.1146/annurev.med.55.091902.103657; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; BOLEN J, 2001, MMWR-MORBID MORTAL W, V51, P948; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Bozzette SA, 2001, NEW ENGL J MED, V344, P817, DOI 10.1056/NEJM200103153441107; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Brown ML, 2001, ANNU REV PUBL HEALTH, V22, P91, DOI 10.1146/annurev.publhealth.22.1.91; BROWN ML, 2002, MED CARE, V40, pIV17; Burton WN, 2002, J OCCUP ENVIRON MED, V44, P523, DOI 10.1097/00043764-200206000-00013; *CDC, 2000, HIV AIDS SURV REP 20, P12; *CDC PREV, 1999, HIV AIDS SURV SUPPL, P7; *CDC PREV, 2002, HIV AIDS SURV REP, P8; Chilcott LA, 1996, PHARMACOECONOMICS, V10, P1, DOI 10.2165/00019053-199600101-00003; CISTERNAN M, 2003, MMWR-MORBID MORTAL W, V52, P1124; Cohen JW, 2003, HEALTH AFFAIR, V22, P129, DOI 10.1377/hlthaff.22.2.129; Colice GL, 2004, CHEST, V125, P2140, DOI 10.1378/chest.125.6.2140; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Druss BG, 2002, HEALTH AFFAIR, V21, P105, DOI 10.1377/hlthaff.21.4.105; Druss BG, 2001, HEALTH AFFAIR, V20, P233, DOI 10.1377/hlthaff.20.6.233; Dunlop DD, 2003, ARTHRIT RHEUM-ARTHR, V49, P101, DOI 10.1002/art.10913; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; FRIED VM, 2003, CHARTBOOK TRENDS HLT; Greenberg PE, 2003, J CLIN PSYCHIAT, V64, P1465, DOI 10.4088/JCP.v64n1211; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; HARDY M, 2002, AHRQ PUBLICATION; Hellinger FJ, 2000, J ACQ IMMUN DEF SYND, V24, P182; Hodgson TA, 1999, PREV MED, V29, P173, DOI 10.1006/pmed.1999.0534; Hodgson TA, 1999, MED CARE, V37, P994, DOI 10.1097/00005650-199910000-00004; Hodgson TA, 2001, MED CARE, V39, P599, DOI 10.1097/00005650-200106000-00008; Hodgson TA, 1999, HEALTH CARE FINANC R, V21, P119; HOGAN P, 2002, DIABETES CARE, V26, P917; Hu XH, 1999, ARCH INTERN MED, V159, P813, DOI 10.1001/archinte.159.8.813; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; *I MED, 1998, SCI OPP PUBL NEEDS I; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kleinman A., 2002, SCI PLACEBO INTERDIS, P1; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013; Lin MC, 2001, CIRCULATION, V103, P2038; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Luo XM, 2004, SPINE, V29, P79, DOI 10.1097/01.BRS.0000105527.13866.0F; MATHERS CD, 2002, 50 WORLD HLTH; Mathews WC, 2000, MED CARE, V38, P750, DOI 10.1097/00005650-200007000-00007; McNeil JM, 2001, JAMA-J AM MED ASSOC, V285, P1571; Michaud CM, 2001, JAMA-J AM MED ASSOC, V285, P535, DOI 10.1001/jama.285.5.535; Minino Arialdi M, 2002, Natl Vital Stat Rep, V50, P1; Nahin RL, 2001, BRIT MED J, V322, P161, DOI 10.1136/bmj.322.7279.161; Narrow WE, 2002, ARCH GEN PSYCHIAT, V59, P115, DOI 10.1001/archpsyc.59.2.115; *NAT CTR HLTH STAT, 1999, MMWR-MORBID MORTAL W, V48, P349; *NAT HEART LUNG BL, 2004, 2004 CHART BOOK CARD; Niederman MS, 1998, CLIN THER, V20, P820, DOI 10.1016/S0149-2918(98)80144-6; *NIH, 1997, PUBLICATION; *NIH, 2000, DIS SPEC EST DIR IND; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; PLEIS JR, 2003, NATL HLTH INTERVIEW, V10; PLEIS JR, 2003, VITAL HLTH STAT, V10; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Richmond J, 1996, JAMA-J AM MED ASSOC, V276, P313; Rizzo JA, 1998, MED CARE, V36, P1471, DOI 10.1097/00005650-199810000-00006; Rost K, 1998, AM J PSYCHIAT, V155, P883, DOI 10.1176/ajp.155.7.883; Russell MW, 1998, AM J CARDIOL, V81, P1110, DOI 10.1016/S0002-9149(98)00136-2; Sandler RS, 2002, GASTROENTEROLOGY, V122, P1500, DOI 10.1053/gast.2002.32978; Snedecor GW., 1968, STAT METHODS; Thom TJ, 1996, IN VIVO, V10, P255; Trupin L, 2003, EUR RESPIR J, V22, P462, DOI 10.1183/09031936.03.00094203; *US CENS BUR, 2004, STAT ABSTR US; Varmus H, 1999, NEW ENGL J MED, V340, P1914, DOI 10.1056/NEJM199906173402411; Walsh JK, 1999, SLEEP, V22, pS386; Ward MM, 2000, RESP MED, V94, P1123, DOI 10.1053/rmed.2000.0933; Watanabe CMH, 2001, P NATL ACAD SCI USA, V98, P6577, DOI 10.1073/pnas.111126298; *WHO, 2002, RED RISKS PROM HEALT, P228; *WHO, 2002, WORLD HLTH REPORT 20, P228; *WHO, 1997, MAJ FIND REC AD HOC; Wilson L, 2000, RESP MED, V94, P204, DOI 10.1053/rmed.1999.0720; Wilson T, 2004, MON LABOR REV, V127, P3; Yelin E, 2002, EUR RESPIR J, V19, P414, DOI 10.1183/09031936.02.00522001; YELIN E, 2003, DIRECT INDIRECT COST; 1997, MMWR MORB MORTAL WKL, V50, P334	89	9	9	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1209	1215		10.1096/fj.05-3727LFE	http://dx.doi.org/10.1096/fj.05-3727LFE			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051686				2023-01-03	WOS:000231843700026
J	Liu, SH; Redeye, V; Kuremsky, JG; Kuhnen, M; Molinolo, A; Bugge, TH; Leppla, SH				Liu, SH; Redeye, V; Kuremsky, JG; Kuhnen, M; Molinolo, A; Bugge, TH; Leppla, SH			Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin	NATURE BIOTECHNOLOGY			English	Article							PROTECTIVE ANTIGEN; LETHAL FACTOR; CELLULAR RECEPTOR; EDEMA FACTOR; BINDING; METASTASIS; INVASION; IDENTIFICATION; SEQUENCE; PROTEASE	Anthrax toxin protective antigen (PrAg) forms a heptamer in which the binding site for lethal factor (LF) spans two adjacent monomers(1,2). This suggested that high cell-type specificity in tumor targeting could be obtained using monomers that generate functional LF-binding sites only through intermolecular complementation. We created PrAg mutants with mutations affecting different LF-binding subsites and containing either urokinase plasminogen activator (uPA) or matrix metalloproteinase (MMP) cleavage sites. Individually, these PrAg mutants had low toxicity as a result of impaired LF binding, but when administered together to uPA- and MMP-expressing tumor cells, they assembled into functional LF-binding heteroheptamers. The mixture of two complementing PrAg variants had greatly reduced toxicity in mice and was highly effective in the treatment of aggressive transplanted tumors of diverse origin. These results show that anthrax toxin, and by implication other multimeric toxins, offer excellent opportunities to introduce multiple-specificity determinants and thereby achieve high therapeutic indices.	Natl Inst Dent & Craniofacial Res, Oral Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NIAID, Microbial Pathogenesis Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Oral Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov; sleppla@niaid.nih.gov		Liu, Shihui/0000-0003-3444-1069	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 DE000699-08, Z01 AI000929-05] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; ARORA N, 1993, J BIOL CHEM, V268, P3334; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Coombs GS, 1998, CHEM BIOL, V5, P475, DOI 10.1016/S1074-5521(98)90004-7; Cunningham K, 2002, P NATL ACAD SCI USA, V99, P7049, DOI 10.1073/pnas.062160399; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Hoang CD, 2004, CHEST, V125, P1843, DOI 10.1378/chest.125.5.1843; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Liu SH, 2000, CANCER RES, V60, P6061; Liu SH, 2003, EXPERT OPIN BIOL TH, V3, P843, DOI 10.1517/14712598.3.5.843; Liu SH, 2003, J BIOL CHEM, V278, P5227, DOI 10.1074/jbc.M210321200; Liu SH, 2003, P NATL ACAD SCI USA, V100, P657, DOI 10.1073/pnas.0236849100; Liu SH, 2001, J BIOL CHEM, V276, P17976, DOI 10.1074/jbc.M011085200; Malatynska E, 1998, PHARMACOLOGY, V57, P117, DOI 10.1159/000028232; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Rosovitz MJ, 2003, J BIOL CHEM, V278, P30936, DOI 10.1074/jbc.M301154200; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Ullmann R, 2004, J PATHOL, V203, P798, DOI 10.1002/path.1584; Varughese M, 1999, INFECT IMMUN, V67, P1860; Wasenius VM, 2003, CLIN CANCER RES, V9, P68	30	56	65	2	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2005	23	6					725	730		10.1038/nbt1091	http://dx.doi.org/10.1038/nbt1091			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	933LA	15895075	Green Accepted			2023-01-03	WOS:000229628700033
J	Wilkinson, GR				Wilkinson, GR			Drug therapy - Drug metabolism and variability among patients in drug response	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CYTOCHROME P4502C9 POLYMORPHISMS; ST-JOHNS-WORT; HELICOBACTER-PYLORI; CLINICAL-PRACTICE; CURE RATES; IN-VITRO; CYP2D6; PHARMACOGENETICS; DISPOSITION; OMEPRAZOLE		Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Wilkinson, GR (corresponding author), Vanderbilt Univ, Dept Pharmacol, 542 Robinson Res Bldg, Nashville, TN 37232 USA.	grant.wilkinson@vanderbilt.edu			NIGMS NIH HHS [GM31304] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031304] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ansell J, 2004, CHEST, V126, p204S, DOI 10.1378/chest.126.3_suppl.204S; BAILEY DG, 1991, LANCET, V337, P268, DOI 10.1016/0140-6736(91)90872-M; Bailey DG, 1998, BRIT J CLIN PHARMACO, V46, P101, DOI 10.1046/j.1365-2125.1998.00764.x; Bertilsson L, 2002, BRIT J CLIN PHARMACO, V53, P111, DOI 10.1046/j.0306-5251.2001.01548.x; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Brandolese R, 2001, CLIN PHARMACOL THER, V70, P391, DOI 10.1067/mcp.2001.118868; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; CAPEWELL S, 1988, LANCET, V2, P480; Chou WH, 2000, J CLIN PSYCHOPHARM, V20, P246, DOI 10.1097/00004714-200004000-00019; Cropp JS, 1997, PHARMACOTHERAPY, V17, P917; D'Andrea G, 2005, BLOOD, V105, P645, DOI 10.1182/blood-2004-06-2111; Dalen P, 1997, THER DRUG MONIT, V19, P543, DOI 10.1097/00007691-199710000-00011; Daly AK, 2003, PHARMACOGENETICS, V13, P247, DOI 10.1097/00008571-200305000-00002; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; *FDA, 2005, FED REGISTER, V70, P11865; Flexner C, 2000, ANNU REV PHARMACOL, V40, P649, DOI 10.1146/annurev.pharmtox.40.1.649; Furuta T, 2000, CLIN PHARMACOL THER, V67, P684, DOI 10.1067/mcp.2000.106826; Furuta T, 1998, ANN INTERN MED, V129, P1027, DOI 10.7326/0003-4819-129-12-199812150-00006; Furuta T, 1999, CLIN PHARMACOL THER, V65, P552, DOI 10.1016/S0009-9236(99)70075-5; Furuta T, 2001, CLIN PHARMACOL THER, V69, P158, DOI 10.1067/mcp.2001.113959; Gasche Y, 2004, NEW ENGL J MED, V351, P2827, DOI 10.1056/NEJMoa041888; Gasche Y, 2005, NEW ENGL J MED, V352, P638; Henderson L, 2002, BRIT J CLIN PHARMACO, V54, P349, DOI 10.1046/j.1365-2125.2002.01683.x; Higashi MK, 2003, AM J MANAG CARE, V9, P493; Kane GC, 2000, MAYO CLIN PROC, V75, P933, DOI 10.4065/75.9.933; Karpen SJ, 2002, J HEPATOL, V36, P832, DOI 10.1016/S0168-8278(02)00129-0; KIMURA S, 1989, AM J HUM GENET, V45, P889; Kirchheiner J, 2005, CLIN PHARMACOL THER, V77, P1, DOI 10.1016/j.clpt.2004.08.009; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lee CR, 2002, PHARMACOGENETICS, V12, P251, DOI 10.1097/00008571-200204000-00010; Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507; Lessard E, 1999, PHARMACOGENETICS, V9, P435; Levy R.H., 2000, METABOLIC DRUG INTER; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Piscitelli SC, 2000, LANCET, V355, P547; Ray WA, 2004, NEW ENGL J MED, V351, P1089, DOI 10.1056/NEJMoa040582; Richelson E, 1997, MAYO CLIN PROC, V72, P835, DOI 10.4065/72.9.835; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; Sindrup SH, 1995, PHARMACOGENETICS, V5, P335, DOI 10.1097/00008571-199512000-00001; Spear BB, 2001, TRENDS MOL MED, V7, P201, DOI 10.1016/S1471-4914(01)01986-4; Steimer W, 2002, CLIN CHIM ACTA, V315, P137, DOI 10.1016/S0009-8981(01)00713-6; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; Thummel KE, 1997, ADV DRUG DELIVER REV, V27, P99, DOI 10.1016/S0169-409X(97)00039-2; Wedlund PJ, 2000, PHARMACOLOGY, V61, P174, DOI 10.1159/000028398; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Wuttke H, 2002, CLIN PHARMACOL THER, V72, P429, DOI 10.1067/mcp.2002.127111; Xie HG, 2001, ANNU REV PHARMACOL, V41, P815, DOI 10.1146/annurev.pharmtox.41.1.815	49	772	805	3	87	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2211	2221		10.1056/NEJMra032424	http://dx.doi.org/10.1056/NEJMra032424			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917386				2023-01-03	WOS:000229333300009
J	Gostin, LO				Gostin, LO			Ethics, the constitution, and the dying process - The case of Theresa Marie Schiavo	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CRUZAN; DEATH; LIFE		Georgetown Univ, Ctr Law, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						*AM MED ASS, 1986, WITHH WITHDR LIF PRO; *AM NURS ASS, 1988, GUID WITHDR WITHH FO; BABINGTON C, 2005, WASH POST       0908, pA6; CERMINARA KL, KEY EVENTS CASE TM S; GOSTIN L, 1991, MILBANK Q, V69, P143, DOI 10.2307/3350124; Gostin LO, 1997, JAMA-J AM MED ASSOC, V278, P1523, DOI 10.1001/jama.278.18.1523; HULSE C, 2005, NY TIMES        0519, pA1; JOHNSON HM, 2005, WASHINGTON POST 0325, pA19; MEISEL A, 2004, RIGHT DIE LAW END LI; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; SANGER D, 2003, NY TIMES, pA23; Wolfson Jay, 2003, REPORT GOVERNOR J BU	12	32	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2403	2407		10.1001/jama.293.19.2403	http://dx.doi.org/10.1001/jama.293.19.2403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	926JX	15900011				2023-01-03	WOS:000229120600028
J	Wirth, L; Allen, AM; Machtay, M				Wirth, Lori; Allen, Aaron M.; Machtay, Mitchell			Altered fractionation: a fractional benefit?	LANCET			English	Editorial Material							ADVANCED LARYNGEAL-CANCER; SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; PHASE-III; NECK-CANCER; ACCELERATED FRACTIONATION; RANDOMIZED-TRIAL; RADIOTHERAPY; HEAD; CHEMOTHERAPY		Dana Farber Canc Inst, Boston, MA 02115 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Harvard University; Dana-Farber Cancer Institute; Jefferson University; Amgen	Wirth, L (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.	Lori_Wirth@dfci.harvard.edu						Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; BOURHIS J, 2004, P AN M AM SOC CLIN, V22, P5505; Bourhis J, 2006, LANCET, V368, P843, DOI 10.1016/S0140-6736(06)69121-6; Butler EB, 1999, INT J RADIAT ONCOL, V45, P21, DOI 10.1016/S0360-3016(99)00101-7; Calais G, 1999, J NATL CANCER I, V91, P2081, DOI 10.1093/jnci/91.24.2081; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; Fu KK, 2000, INT J RADIAT ONCOL, V48, P7, DOI 10.1016/S0360-3016(00)00663-5; Hitt R, 2005, J CLIN ONCOL, V23, P8636, DOI 10.1200/JCO.2004.00.1990; HORIOT JC, 1992, RADIOTHER ONCOL, V25, P231, DOI 10.1016/0167-8140(92)90242-M; Khalil AA, 2003, INT J RADIAT ONCOL, V55, P568, DOI 10.1016/S0360-3016(02)03790-2; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; Overgaard J, 2003, LANCET, V362, P933, DOI 10.1016/S0140-6736(03)14361-9; POSNER M, 2006, AM SOC CLIN ONC ATL; VERMORKEN JB, 2004, P AN M AM SOC CLIN, V23, P5508; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402	16	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 2	2006	368	9538					819	821		10.1016/S0140-6736(06)69300-8	http://dx.doi.org/10.1016/S0140-6736(06)69300-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	082FD	16950339				2023-01-03	WOS:000240371200005
J	Chang, DC; Grant, GB; O'Donnell, K; Wannemuehler, KA; Noble-Wang, J; Rao, CY; Jacobson, LM; Crowell, CS; Sneed, RS; Lewis, FMT; Schaffzin, JK; Kainer, MA; Genese, CA; Alfonso, EC; Jones, DB; Srinivasan, A; Fridkin, SK; Park, BJ				Chang, Douglas C.; Grant, Gavin B.; O'Donnell, Kerry; Wannemuehler, Kathleen A.; Noble-Wang, Judith; Rao, Carol Y.; Jacobson, Lara M.; Crowell, Claudia S.; Sneed, Rodlescia S.; Lewis, Felicia M. T.; Schaffzin, Joshua K.; Kainer, Marion A.; Genese, Carol A.; Alfonso, Eduardo C.; Jones, Dan B.; Srinivasan, Arjun; Fridkin, Scott K.; Park, Benjamin J.		Fusarium Keratitis Investigation T	Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ULCERATIVE KERATITIS; MICROBIAL KERATITIS; FUNGAL KERATITIS; DAILY-WEAR; RISK; SPECTRUM; MEMBERS; COMPLEX; TRENDS	Context Fusarium keratitis is a serious corneal infection, most commonly associated with corneal injury. Beginning in March 2006, the Centers for Disease Control and Prevention received multiple reports of Fusarium keratitis among contact lens wearers. Objective To define the specific activities, contact lens hygiene practices, or products associated with this outbreak. Design, Setting, and Participants Epidemiological investigation of Fusarium keratitis occurring in the United States. A confirmed case was defined as keratitis with illness onset after June 1, 2005, with no history of recent ocular trauma and a corneal culture growing Fusarium species. Data were obtained by patient and ophthalmologist interviews for case patients and neighborhood-matched controls by trained personnel. Available Fusarium isolates from patients' clinical and environmental specimens were genotyped by multilocus sequence typing. Environmental sampling for Fusarium was conducted at a contact lens solution manufacturing plant. Main Outcome Measures Keratitis infection with Fusarium species. Results As of June 30, 2006, we identified 164 confirmed case patients in 33 states and 1 US territory. Median age was 41 years (range, 12-83 years). Corneal transplantation was required or planned in 55 (34%). One hundred fifty-four (94%) of the confirmed case patients wore soft contact lenses. Forty-five case patients and 78 controls were included in the case-control study. Case patients were significantly more likely than controls to report using a specific contact lens solution, ReNu with MoistureLoc (69% vs 15%; odds ratio, 13.3; 95% confidence interval, 3.1-119.5). The prevalence of reported use of ReNu MultiPlus solution was similar between case patients and controls (18% vs 20%; odds ratio, 0.7; 95% confidence interval, 0.2-2.8). Fusarium was not recovered from the factory, warehouse, solution filtrate, or unopened solution bottles; production of implicated lots was not clustered in time. Among 39 isolates tested, at least 10 different Fusarium species were identified, comprising 19 unique multilocus genotypes. Conclusions The findings from this investigation indicate that this outbreak of Fusarium keratitis was associated with use of ReNu with MoistureLoc contact lens solution. Contact lens users should not use ReNu with MoistureLoc.	Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA; Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA; Ctr Dis Control & Prevent, Biostat Off, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol & Lab Branch, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Infect Dis & Epidem Intelligence Serv, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol Elect Program, Atlanta, GA USA; Ctr Dis Control & Prevent, Career Dev Div, Off Workforce & Career Dev, Atlanta, GA USA; ARS, Microbial Genom Res Unit, Natl Ctr Agr Utilizat Res, USDA, Peoria, IL USA; Miami Dade Cty Hlth Dept, Miami, FL USA; Philadelphia Dept Hlth, Philadelphia, PA USA; New York State Dept Hlth, Albany, NY USA; Tennessee Dept Hlth, Nashville, TN USA; New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA; Univ Miami, Sch Med, Bascom Palmer Eye Inst, Miami, FL USA; Baylor Coll Med, Cullen Eye Inst, Houston, TX 77030 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; United States Department of Agriculture (USDA); State University of New York (SUNY) System; Tennessee Department Health; New Jersey Department of Health & Senior Services; Bascom Palmer Eye Institute; University of Miami; Baylor College of Medicine	Chang, DC (corresponding author), 1600 Clifton Rd,MS C-09, Atlanta, GA 30333 USA.	DChang@cdc.gov	Sneed, PhD, MPH, Rodlescia/ABG-8963-2021; Schaffzin, Joshua K/AAZ-9243-2021	Schaffzin, Joshua K/0000-0002-1190-1854; Wannemuehler, Kathleen/0000-0001-9535-6277; Rao, Carol/0000-0001-7187-2189; Grant, Gavin/0000-0002-3271-5735; Sneed, Rodlescia/0000-0001-7732-6197; Kainer, Marion/0000-0001-7678-8744				ALFONSO E, 1986, AM J OPHTHALMOL, V101, P429, DOI 10.1016/0002-9394(86)90641-0; Alfonso EC, 2006, AM J OPHTHALMOL, V142, P154, DOI 10.1016/j.ajo.2006.04.025; Alfonso EC, 2006, ARCH OPHTHALMOL-CHIC, V124, P941, DOI 10.1001/archopht.124.7.ecs60039; Anaissie EJ, 2001, CLIN INFECT DIS, V33, P1871, DOI 10.1086/324501; ASBELL P, 1982, ARCH OPHTHALMOL-CHIC, V100, P77, DOI 10.1001/archopht.1982.01030030079005; Bernal MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P1051, DOI 10.1001/archopht.124.7.ecr60006; Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P400; Cheng KH, 1999, LANCET, V354, P181, DOI 10.1016/S0140-6736(98)09385-4; *CONT LENS COUNC, STAT CONT LENS WEAR; Dart J, 1999, LANCET, V354, P174, DOI 10.1016/S0140-6736(99)90104-6; DART JKG, 1991, LANCET, V338, P650, DOI 10.1016/0140-6736(91)91231-I; de Hoog GS, 2000, ATLAS CLIN FUNGI; Driebe William T Jr, 2003, Ophthalmol Clin North Am, V16, P485, DOI 10.1016/S0896-1549(03)00052-X; Foulks GN, 2006, AM J OPHTHALMOL, V141, P369, DOI 10.1016/j.ajo.2005.08.047; Geiser DM, 2004, EUR J PLANT PATHOL, V110, P473, DOI 10.1023/B:EJPP.0000032386.75915.a0; Khor WB, 2006, JAMA-J AM MED ASSOC, V295, P2867, DOI 10.1001/jama.295.24.2867; KOIDOUTSILIGIANNI A, 1989, AM J OPHTHALMOL, V108, P64, DOI 10.1016/S0002-9394(14)73262-3; LIESEGANG TJ, 1980, AM J OPHTHALMOL, V90, P38, DOI 10.1016/S0002-9394(14)75075-5; Mah-Sadorra JH, 2005, CORNEA, V24, P51, DOI 10.1097/01.ico.0000138839.29823.57; McLaughlin-Borlace L, 1998, J APPL MICROBIOL, V84, P827; *MIN HLTH SING, PUBL AL INCR INC CON; NELSON PE, 1994, CLIN MICROBIOL REV, V7, P479, DOI 10.1128/CMR.7.4.479-504.1994; Nilsson Sven Erik G., 1994, CLAO Journal, V20, P225; O'Donnell K, 2004, J CLIN MICROBIOL, V42, P5109, DOI 10.1128/JCM.42.11.5109-5120.2004; POGGIO EC, 1989, NEW ENGL J MED, V321, P779, DOI 10.1056/NEJM198909213211202; Rattanatam T, 2001, CORNEA, V20, P290, DOI 10.1097/00003226-200104000-00010; Reeb V, 2004, MOL PHYLOGENET EVOL, V32, P1036, DOI 10.1016/j.ympev.2004.04.012; ROSA RH, 1994, OPHTHALMOLOGY, V101, P1005; SCHEIN OD, 1994, ARCH OPHTHALMOL-CHIC, V112, P186, DOI 10.1001/archopht.1994.01090140062024; SCHEIN OD, 1989, NEW ENGL J MED, V321, P773, DOI 10.1056/NEJM198909213211201; SCHEIN OD, 1989, CORNEA, V8, P281; Schein OD, 2005, OPHTHALMOLOGY, V112, P2172, DOI 10.1016/j.ophtha.2005.09.014; SCHEIN OD, 1990, CORNEA, V9, pS55; SIMMONS RB, 1986, J CLIN MICROBIOL, V24, P21, DOI 10.1128/JCM.24.1.21-25.1986; SWOFFORD DL, 2001, PAUP PHYLOGENIETIC A; THOMPSON TTT, 2006, TYLERS Q SOFT CONTEC, V23; TSANG T, 2006, COMMUNICABLE DI 0205; *US FDA, 2006, FDA PUBL HLTH NOT FU; *US PHARM NAT FORM, 2003, STER TEST, pCH71; WILSON LA, 1991, ARCH OPHTHALMOL-CHIC, V109, P1155, DOI 10.1001/archopht.1991.01080080115043; Wong TY, 1997, INT OPHTHALMOL, V21, P127, DOI 10.1023/A:1026462631716; Zhang N, 2006, J CLIN MICROBIOL, V44, P2186, DOI 10.1128/JCM.00120-06	42	411	424	1	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2006	296	8					953	963		10.1001/jama.296.8.953	http://dx.doi.org/10.1001/jama.296.8.953			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076AL	16926355	Bronze			2023-01-03	WOS:000239929300025
J	Gulick, RM; Ribaudo, HJ; Shikuma, CM; Lalama, C; Schackman, BR; Meyer, WA; Acosta, EP; Schouten, J; Squires, KE; Pilcher, CD; Murphy, RL; Koletar, SL; Carlson, M; Reichman, RC; Bastow, B; Klingman, KL; Kuritzkes, DR				Gulick, Roy M.; Ribaudo, Heather J.; Shikuma, Cecilia M.; Lalama, Christina; Schackman, Bruce R.; Meyer, William A., III; Acosta, Edward P.; Schouten, Jeffrey; Squires, Kathleen E.; Pilcher, Christopher D.; Murphy, Robert L.; Koletar, Susan L.; Carlson, Margrit; Reichman, Richard C.; Bastow, Barbara; Klingman, Karin L.; Kuritzkes, Daniel R.		ACTG A5095 Study Team	Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; REVERSE-TRANSCRIPTASE INHIBITOR; SOCIETY-USA PANEL; NAIVE PATIENTS; ABACAVIR HYPERSENSITIVITY; PROTEASE INHIBITORS; DRUG-RESISTANCE; CLINICAL-TRIALS; PLUS INDINAVIR; THERAPY	Context Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen. Objective To compare the safety/efficacy of 3-drug vs 4-drug regimens for initial treatment of HIV-1 infection. Design The AIDS Clinical Trials Group (ACTG) A5095 study, a randomized, double-blind, placebo-controlled study with enrollment and follow-up conducted from March 22, 2001, to March 1, 2005, and enrolling treatment-naive, HIV-1-infected patients with HIV-1 RNA levels of 400 copies/mL or greater from US clinical trials units of the ACTG. Interventions Zidovudine/lamivudine plus efavirenz (3-drug regimen) vs zidovudine/ lamivudine/abacavir plus efavirenz (4-drug regimen). Main Outcome Measures Time to virologic failure ( defined as time to first of 2 successive HIV-1 RNA levels >= 200 copies/mL at or after week 16), CD4 cell count changes, and grade 3 or 4 adverse events. HIV-1 RNA data were intent-to-treat, regardless of treatment changes. Results Seven hundred sixty-five patients with a baseline mean HIV-1 RNA level of 4.86 log(10) ( 72 444) copies/mL and CD4 cell count of 240 cells/mm(3) were randomized. After a median 3-year follow-up, 99 (26%) of 382 and 94 (25%) of 383 patients receiving the 3-drug and 4-drug regimens, respectively, reached protocol-defined virologic failure; time to virologic failure was not significantly different ( hazard ratio, 0.95; 97.5% confidence interval, 0.69-1.33; P=. 73). In planned subgroup analyses, increased risk for virologic failure was seen in non-Hispanic black patients ( adjusted hazard ratio, 1.66; 95% confidence interval, 1.18-2.34; P=. 003). At 3 years, the HIV-1 RNA level was less than 200 copies/mL in 152 (90%) of 169 and 143 (92%) of 156 patients receiving the 3-drug and 4-drug regimens, respectively ( P=. 59), and less than 50 copies/mL in 144 (85%) of 169 and 137 (88%) of 156 patients ( P=. 39). CD4 cell count increases and grade 3 or 4 adverse events were not significantly different. Conclusions In treatment-naive patients, there were no significant differences between the 3-drug and 4-drug antiretroviral regimens; overall, at least approximately 80% of patients had HIV-1 RNA levels less than 50 copies/mL through 3 years. These results support current guidelines recommending 2 nucleosides plus efavirenz for initial treatment of HIV-1 infection; adding abacavir as a fourth drug provided no additional benefit.	Cornell Univ, Weill Med Coll, Div Int Med & Infect Dis, Cornell HIV Clin Trials Unit, New York, NY 10021 USA; Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Boston, MA 02115 USA; Univ Hawaii, Honolulu, HI 96822 USA; QuestDiagnost Inc, Baltimore, MD USA; Univ Alabama, Birmingham, AL USA; Univ Washington, Seattle, WA 98195 USA; Univ So Calif, Med Ctr, Los Angeles, CA USA; Univ N Carolina, Chapel Hill, NC USA; Northwestern Univ, Chicago, IL 60611 USA; Ohio State Univ, Columbus, OH 43210 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Rochester, Rochester, NY USA; Social & Sci Syst Inc, Silver Spring, MD USA; NIAID, Div AIDS, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA	Cornell University; Harvard University; Harvard T.H. Chan School of Public Health; University of Hawaii System; University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; University of North Carolina; University of North Carolina Chapel Hill; Northwestern University; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles; University of Rochester; Social & Scientific Systems; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Jefferson University	Gulick, RM (corresponding author), Cornell Univ, Weill Med Coll, Div Int Med & Infect Dis, Cornell HIV Clin Trials Unit, Box 566,525 E 68th St, New York, NY 10021 USA.	rgulick@med.cornell.edu	Schackman, Bruce R./J-8208-2019	Schackman, Bruce R./0000-0002-1132-2932; Murphy, Robert/0000-0003-3936-2052	NCRR NIH HHS [RR00046, RR00047, RR00052, RR00096, RR00865, RR02635, RR00044] Funding Source: Medline; NIAID NIH HHS [AI 46339, AI 42851, AI 42848, AI 39156, AI 38858, AI 38855, AI 34832, AI 32782, AI 32775, AI 28697, AI 27767, AI 27675, AI 27673, AI 27670, AI 27668, AI 27664, AI 27661, AI 27659, AI 27658, AI 25924, AI 25915, AI 25903, AI 25897, AI 25879, AI 25868, AI 25859, AI 01781, AI 46370, AI 46376, AI 46381, AI 46386, AI 50410, AI 51966, AI, 27660] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865, M01RR002635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027661, P30AI042851, U01AI025924, U01AI027664, U01AI038855, U01AI027675, U01AI027659, U01AI046376, U01AI025897, U01AI025903, U01AI027668, U01AI025868, P30AI028697, U01AI032775, U01AI032782, U01AI025879, P30AI050410, U01AI027670, U01AI046370, U01AI034832, P30AI027767, U01AI046381, U01AI027658, U01AI027660, U01AI046386, U01AI027673, U01AI025859, K24AI051966, P30AI042848, K23AI001781, U01AI039156, U01AI025915, U01AI046339, U01AI038858] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albrecht MA, 2001, NEW ENGL J MED, V345, P398, DOI 10.1056/NEJM200108093450602; Barreiro P, 2002, AIDS, V16, P245, DOI 10.1097/00002030-200201250-00014; Bossi P, 2000, CLIN INFECT DIS, V30, P227, DOI 10.1086/313629; Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891; Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195; Clay PG, 2002, CLIN THER, V24, P1502, DOI 10.1016/S0149-2918(02)80057-1; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Fischl MA, 2003, J INFECT DIS, V188, P625, DOI 10.1086/377311; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Haas DW, 2004, AIDS, V18, P2391; Haddy TB, 1999, J LAB CLIN MED, V133, P15, DOI 10.1053/lc.1999.v133.a94931; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hicks C, 2004, AIDS, V18, P775, DOI 10.1097/00002030-200403260-00008; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Louie M, 2003, J INFECT DIS, V187, P896, DOI 10.1086/368164; LUPO LJ, 2002, 6 INT C DRUG THER HI; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Manfredi R, 2004, AIDS, V18, P2331, DOI 10.1097/00002030-200411190-00017; Markowitz M, 2003, J VIROL, V77, P5037, DOI 10.1128/JVI.77.8.5037-5038.2003; MOORE RD, 2005, 12 C RETR OPP INF FE; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Panel on Clinical Practices for the Treatment of HIV Infection and DHHS Guidelines, 2006, GUID US ANT AG HIV I; Phillips EJ, 2005, AIDS, V19, P979, DOI 10.1097/01.aids.0000171414.99409.fb; Ramratnam B, 2004, JAIDS-J ACQ IMM DEF, V35, P33, DOI 10.1097/00126334-200401010-00004; *REG COMPL CTR, 1992, DIV AIDS TABL GRAD S; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Shafer RW, 2003, NEW ENGL J MED, V349, P2304, DOI 10.1056/NEJMoa030265; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Torti C, 2005, J ANTIMICROB CHEMOTH, V56, P190, DOI 10.1093/jac/dki172; van Praag RME, 2002, AIDS, V16, P719, DOI 10.1097/00002030-200203290-00007; WEGNER S, 2002, 9 C RETR OPP INF FEB; Weverling GJ, 1998, AIDS, V12, pF117, DOI 10.1097/00002030-199811000-00003; World Health Organization, 2005, SCAL ANT THER RES LT; Yeni P, 2006, LANCET, V368, P287, DOI 10.1016/S0140-6736(06)69074-0; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	41	175	178	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					769	781		10.1001/jama.296.7.769	http://dx.doi.org/10.1001/jama.296.7.769			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073SR	16905783	Bronze			2023-01-03	WOS:000239763400018
J	Christie, G; Currie, GP; Plant, P				Christie, Gordon; Currie, Graeme P.; Plant, Paul			ABC of chronic obstructive pulmonary disease - Ventilatory support	BRITISH MEDICAL JOURNAL			English	Editorial Material							NONINVASIVE VENTILATION; RESPIRATORY-FAILURE; EXACERBATIONS		Aberdeen Royal Infirm, Resp Unit, Aberdeen, Scotland; St James Univ Hosp, Dept Resp Med, Leeds LS9 7TF, W Yorkshire, England	University of Aberdeen; Saint James's University Hospital	Christie, G (corresponding author), Aberdeen Royal Infirm, Resp Unit, Aberdeen, Scotland.			Currie, Graeme P/0000-0002-5711-9147				Baudouin S, 2002, THORAX, V57, P192; Lightowler JV, 2003, BMJ-BRIT MED J, V326, P185, DOI 10.1136/bmj.326.7382.185; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0	3	3	3	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 15	2006	333	7559					138	140		10.1136/bmj.333.7559.138	http://dx.doi.org/10.1136/bmj.333.7559.138			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	065JK	16840478	Green Published			2023-01-03	WOS:000239155900030
J	Domek, GJ				Domek, GJ			Social consequences of antiretroviral therapy: preparing for the unexpected futures of HIV-positive children	LANCET			English	Editorial Material							PSYCHOSOCIAL ISSUES; HIV/AIDS; ADOLESCENTS; CARE; AIDS; DISCLOSURE; EFFICACY; ACCESS; HAART; LIFE		Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Domek, GJ (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.	gretchen_domek@hms.harvard.edu						Abadia-Barrero CE, 2006, SOC SCI MED, V62, P1219, DOI 10.1016/j.socscimed.2005.07.006; Abadia-Barrero CE, 2006, AIDS PATIENT CARE ST, V20, P36, DOI 10.1089/apc.2006.20.36; Abadia-Barrero César Ernesto, 2002, Interface (Botucatu), V6, P55, DOI 10.1590/S1414-32832002000200005; Atwine B, 2005, SOC SCI MED, V61, P555, DOI 10.1016/j.socscimed.2004.12.018; Battles HB, 2002, J ADOLESCENT HEALTH, V30, P161, DOI 10.1016/S1054-139X(01)00341-X; BRAZARSH J, 2004, COMM INF INSP TEAM J; Brown LK, 2000, J CHILD PSYCHOL PSYC, V41, P81, DOI 10.1111/1469-7610.00550; COHEN J, 1989, PEDIATRICS, V100, P8; DOMEK GJ, 2005, THESIS U OXFORD I; Drew RS, 1998, AIDS CARE, V10, pS9, DOI 10.1080/09540129850124325; Foster G, 1996, AIDS CARE, V8, P389, DOI 10.1080/09540129650125597; Gebo KA, 1999, AIDS, V13, P963, DOI 10.1097/00002030-199905280-00013; Gerson A C, 2001, J Pediatr Health Care, V15, P161, DOI 10.1067/mph.2001.114835; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Ledlie SW, 2001, AIDS PATIENT CARE ST, V15, P231, DOI 10.1089/10872910152050748; Lee CL, 1999, AIDS PATIENT CARE ST, V13, P41, DOI 10.1089/apc.1999.13.41; Loening-Voysey H, 2001, APPROACHES CARING CH; Matida Luiza Harunari, 2004, Braz J Infect Dis, V8, P419, DOI 10.1590/S1413-86702004000600005; Mialky E, 2001, AIDS PATIENT CARE ST, V15, P575, DOI 10.1089/108729101753287667; O'Hare BAM, 2005, AIDS CARE, V17, P443, DOI 10.1080/09540120412331291779; Pillay AL, 1997, SOC SCI MED, V45, P1493, DOI 10.1016/S0277-9536(97)00079-8; Piot P, 2004, SCIENCE, V304, P1909, DOI 10.1126/science.1101137; Puthanakit T, 2005, CLIN INFECT DIS, V41, P100, DOI 10.1086/430714; Ruiz P, 2000, AM J PSYCHIAT, V157, P110, DOI 10.1176/ajp.157.1.110; Selwyn PA, 1998, ANN INTERN MED, V129, P899, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00012; Shetty Avinash K, 2003, Semin Pediatr Infect Dis, V14, P25, DOI 10.1053/spid.2003.127214; Sowell RL, 1998, AIDS PATIENT CARE ST, V12, P33, DOI 10.1089/apc.1998.12.33; Tramarin A, 2004, AIDS CARE, V16, P213, DOI 10.1080/09540120410001641057; *UNAIDS, 2005, AIDS EP UPD DEC 2005; *UNAIDS, 2001, INV OUR FUT PSYCH SU; Wilfert C, 1999, PEDIATRICS, V103, P164	31	32	32	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	2006	367	9519					1367	1369		10.1016/S0140-6736(06)68584-X	http://dx.doi.org/10.1016/S0140-6736(06)68584-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	037AG	16631916				2023-01-03	WOS:000237118500032
J	Sotelo, J; Briceno, E; Lopez-Gonzalez, MA				Sotelo, J; Briceno, E; Lopez-Gonzalez, MA			Adding chloroquine to conventional treatment for glioblastoma multiforme - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							HARDING-PASSEY MELANOMA; ANTIMALARIAL-DRUGS; MULTIDRUG-RESISTANCE; MONOLAYER-CULTURE; CELLS-INVITRO; GLIOMA-CELLS; RAT GLIOMA; CPG-DNA; QUINACRINE; RADIOTHERAPY	Background: Malignant cell clones resistant to chemotherapy and radiotherapy frequently lead to treatment failure in patients with glioblastoma multiforme. Preliminary studies suggest that adding chloroquine to conventional therapy may improve treatment outcomes. Objective: To examine the effect of adding chloroquine to conventional therapy for glioblastoma multiforme. Design: Randomized, double-blind, placebo-controlled trial. Setting: National Institute of Neurology and Neurosurgery of Mexico. Patients: 30 patients with surgically confirmed glioblastoma confined to 1 cerebral hemisphere, with a Karnofsky performance score greater than 70, no comorbid disease, and age younger than 60 years. Interventions: Oral chloroquine at 150 mg/d for 12 months beginning on postoperative clay 5 or placebo. All patients received conventional chemotherapy and radiotherapy. Measurements: Primary outcome was survival after surgery; surviving patients were followed up to October 2005. Periodic evaluation using the Karnofsky scale and imaging studies, as well as hematologic tests and ophthalmologic examinations, was done in all patients. Results: Median survival after surgery was 24 months for chloroquine-treated patients and 11 months for controls. At the end of the observation period, 6 patients treated with chloroquine had survived 59, 45, 30, 27, 27, and 20 months, respectively; 3 patients from the control group had survived 32, 25, and 22 months, respectively. Although not statistically significantly different, the rate of death with time was approximately half as large in patients receiving chloroquine as in patients receiving placebo (hazard ratio, 0.52 [95% Cl, 0.21 to 1.26]; P = 0.139). Limitations: The observed advantage of chloroquine may be due to chance; differences in pretreatment characteristics and conventional treatment regimens could not be adjusted for because of the small sample size. Conclusions: Chloroquine may improve mid-term survival when given in addition to conventional therapy for glioblastoma multiforme. These results suggest that larger, more definitive studies of chloroquine as adjuvant therapy for glioblastoma are warranted.	Natl Inst Neurol & Neurosurg Mexico, Mexico City 14269, DF, Mexico		Sotelo, J (corresponding author), Natl Inst Neurol & Neurosurg Mexico, Insurgentes Sur 3877, Mexico City 14269, DF, Mexico.	jsotelo@servidor.unam.mx	Gonzalez, Miguel A Lopez/M-2139-2015	Gonzalez, Miguel A Lopez/0000-0002-7172-6963				ALLISON JL, 1965, SCIENCE, V149, P1111, DOI 10.1126/science.149.3688.1111; BECK WT, 1988, BIOCHEM BIOPH RES CO, V153, P959, DOI 10.1016/S0006-291X(88)81321-4; BENNETT A, 1987, BRIT J CANCER, V55, P385, DOI 10.1038/bjc.1987.77; BILLER H, 1982, STRAHLENTHER ONKOL, V158, P450; Bondeson J, 1998, GEN PHARMACOL, V30, P357, DOI 10.1016/S0306-3623(97)00269-3; BRICENO E, THERAPY GLIOBLASTOMA; CAPALA J, 1991, INT J RADIAT BIOL, V60, P497, DOI 10.1080/09553009114552341; Cho J, 2000, NUCLEIC ACIDS RES, V28, P2158, DOI 10.1093/nar/28.10.2158; COHEN SN, 1965, P NATL ACAD SCI USA, V54, P521, DOI 10.1073/pnas.54.2.521; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; FERRANTE A, 1984, PARASITE IMMUNOL, V6, P571, DOI 10.1111/j.1365-3024.1984.tb00826.x; FILIPPOV A, 1989, GEN PHYSIOL BIOPHYS, V8, P113; GIAMPIETRI A, 1980, J NATL CANCER I, V64, P297, DOI 10.1093/jnci/64.2.297; Grossman SA, 2004, SEMIN ONCOL, V31, P635, DOI 10.1053/j.seminoncol.2004.07.005; Hawtrey A, 2002, DRUG DELIV, V9, P47, DOI 10.1080/107175402753413172; HOSTETLER KY, 1985, J BIOL CHEM, V260, P215; INABA M, 1988, CANCER RES, V48, P2064; Itaka K, 2003, BIOMATERIALS, V24, P4495, DOI 10.1016/S0142-9612(03)00347-8; JENSEN PB, 1994, CANCER RES, V54, P2959; Kaneko T, 1996, MOL GEN GENET, V250, P593; Kanzawa T, 2003, J BIOMED BIOTECHNOL, P25; KUNZE H, 1982, BIOCHIM BIOPHYS ACTA, V713, P112, DOI 10.1016/0005-2760(82)90173-4; LAW PY, 1984, J BIOL CHEM, V259, P4096; Lopez-Gonzalez MA, 2000, SURG NEUROL, V53, P157, DOI 10.1016/S0090-3019(99)00177-9; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; National Cancer Institute, 1999, COMM TOX CRIT VERS 2; NIELSEN FC, 1990, PEPTIDES, V11, P1225, DOI 10.1016/0196-9781(90)90156-Y; Nosal R, 2002, THROMB RES, V105, P339, DOI 10.1016/S0049-3848(02)00036-1; PACUSZKA T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P153, DOI 10.1016/0005-2760(91)90036-H; PFAB R, 1985, STRAHLENTHER ONKOL, V161, P711; POZZI D, 1990, MEMBRANE BIOCHEM, V9, P239, DOI 10.3109/09687689009025844; Reyes S, 2001, NEUROSURGERY, V49, P969, DOI 10.1097/00006123-200110000-00033; Riccio ES, 2001, ENVIRON MOL MUTAGEN, V38, P69, DOI 10.1002/em.1052; RUDLING MJ, 1983, CANCER RES, V43, P4600; SALMERON G, 1983, AM J MED, V75, P19, DOI 10.1016/0002-9343(83)91266-4; Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5; Snyder RD, 2000, ENVIRON MOL MUTAGEN, V35, P13, DOI 10.1002/(SICI)1098-2280(2000)35:1<13::AID-EM3>3.0.CO;2-1; Snyder RD, 2002, MUTAT RES-FUND MOL M, V503, P21, DOI 10.1016/S0027-5107(02)00028-3; Sohn TA, 2002, CARCINOGENESIS, V23, P949, DOI 10.1093/carcin/23.6.949; Souhami L, 2004, INT J RADIAT ONCOL, V60, P853, DOI 10.1016/j.ijrobp.2004.04.011; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tchernaenko V, 2003, J MOL BIOL, V326, P751, DOI 10.1016/S0022-2836(02)01360-8; Teulade-Fichou MP, 2003, NUCLEOS NUCLEOT NUCL, V22, P1483, DOI 10.1081/NCN-120023016; Wasserfallen JB, 2004, CANCER, V101, P2098, DOI 10.1002/cncr.20619; Weber SM, 2000, J IMMUNOL, V165, P1534, DOI 10.4049/jimmunol.165.3.1534; Yeo SJ, 2003, J BIOL CHEM, V278, P22563, DOI 10.1074/jbc.M302076200; Yin F, 2003, BIOSENS BIOELECTRON, V19, P297, DOI 10.1016/S0956-5663(03)00197-0; ZAMORA JM, 1988, MOL PHARMACOL, V33, P454; Zhu FG, 2003, IMMUNOLOGY, V109, P255, DOI 10.1046/j.1365-2567.2003.01653.x	49	352	370	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2006	144	5					337	343		10.7326/0003-4819-144-5-200603070-00008	http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021EA	16520474				2023-01-03	WOS:000235965300004
J	Prentice, RL; Caan, B; Chlebowski, RT; Patterson, R; Kuller, LH; Ockene, JK; Margolis, KL; Limacher, MC; Manson, JE; Parker, LM; Paskett, E; Phillips, L; Robbins, J; Rossouw, JE; Sarto, GE; Shikany, JM; Stefanick, ML; Thomson, CA; Van Horn, L; Vitolins, MZ; Wactawski-Wende, J; Wallace, RB; Wassertheil-Smoller, S; Whitlock, E; Yano, K; Adams-Campbell, L; Anderson, GL; Assaf, AR; Beresford, SAA; Black, HR; Brunner, RL; Brzyski, RG; Ford, L; Gass, M; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Hsia, J; Hubbell, FA; Jackson, RD; Johnson, KC; Kotchen, JM; LaCroix, AZ; Lane, DS; Langer, RD; Lasser, NL; Henderson, MM				Prentice, RL; Caan, B; Chlebowski, RT; Patterson, R; Kuller, LH; Ockene, JK; Margolis, KL; Limacher, MC; Manson, JE; Parker, LM; Paskett, E; Phillips, L; Robbins, J; Rossouw, JE; Sarto, GE; Shikany, JM; Stefanick, ML; Thomson, CA; Van Horn, L; Vitolins, MZ; Wactawski-Wende, J; Wallace, RB; Wassertheil-Smoller, S; Whitlock, E; Yano, K; Adams-Campbell, L; Anderson, GL; Assaf, AR; Beresford, SAA; Black, HR; Brunner, RL; Brzyski, RG; Ford, L; Gass, M; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Hsia, J; Hubbell, FA; Jackson, RD; Johnson, KC; Kotchen, JM; LaCroix, AZ; Lane, DS; Langer, RD; Lasser, NL; Henderson, MM			Low-fat dietary pattern and risk of invasive breast cancer - The women's health initiative randomized controlled dietary modification trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADJUVANT CHEMOTHERAPY; DISEASE PREVENTION; SERUM ESTROGEN; GRAIN INTAKE; INTERVENTION; METAANALYSIS; WHOLE; FEASIBILITY; TRASTUZUMAB; VEGETABLES	Context The hypothesis that a low-fat dietary pattern can reduce breast cancer risk has existed for decades but has never been tested in a controlled intervention trial. Objective To assess the effects of undertaking a low-fat dietary pattern on breast cancer incidence. Design and Setting A randomized, controlled, primary prevention trial conducted at 40 US clinical centers from 1993 to 2005. Participants A total of 48 835 postmenopausal women, aged 50 to 79 years, without prior breast cancer, including 18.6% of minority race/ethnicity, were enrolled. Interventions Women were randomly assigned to the dietary modification intervention group (40% [n = 19 541]) or the comparison group (60% [n = 29 294]). The intervention was designed to promote dietary change with the goals of reducing intake of total fat to 20% of energy and increasing consumption of vegetables and fruit to at least 5 servings daily and grains to at least 6 servings daily. Comparison group participants were not asked to make dietary changes. Main Outcome Measure Invasive breast cancer incidence. Results Dietary fat intake was significantly lower in the dietary modification intervention group compared with the comparison group. The difference between groups in change from baseline for percentage of energy from fat varied from 10.7% at year 1 to 8.1% at year 6. Vegetable and fruit consumption was higher in the intervention group by at least 1 serving per day and a smaller, more transient difference was found for grain consumption. The number of women who developed invasive breast cancer (annualized incidence rate) over the 8.1-year average follow-up period was 655 (0.42%) in the intervention group and 1072 (0.45%) in the comparison group (hazard ratio, 0.91; 95% confidence interval, 0.83-1.01 for the comparison between the 2 groups). Secondary analyses suggest a lower hazard ratio among adherent women, provide greater evidence of risk reduction among women having a high-fat diet at baseline, and suggest a dietary effect that varies by hormone receptor characteristics of the tumor. Conclusions Among postmenopausal women, a low-fat dietary pattern did not result in a statistically significant reduction in invasive breast cancer risk over an 8.1-year average follow-up period. However, the nonsignificant trends observed suggesting reduced risk associated with a low-fat dietary pattern indicate that longer, planned, nonintervention follow-up may yield a more definitive comparison.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Kaiser Permanente, Div Res, Oakland, CA USA; Harbor UCLA Res & Educ Inst, Torrance, CA USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Massachusetts, Fallon Clin, Worcester, MA 01605 USA; Univ Minnesota, Minneapolis, MN USA; Univ Florida, Gainesville, FL USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Miami, Miami, FL 33152 USA; Ohio State Univ, Columbus, OH 43210 USA; Emory Univ, Atlanta, GA 30322 USA; Univ Calif Davis, Sacramento, CA 95817 USA; NHLBI, Bethesda, MD 20892 USA; Univ Wisconsin, Madison, WI USA; Univ Alabama Birmingham, Birmingham, AL USA; Stanford Prevent Res Ctr, Stanford, CA USA; Univ Arizona, Tucson, AZ USA; Northwestern Univ, Chicago, IL 60611 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; SUNY Buffalo, Buffalo, NY 14260 USA; Univ Iowa, Iowa City, IA USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA; Pacific Hlth Res Inst, Honolulu, HI USA; MedStar Res Inst, Washington, DC USA; Howard Univ, Washington, DC 20059 USA; Brown Univ, Providence, RI 02912 USA; Univ Washington, Seattle, WA 98195 USA; Rush Univ, Med Ctr, Chicago, IL 60612 USA; Univ Nevada, Reno, NV 89557 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; NCI, Bethesda, MD 20892 USA; Univ Cincinnati, Cincinnati, OH USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ N Carolina, Chapel Hill, NC USA; Wayne State Univ, Sch Med, Detroit, MI USA; Hutzel Hosp, Detroit, MI 48201 USA; George Washington Univ, Washington, DC USA; Univ Calif Irvine, Irvine, CA 92717 USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; SUNY Stony Brook, Stony Brook, NY 11794 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA	Fred Hutchinson Cancer Center; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Massachusetts System; University of Massachusetts Worcester; University of Minnesota System; University of Minnesota Twin Cities; State University System of Florida; University of Florida; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Miami; University System of Ohio; Ohio State University; Emory University; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham; Stanford University; University of Arizona; Northwestern University; Wake Forest University; Wake Forest Baptist Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Iowa; Yeshiva University; Albert Einstein College of Medicine; Kaiser Permanente; Pacific Health Research & Education Institute; Howard University; Brown University; University of Washington; University of Washington Seattle; Rush University; Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Ohio; University of Cincinnati; Baylor College of Medicine; University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University; George Washington University; University of California System; University of California Irvine; University of Tennessee System; University of Tennessee Health Science Center; Medical College of Wisconsin; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center	Prentice, RL (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,M3-A410,POB 19024, Seattle, WA 98109 USA.	rprentice@whi.org	Wactawski-Wende, Jean/AGH-5457-2022	Wactawski-Wende, Jean/0000-0003-3096-9595; Hays-Grudo, Jennifer/0000-0002-8107-1243; Margolis, Karen/0000-0003-1862-7402; Caan, Bette/0000-0002-5803-310X				Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Bingham SA, 2003, LANCET, V362, P212, DOI 10.1016/S0140-6736(03)13913-X; Boyd NF, 2003, BRIT J CANCER, V89, P1672, DOI 10.1038/sj.bjc.6601314; Chatenoud L, 1998, INT J CANCER, V77, P24, DOI 10.1002/(SICI)1097-0215(19980703)77:1&lt;24::AID-IJC5&gt;3.0.CO;2-1; Chlebowski RT, 2005, J CLIN ONCOL, V23, p3S; Coates RJ, 1999, AM J EPIDEMIOL, V149, P1104, DOI 10.1093/oxfordjournals.aje.a009764; COX DR, 1972, J R STAT SOC B, V34, P187; Curb JD, 2003, ANN EPIDEMIOL, V13, pS122, DOI 10.1016/S1047-2797(03)00048-6; Day NE, 2001, INT J EPIDEMIOL, V30, P309, DOI 10.1093/ije/30.2.309; Freedman L, 1996, CONTROL CLIN TRIALS, V17, P509, DOI 10.1016/S0197-2456(96)00016-5; FREEDMAN LS, 1990, CANCER RES, V50, P5710; Fung TT, 2005, INT J CANCER, V116, P116, DOI 10.1002/ijc.20999; Gandini S, 2000, EUR J CANCER, V36, P636, DOI 10.1016/S0959-8049(00)00022-8; Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5; HEITMANN BL, 1995, BRIT MED J, V311, P986; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603; INSULL W, 1990, ARCH INTERN MED, V150, P421, DOI 10.1001/archinte.150.2.421; Jacobs DR, 1998, NUTR CANCER, V30, P85, DOI 10.1080/01635589809514647; Kalbfleisch JD, 2002, STAT ANAL FAILURE TI, P255; Kipnis V, 2001, AM J EPIDEMIOL, V153, P394, DOI 10.1093/aje/153.4.394; Lawlor DA, 2004, CANCER CAUSE CONTROL, V15, P267, DOI 10.1023/B:CACO.0000024225.14618.a8; Nicodemus KK, 2001, CANCER CAUSE CONTROL, V12, P917, DOI 10.1023/A:1013746719385; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6; Patterson RE, 2004, J AM DIET ASSOC, V104, P654, DOI 10.1016/j.jada.2004.01.014; Patterson RE, 2003, J AM DIET ASSOC, V103, P454, DOI 10.1053/jada.2003.50068; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; PIEGORSCH WW, 1994, STAT MED, V13, P153, DOI 10.1002/sim.4780130206; PRENTICE R, 1990, J NATL CANCER I, V82, P129, DOI 10.1093/jnci/82.2.129; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; Riboli E, 2003, AM J CLIN NUTR, V78, p559S, DOI 10.1093/ajcn/78.3.559S; Ritenbaugh C, 2003, ANN EPIDEMIOL, V13, pS87, DOI 10.1016/S1047-2797(03)00044-9; Robins JM, 2000, BIOMETRICS, V56, P779, DOI 10.1111/j.0006-341X.2000.00779.x; Rock CL, 2004, J CLIN ONCOL, V22, P2379, DOI 10.1200/JCO.2004.09.025; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; ROSE DP, 1993, BREAST CANCER RES TR, V27, P253, DOI 10.1007/BF00665695; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; Smith-Warner SA, 2001, JAMA-J AM MED ASSOC, V285, P769, DOI 10.1001/jama.285.6.769; Subar AF, 2003, AM J EPIDEMIOL, V158, P1, DOI 10.1093/aje/kwg092; Tinker Lesley Fels, 1996, P510; Toniolo P, 2000, INT J CANCER, V88, P828, DOI 10.1002/1097-0215(20001201)88:5<828::AID-IJC22>3.0.CO;2-8; [US Department of Health and Human Services and US Department of Agriculture US Department of Health and Human Services and US Department of Agriculture], 1990, NUTR YOUR HLTH DIET; *WORK IARC GROUP E, 2003, IARC HDB CANC PREV, V8; *WORLD CAN RES FUN, 1997, FOOD NUTR PREV CANC; Wu AH, 1999, J NATL CANCER I, V91, P529, DOI 10.1093/jnci/91.6.529	51	549	566	1	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2006	295	6					629	642		10.1001/jama.295.6.629	http://dx.doi.org/10.1001/jama.295.6.629			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010DX	16467232	Bronze			2023-01-03	WOS:000235168200023
J	Pui, CH; Evans, WE				Pui, CH; Evans, WE			Drug therapy - Treatment of acute lymphoblastic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE LYMPHOCYTIC-LEUKEMIA; GENE-EXPRESSION SIGNATURES; THYMIDYLATE SYNTHASE GENE; CENTRAL-NERVOUS-SYSTEM; TERM-FOLLOW-UP; STANDARD-RISK; TREATMENT RESPONSE; BONE-MARROW; CELL TRANSPLANTATION; CRANIAL RADIOTHERAPY		St Jude Childrens Res Hosp, Dept Hematol & Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Coll Med, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Pui, CH (corresponding author), St Jude Childrens Res Hosp, Dept Hematol & Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	ching-hon.pui@stjude.org	Pui, Ching-Hon/N-8076-2018; Evans, William E./C-2069-2012	Pui, Ching-Hon/0000-0003-0303-5658; Evans, William E./0000-0002-9333-5322	NATIONAL CANCER INSTITUTE [R37CA036401, R01CA078224, P30CA021765, R01CA060419, R01CA051001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061393] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA51001, R01 CA60419, R01 CA78224, R37 CA36401, CA21765] Funding Source: Medline; NIGMS NIH HHS [U01 GM61393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Annino L, 2002, BLOOD, V99, P863, DOI 10.1182/blood.V99.3.863; Arico M, 2000, NEW ENGL J MED, V342, P998, DOI 10.1056/NEJM200004063421402; Arico M, 2005, Leukemia, V19, P1145, DOI 10.1038/sj.leu.2403783; Armstrong SA, 2005, J CLIN ONCOL, V23, P6306, DOI 10.1200/JCO.2005.05.047; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Boissel N, 2003, J CLIN ONCOL, V21, P774, DOI 10.1200/JCO.2003.02.053; Bomgaars L, 2004, J CLIN ONCOL, V22, P3916, DOI 10.1200/JCO.2004.01.046; Bostrom BC, 2003, BLOOD, V101, P3809, DOI 10.1182/blood-2002-08-2454; Brown P, 2005, BLOOD, V105, P812, DOI 10.1182/blood-2004-06-2498; Burger B, 2003, J CLIN ONCOL, V21, P184, DOI 10.1200/JCO.2003.04.096; Cario G, 2005, BLOOD, V105, P821, DOI 10.1182/blood-2004-04-1552; Cheng Q, 2005, NAT GENET, V37, P878, DOI 10.1038/ng1612; Cheok MH, 2003, NAT GENET, V34, P85, DOI 10.1038/ng1151; Cheok MH, 2003, NAT GENET, V34, P231, DOI 10.1038/ng0603-231b; Chiaretti S, 2004, BLOOD, V103, P2771, DOI 10.1182/blood-2003-09-3243; Conter V, 2000, LEUKEMIA, V14, P2196, DOI 10.1038/sj.leu.2401963; Davies SM, 2002, BLOOD, V100, P67, DOI 10.1182/blood.V100.1.67; de Bont JM, 2004, LEUKEMIA, V18, P2032, DOI 10.1038/sj.leu.2403538; Duval M, 2002, BLOOD, V99, P2734, DOI 10.1182/blood.V99.8.2734; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Evans WE, 2004, NATURE, V429, P464, DOI 10.1038/nature02626; Evans WE, 1998, NEW ENGL J MED, V338, P499, DOI 10.1056/NEJM199802193380803; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Ferrando AA, 2004, LANCET, V363, P535, DOI 10.1016/S0140-6736(04)15542-6; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Fine BM, 2004, BLOOD, V103, P1043, DOI 10.1182/blood-2003-05-1518; French D, 2005, HUM MOL GENET, V14, P1621, DOI 10.1093/hmg/ddi170; Gaynon PS, 2000, LEUKEMIA, V14, P2223, DOI 10.1038/sj.leu.2401939; Gleissner B, 2002, BLOOD, V99, P1536, DOI 10.1182/blood.V99.5.1536; Goekbuget N, 2001, BLOOD, V98, p802A; Goldberg JM, 2003, J CLIN ONCOL, V21, P3616, DOI 10.1200/JCO.2003.10.116; Graux C, 2004, NAT GENET, V36, P1084, DOI 10.1038/ng1425; Gustafsson G, 2000, LEUKEMIA, V14, P2267, DOI 10.1038/sj.leu.2401961; Hallbook H, 2002, BRIT J HAEMATOL, V118, P748, DOI 10.1046/j.1365-2141.2002.03685.x; Harms DO, 2003, BLOOD, V102, P2736, DOI 10.1182/blood-2002-08-2372; Hijiya N, 2005, LEUKEMIA, V19, P1399, DOI 10.1038/sj.leu.2403843; Hill FGH, 2004, BRIT J HAEMATOL, V124, P33, DOI 10.1046/j.1365-2141.2003.04738.x; Hoelzer D, 2000, SEMIN ONCOL, V27, P540; Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513; Howard SC, 2002, JAMA-J AM MED ASSOC, V288, P2001, DOI 10.1001/jama.288.16.2001; Hunault M, 2004, BLOOD, V104, P3028, DOI 10.1182/blood-2003-10-3560; Hurwitz CA, 2000, CANCER-AM CANCER SOC, V88, P1964; Igarashi S, 2005, J CLIN ONCOL, V23, P6489, DOI 10.1200/JCO.2005.01.982; Imai C, 2005, BLOOD, V106, P376, DOI 10.1182/blood-2004-12-4797; Kager L, 2005, J CLIN INVEST, V115, P110, DOI 10.1172/JCI200522477; Kamps WA, 2002, LEUKEMIA, V16, P1099, DOI 10.1038/sj.leu.2402489; Kantarjian H, 2004, CANCER-AM CANCER SOC, V101, P2788, DOI 10.1002/cncr.20668; Kosaka Y, 2004, BLOOD, V104, P3527, DOI 10.1182/blood-2004-04-1390; Krajinovic M, 2002, LANCET, V359, P1033, DOI 10.1016/S0140-6736(02)08065-0; Kurtzberg J, 2005, J CLIN ONCOL, V23, P3396, DOI 10.1200/JCO.2005.03.199; Lange BJ, 2002, BLOOD, V99, P825, DOI 10.1182/blood.V99.3.825; Larson R. A., 2004, Annals of Hematology, V83, pS127; Laughlin MJ, 2004, NEW ENGL J MED, V351, P2265, DOI 10.1056/NEJMoa041276; Lauten M, 2003, HAEMATOLOGICA, V88, P353; Lee EJ, 2001, J CLIN ONCOL, V19, P4014, DOI 10.1200/JCO.2001.19.20.4014; Lee S, 2005, BLOOD, V105, P3449, DOI 10.1182/blood-2004-09-3785; Linker C, 2002, J CLIN ONCOL, V20, P2464, DOI 10.1200/JCO.2002.07.116; Lipshultz SE, 2005, J CLIN ONCOL, V23, P2629, DOI 10.1200/JCO.2005.12.121; Lipshultz SE, 2004, NEW ENGL J MED, V351, P145, DOI 10.1056/NEJMoa035153; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lugthart S, 2005, CANCER CELL, V7, P375, DOI 10.1016/j.ccr.2005.03.002; Mancini M, 2005, BLOOD, V105, P3434, DOI 10.1182/blood-2004-07-2922; Mattano LA, 2000, J CLIN ONCOL, V18, P3262, DOI 10.1200/JCO.2000.18.18.3262; McCarville MB, 2005, CANCER-AM CANCER SOC, V104, P380, DOI 10.1002/cncr.21134; Mitchell BS, 2003, NEW ENGL J MED, V348, P2597, DOI 10.1056/NEJMp030092; Mitchell CD, 2005, BRIT J HAEMATOL, V129, P734, DOI 10.1111/j.1365-2141.2005.05509.x; Nachman JB, 1998, NEW ENGL J MED, V338, P1663, DOI 10.1056/NEJM199806043382304; Nemecek ER, 2002, CURR OPIN HEMATOL, V9, P316, DOI 10.1097/00062752-200207000-00009; Nygaard U, 2004, CLIN PHARMACOL THER, V75, P274, DOI 10.1016/j.clpt.2003.12.-001; Patte C, 2001, BLOOD, V97, P3370, DOI 10.1182/blood.V97.11.3370; Pession A, 2005, J CLIN ONCOL, V23, P7161, DOI 10.1200/JCO.2005.11.411; Pinheiro JPV, 2004, BRIT J HAEMATOL, V125, P117, DOI 10.1111/j.1365-2141.2004.04863.x; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Pui C.-H., 2004, Annals of Hematology, V83, pS124; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; Pui CH, 2003, LEUKEMIA, V17, P700, DOI 10.1038/sj.leu.2402883; Pui CH, 2005, NAT REV DRUG DISCOV, V4, P369, DOI 10.1038/nrd1724; Pui CH, 2003, NEW ENGL J MED, V349, P1299; Pui CH, 2001, LANCET ONCOL, V2, P597, DOI 10.1016/S1470-2045(01)00516-2; Pui CH, 2003, J CLIN ONCOL, V21, P179, DOI 10.1200/JCO.2003.10.032; Pui CH, 2002, BEST PRACT RES CL HA, V15, P741, DOI 10.1053/beha.2002.0225; Pui CH, 2003, NEW ENGL J MED, V349, P640, DOI 10.1056/NEJMoa035091; Pui CH, 2004, BLOOD, V104, P2690, DOI 10.1182/blood-2004-04-1616; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Pui CH, 2001, LEUKEMIA, V15, P707, DOI 10.1038/sj.leu.2402111; Pui CH, 2003, JAMA-J AM MED ASSOC, V290, P2001, DOI 10.1001/jama.290.15.2001; Relling MV, 2000, LANCET, V356, P285, DOI 10.1016/S0140-6736(00)02503-4; Relling MV, 2001, NAT REV CANCER, V1, P99, DOI 10.1038/35101056; Relling MV, 1999, JNCI-J NATL CANCER I, V91, P2001, DOI 10.1093/jnci/91.23.2001; Rocha JCC, 2005, BLOOD, V105, P4752, DOI 10.1182/blood-2004-11-4544; Rocha V, 2004, NEW ENGL J MED, V351, P2276, DOI 10.1056/NEJMoa041469; Rubnitz JE, 2004, CANCER-AM CANCER SOC, V101, P1677, DOI 10.1002/cncr.20532; Sanders JE, 2005, BLOOD, V105, P3749, DOI 10.1182/blood-2004-08-3312; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Schrappe M, 2000, BLOOD, V95, P3310; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Silverman LB, 2001, BLOOD, V97, P1211, DOI 10.1182/blood.V97.5.1211; Stanulla M, 2005, JAMA-J AM MED ASSOC, V293, P1485, DOI 10.1001/jama.293.12.1485; Sutcliffe MJ, 2005, LEUKEMIA, V19, P734, DOI 10.1038/sj.leu.2403673; Takeuchi J, 2002, LEUKEMIA, V16, P1259, DOI 10.1038/sj.leu.2402526; ten Bosch JV, 2005, LEUKEMIA, V19, P721, DOI 10.1038/sj.leu.2403689; Thomas DA, 2004, BLOOD, V103, P4396, DOI 10.1182/blood-2003-08-2958; Thomas X, 2004, J CLIN ONCOL, V22, P4075, DOI 10.1200/JCO.2004.10.050; Toyoda Y, 2000, J CLIN ONCOL, V18, P1508, DOI 10.1200/JCO.2000.18.7.1508; Tsutsumi S, 2003, CANCER RES, V63, P4882; Vilmer E, 2000, LEUKEMIA, V14, P2257, DOI 10.1038/sj.leu.2401960; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Willenbrock H, 2004, LEUKEMIA, V18, P1270, DOI 10.1038/sj.leu.2403392; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Zaza G, 2005, BLOOD, V106, P1778, DOI 10.1182/blood-2005-01-0143	111	1381	1545	4	159	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 12	2006	354	2					166	178		10.1056/NEJMra052603	http://dx.doi.org/10.1056/NEJMra052603			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	001JE	16407512				2023-01-03	WOS:000234528600009
J	Bradley, TD; Logan, AG; Kimoff, RJ; Series, F; Morrison, D; Ferguson, K; Belenkie, I; Pfeifer, M; Fleetham, J; Hanly, P; Smilovitch, M; Tomlinson, G; Floras, JS				Bradley, TD; Logan, AG; Kimoff, RJ; Series, F; Morrison, D; Ferguson, K; Belenkie, I; Pfeifer, M; Fleetham, J; Hanly, P; Smilovitch, M; Tomlinson, G; Floras, JS		CANPAP Investigators	Continuous positive airway pressure for central sleep apnea and heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEYNE-STOKES RESPIRATION; NASAL CPAP; TRIAL; CARVEDILOL; MORTALITY; SURVIVAL	BACKGROUND: The Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure trial tested the hypothesis that continuous positive airway pressure (CPAP) would improve the survival rate without heart transplantation of patients who have central sleep apnea and heart failure. METHODS: After medical therapy was optimized, 258 patients who had heart failure (mean age [+/-SD], 63+/-10 years; ejection fraction, 24.5+/-7.7 percent) and central sleep apnea (number of episodes of apnea and hypopnea per hour of sleep, 40+/-16) were randomly assigned to receive CPAP (128 patients) or no CPAP (130 patients) and were followed for a mean of two years. During follow-up, sleep studies were conducted and measurements of the ejection fraction, exercise capacity, quality of life, and neurohormones were obtained. RESULTS: Three months after undergoing randomization, the CPAP group, as compared with the control group, had greater reductions in the frequency of episodes of apnea and hypopnea (-21+/-16 vs. -2+/-18 per hour, P<0.001) and in norepinephrine levels (-1.03+/-1.84 vs. 0.02+/-0.99 nmol per liter, P=0.009), and greater increases in the mean nocturnal oxygen saturation (1.6+/-2.8 percent vs. 0.4+/-2.5 percent, P<0.001), ejection fraction (2.2+/-5.4 percent vs. 0.4+/-5.3 percent, P=0.02), and the distance walked in six minutes (20.0+/-55 vs. -0.8+/-64.8 m, P=0.016). There were no differences between the control group and the CPAP group in the number of hospitalizations, quality of life, or atrial natriuretic peptide levels. An early divergence in survival rates without heart transplantation favored the control group, but after 18 months the divergence favored the CPAP group, yet the overall event rates (death and heart transplantation) did not differ (32 vs. 32 events, respectively; P=0.54). CONCLUSIONS: Although CPAP attenuated central sleep apnea, improved nocturnal oxygenation, increased the ejection fraction, lowered norepinephrine levels, and increased the distance walked in six minutes, it did not affect survival. Our data do not support the use of CPAP to extend life in patients who have central sleep apnea and heart failure.	Univ Toronto, Dept Med, Toronto, ON, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; Dalhousie Univ, Dept Med, Halifax, NS, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ Regensburg, Dept Med, D-8400 Regensburg, Germany	University of Toronto; McGill University; Laval University; Dalhousie University; Western University (University of Western Ontario); University of Calgary; University of British Columbia; University of Regensburg	Bradley, TD (corresponding author), Univ Hlth Network, Toronto Gen Hosp, Dept Med, Room 9N-943,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	douglas.bradley@utoronto.ca	Tomlinson, George A/L-5432-2016; Logan, Alexander G/E-4626-2013; Floras, John S./D-4042-2015	Tomlinson, George A/0000-0002-9328-6399; 				BONNET MH, 1992, SLEEP, V15, P526; Bradley TD, 2003, CIRCULATION, V107, P1671, DOI 10.1161/01.CIR.0000061757.12581.15; Bradley TD, 2003, CIRCULATION, V107, P1822, DOI 10.1161/01.CIR.0000061758.05044.64; Bradley TD, 2001, CAN J CARDIOL, V17, P677; BRADLEY TD, 1992, AM REV RESPIR DIS, V145, P377, DOI 10.1164/ajrccm/145.2_Pt_1.377; BUCKLE P, 1992, CHEST, V102, P31, DOI 10.1378/chest.102.1.31; Clark SA, 1998, AM J RESP CRIT CARE, V158, P713, DOI 10.1164/ajrccm.158.3.9708056; DAVIES RJO, 1993, AM REV RESPIR DIS, V147, P630, DOI 10.1164/ajrccm/147.3.630; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; FRANKLIN KA, 1995, LANCET, V345, P1085, DOI 10.1016/S0140-6736(95)90820-X; Freedman NJ, 2004, J CLIN INVEST, V113, P1379, DOI 10.1172/JCI200421748; GUILLEMINAULT C, 1993, SLEEP, V16, P524; GUYATT GH, 1989, J GEN INTERN MED, V4, P101, DOI 10.1007/BF02602348; Hanly PJ, 1996, AM J RESP CRIT CARE, V153, P272, DOI 10.1164/ajrccm.153.1.8542128; Javaheri S, 1998, CIRCULATION, V97, P2154, DOI 10.1161/01.CIR.97.21.2154; JOHNSTONE DE, 1994, CAN J CARDIOL, V10, P613; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; Kaye DM, 2001, CIRCULATION, V103, P2336; Lanfranchi PA, 1999, CIRCULATION, V99, P1435, DOI 10.1161/01.CIR.99.11.1435; Leung RST, 2001, AM J RESP CRIT CARE, V164, P2147, DOI 10.1164/ajrccm.164.12.2107045; MALONE S, 1991, LANCET, V338, P1480; Mansfield DR, 2004, AM J RESP CRIT CARE, V169, P361, DOI 10.1164/rccm.200306-752OC; McCullagh P., 2019, GEN LINEAR MODELS, DOI DOI 10.1007/978-1-4899-3242-6; NAUGHTON MT, 1995, CIRCULATION, V91, P1725, DOI 10.1161/01.CIR.91.6.1725; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V152, P473, DOI 10.1164/ajrccm.152.2.7633695; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V151, P92, DOI 10.1164/ajrccm.151.1.7812579; O'Keeffe ST, 1998, HEART, V80, P377, DOI 10.1136/hrt.80.4.377; Packer M, 1996, CIRCULATION, V94, P2793, DOI 10.1161/01.CIR.94.11.2793; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Redfield MM, 2003, JAMA-J AM MED ASSOC, V289, P194, DOI 10.1001/jama.289.2.194; SCHOENFELD DA, 1982, BIOMETRICS, V38, P163, DOI 10.2307/2530299; Sin DD, 1999, AM J RESP CRIT CARE, V160, P1101, DOI 10.1164/ajrccm.160.4.9903020; Sin DD, 2000, CIRCULATION, V102, P61, DOI 10.1161/01.CIR.102.1.61; STAATS BA, 1984, AM REV RESPIR DIS, V130, P59; Tkacova R, 1997, J AM COLL CARDIOL, V30, P739, DOI 10.1016/S0735-1097(97)00199-X; Usui K, 2005, J AM COLL CARDIOL, V45, P2008, DOI 10.1016/j.jacc.2004.12.080	38	755	784	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2005	353	19					2025	2033		10.1056/NEJMoa051001	http://dx.doi.org/10.1056/NEJMoa051001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981WV	16282177				2023-01-03	WOS:000233119600007
J	Marston, C; Meltzer, H; Majeed, A				Marston, C; Meltzer, H; Majeed, A			Impact on contraceptive practice of making emergency hormonal contraception available over the counter in Great Britain: repeated cross sectional surveys	BRITISH MEDICAL JOURNAL			English	Article							PLAN-B; SALES; FDA	Objective To examine the impact on contraceptive practice of making emergency hormonal contraception available over the counter. Design Analysis of data on contraceptive practice for women aged 16-49 years in the period 2000-2 from the Omnibus Survey, a multipurpose survey in which around 7600 adults living in private households are interviewed each year. Setting Private households in Great Britain. Main outcome measures Use of different types of contraception and rates of unprotected sex. Results After emergency hormonal contraception was made available over the counter, levels of use of different types of contraception by women aged 16-49 remained similar. No significant change occurred in the proportion of women using emergency hormonal contraception (8.4% in 2000,7.9% in 2001, 7.2% in 2002) or having unprotected sex. A change did, however, occur in where women obtained emergency hormonal contraception; a smaller proportion of women obtained emergency hormonal contraception from physicians and a greater proportion bought it over the counter. No significant change occurred in the proportion of women using more reliable methods of contraception, such as the oral contraceptive pill, or in the proportion of women using emergency hormonal contraception more than once during a year. Conclusions Making emergency hormonal contraception available over the counter does not seem to have led to an increase in its use, to an. increase in unprotected sex, or to a decrease in the use of more reliable methods of contraception.	Imperial Coll Fac Med, Dept Primary Care & Social Med, London W6 8RP, England; Off Natl Stat, London SW1V 2QQ, England	Imperial College London	Marston, C (corresponding author), Imperial Coll Fac Med, Dept Primary Care & Social Med, London W6 8RP, England.	c.marston@imperial.ac.uk	Meltzer, Herbert Y/E-8131-2013; Marston, Cicely A/T-3551-2017; Marston, Cicely/ABB-9376-2020	Marston, Cicely A/0000-0002-5529-4646; Majeed, Azeem/0000-0002-2357-9858				*AM LIF LEAG, ALLPRES J BROWN TEST; *AM LIF LEAG, ALL PRES J BROWN TES; Bissell P, 2003, SOC SCI MED, V57, P2367, DOI 10.1016/S0277-9536(03)00129-1; DAWE F, 2002, CONTRACEPTION SEXUAL; DAWE F, 2003, CONTRACEPTION SEXUAL; Drazen JM, 2004, NEW ENGL J MED, V350, P1561, DOI 10.1056/NEJMe048057; Fenichel RR, 2004, BMJ-BRIT MED J, V329, P182, DOI 10.1136/bmj.329.7459.182; Glasier A, 1998, NEW ENGL J MED, V339, P1, DOI 10.1056/NEJM199807023390101; Gold Melanie A, 2004, J Pediatr Adolesc Gynecol, V17, P87, DOI 10.1016/j.jpag.2003.11.018; Grimes DA, 2002, AM J OBSTET GYNECOL, V187, P1536, DOI 10.1067/mob.2002.128521; Harrison-Woolrych M, 2001, BRIT MED J, V322, P186; Jackson RA, 2003, OBSTET GYNECOL, V102, P8, DOI 10.1016/S0029-7844(03)00478-2; Kerins M, 2004, EMERG MED J, V21, P67, DOI 10.1136/emj.2003.007708; Mayor S, 2002, BRIT MED J, V324, P995; Nelson R, 2004, LANCET, V363, P1707, DOI 10.1016/S0140-6736(04)16290-9; Raine T, 2000, OBSTET GYNECOL, V96, P1, DOI 10.1016/S0029-7844(00)00830-9; Rothschild TJ, 2003, NEW ENGL J MED, V348, P82; Vastag B, 2004, JAMA-J AM MED ASSOC, V291, P2805, DOI 10.1001/jama.291.23.2805; Westhoff C, 2003, NEW ENGL J MED, V349, P1830, DOI 10.1056/NEJMcp031990; Williams C, 1996, BRIT MED J, V312, P463, DOI 10.1136/bmj.312.7029.463a	20	99	99	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 30	2005	331	7511					271	273		10.1136/bmj.38519.440266.8F	http://dx.doi.org/10.1136/bmj.38519.440266.8F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953FJ	16009669	Green Published, Green Submitted, Green Accepted, Bronze			2023-01-03	WOS:000231061700020
J	Ryan, DP; Fernandez-del Castillo, C; Willett, CG; Brugge, WR; Sahani, D; Brachtel, EF; Sahani, D				Ryan, DP; Fernandez-del Castillo, C; Willett, CG; Brugge, WR; Sahani, D; Brachtel, EF; Sahani, D			A 58-year-old man with locally advanced pancreatic cancer - Ductal adenocarcinoma of the pancreas, with residual microscopic tumor after chemoradiation therapy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESECTED ADENOCARCINOMA; ADJUVANT IRRADIATION; CHEMOTHERAPY; CARCINOMA; TRIAL; PHASE; PANCREATICODUODENECTOMY; DIAGNOSIS; MORTALITY; SURVIVAL		Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Div Gastroenterol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Duke University	Ryan, DP (corresponding author), Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA 02114 USA.		Castillo, Carlos Fenandez-del/AAO-2602-2020					[Anonymous], 1987, Cancer, V59, P2006; BAKKEVOLD KE, 1992, SCAND J GASTROENTERO, V27, P317, DOI 10.3109/00365529209000081; Balcom JH, 2001, ARCH SURG-CHICAGO, V136, P391, DOI 10.1001/archsurg.136.4.391; Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205; Centeno BA, 1999, FINE NEEDLE ASPIRATION BIOPSY OF THE PANCREAS, P109; CRIST DW, 1987, ANN SURG, V206, P358, DOI 10.1097/00000658-198709000-00014; EVANS DB, 1992, ARCH SURG-CHICAGO, V127, P1335; FOO ML, 1993, INT J RADIAT ONCOL, V26, P483, DOI 10.1016/0360-3016(93)90967-Z; HEYWOOD G, 1998, BIOSCIENCE, V3, pE175; Hoffman JP, 1998, J CLIN ONCOL, V16, P317, DOI 10.1200/JCO.1998.16.1.317; Ichikawa T, 1997, RADIOLOGY, V202, P655, DOI 10.1148/radiology.202.3.9051012; Jimenez RE, 2000, ARCH SURG-CHICAGO, V135, P409, DOI 10.1001/archsurg.135.4.409; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; KLOPPEL G, 2000, WHO CLASSIFICATION T, V2, P221; Lu DSK, 1997, AM J ROENTGENOL, V168, P1439, DOI 10.2214/ajr.168.6.9168704; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2001, ANN SURG, V234, P758, DOI 10.1097/00000658-200112000-00007; PERMERT J, 1991, INT J PANCREATOL, V9, P113; ROSCH T, 1992, GASTROENTEROLOGY, V102, P188; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; Spitz FR, 1997, J CLIN ONCOL, V15, P928, DOI 10.1200/JCO.1997.15.3.928; TEPPER JE, 1986, INT J RADIAT ONCOL, V12, P667, DOI 10.1016/0360-3016(86)90078-7; Vargas R, 2004, AM J ROENTGENOL, V182, P419, DOI 10.2214/ajr.182.2.1820419; WESTERDAHL J, 1993, HEPATO-GASTROENTEROL, V40, P384; WHITTINGTON R, 1991, INT J RADIAT ONCOL, V21, P1137, DOI 10.1016/0360-3016(91)90268-9; WILLETT CG, 1993, ANN SURG, V217, P144, DOI 10.1097/00000658-199302000-00008	26	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2005	352	26					2734	2741		10.1056/NEJMcpc059014	http://dx.doi.org/10.1056/NEJMcpc059014			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	940HH	15987923				2023-01-03	WOS:000230133800012
J	Edwards, M				Edwards, M			Historical keywords - Placebo	LANCET			English	Editorial Material									UCL, Wellcome Trust Ctr Hist Med, London, England	University of London; University College London	Edwards, M (corresponding author), UCL, Wellcome Trust Ctr Hist Med, London, England.	martin.edwards@ucl.ac.uk							0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 19	2005	365	9464					1023	1023						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	907QB	15781087				2023-01-03	WOS:000227731800012
J	Dore, GJ; Cooper, DA				Dore, Gregory J.; Cooper, David A.			HAART's first decade: success brings further challenges	LANCET			English	Editorial Material							HIV; RESISTANCE; INFECTION; AUSTRALIA		Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2010, Australia	University of New South Wales Sydney; Kirby Institute	Dore, GJ (corresponding author), Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2010, Australia.	gdore@nchecr.unsw.edu.au	Dore, Gregory John/ABD-5665-2021	Dore, Gregory John/0000-0002-4741-2622				Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Dore GJ, 2001, J ACQ IMMUN DEF SYND, V26, P283, DOI 10.1097/00126334-200103010-00012; ELSADR W, 2006, 13 C RETR OPP INF 20; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; May MT, 2006, LANCET, V368, P451, DOI 10.1016/S0140-6736(06)69152-6; McDonald AM, 2003, AUST NZ J PUBL HEAL, V27, P608, DOI 10.1111/j.1467-842X.2003.tb00607.x; Michailidis C, 2005, ANTIVIR THER, V10, P417; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pillay D, 2006, AIDS, V20, P21, DOI 10.1097/01.aids.0000196172.35056.b7; Pozniak AL, 2005, HIV MED, V6, P62, DOI 10.1111/j.1468-1293.2005.00293.x	11	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					427	428		10.1016/S0140-6736(06)69128-9	http://dx.doi.org/10.1016/S0140-6736(06)69128-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890810				2023-01-03	WOS:000239569000005
J	Cunningham, D; Allum, WH; Stenning, SP; Thompson, JN; Van de Velde, CJH; Nicolson, M; Scarffe, JH; Lofts, FJ; Falk, SJ; Iveson, TJ; Smith, DB; Langley, RE; Verma, M; Weeden, S; Chua, YJ				Cunningham, David; Allum, William H.; Stenning, Sally P.; Thompson, Jeremy N.; Van de Velde, Cornelis J. H.; Nicolson, Marianne; Scarffe, J. Howard; Lofts, Fiona J.; Falk, Stephen J.; Iveson, Timothy J.; Smith, David B.; Langley, Ruth E.; Verma, Monica; Weeden, Simon; Chua, Yu Jo		MAGIC Trial Participants	Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPH-NODE DISSECTION; OPERABLE GASTRIC-CANCER; ADJUVANT CHEMOTHERAPY; CURATIVE RESECTION; RANDOMIZED-TRIAL; CISPLATIN; FLUOROURACIL; EPIRUBICIN; METAANALYSIS; ADENOCARCINOMA	Background A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma. We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer. Methods We randomly assigned patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus to either perioperative chemotherapy and surgery (250 patients) or surgery alone (253 patients). Chemotherapy consisted of three preoperative and three postoperative cycles of intravenous epirubicin (50 mg per square meter of body-surface area) and cisplatin (60 mg per square meter) on day 1, and a continuous intravenous infusion of fluorouracil (200 mg per square meter per day) for 21 days. The primary end point was overall survival. Results ECF-related adverse effects were similar to those previously reported among patients with advanced gastric cancer. Rates of postoperative complications were similar in the perioperative-chemotherapy group and the surgery group (46 percent and 45 percent, respectively), as were the numbers of deaths within 30 days after surgery. The resected tumors were significantly smaller and less advanced in the perioperative-chemotherapy group. With a median follow-up of four years, 149 patients in the perioperative-chemotherapy group and 170 in the surgery group had died. As compared with the surgery group, the perioperative-chemotherapy group had a higher likelihood of overall survival (hazard ratio for death, 0.75; 95 percent confidence interval, 0.60 to 0.93; P=0.009; five-year survival rate, 36 percent vs. 23 percent) and of progression-free survival (hazard ratio for progression, 0.66; 95 percent confidence interval, 0.53 to 0.81; P<0.001). Conclusions In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival.	Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England; Royal Marsden Hosp, Dept Surg, Sutton SM2 5PT, Surrey, England; Royal Marsden Hosp, Dept Med, London SW3 6JJ, England; Royal Marsden Hosp, Dept Surg, London SW3 6JJ, England; MRC, Clin Trials Unit, Canc Grp, London, England; Aberdeen Royal Infirm, Aberdeen, Scotland; Christie Hosp, Dept Med Oncol, Manchester, Lancs, England; St George Hosp, Dept Med Oncol, London, England; Bristol Haematol & Oncol Ctr, Dept Oncol, Bristol, Avon, England; Southampton Gen Hosp, Med Oncol Unit, Southampton SO9 4XY, Hants, England; Clatterbridge Ctr Oncol, Liverpool, Merseyside, England; Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Medical Research Council Clinical Trials Unit; University of Aberdeen; Christie NHS Foundation Trust; Christie Hospital; St Georges University London; Bristol Haematology & Oncology Centre; University of Southampton; Clatterbridge Cancer Centre; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Cunningham, D (corresponding author), Royal Marsden Hosp, Dept Med, Downs Rd, Sutton SM2 5PT, Surrey, England.	david.cunningham@rmh.nhs.uk	van de Velde, Cornelis/AAY-8360-2020	Iveson, Timothy/0000-0002-4681-2712; Cunningham, David/0000-0001-5158-1069	MRC [MC_U122861327] Funding Source: UKRI; Medical Research Council [MC_U122861327] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALLUM W, 2003, P AN M AM SOC CLIN, V22, P249; ALLUM WH, 1989, BRIT J CANCER, V60, P739, DOI 10.1038/bjc.1989.350; ALLUM WH, 1989, LANCET, V1, P571; Bancewicz J, 2002, LANCET, V359, P1727; Bonenkamp JJ, 1999, NEW ENGL J MED, V340, P908, DOI 10.1056/NEJM199903253401202; Cuschieri A, 1999, BRIT J CANCER, V79, P1522, DOI 10.1038/sj.bjc.6690243; Earle CC, 1999, EUR J CANCER, V35, P1059, DOI 10.1016/S0959-8049(99)00076-3; FINDLAY M, 1994, ANN ONCOL, V5, P609, DOI 10.1093/oxfordjournals.annonc.a058932; Hartgrink HH, 2004, EJSO-EUR J SURG ONC, V30, P643, DOI 10.1016/j.ejso.2004.04.013; Hartgrink HH, 2004, J CLIN ONCOL, V22, P2069, DOI 10.1200/JCO.2004.08.026; Hermanek P, 1987, TNM CLASSIFICATION M; HERMANS J, 1993, J CLIN ONCOL, V11, P1441, DOI 10.1200/JCO.1993.11.8.1441; MACDONALD JS, 1995, ANN SURG ONCOL, V2, P488, DOI 10.1007/BF02307081; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; Mari E, 2000, ANN ONCOL, V11, P837, DOI 10.1023/A:1008377101672; McCulloch P, 2004, COCHRANE DB SYST REV, V4; Ross P, 2002, J CLIN ONCOL, V20, P1996, DOI 10.1200/JCO.2002.08.105; Sasako M, 1997, GASTRIC CANCER -BOOK, P223; SIEWERT JR, 1993, BRIT J SURG, V80, P1015, DOI 10.1002/bjs.1800800829; SUELING HM, 1993, BMJ-BRIT MED J, V307, P591, DOI 10.1136/bmj.307.6904.591; Sumpter K, 2005, BRIT J CANCER, V92, P1976, DOI 10.1038/sj.bjc.6602572; Wagner AD, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub2; Waters JS, 1999, BRIT J CANCER, V80, P269, DOI 10.1038/sj.bjc.6690350; Webb A, 1997, J CLIN ONCOL, V15, P261, DOI 10.1200/JCO.1997.15.1.261	24	4250	4533	8	214	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 6	2006	355	1					11	20		10.1056/NEJMoa055531	http://dx.doi.org/10.1056/NEJMoa055531			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	060DT	16822992				2023-01-03	WOS:000238783200003
J	Parson, A				Parson, A			The long journey from stem cells to medical product	CELL			English	Editorial Material								There is much interest in developing stem cells and the cells derived from them as therapies for treating human disease and injury, but many biological, technological and regulatory hurdles have to be overcome before these cell therapies can be brought to commercial fruition.											0	23	23	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 7	2006	125	1					9	11		10.1016/j.cell.2006.03.024	http://dx.doi.org/10.1016/j.cell.2006.03.024			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	039NY	16615881	Bronze			2023-01-03	WOS:000237314200005
J	Chen, TY; Smith, W; Rosenstock, JL; Lessnau, KD				Chen, TY; Smith, W; Rosenstock, JL; Lessnau, KD			A life-threatening complication of Atkins diet	LANCET			English	Editorial Material							WEIGHT		New York Sch Med, New York, NY 10128 USA; Lenox Hill Hosp, Dept Med, New York, NY 10028 USA	Northwell Health	Lessnau, KD (corresponding author), New York Sch Med, 300 E 93rd St 18B, New York, NY 10128 USA.	KLessnau@pol.net						Astrup A, 2004, LANCET, V364, P897, DOI 10.1016/S0140-6736(04)16986-9; Atkins RC, 1972, ATKINS DIET REVOLUTI; Ballaban-Gil K, 1998, EPILEPSIA, V39, P744, DOI 10.1111/j.1528-1157.1998.tb01160.x; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Toth HL, 2003, AM J KIDNEY DIS, V42, DOI 10.1053/S0272-6386(03)01023-0	5	49	51	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2006	367	9514					958	958		10.1016/S0140-6736(06)68394-3	http://dx.doi.org/10.1016/S0140-6736(06)68394-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	025CE	16546552				2023-01-03	WOS:000236242100040
J	Dominici, F; Peng, RD; Bell, ML; Pham, L; McDermott, A; Zeger, SL; Samet, JM				Dominici, F; Peng, RD; Bell, ML; Pham, L; McDermott, A; Zeger, SL; Samet, JM			Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TIME-SERIES; DISTRIBUTED LAG; DAILY MORTALITY; US CITIES; RESPONSE RELATIONSHIPS; NATIONAL MORBIDITY; UNITED-STATES; CLAIMS DATA; EXPOSURE; MODELS	Context Evidence on the health risks associated with short-term exposure to fine particles (particulate matter <= 2.5 mu m in aerodynamic diameter [PM2.5]) is limited. Results from the new national monitoring network for PM2.5 make possible systematic research on health risks at national and regional scales. Objectives To estimate risks of cardiovascular and respiratory hospital admissions associated with short-term exposure to PM2.5 for Medicare enrollees and to explore heterogeneity of the variation of risks across regions. Design, Setting, and Participants A national database comprising daily time-series data daily for 1999 through 2002 on hospital admission rates (constructed from the Medicare National Claims History Files) for cardiovascular and respiratory outcomes and injuries, ambient PM2.5 levels, and temperature and dew-point temperature for 204 US urban counties (population >200 000) with 11.5 million Medicare enrollees (aged >65 years) living an average of 5.9 miles from a PM2.5 monitor. Main Outcome Measures Daily counts of county-wide hospital admissions for primary diagnosis of cerebrovascular, peripheral, and ischemic heart diseases, heart rhythm, heart failure, chronic obstructive pulmonary disease, and respiratory infection, and injuries as a control outcome. Results There was a short-term increase in hospital admission rates associated with PM2.5 for all of the health outcomes except injuries. The largest association was for heart failure, which had a 1.28% (95% confidence interval, 0.78%-1.78%) increase in risk per 10-mu g/m(3) increase in same-day PM2.5. Cardiovascular risks tended to be higher in counties located in the Eastern region of the United States, which included the Northeast, the Southeast, the Midwest, and the South. Conclusion Short-term exposure to PM2.5 increases the risk for hospital admission for cardiovascular and respiratory diseases.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Yale University	Dominici, F (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, 615 N Wolfe St, Baltimore, MD 21205 USA.	fdominic@jhsph.edu	Bell, Michelle/Y-4608-2018	Bell, Michelle/0000-0002-3965-1359; Zeger, Scott/0000-0001-8907-1603	NIEHS NIH HHS [P30 ES003819, ES012054-03, R01 ES012054, P30 ES 03819] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012054, P30ES003819] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALMON S, 1965, ECONOMETRICA, V33, P178, DOI 10.2307/1911894; BAICKER K, 2004, HLTH AFF MILLWOOD, V23; Bell ML, 2005, EPIDEMIOLOGY, V16, P436, DOI 10.1097/01.ede.0000165817.40152.85; Bell ML, 2004, JAMA-J AM MED ASSOC, V292, P2372, DOI 10.1001/jama.292.19.2372; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Burnett RT, 1997, ENVIRON HEALTH PERSP, V105, P614, DOI 10.2307/3433607; *CLEAN AIR SCI ADV, 2005, REV NAT AMB AIR QUAL; Curriero FC, 2002, AM J EPIDEMIOL, V155, P80, DOI 10.1093/aje/155.1.80; Dominici F, 2000, J ROY STAT SOC A STA, V163, P263, DOI 10.1111/1467-985X.00170; Dominici F, 2004, J AM STAT ASSOC, V99, P938, DOI 10.1198/016214504000000656; Dominici F, 2002, J AM STAT ASSOC, V97, P100, DOI 10.1198/016214502753479266; DOMINID F, 2003, REVISED ANAL TIME SE; DUMOUCHEL WH, 1983, J AM STAT ASSOC, V78, P293, DOI 10.2307/2288631; Everson PJ, 2000, J ROY STAT SOC B, V62, P399, DOI 10.1111/1467-9868.00239; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; Gelman A., 2003, BAYESIAN DATA ANAL; Hartigan J. A., 1975, CLUSTERING ALGORITHM; Havranek EP, 2004, ARCH INTERN MED, V164, P1186, DOI 10.1001/archinte.164.11.1186; Ito K, 2005, EPIDEMIOLOGY, V16, P446, DOI 10.1097/01.ede.0000165821.90114.7f; Kelsall JE, 1997, AM J EPIDEMIOL, V146, P750; Kiyota Y, 2004, AM HEART J, V148, P99, DOI 10.1016/j.ahj.2004.02.013; Kunzli N, 2005, ENVIRON HEALTH PERSP, V113, P201, DOI 10.1289/ehp.7523; Le Tertre A, 2002, J EPIDEMIOL COMMUN H, V56, P773, DOI 10.1136/jech.56.10.773; LINDLEY DV, 1972, J ROY STAT SOC B, V34, P1; Lippmann M, 2000, Res Rep Health Eff Inst, P5; Losina E, 2003, J CLIN EPIDEMIOL, V56, P515, DOI 10.1016/S0895-4356(03)00056-8; MacQueen J., 1967, P BERK S MATH STAT P; McCullagh P., 1989, GEN LINEAR MODELS; Moolgavkar SH, 2000, ENVIRON HEALTH PERSP, V108, P777, DOI 10.2307/3434732; Moolgavkar SH, 2000, INHAL TOXICOL, V12, P75, DOI 10.1080/089583700750019512; *NAT RES COUNC COM, 2004, RES PRIOR AIRB PART, V4; National Center for Environmental Assessment, 2004, AIR QUAL CRIT PART M; *OFF AIR QUAL PLAN, 2000, QUAL ASS PROJ PLAN P; Peng RD, 2006, J R STAT SOC A STAT, V169, P179, DOI 10.1111/j.1467-985X.2006.00410.x; Peng RD, 2005, AM J EPIDEMIOL, V161, P585, DOI 10.1093/aje/kwi075; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Pope CA, 2004, ENVIRON HEALTH PERSP, V112, P339, DOI 10.1289/ehp.6588; *R FDN STAT COMP, 2005, R LANG ENV STAT COMP; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Samoli E, 2005, ENVIRON HEALTH PERSP, V113, P88, DOI 10.1289/ehp.7387; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; SHEPPARD L, 2003, REVISED ANAL TIME SE, P227; Stieb DM, 2003, J AIR WASTE MANAGE, V53, P258, DOI 10.1080/10473289.2003.10466149; Sun QH, 2005, JAMA-J AM MED ASSOC, V294, P3003, DOI 10.1001/jama.294.23.3003; Touloumi G, 1997, AM J EPIDEMIOL, V146, P177, DOI 10.1093/oxfordjournals.aje.a009249; Touloumi G, 2005, EPIDEMIOLOGY, V16, P49, DOI 10.1097/01.ede.0000142152.62400.13; *US EPA, 1997, FED REGISTER, V62, P138; *US EPA OFF RES DE, 1996, AIR QUAL CRIT PART M; Welty LJ, 2005, AM J EPIDEMIOL, V162, P80, DOI 10.1093/aje/kwi157; *WHO, 1977, INT CLASSIFICATION D, V9; Zanobetti A, 2000, Biostatistics, V1, P279, DOI 10.1093/biostatistics/1.3.279	52	1814	1913	11	630	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2006	295	10					1127	1134		10.1001/jama.295.10.1127	http://dx.doi.org/10.1001/jama.295.10.1127			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019GB	16522832	Bronze, Green Accepted			2023-01-03	WOS:000235822500020
J	Howard, BV; Van Horn, L; Hsia, J; Manson, JE; Stefanick, ML; Wassertheil-Smoller, S; Kuller, LH; LaCroix, AZ; Langer, RD; Lasser, NL; Lewis, CE; Limacher, MC; Margolis, KL; Mysiw, J; Ockene, JK; Parker, LM; Perri, MG; Phillips, L; Prentice, RL; Robbins, J; Rossouw, JE; Sarto, GE; Schatz, IJ; Snetselaar, LG; Stevens, VJ; Tinker, LF; Trevisan, M; Vitolins, MZ; Anderson, GL; Assaf, AR; Bassford, T; Beresford, SAA; Black, HR; Brunner, RL; Brzyski, RG; Caan, B; Chlebowski, RT; Gass, M; Granek, I; Greenland, P; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Hubbell, FA; Johnson, KC; Kotchen, JM				Howard, BV; Van Horn, L; Hsia, J; Manson, JE; Stefanick, ML; Wassertheil-Smoller, S; Kuller, LH; LaCroix, AZ; Langer, RD; Lasser, NL; Lewis, CE; Limacher, MC; Margolis, KL; Mysiw, J; Ockene, JK; Parker, LM; Perri, MG; Phillips, L; Prentice, RL; Robbins, J; Rossouw, JE; Sarto, GE; Schatz, IJ; Snetselaar, LG; Stevens, VJ; Tinker, LF; Trevisan, M; Vitolins, MZ; Anderson, GL; Assaf, AR; Bassford, T; Beresford, SAA; Black, HR; Brunner, RL; Brzyski, RG; Caan, B; Chlebowski, RT; Gass, M; Granek, I; Greenland, P; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Hubbell, FA; Johnson, KC; Kotchen, JM			Low-fat dietary pattern and risk of cardiovascular disease - The Women's Health Initiative randomized controlled dietary modification trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BASE-LINE CHARACTERISTICS; CORONARY-HEART-DISEASE; PREVENTION; INTERVENTION; METAANALYSIS; STROKE; CANCER	Context Multiple epidemiologic studies and some trials have linked diet with cardiovascular disease (CVD) prevention, but long-term intervention data are needed. Objective To test the hypothesis that a dietary intervention, intended to be low in fat and high in vegetables, fruits, and grains to reduce cancer, would reduce CVD risk. Design, Setting, and Participants Randomized controlled trial of 48 835 postmenopausal women aged 50 to 79 years, of diverse backgrounds and ethnicities, who participated in the Women's Health Initiative Dietary Modification Trial. Women were randomly assigned to an intervention (19 541 [40%]) or comparison group (29 294 [60%]) in a free-living setting. Study enrollment occurred between 1993 and 1998 in 40 US clinical centers; mean follow-up in this analysis was 8.1 years. Intervention Intensive behavior modification in group and individual sessions designed to reduce total fat intake to 20% of calories and increase intakes of vegetables/fruits to 5 servings/d and grains to at least 6 servings/d. The comparison group received diet-related education materials. Main Outcome Measures Fatal and nonfatal coronary heart disease (CHD), fatal and nonfatal stroke, and CVD (composite of CHD and stroke). Results By year 6, mean fat intake decreased by 8.2% of energy intake in the intervention vs the comparison group, with small decreases in saturated (2.9%), monounsaturated (3.3%), and polyunsaturated (1.5%) fat; increases occurred in intakes of vegetables/fruits (1.1 servings/d) and grains (0.5 serving/d). Low-density lipoprotein cholesterol levels, diastolic blood pressure, and factor VIIc levels were significantly reduced by 3.55 mg/dL, 0.31 mm Hg, and 4.29%, respectively; levels of high-density lipoprotein cholesterol, triglycerides, glucose, and insulin did not significantly differ in the intervention vs comparison groups. The numbers who developed CHD, stroke, and CVD (annualized incidence rates) were 1000 (0.63%), 434 (0.28%), and 1357 (0.86%) in the intervention and 1549 (0.65%), 642 (0.27%), and 2088 (0.88%) in the comparison group. The diet had no significant effects on incidence of CHD (hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.90-1.06), stroke (HR, 1.02; 95% CI, 0.90-1.15), or CVD (HR, 0.98; 95% CI, 0.92-1.05). Excluding participants with baseline CVD (3.4%), the HRs (95% CIs) for CHD and stroke were 0.94 (0.86-1.02) and 1.02 (0.90-1.17), respectively. Trends toward greater reductions in CHD risk were observed in those with lower intakes of saturated fat or trans fat or higher intakes of vegetables/fruits. Conclusions Over a mean of 8.1 years, a dietary intervention that reduced total fat intake and increased intakes of vegetables, fruits, and grains did not significantly reduce the risk of CHD, stroke, or CVD in postmenopausal women and achieved only modest effects on CVD risk factors, suggesting that more focused diet and lifestyle interventions may be needed to improve risk factors and reduce CVD risk.	Howard Univ, MedStar Res Inst, Washington, DC 20059 USA; Northwestern Univ, Chicago, IL 60611 USA; George Washington Univ, Washington, DC USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; Stanford Prevent Res Ctr, Stanford, CA USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Univ Pittsburgh, Pittsburgh, PA USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Calif San Diego, San Diego, CA 92103 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Florida, Gainesville, FL USA; Univ Minnesota, Minneapolis, MN USA; Ohio State Univ, Columbus, OH 43210 USA; Univ Massachusetts, Fallon Clin, Worcester, MA 01605 USA; Univ Miami, Miami, FL 33152 USA; Emory Univ, Atlanta, GA 30322 USA; Univ Calif Davis, Davis, CA 95616 USA; NHLBI, Bethesda, MD 20892 USA; Univ Wisconsin, Madison, WI USA; Univ Hawaii, Honolulu, HI 96822 USA; Univ Iowa, Iowa City, IA USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA; Univ Buffalo, Buffalo, NY USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; Brown Univ, Providence, RI 02912 USA; Univ Arizona, Tucson, AZ USA; Rush Univ, Med Ctr, Chicago, IL 60612 USA; Univ Nevada, Reno, NV 89557 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Kaiser Permanente, Div Res, Oakland, CA USA; Harbor UCLA Res & Educ Inst, Torrance, CA USA; Univ Cincinnati, Cincinnati, OH USA; SUNY Stony Brook, Stony Brook, NY 11794 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ N Carolina, Chapel Hill, NC USA; Wayne State Univ, Sch Med, Hutzel Hosp, Detroit, MI USA; Univ Calif Irvine, Irvine, CA USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA	Howard University; Northwestern University; George Washington University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Stanford University; Yeshiva University; Albert Einstein College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fred Hutchinson Cancer Center; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Alabama System; University of Alabama Birmingham; State University System of Florida; University of Florida; University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; Ohio State University; University of Massachusetts System; University of Massachusetts Worcester; University of Miami; Emory University; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Wisconsin System; University of Wisconsin Madison; University of Hawaii System; University of Iowa; Kaiser Permanente; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Wake Forest University; Wake Forest Baptist Medical Center; Brown University; University of Arizona; Rush University; Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Texas System; University of Texas Health San Antonio; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University System of Ohio; University of Cincinnati; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Baylor College of Medicine; University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University; University of California System; University of California Irvine; University of Tennessee System; University of Tennessee Health Science Center; Medical College of Wisconsin	Howard, BV (corresponding author), MedStar Res Inst, 6495 New Hampshire Ave,Suite 201, Hyattsville, MD 20783 USA.	barbara.v.howard@medstar.net	Greenland, Philip/ABD-5528-2021	Caan, Bette/0000-0002-5803-310X; Margolis, Karen/0000-0003-1862-7402; Perri, Michael/0000-0003-3651-1542; trevisan, maurizio/0000-0001-5479-0050; Hays-Grudo, Jennifer/0000-0002-8107-1243				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; [Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], [No title captured]; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Beresford SAA, 2006, JAMA-J AM MED ASSOC, V295, P643, DOI 10.1001/jama.295.6.643; Bowen D, 2002, J AM DIET ASSOC, V102, P1631, DOI 10.1016/S0002-8223(02)90347-0; Chanmugam P, 2003, J AM DIET ASSOC, V103, P867, DOI 10.1016/S0002-8223(03)00381-X; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Curb JD, 2003, ANN EPIDEMIOL, V13, pS122, DOI 10.1016/S1047-2797(03)00048-6; DAYTON S, 1969, CIRCULATION S2, V60, P111; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Franz MJ, 2002, DIABETES CARE, V25, P148, DOI 10.2337/diacare.25.1.148; Fung TT, 2004, STROKE, V35, P2014, DOI 10.1161/01.STR.0000135762.89154.92; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; Hellerstein MK, 2002, CURR OPIN LIPIDOL, V13, P33, DOI 10.1097/00041433-200202000-00006; Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P39, DOI 10.1001/jama.295.1.39; Jackson RD, 2003, ANN EPIDEMIOL, V13, pS98, DOI 10.1016/S1047-2797(03)00046-2; KEYS A, 1982, PROG BIOCHEM PHARM, V19, P1; Krauss RM, 2000, CIRCULATION, V102, P2284; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; Liu S, 2000, AM J CLIN NUTR, V72, P922; Liu SM, 1999, AM J CLIN NUTR, V70, P412; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; Oh K, 2005, AM J EPIDEMIOL, V161, P672, DOI 10.1093/aje/kwi085; Ornish D, 1998, JAMA-J AM MED ASSOC, V280, P2001, DOI 10.1001/jama.280.23.2001; Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6; Patterson RE, 2003, J AM DIET ASSOC, V103, P454, DOI 10.1053/jada.2003.50068; Pereira MA, 2003, J WOMEN HEALTH GEN-B, V12, P115, DOI 10.1089/154099903321576501; Prentice RL, 2006, JAMA-J AM MED ASSOC, V295, P629, DOI 10.1001/jama.295.6.629; Ritenbaugh C, 2003, ANN EPIDEMIOL, V13, pS87, DOI 10.1016/S1047-2797(03)00044-9; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0; Subar AF, 2003, AM J EPIDEMIOL, V158, P1, DOI 10.1093/aje/kwg092; Tinker Lesley Fels, 1996, P510; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; Wang CY, 1999, BIOMETRICS, V55, P711, DOI 10.1111/j.0006-341X.1999.00711.x; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X	41	756	774	3	93	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2006	295	6					655	666		10.1001/jama.295.6.655	http://dx.doi.org/10.1001/jama.295.6.655			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010DX	16467234	Bronze			2023-01-03	WOS:000235168200025
J	Smith, IE; Chua, S				Smith, IE; Chua, S			ABC of breast diseases - Medical treatment of early breast cancer. III. chemotherapy	BRITISH MEDICAL JOURNAL			English	Editorial Material							ADJUVANT CHEMOTHERAPY											Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Martin M, 2005, NEW ENGL J MED, V352, P2302, DOI 10.1056/NEJMoa043681; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306	4	5	5	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 21	2006	332	7534					161	162		10.1136/bmj.332.7534.161	http://dx.doi.org/10.1136/bmj.332.7534.161			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	006OC	16424494	Green Published			2023-01-03	WOS:000234905800027
J	Tectonidis, M				Tectonidis, M			Crisis in Niger - Outpatient care for severe acute malnutrition	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Med Frontieres, Dept Med, Paris, France	Sanofi-Aventis; Sanofi France	Tectonidis, M (corresponding author), Med Frontieres, Dept Med, Paris, France.							Briend A, 1999, LANCET, V353, P1767, DOI 10.1016/S0140-6736(99)01078-8; Collins S, 2001, LANCET, V358, P498, DOI 10.1016/S0140-6736(01)05630-6	2	21	21	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					224	227		10.1056/NEJMp058240	http://dx.doi.org/10.1056/NEJMp058240			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421363				2023-01-03	WOS:000234661100002
J	Adam, T; Lim, SS; Mehta, S; Bhutta, ZA; Fogstad, H; Mathai, M; Zupan, J; Darmstadt, GL				Adam, T; Lim, SS; Mehta, S; Bhutta, ZA; Fogstad, H; Mathai, M; Zupan, J; Darmstadt, GL			Achieving the millennium development goals for health - Cost effectiveness analysis of strategies for. maternal and neonatal health in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EFFECTIVE INTERVENTIONS; IMPROVING HEALTH	Objective To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. Design Cost effectiveness analysis. Setting Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. Data sources Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantifies came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. Main outcome measures Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. Results The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. Conclusion Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.	Univ Queensland, Sch Populat Hlth, St Lucia, Qld 4067, Australia; WHO, Dept Making Pregnancy Safer, CH-1211 Geneva, Switzerland; Hlth Effects Inst, Boston, MA USA; Aga Khan Univ, Karachi, Pakistan; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA	University of Queensland; World Health Organization; Health Effects Institute (HEI); Aga Khan University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Lim, SS (corresponding author), Univ Queensland, Sch Populat Hlth, St Lucia, Qld 4067, Australia.	s.lim@sph.uq.edu.au	Darmstadt, Gary/AAU-7488-2020; Lim, Stephen S/B-4055-2012	Darmstadt, Gary/0000-0002-7522-5824				ALUER JA, 2003, COS EFF RESOUR ALLOC, V1; [Anonymous], 2022, BMJ, V378, DOI [DOI 10.1136/BMJ.38643.368692.68, 10.1136/bmj-2021-068384, DOI 10.1136/BMJ.O2284]; Baltussen R, 2004, J NUTR, V134, P2678, DOI 10.1093/jn/134.10.2678; BALTUSSEN R, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38645.660093.68; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Department of Reproductive Health and Research World Health Organization, 2004, MAT MORT 2000 EST DE; EDEJER TTT, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38652.550278.7C; Evans DB, 2005, BMJ-BRIT MED J, V331, P1133, DOI 10.1136/bmj.331.7525.1133; Evans DB, 2005, BMJ-BRIT MED J, V331, P1137, DOI 10.1136/bmj.331.7525.1137; EVANS DB, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38658.675243.94; Griffiths UK, 2004, B WORLD HEALTH ORGAN, V82, P643; Horton S, 1996, HEALTH POLICY PLANN, V11, P156, DOI 10.1093/heapol/11.2.156; Kulier R, 2004, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002855.PUB3; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; MOREL C, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38639.702384.AE; NAKHAEE N, 2002, E MEDITERR HLTH J, V8, P53; Nanda G., 2005, ACCELERATING PROGR A; Stevens TP, 2004, COCHRANE DB SYST REV, V3; Terris-Prestholt F, 2003, SEX TRANSM INFECT, V79, P375, DOI 10.1136/sti.79.5.375; WHO UNICEF UNFPA, 2003, PREGN CHILDB POSTP N; World Health Organization, 2002, WHORHR0130; World Health Organization, 2003, WHORHR007; World Health Organization, 2005, WORLD HLTH REPORT 20; World Health Organization, 2003, MAN NEWB PROBL GUID	24	215	221	1	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	2005	331	7525					1107	1110		10.1136/bmj.331.7525.1107	http://dx.doi.org/10.1136/bmj.331.7525.1107			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	985ZI	16282407	Green Published, Bronze			2023-01-03	WOS:000233417300012
J	Hickey, M; Davis, SR; Sturdee, DW				Hickey, M; Davis, SR; Sturdee, DW			Treatment of menopausal symptoms: what shall we do now?	LANCET			English	Review							HORMONE-REPLACEMENT THERAPY; ESTROGEN PLUS PROGESTIN; VENOUS THROMBOEMBOLIC DISEASE; HEALTHY POSTMENOPAUSAL WOMEN; CONJUGATED EQUINE ESTROGENS; MILD COGNITIVE IMPAIRMENT; CORONARY-HEART-DISEASE; LONG-TERM TREATMENT; BREAST-CANCER; HOT FLASHES	During the past few years, many women and doctors have revised their opinions of hormone replacement therapy (HRT) for menopausal symptoms, and a substantial number of individuals have discontinued its use because of concerns about side-effects. Numerous alternatives to HRT are promoted, and assessment of the quality of evidence about the safety and effectiveness of these compounds can be difficult. In this Review, we summarise the data from studies addressing the efficacy, risks, and benefits of frequently prescribed treatments, and offer evidence-based clinical guidelines for the management of menopausal symptoms. Although few comparative studies exist, oestrogen alone or combinations of oestrogen and progestagen are likely to be the most effective treatments for menopausal hot flushes and vaginal dryness. Tibolone is as effective as HRT, however, and might also improve libido. For those who wish to avoid hormonal treatments, there are few effective options. Selective serotonin reuptake inhibitors might be effective in the very short term (less than 12 weeks) and are well tolerated. There is not enough evidence that any of the complementary therapies available are any better than placebo for menopausal vasomotor symptoms, and few safety data exist.	Univ Western Australia, Sch Womens & Infants Hlth, King Edward Mem Hosp, Subiaco, WA 6008, Australia; Alfred Hosp, Monash Med Sch, Dept Med, Womens Hlth Programme, Prahran, Vic 3181, Australia; Heart England NHS Fdn Trust, Solihull Hosp, Dept Womens Hlth, Solihull, W Midlands, England	King Edward Memorial Hospital; University of Western Australia; Florey Institute of Neuroscience & Mental Health; Monash University; Heart of England NHS Foundation Trust	Hickey, M (corresponding author), Univ Western Australia, Sch Womens & Infants Hlth, King Edward Mem Hosp, Subiaco, WA 6008, Australia.	mhickey@obsgyn.uwa.edu.au	Davis, Susan D/GZL-2361-2022; Davis, Susan R/A-3111-2009; Sturdee, David/ABF-9792-2020	Davis, Susan R/0000-0002-2955-0415; Hickey, Martha/0000-0002-3941-082X				Aiello EJ, 2004, MENOPAUSE, V11, P382, DOI 10.1097/01.GME.0000113932.56832.27; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Anderson IM, 2000, J AFFECT DISORDERS, V58, P19, DOI 10.1016/S0165-0327(99)00092-0; ANDREWS H, 2004, J R COLL PHYS ED S13, V34, P2; ANTUNES CMF, 1979, NEW ENGL J MED, V300, P9, DOI 10.1056/NEJM197901043000103; ARCHER D, 2004, N AM MENOPAUSE SOC, V11, P589; ASLAKSEN K, 1982, ACTA OBSTET GYN SCAN, V61, P423, DOI 10.3109/00016348209156584; Bachmann GA, 1998, AM J OBSTET GYNECOL, V178, pS257, DOI 10.1016/S0002-9378(98)70558-7; Bagger YZ, 2004, BONE, V34, P728, DOI 10.1016/j.bone.2003.12.021; BAKER VL, 1994, OBSTET GYN CLIN N AM, V21, P271; Banks E, 2004, BMJ-BRIT MED J, V328, P1291, DOI 10.1136/bmj.328.7451.1291; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495; Beral V, 2005, LANCET, V365, P1543, DOI 10.1016/S0140-6736(05)66455-0; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; Biglia N, 2003, MATURITAS, V45, P29, DOI 10.1016/S0378-5122(03)00087-2; Bjarnason K, 1999, MATURITAS, V32, P161, DOI 10.1016/S0378-5122(99)00033-X; Bolego C, 2003, CURR DRUG TARGETS, V4, P77, DOI 10.2174/1389450033347000; Boothby LA, 2004, MENOPAUSE, V11, P356, DOI 10.1097/01.GME.0000094356.92081.EF; Borrelli F, 2002, EUR J CLIN PHARMACOL, V58, P235, DOI 10.1007/s00228-002-0457-2; Brown JS, 2001, OBSTET GYNECOL, V98, P1045, DOI 10.1016/S0029-7844(01)01630-1; Bruce D, 2004, CLIMACTERIC, V7, P261, DOI 10.1080/13697130410001713805; Burger HG, 2000, J CLIN ENDOCR METAB, V85, P2832, DOI 10.1210/jc.85.8.2832; Burkhardt MS, 2004, J ALZHEIMERS DIS, V6, P221; Bygdeman M, 1996, MATURITAS, V23, P259, DOI 10.1016/0378-5122(95)00955-8; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; Cardozo L, 1998, OBSTET GYNECOL, V92, P722, DOI 10.1016/S0029-7844(98)00175-6; Carlson MC, 2001, NEUROLOGY, V57, P2210, DOI 10.1212/WNL.57.12.2210; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cherry N, 2002, LANCET, V360, P2001; Clarke SC, 2002, BJOG-INT J OBSTET GY, V109, P1056, DOI 10.1111/j.1471-0528.2002.01544.x; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Crisafulli A, 2004, MENOPAUSE, V11, P400, DOI 10.1097/01.GME.0000109314.11228.E5; CRITCHLEY H, 2004, P 47 RCOG STUD GROUP; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Cushman M, 2004, JAMA-J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573; DAVID A, 1988, AM J OBSTET GYNECOL, V158, P1107, DOI 10.1016/0002-9378(88)90230-X; DAVIS SR, 1995, MATURITAS, V21, P227, DOI 10.1016/0378-5122(94)00898-H; Davis SR, 1999, RECENT PROG HORM RES, V54, P185; Dennerstein L, 2004, MENOPAUSE, V11, P563, DOI 10.1097/01.GME.0000113844.74462.F6; DENNERSTEIN L, 1978, BRIT J OBSTET GYNAEC, V85, P852, DOI 10.1111/j.1471-0528.1978.tb15842.x; Durna EM, 2002, MED J AUSTRALIA, V177, P347, DOI 10.5694/j.1326-5377.2002.tb04835.x; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Evans ML, 2005, OBSTET GYNECOL, V105, P161, DOI 10.1097/01.AOG.0000147840.06947.46; Farish E, 2000, Climacteric, V3, P125, DOI 10.3109/13697130009167614; Faure ED, 2002, MENOPAUSE, V9, P329, DOI 10.1097/00042192-200209000-00005; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; FREEDMAN RR, 1995, MENOPAUSE, V2, P211, DOI 10.1097/00042192-199502040-00005; Freedman RR, 2001, AM J HUM BIOL, V13, P453, DOI 10.1002/ajhb.1077; GOLDBERG RM, 1994, J CLIN ONCOL, V12, P155, DOI 10.1200/JCO.1994.12.1.155; Gomes MPV, 2004, ARCH INTERN MED, V164, P1965, DOI 10.1001/archinte.164.18.1965; Gompel A, 2000, EUR J CANCER, V36, pS76; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grady D, 2003, OBSTET GYNECOL, V102, P1233, DOI 10.1016/j.obstetgynecol.2003.09.025; Green PK, 1996, CANCER CAUSE CONTROL, V7, P575, DOI 10.1007/BF00051699; Grodstein F, 1998, ANN INTERN MED, V128, P705, DOI 10.7326/0003-4819-128-9-199805010-00001; Grodstein F, 2004, OBSTET GYNECOL, V103, P254, DOI 10.1097/01.AOG.0000107290.33034.6f; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Guttuso T, 2003, OBSTET GYNECOL, V101, P337, DOI 10.1016/S0029-7844(02)02712-6; Hammar M, 1998, BRIT J OBSTET GYNAEC, V105, P904, DOI 10.1111/j.1471-0528.1998.tb10237.x; HAMMOND MG, 1984, J CLIN ENDOCR METAB, V58, P1158, DOI 10.1210/jcem-58-6-1158; Harman SM, 2005, CLIMACTERIC, V8, P3, DOI 10.1080/13697130500042417; Haskell SG, 2004, J WOMENS HEALTH, V13, P438, DOI 10.1089/154099904323087132; HENDERSON BE, 1983, BRIT J CANCER, V47, P749, DOI 10.1038/bjc.1983.127; Hoda Daanish, 2003, Breast J, V9, P431, DOI 10.1046/j.1524-4741.2003.09526.x; Holmberg L, 2004, LANCET, V363, P453, DOI 10.1016/S0140-6736(04)15493-7; HORWITZ RI, 1978, NEW ENGL J MED, V299, P1089, DOI 10.1056/NEJM197811162992001; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Huntley A, 2003, MENOPAUSE, V10, P58, DOI 10.1097/01.GME.0000030262.75610.9B; Hyder SM, 2001, INT J CANCER, V92, P469, DOI 10.1002/ijc.1236; Irvin JH, 1996, J PSYCHOSOM OBST GYN, V17, P202, DOI 10.3109/01674829609025684; Kanis JA, 1997, OSTEOPOROSIS INT, V7, P108, DOI 10.1007/BF03194355; KHAN SA, 1994, BRIT J CLIN PRACT, V48, P240; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; Komesaroff P A, 2001, Climacteric, V4, P144; Krebs EE, 2004, OBSTET GYNECOL, V104, P824, DOI 10.1097/01.AOG.0000140688.71638.d3; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P52; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P123; Landgren MB, 2002, BJOG-INT J OBSTET GY, V109, P1109, DOI 10.1111/j.1471-0528.2002.02020.x; Laughlin GA, 2000, J CLIN ENDOCR METAB, V85, P645, DOI 10.1210/jc.85.2.645; Lawlor DA, 2003, J CLIN EPIDEMIOL, V56, P155; Lawton B, 2003, BRIT MED J, V327, P845, DOI 10.1136/bmj.327.7419.845; LEBHERZ TB, 1969, OBSTET GYNECOL, V33, P795; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Lemaitre RN, 2002, ARCH INTERN MED, V162, P1954, DOI 10.1001/archinte.162.17.1954; Leonetti HB, 1999, OBSTET GYNECOL, V94, P225, DOI 10.1016/S0029-7844(99)00266-5; Lethaby A., 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000402, DOI 10.1002/14651858.CD000402, 10.1002/14651858.CD000402.pub2]; Lindh-Astrand L, 2004, MATURITAS, V48, P97, DOI 10.1016/S0378-5122(03)00187-7; Lobo RA, 2003, FERTIL STERIL, V79, P1341, DOI 10.1016/S0015-0282(03)00358-3; Lokkegaard E, 2002, MATURITAS, V42, P209, DOI 10.1016/S0378-5122(02)00076-2; Lontos S, 2003, MED J AUSTRALIA, V179, P390, DOI 10.5694/j.1326-5377.2003.tb05606.x; Loprinzi CL, 2002, J CLIN ONCOL, V20, P1578, DOI 10.1200/JCO.20.6.1578; Loprinzi CL, 2000, LANCET, V356, P2059, DOI 10.1016/S0140-6736(00)03403-6; Loprinzi CL, 1998, J CLIN ONCOL, V16, P2377, DOI 10.1200/JCO.1998.16.7.2377; Lowe GDO, 2001, THROMB HAEMOSTASIS, V86, P550; MACLENNAN AH, 2002, COCHRANE DB SYST REV, V1; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; McBee WL, 1997, ENDOCRIN METAB CLIN, V26, P329, DOI 10.1016/S0889-8529(05)70250-4; Milner MH, 1996, OBSTET GYNECOL, V87, P593, DOI 10.1016/0029-7844(95)00468-8; MORRISON JC, 1980, AM J OBSTET GYNECOL, V138, P99, DOI 10.1016/0002-9378(80)90017-4; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Munoz GH, 2003, MATURITAS, V44, pS59, DOI 10.1016/S0378-5122(02)00349-3; NACHTIGALL LE, 1994, FERTIL STERIL, V61, P178; Nachtigall LE, 2000, MENOPAUSE, V7, P243, DOI 10.1097/00042192-200007040-00006; Naftolin F, 2004, CLIMACTERIC, V7, P333, DOI 10.1080/13697130400014615; Naftolin F, 2004, FERTIL STERIL, V81, P1498, DOI 10.1016/j.fertnstert.2004.02.095; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; PAGANINIHILL A, 1989, BRIT J CANCER, V59, P445, DOI 10.1038/bjc.1989.91; Palomba S, 2003, MATURITAS, V45, P267, DOI 10.1016/S0378-5122(03)00153-1; Pandya KJ, 2000, ANN INTERN MED, V132, P788, DOI 10.7326/0003-4819-132-10-200005160-00004; Pasqualini JR, 1996, J CLIN ENDOCR METAB, V81, P1460, DOI 10.1210/jc.81.4.1460; PATERSON MEL, 1982, BRIT J OBSTET GYNAEC, V89, P464, DOI 10.1111/j.1471-0528.1982.tb03638.x; Post MS, 2003, AM J OBSTET GYNECOL, V189, P1221, DOI 10.1067/S0002-9378(03)00599-4; Prestwood KM, 2003, JAMA-J AM MED ASSOC, V290, P1042, DOI 10.1001/jama.290.8.1042; Pukkala E, 2001, CANCER CAUSE CONTROL, V12, P111, DOI 10.1023/A:1008934919159; Raudaskoski T, 2002, BJOG-INT J OBSTET GY, V109, P136, DOI 10.1016/S1470-0328(02)01167-9; Riphagen F E, 2000, Climacteric, V3, P199, DOI 10.1080/13697130008500114; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Santoro NF, 2004, MENOPAUSE, V11, P11; Scarabin PY, 2003, LANCET, V362, P428, DOI 10.1016/S0140-6736(03)14066-4; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; SCHIFF I, 1980, JAMA-J AM MED ASSOC, V244, P1443, DOI 10.1001/jama.244.13.1443; Schindler DE, 2003, FRONT ECOL ENVIRON, V1, P31, DOI 10.1890/1540-9295(2003)001[0031:PSATEO]2.0.CO;2; Shanafelt TD, 2002, MAYO CLIN PROC, V77, P1207, DOI 10.4065/77.11.1207; Shifren JL, 2000, NEW ENGL J MED, V343, P682, DOI 10.1056/NEJM200009073431002; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Simpson E, 2000, TRENDS ENDOCRIN MET, V11, P184, DOI 10.1016/S1043-2760(00)00254-X; Slater CC, 2001, MENOPAUSE, V8, P200, DOI 10.1097/00042192-200105000-00009; SLOWINSKASRZEDNICKA J, 1992, J ENDOCRINOL INVEST, V15, P533, DOI 10.1007/BF03348801; Stearns V, 2003, JNCI-J NATL CANCER I, V95, P1758, DOI 10.1093/jnci/djg108; Stearns V, 2000, ANN ONCOL, V11, P17, DOI 10.1023/A:1008382706068; Stearns V, 2003, JAMA-J AM MED ASSOC, V289, P2827, DOI 10.1001/jama.289.21.2827; Stearns V, 2002, LANCET, V360, P1851, DOI 10.1016/S0140-6736(02)11774-0; Sturdee DW, 2004, CLIMACTERIC, V7, P404, DOI 10.1080/13697130400012270; STURDEE DW, 1978, BRIT MED J, V2, P79, DOI 10.1136/bmj.2.6130.79; Tice JA, 2003, JAMA-J AM MED ASSOC, V290, P207, DOI 10.1001/jama.290.2.207; TKINSON C, 2004, BREAST CANCER RES, V6, P2170; Unfer V, 2004, FERTIL STERIL, V82, P145, DOI 10.1016/j.fertnstert.2003.11.041; *US FDA, WITHDR GUID ESTR EST; van de Weijer PHM, 2002, MATURITAS, V42, P187, DOI 10.1016/S0378-5122(02)00080-4; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Warren MP, 2004, AM J OBSTET GYNECOL, V190, P1141, DOI 10.1016/j.ajog.2003.09.033; Warren R, 2004, MATURITAS, V49, P67, DOI 10.1016/j.maturitas.2004.06.013; Weiderpass E, 1999, J NATL CANCER I, V91, P1131, DOI 10.1093/jnci/91.13.1131; Weitzner MA, 2002, J PAIN SYMPTOM MANAG, V23, P337, DOI 10.1016/S0885-3924(02)00379-2; Wells M, 2002, BMJ-BRIT MED J, V325, P239, DOI 10.1136/bmj.325.7358.239; *WHO, 1966, WHO TECHN REP SER, V7, P236; *WRIT GROUP CONS P, 2004, ADV MED PRACT REG US; Wyon Y, 2004, CLIMACTERIC, V7, P153, DOI 10.1080/13697130410001713814; ZUMOFF B, 1995, J CLIN ENDOCR METAB, V80, P1429, DOI 10.1210/jc.80.4.1429	155	90	96	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 30	2005	366	9483					409	421		10.1016/S0140-6736(05)66519-1	http://dx.doi.org/10.1016/S0140-6736(05)66519-1			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	950IB	16054942				2023-01-03	WOS:000230849700029
J	Merchant, RC; Mayer, KH				Merchant, RC; Mayer, KH			Perspectives on new recommendations for nonoccupational HIV postexposure prophylaxis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							EXPOSURE		Brown Med Sch, Dept Emergency Med, Providence, RI USA; Brown Med Sch, Dept Med, Providence, RI USA; Brown Med Sch, Dept Community Hlth, Providence, RI USA	Brown University; Brown University; Brown University	Merchant, RC (corresponding author), Rhode Isl Hosp, Dept Emergency Med, 593 Eddy St,Potter 228, Providence, RI 02903 USA.	rmerchant@lifespan.org						*AIDS I NEW YORK D, 1998, HIV PROPH FOLL SEX A; *AIDS I NEW YORK S, 2004, HIV PROPH FOLL NON E; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Bassett IV, 2004, CLIN INFECT DIS, V39, P395, DOI 10.1086/422459; *CAL TASK FORC NON, 2005, OFF HIV POST EXP PRO; Murillo-Zumbado Gustavo, 2021, Tecnología en Marcha, V34, P130, DOI [10.18845/tm.v34i4.5274, 10.1103/PhysRevE.106.055304]; *DEP HLTH COMM MAS, 2000, CLIN ADV HIV PROPH N; Merchant RC, 2003, ACAD EMERG MED, V10, P1345, DOI 10.1197/S1069-6563(03)00537-2; MERCHANT RC, 2002, NONOCCUPATIONAL HIV; MYLES JE, 2001, OFFERING HIV PROPHYL; National Association of State Public Health Veterinarians Inc. (NASPHV), 2005, MMWR Recomm Rep, V54, P1; *PAN CLIN PRACT TR, 2004, GUID US ANT AG HIV 1; Rey D, 2000, AIDS CARE, V12, P695, DOI 10.1080/09540120020014228; 1996, MMWR MORB MORTAL WKL, V45, P468	14	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2407	2409		10.1001/jama.293.19.2407	http://dx.doi.org/10.1001/jama.293.19.2407			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926JX	15900012				2023-01-03	WOS:000229120600029
J	Krosnar, K				Krosnar, K			Cross-border trade in medicines causes concern in the EU	LANCET			English	Editorial Material																			0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1297	1298		10.1016/S0140-6736(05)61011-2	http://dx.doi.org/10.1016/S0140-6736(05)61011-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15828082				2023-01-03	WOS:000228219600012
J	Darmstadt, GL; Saha, SK; Ahmed, ASMNU; Chowdhury, MAKA; Law, PA; Ahmed, S; Alam, MA; Black, RE; Santosham, M				Darmstadt, GL; Saha, SK; Ahmed, ASMNU; Chowdhury, MAKA; Law, PA; Ahmed, S; Alam, MA; Black, RE; Santosham, M			Effect of topical treatment with skin barrier-enhancing emollients on nosocomial infections in preterm infants in Bangladesh: a randomised controlled trial	LANCET			English	Article							BIRTH-WEIGHT INFANTS; EPIDERMAL WATER-LOSS; NEONATAL-MORTALITY; OINTMENT THERAPY; NEWBORN-INFANTS; BLOOD; SEPSIS; CARE; RATES; ACID	Background Infections and complications of prematurity are main causes of neonatal mortality. Very low birthweight premature infants have compromised skin barrier function, and are at especially high risk for serious infections and mortality. Our aim was to ascertain whether topical application of emollients to enhance skin barrier function would prevent nosocomial infections in this population. Methods We randomly assigned infants born before week 33 of gestation after admission to Dhaka Shishu Hospital, Bangladesh, to daily massage with sunflower seed oil (n=159) or Aquaphor (petrolatum, mineral oil, mineral wax, lanolin alcohol; n=157). We then compared incidence of nosocomial infections among infants in these two groups with an untreated control group (n=181) by an intention-to-treat analysis. Findings 20 patients in the control group, and 22 in each of the treatment groups left the hospital early, but were included in the final analysis. Overall, infants treated with sunflower seed oil were 41% less likely to develop nosocomial infections than controls (adjusted incidence rate ratio [IRR] 0.59, 95% CI 0.37-0.96, p=0.032). Aquaphor did not significantly reduce the risk of infection (0.60, 0.35-1.03, p=0.065). No adverse events were seen. Interpretation Our findings confirm that skin application of sunflower seed oil provides protection against nosocomial infections in preterm. very low birthweight infants. The low cost, availability, simplicity, and effect of treatment make it an important intervention for very low birthweight infants admitted to hospital in developing countries.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Populat & Family Hlth Sci, Baltimore, MD USA; Save Children USA, Washington, DC USA; Dhaka Shishu Hosp, Bangladesh Inst Child Hlth, Dept Microbiol, Dhaka, Bangladesh; Dhaka Shishu Hosp, Bangladesh Inst Child Hlth, Dept Neonatol, Dhaka, Bangladesh; Dhaka Shishu Hosp, Bangladesh Inst Child Hlth, Dept Haematol & Pathol, Dhaka, Bangladesh; Kumudini Womens Med Coll, Dept Pediat, Mirzapur, Tangail, Bangladesh	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Save the Children	Darmstadt, GL (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth E8153, 615 N Wolfe St, Baltimore, MD 21205 USA.	gdarmsta@jhsph.edu	Darmstadt, Gary/AAU-7488-2020	Black, Robert/0000-0001-9926-7984; Darmstadt, Gary/0000-0002-7522-5824				Agarwal KN, 2000, INDIAN J MED RES, V112, P212; Ahmed A S M Nawshad Uddin, 2002, Indian Pediatr, V39, P1034; BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; BHATIA B D, 1988, Indian Pediatrics, V25, P1058; Bhutta Z., 1999, SEMIN NEONATOL, V4, P159, DOI [10.1016/S1084-2756(99)90040-4, DOI 10.1016/S1084-2756(99)90040-4]; DANGIO CT, 1989, J PEDIATR-US, V114, P1029, DOI 10.1016/S0022-3476(89)80457-3; DARMSTADT G, IN PRESS J PERINATOL; Darmstadt GL, 2004, PEDIATR INFECT DIS J, V23, P719, DOI 10.1097/01.inf.0000133047.50836.6f; Darmstadt GL, 1998, J CLIN INVEST, V101, P128, DOI 10.1172/JCI680; Darmstadt GL, 2002, ACTA PAEDIATR, V91, P546, DOI 10.1080/080352502753711678; Darmstadt GL, 2000, PEDIATR CLIN N AM, V47, P757, DOI 10.1016/S0031-3955(05)70239-X; DARMSTADT GL, 2002, J HEALTH POPUL NUTR, V20, P175; Darmstadt GL., 1998, EUR J PEDIAT DERMATO, V8, P221; Darmstadt GL., 2003, PERINATOLOGY, V5, P205; DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5; Edwards WH, 2004, PEDIATRICS, V113, P1195, DOI 10.1542/peds.113.5.1195; FERNANDEZ A, 1987, Indian Pediatrics, V24, P1111; FRIEDMAN Z, 1976, PEDIATRICS, V58, P650; GRUBAUER G, 1989, J LIPID RES, V30, P323; HAMMARLUND K, 1979, ACTA PAEDIATR SCAND, V68, P795; JOHANSON RB, 1992, ACTA PAEDIATR, V81, P859, DOI 10.1111/j.1651-2227.1992.tb12123.x; Kalia YN, 1998, J INVEST DERMATOL, V111, P320, DOI 10.1046/j.1523-1747.1998.00289.x; KEYWORTH N, 1992, ARCH DIS CHILD-FETAL, V67, P797, DOI 10.1136/adc.67.7_Spec_No.797; Kumhar GD, 2002, J HEALTH POPUL NUTR, V20, P343; LANE AT, 1993, PEDIATRICS, V92, P415; MaoQiang M, 1996, J INVEST DERMATOL, V106, P1096, DOI 10.1111/1523-1747.ep12340135; Merialdi M, 2003, J NUTR, V133, p1626S, DOI 10.1093/jn/133.5.1626S; MULLANY L, IN PRESS J TROP PEDI; *NAT COMM CLIN LAB, 1998, 1 NCCLS, V18; Nopper AJ, 1996, J PEDIATR-US, V128, P660, DOI 10.1016/S0022-3476(96)80132-6; Pabst R C, 1999, J Perinatol, V19, P278, DOI 10.1038/sj.jp.7200157; SAHA SK, 1992, T ROY SOC TROP MED H, V86, P554, DOI 10.1016/0035-9203(92)90109-P; Saha SK, 2001, J CLIN MICROBIOL, V39, P3583, DOI 10.1128/JCM.39.10.3583-3585.2001; Saving Newborn Lives, 2001, SAV NEWB LIV STAT WO, P1; SCHURER N, 1995, SKIN PHARMACOL, V8, P30; Stoll BJ, 2002, PEDIATRICS, V110, P285, DOI 10.1542/peds.110.2.285; Wallace M, 1998, INFECT CONT HOSP EP, V19, P689; Williams M., 2001, TXB NEONATAL DERMATO, P46; Williams M L, 1998, J Investig Dermatol Symp Proc, V3, P75; Yasmin S, 2001, B WORLD HEALTH ORGAN, V79, P608; Yoshio H, 2003, PEDIATR RES, V53, P211, DOI 10.1203/01.PDR.0000047471.47777.B0; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	43	124	129	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 19	2005	365	9464					1039	1045						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	907QB	15781099				2023-01-03	WOS:000227731800028
J	Morse, CG; Kovacs, JA				Morse, Caryn G.; Kovacs, Joseph A.			Metabolic and skeletal complications of HIV infection - The price of success	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMBINATION ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE INHIBITORS; LIPID-LOWERING THERAPY; BONE-MINERAL DENSITY; DISEASE RISK-FACTORS; PROTEASE-INHIBITOR; INSULIN-RESISTANCE; ADIPOSE-TISSUE; FAT REDISTRIBUTION; DIABETES-MELLITUS	Over the past 10 years, in conjunction with the broad availability of potent antiretroviral regimens, the care of human immunodeficiency virus (HIV) infected patients has shifted from prevention and treatment of opportunistic infections and malignancies to management of the metabolic and related complications associated with HIV infection and its treatment. Metabolic disorders, including lipodystrophy, dyslipidemia, and insulin resistance, occur at a high rate in HIV-infected individuals receiving highly active antiretroviral therapy ( HAART). These disorders are associated with increased risk of cardiovascular disease and have become an important cause of morbidity and mortality in HIV-infected patients. Herein, we present the case of a patient with HIV infection who responded well to HAART but developed multiple complications potentially related to this therapy. This article reviews the clinical characteristics of the metabolic and skeletal disturbances observed in HIV infection and discusses strategies for their management.	NIAID, Ctr Clin, HIV AIDS Program, Crit Care Med Dept,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kovacs, JA (corresponding author), NIAID, Ctr Clin, HIV AIDS Program, Crit Care Med Dept,NIH, Bldg 10,Room 2C145,MSC 1662, Bethesda, MD 20892 USA.	jkovacs@nih.gov	Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880; Morse, Caryn/0000-0002-1177-4365	CLINICAL CENTER [ZIACL008075, Z01CL001159, ZIACL001159, Z01CL008075] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	CLINICAL CENTER; Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ammassari A, 2002, JAIDS-J ACQ IMM DEF, V31, pS140, DOI 10.1097/00126334-200212153-00011; Amorosa V, 2006, CLIN INFECT DIS, V42, P108, DOI 10.1086/498511; Bacchetti P, 2005, JAIDS-J ACQ IMM DEF, V40, P121, DOI 10.1097/01.qai.0000182230.47819.aa; Bauer M, 2000, PHARMACOEPIDEM DR S, V9, P187, DOI 10.1002/1099-1557(200005/06)9:3<187::AID-PDS494>3.0.CO;2-J; Behrens G, 1999, AIDS, V13, pF63, DOI 10.1097/00002030-199907090-00001; Blanch J, 2004, CLIN INFECT DIS, V38, P1469; Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048; Bruera D, 2003, AIDS, V17, P1917, DOI 10.1097/00002030-200309050-00010; Bucher HC, 2003, AIDS, V17, P2451, DOI 10.1097/00002030-200311210-00007; Calza L, 2005, AIDS, V19, P1051, DOI 10.1097/01.aids.0000174451.78497.8f; Calza L, 2005, AIDS, V19, P1103, DOI 10.1097/01.aids.0000174458.86121.43; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 2002, JAMA-J AM MED ASSOC, V288, P207, DOI 10.1001/jama.288.2.207; Carr A, 2003, LANCET, V361, P726, DOI 10.1016/S0140-6736(03)12656-6; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 2004, LANCET, V363, P429, DOI 10.1016/S0140-6736(04)15489-5; Carr A, 2001, AIDS, V15, P1811, DOI 10.1097/00002030-200109280-00010; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; den Boer MAM, 2006, ARTERIOSCL THROM VAS, V26, P124, DOI 10.1161/01.ATV.0000194073.87647.10; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; *DHHS PAN ANT GUID, GUID US ANT AG HIV 1; Dube MP, 2002, CLIN INFECT DIS, V35, P475, DOI 10.1086/341489; Dube MP, 1997, LANCET, V350, P713, DOI 10.1016/S0140-6736(05)63513-1; ELSADR W, 2006, 13 C RETR OPP INF FE; Falutz J, 2005, AIDS, V19, P1279, DOI 10.1097/01.aids.0000180099.35146.30; Fontas E, 2004, J INFECT DIS, V189, P1056, DOI 10.1086/381783; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010; FRIISMOLLER N, 2006, 13 C RETR OPP INF FE; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Galli M, 2002, ARCH INTERN MED, V162, P2621, DOI 10.1001/archinte.162.22.2621; Gerber MT, 2004, CLIN INFECT DIS, V39, P419, DOI 10.1086/422144; GRUNFELD C, 1989, AM J MED, V86, P27, DOI 10.1016/0002-9343(89)90225-8; Guaraldi G, 2001, CLIN INFECT DIS, V33, P414, DOI 10.1086/321870; GUARALDI G, 2005, 7 WORKSH ADV DRUG RE; Hadigan C, 2004, ANN INTERN MED, V140, P786, DOI 10.7326/0003-4819-140-10-200405180-00008; Hadigan C, 2001, CLIN INFECT DIS, V32, P130, DOI 10.1086/317541; Hadigan C, 2000, JAMA-J AM MED ASSOC, V284, P472, DOI 10.1001/jama.284.4.472; Hadigan C, 2001, J CLIN ENDOCR METAB, V86, P939, DOI 10.1210/jc.86.2.939; Heath KV, 2002, J ACQ IMMUN DEF SYND, V30, P440, DOI [10.1097/00042560-200208010-00010, 10.1097/01.QAI.0000021701.48448.20]; Jemsek JG, 2006, CLIN INFECT DIS, V42, P273, DOI 10.1086/498505; Jones PH, 2005, AM J CARDIOL, V95, P120, DOI 10.1016/j.amjcard.2004.08.076; KLEIN D, 2006, 13 C RETR OPP INF FE; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Koller E, 2000, AIDS PATIENT CARE ST, V14, P405, DOI 10.1089/108729100416614; Lafaurie M, 2005, JAIDS-J ACQ IMM DEF, V38, P393, DOI 10.1097/01.qai.0000152834.02912.98; Lai KA, 2005, J BONE JOINT SURG AM, V87A, P2155, DOI 10.2106/JBJS.D.02959; LEE G, 2005, 7 WORKSH ADV DRUG RE; Lee GA, 2004, AIDS, V18, P641, DOI 10.1097/00002030-200403050-00008; Lenhard JM, 2000, ARTERIOSCL THROM VAS, V20, P2625, DOI 10.1161/01.ATV.20.12.2625; Lichtenstein K, 2006, 13 C RETR OPP INF FE; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Mallal SA, 2000, AIDS, V14, P1309, DOI 10.1097/00002030-200007070-00002; Mallon PWG, 2003, AIDS, V17, P971, DOI 10.1097/00002030-200305020-00005; Martin A, 2004, AIDS, V18, P1029, DOI 10.1097/00002030-200404300-00011; Martinez E, 1999, AIDS, V13, P805, DOI 10.1097/00002030-199905070-00009; Martinez E, 2001, LANCET, V357, P592, DOI 10.1016/S0140-6736(00)04056-3; Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010; McComsey GA, 2004, CLIN INFECT DIS, V38, P263, DOI 10.1086/380790; Meigs JB, 2000, JAMA-J AM MED ASSOC, V283, P221, DOI 10.1001/jama.283.2.221; Miller KD, 2002, ANN INTERN MED, V137, P17, DOI 10.7326/0003-4819-137-1-200207020-00008; Mondy K, 2003, CLIN INFECT DIS, V36, P482, DOI 10.1086/367569; Monier P, 2000, CLIN INFECT DIS, V31, P1488, DOI 10.1086/317503; MORSE C, 2005, 7 WORKSH ADV DRUG RE; Mulligan K, 2006, JAIDS-J ACQ IMM DEF, V41, P590, DOI 10.1097/01.qai.0000214811.72916.67; MULLIGAN K, 2005, 7 WORKSH ADV DRUG RE; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Mussini C, 2005, AIDS, V19, P287; Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007; NOOR M, 2005, 7 WORKSH ADV DRUG RE; Noordam JC, 2002, J CHEMOMETR, V16, P1, DOI 10.1002/cem.656; Palacios R, 2002, J ACQ IMMUN DEF SYND, V30, P536, DOI 10.1097/00126334-200208150-00012; Palella FJ, 2004, CLIN INFECT DIS, V38, P903, DOI 10.1086/381684; Rodriguez-French A, 2004, JAIDS-J ACQ IMM DEF, V35, P22, DOI 10.1097/00126334-200401010-00003; Ruiz L, 2001, J ACQ IMMUN DEF SYND, V27, P229, DOI 10.1097/00126334-200107010-00003; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; Sanne I, 2003, JAIDS-J ACQ IMM DEF, V32, P18, DOI 10.1097/00126334-200301010-00004; Schambelan M, 2002, JAIDS-J ACQ IMM DEF, V31, P257, DOI 10.1097/00126334-200211010-00001; Shankar SS, 2005, AM HEART J, V150, DOI 10.1016/j.ahj.2005.06.005; Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009; SLAMA L, 2006, 13 C RETR OPP INF FE; Stein JH, 2003, AM J CARDIOL, V92, P270, DOI 10.1016/S0002-9149(03)00622-2; Stein JH, 2001, CIRCULATION, V104, P257, DOI 10.1161/01.CIR.104.3.257; Sutinen J, 2003, ANTIVIR THER, V8, P199; Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030-200003100-00005; Tien PC, 2003, JAIDS-J ACQ IMM DEF, V34, P461, DOI 10.1097/00126334-200312150-00003; van der Valk M, 2001, AIDS, V15, P847, DOI 10.1097/00002030-200105040-00005; van Leth F, 2004, PLOS MED, V1, P64, DOI 10.1371/journal.pmed.0010019; Walli R, 1998, AIDS, V12, pF167, DOI 10.1097/00002030-199815000-00001; Wanke C, 1999, AIDS, V13, P2099, DOI 10.1097/00002030-199910220-00013; Wood R, 2004, JAIDS-J ACQ IMM DEF, V36, P684, DOI 10.1097/00126334-200406010-00005; Yanovski JA, 1999, J CLIN ENDOCR METAB, V84, P1925, DOI 10.1210/jc.84.6.1925; 2006, DIABETES CARE S1, V29, pS3	95	72	75	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					844	854		10.1001/jama.296.7.844	http://dx.doi.org/10.1001/jama.296.7.844			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073SR	16905789				2023-01-03	WOS:000239763400024
J	Freeman, D; Price, D				Freeman, Daryl; Price, David			ABC of chronic obstructive pulmonary disease - Primary care and palliative care	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Aberdeen, Foresterhill Hlth Ctr, Dept Gen Practice & Primary Care, Aberdeen AB9 1FX, Scotland	University of Aberdeen	Freeman, D (corresponding author), Univ Aberdeen, Foresterhill Hlth Ctr, Dept Gen Practice & Primary Care, Aberdeen AB9 1FX, Scotland.		Price, David/H-2837-2019; Young, John D/M-9756-2016	Price, David/0000-0002-9728-9992; 				Abernethy AP, 2003, BRIT MED J, V327, P523, DOI 10.1136/bmj.327.7414.523; Bellamy David, 2006, Prim Care Respir J, V15, P48, DOI 10.1016/j.pcrj.2005.11.003; Davis CL, 1997, BRIT MED J, V315, P931	3	12	12	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 22	2006	333	7560					188	190		10.1136/bmj.333.7560.188	http://dx.doi.org/10.1136/bmj.333.7560.188			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	068DJ	16858049	Green Published			2023-01-03	WOS:000239352100024
J	Riley, J; Ross, JR				Riley, J; Ross, JR			Reforming drug-control policy for palliative care in Romania	LANCET			English	Editorial Material									Royal Marsden Hosp Fdn Trust, Dept Palliat Med, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Riley, J (corresponding author), Royal Marsden Hosp Fdn Trust, Dept Palliat Med, London SW3 6JJ, England.	Julia.riley@rmh.nhs.uk						[Anonymous], 2000, ACH BAL NAT OP CONTR; *IARC, 2006, CANCERMONDIAL   0119; International Narcotics Control Board, 1996, REP INT NARC CONTR B; International Narcotics Control Board, 2005, REP INT NARC CONTR B; Mosoiu D, 2006, LANCET, V367, P2110, DOI 10.1016/S0140-6736(06)68482-1; Stewart B.W., 2003, WORLD CANC REPORT; *WHO, 2002, REG OFF EUR ASS AV O; World Health Organization, 1996, CANC PAIN REL; World Health Organization (WHO), 2005, ESS MED	9	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 24	2006	367	9528					2040	2041		10.1016/S0140-6736(06)68483-3	http://dx.doi.org/10.1016/S0140-6736(06)68483-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	058HZ	16798370				2023-01-03	WOS:000238657400007
J	Schmidt, B; Roberts, RS; Davis, P; Doyle, LW; Barrington, KJ; Ohlsson, A; Solimano, A; Tin, W				Schmidt, B; Roberts, RS; Davis, P; Doyle, LW; Barrington, KJ; Ohlsson, A; Solimano, A; Tin, W		Caffeine Apnea Prematurity Trial G	Caffeine therapy for apnea of prematurity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BIRTH-WEIGHT INFANTS; METABOLIC-RATE; BRONCHOPULMONARY DYSPLASIA; METHYLXANTHINE THERAPY; OXYGEN-CONSUMPTION; IDIOPATHIC APNEA; THEOPHYLLINE; AMINOPHYLLINE; RETINOPATHY; POPULATION	Background: Methylxanthines reduce the frequency of apnea of prematurity and the need for mechanical ventilation during the first seven days of therapy. It is uncertain whether methylxanthines have other short- and long-term benefits or risks in infants with very low birth weight. Methods: We randomly assigned 2006 infants with birth weights of 500 to 1250 g during the first 10 days of life to receive either caffeine or placebo, until drug therapy for apnea of prematurity was no longer needed. We evaluated the short-term outcomes before the first discharge home. Results: Of 963 infants who were assigned to caffeine and who remained alive at a postmenstrual age of 36 weeks, 350 (36 percent) received supplemental oxygen, as did 447 of the 954 infants (47 percent) assigned to placebo (adjusted odds ratio, 0.63; 95 percent confidence interval, 0.52 to 0.76; P < 0.001). Positive airway pressure was discontinued one week earlier in the infants assigned to caffeine (median postmenstrual age, 31.0 weeks; interquartile range, 29.4 to 33.0) than in the infants in the placebo group (median postmenstrual age, 32.0 weeks; interquartile range, 30.3 to 34.0; P < 0.001). Caffeine reduced weight gain temporarily. The mean difference in weight gain between the group receiving caffeine and the group receiving placebo was greatest after two weeks (mean difference, -23 g; 95 percent confidence interval, -32 to -13; P < 0.001). The rates of death, ultrasonographic signs of brain injury, and necrotizing enterocolitis did not differ significantly between the two groups. Conclusions: Caffeine therapy for apnea of prematurity reduces the rate of bronchopulmonary dysplasia in infants with very low birth weight. (ClinicalTrials.gov number, NCT00182312.).	McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada; Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada; James Cook Univ, Dept Pediat, Middlesbrough, Cleveland, England	McMaster University; McMaster University; University of Melbourne; McGill University; University of Toronto; University of British Columbia	Schmidt, B (corresponding author), McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Rm 3N11E,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	schmidt@mcmaster.ca	Doyle, Lex/AAJ-5205-2021; Herlenius, Eric/B-7260-2008; Pfister, Riccardo E/N-7082-2014	Doyle, Lex/0000-0002-7667-7312; Herlenius, Eric/0000-0002-6859-0620; Pfister, Riccardo E/0000-0002-7395-0512; Ringstedt, Thomas/0000-0003-0294-9351; Barrington, Keith/0000-0001-9669-5094				Allen MC, 2002, MENT RETARD DEV D R, V8, P221, DOI 10.1002/mrdd.10044; Ambalavanan N, 2003, CLIN PERINATOL, V30, P305, DOI 10.1016/S0095-5108(03)00021-6; BARRINGTON K, 1991, PEDIATR RES, V29, P372, DOI 10.1038/pr.1991.72500; Bauer J, 2001, PEDIATRICS, V107, P660, DOI 10.1542/peds.107.4.660; Boutilier RG, 2001, J EXP BIOL, V204, P3171; Carnielli VP, 2000, ARCH DIS CHILD-FETAL, V83, pF39, DOI 10.1136/fn.83.1.F39; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; Eichenwald EC, 1997, PEDIATRICS, V100, P354, DOI 10.1542/peds.100.3.354; Erenberg A, 2000, PHARMACOTHERAPY, V20, P644, DOI 10.1592/phco.20.7.644.35167; *FOOD DRUG ADM, 2000, 020793 CAFCIT NDA FO; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P93, DOI 10.1111/j.1600-0773.1995.tb00111.x; GARNER A, 1984, PEDIATRICS, V74, P127; GERHARDT T, 1979, PEDIATRICS, V63, P537; Henderson-Smart D, 2004, COCHRANE DB SYST REV, V4; Henderson-Smart DJ, 2001, COCHRANE DB SYST REV, V3; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; Martin Richard J, 2004, Paediatr Respir Rev, V5 Suppl A, pS377, DOI 10.1016/S1526-0542(04)90067-X; Millar David, 2004, Semin Neonatol, V9, P239, DOI 10.1016/j.siny.2003.11.008; MILSAP RL, 1980, CLIN PHARMACOL THER, V28, P536, DOI 10.1038/clpt.1980.199; Pesce AJ, 1998, CLIN CHEM, V44, P1124; Pinto-Martin JA, 2001, PEDIATRICS, V108, P238; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; Schmidt B, 2005, BIOL NEONATE, V88, P208, DOI 10.1159/000087584; Schmidt B, 2003, JAMA-J AM MED ASSOC, V289, P1124, DOI 10.1001/jama.289.9.1124; Schmidt B, 1999, J PEDIATR-US, V135, P526, DOI 10.1016/S0022-3476(99)70180-0; SHENNAN AT, 1988, PEDIATRICS, V82, P527; THURSTON JH, 1978, SCIENCE, V201, P649, DOI 10.1126/science.209541; Walsh MC, 2004, PEDIATRICS, V114, P1305, DOI 10.1542/peds.2004-0204; 1987, ARCH OPHTHALMOL, V105, P1498; 1987, ARCH OPHTHALMOL, V105, P906	30	670	718	2	64	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2006	354	20					2112	2121		10.1056/NEJMoa054065	http://dx.doi.org/10.1056/NEJMoa054065			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	043BX	16707748	Green Published			2023-01-03	WOS:000237575400005
J	Colvin, L; Forbes, K; Fallon, M				Colvin, L; Forbes, K; Fallon, M			ABC of palliative care - Difficult pain	BRITISH MEDICAL JOURNAL			English	Editorial Material									Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; Bristol Oncol Ctr, Bristol, Avon, England; Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland	University of Edinburgh; Bristol Haematology & Oncology Centre; University of Edinburgh	Colvin, L (corresponding author), Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.			Colvin, Lesley/0000-0002-1563-8600; Fallon, Marie/0000-0001-9214-0091				Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; World Health Organization, 1996, CANC PAIN REL	3	22	23	1	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 6	2006	332	7549					1081	1083		10.1136/bmj.332.7549.1081	http://dx.doi.org/10.1136/bmj.332.7549.1081			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	042HI	16675817	Green Published, Green Submitted			2023-01-03	WOS:000237518400023
J	Copland, JA; Marlow, LA; Kurakata, S; Fujiwara, K; Wong, AKC; Kreinest, PA; Williams, SF; Haugen, BR; Klopper, JP; Smallridge, RC				Copland, JA; Marlow, LA; Kurakata, S; Fujiwara, K; Wong, AKC; Kreinest, PA; Williams, SF; Haugen, BR; Klopper, JP; Smallridge, RC			Novel high-affinity PPAR gamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21(WAF1/CIP1)	ONCOGENE			English	Article						peroxisome proliferator-activated receptor gamma; paclitaxel; anaplastic thyroid carcinoma; RS5444; p21(WAF1/CIP1); combinatorial therapy; thiazolidinedione	ACTIVATED-RECEPTOR-GAMMA; PANCREATIC-CANCER CELLS; IN-VITRO; DIFFERENTIATION MARKERS; INDEPENDENT GROWTH; PROSTATE-CANCER; GENE-EXPRESSION; CYCLE ARREST; APOPTOSIS; LIGANDS	Peroxisome proliferator-activated receptor gamma (PPARc) agonists demonstrate antitumor activity likely through transactivating genes that regulate cell proliferation, apoptosis, and differentiation. The PAX8/PPARc fusion oncogene, which is common in human follicular thyroid carcinomas appears to act via dominant negative suppression of wild-type PPARc, suggesting that it may be a tumor suppressor gene in thyroid cells. We have identified a novel high-affinity PPARc agonist (RS5444) that is dependent upon PPARc for its biological activity. This is the first report of this molecule and its antitumor activity. In vitro, the IC50 for growth inhibition is similar to 0.8 nM while anaplastic thyroid carcinoma (ATC) tumor growth was inhibited three-to fourfold in nude mice. siRNA against PPARc and a pharmacological antagonist demonstrated that functional PPARc was required for growth inhibitory activity of RS5444. RS5444 upregulated the cell cycle kinase inhibitor, p21(WAF1/CIP1). Silencing p21(WAF1CIP1) rendered cells insensitive to RS5444. RS5444 plus paclitaxel demonstrated additive antiproliferative activity in cell culture and minimal ATC tumor growth in vivo. RS5444 did not induce apoptosis but combined with paclitaxel, doubled the apoptotic index compared to that of paclitaxel. Our data indicate that functional PPARc is a molecular target for therapy in ATC. We demonstrated that RS5444, a thiazolidinedione (Tzd) derivative, alone or in combination with paclitaxel, may provide therapeutic benefit to patients diagnosed with ATC.	Mayo Clin, Coll Med, Dept Canc Biol, Ctr Comprehens Canc, Jacksonville, FL 33224 USA; Sankyo Pharma Res Inst, La Jolla, CA USA; Sankyo Co Ltd, Shinagawa Ku, Tokyo 140, Japan; Sankyo Pharma Res Inst, La Jolla, CA USA; Mayo Clin, Coll Med, Dept Internal Med, Div Endocrinol, Jacksonville, FL 33224 USA; Univ Colorado, Ctr Canc, Dept Med, Div Endocrinol Diabet & Metab, Denver, CO 80262 USA; Hlth Sci Ctr, Aurora, CO USA	Mayo Clinic; Daiichi Sankyo Company Limited; Mayo Clinic; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Copland, JA (corresponding author), Mayo Clin, Coll Med, Dept Canc Biol, Ctr Comprehens Canc, 4500 San Pablo Rd, Jacksonville, FL 33224 USA.	copland.john@mayo.edu		Marlow, Laura/0000-0002-4726-9889	NCI NIH HHS [P30CA15083, CA100560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015083, R01CA100560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ain KB, 1996, J CLIN ENDOCR METAB, V81, P3650, DOI 10.1210/jc.81.10.3650; Ain KB, 2000, THYROID, V10, P587, DOI 10.1089/thy.2000.10.587; Aldred MA, 2003, ONCOGENE, V22, P3412, DOI 10.1038/sj.onc.1206400; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; Bauer AJ, 2002, THYROID, V12, P953, DOI 10.1089/105072502320908286; Belletti B, 1999, ONCOGENE, V18, P4860, DOI 10.1038/sj.onc.1202869; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Castrillo A, 2001, J BIOL CHEM, V276, P34082, DOI 10.1074/jbc.M102472200; Chang TH, 2000, CANCER RES, V60, P1129; Chang TH, 2002, CLIN CANCER RES, V8, P1206; Chen F, 2005, CELL SIGNAL, V17, P809, DOI 10.1016/j.cellsig.2004.11.002; Chung SH, 2002, JPN J CANCER RES, V93, P1358, DOI 10.1111/j.1349-7006.2002.tb01245.x; Davies GF, 2002, J PHARMACOL EXP THER, V300, P72, DOI 10.1124/jpet.300.1.72; de la Lastra CA, 2004, CURR PHARM DESIGN, V10, P3505; Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145; Dwight T, 2003, J CLIN ENDOCR METAB, V88, P4440, DOI 10.1210/jc.2002-021690; Eibl G, 2001, BIOCHEM BIOPH RES CO, V287, P522, DOI 10.1006/bbrc.2001.5619; Elnemr A, 2000, INT J ONCOL, V17, P1157; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Fujiwara T, 2000, LIFE SCI, V67, P2405, DOI 10.1016/S0024-3205(00)00829-8; Fujiwara T, 1998, LIFE SCI, V63, P2039, DOI 10.1016/S0024-3205(98)00482-2; Galli A, 2004, GUT, V53, P1688, DOI 10.1136/gut.2003.031997; Girnun GD, 2003, GASTROENTEROLOGY, V124, P564, DOI 10.1053/gast.2003.50070; Guan You-Fei, 1999, Neoplasia (New York), V1, P330, DOI 10.1038/sj.neo.7900050; Han SW, 2004, CLIN CANCER RES, V10, P1911, DOI 10.1158/1078-0432.CCR-03-0985; Hayashi N, 2004, INT J ONCOL, V24, P89; Hong J, 2004, ENDOCRINOLOGY, V145, P5774, DOI 10.1210/en.2004-0686; Huang JW, 2005, MOL PHARMACOL, V67, P1342, DOI 10.1124/mol.104.007732; Itami A, 2001, INT J CANCER, V94, P370, DOI 10.1002/ijc.1488; Kawa S, 2002, PANCREAS, V24, P1, DOI 10.1097/00006676-200201000-00001; Kim S, 2005, MOL CANCER THER, V4, P632, DOI 10.1158/1535-7163.MCT-04-0293; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Klopper JP, 2004, MOL CANCER THER, V3, P1011; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubota T, 1998, CANCER RES, V58, P3344; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; Lovekamp-Swan T, 2005, MOL CELL ENDOCRINOL, V233, P15, DOI 10.1016/j.mce.2005.01.011; Lu ML, 2005, J BIOL CHEM, V280, P6742, DOI 10.1074/jbc.M411519200; Lui WO, 2005, ONCOGENE, V24, P1467, DOI 10.1038/sj.onc.1208135; Margeli A., 2003, Angiogenesis, V6, P165, DOI 10.1023/B:AGEN.0000021377.13669.c0; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; McIver Bryan, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P221, DOI 10.2174/1568008043339802; Motomura W, 2000, CANCER RES, V60, P5558; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; Nakashiro K, 2001, AM J PATHOL, V159, P591, DOI 10.1016/S0002-9440(10)61730-0; Palakurthi SS, 2001, CANCER RES, V61, P6213; Panigrahy D, 2003, EXPERT OPIN INV DRUG, V12, P1925, DOI 10.1517/13543784.12.12.1925; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Perez-Ortiz JM, 2004, J BIOL CHEM, V279, P8976, DOI 10.1074/jbc.M308518200; Place AE, 2003, CLIN CANCER RES, V9, P2798; Powell JG, 2004, ONCOGENE, V23, P3634, DOI 10.1038/sj.onc.1207399; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rumi MAK, 2004, GENES CELLS, V9, P1113, DOI 10.1111/j.1365-2443.2004.00793.x; Sato K, 2001, ENDOCR J, V48, P635, DOI 10.1507/endocrj.48.635; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Shiau CW, 2005, CANCER RES, V65, P1561, DOI 10.1158/0008-5472.CAN-04-1677; Smith WM, 2001, HUM GENET, V109, P146, DOI 10.1007/s004390100563; TAKASHIMA T, 2001, TRENDS MOL MED, V7, P395; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Turturro F, 2004, CLIN CANCER RES, V10, P7022, DOI 10.1158/1078-0432.CCR-04-0879; Vogt T, 2003, CANCER, V98, P2251, DOI 10.1002/cncr.11775; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Xu GP, 2001, J CLIN ENDOCR METAB, V86, P1769, DOI 10.1210/jc.86.4.1769; Yang HL, 2003, J CLIN ENDOCR METAB, V88, P763, DOI 10.1210/jc.2002-020992; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Yeung SCJ, 2000, CANCER RES, V60, P650; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yin F, 2004, ONCOGENE, V23, P4614, DOI 10.1038/sj.onc.1207598; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Yuan JY, 2005, UROLOGY, V65, P594, DOI 10.1016/j.urology.2004.10.019	77	120	128	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2304	2317		10.1038/sj.onc.1209267	http://dx.doi.org/10.1038/sj.onc.1209267			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331265				2023-01-03	WOS:000236764300003
J	Krauss, B; Green, SM				Krauss, B; Green, SM			Procedural sedation and analgesia in children	LANCET			English	Review							PEDIATRIC EMERGENCY-DEPARTMENT; ADVERSE EVENTS; CONSCIOUS SEDATION; ORAL MIDAZOLAM; KETAMINE SEDATION; CONTROLLED TRIAL; SAFETY PROFILE; NITROUS-OXIDE; INTRAMUSCULAR KETAMINE; DISSOCIATIVE SEDATION	Procedural sedation and analgesia for children-the use of sedative, analgesic, or dissociative drugs to relieve anxiety and pain associated with diagnostic and therapeutic procedures-is now widely practised by a diverse group of specialists outside the operating theatre. We review the principles underlying safe and effective procedural sedation and analgesia and the spectrum of procedures for which it is currently done. We discuss the decision-making process used to determine appropriate drug selection, dosing, and sedation endpoint. We detail the pharmacopoeia for procedural sedation and analgesia, reviewing the pharmacology and adverse effects of these drugs. International differences in practice are described along with current areas of controversy and future directions.	Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Loma Linda Univ, Med Ctr, Dept Emergency Med, Loma Linda, CA USA; Childrens Hosp, Loma Linda, CA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Loma Linda University; Children's Hospital Los Angeles	Krauss, B (corresponding author), Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	baruch.krauss@childrens.harvard.edu	Soleimanpour, Hassan/AAZ-4667-2020; Krauss, Baruch/U-6182-2019; Golzari, Samad EJ/L-5785-2017	Soleimanpour, Hassan/0000-0002-1311-4096; Golzari, Samad EJ/0000-0003-3815-8770				Abbott/American Association of Critical-Care Nurses, 2004, Crit Care Nurse, V24, P33; Acworth JP, 2001, EMERG MED J, V18, P39, DOI 10.1136/emj.18.1.39; Agrawal D, 2004, ANN EMERG MED, V43, P247, DOI 10.1016/S0196-0644(03)00721-2; Agrawal D, 2003, ANN EMERG MED, V42, P636, DOI 10.1016/S0196-0644(03)00516-X; *AM AC PER, 2001, J PERIODONTOL, V72, P968; *AM NURS ASS, 1992, SCI NURS, V9, P55; American Academy of Pediatric Dentistry, 2004, Pediatr Dent, V26, P104; Annequin D, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e47; [Anonymous], 1985, PEDIATRICS, V76, P317; [Anonymous], 1990, PEDIATRICS, V86, P484; [Anonymous], COMPR ACCR MAN HOSP; Antmen B, 2005, PEDIATR ANESTH, V15, P214, DOI 10.1111/j.1460-9592.2004.01411.x; *ASS OP ROOM NURS, 1993, AORN J, V57, P978; *AUSTR COLL EM MED, 2003, EMERG MED FREMANTLE, V15, P205; Barbi E, 2003, ARCH PEDIAT ADOL MED, V157, P1097, DOI 10.1001/archpedi.157.11.1097; BARSAN WG, 1989, AM J EMERG MED, V7, P155, DOI 10.1016/0735-6757(89)90128-9; Bassett KE, 2003, ANN EMERG MED, V42, P773, DOI 10.1016/S0196-0644(03)00619-X; BATES BA, 1994, ANN EMERG MED, V24, P646, DOI 10.1016/S0196-0644(94)70274-8; Beekman RP, 1996, EUR J PEDIATR, V155, P820; BELL GD, 1991, GUT, V32, P823, DOI 10.1136/gut.32.7.823; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V254, P1073; BILLMIRE DA, 1985, J TRAUMA, V25, P1079; Burton JH, 2002, ANN EMERG MED, V40, P496, DOI 10.1067/mem.2002.126607; Burton JH, 1998, ACAD EMERG MED, V5, P112, DOI 10.1111/j.1553-2712.1998.tb02594.x; *CAN ASS EM PHYS, 1999, J EMERGENCY MED, V17, P145; Chen BK, 2001, CURR OPIN PEDIATR, V13, P324, DOI 10.1097/00008480-200108000-00007; Chen E, 1999, J CONSULT CLIN PSYCH, V67, P481, DOI 10.1037/0022-006X.67.4.481; Chumpa A, 2001, AM J EMERG MED, V19, P545, DOI 10.1053/ajem.2001.27141; Cohen LL, 2001, J PEDIATR PSYCHOL, V26, P367, DOI 10.1093/jpepsy/26.6.367; CONNORS K, 1994, ANN EMERG MED, V24, P1074, DOI 10.1016/S0196-0644(94)70236-5; COTE CJ, 1986, CAN J ANAESTH, V33, P315, DOI 10.1007/BF03010743; Cote CJ, 2000, PEDIATRICS, V105, P805, DOI 10.1542/peds.105.4.805; Cote CJ, 2000, PEDIATRICS, V106, P633, DOI 10.1542/peds.106.4.633; Cravero JP, 2004, ANESTH ANALG, V99, P1355, DOI 10.1213/01.ANE.0000134810.60270.E8; Davies FC, 1998, J ACCID EMERG MED, V15, P244; Dickinson R, 2001, ACAD EMERG MED, V8, P74, DOI 10.1111/j.1553-2712.2001.tb00558.x; Duff AJA, 2003, ARCH DIS CHILD, V88, P931, DOI 10.1136/adc.88.10.931; Egelhoff JC, 1997, AM J ROENTGENOL, V168, P1259, DOI 10.2214/ajr.168.5.9129423; *EM NURS ASS, 2000, CONSC SED POS STAT; Everitt Ian, 2002, Emerg Med (Fremantle), V14, P62, DOI 10.1046/j.1442-2026.2002.00285.x; Faigel DO, 2002, GASTROINTEST ENDOSC, V56, P613; FATOVICH DM, 1995, ANN EMERG MED, V25, P209, DOI 10.1016/S0196-0644(95)70326-8; FRANK NC, 1995, J PEDIATR PSYCHOL, V20, P277, DOI 10.1093/jpepsy/20.3.277; *GEN DENT COUNC, 1999, SAAD DIG, V16, P16; *GEN DENT COUNC, 1999, SAAD DIG, V16, P17; Ghaffar S, 2002, J AM SOC ECHOCARDIOG, V15, P980, DOI 10.1067/mje.2002.121274; Gill M, 2003, ANN EMERG MED, V41, P234, DOI 10.1067/mem.2003.53; GLASIER CM, 1995, AM J NEURORADIOL, V16, P111; Godwin SA, 2005, ANN EMERG MED, V45, P177, DOI 10.1016/j.annemergmed.2004.11.002; Golparvar M, 2004, PEDIATR ANESTH, V14, P924, DOI 10.1111/j.1460-9592.2004.01349.x; Gorman R, 2002, PEDIATRICS, V110, P836; Green SM, 1996, ACAD EMERG MED, V3, P598; Green SM, 2004, ANN EMERG MED, V44, P460, DOI 10.1016/j.annemergmed.2004.06.006; Green SM, 2003, ANN EMERG MED, V42, P792, DOI 10.1016/S0196-0644(03)00746-7; Green SM, 2003, ANN EMERG MED, V42, P647, DOI 10.1016/S0196-0644(03)00636-X; Green SM, 2002, ANN EMERG MED, V39, P433, DOI 10.1067/mem.2002.122770; Green SM, 2002, ACAD EMERG MED, V9, P35, DOI 10.1197/aemj.9.1.35; Green SM, 1998, ACAD EMERG MED, V5, P971, DOI 10.1111/j.1553-2712.1998.tb02773.x; Green SM, 1998, ANN EMERG MED, V31, P688, DOI 10.1016/S0196-0644(98)70226-4; Green SM, 2000, ANN EMERG MED, V35, P35, DOI 10.1016/S0196-0644(00)70102-8; Green SM, 2001, J PEDIATR GASTR NUTR, V32, P26, DOI 10.1097/00005176-200101000-00010; Green SM, 2000, ANN EMERG MED, V36, P480, DOI 10.1067/mem.2000.111426; GREENBERG SB, 1993, AM J ROENTGENOL, V161, P639, DOI 10.2214/ajr.161.3.8352124; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Guenther E, 2003, ANN EMERG MED, V42, P783, DOI 10.1016/S0196-0644(03)00634-6; HENNRIKUS WL, 1995, J BONE JOINT SURG AM, V77A, P335, DOI 10.2106/00004623-199503000-00001; Iverson RE, 1999, PLAST RECONSTR SURG, V104, P1559, DOI 10.1097/00006534-199910000-00054; KAUFFMAN RE, 1993, PEDIATRICS, V92, P471; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Kim G, 2003, ACAD EMERG MED, V10, P140, DOI 10.1111/j.1553-2712.2003.tb00031.x; Klein EJ, 2002, PEDIATRICS, V109, P894, DOI 10.1542/peds.109.5.894; Knape J T, 1999, Ned Tijdschr Geneeskd, V143, P1098; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; KRAUSS B, 1999, PEDIAT PROCEDURAL SE; Levati A, 2004, Minerva Anestesiol, V70, P675; Litman RS, 1999, ARCH PEDIAT ADOL MED, V153, P1085, DOI 10.1001/archpedi.153.10.1085; Lowrie L, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e30; Luhmann JD, 2001, ANN EMERG MED, V37, P20, DOI 10.1067/mem.2001.112003; Malviya S, 1997, ANESTH ANALG, V85, P1207, DOI 10.1097/00000539-199712000-00005; Mandell GA, 1997, J NUCL MED, V38, P1640; MANULI MA, 1994, AM J ROENTGENOL, V162, P466; Mason KP, 2004, RADIOLOGY, V230, P537, DOI 10.1148/radiol.2302030107; Massanari M, 1997, CLIN PEDIATR, V36, P681, DOI 10.1177/000992289703601202; *MED ASS S AFR, 1997, S AFR MED J, V87, P484; Miner JR, 2005, ACAD EMERG MED, V12, P124, DOI 10.1197/j.aem.2004.08.054; Moro-Sutherland DM, 2000, ACAD EMERG MED, V7, P1370, DOI 10.1111/j.1553-2712.2000.tb00494.x; Nasraway SA, 2002, CRIT CARE MED, V30, P117, DOI 10.1097/00003246-200201000-00019; Nichols DP, 2005, PEDIATR ANESTH, V15, P199, DOI 10.1111/j.1460-9592.2005.01416.x; *NZ COLL AN, 1992, SAAD DIG, V9, P70; OJALA R, 1999, EMERG MED AUSTRALAS, V11, P258; Olson DM, 2001, PEDIATRICS, V108, P163, DOI 10.1542/peds.108.1.163; OLSSON GL, 1984, ACTA ANAESTH SCAND, V28, P567, DOI 10.1111/j.1399-6576.1984.tb02121.x; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; PEREIRA JK, 1993, PEDIATR RADIOL, V23, P341, DOI 10.1007/BF02011952; Picard P, 2000, ANESTH ANALG, V90, P963; Pitetti RD, 2003, ARCH PEDIAT ADOL MED, V157, P1090, DOI 10.1001/archpedi.157.11.1090; Poirier MP, 1998, AM J EMERG MED, V16, P350, DOI 10.1016/S0735-6757(98)90125-5; Pomeranz ES, 2000, PEDIATRICS, V105, P1110, DOI 10.1542/peds.105.5.1110; Powers SW, 1999, J PEDIATR PSYCHOL, V24, P131, DOI 10.1093/jpepsy/24.2.131; QURESHI FA, 1995, PEDIATR EMERG CARE, V11, P93, DOI 10.1097/00006565-199504000-00009; Roback MG, 2004, ANN EMERG MED, V44, P454, DOI 10.1016/j.annemergmed.2004.03.015; ROWLAND AS, 1995, AM J EPIDEMIOL, V141, P531, DOI 10.1093/oxfordjournals.aje.a117468; Schenarts CL, 2001, ACAD EMERG MED, V8, P1, DOI 10.1111/j.1553-2712.2001.tb00537.x; SCHWANDA AE, 1993, AM J PEDIAT HEMATOL, V15, P370; *SCOTT INT GUID, 2002, SAAD DIG, V19, P3; Sedik H, 2001, ARCH PEDIAT ADOL MED, V155, P665, DOI 10.1001/archpedi.155.6.665; Shannon M, 1997, J PEDIATR-US, V131, P582, DOI 10.1016/S0022-3476(97)70066-0; Sherwin TS, 2000, ANN EMERG MED, V35, P229, DOI 10.1016/S0196-0644(00)70073-4; *SOC GASTR NURS AS, 2004, GASTROENTEROL NURS, V27, P142; Soto RG, 2004, ANESTH ANALG, V99, P379; Standing Dental Advisory Committee, 2004, SAAD Dig, V21, P20; STEVENS B, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001069.P1B2; Tait AR, 2005, ANESTH ANALG, V100, P59, DOI 10.1213/01.ANE.0000139653.53618.91; Tanaka M, 2000, ANESTHESIOLOGY, V93, P1217, DOI 10.1097/00000542-200011000-00014; THEROUX MC, 1993, PEDIATRICS, V91, P624; Treston Greg, 2004, Emerg Med Australas, V16, P145, DOI 10.1111/j.1742-6723.2004.00583.x; *UK NAT CLIN GUID, 2002, INT J PAEDIATR DENT, V12, P359; Vargo JJ, 2002, GASTROENTEROLOGY, V123, P8, DOI 10.1053/gast.2002.34232; Vargo JJ, 2002, GASTROINTEST ENDOSC, V55, P826, DOI 10.1067/mge.2002.124208; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4; Warner MA, 1999, ANESTHESIOLOGY, V90, P896; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131; Weber F, 2005, ACTA ANAESTH SCAND, V49, P277, DOI 10.1111/j.1399-6576.2005.00626.x; Wilson JA, 1997, J ACCID EMERG MED, V14, P70	127	326	348	1	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2006	367	9512					766	780		10.1016/S0140-6736(06)68230-5	http://dx.doi.org/10.1016/S0140-6736(06)68230-5			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517277				2023-01-03	WOS:000235906000031
J	Fidler, H; Thompson, C; Freeman, A; Hogan, D; Walker, G; Weinman, J				Fidler, H; Thompson, C; Freeman, A; Hogan, D; Walker, G; Weinman, J			Barriers to implementing a policy not to attempt resuscitation in acute medical admissions: prospective, cross sectional study of a successive cohort	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To establish whether acutely unwell patients admitted to hospital wish to participate in discussions about resuscitation. Design Prospective, cross sectional study of a successive cohort of patients. Setting Admission through the emergency department. Participants 374 adult patients. Main outcome measure Whether acutely unwell patients wished to participate in discussions about resuscitation. Results Of the total sample, 74 patients consented to take part in the Study and provide full data. Of the remaining patients, 189 could not be approached for practical reasons and 111 did not wish to participate. Of the 74 patients who read the leallet, 65 (88%) reported having little or no prior knowledge, 70 (95%) understood it, 56 (76%) preferred for resuscitation decisions to be discussed with them, and 55 (74%) did not mind discussing resuscitation within 24 hours of admission and overall showed a decline in their anxiety score. Conclusion Many patients admitted through the emergency department for medical reasons cannot participate in their decision not to attempt resuscitation within 24 hours of admission. Patients who were willing to participate rated the information leaflet that was provided positively.	Inst Psychiat, Dept Psychol, Hlth Psychol Sect, London SE5 8AH, England; Univ Hosp Lewisham, Dept Gastroenterol, London SE13 6LH, England; Univ Hosp Lewisham, Emergency Dept, London SE13 6LH, England	University of London; King's College London; University of London; King's College London; University of London; King's College London	Weinman, J (corresponding author), Inst Psychiat, Dept Psychol, Hlth Psychol Sect, London SE5 8AH, England.	john.weinman@kcl.ac.uk		Weinman, John Alfred/0000-0002-6786-0166				*BMA RES COUNC UK, 2002, DEC REL CARD RES JOI; Cauchi L, 2004, RESUSCITATION, V63, P157, DOI 10.1016/j.resuscitation.2004.05.017; KIRK P, 2004, BRIT MED J, V328, P1344; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Vedula KC, 2004, ANN EMERG MED, V44, pS68, DOI 10.1016/j.annemergmed.2004.07.226	5	12	12	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2006	332	7539					461	462		10.1136/bmj.38740.855914.BE	http://dx.doi.org/10.1136/bmj.38740.855914.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018VM	16473857	Bronze, Green Published			2023-01-03	WOS:000235792900018
J	Wang, DS; Mangin, JM; Moonen, G; Rigo, JM; Legendre, P				Wang, DS; Mangin, JM; Moonen, G; Rigo, JM; Legendre, P			Mechanisms for picrotoxin block of alpha(2) homomeric glycine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; CHLORIDE CHANNELS; CONFORMATIONAL-CHANGE; CRAYFISH MUSCLE; NEURONS; BINDING; GABA; ZEBRAFISH; RESIDUE; RAT	It is well known that the convulsant alkaloid picrotoxin (PTX) can inhibit neuronal gamma-aminobutyric acid ( GABA) and homomeric glycine receptors (GlyR). However, the mechanism for PTX block of alpha(2) homomeric GlyR is still unclear compared with that of alpha(1) homomeric GlyR, GABA(A), and GABA(C) receptors. Furthermore, PTX effects on GlyR kinetics have been poorly explored at the single-channel level. Hence, we used the patch-clamp technique in the outside-out configuration to investigate the mechanism of PTX suppression of currents carried by alpha(2) homomeric GlyRs stably transfected into Chinese hamster ovary cells. PTX inhibited the alpha(2) homomeric GlyR current elicited by glycine in a concentration-dependent and voltage-independent manner. Both competitive and noncompetitive mechanisms were observed. PTX decreased the mean open time of the GlyR channel in a concentration-dependent manner, suggesting that PTX can block channel openings and bind to the receptor in the open channel conformation. When PTX and glycine were co-applied, a small rebound current was observed during drug washout. Application of PTX during the deactivation phase of glycine-induced currents eliminated the rebound current and accelerated the deactivation time course in a concentration-dependent manner. PTX could not bind to the unbound conformation of GlyR, but could be trapped at its binding site when the channel closed during glycine dissociation. Based on these observations, we propose a kinetic Markov model in which PTX binds to the alpha(2) homomeric GlyR in both the open channel state and the fully liganded closed state. Our data suggest a new allosteric mechanism for PTX inhibition of wild-type homomeric alpha(2) GlyR.	Univ Paris 06, CNRS, Unite Mixte Rech 7102, F-75252 Paris 05, France; Fac Med, Ctr Rech Neurobiol Cellulaire & Mol, B-4020 Liege 2, Belgium; Univ Hasselt, Ctr Biomed Res, B-3590 Diepenbeek, Belgium; Fourth Mil Med Univ, Dept Anat, Xian 710032, Peoples R China	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Hasselt University; Air Force Military Medical University	Legendre, P (corresponding author), Univ Paris 06, CNRS, Unite Mixte Rech 7102, 9 Quai St Bernard, F-75252 Paris 05, France.	pascal.legendre@snv.jussieu.fr	Rigo, Jean-Michel/E-3456-2010	Rigo, Jean-Michel/0000-0002-0031-526X; Mangin, Jean-Marie/0000-0002-7804-0251				Adelsberger H, 1998, EUR J NEUROSCI, V10, P179, DOI 10.1046/j.1460-9568.1998.00038.x; ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; Buhr A, 2001, J BIOL CHEM, V276, P7775, DOI 10.1074/jbc.M008907200; Burzomato V, 2004, J NEUROSCI, V24, P10924, DOI 10.1523/JNEUROSCI.3424-04.2004; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; Colquhoun D, 2004, TRENDS NEUROSCI, V27, P337, DOI 10.1016/j.tins.2004.04.010; Colquhoun David, 1995, P397; Das P, 2005, J PHARMACOL EXP THER, V314, P320, DOI 10.1124/jpet.104.080325; Dibas MI, 2002, J BIOL CHEM, V277, P9112, DOI 10.1074/jbc.M111356200; Etter A, 1999, J NEUROCHEM, V72, P318, DOI 10.1111/jnc.1999.72.1.318; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; Flint AC, 1998, NEURON, V20, P43, DOI 10.1016/S0896-6273(00)80433-X; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; Gentet LJ, 2002, J PHYSIOL-LONDON, V544, P97, DOI 10.1113/jphysiol.2001.015321; Grudzinska J, 2005, NEURON, V45, P727, DOI 10.1016/j.neuron.2005.01.028; GURLEY D, 1995, RECEPTOR CHANNEL, V3, P13; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harvey RJ, 2000, EUR J NEUROSCI, V12, P994, DOI 10.1046/j.1460-9568.2000.00993.x; Hawthorne R, 2005, J BIOL CHEM, V280, P35836, DOI 10.1074/jbc.M506645200; INOUE M, 1988, NEUROSCI RES, V5, P380, DOI 10.1016/0168-0102(88)90024-7; KUHSE J, 1991, FEBS LETT, V283, P73, DOI 10.1016/0014-5793(91)80557-J; Legendre P, 1997, J NEUROPHYSIOL, V77, P2400, DOI 10.1152/jn.1997.77.5.2400; Legendre P, 1998, J NEUROSCI, V18, P2856; Legendre P, 2000, J NEUROSCI, V20, P140, DOI 10.1523/JNEUROSCI.20-01-00140.2000; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; LYNCH JW, 1995, J BIOL CHEM, V270, P13799, DOI 10.1074/jbc.270.23.13799; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; MACONOCHIE DJ, 1995, J GEN PHYSIOL, V106, P113, DOI 10.1085/jgp.106.1.113; Mangin JA, 2003, J PHYSIOL-LONDON, V553, P369, DOI 10.1113/jphysiol.2003.052142; Mangin JM, 2005, MOL PHARMACOL, V67, P1783, DOI 10.1124/mol.104.007435; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Qian HH, 2005, MOL PHARMACOL, V67, P470, DOI 10.1124/mol.104.003996; RUNDSTROM N, 1994, P NATL ACAD SCI USA, V91, P8950, DOI 10.1073/pnas.91.19.8950; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; TRILLER A, 1990, New Biologist, V2, P637; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Yoon KW, 1998, NEUROSCIENCE, V87, P807, DOI 10.1016/S0306-4522(98)00158-4; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Zhorov BS, 2000, BIOPHYS J, V78, P1786, DOI 10.1016/S0006-3495(00)76729-4	41	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3841	3855		10.1074/jbc.M511022200	http://dx.doi.org/10.1074/jbc.M511022200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16344549	hybrid, Green Submitted			2023-01-03	WOS:000235275300012
J	Tattevin, P; Souala, F; Revest, M; Taussig, D; Michelet, C				Tattevin, P; Souala, F; Revest, M; Taussig, D; Michelet, C			Confusion, memory disorders, and ophthalmoparesis in a patient with AIDS	LANCET			English	Editorial Material							WERNICKES ENCEPHALOPATHY		Pontchaillou Univ Med Ctr, Dept Infect Dis, F-35033 Rennes, France; Pontchaillou Univ Med Ctr, Dept Neurol, F-35033 Rennes, France	CHU Rennes; CHU Rennes	Tattevin, P (corresponding author), Pontchaillou Univ Med Ctr, Dept Infect Dis, Rue Guilloux, F-35033 Rennes, France.	pierre.tattevin@chu-rennes.fr	Revest, Matthieu/L-9533-2015; Tattevin, Pierre/L-7046-2015					Alcaide ML, 2003, INT J STD AIDS, V14, P712, DOI 10.1258/095646203322387992; Kaineg B, 2005, NEW ENGL J MED, V352, pE18, DOI 10.1056/NEJMicm040862; NADEL AM, 1976, JAMA-J AM MED ASSOC, V235, P2403, DOI 10.1001/jama.235.22.2403; Ogershok PR, 2002, AM J MED SCI, V323, P107, DOI 10.1097/00000441-200202000-00010; VORTMEYER AO, 1992, J NEUROL NEUROSUR PS, V55, P826, DOI 10.1136/jnnp.55.9.826	5	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 28	2006	367	9507					368	368		10.1016/S0140-6736(06)68075-6	http://dx.doi.org/10.1016/S0140-6736(06)68075-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	009AX	16443045				2023-01-03	WOS:000235084600034
J	Adams, RJ; Brambilla, D				Adams, RJ; Brambilla, D		STOP 2 Trial Investigators	Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-TRIALS; CEREBROVASCULAR ACCIDENTS; TRANSCRANIAL DOPPLER; PLASMA HEMOGLOBIN; RECURRENT STROKE; ANEMIA; THERAPY; CHILDREN; RISK; ULTRASONOGRAPHY	Background Prophylactic transfusion prevents strokes in children with sickle cell anemia who have abnormalities on transcranial Doppler ultrasonographic examination. However, it is not known how long transfusion should be continued in these children. Methods We studied children with sickle cell disease who had a high risk of stroke on the basis of a transcranial Doppler screening examination and who had received transfusions for 30 months or longer, during which time the Doppler readings became normal. The children were randomly assigned to continued transfusion or no continued transfusion. Children with severe stenotic lesions on cerebral magnetic resonance angiography were excluded. The composite primary end point was stroke or reversion to a result on Doppler examination indicative of a high risk of stroke. Results The study was stopped after 79 children of a planned enrollment of 100 underwent randomization. Among the 41 children in the transfusion-halted group, high-risk Doppler results developed in 14 and stroke in 2 others within a mean (+/-SD) of 4.5+/-2.6 months (range, 2.1 to 10.1) of the last transfusion. Neither of these events of the composite end point occurred in the 38 children who continued to receive transfusions. The average of the last two transcranial Doppler results before transfusion was started was the only predictor of the composite end point (P=0.05). Conclusions Discontinuation of transfusion for the prevention of stroke in children with sickle cell disease results in a high rate of reversion to abnormal blood-flow velocities on Doppler studies and stroke.	Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA; Med Univ S Carolina, Charleston, SC 29425 USA; Univ Miami, Sch Med, Miami, FL USA; Childrens Hosp Oakland, Oakland, CA USA; Childrens Natl Med Ctr, Washington, DC 20010 USA; E Carolina Univ, Greenville, NC USA; Columbia Univ, New York, NY USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Emory Univ, Sch Med, Atlanta, GA USA; Grady Hlth Syst, Atlanta, GA USA; Morehouse Sch Med, Atlanta, GA 30310 USA; Childrens Healthcare Atlanta, Atlanta, GA USA; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Hlth Network, Toronto, ON, Canada; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Childrens Mercy Hosp, Kansas City, MO 64108 USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Sch Med, Baltimore WAshington Sickle Cell Res Consortium, Baltimore, MD USA; Sinai Hosp, Baltimore, MD 21215 USA; Univ Maryland, Baltimore, MD 21201 USA; Georgetown Univ, Washington, DC USA; Univ Alabama Birmingham, Birmingham, AL USA; Columbus Reg Med Ctr, Columbus, GA USA; Suny Downstate Med Ctr, Kings Cty Hosp Ctr, Brooklyn, NY 11203 USA; Univ So Calif, Los Angeles, CA USA; Louisiana State Univ, New Orleans, LA USA; Tulane Univ, Sch Med, New Orleans, LA 70112 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; NHLBI, Bethesda, MD 20892 USA	University System of Georgia; Augusta University; Medical University of South Carolina; University of Miami; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Children's National Health System; University of North Carolina; East Carolina University; Columbia University; University of Mississippi; University of Mississippi Medical Center; Emory University; Morehouse School of Medicine; Children's Healthcare of Atlanta (CHOA); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Children's Mercy Hospital; St Jude Children's Research Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Johns Hopkins University; Sinai Hospital of Baltimore; University System of Maryland; University of Maryland Baltimore; Georgetown University; University of Alabama System; University of Alabama Birmingham; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Southern California; Louisiana State University System; Tulane University; Cincinnati Children's Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Adams, RJ (corresponding author), Med Coll Georgia, Dept Neurol, 1429 Harper St,HF 1154, Augusta, GA 30912 USA.	rjadams@mcg.edu	McCarville, M Beth/N-2471-2018; Warrier, Rajasekharan P/D-4512-2011	McCarville, M Beth/0000-0002-2888-443X; Brambilla, Donald/0000-0002-7276-4689	NHLBI NIH HHS [U01 HL 052193, U01 HL 052016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL052016, U01HL052193] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS R, 1992, NEW ENGL J MED, V326, P605, DOI 10.1056/NEJM199202273260905; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Adams RJ, 1998, CONTROL CLIN TRIALS, V19, P110, DOI 10.1016/S0197-2456(97)00099-8; Bernaudin F, 2005, PEDIATR RADIOL, V35, P242, DOI 10.1007/s00247-005-1419-5; BRASS LM, 1991, STROKE, V22, P27, DOI 10.1161/01.STR.22.1.27; COHEN AR, 1992, BLOOD, V79, P1657; COX DR, 1972, J R STAT SOC B, V34, P187; Files B, 2002, J PEDIAT HEMATOL ONC, V24, P284, DOI 10.1097/00043426-200205000-00013; Goldstein LB, 2001, STROKE, V32, P280, DOI 10.1161/01.STR.32.1.280; LAKATOS E, 1988, BIOMETRICS, V44, P229, DOI 10.2307/2531910; LAKATOS E, 1988, BIOMETRICS, V44, P923; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; MILLER ST, 1992, J PEDIATR-US, V120, P54, DOI 10.1016/S0022-3476(05)80597-9; NEELY CL, 1969, AM J CLIN PATHOL, V52, P167; *NIH, 1997, CLIN AL PER TRANSF L; Ohene-Frempong K, 1998, BLOOD, V91, P288; Patel RP, 2004, FREE RADICAL BIO MED, V36, P399, DOI 10.1016/j.freeradbiomed.2003.11.019; PEGELOW CH, 1995, J PEDIATR-US, V126, P896, DOI 10.1016/S0022-3476(95)70204-0; Prengler M, 2002, ANN NEUROL, V51, P543, DOI 10.1002/ana.10192; Rana S, 1997, J PEDIATR-US, V131, P757, DOI 10.1016/S0022-3476(97)70108-2; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Sakhalkar VS, 2004, AM J HEMATOL, V76, P57, DOI 10.1002/ajh.20016; SAS Institute, 2003, SAS STAT SOFTW VERS; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V290, P756; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V289, P1645, DOI 10.1001/jama.289.13.1645; Walters MC, 2000, BLOOD, V95, P1918; WANG WC, 1991, J PEDIATR-US, V118, P377, DOI 10.1016/S0022-3476(05)82150-X; Ware RE, 2004, J PEDIATR-US, V145, P346, DOI 10.1016/j.jpeds.2004.04.058; WILIMAS J, 1980, J PEDIATR-US, V96, P205, DOI 10.1016/S0022-3476(80)80803-1; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	30	385	394	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	2005	353	26					2769	2778						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	997LK	16382063				2023-01-03	WOS:000234246700008
J	Masip, J; Roque, M; Sanchez, B; Fernandez, R; Subirana, M; Exposito, JA				Masip, J; Roque, M; Sanchez, B; Fernandez, R; Subirana, M; Exposito, JA			Noninvasive ventilation in acute cardiogenic pulmonary edema - Systematic review and meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							POSITIVE AIRWAY PRESSURE; ACUTE RESPIRATORY-FAILURE; SUPPORT VENTILATION; FACE MASK; RANDOMIZED-TRIAL; MYOCARDIAL-INFARCTION; OXYGEN-THERAPY; HEART-FAILURE; BILEVEL; BIAS	Context In patients with acute cardiogenic pulmonary edema noninvasive ventilation may reduce intubation rate, but the impact on mortality and the superiority of one technique over another have not been clearly established. Objective To systematically review and quantitatively synthesize the short-term effect of noninvasive ventilation on major clinical outcomes. Data Sources MEDLINE and EMBASE (from inception to October 2005) and Cochrane databases (library issue 4, 2005) were searched to identify relevant randomized controlled trials and systematic reviews published from January 1, 1988, to October 31,2005. Study Selection and Data Extraction included trials were all parallel studies comparing noninvasive ventilation to conventional oxygen therapy in patients with acute pulmonary edema. Comparisons of different techniques, either continuous positive airway pressure (CPAP) or bilevel noninvasive pressure support ventilation (NIPSV), were also included. Data Synthesis Fifteen trials were selected. Overall, noninvasive ventilation significantly reduced the mortality rate by nearly 45% compared with conventional therapy (risk ratio [RR], 0.55; 95% confidence interval [CI], 0.40-0.78; P=.72 for heterogeneity). The results were significant for CPAP (RR, 0.53; 95% Cl, 0.35-0.81; P=.44 for heterogeneity) but not for NIPSV (RR, 0.60; 95% Cl, 0.34-1.05; P=.76 for heterogeneity), although there were fewer studies in the latter. Both modalities showed a significant decrease in the "need to intubate" rate compared with conventional therapy: CPAP (RR, 0.40; 95% Cl, 0.27-0.58; P=.21 for heterogeneity), NIPSV (RR, 0.48; 95% Cl, 0.30-0.76; P=.24 for heterogeneity), and together (RR, 0.43; 95% Cl, 0.32-0.57; P=.20 for heterogeneity). There were no differences in intubation or mortality rates in the analysis of studies comparing the 2 techniques. Conclusions Noninvasive ventilation reduces the need for intubation and mortality in patients with acute cardiogenic pulmonary edema. Although the level of evidence is higher for CPAP, there are no significant differences in clinical outcomes when comparing CPAP vs NIPSV.	Univ Barcelona, ICU Dept, Hosp Dos Maig Consorci Sanitari Integral Barcelon, Barcelona 08025, Spain; Univ Autonoma Barcelona, Hosp Santa Cruz & San Pablo, Iberoamer Cochrane Ctr, E-08193 Barcelona, Spain; Hosp Sabadell, Corp Parc Tauli, Serv Med Intens, Sabadell, Spain	University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona; Parc Tauli Hospital Universitari	Masip, J (corresponding author), Univ Barcelona, ICU Dept, Hosp Dos Maig Consorci Sanitari Integral Barcelon, Dos Maig 301, Barcelona 08025, Spain.	jmasip@ub.edu	Subirana, Mireia/AAD-5377-2019; Fernandez, Rafael/A-9586-2010	Subirana, Mireia/0000-0003-1577-4159; Fernandez, Rafael/0000-0001-5711-5317; Roque i Figuls, Marta/0000-0003-0043-1364				Antonelli M, 2001, INTENS CARE MED, V27, P1718, DOI 10.1007/s00134-001-1114-4; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bellone A, 2005, INTENS CARE MED, V31, P807, DOI 10.1007/s00134-005-2649-6; Bellone A, 2004, CRIT CARE MED, V32, P1860, DOI 10.1097/01.CCM.0000139694.47326.B6; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BOLLAERT PE, 2002, AM J RESP CRIT CARE, V165, pA387; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Burns KEA, 2005, CRIT CARE MED, V33, P1477, DOI 10.1097/01.CCM.0000168042.59035.D8; Chadda K, 2002, CRIT CARE MED, V30, P2457, DOI 10.1097/00003246-200211000-00009; Crane SD, 2004, EMERG MED J, V21, P155, DOI 10.1136/emj.2003.005413; Craven RA, 2000, ACAD EMERG MED, V7, P1065, DOI 10.1111/j.1553-2712.2000.tb02102.x; Cross AM, 2003, EMERG MED J, V20, P531, DOI 10.1136/emj.20.6.531; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; [赫朝霞 Hao Chaoxia], 2002, [江西医学院学报, Acta Academiae Medicinae Jiangxi], V42, P48; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kelly CA, 2002, EUR HEART J, V23, P1379, DOI 10.1053/euhj.2001.3156; L'Her E, 2004, INTENS CARE MED, V30, P882, DOI 10.1007/s00134-004-2183-y; Levitt MA, 2001, J EMERG MED, V21, P363, DOI 10.1016/S0736-4679(01)00385-7; LIESCHING TN, 2003, AM J RESP CRIT CARE, V167, pA864; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; Lin M, 1991, J Formos Med Assoc, V90, P736; Mackay CA, 2000, AM J RESP CRIT CAR S, V161, pA416; Masip J, 2000, LANCET, V356, P2126, DOI 10.1016/S0140-6736(00)03492-9; Masip J, 2004, AM J RESP CRIT CARE, V169, P1072, DOI 10.1164/ajrccm.169.9.954; MASIP J, 2005, EUR J HEART FAIL S1, V4, P11; Mehta S, 1997, CRIT CARE MED, V25, P620, DOI 10.1097/00003246-199704000-00011; Mehta S, 2005, INTENS CARE MED, V31, P757, DOI 10.1007/s00134-005-2650-0; Moritz F, 2003, EUR J EMERG MED, V10, P204, DOI 10.1097/00063110-200309000-00009; Nava S, 2003, AM J RESP CRIT CARE, V168, P1432, DOI 10.1164/rccm.200211-1270OC; Nieminen MS, 2005, EUR HEART J, V26, P384; Pang D, 1998, CHEST, V114, P1185, DOI 10.1378/chest.114.4.1185; Park M, 2004, CRIT CARE MED, V32, P2407, DOI 10.1097/01.CCM.0000147770.20400.10; Park M, 2001, Arq Bras Cardiol, V76, P221; Picot J, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004104.PUB3; RASANEN J, 1985, AM J CARDIOL, V55, P296, DOI 10.1016/0002-9149(85)90364-9; Rusterholtz T, 1999, INTENS CARE MED, V25, P21, DOI 10.1007/s001340050782; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sharon A, 2000, J AM COLL CARDIOL, V36, P832, DOI 10.1016/S0735-1097(00)00785-3; Takeda S, 1997, ANESTH ANALG, V84, P1091, DOI 10.1097/00000539-199705000-00025; Takeda S, 1998, JPN CIRC J, V62, P553, DOI 10.1253/jcj.62.553; VAISANEN IT, 1987, CHEST, V92, P481, DOI 10.1378/chest.92.3.481; Wysocki M, 1999, INTENS CARE MED, V25, P1, DOI 10.1007/s001340050778	42	362	401	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	2005	294	24					3124	3130		10.1001/jama.294.24.3124	http://dx.doi.org/10.1001/jama.294.24.3124			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	997UL	16380593				2023-01-03	WOS:000234274200029
J	Bellouin, N; Boucher, O; Haywood, J; Reddy, MS				Bellouin, N; Boucher, O; Haywood, J; Reddy, MS			Global estimate of aerosol direct radiative forcing from satellite measurements	NATURE			English	Article							OPTICAL-PROPERTIES; PRODUCTS; ALGORITHM	Atmospheric aerosols cause scattering and absorption of incoming solar radiation. Additional anthropogenic aerosols released into the atmosphere thus exert a direct radiative forcing on the climate system(1). The degree of present-day aerosol forcing is estimated from global models that incorporate a representation of the aerosol cycles(1-3). Although the models are compared and validated against observations, these estimates remain uncertain. Previous satellite measurements of the direct effect of aerosols contained limited information about aerosol type, and were confined to oceans only(4,5). Here we use state-of-the-art satellite-based measurements of aerosols(6-8) and surface wind speed(9) to estimate the clear-sky direct radiative forcing for 2002, incorporating measurements over land and ocean. We use a Monte Carlo approach to account for uncertainties in aerosol measurements and in the algorithm used. Probability density functions obtained for the direct radiative forcing at the top of the atmosphere give a clear-sky, global, annual average of -1.9 W m(-2) with standard deviation, +/-0.3 W m(-2). These results suggest that present-day direct radiative forcing is stronger than present model estimates, implying future atmospheric warming greater than is presently predicted, as aerosol emissions continue to decline(10).	Met Off, Exeter EX1 3PB, Devon, England; NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08540 USA	Met Office - UK; National Oceanic Atmospheric Admin (NOAA) - USA	Bellouin, N (corresponding author), Met Off, Exeter EX1 3PB, Devon, England.	nicolas.bellouin@metoffice.gov.uk	Boucher, Olivier/J-5810-2012; Boucher, Olivier/K-7483-2012; Haywood, Jim/GQA-6691-2022	Boucher, Olivier/0000-0003-2328-5769; Boucher, Olivier/0000-0003-2328-5769; Haywood, Jim/0000-0002-2143-6634; Bellouin, Nicolas/0000-0003-2109-9559				Andreae MO, 2005, NATURE, V435, P1187, DOI 10.1038/nature03671; Bellouin N, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017121; Christopher SA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL014803; Collins WD, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001365; COX C, 1954, J MAR RES, V13, P198; Dubovik O, 2002, J ATMOS SCI, V59, P590, DOI 10.1175/1520-0469(2002)059<0590:VOAAOP>2.0.CO;2; Herman JR, 1997, J GEOPHYS RES-ATMOS, V102, P16911, DOI 10.1029/96JD03680; Kaufman YJ, 1997, J GEOPHYS RES-ATMOS, V102, P17051, DOI 10.1029/96JD03988; Keil A, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002315; Key JR, 1998, COMPUT GEOSCI, V24, P443, DOI 10.1016/S0098-3004(97)00130-1; Kirkevag A, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000886; Osborne SR, 2005, ATMOS RES, V73, P173, DOI 10.1016/j.atmosres.2004.09.002; Platnick S, 2003, IEEE T GEOSCI REMOTE, V41, P459, DOI 10.1109/TGRS.2002.808301; RAMASWARNY V, 2001, CLIMATE CHANGE 2001; Reddy MS, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD004757; Remer LA, 2005, J ATMOS SCI, V62, P947, DOI 10.1175/JAS3385.1; Roberts DL, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004676; Schaaf CB, 2002, REMOTE SENS ENVIRON, V83, P135, DOI 10.1016/S0034-4257(02)00091-3; Smirnov A, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003879; Stier P, 2005, ATMOS CHEM PHYS, V5, P1125, DOI 10.5194/acp-5-1125-2005; Takemura T, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005029; Tanre D, 1997, J GEOPHYS RES-ATMOS, V102, P16971, DOI 10.1029/96JD03437; Wentz FJ, 1997, J GEOPHYS RES-OCEANS, V102, P8703, DOI 10.1029/96JC01751	23	355	374	10	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	2005	438	7071					1138	1141		10.1038/nature04348	http://dx.doi.org/10.1038/nature04348			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	995OF	16372005				2023-01-03	WOS:000234111500046
J	Roland, M				Roland, M			Deprivation and volunteering by general practices: cross sectional analysis of a national primary care system	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Roland, M (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.	m.roland@man.ac.uk						COAST J, 2005, BRIT MED J, V331, P14444; Duckett S, 2003, ANN ROY COLL SURG, V85, P195, DOI 10.1308/003588403321661389; Maddison P, 2004, BRIT MED J, V329, P1325, DOI 10.1136/bmj.329.7478.1325; ROLAND M, 1998, SPECIALIST OUTREACH; Salisbury C, 2005, BMJ-BRIT MED J, V331, P1441, DOI 10.1136/bmj.38670.494734.7C; SANDERSON D, 2002, EVALUATION GPS SPECI; SCHOFIELD JK, 2005, BRIT J DERMATOL S1, V153, pO1	7	6	6	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	DEC 17	2005	331	7530					1448	1449		10.1136/bmj.38676.769711.7C	http://dx.doi.org/10.1136/bmj.38676.769711.7C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	996EE	16339218	Green Published			2023-01-03	WOS:000234156400024
J	Jessup, JM; Stewart, A; Greene, FL; Minsky, BD				Jessup, JM; Stewart, A; Greene, FL; Minsky, BD			Adjuvant chemotherapy for stage III colon cancer - Implications of race/ethnicity, age, and differentiation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DATA-BASE REPORT; COLORECTAL-CANCER; BOWEL PROJECT; AFRICAN-AMERICANS; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; POOLED ANALYSIS; BREAST-CANCER; THERAPY; FLUOROURACIL	Context A 1990 National Institutes of Health Consensus Conference recommended that patients with stage III colon cancer receive adjuvant chemotherapy because survival was improved in clinical trials in patients who received a 5-fluorouracil-based regimen. Objective To determine whether adjuvant chemotherapy is used in the community as a standard of practice that improves outcome and whether it failed to benefit any specific sets of patients. Design, Setting, and Participants Prospective data from 85 934 patients with stage III colon cancer from 560 hospital cancer registries were entered into the National Cancer Data Base between 1990 and 2002 and included standard clinical, pathological, and first course of treatment variables. Main Outcome Measures Prevalence of adjuvant chemotherapy usage and 5-year survival in patients treated in US hospitals. Results Adjuvant chemotherapy use increased from 39% in 1991 to 64% in 2002 but was lower in black, female, and elderly patients. It improved 5-year survival from almost 8% in 1991 to more than 16% in 1997 compared with surgery alone. Adjuvant chemotherapy increases survival in elderly patients as much as it does in younger patients. However, the benefit of adjuvant chemotherapy in blacks and, those with high-grade cancers is not as great. Conclusions Adjuvant chemotherapy use has increased from 1990 to 2002 for patients with stage III colon cancer with an associated increase in 5-year survival of 16%. The benefit of adjuvant chemotherapy seems to be lower in black patients and high-grade cancers. Women have the same benefit but are less often treated. Elderly patients have the same benefit as younger patients but are less frequently treated. New options for adjuvant therapy in 2004-2005 may further improve the outcome of patients with stage III colon cancer.	NCI, Canc Diag Program, Div Canc Treatment & Diag, Rockville, MD 20892 USA; Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA; Amer Coll Surg, Canc Dept, Chicago, IL USA; Carolinas Med Ctr, Dept Surg, Charlotte, NC 28203 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University; American College of Surgeons; Carolinas Medical Center; Memorial Sloan Kettering Cancer Center	Jessup, JM (corresponding author), NCI, Canc Diag Program, Div Canc Treatment & Diag, Execut Plaza N 6040,6130 Execut Blvd, Rockville, MD 20892 USA.	jessupj@mail.nih.gov						*AM COLL SURG COMM, 1990, DATA ACQ MAN; Andre T, 2003, J CLIN ONCOL, V21, P2896, DOI 10.1200/JCO.2003.10.065; Ayanian JZ, 2003, J CLIN ONCOL, V21, P1293, DOI 10.1200/JCO.2003.06.178; Beart R W, 1995, J Am Coll Surg, V181, P225; Bouchardy C, 2001, BRIT J CANCER, V85, P1251, DOI 10.1054/bjoc.2001.2035; COX DR, 1972, J R STAT SOC B, V34, P187; DAYAL H, 1987, J CHRON DIS, V40, P857, DOI 10.1016/0021-9681(87)90185-8; Dignam JJ, 1999, JNCI-J NATL CANCER I, V91, P1933, DOI 10.1093/jnci/91.22.1933; Fremgen AM, 1999, CA-CANCER J CLIN, V49, P145, DOI 10.3322/canjclin.49.3.145; Gill S, 2004, J CLIN ONCOL, V22, P1797, DOI 10.1200/JCO.2004.09.059; GORDON B, 1994, DATA EXCHANGE STANDA, V1; Greene FL, 2002, ANN SURG, V236, P416, DOI 10.1097/00000658-200210000-00003; Greene FL, 2002, AJCC CANC STAGING MA, P113; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; Hershman D, 2003, J NATL CANCER I, V95, P1545, DOI 10.1093/jnci/djg073; Jessup JM, 1996, CANCER-AM CANCER SOC, V78, P918; Jessup JM, 1998, CANCER, V83, P2408, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2408::AID-CNCR22>3.0.CO;2-G; Keku T, 2002, CANCER EPIDEM BIOMAR, V11, P1611; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; Mahoney T, 2000, ARCH SURG-CHICAGO, V135, P182, DOI 10.1001/archsurg.135.2.182; Malin JL, 2002, J NATL CANCER I, V94, P835, DOI 10.1093/jnci/94.11.835; McCollum AD, 2002, JNCI-J NATL CANCER I, V94, P1160; Menck HR, 1997, CANCER, V80, P2296, DOI 10.1002/(SICI)1097-0142(19971215)80:12<2296::AID-CNCR11>3.0.CO;2-P; Menck HR, 1998, CANCER, V83, P2649, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2649::AID-CNCR32>3.0.CO;2-V; Mettlin CJ, 1997, CANCER, V79, P2052, DOI 10.1002/(SICI)1097-0142(19970515)79:10<2052::AID-CNCR29>3.0.CO;2-S; Milano G, 1999, BRIT J CANCER, V79, P627, DOI 10.1038/sj.bjc.6690098; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; O'Connell MJ, 1998, J CLIN ONCOL, V16, P295, DOI 10.1200/JCO.1998.16.1.295; Potosky AL, 2002, J CLIN ONCOL, V20, P1192, DOI 10.1200/JCO.20.5.1192; Sargent DJ, 2001, NEW ENGL J MED, V345, P1091, DOI 10.1056/NEJMoa010957; Schneider EC, 2004, J CLIN ONCOL, V22, P2985, DOI 10.1200/JCO.2004.09.087; Schrag D, 2001, J NATL CANCER I, V93, P850, DOI 10.1093/jnci/93.11.850; SHAMBAUGH E, 1995, STAT EPIDEMIOLOGY CA; Shepherd T, 2000, GASTROENTEROLOGY, V118, P1039, DOI 10.1016/S0016-5085(00)70356-8; STEELE GD, 1994, CANCER, V74, P1979, DOI 10.1002/1097-0142(19941001)74:7<1979::AID-CNCR2820740725>3.0.CO;2-J; Sundararajan V, 2002, ANN INTERN MED, V136, P349, DOI 10.7326/0003-4819-136-5-200203050-00007; Sundararajan V, 2001, CANCER J, V7, P213; Townsley CA, 2005, J CLIN ONCOL, V23, P3112, DOI 10.1200/JCO.2005.00.141; VanEenwyk J, 2002, CANCER, V95, P39, DOI 10.1002/cncr.10645; *WHO, 1992, INT CLASS DIS ONC; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; Wolmark N, 1999, J CLIN ONCOL, V17, P3553, DOI 10.1200/JCO.1999.17.11.3553; WOLMARK N, 1996, P AN M AM SOC CLIN, V15, P460	43	244	250	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	2005	294	21					2703	2711		10.1001/jama.294.21.2703	http://dx.doi.org/10.1001/jama.294.21.2703			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	990EV	16333005	Bronze			2023-01-03	WOS:000233726900018
J	Chodosh, J; Morton, SC; Mojica, W; Maglione, M; Suttorp, MJ; Hilton, L; Rhodes, S; Shekelle, P				Chodosh, J; Morton, SC; Mojica, W; Maglione, M; Suttorp, MJ; Hilton, L; Rhodes, S; Shekelle, P			Meta-analysis: Chronic disease self-management programs for older adults	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; DEPENDENT DIABETES-MELLITUS; LIFE-STYLE MODIFICATION; BLOOD-PRESSURE; PRIMARY-CARE; PATIENT EDUCATION; METABOLIC-CONTROL; GLYCEMIC CONTROL; CHRONIC ILLNESS; CARDIOVASCULAR-DISEASE	Background: Although enthusiasm is growing for self-management programs for chronic conditions, there are conflicting data regarding their effectiveness and no agreement on their essential components. Purpose: To assess the effectiveness and essential components of self-management programs for hypertension, osteoarthritis, and diabetes mellitus. Data Sources: The authors searched multiple sources dated through September 2004, including the Cochrane Library, MEDLINE, PSycINFO, and Nursing and Allied Health databases, and bibliographies of 87 previous reviews. Study Selection: Randomized trials that compared outcomes of self-management interventions with a control or with usual care for diabetes mellitus, osteoarthritis, or hypertension; outcomes included hemoglobin A,c level, fasting blood glucose level, weight, blood pressure, pain, or function. Data Extraction: Two reviewers independently identified trials and extracted data regarding whether the intervention used tailored adjustments to meet individual patient needs, a group setting, feedback, and psychological services, and whether the intervention was provided by the patient's usual physician. Data Synthesis: Of 780 studies screened, 53 studies contributed data to the random-effects meta-analysis (26 diabetes studies, 14 osteoarthritis studies, and 13 hypertension studies). Self-management interventions led to a statistically and clinically significant pooled effect size of -0.36 (95% CI, -0.52 to -0.21) for hemoglobin A,c, equivalent to a reduction in hemoglobin A,, level of about 0.81%. Self-management interventions decreased systolic blood pressure by 5 mm Hg (effect size, -0.39 [CI, -0.51 to -0.28]) and decreased diastolic blood pressure by 4.3 mm Hg (effect size, -0.51 [CI, -0.73 to -0.30]). Pooled effects of self-management interventions were statistically significant but clinically trivial for pain and function outcomes for osteoarthritis. No consistent results supported any of the 5 characteristics examined as essential for program success. Limitations: Studies had variable quality, and possible publication bias was evident. Conclusions: Self-management programs for diabetes mellitus and hypertension probably produce clinically important benefits. The elements of the programs most responsible for benefits cannot be determined from existing data, and this inhibits specification of optimally effective or cost-effective programs. Osteoarthritis self-management programs do not appear to have clinically beneficial effects on pain or function.	Greater Los Angeles Vet Affairs Healthcare Syst, GRECC 11G, Los Angeles, CA 90073 USA; So Calif Evidence Based Practice Ctr, RAND Hlth Div, Santa Monica, CA USA; Univ Calif Los Angeles, Los Angeles, CA USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; RAND Corporation; University of California System; University of California Los Angeles	Chodosh, J (corresponding author), Greater Los Angeles Vet Affairs Healthcare Syst, GRECC 11G, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.			Chodosh, Joshua/0000-0001-7784-4306				Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083; Barlow JH, 2000, HEALTH EDUC RES, V15, P665, DOI 10.1093/her/15.6.665; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Birtwhistle RV, 2004, BMJ-BRIT MED J, V328, P204, DOI 10.1136/bmj.37967.374063.EE; Blixen CE, 2004, J TELEMED TELECARE, V10, P44, DOI 10.1258/135763304322764194; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; Boule NG, 2001, JAMA-J AM MED ASSOC, V286, P1218, DOI 10.1001/jama.286.10.1218; Brown SA, 2002, DIABETES CARE, V25, P259, DOI 10.2337/diacare.25.2.259; CAMPBELL LV, 1990, DIABETES CARE, V13, P841, DOI 10.2337/diacare.13.8.841; Cappuccio FP, 2004, BMJ-BRIT MED J, V329, P145, DOI 10.1136/bmj.38121.684410.AE; CARNEY N, 2000, ASSESSMENT SELF CARE; *CDCP, 1997, UNR PREV OPP RED HLT; Cooper AR, 2000, BRIT J GEN PRACT, V50, P958; *CTR ADV HLTH, 1996, IND BIBL SELF MAN PE; DERAMOMELKUS GA, 1992, DIABETES CARE, V15, P864, DOI 10.2337/diacare.15.7.864; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Edworthy SM, 1999, J RHEUMATOL, V26, P1793; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ellis SE, 2004, PATIENT EDUC COUNS, V52, P97, DOI 10.1016/S0738-3991(03)00016-8; ELSHAWS EB, 1994, DIABETES EDUCATOR, V20, P228, DOI 10.1177/014572179402000309; Falkenberg M G, 1986, Scand J Prim Health Care, V4, P157, DOI 10.3109/02813438609014823; FRANSEN M, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004376; Fried LP, 2000, EPIDEMIOL REV, V22, P95, DOI 10.1093/oxfordjournals.epirev.a018031; FROST G, 1994, DIABETIC MED, V11, P397, DOI 10.1111/j.1464-5491.1994.tb00292.x; GIVEN CW, 1984, PATIENT EDUC COUNS, V6, P131, DOI 10.1016/0738-3991(84)90070-3; Glasgow RE, 2001, PATIENT EDUC COUNS, V44, P119, DOI 10.1016/S0738-3991(00)00186-5; GLASGOW RE, 1992, PATIENT EDUC COUNS, V19, P61, DOI 10.1016/0738-3991(92)90102-O; GOEPPINGER J, 1989, ARTHRITIS RHEUM, V32, P706, DOI 10.1002/anr.1780320608; GONZALEZFERNANDEZ RA, 1990, AM J CARDIOL, V65, P1384, DOI 10.1016/0002-9149(90)91332-Z; Goudswaard AN, 2004, DIABETIC MED, V21, P491, DOI 10.1111/j.1464-5491.2004.01153.x; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; GRUMAN J, 2002, MONOGRAPH CTR ADV HL; HAFNER RJ, 1982, BIOFEEDBACK SELF-REG, V7, P305, DOI 10.1007/BF00998923; Hedges L.V., 2014, STAT METHODS META AN; HOELSCHER TJ, 1986, J CONSULT CLIN PSYCH, V54, P217, DOI 10.1037/0022-006X.54.2.217; Hopman-Rock M, 2000, J RHEUMATOL, V27, P1947; Hughes SL, 2004, GERONTOLOGIST, V44, P217, DOI 10.1093/geront/44.2.217; Ismail K, 2004, LANCET, V363, P1589, DOI 10.1016/S0140-6736(04)16202-8; Jaber LA, 1996, ANN PHARMACOTHER, V30, P238, DOI 10.1177/106002809603000305; JACOB RG, 1985, BEHAV MODIF, V9, P32, DOI 10.1177/01454455850091003; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jennings P E, 1987, Diabetes Educ, V13, P390, DOI 10.1177/014572178701300407; JORGENSEN RS, 1981, BEHAV RES THER, V19, P467, DOI 10.1016/0005-7967(81)90073-5; KEEFE FJ, 1990, BEHAV THER, V21, P435, DOI 10.1016/S0005-7894(05)80357-0; Keyserling TC, 2002, DIABETES CARE, V25, P1576, DOI 10.2337/diacare.25.9.1576; Khaw KT, 2004, ANN INTERN MED, V141, P413, DOI 10.7326/0003-4819-141-6-200409210-00006; Kim HS, 2003, J ADV NURS, V44, P256, DOI 10.1046/j.1365-2648.2003.02800.x; KORHONEN T, 1983, DIABETES CARE, V6, P256, DOI 10.2337/diacare.6.3.256; KOSTIS JB, 1992, AM HEART J, V123, P466, DOI 10.1016/0002-8703(92)90662-F; Kwon HS, 2004, DIABETES CARE, V27, P478, DOI 10.2337/diacare.27.2.478; LAGRONE R, 1988, J CLIN PSYCHOL, V44, P271, DOI 10.1002/1097-4679(198803)44:2<271::AID-JCLP2270440230>3.0.CO;2-Q; Levetan CS, 2002, DIABETES CARE, V25, P2, DOI 10.2337/diacare.25.1.2; LORIG K, 1989, ARTHRITIS RHEUM, V32, P91, DOI 10.1002/anr.1780320116; LORIG K, 1986, J RHEUMATOL, V13, P763; LORIG K, 1985, ARTHRITIS RHEUM, V28, P680, DOI 10.1002/art.1780280612; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Mazzuca K B, 1997, J Community Health Nurs, V14, P211, DOI 10.1207/s15327655jchn1404_1; MCCULLOCH DK, 1983, BRIT MED J, V287, P1858, DOI 10.1136/bmj.287.6408.1858; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; MOORE H, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004097.PUB3; MUHLHAUSER I, 1993, CLIN EXP HYPERTENS, V15, P125, DOI 10.3109/10641969309041615; Newman S, 2004, LANCET, V364, P1523, DOI 10.1016/S0140-6736(04)17277-2; Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561; Ravaud P, 2004, ANN RHEUM DIS, V63, P703, DOI 10.1136/ard.2003.009803; RAZ I, 1988, DIABETES CARE, V11, P67, DOI 10.2337/diacare.11.1.67; Ridgeway NA, 1999, SOUTHERN MED J, V92, P667, DOI 10.1097/00007611-199907000-00004; Rosenthal R., 1991, METAANALYTIC PROCEDU, V6; Schroeder K, 2004, ARCH INTERN MED, V164, P722, DOI 10.1001/archinte.164.7.722; Schroeder K., 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004804; Selvin E, 2004, ANN INTERN MED, V141, P421, DOI 10.7326/0003-4819-141-6-200409210-00007; SHEKELLE P, 2005, CHRONIC DIS SELF MAN; SHEKELLE PG, 1999, INTERVENTIONS INCREA; Simmons D, 2004, DIABETIC MED, V21, P214, DOI 10.1111/j.1464-5491.2004.01047.x; Solomon DH, 2002, J RHEUMATOL, V29, P362; SOUTHAM MA, 1982, ARCH GEN PSYCHIAT, V39, P715; Sweeting H L, 1994, J Nurs Manag, V2, P187, DOI 10.1111/j.1365-2834.1994.tb00152.x; TAYLOR CB, 1977, ARCH GEN PSYCHIAT, V34, P339; Tu K S, 1993, Diabetes Educ, V19, P25; VANNINEN E, 1992, DIABETOLOGIA, V35, P340, DOI 10.1007/BF00401201; Victor CR, 2004, J EVAL CLIN PRACT, V10, P63, DOI 10.1111/j.1365-2753.2003.00395.x; Warsi A, 2004, ARCH INTERN MED, V164, P1641, DOI 10.1001/archinte.164.15.1641; Warsi A, 2003, ARTHRITIS RHEUM-US, V48, P2207, DOI 10.1002/art.11210; WEINBERER M, 1995, J GEN INTERN MED, V10, P59, DOI 10.1007/BF02600227; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006; WHITE N, 1986, DIABETES CARE, V9, P490, DOI 10.2337/diacare.9.5.490; WIERENGA ME, 1994, PATIENT EDUC COUNS, V23, P33	88	539	546	5	85	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 20	2005	143	6					427	438		10.7326/0003-4819-143-6-200509200-00007	http://dx.doi.org/10.7326/0003-4819-143-6-200509200-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	967OG	16172441				2023-01-03	WOS:000232099900004
J	Reichert, JM; Rosensweig, CJ; Faden, LB; Dewitz, MC				Reichert, JM; Rosensweig, CJ; Faden, LB; Dewitz, MC			Monoclonal antibody successes in the clinic	NATURE BIOTECHNOLOGY			English	Article							MOUSE		Tufts Univ, Ctr Study Drug Dev, Boston, MA 02111 USA	Tufts University	Reichert, JM (corresponding author), Tufts Univ, Ctr Study Drug Dev, 192 S St,Suite 550, Boston, MA 02111 USA.	janice.reichert@tufts.edu		Rosensweig, Clark/0000-0001-6364-2025; Reichert, Janice/0000-0003-0400-1951				BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; Carson D A, 1986, Adv Immunol, V38, P275, DOI 10.1016/S0065-2776(08)60009-7; COLE SPC, 1984, MOL CELL BIOCHEM, V62, P109; FLEMING T, 2004, RED BOOK; INGLIS TJJ, 1993, LANCET, V341, P303, DOI 10.1016/0140-6736(93)92651-9; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470; Milstein C, 1999, BIOESSAYS, V21, P966, DOI 10.1002/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.0.CO;2-Z; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; Pasqualini R, 2004, P NATL ACAD SCI USA, V101, P257, DOI 10.1073/pnas.0305834101; Reichert J, 2004, NAT REV DRUG DISCOV, V3, P383, DOI 10.1038/nrd1386; Reichert JM, 2002, CURR OPIN MOL THER, V4, P110; Reichert JM, 2001, NAT BIOTECHNOL, V19, P819, DOI 10.1038/nbt0901-819	14	559	699	5	90	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2005	23	9					1073	1078		10.1038/nbt0905-1073	http://dx.doi.org/10.1038/nbt0905-1073			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	963GA	16151394				2023-01-03	WOS:000231790600020
J	Wu, AM; Senter, PD				Wu, AM; Senter, PD			Arming antibodies: prospects and challenges for immunoconjugates	NATURE BIOTECHNOLOGY			English	Review							ACUTE MYELOID-LEUKEMIA; SINGLE-CHAIN FV; PHASE-I TRIAL; SITE-SPECIFIC CONJUGATION; SENSITIVE DIPEPTIDE PRODRUGS; STREPTAVIDIN FUSION PROTEIN; NON-HODGKINS-LYMPHOMA; ED-B DOMAIN; MONOCLONAL-ANTIBODY; TARGETED CHEMOTHERAPY	Immunoconjugates-monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs ( ineffective when administered systemically alone)-are becoming a significant component of anticancer treatments. By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector molecules, immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional chemotherapeutic drugs. Two radioimmunoconjugates, ibritumomab tiuxetan ( Zevalin) and tositumomab-(131)l ( Bexxar), and one drug conjugate, gemtuzumab ozogamicin ( Mylotarg), are now on the market. For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs. Pretargeting strategies, which separate the two functions of antibody-based localization and delivery or generation of the toxic agent into two steps, also promise to afford superior tumor targeting and therapeutic efficacy. Several challenges in optimizing immunoconjugates remain, however, including poor intratumoral mAb uptake, normal tissue conjugate exposure and issues surrounding drug potency and conditional release from mAb carriers. Nonetheless, highly promising results from preclinical models will continue to drive the clinical development of this therapeutic class.	Univ Calif Los Angeles, Crump Inst Mol Imaging, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wu, AM (corresponding author), Univ Calif Los Angeles, Crump Inst Mol Imaging, Dept Mol & Med Pharmacol, David Geffen Sch Med, Box 951770,700 Westwood Plaza, Los Angeles, CA 90095 USA.	awu@mednet.ucla.edu		Wu, Anna/0000-0001-8487-823X	NATIONAL CANCER INSTITUTE [R43CA088583, P50CA092131, P50CA086306, P01CA043904] Funding Source: NIH RePORTER; NCI NIH HHS [CA92131, CA86306, CA088583, CA43904] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams GP, 2001, CANCER RES, V61, P4750; Adams GP, 2000, NUCL MED BIOL, V27, P339, DOI 10.1016/S0969-8051(00)00103-7; Adams GP, 2004, CANCER RES, V64, P6200, DOI 10.1158/0008-5472.CAN-03-2382; Albrecht H, 2004, BIOCONJUGATE CHEM, V15, P16, DOI 10.1021/bc030018+; Arano Y, 1998, Q J NUCL MED, V42, P262; Beeson C, 2003, BIOCONJUGATE CHEM, V14, P927, DOI 10.1021/bc025655z; Begent RHJ, 1996, NAT MED, V2, P979, DOI 10.1038/nm0996-979; Bhatia J, 2000, INT J CANCER, V85, P571; Boghaert ER, 2004, CLIN CANCER RES, V10, P4538, DOI 10.1158/1078-0432.CCR-04-0037; Borghaei H, 2004, SEMIN NUCL MED, V34, P4, DOI 10.1053/j.semnuclmed.2003.11.002; Borsi L, 2002, INT J CANCER, V102, P75, DOI 10.1002/ijc.10662; Bross PF, 2001, CLIN CANCER RES, V7, P1490; Corneillie TM, 2004, BIOCONJUGATE CHEM, V15, P1389, DOI 10.1021/bc049825e; Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935; Damle NK, 2004, EXPERT OPIN BIOL TH, V4, P1445, DOI 10.1517/14712598.4.9.1445; Damle NK, 2003, CURR OPIN PHARMACOL, V3, P386, DOI 10.1016/S1471-4892(03)00083-3; DiJoseph JF, 2005, CANCER IMMUNOL IMMUN, V54, P11, DOI 10.1007/s00262-004-0572-2; DiJoseph JF, 2004, BLOOD, V103, P1807, DOI 10.1182/blood-2003-07-2466; Doronina SO, 2003, NAT BIOTECHNOL, V21, P778, DOI 10.1038/nbt832; DUBEL S, 1995, J IMMUNOL METHODS, V178, P201, DOI 10.1016/0022-1759(94)00257-W; Dubowchik GM, 1999, PHARMACOL THERAPEUT, V83, P67, DOI 10.1016/S0163-7258(99)00018-2; Dubowchik GM, 2002, BIOCONJUGATE CHEM, V13, P855, DOI 10.1021/bc025536j; Dubowchik GM, 1998, BIOORG MED CHEM LETT, V8, P3347, DOI 10.1016/S0960-894X(98)00610-6; Dubowchik GM, 1998, BIOORG MED CHEM LETT, V8, P3341, DOI 10.1016/S0960-894X(98)00609-X; Feldhaus MJ, 2004, J IMMUNOL METHODS, V290, P69, DOI 10.1016/j.jim.2004.04.009; Forero A, 2004, BLOOD, V104, P227, DOI 10.1182/blood-2003-09-3284; FOSELLA FV, 2005, 41 ANN M AM SOC CLIN; Francis RJ, 2002, BRIT J CANCER, V87, P600, DOI 10.1038/sj.bjc.6600517; Francisco JA, 2003, BLOOD, V102, P1458, DOI 10.1182/blood-2003-01-0039; Giles FJ, 2001, CANCER-AM CANCER SOC, V92, P406, DOI 10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U; GOODWIN DA, 1988, J NUCL MED, V29, P226; Goshorn S, 2001, CANCER BIOTHER RADIO, V16, P109, DOI 10.1089/108497801300189209; GREENMAN L, 1994, NEW STATESMAN SOC, V7, P13, DOI 10.1038/ng0594-13; Griffiths GL, 2003, CLIN CANCER RES, V9, P6567; Hamann PR, 2005, BIOCONJUGATE CHEM, V16, P346, DOI 10.1021/bc049795f; Hamann PR, 2002, BIOCONJUGATE CHEM, V13, P40, DOI 10.1021/bc0100206; Hamann PR, 2002, BIOCONJUGATE CHEM, V13, P47, DOI 10.1021/bc010021y; Hamblett KJ, 2004, CLIN CANCER RES, V10, P7063, DOI 10.1158/1078-0432.CCR-04-0789; He J, 2004, J NUCL MED, V45, P1087; Henry MD, 2004, CANCER RES, V64, P7995, DOI 10.1158/0008-5472.CAN-04-1722; Hoogenboom HR, 2000, IMMUNOL TODAY, V21, P371, DOI 10.1016/S0167-5699(00)01667-4; Huhalov A, 2004, Q J NUCL MED MOL IM, V48, P279; Irving RA, 2001, J IMMUNOL METHODS, V248, P31, DOI 10.1016/S0022-1759(00)00341-0; JAIN RK, 1990, FRONT RADIAT THER ON, V24, P32; Jain RK, 1990, FRONT RAD THER ONCOL, V24; Jhanwar YS, 2005, J NUCL MED, V46, p141S; Kenanova V, 2005, CANCER RES, V65, P622; Larson SM, 1997, CANCER-AM CANCER SOC, V80, P2458; Law CL, 2004, CLIN CANCER RES, V10, P7842, DOI 10.1158/1078-0432.CCR-04-1028; LEDOUSSAL JM, 1989, J NUCL MED, V30, P1358; Li L, 2002, BIOCONJUGATE CHEM, V13, P985, DOI 10.1021/bc025565u; Linenberger ML, 2005, LEUKEMIA, V19, P176, DOI 10.1038/sj.leu.2403598; Linenberger ML, 2001, BLOOD, V98, P988, DOI 10.1182/blood.V98.4.988; Lipovsek D, 2004, J IMMUNOL METHODS, V290, P51, DOI 10.1016/j.jim.2004.04.008; LONBERG N, 1994, NATURE, V368, P856, DOI 10.1038/368856a0; LUTZ RL, 2005, 96 ANN M AM ASS CANC; Mayer A, 2004, BRIT J CANCER, V90, P2402, DOI 10.1038/sj.bjc.6601888; Milenic DE, 2004, NAT REV DRUG DISCOV, V3, P488, DOI 10.1038/nrd1413; Mosure KW, 1997, CANCER CHEMOTH PHARM, V40, P251, DOI 10.1007/s002800050655; Natarajan A, 2005, BIOCONJUGATE CHEM, V16, P113, DOI 10.1021/bc0498121; Olafsen T, 2005, CANCER RES, V65, P5907, DOI 10.1158/0008-5472.CAN-04-4472; Olafsen T, 2004, PROTEIN ENG DES SEL, V17, P315, DOI 10.1093/protein/gzh040; Olafsen T, 2004, PROTEIN ENG DES SEL, V17, P21, DOI 10.1093/protein/gzh009; Payne G, 2003, CANCER CELL, V3, P207, DOI 10.1016/S1535-6108(03)00057-6; Robinson MK, 2005, CANCER RES, V65, P1471, DOI 10.1158/0008-5472.CAN-04-2008; ROSSI EA, 2005, IN PRESS CLIN CANC R; Ruiz-Cabello F, 2002, SEMIN CANCER BIOL, V12, P15, DOI 10.1006/scbi.2001.0406; Saad ED, 2002, AM J CLIN ONCOL-CANC, V25, P451, DOI 10.1097/00000421-200210000-00005; SAGA T, 1995, P NATL ACAD SCI USA, V92, P8999, DOI 10.1073/pnas.92.19.8999; Saleh MN, 2000, J CLIN ONCOL, V18, P2282, DOI 10.1200/JCO.2000.18.11.2282; Santimaria M, 2003, CLIN CANCER RES, V9, P571; Schultz J, 2000, CANCER RES, V60, P6663; Senter PD, 2001, ADV DRUG DELIVER REV, V53, P247, DOI 10.1016/S0169-409X(01)00206-X; Sharkey RM, 2005, J NUCL MED, V46, P620; Sharkey RM, 2005, J NUCL MED, V46, p115S; SHARKEY RM, 2005, IN PRESS CLIN CANC R; Sharma Surinder K, 2005, Curr Opin Investig Drugs, V6, P611; Siemers NO, 1997, BIOCONJUGATE CHEM, V8, P510, DOI 10.1021/bc9700751; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; Sievers EL, 2001, CURR OPIN ONCOL, V13, P522, DOI 10.1097/00001622-200111000-00016; SLAVINCHIORINI DC, 1995, CANCER RES, V55, pS5957; Smith SV, 2004, CURR OPIN MOL THER, V6, P666; Smith-Jones PM, 2004, NAT BIOTECHNOL, V22, P701, DOI 10.1038/nbt968; STUDER M, 1992, BIOCONJUGATE CHEM, V3, P424, DOI 10.1021/bc00017a012; Sundaresan G, 2003, J NUCL MED, V44, P1962; Tassone P, 2004, BLOOD, V104, P3688, DOI 10.1182/blood-2004-03-0963; THORPE PE, 1988, CANCER RES, V48, P6396; Tolcher AW, 2003, J CLIN ONCOL, V21, P211, DOI 10.1200/JCO.2003.05.137; Torgov MY, 2005, BIOCONJUGATE CHEM, V16, P717, DOI 10.1021/bc050039z; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; VITETTA ES, 1993, IMMUNOL TODAY, V14, P252, DOI 10.1016/0167-5699(93)90041-I; Wahl RL, 2005, J NUCL MED, V46, p128S; Waibel R, 1999, NAT BIOTECHNOL, V17, P897, DOI 10.1038/12890; Walker MA, 2004, BIOORG MED CHEM LETT, V14, P4323, DOI 10.1016/j.bmcl.2004.05.089; Walker MA, 2002, BIOORG MED CHEM LETT, V12, P217, DOI 10.1016/S0960-894X(01)00707-7; Wang Y, 2001, BIOCONJUGATE CHEM, V12, P807, DOI 10.1021/bc0100307; Wang ZM, 2003, CANCER BIOTHER RADIO, V18, P365, DOI 10.1089/108497803322285116; Weiden PL, 2000, CANCER BIOTHER RADIO, V15, P15, DOI 10.1089/cbr.2000.15.15; Wong JYC, 2004, CLIN CANCER RES, V10, P5014, DOI 10.1158/1078-0432.CCR-03-0576; Wong JYC, 2003, CLIN CANCER RES, V9, P5842; Wu AM, 2000, Q J NUCL MED, V44, P268; Xie HS, 2004, J PHARMACOL EXP THER, V308, P1073, DOI 10.1124/jpet.103.060533; Yazaki PJ, 2001, BIOCONJUGATE CHEM, V12, P220, DOI 10.1021/bc000092h	103	837	1060	8	231	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2005	23	9					1137	1146		10.1038/nbt1141	http://dx.doi.org/10.1038/nbt1141			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	963GA	16151407				2023-01-03	WOS:000231790600031
J	Vidal, L; Shavit, M; Fraser, A; Paul, M; Leibovici, L				Vidal, L; Shavit, M; Fraser, A; Paul, M; Leibovici, L			Systematic comparison of four sources of drug information regarding adjustment of dose for renal function	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To compare advice on dosage adjustment for renal impairment provided by four commonly used secondary pharmacotherapeutic sources. Design Systematic comparison of the definitions of renal impairment, recommendations for dosage adjustment, and the evidence in support of these recommendations in four information sources. Data sources British National Formulary, Martindale: the Complete Drug Reference, American Hospital Formulary System Drug Information, and Drug Prescribing in Renal Failure. Review methods Two reviewers independently extracted data on recommendations for dosage adjustment for impaired renal function of 100 drugs often used in our hospital. Results The four sources differed in their recommendations for adjustments of dosage and dosing interval. They vary in their definitions of renal impairment; some are qualitative and remain unclear, All sources provide only a general description; the methods on which the advice is based and references for original data are rarely presented. Conclusions The remarkable variation in definitions and recommendations, along with scarce details of the methods used to reach this advice, makes the available sources of drug information ill suited for clinical use. The methods used to retrieve information and use data should be described and made available to the reader. Advice on drug prescription, dose and dosing interval, contraindications, and adverse effects should be evidence based.	Rabin Med Ctr, Dept Med E, Res Unit, Petah Tiqwa, Israel	Rabin Medical Center	Leibovici, L (corresponding author), Rabin Med Ctr, Dept Med E, Res Unit, Beilinson Campus, Petah Tiqwa, Israel.	leibovic@post.tau.ac.il		Fraser, Abigail/0000-0002-7741-9470				Aronoff GR, 1999, DRUG PRESCRIBING REN; *JOINT FORM COMM, 2004, BRIT NAT FORM; Jones CA, 1998, AM J KIDNEY DIS, V32, P992, DOI 10.1016/S0272-6386(98)70074-5; MCEVOY GK, 2004, AM HOSP FORMULARY SY; Sweetman SC., 2004, MARTINDALE COMPLETE	5	67	68	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 30	2005	331	7511					263	266		10.1136/bmj.38476.471088.3A	http://dx.doi.org/10.1136/bmj.38476.471088.3A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953FJ	15905228	Green Published, Bronze			2023-01-03	WOS:000231061700017
J	Hohmann, AG; Suplita, RL; Bolton, NM; Neely, MH; Fegley, D; Mangieri, R; Krey, JF; Walker, JM; Holmes, PV; Crystal, JD; Duranti, A; Tontini, A; Mor, M; Tarzia, G; Piomelli, D				Hohmann, AG; Suplita, RL; Bolton, NM; Neely, MH; Fegley, D; Mangieri, R; Krey, JF; Walker, JM; Holmes, PV; Crystal, JD; Duranti, A; Tontini, A; Mor, M; Tarzia, G; Piomelli, D			An endocannabinoid mechanism for stress-induced analgesia	NATURE			English	Article							STIMULUS-EVOKED ACTIVITY; DORSAL-HORN; NEURONS; BRAIN; SUPPRESSION; INHIBITORS; RECEPTORS; LIPASE; ESTERS; FORMS	Acute stress suppresses pain by activating brain pathways that engage opioid or non-opioid mechanisms. Here we show that an opioid-independent form of this phenomenon, termed stress-induced analgesia(1), is mediated by the release of endogenous marijuana-like (cannabinoid) compounds in the brain. Blockade of cannabinoid CB1 receptors in the periaqueductal grey matter of the midbrain prevents non-opioid stress-induced analgesia. In this region, stress elicits the rapid formation of two endogenous cannabinoids, the lipids 2-arachidonoylglycerol(2) (2-AG) and anandamide(3). A newly developed inhibitor of the 2-AG-deactivating enzyme, monoacylglycerol lipase(4,5), selectively increases 2-AG concentrations and, when injected into the periaqueductal grey matter, enhances stress-induced analgesia in a CB1-dependent manner. Inhibitors of the anandamide-deactivating enzyme fatty-acid amide hydrolase(6), which selectively elevate anandamide concentrations, exert similar effects. Our results indicate that the coordinated release of 2-AG and anandamide in the periaqueductal grey matter might mediate opioid-independent stress-induced analgesia. These studies also identify monoacylglycerol lipase as a previously unrecognized therapeutic target.	Univ Georgia, Dept Psychol, Neurosci & Behav Program, Athens, GA 30602 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Drug Discovery, Irvine, CA 92697 USA; Brown Univ, Dept Psychol, Schrier Res Lab, Providence, RI 02912 USA; Brown Univ, Dept Neurosci, Schrier Res Lab, Providence, RI 02912 USA; Univ Urbino Carlo Bo, Inst Med Chem, I-61029 Urbino, Italy; Univ Parma, Dept Pharmaceut, I-43100 Parma, Italy	University System of Georgia; University of Georgia; University of California System; University of California Irvine; University of California System; University of California Irvine; Brown University; Brown University; University of Urbino; University of Parma	Hohmann, AG (corresponding author), Univ Georgia, Dept Psychol, Neurosci & Behav Program, Athens, GA 30602 USA.	ahohmann@uga.edu; piomelli@uci.edu	Mangieri, Regina/N-1602-2019; Mor, Marco/D-2394-2009	Mangieri, Regina/0000-0002-4499-6183; Mor, Marco/0000-0003-0199-1849				AKIL H, 1986, ANN NY ACAD SCI, V467, P140, DOI 10.1111/j.1749-6632.1986.tb14625.x; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; CANNON JT, 1982, BRAIN RES, V243, P315, DOI 10.1016/0006-8993(82)90255-4; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Dinh TP, 2004, MOL PHARMACOL, V66, P1260, DOI 10.1124/mol.104.002071; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HOHMANN AG, 1995, LIFE SCI, V56, P2111, DOI 10.1016/0024-3205(95)00196-D; Hohmann AG, 1999, J NEUROPHYSIOL, V81, P575, DOI 10.1152/jn.1999.81.2.575; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Kozak KR, 2004, CURR PHARM DESIGN, V10, P659, DOI 10.2174/1381612043453081; LEWIS JW, 1980, SCIENCE, V208, P623, DOI 10.1126/science.7367889; Martin WJ, 1996, J NEUROSCI, V16, P6601; MARTIN WJ, 1995, LIFE SCI, V56, P2103, DOI 10.1016/0024-3205(95)00195-C; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Meng ID, 1998, NATURE, V395, P381, DOI 10.1038/26481; Mor M, 2004, J MED CHEM, V47, P4998, DOI 10.1021/jm031140x; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Tarzia G, 2003, J MED CHEM, V46, P2352, DOI 10.1021/jm021119g; TERMAN GW, 1986, BRAIN RES, V368, P101, DOI 10.1016/0006-8993(86)91046-2; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Valverde O, 2000, EUR J NEUROSCI, V12, P533, DOI 10.1046/j.1460-9568.2000.00929.x; Vaughan CW, 2000, MOL PHARMACOL, V57, P288; Walker JM, 2005, HANDB EXP PHARMACOL, V168, P509; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	30	559	591	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1108	1112		10.1038/nature03658	http://dx.doi.org/10.1038/nature03658			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15973410	Green Published			2023-01-03	WOS:000229970400051
J	Scolding, N				Scolding, N			Stem-cell therapy: hope and hype	LANCET			English	Editorial Material							PURKINJE NEURONS; REPAIR		Univ Bristol, Frenchay Hosp, Dept Neurol, Inst Clin Neurosci, Bristol BS16 1LE, Avon, England	University of Bristol	Scolding, N (corresponding author), Univ Bristol, Frenchay Hosp, Dept Neurol, Inst Clin Neurosci, Bristol BS16 1LE, Avon, England.	n.j.scolding@bristol.ac.uk						Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3; Devine SM, 2003, BLOOD, V101, P2999, DOI 10.1182/blood-2002-06-1830; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Gussoni E, 2002, J CLIN INVEST, V110, P807, DOI 10.1172/JCI200216098; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; KITE M, 2000, TIMES LOND      1216; Klimanskaya I, 2005, LANCET, V365, P1636, DOI 10.1016/S0140-6736(05)66473-2; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; LAPHAM LW, 1968, SCIENCE, V159, P310, DOI 10.1126/science.159.3812.310; Pochampally RR, 2004, P NATL ACAD SCI USA, V101, P9282, DOI 10.1073/pnas.0401558101; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Rehen SK, 2005, J NEUROSCI, V25, P2176, DOI 10.1523/JNEUROSCI.4560-04.2005; Rice CM, 2004, LANCET, V364, P193, DOI 10.1016/S0140-6736(04)16633-6; Rice CM, 2003, TRANSFUSION MED, V13, P351, DOI 10.1111/j.1365-3148.2003.00463.x; SAMPLE I, 2004, GUARDIAN        0819; Sigurjonsson OE, 2005, P NATL ACAD SCI USA, V102, P5227, DOI 10.1073/pnas.0501029102; Smith LC, 2004, CLONING STEM CELLS, V6, P126, DOI 10.1089/1536230041372319; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9; 2001, LANCET, V358, P163	22	10	11	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2073	2075		10.1016/S0140-6736(05)66554-3	http://dx.doi.org/10.1016/S0140-6736(05)66554-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964432				2023-01-03	WOS:000229858800009
J	Harding, R; Higginson, IJ				Harding, R; Higginson, IJ			Palliative care in sub-Saharan Africa	LANCET			English	Article							OF-LIFE CARE; ANTIRETROVIRAL THERAPY; DEVELOPING-COUNTRIES; SOUTH-AFRICA; GOOD DEATH; UGANDA; CANCER; AIDS; END; SERVICES	Control of pain and symptoms and terminal care are necessary for quality HIV and cancer care in sub-Saharan Africa. However, what constitutes feasible, accessible, and effective palliative care, and how to develop such services, remains to be resolved. Africa-specific palliative care includes components that carry resource implications. Home and community-based care has been largely successful, but community capacity and the resources and clinical supervision necessary to sustain quality care are lacking. Coverage and referrals must be primary concerns. Simple lay and professional protocols have been developed, but opioid availability remains a major constraint. Areas of good practice, and areas where further success may be achieved include: attention to community needs and capacity; explicit frameworks for service development and palliative-care integration throughout the disease course (including antiretroviral provision); further education and protocols; strengthening and dissemination of diverse referral and care systems; increasing advocacy; and funding and technical skills to build audit and quality assessment.	Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Palliat Care & Policy, Weston Educ Ctr, London SE5 9PJ, England	University of London; King's College London	Harding, R (corresponding author), Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Palliat Care & Policy, Weston Educ Ctr, Cutcombe Rd, London SE5 9PJ, England.	Richard.harding@kcl.ac.uk	Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313				ADAMOLEKUN K, 1998, OMEGA, V36, P23; ARCHETTI J, 2003, REACT OUT MBUYA PARI; ARCHETTI J, REACT OUT MBUYA PARI; Bateman C, 2001, S AFR MED J, V91, P364; Bateman Chris, 2002, S Afr Med J, V92, P936; Beck SL, 1999, J PAIN SYMPTOM MANAG, V17, P16, DOI 10.1016/S0885-3924(98)00120-1; Bicego G, 2003, SOC SCI MED, V56, P1235, DOI 10.1016/S0277-9536(02)00125-9; Browde S, 2001, SAMJ S AFR MED J, V91, P732; CAMPBELL L, 2001, S AFR J HIV MED, V6, P9; Crowe S, 2001, Nurs Times, V97, P26; *CTR AIDS DEV RES, 2002, INT COMM BAS HOM CAR; Defilippi K, 2000, Int J Palliat Nurs, V6, P108; *DEP STAT HLTH, 2001, GAMB HANDS CAR HIV T; DREW R, 2001, OPTIONS EXTENDING RE; Drew RS, 1997, TROP DOCT, V27, P210, DOI 10.1177/004947559702700408; Easterbrook P, 2001, J ROY SOC MED, V94, P442, DOI 10.1177/014107680109400907; FOSTER S, 1991, SOC SCI MED, V32, P1201, DOI 10.1016/0277-9536(91)90035-B; GELFAND M, 1983, CENT AFR J MED, V29, P111; *GRAH HOSP, 2002, QUAL LIF PROJ; Gwyther E, 2002, J PAIN SYMPTOM MANAG, V24, P236, DOI 10.1016/S0885-3924(02)00455-4; Harding R, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-33; Harding R, 2004, PALLIATIVE CARE SUBS; Harries AD, 2001, INT J TUBERC LUNG D, V5, P1000; Hartwig K, 2001, J PALLIATIVE CARE, V17, P121, DOI 10.1177/082585970101700209; Higginson IJ, 2002, PALLIATIVE MED, V16, P546, DOI 10.1191/0269216302pm576xx; HIGGINSON IJ, 2003, WHIT HOUS C HIV PALL; *HOSP AFR UG, 2003, 10 ANN REP APR 2002; *HOSP AFR UG, 2002, PALL MED PAIN SYMPT; *ISL HOSP BER SERV, 2003, ISL HOSP; JACKSON H, 1995, AIDS CARE, V7, P663, DOI 10.1080/09540129550126317; Jagwe Jack G M, 2002, J Palliat Med, V5, P160; JORDAN IB, 1995, TROP DOCT, V25, P21, DOI 10.1177/004947559502500107; Kaleeba N, 1997, AIDS CARE, V9, P13, DOI 10.1080/09540129750125307; KEBIRUNGI H, 2003, J PALLIAT CARE, V5, P2; KIHARA M, 2003, HLTH EXCHANGE   0821, P21; Kikule E, 2003, BRIT MED J, V327, P192, DOI 10.1136/bmj.327.7408.192; KRAUS P, 2002, PROG PALLIAT CARE, V10, P168; MACLACHLAN M, 1993, J ROY SOC HEALTH, V113, P136, DOI 10.1177/146642409311300309; Merriman A, 1999, J PALLIATIVE CARE, V15, P50, DOI 10.1177/082585979901500108; Merriman A, 2002, J PAIN SYMPTOM MANAG, V24, P252, DOI 10.1016/S0885-3924(02)00447-5; MERRIMAN A, 2002, INNOVATIONS END  MAY; MERRIMAN A, 2001, HOSPICE UGANDA J PAL, V4, P9; Minja B M, 1989, J Palliat Care, V5, P31; Moore J, 2003, PALLIATIVE CARE 21 C; Morris K, 2003, LANCET ONCOL, V4, P5, DOI 10.1016/S1470-2045(03)00969-0; MOSS V, 2003, P 6 INT C HEALTHC RE; Murray SA, 2003, BRIT MED J, V326, P368, DOI 10.1136/bmj.326.7385.368; MUSOKE RK, 2000, P PAPOS 2000 C SCI P; MUSOKE SF, AVAILABILITY MORPHIN; MWANGIPOWELL F, 2003, KEN PALL CAR WORKSH; Ngalula J, 2002, TROP MED INT HEALTH, V7, P873, DOI 10.1046/j.1365-3156.2002.00922.x; Nyambedha EO, 2003, SOC SCI MED, V57, P301, DOI 10.1016/S0277-9536(02)00359-3; Qurishi N, 2003, LANCET, V362, P1708, DOI 10.1016/S0140-6736(03)14844-1; Ramsay S, 2003, LANCET, V362, P1812, DOI 10.1016/S0140-6736(03)14945-8; Ramsay S, 2001, LANCET, V358, P734, DOI 10.1016/S0140-6736(01)05942-6; Sabin CA, 2002, AIDS, V16, pS61, DOI 10.1097/00002030-200216004-00009; Selwyn Peter A, 2003, J Palliat Med, V6, P475, DOI 10.1089/109662103322144853; Sepulveda C, 2003, BRIT MED J, V327, P209, DOI 10.1136/bmj.327.7408.209; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; *SO AFR AIDS TRAIN, 2001, COUNS GUID PALL CAR; Soares LGL, 2003, J PAIN SYMPTOM MANAG, V26, P693, DOI 10.1016/S0885-3924(03)00251-3; Solanke TF, 1997, ANN NY ACAD SCI, V809, P109, DOI 10.1111/j.1749-6632.1997.tb48074.x; Somse P, 1998, AIDS EDUC PREV, V10, P558; Soyannwo A, 2001, Niger Postgrad Med J, V8, P175; Stjernsward J, 2002, J PAIN SYMPTOM MANAG, V24, P257, DOI 10.1016/S0885-3924(02)00451-7; Swartz L, 2002, BMJ-BRIT MED J, V325, P914, DOI 10.1136/bmj.325.7370.914; *U WISC PAIN POL S, 2003, DISS HOSP UG APPR OB; UNAIDS, 2003, AIDS EP UPD; Walter T, 2003, BMJ-BRIT MED J, V327, P218, DOI 10.1136/bmj.327.7408.218; *WHO, 2003, EXT ESS CAR INT MAN; *WHO, 2002, PROGR REP COMM HLTH; *WHO IMAI, 2003, PALL CAR SYMPT MAN E; Williams S, 2000, PALLIATIVE MED, V14, P225, DOI 10.1191/026921600673636094; World Health Organization, 2002, NAT CANC CONTR PROGR; World Health Organization, 1996, CANC PAIN REL; World Health Organization, 1996, CANC PAIN REL GUID O; 1984, LANCET, V323, P1136; 2003, HANDS CAR HOM BAS CA; 2000, AIDS PALL CAR UNAIDS	79	149	149	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1971	1977		10.1016/S0140-6736(05)66666-4	http://dx.doi.org/10.1016/S0140-6736(05)66666-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936427				2023-01-03	WOS:000229587800034
J	Hampton, T				Hampton, T			Breaking barriers in transdermal drug delivery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item								The first successful method of transdermal drug administration was in the formof a skin patch. Since then the use of patches has constantly progressed as new, less irritating chemical permeation enhancers are developed. This form of drug delivery is now applied in areas such as contraception, hormone-replacement and smoking cessation.										Karande P, 2005, P NATL ACAD SCI USA, V102, P4688, DOI 10.1073/pnas.0501176102	1	13	14	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	2005	293	17					2083	2083		10.1001/jama.293.17.2083	http://dx.doi.org/10.1001/jama.293.17.2083			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	922AO	15870404				2023-01-03	WOS:000228808200005
J	Kravitz, RL; Epstein, RM; Feldman, MD; Franz, CE; Azari, R; Wilkes, MS; Hinton, L; Franks, P				Kravitz, RL; Epstein, RM; Feldman, MD; Franz, CE; Azari, R; Wilkes, MS; Hinton, L; Franks, P			Influence of patients' requests for direct-to-consumer advertised antidepressants - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY IMPROVEMENT PROGRAMS; STANDARDIZED PATIENTS; PRIMARY-CARE; PRESCRIPTION DRUGS; OFFICE PRACTICE; DEPRESSION; GUIDELINES; PHYSICIAN; DISORDERS; PROMOTION	Context Direct-to-consumer (DTC) advertising of prescription drugs in the United States is both ubiquitous and controversial. Critics charge that it leads to overprescribing, while proponents counter that it helps avert underuse of effective treatments, especially for conditions that are poorly recognized or stigmatized. Objective To ascertain the effects of patients' DTC-related requests on physicians' initial treatment decisions in patients with depressive symptoms. Design Randomized trial using standardized patients (SPs). Six SP roles were created by crossing 2 conditions (major depression or adjustment disorder with depressed mood) with 3 request types (brand-specific, general, or none). Setting Off ices of primary care physicians in Sacramento, Calif; San Francisco, Calif; and Rochester, NY, between May 2003 and May 2004. Participants One hundred fifty-two family physicians and general internists recruited from solo and group practices and health maintenance organizations; cooperation rates ranged from 53% to 61%. Interventions The SPs were randomly assigned to make 298 unannounced visits, with assignments constrained so physicians saw 1 SP with major depression and 1 with adjustment disorder. The SPs. made a brand-specific drug request, a general drug request, or no request (control condition) in approximately one third of visits. Main Outcome Measures Data on prescribing, mental health referral, and primary care follow-up obtained from SP written reports, visit audiorecordings, chart review, and analysis of written prescriptions and drug samples. The effects of request type on prescribing were evaluated using contingency tables and confirmed in generalized linear mixed models that accounted for clustering and adjusted for site, physician, and visit characteristics. Results Standardized patient role fidelity was excellent, and the suspicion rate that physicians had seen an SP was 13%. In major depression, rates of antidepressant prescribing were 53%, 76%, and 31% for SPs making brand-specific, general, and no requests, respectively (P<.001). In adjustment disorder, antidepressant prescribing rates were 55%, 39%, and 10%, respectively (P<.001). The results were confirmed in multivariate models. Minimally acceptable initial care (any combination of an antidepressant, mental health referral, or follow-up within 2 weeks) was offered to 98% of SPs in the major depression role making a general request, 90% of those making a brand-specific request, and 56% of those,making no request (P<.001). Conclusions Patients' requests have a profound effect on physician prescribing in major depression and adjustment disorder. Direct-to-consumer advertising may have competing effects on quality, potentially both averting underuse and promoting overuse.	Univ Calif Davis, Ctr Hlth Serv Res Primary Care, Sacramento, CA 95817 USA; Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA; Univ Calif Davis, Dept Stat, Sacramento, CA 95817 USA; Univ Calif Davis, Dept Psychiat, Sacramento, CA 95817 USA; Univ Calif Davis, Dept Family & Community Med, Sacramento, CA 95817 USA; Univ Rochester, Sch Med & Dent, Dept Family Med, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Improve Commun Hlth Care, Rochester, NY USA; Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of Rochester; University of Rochester; University of Rochester; University of California System; University of California San Francisco	Kravitz, RL (corresponding author), Univ Calif Davis, Ctr Hlth Serv Res, 2103 Stockton Blvd,Suite 2224,GB, Sacramento, CA 95817 USA.	rlkravitz@ucdavis.edu	Kravitz, Richard/AAF-7425-2021	Kravitz, Richard/0000-0001-5575-529X; Franz, Carol/0000-0002-8987-1755	NIA NIH HHS [K23 AG019809, K23-AG19809] Funding Source: Medline; NIMH NIH HHS [R01 MH064683-03, R01 MH064683-02, R01 MH064683-01A1, R01 MH064683] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH064683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG019809] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; *AM PSYCH ASS, 2000, DIAGN STAT MAN MENT, P775; *AM PSYCH ASS, 2000, DIAGN STAT MAN MENT, P349; Anderson IM, 2000, J PSYCHOPHARMACOL, V14, P3, DOI 10.1177/026988110001400101; Barbey JT, 1998, J CLIN PSYCHIAT, V59, P42; Barret JE, 2001, J FAM PRACTICE, V50, P405; Becker H, 2003, WESTERN J NURS RES, V25, P746, DOI 10.1177/0193945903253002; Bell RA, 2000, J FAM PRACTICE, V49, P329; Bell RA, 1999, J GEN INTERN MED, V14, P651, DOI 10.1046/j.1525-1497.1999.01049.x; Bell RA, 1999, J FAM PRACTICE, V48, P446; Beullens J, 1997, FAM PRACT, V14, P58, DOI 10.1093/fampra/14.1.58; Carney PA, 1999, J FAM PRACTICE, V48, P958; Cohen LJ, 1997, ANN PHARMACOTHER, V31, P782, DOI 10.1177/106002809703100620; CooperPatrick L, 1997, J GEN INTERN MED, V12, P431, DOI 10.1046/j.1525-1497.1997.00075.x; Donohue JM, 2004, MED CARE, V42, P1176, DOI 10.1097/00005650-200412000-00004; Ferguson JM, 2001, J CLIN PSYCHIAT, V62, P22; Glassman P A, 2000, Jt Comm J Qual Improv, V26, P644; Gorter S, 2002, J RHEUMATOL, V29, P1496; Guiton G, 2004, ADV HEALTH SCI EDUC, V9, P179, DOI 10.1023/B:AHSE.0000038174.87790.7b; Gunnell D, 2005, BMJ-BRIT MED J, V330, P385, DOI 10.1136/bmj.330.7488.385; Hollon MF, 1999, JAMA-J AM MED ASSOC, V281, P382, DOI 10.1001/jama.281.4.382; Holmer AF, 1999, JAMA-J AM MED ASSOC, V281, P380, DOI 10.1001/jama.281.4.380; Judd LL, 2004, AM J PSYCHIAT, V161, P1864, DOI 10.1176/appi.ajp.161.10.1864; *KAIS FAM FDN, 2004, PRESCR DRUG TRENDS; Kramer PD, 1997, LISTENING PROZAC; Kravitz RL, 2000, WESTERN J MED, V173, P221, DOI 10.1136/ewjm.173.4.221; Kravitz RL, 2003, ARCH INTERN MED, V163, P1673, DOI 10.1001/archinte.163.14.1673; Kravitz RL, 2002, HEALTH SERV RES, V37, P217; Kravitz RL, 2002, MED CARE, V40, P38, DOI 10.1097/00005650-200201000-00006; Luck J, 2002, BMJ-BRIT MED J, V325, P679, DOI 10.1136/bmj.325.7366.679; *MAN MAJ DEPR DIS, 2000, VET HLTH ADM DEP DEF; McCulloch C.E., 2001, GEN LINEAR MIXED MOD; Mello MM, 2003, JAMA-J AM MED ASSOC, V289, P477, DOI 10.1001/jama.289.4.477; Mintzes B, 2002, BRIT MED J, V324, P278, DOI 10.1136/bmj.324.7332.278; *NAT I HLTH CAR MA, 2000, RES BRIEF PRESCR DRU, P8; *OFF MED POL DIV D, ATT BEH ASS DIR TO C; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; Raingruber B, 2002, ARCH PSYCHIAT NURS, V16, P201, DOI 10.1053/apnu.2002.36230; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; Rost K, 1993, J Rural Health, V9, P57, DOI 10.1111/j.1748-0361.1993.tb00495.x; Simon GE, 2002, GEN HOSP PSYCHIAT, V24, P213, DOI 10.1016/S0163-8343(02)00198-6; TAMBLYN RM, 1992, ACAD MED, V67, pS22, DOI 10.1097/00001888-199210000-00027; Unutzer J, 2001, ARCH GEN PSYCHIAT, V58, P935, DOI 10.1001/archpsyc.58.10.935; van der Klink JJL, 2003, SCAND J WORK ENV HEA, V29, P478, DOI 10.5271/sjweh.756; Weissman JS, 2004, HEALTH AFFAIR, V23, pW4219, DOI 10.1377/hlthaff.W4.219; WEISSMAN JS, 2003, HLTH AFF MILLWO 0226, DOI DOI 10.1377/HLTHAFF.W3.28; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Wells KB, 1999, ARCH FAM MED, V8, P529, DOI 10.1001/archfami.8.6.529; Wilkes MS, 2000, HEALTH AFFAIR, V19, P110, DOI 10.1377/hlthaff.19.2.110; ZAMANIYAN F, 2003, DRUG ADVERTISING SPE	50	425	428	0	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	2005	293	16					1995	2002		10.1001/jama.293.16.1995	http://dx.doi.org/10.1001/jama.293.16.1995			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	919XS	15855433	Green Accepted, Bronze			2023-01-03	WOS:000228651500025
J	Boden, G; Sargrad, K; Homko, C; Mozzoli, M; Stein, TP				Boden, G; Sargrad, K; Homko, C; Mozzoli, M; Stein, TP			Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-FAT DIET; CALORIC REQUIREMENTS; SERUM LEPTIN; WEIGHT; HYPERINSULINEMIA; REAPPRAISAL; NUTRITION; ADULTS	Background: it is not known how a low-carbohydrate, high-protein, high-fat diet causes weight loss or how it affects blood glucose levels in patients with type 2 diabetes. Objective: To determine effects of a strict low-carbohydrate diet on body weight, body water, energy intake and expenditure, glycemic control, insulin sensitivity, and lipid levels in obese patients with type 2 diabetes. Design: Inpatient comparison of 2 diets. Setting: General clinical research center of a university hospital. Patients: 10 obese patients with type 2 diabetes. Intervention: Usual diets for 7 days followed by a low-carbohydrate diet for 14 days. Measurements: Body weight, water, and composition; energy intake and expenditure; diet satisfaction; hemoglobin A(1c); insulin sensitivity; 24-hour urinary ketone excretion; and plasma profiles of glucose, insulin, leptin, and ghrelin. Results: on the low-carbohydrate rate diet, mean energy intake decreased from 3111 kcal/d to 2164 kcal/d. The mean energy deficit of 1027 kcal/d (median, 737 kcal/d) completely accounted for the weight loss of 1.65 kg in 14 days (median, 1.34 kg in 14 days). Mean 24-hour plasma profiles of glucose levels normalized, mean hemoglobin A(1c) decreased from 7.3% to 6.8%, and insulin sensitivity improved by approximately 75%. Mean plasma triglyceride and cholesterol levels decreased (change, -35% and -10%, respectively). Limitations: The study was limited by the short duration, small number of participants, and lack of a strict control group. Conclusion: in a small group of obese patients with type 2 diabetes, a low-carbohydrate diet followed for 2 weeks resulted in spontaneous reduction in energy intake to a level appropriate to their height; weight loss that was completely accounted for by reduced caloric intake; much improved 24-hour blood glucose profiles, insulin sensitivity, and hemoglobin A(1c); and decreased plasma triglycericle and cholesterol levels. The long-term effects of this diet, however, remain uncertain.	Temple Univ, Sch Med, Philadelphia, PA USA; Univ Med & Dent New Jersey, Sch Osteopath Med, Stratford, NJ 08084 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center	Boden, G (corresponding author), Temple Univ Hosp & Med Sch, 3401 N Broad St, Philadelphia, PA 19140 USA.		Stein, T. Peter/R-4244-2019		NCRR NIH HHS [M01-RR-00349] Funding Source: Medline; NHLBI NIH HHS [R01-HL0733267] Funding Source: Medline; NIA NIH HHS [R01-AG15353] Funding Source: Medline; NIDDK NIH HHS [R01-DK58895, R01-DK066003] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066003, R01DK058895] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINS R, 1992, DR ATKINS NEW DIET R; Atkins R.C., 1972, DR ATKINS DIET REVOL; Boden G, 2003, DIABETES, V52, P133, DOI 10.2337/diabetes.52.1.133; Boden G, 1997, J CLIN INVEST, V100, P1107, DOI 10.1172/JCI119621; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; CAMPFIELD LA, 2003, HDB OBESITY, P461; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Freedman MR, 2001, OBES RES, V9, p1S, DOI 10.1038/oby.2001.113; GARG A, 1994, JAMA-J AM MED ASSOC, V271, P1421, DOI 10.1001/jama.271.18.1421; Greene P, 2003, OBES RES, V11, pA23; HAWK PB, 1947, PRACTICAL PHYSL CHEM, P814; HILL AJ, 1983, J PSYCHIATR RES, V17, P203, DOI 10.1016/0022-3956(82)90023-1; HOLT SHA, 1995, APPETITE, V24, P43, DOI 10.1016/S0195-6663(95)80005-0; Homko CJ, 2003, DIABETES, V52, P487, DOI 10.2337/diabetes.52.2.487; JENKINS DJA, 1984, LANCET, V2, P388; LEWIS SB, 1977, AM J CLIN NUTR, V30, P160, DOI 10.1093/ajcn/30.2.160; LUKASKI HC, 1987, AM J CLIN NUTR, V46, P537, DOI 10.1093/ajcn/46.4.537; MOLINA JM, 1990, AM J PHYSIOL, V258, pE16, DOI 10.1152/ajpendo.1990.258.1.E16; OWEN OE, 1986, AM J CLIN NUTR, V44, P1; OWEN OE, 1980, DIABETES, V29, P365, DOI 10.2337/diab.29.5.365; OWEN OE, 1987, AM J CLIN NUTR, V46, P875, DOI 10.1093/ajcn/46.6.875; RICH AJ, 1988, J PARENTER ENTERAL N, V13, pS7; RODIN J, 1985, METABOLISM, V34, P826, DOI 10.1016/0026-0495(85)90106-4; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; SCHOELLER DA, 1986, AM J PHYSIOL, V250, pR823, DOI 10.1152/ajpregu.1986.250.5.R823; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEELE R, 1956, AM J PHYSIOL, V187, P15, DOI 10.1152/ajplegacy.1956.187.1.15; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; TAPPY L, 1988, DIABETES, V37, P1212, DOI 10.2337/diabetes.37.9.1212; VANITALLIE TB, 1977, NEW ENGL J MED, V297, P1158, DOI 10.1056/NEJM197711242972106; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	33	339	347	1	79	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	2005	142	6					403	411		10.7326/0003-4819-142-6-200503150-00006	http://dx.doi.org/10.7326/0003-4819-142-6-200503150-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906DQ	15767618				2023-01-03	WOS:000227621100002
J	Qin, WP; Yang, TL; Ho, L; Zhao, Z; Wang, J; Chen, LH; Zhao, W; Thiyagarajan, M; MacGrogan, D; Rodgers, JT; Puigserver, P; Sadoshima, J; Deng, HT; Pedrini, S; Gandy, S; Sauve, AA; Pasinetti, GM				Qin, Weiping; Yang, Tianle; Ho, Lap; Zhao, Zhong; Wang, Jun; Chen, Linghong; Zhao, Wei; Thiyagarajan, Meenakshisundaram; MacGrogan, Donal; Rodgers, Joseph T.; Puigserver, Pere; Sadoshima, Junichi; Deng, Haiteng; Pedrini, Steven; Gandy, Samuel; Sauve, Anthony A.; Pasinetti, Giulio M.			Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT HISTONE DEACETYLASE; TRANSGENIC MICE; PROTEIN; FAMILY; LONGEVITY; NICOTINAMIDE; INHIBITION; REGULATOR	Nicotinamide adenine dinucleotide(NAD)(+)-dependent sirtuins have been identified to be key regulators in the lifespan extending effects of calorie restriction (CR) in a number of species. In this study we report for the first time that promotion of the NAD(+)-dependent sirtuin, SIRT1-mediated deacetylase activity, may be a mechanism by which CR influences Alzheimer disease (AD)-type amyloid neuropathology. Most importantly, were port that the predicted attenuation of beta-amyloid content in the brain during CR can be reproduced in mouse neurons in vitro by manipulating cellular SIRT1 expression/activity through mechanisms involving the regulation of the serine/threonine Rho kinase ROCK1, known in part for its role in the inhibition of the non-amyloidogenic alpha-secretase processing of the amyloid precursor protein. Conversely, we found that the expression of constitutively active ROCK1 in vitro cultures significantly prevented SIRT1-mediated response, suggesting that alpha-secretase activity is required for SIRT1-mediated prevention of AD-type amyloid neuropathology. Consistently we found that the expression of exogenous human ( h) SIRT1 in the brain of hSIRT1 transgenics also resulted in decreased ROCK1 expression and elevated alpha-secretase activity in vivo. These results demonstrate for the first time a role for SIRT1 activation in the brain as a novel mechanism through which CR may influence AD amyloid neuropathology. The study provides a potentially novel pharmacological strategy for AD prevention and/or treatment.	Cornell Univ, Weill Med Coll, Dept Pharmacol, Tri Inst Program Chem Biol, New York, NY 10021 USA; Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA; Bronx Vet Affairs Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY 10468 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Newark, NJ 07103 USA; Rockefeller Univ, Proteom Resource Ctr, New York, NY 10021 USA; Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA	Cornell University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rockefeller University; Jefferson University	Pasinetti, GM (corresponding author), Cornell Univ, Weill Med Coll, Dept Pharmacol, Tri Inst Program Chem Biol, New York, NY 10021 USA.	as2004@med.cornell.edu; giulio.pasinetti@mssm.edu	MacGrogan, Donal/AAR-7392-2021; MacGrogan, Donal/E-8604-2016; Zhao, Wei/A-2206-2010	MacGrogan, Donal/0000-0003-2808-8422; MacGrogan, Donal/0000-0003-2808-8422; Pasinetti, Giulio/0000-0002-1524-5196; Sadoshima, Junichi/0000-0003-3724-4132; Pedrini, Steve/0000-0002-6409-8022; Rodgers, Joseph/0000-0002-6598-5520; Zhao, Wei/0000-0002-3449-2395	NATIONAL INSTITUTE ON AGING [P01AG010491] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG010491, P01 AG010491-14] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burns M, 2003, J NEUROSCI, V23, P5645; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Gandy S, 2002, NEUROBIOL AGING, V23, P1009, DOI 10.1016/S0197-4580(02)00125-2; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; Hisahara S, 2005, J PHARMACOL SCI, V98, P200, DOI 10.1254/jphs.FMJ05001X2; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Lamming DW, 2004, MOL MICROBIOL, V53, P1003, DOI 10.1111/j.1365-2958.2004.04209.x; Luchsinger JA, 2002, ARCH NEUROL-CHICAGO, V59, P1258, DOI 10.1001/archneur.59.8.1258; Mattson MP, 2003, NEUROLOGY, V60, P690, DOI 10.1212/01.WNL.0000042785.02850.11; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Patel NV, 2005, NEUROBIOL AGING, V26, P995, DOI 10.1016/j.neurobiolaging.2004.09.014; Pedrini S, 2005, PLOS MED, V2, P69, DOI 10.1371/journal.pmed.0020018; Qin WP, 2003, J BIOL CHEM, V278, P50970, DOI 10.1074/jbc.M307699200; Rezai-Zadeh K, 2005, J NEUROSCI, V25, P8807, DOI 10.1523/JNEUROSCI.1521-05.2005; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Sauve AA, 2005, MOL CELL, V17, P595, DOI 10.1016/j.molcel.2004.12.032; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang W, 2005, INT J MOD PHYS B, V19, P659, DOI 10.1142/S0217979205029262	31	504	524	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21745	21754		10.1074/jbc.M602909200	http://dx.doi.org/10.1074/jbc.M602909200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16751189	hybrid			2023-01-03	WOS:000239387100020
J	Estruch, R; Martinez-Gonzalez, MA; Corella, D; Salas-Salvado, J; Ruiz-Gutierrez, V; Covas, MI; Fiol, M; Gomez-Gracia, E; Lopez-Sabater, MC; Vinyoles, E; Aros, F; Conde, M; Lahoz, C; Lapetra, J; Saez, G; Ros, E				Estruch, Ramon; Martinez-Gonzalez, Miguel Angel; Corella, Dolores; Salas-Salvado, Jordi; Ruiz-Gutierrez, Valentina; Covas, Maria Isabel; Fiol, Miguel; Gomez-Gracia, Enrique; Lopez-Sabater, Mari Carmen; Vinyoles, Ernest; Aros, Fernando; Conde, Manuel; Lahoz, Carlos; Lapetra, Jose; Saez, Guillermo; Ros, Emilio		PREDIMED Study Investigators	Effects of a Mediterranean-style diet on cardiovascular risk factors - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							MONOUNSATURATED FATTY-ACIDS; CORONARY-HEART-DISEASE; VIRGIN OLIVE OIL; BLOOD-PRESSURE; LINOLENIC ACID; RED WINE; ENDOTHELIAL FUNCTION; NUT CONSUMPTION; SERUM-LIPIDS; HYPERTENSION	Background: The Mediterranean diet has been shown to have beneficial effects on cardiovascular risk factors. Objective: To compare the short-term effects of 2 Mediterranean diets versus those of a low-fat diet on intermediate markers of cardiovascular risk. Design: Substudy of a multicenter, randomized, primary prevention trial of cardiovascular disease (Prevencion con Dieta Mediterranea [PREDIMED) Study). Setting: Primary care centers affiliated with 10 teaching hospitals. Participants: 772 asymptomatic persons 55 to 80 years of age at high cardiovascular risk who were recruited from October 2003 to March 2004. Interventions: Participants were assigned to a low-fat diet (n = 257) or to 1 of 2 Mediterranean diets. Those allocated to Mediterranean diets received nutritional education and either free virgin olive oil, 1 liter per week (n = 257), or free nuts, 30 g/d (n = 258). The authors evaluated outcome changes at 3 months. Measurements: Body weight, blood pressure, lipid profile, glucose levels, and inflammatory molecules. Results: The completion rate was 99.6%. Compared with the low-fat diet, the 2 Mediterranean diets produced beneficial changes in most outcomes. Compared with the low-fat diet, the mean changes in the Mediterranean diet with olive oil group and the Mediterranean diet with nuts group were -0.39 mmol/L (95% Cl, -0.70 to - 0.07 mmol/L) and - 0.30 mmol/L (Cl, -0.58 to - 0.01 mmol/L), respectively, for plasma glucose levels; -5.9 mm Hg (Cl, -8.7 to -3.1 mm Hg) and - 7.1 mm Hg (Cl, -10.0 to -4.1 mm Hg), respectively, for systolic blood pressure; and -0.38 (Cl, -0.55 to - 0.22) and - 0.26 (Cl, -0.42 to -0.10), respectively, for the cholesterol-high-density lipoprotein cholesterol ratio. The Mediterranean diet with olive oil reduced C-reactive protein levels by 0.54 mg/L (Cl, 1.04 to 0.03 mg/L) compared with the low-fat diet. Limitations: This short-term study did not focus on clinical outcomes. Nutritional education about low-fat diet was less intense than education about Mediterranean diets. Conclusion: Compared with a low-fat diet, Mediterranean diets supplemented with olive oil or nuts have beneficial effects on cardiovascular risk factors.	Univ Barcelona, Municipal Inst Med Res IMIM, IDIBAPS, Inst Invest Biomed August Pi Sunyer, Barcelona, Spain; Catalan Inst Hlth, Barcelona, Spain; Univ Valencia, Valencia, Spain; Univ Navarra, Univ Navarra Clin, E-31080 Pamplona, Spain; Univ Rovira & Virgili, E-43201 Reus, Tarragona, Spain; Univ Seville, Hosp Univ Virgen Rocio, CSIC, Inst Grasa, Seville, Spain; San Pablo Hlth Ctr, Seville, Spain; Hosp Son Dureta, Palma de Mallorca, Spain; Univ Malaga, E-29071 Malaga, Spain; Hosp Txangorritxu, Vitoria, Spain; Hosp Carlos III, Madrid, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Valencia; University of Navarra; Universitat Rovira i Virgili; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de la Grasa (IG); University of Sevilla; Virgen del Rocio University Hospital; Hospital Universitari Son Espases; Hospital Universitari Son Dureta; Universidad de Malaga; Hospital Carlos III	Estruch, R (corresponding author), Hosp Clin Barcelona, Dept Internal Med, Villarroel 170, E-08036 Barcelona, Spain.	restruch@clinic.ub.es	Martinez-Gonzalez, Miguel A./AAE-7669-2019; IBIS, SALUD PÚBLICA/C-1707-2016; Salas-Salvado, Jordi/C-7229-2017; IBIS, ATENCION PRIMARIA/I-3524-2016; Vinyoles, Ernest/GRX-4615-2022; Estruch, Ramon/AAZ-3723-2020; Fiol, Miguel/F-6793-2016	Salas-Salvado, Jordi/0000-0003-2700-7459; Fiol, Miguel/0000-0002-5370-1391; Saez, Guillermo/0000-0002-8164-4048; Ros, Emilio/0000-0002-2573-1294; Lahoz, Carlos/0000-0001-5690-7558; Lopez-Sabater, Maria Carmen/0000-0002-8670-7044; Vinyoles, Ernest/0000-0002-8725-9431; Martinez-Gonzalez, Miguel A./0000-0002-3917-9808				Alonso A, 2006, PUBLIC HEALTH NUTR, V9, P251, DOI 10.1079/PHN2005836; Alonso A, 2004, LIPIDS, V39, P1233, DOI 10.1007/s11745-004-1352-x; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Appel LJ, 2005, JAMA-J AM MED ASSOC, V294, P2455, DOI 10.1001/jama.294.19.2455; Beauchamp GK, 2005, NATURE, V437, P45, DOI 10.1038/437045a; BERNELMANS WJ, 2002, AM J CLIN NUTR, V75, P221; Carluccio MA, 2003, ARTERIOSCL THROM VAS, V23, P622, DOI 10.1161/01.ATV.0000062884.69432.A0; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Chrysohoou C, 2004, J AM COLL CARDIOL, V44, P152, DOI 10.1016/j.jacc.2004.03.039; Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112; Djousse L, 2005, HYPERTENSION, V45, P368, DOI 10.1161/01.HYP.0000154679.41568.e6; Djousse L, 2003, AM J CLIN NUTR, V78, P1098, DOI 10.1093/ajcn/78.6.1098; ELOSUA R, 1994, AM J EPIDEMIOL, V139, P1197, DOI 10.1093/oxfordjournals.aje.a116966; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Estruch R, 2004, ATHEROSCLEROSIS, V175, P117, DOI 10.1016/j.atherosclerosis.2004.03.006; EXLER J, 1986, PUBLICATION HNIS; Ferrara LA, 2000, ARCH INTERN MED, V160, P837, DOI 10.1001/archinte.160.6.837; Franz MJ, 2002, DIABETES CARE, V25, P148, DOI 10.2337/diacare.25.1.148; Fuentes F, 2001, ANN INTERN MED, V134, P1115, DOI 10.7326/0003-4819-134-12-200106190-00011; Garcia-Lorda P, 2003, EUR J CLIN NUTR, V57, pS8, DOI 10.1038/sj.ejcn.1601802; Gardner CD, 2005, ANN INTERN MED, V142, P725, DOI 10.7326/0003-4819-142-9-200505030-00007; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Harris WS, 2005, CIRCULATION, V111, P2872, DOI 10.1161/CIRCULATIONAHA.105.545640; Jiang R, 2006, AM J EPIDEMIOL, V163, P222, DOI 10.1093/aje/kwj033; Jiang R, 2002, JAMA-J AM MED ASSOC, V288, P2554, DOI 10.1001/jama.288.20.2554; Katan MB, 1997, NEW ENGL J MED, V337, P563; Keys A, 1997, Nutrition, V13, P250; KNOOPS KT, 2006, EUR J CLIN NUTR; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Krauss RM, 2000, CIRCULATION, V102, P2284; Kris-Etherton PM, 1999, CIRCULATION, V100, P1253, DOI 10.1161/01.CIR.100.11.1253; Kris-Etherton PM, 2001, NUTR REV, V59, P103, DOI 10.1111/j.1753-4887.2001.tb06996.x; Lopez-Garcia E, 2004, AM J CLIN NUTR, V80, P1029, DOI 10.1093/ajcn/80.4.1029; Martinez-Gonzalez MA, 2004, EUR J CLIN NUTR, V58, P1550, DOI 10.1038/sj.ejcn.1602004; Martinez-Gonzalez MA, 2004, EUR J EPIDEMIOL, V19, P9, DOI 10.1023/B:EJEP.0000013351.60227.7b; MARTINMORENO JM, 1993, INT J EPIDEMIOL, V22, P512, DOI 10.1093/ije/22.3.512; Mataix V.J., 2003, TABLA COMPOSICION AL; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MENOTTI A, 1990, PREV MED, V19, P270, DOI 10.1016/0091-7435(90)90027-H; Mensink RP, 2003, AM J CLIN NUTR, V77, P1146, DOI 10.1093/ajcn/77.5.1146; Miro-Casas E, 2003, EUR J CLIN NUTR, V57, P186, DOI 10.1038/sj.ejcn.1601532; Nigg CR, 1999, GERONTOLOGIST, V39, P473, DOI 10.1093/geront/39.4.473; Obarzanek E, 2001, AM J CLIN NUTR, V74, P80; Perona JS, 2004, CLIN NUTR, V23, P1113, DOI 10.1016/j.clnu.2004.02.004; Psaltopoulou T, 2004, AM J CLIN NUTR, V80, P1012, DOI 10.1093/ajcn/80.4.1012; Ros E, 2004, CIRCULATION, V109, P1609, DOI 10.1161/01.CIR.0000124477.91474.FF; Ros E, 2003, AM J CLIN NUTR, V78, p617S, DOI 10.1093/ajcn/78.3.617S; Sabate J, 2003, AM J CLIN NUTR, V78, p647S, DOI 10.1093/ajcn/78.3.647S; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; STRAZZULLO P, 1986, J HYPERTENS, V4, P407, DOI 10.1097/00004872-198608000-00003; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Visioli F, 2001, Curr Atheroscler Rep, V3, P64, DOI 10.1007/s11883-001-0012-0; Willett W., 1998, NUTR EPIDEMIOLOGY, V30, P321, DOI [DOI 10.1093/AJCN/69.5.1020, DOI 10.1093/acprof:oso/9780195122978.003.13]; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; Yu-Poth S, 1999, AM J CLIN NUTR, V69, P632; Zambon D, 2000, ANN INTERN MED, V132, P538, DOI 10.7326/0003-4819-132-7-200004040-00039	59	1224	1244	4	415	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2006	145	1					1	11		10.7326/0003-4819-145-1-200607040-00004	http://dx.doi.org/10.7326/0003-4819-145-1-200607040-00004			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	062IS	16818923				2023-01-03	WOS:000238938400001
J	Ferradini, L; Jeannin, A; Pinoges, L; Izopet, J; Odhiambo, D; Mankhambo, L; Karungi, G; Szumilin, E; Balandine, S; Fedida, G; Carrieri, MP; Spire, B; Ford, N; Tassie, JM; Guerin, PI; Brasher, C				Ferradini, L; Jeannin, A; Pinoges, L; Izopet, J; Odhiambo, D; Mankhambo, L; Karungi, G; Szumilin, E; Balandine, S; Fedida, G; Carrieri, MP; Spire, B; Ford, N; Tassie, JM; Guerin, PI; Brasher, C			Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment	LANCET			English	Article; Proceedings Paper	12th Conference on Retroviruses and Opportunistic Infections	FEB 22-25, 2005	Boston, MA				RESOURCE-POOR SETTINGS; DRUG-RESISTANCE; ADHERENCE; SURVIVAL; INTERRUPTION; KHAYELITSHA; COMBINATION; HIV/AIDS; ACCESS; SAFETY	Background The recording of outcomes from large-scale, simplified HAART (highly active antiretroviral therapy) programmes in sub-Saharan Africa is critical. We aimed to assess the effectiveness of such a programme held by Medecins Sans Fronteires (MSF) in the Chiradzulu district, Malawi. Methods We scaled up and simplified HAART in this programme since August, 2002. We analysed survival indicators, CD4 count evolution, virological response, and adherence to treatment. We included adults who all started HAART 6 months or more before the analysis. HIV-1 RNA plasma viral load and self-reported adherence were assessed on a subsample of patients, and antiretroviral resistance mutations were analysed in plasma with viral loads greater than 1000 copies per mL. Analysis was by intention to treat. Findings Of the 1308 patients who were eligible, 827 (64%) were female, the median age was 34.9 years (IQR 29.9-41.0), and 1023 (78%) received d4T/3TC/NVP (stavudine, lamivudine, and nevirapine) as a fixed-dose combination. At baseline, 1266 individuals (97%) were HAART-naive, 357 (27%) were at WHO stage IV, 311 (33%) had a body-mass index of less than 18.5 kg/m(2), and 208 (21%) had a CD4 count lower than 50 cells per mu L. At follow-up (median 8.3 months, IQR 5.5-13.1),967 (74%) were still on HAART, 243 (19%) had died, 91 (7%) were lost to follow-up, and seven (0.5%) discontinued treatment. Low body-mass index, WHO stage IV, male sex, and baseline CD4 count lower than 50 cells per mu L were independent determinants of death in the first 6 months. At 12 months, the probability of individuals still in care was 0.76 (95% CI 0.73-0.78) and the median CD4 gain was 165 (IQR 67-259) cells per mu L. In the cross-sectional survey (n = 398), 334 (84%) had a viral load of less than 400 copies per mL. Of several indicators measuring adherence, self-reported poor adherence (<80%) in the past 4 days was the best predictor of detectable viral load (odds ratio 5.4, 95% CI 1.9-15.6). Interpretation These data show that large numbers of people can rapidly benefit from antiretroviral therapy in rural resource-poor settings and strongly supports the implementation of such large-scale simplified programmes in Africa.	Epictr, Paris, France; Med Sans Frontieres, Paris, France; Purpan Hosp, Toulouse, France; Minist Hlth, Chiradzulu, Malawi; INSERM, U379, F-13258 Marseille, France	Doctors Without Borders; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Ferradini, L (corresponding author), MSF F Mission Cambodge, 8 Rue St Sabin, F-75011 Paris, France.	msffr.comed@online.com.kh	IZOPET, Jacques/L-5756-2014; Spire, Bruno/F-5546-2013; Brasher, Chris/Y-4488-2019	Spire, Bruno/0000-0002-3546-8020; Brasher, Chris/0000-0003-1037-3604; Guerin, Philippe/0000-0002-6008-2963; Carrieri, Patrizia/0000-0002-6794-4837				Adje C, 2001, J ACQ IMMUN DEF SYND, V26, P501, DOI 10.1097/00126334-200104150-00018; Bangsberg DR, 2003, AIDS, V17, P1925, DOI 10.1097/00002030-200309050-00011; Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006; Calmy A, 2004, AIDS, V18, P2353; Carrieri MP, 2003, ANTIVIR THER, V8, P585; Carrieri P, 2001, J ACQ IMMUN DEF SYND, V28, P232, DOI 10.1097/00042560-200111010-00005; Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891; Chimzizi R, 2005, INT J TUBERC LUNG D, V9, P582; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Coetzee D, 2004, AIDS, V18, pS27, DOI 10.1097/00002030-200406003-00006; Dabis F, 2005, INT J EPIDEMIOL, V34, P979, DOI 10.1093/ije/dyi164; Deeks SG, 2003, LANCET, V362, P2002, DOI 10.1016/S0140-6736(03)15022-2; Frater John, 2002, J HIV Ther, V7, P92; *FRENCH ANRS NAT A, AC11 RES GROUP HIV 1; French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06; Galvao J, 2002, LANCET, V360, P1862, DOI 10.1016/S0140-6736(02)11775-2; Izopet J, 2000, AIDS, V14, P2247, DOI 10.1097/00002030-200010200-00005; Izopet J, 2002, J INFECT DIS, V185, P1506, DOI 10.1086/340215; *JOINT UN PROGR HI, 2004, UNAIDS REP GLOB AIDS; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Koenig SP, 2004, AIDS, V18, pS21, DOI 10.1097/00002030-200406003-00005; Kumarasamy N, 2003, AIDS, V17, P2267, DOI 10.1097/00002030-200310170-00019; Kuritzkes DR, 2004, AIDS, V18, pS45, DOI 10.1097/00002030-200406003-00009; Lange JMA, 2004, AIDS, V18, pS69, DOI 10.1097/00002030-200406003-00013; Laurent C, 2002, AIDS, V16, P1363, DOI 10.1097/00002030-200207050-00008; Laurent C, 2004, LANCET, V364, P29, DOI 10.1016/S0140-6736(04)16586-0; Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012; *MED SANS FRONT CA, 2005, MSF HIV AIDS TREATM; Mekonnen Y, 2003, ETHIOPIAN MED J, V41, P61; *MIN HLTH POP MAL, 2004, TREATM AIDS 2 YEAR P; Moatti JP, 2004, AIDS, V18, pS55, DOI 10.1097/00002030-200406003-00011; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; *MSF WHO, 2004, ANT THER PRIM HLTH C; Orrell C, 2003, AIDS, V17, P1369, DOI 10.1097/00002030-200306130-00011; Pasquier C, 1999, J VIROL METHODS, V81, P123, DOI 10.1016/S0166-0934(99)00057-9; Tang AM, 2002, JAIDS-J ACQ IMM DEF, V31, P230, DOI 10.1097/00126334-200210010-00014; Teixeira PR, 2004, AIDS, V18, pS5, DOI 10.1097/00002030-200406003-00002; van der Sande MAB, 2004, JAIDS-J ACQ IMM DEF, V37, P1288, DOI 10.1097/01.qai.0000122708.59121.03; Walsh JC, 2002, AIDS, V16, P269, DOI 10.1097/00002030-200201250-00017; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; *WHO, 2005, PROGR GLOB ACC HIV A; *WHO, 2003, PREQ WHO LIST; *WHO, TREATING 3 MILLION 2; *WHO, GUID SURV HIV DRUG R; *WHO MSF UNAIDS, 2003, JOINT REP PROC ARVS; World Health Organization, 2004, SCAL ANT THER RES LT	46	363	368	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	2006	367	9519					1335	1342		10.1016/S0140-6736(06)68580-2	http://dx.doi.org/10.1016/S0140-6736(06)68580-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	037AG	16631912				2023-01-03	WOS:000237118500028
J	Bernat, JL				Bernat, JL			Chronic disorders of consciousness	LANCET			English	Review							PERSISTENT VEGETATIVE STATE; SEVERE BRAIN-INJURY; GLASGOW COMA SCALE; SOMATOSENSORY EVOKED-POTENTIALS; REGIONAL CEREBRAL METABOLISM; SENSORY MODALITY ASSESSMENT; MEDICAL DECISION-MAKING; DIFFUSE AXONAL INJURY; WESSEX HEAD-INJURY; LOCKED-IN SYNDROME	The vegetative state and the minimally conscious state are disorders of consciousness that can be acute and reversible or chronic and irreversible. Diffuse lesions of the thalami, cortical neurons, or the white-matter tracts that connect them cause the vegetative state, which is wakefulness without awareness. Functional imaging with PET and functional MRI shows activation of primary cortical areas with stimulation, but not of secondary areas or distributed neural networks that would indicate awareness. Vegetative state has a poor prognosis for recovery of awareness when present for more than a year in traumatic cases and for 3 months in non-traumatic cases. Patients in minimally conscious state are poorly responsive to stimuli, but show intermittent awareness behaviours. Indeed, findings of preliminary functional imaging studies suggest that some patients could have substantially intact awareness. The outcomes of minimally conscious state are variable. Stimulation treatments have been disappointing in vegetative state but occasionally improve minimally conscious state. Treatment decisions for patients in vegetative state or minimally conscious state should follow established ethical and legal principles and accepted practice guidelines of professional medical specialty societies.	Dartmouth Med Sch, Hanover, NH USA	Dartmouth College	Bernat, JL (corresponding author), Dartmouth Hitchcock Med Ctr, Neurol Sect, Lebanon, NH 03756 USA.	bernat@dartmouth.edu						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Alkire MT, 1997, ANESTHESIOLOGY, V86, P549, DOI 10.1097/00000542-199703000-00006; Alkire MT, 1999, ANESTHESIOLOGY, V90, P701, DOI 10.1097/00000542-199903000-00011; Allain P, 1998, CORTEX, V34, P629, DOI 10.1016/S0010-9452(08)70520-3; Andrews K, 2004, NEUROREHABILITATION, V19, P299; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ANDREWS K, 1992, BRIT MED J, V305, P486, DOI 10.1136/bmj.305.6852.486; ANDREWS K, 1993, BMJ-BRIT MED J, V300, P1597; Annas GJ, 2005, NEW ENGL J MED, V352, P1710, DOI 10.1056/NEJMlim050643; [Anonymous], 2003, Clin Med (Lond), V3, P249; [Anonymous], 2005, ANN INTERN MED, V142, P1019, DOI 10.7326/0003-4819-142-12_Part_1-200506210-00013; [Anonymous], 1989, NEUROLOGY, V39, P125; [Anonymous], 1990, JAMA, V263, P426; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; Asai A, 1999, J MED ETHICS, V25, P302, DOI 10.1136/jme.25.4.302; ASHWAL S, 1994, PEDIATR NEUROL, V10, P27, DOI 10.1016/0887-8994(94)90063-9; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Ashwal S, 2004, NEUROREHABILITATION, V19, P349; Ashwal S, 2003, BRAIN DEV-JPN, V25, P535, DOI 10.1016/S0387-7604(03)00095-0; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; ASHWAL S, 1995, NEW ENGL J MED, V333, P130, DOI 10.1056/NEJM199507133330216; ASHWAL S, 1992, ANN NEUROL, V32, P570, DOI 10.1002/ana.410320414; Ashwal Stephen, 2002, Semin Pediatr Neurol, V9, P19, DOI 10.1053/spen.2002.30334; Baars BJ, 2003, TRENDS NEUROSCI, V26, P671, DOI 10.1016/j.tins.2003.09.015; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Bekinschtein T, 2004, J NEUROL NEUROSUR PS, V75, P788, DOI 10.1136/jnnp.2003.034876; Beresford HR, 1997, ANN NY ACAD SCI, V835, P386, DOI 10.1111/j.1749-6632.1997.tb48644.x; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bernat J L, 1992, J Clin Ethics, V3, P176; Bernat JL, 2004, NEUROCRIT CARE, V1, P107, DOI 10.1385/NCC:1:1:107; Bernat JL, 2002, NEUROLOGY, V58, P337, DOI 10.1212/WNL.58.3.337; Bernat JL, 2001, NEUROLOGY, V56, P144, DOI 10.1212/WNL.56.2.144; BERNAT JL, 2002, ETHICAL ISSUES NEURO, P283; Beuthien-Baumann B, 2003, NUCL MED COMMUN, V24, P643, DOI 10.1097/00006231-200306000-00005; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Block N, 1997, NATURE CONSCIOUSNESS; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Bonito V, 2002, NEUROL SCI, V23, P131, DOI 10.1007/s100720200040; Borthwick CJ, 2004, NEUROREHABILITATION, V19, P381; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRIERLEY JB, 1971, LANCET, V2, P560; *BRIT MED ASS, 1996, BMA GUID TREATM DEC; BRUNKO E, 1987, ELECTROEN CLIN NEURO, V66, P15, DOI 10.1016/0013-4694(87)90133-7; Bush MC, 2003, OBSTET GYNECOL SURV, V58, P738, DOI 10.1097/01.OGX.0000093268.20608.53; Cairns H, 1941, BRAIN, V64, P273, DOI 10.1093/brain/64.4.273; Carver AC, 1999, NEUROLOGY, V53, P284, DOI 10.1212/WNL.53.2.284; CELESIA, 1993, ANN NEUROL, V33, P386; Chalela JA, 2001, NEUROLOGY, V56, P481, DOI 10.1212/WNL.56.4.481; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Coleman D, 2002, NEUROLOGY, V58, P506, DOI 10.1212/WNL.58.3.506; Coleman MR, 2005, J NEUROL NEUROSUR PS, V76, P432, DOI 10.1136/jnnp.2004.045930; DANZE F, 1989, Neurosurgical Review, V12, P477, DOI 10.1007/BF01790694; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Doder M, 1999, J NEUROL NEUROSUR PS, V66, P380, DOI 10.1136/jnnp.66.3.380; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Elliott L, 2005, J NEUROL NEUROSUR PS, V76, P298, DOI 10.1136/jnnp.2004.047357; Els T, 2004, ACTA NEUROL SCAND, V110, P361, DOI 10.1111/j.1600-0404.2004.00342.x; Farah MJ, 2005, TRENDS COGN SCI, V9, P34, DOI 10.1016/j.tics.2004.12.001; Fins JJ, 2005, PROG BRAIN RES, V150, P565, DOI 10.1016/S0079-6123(05)50040-2; FRANK LM, 1985, NEUROLOGY, V35, P931, DOI 10.1212/WNL.35.6.931; Garrard P, 2002, J NEUROL NEUROSUR PS, V73, P191, DOI 10.1136/jnnp.73.2.191; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2005, PROG BRAIN RES, V150, P381, DOI 10.1016/S0079-6123(05)50027-X; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2003, J HEAD TRAUMA REHAB, V18, P4, DOI 10.1097/00001199-200301000-00003; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Giacino JT, 1996, NEUROREHABILITATION, V6, P69, DOI 10.3233/NRE-1996-6108; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; Grubb A, 1996, LANCET, V348, P35, DOI 10.1016/S0140-6736(96)02030-2; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; Hamel MB, 2002, CRIT CARE MED, V30, P1191, DOI 10.1097/00003246-200206000-00002; HANSOTIA PL, 1985, ARCH NEUROL-CHICAGO, V42, P1048, DOI 10.1001/archneur.1985.04060100030015; Hattori N, 2003, J NUCL MED, V44, P1709; HAWKES CH, 1974, NEUROLOGY, V24, P1015, DOI 10.1212/WNL.24.11.1015; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; Hook CC, 2005, MAYO CLIN PROC, V80, P1449, DOI 10.4065/80.11.1449; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; Howard RS, 1999, BLUE BOOK PRACT NEUR, V22, P91; HOWARD RS, 1995, BRIT MED J, V310, P341, DOI 10.1136/bmj.310.6976.341; Howsepian AA, 1996, ISSUES LAW MED, V12, P3; Isono M, 2002, BRAIN INJURY, V16, P705, DOI 10.1080/02699050210127303; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; JENNETT B, 2002, VEGETATIVE STATE MED; Jones SJ, 2000, BRAIN, V123, P1007, DOI 10.1093/brain/123.5.1007; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Keown J, 1997, Law Q Rev, V113, P481; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Koeda T, 1998, BRAIN DEV-JPN, V20, P124, DOI 10.1016/S0387-7604(98)00004-7; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Kretschmer E, 1940, Z GESAMTE NEUROL PSY, V169, P576, DOI 10.1007/BF02871384; Krimchansky BZ, 2004, BRAIN INJURY, V18, P1099, DOI 10.1080/02699050310001646206; LAHRMANN H, 2004, PALLIATIVE CARE NEUR, P135; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2004, NEUROREHABILITATION, V19, P335; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2002, ACTA NEUROL BELG, V102, P176; Laureys S., 2003, European Journal of Neurology, V10, P224; Laureys S, 2000, LANCET, V355, P1825, DOI 10.1016/S0140-6736(05)73084-1; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Lavrijsen JCM, 2005, J NEUROL NEUROSUR PS, V76, P1420, DOI 10.1136/jnnp.2004.058198; Lo B, 2002, NEW ENGL J MED, V346, P1489, DOI 10.1056/NEJM200205093461912; Lombardi F, 2002, CLIN REHABIL, V16, P464, DOI 10.1191/0269215502cr519oa; Lou HC, 2004, P NATL ACAD SCI USA, V101, P6827, DOI 10.1073/pnas.0400049101; Luaute J, 2005, ARCH PHYS MED REHAB, V86, P917, DOI 10.1016/j.apmr.2004.08.011; Madl C, 1996, ARCH NEUROL-CHICAGO, V53, P512, DOI 10.1001/archneur.1996.00550060054017; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Majerus S, 2000, NEUROPSYCHOL REHABIL, V10, P167, DOI 10.1080/096020100389237; MAROSI M, 1993, LANCET, V341, P1473, DOI 10.1016/0140-6736(93)90914-3; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; MCQUILLEN MP, 1991, ISSUES LAW MED, V6, P373; *MED EX DISTR 6, 2005, PASC PIN COUNT FLOR; Mega MS, 1997, NEUROPSY NEUROPSY BE, V10, P254; Meisel Alan, 1992, Law Med Health Care, V20, P340; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Montane E, 2004, NEUROLOGY, V63, P1357; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90066-8; MULLIE A, 1988, LANCET, V1, P137; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; ODell MW, 1996, NEUROREHABILITATION, V6, P45, DOI 10.3233/NRE-1996-6106; Oksenberg A, 2000, SLEEP, V23, P953; Pape TLB, 2005, J REHABIL RES DEV, V42, P19, DOI 10.1682/JRRD.2004.03.0033; Papermaster DS, 2001, INVEST OPHTH VIS SCI, V42, P1; PATTERSON JR, 1986, STROKE, V17, P758, DOI 10.1161/01.STR.17.4.758; Payne K, 1996, ANN INTERN MED, V125, P104, DOI 10.7326/0003-4819-125-2-199607150-00004; Phipps E, 1999, AM J PHYS MED REHAB, V78, P77, DOI 10.1097/00002060-199901000-00020; Pilon M, 1996, BRAIN INJURY, V10, P421, DOI 10.1080/026990596124287; Plum F, 1980, DIAGNOSIS STUPOR COM, Vthird; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; ROSENBERG GA, 1977, ANN NEUROL, V2, P167, DOI 10.1002/ana.410020215; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; *ROYAL COLL PHYS, 2003, REH FOLL ACQ BRAIN I, P8; Rudolf J, 1999, J NEUROSURG ANESTH, V11, P17, DOI 10.1097/00008506-199901000-00004; Sandel ME, 1996, NEUROREHABILITATION, V6, P9, DOI 10.3233/NRE-1996-6103; Schaafsma A, 2003, J NEUROL SCI, V210, P23, DOI 10.1016/S0022-510X(03)00063-7; Schiff N, 1999, J COGNITIVE NEUROSCI, V11, P650, DOI 10.1162/089892999563715; Schiff ND, 2005, PROG BRAIN RES, V150, P473, DOI 10.1016/S0079-6123(05)50033-5; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Shewmon DA, 2004, NEUROREHABILITATION, V19, P343; Shewmon DA, 2002, NEUROLOGY, V58, P506; SHEWMON DA, 1989, NEUROL CLIN, V7, P823, DOI 10.1016/S0733-8619(18)30392-X; Shewmon DA, 1999, DEV MED CHILD NEUROL, V41, P364, DOI 10.1017/S0012162299000821; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; Shiel A, 2004, BRIT J NEUROSURG, V18, P5, DOI 10.1080/02688690410001660625; Showalter PEC, 2000, BRAIN INJURY, V14, P997; Smith E, 2005, BMJ-BRIT MED J, V330, P406, DOI 10.1136/bmj.330.7488.406; SNYDER BD, 1983, ANN NEUROL, V14, P152; Stepan C, 2004, EUR J NEUROL, V11, P461, DOI 10.1111/j.1468-1331.2004.00817.x; Strens LHA, 2004, BRAIN INJURY, V18, P213, DOI 10.1080/0269905031000149533; TEASDALE G, 1974, LANCET, V2, P81; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; Volicer L, 1997, ARCH NEUROL-CHICAGO, V54, P1382, DOI 10.1001/archneur.1997.00550230051016; Wade DT, 2001, BMJ-BRIT MED J, V322, P352, DOI 10.1136/bmj.322.7282.352; WALSHE TM, 1985, ARCH NEUROL-CHICAGO, V42, P1045, DOI 10.1001/archneur.1985.04060100027014; *WHO, 1989, STAT PERS VEG STAT; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; Wijdicks Eelco F. M., 2001, BRAIN DEATH; Wijdicks EFM, 2005, MAYO CLIN PROC, V80, P1037, DOI 10.4065/80.8.1037; Wilson BA, 2001, BRAIN INJURY, V15, P1083, DOI 10.1080/02699050110082197; Wilson FC, 2002, NEUROREHABILITATION, V17, P231; Winslade WJ, 2004, J HEAD TRAUMA REHAB, V19, P178, DOI 10.1097/00001199-200403000-00008; WROBLEWSKI BA, 1994, J HEAD TRAUMA REHAB, V9, P19, DOI 10.1097/00001199-199409000-00004; Yamamoto T, 2005, ACTA NEUROCHIR SUPPL, V93, P101; Yamamoto T, 2003, ACTA NEUROCHIR SUPPL, V87, P15; Yingling CD, 2001, CLIN NEUROPHYSIOL, V112, P157, DOI 10.1016/S1388-2457(00)00507-1; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; ZASLER ND, 1995, J HEAD TRAUMA REHAB, V10, P101, DOI 10.1097/00001199-199508000-00010; Zasler ND, 2004, NEUROREHABILITATION, V19, P285; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263; Zeman A, 1997, LANCET, V350, P795, DOI 10.1016/S0140-6736(97)06447-7; Zeman A., 2003, ADV CLIN NEUROSCI RE, V3, P12; [No title captured]	198	209	224	1	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 8	2006	367	9517					1181	1192		10.1016/S0140-6736(06)68508-5	http://dx.doi.org/10.1016/S0140-6736(06)68508-5			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	030ZH	16616561				2023-01-03	WOS:000236673400027
J	Braitstein, P; Brinkhof, MWG; Dabis, F; Schechter, M; Boulle, A; Miotti, P; Wood, R; Laurent, C; Sprinz, E; Seyler, C; Bangsberg, DR; Balestre, E; Sterne, JAC; May, M; Egger, M				Braitstein, P; Brinkhof, MWG; Dabis, F; Schechter, M; Boulle, A; Miotti, P; Wood, R; Laurent, C; Sprinz, E; Seyler, C; Bangsberg, DR; Balestre, E; Sterne, JAC; May, M; Egger, M		ART-LINC Grp; ART-CC Grp	Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries	LANCET			English	Article							HIV-INFECTED PATIENTS; SUB-SAHARAN AFRICA; RESOURCE-POOR SETTINGS; OPPORTUNISTIC INFECTIONS; OBSERVATIONAL DATABASE; WORLD-HEALTH; COHORT; SURVIVAL; AIDS; TUBERCULOSIS	Background Highly active antiretroviral therapy (HAART) is being scaled up in developing countries. We compared baseline characteristics and outcomes during the first year of HAART between HIV-1-infected patients in low-income and high-income settings. Methods 18 HAART programmes in Africa, Asia, and South America (low-income settings) and 12 HIV cohort studies from Europe and North America (high-income settings) provided data for 4810 and 22 217, respectively, treatment-naive adult patients starting HAART. All patients from high-income settings and 2725 (57%) patients from low-income settings were actively followed-up and included in survival analyses. Findings Compared with high-income countries, patients starting HAART in low-income settings had lower CD4 cell counts (median 108 cells per mu L vs 234 cells per mu L), were more likely to be female (51% vs 25%), and more likely to start treatment with a non-nucleoside reverse transcriptase inhibitor (NNRTI) (70% vs 23%). At 6 months, the median number of CD4 cells gained (106 cells per mu L vs 103 cells per mu L) and the percentage of patients reaching HIV-1 RNA levels lower than 500 copies/mL (76% vs 77%) were similar. Mortality was higher in low-income settings (124 deaths during 2236 person-years of follow-up) than in high-income settings (414 deaths during 20 532 person-years). The adjusted hazard ratio (HR) of mortality comparing tow-income with high-income settings fell from 4.3 (95% CI 1.6-11.8) during the first month to 1.5 (0.7-3.0) during months 7-12. The provision of treatment free of charge in low-income settings was associated with lower mortality (adjusted HR 0.23; 95% CI 0.08-0.61). Interpretation Patients starting HAART in resource-poor settings have increased mortality rates in the first months on therapy, compared with those in developed countries. Timely diagnosis and assessment of treatment eligibility, coupled with free provision of HAART, might reduce this excess mortality.	Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland	University of Bern	Egger, M (corresponding author), Univ Bern, Dept Social & Prevent Med, Finkenhubelweg 11, CH-3012 Bern, Switzerland.	egger@ispm.unibe.ch	Sterne, Jonathan/Z-3106-2019; Wood, Robin/G-8509-2011; sprinz, eduardo/V-7961-2019; hlupeni, admire/M-1539-2018; Boulle, Andrew/C-1413-2008; DABIS, FRANCOIS/S-9298-2019; VALLET, Yannick/F-9979-2011; Schechter, Mauro/AAG-7445-2020; May, Margaret/E-8099-2013	Sterne, Jonathan/0000-0001-8496-6053; sprinz, eduardo/0000-0003-4343-8304; Boulle, Andrew/0000-0002-7713-8062; DABIS, FRANCOIS/0000-0002-1614-8857; Laurent, Christian/0000-0003-2658-7113; Brinkhof, Martin/0000-0002-9319-665X; Egger, Matthias/0000-0001-7462-5132; May, Margaret/0000-0002-9733-1003	MRC [G0100221] Funding Source: UKRI; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054907] Funding Source: NIH RePORTER; Medical Research Council [G0100221] Funding Source: Medline; NIMH NIH HHS [R01 MH054907] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aaron L, 2004, CLIN MICROBIOL INFEC, V10, P388, DOI 10.1111/j.1469-0691.2004.00758.x; Abbasi K, 1999, BMJ-BRIT MED J, V318, P1003, DOI 10.1136/bmj.318.7189.1003; Anglaret X, 2004, JAIDS-J ACQ IMM DEF, V35, P320, DOI 10.1097/00126334-200403010-00015; Attia A, 2001, J ACQ IMMUN DEF SYND, V28, P478, DOI 10.1097/00042560-200112150-00012; Badri M, 2004, AIDS, V18, P1159, DOI 10.1097/00002030-200405210-00009; Becker SL, 2001, J ACQ IMMUN DEF SYND, V26, P72, DOI 10.1097/00126334-200101010-00011; Binquet C, 2001, AM J EPIDEMIOL, V153, P386, DOI 10.1093/aje/153.4.386; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Dabis F, 2005, INT J EPIDEMIOL, V34, P979, DOI 10.1093/ije/dyi164; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Egger M, 2005, INT J EPIDEMIOL, V34, P509, DOI 10.1093/ije/dyi110; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; French N, 1999, J ACQ IMMUN DEF SYND, V22, P509; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Gutierrez RG, 2002, STATA J, V2, P22, DOI 10.1177/1536867X0200200102; Hogg RS, 1999, CAN MED ASSOC J, V160, P659; Holmes CB, 2003, CLIN INFECT DIS, V36, P652, DOI 10.1086/367655; Ivers LC, 2005, CLIN INFECT DIS, V41, P217, DOI 10.1086/431199; Keiding N, 1997, STAT MED, V16, P215; Laurent C, 2005, JAIDS-J ACQ IMM DEF, V38, P14, DOI 10.1097/00126334-200501010-00003; Lawn SD, 2005, LANCET INFECT DIS, V5, P361, DOI 10.1016/S1473-3099(05)70140-7; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; May M, 2004, STAT MED, V23, P2375, DOI 10.1002/sim.1825; Mocroft A, 1999, AIDS, V13, P1255, DOI 10.1097/00002030-199907090-00016; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Narita M, 1998, AM J RESP CRIT CARE, V158, P157, DOI 10.1164/ajrccm.158.1.9712001; Nieuwkerk PT, 2001, ARCH INTERN MED, V161, P1962, DOI 10.1001/archinte.161.16.1962; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; SCHNEIDER M, 2005, HQ03463871 UNAIDS JO; Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908; Seyler C, 2005, AM J RESP CRIT CARE, V172, P123, DOI 10.1164/rccm.200410-1342OC; Sterne JAC, 2005, LANCET, V366, P378, DOI 10.1016/S0140-6736(05)67022-5; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; van der Loeff MFS, 2002, AIDS, V16, P1775, DOI 10.1097/00002030-200209060-00010; Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; Whitehead M, 2001, LANCET, V358, P833, DOI 10.1016/S0140-6736(01)05975-X; [WHO] World Health Organization, 2005, PREV CHRON DIS VIT I, P1; Yamey G, 2001, BRIT MED J, V322, P257; Zhou J, 2005, HIV MED, V6, P216, DOI 10.1111/j.1468-1293.2005.00292.x; Zhou J, 2005, JAIDS-J ACQ IMM DEF, V38, P174, DOI 10.1097/01.qai.0000145351.96815.d5	45	902	921	0	47	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 11	2006	367	9513					817	824						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021WL	16530575				2023-01-03	WOS:000236016500026
J	Kendall, MJ; Mehta, DK				Kendall, MJ; Mehta, DK			Sick children deserve a better deal	LANCET			English	Editorial Material									Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Royal Pharmaceut Soc Great Britain, London, England	University of Birmingham	Kendall, MJ (corresponding author), Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England.	m.j.kendall@bham.ac.uk						Caldwell PHY, 2004, LANCET, V364, P803, DOI 10.1016/S0140-6736(04)16942-0; Choonara I, 2002, DRUG SAFETY, V25, P1, DOI 10.2165/00002018-200225010-00001; COPE L, 1996, A HEY BOOK CHILDRENS; *EUR MED AG, 2004, MED CHILDR EUR PAED; HEY E, 2003, NEONATAL FORMULARY; *PAED FORM COMM, 2005, BNF CHILDR; TOMLIN S, 2005, PAEDIAT FORMULARY	7	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 28	2006	367	9507					281	283		10.1016/S0140-6736(06)68048-3	http://dx.doi.org/10.1016/S0140-6736(06)68048-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443023				2023-01-03	WOS:000235084600007
J	Oh-Park, M; Dove, C; Sheskier, S; Sheehan, P				Oh-Park, M; Dove, C; Sheskier, S; Sheehan, P			Charcot neuroarthropathy in the era of HAART	LANCET			English	Editorial Material									Montefiore Med Ctr, Albert Einstein Coll Med, Dept Rehabil Med, Bronx, NY 10467 USA; Hosp Joint Dis & Med Ctr, Diabet Foot & Ankle Ctr, New York, NY 10003 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; NYU Langone Medical Center; Hospital for Joint Disease NYULMC	Oh-Park, M (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Rehabil Med, Bronx, NY 10467 USA.	mohpark@pol.net						Armstrong DG, 1997, DIABETIC MED, V14, P357, DOI 10.1002/(SICI)1096-9136(199705)14:5<357::AID-DIA341>3.3.CO;2-#; Keswani SC, 2002, AIDS, V16, P2105, DOI 10.1097/00002030-200211080-00002; Nolan D, 2004, ANTIVIR THER, V9, P849; Sutliff RL, 2002, AM J PHYSIOL-HEART C, V283, pH2363, DOI 10.1152/ajpheart.00151.2002	4	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 21	2006	367	9506					274	274		10.1016/S0140-6736(06)68039-2	http://dx.doi.org/10.1016/S0140-6736(06)68039-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427498				2023-01-03	WOS:000234810600034
J	McDermott, MM; Liu, K; Ferrucci, L; Criqui, MH; Greenland, P; Guralnik, JM; Tian, L; Schneider, JR; Pearce, WH; Tan, J; Martin, GJ				McDermott, MM; Liu, K; Ferrucci, L; Criqui, MH; Greenland, P; Guralnik, JM; Tian, L; Schneider, JR; Pearce, WH; Tan, J; Martin, GJ			Physical performance in peripheral arterial disease: A slower rate of decline in patients who walk more	ANNALS OF INTERNAL MEDICINE			English	Article							ANKLE BRACHIAL INDEX; LEG SYMPTOMS; CLINICAL CHARACTERISTICS; EXERCISE REHABILITATION; CALTRAC ACCELEROMETER; OCCLUSIVE DISEASE; LONGITUDINAL DATA; 6-MINUTE WALK; RISK-FACTORS; PREVALENCE	Background: Exercise rehabilitation programs increase treadmill walking performance in patients with peripheral arterial disease (PAD) and intermittent claudication. However, it is unknown whether patients with PAD who walk for exercise regularly have less functional decline than those with less walking activity. Objective: To determine whether patients with PAD who report that they walk for exercise 3 or more times per week have less annual functional decline than those who walk for exercise less frequently. Design: Prospective cohort study with a median follow-up of 36 months (interquartile range, 24 to 36 months). Setting: Academic medical center. Participants: 417 men and women with PAID. Measurements: Participants were classified at baseline and annually according to the number of times they reportedly walked for exercise each week. Functional assessments (6-minute walk distance, 4-meter walking speed, summary performance score) were measured at baseline and annually. Results were adjusted for age, sex, ethnicity, comorbid conditions, body mass index, ankle-brachial index, education, leg symptoms, cigarette use, geriatric depression score, previous year's level of functioning, and patterns of missing data. Results: Compared with those who exercised less frequently, patients who walked for exercise 3 or more times per week had a significantly smaller average annual decline in 6-minute walking distance (-48.0 feet per year compared with - 56.6 feet per year for those who walked 1 to 2 times per week and - 79.4 feet per year for nonexercisers; P for trend = 0.037). Patients who walked for exercise at least 3 times per week experienced a smaller average annual decline in the usual-paced 4-meter walking velocity (-0.014 m/s per year compared with - 0.022 m/s per year for those who walked 1 to 2 times per week and - 0.045 m/s per year for nonexercisers; P = 0.005). Similar findings were observed for the fast-paced 4-meter walk. The subset of asymptomatic patients who walked for exercise 3 or more times per week had annual declines in 6-minute walking performance (P = 0.107), normal-paced walking velocity (P = 0.065), and the summary performance score (P = 0.115); however, these declines were smaller than those observed in asymptomatic participants who walked fewer than 3 times per week. Limitations: Because this was an observational study, associations reported here cannot be construed as causal relationships. Sample sizes for subgroup analyses were small, which limited statistical power. Conclusion: Among patients with PAD, self-directed walking exercise performed at least 3 times weekly is associated with significantly less functional decline during the subsequent year. Similar trends were observed in the subset of asymptomatic patients with PAD. These findings may be particularly important for the numerous patients with PAD who do not have access to supervised walking exercise programs.	Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Evanston NW Hosp, Evanston, IL USA; NIA, Baltimore, MD 21224 USA; Univ Calif San Diego, La Jolla, CA 92093 USA	Northwestern University; Feinberg School of Medicine; NorthShore University Health System; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of California System; University of California San Diego	McDermott, MM (corresponding author), 675 N St Clair,Suite 18-200, Chicago, IL 60611 USA.	mdm608@northwestern.edu	Greenland, Philip/ABD-5528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058099, R01HL064739] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00048] Funding Source: Medline; NHLBI NIH HHS [R01-HL58099, R01-HL64739] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; BERNSTEIN EF, 1982, SURG CLIN N AM, V62, P473; Criqui M H, 1996, Vasc Med, V1, P65; Falcone Rita A, 2003, J Cardiopulm Rehabil, V23, P170, DOI 10.1097/00008483-200305000-00002; Fitzmaurice GM, 2001, STAT MED, V20, P1009, DOI 10.1002/sim.718; GARDNER AW, 1995, JAMA-J AM MED ASSOC, V274, P975, DOI 10.1001/jama.274.12.975; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; GURALNIK JM, 1995, N IH PUBL; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HIATT WR, 1995, CIRCULATION, V91, P1472, DOI 10.1161/01.CIR.91.5.1472; Hirsch AT, 2001, VASC MED, V6, P87, DOI 10.1191/135886301701568756; Hirsch AT, 2001, JAMA-J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LENG GC, 2000, COCHRANE DB SYST REV, V2; LITTLE RJA, 1995, J AM STAT ASSOC, V90, P1112, DOI 10.2307/2291350; Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449; McDermott MM, 2000, J VASC SURG, V32, P1164, DOI 10.1067/mva.2000.108640; McDermott MM, 2002, J GEN INTERN MED, V17, P895, DOI 10.1046/j.1525-1497.2002.20307.x; McDermott MM, 2002, ANN INTERN MED, V136, P873, DOI 10.7326/0003-4819-136-12-200206180-00008; McDermott MM, 2001, JAMA-J AM MED ASSOC, V286, P1599; McDermott MM, 2001, J GEN INTERN MED, V16, P384, DOI 10.1046/j.1525-1497.2001.016006384.x; McDermott MM, 1997, J GEN INTERN MED, V12, P209, DOI 10.1046/j.1525-1497.1997.012004209.x; McDermott MM, 2000, ANGIOLOGY, V51, P91, DOI 10.1177/000331970005100201; McDermott MM, 2004, JAMA-J AM MED ASSOC, V292, P453, DOI 10.1001/jama.292.4.453; MILLER DJ, 1994, MED SCI SPORT EXER, V26, P376; Montgomery PS, 1998, J AM GERIATR SOC, V46, P706, DOI 10.1111/j.1532-5415.1998.tb03804.x; OGREN M, 1995, BMJ-BRIT MED J, V310, P1294, DOI 10.1136/bmj.310.6990.1294; OLIN JW, 1998, AM J MED CONTINUING, P10; Regensteiner JG, 1997, ANGIOLOGY, V48, P291, DOI 10.1177/000331979704800402; Regensteiner Judith G., 2004, Current Drug Targets - Cardiovascular & Haematological Disorders, V4, P233, DOI 10.2174/1568006043336195; Richardson M T, 1995, J Cardiopulm Rehabil, V15, P107, DOI 10.1097/00008483-199503000-00003; Rucker-Whitaker C, 2004, J AM GERIATR SOC, V52, P922, DOI 10.1111/j.1532-5415.2004.52259.x; SALLIS JF, 1990, MED SCI SPORT EXER, V22, P698, DOI 10.1249/00005768-199010000-00023; Selvin E, 2004, CIRCULATION, V110, P738, DOI 10.1161/01.CIR.0000137913.26087.F0; Stewart KJ, 2002, NEW ENGL J MED, V347, P1941, DOI 10.1056/NEJMra021135; Swan PD, 1997, BRIT J SPORT MED, V31, P235, DOI 10.1136/bjsm.31.3.235; *TASC, 2000, J VASC SURG, V31, pS118; *TASC, 2000, J VASC SURG 2, V31, pS83	40	88	96	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 3	2006	144	1					10	20		10.7326/0003-4819-144-1-200601030-00005	http://dx.doi.org/10.7326/0003-4819-144-1-200601030-00005			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	000PL	16389250				2023-01-03	WOS:000234474200002
J	Ness, KK; Mertens, AC; Hudson, MM; Wall, MM; Leisenring, WM; Oeffinger, KC; Sklar, CA; Robison, LL; Gurney, JG				Ness, KK; Mertens, AC; Hudson, MM; Wall, MM; Leisenring, WM; Oeffinger, KC; Sklar, CA; Robison, LL; Gurney, JG			Limitations on physical performance and daily activities among long-term survivors of childhood cancer	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; HEALTH-STATUS; BRAIN-TUMORS; ADOLESCENT CANCER; ADULT SURVIVORS; RADIATION-THERAPY; NEURO-BLASTOMA; CHILDREN; COMPLICATIONS; NEUROBLASTOMA	Background: Survivors of childhood cancer may experience important disease- and treatment-related late effects, including functional limitations. Objective: This study evaluated performance limitations and restricted abilities to participate in personal care, to engage in routine activities like shopping or housework, and to attend work or school (participation restrictions) in a cohort of survivors of childhood cancer. Setting: Epidemiologic survey and 26 institutions that treat childhood cancer. Patients: Participants included 11 481 persons who were treated for primary brain cancer, leukemia, Hodgkin disease, non-Hodgkin lymphoma, kidney tumor, neuroblastoma, soft-tissue sarcoma, or malignant bone tumor before the age of 21 years and who survived at least 5 years after diagnosis. The comparison group included 3839 siblings of survivors of childhood cancer. Measurement: Medical data were abstracted, and participants or parents (if the participants were < 18 years of age at survey completion) completed a 24-page questionnaire. Results: Compared with siblings, survivors were more likely to report performance limitations (risk ratio, 1.8 [95% Cl, 1.7 to 2.0]) and to report restricted participation in personal care skills (risk ratio, 4.7 [Cl, 3.0 to 7.2]), routine activities (risk ratio, 4.7 [Cl, 3.6 to 6.2]), and the ability to attend work or school (risk ratio, 5.9 [Cl, 4.5 to 7.6]). Survivors of brain (26.6%) and bone (36.9%) cancer were most likely to report performance limitations, restricted ability to do routine activities (20.9% and 8.5%, respectively), and restricted ability to attend work or school (20.0% and 11.2%, respectively). Survivors of brain cancer were also most likely to report restricted abilities to perform personal care (10.5%). Limitations: There was the potential for participants to be healthier or more physically capable than nonparticipants or for persons to be more motivated to participate in this study if they had functional deficits. In addition, the nature of the questionnaire did not allow specific physical limitations to be measured. Conclusion: Long-term survivors of childhood cancer are at increased risk for functional limitations in physical performance and in participation in activities needed for daily living.	Univ Minnesota, Dept Pediat, Div Epidemiol & Clin Res, Minneapolis, MN 55455 USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of Minnesota System; University of Minnesota Twin Cities; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Fred Hutchinson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Memorial Sloan Kettering Cancer Center	Ness, KK (corresponding author), Univ Minnesota, Dept Pediat, Div Epidemiol & Clin Res, Mayo Mail Code 715,420 Delaware St SE, Minneapolis, MN 55455 USA.	ness@epi.umn.edu	Hudson, Melissa M/N-4441-2018; Ness, Kirsten K/N-2550-2018; Robison, Leslie/N-8122-2018; Wall, Melanie/AAE-7828-2019	Hudson, Melissa M/0000-0001-6984-2407; Ness, Kirsten K/0000-0002-2084-1507; 	NATIONAL CANCER INSTITUTE [U01CA055727, U24CA055727] Funding Source: NIH RePORTER; NCI NIH HHS [U24 CA055727, CA 55727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcoser Pat Wills, 2003, J Pediatr Nurs, V18, P103, DOI 10.1053/jpdn.2003.10; Anderson DM, 2001, CANCER-AM CANCER SOC, V92, P2709, DOI 10.1002/1097-0142(20011115)92:10<2709::AID-CNCR1625>3.0.CO;2-D; AZIZKHAN RG, 1985, SURGERY, V97, P514; Balis FM, 2002, PRINCIPLES PRACTICE, V4th, P237; Boulad F, 1998, Curr Probl Pediatr, V28, P273; Crom DB, 1999, INT J CANCER, P25; Cruccetti A, 2000, J PEDIATR SURG, V35, P724, DOI 10.1053/jpsu.2000.6076; Damron TA, 1997, SEMIN SURG ONCOL, V13, P3, DOI 10.1002/(SICI)1098-2388(199701/02)13:1<3::AID-SSU2>3.3.CO;2-5; DREYER ZE, 2002, PRINCIPLES PRACTICE, P1431; Felder-Puig R, 1998, CANCER, V83, P69, DOI 10.1002/(SICI)1097-0142(19980701)83:1<69::AID-CNCR10>3.0.CO;2-A; Foreman NK, 1999, J NEURO-ONCOL, V41, P47, DOI 10.1023/A:1006145724500; Freeman CR, 2002, MED PEDIATR ONCOL, V39, P99, DOI 10.1002/mpo.10116; GARRE ML, 1994, AM J PEDIAT HEMATOL, V16, P143; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Gurney JG, 2003, J CLIN ENDOCR METAB, V88, P4731, DOI 10.1210/jc.2003-030784; Gurney JG, 2003, CANCER-AM CANCER SOC, V97, P663, DOI 10.1002/cncr.11095; Gustavsson A, 2003, ACTA ONCOL, V42, P589, DOI 10.1080/02841860310013346; Habrand JL, 2001, CHILD NERV SYST, V17, P121, DOI 10.1007/s003810000365; Hejna MJ, 1997, SEMIN SURG ONCOL, V13, P18, DOI 10.1002/(SICI)1098-2388(199701/02)13:1<18::AID-SSU4>3.0.CO;2-7; Hudson Melissa M, 2004, J Pediatr Oncol Nurs, V21, P170, DOI 10.1177/1043454204264388; Hudson MM, 2003, JAMA-J AM MED ASSOC, V290, P1583, DOI 10.1001/jama.290.12.1583; Ilveskoski I, 1996, NEUROPEDIATRICS, V27, P124, DOI 10.1055/s-2007-973762; Jenkin D, 1998, MED PEDIATR ONCOL, V31, P506, DOI 10.1002/(SICI)1096-911X(199812)31:6<506::AID-MPO7>3.0.CO;2-X; Kaaijk Patricia, 2003, Expert Rev Anticancer Ther, V3, P79, DOI 10.1586/14737140.3.1.79; KAJANTI M, 1983, ANN CLIN RES, V15, P1; Kalapurakal JA, 2004, LANCET ONCOL, V5, P37, DOI 10.1016/S1470-2045(03)01322-6; Kennedy CR, 1999, INT J CANCER, P106; LANNERING B, 1990, MED PEDIATR ONCOL, V18, P304, DOI 10.1002/mpo.2950180410; Laverdiere C, 2005, PEDIATR BLOOD CANCER, V45, P324, DOI 10.1002/pbc.20331; Laverdiere C, 2005, PEDIAT ONCOL, P277; Macedoni-Luksic M, 2003, PEDIATR HEMAT ONCOL, V20, P89, DOI 10.1080/0880010390158595; MANKIN HJ, 1992, ORTHOPEDICS, V15, P1147; Marina N, 1997, PEDIATR CLIN N AM, V44, P1021, DOI 10.1016/S0031-3955(05)70543-5; Massey B, 2001, PHYS THER, V81, P9; MAYFIELD JK, 1981, J BONE JOINT SURG AM, V63, P183, DOI 10.2106/00004623-198163020-00002; McGoveran BM, 1999, CAN J SURG, V42, P37; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Meister L A, 1993, Curr Probl Pediatr, V23, P102, DOI 10.1016/0045-9380(93)90019-9; Mertens AC, 2002, CANCER, V95, P2431, DOI 10.1002/cncr.10978; Meyer WH, 2004, CANCER TREAT REV, V30, P269, DOI 10.1016/j.ctrv.2003.11.001; Nagarajan R, 2002, J CLIN ONCOL, V20, P4493, DOI 10.1200/JCO.2002.09.006; Ng Andrea K, 2004, Curr Hematol Rep, V3, P27; NITSCHKE R, 1988, J CLIN ONCOL, V6, P1271, DOI 10.1200/JCO.1988.6.8.1271; Oeffinger KC, 2004, CA-CANCER J CLIN, V54, P208, DOI 10.3322/canjclin.54.4.208; Packer RJ, 2003, J CLIN ONCOL, V21, P3255, DOI 10.1200/JCO.2003.01.202; PASTORE G, 1987, MED PEDIATR ONCOL, V15, P1, DOI 10.1002/mpo.2950150102; PASTORE G, 1982, MED PEDIATR ONCOL, V10, P369, DOI 10.1002/mpo.2950100407; Rao BN, 2003, MED PEDIATR ONCOL, V41, P584, DOI 10.1002/mpo.10405; Refaat Y, 2002, CLIN ORTHOP RELAT R, P298; Robison LL, 2004, CANCER EPIDEM BIOMAR, V13, P1093; Robison LL, 2003, BRIT J HAEMATOL, V122, P345, DOI 10.1046/j.1365-2141.2003.04499.x; Robison LL, 2003, CURR PROB CANCER, V27, P212, DOI 10.1016/S0147-0272(03)00029-1; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; Scarborough MT, 1997, SEMIN SURG ONCOL, V13, P25, DOI 10.1002/(SICI)1098-2388(199701/02)13:1<25::AID-SSU5>3.0.CO;2-6; Schindler OS, 1998, CLIN ORTHOP RELAT R, P157; Schwartz CL, 2003, CURR OPIN PEDIATR, V15, P10, DOI 10.1097/00008480-200302000-00003; SHAMBERGER RC, 2002, PRINCIPLES PRACTICE, P351; SIM FH, 1987, CLIN ORTHOP RELAT R, P188; Sklar C, 2002, J PEDIATR ENDOCR MET, V15, P669; Sklar CA, 2000, UROL CLIN N AM, V27, P563, DOI 10.1016/S0094-0143(05)70103-8; SMITH MA, 2002, PRINCIPLES PRACTICE, P1; Smith Malcolm, 2004, J Pediatr Oncol Nurs, V21, P160, DOI 10.1177/1043454204264407; Springfield DS, 1997, SEMIN SURG ONCOL, V13, P11, DOI 10.1002/(SICI)1098-2388(199701/02)13:1<11::AID-SSU3>3.3.CO;2-L; TARBELL NJ, 2002, PRINCIPLES PRACTICE, P369; van den Berg Hendrik, 2003, Cancer Chemother Biol Response Modif, V21, P683; WHO, 2002, WHOEIPGPECAS013; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	67	232	234	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2005	143	9					639	647		10.7326/0003-4819-143-9-200511010-00007	http://dx.doi.org/10.7326/0003-4819-143-9-200511010-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980PN	16263886				2023-01-03	WOS:000233030600003
J	Collins, ED; Kleber, HD; Whittington, RA; Heitler, NE				Collins, ED; Kleber, HD; Whittington, RA; Heitler, NE			Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RAPID OPIATE DETOXIFICATION; ULTRARAPID OPIOID DETOXIFICATION; GENERAL-ANESTHESIA; FOLLOW-UP; INPATIENT DETOXIFICATION; WITHDRAWAL SYMPTOMS; SYSTEMATIC REVIEWS; ADDICTED PATIENTS; DEEP SEDATION; MAINTENANCE	Context Rapid opioid detoxification with opioid antagonist induction using general anesthesia has emerged as an expensive, potentially dangerous, unproven approach to treat opioid dependence. Objective To determine how anesthesia-assisted detoxification with rapid antagonist induction for heroin dependence compared with 2 alternative detoxification and antagonist induction methods. Design, Setting, and Patients A total of 106 treatment-seeking heroin-dependent patients, aged 21 through 50 years, were randomly assigned to 1 of 3 inpatient withdrawal treatments over 72 hours followed by 12 weeks of outpatient naltrexone maintenance with relapse prevention psychotherapy. This randomized trial was conducted between 2000 and 2003 at Columbia University Medical Center's Clinical Research Center. Outpatient treatment occurred at the Columbia University research service for substance use disorders. Patients were included if they had an American Society of Anesthesiologists physical status of I or 11, were without major comorbid psychiatric illness, and were not dependent on other drugs or alcohol. Interventions Anesthesia-assisted rapid opioid detoxification with naltrexone induction, buprenorphine-assisted rapid opioid detoxification with naltrexone induction, and clonidine-assisted opioid detoxification with delayed naltrexone induction. Main Outcome Measures Withdrawal severity scores on objective and subjective scales; proportions of patients receiving naltrexone, completing inpatient detoxification, and retained in treatment; proportion of opioid-positive urine specimens. Results Mean withdrawal severities were comparable across the 3 treatments. Compared with clonidine-assisted detoxification, the anesthesia- and buprenorphine-assisted detoxification interventions had significantly greater rates of naltrexone induction (94% anesthesia, 97% buprenorphine, and 21 % clonidine), but the groups did not differ in rates of completion of inpatient detoxification. Treatment retention over 12 weeks was not significantly different among groups with 7 of 35 (20%) retained in the anesthesia-assisted group, 9 of 37 (24%) in the buprenorphine-assisted group, and 3 of 34 (9%) in the clonidine-assisted group. Induction with 50 mg of naltrexone significantly reduced the risk of dropping out (odds ratio, 0.28; 95% confidence interval, 0.15-0.51). There were no significant group differences in proportions of opioid-positive urine specimens. The anesthesia procedure was associated with 3 potentially life-threatening adverse events. Conclusion These data do not support the use of general anesthesia for heroin detoxification and rapid opioid antagonist induction.	Columbia Univ, Coll Phys & Surg, Div Subst Abuse, Dept Psychiat, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Div Subst Abuse, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Anesthesiol, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute; Columbia University	Collins, ED (corresponding author), Columbia Univ, Coll Phys & Surg, Div Subst Abuse, Dept Psychiat, 1051 Riverside Dr,Unit 120, New York, NY 10032 USA.	edc3@columbia.edu			NCRR NIH HHS [M01-RR-00645] Funding Source: Medline; NIDA NIH HHS [DA-00317, DA-12644, DA-14284] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012644, K05DA014284] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Albanese AP, 2000, J ADDICT DIS, V19, P11, DOI 10.1300/J069v19n02_02; Ali R, 2003, DRUG ALCOHOL REV, V22, P425, DOI 10.1080/09595230310001613949; Amato L, 2005, J SUBST ABUSE TREAT, V28, P321, DOI 10.1016/j.jsat.2005.02.007; Amato L, 2004, DRUG ALCOHOL DEPEN, V73, P219, DOI 10.1016/j.drugalcdep.2003.11.002; Bartter T, 1996, AM J DRUG ALCOHOL AB, V22, P489, DOI 10.3109/00952999609001675; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Bell JR, 1999, MED J AUSTRALIA, V171, P26, DOI 10.5694/j.1326-5377.1999.tb123493.x; Berger VW, 1999, CONTROL CLIN TRIALS, V20, P319, DOI 10.1016/S0197-2456(99)00014-8; Brewer C, 1999, HOSP MED, V60, P70; BREWER C, 1988, BRIT J PSYCHIAT, V153, P340, DOI 10.1192/bjp.153.3.340; Brewer C, 1997, ADDICT BIOL, V2, P291, DOI 10.1080/13556219772589; BREWER C, 1997, BR J INTENS CARE, P138; Carnwath T, 1998, DRUG ALCOHOL DEPEN, V50, P251, DOI 10.1016/S0376-8716(98)00040-4; Carreno JE, 2002, ADDICT BIOL, V7, P243, DOI 10.1080/135562102200120479; CARROLL KM, 1991, AM J DRUG ALCOHOL AB, V17, P249, DOI 10.3109/00952999109027550; Comer SD, 2001, PSYCHOPHARMACOLOGY, V154, P28, DOI 10.1007/s002130000623; Cucchia AT, 1998, DRUG ALCOHOL DEPEN, V52, P243, DOI 10.1016/S0376-8716(98)00100-8; Elman I, 2001, DRUG ALCOHOL DEPEN, V61, P163, DOI 10.1016/S0376-8716(00)00139-3; Gold CG, 1999, ANESTHESIOLOGY, V91, P1639, DOI 10.1097/00000542-199912000-00015; Golden SA, 2004, J ADDICT DIS, V23, P65, DOI 10.1300/J069v23n01_06; GONZALEZ JP, 1988, DRUGS, V35, P192, DOI 10.2165/00003495-198835030-00002; GOSSOP M, 1986, BRIT MED J, V293, P103, DOI 10.1136/bmj.293.6539.103; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hamilton RJ, 2002, ACAD EMERG MED, V9, P63, DOI 10.1197/aemj.9.1.63; HANDELSMAN L, 1987, AM J DRUG ALCOHOL AB, V13, P293, DOI 10.3109/00952998709001515; Heatherton B, 2000, J ADDICT DIS, V19, P109, DOI 10.1300/J069v19n02_09; Hensel M, 2000, BRIT J ANAESTH, V84, P236, DOI 10.1093/oxfordjournals.bja.a013408; Hoffman WE, 1998, J NEUROSURG ANESTH, V10, P205; Hoffman WE, 1998, J CLIN ANESTH, V10, P372, DOI 10.1016/S0952-8180(98)00047-6; Justins D, 1998, HOSP MED, V59, P180; Kaye AD, 2003, CAN J ANAESTH, V50, P663, DOI 10.1007/BF03018708; KELMAN HARVEY, 1964, MINN MED, V47, P525; Kienbaum P, 1998, ANESTHESIOLOGY, V88, P1154, DOI 10.1097/00000542-199805000-00004; Kienbaum P, 2000, CRIT CARE MED, V28, P969, DOI 10.1097/00003246-200004000-00010; KLEBER HD, 1982, J CLIN PSYCHIAT, V43, P30; KLEBER HD, 1985, ARCH GEN PSYCHIAT, V42, P391; Kleber HD, 1998, ADDICTION, V93, P1629; Kolb L, 1938, AM J PSYCHIAT, V94, P759, DOI 10.1176/ajp.94.4.759; Krabbe PFM, 2003, ADDICT BIOL, V8, P351, DOI 10.1080/13556210310001602275; Lawental E, 2000, J SUBST ABUSE, V11, P173, DOI 10.1016/S0899-3289(00)00019-5; Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033; LOIMER N, 1990, BRIT J PSYCHIAT, V157, P748, DOI 10.1192/bjp.157.5.748; McGregor C, 2002, DRUG ALCOHOL DEPEN, V68, P5, DOI 10.1016/S0376-8716(02)00077-7; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; METZGER DS, 1993, J ACQ IMMUN DEF SYND, V6, P1049; NEWMAN MK, 1941, ARCH PHYSL THER, V22, P161; O'Connor PG, 1998, JAMA-J AM MED ASSOC, V279, P229, DOI 10.1001/jama.279.3.229; OBRIEN CP, 2004, TXB SUBSTANCE ABUSE; OConnor PG, 1997, ANN INTERN MED, V127, P526, DOI 10.7326/0003-4819-127-7-199710010-00004; Office of National Drug Control Policy, 2004, NAT DRUG CONTR STRAT; PEACHEY JE, 1988, BRIT J ADDICT, V83, P193; Pfab R, 1999, J TOXICOL-CLIN TOXIC, V37, P43, DOI 10.1081/CLT-100102407; PRESSLICH O, 1989, J TOXICOL-CLIN TOXIC, V27, P263, DOI 10.3109/15563658908994422; Rabinowitz J, 1998, PSYCHIATR SERV, V49, P831, DOI 10.1176/ps.49.6.831; Rabinowitz J, 2002, AM J ADDICTION, V11, P52, DOI 10.1080/10550490252801639; Rabinowitz J, 1997, DRUG ALCOHOL DEPEN, V47, P77, DOI 10.1016/S0376-8716(97)00073-2; Rothenberg JL, 2002, J SUBST ABUSE TREAT, V23, P351, DOI 10.1016/S0740-5472(02)00301-X; SAN L, 1995, AM J PSYCHIAT, V152, P956; Shreeram SS, 2001, AM J PSYCHIAT, V158, P970, DOI 10.1176/appi.ajp.158.6.970; Simon DL, 1997, J ADDICT DIS, V16, P103, DOI 10.1300/J069v16n01_07; Spanagel R, 1998, DRUG ALCOHOL DEPEN, V52, P251, DOI 10.1016/S0376-8716(98)00106-9; Spanagel R, 1999, LANCET, V354, P2017, DOI 10.1016/S0140-6736(99)90248-9; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P363, DOI 10.1001/jama.277.5.363; Strang J, 1997, BRIT MED J, V315, P1249, DOI 10.1136/bmj.315.7118.1249; *SUBST AB MENT HLT, 2004, NAT SURV SUBST AB TR; Tillim SJ, 1942, AM J PSYCHIAT, V99, P84, DOI 10.1176/ajp.99.1.84; Tornay CB, 2003, DRUG ALCOHOL DEPEN, V69, P283, DOI 10.1016/S0376-8716(02)00326-5; Tretter F, 1998, ADDICTION, V93, P269, DOI 10.1046/j.1360-0443.1998.93226910.x; Umbricht A, 1999, DRUG ALCOHOL DEPEN, V56, P181, DOI 10.1016/S0376-8716(99)00033-2; WANG RIH, 1974, CLIN PHARMACOL THER, V16, P653; Whittington RA, 2000, ANESTHESIOLOGY, V93, P1363, DOI 10.1097/00000542-200011000-00039	71	90	91	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	2005	294	8					903	913		10.1001/jama.294.8.903	http://dx.doi.org/10.1001/jama.294.8.903			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957JM	16118380	Bronze			2023-01-03	WOS:000231366100020
J	Kinra, S; Lewendon, G; Nelder, R; Herriott, N; Mohan, R; Hort, M; Harrison, S; Murray, V				Kinra, S; Lewendon, G; Nelder, R; Herriott, N; Mohan, R; Hort, M; Harrison, S; Murray, V			Evacuation decisions in a chemical air pollution incident: cross sectional survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To compare the health outcomes in sheltered and evacuated populations after a chemical incident in a plastics factory. Design Cross sectional survey. Setting Urban area in southwest England. Participants 1750 residents from the area exposed to the chemical smoke, of which 472 were evacuated and the remaining 1278 were advised to shelter indoors. Main outcome measure Number of adverse health symptoms. A case was defined by the presence of four or more symptoms. Main results 1096 residents (63%; 299 evacuated, 797 sheltered) provided data for analyses. The mean symptom score and proportion of cases were higher in evacuated people than in the sheltered population (evacuated: symptom score 1.9, cases 19.7% (n=59); sheltered: symptom score 1.0, cases 9.5% (n=76); P<0.001 for both). The difference between the two groups attenuated markedly at the end of two weeks from the start of the incident. The two main modifiable risk factors for the odds of becoming a case were evacuation (odds ratio 2.5, 95% confidence interval 1.7 to 3.8) and direct exposure to smoke for more than two hours on the first day of the incident (2.0, 1.7 to 2.3). The distance of residence from the factory or level of exposure before intervention (first six hours) had little effect on the odds of a person becoming a case. Conclusions Sheltering may have been a better protective action than evacuation in this chemical incident, which is consistent with the prevailing expert view. Although this study has limitations, it is based oil a real event. Evacuations carry their own risks and resource implications; increased awareness may help to reduce unnecessary evacuations in the future.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Plymouth Teaching Primary Care Trust, Publ Hlth Dev Unit, Plymouth PL1 2AD, Devon, England; Guys & St Thomas Hosp Trust, Hlth Protect Agcy, Chem Hazards Unit, London SE14 5ER, England; SW Peninsula Hlth Protect Unit, Devon Team, Dartington TQ9 6JE, England	University of Bristol; University of Plymouth; Guy's & St Thomas' NHS Foundation Trust; Health Protection Agency	Kinra, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	Sanjay.Kinra@bristol.ac.uk						Bauer U, 1998, PUBLIC HEALTH REP, V113, P62; BAXTER PJ, 1995, OCCUP ENVIRON MED, V52, P694, DOI 10.1136/oem.52.10.694; BOFFETTA P, 1993, SCAND J WORK ENV HEA, V19, P67; DAYAL HH, 1994, J EPIDEMIOL COMMUN H, V48, P560, DOI 10.1136/jech.48.6.560; ESSERY G, 1994, SAFETY HLTH PRACTITI, V12, P22; ESSERY GL, 1991, J LOSS PREVENT PROC, V4, P44, DOI 10.1016/0950-4230(91)80006-G; Fiedler N, 1999, ENVIRON HEALTH PERSP, V107, P343, DOI 10.2307/3434537; GRAY J, 1981, J HAZARD MATER, V4, P357, DOI 10.1016/0304-3894(81)87006-9; JONES A, 2004, UK MET OFFICES NEXT, V3; JONES A, 2004, IN PRESS UK MET OFFI, V3; KIZER KW, 1984, J OCCUP ENVIRON MED, V26, P33, DOI 10.1097/00043764-198401000-00008; MORRIS RD, 1997, HUMAN HLTH EFFECTS S; *NAT TRANSP, 1983, RAILR ACC REP DER IL; *NAT TRANSP SAF BO, 1983, RAILR ACC REP DER IL; *NHS EX, 2000, DEL REL BIOL CHEM AG; PURDY G, 1985, ASSESSMENT CONTROL M; REGGIANI G, 1978, ARCH TOXICOL, V40, P161, DOI 10.1007/BF00364649; SORENSEN JH, 1987, J HAZARD MATER, V14, P247, DOI 10.1016/0304-3894(87)87017-6; Williams FLR, 2002, OCCUP ENVIRON MED, V59, P2, DOI 10.1136/oem.59.1.2	19	13	13	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 25	2005	330	7506					1471	1474		10.1136/bmj.330.7506.1471	http://dx.doi.org/10.1136/bmj.330.7506.1471			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942NR	15976419	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000230289600015
J	Mahawar, KK				Mahawar, KK			Misguided enthusiasm	LANCET			English	Editorial Material									Arrowe Pk Hosp, Wirral CH49 5PE, Merseyside, England		Mahawar, KK (corresponding author), Arrowe Pk Hosp, Wirral CH49 5PE, Merseyside, England.	kamal_mahawat@hotmail.com	Mahawar, Kamal/L-1884-2019	Mahawar, Kamal/0000-0003-2551-3462					0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	2005	365	9474					1901	1901		10.1016/S0140-6736(05)66624-X	http://dx.doi.org/10.1016/S0140-6736(05)66624-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924989				2023-01-03	WOS:000229481400031
J	Ward, H; Cassell, J; Williams, S; Aylin, P				Ward, H; Cassell, J; Williams, S; Aylin, P			Dr Foster's case notes - Hospital indicators of poor sexual health	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England	Imperial College London	Ward, H (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England.		Ward, Helen/A-1836-2009; Aylin, Paul/A-1073-2014	Ward, Helen/0000-0001-8238-5036; Aylin, Paul/0000-0003-4589-1743; Cassell, Jackie/0000-0003-0777-0385				Department of Health, 2004, CHOOS HLTH MAK HLTH; Simms I, 2005, SEX TRANSM DIS, V32, P220, DOI 10.1097/01.olq.0000149848.03733.c1; Sowter MC, 2001, BRIT J OBSTET GYNAEC, V108, P204, DOI 10.1111/j.1471-0528.2001.00037.x; 2004, FOCUS PREVENTION HIV	4	2	2	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAY 21	2005	330	7501					1173	+		10.1136/bmj.330.7501.1173	http://dx.doi.org/10.1136/bmj.330.7501.1173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929CU	15905255	Green Published			2023-01-03	WOS:000229320500014
J	Brain, EGC; Bachelot, T; Serin, D; Kirscher, S; Graic, Y; Eymard, JC; Extra, JM; Combe, M; Fourme, E; Nogues, C; Rouesse, J				Brain, EGC; Bachelot, T; Serin, D; Kirscher, S; Graic, Y; Eymard, JC; Extra, JM; Combe, M; Fourme, E; Nogues, C; Rouesse, J		RAPP-01 Trial Investigators	Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	40th Annual Meeting of the American-Society-of-Clinical-Oncology	JUN 05-08, 2004	New Orleans, LA	Amer Soc Clin Oncol			CHEMOTHERAPY; CYCLOPHOSPHAMIDE; TRIAL; RECOMMENDATIONS; MULTICENTER; PACLITAXEL; THERAPY; COLITIS; REGIMEN	Context Adjuvant chemotherapy with new cytotoxic agents for breast cancer must be properly assessed for toxicity. Objective To describe adverse events associated with adjuvant chemotherapy for breast cancer, which led to premature termination of a clinical trial. Design, Setting, and Patients We conducted a prospective randomized multicenter study (Reposant sur des Arguments Pronostiques et Predictifs [RAPP]-01) to compare the effectiveness of 2 chemotherapy regimens. Patients (women aged 18-70 years) had primary unilateral breast cancer and either a moderate number of positive axillary lymph nodes (:53) or no positive axillary lymph nodes (NO), but were at a high risk of relapse. Patients were treated at 11 French cancer referral centers from June 1999 through January 2003. Primary prophylaxis for febrile neutropenia was not recommended in the study protocol. Interventions Doxorubicin, 50 mg/m(2), plus docetaxel, 75 mg/m(2), or doxorubicin, 60 mg/m(2), plus cyclophosphamide, 600 mg/m(2), given postoperatively for 4 courses. Main Outcome Measures The main end point was the disease-free survival rate at 5 years, as estimated using the Kaplan-Meier product limit method. Secondary end points included safety, which is the focus of this article, and overall survival. Results A total of 627 women were enrolled. Median follow-up is currently too short (24 months) to analyze the primary end point. The trial was terminated prematurely when 2 deaths related to drug toxicity and 1 case of perforative peritonitis occurred among patients with febrile neutropenia, all in the doxorubicin-docetaxel group. The incidence of febrile neutropenia was significantly higher with the doxorubicin-docetaxel regimen (40.8%) than with the doxorubicin-cyclophosphamide regimen (7.1 %) (P<.001). Conclusions A high risk of life-threatening complications associated with the doxorubicin-docetaxel regimen was found in this open-label controlled trial. The doxorubicin-docetaxel combination should not be considered as an alternative to the doxorubicin-cyclophosphamide regimen outside carefully designed studies that include primary prophylaxis for febrile neutropenia.	Rene Huguenin Canc Ctr, Dept Med Oncol, F-92210 St Cloud, France; Rene Huguenin Canc Ctr, Dept Biostat, F-92210 St Cloud, France; Leon Berard Canc Ctr, Dept Med Oncol, Lyon, France; St Catherine Inst Breast Clin, Avignon, France; Henri Becquerel Canc Ctr, Dept Radiotherapy, Rouen, France; Jean Godinot Canc Ctr, Dept Med Oncol, Reims, France; Inst Curie, Dept Med Oncol, Paris, France; Ctr Hosp Mans, Dept Med, Le Mans, France	Rene Huguenin Hospital; Rene Huguenin Hospital; UNICANCER; Centre Leon Berard; UNICANCER; Centre Henri Becquerel; UNICANCER; Institut Jean Godinot; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre Hospitalier Le Mans	Brain, EGC (corresponding author), Rene Huguenin Canc Ctr, Dept Med Oncol, 35 Rue Dailly, F-92210 St Cloud, France.	e.brain@stcloud-huguenin.org						Adenis A, 2001, J CLIN ONCOL, V19, P602, DOI 10.1200/JCO.2001.19.3.602; Bear HD, 2003, J CLIN ONCOL, V21, P4165, DOI 10.1200/JCO.2003.12.005; Blay JY, 2000, PRESSE MED, V29, P2004; Cardoso F, 2002, CANCER TREAT REV, V28, P275, DOI 10.1016/S0305-7372(02)00091-9; Fisher B, 2001, J CLIN ONCOL, V19, P931, DOI 10.1200/JCO.2001.19.4.931; Fumoleau P, 2003, J CLIN ONCOL, V21, P1190, DOI 10.1200/JCO.2003.99.223; Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Ibrahim NK, 2000, LANCET, V355, P281, DOI 10.1016/S0140-6736(99)06195-4; Jassem J, 2001, J CLIN ONCOL, V19, P1707, DOI 10.1200/JCO.2001.19.6.1707; Li ZY, 2004, CANCER-AM CANCER SOC, V101, P1508, DOI 10.1002/cncr.20546; MACKEY JR, 2001, P AN M AM SOC CLIN, V20, pA10; MAMOUNAS EP, 2003, P AN M AM SOC CLIN, V22, P4; MARTIN M, 2004, P AN M AM SOC CLIN, V23, P32; Misset JL, 1999, ANN ONCOL, V10, P553, DOI 10.1023/A:1026418831238; Nabholtz JM, 2003, J CLIN ONCOL, V21, P968, DOI 10.1200/JCO.2003.04.040; Nabholtz JM PT, 2002, P AN M AM SOC CLIN, V21, p36a; *NAT CANC I, COMM TOX CRIT VERS 2; Nowak AK, 2004, LANCET ONCOL, V5, P372, DOI 10.1016/S1470-2045(04)01494-9; Ozer H, 2000, J CLIN ONCOL, V18, P3558, DOI 10.1200/JCO.2000.18.20.3558; Stollman N, 2004, LANCET, V363, P631, DOI 10.1016/S0140-6736(04)15597-9; TALCOTT JA, 1992, J CLIN ONCOL, V10, P316, DOI 10.1200/JCO.1992.10.2.316	22	40	42	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2367	2371		10.1001/jama.293.19.2367	http://dx.doi.org/10.1001/jama.293.19.2367			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926JX	15900007				2023-01-03	WOS:000229120600024
J	Hayden, JA; van Tulder, MW; Malmivaara, AV; Koes, BW				Hayden, JA; van Tulder, MW; Malmivaara, AV; Koes, BW			Meta-analysis: Exercise therapy for nonspecific low back pain	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; 3 ACTIVE THERAPIES; 2-YEAR FOLLOW-UP; CLINICAL-TRIAL; CONSERVATIVE TREATMENT; FUNCTIONAL RESTORATION; PHYSICAL-THERAPY; GRADED ACTIVITY; CONVENTIONAL PHYSIOTHERAPY; PROPHYLACTIC MANAGEMENT	Background: Exercise therapy is widely used as an intervention in low back pain. Objective: To evaluate the effectiveness of exercise therapy in adult nonspecific acute, subacute, and chronic low back pain versus no treatment and other conservative treatments. Data Sources: MEDLINE, EMBASE, Psychinfo, CINAHL, and Cochrane Library databases to October 2004; citation searches and bibliographic reviews of previous systematic reviews. Study Selection: Randomized, controlled trials evaluating exercise therapy for adult nonspecific low back pain and measuring pain, function, return to work or absenteeism, and global improvement outcomes. Data Extraction: Two reviewers independently selected studies and extracted data on study characteristics, quality, and outcomes at short-, intermediate-, and long-term follow-up. Data Synthesis: 61 randomized, controlled trials (6390 participants) met inclusion criteria: acute (11 trials), subacute (6 trials), and chronic (43 trials) low back pain (1 trial was unclear). Evidence suggests that exercise therapy is effective in chronic back pain relative to comparisons at all follow-up periods. Pooled mean improvement (of 100 points) was 7.3 points (95% Cl, 3.7 to 10.9 points) for pain and 2.5 points (Cl, 1.0 to 3.9 points) for function at earliest follow-up. In studies investigating patients (people seeking care for back pain), mean improvement was 13.3 points (Cl, 5.5 to 21.1 points) for pain and 6.9 points (Cl, 2.2 to 11.7 points) for function, compared with studies where some participants had been recruited from a general population (for example, with advertisements). Some evidence suggests effectiveness of a graded-activity exercise program in subacute low back pain in occupational settings, although the evidence for other types of exercise therapy in other populations is inconsistent. In acute low back pain, exercise therapy and other programs were equally effective (pain, 0.03 point [Cl, -1.3 to 1.4 points]). Limitations: Limitations of the literature, including low-quality studies with heterogeneous outcome measures inconsistent and poor reporting, and possibility of publication bias. Conclusions: Exercise therapy seems to be slightly effective at decreasing pain and improving function in adults with chronic low back pain, particularly in health care populations. In subacute low back pain populations, some evidence suggests that a graded-activity program improves absenteeism outcomes, although evidence for other types of exercise is unclear. In acute low back pain populations, exercise therapy is as effective as either no treatment or other conservative treatments.	Inst Work & Hlth, Toronto, ON M5G 2E9, Canada; Univ Toronto, Toronto, ON, Canada; Vrije Univ Amsterdam, Inst Res Extramural Med, NL-1081 HV Amsterdam, Netherlands; Natl Res & Dev Ctr Welf & Hlth, Finnish Off Hlth Care Technol Assessment, Helsinki, Finland; Erasmus Univ, Med Ctr, Rotterdam, Netherlands	Institute for Work & Health; University of Toronto; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC	Hayden, JA (corresponding author), Inst Work & Hlth, 481 Univ Ave,Suite 800,8th Floor, Toronto, ON M5G 2E9, Canada.	jhayden@iwh.on.ca	van Tulder, Maurits/AAB-9785-2022; Koes, Bart w/K-4614-2016	van Tulder, Maurits/0000-0002-7589-8471; Koes, Bart w/0000-0002-0450-9969; Hayden, Jill Alison/0000-0001-7026-144X				Abenhaim L, 2000, SPINE, V25, p1S, DOI 10.1097/00007632-200002151-00001; Albright J, 2001, PHYS THER, V81, P1641; Alexandre NMC, 2001, REV SAUDE PUBL, V35, P356, DOI 10.1590/S0034-89102001000400004; Aure OF, 2003, SPINE, V28, P525, DOI 10.1097/00007632-200303150-00002; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bendix A F, 1995, Eur Spine J, V4, P148, DOI 10.1007/BF00298239; Bendix AF, 1998, SPINE, V23, P717, DOI 10.1097/00007632-199803150-00013; Bendix AF, 1997, SCAND J REHABIL MED, V29, P81; Bendix T, 2000, SPINE, V25, P2494, DOI 10.1097/00007632-200010010-00012; Bentsen H, 1997, SPINE, V22, P1494, DOI 10.1097/00007632-199707010-00014; Bombardier C, 2001, J RHEUMATOL, V28, P431; Bronfort G, 1996, J Manipulative Physiol Ther, V19, P570; BUSWELL J, 1982, NZ J PHYSIOTHER, V10, P13; Calmels P., 2004, Annales de Readaptation et de Medecine Physique, V47, P20, DOI 10.1016/j.annrmp.2003.07.001; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Chok B, 1999, PHYS THER, V79, P1032, DOI 10.1093/ptj/79.11.1032; Dalichau S, 2000, Z ORTHOP GRENZGEB, V138, P8, DOI 10.1055/s-2000-10106; DAVIES JE, 1979, RHEUMATOL REHABIL, V18, P243, DOI 10.1093/rheumatology/18.4.243; DELITTO A, 1993, PHYS THER, V73, P216, DOI 10.1093/ptj/73.4.216; DELITTO A, 1993, PHYS THER, V73, P226, DOI 10.1093/ptj/73.4.226; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Descarreaux M, 2002, J MANIP PHYSIOL THER, V25, P497, DOI 10.1067/mmt.2002.127078; DEYO RA, 1990, NEW ENGL J MED, V322, P1627, DOI 10.1056/NEJM199006073222303; Deyo RA, 1998, SPINE, V23, P2003, DOI 10.1097/00007632-199809150-00018; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; ELNAGGAR IM, 1991, SPINE, V16, P967, DOI 10.1097/00007632-199108000-00018; Ernst E, 2003, FORSCH KOMP KLAS NAT, V10, P325, DOI 10.1159/000075886; EVANS C, 1987, Physiotherapy Canada, V39, P96; FAAS A, 1995, SPINE, V20, P941, DOI 10.1097/00007632-199504150-00012; FAAS A, 1993, SPINE, V18, P1388; FARRELL JP, 1982, MED J AUSTRALIA, V1, P160, DOI 10.5694/j.1326-5377.1982.tb132242.x; Frost H, 2004, BRIT MED J, V329, P708, DOI 10.1136/bmj.38216.868808.7C; Frost H, 1998, PAIN, V75, P273, DOI 10.1016/S0304-3959(98)00005-0; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; Galantino ML, 2004, ALTERN THER HEALTH M, V10, P56; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; Glomsrod B, 2001, J REHABIL MED, V33, P26; Gur A, 2003, LASER SURG MED, V32, P233, DOI 10.1002/lsm.10134; HANSEN FR, 1993, SPINE, V18, P98, DOI 10.1097/00007632-199301000-00015; Hayden JA, 2005, ANN INTERN MED, V142, P776, DOI 10.7326/0003-4819-142-9-200505030-00014; Hemmila HM, 1997, ARCH PHYS MED REHAB, V78, P571, DOI 10.1016/S0003-9993(97)90420-2; Hemmila HM, 2002, J MANIP PHYSIOL THER, V25, P99, DOI 10.1067/mmt.2002.122329; Hides J A, 2001, Spine (Phila Pa 1976), V26, pE243, DOI 10.1097/00007632-200106010-00004; Hides JA, 1996, SPINE, V21, P2763, DOI 10.1097/00007632-199612010-00011; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; HILDE G, 1998, PHYS THER REV, V3, P107; Hildebrandt V H, 2000, Ned Tijdschr Geneeskd, V144, P2258; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JOHANNSEN F, 1995, J ORTHOP SPORT PHYS, V22, P52, DOI 10.2519/jospt.1995.22.2.52; Jousset N, 2004, SPINE, V29, P487, DOI 10.1097/01.BRS.0000102320.35490.43; Kankaanpaa M, 1999, SPINE, V24, P1034, DOI 10.1097/00007632-199905150-00019; Kendall PH, 1968, PHYSIOTHERAPY, V54, P154; Kool J, 2004, J REHABIL MED, V36, P49, DOI 10.1080/16501970310020104; Kopec JA, 2000, SPINE, V25, P3110, DOI 10.1097/00007632-200012150-00005; Kuukkanen TM, 2000, CLIN REHABIL, V14, P192, DOI 10.1191/026921500667300454; Liddle SD, 2004, PAIN, V107, P176, DOI 10.1016/j.pain.2003.10.017; Lidstrom A, 1970, Scand J Rehabil Med, V2, P37; Lie Hakon, 1999, Tidsskrift for den Norske Laegeforening, V119, P2051; LINDSTROM I, 1992, SPINE, V17, P641, DOI 10.1097/00007632-199206000-00003; LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/ptj/72.4.279; LINDSTROM I, 1994, THESIS GOTEBERG SWED; Ljunggren AE, 1997, SPINE, V22, P1610, DOI 10.1097/00007632-199707150-00017; Lonn JH, 1999, SPINE, V24, P865, DOI 10.1097/00007632-199905010-00006; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; MANNICHE C, 1988, LANCET, V2, P1473; MANNICHE C, 1991, PAIN, V47, P53, DOI 10.1016/0304-3959(91)90011-L; Mannion AF, 1999, SPINE, V24, P2435, DOI 10.1097/00007632-199912010-00004; Mannion AF, 2001, SPINE, V26, P920, DOI 10.1097/00007632-200104150-00015; Mannion AF, 2001, RHEUMATOLOGY, V40, P772, DOI 10.1093/rheumatology/40.7.772; Moffett JK, 1999, BRIT MED J, V319, P279, DOI 10.1136/bmj.319.7205.279; Moseley L, 2002, AUST J PHYSIOTHER, V48, P297, DOI 10.1016/S0004-9514(14)60169-0; Niemisto L, 2003, SPINE, V28, P2185, DOI 10.1097/01.BRS.0000085096.62603.61; Pengel HM, 2002, CLIN REHABIL, V16, P811, DOI 10.1191/0269215502cr562oa; Petersen T, 2002, SPINE, V27, P1702, DOI 10.1097/00007632-200208150-00004; Preyde M, 2000, CAN MED ASSOC J, V162, P1815; Rasmussen-Barr E, 2003, MANUAL THER, V8, P233, DOI 10.1016/S1356-689X(03)00053-5; RISCH SV, 1993, SPINE, V18, P232, DOI 10.1097/00007632-199302000-00010; Rittweger J, 2002, SPINE, V27, P1829, DOI 10.1097/00007632-200209010-00003; Salaffi F, 2004, EUR J PAIN, V8, P283, DOI 10.1016/j.ejpain.2003.09.004; Seferlis T, 1998, Eur Spine J, V7, P461; Seferlis T, 2000, SCAND J PRIM HEALTH, V18, P53; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Soukup M G, 2001, Physiother Res Int, V6, P27, DOI 10.1002/pri.211; Soukup MG, 1999, SPINE, V24, P1585, DOI 10.1097/00007632-199908010-00013; Staal JB, 2004, ANN INTERN MED, V140, P77, DOI 10.7326/0003-4819-140-2-200401200-00007; STANKOVIC R, 1995, SPINE, V20, P469, DOI 10.1097/00007632-199502001-00010; STANKOVIC R, 1990, SPINE, V15, P120, DOI 10.1097/00007632-199002000-00014; Storheim K, 2003, J REHABIL MED, V35, P132, DOI 10.1080/16501970310010484; Torstensen TA, 1998, SPINE, V23, P2616, DOI 10.1097/00007632-199812010-00017; Tritilanunt Tipawan, 2001, Journal of the Medical Association of Thailand, V84, pS528; TURNER JA, 1990, J CONSULT CLIN PSYCH, V58, P573, DOI 10.1037/0022-006X.58.5.573; Underwood MR, 1998, FAM PRACT, V15, P9, DOI 10.1093/fampra/15.1.9; van Tulder M, 2000, SPINE, V25, P2784, DOI 10.1097/00007632-200011010-00011; van Tulder M, 2003, SPINE, V28, P1290, DOI 10.1097/01.BRS.0000065484.95996.AF; Von Korff M, 2000, SPINE, V25, P3140, DOI 10.1097/00007632-200012150-00009; Waddell G, 1997, BRIT J GEN PRACT, V47, P647; WATERWORTH RF, 1985, NEW ZEAL MED J, V98, P372; Yelland MJ, 2004, SPINE, V29, P9, DOI 10.1097/01.BRS.0000105529.07222.5B; Yeung CKN, 2003, J ALTERN COMPLEM MED, V9, P479, DOI 10.1089/107555303322284767; Yozbatiran Nuray, 2004, Pain Clinic, V16, P35, DOI 10.1163/156856904322858684; ZYLBERGOLD RS, 1981, ARCH PHYS MED REHAB, V62, P176	101	352	371	2	57	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 3	2005	142	9					765	775		10.7326/0003-4819-142-9-200505030-00013	http://dx.doi.org/10.7326/0003-4819-142-9-200505030-00013			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	922GW	15867409	Green Published			2023-01-03	WOS:000228825800006
J	Feudtner, C				Feudtner, C			Control of suffering on the slippery slope of care	LANCET			English	Editorial Material							PHYSICIANS; ATTITUDES; EUTHANASIA		Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia	Feudtner, C (corresponding author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.	feudtner@email.chop.edu	Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434				CARTER B, 2004, PALLIATIVE CARE INFA; Cuttini M, 2000, LANCET, V355, P2112, DOI 10.1016/S0140-6736(00)02378-3; De Vries R, 2003, B HIST MED, V77, P752, DOI 10.1353/bhm.2003.0146; Ganzini L, 2001, JAMA-J AM MED ASSOC, V285, P2363, DOI 10.1001/jama.285.18.2363; Gardner H., 2006, CHANGING MINDS ART S; Milstein Jay M, 2003, J Perinatol, V23, P333, DOI 10.1038/sj.jp.7210903; Pernick M., 1996, BLACK STORK EUGENICS; Ryynanen OP, 2002, PUBLIC HEALTH, V116, P322, DOI 10.1038/sj.ph.1900875; Saigal S, 1999, JAMA-J AM MED ASSOC, V281, P1991, DOI 10.1001/jama.281.21.1991; THOMASMA DC, 1998, ASKING DIE INSIDE DU; Wolfe J, 1999, J CLIN ONCOL, V17, P1274, DOI 10.1200/JCO.1999.17.4.1274	11	7	7	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1284	1286		10.1016/S0140-6736(05)61004-5	http://dx.doi.org/10.1016/S0140-6736(05)61004-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823363				2023-01-03	WOS:000228219600005
J	Back, AL; Arnold, RM				Back, AL; Arnold, RM			Dealing with conflict in caring for the seriously ill - "It was just out of the question"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; DOCTOR-NURSE GAME; INTERPERSONAL CONFLICTS; PROLONGED STAY; CRITICALLY-ILL; FOLLOW-UP; COMMUNICATION; LIFE; PHYSICIANS; END	Physicians often assume that conflict is undesirable and destructive, yet conflict handled Well can be productive, and the clarity that results can lead to clearer decision making and greater family, patient, and clinician satisfaction. We review the course of Mrs B, an 84-year-old woman with advanced dementia and an advance directive stating no artificial hydration or nutrition. Over the course of her illness, her family and physicians had conflicting opinions about the use of short-term tube feeding and intravenous hydration in her care. We describe the conflicts that arose between her physicians and family and a typology of conflicts common in care of patients who are seriously ill (family vs team, team member vs team member). Drawing from the business, psychology, and mediation literature, we describe useful communication tools and common pitfalls. We outline a step-wise approach that physicians can use to deal with conflicts and the use of treatment trials as a strategy to address conflicts about the use of life-sustaining medical interventions.	Univ Washington, Dept Med, Seattle, WA USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA USA	University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Back, AL (corresponding author), Seattle Canc Care Alliance, 825 Eastlake Ave E,POB 19023, Seattle, WA 98109 USA.	tonyback@u.washington.edu			PHS HHS [R25 92055] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM MED ASS, 2004, END PAT PHYS REL; Andrew L B, 1999, Physician Exec, V25, P38; Aschenbrener C A, 1999, Physician Exec, V25, P44; Aulisio MP, 2004, CRIT CARE CLIN, V20, P505, DOI 10.1016/j.ccc.2004.03.006; Azoulay E, 2000, CRIT CARE MED, V28, P3044, DOI 10.1097/00003246-200008000-00061; Bowman KW, 2000, J PALLIATIVE CARE, V16, pS17, DOI 10.1177/082585970001601S05; Breen CM, 2001, J GEN INTERN MED, V16, P283, DOI 10.1046/j.1525-1497.2001.00419.x; Brett AS, 2003, ARCH INTERN MED, V163, P1645, DOI 10.1001/archinte.163.14.1645; Burns JP, 2003, CRIT CARE MED, V31, P2107, DOI 10.1097/01.CCM.0000069732.65524.72; Charon R, 2001, JAMA-J AM MED ASSOC, V286, P1897, DOI 10.1001/jama.286.15.1897; Dowdy MD, 1998, CRIT CARE MED, V26, P252, DOI 10.1097/00003246-199802000-00020; DUBLER N, 2003, BIOETHICS MED GUIDE; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; FARBER NJ, 1990, ACAD MED, V65, P713, DOI 10.1097/00001888-199011000-00019; Fetters MD, 2001, CRIT CARE MED, V29, P921, DOI 10.1097/00003246-200105000-00001; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Fisher R., 1991, GETTING YES NEGOTIAT; Frederich Michael E, 2002, J Palliat Med, V5, P155; GABBARD GO, 1985, JAMA-J AM MED ASSOC, V254, P2926, DOI 10.1001/jama.254.20.2926; Goleman Daniel., 2002, PRIMAL LEADERSHIP LE; Goold SD, 2000, JAMA-J AM MED ASSOC, V283, P909, DOI 10.1001/jama.283.7.909; Green P, 2004, AM J DRUG ALCOHOL AB, V30, P489, DOI 10.1081/ADA-120037390; GROSS JJ, 1993, J PERS SOC PSYCHOL, V64, P970, DOI 10.1037/0022-3514.64.6.970; Jain A, 1999, BRIT MED J, V318, P1596, DOI 10.1136/bmj.318.7198.1596; Jameson JK, 2003, J HEALTH COMMUN, V8, P563, DOI 10.1080/716100415; Kalisch B J, 1977, J Nurs Adm, V7, P50, DOI 10.1097/00005110-197701000-00014; Kressel Kenneth, 2002, J Health Care Law Policy, V5, P364; Kristjanson LJ, 1997, J PALLIATIVE CARE, V13, P5; LEVENSON RW, 1994, J PERS SOC PSYCHOL, V67, P56, DOI 10.1037/0022-3514.67.1.56; Levine C, 1999, Trustee, V52, P24; Levine C, 2004, CLIN MED, V4, P244, DOI 10.7861/clinmedicine.4-3-244; Levinson W, 1999, JAMA-J AM MED ASSOC, V282, P1477, DOI 10.1001/jama.282.15.1477; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Lilly CM, 2000, AM J MED, V109, P469, DOI 10.1016/S0002-9343(00)00524-6; Lilly CM, 2003, CRIT CARE MED, V31, pS394, DOI 10.1097/01.CCM.0000065279.77449.B4; McDonagh JR, 2004, CRIT CARE MED, V32, P1484, DOI 10.1097/01.CCM.0000127262.16690.65; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Orr Robert D., 2001, American Journal of Bioethics, V1, P45, DOI 10.1162/152651601317139397; PORTER S, 1991, J ADV NURS, V16, P728, DOI 10.1111/j.1365-2648.1991.tb01731.x; Prendergast TJ, 2000, JAMA-J AM MED ASSOC, V283, P3200; PRESCOTT PA, 1985, ANN INTERN MED, V103, P127, DOI 10.7326/0003-4819-103-1-127; Rabeneck L, 1997, LANCET, V349, P496, DOI 10.1016/S0140-6736(96)07369-2; Rosenbaum JR, 2004, AM J MED, V116, P402, DOI 10.1016/j.amjmed.2003.09.044; Rosenstein AH, 2002, AM J NURS, V102, P26, DOI 10.1097/00000446-200206000-00040; Roter DL, 2004, ANNU REV PUBL HEALTH, V25, P497, DOI 10.1146/annurev.publhealth.25.101802.123134; Schneiderman LJ, 2003, JAMA-J AM MED ASSOC, V290, P1166, DOI 10.1001/jama.290.9.1166; Schnohr P, 2001, EUR HEART J SUPPL, V3, pH1; STEIN LI, 1967, ARCH GEN PSYCHIAT, V16, P699; STEIN LI, 1990, NEW ENGL J MED, V322, P546, DOI 10.1056/NEJM199002223220810; Stone D., 1999, DIFFICULT CONVERSATI; Studdert DM, 2003, INTENS CARE MED, V29, P1489, DOI 10.1007/s00134-003-1853-5; Studdert DM, 2003, PEDIATRICS, V112, P553, DOI 10.1542/peds.112.3.553; TANNEN D, 2000, YOU JUST DONT UNDERS; Taylor SR, 2004, BMJ-BRIT MED J, V329, P233, DOI 10.1136/bmj.329.7459.233; The AM, 2002, BRIT MED J, V325, P1326, DOI 10.1136/bmj.325.7376.1326; Thomas EJ, 2003, CRIT CARE MED, V31, P956, DOI 10.1097/01.CCM.0000056183.89175.76; TOMLINSON T, 1990, GERONTOLOGIST, V30, P54, DOI 10.1093/geront/30.1.54; Ury W., 1991, GETTING PAST NO NEGO; VAILLANT GE, 1972, NEW ENGL J MED, V287, P372, DOI 10.1056/NEJM197208242870802; Valdimarsdottir U, 2004, PALLIATIVE MED, V18, P432, DOI 10.1191/0269216304pm891oa; Weitzman PF, 2003, CLIN PSYCHOL REV, V23, P523, DOI 10.1016/S0272-7358(02)00209-X; Weitzman PF, 2001, INT J AGING HUM DEV, V52, P281, DOI 10.2190/H3LH-59KQ-8WJP-ULM5	62	84	86	1	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	2005	293	11					1374	1381		10.1001/jama.293.11.1374	http://dx.doi.org/10.1001/jama.293.11.1374			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	907EP	15769971				2023-01-03	WOS:000227698600026
J	Rutkowski, S; Bode, U; Deinlein, F; Ottensmeier, H; Warmuth-Metz, M; Soerensen, N; Graf, N; Emser, A; Pietsch, T; Wolff, JEA; Kortmann, RD; Kuehl, J				Rutkowski, S; Bode, U; Deinlein, F; Ottensmeier, H; Warmuth-Metz, M; Soerensen, N; Graf, N; Emser, A; Pietsch, T; Wolff, JEA; Kortmann, RD; Kuehl, J			Treatment of early childhood medulloblastoma by postoperative chemotherapy alone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MALIGNANT BRAIN-TUMORS; STUDY-GROUP ANZCCSG; YOUNG-CHILDREN; PREIRRADIATION CHEMOTHERAPY; MOPP CHEMOTHERAPY; INFANTS; IRRADIATION; RADIATION; AGE; PATTERNS	BACKGROUND: The prognosis for young children with medulloblastoma is poor, and survivors are at high risk for cognitive deficits. We conducted a trial of the treatment of this brain tumor by intensive postoperative chemotherapy alone. METHODS: After surgery, children received three cycles of intravenous chemotherapy (cyclophosphamide, vincristine, methotrexate, carboplatin, and etoposide) and intraventricular methotrexate. Treatment was terminated if a complete remission was achieved. Leukoencephalopathy and cognitive deficits were evaluated. RESULTS: Forty-three children were treated according to protocol. In children who had complete resection (17 patients), residual tumor (14), and macroscopic metastases (12), the five-year progression-free and overall survival rates (+/-SE) were 82+/-9 percent and 93+/-6 percent, 50+/-13 percent and 56+/-14 percent, and 33+/-14 percent and 38+/-15 percent, respectively. The rates in 31 patients without macroscopic metastases were 68+/-8 percent and 77+/-8 percent. Desmoplastic histology, metastatic disease, and an age younger than two years were independent prognostic factors for tumor relapse and survival. Treatment strategies at relapse were successful in 8 of 16 patients. There were no major instances of unexpected toxicity. In 19 of 23 children, asymptomatic leukoencephalopathy was detected by magnetic resonance imaging. After treatment, the mean IQ was significantly lower than that of healthy controls within the same age group but higher than that of patients in a previous trial who had received radiotherapy. CONCLUSIONS: Postoperative chemotherapy alone is a promising treatment for medulloblastoma in young children without metastases.	Univ Wurzburg, Dept Neuroradiol, Wurzburg, Germany; Univ Wurzburg, Dept Pediat Neurosurg, Wurzburg, Germany; Univ Bonn, Dept Neuropathol, Natl Reference Ctr Brain Tumors, D-5300 Bonn, Germany; Univ Bonn, Childrens Hosp, Dept Pediat Oncol, D-5300 Bonn, Germany; Univ Homburg, Childrens Hosp, Dept Pediat Oncol, D-6650 Homburg, Germany; Univ Mainz, Inst Med Stat Epidemiol & Informat, D-6500 Mainz, Germany; Univ Regensburg, Childrens Hosp, Dept Pediat Oncol, D-8400 Regensburg, Germany; Univ Leipzig, Dept Radiotherapy, D-7010 Leipzig, Germany	University of Wurzburg; University of Wurzburg; University of Bonn; University of Bonn; Johannes Gutenberg University of Mainz; University of Regensburg; Leipzig University	Rutkowski, S (corresponding author), Univ Wurzburg, Childrens Hosp, Dept Pediat Oncol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	rutkowski@mail.uni-wuerzburg.de	Graf, Norbert/H-1328-2011	Graf, Norbert/0000-0002-2248-323X; Wolff, Johannes/0000-0003-0278-1309				Ater JL, 1997, J NEURO-ONCOL, V32, P243, DOI 10.1023/A:1005744527443; ATTARDMONTALTO S, 1993, BRIT J RADIOL, V66, P807, DOI 10.1259/0007-1285-66-789-807; BARAM TZ, 1987, CANCER, V60, P173, DOI 10.1002/1097-0142(19870715)60:2<173::AID-CNCR2820600209>3.0.CO;2-F; CHANG CH, 1969, RADIOLOGY, V93, P1351, DOI 10.1148/93.6.1351; DUFFNER PK, 1993, NEW ENGL J MED, V328, P1725, DOI 10.1056/NEJM199306173282401; Eberhart CG, 2002, CANCER-AM CANCER SOC, V94, P552, DOI 10.1002/cncr.10189; EVANS AE, 1990, J NEUROSURG, V72, P572, DOI 10.3171/jns.1990.72.4.0572; FAZEKAS F, 1989, EUR NEUROL, V29, P164, DOI 10.1159/000116401; Gottschling S, 2003, MED PEDIATR ONCOL, V41, P491, DOI 10.1002/mpo.10117; Hartsell WF, 1997, INT J RADIAT ONCOL, V39, P15, DOI 10.1016/S0360-3016(97)00136-3; HOPPEHIRSCH E, 1995, CHILD NERV SYST, V11, P340, DOI 10.1007/BF00301666; Jenkin D, 1998, MED PEDIATR ONCOL, V31, P506, DOI 10.1002/(SICI)1096-911X(199812)31:6<506::AID-MPO7>3.0.CO;2-X; Kaatsch P, 2001, CANCER-AM CANCER SOC, V92, P3155, DOI 10.1002/1097-0142(20011215)92:12<3155::AID-CNCR10158>3.0.CO;2-C; Kellie SJ, 1999, CHILD NERV SYST, V15, P592, DOI 10.1007/s003810050548; Kiltie AE, 1997, MED PEDIATR ONCOL, V28, P348, DOI 10.1002/(SICI)1096-911X(199705)28:5<348::AID-MPO4>3.0.CO;2-H; Kuehl J, 1995, MED PEDIAT ONCOL S, V25, P250; MULHERN RK, 1989, J CLIN ONCOL, V7, P1660, DOI 10.1200/JCO.1989.7.11.1660; Packer RJ, 2003, PEDIATR NEUROSURG, V39, P60, DOI 10.1159/000071316; Palmer SL, 2001, J CLIN ONCOL, V19, P2302, DOI 10.1200/JCO.2001.19.8.2302; Riva D, 2002, NEUROLOGY, V59, P48, DOI 10.1212/WNL.59.1.48; Ruggiero A, 2001, PEDIATR DRUGS, V3, P237, DOI 10.2165/00128072-200103040-00001; Vezmar S, 2003, CHEMOTHERAPY, V49, P92, DOI 10.1159/000069773; WHITE L, 1993, CANCER CHEMOTH PHARM, V32, P403, DOI 10.1007/BF00735928; White L, 1998, J PEDIAT HEMATOL ONC, V20, P125, DOI 10.1097/00043426-199803000-00007; Zeltzer PM, 1999, J CLIN ONCOL, V17, P832, DOI 10.1200/JCO.1999.17.3.832	25	499	517	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 10	2005	352	10					978	986		10.1056/NEJMoa042176	http://dx.doi.org/10.1056/NEJMoa042176			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904JC	15758008	Bronze			2023-01-03	WOS:000227491200006
J	Olaussen, KA; Dunant, A; Fouret, P; Brambilla, E; Andre, F; Haddad, V; Taranchon, E; Filipits, M; Pirker, R; Popper, HH; Stahel, R; Sabatier, L; Pignon, J; Tursz, T; Le Chevalier, T; Soria, JC				Olaussen, Ken A.; Dunant, Ariane; Fouret, Pierre; Brambilla, Elisabeth; Andre, Fabrice; Haddad, Vincent; Taranchon, Estelle; Filipits, Martin; Pirker, Robert; Popper, Helmut H.; Stahel, Rolf; Sabatier, Laure; Pignon, Jean-Pierre; Tursz, Thomas; Le Chevalier, Thierry; Soria, Jean-Charles		IALT Bio Investigators	DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUCLEOTIDE EXCISION-REPAIR; MESSENGER-RNA LEVELS; GENE-EXPRESSION; TUMOR RESPONSE; SURVIVAL; POLYMORPHISM; ASSOCIATION; RECOMBINATION; RESISTANCE; CARCINOMA	Background: Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non-small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit of chemotherapy. Methods: We used immunohistochemical analysis to determine the expression of the excision repair cross-complementation group 1 (ERCC1) protein in operative specimens of non-small-cell lung cancer. The patients had been enrolled in the International Adjuvant Lung Cancer Trial, thereby allowing a comparison of the effect of adjuvant cisplatin-based chemotherapy on survival, according to ERCC1 expression. Overall survival was analyzed with a Cox model adjusted for clinical and pathological factors. Results: Among 761 tumors, ERCC1 expression was positive in 335 (44%) and negative in 426 (56%). A benefit from cisplatin-based adjuvant chemotherapy was associated with the absence of ERCC1 (test for interaction, P=0.009). Adjuvant chemotherapy, as compared with observation, significantly prolonged survival among patients with ERCC1-negative tumors (adjusted hazard ratio for death, 0.65; 95% confidence interval [CI], 0.50 to 0.86; P=0.002) but not among patients with ERCC1-positive tumors (adjusted hazard ratio for death, 1.14; 95% CI, 0.84 to 1.55; P=0.40). Among patients who did not receive adjuvant chemotherapy, those with ERCC1-positive tumors survived longer than those with ERCC1-negative tumors (adjusted hazard ratio for death, 0.66; 95% CI, 0.49 to 0.90; P=0.009). Conclusions: Patients with completely resected non-small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ERCC1-positive tumors do not.	Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France; Commissariat Energie Atom, Lab Radiobiol & Oncol, Fontenay Aux Roses, France; Univ Paris 11, Paris, France; Inst Gustave Roussy, Biostat & Epidemiol Unit, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Pathol & Translat Res, F-94805 Villejuif, France; Ctr Hosp Univ Albert Michallon, Dept Pathol, Grenoble, France; Univ Paris 06, Paris, France; Med Univ Vienna, Dept Internal Med, Vienna, Austria; Univ Med Sch Graz, Inst Pathol, Graz, Austria; Univ Spital Zurich, Klin & Poliklin Onkol, Zurich, Switzerland	UNICANCER; Gustave Roussy; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; CHU Grenoble Alpes; UDICE-French Research Universities; Sorbonne Universite; Medical University of Vienna; University of Zurich; University Zurich Hospital	Soria, JC (corresponding author), Inst Gustave Roussy, Dept Med, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	soria@igr.fr	Chabowski, Mariusz/H-9847-2019; Soria, Jean-Charles/F-3619-2014; ANDRE, François/E-5555-2015; ANDRE, Fabrice/AAL-2683-2020; Le Discorde, Magali/A-5127-2009	Chabowski, Mariusz/0000-0002-9232-4525; ANDRE, Fabrice/0000-0001-5795-8357; Le Discorde, Magali/0000-0001-5126-0900; Sabatier, Laure/0000-0003-0552-6549; PIGNON, Jean-Pierre/0000-0003-2047-1582; Olaussen, Ken/0000-0002-3115-8914; Filipits, Martin/0000-0003-2847-4534				Al-Haddad S, 1999, AM J PATHOL, V155, P2057, DOI 10.1016/S0002-9440(10)65524-1; Altaha R, 2004, INT J MOL MED, V14, P959; Brambilla E, 2005, LUNG CANCER-J IASLC, V49, pS44, DOI 10.1016/S0169-5002(05)80261-2; Chen PC, 2000, CANCER EPIDEM BIOMAR, V9, P843; DABHOLKAR M, 1992, J NATL CANCER I, V84, P1512, DOI 10.1093/jnci/84.19.1512; DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; DOUILLARD JY, 2005, J CLIN ONCOL, V23, pA7013; Gurublihagavatula S, 2005, SEMIN RESP CRIT CARE, V26, P298, DOI 10.1055/s-2005-871988; Handra-Luca A, 2003, AM J PATHOL, V163, P957, DOI 10.1016/S0002-9440(10)63455-4; Jemal A, 2005, CA-CANCER J CLIN, V55, P259; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Joshi MBM, 2005, CLIN CANCER RES, V11, P2215; KIM DY, 2003, P AN M AM SOC CLIN, V22, P1079; Langer R, 2005, CLIN CANCER RES, V11, P7462, DOI 10.1158/1078-0432.CCR-05-0042; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Lord RVN, 2002, CLIN CANCER RES, V8, P2286; McShane LM, 2005, J CLIN ONCOL, V23, P9067, DOI 10.1200/JCO.2004.01.0454; Metzger R, 1998, J CLIN ONCOL, V16, P309, DOI 10.1200/JCO.1998.16.1.309; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Murray David, 2003, Am J Clin Oncol, V26, pe169, DOI 10.1097/01.coc.0000091359.11281.f4; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; Nix P, 2004, CANC THER, P47; Park David J, 2003, Clin Adv Hematol Oncol, V1, P162; Reed E, 1998, CANCER TREAT REV, V24, P331, DOI 10.1016/S0305-7372(98)90056-1; Reed E, 2000, ONCOL REP, V7, P1123; Rosell R, 2002, LUNG CANCER, V38, P217, DOI 10.1016/S0169-5002(02)00224-6; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Sargent RG, 2000, NUCLEIC ACIDS RES, V28, P3771, DOI 10.1093/nar/28.19.3771; Shirota Y, 2001, J CLIN ONCOL, V19, P4298, DOI 10.1200/JCO.2001.19.23.4298; Simon GR, 2005, CHEST, V127, P978, DOI 10.1378/chest.127.3.978; Strauss GM, 2004, J CLIN ONCOL, V22, p621S; Sturgis EM, 2002, ARCH OTOLARYNGOL, V128, P1084, DOI 10.1001/archotol.128.9.1084; Viguier J, 2005, CLIN CANCER RES, V11, P6212, DOI 10.1158/1078-0432.CCR-04-2216; Wachters FM, 2005, LUNG CANCER-J IASLC, V50, P211, DOI 10.1016/j.lungcan.2005.06.013; Warnecke-Eberz U, 2004, CLIN CANCER RES, V10, P3794, DOI 10.1158/1078-0432.CCR-03-0079; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Yu JJ, 1997, MUTAT RES-GENOMICS, V382, P13, DOI 10.1016/S1383-5726(97)00004-6; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; Zhou W, 2004, CLIN CANCER RES, V10, P4939, DOI 10.1158/1078-0432.CCR-04-0247	41	1416	1528	4	106	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2006	355	10					983	991		10.1056/NEJMoa060570	http://dx.doi.org/10.1056/NEJMoa060570			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080UF	16957145				2023-01-03	WOS:000240273300004
J	Tan, M; Li, P; Sun, M; Yin, G; Yu, D				Tan, M.; Li, P.; Sun, M.; Yin, G.; Yu, D.			Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCa and Src inhibitors	ONCOGENE			English	Article						breast cancer; invasion; metastasis; Src; PKC alpha; ErbB2	PROTEIN-KINASE-C; TUMOR PROGRESSION; FAMILY KINASES; EXPRESSION; OVEREXPRESSION; METASTASIS; THERAPY; PHOSPHORYLATION; TRANSFORMATION; INVASIVENESS	Although ErbB2 is known to enhance breast cancer metastasis, the signaling events responsible for this remain elusive. alpha-Isozyme of protein kinase C (PKC alpha), which is involved in cancer development and progression, has been suggested to be activated by ErbB2 without direct evidence. In addition, the roles of PKC alpha in ErbB2-mediated cancer cell malignancy have not been clearly identifed. In this study, we investigated whether ErbB2 can activate PKC alpha and determined what role PKCa plays in ErbB2-mediated breast cancer cell invasion. We expressed wild-type and mutant ErbB2 with altered signaling capacities in MDA-MB-435 breast cancer cells and revealed that overexpression or activation of ErbB2 in MDA-MB-435 cells upregulated and activated PKC alpha and that downregulation of ErbB2by small-interfering RNA decreased the expression and activity of PKC alpha in BT474 breast cancer cells. These in vitro results were supported by data from breast cancer patient samples. In 150 breast cancer tumor samples, ErbB2-overexpressing tumors showed significantly higher positive rates of PKCa membrane immunohistochemistry staining than that of ErbB2-low-expressing tumors. Mechanistically, we found that PKC alpha is co-immunoprecipitated with Src and PKC alpha expression and activity can be decreased by Src inhibitor PP2 and by the expression of a dominantnegative mutant of Src. Moreover, ErbB2-mediated upregulation of urokinase-type plasminogen activator receptor (uPAR) is reduced by either the PKC alpha inhibitor Go6976 or the Src inhibitor PP2, and the combination of Go6976 with PP2 is superior to either agent alone in suppressing uPAR expression and cell invasion. These results demonstrate that PKC alpha is critical for ErbB2-mediated cancer cell invasion and provide valuable insights for current and future PKC alpha and Src inhibitor clinical trials.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yu, D (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dyu@mdanderson.org	Tan, Ming/ABD-5847-2021; Yin, Guosheng/D-3214-2009	Tan, Ming/0000-0003-2007-9898; Yu, Dihua/0000-0001-6231-9381; Yin, Guosheng/0000-0003-3276-1392	NCI NIH HHS [2R01-CA60488, 1R01-CA109570, P30-CA16672, P01-CA099031, R01-CA112567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109570, P30CA016672, R01CA112567, P01CA099031, R01CA060488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Boyd DD, 2004, CLIN CANCER RES, V10, P1545, DOI 10.1158/1078-0432.CCR-1565-02; de Bono JS, 2003, BREAST CANCER RES, V5, P154, DOI 10.1186/bcr597; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; GUM R, 1995, ANTICANCER RES, V15, P1167; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Huigsloot M, 2003, MOL PHARMACOL, V64, P965, DOI 10.1124/mol.64.4.965; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Johnson MD, 1999, EXP CELL RES, V247, P105, DOI 10.1006/excr.1998.4336; Kos KS, 2003, CANCER-AM CANCER SOC, V98, P1377, DOI 10.1002/cncr.11656; Lahn M, 2004, ONCOLOGY-BASEL, V67, P1, DOI 10.1159/000080279; Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Masur K, 2001, MOL BIOL CELL, V12, P1973, DOI 10.1091/mbc.12.7.1973; Michie AM, 2005, IMMUNOL LETT, V96, P155, DOI 10.1016/j.imlet.2004.08.013; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Morse-Gaudio M, 1998, INT J ONCOL, V12, P1349; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Palka HL, 1997, J CELL SCI, V110, P2359; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tan M, 1999, CANCER RES, V59, P1620; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tan M, 1997, CANCER RES, V57, P1199; VADERGREER P, 1994, ANN REV CELL BIOL, V10, P251; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112	39	74	75	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3286	3295		10.1038/sj.onc.1209361	http://dx.doi.org/10.1038/sj.onc.1209361			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16407820				2023-01-03	WOS:000237951200007
J	Yeh, P; Tschumi, AI; Kishony, R				Yeh, P; Tschumi, AI; Kishony, R			Functional classification of drugs by properties of their pairwise interactions	NATURE GENETICS			English	Article							MULTICOMPONENT THERAPEUTICS; ESCHERICHIA-COLI; NETWORK MOTIFS; ANTIBIOTICS; RESISTANCE; BIOLOGY; PRINCIPLES; MECHANISMS; EPISTASIS; CANCER	Multidrug treatments are increasingly important in medicine and for probing biological systems(1-6). Although many studies have focused on interactions between specific drugs, little is known about the system properties of a full drug interaction network(6). Like their genetic counterparts, two drugs may have no interaction, or they may interact synergistically or antagonistically to increase or suppress their individual effects. Here we use a sensitive bioluminescence technique(7,8) to provide quantitative measurements of pairwise interactions among 21 antibiotics that affect growth rate in Escherichia coli. We find that the drug interaction network possesses a special property: it can be separated into classes of drugs such that any two classes interact either purely synergistically or purely antagonistically. These classes correspond directly to the cellular functions affected by the drugs. This network approach provides a new conceptual framework for understanding the functional mechanisms of drugs and their cellular targets and can be applied in systems intractable to mutant screening, biochemistry or microscopy.	Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	Kishony, R (corresponding author), Harvard Univ, Bauer Ctr Genom Res, 7 Divin Ave, Cambridge, MA 02138 USA.	rkishony@cgr.harvard.edu						Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Bjarnason J, 2003, J BACTERIOL, V185, P4973, DOI 10.1128/JB.185.16.4973-4982.2003; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Borisy AA, 2003, P NATL ACAD SCI USA, V100, P7977, DOI 10.1073/pnas.1337088100; Davierwala AP, 2005, NAT GENET, V37, P1147, DOI 10.1038/ng1640; Gardner TS, 2003, SCIENCE, V301, P102, DOI 10.1126/science.1081900; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Hecht SM, 2000, J NAT PROD, V63, P158, DOI 10.1021/np990549f; Hoffman LR, 2005, NATURE, V436, P1171, DOI 10.1038/nature03912; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609; Kishony Roy, 2003, J Biol, V2, P14, DOI 10.1186/1475-4924-2-14; Komarova NL, 2005, P NATL ACAD SCI USA, V102, P9714, DOI 10.1073/pnas.0501870102; Leeb M, 2004, NATURE, V431, P892, DOI 10.1038/431892a; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; LOEWE S, 1953, ARZNEIMITTEL-FORSCH, V3, P285; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Nathan C, 2004, NATURE, V431, P899, DOI 10.1038/431899a; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Perlman ZE, 2004, SCIENCE, V306, P1194, DOI 10.1126/science.1100709; Remold SK, 2004, NAT GENET, V36, P423, DOI 10.1038/ng1324; Schreiber SL, 2003, CHEM ENG NEWS, V81, P51, DOI 10.1021/cen-v081n009.p051; SCOTT GM, 2001, HDB ESSENTIAL ANTIBI; Segre D, 2005, NAT GENET, V37, P77, DOI 10.1038/ng1489; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; Walsh C., 2003, ANTIBIOTICS ACTIONS	30	252	256	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2006	38	4					489	494		10.1038/ng1755	http://dx.doi.org/10.1038/ng1755			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16550172				2023-01-03	WOS:000236340500025
J	Neher, JO				Neher, JO			First response	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Valley Family Med, Renton, WA 98055 USA; Univ Washington, Renton, WA 98055 USA	University of Washington	Neher, JO (corresponding author), Valley Family Med, 3915 Talbot Rd S,Suite 401, Renton, WA 98055 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2006	144	4					301	302		10.7326/0003-4819-144-4-200602210-00014	http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	015HS	16490918				2023-01-03	WOS:000235543100011
J	Fry, AM; Shay, DK; Holman, RC; Curns, AT; Anderson, LJ				Fry, AM; Shay, DK; Holman, RC; Curns, AT; Anderson, LJ			Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY SYNCYTIAL VIRUS; COMMUNITY-ACQUIRED PNEUMONIA; INFLUENZA VACCINATION; RISK-FACTORS; ANTIBODY-RESPONSE; INFECTION; DISEASE; POPULATION; STROKE; MORTALITY	Context Pneumonia causes significant mortality and morbidity among persons aged 65 years or older. However, few studies have explored trends according to age groups, which may affect intervention strategies. Objectives To examine trends in hospitalizations for pneumonia among persons aged 65 years or older and to compare characteristics, outcomes, and comorbid diagnoses. Design, Setting, and Patients Data from 1988 through 2002 on pneumonia and comorbid diagnoses among patients aged 65 to 74 years, 75 to 84 years, and 85 years or older from the National Hospital Discharge Survey. Main Outcome Measures Hospitalization rates by first-listed and any-listed discharge codes for pneumonia; proportions of hospitalizations reporting comorbid diagnoses for the 3 age groups (65-74 years, 75-84 years, >= 85 years). Results Hospitalization rates by both first-listed and any-listed discharge codes for pneumonia increased by 20% from 1988-1990 to 2000-2002 for patients aged 65 to 74 years (P=.01) and for patients aged 75 to 84 years (P<.001). Rates of hospitalization for pneumonia were 2-fold higher for patients aged 85 years or older (51 per 1000 population for first-listed discharge code of pneumonia; 95% confidence interval [CI], 46-55 per 1000 population) than among patients aged 75 to 84 years (26 per 1000 population; 95% Cl, 24-28 per 1000 population), but did not significantly increase from 1988-1990 to 2000-2002. The proportion of patients aged 65 years or older diagnosed with pneumonia and a chronic cardiac disease, chronic pulmonary disease, or diabetes mellitus increased from 66% (SE, 1.0%) in 1988-1990 to 77% (SE, 0.8%) in 2000-2002. The risk of death during a hospitalization for pneumonia compared with the risk of death during a hospital stay for the 10 other most frequent causes of hospitalization was 1.5 (95% Cl, 1.4-1.7) and remained constant from 19881990 to 2000-2002. Conclusions Hospitalization rates for pneumonia have increased among US adults aged 64 to 74 years and aged 75 to 84 years during the past 15 years. Among those aged 85 years or older, at least 1 in 20 patients were hospitalized each year due to pneumonia. Concomitantly, the proportion of comorbid chronic diseases has increased. Efforts to prevent pneumonia should include reducing preventable comorbid conditions and improving vaccine effectiveness and vaccination programs in elderly persons.	Ctr Dis Control & Prevent, Resp & Enter Viruses Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Influenza Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Off Director, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Fry, AM (corresponding author), Ctr Dis Control & Prevent, Resp & Enter Viruses Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, 1600 Clifton Rd,Mailstop A-34, Atlanta, GA 30333 USA.	afry@cdc.gov		Shay, David/0000-0001-9619-4820				[Anonymous], 1979, HLTH PEOPL SURG GEN; [Anonymous], 1996, US BUREAU CENSUS CUR; [Anonymous], 1997, MMWR MORB MORT WKLY, V46, P1; Barker WH, 1997, STROKE, V28, P284, DOI 10.1161/01.STR.28.2.284; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P842; de Jong JC, 2000, J MED VIROL, V61, P94, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;94::AID-JMV15&gt;3.0.CO;2-C; Dennison C, 2000, Vital Health Stat 1, P1; Dorrell L, 1997, INT J STD AIDS, V8, P776, DOI 10.1258/0956462971919264; Falsey AR, 1998, VACCINE, V16, P1775, DOI 10.1016/S0264-410X(98)00142-X; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Falsey AR, 2000, CLIN MICROBIOL REV, V13, P371, DOI 10.1128/CMR.13.3.371-384.2000; Farr BM, 2000, RESP MED, V94, P954, DOI 10.1053/rmed.2000.0865; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; GILLIUM BS, 1996, TRENDS HOSP UTILIZAT; Goronzy JJ, 2001, J VIROL, V75, P12182, DOI 10.1128/JVI.75.24.12182-12187.2001; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; Greenlund KJ, 2004, ARCH INTERN MED, V164, P2113, DOI 10.1001/archinte.164.19.2113; Han LL, 1999, J INFECT DIS, V179, P25, DOI 10.1086/314567; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Hoyert D L, 2001, Natl Vital Stat Rep, V49, P1; Jackson LA, 2003, NEW ENGL J MED, V348, P1747, DOI 10.1056/NEJMoa022678; Jackson ML, 2004, CLIN INFECT DIS, V39, P1642, DOI 10.1086/425615; Kaplan V, 2003, ARCH INTERN MED, V163, P317, DOI 10.1001/archinte.163.3.317; Kaplan V, 2002, AM J RESP CRIT CARE, V165, P766, DOI 10.1164/ajrccm.165.6.2103038; KOIVULA I, 1994, AM J MED, V96, P313, DOI 10.1016/0002-9343(94)90060-4; KOZAK LJ, 2005, VITAL HLTH STAT, V13, P1729; MARRIE TJ, 1994, CLIN INFECT DIS, V18, P501, DOI 10.1093/clinids/18.4.501; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; MCELHANEY JE, 1990, J AM GERIATR SOC, V38, P652, DOI 10.1111/j.1532-5415.1990.tb01424.x; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238; Mortensen EM, 2003, CLIN INFECT DIS, V37, P1617, DOI 10.1086/379712; Muder RR, 1998, AM J MED, V105, P319, DOI 10.1016/S0002-9343(98)00262-9; *NAT CTR HLTH STAT, 2004, NAT HOSP DISCH SURV; *NAT HLTH INT SURV, INFL VACC DAT; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Remarque EJ, 1999, EXP GERONTOL, V34, P109, DOI 10.1016/S0531-5565(98)00060-6; Shah BV, 1996, SUDAAN USERS MANUAL; Shahar E, 1997, STROKE, V28, P275, DOI 10.1161/01.STR.28.2.275; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; Simonsen L, 1998, ARCH INTERN MED, V158, P1923, DOI 10.1001/archinte.158.17.1923; Thompson WW, 2005, ARCH INTERN MED, V165, P2038, DOI 10.1001/archinte.165.17.2038-b; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; *US BUR CENS, 2003, INT EST POP AG SEX R; US Dept of Health and Human Services . International Classification of Diseases, 1988, INT CLASS DIS; *US EPA, 1991, NAT AIR QUAL EM TREN; Walsh EE, 2004, J INFECT DIS, V189, P233, DOI 10.1086/380907	52	313	328	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	2005	294	21					2712	2719		10.1001/jama.294.21.2712	http://dx.doi.org/10.1001/jama.294.21.2712			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	990EV	16333006	Bronze			2023-01-03	WOS:000233726900019
J	Baggini, J; Pym, M				Baggini, J; Pym, M			End of life: the humanist view	LANCET			English	Editorial Material									Philosophers Magazine, Surrey SM2 6LZ, England; British Humanist Assoc, London W1E 6HD, England		Baggini, J (corresponding author), Philosophers Magazine, Surrey SM2 6LZ, England.	Editor@philosophers.co.uk							0	15	15	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2005	366	9492					1235	1237		10.1016/S0140-6736(05)67486-7	http://dx.doi.org/10.1016/S0140-6736(05)67486-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	970LK	16198772				2023-01-03	WOS:000232311300033
J	Oransky, I				Oransky, I			Dame Cicely Mary Strode Saunders - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com							0	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 20	2005	366	9486					628	628		10.1016/S0140-6736(05)67127-9	http://dx.doi.org/10.1016/S0140-6736(05)67127-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958EB	16189851				2023-01-03	WOS:000231426400016
J	Bower, M; Gazzard, B; Mandalia, S; Newsom-Davis, T; Thirlwell, C; Dhillon, T; Young, AM; Powles, T; Gaya, A; Nelson, M; Stebbing, J				Bower, M; Gazzard, B; Mandalia, S; Newsom-Davis, T; Thirlwell, C; Dhillon, T; Young, AM; Powles, T; Gaya, A; Nelson, M; Stebbing, J			A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYCLOPHOSPHAMIDE; SURVIVAL; CHEMOTHERAPY; VINCRISTINE; DOXORUBICIN; IMPACT; COMBINATION; INHIBITORS; SARCOMA	Background: The established international Prognostic index for lymphomas has not included patients with systemic AIDS-related non-Hodgkin lymphoma. Objective: To establish the most appropriate prognostic index for use in patients with systemic AIDS-related non-Hodgkin lymphoma. Design: A prospective study involving univariate and multivariable analyses of patients with AIDS-related non-Hodgkin lymphoma whose data were used to examine standard and new criteria for survival after diagnosis. Setting: The Chelsea and Westminster cohort of HIV-1-infected persons. Patients: 9621 HIV-positive patients, 111 in whom AIDS-related non-Hodgkin lymphoma was treated after 1996, in the era of highly active antiretroviral therapy (HAART). Intervention: Cox proportional hazards regression analysis to determine the prognostic significance of multiple clinicopathologic variables. Results: Survival of patients with AIDS-related non-Hodgkin lymphoma has increased in the HAART era (log-rank chi-square, 9.23; P = 0.002). Univariate analyses using the established International Prognostic Index factors of age, tumor stage, lactate dehydrogenase level, Eastern Cooperative Oncology Group performance status, and number of extranodal sites were confirmed to be significant variables. Regression modeling for patients in whom disease was diagnosed after 1996 revealed only 2 independent predictors of death: International Prognostic Index risk group and CD4 cell count. These predictors yielded 4 internally validated risk strata with predicted 1-year survival rates of 82%, 47%, 20%, and 15% (P < 0.001). Prognostic risk scores in the highest quartile yielded a likelihood ratio for death of 7.90 (hazard ratio, 1.0), whereas a prognostic score less than 1.0 yielded a likelihood ratio of 0.23 (hazard ratio, 0.15 [95% Cl, 0.06 to 0.33]). Limitations: The sample was small, and different HAART regimens were used. Conclusions: For patients with AIDS-related non-Hodgkin lymphoma that was diagnosed in the era of HAART, application of the International Prognostic Index remains useful. The addition of CD4 cell count provides further independent prognostic information. Patients who present with AIDS-related non-Hodgkin lymphoma and a low CD4 cell count have a poor prognosis; this information can be used to guide therapeutic options.	Chelsea & Westminster Hosp, London SW10 9NH, England	Imperial College London	Bower, M (corresponding author), Chelsea & Westminster Hosp, 369 Fulham Rd, London SW10 9NH, England.	m.bower@imperial.ac.uk; j.stebbing@imperial.ac.uk		Bower, Mark/0000-0002-4077-6351; Stebbing, Justin/0000-0002-1117-6947				Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823; Benzel J E, 1968, Del Med J, V40, P78; Bower M, 2004, BLOOD, V104, P2943, DOI 10.1182/blood-2004-05-1747; Cortes J, 2002, CANCER, V94, P1492, DOI 10.1002/cncr.10365; Efron B, 1996, P NATL ACAD SCI USA, V93, P13429, DOI 10.1073/pnas.93.23.13429; EFRON B, 1983, AM STAT, V37, P36, DOI 10.2307/2685844; Efron B., 1993, INTRO BOOTSTRAP, DOI [10.1007/978-1-4899-4541-9, DOI 10.1007/978-1-4899-4541-9]; Efron B., 1986, STAT SCI, P54; Gabarre J, 2004, HAEMATOLOGICA, V89, P1100; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; Jacobson LP, 1999, J ACQ IMMUN DEF SYND, V21, pS34; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; LITTLE R, 1999, P AN M AM SOC CLIN, V18, pA10; Little RF, 2003, BLOOD, V101, P4653, DOI 10.1182/blood-2002-11-3589; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Matthews GV, 2000, BLOOD, V96, P2730; Mocroft A, 2000, LANCET, V356, P291, DOI 10.1016/S0140-6736(00)02504-6; Murdaca G, 2002, AIDS, V16, P304, DOI 10.1097/00002030-200201250-00029; Navarro JT, 1998, HAEMATOLOGICA, V83, P508; Navarro JT, 2001, BRIT J HAEMATOL, V112, P909, DOI 10.1046/j.1365-2141.2001.02656.x; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Ratner L, 2001, J CLIN ONCOL, V19, P2171, DOI 10.1200/JCO.2001.19.8.2171; ROSENBERG SA, 1977, CANCER TREAT REP, V61, P1023; Rossi G, 1999, CANCER-AM CANCER SOC, V86, P2391, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2391::AID-CNCR29>3.0.CO;2-0; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Sparano JA, 2004, J CLIN ONCOL, V22, P1491, DOI 10.1200/JCO.2004.08.195; Stebbing J, 2004, J CLIN ONCOL, V22, P2177, DOI 10.1200/JCO.2004.11.097; Stebbing J, 2004, CANCER TREAT REV, V30, P249, DOI 10.1016/j.ctrv.2003.12.004; Stebbing J, 2004, INT J CANCER, V108, P473, DOI 10.1002/ijc.11601; Stebbing J, 2003, LANCET ONCOL, V4, P438, DOI 10.1016/S1470-2045(03)01142-2; Stebbing J, 2003, J ANTIMICROB CHEMOTH, V51, P1095, DOI 10.1093/jac/dkg199; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; THIRLWELL C, 2002, 6 INT C DRUG THER HI, P94; Vaccher E, 2001, CANCER-AM CANCER SOC, V91, P155, DOI 10.1002/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	38	88	93	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 16	2005	143	4					265	273		10.7326/0003-4819-143-4-200508160-00007	http://dx.doi.org/10.7326/0003-4819-143-4-200508160-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955PA	16103470				2023-01-03	WOS:000231237100003
J	Hay, EM; Mullis, R; Lewis, M; Vohora, K; Main, CJ; Watson, P; Dziedzic, KS; Sim, J; Lowe, CM; Croft, PR				Hay, EM; Mullis, R; Lewis, M; Vohora, K; Main, CJ; Watson, P; Dziedzic, KS; Sim, J; Lowe, CM; Croft, PR			Comparison of physical treatments versus a brief pain-management programme for back pain in primary care: a randomised clinical trial in physiotherapy practice	LANCET			English	Article							LOCAL CORTICOSTEROID INJECTION; INTERVENTION; MANIPULATION; DISABILITY; DISTRESS; THERAPY	Background Recommendations for the management of low back pain in primary care emphasise the importance of recognising and addressing psychosocial factors at an early stage. We compared the effectiveness of a brief pain-management programme with physiotherapy incorporating manual therapy for the reduction of disability at 12 months in patients consulting primary care with subacute low back pain. Methods For this pragmatic, multicentre, randomised clinical trial, eligible participants consulted primary care with non-specific low back pain of less than 12 weeks' duration. They were randomly assigned either a programme of pain management (n=201) or manual therapy (n=201). The primary outcome was change in the score on the Roland and Morris disability questionnaire at 12 months. Analysis was by intention to treat. Findings Of 544 patients assessed for eligibility, 402 were recruited (mean age 40.6 years) and 329 (82%) reached 12-month follow-up. Mean disability scores were 13.8 (SD 4.8) for the pain-management group and 13.3 (4.9) for the manual-therapy group. The mean decreases in disability scores were 8.8 (6.4) and 8.8 (6.1) at 12 months (difference 0 [95% CI -1.3 to 1.41, p=0.99), and median numbers of physiotherapy visits per patient were three (IQR one to five) and four (two to five), respectively (p=0.001). One adverse reaction (an exacerbation of pain after the initial assessment) was recorded. Interpretation Brief pain management techniques delivered by appropriately trained clinicians offer an alternative to physiotherapy incorporating manual therapy and could provide a more efficient first-line approach for management of non-specific subacute low back pain in primary care.	Keele Univ, Primary Care Serv Res Ctr, Keele ST5 5BG, Staffs, England; Staffordshire Rheumatol Ctr, Stoke On Trent, Staffs, England; Univ Manchester, Unit Chron Dis Epidemiol, Manchester, Lancs, England; Univ Leicester, Dept Anaesthesia & Pain Management, Leicester, Leics, England; Nuffield Orthopaed Ctr NHS Trust, Physiotherapy Res Unit, Oxford, England	Keele University; University of Manchester; University of Leicester; Nuffield Orthopaedic Centre; University of Oxford	Hay, EM (corresponding author), Keele Univ, Primary Care Serv Res Ctr, Keele ST5 5BG, Staffs, England.	e.m.hay@cphc.keele.ac.uk						Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; Bombardier C, 2001, J RHEUMATOL, V28, P431; Bronfort Gert, 2004, Spine J, V4, P335, DOI 10.1016/j.spinee.2003.06.002; BURTON AK, 1995, SPINE, V20, P722, DOI 10.1097/00007632-199503150-00014; Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011; Clinical Standards Advisory Group on Back Pain, 1994, BACK PAIN; Croft PR, 1995, SPINE, V20, P2731, DOI 10.1097/00007632-199512150-00015; Damush TM, 2003, ARCH INTERN MED, V163, P2632, DOI 10.1001/archinte.163.21.2632; DUNN KM, IN PRESS SPINE; Frost H, 1998, PAIN, V75, P273, DOI 10.1016/S0304-3959(98)00005-0; Guzman J, 2002, COCHRANE DB SYST REV, V1, P1, DOI [10.1002/14651858.CD000963, DOI 10.1002/14651858.CD000963]; Hay EM, 1999, BRIT MED J, V319, P964, DOI 10.1136/bmj.319.7215.964; Hay EM, 2003, ANN RHEUM DIS, V62, P394, DOI 10.1136/ard.62.5.394; Karjalainen K, 2003, SPINE, V28, P533, DOI 10.1097/00007632-200303150-00004; KENDALL NA, GUIDE ASSESSING PSYC; KLENERMAN L, 1995, SPINE, V20, P478, DOI 10.1097/00007632-199502001-00012; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; Kori S, 1990, PAIN MANAG, V3, P35; Linton SJ, 2000, SPINE, V25, P2825, DOI 10.1097/00007632-200011010-00017; MAIN CJ, 1992, SPINE, V17, P42, DOI 10.1097/00007632-199201000-00007; Main CJ, 2002, BMJ-BRIT MED J, V325, P534, DOI 10.1136/bmj.325.7363.534; Main CJ, 1984, CURR CONCEPTS PAIN, V2, P10; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Moore JE, 2000, PAIN, V88, P145, DOI 10.1016/S0304-3959(00)00314-6; Mullis R, 2004, RHEUMATOLOGY, V43, P86; *RCGP, 1996, GUID MAN AC LOW BACK; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROSENSTIEL AK, 1983, PAIN, V17, P33, DOI 10.1016/0304-3959(83)90125-2; Underwood M, 2004, BMJ-BRIT MED J, V329, P1377, DOI 10.1136/bmj.38282.669225AE	29	146	147	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2005	365	9476					2024	2030		10.1016/S0140-6736(05)66696-2	http://dx.doi.org/10.1016/S0140-6736(05)66696-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934IB	15950716				2023-01-03	WOS:000229701400024
J	Bourhis, J; Overgaard, J; Audry, H; Ang, KK; Saunders, M; Bernier, J; Horiot, JC; Le Maitre, A; Pajak, TF; Paulsen, MG; O'Sullivan, B; Dobrowsky, W; Hliniak, A; Skladowski, K; Hay, JH; Pinto, LH; Fallai, C; Fu, KK; Sylvester, R; Pignon, JP				Bourhis, Jean; Overgaard, Jens; Audry, Helene; Ang, Kian K.; Saunders, Michele; Bernier, Jacques; Horiot, Jean-Claude; Le Maitre, Aurlie; Pajak, Thomas F.; Paulsen, Michael G.; O'Sullivan, Brian; Dobrowsky, Werner; Hliniak, Andrzej; Skladowski, Krzysztof; Hay, John H.; Pinto, Luiz H. J.; Fallai, Carlo; Fu, Karen K.; Sylvester, Richard; Pignon, Jean-Pierre		Carcinomas, MAR	Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis	LANCET			English	Article							SQUAMOUS-CELL CARCINOMA; CONVENTIONAL RADIOTHERAPY; RANDOMIZED-TRIAL; RADIATION-THERAPY; FRACTIONATION; CHEMOTHERAPY	Background Several trials have studied the role of unconventional fractionated radiotherapy in head and neck squamous cell carcinoma, but the effect of such treatment on survival is not clear. The aim of this meta-analysis was to assess whether this type of radiotherapy could improve survival. Methods Randomised trials comparing conventional radiotherapy with hyperfractionated or accelerated radiotherapy, or both, in patients with non-metastatic HNSCC were identified and updated individual patient data were obtained. Overall survival was the main endpoint. Trials were grouped in three pre-specified categories: hyperfractionated, accelerated, and accelerated with total dose reduction. Findings 15 trials with 6515 patients were included. The median follow-up was 6 years. Tumours sites were mostly oropharynx and larynx; 5221 (74%) patients had stage III-IV disease (International Union Against Cancer, 1987). There was a significant survival benefit with altered fractionated radiotherapy, corresponding to an absolute benefit of 3.4% at 5 years (hazard ratio 0.92, 95% CI 0.86-0.97; p=0.003). The benefit was significantly higher with hyperfractionated radiotherapy (8% at 5 years) than with accelerated radiotherapy (2% with accelerated fractionation without total dose reduction and 1.7% with total dose reduction at 5 years, p=0.02). There was a benefit on locoregional control in favour of altered fractionation versus conventional radiotherapy (6.4% at 5 years; p<0.0001), which was particularly efficient in reducing local failure, whereas the benefit on nodal control was less pronounced. The benefit was significantly higher in the youngest patients (hazard ratio 0.78 [0.65-0.94] for under 50 year olds, 0.95 [0.83-1.09] for 51-60 year olds, 0.92 [0.81-1.06] for 61-70 year olds, and 1.08 [0.89-1.30] for over 70 year olds; test for trends p=0.007). Interpretation Altered fractionated radiotherapy improves survival in patients with head and neck squamous cell carcinoma. Comparison of the different types of altered radiotherapy suggests that hyperfractionation has the greatest benefit.	Inst Gustave Roussy, Dept Biostat & Epidemiol, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Radiat Oncol, Villejuif, France; Danish Canc Soc, Dept Expt Clin Oncol, DK-8000 Aarhus, Denmark; Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; Mt Vernon Hosp, Northwood HA6 2RN, Middx, England; Univ Geneva, Fac Med, CH-1211 Geneva 4, Switzerland; Ctr F Leclerc, Dijon, France; RTOG Stat Headquarters, Philadelphia, PA USA; So Zone Radiat Oncol Mater Ctr, Brisbane, Qld, Australia; Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON M4X 1K9, Canada; Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Oncol Inst Ctr, Warsaw, Poland; Maria Curie Mem Inst, Gliwice, Poland; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Inst Nacl Canc, Rio De Janeiro, Brazil; Ist Nazl Tumori, Dipartimento Radiotherapia, I-20133 Milan, Italy; Univ Calif San Francisco, San Francisco, CA 94143 USA; EORTC Stat Headquarters, Brussels, Belgium	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Danish Cancer Society; University of Texas System; UTMD Anderson Cancer Center; University of Geneva; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Newcastle General Hospital; Maria Sklodowska-Curie National Research Institute of Oncology; British Columbia Cancer Agency; National Cancer Institute (Inca); Fondazione IRCCS Istituto Nazionale Tumori Milan; University of California System; University of California San Francisco	Pignon, J (corresponding author), Inst Gustave Roussy, Dept Biostat & Epidemiol, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	jppignon@igr.fr	Fallai, Carlo/J-3936-2017; Składowski, Krzysztof/GLV-3023-2022; Bernier, Jacques/AAE-7248-2020; Poulsen, Michael/F-4858-2010; Pinto, Luiz Henrique/D-9561-2013	Fallai, Carlo/0000-0001-8070-0282; Składowski, Krzysztof/0000-0002-0554-6171; Bernier, Jacques/0000-0002-0138-9906; Poulsen, Michael/0000-0002-3410-1382; Bourhis, Jean/0000-0001-5162-1171; PIGNON, Jean-Pierre/0000-0003-2047-1582	NCI NIH HHS [2U10CA11488-36] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE O, 1995, NEW ENGL J MED, V333, P1444; ALBERTI W, 1995, BRIT MED J, V311, P899; [Anonymous], 1992, Lancet, V339, P1; BOURHIS J, 2004, P AN M AM SOC CLIN, V22, P488; Bourhis J, 2006, J CLIN ONCOL, V24, p280S; Bourhis J, 2006, J CLIN ONCOL, V24, P2873, DOI 10.1200/JCO.2006.08.057; Cummings B., 2000, Radiotherapy and Oncology, V56, pS8; DATTA N R, 1989, International Journal of Radiation Oncology, Biology, Physics, V17, P132; Dische S, 1997, RADIOTHER ONCOL, V44, P123, DOI 10.1016/S0167-8140(97)00094-7; Dobrowsky W, 2000, RADIOTHER ONCOL, V57, P119, DOI 10.1016/S0167-8140(00)00233-4; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Fu KK, 2000, INT J RADIAT ONCOL, V48, P7, DOI 10.1016/S0360-3016(00)00663-5; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hliniak A, 2002, RADIOTHER ONCOL, V62, P1, DOI 10.1016/S0167-8140(01)00494-7; HORIOT JC, 1992, RADIOTHER ONCOL, V25, P231, DOI 10.1016/0167-8140(92)90242-M; Horiot JC, 1997, RADIOTHER ONCOL, V44, P111, DOI 10.1016/S0167-8140(97)00079-0; Jackson SM, 1997, RADIOTHER ONCOL, V43, P39, DOI 10.1016/S0167-8140(97)01944-0; Khalil AA, 2003, INT J RADIAT ONCOL, V55, P568, DOI 10.1016/S0360-3016(02)03790-2; MARCIAL VA, 1987, INT J RADIAT ONCOL, V13, P41, DOI 10.1016/0360-3016(87)90258-6; Olmi P, 2003, INT J RADIAT ONCOL, V55, P78, DOI 10.1016/S0360-3016(02)03792-6; Overgaard J, 2003, LANCET, V362, P933, DOI 10.1016/S0140-6736(03)14361-9; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; PIGNON JP, 2000, COCHRANE LIB; PINTO LHJ, 1991, INT J RADIAT ONCOL, V21, P557, DOI 10.1016/0360-3016(91)90670-Y; Poulsen MG, 2001, RADIOTHER ONCOL, V60, P113, DOI 10.1016/S0167-8140(01)00347-4; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; Skladowski K, 2000, RADIOTHER ONCOL, V55, P101, DOI 10.1016/S0167-8140(00)00139-0; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	29	766	783	0	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 2	2006	368	9538					843	854		10.1016/S0140-6736(06)69121-6	http://dx.doi.org/10.1016/S0140-6736(06)69121-6			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	082FD	16950362				2023-01-03	WOS:000240371200032
J	Nicolaidis, C				Nicolaidis, Christina			My mother's choice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												nicolaid@ohsu.edu	Nicolaidis, Christina/X-6468-2019; Nicolaidis, Christina/CAC-0028-2022	Nicolaidis, Christina/0000-0002-9394-5956; Nicolaidis, Christina/0000-0002-9394-5956					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2006	296	8					907	908		10.1001/jama.296.8.907	http://dx.doi.org/10.1001/jama.296.8.907			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076AL	16926344				2023-01-03	WOS:000239929300001
J	Alam, NH; Yunus, M; Faruque, ASG; Gyr, N; Sattar, S; Parvin, S; Ahmed, JU; Salam, MA; Sack, DA				Alam, Nur H.; Yunus, Mohammed; Faruque, Abu S. G.; Gyr, Niklaus; Sattar, Samima; Parvin, Shahanaz; Ahmed, Jamal U.; Salam, Mohammed A.; Sack, David A.			Symptomatic hyponatremia during treatment of dehydrating diarrheal disease with reduced osmolarity oral rehydration. solution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; EFFICACY; HYPOGLYCEMIA; CHILDREN; SURVEILLANCE; SHIGELLOSIS; PREVALENCE; ABSORPTION; CHILDHOOD; STANDARD	Context In May 2002, the World Health Organization and the United Nations Children's Fund recommended that the formulation of oral rehydration solution (ORS) for treatment of patients with diarrhea be changed to one with a reduced osmolarity and that safety of the new formulation, particularly development of symptomatic hyponatremia, be monitored. Objective To measure the rates of symptomatic hyponatremia during treatment of patients with diarrhea with reduced osmolarity ORS. Design, Settings, and Patients A phase 4 trial conducted at the Dhaka hospital (December 1, 2002-November 30, 2003) and Matlab hospital (February 2, 2003-January 31, 2004) of the International Centre for Diarrhoeal Disease Research Bangladesh: Centre for Health and Population Research, Dhaka, Bangladesh. All patients admitted with uncomplicated watery diarrhea were treated with the newly recommended ORS and monitored. Patients developing neurological symptoms (seizure or altered consciousness) were transferred to the special care ward for treatment and investigated to identify the cause of the symptoms. Patient records of the Dhaka hospital were reviewed during the previous year when the old ORS formulation was used. Intervention Reduced osmolarity ORS. Main Outcome Measure Incidence rate of symptomatic hyponatremia in a 1-year period. Results A total of 53 280 patients, including 22 536 children younger than 60 months, were monitored at the Dhaka and Matlab hospitals. Twenty-four patients, none older than 36 months, developed seizures or altered consciousness associated with hyponatremia, with an overall incidence rate of 0.05% (95% confidence interval [CI], 0.03%-0.07%) at the Dhaka hospital and 0.03% (95% Cl, 0.01 %-0.09%) at the Matlab hospital. During the previous year, 47 patients at the Dhaka hospital had symptoms associated with hyponatremia, for an estimated incidence rate of 0.10% (95% Cl, 0.07%-0.13%). The reduction in the rates was statistically significant (odds ratio, 0.50; 95% Cl, 0.29-0.85; P=.009). Conclusion The risk of symptoms associated with hyponatremia in patients treated with the reduced osmolarity ORS is minimal and did not increase with the change in formulation.	Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Div Clin Sci, Dhaka 1000, Bangladesh; Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Div Publ Hlth Sci, Dhaka 1000, Bangladesh; Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); University of Basel	Alam, NH (corresponding author), Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Div Clin Sci, GPO Box 128, Dhaka 1000, Bangladesh.	nhalam@icddrb.org						Alam NH, 1999, LANCET, V354, P296, DOI 10.1016/S0140-6736(98)09332-5; Alam NH, 2001, PEDIATRICS, V107, P613, DOI 10.1542/peds.107.4.613; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BENNISH ML, 1990, NEW ENGL J MED, V322, P1357, DOI 10.1056/NEJM199005103221905; CHEN LC, 1981, POPUL DEV REV, V7, P55, DOI 10.2307/1972764; Duggan C, 2004, JAMA-J AM MED ASSOC, V291, P2628, DOI 10.1001/jama.291.21.2628; ELMOUGI M, 1994, J PEDIATR GASTR NUTR, V19, P83, DOI 10.1097/00005176-199407000-00013; Farthing M J, 1989, Acta Paediatr Scand Suppl, V364, P23; Faruque ASG, 1996, SCAND J INFECT DIS, V28, P87, DOI 10.3109/00365549609027156; FAYAD IM, 1992, LANCET, V339, P389, DOI 10.1016/0140-6736(92)90079-I; Fontaine O, 2000, COCHRANE DB SYST REV; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; Hahn S, 2001, BMJ-BRIT MED J, V323, P81, DOI 10.1136/bmj.323.7304.81; HIRSCHHORN N, 1966, LANCET, V2, P128; HUNT JB, 1989, ALIMENT PHARM THERAP, V3, P565; HUNT JB, 1994, GUT, V35, P211, DOI 10.1136/gut.35.2.211; HUNT JB, 1992, GUT, V33, P1652, DOI 10.1136/gut.33.12.1652; HUSKINS WC, 1994, J PEDIATR-US, V125, P14, DOI 10.1016/S0022-3476(94)70115-6; ISLAM SS, 1986, T ROY SOC TROP MED H, V80, P748, DOI 10.1016/0035-9203(86)90374-3; JONES RG, 1966, LANCET, V2, P643; Khan WA, 1999, PEDIATRICS, V103, part. no., DOI 10.1542/peds.103.2.e18; Mahalanabis D, 1974, J Trop Pediatr Environ Child Health, V20, P82; MITRA AK, 1991, T ROY SOC TROP MED H, V85, P685, DOI 10.1016/0035-9203(91)90396-G; Molla A M, 1981, Indian Pediatr, V18, P181; MOLLA AM, 1981, J PEDIATR-US, V98, P835, DOI 10.1016/S0022-3476(81)80863-3; Murphy C, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003754.PUB2; Nalin DR, 2004, JAMA-J AM MED ASSOC, V291, P2632, DOI 10.1001/jama.291.21.2632; RAHAMAN MM, 1982, AM J PUBLIC HEALTH, V72, P1124, DOI 10.2105/AJPH.72.10.1124; RAIZADA N, 1992, Indian Pediatrics, V29, P461; RAUTANEN T, 1993, ACTA PAEDIATR, V82, P52, DOI 10.1111/j.1651-2227.1993.tb12516.x; ROLSTON DDK, 1990, GUT, V31, P1115, DOI 10.1136/gut.31.10.1115; SAMADI AR, 1985, BRIT MED J, V290, P1615, DOI 10.1136/bmj.290.6482.1615; Santosham M, 1996, J PEDIATR-US, V128, P45, DOI 10.1016/S0022-3476(96)70426-2; STOLL BJ, 1982, BRIT MED J, V285, P1185, DOI 10.1136/bmj.285.6349.1185; Thillainayagam AV, 1998, GASTROENTEROLOGY, V114, P197, DOI 10.1016/S0016-5085(98)70647-X; Uemura N, 2002, BRAIN DEV-JPN, V24, P745, DOI 10.1016/S0387-7604(02)00097-9; Victora CG, 2000, B WORLD HEALTH ORGAN, V78, P1246; WALKERSMITH JA, 1992, J PEDIATR GASTR NUTR, V14, P113, DOI 10.1097/00005176-199201000-00023; Wang Y C, 1993, Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi, V34, P451; WHO, 1995, WHOCDR953; *WHO, 2001, WHOFCHCAH0122 UNICEF	41	27	29	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2006	296	5					567	573		10.1001/jama.296.5.567	http://dx.doi.org/10.1001/jama.296.5.567			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069YW	16882963	Bronze			2023-01-03	WOS:000239486900021
J	Lau, S; Matricardi, PM				Lau, S; Matricardi, PM			Worms, asthma, and the hygiene hypothesis	LANCET			English	Editorial Material							ALLERGIC REACTIVITY; ATOPY; CHILDREN; SCHOOLCHILDREN; ASSOCIATION; INFECTIONS; PARASITES; SYMPTOMS; EXPOSURE; TRIAL		Charite Univ Med Ctr, Dept Paediat Pneumol & Immunol, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Lau, S (corresponding author), Charite Univ Med Ctr, Dept Paediat Pneumol & Immunol, D-13353 Berlin, Germany.	susanne.lau@charite.de						BUIJS J, 1994, AM J EPIDEMIOL, V140, P839, DOI 10.1093/oxfordjournals.aje.a117332; Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2; Cooper PJ, 2002, CLIN EXP IMMUNOL, V128, P398, DOI 10.1046/j.1365-2249.2002.01908.x; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Falcone FH, 2005, TRENDS PARASITOL, V21, P157, DOI 10.1016/j.pt.2005.02.002; GROVE DI, 1982, ALLERGY, V37, P139, DOI 10.1111/j.1398-9995.1982.tb01889.x; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON SG, 1968, LANCET, V1, P1118; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; *PAN AM HLTH ORG, 2001, EC HLTH SIT AN TREND; Pelosi U, 2005, ALLERGY, V60, P626, DOI 10.1111/j.1398-9995.2005.00747.x; Schafer T, 2005, ALLERGY, V60, P1014, DOI 10.1111/j.1398-9995.2005.00801.x; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Tedeschi A, 2003, CLIN EXP ALLERGY, V33, P449, DOI 10.1046/j.1365-2222.2003.01628.x; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	23	13	14	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 13	2006	367	9522					1556	1558		10.1016/S0140-6736(06)68670-4	http://dx.doi.org/10.1016/S0140-6736(06)68670-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	043JT	16698395				2023-01-03	WOS:000237598000007
J	Palumbo, A; Bringhen, S; Coravito, T; Merla, E; Capporella, V; Callea, V; Cangialosi, C; Grasso, M; Rossini, F; Galli, M; Catalano, L; Zamagni, E; Petrucci, MT; De Stefano, V; Ceccarelli, M; Ambrosini, MT; Avonto, I; Falco, P; Ciccone, G; Liberati, AM; Musto, P; Boccadoro, M				Palumbo, A; Bringhen, S; Coravito, T; Merla, E; Capporella, V; Callea, V; Cangialosi, C; Grasso, M; Rossini, F; Galli, M; Catalano, L; Zamagni, E; Petrucci, MT; De Stefano, V; Ceccarelli, M; Ambrosini, MT; Avonto, I; Falco, P; Ciccone, G; Liberati, AM; Musto, P; Boccadoro, M		GIMEMA	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial	LANCET			English	Article							LOW-DOSE THALIDOMIDE; SALVAGE THERAPY; DEXAMETHASONE; COMBINATION; DOXORUBICIN; CYCLOPHOSPHAMIDE; TRANSPLANTATION; VINCRISTINE; EFFICACY; VAD	Background Since 1960, oral melphalan and prednisone (MP) has been regarded as the standard of care in elderly multiple myeloma patients. This multicentre randomised trial compared oral MP plus thalidomide (MPT) with MP alone in patients aged 60-85 years. Methods Patients with newly diagnosed multiple myeloma were randomly assigned to receive oral MP for six 4-week cycles plus thalidomide (n=129; 100 mg per day continuously until any sign of relapse or progressive disease) or MP alone (n=126). Analysis was intention-to-treat. This study is registered at ClinicalTrial.gov, number NCT00232934. Results Patients treated with thalidomide had higher response rates and longer event-free survival (primary endpoints) than patients who were not. Combined complete or partial response rates were 76.0% for MPT and 47.6% for MP alone (absolute difference 28.3%, 95% CI 16.5-39.1), and the near-complete or complete response rates were 27.9% and 7.2%, respectively. 2-year event-free survival rates were 54% for MPT and 27% for MP (hazard ratio [HR] for MPT 0.51, 95% CI 0.35-0.75, p=0.0006). 3-year survival rates were 80% for MPT and 64% for MP (HR for MPT 0.68, 95% CI 0.38-1.22, p=0.19). Rates of grade 3 or 4 adverse events were 48% in MPT patients and 25% in MP patients (p=0.0002). Introduction of enoxaparin prophylaxis reduced rate of thromboembolism from 20% to 3% (p=0.005). Conclusion Oral MPT is an effective first-line treatment for elderly patients with multiple myeloma. Anticoagulant prophylaxis reduces frequency of thrombosis. Longer follow-up is needed to assess effect on overall survival.	Univ Turin, Div Ematol, Azienda Osped S Giovanni Battista, I-10126 Turin, Italy; Univ Roma Tor Vergata, Osped S Eugenio, Div Ematol, Rome, Italy; IRCCS Casa Sollievo Sofferenza, UO Ematol & Trapianto Cellule Staminali, San Giovanni Rotondo, Italy; Ctr Riferimento Oncol Reg, UO Ematol, Rionero In Vulture, Italy; Osped San Camillo de Lellis, Rieti, Italy; Osped Riuniti Reggio Calabria, Div Ematol, Reggio Di Calabria, Italy; Azienda Osped Cervello, Div Ematol & Trapianto Midollo Osseo, Palermo, Italy; Azienda Osped S Croce & Carle, Div Ematol, Cuneo, Italy; HS Gerardo, Monza, Italy; Osped Riuniti Bergamo, Div Ematol, Bergamo, Italy; Univ Naples Federico II, Cattedra & Div Ematol, Naples, Italy; Univ Bologna, Ist Ematol & Oncol Med Seragnoli, I-40126 Bologna, Italy; Univ Roma La Sapienza, Dipartimento Biotecnol, Rome, Italy; Univ Cattolica Sacro Cuore, Ist Ematol, I-00168 Rome, Italy; Azienda Osped S Giovanni Battista, Unita Epidemiol Tumori, Turin, Italy; CPO Piemonte, Turin, Italy; Monteluce Policlin, Med Clin 1, Perugia, Italy	A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin; Sant'Eugenio Hospital; University of Rome Tor Vergata; IRCCS Casa Sollievo Della Sofferenza; IRCCS CROB; Ospedali Riuniti di Bergamo; University of Naples Federico II; University of Bologna; Sapienza University Rome; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; Centro di Riferimento per Epidemiologia e la Prevenzione Oncologica in Piemonte	Palumbo, A (corresponding author), Univ Turin, Div Ematol, Azienda Osped S Giovanni Battista, I-10126 Turin, Italy.	appalumbo@yahoo.com	De Stefano, Valerio/J-3650-2018; Ciccone, Giovannino/K-3136-2016; Liberati, Anna Marina/C-1925-2017	De Stefano, Valerio/0000-0002-5178-5827; Ciccone, Giovannino/0000-0001-7644-9574; Boccadoro, Mario/0000-0001-8130-5209; Zamagni, Elena/0000-0003-1422-7305; Musto, Pellegrino/0000-0003-3277-6594				[Anonymous], 1998, J Clin Oncol, V16, P3832; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; BOCCADORO M, 1991, J CLIN ONCOL, V9, P444, DOI 10.1200/JCO.1991.9.3.444; Cavo M, 2005, BLOOD, V106, P35, DOI 10.1182/blood-2005-02-0522; Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Dingli D, 2005, HAEMATOLOGICA, V90, P1650; Durie BGM, 2002, SEMIN ONCOL, V29, P34, DOI 10.1053/sonc.2002.34075; Durie Brian G M, 2003, Hematol J, V4, P379; FANCON T, 2004, BLOOD, V104, P206; Ferlay J., 2004, IARC CANCERBASE; Garcia-Sanz R, 2004, LEUKEMIA, V18, P856, DOI 10.1038/sj.leu.2403322; Geitz H, 1996, IMMUNOPHARMACOLOGY, V31, P213, DOI 10.1016/0162-3109(95)00050-X; Ghobrial Irene M, 2003, J Support Oncol, V1, P194; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kropff MH, 2003, BRIT J HAEMATOL, V122, P607, DOI 10.1046/j.1365-2141.2003.04473.x; Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875; Moehler TM, 2001, BLOOD, V98, P3846, DOI 10.1182/blood.V98.13.3846; Offidani M, 2004, EUR J HAEMATOL, V72, P403, DOI 10.1111/j.1600-0609.2004.00238.x; Osman K, 2001, NEW ENGL J MED, V344, P1951, DOI 10.1056/NEJM200106213442516; Palumbo A, 2005, CANCER-AM CANCER SOC, V104, P1428, DOI 10.1002/cncr.21342; Palumbo A, 2004, BLOOD, V104, P3052, DOI 10.1182/blood-2004-02-0408; Palumbo A, 2004, HEMATOL J, V5, P318, DOI 10.1038/sj.thj.6200403; Prandoni P, 2005, LANCET ONCOL, V6, P401, DOI 10.1016/S1470-2045(05)70207-2; Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Tosi P, 2002, HAEMATOLOGICA, V87, P408; Tosi P, 2005, EUR J HAEMATOL, V74, P212, DOI 10.1111/j.1600-0609.2004.00382.x; Turk BE, 1996, P NATL ACAD SCI USA, V93, P7552, DOI 10.1073/pnas.93.15.7552; Weber D, 2003, J CLIN ONCOL, V21, P16, DOI 10.1200/JCO.2003.03.139; Yakoub-Agha Ibrahim, 2002, Hematol J, V3, P185, DOI 10.1038/sj.thj.6200175; Zangari M, 2002, BLOOD, V100, P1168, DOI 10.1182/blood-2002-01-0335; Zangari M, 2004, BRIT J HAEMATOL, V126, P715, DOI 10.1111/j.1365-2141.2004.05078.x; Zeldis JB, 1999, CLIN THER, V21, P319, DOI 10.1016/S0149-2918(00)88289-2; Zervas K, 2004, ANN ONCOL, V15, P134, DOI 10.1093/annonc/mdh026	36	633	669	2	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 11	2006	367	9513					825	831		10.1016/S0140-6736(06)68338-4	http://dx.doi.org/10.1016/S0140-6736(06)68338-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021WL	16530576				2023-01-03	WOS:000236016500027
J	Gallant, JE; DeJesus, E; Arribas, JR; Pozniak, AL; Gazzard, B; Campo, RE; Lu, B; McColl, D; Chuck, S; Enejosa, J; Toole, JJ; Cheng, AK				Gallant, JE; DeJesus, E; Arribas, JR; Pozniak, AL; Gazzard, B; Campo, RE; Lu, B; McColl, D; Chuck, S; Enejosa, J; Toole, JJ; Cheng, AK		Study 934 Grp	Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; VIRUS-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; FANCONI-SYNDROME; SERUM CREATININE; DRUG-RESISTANCE; RENAL-FAILURE; ABACAVIR; ADULTS; ABNORMALITIES	BACKGROUND: Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere. METHODS: We conducted an open-label, noninferiority study involving 517 patients with HIV infection who had not previously received antiretroviral therapy and who were randomly assigned to receive either a regimen of tenofovir disoproxil fumarate (DF), emtricitabine, and efavirenz once daily (tenofovir-emtricitabine group) or a regimen of fixed-dose zidovudine and lamivudine twice daily plus efavirenz once daily (zidovudine-lamivudine group). The primary end point was the proportion of patients without baseline resistance to efavirenz in whom the HIV RNA level was less than 400 copies per milliliter at week 48 of the study. RESULTS: Through week 48, significantly more patients in the tenofovir-emtricitabine group reached and maintained the primary end point of less than 400 copies of HIV RNA per milliliter than did those in the zidovudine-lamivudine group (84 percent vs. 73 percent, respectively; 95 percent confidence interval for the difference, 4 to 19 percent; P=0.002). This difference excludes the inferiority of the tenofovir DF, emtricitabine, and efavirenz regimen, indicating a significantly greater response with this regimen. Significant differences were also seen in the proportion of patients with HIV RNA levels of less than 50 copies per milliliter (80 percent in the tenofovir-emtricitabine group vs. 70 percent in the zidovudine-lamivudine group; 95 percent confidence interval for the difference, 2 to 17 percent; P=0.02) and in increases in CD4 cell counts (190 vs. 158 cells per cubic millimeter, respectively; 95 percent confidence interval for the difference, 9 to 55; P=0.002). More patients in the zidovudine-lamivudine group than in the tenofovir-emtricitabine group had adverse events resulting in discontinuation of the study drugs (9 percent vs. 4 percent, respectively; P=0.02). In none of the patients did the K65R mutation develop. CONCLUSIONS: Through week 48, the combination of tenofovir DF and emtricitabine plus efavirenz fulfilled the criteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efavirenz and proved superior in terms of virologic suppression, CD4 response, and adverse events resulting in discontinuation of the study drugs.	Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21287 USA; Orlando Immunol Ctr, Orlando, FL USA; Hosp La Paz, Madrid, Spain; Chelsea & Westminster Hosp, London, England; Univ Miami, Miami, FL 33152 USA; Gilead Sci Inc, Foster City, CA 94404 USA	Johns Hopkins University; Orlando Immunology Center; Hospital Universitario La Paz; Imperial College London; University of Miami; Gilead Sciences	Gallant, JE (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, 1830 E Monument St,Rm 443, Baltimore, MD 21287 USA.	jgallant@jhmi.edu	Arribas, Jose/A-1595-2015	Arribas, Jose/0000-0002-7410-9450				Bogner JR, 2001, J ACQ IMMUN DEF SYND, V27, P237, DOI 10.1097/00126334-200107010-00004; CASSETTI I, 2005, 3 IAS INT AIDS SOC C; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Creput C, 2003, AIDS, V17, P935, DOI 10.1097/00002030-200304110-00026; DeJesus E, 2004, CLIN INFECT DIS, V39, P1038, DOI 10.1086/424009; *DEP HLTH HUM SERV, 2005, PAN CLIN PRACT TREAT; Dube MP, 2005, AIDS, V19, P1807, DOI 10.1097/01.aids.0000183629.20041.bb; Gallant JE, 2005, CLIN INFECT DIS, V40, P1194, DOI 10.1086/428840; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Heath KV, 2002, J ACQ IMMUN DEF SYND, V30, P440, DOI [10.1097/00042560-200208010-00010, 10.1097/01.QAI.0000021701.48448.20]; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; Karras A, 2003, CLIN INFECT DIS, V36, P1070, DOI 10.1086/368314; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Mallal SA, 2000, AIDS, V14, P1309, DOI 10.1097/00002030-200007070-00002; Martin A, 2004, AIDS, V18, P1029, DOI 10.1097/00002030-200404300-00011; McComsey GA, 2004, CLIN INFECT DIS, V38, P263, DOI 10.1086/380790; MILLER MD, 2002, 6 INT C DRUG THER HI; MOYLE G, 2005, 12 C RETR OPP INF BO; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *REG COMPL CTR, 1992, DIV AIDS DAIDS TABL; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Rollot F, 2003, CLIN INFECT DIS, V37, pE174, DOI 10.1086/379829; Saint-Marc T, 2000, AIDS, V14, P37, DOI 10.1097/00002030-200001070-00005; Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; US Department of Health and Human Services Food and Drug Administration, 2002, GUID IND ANT DRUGS U; Verhelst D, 2002, AM J KIDNEY DIS, V40, P1331, DOI 10.1053/ajkd.2002.36924	27	712	736	3	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					251	260		10.1056/NEJMoa051871	http://dx.doi.org/10.1056/NEJMoa051871			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421366				2023-01-03	WOS:000234661100005
J	Mohr, I				Mohr, I			To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control	ONCOGENE			English	Review						translational control; oncolytic virus	HERPES-SIMPLEX-VIRUS; VESICULAR STOMATITIS-VIRUS; HOST SHUTOFF PROTEIN; CAP-DEPENDENT TRANSLATION; INITIATION-FACTOR 4E; RNA-BINDING-PROTEIN; TYPE-1 MUTANT G207; MESSENGER-RNA; GAMMA(1)34.5 PROTEIN; WILD-TYPE	To ensure that their mRNAs are translated and that the viral proteins necessary for assembling the next generation of infectious progeny are produced, viruses must effectively seize control of the translational machinery within their host cells. In many cases, the ability to productively engage host translational components can determine if a given cell type can support viral replication, illustrating the critical importance of this task in the viral life cycle. Failure to interface properly with the host translational apparatus can compromise the productive growth cycle, resulting in an abortive infection and radically restricting viral replication. Not only have viruses become facile at commandeering this machinery, they are also particularly adept at manipulating cellular translation control pathways for their own ends. In this review, the mechanisms by which numerous viruses manipulate host translational control circuits are discussed. Furthermore, particular attention is devoted to understanding how interfering with the ability of a virus to properly regulate translation in its host can be exploited to generate oncolytic strains that selectively replicate in cancer cells.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University	Mohr, I (corresponding author), NYU, Sch Med, Dept Microbiol, MSB-214,550 1st Ave, New York, NY 10016 USA.	ian.mohr@med.nyu.edu						Advani SJ, 1999, CANCER RES, V59, P2055; Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Ahmed M, 2004, VIROLOGY, V330, P34, DOI 10.1016/j.virol.2004.08.039; Andreansky S, 1997, CANCER RES, V57, P1502; Andreansky SS, 1996, P NATL ACAD SCI USA, V93, P11313, DOI 10.1073/pnas.93.21.11313; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Barber GN, 2005, ONCOGENE, V24, P7710, DOI 10.1038/sj.onc.1209042; BARTKOSKI M, 1976, J VIROL, V20, P583, DOI 10.1128/JVI.20.3.583-588.1976; BOLOVAN CA, 1994, J VIROL, V68, P48, DOI 10.1128/JVI.68.1.48-55.1994; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; CAI WH, 1993, J VIROL, V67, P7501, DOI 10.1128/JVI.67.12.7501-7512.1993; Caron S, 2004, MOL CELL BIOL, V24, P4920, DOI 10.1128/MCB.24.11.4920-4928.2004; Cerveny M, 2003, VIROLOGY, V307, P290, DOI 10.1016/S0042-6822(02)00075-2; CHAMBERS R, 1995, P NATL ACAD SCI USA, V92, P1411, DOI 10.1073/pnas.92.5.1411; Cheng GF, 2001, VIROLOGY, V290, P115, DOI 10.1006/viro.2001.1148; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; Chung RY, 1999, J VIROL, V73, P7556, DOI 10.1128/JVI.73.9.7556-7564.1999; Connor JH, 2004, J VIROL, V78, P8960, DOI 10.1128/JVI.78.17.8960-8970.2004; Connor JH, 2002, J VIROL, V76, P10177, DOI 10.1128/JVI.76.20.10177-10187.2002; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Cuesta R, 2000, EMBO J, V19, P3465, DOI 10.1093/emboj/19.13.3465; Doepker RC, 2004, J VIROL, V78, P4684, DOI 10.1128/JVI.78.9.4684-4699.2004; Duerst RJ, 2004, VIROLOGY, V322, P158, DOI 10.1016/j.virol.2004.01.019; ELSHIEKH NA, 1991, J VIROL, V65, P6430, DOI 10.1128/JVI.65.12.6430-6437.1991; Everett RD, 2000, BIOESSAYS, V22, P761, DOI 10.1002/1521-1878(200008)22:8<761::AID-BIES10>3.0.CO;2-A; Everly DN, 2002, J VIROL, V76, P8560, DOI 10.1128/JVI.76.17.8560-8571.2002; Faria PA, 2005, MOL CELL, V17, P93, DOI 10.1016/j.molcel.2004.11.023; Feng PH, 2001, J VIROL, V75, P10272, DOI 10.1128/JVI.75.21.10272-10280.2001; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gromeier M, 1996, P NATL ACAD SCI USA, V93, P2370, DOI 10.1073/pnas.93.6.2370; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Gross JD, 2003, CELL, V115, P739, DOI 10.1016/S0092-8674(03)00975-9; Hagglund R, 2004, J VIROL, V78, P2169, DOI 10.1128/JVI.78.5.2169-2178.2004; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Halford WP, 2001, J VIROL, V75, P3240, DOI 10.1128/JVI.75.7.3240-3249.2001; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; Hunter WD, 1999, J VIROL, V73, P6319, DOI 10.1128/JVI.73.8.6319-6326.1999; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; JACQUEMONT B, 1975, J VIROL, V15, P707, DOI 10.1128/JVI.15.4.707-713.1975; Kahvejian A, 2001, COLD SPRING HARB SYM, V66, P293, DOI 10.1101/sqb.2001.66.293; Kahvejian A, 2005, GENE DEV, V19, P104, DOI 10.1101/gad.1262905; Kauder SE, 2004, J CLIN INVEST, V113, P1743, DOI 10.1172/JCI200421323; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KESARI S, 1995, LAB INVEST, V73, P636; Kesari S, 1998, J GEN VIROL, V79, P525, DOI 10.1099/0022-1317-79-3-525; Khaleghpour K, 2001, MOL CELL, V7, P205, DOI 10.1016/S1097-2765(01)00168-X; Khoo D, 2002, J VIROL, V76, P11971, DOI 10.1128/JVI.76.23.11971-11981.2002; Kramm CM, 1997, HUM GENE THER, V8, P2057, DOI 10.1089/hum.1997.8.17-2057; Lasner TM, 1998, J NEUROVIROL, V4, P100, DOI 10.3109/13550289809113487; Leib DA, 2000, P NATL ACAD SCI USA, V97, P6097, DOI 10.1073/pnas.100415697; Leib DA, 1999, J EXP MED, V189, P663, DOI 10.1084/jem.189.4.663; Lichtenstein DL, 2004, CANCER GENE THER, V11, P819, DOI 10.1038/sj.cgt.7700765; Lichty BD, 2004, TRENDS MOL MED, V10, P210, DOI 10.1016/j.molmed.2004.03.003; Liu BL, 2003, GENE THER, V10, P292, DOI 10.1038/sj.gt.3301885; Lium EK, 1997, J VIROL, V71, P8602, DOI 10.1128/JVI.71.11.8602-8614.1997; MACLEAN AR, 1991, J GEN VIROL, V72, P631, DOI 10.1099/0022-1317-72-3-631; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Marissen WE, 2000, CELL DEATH DIFFER, V7, P1234, DOI 10.1038/sj.cdd.4400750; MARKERT JM, 1993, NEUROSURGERY, V32, P597, DOI 10.1227/00006123-199304000-00016; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Markovitz NS, 1997, J VIROL, V71, P5560, DOI 10.1128/JVI.71.7.5560-5569.1997; MEIGNIER B, 1990, J INFECT DIS, V162, P313, DOI 10.1093/infdis/162.2.313; MEIGNIER B, 1988, J INFECT DIS, V158, P602, DOI 10.1093/infdis/158.3.602; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Mohr I, 2004, INT REV IMMUNOL, V23, P199, DOI 10.1080/08830180490265600; Mohr I, 2003, EXPERT OPIN BIOL TH, V3, P113, DOI 10.1517/eobt.3.1.113.20950; Mohr I, 1996, EMBO J, V15, P4759, DOI 10.1002/j.1460-2075.1996.tb00853.x; Mohr I, 2001, J VIROL, V75, P5189, DOI 10.1128/JVI.75.11.5189-5196.2001; Mulvey M, 2004, J VIROL, V78, P10193, DOI 10.1128/JVI.78.18.10193-10196.2004; Mulvey M, 2003, J VIROL, V77, P10917, DOI 10.1128/JVI.77.20.10917-10928.2003; Mulvey M, 1999, J VIROL, V73, P3375, DOI 10.1128/JVI.73.4.3375-3385.1999; Murphy JA, 2003, J VIROL, V77, P9337, DOI 10.1128/JVI.77.17.9337-9345.2003; Nakamura H, 2002, J CLIN INVEST, V109, P871, DOI 10.1172/JCI200210623; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Pe'ery T, 2000, COLD SPRING HARBOR M, V39, P371; Peters GA, 2002, J VIROL, V76, P11054, DOI 10.1128/JVI.76.21.11054-11064.2002; Poppers J, 2000, J VIROL, V74, P11215, DOI 10.1128/JVI.74.23.11215-11221.2000; Pyles RB, 1997, HUM GENE THER, V8, P533, DOI 10.1089/hum.1997.8.5-533; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; QUIROZ E, 1988, AM J TROP MED HYG, V39, P312, DOI 10.4269/ajtmh.1988.39.312; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; RANDAZZO BP, 1995, VIROLOGY, V211, P94, DOI 10.1006/viro.1995.1382; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; READ GS, 1983, J VIROL, V46, P498, DOI 10.1128/JVI.46.2.498-512.1983; Rodriguez LL, 2002, VIRUS RES, V85, P211, DOI 10.1016/S0168-1702(02)00026-6; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; ROIZMAN B, 2001, FIELDS VIROLOGY, P2239; SACKS WR, 1987, J VIROL, V61, P829, DOI 10.1128/JVI.61.3.829-839.1987; Sandri-Goldin RM, 2004, J VIROL, V78, P4389, DOI 10.1128/JVI.78.9.4389-4396.2004; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; SINKOVICS J, 1993, INTERVIROLOGY, V36, P193, DOI 10.1159/000150339; Smith TJ, 2002, J VIROL, V76, P2054, DOI 10.1128/JVI.76.5.2054-2061.2002; STANNERS CP, 1971, J CELL PHYSIOL, V77, P31, DOI 10.1002/jcp.1040770105; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; STOW ND, 1986, J GEN VIROL, V67, P2571, DOI 10.1099/0022-1317-67-12-2571; STRELOW LI, 1995, J VIROL, V69, P6779, DOI 10.1128/JVI.69.11.6779-6786.1995; Sundaresan P, 2000, J VIROL, V74, P3832, DOI 10.1128/JVI.74.8.3832-3841.2000; Taneja S, 2001, P NATL ACAD SCI USA, V98, P8804, DOI 10.1073/pnas.161011798; THOMAS G, 1986, J CELL BIOL, V103, P2137, DOI 10.1083/jcb.103.6.2137; THOMAS G, 1979, CELL BIOL INT REP, V3, P307, DOI 10.1016/S0309-1651(79)80001-6; THOMAS G, 1981, P NATL ACAD SCI-BIOL, V78, P5712, DOI 10.1073/pnas.78.9.5712; Todo T, 2001, P NATL ACAD SCI USA, V98, P6396, DOI 10.1073/pnas.101136398; Walsh D, 2005, J VIROL, V79, P8057, DOI 10.1128/JVI.79.13.8057-8064.2005; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Xi QR, 2005, J VIROL, V79, P5676, DOI 10.1128/JVI.79.9.5676-5683.2005; Xi QR, 2004, GENE DEV, V18, P1997, DOI 10.1101/gad.1212504; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557	127	23	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7697	7709		10.1038/sj.onc.1209053	http://dx.doi.org/10.1038/sj.onc.1209053			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299530	Bronze			2023-01-03	WOS:000233372600006
J	Russo, T; Volterra, V				Russo, T; Volterra, V			Comment on "Children creating core properties of language: Evidence from an emerging sign language in Nicaragua"	SCIENCE			English	Editorial Material							FACULTY		Univ Calabria, Dept Philosophy, I-87036 Arcavacata Di Rende, CS, Italy; CNR, Inst Cognit Sci & Technol, I-00161 Rome, Italy	University of Calabria; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze e Tecnologie della Cognizione (ISTC-CNR)	Russo, T (corresponding author), Univ Calabria, Dept Philosophy, Via Piero Bucci, I-87036 Arcavacata Di Rende, CS, Italy.	t.russo@mclink.it; virginia.volterra@istc.cnr.it	volterra, virginia/C-4322-2015	VOLTERRA, VIRGINIA/0000-0003-3018-9951				BATES E, 1984, MONOGR SOC RES CHILD, V49, P130; Boyes-Braem P., 2001, HANDS ARE HEAD MOUTH; Fusellier-Souza I., 2001, ACQUISITION INTERACT, V15, P61; Fusellier-Souza Ivani., 2004, THESIS U PARIS FRANC; Hauser MD, 2002, SCIENCE, V298, P1569, DOI 10.1126/science.298.5598.1569; LAUDANNA A, 1991, APPL PSYCHOLINGUIST, V12, P135, DOI 10.1017/S0142716400009115; McNeill D., 1992, HAND MIND WHAT GESTU; McNeill D., 2002, ACTA LINGUIST HAF, V34, P7, DOI DOI 10.1080/03740463.2002.10414607; Pinker S, 2005, COGNITION, V95, P201, DOI 10.1016/j.cognition.2004.08.004; PIZZUTO E, 2003, COARTICOLAZIONE, P59; Senghas A, 2004, SCIENCE, V305, P1779, DOI 10.1126/science.1100199; Volterra V., 1994, GESTURE LANGUAGE HEA	12	9	9	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2005	309	5731								10.1126/science.1107876	http://dx.doi.org/10.1126/science.1107876			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	941KD	15994513				2023-01-03	WOS:000230212800028
J	Akram, R				Akram, R			I am a better doctor now	LANCET			English	Editorial Material									Univ Hosp Aintree, Aintree Cardiac Ctr, Liverpool L9 7AL, Merseyside, England		Akram, R (corresponding author), Univ Hosp Aintree, Aintree Cardiac Ctr, Liverpool L9 7AL, Merseyside, England.	razasida@hotmail.com							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2005	365	9477					2149	2149		10.1016/S0140-6736(05)66740-2	http://dx.doi.org/10.1016/S0140-6736(05)66740-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936LZ	15964455				2023-01-03	WOS:000229858800034
J	Merriman, A; Kaur, M				Merriman, A; Kaur, M			Palliative care in Africa: an appraisal	LANCET			English	Editorial Material									Hospice Africa, Policy & Int Programmes, Kampala, Uganda		Merriman, A (corresponding author), Hospice Africa, Policy & Int Programmes, POB 7757, Kampala, Uganda.	anne@hospiceafrica.or.ug						Defilippi K, 2004, PALLIATIVE MED, V18, P583, DOI 10.1191/0269216304pm954ed; GARBUS L, 2003, HIV AIDS UGANDA; Kikule E, 2003, BRIT MED J, V327, P192, DOI 10.1136/bmj.327.7408.192; MERRIMAN A, 1991, J CHRISTIAN MED COMM; Murray SA, 2003, BRIT MED J, V326, P368, DOI 10.1136/bmj.326.7385.368; Sepulveda C, 2003, BRIT MED J, V327, P209, DOI 10.1136/bmj.327.7408.209; *USAID, 2005, PRES EM PLAN AIDS RE; *WHO, 2005, PALL CAR	8	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1909	1911		10.1016/S0140-6736(05)66638-X	http://dx.doi.org/10.1016/S0140-6736(05)66638-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936406				2023-01-03	WOS:000229587800007
J	Systrom, DM; Wittram, C; Harris, NL; Thorner, AR; Mark, EJ				Systrom, DM; Wittram, C; Harris, NL; Thorner, AR; Mark, EJ			A 67-year-old man with acute respiratory failure - Hypersensitivity pneumonitis due to M-avium complex infection (hot-tub lung).	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESOLUTION COMPUTED-TOMOGRAPHY; COMMUNITY-ACQUIRED PNEUMONIA; THIN-SECTION CT; INTERSTITIAL PNEUMONIA; MYCOPLASMA-PNEUMONIAE; EXPOSURE; DISEASE		Massachusetts Gen Hosp, Dept Pulm & Crit Care, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Systrom, DM (corresponding author), Massachusetts Gen Hosp, Dept Pulm & Crit Care, Boston, MA 02114 USA.			Systrom, David/0000-0002-9610-6330				Agusti C, 2002, AM J RESP CRIT CARE, V166, P426; Aksamit Timothy R, 2003, Semin Respir Infect, V18, P33, DOI 10.1053/srin.2003.50003; American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, AM J RESP CRIT CARE, V165, P277, DOI [10.1164/ajrccm.165.2.ats01, DOI 10.1164/AJRCCM.165.2.ATS01]; BLACKMORE TK, 1995, PATHOLOGY, V27, P177, DOI 10.1080/00313029500169832; Burns MJ, 1997, CHEST, V111, P816, DOI 10.1378/chest.111.3.816; Cappelluti E, 2003, ARCH INTERN MED, V163, P845, DOI 10.1001/archinte.163.7.845; Choi YH, 2000, CHEST, V117, P117, DOI 10.1378/chest.117.1.117; Embil J, 1997, CHEST, V111, P813, DOI 10.1378/chest.111.3.813; Gruden JF, 1999, RADIOLOGY, V210, P711, DOI 10.1148/radiology.210.3.r99mr21711; Hunninghake GW, 2003, CHEST, V124, P1215, DOI 10.1378/chest.124.4.1215; Johkoh T, 1999, RADIOLOGY, V212, P567, DOI 10.1148/radiology.212.2.r99au05567; Kahana LM, 1997, CHEST, V111, P242, DOI 10.1378/chest.111.1.242; Khoor A, 2001, AM J CLIN PATHOL, V115, P755, DOI 10.1309/JRDC-0MJV-ACA3-2U9L; Marchiori E, 2001, J THORAC IMAG, V16, P127, DOI 10.1097/00005382-200104000-00012; Marrie TJ, 1996, AM J MED, V101, P508, DOI 10.1016/S0002-9343(96)00255-0; Miyashita N, 2004, RESP MED, V98, P542, DOI 10.1016/j.rmed.2003.11.012; Nobauer-Huhmann IM, 2001, EUR RADIOL, V11, P2436, DOI 10.1007/s003300101103; Pham RV, 2003, J THORAC IMAG, V18, P48, DOI 10.1097/00005382-200301000-00008; Philit F, 2002, AM J RESP CRIT CARE, V166, P1235, DOI 10.1164/rccm.2112056; Rickman OB, 2002, MAYO CLIN PROC, V77, P1233, DOI 10.4065/77.11.1233; Schwartzstein RM, 2000, NEW ENGL J MED, V343, P642, DOI 10.1056/NEJM200008313430908; VERWEIJ PE, 1995, CLIN INFECT DIS, V20, P440, DOI 10.1093/clinids/20.2.440; 2003, MMWR MORB MORTAL WKL, V52, P269	23	9	10	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1238	1246		10.1056/NEJMcpc059003	http://dx.doi.org/10.1056/NEJMcpc059003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788501				2023-01-03	WOS:000227832300012
J	Sanders, J; Peters, TJ; Campbell, R				Sanders, Julia; Peters, Tim J.; Campbell, Rona			Effectiveness and acceptability of lidocaine spray in reducing perineal pain during spontaneous vaginal delivery: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSITION	Objectives To evaluate the effectiveness and acceptability of a lidocaine spray in reducing perineal pain during spontaneous vaginal delivery. Design Randomised controlled trial. Setting Consultant led obstetric unit. Participants 185 women who had a spontaneous vaginal delivery without epidural analgesia. Interventions Topically applied local anaesthetic spray (93 women) and placebo spray (92 women). Main outcome measure Primary outcome measure was pain during delivery (0-100 scale). The 16 secondary outcome measures included second degree perineal trauma during delivery, trauma of the genital tract, and dyspareunia by two months. Results Lidocaine spray did not reduce pain during spontaneous vaginal delivery: mean 77 and 72 on a scale of 0-100 in the lidocaine and placebo groups, respectively (difference between means 4.8, 95% confidence interval - 1.7 to 11.2). Lidocaine spray may reduce genital tract trauma during delivery, in particular second degree perineal trauma. The intervention was highly acceptable to the women and midwives. Conclusions Although lidocaine spray applied to the perineum during spontaneous vaginal delivery did not reduce perineal pain, it was acceptable to both the women and the midwives.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Bristol, Dept Community Based Med, Acad Unit Primary Hlth Care, Bristol BS8 1TH, Avon, England	University of Bristol; University of Bristol	Sanders, J (corresponding author), Univ Wales Hosp, Midwifery Led Unit, Cardiff CF14 4XN, Wales.	julia.sanders@cardiffandvale.wales.nhs.uk		Peters, Tim/0000-0003-2881-4180				Armitage P., 2002, STAT METHODS MED RES, V4th; BARKER DP, 1995, ARCH DIS CHILD-FETAL, V72, pF203, DOI 10.1136/fn.72.3.F203; BARRETT DA, 1994, ARCH DIS CHILD-FETAL, V71, pF122, DOI 10.1136/fn.71.2.F122; BLANKENBAKER WL, 1975, ANESTHESIOLOGY, V42, P325, DOI 10.1097/00000542-197503000-00016; GUPTA JK, 2000, DATABASE SYST REV; HODNETT ED, 1987, RES NURS HEALTH, V10, P301, DOI 10.1002/nur.4770100503; Johanson RBMB., 2000, COCHRANE DB SYST REV, V2, DOI 10.1002/14651858.CD000224; KUMAR R, 1984, J PSYCHOSOM RES, V28, P43, DOI 10.1016/0022-3999(84)90039-4; Labrecque H, 2000, AM J OBSTET GYNECOL, V182, P76, DOI 10.1016/S0002-9378(00)70493-5; McCandlish R, 1998, BRIT J OBSTET GYNAEC, V105, P1262, DOI 10.1111/j.1471-0528.1998.tb10004.x; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; *NAT PER EP UN, 1986, CLASS BIBL CONTR TRI; NIVEN C, 1984, SOC SCI MED, V19, P1347, DOI 10.1016/0277-9536(84)90023-6; PETRIE RH, 1974, AM J OBSTET GYNECOL, V120, P791, DOI 10.1016/0002-9378(74)90583-3; PHILIPSON EH, 1984, AM J OBSTET GYNECOL, V149, P403, DOI 10.1016/0002-9378(84)90154-6; Pocock SJ., 2013, CLIN TRIALS PRACTICA; Renfrew MJ, 1998, BIRTH-ISS PERINAT C, V25, P143; Sanders J, 2005, MIDWIFERY, V21, P154, DOI 10.1016/j.midw.2004.12.003; Shipman MK, 1997, BRIT J OBSTET GYNAEC, V104, P787, DOI 10.1111/j.1471-0528.1997.tb12021.x; SIKORSKI J, 1995, ANTENATAL CARE PROJE; STEWART P, 1989, BRIT J OBSTET GYNAEC, V96, P327, DOI 10.1111/j.1471-0528.1989.tb02393.x; THOMAS J, 1969, BRIT J ANAESTH, V41, P442, DOI 10.1093/bja/41.5.442; WALDENSTROM U, 1991, BIRTH-ISS PERINAT C, V18, P5, DOI 10.1111/j.1523-536X.1991.tb00045.x; ZANDOR G, 1974, ACTA OBSTET GYNECO S, V34, P51; 2004, COCHRANE DATABASE SY	25	9	10	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 15	2006	333	7559					117	119		10.1136/bmj.38878.833241.7C	http://dx.doi.org/10.1136/bmj.38878.833241.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	065JK	16807257	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000239155900014
J	Ugolev, Y; Molshanski-Mor, S; Weinbaum, C; Pick, E				Ugolev, Yelena; Molshanski-Mor, Shahar; Weinbaum, Carolyn; Pick, Edgar			Liposomes comprising anionic but not neutral phospholipids cause dissociation of rac(1 or 2)center dot RhoGDI complexes and support amphiphile-independent NADPH oxidase activation by such complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CELL-FREE SYSTEM; GTP-BINDING PROTEIN; RESPIRATORY BURST OXIDASE; DEPENDENT SUPEROXIDE PRODUCTION; ADENINE-DINUCLEOTIDE PHOSPHATE; SODIUM DODECYL-SULFATE; RHO PROTEINS; POLYMORPHONUCLEAR LEUKOCYTES; MEMBRANE TRANSLOCATION; CYTOSOLIC COMPONENT	Activation of the phagocyte NADPH oxidase involves the assembly of a membrane-localized cytochrome b(559) with the cytosolic components p47(phox), p67(phox), p40(phox), and the GTPase Rac (1 or 2). In resting phagocytes, Rac is found in the cytosol as a prenylated protein in the GDP-bound form, associated with the Rho GDP dissociation inhibitor (RhoGDI). In the process of NADPH oxidase activation, Rac is dissociated from RhoGDI and translocates to the membrane, in concert with the other cytosolic components. The mechanism responsible for dissociation of Rac from RhoGDI is poorly understood. We generated Rac(1 or 2)center dot RhoGDI complexes in vitro from recombinant Rac(1 or 2), prenylated enzymatically, and recombinant RhoGDI, and purified these by anion exchange chromatography. Exposing Rac(1 or 2)center dot(GDP)center dot RhoGDI complexes to liposomes containing four different anionic phospholipids caused the dissociation of Rac(1 or 2)( GDP) from RhoGDI and its binding to the anionic liposomes. Rac2(GDP)center dot RhoGDI complexes were more resistant to dissociation, reflecting the lesser positive charge of Rac2. Liposomes consisting of neutral phospholipid did not cause dissociation of Rac(1 or 2)center dot RhoGDI complexes. Rac1 exchanged to the hydrolysis-resistant GTP analogue, GMPPNP, associated with RhoGDI with lower affinity than Rac1( GDP) and Rac1(GMPPNP)center dot RhoGDI complexes were more readily dissociated by anionic liposomes. Rac1(GMPPNP)center dot RhoGDI complexes elicited NADPH oxidase activation in native phagocyte membrane liposomes in the presence of p67(phox), without the need for an anionic amphiphile, as activator. Both Rac1(GDP)center dot RhoGDI and Rac1(GMPPNP)center dot RhoGDI complexes elicited amphiphile-independent, p67(phox)-dependent NADPH oxidase activation in phagocyte membrane liposomes enriched in anionic phospholipids but not in membrane liposomes enriched in neutral phospholipids.	Tel Aviv Univ, Dept Human Microbiol, Sackler Sch Med, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Ela Kodesz Inst Host Def Infect Dis, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Duke University	Pick, E (corresponding author), Tel Aviv Univ, Dept Human Microbiol, Sackler Sch Med, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel.	epick@post.tau.ac.il	Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233	NIGMS NIH HHS [GM46372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; Alloul N, 2001, BIOCHEMISTRY-US, V40, P14557, DOI 10.1021/bi0117347; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bokoch GM, 2005, TRENDS CELL BIOL, V15, P163, DOI 10.1016/j.tcb.2005.01.002; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CHUANG TH, 1993, J BIOL CHEM, V268, P775; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; Dang PMC, 2002, P NATL ACAD SCI USA, V99, P4262, DOI 10.1073/pnas.072345299; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; DINITTO JP, 2003, SCI STKE, pRE16, DOI DOI 10.1126/STKE.2132003RE16; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Dransart E, 2005, TRAFFIC, V6, P957, DOI 10.1111/j.1600-0854.2005.00335.x; Dransart E, 2005, J BIOL CHEM, V280, P4674, DOI 10.1074/jbc.M409741200; Ebisu K, 2001, J BIOL CHEM, V276, P24498, DOI 10.1074/jbc.M101122200; Faure J, 1999, EUR J BIOCHEM, V262, P879, DOI 10.1046/j.1432-1327.1999.00458.x; Forget MA, 2002, BIOCHEM J, V361, P243, DOI 10.1042/0264-6021:3610243; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Gillooly DJ, 2001, J CELL BIOL, V155, P15, DOI 10.1083/jcb.200109001; Gorzalczany Y, 2002, J BIOL CHEM, V277, P18605, DOI 10.1074/jbc.M202114200; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; Henriques C, 2003, PARASITOL RES, V89, P123, DOI 10.1007/s00436-002-0728-y; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Longenecker KL, 2001, ACTA CRYSTALLOGR D, V57, P679, DOI 10.1107/S0907444901003122; MASON RJ, 1972, J CLIN INVEST, V51, P2399, DOI 10.1172/JCI107052; MCPHAIL LC, 1993, EUR J HAEMATOL, V51, P294; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Mesmin B, 2004, J BIOL CHEM, V279, P49876, DOI 10.1074/jbc.M406903200; Michaelson D, 2005, MOL BIOL CELL, V16, P1606, DOI 10.1091/mbc.E04-11-0960; Mizrahi A, 2005, J BIOL CHEM, V280, P3802, DOI 10.1074/jbc.M410257200; Mizrahi A, 2006, J LEUKOCYTE BIOL, V79, P881, DOI 10.1189/jlb.1005553; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; Papaharalambus C, 2005, J BIOL CHEM, V280, P18790, DOI 10.1074/jbc.M410081200; Peng GH, 2003, BIOCHEM J, V373, P221, DOI 10.1042/BJ20021629; Perisic O, 2004, ADV ENZYME REGUL, V44, P279, DOI 10.1016/j.advenzreg.2003.11.003; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; PICK E, 1987, J BIOL CHEM, V262, P16476; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Read PW, 2000, PROTEIN SCI, V9, P376; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Sarfstein R, 2004, J BIOL CHEM, V279, P16007, DOI 10.1074/jbc.M312394200; SASAKI T, 1993, J BIOL CHEM, V268, P23959; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; Sigal N, 2003, INFLAMMATION, V27, P147, DOI 10.1023/A:1023869828688; Sigal N, 2003, J BIOL CHEM, V278, P4854, DOI 10.1074/jbc.M211011200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Szabo A.G., 2000, SPECTROPHOTOMETRY SP, P33; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAMURA M, 1988, J BIOL CHEM, V263, P17621; Taylor RM, 2004, BBA-BIOMEMBRANES, V1663, P201, DOI 10.1016/j.bbamem.2004.03.009; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; UEDA T, 1990, J BIOL CHEM, V265, P9373; Ueyama T, 2005, J IMMUNOL, V175, P2381, DOI 10.4049/jimmunol.175.4.2381; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Williams DA, 2000, BLOOD, V96, P1646; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yamauchi A, 2004, J IMMUNOL, V173, P5971, DOI 10.4049/jimmunol.173.10.5971; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; Zalcman G, 1999, Prog Mol Subcell Biol, V22, P85; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhao XX, 2003, J BIOL CHEM, V278, P40788, DOI 10.1074/jbc.M302208200	102	27	28	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19204	19219		10.1074/jbc.M600042200	http://dx.doi.org/10.1074/jbc.M600042200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16702219	hybrid			2023-01-03	WOS:000238847000035
J	Chewning, B				Chewning, B			Commentary: The healthy adherer and the placebo effect	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Wisconsin, Sch Pharm, Sonderegger Res Inst, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Chewning, B (corresponding author), Univ Wisconsin, Sch Pharm, Sonderegger Res Inst, Madison, WI 53705 USA.	bachewning@pharmacy.wisc.edu						Barrett B, 2006, PERSPECT BIOL MED, V49, P178, DOI 10.1353/pbm.2006.0019; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; SIMPSON SH, 1996, BRIT MED J, V333, P15	4	20	20	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 1	2006	333	7557					18	19		10.1136/bmj.333.7557.18	http://dx.doi.org/10.1136/bmj.333.7557.18			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	062CT	16809709	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000238922900020
J	Kaptchuk, TJ; Stason, WB; Davis, RB; Legedza, ATR; Schnyer, RN; Kerr, CE; Stone, DA; Nam, BH; Kirsch, I; Goldman, RH				Kaptchuk, TJ; Stason, WB; Davis, RB; Legedza, ATR; Schnyer, RN; Kerr, CE; Stone, DA; Nam, BH; Kirsch, I; Goldman, RH			Sham device versus inert pill: randomised controlled trial of two placebo treatments	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LONGITUDINAL DATA-ANALYSIS; SIDE; ACUPUNCTURE; NEEDLE; CONSENT	Objective To investigate whether a sham device (a validated sham acupuncture needle) has a greater placebo effect than all inert pill in patients with persistent arm pain. Design A single blind randomised controlled trial created from the two week placebo run-in periods for two nested trials that compared acupuncture and amitriptyline with their respective placebo controls. Comparison of participants who remained oil placebo continued beyond the run-in period to the end of the Study. Setting Academic medical centre. Participants 270 adults with arm pain due to repetitive use that had lasted at least three months despite treatment and who scored ! 3 oil a 10 point pain scale. Interventions Acupuncture with sham device twice a week for six weeks or placebo pill once a day for eight weeks. Main outcome measures Arm pain measured oil a 10 point pain scale. Secondary Outcomes were symptoms measured by the Levine symptom severity scale, function measured by Pransky's upper extremity function scale, and grip strength. Results Pain decreased during the two week placebo run-in period in both the sham device and placebo pill groups, but changes were not different between the groups (- 0.14, 95% confidence interval - 0.52 to 0.25, P = 0.49). Changes in severity scores for arm symptoms and grip strength were similar between groups, but arm function improved more in the placebo pill group (2.0, 0.06 to 3.92, P = 0.04). Longitudinal regression analyses that followed participants throughout the treatment period showed significantly greater downward slopes per week oil the 10 point arm pain scale in the sham device group than in the placebo pill group (- 0.33 (- 0.40 to - 0.26) v - 0.15 (- 0.2 t to 0.09), P = 0.0001) and oil the symptom severity scale (- 0.07 (- 0.09 to - 0.05) v - 0.05 (- 0.06 to - 0.03), P 0.02). Differences were not significant, however, oil the function scale or for g-rip strength. Reported adverse effects were different in the two groups. Conclusions The sham device had greater effects than the placebo pill on self reported pain and severity of symptoms over the entire course of treatment but not during the two week placebo run ill. Placebo effects seem to be malleable and depend oil the behaviours embedded in medical rituals.	Harvard Univ, Sch Med, Osher Inst, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; City Coll Greece, SE European Res Ctr, Thessaloniki 54624, Greece; Univ Plymouth, Plymouth PL4 8AA, Devon, England; Harvard Univ, Sch Med, Cambridge Hosp, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Plymouth; Harvard University; Cambridge Health Alliance; Cambridge Hospital	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Osher Inst, Boston, MA 02215 USA.	ted_kaptchuk@hms.harvard.edu	Kirsch, Irving/P-9316-2019; Kerr, Catherine E/D-3299-2009		NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000402] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005; COOPER WD, 1983, BRIT J CLIN PRACT, V37, P99; *DEP HHS, EL UND MECH PLAC EFF; ENGREN T, 1971, EXPT PSYCHOL; Goldberger JJ, 1997, AM HEART J, V134, P119, DOI 10.1016/S0002-8703(97)70115-7; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kleinhenz J, 1999, PAIN, V83, P235, DOI 10.1016/S0304-3959(99)00107-4; Kleinman A., 2002, SCI PLACEBO INTERDIS, P1; Kong J, 2006, J NEUROSCI, V26, P381, DOI 10.1523/JNEUROSCI.3556-05.2006; LAMB GC, 1994, ARCH INTERN MED, V154, P2753, DOI 10.1001/archinte.1994.00420230150018; LEVINE DW, 1993, J BONE JOINT SURG AM, V75A, P1585, DOI 10.2106/00004623-199311000-00002; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Miller FG, 2004, JAMA-J AM MED ASSOC, V291, P599, DOI 10.1001/jama.291.5.599; MYERS ED, 1984, BRIT J CLIN PHARMACO, V17, P21, DOI 10.1111/j.1365-2125.1984.tb04993.x; MYERS MG, 1987, CLIN PHARMACOL THER, V42, P250, DOI 10.1038/clpt.1987.142; OConnor AM, 1996, J CLIN EPIDEMIOL, V49, P1271, DOI 10.1016/S0895-4356(96)00177-1; Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016; Pransky G, 1997, J OCCUP ENVIRON MED, V39, P1195, DOI 10.1097/00043764-199712000-00014; REITER B, 1999, ORTHOPAEDIC PHYS EXA; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; TENNER E, 1996, WHY THINGS BIT BACK; Vase L, 2002, PAIN, V99, P443, DOI 10.1016/S0304-3959(02)00205-1; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; White P, 2003, PAIN, V106, P401, DOI 10.1016/j.pain.2003.08.013; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	27	356	365	0	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 18	2006	332	7538					391	394		10.1136/bmj.38726.603310.55	http://dx.doi.org/10.1136/bmj.38726.603310.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017HZ	16452103	Bronze, Green Published			2023-01-03	WOS:000235686000016
J	Sherman, KJ; Cherkin, DC; Erro, J; Miglioretti, DL; Deyo, RA				Sherman, KJ; Cherkin, DC; Erro, J; Miglioretti, DL; Deyo, RA			Comparing yoga, exercise, and a self-care book for chronic low back pain - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							IMPORTANT DIFFERENCE; NATIONAL-SURVEY; HATHA YOGA; THERAPY; OUTCOMES; DISABILITY; PATTERNS	Background: Chronic low back pain is a common problem that has only modestly effective treatment options. Objective: To determine whether yoga is more effective than conventional therapeutic exercise or a self-care book for patients with chronic low back pain. Design: Randomized, controlled trial. Setting: A nonprofit, integrated health care system. Patients: 101 adults with chronic low back pain. Intervention: 12-week sessions of yoga or conventional therapeutic exercise classes or a self-care book. Measurements: Primary outcomes were back-related functional status (modified 24-point Roland Disability Scale) and "bothersomeness" of pain (11-point numerical scale). The primary time point was 12 weeks. Clinically significant change was considered to be 2.5 points on the functional status scale and 1.5 points on the bothersomeness scale. Secondary outcomes were days of restricted activity, general health status, and medication use. Results: After adjustment for baseline values, back-related function in the yoga group was superior to the book and exercise groups at 12 weeks (yoga vs. book: mean difference, -3.4 [95% CI, -5.1 to - 1.6] [P < 0.001]; yoga vs. exercise: mean difference, -1.8 [CI, -3.5 to - 0.1] [P = 0.034]). No significant differences in symptom bothersomeness were found between any 2 groups at 12 weeks; at 26 weeks, the yoga group was superior to the book group with respect to this measure (mean difference, -2.2 [CI, -3.2 to - 1.2]; P < 0.001). At 26 weeks, back-related function in the yoga group was superior to the book group (mean difference, -3.6 [CI, -5.4 to - 1.8]; P < 0.001). Conclusions: Yoga was more effective than a self-care book for improving function and reducing chronic low back pain, and the benefits persisted for at least several months.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Seattle, WA 98195 USA	Group Health Cooperative; University of Washington; University of Washington Seattle	Sherman, KJ (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	Sherman.k@ghc.org			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT001215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR048093] Funding Source: NIH RePORTER; NCCIH NIH HHS [R21AT 001215] Funding Source: Medline; NIAMS NIH HHS [P60AR48093] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALDWIN MC, 1999, DISS ABSTR INT A, V60, P1031; Barnes Patricia M, 2004, Adv Data, P1; Bogduk N, 2004, MED J AUSTRALIA, V180, P79, DOI 10.5694/j.1326-5377.2004.tb05805.x; Bombardier C, 2001, J RHEUMATOL, V28, P431; Cherkin DC, 1996, SPINE, V21, P2900, DOI 10.1097/00007632-199612150-00023; DEYO RA, 1988, ARCH PHYS MED REHAB, V69, P1044; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Galantino ML, 2004, ALTERN THER HEALTH M, V10, P56; GOLBUS S, 2000, CURRENT HLTH, V2, P30; Hayden JA, 2005, ANN INTERN MED, V142, P765, DOI 10.7326/0003-4819-142-9-200505030-00013; Hayden JA, 2005, ANN INTERN MED, V142, P776, DOI 10.7326/0003-4819-142-9-200505030-00014; Jacobs BP, 2004, ALTERN THER HEALTH M, V10, P80; Kraftsow, 1999, YOGA WELLNESS; LEVIN JR, 1994, PSYCHOL BULL, V115, P153, DOI 10.1037/0033-2909.115.1.153; Liddle SD, 2004, PAIN, V107, P176, DOI 10.1016/j.pain.2003.10.017; MOORE JEL, 1999, BACK PAIN HELPBOOK; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; Redelmeier DA, 1996, J CLIN EPIDEMIOL, V49, P1215, DOI 10.1016/S0895-4356(96)00206-5; RIESS P, 1986, 861584 PHS; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632-200012150-00006; Saper RB, 2004, ALTERN THER HEALTH M, V10, P44; Sovik R, 2000, PROG BRAIN RES, V122, P491; SPILNER M, 1999, PREVENTION       FEB, P53; van Tulder M, 2000, SPINE, V25, P2784, DOI 10.1097/00007632-200011010-00011; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; Williams K., 2003, INT J YOGA THERAP, V13, P55; Williams KA, 2005, PAIN, V115, P107, DOI 10.1016/j.pain.2005.02.016; Wolsko PM, 2003, SPINE, V28, P292, DOI 10.1097/00007632-200302010-00018; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 2001, NURSING, V31, P20; 1998, HARV HLTH LETT, V24, P4	32	290	297	4	81	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 20	2005	143	12					849	856		10.7326/0003-4819-143-12-200512200-00003	http://dx.doi.org/10.7326/0003-4819-143-12-200512200-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995CL	16365466				2023-01-03	WOS:000234077400001
J	Salisbury, C; Noble, A; Horrocks, S; Crosby, Z; Harrison, V; Coast, J; de Berker, D; Peters, T				Salisbury, C; Noble, A; Horrocks, S; Crosby, Z; Harrison, V; Coast, J; de Berker, D; Peters, T			Evaluation of a general practitioner with special interest service for dermatology: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To assess the effectiveness, accessibility, and acceptability of a general practitioner with special interest service for skin problems compared with a hospital dermatology clinic. Design Randomised controlled trial. Setting General practitioner with special interest dermatology service and hospital dermatology clinic. Participants Adults referred to a hospital dermatology clinic and assessed by a consultant: or the general practitioner with special interest service. Suitable patients had non-urgent. skin problems and had been identified from the referral letter as suitable for management by a general practitioner with special interest. Interventions Participants were randomised in 2:1 ratio to receive management by a general practitioner with special interest or usual hospital outpatient care. Main outcome measures Primary outcomes were disease related quality of life (dermatology life quality index) and improvement in patients' perception of access to services, assessed nine months after randomisation. Secondary outcomes were patient satisfaction, preference for site of care, proportion of failed appointments, and waiting tunes to first appointment. Results 49% of the participants were judged suitable for care by the general practitioner with special interest service. Of 768 patients eligible, 556 (72.4%) were randomised (354 to general practitioner with special interest, 202 to hospital outpatient care). After nine months, 422 (76%) were followed tip. No noticeable differences were found between the groups in clinical outcome (median dermatology life quality index score = 1 both arms, ratio of geometric means 0.99, 95% confidence interval 0.85 to 1.15). The general practitioner with special interest service was more accessible (difference between means on access scale 14, 11 to 19) and waited a mean of 40 (35 to 46) days less. Patients expressed slightly greater satisfaction with consultations with a general practitioner with special interest (difference in mean satisfaction score 4, 1 to 7) and at baseline and after nine months 61% said they preferred care at the service. Conclusions The general practitioner with special interest service for dermatology was more accessible than hospital outpatient care and was preferred by patients, achieving similar clinical outcomes.	Univ Bristol, Dept Community Based Med, Acad Unit Primary Hlth Care, Bristol BS6 6JL, Avon, England; Univ W England, Fac Hlth & Social Care, Bristol BS16 1DD, Avon, England; Univ Southampton, Dept Primary Hlth Care, Lymington SO41 9GH, Hants, England; Bristol S Primary Care Trust, Bristol BS2 8EE, Avon, England; Bristol W Primary Care Trust, Bristol BS2 8EE, Avon, England; Bristol N Primary Care Trust, Bristol BS2 8EE, Avon, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; United Bristol Hlth Care Trust, Dermatol Clin, Bristol BS2 8HW, Avon, England; Univ Bristol, Dept Community Based Med, Acad Unit Primary Hlth Care, Bristol BS8 1AU, Avon, England	University of Bristol; University of West England; University of Southampton; University of Bristol; University of Bristol	Salisbury, C (corresponding author), Univ Bristol, Dept Community Based Med, Acad Unit Primary Hlth Care, Bristol BS6 6JL, Avon, England.	c.salisbury@bristol.ac.uk	Salisbury, Chris/C-6724-2008	Salisbury, Chris/0000-0002-4378-3960; Peters, Tim/0000-0003-2881-4180; Coast, Joanna/0000-0002-3537-5166				Audit Commission, 2004, QUICK TREATM CLOS HO; BAKER R, 1990, BRIT J GEN PRACT, V40, P487; Bowling A, 2001, BRIT J GEN PRACT, V51, P264; Coast J, 2005, BMJ-BRIT MED J, V331, P1444, DOI 10.1136/bmj.38676.446910.7C; *DEP HLTH, 2003, ACT DERM GOOD PRACT; *DEP HLTH, 2002, IMPL SCHEM GEN PRACT; Department of Health, 2000, NHS PLAN PLAN INV PL; Department of Health, 2003, PRACT SPEC INT BRING; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Jones R, 2002, BRIT J GEN PRACT, V52, P833; Nocon A, 2004, BRIT J GEN PRACT, V54, P50; Powell John, 2002, J Health Serv Res Policy, V7, P177, DOI 10.1258/135581902760082490; *ROYAL COLL GEN PR, 2003, GUID APP GEN PRACT S; SANDERSON D, 2002, EVALUATION GPS SPECI	14	46	46	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 17	2005	331	7530					1441	1444		10.1136/bmj.38670.494734.7C	http://dx.doi.org/10.1136/bmj.38670.494734.7C			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	996EE	16332728	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000234156400022
J	Gordon, RJ; Lowy, FD				Gordon, RJ; Lowy, FD			Current concepts - Bacterial infections in drug users	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESISTANT STAPHYLOCOCCUS-AUREUS; IMMUNODEFICIENCY-VIRUS-INFECTION; DETROIT-MEDICAL-CENTER; BLACK-TAR HEROIN; RISK-FACTORS; NECROTIZING FASCIITIS; NARCOTIC ADDICTS; WOUND BOTULISM; ENDOCARDITIS; INJECTION		Columbia Univ Coll Phys & Surg, Div Infect Dis, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Gordon, RJ (corresponding author), Columbia Univ Coll Phys & Surg, Div Infect Dis, Dept Med, Box 82,630 W 168th St, New York, NY 10032 USA.	rj216@columbia.edu			NIDA NIH HHS [DA-15018, DA-09655] Funding Source: Medline; ODCDC CDC HHS [CCR223380-01] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015018] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); ODCDC CDC HHS; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALCABES P, 1995, CLIN INFECT DIS, V20, P1467, DOI 10.1093/clinids/20.6.1467; Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564; Bassetti S, 2004, INFECTION, V32, P163, DOI 10.1007/s15010-004-3106-0; Binswanger IA, 2000, CLIN INFECT DIS, V30, P579, DOI 10.1086/313703; Bohlen LM, 2000, EMERG INFECT DIS, V6, P175; Boschini A, 1996, CLIN INFECT DIS, V23, P107, DOI 10.1093/clinids/23.1.107; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P919; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P88; Centers for Disease Control and Prevention (CDC), 2016, DEV WAT MAN PROGR RE; CHAMBERS HF, 1988, ANN INTERN MED, V109, P619, DOI 10.7326/0003-4819-109-8-619; CHAMBERS HF, 1987, ANN INTERN MED, V106, P833, DOI 10.7326/0003-4819-106-6-833; CHANDRASEKAR PH, 1986, REV INFECT DIS, V8, P904; Charlebois ED, 2002, CLIN INFECT DIS, V34, P425, DOI 10.1086/338069; CHERUBIN CE, 1993, ANN INTERN MED, V119, P1017, DOI 10.7326/0003-4819-119-10-199311150-00009; Chin DP, 2000, JAMA-J AM MED ASSOC, V283, P2968, DOI 10.1001/jama.283.22.2968; Cicalini S, 2001, J INFECTION, V42, P267, DOI 10.1053/jinf.2001.0812; CRANE LR, 1986, REV INFECT DIS, V8, P364; CRAVEN DE, 1986, AM J MED, V80, P770, DOI 10.1016/0002-9343(86)90614-5; DWORKIN RJ, 1989, LANCET, V2, P1071; Fleisch F, 2001, CLIN INFECT DIS, V32, P581, DOI 10.1086/318716; HART GJ, 1989, AIDS, V3, P261, DOI 10.1097/00002030-198905000-00002; Havlir DV, 1999, NEW ENGL J MED, V340, P367, DOI 10.1056/NEJM199902043400507; HECHT SR, 1992, ANN INTERN MED, V117, P560, DOI 10.7326/0003-4819-117-7-560; HEMINGWAY DM, 1992, SCOT MED J, V37, P116, DOI 10.1177/003693309203700407; HIND CRK, 1990, THORAX, V45, P957, DOI 10.1136/thx.45.12.957; Hoeger PH, 1996, ACTA DERM-VENEREOL, V76, P239; Kimura AC, 2004, CLIN INFECT DIS, V38, pE87, DOI 10.1086/383471; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; LEVINE DP, 1986, REV INFECT DIS, V8, P374; LEVINE DP, 2005, MANDELL DOUGLAS BENN, V2, P3462; Levine DP., 1991, INFECT INTRAVENOUS D; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; LOURIA DB, 1967, ANN INTERN MED, V67, P1, DOI 10.7326/0003-4819-67-1-1; LY LT, 2004, ANN M INF DIS SOC AM; MAENZA JR, 2004, INFECT DIS, P1297; Malakmadze N, 2005, CLIN INFECT DIS, V40, P366, DOI 10.1086/427112; MARANTZ PR, 1987, ANN INTERN MED, V106, P823, DOI 10.7326/0003-4819-106-6-823; Miller LG, 2005, NEW ENGL J MED, V352, P1445, DOI 10.1056/NEJMoa042683; Miro JM, 2002, INFECT DIS CLIN N AM, V16, P273, DOI 10.1016/S0891-5520(01)00008-3; Murphy EL, 2001, CLIN INFECT DIS, V33, P35, DOI 10.1086/320879; NELSON KE, 1991, J INFECT DIS, V164, P457, DOI 10.1093/infdis/164.3.457; Palepu A, 2001, CAN MED ASSOC J, V165, P415; Pascual F Brian, 2003, MMWR Surveill Summ, V52, P1; Passaro DJ, 1998, JAMA-J AM MED ASSOC, V279, P859, DOI 10.1001/jama.279.11.859; Perlman DC, 1999, SOC SCI MED, V48, P1441, DOI 10.1016/S0277-9536(98)00448-1; Perper J A, 1992, Recent Dev Alcohol, V10, P363; Petrosillo N, 2002, CLIN INFECT DIS, V34, P677, DOI 10.1086/338813; Quagliarello B, 2002, CLIN INFECT DIS, V35, P671, DOI 10.1086/342196; SAPICO FL, 1980, REV INFECT DIS, V2, P196; SARAVOLATZ LD, 1982, ANN INTERN MED, V96, P11, DOI 10.7326/0003-4819-96-1-11; SCHEIDEGGER C, 1990, REV INFECT DIS, V12, P165; SCHEIDEGGER C, 1989, REV INFECT DIS, V11, P486; SELWYN PA, 1993, ANN INTERN MED, V119, P1044, DOI 10.7326/0003-4819-119-10-199311150-00013; SHEKAR R, 1985, J INFECT DIS, V151, P203, DOI 10.1093/infdis/151.2.203; SILVERMAN HS, 1985, NEW ENGL J MED, V312, P1706; Spijkerman IJB, 1996, J CLIN EPIDEMIOL, V49, P1149, DOI 10.1016/0895-4356(96)00180-1; STEIN MD, 1990, J GEN INTERN MED, V5, P249, DOI 10.1007/BF02600544; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; *SUBST AB MENT HLT, 2004, 2003 NAT SURV DRUG U; SUMMANEN PH, 1995, CLIN INFECT DIS, V20, pS279, DOI 10.1093/clinids/20.Supplement_2.S279; TORRESTORTOSA M, 1994, EUR J CLIN MICROBIOL, V13, P559, DOI 10.1007/BF01971306; TUAZON CU, 1975, ANN INTERN MED, V82, P788, DOI 10.7326/0003-4819-82-6-788; Tumbarello M, 1998, J ACQ IMMUN DEF SYND, V18, P39, DOI 10.1097/00042560-199805010-00006; *UN OFF DRUGS CRIM, 2005, WORLD DRUG REP, V1; *UN OFF DRUGS CRIM, 2004, WORLD DRUG REP, V1; VLAHOV D, 1992, PUBLIC HEALTH REP, V107, P595; Werner SB, 2000, CLIN INFECT DIS, V31, P1018, DOI 10.1086/318134; Wilson LE, 2002, J INFECT DIS, V185, P1761, DOI 10.1086/340827; Zetola N, 2005, LANCET INFECT DIS, V5, P275, DOI 10.1016/S1473-3099(05)70112-2; Zinderman CE, 2004, EMERG INFECT DIS, V10, P941, DOI 10.3201/eid1005.030604; 2003, EUROSURVELL WKLY, V7, P5; 1998, MMWR MORB MORTAL WKL, V47, P149; 1997, MMWR MORB MORTAL WKL, V46, P510; 2001, MMWR MORB MORTAL WKL, V50, P381; 2003, MMWR MORB MORTAL WKL, V52, P992; 1991, MMWR MORB MORTAL WKL, V40, P485; 2000, MMWR MORB MORTAL WKL, V49, P543	79	219	221	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1945	1954		10.1056/NEJMra042823	http://dx.doi.org/10.1056/NEJMra042823			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979VJ	16267325				2023-01-03	WOS:000232972800010
J	Sharland, M; Kendall, H; Yeates, D; Randall, A; Hughes, G; Glasziou, P; Mant, D				Sharland, M; Kendall, H; Yeates, D; Randall, A; Hughes, G; Glasziou, P; Mant, D			Antibiotic prescribing in general practice and hospital admissions for peritonsillar abscess, mastoiditis, and rheumatic fever in children: time trend analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-TRACT INFECTIONS		Univ Oxford, Div Publ Hlth & Primary Care, Hlth Care Epidemiol Unit, Oxford OX3 7LF, England; Univ London St Georges Hosp, Paediat Infect Dis Unit, London SW17 0QT, England; Prescript Pricing Author, Pharmaceut Directorate, Newcastle Upon Tyne NE1 6SN, Tyne & Wear, England; Med & Healthcare Prod Regulatory Agcy, GPRD Div, London SW8 5NQ, England	University of Oxford; St Georges University London; The Medicines & Healthcare Products Regulatory Agency	Mant, D (corresponding author), Univ Oxford, Div Publ Hlth & Primary Care, Hlth Care Epidemiol Unit, Oxford OX3 7LF, England.	david.mant@dphpc.ox.ac.uk	Mant, David CA/C-7763-2009; Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X; Hughes, Gwenda/0000-0003-2090-7702; sharland, mike/0000-0001-8626-8291	MRC [G0000340] Funding Source: UKRI; Medical Research Council [G0000340] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arroll B, 2003, BRIT J GEN PRACT, V53, P871; *DEP HLTH STAND ME, 2000, PATH LEAST RES MAIN; Little P, 2002, BRIT J GEN PRACT, V52, P187; Majeed A, 2004, BRIT MED J, V329, P879, DOI 10.1136/bmj.329.7471.879; Van Zuijlen DA, 2001, PEDIATR INFECT DIS J, V20, P140, DOI 10.1097/00006454-200102000-00004	5	110	110	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	2005	331	7512					328	329		10.1136/bmj.38503.706887.AE1	http://dx.doi.org/10.1136/bmj.38503.706887.AE1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	15967760	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000231259800020
J	Vetter, NJ				Vetter, NJ			Effects of locality based community hospital care on independence in older people needing rehabilitation: randomised controlled trial - Commentary: Intermediate care: policy before evidence	BRITISH MEDICAL JOURNAL			English	Editorial Material									Cardiff Univ, Sch Med, Cardiff CF14 4XL, Wales	Cardiff University	Vetter, NJ (corresponding author), Cardiff Univ, Sch Med, Cardiff CF14 4XL, Wales.	njvetter@hotmail.com						Green J, 2005, BMJ-BRIT MED J, V331, P317, DOI 10.1136/bmj.38498.387569.8F; Griffiths P, 2005, INT J NURS STUD, V42, P107, DOI 10.1016/j.ijnurstu.2004.07.010; GRIMLEY EJ, 2001, BMJ-BRIT MED J, V322, P807; Walker L, 2005, AGE AGEING, V34, P238, DOI 10.1093/ageing/afi055; Walsh B, 2005, BRIT MED J, V330, P699, DOI 10.1136/bmj.38397.633588.8F	5	8	8	1	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 6	2005	331	7512					320	320		10.1136/bmj.38524.543137.7C	http://dx.doi.org/10.1136/bmj.38524.543137.7C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	955WZ	15994658	Green Published, Bronze			2023-01-03	WOS:000231259800014
J	Morrissey, DV; Lockridge, JA; Shaw, L; Blanchard, K; Jensen, K; Breen, W; Hartsough, K; Machemer, L; Radka, S; Jadhav, V; Vaish, N; Zinnen, S; Vargeese, C; Bowman, K; Shaffer, CS; Jeffs, LB; Judge, A; MacLachlan, I; Polisky, B				Morrissey, DV; Lockridge, JA; Shaw, L; Blanchard, K; Jensen, K; Breen, W; Hartsough, K; Machemer, L; Radka, S; Jadhav, V; Vaish, N; Zinnen, S; Vargeese, C; Bowman, K; Shaffer, CS; Jeffs, LB; Judge, A; MacLachlan, I; Polisky, B			Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs	NATURE BIOTECHNOLOGY			English	Article							PLASMID-LIPID PARTICLES; SHORT INTERFERING RNA; GENE-EXPRESSION; MOUSE MODEL; DNA; REPLICATION; INDUCTION	The efficacy of lipid-encapsulated, chemically modified short interfering RNA ( siRNA) targeted to hepatitis B virus (HBV) was examined in an in vivo mouse model of HBV replication. Stabilized siRNA targeted to the HBV RNA was incorporated into a specialized liposome to form a stable nucleic-acid-lipid particle (SNALP) and administered by intravenous injection into mice carrying replicating HBV. The improved efficacy of siRNA-SNALP compared to unformulated siRNA correlates with a longer half-life in plasma and liver. Three daily intravenous injections of 3 mg/kg/day reduced serum HBV DNA >1.0 log(10). The reduction in HBV DNA was specific, dose-dependent and lasted for up to 7 d after dosing. Furthermore, reductions were seen in serum HBV DNA for up to 6 weeks with weekly dosing. The advances demonstrated here, including persistence of in vivo activity, use of lower doses and reduced dosing frequency are important steps in making siRNA a clinically viable therapeutic approach.	Sirna Therapeut Inc, Boulder, CO 80301 USA; Protiva Biotherapeut Inc, Burnaby, BC V5G 4Y1, Canada		Morrissey, DV (corresponding author), Sirna Therapeut Inc, 2950 Wilderness Pl, Boulder, CO 80301 USA.	morrisseyd@sirna.com						Ambegia E, 2005, BBA-BIOMEMBRANES, V1669, P155, DOI 10.1016/j.bbamem.2005.02.001; Bally MM, 1993, LIPOSOME TECHNOLOGY, P27; Buckwold VE, 1996, J VIROL, V70, P5845, DOI 10.1128/JVI.70.9.5845-5851.1996; Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703; Fenske DB, 2002, METHOD ENZYMOL, V346, P36; Fenske DB, 2001, CURR OPIN MOL THER, V3, P153; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Jeffs LB, 2005, PHARM RES-DORDR, V22, P362, DOI 10.1007/s11095-004-1873-z; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Morrissey DV, 2005, HEPATOLOGY, V41, P1349, DOI 10.1002/hep.20702; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sandberg JA, 2000, J CLIN PHARMACOL, V40, P1462; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Wheeler JJ, 1999, GENE THER, V6, P271, DOI 10.1038/sj.gt.3300821; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; Yang PL, 2002, P NATL ACAD SCI USA, V99, P13825, DOI 10.1073/pnas.202398599	19	919	1126	4	152	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2005	23	8					1002	1007		10.1038/nbt1122	http://dx.doi.org/10.1038/nbt1122			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	952QF	16041363				2023-01-03	WOS:000231019900034
J	Turner, RB; Bauer, R; Woelkart, K; Hulsey, TC; Gangemi, JD				Turner, RB; Bauer, R; Woelkart, K; Hulsey, TC; Gangemi, JD			An evaluation of Echinacea angustifolia in experimental rhinovirus infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLEMASTINE FUMARATE; COMMON COLD; COMPLICATIONS; COMMUNITY; SEVERITY; CHILDREN; TRIAL; VIRUS	BACKGROUND: Echinacea has been widely used as an herbal remedy for the common cold, but efficacy studies have produced conflicting results, and there are a variety of echinacea products on the market with different phytochemical compositions. We evaluated the effect of chemically defined extracts from Echinacea angustifolia roots on rhinovirus infection. METHODS: Three preparations of echinacea, with distinct phytochemical profiles, were produced by extraction from E. angustifolia roots with supercritical carbon dioxide, 60 percent ethanol, or 20 percent ethanol. A total of 437 volunteers were randomly assigned to receive either prophylaxis (beginning seven days before the virus challenge) or treatment (beginning at the time of the challenge) either with one of these preparations or with placebo. The results for 399 volunteers who were challenged with rhinovirus type 39 and observed in a sequestered setting for five days were included in the data analysis. RESULTS: There were no statistically significant effects of the three echinacea extracts on rates of infection or severity of symptoms. Similarly, there were no significant effects of treatment on the volume of nasal secretions, on polymorphonuclear leukocyte or interleukin-8 concentrations in nasal-lavage specimens, or on quantitative-virus titer. CONCLUSIONS: The results of this study indicate that extracts of E. angustifolia root, either alone or in combination, do not have clinically significant effects on infection with a rhinovirus or on the clinical illness that results from it.	Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; Karl Franzens Univ Graz, Graz, Austria; Med Univ S Carolina, Charleston, SC 29425 USA; Clemson Univ, Clemson, SC USA	University of Virginia; University of Graz; Medical University of South Carolina; Clemson University	Turner, RB (corresponding author), Univ Virginia, Sch Med, POB 800386, Charlottesville, VA 22908 USA.	rbt2n@virginia.edu	Bauer, Rudolf/F-8468-2010	Bauer, Rudolf/0000-0002-0057-5547	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001146] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01 AT001146] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Barrett B, 2003, PHYTOMEDICINE, V10, P66, DOI 10.1078/094471103321648692; Bauer R, 2000, HERBS BOT TEAS, P45; DOE J, 1999, WHO MONOGRAPHS SELEC, V1, P125; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Gwaltney J.M., 1989, DIAGNOSTIC PROCEDURE, P579; Gwaltney JM, 1996, ANTIVIR RES, V29, P287, DOI 10.1016/0166-3542(95)00935-3; GWALTNEY JM, 1992, PROG MED VIROL, V39, P256; Gwaltney JM, 1996, CLIN INFECT DIS, V22, P656, DOI 10.1093/clinids/22.4.656; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Melchart D., 2000, COCHRANE DB SYST REV; Nicholson KG, 1996, BMJ-BRIT MED J, V313, P1119, DOI 10.1136/bmj.313.7065.1119; Pitkaranta A, 1998, J PEDIATR-US, V133, P390, DOI 10.1016/S0022-3476(98)70276-8; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; RAO SS, 1995, AM J RHINOL, V9, P49, DOI 10.2500/105065895781874114; Seemungal TAR, 2000, EUR RESPIR J, V16, P677, DOI 10.1034/j.1399-3003.2000.16d19.x; SMYTH AR, 1995, ARCH DIS CHILD, V73, P117, DOI 10.1136/adc.73.2.117; Turner RB, 1997, CLIN INFECT DIS, V25, P824, DOI 10.1086/515546; Turner RB, 1999, JAMA-J AM MED ASSOC, V281, P1797, DOI 10.1001/jama.281.19.1797; Turner RB, 1998, CLIN INFECT DIS, V26, P840, DOI 10.1086/513922; Turner RB, 1996, AM J RHINOL, V10, P167, DOI 10.2500/105065896781794888; WALD ER, 1991, PEDIATRICS, V87, P129; Winther B, 2002, PEDIATRICS, V109, P826, DOI 10.1542/peds.109.5.826; Wolkart K, 2004, PHARM BIOL, V42, P443, DOI 10.1080/13880200490894815; 2002, MED LETT DRUGS THER, V44, P29	24	136	144	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	2005	353	4					341	348		10.1056/NEJMoa044441	http://dx.doi.org/10.1056/NEJMoa044441			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	949JW	16049208	Bronze			2023-01-03	WOS:000230782800006
J	Shekelle, PG; Morton, SC; Suftorp, MJ; Buscemi, N; Friesen, C				Shekelle, PG; Morton, SC; Suftorp, MJ; Buscemi, N; Friesen, C			Challenges in systematic reviews of complementary and alternative medicine topics	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-BACK-PAIN; CLINICAL-TRIALS; MANIPULATIVE THERAPY; PUBLICATION BIAS; PLACEBO; METAANALYSIS; ACUPUNCTURE; DEPRESSION; STROKE	The use of complementary and alternative medicine (CAM) continues to grow in the United States. The Agency for Healthcare Research and Quality has devoted a substantial proportion of the Evidence-based Practice Center (EPC) program to systematic reviews of CAM. Such syntheses present different challenges from those conducted on western medicine topics, and in many ways are more difficult. We discuss 3 challenges: identifying evidence about CAM, assessing the quality of individual studies, and addressing rare serious adverse events. We use illustrations from EPC evidence reports to show readers approaches to the 3 areas and then present specific recommendations for each issue.	RAND Corp, So Calif Evidence Based Pract Ctr, Santa Monica, CA 90401 USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Shekelle, PG (corresponding author), RAND Corp, So Calif Evidence Based Pract Ctr, 1776 Main St, Santa Monica, CA 90401 USA.	Paul_Shekelle@rand.org		Friesen, Carol/0000-0001-6437-9126				ALDERSON P, 2004, HANDSEARCHING COCHRA; Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1997, NATURE, V385, P480, DOI 10.1038/385480c0; Ezzo J, 1998, JAMA-J AM MED ASSOC, V280, P1628, DOI 10.1001/jama.280.18.1628; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Kalauokalani D, 2001, SPINE, V26, P1418, DOI 10.1097/00007632-200107010-00005; Kernan WN, 2000, NEW ENGL J MED, V343, P1826, DOI 10.1056/NEJM200012213432501; KLEIJNEN J, 1992, PHARM WEEKBLAD, V14, P316, DOI 10.1007/BF01977620; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; Moher D, 2003, Health Technol Assess, V7, P1; Moher David, 2002, BMC Pediatr, V2, P3, DOI 10.1186/1471-2431-2-3; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; Murphy Linda S, 2003, BMC Complement Altern Med, V3, P3, DOI 10.1186/1472-6882-3-3; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; Rochon PA, 1999, J CLIN EPIDEMIOL, V52, P113, DOI 10.1016/S0895-4356(98)00149-8; Rothwell DM, 2001, STROKE, V32, P1054, DOI 10.1161/01.STR.32.5.1054; Sampson Margaret, 2003, BMC Pediatr, V3, P1, DOI 10.1186/1471-2431-3-1; Shekelle P, 2003, AHRQ PUBLICATION, V03-E023; Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537; Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755; Sherman KJ, 2002, J ALTERN COMPLEM MED, V8, P11, DOI 10.1089/107555302753507140; TRIANO JJ, 1995, SPINE, V20, P948, DOI 10.1097/00007632-199504150-00013; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; *US NAT LIB MED, 2005, FACT SHEET RESP INQ; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840; 2000, JAMA, V283, P2228	33	57	58	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2005	142	12	2	S			1042	1047		10.7326/0003-4819-142-12_Part_2-200506211-00003	http://dx.doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938CN	15968028				2023-01-03	WOS:000229977600003
J	Medoff, BD; Shepard, JO; Smith, RN; Kratz, A				Medoff, BD; Shepard, JO; Smith, RN; Kratz, A			A 22-year-old woman with back and leg pain and respiratory failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SICKLE-CELL-DISEASE; ACUTE LUNG INJURY; INHALED NITRIC-OXIDE; ACUTE CHEST SYNDROME; EXTRACORPOREAL MEMBRANE-OXYGENATION; DISTRESS-SYNDROME; PULMONARY-HYPERTENSION; RECRUITMENT MANEUVER; COMPUTED-TOMOGRAPHY; PATIENT		Massachusetts Gen Hosp, Dept Med, Ctr Immunol & Inflammatory Dis, Pulm & Crit Care Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Medoff, BD (corresponding author), Massachusetts Gen Hosp, Dept Med, Ctr Immunol & Inflammatory Dis, Pulm & Crit Care Unit, Boston, MA 02114 USA.			Medoff, Benjamin/0000-0002-2558-0449				*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V42, P1301; Adhikari N, 2004, JAMA-J AM MED ASSOC, V291, P1629, DOI 10.1001/jama.291.13.1629; ARDS Clinical Trials Network, 2003, CRIT CARE MED, V31, P2592, DOI 10.1097/01.CCM.0000090001.91640.45; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brower RG, 2004, CRIT CARE MED, V32, P907; Bugedo G, 2003, INTENS CARE MED, V29, P218, DOI 10.1007/s00134-002-1618-6; Claster S, 2003, BRIT MED J, V327, P1151, DOI 10.1136/bmj.327.7424.1151; COLLINS FS, 1982, AM J MED, V73, P814, DOI 10.1016/0002-9343(82)90763-X; Fedullo PF, 2001, NEW ENGL J MED, V345, P1465, DOI 10.1056/NEJMra010902; FELLAHI JL, 1995, ANESTHESIOLOGY, V83, P635, DOI 10.1097/00000542-199509000-00028; Ferguson ND, 2002, INTENS CARE MED, V28, P1073, DOI 10.1007/s00134-002-1354-y; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477; Head CA, 1997, J CLIN INVEST, V100, P1193, DOI 10.1172/JCI119631; Lim CM, 2003, CRIT CARE MED, V31, P411, DOI 10.1097/01.CCM.0000048631.88155.39; Mak V, 2003, THORAX, V58, P726, DOI 10.1136/thorax.58.8.726; Martin GS, 2002, CRIT CARE MED, V30, P2175, DOI 10.1097/00003246-200210000-00001; Masiakos PT, 1999, ARCH SURG-CHICAGO, V134, P375, DOI 10.1001/archsurg.134.4.375; Medoff BD, 2000, CRIT CARE MED, V28, P1210, DOI 10.1097/00003246-200004000-00051; Moloney ED, 2004, BRIT J ANAESTH, V92, P261, DOI 10.1093/bja/aeh031; Petz LD, 1997, TRANSFUSION, V37, P382, DOI 10.1046/j.1537-2995.1997.37497265338.x; Platt OS, 2000, NEW ENGL J MED, V342, P1904, DOI 10.1056/NEJM200006223422510; PLATT OS, 2000, NEW ENGL J MED, V343, P591; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; ROTHEN HU, 1993, BRIT J ANAESTH, V71, P788, DOI 10.1093/bja/71.6.788; Schwarz MI, 2004, CHEST, V125, P1530, DOI 10.1378/chest.125.4.1530; Slutsky AS, 2001, NEW ENGL J MED, V345, P610, DOI 10.1056/NEJM200108233450811; STOWELL CP, 2002, ROSSIS PRINCIPLES TR, P483; Taylor RW, 2004, JAMA-J AM MED ASSOC, V291, P1603, DOI 10.1001/jama.291.13.1603; Vichinsky EP, 2000, NEW ENGL J MED, V342, P1855, DOI 10.1056/NEJM200006223422502; Vichinsky EP, 2004, NEW ENGL J MED, V350, P857, DOI 10.1056/NEJMp038250; Vichinsky EP, 2000, NEW ENGL J MED, V343, P824; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	33	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2425	2434		10.1056/NEJMcpc059012	http://dx.doi.org/10.1056/NEJMcpc059012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944428				2023-01-03	WOS:000229638900011
J	Brinton, LA; Lacey, JV; Trimble, EL				Brinton, LA; Lacey, JV; Trimble, EL			Hormones and endometrial cancer - new data from the Million Women Study	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; SYMPTOMS		NCI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brinton, LA (corresponding author), NCI, Bethesda, MD 20892 USA.	brinton@nih.gov	Brinton, Louise A/G-7486-2015; Trimble, Edward/J-9647-2019	Brinton, Louise A/0000-0003-3853-8562; Trimble, Edward/0000-0001-5028-0598				Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Barrett-Connor E, 2005, ANNU REV PUBL HEALTH, V26, P115, DOI 10.1146/annurev.publhealth.26.021304.144637; Col NF, 2004, ARCH INTERN MED, V164, P1634, DOI 10.1001/archinte.164.15.1634; FERENCZY A, 1989, AM J OBSTET GYNECOL, V160, P126, DOI 10.1016/0002-9378(89)90103-8; Grady D, 1997, J NATL CANCER I, V89, P1088, DOI 10.1093/jnci/89.15.1088; Grady D, 2003, NEW ENGL J MED, V348, P1835, DOI 10.1056/NEJMp030038; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531; Nelson HD, 2004, JAMA-J AM MED ASSOC, V291, P1610, DOI 10.1001/jama.291.13.1610; Newcomb PA, 2003, CANCER CAUSE CONTROL, V14, P195, DOI 10.1023/A:1023066304473; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rymer J, 2003, BRIT MED J, V326, P322, DOI 10.1136/bmj.326.7384.322; Rymer J, 2000, BMJ-BRIT MED J, V321, P1516, DOI 10.1136/bmj.321.7275.1516	13	12	13	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 30	2005	365	9470					1517	1518		10.1016/S0140-6736(05)66431-8	http://dx.doi.org/10.1016/S0140-6736(05)66431-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	921HL	15866289				2023-01-03	WOS:000228754800004
J	Wu, JYF; Leung, WYS; Chang, S; Lee, B; Zee, B; Tong, PCY; Chan, JCN				Wu, Jennifer Y. F.; Leung, Wilson Y. S.; Chang, Sophie; Lee, Benjamin; Zee, Benny; Tong, Peter C. Y.; Chan, Juliana C. N.			Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TYPE-2 DIABETES-MELLITUS; INTERVENTION; HYPERTENSION; BEHAVIORS; THERAPY; SYSTEM; CARE	Objective To investigate the effects of compliance and periodic telephone counselling by a pharmacist on mortality in patients receiving polypharmacy. Design Two year randomised controlled trial. Setting Hospital,medical clinic. Participants 502 of 1011 patients receiving five or more drugs for chronic disease found to be non-compliant at the screening visit were invited for randomisation to either the telephone counselling group (n = 219) or control group (n = 223) at enrolment 12-16 weeks later. Main outcome measures Primary outcome was all cause mortality in randomised patients. Associations between compliance and mortality in the entire cohort of 10 11 patients were also examined. Patients were defined as compliant with a drug if they took 80-120% of the prescribed daily dose. To calculate a compliance score for the whole treatment regimen, the number of drugs that the patient was fully compliant with was divided by the total number of prescribed drugs and expressed as a percentage. Only patients who complied with all recommended drugs were considered compliant (100% score). Results 60 of the 502 eligible patients defaulted and only 442 patients were randomised. After two years, 31 (52%) of the defaulters had died, 38 (17%) of the control group had died, and 25 (11%) of the intervention group had died. After adjustment for confounders, telephone counselling was associated with a 41% reduction in the risk of death (relative risk 0.59, 95% confidence interval 0.35 to 0.97; P = 0.039). The number needed to treat to prevent one death at two years was 16. Other predictors included old age, living alone, rate of admission to hospital, compliance score, number of drugs for chronic disease, and non-treatment with lipid lowering drugs at screening visit. In the cohort of 10 11 patients, the adjusted relative risk for death was 1.61 (1.05 to 2.48; P = 0.029) and 2.87 (1.80 to 2.57; P < 0.001) in patients with compliance scores of 34-66% and 0-33% compared with those who had a compliance score of 67% or more. Conclusion In patients receiving polypharmacy, poor compliance was associated with increased mortality. Periodic telephone counselling by the pharmacist improved compliance and reduced mortality.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; Prince Wales Hosp, Dept Pharm, Sydney, NSW, Australia; Chinese Univ Hong Kong, Sch Pharm, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Ctr Clin Trials, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong	Chan, JCN (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	jchan@cuhk.edu.hk	Chan, Juliana/B-7918-2016; Wu, Jennifer/GRX-1831-2022; Zee, Benny Chung Ying/G-5606-2017	Chan, Juliana/0000-0003-1325-1194; Zee, Benny Chung Ying/0000-0002-7238-845X				COLLEY CA, 1993, J GEN INTERN MED, V8, P278, DOI 10.1007/BF02600099; Day SJ, 2000, BRIT MED J, V321, P504, DOI 10.1136/bmj.321.7259.504; De Geest S, 2003, EUR J CARDIOVASC NUR, V2, P323, DOI [DOI 10.1016/S1474-5151(03)00091-4, 10.1016/S1474-5151(03)00091-4]; Friedman RH, 1996, AM J HYPERTENS, V9, P285, DOI 10.1016/0895-7061(95)00353-3; Grancelli H, 2003, J CARD FAIL, V9, P172, DOI 10.1054/jcaf.2003.33; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Guthrie RM, 2001, CLIN THER, V23, P970, DOI 10.1016/S0149-2918(01)80084-9; Haynes RB, 1996, LANCET, V348, P383; Muhlhauser I, 2002, DIABETOLOGIA, V45, P1723, DOI 10.1007/s00125-002-0987-2; PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P39, DOI 10.1037/0278-6133.13.1.39; Robinson JG, 2000, AM J CARDIOL, V85, P305, DOI 10.1016/S0002-9149(99)00737-7; Schwarzer R, 2001, CURR DIR PSYCHOL SCI, V10, P47, DOI 10.1111/1467-8721.00112; Vijan S, 2003, ANN INTERN MED, V138, P593, DOI 10.7326/0003-4819-138-7-200304010-00018; Vijan S, 2004, ANN INTERN MED, V140, P650, DOI 10.7326/0003-4819-140-8-200404200-00013	14	144	154	1	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2006	333	7567					522	525		10.1136/bmj.38905.447118.2F	http://dx.doi.org/10.1136/bmj.38905.447118.2F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	084LD	16916809	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000240533500015
J	Katsnelson, A				Katsnelson, Alla			Abe Abuchowski	NATURE BIOTECHNOLOGY			English	Biographical-Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2006	24	9					1050	1050		10.1038/nbt0906-1050	http://dx.doi.org/10.1038/nbt0906-1050			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	083YK	16964200				2023-01-03	WOS:000240495200008
J	Liu, ZL; Xiong, TB; Meads, C				Liu, Zulian; Xiong, Tengbin; Meads, Catherine			Clinical effectiveness of treatment with hyperbaric oxygen for neonatal hypoxic-ischaemic encephalopathy: systematic review of Chinese literature	BRITISH MEDICAL JOURNAL			English	Review								Objectives To investigate the clinical effectiveness of treatment with hyperbaric oxygen for neonates with hypoxic-ischaemic encephalopathy. This treatment is frequently used in China but much less often in the West. Data sources Western (Cochrane controlled trials register and database of systematic reviews, Medline, Embase, CINAHL, and HealthSTAR) and Chinese (China Hospital Digital Library, Chinese Medical journal Network) databases and hand search of Chinese journals. No language restrictions. Review methods Randomised or quasi-randomised controlled trials of treatment with hyperbaric oxygen compared with "usual care" in term neonates with hypoxic-ischaemic encephalopathy. Outcomes included mortality and long term neurological sequelae. Standardised forms were used to extract and compare data. Criteria of York Centre for Reviews and Dissemination were used to assess quality. Analysis was mainly qualitative but included meta-analysis. Results 20 trials were found, mainly from Chinese sources. The reporting quality of trials was poor by Western (CONSORT) standards. Treatment with hyperbaric oxygen had better outcomes than the comparator in almost all trials. The odds ratios of the meta-analyses were 0.26 (95% confidence interval 0.14 to 0.46) for mortality and 0.41 (0.27 to 0.6 1) for neurological sequelae. Conclusion Treatment with hyperbaric oxygen possibly reduces mortality and neurological sequelae in term neonates with hypoxic-ischaemic encephalopathy. Because of the poor quality of reporting in all trials and the possibility of publication bias, an adequately powered, high quality randomised controlled trial is needed to investigate these findings. The Chinese medical literature may be a rich source of evidence to inform clinical practice and other systematic reviews.	Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Meads, C (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.	c.a.meads@bham.ac.uk		Meads, Catherine/0000-0002-2368-0665				AKSENOW I, 2004, UND HYP MED SOC ANN; CHEN ZL, 1995, CHIN J PRACTICAL PED, V2, P86; CHEN ZP, 2000, HUA XIA MED, V2, P155; DING YY, 2003, CHIN J MOD CLIN MED, P1; HE KM, 2000, CHIN J CONT PEDIAT, V2, P345; JACOBS S, 2003, COCHRANE DB SYST REV, V4; KENT A, 2003, COCHRANE DB SYST REV, V2, DOI UNSP CD004494; KHAN KS, 2001, 4 NHS CRD; LI HY, 2004, CHIN J MODERN CHINES, V2; LIN XZ, 2000, J NEONATAL, V15, P172; LIU HL, 2003, CHIN J PRACT CHIN MO, V3, P770; LU DF, 2001, J CHIN PHYS, V29, P38; LU HY, 2003, J XIANNING COLL MED, V17, P115; LU JF, 1999, J GUANGXI MED U, V16, P703; Ramaswami R. A., 2000, Hong Kong Medical Journal, V6, P108; *RICHM HYP HLTH CT, SUMM INT IND HYP OXY; SI AH, 1999, J HYPERBARIC OXYGENA, P8; SONG XM, 2000, CHIN J PRACTICAL PED, V15, P762; SUN JH, 2000, J APPL CLIN PEDIAT, V15, P266; SUN XJ, 1998, CHIN J BIRTH HLTH HE, V6, P79; WANG AH, 2002, CHIN J PRIMARY MED P, V9, P503; WANG MM, 1999, NINGXIA MED J, V21, P113; WANG SL, 2001, SHANGDONG MED J, V41, P38; WANG XJ, 2001, CHIN J CONT PEDIAT, V3, P273; Wei X, 2004, BRAIN, V127, P2629, DOI 10.1093/brain/awh316; WEN R, 2001, CHIN MED J METALLURG, V18, P304; Whitelaw A, 2000, Semin Neonatol, V5, P33, DOI 10.1053/siny.1999.0113; YUAN XW, 1999, MOD DIAGN TREAT, V10, P174; ZHANG XH, 2000, CHIN J BIRTH HLTH HE, V8, P35	29	20	29	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 19	2006	333	7564					374	376		10.1136/bmj.38776.731655.2F	http://dx.doi.org/10.1136/bmj.38776.731655.2F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	078OD	16690641	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000240112200016
J	Gill, M; Goldacre, MJ; Yeates, DGR				Gill, Mike; Goldacre, Michael J.; Yeates, David G. R.			Changes in safety on England's roads: analysis of hospital statistics	BRITISH MEDICAL JOURNAL			English	Article								Objective To compare trends in the numbers of people with serious traffic injuries according to police statistics and hospital episode statistics (HES). Design Descriptive study based on two independent population based data sources. Setting Police statistics and hospital episode statistics in England. Main outcome measures Rates of injury and death and their change over time reported in each data source, for 1996 to 2004. Results According to police statistics, rates of people killed or seriously injured on the roads fell consistently from 85.9 per 100 000 in 1996 to 59.4 per 100 000 in 2004. Over the same time, however, hospital admission rates for traffic injuries were almost unchanged at 90.0 in 1996 and 91.1 in 2004. Both datasets showed a significant reduction in rates of injury in children aged <= 15, but the reduction in hospital admission rates was substantially less than the reduction shown in the police statistics. The definition of serious injury in police statistics includes every hospital admission; in each year, none the less, the number of admissions exceeded the number of injuries reported in the police system. Conclusions The overall fall seen in police statistics for non-fatal road traffic injuries probably represents a fall in completeness of reporting of these injuries.	Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England; Govt Off SE, SE Publ Hlth Grp, Surrey GU1 4GA, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.	michael.goldacre@dphpc.ox.ac.uk						*DEP TRANSP, 2004, TOM ROADS SAF EV 1 3; *DEP TRANSP NAT ST, ROAD ACC STAT STATS1; SIMPSON HF, 1996, COMP HOSP POLICE CAS; World Health Organization, EUR HLTH ALL DAT	4	20	20	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 8	2006	333	7558					73	75		10.1136/bmj.38883.593831.4F	http://dx.doi.org/10.1136/bmj.38883.593831.4F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	065BA	16798753	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000239133200016
J	Wiedemann, HP; Wheeler, AP; Bernard, GR; Thompson, BT; Hayden, D; deBoisblanc, B; Connors, AF; Hite, RD; Harabin, AL				Wiedemann, HP; Wheeler, AP; Bernard, GR; Thompson, BT; Hayden, D; deBoisblanc, B; Connors, AF; Hite, RD; Harabin, AL		Natl Heart Lung Blood Inst Acute	Comparison of two fluid-management strategies in acute lung injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; CRITICALLY ILL PATIENTS; PRESSURE PULMONARY-EDEMA; GOAL-DIRECTED THERAPY; OXYGEN DELIVERY; SEPTIC SHOCK; SUPRANORMAL VALUES; PROSPECTIVE TRIAL; PATIENT SAFETY; FUROSEMIDE	BACKGROUND: Optimal fluid management in patients with acute lung injury is unknown. Diuresis or fluid restriction may improve lung function but could jeopardize extrapulmonary-organ perfusion. METHODS In a randomized study, we compared a conservative and a liberal strategy of fluid management using explicit protocols applied for seven days in 1000 patients with acute lung injury. The primary end point was death at 60 days. Secondary end points included the number of ventilator-free days and organ-failure-free days and measures of lung physiology. RESULTS: The rate of death at 60 days was 25.5 percent in the conservative-strategy group and 28.4 percent in the liberal-strategy group (P=0.30; 95 percent confidence interval for the difference, -2.6 to 8.4 percent). The mean (+/-SE) cumulative fluid balance during the first seven days was -136+/-491 ml in the conservative-strategy group and 6992+/-502 ml in the liberal-strategy group (P<0.001). As compared with the liberal strategy, the conservative strategy improved the oxygenation index ([mean airway pressure x the ratio of the fraction of inspired oxygen to the partial pressure of arterial oxygen] x 100) and the lung injury score and increased the number of ventilator-free days (14.6+/-0.5 vs. 12.1+/-0.5, P<0.001) and days not spent in the intensive care unit (13.4+/-0.4 vs. 11.2+/-0.4, P<0.001) during the first 28 days but did not increase the incidence or prevalence of shock during the study or the use of dialysis during the first 60 days (10 percent vs. 14 percent, P=0.06). CONCLUSIONS: Although there was no significant difference in the primary outcome of 60-day mortality, the conservative strategy of fluid management improved lung function and shortened the duration of mechanical ventilation and intensive care without increasing nonpulmonary-organ failures. These results support the use of a conservative strategy of fluid management in patients with acute lung injury.	Cleveland Clin, Dept Pulm Allergy & Crit Care Med, Cleveland, OH 44195 USA; Vanderbilt Univ, Nashville, TN USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA; Case Western Reserve Univ, Metrohlth Med Ctr, Cleveland, OH USA; Wake Forest Univ, Hlth Sci Ctr, Winston Salem, NC 27109 USA; NHLBI, NIH, Bethesda, MD 20892 USA	Cleveland Clinic Foundation; Vanderbilt University; Harvard University; Massachusetts General Hospital; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Case Western Reserve University; MetroHealth System; Wake Forest University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Wiedemann, HP (corresponding author), Cleveland Clin, Dept Pulm Allergy & Crit Care Med, 9500 Euclid Ave,Desk A-90, Cleveland, OH 44195 USA.	wiedemh@ccf.org		Wiedemann, Herbert/0000-0002-4587-4401; NOIRI, Eisei/0000-0002-9515-7582; Connors, Alfred F./0000-0001-7123-3360	DIVISION OF LUNG DISEASES [N01HR016146] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HR-46046-64, N01-HR-16146-54] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI J, 1979, J CLIN INVEST, V64, P1494, DOI 10.1172/JCI109608; Barnes Kathleen C, 2005, Proc Am Thorac Soc, V2, P195, DOI 10.1513/pats.200502-013AC; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Drazen JM, 2003, NEW ENGL J MED, V348, P1377, DOI 10.1056/NEJMe030031; FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; HUDSON LD, 1992, AM REV RESPIR DIS, V146, P540; HUMPHREY H, 1990, CHEST, V97, P1176, DOI 10.1378/chest.97.5.1176; HYERS TM, 1990, CHEST, V97, P1025, DOI 10.1378/chest.97.5.1025; Landis E.M., 1963, HDB PHYSL SECTION 2, P961; LONG R, 1988, J APPL PHYSIOL, V65, P1736, DOI 10.1152/jappl.1988.65.4.1736; MARTIN C, 1990, ACTA ANAESTH SCAND, V34, P413, DOI 10.1111/j.1399-6576.1990.tb03114.x; Martin GS, 2002, CRIT CARE MED, V30, P2175, DOI 10.1097/00003246-200210000-00001; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; MOLLOY WD, 1985, CIRCULATION, V72, P1365, DOI 10.1161/01.CIR.72.6.1365; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; Moss M, 2002, CRIT CARE MED, V30, P1679, DOI 10.1097/00003246-200208000-00001; MURRAY JF, 1989, AM REV RESPIR DIS, V139, P1065; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PREWITT RM, 1981, J CLIN INVEST, V67, P409, DOI 10.1172/JCI110049; Reising CA, 1999, J SURG RES, V82, P56, DOI 10.1006/jsre.1998.5513; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rizvi K, 2005, CRIT CARE MED, V33, P98, DOI 10.1097/01.CCM.0000150650.70142.E9; SCHULLER D, 1991, CHEST, V100, P1068, DOI 10.1378/chest.100.4.1068; Schuster D P, 1993, New Horiz, V1, P478; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SIBBALD WJ, 1985, CHEST, V87, P585, DOI 10.1378/chest.87.5.585; SIMMONS RS, 1987, AM REV RESPIR DIS, V135, P924, DOI 10.1164/arrd.1987.135.4.924; Steinbrook R, 2003, NEW ENGL J MED, V349, P629, DOI 10.1056/NEJMp038133; Steinbrook R, 2003, NEW ENGL J MED, V348, P1393, DOI 10.1056/NEJMhpr030349; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213; YU MH, 1993, CRIT CARE MED, V21, P830, DOI 10.1097/00003246-199306000-00009	37	2275	2393	2	82	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	2006	354	24					2564	2575						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	052KU	16714767				2023-01-03	WOS:000238233400006
J	Wiese, JG; Holman, RL				Wiese, JG; Holman, RL			Update in hospital medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA; Cogent Healthcare, Nashville, TN USA	Tulane University	Wiese, JG (corresponding author), Tulane Univ, Sch Med, Dept Med, SL-12,1430 Tulane Ave, New Orleans, LA 70112 USA.							Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304	1	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2006	144	3					195	200		10.7326/0003-4819-144-3-200602070-00008	http://dx.doi.org/10.7326/0003-4819-144-3-200602070-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008XS	16461964				2023-01-03	WOS:000235074800006
J	Leape, LL; Fromson, JA				Leape, LL; Fromson, JA			Problem doctors: Is there a system-level solution?	ANNALS OF INTERNAL MEDICINE			English	Article							IMPAIRED PHYSICIANS; ALCOHOL; COMORBIDITY; PREVALENCE; BEHAVIOR; SUICIDE; PATIENT; ABUSE	Physician performance failures are not rare and pose substantial threats to patient welfare and safety. Few hospitals respond to such failures promptly or effectively. Failure to ensure the quality and safety of the performance of colleagues is a breach of medicine's fiduciary responsibility to the public. A major reason for this deficiency is the hospitals' lack of formal systems to monitor physician performance and to identify and correct shortcomings. To develop and implement these systems, hospitals need better performance measures and substantial expansion of external programs for assessment and remediation. This is a task well beyond the capacities of individual hospitals; a national effort is required. The authors call on the Federation of State Medical Boards, the American Board of Medical Specialties, and the Joint Commission on Accreditation of Healthcare Organizations (organizations that already bear a fiduciary responsibility for ensuring safe, competent care) to collaborate on developing better methods for measuring performance and to expand programs for helping practitioners who are deficient.	Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Leape, LL (corresponding author), Harvard Univ, Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02215 USA.	leape@hsph.harvard.edu	Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213				*AM BOARD MED SPEC, 2004, STAT MAINT CERT PROG; BARNARD A, 2002, BOSTON GLOBE    0520, pA1; Benzer D G, 1995, Wis Med J, V94, P455; BLONDELL RD, 1993, PRIMARY CARE, V20, P209; BREWSTER JM, 1986, JAMA-J AM MED ASSOC, V255, P1913, DOI 10.1001/jama.255.14.1913; CLARE AW, 1990, ALCOHOL ALCOHOLISM, V25, P277, DOI 10.1093/oxfordjournals.alcalc.a045001; *COLL PHYS SURG AL, 2004, PHYS ACH REV; *DEP VET AFF, 2004, DRUG FREE WORKPL PRO; Diaz A L, 1991, West J Nurs Res, V13, P97, DOI 10.1177/019394599101300107; Epstein RM, 2002, JAMA-J AM MED ASSOC, V287, P226, DOI 10.1001/jama.287.2.226; *FED STAT MED BOAR, 2005, IPE OV; *FED STAT MED BOAR, 2003, SUMM 2002 BOARD ACT; *FED STAT MED BOAR, 2000, REP SPEC COMM PROF C; Fromson J, 2004, ADDRESSING CLIN PERF; Hickson GB, 2002, JAMA-J AM MED ASSOC, V287, P2951, DOI 10.1001/jama.287.22.2951; HUGHES PH, 1992, JAMA-J AM MED ASSOC, V267, P2333, DOI 10.1001/jama.267.17.2333; Kaufman A.S., 2006, ASSESSING ADOLESCENT, V3rd; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Landon BE, 2003, JAMA-J AM MED ASSOC, V290, P1183, DOI 10.1001/jama.290.9.1183; Linney B J, 1997, Physician Exec, V23, P55; Lipner RS, 2002, ACAD MED, V77, pS64, DOI 10.1097/00001888-200210001-00021; MCAULIFFE WE, 1991, AM J PUBLIC HEALTH, V81, P177, DOI 10.2105/AJPH.81.2.177; *MED BOARD CAL, 2005, MED BOARDS DIV PROGR; Neff KE, 2000, ENHANCING PHYS PERFO, P45; Papadakis MA, 2004, ACAD MED, V79, P244, DOI 10.1097/00001888-200403000-00011; Powell DH, 1994, PROFILES COGNITIVE A; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Rosenstein AH, 2005, AM J NURS, V105, P54, DOI 10.1097/00000446-200501000-00025; Samkoff J S, 1990, Pa Med, V93, P40; Schernhammer E, 2005, NEW ENGL J MED, V352, P2473, DOI 10.1056/NEJMp058014; Schernhammer ES, 2004, AM J PSYCHIAT, V161, P2295, DOI 10.1176/appi.ajp.161.12.2295; Sharpe V.A., 1998, MED HARM HIST CONCEP; Skipper GE, 1997, J ADDICT DIS, V16, P67, DOI 10.1300/J069v16n03_07; TALBOTT GD, 1980, POSTGRAD MED, V68, P56, DOI 10.1080/00325481.1980.11715621; TRUNKEY DD, 2007, J AM COLL SURGEONS, V192, P385; Watkins JP, 2000, J SUBST ABUSE TREAT, V19, P51, DOI 10.1016/S0740-5472(99)00099-9; 2005, NBME POST LICENSURE	37	175	176	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2006	144	2					107	115		10.7326/0003-4819-144-2-200601170-00008	http://dx.doi.org/10.7326/0003-4819-144-2-200601170-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	004AX	16418410				2023-01-03	WOS:000234725500007
J	Morgan, SG; Bassett, KL; Wright, JM; Evans, RG; Barer, ML; Caetano, PA; Black, CD				Morgan, SG; Bassett, KL; Wright, JM; Evans, RG; Barer, ML; Caetano, PA; Black, CD			"Breakthrough" drugs and growth in expenditure on prescription drugs in Canada	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ British Columbia, Ctr Hlth Serv & Policy Res, Dept Family Practice, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Ctr Hlth Serv & Policy Res, Dept Pharmacol & Therapeut, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Morgan, SG (corresponding author), Univ British Columbia, Ctr Hlth Serv & Policy Res, Dept Family Practice, 429-2194 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	morgan@chspr.ubc.ca	Morgan, Steven/J-8814-2015	Morgan, Steven/0000-0002-7529-0028				*CAN I HLTH INF, 2005, DRUG EXP CAN 1985 20; Davis Peter, 2004, Aust Health Rev, V28, P171; *IMS, 2005, GLOB PHARM SAL REG 1; *PAT MED PRIC REV, 2004, ANN REP 2003, P49; World Health Organization, 2004, GUID ATC CLASS DDD A	5	57	57	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	2005	331	7520					815	816		10.1136/bmj.38582.703866.AE	http://dx.doi.org/10.1136/bmj.38582.703866.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	974BC	16141448	Green Published, Bronze			2023-01-03	WOS:000232565300020
J	Cullen, M; Steven, N; Billingham, L; Gaunt, C; Hastings, M; Simmonds, P; Stuart, N; Rea, D; Bower, M; Fernando, I; Huddart, R; Gollins, S; Stanley, A				Cullen, M; Steven, N; Billingham, L; Gaunt, C; Hastings, M; Simmonds, P; Stuart, N; Rea, D; Bower, M; Fernando, I; Huddart, R; Gollins, S; Stanley, A		SIGNIFICANT Trial Grp	Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUTROPENIC CANCER-PATIENTS; CONTROLLED PHASE-III; ANTIBIOTIC-PROPHYLAXIS; METAANALYSIS; ASSOCIATION; INFECTIONS; GUIDELINES; RESISTANCE; THERAPY; FEVER	BACKGROUND: The role of prophylactic antibacterial agents after chemotherapy remains controversial. METHODS: We conducted a randomized, double-blind, placebo-controlled trial in patients who were receiving cyclic chemotherapy for solid tumors or lymphoma and who were at risk for temporary, severe neutropenia (fewer than 500 neutrophils per cubic millimeter). Patients were randomly assigned to receive either 500 mg of levofloxacin once daily or matching placebo for seven days during the expected neutropenic period. The primary outcome was the incidence of clinically documented febrile episodes (temperature of more than 38 degreesC) attributed to infection. Secondary outcomes included the incidence of all probable infections, severe infections, and hospitalization but did not include a systematic evaluation of antibacterial resistance. RESULTS: A total of 1565 patients underwent randomization (784 to placebo and 781 to levofloxacin). The tumors included breast cancer (35.4 percent), lung cancer (22.5 percent), testicular cancer (14.4 percent), and lymphoma (12.8 percent). During the first cycle of chemotherapy, 3.5 percent of patients in the levofloxacin group had at least one febrile episode, as compared with 7.9 percent in the placebo group (P<0.001). During the entire chemotherapy course, 10.8 percent of patients in the levofloxacin group had at least one febrile episode, as compared with 15.2 percent of patients in the placebo group (P=0.01); the respective rates of probable infection were 34.2 percent and 41.5 percent (P=0.004). Hospitalization was required for the treatment of infection in 15.7 percent of patients in the levofloxacin group and 21.6 percent of patients in the placebo group (P=0.004). The respective rate of severe infection was 1.0 percent and 2.0 percent (P=0.15), with four infection-related deaths in each group. An organism was isolated in 9.2 percent of probable infections. CONCLUSIONS: Among patients receiving chemotherapy for solid tumors or lymphoma, the prophylactic use of levofloxacin reduces the incidence of fever, probable infection, and hospitalization.	Univ Hosp Birmingham, Ctr Canc, Birmingham, W Midlands, England; Ysbyty Gwynedd, Bangor, Gwynedd, Wales; Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England; Natl Publ Hlth Serv Wales, Cardiff, Wales; Royal S Hampshire Hosp, Southampton, Hants, England; Glan Clwyd, Rhyl, Wales; Chelsea & Westminster Hosp, London, England; Royal Marsden Hosp, London SW3 6JJ, England; City Hosp, Birmingham, W Midlands, England	University of Birmingham; Cancer Research UK; University of Birmingham; Imperial College London; Royal Marsden NHS Foundation Trust; University of Birmingham	Cullen, M (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, Birmingham B15 2TH, W Midlands, England.	cullen@uhb.nhs.uk		Billingham, Lucinda/0000-0001-8581-4262; huddart, robert/0000-0003-3604-1990; Bower, Mark/0000-0002-4077-6351				Bucaneve G, 2005, NEW ENGL J MED, V353, P977, DOI 10.1056/NEJMoa044097; Cruciani M, 1996, CLIN INFECT DIS, V23, P795, DOI 10.1093/clinids/23.4.795; Engels EA, 1998, J CLIN ONCOL, V16, P1179, DOI 10.1200/JCO.1998.16.3.1179; Freifeld A, 1999, NEW ENGL J MED, V341, P305, DOI 10.1056/NEJM199907293410501; FREIFELD A, 2004, P AN M AM SOC CLIN, V23, P747; FU KP, 1992, ANTIMICROB AGENTS CH, V36, P860, DOI 10.1128/AAC.36.4.860; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Hughes WT, 1997, CLIN INFECT DIS, V25, P551, DOI 10.1086/513764; Kern WV, 1999, NEW ENGL J MED, V341, P312, DOI 10.1056/NEJM199907293410502; Klastersky J, 2000, J CLIN ONCOL, V18, P3038, DOI 10.1200/JCO.2000.18.16.3038; Leonard RCF, 2003, BRIT J CANCER, V89, P2062, DOI 10.1038/sj.bjc.6601279; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; Ozer H, 2000, J CLIN ONCOL, V18, P3558, DOI 10.1200/JCO.2000.18.20.3558; SPIERS ASD, 1974, BMJ-BRIT MED J, V4, P440, DOI 10.1136/bmj.4.5942.440; SULLIVAN KM, 2001, PREVENTING OPPORTUNI, P392; Tjan-Heijnen VCG, 2001, ANN ONCOL, V12, P1359, DOI 10.1023/A:1012545507920; Tjan-Heijnen VCG, 2003, ANN ONCOL, V14, P248, DOI 10.1093/annonc/mdg073; VERHOEF J, 1993, CLIN INFECT DIS, V17, pS359, DOI 10.1093/clinids/17.Supplement_2.S359	18	271	290	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	2005	353	10					988	998		10.1056/NEJMoa050078	http://dx.doi.org/10.1056/NEJMoa050078			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	961YQ	16148284				2023-01-03	WOS:000231698200004
J	Melchart, D; Streng, A; Hoppe, A; Brinkhaus, B; Witt, C; Wagenpfeil, S; Pfaffenrath, V; Hammes, M; Hummelsberger, J; Irnich, D; Weidenhammer, W; Willich, SN; Linde, K				Melchart, D; Streng, A; Hoppe, A; Brinkhaus, B; Witt, C; Wagenpfeil, S; Pfaffenrath, V; Hammes, M; Hummelsberger, J; Irnich, D; Weidenhammer, W; Willich, SN; Linde, K			Acupuncture in patients with tension-type headache: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLACEBO; MIGRAINE	Objective To investigate the effectiveness of acupuncture compared with minimal acupuncture and with no acupuncture in patients with tension-type headache. Design Three armed randomised controlled multicentre trial. Setting 28 outpatient centres in Germany. Participants 270 patients (74% women, mean age 43 (SD 13) years) with episodic or chronic tension-type headache. Interventions Acupuncture, minimal acupuncture (superficial needling at non-acupuncture points), or waiting list control. Acupuncture and minimal acupuncture were administered by specialised physicians and consisted of 12 sessions per patient over eight weeks. Main outcome measure Difference in numbers of days with headache between the four weeks before randomisation and weeks 9-12 after randomisation, as recorded by participants in headache diaries. Results The number of days with headache decreased by 7.2 (SD 6.5) days in the acupuncture group compared with 6.6 (SD 6.0) days in the minimal acupuncture group and 1.5 (SD 3.7) days in the waiting list group (difference: acupuncture v minimal acupuncture, 0.6 days, 95% confidence interval - 1.5 to 2.6 days, P = 0.58; acupuncture v waiting list, 5.7 days, 3.9 to 7.5 days, P < 0.00 1). The proportion of responders (at least 50% reduction in days with headache) was 46% in the acupuncture group, 35% in the minimal acupuncture group, and 4% in the waiting list group. Conclusions The acupuncture intervention investigated in this trial was more effective than no treatment but not significantly more effective than minimal acupuncture for the treatment of tension-type headache.	Tech Univ Munich, Dept Internal Med 2, Ctr Complementary Med Res, D-80801 Munich, Germany; Tech Univ Munich, Inst Med Stat & Epidemiol, D-8000 Munich, Germany; Tech Univ Munich, Dept Neurol, D-8000 Munich, Germany; Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; Univ Munich, Dept Anesthesiol, Munich, Germany; Univ Zurich Hosp, Dept Internal Med, Div Complementary Med, Zurich, Switzerland	Technical University of Munich; Technical University of Munich; Technical University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; University of Zurich; University Zurich Hospital	Linde, K (corresponding author), Tech Univ Munich, Dept Internal Med 2, Ctr Complementary Med Res, Kaiserstr 9, D-80801 Munich, Germany.	Klaus.Linde@lrz.tu-muenchen.de	Streng, Andrea/AAR-4986-2020; Witt, Claudia M./AAX-2370-2021; Brinkhaus, Benno/AAU-2428-2021	Streng, Andrea/0000-0003-2377-7106; Witt, Claudia M./0000-0002-5440-7805; Brinkhaus, Benno/0000-0001-6290-744X; Linde, Klaus/0000-0002-2902-970X				BOGAARDS MC, 1994, CLIN J PAIN, V10, P174, DOI 10.1097/00002508-199409000-00003; BULLINGER M, 1998, SF 36 FRAGEBOGEN GES; CARLSSON J, 1990, CEPHALALGIA, V10, P131, DOI 10.1046/j.1468-2982.1990.1003131.x; Dillmann U, 1994, Schmerz, V8, P100, DOI 10.1007/BF02530415; GEISSNER E, 1991, SCHMERUEMPFINDUNGS; HANSEN PE, 1985, CEPHALALGIA, V5, P137, DOI 10.1046/j.1468-2982.1985.0503137.x; Hautzinger M., 1991, ALLGEMEINE DEPRESSIO; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Irnich D, 2002, SCHMERZ, V16, P93, DOI 10.1007/s004820100094; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011; Karst M, 2001, CEPHALALGIA, V21, P637, DOI 10.1046/j.1468-2982.2001.00198.x; Melchart D, 1999, CEPHALALGIA, V19, P779, DOI 10.1046/j.1468-2982.1999.1909779.x; Melchart D, 2003, FORSCH KOMP KLAS NAT, V10, P179, DOI 10.1159/000073473; Nagel B, 2002, SCHMERZ, V16, P263, DOI 10.1007/s00482-002-0162-1; Pfaffenrath V, 1998, SCHMERZ, V12, P156, DOI 10.1007/s004820050138; SCHOENEN J, 1995, CEPHALALGIA, V15, P165, DOI 10.1046/j.1468-2982.1995.015003165.x; Schwartz BS, 1998, JAMA-J AM MED ASSOC, V279, P381, DOI 10.1007/s11916-010-0146-2; TAVOLA T, 1992, PAIN, V48, P325, DOI 10.1016/0304-3959(92)90080-U; Vickers AJ, 2004, BRIT MED J, V328, P744, DOI 10.1136/bmj.38029.421863.EB; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; Welch KMA, 1997, CEPHALALGIA, V17, P1, DOI 10.1046/j.1468-2982.1997.1701001.x; White AR, 2000, CEPHALALGIA, V20, P632, DOI 10.1046/j.1468-2982.2000.00097.x; Xue CCL, 2004, HEADACHE, V44, P333, DOI 10.1111/j.1526-4610.2004.04077.x	24	242	268	4	60	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 13	2005	331	7513					376	379		10.1136/bmj.38512.405440.8F	http://dx.doi.org/10.1136/bmj.38512.405440.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	956SK	16055451	Green Published			2023-01-03	WOS:000231319900013
J	Jaar, BG; Coresh, J; Plantinga, LC; Fink, NE; Klag, MJ; Levey, AS; Levin, NW; Sadler, JH; Kliger, A; Powe, NR				Jaar, BG; Coresh, J; Plantinga, LC; Fink, NE; Klag, MJ; Levey, AS; Levin, NW; Sadler, JH; Kliger, A; Powe, NR			Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	36th Annual Meeting of the American-Society-of-Nephrology	NOV 12-17, 2003	SAN DIEGO, CA	Amer Soc Nephrol			RESIDUAL RENAL-FUNCTION; LONG-TERM CAPD; ADJUSTED MORTALITY-RATES; QUALITY-OF-LIFE; SURVIVAL; MODALITY; ADEQUACY; COMORBIDITY; CLEARANCE; THERAPY	Background: The influence of type of dialysis on survival of patients with end-stage renal disease (ESRD) is controversial. Objective: To compare risk for death among patients with ESRD who receive peritoneal dialysis or hemodialysis. Design: Prospective cohort study. Setting: 81 dialysis clinics in 19 U.S. states. Patients: 1041 patients starting dialysis (274 patients receiving peritoneal dialysis and 767 patients receiving hemodialysis) at baseline. Measurements: Patients were followed for up to 7 years and censored at transplantation or loss to follow-up. Cox proportional hazards regression stratified by clinic was used to compare the risk for death with peritoneal dialysis versus hemodialysis. Results: Twenty-five percent of patients undergoing peritoneal dialysis and 5% of hemodialysis patients switched type of dialysis. After adjustment, the risk for death did not differ between patients undergoing peritoneal dialysis and those undergoing hemodialysis during the first year (relative hazard, 1.39 [95% CI, 0.64 to 3.06]), but the risk became significantly higher among those undergoing peritoneal dialysis in the second year (relative hazard, 2.34 [CI, 1.19 to 4.59]). After stratification, the survival rate was no different for patients who had the highest propensity of being initially treated with peritoneal dialysis. Results were consistent with adjustment based on a propensity score model and in sensitivity analyses that used as-treated models and models in which switches in type of dialysis were treated as treatment failures. Results were similar but stronger in analyses that were restricted to patients who were treated only in clinics offering both types of dialysis. Limitations: Patients were not randomly assigned to their initial type of dialysis. Also, more patients undergoing peritoneal dialysis than hemodialysis switched type of dialysis over time, and the reason for switching was often a consequence of the technique. Conclusions: The risk for death in patients with ESRD undergoing dialysis depends on dialysis type. Further studies are needed to evaluate a possible survival benefit of a timely change from peritoneal dialysis to hemodialysis.	Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Sch Publ Hlth, Baltimore, MD 21218 USA; Johns Hopkins Univ, Independent Dialysis Fdn, Baltimore, MD 21218 USA; Renal Res Inst, New York, NY USA; Hosp St Raphael, New Haven, CT USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Renal Research Institute; Hospital Saint Raphael	Jaar, BG (corresponding author), Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-500, Baltimore, MD 21205 USA.	bjaar@jhmi.edu	Kliger, Alan/AAN-6653-2021; Jaar, Bernard/B-1917-2009	Jaar, Bernard/0000-0003-1210-7115	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008365] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059616, T32DK007024] Funding Source: NIH RePORTER; AHRQ HHS [HS08365] Funding Source: Medline; NHLBI NIH HHS [HL62985] Funding Source: Medline; NIDDK NIH HHS [DK59616, DK07024] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Athienites NV, 2000, SEMIN DIALYSIS, V13, P320, DOI 10.1046/j.1525-139x.2000.00095.x; Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158; BLOEMBERGEN WE, 1995, J AM SOC NEPHROL, V6, P177; Churchill DN, 1998, J AM SOC NEPHROL, V9, P1285; Collins AJ, 1999, AM J KIDNEY DIS, V34, P1065, DOI 10.1016/S0272-6386(99)70012-0; Enia G, 2001, NEPHROL DIAL TRANSPL, V16, P1459, DOI 10.1093/ndt/16.7.1459; Fenton SSA, 1997, AM J KIDNEY DIS, V30, P334, DOI 10.1016/S0272-6386(97)90276-6; Foley RN, 1998, J AM SOC NEPHROL, V9, P267; Ganesh SK, 2003, J AM SOC NEPHROL, V14, P415, DOI 10.1097/01.ASN.0000043140.23422.4F; HELD PJ, 1994, KIDNEY INT, V45, P1163, DOI 10.1038/ki.1994.154; Kim S S, 1994, Adv Perit Dial, V10, P282; Kimak E, 2000, CLIN CHEM LAB MED, V38, P421, DOI 10.1515/CCLM.2000.061; Korevaar JC, 2003, KIDNEY INT, V64, P2222, DOI 10.1046/j.1523-1755.2003.00321.x; Kraus MA, 1996, ADV PERIT D, V12, P89; Kronenberg F, 2003, KIDNEY INT, V63, pS113, DOI 10.1046/j.1523-1755.63.s84.23.x; Lee SW, 1998, PERITON DIALYSIS INT, V18, P435; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Li PKT, 2003, ANN INTERN MED, V139, P105, DOI 10.7326/0003-4819-139-2-200307150-00010; Locatelli F, 2004, J AM SOC NEPHROL, V15, pS25, DOI 10.1097/01.ASN.0000093239.32602.04; Locatelli F, 2001, J AM SOC NEPHROL, V12, P2411, DOI 10.1681/ASN.V12112411; Mattana J, 1997, J AM SOC NEPHROL, V8, P1342; Menon MK, 2001, NEPHROL DIAL TRANSPL, V16, P2207, DOI 10.1093/ndt/16.11.2207; Miskulin DC, 2002, AM J KIDNEY DIS, V39, P324, DOI 10.1053/ajkd.2002.30552; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Rubin HR, 2004, JAMA-J AM MED ASSOC, V291, P697, DOI 10.1001/jama.291.6.697; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Stack AG, 2003, KIDNEY INT, V64, P1071, DOI 10.1046/j.1523-1755.2003.00165.x; Suda T, 2000, NEPHROL DIAL TRANSPL, V15, P396, DOI 10.1093/ndt/15.3.396; Takeda K, 1998, AM J KIDNEY DIS, V32, P482, DOI 10.1053/ajkd.1998.v32.pm9740166; Tanna MM, 2000, AM J KIDNEY DIS, V36, P1175, DOI 10.1053/ajkd.2000.19832; Termorshuizen F, 2003, J AM SOC NEPHROL, V14, P2851, DOI 10.1097/01.ASN.0000091585.45723.9E; Termorshuizen F, 2003, AM J KIDNEY DIS, V41, P1293, DOI 10.1016/S0272-6386(03)00362-7; *US REN DAT SYST, 1999, US REN DAT SYST 1999; *US REN DAT SYST, 2003, US REN DAT SYST 2003; Van Biesen W, 2000, J AM SOC NEPHROL, V11, P116, DOI 10.1681/ASN.V111116; Winkelmayer WC, 2002, J AM SOC NEPHROL, V13, P2353, DOI 10.1097/01.ASN.0000025785.41314.76; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Wu AW, 2004, J AM SOC NEPHROL, V15, P743, DOI 10.1097/01.ASN.0000113315.81448.CA; Xue JL, 2002, KIDNEY INT, V61, P741, DOI 10.1046/j.1523-1755.2002.00176.x	39	238	245	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 2	2005	143	3					174	183		10.7326/0003-4819-143-3-200508020-00003	http://dx.doi.org/10.7326/0003-4819-143-3-200508020-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	951TM	16061915				2023-01-03	WOS:000230953900002
J	Cancelas, JA; Lee, AW; Prabhakar, R; Stringer, KF; Zheng, Y; Williams, DA				Cancelas, JA; Lee, AW; Prabhakar, R; Stringer, KF; Zheng, Y; Williams, DA			Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; ADHESION MOLECULES; PROGENITOR CELLS; MOBILIZATION; MARROW; CHEMOTHERAPY; ENGRAFTMENT; POLARITY; FAMILY; ROLES	The molecular events that regulate engraftment and mobilization of hematopoietic stem cells and progenitors (HSC/Ps) are still incompletely defined(1,2). We have examined the role of the Rho GTPases Rac1 and Rac2 in HSC engraftment and mobilization. Rac1, but not the hematopoietic-specific Rac2, is required for the engraftment phase of hematopoietic reconstitution, because Rac1(-/-) HSCs did not rescue in vivo hematopoiesis after transplantation, but deletion of Rac1 after engraftment did not impair steady-state hematopoiesis. Rac1(-/-) HSC/Ps showed impaired spatial localization to the endosteum but near-normal homing to the medullary cavity in vivo. Interaction with the bone marrow microenvironment in vitro was markedly altered. Whereas post-engraftment deletion of Rac1 alone did not impair hematopoiesis, deficiency of both Rac1 and Rac2 led to massive mobilization of HSCs from the marrow associated with ineffective hematopoiesis and intense selection for Rac-expressing HSCs. This mobilization was reversible by re-expression of Rac1. In addition, a rationally designed, reversible small-molecule inhibitor of Rac activation led to transient mobilization of engraftable HSC/Ps. Rac proteins thus differentially regulate engraftment and mobilization phenotypes, suggesting that these biological processes and steady-state hematopoiesis are biochemically separable and that Rac proteins may be important molecular targets for stem cell modification.	Cincinnati Childrens Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA; Cincinnati Childrens Res Fdn, Div Pathol, Cincinnati, OH 45229 USA; Univ Cincinnati, Med Ctr, Hoxworth Blood Ctr, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Williams, DA (corresponding author), Cincinnati Childrens Res Fdn, Div Expt Hematol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	david.williams@cchmc.org	Zheng, Yi/J-7235-2015; Cancelas, Jose/AAR-9324-2020	Zheng, Yi/0000-0001-7089-6074; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK62752] Funding Source: Medline; NIGMS NIH HHS [R01 GM60523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGGS DR, 1984, AM J HEMATOL, V16, P277, DOI 10.1002/ajh.2830160309; Cancelas JA, 1998, TRANSFUSION, V38, P1063, DOI 10.1046/j.1537-2995.1998.38111299056318.x; Christopherson KW, 2003, EXP HEMATOL, V31, P1126, DOI 10.1016/j.exphem.2003.07.002; Conca A, 2004, NEUROPSYCHIATRIE, V18, P1; Cottler-Fox Michele H, 2003, Hematology Am Soc Hematol Educ Program, P419; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Driessen RL, 2003, EXP HEMATOL, V31, P1284, DOI 10.1016/j.exphem.2003.08.015; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Gu Y, 2001, J BIOL CHEM, V276, P15929, DOI 10.1074/jbc.M010445200; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Jansen M, 2005, STEM CELLS, V23, P335, DOI 10.1634/stemcells.2004-0216; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Levesque JP, 1999, EXP HEMATOL, V27, P579, DOI 10.1016/S0301-472X(98)00069-1; Levesque JP, 2003, EXP HEMATOL, V31, P109, DOI 10.1016/S0301-472X(02)01028-7; Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293; Papayannopoulou T, 2004, BLOOD, V103, P1580, DOI 10.1182/blood-2003-05-1595; PAPAYANNOPOULOU T, 1977, P NATL ACAD SCI USA, V74, P2923, DOI 10.1073/pnas.74.7.2923; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; PLOEMACHER RE, 1991, BLOOD, V78, P2527; Roberts AW, 1997, BLOOD, V89, P2736, DOI 10.1182/blood.V89.8.2736; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Scott LM, 2003, MOL CELL BIOL, V23, P9349, DOI 10.1128/MCB.23.24.9349-9360.2003; Simmons PJ, 1997, BAILLIERE CLIN HAEM, V10, P485, DOI 10.1016/S0950-3536(97)80022-4; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	31	220	227	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2005	11	8					886	891		10.1038/nm1274	http://dx.doi.org/10.1038/nm1274			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	951XC	16025125				2023-01-03	WOS:000230964700035
J	Sterne, JAC; Hernan, MA; Ledergerber, B; Tilling, K; Weber, R; Sendi, P; Rickenbach, M; Robins, JM; Egger, M				Sterne, JAC; Hernan, MA; Ledergerber, B; Tilling, K; Weber, R; Sendi, P; Rickenbach, M; Robins, JM; Egger, M		Swiss HIV Cohort Study	Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study	LANCET			English	Article							MARGINAL STRUCTURAL MODELS; IMMUNODEFICIENCY-VIRUS-INFECTION; SWISS HIV COHORT; COMBINATION THERAPIES; CLINICAL PROGRESSION; CONTROLLED-TRIAL; CELL COUNT; MORTALITY; SURVIVAL; METAANALYSIS	Background Evidence on the effectiveness of highly active antiretroviral therapy (HAART) for HIV-infected individuals is limited. Most clinical trials examined surrogate endpoints over short periods of follow-up and there has been no placebo-controlled randomised trial of HAART. Estimation of treatment effects in observational studies is problematic, because of confounding by indication. We aimed to use novel methodology to overcome this problem in the Swiss HIV Cohort Study. Methods Patients were included if they had been examined after January 1996, when HAART became available in Switzerland, were not on HAART, and were free of AIDS at baseline. Cox regression models were weighted to create a statistical population in which the probability of being treated at each time point was unrelated to prognostic factors. Results Low CD4 counts and increasing HIV-1 viral load were associated with increased probability of starting HAART. Overall hazard ratios were 0.14 (95% CI 0.07-0.29) for HAART compared with no treatment, and 0.49 (0.31-0.79) compared with dual therapy. Compared with no treatment, HAART became more beneficial with increasing time since initiation but was less beneficial for patients whose presumed mode of transmission was via intravenous drug use (hazard ratio 0.27, 0.12-0.61) than for other patients (0.08, 0.03-0.19). Interpretation Our results, which are appropriately controlled for confounding by indication, are consistent with reported declines in rates of AIDS and death in developed countries, and provide a context in which to consider adverse effects of HAART.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Zurich, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland; Univ Basel Hosp, Inst Clin Epidemiol, CH-4031 Basel, Switzerland; Univ Basel Hosp, Div Infect Dis, CH-4031 Basel, Switzerland; Swiss HIV Cohort Study, Ctr Data, Lausanne, Switzerland; Univ Bern, Dept Social & Prevent Med, Bern, Switzerland	University of Bristol; Harvard University; Harvard T.H. Chan School of Public Health; University of Zurich; University of Basel; University of Basel; University of Bern	Sterne, JAC (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall,Whiteladies Rd, Bristol BS8 2PR, Avon, England.	jonathan.sterne@bristol.ac.uk	Weber, Rainer/D-5175-2012; Sendi, Pedram/AAC-2067-2019; VALLET, Yannick/F-9979-2011; Tilling, Kate/AAY-1578-2021; Sterne, Jonathan/Z-3106-2019; Ledergerber, Bruno/B-5656-2009; Sendi, Parham/R-3286-2018	Sterne, Jonathan/0000-0001-8496-6053; Ledergerber, Bruno/0000-0002-6881-4401; Tilling, Kate/0000-0002-1010-8926; Sendi, Parham/0000-0002-7347-6312; Egger, Matthias/0000-0001-7462-5132	MRC [G0100221] Funding Source: UKRI; NIAID NIH HHS [K08-AI-49392, AI32475, R37 AI032475] Funding Source: Medline; Medical Research Council [G0100221] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI049392, R01AI032475, R37AI032475] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babiker A, 2000, AIDS RES HUM RETROV, V16, P1123; Barkan SE, 1998, EPIDEMIOLOGY, V9, P117, DOI 10.1097/00001648-199803000-00004; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Choi HK, 2002, LANCET, V359, P1173, DOI 10.1016/S0140-6736(02)08213-2; Cole SR, 2003, AM J EPIDEMIOL, V158, P687, DOI 10.1093/aje/kwg206; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Fewell Z, 2004, STATA J, V4, P402, DOI 10.1177/1536867X0400400403; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Gebhardt M, 1998, AIDS, V12, P1195, DOI 10.1097/00002030-199810000-00012; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; Hernan MA, 2001, J AM STAT ASSOC, V96, P440, DOI 10.1198/016214501753168154; Hirsch MS, 2002, NEW ENGL J MED, V347, P438, DOI 10.1056/NEJMe020072; Hogg RS, 1999, CAN MED ASSOC J, V160, P659; Hughes MD, 1998, AIDS, V12, P1823, DOI 10.1097/00002030-199814000-00014; Jordan R, 2002, BMJ-BRIT MED J, V324, P757, DOI 10.1136/bmj.324.7340.757; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; LEDERGERBER B, 1994, SOZ PRAVENTIV MED, V39, P387, DOI 10.1007/BF01299670; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Levin BR, 2001, EMERG INFECT DIS, V7, P505, DOI 10.3201/eid0707.017704; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pezzotti P, 1999, AIDS, V13, P249, DOI 10.1097/00002030-199902040-00013; Phillips AN, 1999, AIDS, V13, P2075, DOI 10.1097/00002030-199910220-00010; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623; Walker AM, 1996, EPIDEMIOLOGY, V7, P335; Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008	37	422	438	0	32	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 30	2005	366	9483					378	384		10.1016/S0140-6736(05)67022-5	http://dx.doi.org/10.1016/S0140-6736(05)67022-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	950IB	16054937				2023-01-03	WOS:000230849700024
J	Casarett, D; Karlawish, J; Morales, K; Crowley, R; Mirsch, T; Asch, DA				Casarett, D; Karlawish, J; Morales, K; Crowley, R; Mirsch, T; Asch, DA			Improving the use of hospice services in nursing homes - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE CARE; HEALTH-CARE; ADVANCE DIRECTIVES; END; COMPLETION; PATIENT; PAIN; PREFERENCES; MANAGEMENT; PHYSICIANS	Context Hospice care may improve the quality of end-of-life care for nursing home residents, but hospice is underutilized by this population, at least in part because physicians are not aware of their patients' preferences. Objective To determine whether it is possible to increase hospice utilization and improve the quality of end-of-life care by identifying residents whose goals and preferences are consistent with hospice care. Design, Setting, and Participants Randomized controlled trial (December 2003-December 2004) of nursing home residents and their surrogate decision makers (N=205) in 3 US nursing homes. Intervention A structured interview identified residents whose goals for care, treatment preferences, and palliative care needs made them appropriate for hospice care. These residents' physicians were notified and asked to authorize a hospice informational visit. Main Outcome Measures The primary outcome measures were (1) hospice enrollment within 30 days of the intervention and (2) families' ratings of the quality of care for residents who died during the 6-month follow-up period. Results Of the 205 residents in the study sample, 107 were randomly assigned to receive the intervention, and 98 received usual care. Intervention residents were more likely than usual care residents to enroll in hospice within 30 days (21/107 [20%] vs 1/98 [1%]; P<.001 [Fisher exact test]) and to enroll in hospice during the follow-up period (27/207 [25%] vs 6/98 [6%]; P<.001). Intervention residents had fewer acute care admissions (mean: 0.28 vs 0.49; P=.04 [Wilcoxon rank sum test]) and spent fewer days in an acute care setting (mean: 1.2 vs 3.0; P=.03 [Wilcoxon rank sum test]). Families of intervention residents rated the resident's care more highly than did families of usual care residents (mean on a scale of 1-5: 4.1 vs 2.5; P=.04 [Wilcoxon rank sum test]). Conclusion A simple communication intervention can increase rates of hospice referrals and families' ratings of end-of-life care and may also decrease utilization of acute care resources.	Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA; Univ Penn, Div Geriatr Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Temple Univ, Sch Law, Philadelphia, PA 19122 USA; Holy Redeemer Home Hlth & Hospice Care, Philadelphia, PA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Pennsylvania Medicine; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Casarett, D (corresponding author), 3615 Chestnut St, Philadelphia, PA 19104 USA.	casarett@mail.med.upenn.edu		Asch, David/0000-0002-7970-286X				Baer WM, 2000, J AM GERIATR SOC, V48, P879, DOI 10.1111/j.1532-5415.2000.tb06883.x; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Boockvar K, 2004, ARCH INTERN MED, V164, P545, DOI 10.1001/archinte.164.5.545; Byock IR, 1996, J PAIN SYMPTOM MANAG, V11, P69, DOI 10.1016/0885-3924(95)00154-9; Casarett D, 2005, J AM GERIATR SOC, V53, P249, DOI 10.1111/j.1532-5415.2005.53110.x; Casarett DJ, 2004, J AM GERIATR SOC, V52, P1923, DOI 10.1111/j.1532-5415.2004.52520.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Cohen-Mansfield J, 1999, J CLIN EPIDEMIOL, V52, P273, DOI 10.1016/S0895-4356(98)00156-5; *CTR MED MED SERV, LAST YEAR LIF STUD S; *CTR MED MED SERV, MDS QUAL IND RES REP; Daugherty CK, 2002, J CLIN ONCOL, V20, P2752, DOI 10.1200/JCO.2002.20.11.2752; Desbiens NA, 1998, J PAIN SYMPTOM MANAG, V16, P281, DOI 10.1016/S0885-3924(98)00092-X; Dexter PR, 1998, ANN INTERN MED, V128, P102, DOI 10.7326/0003-4819-128-2-199801150-00005; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hanson Laura C, 2002, J Palliat Med, V5, P117; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Happ MB, 2002, J AM GERIATR SOC, V50, P829, DOI 10.1046/j.1532-5415.2002.50207.x; HAUPT BJ, 2003, VITAL HLTH STAT 13, V154, P1; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; KANE RL, 1984, LANCET, V1, P890; KATZ S, 1976, MED CARE, V14, P116, DOI 10.1097/00005650-197605001-00018; KEAY TJ, 1994, J AM GERIATR SOC, V42, P853, DOI 10.1111/j.1532-5415.1994.tb06557.x; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Levy CR, 2004, J AM GERIATR SOC, V52, P1247, DOI 10.1111/j.1532-5415.2004.52352.x; Lilly CM, 2000, AM J MED, V109, P469, DOI 10.1016/S0002-9343(00)00524-6; McGorty EK, 2003, J EVAL CLIN PRACT, V9, P363, DOI 10.1046/j.1365-2753.2003.00406.x; Meier DE, 1996, ARCH INTERN MED, V156, P1227, DOI 10.1001/archinte.156.11.1227; Miller SC, 2003, J AM GERIATR SOC, V51, P798, DOI 10.1046/j.1365-2389.2003.51253.x; Miller SC, 2003, J PAIN SYMPTOM MANAG, V26, P791, DOI 10.1016/S0885-3924(03)00284-7; Miller SC, 2001, AM J MED, V111, P38, DOI 10.1016/S0002-9343(01)00747-1; Miller SC, 2002, J AM GERIATR SOC, V50, P507, DOI 10.1046/j.1532-5415.2002.50118.x; Miller Susan C, 2003, J Palliat Med, V6, P725, DOI 10.1089/109662103322515239; Mitchell SL, 2004, ARCH INTERN MED, V164, P321, DOI 10.1001/archinte.164.3.321; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; *NAT HOSP PALL CAR, HSP FACTS FIG; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; REILLY BM, 1995, ARCH INTERN MED, V155, P2202, DOI 10.1001/archinte.155.20.2202; Richter K P, 1995, Arch Fam Med, V4, P609, DOI 10.1001/archfami.4.7.609; RICKERSON E, IN PRESS J AM GERIAT; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SCULLY T, 2002, COMMUNICATION   0524; TENO J, BROWN ATLAS DYING US; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P752, DOI 10.1016/S0885-3924(01)00331-1; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Tolle SW, 2000, NURS RES, V49, P310, DOI 10.1097/00006199-200011000-00003; Wenger NS, 2000, J AM GERIATR SOC, V48, pS44, DOI 10.1111/j.1532-5415.2000.tb03140.x; Wenger NS, 2001, JAMA-J AM MED ASSOC, V285, P2880, DOI 10.1001/jama.285.22.2880; Zerzan J, 2000, JAMA-J AM MED ASSOC, V284, P2489, DOI 10.1001/jama.284.19.2489	51	157	158	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	2005	294	2					211	217		10.1001/jama.294.2.211	http://dx.doi.org/10.1001/jama.294.2.211			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	944DO	16014595				2023-01-03	WOS:000230406100025
J	Hayden, JA; van Tulder, MW; Tomlinson, G				Hayden, JA; van Tulder, MW; Tomlinson, G			Systematic review: Strategies for using exercise therapy to improve outcomes in chronic low back pain	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; 1-YEAR FOLLOW-UP; PHYSICAL-THERAPY; CLINICAL-TRIAL; CONVENTIONAL PHYSIOTHERAPY; FUNCTIONAL RESTORATION; PROGRAM; SUBACUTE; MANIPULATION; INTENSITY	Background: Exercise therapy encompasses a heterogeneous group of interventions. There continues to be uncertainty about the most effective exercise approach in chronic low back pain. Purpose: To identify particular exercise intervention characteristics that decrease pain and improve function in adults with nonspecific chronic low back pain. Data Sources: MEDLINE, EMBASE, Psychinfo, CINAHL, and Cochrane Library databases to October 2004 and citation searches and bibliographic reviews of previous systematic reviews. Study Selection: Randomized, controlled trials evaluating exercise therapy in populations with chronic (> 12 weeks duration) low back pain. Data Extraction: Two reviewers independently extracted data on exercise intervention characteristics: program design (individually designed or standard program), delivery type (independent home exercises, group, or individual supervision), dose or intensity (hours of intervention time), and inclusion of additional conservative interventions. Data Synthesis: 43 trials of 72 exercise treatment and 31 comparison groups were included. Bayesian multivariable randomeffects meta-regression found improved pain scores for individually designed programs (5.4 points [95% credible interval (Cri), 1.3 to 9.5 points]), supervised home exercise (6.1 points [Crl, -0.2 to 12.4 points]), group (4.8 points [Crl, 0.2 to 9.4 points]), and individually supervised programs (5.9 points [Crl, 2.1 to 9.8 points]) compared with home exercises only. High-dose exercise programs fared better than low-dose exercise programs (1.8 points [Cri, -2.1 to 5.5 points]). Interventions that included additional conservative care were better (5.1 points [Crl, 1.8 to 8.4 points]). A model including these most effective intervention characteristics would be expected to demonstrate important improvement in pain (18.1 points [Crl, 11.1 to 25.0 points] compared with no treatment and 13.0 points [CrI, 6.0 to 19.9 points] compared with other conservative treatment) and small improvement in function (5.5 points [CrI, 0.5 to 10.5 points] compared with no treatment and 2.7 points [Cri, -1.7 to 7.1 points] compared with other conservative treatment). Stretching and strengthening demonstrated the largest improvement over comparisons. Limitations: Limitations of the literature, including low-quality studies with heterogeneous outcome measures and inconsistent and poor reporting; publication bias. Conclusions: Exercise therapy that consists of individually designed programs, including stretching or strengthening, and is delivered with supervision may improve pain and function in chronic nonspecific low back pain. Strategies should be used to encourage adherence. Future studies should test this multivariable model and further assess specific patient-level characteristics and exercise types.	Inst Work & Hlth, Toronto, ON M5G 2E9, Canada; Univ Toronto, Toronto, ON, Canada; Vrije Univ Amsterdam, Med Ctr, Inst Res Extramural Med, NL-1081 HV Amsterdam, Netherlands	Institute for Work & Health; University of Toronto; Vrije Universiteit Amsterdam	Hayden, JA (corresponding author), Inst Work & Hlth, 481 Univ Ave,Suite 800,8th Floor, Toronto, ON M5G 2E9, Canada.	jhayden@iwh.on.ca	Tomlinson, George A/L-5432-2016; van Tulder, Maurits/AAB-9785-2022	Tomlinson, George A/0000-0002-9328-6399; van Tulder, Maurits/0000-0002-7589-8471; Hayden, Jill Alison/0000-0001-7026-144X				Abenhaim L, 2000, SPINE, V25, p1S, DOI 10.1097/00007632-200002151-00001; Albright J, 2001, PHYS THER, V81, P1641; Alexandre NMC, 2001, REV SAUDE PUBL, V35, P356, DOI 10.1590/S0034-89102001000400004; Aure OF, 2003, SPINE, V28, P525, DOI 10.1097/00007632-200303150-00002; Bendix A F, 1995, Eur Spine J, V4, P148, DOI 10.1007/BF00298239; Bendix T, 2000, SPINE, V25, P2494, DOI 10.1097/00007632-200010010-00012; Bentsen H, 1997, SPINE, V22, P1494, DOI 10.1097/00007632-199707010-00014; Bombardier C, 2001, J RHEUMATOL, V28, P431; Bronfort G, 1996, J Manipulative Physiol Ther, V19, P570; BUSWELL J, 1982, NZ J PHYSIOTHER, V10, P13; Calmels P., 2004, Annales de Readaptation et de Medecine Physique, V47, P20, DOI 10.1016/j.annrmp.2003.07.001; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Dalichau S, 2000, Z ORTHOP GRENZGEB, V138, P8, DOI 10.1055/s-2000-10106; Descarreaux M, 2002, J MANIP PHYSIOL THER, V25, P497, DOI 10.1067/mmt.2002.127078; DEYO RA, 1990, NEW ENGL J MED, V322, P1627, DOI 10.1056/NEJM199006073222303; ELNAGGAR IM, 1991, SPINE, V16, P967, DOI 10.1097/00007632-199108000-00018; Faas A, 1996, SPINE, V21, P2874, DOI 10.1097/00007632-199612150-00016; Frost H, 2004, BRIT MED J, V329, P708, DOI 10.1136/bmj.38216.868808.7C; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; Galantino ML, 2004, ALTERN THER HEALTH M, V10, P56; Gelman A., 2003, TEXTS STAT SCI; Gur A, 2003, LASER SURG MED, V32, P233, DOI 10.1002/lsm.10134; HANSEN FR, 1993, SPINE, V18, P98, DOI 10.1097/00007632-199301000-00015; Hayden JA, 2005, ANN INTERN MED, V142, P765, DOI 10.7326/0003-4819-142-9-200505030-00013; Hemmila HM, 1997, ARCH PHYS MED REHAB, V78, P571, DOI 10.1016/S0003-9993(97)90420-2; HILDE G, 1998, PHYS THER REV, V3, P107; Hildebrandt V H, 2000, Ned Tijdschr Geneeskd, V144, P2258; JOHANNSEN F, 1995, J ORTHOP SPORT PHYS, V22, P52, DOI 10.2519/jospt.1995.22.2.52; Jousset N, 2004, SPINE, V29, P487, DOI 10.1097/01.BRS.0000102320.35490.43; Kankaanpaa M, 1999, SPINE, V24, P1034, DOI 10.1097/00007632-199905150-00019; Kendall PH, 1968, PHYSIOTHERAPY, V54, P154; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; Kuukkanen TM, 2000, CLIN REHABIL, V14, P192, DOI 10.1191/026921500667300454; Lidstrom A, 1970, Scand J Rehabil Med, V2, P37; Lie Hakon, 1999, Tidsskrift for den Norske Laegeforening, V119, P2051; Ljunggren AE, 1997, SPINE, V22, P1610, DOI 10.1097/00007632-199707150-00017; MANNICHE C, 1988, LANCET, V2, P1473; Mannion AF, 1999, SPINE, V24, P2435, DOI 10.1097/00007632-199912010-00004; Moseley L, 2002, AUST J PHYSIOTHER, V48, P297, DOI 10.1016/S0004-9514(14)60169-0; Niemisto L, 2003, SPINE, V28, P2185, DOI 10.1097/01.BRS.0000085096.62603.61; Nordin M, 1999, NEUROL CLIN, V17, P75, DOI 10.1016/S0733-8619(05)70115-8; Petersen T, 2002, SPINE, V27, P1702, DOI 10.1097/00007632-200208150-00004; Preyde M, 2000, CAN MED ASSOC J, V162, P1815; Rasmussen-Barr E, 2003, MANUAL THER, V8, P233, DOI 10.1016/S1356-689X(03)00053-5; RISCH SV, 1993, SPINE, V18, P232, DOI 10.1097/00007632-199302000-00010; Rittweger J, 2002, SPINE, V27, P1829, DOI 10.1097/00007632-200209010-00003; Salaffi F, 2004, EUR J PAIN, V8, P283, DOI 10.1016/j.ejpain.2003.09.004; Soukup MG, 1999, SPINE, V24, P1585, DOI 10.1097/00007632-199908010-00013; Spiegelhalter D., 2003, WINBUGS USER MANUAL; Spiegelhalter DJ, 2004, BAYESIAN APPROACHES, DOI DOI 10.1002/0470092602; Torstensen TA, 1998, SPINE, V23, P2616, DOI 10.1097/00007632-199812010-00017; Tritilanunt Tipawan, 2001, Journal of the Medical Association of Thailand, V84, pS528; TURNER JA, 1990, J CONSULT CLIN PSYCH, V58, P573, DOI 10.1037/0022-006X.58.5.573; van Tulder M, 2003, SPINE, V28, P1290, DOI 10.1097/01.BRS.0000065484.95996.AF; Yelland MJ, 2004, SPINE, V29, P9, DOI 10.1097/01.BRS.0000105529.07222.5B; Yeung CKN, 2003, J ALTERN COMPLEM MED, V9, P479, DOI 10.1089/107555303322284767; Yozbatiran Nuray, 2004, Pain Clinic, V16, P35, DOI 10.1163/156856904322858684; ZYLBERGOLD RS, 1981, ARCH PHYS MED REHAB, V62, P176	59	523	536	2	92	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 3	2005	142	9					776	785		10.7326/0003-4819-142-9-200505030-00014	http://dx.doi.org/10.7326/0003-4819-142-9-200505030-00014			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	922GW	15867410				2023-01-03	WOS:000228825800007
J	Reyes, F; Lepage, E; Ganem, G; Molina, TJ; Brice, P; Coiffier, B; Morel, P; Ferme, C; Bosly, A; Lederlin, P; Laurent, G; Tilly, H; Aoudjane, M; Assouline, D; Audhuy, B; Azagury, M; Bauduer, F; Baumelou, E; Bichoffe, MA; Biron, P; Blanc, M; Bordessoulle, D; Bosly, A; Bouabdallah, R; Bourquard, P; Brice, P; Mounier, N; Simon, D; Gisselbrecht, C; Dombret, H; Briere, J; Caillot, D; Casanovas, O; Flesch, M; Chauffert, B; Cassuto, GP; Castaigne, S; Christian, B; Coiffier, B; Colin, P; Pinon-Netter, G; Conroy, T; Cure, H; Delmer, A; Delwail, V; Devidas, A; Dreyfus, F; Dupont, G; Eisenmann, JC; Fabbro, M; Ferme, C; Fillet, G; Furchart, C; Gabarre, J; Gabez, M; Gautier, M; Haioun, C; Divine, M; Belhadj, K; Reyes, F; Herbrecht, R; Hermine, O; Varet, B; Janvier, M; Jourdan, E; Kamioner, D; Kerneis, Y; Morvan, F; Lederlin, P; Lefort, S; Lepeu, G; Lotz, JP; Machover, D; Marechal, F; Marit, G; Martin, C; Meyer, S; Morel, P; Dupriez, B; Munck, JN; Ferme, C; Carde, P; Offner, F; Pavlovitch, JM; Plantier, I; Orfeuvre, H; Peaud, PY; Peny, AM; Platini, C; Pullik, M; Quesnel, B; Morschausher, F; Reman, O; Leporrier, M; Rose, C; Rodon, P; Rossi, JF; Salles, B; Schlaifer, D; Huguet, F; Huyn, A; Sebban, C; Simon, M; Solal-Celigny, P; Sotto, JJ; Soussain, C; Allard, C; Tertian, G; Tilly, H; Thyss, A; Traulle, C; Travade, P; Van Hoof, A; Zini, JM; Briere, J; Diebold, J; Fabiani, B; Gaulard, P; Guettier, C; Molina, T; Petrella, T				Reyes, F; Lepage, E; Ganem, G; Molina, TJ; Brice, P; Coiffier, B; Morel, P; Ferme, C; Bosly, A; Lederlin, P; Laurent, G; Tilly, H; Aoudjane, M; Assouline, D; Audhuy, B; Azagury, M; Bauduer, F; Baumelou, E; Bichoffe, MA; Biron, P; Blanc, M; Bordessoulle, D; Bosly, A; Bouabdallah, R; Bourquard, P; Brice, P; Mounier, N; Simon, D; Gisselbrecht, C; Dombret, H; Briere, J; Caillot, D; Casanovas, O; Flesch, M; Chauffert, B; Cassuto, GP; Castaigne, S; Christian, B; Coiffier, B; Colin, P; Pinon-Netter, G; Conroy, T; Cure, H; Delmer, A; Delwail, V; Devidas, A; Dreyfus, F; Dupont, G; Eisenmann, JC; Fabbro, M; Ferme, C; Fillet, G; Furchart, C; Gabarre, J; Gabez, M; Gautier, M; Haioun, C; Divine, M; Belhadj, K; Reyes, F; Herbrecht, R; Hermine, O; Varet, B; Janvier, M; Jourdan, E; Kamioner, D; Kerneis, Y; Morvan, F; Lederlin, P; Lefort, S; Lepeu, G; Lotz, JP; Machover, D; Marechal, F; Marit, G; Martin, C; Meyer, S; Morel, P; Dupriez, B; Munck, JN; Ferme, C; Carde, P; Offner, F; Pavlovitch, JM; Plantier, I; Orfeuvre, H; Peaud, PY; Peny, AM; Platini, C; Pullik, M; Quesnel, B; Morschausher, F; Reman, O; Leporrier, M; Rose, C; Rodon, P; Rossi, JF; Salles, B; Schlaifer, D; Huguet, F; Huyn, A; Sebban, C; Simon, M; Solal-Celigny, P; Sotto, JJ; Soussain, C; Allard, C; Tertian, G; Tilly, H; Thyss, A; Traulle, C; Travade, P; Van Hoof, A; Zini, JM; Briere, J; Diebold, J; Fabiani, B; Gaulard, P; Guettier, C; Molina, T; Petrella, T		GELA	ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; LARGE-CELL LYMPHOMA; LIMITED-STAGE; BRIEF CHEMOTHERAPY; REGIMEN; MANAGEMENT; GRADE	BACKGROUND: Chemoradiotherapy is standard treatment for localized aggressive lymphoma. To determine the optimal therapy for nonelderly persons with low-risk localized lymphoma, we conducted a randomized trial comparing chemoradiotherapy with chemotherapy alone. METHODS: Previously untreated patients less than 61 years old with localized stage I or II aggressive lymphoma and no adverse prognostic factors according to the International Prognostic Index were randomly assigned to three cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus involved-field radiotherapy (329 patients) or chemotherapy alone with dose-intensified doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus sequential consolidation (318 patients). RESULTS: With a median follow-up of 7.7 years, event-free and overall survival rates were significantly higher in the group given chemotherapy alone than in the group given CHOP plus radiotherapy (P<0.001 and P=0.001, respectively). The five-year estimates of event-free survival were 82 percent (95 percent confidence interval, 78 to 87 percent) for patients receiving chemotherapy alone and 74 percent (95 percent confidence interval, 69 to 78 percent) for those receiving chemoradiotherapy. The respective five-year estimates of overall survival were 90 percent (95 percent confidence interval, 87 to 93 percent) and 81 percent (95 percent confidence interval, 77 to 86 percent). In a multivariate analysis, event-free and overall survival rates were affected by treatment group, independently of tumor stage and the presence or absence of bulky disease. CONCLUSIONS: In patients under 61 years of age, chemotherapy with three cycles of ACVBP followed by sequential consolidation is superior to three cycles of CHOP plus radiotherapy for the treatment of low-risk localized lymphoma.	Hop Henri Mondor, Assistance Publ Hop Paris, F-94010 Creteil, France; Clin Victor Hugo, Le Mans, France; Hop Hotel Dieu, Assistance Publ Hop Paris, F-75181 Paris, France; Hop St Louis, Assistance Publ Hop Paris, Paris, France; Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France; Inst Gustave Roussy, Villejuif, France; Ctr Hosp Brabois, Nancy, France; Hop Purpan, Toulouse, France; Ctr Henri Becquerel, F-76038 Rouen, France; Clin Univ Mt Godinne, Yvoir, Belgium	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; CHU Lyon; UNICANCER; Gustave Roussy; CHU de Nancy; CHU de Toulouse; UNICANCER; Centre Henri Becquerel; Universite Catholique Louvain; Universite Catholique Louvain Hospital	Reyes, F (corresponding author), Hop Henri Mondor, Serv Hematol Clin, F-94010 Creteil, France.	felix.reyes@hmn.ap-hop-paris.fr	Herbrecht, Raoul/GVU-1333-2022; Hermine, Olivier/Q-7072-2018; Conroy, Thierry/X-8127-2019; Herbrecht, Raoul/AAT-1763-2021; de Salles, Belmiro Freitas/C-6281-2018; Herbrecht, Raoul/D-3471-2013; Molina, Thierry/ABA-5214-2020	Herbrecht, Raoul/0000-0002-9381-4876; Molina, Thierry/0000-0002-3929-9754				Aleman BMP, 2003, NEW ENGL J MED, V348, P2396, DOI 10.1056/NEJMoa022628; Andre M, 2004, BLOOD, V103, P1222, DOI 10.1182/blood-2003-04-1124; Armitage JO, 2003, J CLIN ONCOL, V21, P897, DOI 10.1200/JCO.2003.07.113; Blayney DW, 2003, J CLIN ONCOL, V21, P2466, DOI 10.1200/JCO.2003.06.137; CABANILLAS F, 1980, CANCER, V46, P2356, DOI 10.1002/1097-0142(19801201)46:11<2356::AID-CNCR2820461107>3.0.CO;2-X; CHEN MG, 1979, CANCER, V43, P1245, DOI 10.1002/1097-0142(197904)43:4<1245::AID-CNCR2820430412>3.0.CO;2-Z; Cheson, 2000, J CLIN ONCOL, V18, P2351; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; CONNORS J, 2004, NONHODGKINS LYMPHOMA, P201; CONNORS JM, 1987, ANN INTERN MED, V107, P25, DOI 10.7326/0003-4819-107-1-25; COX DR, 1972, J R STAT SOC B, V34, P187; Dumontet C, 2002, BRIT J HAEMATOL, V118, P210, DOI 10.1046/j.1365-2141.2002.03565.x; Jaffe ES, 2001, PATHOLOGY GENETICS T, V3; JONES SE, 1989, J CLIN ONCOL, V7, P1186, DOI 10.1200/JCO.1989.7.9.1186; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Miller TP, 2001, BLOOD, V98, p724A; Miller TP, 1998, NEW ENGL J MED, V339, P21, DOI 10.1056/NEJM199807023390104; Pfreundschuh M, 2004, BLOOD, V104, P626, DOI 10.1182/blood-2003-06-2094; ROSENBERG SA, 1982, CANCER, V49, P2112; SAVAGE KJ, 2004, NON HODGKINS LYMPHOM, P97; Shenkier TN, 2002, J CLIN ONCOL, V20, P197, DOI 10.1200/JCO.20.1.197; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; STANSFELD AG, 1988, LANCET, V1, P372; Tilly H, 2003, BLOOD, V102, P4284, DOI 10.1182/blood-2003-02-0542; Tilly H, 2000, J CLIN ONCOL, V18, P1309, DOI 10.1200/JCO.2000.18.6.1309; Zinzani PL, 1999, BLOOD, V94, P3289, DOI 10.1182/blood.V94.10.3289.422k32_3289_3293	28	248	261	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1197	1205		10.1056/NEJMoa042040	http://dx.doi.org/10.1056/NEJMoa042040			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788496				2023-01-03	WOS:000227832300006
J	Margolis, TP; Whitcher, JP				Margolis, Todd P.; Whitcher, John P.			Fusarium - A new culprit in the contact lens case	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORNEAL ULCERATION; ETIOLOGIC DIAGNOSIS; SOUTH FLORIDA; KERATITIS; WEAR; SPECTRUM; OUTBREAK; NEPAL		Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Margolis, TP (corresponding author), Univ Calif San Francisco, Francis I Proctor Fdn, Med Sci Bldg,S-310,513 Parnassus Ave,Box 0412, San Francisco, CA 94143 USA.	todd.margolis@ucsf.edu			NATIONAL EYE INSTITUTE [R01EY010008, P30EY002162] Funding Source: NIH RePORTER; NEI NIH HHS [EY10008, EY02162] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALFONSO E, 1986, AM J OPHTHALMOL, V101, P429, DOI 10.1016/0002-9394(86)90641-0; Alfonso EC, 2006, ARCH OPHTHALMOL-CHIC, V124, P941, DOI 10.1001/archopht.124.7.ecs60039; Bernal MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P1051, DOI 10.1001/archopht.124.7.ecr60006; Chang DC, 2006, JAMA-J AM MED ASSOC, V296, P953, DOI 10.1001/jama.296.8.953; ERIE JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P1665, DOI 10.1001/archopht.1993.01090120087027; Gonzales C A, 1996, Ophthalmic Epidemiol, V3, P159, DOI 10.3109/09286589609080122; HAGAN M, 1995, BRIT J OPHTHALMOL, V79, P1024, DOI 10.1136/bjo.79.11.1024; Khor WB, 2006, JAMA-J AM MED ASSOC, V295, P2867, DOI 10.1001/jama.295.24.2867; LIESEGANG TJ, 1980, AM J OPHTHALMOL, V90, P38, DOI 10.1016/S0002-9394(14)75075-5; RAPUANAO CJ, 2005, BACTERIAL KERATITIS, P11; *REG OFF SE AS, 2004, GUID MAN CORN ULC PR, P1; ROSA RH, 1994, OPHTHALMOLOGY, V101, P1005; *SING HLTH MIN HLT, 2006, INCR INC CONT LENS R; Srinivasan M, 1997, BRIT J OPHTHALMOL, V81, P965, DOI 10.1136/bjo.81.11.965; Upadhyay MP, 2001, BRIT J OPHTHALMOL, V85, P388, DOI 10.1136/bjo.85.4.388; UPADHYAY MP, 1991, AM J OPHTHALMOL, V111, P92, DOI 10.1016/S0002-9394(14)76903-X; Whitcher JP, 1997, BRIT J OPHTHALMOL, V81, P622, DOI 10.1136/bjo.81.8.622; 2006, MMWR MORB MORTAL WKL, V55, P400; 2006, FUSARIUM KERATITIS U	19	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2006	296	8					985	987		10.1001/jama.296.8.985	http://dx.doi.org/10.1001/jama.296.8.985			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076AL	16929565				2023-01-03	WOS:000239929300028
J	Pobbati, AV; Stein, A; Fasshauer, D				Pobbati, Ajaybabu V.; Stein, Alexander; Fasshauer, Dirk			N- to C-terminal SNARE complex assembly promotes rapid membrane fusion	SCIENCE			English	Article							T-SNARE; SYNAPTIC EXOCYTOSIS; PROTEINS; VESICLES; DOMAIN; CORE	Assembly of the soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) syntaxin 1, SNAP-25, and synaptobrevin 2 is thought to be the driving force for the exocytosis of synaptic vesicles. However, whereas exocytosis is triggered at a millisecond time scale, the SNARE-mediated fusion of liposomes requires hours for completion, which challenges the idea of a key role for SNAREs in the final steps of exocytosis. We found that liposome fusion was dramatically accelerated when a stabilized syntaxin/SNAP-25 acceptor complex was used. Thus, SNARES do have the capacity to execute fusion at a speed required for neuronal secretion, demonstrating that the maintenance of acceptor complexes is a critical step in biological fusion reactions.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany	Max Planck Society	Fasshauer, D (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Fassberg 11, D-37077 Gottingen, Germany.	dfassha@gwdg.de	Fasshauer, Dirk/B-1563-2013; Stein, Alexander/I-4950-2012	Fasshauer, Dirk/0000-0002-1040-4282; Stein, Alexander/0000-0002-2696-0611	NIGMS NIH HHS [P01 GM072694] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM072694] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bowen ME, 2004, BIOPHYS J, V87, P3569, DOI 10.1529/biophysj.104.048637; Chen XC, 2002, NEURON, V33, P397, DOI 10.1016/S0896-6273(02)00583-4; Dieter B, 2002, PFLUG ARCH EUR J PHY, V443, P333, DOI 10.1007/s00424-001-0742-4; Fasshauer D, 2004, J BIOL CHEM, V279, P7613, DOI 10.1074/jbc.M312064200; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Fix M, 2004, P NATL ACAD SCI USA, V101, P7311, DOI 10.1073/pnas.0401779101; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Liu TT, 2005, BIOPHYS J, V89, P2458, DOI 10.1529/biophysj.105.062539; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Pelham HRB, 1995, COLD SPRING HARB SYM, V60, P105, DOI 10.1101/SQB.1995.060.01.013; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Sabatini BL, 1996, NATURE, V384, P170, DOI 10.1038/384170a0; Sorensen JB, 2006, EMBO J, V25, P955, DOI 10.1038/sj.emboj.7601003; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174	24	269	275	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2006	313	5787					673	676		10.1126/science.1129486	http://dx.doi.org/10.1126/science.1129486			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888141	Green Published			2023-01-03	WOS:000239667500045
J	O'Reilly, J; Lowson, K; Young, J; Forster, A; Green, J; Small, N				O'Reilly, Jacqueline; Lowson, Karin; Young, John; Forster, Anne; Green, John; Small, Neil			A cost effectiveness analysis within a randomised controlled trial of post-acute care of older people in a community hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OXFORDSHIRE; BEDS	Objective To assess the cost effectiveness of post-acute care for older people in a locality based community hospital compared with a department for care of elderly people in a district general hospital, which admits patients aged over 76 years with acute medical conditions. Design Cost effectiveness analysis within a randomised controlled trial. Setting Community hospital and district general hospital in Yorkshire, England. Participants 220 patients needing rehabilitation after an acute illness for which they required admission to hospital. Interventions Multidisciplinary care in the district general hospital or prompt transfer to the community hospital. Main outcome measures EuroQol EQ-5D scores transformed into quality adjusted life years (QALYs), and health and social service costs over six months from randomisation. Results The mean QALY score for the community hospital group was marginally non-significantly higher than that for the district general hospital group (0.38 v 0.35) at six months after recruitment. The mean (standard deviation) costs per patient of the health and social services resources used were similar for both groups: community hospital group 7233 pound (E10 567; $13 341) (5031) pound, district general hospital group 7351 pound (6229) pound, and these findings were robust to several sensitivity analyses. The incremental cost effectiveness ratio for community hospital care dominated. A cost effectiveness acceptability curve, based on bootstrapped simulations, suggests that at a willingness to pay threshold of 10 pound 000 per QALY, 51% of community hospital cases will be cost effective, which rises to 53% of cases when the threshold is 30 pound 000 per QALY. Conclusion Post-acute care for older people in a locality based community hospital is of similar cost effectiveness to that of an elderly care department in a district general hospital.	Univ York, York Hlth Econ Consortium, York YO10 5NH, N Yorkshire, England; St Lukes Hosp, Acad Unit Elderly Care & Rehabil, Bradford BD5 0NA, W Yorkshire, England; Univ Bradford, Sch Hlth Studies, Bradford BD7 1DP, W Yorkshire, England	University of York - UK; University of Bradford	Lowson, K (corresponding author), Univ York, York Hlth Econ Consortium, York YO10 5NH, N Yorkshire, England.	kvl2@york.ac.uk		young, john/0000-0003-4085-9306; Forster, Anne/0000-0001-7466-4414				BAKER JE, 1986, J EPIDEMIOL COMMUN H, V40, P117, DOI 10.1136/jech.40.2.117; Briggs AH, 1997, HEALTH ECON, V6, P327, DOI 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W; Briggs AH, 1999, STAT MED, V18, P3245, DOI 10.1002/(SICI)1097-0258(19991215)18:23<3245::AID-SIM314>3.0.CO;2-2; *CIPFA, 2002, HLTH SERV FIN DAT CO; Cook PJ, 1998, AGE AGEING, V27, P357, DOI 10.1093/ageing/27.3.357; *DEP HLTH, 2002, REF COSTS 2002; *DEP HLTH, 2006, CM6737; *DEP HLTH, 2000, NHS PLAN; Green J, 2005, BMJ-BRIT MED J, V331, P317, DOI 10.1136/bmj.38498.387569.8F; Hine C, 1996, J ROY SOC MED, V89, P681, DOI 10.1177/014107689608901207; Meads G, 2001, BRIT J GEN PRACT, V51, P91; NETTEN A, 2002, UNIT COSTS HLTH SOCI; Seamark D, 2001, BRIT J GEN PRACT, V51, P125; 1996, EUROQOL EQ 5D USER G	14	13	13	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 29	2006	333	7561					228	231		10.1136/bmj.38887.558576.7C	http://dx.doi.org/10.1136/bmj.38887.558576.7C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	070CC	16861254	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000239496900019
J	Truby, H; Baic, S; Delooy, A; Fox, KR; Livingstone, MBE; Logan, CM; Macdonald, IA; Morgan, LM; Taylor, MA; Millward, DJ				Truby, Helen; Baic, Sue; deLooy, Anne; Fox, Kenneth R.; Livingstone, M. Barbara E.; Logan, Catherine M.; Macdonald, Ian A.; Morgan, Linda M.; Taylor, Moira A.; Millward, D. J.			Randomised controlled trial of four commercial weight loss programmes in the UK: initial findings from the BBC "diet trials"	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; STRATEGIES	Objective To compare the effectiveness of four commercial weight loss diets available to adults in the United Kingdom. Design Six month multicentre randomised unblinded controlled trial. Setting Community based sample of otherwise healthy overweight and obese adults. Interventions Dr Atkins' new diet revolution, Slim-Fast plan, Weight Watchers pure points programme, and Rosemary Conley's eat yourself slim diet and fitness plan. Main outcome measures Weight and body fat changes over six months. Results All diets resulted in significant loss of body fat and weight over six months. Groups did not differ significantly but loss of body fat and weight was greater in all groups compared with the control group. In an intention to treat analysis, average weight loss was 5.9 kg and average fat loss was 4.4 kg over six months. The Atkins diet resulted in significantly higher weight loss during the first four weeks, but by the end was no more or less effective than the other diets. Conclusions Clinically useful weight loss and fat loss can be achieved in adults who are motivated to follow commercial diets for a substantial period. Given the limited resources for weight management in the NHS, healthcare practitioners should discuss with their patients programmes known to be effective.	Univ Surrey, Sch Biomed & Mol Sci, Ctr Nutr Dietet & Food, Surrey GU2 7XH, England; Univ Bristol, Dept Exercise & Hlth Sci, Ctr Sports Exercise & Hlth Sci, Bristol BS8 1TP, Avon, England; Univ Plymouth, Fac Hlth & Social Work, Plymouth PL4 8AA, Devon, England; Univ Ulster, No Ireland Ctr Food & Hlth, Coleraine BT52 1SA, Londonderry, North Ireland; Univ Nottingham, Sch Med, Integrated Syst Biol & Med, Inst Clin Res,Queens Med Ctr, Nottingham NG7 2UH, England; Univ Nottingham, Sch Med, Integrated Syst Biol & Med, Sch Biomed Sci,Queens Med Ctr, Nottingham NG7 2UH, England	University of Surrey; University of Bristol; University of Plymouth; Ulster University; University of Nottingham; University of Nottingham	Truby, H (corresponding author), Univ Surrey, Sch Biomed & Mol Sci, Ctr Nutr Dietet & Food, Surrey GU2 7XH, England.	h.truby@surrey.ac.uk	Fox, Kenneth/B-5897-2014	Macdonald, Ian/0000-0002-7540-9850; Fox, Kenneth/0000-0003-2216-4287; Taylor, Moira/0000-0003-4100-8343; Truby, Helen/0000-0002-1992-1649				ATKINS RC, 1999, ATKINS NEW DIET REVO; Crowe TC, 2005, OBES REV, V6, P235, DOI 10.1111/j.1467-789X.2005.00196.x; *DEP HLTH, 1999, WHIT PAP PUBL HLTH S; Foster GD, 1997, J CONSULT CLIN PSYCH, V65, P79, DOI 10.1037/0022-006X.65.1.79; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; FREEDMAN M, 2001, OBESITY REV S1, V9, P1, DOI DOI 10.1038/0BY.2001.113; French SA, 1999, INT J OBESITY, V23, P320, DOI 10.1038/sj.ijo.0800822; Harvey-Berino J, 1998, OBES RES, V6, P202, DOI 10.1002/j.1550-8528.1998.tb00338.x; KARVETTI RL, 1992, EUR J CLIN NUTR, V46, P743; Lean MEJ, 1997, EUR J CLIN NUTR, V51, P243, DOI 10.1038/sj.ejcn.1600391; Newman DJ, 2002, ANN CLIN BIOCHEM, V39, P89, DOI 10.1258/0004563021901847; Offer A, 2001, SOC HIST MED, V14, P79, DOI 10.1093/shm/14.1.79; Perri MG, 1998, CLIN PSYCHOL-SCI PR, V5, P526, DOI 10.1111/j.1468-2850.1998.tb00172.x; Royal College of Physicians, 2004, STOR PROBL MED CAS S; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; STERN I, ANN INT MED, V140, P769; STERN L, ANN INTERN MED, V140, P769; Vlad Ioana, 2003, BMJ, V327, P1308, DOI 10.1136/bmj.327.7427.1308-d	18	159	161	0	35	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 3	2006	332	7553					1309	1311		10.1136/bmj.38833.411204.80	http://dx.doi.org/10.1136/bmj.38833.411204.80			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	051YG	16720619	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000238197000022
J	Hsieh, LLC; Kuo, CH; Lee, LH; Yen, AMF; Chien, KL; Chen, THH				Hsieh, LLC; Kuo, CH; Lee, LH; Yen, AMF; Chien, KL; Chen, THH			Treatment of low back pain by acupressure and physical therapy: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALTERNATIVE MEDICINE; QUESTIONNAIRE	Objective To evaluate the effectiveness of acupressure for treating low back pain in terms of disability, pain scores, and functional status. Design Randomised controlled trial. Setting Orthopaedic clinic in Kaohsiung, Taiwan. Participants 129 patients with chronic low back pain. Intervention Acupressure or physical therapy for one month. Main outcome measures Self administered Chinese versions of standard outcome measures for low back pain (primary outcome: Roland and Morris disability questionnaire) at baseline, after treatment, and at six month follow-up. Results The mean total Roland and Morris disability questionnaire score after treatment was significantly lower in die acupressure group than in the physical therapy group regardless of the difference in absolute score (- 3.8, 95% confidence interval - 5.7 to - 1.9) or mean change from the baseline (- 4.64, - 6.39 to - 2.89). Acupressure conferred an 89% (95% confidence interval 61% to 97%) reduction in significant disability compared with physical therapy. The improvement in disability score in the acupressure group compared with the physical group remained at six month follow-up. Statistically significant differences also occurred between the two groups for all six domains of the core outcome, pain visual scale, and modified Oswestry disability questionnaire after treatment and at six month follow-up. Conclusions Acupressure was effective in reducing low back pain in terms of disability, pain scores, and functional status. The benefit was sustained for six months.	Natl Taiwan Univ, Inst Prevent Med, Coll Publ Hlth, Taipei 10764, Taiwan; Orthoped Special Clin, Kaohsiung, Taiwan; Chang Gung Mem Hosp, Kaohsiung, Taiwan	National Taiwan University; Chang Gung Memorial Hospital	Chen, THH (corresponding author), Natl Taiwan Univ, Inst Prevent Med, Coll Publ Hlth, Taipei 10764, Taiwan.	stony@episerv.cph.ntu.edu.tw		Chen, Hsiu-Hsi/0000-0002-5799-6705; CHIEN, KUO-LIONG/0000-0003-4979-8351				Altman DG, 1991, PRACTICAL STAT MED R; COSTE J, 1993, REV RHUM, V60, P335; Deyo RA, 1998, SPINE, V23, P2003, DOI 10.1097/00007632-199809150-00018; Efron B., 1993, INTRO BOOTSTRAP; Ehrlich GE, 1999, LOW BACK PAIN INITIA; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1998, ARCH INTERN MED, V158, P2235, DOI 10.1001/archinte.158.20.2235; FLESKETH T, 1997, BRIT MED J, V315, P115; Flynn TW, 2003, ARCH PHYS MED REHAB, V84, P1057, DOI 10.1016/S0003-9993(03)00048-0; Hesketh T, 1997, BRIT MED J, V315, P115, DOI 10.1136/bmj.315.7100.115; Hsieh LLC, 2004, PREV MED, V39, P168, DOI 10.1016/j.ypmed.2004.01.036; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; MELZACK R, 1971, ANESTHESIOLOGY, V34, P50; Mills SY, 2001, BRIT MED J, V322, P158, DOI 10.1136/bmj.322.7279.158; Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632-200012150-00006; Suzukamo Yoshimi, 2003, J Orthop Sci, V8, P543, DOI 10.1007/s00776-003-0679-x	16	85	89	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	2006	332	7543					696	698A		10.1136/bmj.38744.672616.AE	http://dx.doi.org/10.1136/bmj.38744.672616.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	027VH	16488895	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000236443300018
J	Ji, SP; Zhang, Y; Van Cleemput, J; Jiang, W; Liao, MX; Li, L; Wan, Q; Backstrom, JR; Zhang, X				Ji, SP; Zhang, Y; Van Cleemput, J; Jiang, W; Liao, MX; Li, L; Wan, Q; Backstrom, JR; Zhang, X			Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse	NATURE MEDICINE			English	Article							SEROTONIN; PROTEIN; INHIBITION; NEURONS; REWARD; CELLS; RATS	The widespread distribution of the tumor suppressor PTEN (phosphatase and tensin homolog deleted on chromosome 10) in the adult brain(1) suggests its role in a broad range of brain functions. Here we show evidence supporting a physical interaction of PTEN with a region in the third intracellular loop (3L4F) of the serotonin 5-HT2C receptor (5-HT2cR, formerly 5-HT1c receptor(2)) in cell cultures. PTEN limits agonist-induced phosphorylation of 5-HT2cR through its protein phosphatase activity. We showed the probable existence of PTEN:5-HT2cR complexes in putative dopaminergic neurons in the rat ventral tegmental area (VTA), a brain region in which virtually all abused drugs exert rewarding effects by activating its dopamine neurons(3,4). We synthesized the interfering peptide Tat-3L4F, which is able to disrupt PTEN coupling with 5-HT2cR. Systemic application of Tat-3L4F or the 5-HT2cR agonist Ro600175 suppressed the increased firing rate of VTA dopaminergic neurons induced by Delta 9-tetrahydrocannabinol (THC), the psychoactive ingredient of marijuana. Using behavioral tests, we found that Tat-3L4F or Ro600175 blocks conditioned place preference of THC or nicotine, and that Ro600175, but not Tat-3L4F, produces anxiogenic effects, penile erection, hypophagia and motor functional suppression. These results suggest a potential strategy for treating drug addiction with the Tat-3L4F peptide.	Univ Saskatchewan, Neuropsychiat Res Unit, Dept Psychiat, Saskatoon, SK S7N 5E4, Canada; Toronto Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; Toronto Hosp, Dept Physiol, Toronto, ON M5T 2S8, Canada; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA	University of Saskatchewan; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Vanderbilt University	Zhang, X (corresponding author), Univ Saskatchewan, Neuropsychiat Res Unit, Dept Psychiat, 103 Wiggins Rd, Saskatoon, SK S7N 5E4, Canada.	zhangxia@duke.usask.ca		Zhang, Xia/0000-0002-4811-3229				Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Alves SH, 2004, BEHAV PHARMACOL, V15, P37, DOI 10.1097/00008877-200402000-00005; Backstrom JR, 1997, J NEUROSCI METH, V77, P109, DOI 10.1016/S0165-0270(97)00102-7; Backstrom JR, 2000, J BIOL CHEM, V275, P23620, DOI 10.1074/jbc.M000922200; Braida D, 2004, EUR J PHARMACOL, V506, P63, DOI 10.1016/j.ejphar.2004.10.043; BUNNEY BS, 1973, J PHARMACOL EXP THER, V185, P560; Cheer JF, 2000, NEUROSCIENCE, V99, P661, DOI 10.1016/S0306-4522(00)00241-4; Clifton PG, 2000, PSYCHOPHARMACOLOGY, V152, P256, DOI 10.1007/s002130000504; Di Matteo V, 2002, PHARMACOL BIOCHEM BE, V71, P727, DOI 10.1016/S0091-3057(01)00705-5; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Grottick AJ, 2000, J PHARMACOL EXP THER, V295, P1183; Hannesson DK, 2001, J NEUROSCI, V21, P4443, DOI 10.1523/JNEUROSCI.21-12-04443.2001; Higgins GA, 2003, EUR J PHARMACOL, V480, P151, DOI 10.1016/j.ejphar.2003.08.102; JOHNSON SW, 1992, J NEUROSCI, V12, P483; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Li L, 2003, J CELL BIOCHEM, V88, P24, DOI 10.1002/jcb.10312; Lupica CR, 2004, BRIT J PHARMACOL, V143, P227, DOI 10.1038/sj.bjp.0705931; Nestler EJ, 2004, TRENDS PHARMACOL SCI, V25, P210, DOI 10.1016/j.tips.2004.02.005; Ning K, 2004, J NEUROSCI, V24, P4052, DOI 10.1523/JNEUROSCI.5449-03.2004; POMPEIANO M, 1994, MOL BRAIN RES, V23, P163, DOI 10.1016/0169-328X(94)90223-2; Rice HB, 2002, PHARMACOL BIOCHEM BE, V73, P545, DOI 10.1016/S0091-3057(02)00839-0; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Steelman LS, 2004, EXPERT OPIN THER TAR, V8, P537, DOI 10.1517/14728222.8.6.537; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Szabo B, 2002, EUR J NEUROSCI, V15, P2057, DOI 10.1046/j.1460-9568.2002.02041.x; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Wood MD, 2003, CNS NEUROL DISORD-DR, V2, P383, DOI 10.2174/1568007033482698; Zhang X, 2001, J NEUROSCI, V21, P3674, DOI 10.1523/JNEUROSCI.21-10-03674.2001	30	123	126	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					324	329		10.1038/nm1349	http://dx.doi.org/10.1038/nm1349			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16474401				2023-01-03	WOS:000235802900032
J	Cohen, AT; Davidson, BL; Gallus, AS; Lassen, MR; Prins, MH; Tomkowski, W; Turpie, AGG; Egberts, JFM; Lensing, AWA				Cohen, AT; Davidson, BL; Gallus, AS; Lassen, MR; Prins, MH; Tomkowski, W; Turpie, AGG; Egberts, JFM; Lensing, AWA		ARTEMIS Investigators	Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEEP-VEIN THROMBOSIS; FATAL PULMONARY-EMBOLISM; THROMBOPROPHYLAXIS; METAANALYSIS; ENOXAPARIN; SURGERY; HEPARIN	Objective To determine the efficacy and safety of the anticoagulant fordaparinux in older acute medical inpatients at moderate to high risk of venous thromboembolism. Design Double blind randomised placebo controlled trial. Setting 15 centres in eight countries. Participants 849 medical patients aged 60 or more admitted to hospital for congestive heart failure, acute respiratory illness in the presence of chronic lung disease, or acute infectious or inflammatory disease and expected to remain in bed for at least four days. Interventions 2.5 mg fondaparinux or placebo subcutaneously once daily for six to 14 clays. Outcome measure The primary efficacy Outcome was venous thromboembolism detected by routine bilateral venography along with symptomatic venous thromboembolism LIP to clay 15. Secondary outcomes were bleeding and death. Patients were followed up at one month. Results 425 patients in the fondaparinux group and 414 patients in the placebo group were evaluable for safety analysis (10 were not treated). 644 patients (75.9%) were available for the primary efficacy analysis. Venous thromboembolism was detected ill 5.6% (18/321) of patients treated with fondaparinux and 10.5% (34/323) of patients given placebo, a relative risk reduction of 46.7% (95% confidence interval 7.7% to 69.30%). Symptomatic venous thromboembolism Occurred in five patients in the placebo group and none in the fondaparinux group (P = 0.029). Major bleeding occurred in one patient (0.2%) in each group. At the end of follow-up, 14 Patients in the fondaparinux group (3.3%) and 25 in die placebo group (6.0%) had died. Conclusion Fondaparinux is effective in the prevention of asymptomatic mid symptomatic venous thromboembolic events in older acute medical patients. The frequency of major bleeding was similar for both fondaparinux and placebo treated patients.	Guys Kings & St Thomas Sch Med, Dept Surg, London SE5 9PJ, England; Univ Washington, Sch Med, Seattle, WA USA; Swedish Med Ctr, Seattle, WA USA; Flinders Med Ctr, Dept Haematol, Adelaide, SA, Australia; Dept Clin Res, Spine Clin, Horsholm, Denmark; Acad Hosp Maastricht, Dept Clin Epidemiol & Technol Assessment, Maastricht, Netherlands; Natl TB & Lung Dis Res Inst, Warsaw, Poland; Hamilton Hlth Sci, Dept Med, Hamilton, ON, Canada; NV Organon, Clin Dev, NL-5340 BH Oss, Netherlands; Univ Amsterdam, Acad Med Ctr, Ctr Vasc Med, NL-1105 AZ Amsterdam, Netherlands	University of London; King's College London; University of Washington; University of Washington Seattle; Swedish Medical Center; Flinders Medical Centre; Maastricht University; Maastricht University Medical Centre (MUMC); McMaster University; Merck & Company; University of Amsterdam; Academic Medical Center Amsterdam	Cohen, AT (corresponding author), Guys Kings & St Thomas Sch Med, Dept Surg, London SE5 9PJ, England.	alexander.cohen@kcl.ac.uk		Gallus, Alexander/0000-0001-7347-9989				Ageno W, 2002, HAEMATOLOGICA, V87, P746; Alikhan R, 2001, BLOOD, V98, p271A; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Baglin TP, 1997, J CLIN PATHOL, V50, P609, DOI 10.1136/jcp.50.7.609; Buller HR, 2003, NEW ENGL J MED, V349, P1695; Cohen A. T., 2000, Seminars in Hematology, V37, P19, DOI 10.1016/S0037-1963(00)90096-9; Cohen AT, 1996, HAEMOSTASIS, V26, P65; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Hampton KK, 2003, INT J CLIN PRACT, V57, P424; HEIR JA, 2002, ARCH INTERN MED, V162, P1245; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24; LINDBLAD B, 1991, BRIT MED J, V302, P709, DOI 10.1136/bmj.302.6778.709; Mismetti P, 2000, THROMB HAEMOSTASIS, V83, P14; Mismetti P, 2002, HAEMATOLOGICA, V87, P673; Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103; SANDLER DA, 1989, J ROY SOC MED, V82, P203, DOI 10.1177/014107688908200407; Turpie AGG, 2002, ARCH INTERN MED, V162, P1833, DOI 10.1001/archinte.162.16.1833; WEINMANN EE, 1994, NEW ENGL J MED, V331, P1630, DOI 10.1056/NEJM199412153312407	20	602	631	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2006	332	7537					325	327		10.1136/bmj.38733.466748.7C	http://dx.doi.org/10.1136/bmj.38733.466748.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012YI	16439370	Green Published, Bronze			2023-01-03	WOS:000235376400014
J	Simantirakis, EN; Schiza, SE; Chrysostomakis, SI; Chlouverakis, GI; Klapsinos, NC; Siafakas, NM; Vardas, PE				Simantirakis, EN; Schiza, SE; Chrysostomakis, SI; Chlouverakis, GI; Klapsinos, NC; Siafakas, NM; Vardas, PE			Atrial overdrive pacing for the obstructive sleep apnea-hypopnea syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; HEART-FAILURE; BLOOD-PRESSURE; THERAPY; CPAP; DISTURBANCES; MECHANISMS	BACKGROUND: The role of atrial overdrive pacing (AOP) in sleep apnea remains uncertain. We prospectively evaluated the effect of AOP after 24 hours and after one month in patients with the obstructive sleep apnea-hypopnea syndrome and compared it with the use of nasal continuous positive airway pressure (n-CPAP). METHODS: We studied 16 patients with a moderate or severe case of the obstructive sleep apnea-hypopnea syndrome (baseline mean apnea-hypopnea index, 49) and normal left ventricular systolic function in whom a dual-chamber pacemaker had been implanted. After 48 hours, the patients were randomly assigned to AOP (pacing at 15 bpm above the spontaneous mean nocturnal heart rate) or backup atrial pacing (pacing at a heart rate below 40 bpm); the latter group began n-CPAP therapy one day later. After one month, the two groups switched therapies and were followed for an additional month. Polysomnographic studies were performed at baseline, on the first night after randomization, at crossover, and at the end of the study. RESULTS: During AOP, no significant changes were observed in any of the respiratory variables measured. The change in the apnea-hypopnea index at one month with AOP was +0.2 (95 percent confidence interval, -2.7 to +2.3; P=0.87). In contrast, all variables improved significantly after one month of n-CPAP (change in the apnea-hypopnea index, -46.3; 95 percent confidence interval, -56.2 to -36.5; P<0.001). CONCLUSIONS: Nasal continuous positive airway pressure therapy is highly effective for the treatment of the obstructive sleep apnea-hypopnea syndrome, whereas AOP has no significant effect.	Heraklion Univ Hosp, Dept Cardiol, Iraklion, Crete, Greece; Heraklion Univ Hosp, Dept Pneumol, Iraklion, Crete, Greece	University Hospital of Heraklion; University Hospital of Heraklion	Vardas, PE (corresponding author), Heraklion Univ Hosp, Dept Cardiol, POB 1352, Iraklion, Crete, Greece.	cardio@med.uoc.gr	Chrysostomakis, Stavros/AAV-3536-2020; Vardas, Panos/AAD-5219-2022; Vardas, Panos/AAP-5694-2021; Siafakas, Nikolas/AAI-3324-2020; vardas, panos/ABF-7144-2020	Chrysostomakis, Stavros/0000-0001-6956-2878				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Dimsdale JE, 2000, HYPERTENSION, V35, P144, DOI 10.1161/01.HYP.35.1.144; Garrigue S, 2002, NEW ENGL J MED, V346, P404, DOI 10.1056/NEJMoa011919; GARRIGUE S, 2002, NEW ENGL J MED, V346, P872; George CFP, 2001, THORAX, V56, P508, DOI 10.1136/thorax.56.7.508; Harbison J, 2000, CHEST, V118, P591, DOI 10.1378/chest.118.3.591; HUDGEL DW, 1992, CHEST, V101, P541, DOI 10.1378/chest.101.2.541; Javaheri S, 2000, CIRCULATION, V101, P392, DOI 10.1161/01.CIR.101.4.392; Kato I, 2001, PSYCHIAT CLIN NEUROS, V55, P257, DOI 10.1046/j.1440-1819.2001.00849.x; Lacasse Y, 2002, EUR RESPIR J, V19, P499, DOI 10.1183/09031936.02.00216902; Luthje L, 2005, AM J RESP CRIT CARE, V172, P118, DOI 10.1164/rccm.200409-1258OC; Narkiewicz K, 1999, CIRCULATION, V100, P2332, DOI 10.1161/01.CIR.100.23.2332; Pepin JL, 1999, AM J RESP CRIT CARE, V160, P1124, DOI 10.1164/ajrccm.160.4.9802027; Pepin JL, 2005, EUR RESPIR J, V25, P343, DOI 10.1183/09031936.05.00132703; Redline S, 1998, AM J RESP CRIT CARE, V157, P858, DOI 10.1164/ajrccm.157.3.9709042; ROLFE I, 1991, AM REV RESPIR DIS, V144, P1130, DOI 10.1164/ajrccm/144.5.1130; Ryan CM, 2005, CHEST, V127, P536, DOI 10.1378/chest.127.2.536; Schulz R, 2000, THORAX, V55, P1046, DOI 10.1136/thorax.55.12.1046; Simantirakis EN, 2004, EUR HEART J, V25, P1070, DOI 10.1016/j.ehj.2004.04.017; Sinha AM, 2004, J AM COLL CARDIOL, V44, P68, DOI 10.1016/j.jacc.2004.03.040; SMITH PL, 1994, AM J RESP CRIT CARE, V150, P1738; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; SULLIVAN CE, 1981, LANCET, V1, P862; Tkacova R, 2000, J HYPERTENS, V18, P1257, DOI 10.1097/00004872-200018090-00012; Vgontzas AN, 2003, J INTERN MED, V254, P32, DOI 10.1046/j.1365-2796.2003.01177.x; WILCOX I, 1993, SLEEP, V16, P539, DOI 10.1093/sleep/16.6.539; Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746; Ziegler MG, 2001, CHEST, V120, P887, DOI 10.1378/chest.120.3.887; 1995, AM J RESP CRIT CARE, V151, P578	29	67	70	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	2005	353	24					2568	2577		10.1056/NEJMoa050610	http://dx.doi.org/10.1056/NEJMoa050610			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	993BA	16354893				2023-01-03	WOS:000233926500006
J	Clark, AM; Harding, L; Vandermeer, B; McAlister, FA				Clark, AM; Harding, L; Vandermeer, B; McAlister, FA			Meta-analysis: Secondary prevention programs for patients with coronary artery disease	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-LIFE; CARDIAC REHABILITATION PROGRAM; MULTIFACTORIAL INTERVENTION PROGRAM; HIGH CARDIOVASCULAR RISK; ISCHEMIC-HEART-DISEASE; FOLLOW-UP; PRIMARY-CARE; BYPASS-SURGERY	Background: Although supervised exercise programs reduce mortality in survivors of myocardial infarction, the effects of other types of cardiac secondary prevention programs are unknown. Purpose: To determine the effectiveness of secondary cardiac prevention programs with and without exercise components. Data Sources: The authors searched MEDLINE (1966-2004), the Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, SIGLE, and the Cochrane Effective Practice and Organization of Care Study Registry. They also contacted primary study authors and hand-searched bibliographies provided by the Centers for Medicare & Medicaid Services. Study Selection: Randomized clinical trials. Data Extraction: Two reviewers chose studies and extracted data independently; random-effects summary risk ratios were calculated. Data Synthesis: The authors identified 63 randomized trials (21 295 patients with coronary disease). The summary risk ratio was 0.85 (95% Cl, 0.77 to 0.94) for all-cause mortality, but this result differed over time with a risk ratio of 0.97 (Cl, 0.82 to 1.14) at 12 months and 0.53 (Cl, 0.35 to 0.81) at 24 months. The summary risk ratio was 0.83 (Cl, 0.74 to 0.94) for recurrent myocardial infarction over a median follow-up of 12 months. Effects were similar for programs that included risk factor education or counseling with a structured exercise component (risk ratio, 0.88 [Cl, 0.74 to 1.04] for mortality and 0.62 [Cl, 0.44 to 0.87] for myocardial infarction), for programs that included risk factor education or counseling without an exercise component (risk ratio, 0.87 [Cl, 0.76 to 0.99] for mortality and 0.86 [Cl, 0.72 to 1.03] for myocardial infarction), and for programs that were solely exercise-based (risk ratio, 0.72 [Cl, 0.54 to 0.95] for mortality and 0.76 [Cl, 0.57 to 1.01] for myocardial infarction). Most of these programs improved quality of life or functional status, but effect sizes were small. Limitations: Although these programs may reduce total health care costs, published data on the costs of the programs are inadequate to conclusively comment on their cost-effectiveness. Conclusions: A wide variety of secondary prevention programs improve health outcomes in patients with coronary disease.	Univ Alberta Evidence Based Practice Ctr, Edmonton, AB, Canada	University of Alberta	McAlister, FA (corresponding author), Univ Alberta Hosp, Div Gen Internal Med, 2E3-24 WMC,8440 112th St, Edmonton, AB T6G 2R7, Canada.	Finlay.McAlister@ualberta.ca	McAlister, Finlay/C-4151-2013	McAlister, Finlay/0000-0001-7435-3341	PHS HHS [290-02-0023] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGREN B, 1989, EUR HEART J, V10, P451, DOI 10.1093/oxfordjournals.eurheartj.a059509; Allen JK, 2002, AM HEART J, V144, P678, DOI 10.1067/mhj.2002.124837; Allison TG, 2000, AM J CARDIOL, V86, P133, DOI 10.1016/S0002-9149(00)00848-1; Allison TG, 1999, MAYO CLIN PROC, V74, P466; *AM HEART ASS, 2004, HEART DIS STROK STAT; Balady GJ, 2000, CIRCULATION, V102, P1069, DOI 10.1161/01.CIR.102.9.1069; BALLANTYNE FC, 1982, CIRCULATION, V65, P913, DOI 10.1161/01.CIR.65.5.913; Belardinelli R, 2001, J AM COLL CARDIOL, V37, P1891, DOI 10.1016/S0735-1097(01)01236-0; BELL J, 1998, THESIS U LONDON LOND; BENGTSSON K, 1983, SCAND J REHABIL MED, V15, P1; BERTIE J, 1992, J ROY COLL PHYS LOND, V26, P147; BETHELL HJN, 1990, BRIT HEART J, V64, P370; Campbell NC, 1998, HEART, V80, P447, DOI 10.1136/hrt.80.5.447; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1434, DOI 10.1136/bmj.316.7142.1434; Carlsson R, 1998, SCAND CARDIOVASC J, V32, P1, DOI 10.1080/140174398427956-1; Carlsson R, 1997, HEART, V77, P256, DOI 10.1136/hrt.77.3.256; CARSON P, 1982, J ROY COLL PHYS LOND, V16, P147; Cooper AF, 2002, CLIN REHABIL, V16, P541, DOI 10.1191/0269215502cr524oa; CUPPLES ME, 1994, BRIT MED J, V309, P993, DOI 10.1136/bmj.309.6960.993; Cupples ME, 1999, BMJ-BRIT MED J, V319, P687, DOI 10.1136/bmj.319.7211.687; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; Dinnes J, 1999, QUAL HEALTH CARE, V8, P65, DOI 10.1136/qshc.8.1.65; DOROSSIEV D, 1983, EURO REPORTS STUDIES, V84; Dugmore LD, 1999, HEART, V81, P359, DOI 10.1136/hrt.81.4.359; Engblom E, 1997, J Cardiopulm Rehabil, V17, P29, DOI 10.1097/00008483-199701000-00004; ENGBLOM E, 1992, EUR HEART J, V13, P232, DOI 10.1093/oxfordjournals.eurheartj.a060152; ERDMAN RAM, 1986, J CARDIOPULM REHABIL, V6, P206, DOI DOI 10.1097/00008483-198606000-00001; FITZGERALD JF, 1994, ARCH INTERN MED, V154, P1721, DOI 10.1001/archinte.154.15.1721; FLETCHER BJ, 1994, AM J CARDIOL, V73, P170, DOI 10.1016/0002-9149(94)90209-7; FrasureSmith N, 1997, LANCET, V350, P473, DOI 10.1016/S0140-6736(97)02142-9; Fridlund B, 1991, Scand J Caring Sci, V5, P23; HAMALAINEN H, 1989, EUR HEART J, V10, P55; Hamalainen H, 1995, EUR HEART J, V16, P1839; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; Heldal M, 2000, SCAND CARDIOVASC J, V34, P59; Higgins HC, 2001, PATIENT EDUC COUNS, V43, P219, DOI 10.1016/S0738-3991(00)00164-6; HOLMBACK AM, 1994, ARCH PHYS MED REHAB, V75, P551; Johnston M, 1999, PSYCHOSOM MED, V61, P225, DOI 10.1097/00006842-199903000-00015; Jolly K, 1999, BMJ-BRIT MED J, V318, P706; Jones DA, 1996, BRIT MED J, V313, P1517, DOI 10.1136/bmj.313.7071.1517; KALLIO V, 1979, LANCET, V2, P1091; Lavie Carl J., 1999, Cardiology Clinics, V17, P233, DOI 10.1016/S0733-8651(05)70067-9; Lear SA, 2003, EUR HEART J, V24, P1920, DOI 10.1016/j.ehj.2003.08.015; LEIZOROVICZ A, 1991, EUR HEART J, V12, P612; Lichtman JH, 2004, AM HEART J, V147, P522, DOI 10.1016/j.ahj.2003.06.003; Linfante A, 2004, CIRCULATION, V110, P664; Lisspers J, 1999, J PSYCHOSOM RES, V46, P143, DOI 10.1016/S0022-3999(98)00074-9; Majeed FA, 1996, PUBLIC HEALTH, V110, P7, DOI 10.1016/S0033-3506(96)80027-8; Majumdar SR, 2004, J AM COLL CARDIOL, V43, P1738, DOI 10.1016/j.jacc.2003.12.043; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; Marchionni N, 2003, CIRCULATION, V107, P2201, DOI 10.1161/01.CIR.0000066322.21016.4A; Masley S, 2001, J FAM PRACTICE, V50, P235; McAlister FA, 2001, BRIT MED J, V323, P957, DOI 10.1136/bmj.323.7319.957; McHugh F, 2001, HEART, V86, P317, DOI 10.1136/heart.86.3.317; Milani RV, 1998, AM J CARDIOL, V81, P1233, DOI 10.1016/S0002-9149(98)00121-0; MILLER NH, 1984, CIRCULATION, V70, P645, DOI 10.1161/01.CIR.70.4.645; Moher M, 2001, BMJ-BRIT MED J, V322, P1338, DOI 10.1136/bmj.322.7298.1338; Murchie P, 2004, FAM PRACT, V21, P567, DOI 10.1093/fampra/cmh514; Murchie P, 2003, BRIT MED J, V326, P84, DOI 10.1136/bmj.326.7380.84; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Naylor M D, 1999, J Cardiovasc Nurs, V14, P44; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Niebauer J, 1997, CIRCULATION, V96, P2534, DOI 10.1161/01.CIR.96.8.2534; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE N, 1991, AM J CARDIOL, V67, P1084, DOI 10.1016/0002-9149(91)90870-Q; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; Oliver S, 2004, HEALTH TECHNOL ASSES, V8, P1; Ornish D, 1998, JAMA-J AM MED ASSOC, V280, P2001, DOI 10.1001/jama.280.23.2001; ORNISH D, 1983, JAMA-J AM MED ASSOC, V249, P54, DOI 10.1001/jama.249.1.54; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; Raftery JP, 2005, BRIT MED J, V330, P707, DOI 10.1136/bmj.38342.665417.8F; ROVIARO S, 1984, J BEHAV MED, V7, P61, DOI 10.1007/BF00845347; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; Seki E, 2003, CIRC J, V67, P73, DOI 10.1253/circj.67.73; SHAW LW, 1981, AM J CARDIOL, V48, P39, DOI 10.1016/0002-9149(81)90570-1; Shephard RJ, 1999, CIRCULATION, V99, P963, DOI 10.1161/01.CIR.99.7.963; SIVARAJAN ES, 1982, CIRCULATION, V65, P1420, DOI 10.1161/01.CIR.65.7.1420; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Stagmo M, 2001, J CARDIOVASC RISK, V8, P243, DOI 10.1097/00043798-200108000-00009; Stahle A, 2000, SCAND J REHABIL MED, V32, P111; STERN MJ, 1983, ARCH INTERN MED, V143, P1719, DOI 10.1001/archinte.143.9.1719; Sundin O, 2003, INT J BEHAV MED, V10, P191, DOI 10.1207/S15327558IJBM1003_01; Taylor C B, 1997, J Cardiopulm Rehabil, V17, P157, DOI 10.1097/00008483-199705000-00002; Taylor RS, 2004, AM J MED, V116, P682, DOI 10.1016/j.amjmed.2004.01.009; Toobert DJ, 2000, ANN BEHAV MED, V22, P1, DOI 10.1007/BF02895162; Vale MJ, 2003, ARCH INTERN MED, V163, P2775, DOI 10.1001/archinte.163.22.2775; Vale MJ, 2002, J CLIN EPIDEMIOL, V55, P245, DOI 10.1016/S0895-4356(01)00460-7; VERMEULEN A, 1983, AM HEART J, V105, P798, DOI 10.1016/0002-8703(83)90243-0; WILHELMSEN L, 1975, PREV MED, V4, P491, DOI 10.1016/0091-7435(75)90035-3; Witt BJ, 2004, J AM COLL CARDIOL, V44, P988, DOI 10.1016/j.jacc.2004.05.062; Wosornu D, 1996, EUR HEART J, V17, P854; Young W, 2003, CAN MED ASSOC J, V169, P905; Yu CM, 2003, AM J CARDIOL, V91, P321, DOI 10.1016/S0002-9149(02)03159-4; Yusuf S, 2002, LANCET, V360, P2, DOI 10.1016/S0140-6736(02)09358-3; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; 2003, EUR J CARDIOVASC PRE, V10, P429	96	690	728	1	66	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2005	143	9					659	672		10.7326/0003-4819-143-9-200511010-00010	http://dx.doi.org/10.7326/0003-4819-143-9-200511010-00010			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	980PN	16263889				2023-01-03	WOS:000233030600006
J	Narita, N; Fujieda, S; Tokuriki, M; Takahashi, N; Tsuzuki, H; Ohtsubo, T; Matsumoto, H				Narita, N; Fujieda, S; Tokuriki, M; Takahashi, N; Tsuzuki, H; Ohtsubo, T; Matsumoto, H			Inhibition of histone deacetylase 3 stimulates apoptosis induced by heat shock under acidic conditions in human maxillary cancer	ONCOGENE			English	Article						cDNA array; hyperthermia; low pH; HDAC3; head and neck cancer	HISTONE DEACETYLASE INHIBITOR; EPIDERMAL-GROWTH-FACTOR; IN-VITRO; SIGNAL-TRANSDUCTION; RANDOMIZED-TRIAL; NITRIC-OXIDE; TUMOR-GROWTH; EXPRESSION; CELLS; P53	To elucidate the molecular mechanisms for the enhancement of heat-induced apoptosis on exposure to acidic conditions, human maxillary carcinoma IMC-3 cells were heat-shocked at 44 degrees C for 30 min at either pH 7.4 or 6.7. Analyses with cDNA arrays, the reverse transcription polymerase chain reaction (RT-PCR), and Western blotting were performed. We found that histone deacetylase 3 (HDAC3) was specifically induced after hyperthermia at 44 degrees C for 30 min at pH 6.7. Although the cytotoxicity of heating at 44 degrees C for 30 min was enhanced by decreasing the pH from 7.4 to 6.7, it was enhanced even more by antisense RNA oligonucleotides for HDAC3. The induction of G(2)/M arrest after heating occurred earlier at pH 6.7 than at pH 7.4. The inhibition of HDAC3 by the antisense RNA oligonucleotides suppressed partially the induction of G2/M arrest, resulting in an enhancement of the apoptosis caused by the heating under acidic conditions. Antisense RNA oligonucleotides for HDAC3 enhanced apoptosis 48 h after hyperthermia at 43 degrees C for 30 min in vivo. Analyses of p65 activity suggested that NF-KB is involved in this enhancement of hyperthermia. HDAC3 may be a novel target enhancing hyperthermia and combined treatment with hyperthermia and HDAC inhibitors is a possible modality for cancer therapy.	Univ Fukui, Dept Otorhinolaryngol, Matsuoka, Fukui 9101193, Japan; Univ Fukui, Fac Med Sci, Dept Expt Radiol & Hlth Phys, Matsuoka, Fukui 9101193, Japan	University of Fukui; University of Fukui	Narita, N (corresponding author), Univ Fukui, Dept Otorhinolaryngol, Matsuoka, Fukui 9101193, Japan.	norihiko@fmsrsa.fukui-med.ac.jp	Narita, Norihiko/AAA-4801-2022	Narita, Norihiko/0000-0001-9765-9669				AKIN RE, 2004, J BIOL CHEM, V297, P51218; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Dahl O, 2002, INT J HYPERTHER, V18, P25, DOI 10.1080/02656730110083756; ENGIN K, 1995, CLIN CANCER RES, V1, P139; FUJIEDA S, 1995, J IMMUNOL, V155, P2318; Gan YH, 2005, J BIOL CHEM, V280, P16467, DOI 10.1074/jbc.M412960200; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; HARMON BV, 1990, INT J RADIAT BIOL, V58, P845, DOI 10.1080/09553009014552221; Huang YH, 2002, CANCER RES, V62, P2913; Jin ZH, 2004, INT J RADIAT ONCOL, V59, P852, DOI 10.1016/j.ijrobp.2004.01.033; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Levenson VV, 2000, CANCER RES, V60, P5027; Liu F, 2004, J BIOL CHEM, V279, P34537, DOI 10.1074/jbc.M402475200; Marshall John L, 2002, J Exp Ther Oncol, V2, P325, DOI 10.1046/j.1359-4117.2002.01039.x; Matsumoto H, 1997, INT J RADIAT ONCOL, V38, P1089, DOI 10.1016/S0360-3016(97)00300-3; Matsumoto H, 1998, INT J ONCOL, V13, P741; Matsumoto H, 1998, INT J RADIAT ONCOL, V41, P915, DOI 10.1016/S0360-3016(98)00121-7; Matsumoto H, 1999, CANCER RES, V59, P3239; MIZOGUCHI H, 1991, INT J CANCER, V49, P738, DOI 10.1002/ijc.2910490518; MORONI MC, 1992, J BIOL CHEM, V267, P2714; Mukhopadhyay T, 1996, CRIT REV ONCOGENESIS, V7, P151, DOI 10.1615/CritRevOncog.v7.i3-4.20; Murata M, 2000, JPN J CANCER RES, V91, P1154, DOI 10.1111/j.1349-7006.2000.tb00899.x; Narita N, 2002, INT J RADIAT ONCOL, V53, P190, DOI 10.1016/S0360-3016(02)02727-X; Ohnishi K, 2001, INT J HYPERTHER, V17, P415, DOI 10.1080/02656730110063604; Ohtsubo T, 2001, INT J RADIAT ONCOL, V49, P1391, DOI 10.1016/S0360-3016(00)01590-X; Ohtsubo T, 2000, INT J HYPERTHER, V16, P481, DOI 10.1080/02656730050199331; OVERGAARD J, 1995, LANCET, V345, P540, DOI 10.1016/S0140-6736(95)90463-8; Park HJ, 1999, BRIT J CANCER, V80, P1892, DOI 10.1038/sj.bjc.6690617; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; RHEE JG, 1984, INT J RADIAT ONCOL, V10, P393, DOI 10.1016/0360-3016(84)90060-9; Ru K, 1999, ONCOL RES, V11, P505; Sasakawa Y, 2002, BIOCHEM PHARMACOL, V64, P1079, DOI 10.1016/S0006-2952(02)01261-3; Sneed PK, 1998, INT J RADIAT ONCOL, V40, P287, DOI 10.1016/S0360-3016(97)00731-1; Sugimoto C, 1999, INT J CANCER, V82, P860, DOI 10.1002/(SICI)1097-0215(19990909)82:6<860::AID-IJC15>3.0.CO;2-6; Takahashi A, 2003, INT J HYPERTHER, V19, P145, DOI 10.1080/02656730210166131; Takahashi I, 2002, SURGERY, V131, pS78, DOI 10.1067/msy.2002.119308; Takasu T, 1998, CANCER RES, V58, P2504; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yu XD, 2002, J NATL CANCER I, V94, P504	43	23	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7346	7354		10.1038/sj.onc.1208879	http://dx.doi.org/10.1038/sj.onc.1208879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16044157				2023-01-03	WOS:000233142100011
J	Spinewine, A; Swine, C; Dhillon, S; Franklin, BD; Tulkens, PM; Wilmotte, L; Lorant, V				Spinewine, A; Swine, C; Dhillon, S; Franklin, BD; Tulkens, PM; Wilmotte, L; Lorant, V			Appropriateness of use of medicines in elderly inpatients: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IN-HOSPITAL INPATIENTS; INTERNAL-MEDICINE; OLDER PATIENTS; HEALTH-CARE; GERIATRICS; PHYSICIAN; BEHAVIOR	Objectives To explore the processes leading to inappropriate use of medicines for elderly patients admitted for acute care. Design Qualitative study with semistructured interviews with doctors, nurses, and pharmacists; focus groups with inpatients; and observation on die ward by clinical pharmacists for one month. Setting Five acute wards for care of the elderly in Belgium. Participants 5 doctors, 4 nurses, and 3 pharmacists from five acute wards for the interviews; all professionals and patients on two acute wards for the observation and 17 patients (from the same two wards) for the focus groups. Results Several factors contributed to inappropriate prescribing, counselling, and transfer of information on medicines to primary care. Firstly, review of treatment was driven by acute considerations, the transfer of information on medicines from primary to secondary care was limited, and prescribing was often not tailored to elderly patients. Secondly, some doctors had a passive attitude towards learning: they thought it would take too long to find the information they needed about medicines and lacked self directed learning. Finally, a paternalistic doctor-patient relationship and difficulties in sharing decisions about treatment between prescribers led to inappropriate use of medicines. Several factors, such as the input of geriatricians and good communication between members of the multidisciplinary geriatric team, led to better use of medicines. Conclusions In this setting, improvements targeted at the abilities of individuals, better doctor-patient and doctor-doctor relationships, and systems for transferring information between care settings will increase the appropriate use of medicines in elderly people.	Catholic Univ Louvain, Sch Pharm, Ctr Clin Pharm, B-1200 Brussels, Belgium; Mt Godinne Univ Hosp, Dept Geriatr Med, B-5530 Yvoir, Belgium; Univ Hertfordshire, Sch Pharm, Hatfield AL10 9AB, Herts, England; Hammersmith Hosp NHS Trust, Acad Pharm Unit, London W12 0HS, England; Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium; Catholic Univ Louvain, Sch Publ Hlth, B-3000 Louvain, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain Hospital; University of Hertfordshire; Imperial College London; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain	Spinewine, A (corresponding author), Catholic Univ Louvain, Sch Pharm, Ctr Clin Pharm, B-1200 Brussels, Belgium.	anne.spinewine@facm.ucl.ac.be	; Tulkens, Paul/B-2087-2015	/0000-0002-2663-332X; Franklin, Bryony/0000-0002-2892-1245; Tulkens, Paul/0000-0002-7121-3623				Al-Rashed SA, 2002, BRIT J CLIN PHARMACO, V54, P657, DOI 10.1046/j.1365-2125.2002.01707.x; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; BURNS JMA, 1992, AGE AGEING, V21, P178, DOI 10.1093/ageing/21.3.178; Cook DJ, 2004, LANCET, V363, P1224, DOI 10.1016/S0140-6736(04)15955-2; Dean B, 2002, QUAL SAF HEALTH CARE, V11, P340, DOI 10.1136/qhc.11.4.340; Dean B, 2002, LANCET, V359, P1373, DOI 10.1016/S0140-6736(02)08350-2; Department of Health, SINGL ASS PROC; Dickinson D, 2003, BRIT MED J, V327, P861, DOI 10.1136/bmj.327.7419.861-a; Gafni A, 1998, SOC SCI MED, V47, P347, DOI 10.1016/S0277-9536(98)00091-4; Hanlon JT, 2000, ANN PHARMACOTHER, V34, P360, DOI 10.1345/aph.19140; KROENKE LTCK, 1990, J AM GERIATR SOC, V38, P31, DOI 10.1111/j.1532-5415.1990.tb01593.x; Larson EB, 2001, ANN INTERN MED, V134, P997, DOI 10.7326/0003-4819-134-10-200105150-00013; Mangione-Smith R, 2002, HEALTH SERV RES, V37, P1603, DOI 10.1111/1475-6773.10482; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; Mold F, 2003, HEALTH SOC CARE COMM, V11, P405, DOI 10.1046/j.1365-2524.2003.00443.x; National Service Framework for Older People, 2001, MED OLD PEOPL IMPL M; OWENS NJ, 1990, J AM GERIATR SOC, V38, P1082, DOI 10.1111/j.1532-5415.1990.tb01369.x; Rathore SS, 2003, AM J MED, V114, P307, DOI 10.1016/S0002-9343(02)01531-0; Rochon PA, 1999, JAMA-J AM MED ASSOC, V282, P113, DOI 10.1001/jama.282.2.113; Rolfe IE, 2002, MED EDUC, V36, P345, DOI 10.1046/j.1365-2923.2002.01170.x; Schmader KE, 2004, AM J MED, V116, P394, DOI 10.1016/j.amjmed.2003.10.031; Strauss A., 1990, BASICS GROUNDED THEO; Thomas DC, 2003, ANN INTERN MED, V139, P628, DOI 10.7326/0003-4819-139-7-200310070-00037; Tomlin Z, 1999, BMJ-BRIT MED J, V318, P1532, DOI 10.1136/bmj.318.7197.1532	24	66	69	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 22	2005	331	7522					935	938		10.1136/bmj.38551.410012.06	http://dx.doi.org/10.1136/bmj.38551.410012.06			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979UR	16093254	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000232970900020
J	Castello, L; Froio, T; Cavallini, G; Biasi, F; Sapino, A; Leonarduzzi, G; Bergamini, E; Poli, G; Chiarpotto, E				Castello, L; Froio, T; Cavallini, G; Biasi, F; Sapino, A; Leonarduzzi, G; Bergamini, E; Poli, G; Chiarpotto, E			Calorie restriction protects against age-related rat aorta sclerosis	FASEB JOURNAL			English	Article						TGF beta 1; ageing; MAPK; oxidative stress; aortic fibrosclerosis	FREE-RADICAL THEORY; GROWTH-FACTOR-BETA; TGF-BETA; AUTOPHAGIC PROTEOLYSIS; DIETARY RESTRICTION; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; PROMOTER-REGION; GENE-EXPRESSION; END-PRODUCT	Many theories have been advanced to account for the ageing process, among which the free radical theory deserves much attention. Numerous studies have also shown an association between tissue fibrosis and oxidative stress. Of note, fibrosis may be considered a significant index of tissue ageing. Calorie restriction (CR) has been demonstrated to maintain many physiological processes in a youthful state until a very advanced age. However the anti-ageing mechanisms of CR are still not fully understood. We thus evaluated the effect of CR on oxidative damage and its relationship with fibrosis during ageing. We found a significant increase of both oxidative stress and fibrosis parameters in the aortae from aged vs. young rats. CR reversed both phenomena. CR also protected against the age-associated increase of Jun-N-terminal kinase and p-38 activities, involved in TGF beta 1 expression and signaling. On the contrary, extracellular regulated kinases did not show any age-related change. CR similarly reversed the age-related increase of AP-1 DNA binding activity and the AP-1-dependent increase of vimentin gene expression. In parallel, CR reversed the age-related morphological alterations of the aorta wall cell composition. These data further support the relationship between oxidative stress and fibrosis in different diseases and during ageing. The protection exerted by CR against fibrosclerosis might be due to a decrease of oxidative stress, with consequent decreased MAPK activity and down-regulation of AP-1 activation and of TGF beta 1 expression and signaling.	Univ Turin, Dept Clin & Biol Sci, I-10043 Turin, Italy; Univ Pisa, Interdepartmental Res Ctr Biol & Pathol Ageing, I-56100 Pisa, Italy; Italian Natl Res Council, Turin, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10124 Turin, Italy	University of Turin; University of Pisa; Consiglio Nazionale delle Ricerche (CNR); University of Turin	Chiarpotto, E (corresponding author), Univ Turin, Dept Clin & Biol Sci, Reg Gonzole 10, I-10043 Turin, Italy.	elena.chiarpotto@unito.it	Sapino, Anna/J-4113-2018; Leonarduzzi, Gabriella/AAA-6575-2019; Sapino, Anna/AGY-9901-2022	Sapino, Anna/0000-0003-3542-9571; Sapino, Anna/0000-0003-3542-9571; LEONARDUZZI, Gabriella Marisa/0000-0002-3422-821X				Abrass CK, 2000, ADV RENAL REPLACE TH, V7, P4, DOI 10.1016/S1073-4449(00)70001-X; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Burt DJ, 2003, DIABETOLOGIA, V46, P531, DOI 10.1007/s00125-003-1075-y; Camandola S, 1997, BIOFACTORS, V6, P173, DOI 10.1002/biof.5520060211; Cavallini G, 2001, EXP GERONTOL, V36, P497, DOI 10.1016/S0531-5565(00)00224-2; Cefalu WT, 1999, TOXICOL SCI, V52, P49, DOI 10.1093/toxsci/52.suppl_1.49; CHIARPOTTO E, 1995, BIOCHEM BIOPH RES CO, V207, P477, DOI 10.1006/bbrc.1995.1213; de Souza RR, 2002, BIOGERONTOLOGY, V3, P325, DOI 10.1023/A:1021312027486; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Donati A, 2001, J GERONTOL A-BIOL, V56, pB375, DOI 10.1093/gerona/56.9.B375; Duffy PH, 2001, AGING-CLIN EXP RES, V13, P263; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fornieri C, 1999, CONNECT TISSUE RES, V40, P131, DOI 10.3109/03008209909029109; Fulle S, 2004, EXP GERONTOL, V39, P17, DOI 10.1016/j.exger.2003.09.012; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; Harman D, 2003, ANTIOXID REDOX SIGN, V5, P557, DOI 10.1089/152308603770310202; Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Hutter D, 2000, J GERONTOL A-BIOL, V55, pB125, DOI 10.1093/gerona/55.3.B125; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772; Kim HJ, 2002, MECH AGEING DEV, V123, P1589, DOI 10.1016/S0047-6374(02)00094-5; Kim JW, 2004, J GERONTOL A-BIOL, V59, P876; KIM SJ, 1989, J BIOL CHEM, V264, P402; Knapowski J, 2002, J PHYSIOL PHARMACOL, V53, P135; Kumagai T, 2000, BIOCHEM BIOPH RES CO, V273, P437, DOI 10.1006/bbrc.2000.2967; Lane MA, 1998, J ANTI-AGING MED, V1, P315, DOI DOI 10.1089/rej.1.1998.1.315; Lee J, 1999, FREE RADICAL BIO MED, V26, P260, DOI 10.1016/S0891-5849(98)00195-6; Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483; Li ZH, 1997, EXP MOL PATHOL, V64, P1, DOI 10.1006/exmp.1997.2204; Li ZH, 1999, HYPERTENSION, V33, P116, DOI 10.1161/01.HYP.33.1.116; Massague J, 2000, GENE DEV, V14, P627; Mattison JA, 2003, EXP GERONTOL, V38, P35, DOI 10.1016/S0531-5565(02)00146-8; Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nitti M, 2002, BIOCHEM BIOPH RES CO, V294, P547, DOI 10.1016/S0006-291X(02)00512-0; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; Parola M, 1996, BIOCHEM BIOPH RES CO, V222, P261, DOI 10.1006/bbrc.1996.0732; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; POLI G, 2003, SIGNAL TRANSDUCTION, P180; Poli Giuseppe, 2000, Molecular Aspects of Medicine, V21, P49, DOI 10.1016/S0098-2997(00)00004-2; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raju J, 2003, CANCER RES, V63, P6595; Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009-9120(96)00003-6; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P575, DOI 10.1016/S0891-5849(02)00886-9; Torrens C, 2003, J PHYSIOL-LONDON, V547, P77, DOI 10.1113/jphysiol.2002.026120; UCHIDA K, 1994, METHOD ENZYMOL, V233, P371; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang DS, 2003, BIOCHEM BIOPH RES CO, V310, P236, DOI 10.1016/j.bbrc.2003.09.003; Weigert C, 2000, J AM SOC NEPHROL, V11, P2007, DOI 10.1681/ASN.V11112007; Weindruch R., 1988, RETARDATION AGING DI; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898; Yu BP, 2002, J NUTR SCI VITAMINOL, V48, P257, DOI 10.3177/jnsv.48.257; Zanetti M, 2004, ATHEROSCLEROSIS, V175, P253, DOI 10.1016/j.atherosclerosis.2004.05.001	59	46	47	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1863	+		10.1096/fj.04-2864fje	http://dx.doi.org/10.1096/fj.04-2864fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16150801				2023-01-03	WOS:000232315700023
J	Tulsky, JA				Tulsky, JA			Beyond advance directives. Importance of communication skills at the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; SERIOUSLY ILL; DECISION-MAKING; CANCER-PATIENTS; CARDIOPULMONARY-RESUSCITATION; SUSTAINING TREATMENT; FAMILY SATISFACTION; PATIENT PREFERENCES; PHYSICIANS; SURVIVAL	Patients and their families struggle with myriad choices concerning medical treatments that frequently precede death. Advance directives have been proposed as a tool to facilitate end-of-life decision making, yet frequently fail to achieve this goal. In the context of the case of a man with metastatic cancer for whom an advance directive was unable to prevent a traumatic death, I review the challenges in creating and implementing advance directives, discuss factors that can affect clear decision making; including trust, uncertainty, emotion, hope, and the presence of multiple medical providers; and offer practical suggestions for physicians. Advance care planning remains a useful tool for approaching conversations with patients about the end of life. However, such planning should occur within a framework that emphasizes responding to patient and family emotions and focuses more on goals for care and less on specific treatments.	Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC 27705 USA; Vet Affairs Med Ctr, Ctr Palliat Care, Durham, NC USA; Vet Affairs Med Ctr, Dept Med, Durham, NC USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Tulsky, JA (corresponding author), Duke Univ, Med Ctr, Ctr Palliat Care, Hock Plaza,2424 Erwin Rd,Suite 1105, Durham, NC 27705 USA.	jtulsky@duke.edu			NCI NIH HHS [R01 CA100387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott KH, 2001, CRIT CARE MED, V29, P197, DOI 10.1097/00003246-200101000-00040; Arnold RM, 2003, CRIT CARE MED, V31, pS347, DOI 10.1097/01.CCM.0000065123.23736.12; Arora NK, 2003, SOC SCI MED, V57, P791, DOI 10.1016/S0277-9536(02)00449-5; Back AL, 2005, JAMA-J AM MED ASSOC, V293, P1374, DOI 10.1001/jama.293.11.1374; Back Anthony L, 2003, Ann Intern Med, V138, P439; Baker DW, 2003, J GEN INTERN MED, V18, P343, DOI 10.1046/j.1525-1497.2003.20522.x; Baker R, 2000, J AM GERIATR SOC, V48, pS61, DOI 10.1111/j.1532-5415.2000.tb03143.x; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BOHNER G, 1994, EUR J SOC PSYCHOL, V24, P207, DOI 10.1002/ejsp.2420240115; Breen CM, 2001, J GEN INTERN MED, V16, P283, DOI 10.1046/j.1525-1497.2001.00419.x; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; Bricker Leslie J, 2003, J Palliat Med, V6, P511, DOI 10.1089/109662103322144880; Bruera E, 2001, J CLIN ONCOL, V19, P2883, DOI 10.1200/JCO.2001.19.11.2883; Butow PN, 2002, SUPPORT CARE CANCER, V10, P161, DOI 10.1007/s005200100290; Butow PN, 2002, PSYCHO-ONCOLOGY, V11, P47, DOI 10.1002/pon.556; Christakis Nicholas, 1999, DEATH FORETOLD PROPH; Covinsky KE, 2000, J AM GERIATR SOC, V48, pS187, DOI 10.1111/j.1532-5415.2000.tb03131.x; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Ditto PH, 2001, ARCH INTERN MED, V161, P421, DOI 10.1001/archinte.161.3.421; Eden O. B., 1994, Palliative Medicine, V8, P105, DOI 10.1177/026921639400800203; Eliasson AH, 1999, ARCH INTERN MED, V159, P2213, DOI 10.1001/archinte.159.18.2213; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; Fogarty LA, 1999, J CLIN ONCOL, V17, P371, DOI 10.1200/JCO.1999.17.1.371; FORD S, 1994, BRIT J CANCER, V70, P767, DOI 10.1038/bjc.1994.393; Ford S, 1996, SOC SCI MED, V42, P1511, DOI 10.1016/0277-9536(95)00265-0; Gattellari M, 2002, J CLIN ONCOL, V20, P503, DOI 10.1200/JCO.20.2.503; Gattellari M, 2001, SOC SCI MED, V52, P1865, DOI 10.1016/S0277-9536(00)00303-8; GOOD MJD, 1990, CULT MED PSYCHIAT, V14, P59; Gordon GH, 2000, PATIENT EDUC COUNS, V40, P59, DOI 10.1016/S0738-3991(99)00069-5; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; Heaven CM, 1997, PALLIATIVE MED, V11, P283, DOI 10.1177/026921639701100404; Henman MJ, 2002, PSYCHO-ONCOLOGY, V11, P295, DOI 10.1002/pon.566; HERTH K, 1990, J ADV NURS, V15, P1250, DOI 10.1111/j.1365-2648.1990.tb01740.x; Heyland DK, 2003, J CRIT CARE, V18, P3, DOI 10.1053/jcrc.2003.YJCRC2; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; Keating NL, 2004, ARCH INTERN MED, V164, P1015, DOI 10.1001/archinte.164.9.1015; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Koopmeiners L, 1997, Oncol Nurs Forum, V24, P1507; Kreitler S, 1999, CANCER INVEST, V17, P514, DOI 10.3109/07357909909032861; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; Lee MA, 2000, J AM GERIATR SOC, V48, P1219, DOI 10.1111/j.1532-5415.2000.tb02594.x; Levine LJ, 1997, SOC COGNITION, V15, P157, DOI 10.1521/soco.1997.15.3.157; Levinson W, 2000, JAMA-J AM MED ASSOC, V284, P1021, DOI 10.1001/jama.284.8.1021; Lilly CM, 2000, AM J MED, V109, P469, DOI 10.1016/S0002-9343(00)00524-6; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Lo B, 2004, ARCH INTERN MED, V164, P1501, DOI 10.1001/archinte.164.14.1501; Maguire P, 1999, EUR J CANCER, V35, P1415, DOI 10.1016/S0959-8049(99)00178-1; McDonagh JR, 2004, CRIT CARE MED, V32, P1484, DOI 10.1097/01.CCM.0000127262.16690.65; Mishler E.G., 1984, DISCOURSE MED DIALEC; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; Pochard F, 2001, CRIT CARE MED, V29, P1893, DOI 10.1097/00003246-200110000-00007; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; ROSENBERG M, 1993, ARCH INTERN MED, V153, P1370, DOI 10.1001/archinte.153.11.1370; Rosenfeld KE, 1996, ARCH INTERN MED, V156, P1558, DOI 10.1001/archinte.156.14.1558; Schneiderman LJ, 2003, JAMA-J AM MED ASSOC, V290, P1166, DOI 10.1001/jama.290.9.1166; SELL L, 1993, RESP MED, V87, P61, DOI 10.1016/S0954-6111(05)80315-4; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Tarrant C, 2003, BRIT J GEN PRACT, V53, P798; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; Tolle SW, 1998, J AM GERIATR SOC, V46, P1097, DOI 10.1111/j.1532-5415.1998.tb06647.x; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; Tulsky James A, 2002, J Palliat Med, V5, P339, DOI 10.1089/109662102320135225; Waisel DB, 2002, J CLIN ANESTH, V14, P467, DOI 10.1016/S0952-8180(02)00401-4; WALKER RM, 1991, JAMA-J AM MED ASSOC, V266, P2407, DOI 10.1001/jama.266.17.2407; Wallace SK, 2002, SUPPORT CARE CANCER, V10, P425, DOI 10.1007/s00520-002-0353-4; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wenrich MD, 2001, ARCH INTERN MED, V161, P868, DOI 10.1001/archinte.161.6.868; Yates J L, 1997, J Aging Soc Policy, V9, P29	72	264	267	1	50	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	2005	294	3					359	365		10.1001/jama.294.3.359	http://dx.doi.org/10.1001/jama.294.3.359			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	946YL	16030281				2023-01-03	WOS:000230609100021
J	Ockene, JK; Barad, DH; Cochrane, BB; Larson, JC; Gass, M; Wassertheil-Smoller, S; Manson, JE; Barnabei, VM; Lane, DS; Brzyski, RG; Rosal, MC; Wylie-Rosett, J; Hays, J				Ockene, JK; Barad, DH; Cochrane, BB; Larson, JC; Gass, M; Wassertheil-Smoller, S; Manson, JE; Barnabei, VM; Lane, DS; Brzyski, RG; Rosal, MC; Wylie-Rosett, J; Hays, J			Symptom experience after discontinuing use of estrogen plus progestin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; ATTITUDES; TRIALS; KNEE	Context Little is known about women's experiences after stopping menopausal hormone therapy. Objective To describe women's symptoms and management strategies after stopping the intervention in a large estrogen plus progestin trial. Design, Setting, and Participants Cross-sectional survey of 8405 women (89.9%; N = 9351) at 40 clinical centers who were still taking study pills (conjugated equine estrogens plus medroxyprogesterone [CEE + MPA] or placebo) when the estrogen plus progestin intervention (Women's Health Initiative) was stopped. Surveys were mailed 8 to 12 months after the stop date. Logistic regression was used to model vasomotor symptoms and pain or stiffness symptoms as functions of former treatment and baseline symptoms, adjusted for appropriate covariates. Main Outcome Measures Symptoms (vasomotor or pain and stiffness) and management strategies. Results Respondents' mean (SD) age at trial stop date was 69.1 (6.7) years. They averaged 5.7 years of taking study pills. Moderate or severe vasomotor symptoms after discontinuing study pill use were reported by 21.2% of former CEE + MPA and 4.8% of placebo group respondents overall and by 55.5% and 21.3%, respectively, with these symptoms at baseline (randomization). Compared with respondents in the former placebo group, moderate or severe vasomotor symptoms (adjusted odds ratio [AOR] 5.82; 95% confidence interval [CI], 4.92-6.89) and pain or stiffness symptoms (AOR, 2.16; 95% Cl, 1.95-2.40) were more likely in respondents in the former CEE + MPA group. Both vasomotor symptoms (AOR, 5.36; 95% Cl, 4.51-6.38) and pain or stiffness symptoms (AOR, 3.21; 95% Cl, 2.90-3.56) also were more likely in women with these symptoms at baseline. Women reported a wide range of strategies to manage symptoms. Conclusions More than half of the women with vasomotor symptoms at randomization to active CEE + MPA also reported these symptoms after discontinuing use of the study pills. However, these participants did not include women who were unwilling to be randomized or who had stopped taking the study pills earlier. These findings should be considered when advising women to treat menopausal symptoms with hormone therapy for as short duration as possible. Investigation of alternative strategies to manage menopausal symptoms is warranted.	Univ Massachusetts, Sch Med, Div Prevent & Behav Med, Worcester, MA 01655 USA; Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA USA; Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA; SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA; Univ Texas, Hlth Sci Ctr, Dept Obstet & Gynecol, San Antonio, TX 78284 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Massachusetts System; University of Massachusetts Worcester; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Fred Hutchinson Cancer Center; University System of Ohio; University of Cincinnati; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Medical College of Wisconsin; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine	Ockene, JK (corresponding author), Univ Massachusetts, Sch Med, Div Prevent & Behav Med, 55 Lake Ave N, Worcester, MA 01655 USA.	Judith.Ockene@umassmed.edu	Barad, David/AAF-4332-2021	Hays-Grudo, Jennifer/0000-0002-8107-1243; Barnabei, Vanessa/0000-0002-9650-0143				*AM COLL OBST GYN, 2004, OBSTET GYNECOL, V104, pS62; *AM COLL OBST GYN, QUEST ANSW HORM THER; Avis NE, 2001, SOC SCI MED, V52, P345, DOI 10.1016/S0277-9536(00)00147-7; BARNABEI V, IN PRESS OBSTET GYNE; Barnabei VM, 2002, OBSTET GYNECOL, V100, P1209, DOI 10.1016/S0029-7844(02)02369-4; BARRETTCONNOR E, 2002, BEST CLIN PRACTICES; Blumel JE, 2004, MENOPAUSE, V11, P57, DOI 10.1097/01.GME.0000075503.60230.61; Collins D, 2003, QUAL LIFE RES, V12, P229, DOI 10.1023/A:1023254226592; Conboy L, 2001, MATURITAS, V38, P129, DOI 10.1016/S0378-5122(00)00211-5; Drennan J, 2003, J ADV NURS, V42, P57, DOI 10.1046/j.1365-2648.2003.02579.x; *FOOD DRUG ADM, FDA UPD HORM THER IN; Freedman L, 1996, CONTROL CLIN TRIALS, V17, P509, DOI 10.1016/S0197-2456(96)00016-5; Gordon FT, 1996, HORM BEHAV, V30, P244, DOI 10.1006/hbeh.1996.0029; Gordon S, 2004, OBSTET GYNECOL, V103, P267, DOI 10.1097/01.AOG.0000110247.98588.ff; Grady D, 2003, OBSTET GYNECOL, V102, P1233, DOI 10.1016/j.obstetgynecol.2003.09.025; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Hammar M, 1999, MATURITAS, V31, P117, DOI 10.1016/S0378-5122(98)00101-7; HANNAN MT, 1990, ARTHRITIS RHEUM-US, V33, P525, DOI 10.1002/art.1780330410; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Matthews KA, 1997, AM PSYCHOL, V52, P101, DOI 10.1037/0003-066X.52.2.101; *N AM MEN SOC, 2003, MEN GUID; *N AM MEN SOC, ESTR PROG US PER POS; National Institute of Aging, 2001, MEN ON WOM STOR EV W; Nevitt MC, 2001, ARTHRITIS RHEUM-US, V44, P811, DOI 10.1002/1529-0131(200104)44:4<811::AID-ANR137>3.0.CO;2-F; Newton KM, 2002, OBSTET GYNECOL, V100, P18, DOI 10.1016/S0029-7844(02)02005-7; Reginster JY, 2003, OSTEOARTHR CARTILAGE, V11, P87, DOI 10.1053/joca.2002.0872; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; ROTHERT M, 1994, EXP GERONTOL, V29, P463, DOI 10.1016/0531-5565(94)90026-4; Santoro NF, 2004, MENOPAUSE, V11, P11; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0; Will Constance I, 2003, J Holist Nurs, V21, P368, DOI 10.1177/0898010103258605; Zethraeus N, 1997, BRIT J OBSTET GYNAEC, V104, P1191, DOI 10.1111/j.1471-0528.1997.tb10945.x	36	131	134	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	2005	294	2					183	193		10.1001/jama.294.2.183	http://dx.doi.org/10.1001/jama.294.2.183			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	944DO	16014592	Bronze			2023-01-03	WOS:000230406100022
J	Haas, JS; Phillips, KA; Gerstenberger, EP; Seger, AC				Haas, JS; Phillips, KA; Gerstenberger, EP; Seger, AC			Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997-2000	ANNALS OF INTERNAL MEDICINE			English	Article							CONVERTING-ENZYME-INHIBITORS; PHARMACY BENEFITS; PHYSICIAN; COMPANIES	Background: Generic substitution is one mechanism of curtailing prescription drug expenditures. Limited information is available about the potential savings associated with generic substitution. Objective: To estimate the potential savings associated with broad substitution of generic drugs. Design: Cross-sectional, nationally representative survey of noninstitutionalized adults. Setting: United States. Participants: Adults included in the Medical Expenditure Panel Survey Household Component, 1997-2000. Measurements: Use of a multisource drug (that is, a drug available in a brand-name and >= 1 generic formulation) or a generic drug and the potential cost savings associated with broad generic substitution for all multisource products. Results: Fifty-six percent of all outpatient drugs were multisource products, accounting for 41% of total outpatient drug expenditures. Of these multisource drugs, 61% were dispensed as a generic. If a generic had been substituted for all corresponding brand-name outpatient drugs in 2000, the median annual savings in drug expenditures per person would have been $45.89 (interquartile range, $10.35 to 158.06) for adults younger than 65 years of age and $78.05 (interquartile range, $19.94 to $241.72) for adults at least 65 years of age. in these age groups, the national savings would have been $5.9 billion (95% Cl, $5.5 billion to $6.2 billion) and $2.9 billion (Cl, $2.6 billion to $3.1 billion), respectively, representing approximately 11% of drug expenditures. Limitations: Specific information about an individual's formulary was not available, so the authors could not estimate how much of the potential savings would benefit an individual or his or her health plan. Conclusion: Although broad substitution of generic drugs would affect only a modest percentage of drug expenditures, it could result in substantial absolute savings.	Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02120 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Harvard University; Brigham & Women's Hospital; University of California System; University of California San Francisco	Haas, JS (corresponding author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA.	jhaas@partners.org		HAAS, JENNIFER/0000-0001-7227-851X				ANDERSON GF, 2004, HLTH AFF MILLWOOD, V4, P396; Bae JP, 1997, HEALTH SERV RES, V32, P87; Banahan BF, 1997, ARCH INTERN MED, V157, P2080, DOI 10.1001/archinte.157.18.2080; Brennan TA, 2004, ANN INTERN MED, V141, P126, DOI 10.7326/0003-4819-141-2-200407200-00011; Cohen JW, 1996, INQUIRY-J HEALTH CAR, V33, P373; COHEN SB, AHCRP PUB; CRUICKSHANK JM, 1988, BRIT MED J, V297, P1597, DOI 10.1136/bmj.297.6663.1597; CUBANSKI J, 2004, HLTH AFF W, V4, P198; DeCara JM, 1998, CHEST, V113, P261, DOI 10.1378/chest.113.2.261; Dong BJ, 1997, JAMA-J AM MED ASSOC, V277, P1205, DOI 10.1001/jama.277.15.1205; Fischer MA, 2003, HEALTH SERV RES, V38, P1051, DOI 10.1111/1475-6773.00162; Gaither CA, 2001, J AM PHARM ASS, V41, P729, DOI [10.1016/S1086-5802(16)31308-0, DOI 10.1016/S1086-5802(16)31308-0]; Ganther J M, 2000, J Am Pharm Assoc (Wash), V40, P378; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; HARRIS G, 2003, NY TIMES        1005, P1; Hellerstein JK, 1998, RAND J ECON, V29, P108, DOI 10.2307/2555818; HENRY J, 2003, FAMILY FDN; *HJ KAIS FAM FDN, 2001, KAIS COMM MED UN; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; *MEDC HLTH SOL INC, ANT 1 TIM GEN 2004 2; MOELLER JF, 1996, AHRQ PUB; MOON N, 2004, BENEFICIARIES FARE N; Mott DA, 2002, MED CARE, V40, P662, DOI 10.1097/00005650-200208000-00006; Murphy JE, 1999, ARCH INTERN MED, V159, P429, DOI 10.1001/archinte.159.5.429; Nightingale SL, 1998, JAMA-J AM MED ASSOC, V279, P645, DOI 10.1001/jama.279.9.645-b; *NIH CAR MAN FDN, 2002, PRIM GEN DRUGS PAT P; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; Robinson AR, 2004, ARCH INTERN MED, V164, P427, DOI 10.1001/archinte.164.4.427; Schneeweiss S, 2004, MED CARE, V42, P653, DOI 10.1097/01.mlr.0000129497.10930.a2; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; Suh DC, 1999, PHARM WORLD SCI, V21, P260, DOI 10.1023/A:1008781619011; *US FOOD DRUG ADM, NEW FDA IN IMPR; 2002, FORMULARY, V38, P499; 2001, PRESCRIPTION DRUG TR	34	185	192	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 7	2005	142	11					891	897		10.7326/0003-4819-142-11-200506070-00006	http://dx.doi.org/10.7326/0003-4819-142-11-200506070-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932LX	15941695				2023-01-03	WOS:000229556300002
J	Hepple, RT; Baker, DJ; Kaczor, JJ; Krause, DJ				Hepple, RT; Baker, DJ; Kaczor, JJ; Krause, DJ			Long-term caloric restriction abrogates the age-related decline in skeletal muscle aerobic function	FASEB JOURNAL			English	Article						aging; oxygen uptake; mitochondria; rats; sarcopenia	MITOCHONDRIAL PROTON LEAK; DIETARY RESTRICTION; BLOOD-FLOW; F344BNF1-HYBRID RATS; OXIDATIVE CAPACITY; FOOD RESTRICTION; GENE-EXPRESSION; EXERCISE; FISCHER-344; RESPONSES	The purpose of this study was to determine the effect of long-term caloric restriction (CR) on the age-associated decline of skeletal muscle aerobic function. Skeletal muscle maximal aerobic performance (VO(2)max) was assessed in ad libitum (AL) and CR rats aged 8-10 months and 35 months using a pump-perfused hindlimb model to match oxygen delivery to muscle mass between groups. Whereas there was a 46% decline in muscle mass- specific VO2max between 8 10 mo (524 +/- 13 mu mol center dot min(-1)similar to 100 g(-1); mean SE) and 35 mo (281 +/- 54 mu mol(.)min(-1)center dot 100 g(- 1)) in AL rats, not only did CR rats begin at the same point in 8-10 mo old rats (490 +/- 42 mu mol center dot min(-1)center dot 100 g(-1)), we found no decline in 35 mo old CR animals (484 +/- 49 mu mol center dot min(-1)center dot 100g(-1)). Interestingly, although most markers of oxidative capacity began at a lower point in young adult CR animals, CR rats exhibited a higher in situ activity of complex IV at VO2max. This activity allows the young adult CR animals to exhibit normal aerobic capacity despite the lower oxidative enzyme activities. In stark contrast to the 19-41% decline in activities of citrate synthase, complexes I-III, and complex IV in homogenates prepared from the plantaris muscle and mixed region of gastrocnemius muscle with aging in AL rats, no age-related decline was found in CR animals. Thus, our results showed that CR preserves aerobic function in aged skeletal muscles by facilitating a higher in situ function of complex IV and by preventing the age-related decline in mitochondrial oxidative capacity.	Univ Calgary, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Fac Med, Calgary, AB, Canada; McMaster Univ, Dept Pediat, Hamilton, ON, Canada	University of Calgary; University of Calgary; McMaster University	Hepple, RT (corresponding author), Univ Calgary, Fac Kinesiol, 2500 Univ Dr,NW, Calgary, AB T2N 1N4, Canada.	hepple@ucalgary.ca	Kaczor, Jan/A-1990-2008; Kaczor, Jan/AAH-5078-2021; Kaczor, Jan/ABC-6283-2021	Kaczor, Jan/0000-0002-6370-2160; Hepple, Russell/0000-0003-3640-486X				ARMSTRONG RB, 1985, J APPL PHYSIOL, V59, P1322, DOI 10.1152/jappl.1985.59.4.1322; Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Bevilacqua L, 2004, AM J PHYSIOL-ENDOC M, V286, pE852, DOI 10.1152/ajpendo.00367.2003; BOREHAM CAG, 1988, J ANAT, V157, P111; Bota DA, 2002, FEBS LETT, V532, P103, DOI 10.1016/S0014-5793(02)03638-4; Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212; Bronikowski AM, 2003, PHYSIOL GENOMICS, V12, P129, DOI 10.1152/physiolgenomics.00082.2002; Brown M, 1996, J GERONTOL A-BIOL, V51, pB117, DOI 10.1093/gerona/51A.2.B117; BUA EA, 2004, FASEB J; DAVIES KJA, 1981, ARCH BIOCHEM BIOPHYS, V209, P539, DOI 10.1016/0003-9861(81)90312-X; Desai VG, 1996, ARCH BIOCHEM BIOPHYS, V333, P145, DOI 10.1006/abbi.1996.0375; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Glantz S.A., 2002, PRIMER BIOSTATISTICS; GOODRICK CL, 1980, GERONTOLOGY, V26, P22, DOI 10.1159/000212390; GORSKI J, 1986, AM J PHYSIOL, V250, pE441, DOI 10.1152/ajpendo.1986.250.4.E441; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; HAGBERG JM, 1985, J APPL PHYSIOL, V58, P2041, DOI 10.1152/jappl.1985.58.6.2041; Hagen JL, 2004, J GERONTOL A-BIOL, V59, P1099, DOI 10.1093/gerona/59.11.1099; Hepple RT, 2004, J GERONTOL A-BIOL, V59, P1111, DOI 10.1093/gerona/59.11.1111; Hepple RT, 2004, J APPL PHYSIOL, V96, P2257, DOI 10.1152/japplphysiol.01309.2003; Hepple RT, 2003, J APPL PHYSIOL, V95, P705, DOI 10.1152/japplphysiol.00058.2003; Hepple RT, 2003, J APPL PHYSIOL, V94, P744, DOI 10.1152/japplphysiol.00737.2002; Hepple RT, 2002, J PHYSIOL-LONDON, V541, P1003, DOI 10.1113/jphysiol.2001.013649; Holloszy JO, 1997, J APPL PHYSIOL, V82, P399, DOI 10.1152/jappl.1997.82.2.399; INGRAM DK, 1987, J GERONTOL, V42, P78, DOI 10.1093/geronj/42.1.78; Kanda K, 2002, MICROSC RES TECHNIQ, V59, P301, DOI 10.1002/jemt.10208; Kent-Braun JA, 2002, J APPL PHYSIOL, V93, P1813, DOI 10.1152/japplphysiol.00091.2002; Lal SB, 2001, J GERONTOL A-BIOL, V56, pB116, DOI 10.1093/gerona/56.3.B116; Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee CM, 1998, ANN NY ACAD SCI, V854, P182, DOI 10.1111/j.1749-6632.1998.tb09901.x; Lipman RD, 1996, J GERONTOL A-BIOL, V51, pB54, DOI 10.1093/gerona/51A.1.B54; MASORO EJ, 2003, SCI AGING KNOWLEDGE, pRE2; Mathieu-Costello O, 2003, FASEB J, V17, pA1279; Mayhew M, 1998, BIOCHEM BIOPH RES CO, V251, P95, DOI 10.1006/bbrc.1998.9438; MCCARTER R, 1987, J GERONTOL, V42, P432, DOI 10.1093/geronj/42.4.432; McCarter RJM, 1997, AGING-CLIN EXP RES, V9, P73, DOI 10.1007/BF03340130; MCKIERNAN S, 2004, FASEB J; Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9; Miller RA, 2000, J GERONTOL A-BIOL, V55, pB117, DOI 10.1093/gerona/55.3.B117; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; Musch TI, 2004, J APPL PHYSIOL, V96, P81, DOI 10.1152/japplphysiol.00729.2003; OGAWA T, 1992, CIRCULATION, V86, P494, DOI 10.1161/01.CIR.86.2.494; Osborne TB, 1917, SCIENCE, V45, P294, DOI 10.1126/science.45.1160.294; Paterson DH, 2004, J AM GERIATR SOC, V52, P1632, DOI 10.1111/j.1532-5415.2004.52454.x; Payne AM, 2003, J APPL PHYSIOL, V95, P2554, DOI 10.1152/japplphysiol.00758.2003; Poole JG, 2003, AM J PHYSIOL-HEART C, V284, pH1251, DOI 10.1152/ajpheart.00790.2002; Proctor DN, 1998, J APPL PHYSIOL, V85, P68, DOI 10.1152/jappl.1998.85.1.68; Russell JA, 2003, AM J PHYSIOL-HEART C, V285, pH251, DOI 10.1152/ajpheart.01086.2002; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; Srere P.A., 1969, METHODS ENZYMOLOGY, V13, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492	53	57	58	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1320	+		10.1096/fj.04-3535fje	http://dx.doi.org/10.1096/fj.04-3535fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15955841				2023-01-03	WOS:000230207800016
J	Kathiresan, S; Kelsey, PB; Steere, AC; Foster, CS; Curvelo, MS; Stone, JR; Harris, NL; Stone, JR; Johnsen, AK				Kathiresan, S; Kelsey, PB; Steere, AC; Foster, CS; Curvelo, MS; Stone, JR; Harris, NL; Stone, JR; Johnsen, AK			Case 14-2005: A 38-year-old man with fever and blurred vision - Systemic small-vessel vasculitis involving small vessels and small arteries; probably immune-complex vasculitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LEUKOCYTOCLASTIC VASCULITIS		Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Div Gastroenterol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Div Rheumatol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kathiresan, S (corresponding author), Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.			Steere, Allen/0000-0002-5268-9853				Bansal R, 2003, INT J CARDIOL, V88, P91, DOI 10.1016/S0167-5273(02)00371-6; Blanco R, 1998, MEDICINE, V77, P403, DOI 10.1097/00005792-199811000-00007; BOLOGNA JL, 2001, HARRISONS PRINCIPLES, P329; Costedoat-Chalumeau N, 2002, RHEUMATOLOGY, V41, P708, DOI 10.1093/rheumatology/41.6.708; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; HANNEDOUCHE T, 1987, J ANTIMICROB CHEMOTH, V20, P3, DOI 10.1093/jac/20.1.3; Iannone F, 2003, ANN RHEUM DIS, V62, P785, DOI 10.1136/ard.62.8.785; Inoue M, 1998, HUM PATHOL, V29, P223, DOI 10.1016/S0046-8177(98)90039-9; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Levin S, 1995, Curr Clin Top Infect Dis, V15, P19; LIGHTFOOT RW, 1990, ARTHRITIS RHEUM, V33, P1088; Lotti TM, 1999, ADV EXP MED BIOL, V455, P115; Lum PNL, 2000, DIAGN MICR INFEC DIS, V37, P275, DOI 10.1016/S0732-8893(00)00151-6; *MASS GEN HOSP, 2003, NEW ENGL J MED, V348, P834; MORGAN CM, 1986, RETINA-J RET VIT DIS, V6, P205, DOI 10.1097/00006982-198606040-00002; MOUTSOPOULOS HM, 1983, ANN RHEUM DIS, V42, P192, DOI 10.1136/ard.42.2.192; Sakane T, 1999, NEW ENGL J MED, V341, P1284, DOI 10.1056/NEJM199910213411707; SOMER T, 1995, CLIN INFECT DIS, V20, P1010, DOI 10.1093/clinids/20.4.1010; ten Holder SM, 2002, ANN PHARMACOTHER, V36, P130, DOI 10.1345/1542-6270(2002)036<0130:CASMOD>2.0.CO;2	20	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2005	352	19					2003	2012		10.1056/NEJMcpc059010	http://dx.doi.org/10.1056/NEJMcpc059010			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	924YL	15888702				2023-01-03	WOS:000229017100013
J	Smith, GD; Bracha, Y; Svendsen, KH; Neaton, JD; Haffner, SM; Kuller, LH				Smith, GD; Bracha, Y; Svendsen, KH; Neaton, JD; Haffner, SM; Kuller, LH		Multiple Risk Factor Intervention	Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial	ANNALS OF INTERNAL MEDICINE			English	Article							IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; BODY-FAT DISTRIBUTION; 10-YEAR FOLLOW-UP; INSULIN-RESISTANCE; PRIMARY PREVENTION; CARDIOVASCULAR-DISEASE; MEN; HEALTHY; DIET	Background: weight loss and increased physical exercise reduce the risk for diabetes in people with impaired glucose tolerance. Randomized trial evidence on the effect of these interventions on people without impaired glucose tolerance is lacking. Objective: To examine the influence of a comprehensive intervention program on the risk for developing diabetes in men without impaired glucose tolerance and in a post hoc subgroup analysis by baseline cigarette smoking status. Design: Randomized, controlled trial. Setting: 22 clinical centers for the Multiple Risk Factor Intervention Trial (MRFIT). Participants: 12 866 men age 35 to 57 years at risk for cardiovascular disease were randomly assigned to either a special intervention or usual care group and followed for 6 to 7 years; this report focuses on 11 827 men without diabetes or impaired glucose tolerance at entry for whom follow-up glucose measurements were available. Measurements: Cardiovascular disease risk factors, fasting blood glucose levels, and diabetes medication history were assessed before randomization and annually. Intervention: Men in the special intervention group were counseled to change diet (reduce saturated fat, cholesterol, and calorie intake), to stop smoking, and to increase physical activity. Blood pressure was treated more intensively in the special intervention group than in the usual care group. Results: 11.5% of the special intervention group and 10.8% of the usual care group developed diabetes over 6 years of follow-up (hazard ratio, 1.08 [95% Cl, 0.96 to 1.20]). The special intervention-usual care hazard ratio for diabetes was 1.26 (Cl, 1.10 to 1.45) among smokers (63%) and 0.82 (Cl, 0.68 to 0.98) among nonsmokers (37%). These estimates differed significantly (P = 0.0003). Weight gain after smoking cessation and the use of anti hypertensive drugs may have counterbalanced the beneficial effect of the lifestyle intervention for the special intervention group smokers, while the lifestyle intervention was beneficial among nonsmokers. Conclusions: In nonsmokers, an intervention program that included nutrition counseling to produce reductions in weight, serum cholesterol, and (along with anti hypertensive medication) blood pressure reduced the risk for diabetes.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Minneapolis Med Res Fdn Inc, Minneapolis, MN USA; Univ Minnesota, Minneapolis, MN USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Univ Pittsburgh, Pittsburgh, PA USA	University of Bristol; Minneapolis Medical Research Foundation; University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; University of Texas Health San Antonio; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall,Whiteladies Rd, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068140] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL68140] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 2000, Diabetes Care, V23 Suppl 1, pS1; CAGGIULA AW, 1981, PREV MED, V10, P443, DOI 10.1016/0091-7435(81)90060-8; Cutler JA, 1997, AM J CLIN NUTR, V65, P184; DIGGLE PJ, 2001, ANAL LONGITUDINAL DA, V322, P226; Eberly LE, 2003, DIABETES CARE, V26, P848, DOI 10.2337/diacare.26.3.848; Eriksson J, 1997, DIABETOLOGIA, V40, P125; ERIKSSON KF, 1996, ANN MED, V28, P445; FACCHINI FS, 1992, LANCET, V339, P1128, DOI 10.1016/0140-6736(92)90730-Q; HANSEN BC, 1993, DIABETES, V42, P1809, DOI 10.2337/diabetes.42.12.1809; HELLENIUS ML, 1993, ATHEROSCLEROSIS, V103, P81, DOI 10.1016/0021-9150(93)90042-S; HELLENIUS MLB, 1995, J INTERN MED, V238, P121, DOI 10.1111/j.1365-2796.1995.tb00909.x; HJERMANN I, 1981, LANCET, V2, P1303; HJERMANN I, 1980, SCAND J CLIN LAB INV, V40, P89, DOI 10.3109/00365518009091532; Jarrett R J, 1984, Diabet Med, V1, P279; JARRETT RJ, 1987, J EPIDEMIOL COMMUN H, V41, P145, DOI 10.1136/jech.41.2.145; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI; KATZEL LI, 1995, JAMA-J AM MED ASSOC, V274, P1915, DOI 10.1001/jama.274.24.1915; KEEN H, 1982, DIABETOLOGIA, V22, P73, DOI 10.1007/BF00254832; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KNOWLER WC, 1995, DIABETES, V44, P483, DOI 10.2337/diabetes.44.5.483; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Koh-Banerjee P, 2004, AM J EPIDEMIOL, V159, P1150, DOI 10.1093/aje/kwh167; LANE MA, 1995, AM J PHYSIOL-ENDOC M, V268, pE941, DOI 10.1152/ajpendo.1995.268.5.E941; LITHELL H, 1992, CLIN EXP HYPERTENS A, V14, P151, DOI 10.3109/10641969209036178; MANSON JE, 1994, AM J PREV MED, V10, P172, DOI 10.1016/S0749-3797(18)30615-9; MARSHALL JA, 1991, AM J EPIDEMIOL, V134, P590, DOI 10.1093/oxfordjournals.aje.a116132; Melander A, 1996, DIABETIC MED, V13, pS20; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; NEATON JD, 1987, CONTROL CLIN TRIALS, V8, pS41; ODEA K, 1991, MED J AUSTRALIA, V155, P258, DOI 10.5694/j.1326-5377.1991.tb142236.x; ODEA K, 1984, DIABETES, V33, P596, DOI 10.2337/diabetes.33.6.596; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; PAGE RCL, 1993, Q J MED, V86, P145; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RIMM EB, 1995, BRIT MED J, V310, P555, DOI 10.1136/bmj.310.6979.555; ROBERTS J, 1966, VITAL HLTH STAT SERI; SARTOR G, 1980, DIABETES, V29, P41, DOI 10.2337/diabetes.29.1.41; SHATEN BJ, 1993, DIABETES CARE, V16, P1331, DOI 10.2337/diacare.16.10.1331; SHERWIN R, 1981, PREV MED, V10, P402, DOI 10.1016/0091-7435(81)90058-X; SHINTANI TT, 1991, AM J CLIN NUTR, V53, pS1647; Simpson RW, 2003, DIABETES RES CLIN PR, V59, P165, DOI 10.1016/S0168-8227(02)00275-9; STERN MP, 1991, DIABETES CARE, V14, P399, DOI 10.2337/diacare.14.5.399; Sterne JAC, 2001, BMJ-BRIT MED J, V322, P226, DOI 10.1136/bmj.322.7280.226; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Wang XL, 1999, INT J MOL MED, V4, P537; WIDDOWSON GM, 1986, CONTROL CLIN TRIALS, V7, pS17; Wing RR, 1998, DIABETES CARE, V21, P350, DOI 10.2337/diacare.21.3.350; WOOD DA, 1994, BRIT MED J, V308, P313, DOI 10.1136/bmj.308.6924.313; YOUNG CM, 1981, COMMITTEE FOOD CONSU; ZIMMET PZ, 1995, DIABETES CARE, V18, P1050, DOI 10.2337/diacare.18.7.1050; ZIMMET PZ, 1992, DIABETES CARE, V15, P232, DOI 10.2337/diacare.15.2.232; 1977, J CHRONIC DIS, V30, P261	52	103	106	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	2005	142	5					313	322		10.7326/0003-4819-142-5-200503010-00006	http://dx.doi.org/10.7326/0003-4819-142-5-200503010-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	902BB	15738450				2023-01-03	WOS:000227325100001
J	Smith, PL; Maloney, KN; Pothen, RG; Clardy, J; Clapham, DE				Smith, Paula L.; Maloney, Katherine N.; Pothen, Randy G.; Clardy, Jon; Clapham, David E.			Bisandrographolide from Andrographis paniculata activates TRPV4 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING TRPV4; EPOXYEICOSATRIENOIC ACIDS; CARDIOVASCULAR ACTIVITY; CAPSAICIN RECEPTOR; ANESTHETIZED RAT; ION-CHANNEL; KERATINOCYTES; HEAT; SKIN; 14-DEOXY-11,12-DIDEHYDROANDROGRAPHOLIDE	Many transient receptor potential ( TRP) channels are activated or blocked by various compounds found in plants; two prominent examples include the activation of TRPV1 channels by capsaicin and the activation of TRPM8 channels by menthol. We sought to identify additional plant compounds that are active on other types of TRP channels. Wescreenedalibraryofextractsfrom50Chinese herbal plants using a calcium-imaging assay to find compounds active on TRPV3 and TRPV4 channels. An extract from the plant Andrographis paniculata potently activated TRPV4 channels. The extract was fractionated further, and the active compound was identified as bisandrographolide A ( BAA). We used purified compoundtocharacterizetheactivityofBAAoncertainTRPVchannel subtypes. Although BAA activated TRPV4 channels with an EC50 of 790 - 950 nM, it did not activate or block activation of TRPV1, TRPV2, or TRPV3 channels. BAA activated a large TRPV4- like current in immortalized mouse keratinocytes ( 308 cells) that have been shown to express TRPV4 protein endogenously. This compound also activated TRPV4 currents in cell- free outside- out patches from HEK293T cells overexpressing TRPV4 cDNA, suggesting that BAA can activate the channel in a membrane- delimited manner. Another related compound, andrographolide, found in abundance in the plant Andrographis was unable to activate or block activation of TRPV4 channels. These experiments show that BAAactivates TRPV4 channels, and we discuss the possibility that activation ofTRPV4byBAAcould play a role in some of the effects of Andrographis extract described in traditional medicine.	Childrens Hosp, Howard Hughes Med Inst, Dept Cardiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Clapham, DE (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Dept Cardiol, 1309 Enders Res Bldg,320 Longwood Ave, Boston, MA 02115 USA.	dclapham@enders.tch.harvard.edu	Clapham, David/R-5974-2019; Clapham, David/S-1123-2019	Clapham, David/0000-0002-4459-9428	NATIONAL CANCER INSTITUTE [R01CA024487] Funding Source: NIH RePORTER; NCCIH NIH HHS [R21AT00197] Funding Source: Medline; NCI NIH HHS [CA24487] Funding Source: Medline; NHLBI NIH HHS [T32 HL007572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; *CAMBR SOFT CORP, 2004, TRAD CHIN MED DAT VE; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; Earley S, 2005, CIRC RES, V97, P1270, DOI 10.1161/01.RES.0000194321.60300.d6; Gopinath Preethi, 2005, BMC Womens Health, V5, P2, DOI 10.1186/1472-6874-5-2; Guler AD, 2002, J NEUROSCI, V22, P6408; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Ladd PA, 2003, J BIOL CHEM, V278, P35184, DOI 10.1074/jbc.M301666200; Lansdown ABG, 2002, WOUND REPAIR REGEN, V10, P271, DOI 10.1046/j.1524-475X.2002.10502.x; Lee HS, 2005, J NEUROSCI, V25, P1304, DOI 10.1523/JNEUROSCI.4745.04.2005; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; MATSUDA T, 1994, CHEM PHARM BULL, V42, P1216, DOI 10.1248/cpb.42.1216; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Moqrich A, 2005, SCIENCE, V307, P1468, DOI 10.1126/science.1108609; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207; Xu HX, 2006, NAT NEUROSCI, V9, P628, DOI 10.1038/nn1692; YUSPA SH, 1983, J INVEST DERMATOL, V81, pS162, DOI 10.1111/1523-1747.ep12540999; Zhang CY, 1997, J ETHNOPHARMACOL, V56, P97, DOI 10.1016/S0378-8741(97)01509-2; Zhang CY, 1998, PHARMACOL RES, V38, P413, DOI 10.1006/phrs.1998.0373; Zhang CY, 1996, CLIN EXP PHARMACOL P, V23, P675, DOI 10.1111/j.1440-1681.1996.tb01756.x; Zhang CY, 1999, PHYTOTHER RES, V13, P157, DOI 10.1002/(SICI)1099-1573(199903)13:2&lt;157::AID-PTR388&gt;3.0.CO;2-B; Zhang CY, 1998, CLIN EXP PHARMACOL P, V25, P424, DOI 10.1111/j.1440-1681.1998.tb02226.x; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	37	104	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29897	29904		10.1074/jbc.M605394200	http://dx.doi.org/10.1074/jbc.M605394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16899456	hybrid			2023-01-03	WOS:000240896300051
J	Walker, SP; Chang, SM; Powell, CA; Simonoff, E; Grantham-McGregor, SM				Walker, Susan P.; Chang, Susan M.; Powell, Christine A.; Simonoff, Emily; Grantham-McGregor, Sally M.			Effects of psychosocial stimulation and dietary supplementation in early childhood on psychosocial functioning in late adolescence: follow-up of randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							NUTRITIONAL SUPPLEMENTATION; JAMAICAN CHILDREN; BEHAVIOR; GROWTH; SCHOOL; HOME; DEPRESSION; COGNITION; LIFE	Objective To determine whether dietary supplementation or psychosocial stimulation given to growth retarded (stunted) children age 9-24 months has long term benefits for their psychosocial functioning in late adolescence. Design Sixteen year follow-up study of a randomised controlled trial. Setting Poor neighbourhoods in Kingston,Jamaica. Participants Of 129 stunted children identified at age 9-24 months, 103 adolescents aged 17-18 were followed up. Intervention Supplementation with 1 kg milk based formula each week or psychosocial stimulation (weekly play sessions with mother and child), or both, for two years. Main outcome measures Anxiety, depression, self esteem, and antisocial behaviour assessed by questionnaires administered by interviewers; attention deficit, hyperactivity, and oppositional behaviour assessed by interviews with parents. Results Primary analysis indicated that participants who received stimulation had significantly different overall scores from those who did not (F = 2.047, P = 0.049). Supplementation had no significant effect (F = 1.505, P = 0.17). Participants who received stimulation reported less anxiety (mean difference - 2.81, 95% confidence interval - 5.02 to - 0.61), less depression (- 0.43, - 0.78 to - 0.07), and higher self esteem (1.55, 0.08 to 3.02) and parents reported fewer attention problems (- 3.34, - 6.48 to - 0.19). These differences are equivalent to effect sizes of 0.40-0.49 standard deviations. Conclusions Stimulation in early childhood has sustained benefits to stunted children's emotional outcomes and attention.	Univ W Indies, Res Inst Trop Med, Epidemiol Res Unit, Kingston 7, Jamaica; Inst Psychiat, London SE5 8AF, England; Inst Child Hlth, London WC1N 1EH, England	University West Indies Mona Jamaica; University of London; King's College London; University of London; University College London	Walker, SP (corresponding author), Univ W Indies, Res Inst Trop Med, Epidemiol Res Unit, Kingston 7, Jamaica.	susan.walker@uwirnona.edu.jm	Simonoff, Emily A/B-7593-2011	Simonoff, Emily/0000-0002-5450-0823	Wellcome Trust [066088] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baker-Henningham H, 2005, ARCH DIS CHILD, V90, P1230, DOI 10.1136/adc.2005.073015; Chang SM, 2002, J CHILD PSYCHOL PSYC, V43, P775, DOI 10.1111/1469-7610.00088; Conners CK, 1998, J ABNORM CHILD PSYCH, V26, P257, DOI 10.1023/A:1022602400621; COSTELLO EJ, 1988, J AM ACAD CHILD PSY, V27, P726, DOI 10.1097/00004583-198811000-00011; FARRAN DC, 2000, HDB EARLY CHILDHOOD, P501; GALLER JR, 1989, J AM ACAD CHILD PSY, V28, P254, DOI 10.1097/00004583-198903000-00018; Gardner JMM, 1999, J CHILD PSYCHOL PSYC, V40, P819, DOI 10.1111/1469-7610.00497; HAMIL PVV, 1977, VITAL HLTH STAT SERI, V11; Olds D, 1998, JAMA-J AM MED ASSOC, V280, P1238, DOI 10.1001/jama.280.14.1238; Olweus D, 1989, CROSS NATL RES SELF; REYNOLDS CR, 1978, J ABNORM CHILD PSYCH, V6, P271, DOI 10.1007/BF00919131; RICHARDSON SA, 1975, J BIOSOC SCI, V7, P255, DOI 10.1017/S0021932000010142; RICHARDSON SA, 1972, J HEALTH SOC BEHAV, V13, P276, DOI 10.2307/2136764; WALKER SP, 1991, AM J CLIN NUTR, V54, P642, DOI 10.1093/ajcn/54.4.642; Walker SP, 2005, LANCET, V366, P1804, DOI 10.1016/S0140-6736(05)67574-5; Walker SP, 2000, J PEDIATR-US, V137, P36, DOI 10.1067/mpd.2000.106227; WARR P, 1983, TRAV HUMAIN, V46, P355; Yoshikawa H, 1995, FUTURE CHILD, V5, P51, DOI 10.2307/1602367	18	64	67	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 2	2006	333	7566					472	474		10.1136/bmj.38897.555208.2F	http://dx.doi.org/10.1136/bmj.38897.555208.2F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	085QP	16877454	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000240618900019
J	Dykxhoorn, DM; Lieberman, J				Dykxhoorn, Derek M.; Lieberman, Judy			Knocking down disease with siRNAs	CELL			English	Editorial Material							SMALL INTERFERING RNA; FAS PROTECTS MICE; IN-VIVO; GENE; INHIBITION; EXPRESSION; MICRORNAS		Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Lieberman, J (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA.	lieberman@cbr.med.harvard.edu	Lieberman, Judy/A-2717-2015; Dykxhoorn, Derek M/D-1357-2015		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI056900] Funding Source: NIH RePORTER; NIAID NIH HHS [U19 AI056900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; Hamar P, 2004, P NATL ACAD SCI USA, V101, P14883, DOI 10.1073/pnas.0406421101; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Li BJ, 2005, NAT MED, V11, P944, DOI 10.1038/nm1280; Lu SH, 2004, J VIROL, V78, P12868, DOI 10.1128/JVI.78.23.12868-12876.2004; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122; Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Song EW, 2003, J VIROL, V77, P7174, DOI 10.1128/JVI.77.13.7174-7181.2003; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	23	169	179	0	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 28	2006	126	2					231	235		10.1016/j.cell.2006.07.007	http://dx.doi.org/10.1016/j.cell.2006.07.007			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	070VD	16873051	Green Published, Bronze			2023-01-03	WOS:000239552600005
J	Coffey, DS; Getzenberg, RH; DeWeese, TL				Coffey, Donald S.; Getzenberg, Robert H.; DeWeese, Theodore L.			Hyperthermic biology and cancer therapies a hypothesis for the "Lance Armstrong effect"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NUCLEAR-MATRIX PROTEINS; PROSTATE-CANCER; DNA ORGANIZATION; FEVER; IDENTIFICATION; RADIATION; CELLS; SEX		Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Getzenberg, RH (corresponding author), Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Dept Urol, Marburg 121,600 N Wolfe St, Baltimore, MD 21287 USA.	rgetzen1@jhmi.edu						Barone JG, 2000, UROLOGY, V56, P1068, DOI 10.1016/S0090-4295(00)00788-3; Brizel DM, 1996, CANCER RES, V56, P5347; Chen Q, 2006, CANCER IMMUNOL IMMUN, V55, P299, DOI 10.1007/s00262-005-0022-9; CIEJEK EM, 1983, NATURE, V306, P607, DOI 10.1038/306607a0; Dewhirst MW, 2005, INT J HYPERTHER, V21, P779, DOI 10.1080/02656730500271668; di Pietro A, 2005, INT J BIOCHEM CELL B, V37, P2437, DOI 10.1016/j.biocel.2005.06.014; Dynlacht JR, 2000, RADIAT RES, V154, P515, DOI 10.1667/0033-7587(2000)154[0515:DPODFA]2.0.CO;2; Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550; FERGUSON MWJ, 1982, NATURE, V296, P850, DOI 10.1038/296850a0; GETZENBERG RH, 1991, CANCER RES, V51, P6514; GETZENBERG RH, 1990, MOL ENDOCRINOL, V4, P1336, DOI 10.1210/mend-4-9-1336; Greisman LA, 2002, CURR OPIN INFECT DIS, V15, P241, DOI 10.1097/00001432-200206000-00005; Guan K, 2006, NATURE, V440, P1199, DOI 10.1038/nature04697; HAHN GM, 1975, P NATL ACAD SCI USA, V72, P937, DOI 10.1073/pnas.72.3.937; Horwich A, 2006, LANCET, V367, P754, DOI 10.1016/S0140-6736(06)68305-0; Ito A, 2006, CANCER IMMUNOL IMMUN, V55, P320, DOI 10.1007/s00262-005-0049-y; KLUGER MJ, 1975, SCIENCE, V188, P166, DOI 10.1126/science.1114347; Lepock JR, 2001, CELL STRESS CHAPERON, V6, P136, DOI 10.1379/1466-1268(2001)006<0136:TNMIAT>2.0.CO;2; Lupold SE, 2002, CANCER RES, V62, P4029; Paul B, 2005, CANCER RES, V65, P4097, DOI 10.1158/0008-5472.CAN-04-4523; PIENTA KJ, 1989, CANCER RES, V49, P2525; Roti JLR, 1998, CELL STRESS CHAPERON, V3, P245, DOI 10.1379/1466-1268(1998)003<0245:NMAATF>2.3.CO;2; Rylander MN, 2005, ANN NY ACAD SCI, V1066, P222, DOI 10.1196/annals.1363.009; Takaha N, 2002, CANCER RES, V62, P647; Vertrees RA, 2000, ANN THORAC SURG, V69, P1675, DOI 10.1016/S0003-4975(00)01421-1; VOGELSTEIN B, 1980, CELL, V22, P79, DOI 10.1016/0092-8674(80)90156-7; Westermann AM, 2005, CANCER, V104, P763, DOI 10.1002/cncr.21128	27	71	73	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	2006	296	4					445	448		10.1001/jama.296.4.445	http://dx.doi.org/10.1001/jama.296.4.445			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	066PN	16868303				2023-01-03	WOS:000239242500031
J	Jarcho, JA				Jarcho, John A.			Biventricular pacing	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC-RESYNCHRONIZATION THERAPY; CHRONIC HEART-FAILURE; BUNDLE-BRANCH-BLOCK; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; INTRAVENTRICULAR-CONDUCTION DELAY; CHRONIC ATRIAL-FIBRILLATION; LEFT-VENTRICULAR FUNCTION; DILATED CARDIOMYOPATHY; SINUS RHYTHM; QRS DURATION		Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Jarcho, JA (corresponding author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.							Abraham WT, 2003, CIRCULATION, V108, P2596, DOI 10.1161/01.CIR.0000096580.26969.9A; Abraham WT, 2004, CIRCULATION, V110, P2864, DOI 10.1161/01.CIR.0000146336.92331.D1; Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Auricchio A, 2002, J AM COLL CARDIOL, V39, P2026, DOI 10.1016/S0735-1097(02)01895-8; Auricchio A, 2004, CIRCULATION, V109, P300, DOI 10.1161/01.CIR.0000115583.20268.E1; Baldasseroni S, 2002, AM HEART J, V143, P398, DOI 10.1067/mhj.2002.121264; Bardy GH, 2005, NEW ENGL J MED, V352, P2146; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Bax JJ, 2004, J AM COLL CARDIOL, V44, P1, DOI 10.1016/j.jacc.2004.02.055; Bax JJ, 2004, J AM COLL CARDIOL, V44, P1834, DOI 10.1016/j.jacc.2004.08.016; Breithardt OA, 2003, J AM COLL CARDIOL, V41, P765, DOI 10.1016/S0735-1097(02)02937-6; Breithardt OA, 2003, J AM COLL CARDIOL, V41, P1853, DOI 10.1016/S0735-1097(03)00552-7; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Cazeau S, 1996, PACE, V19, P1748, DOI 10.1111/j.1540-8159.1996.tb03218.x; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Garrigue S, 2002, HEART, V87, P529, DOI 10.1136/heart.87.6.529; Ghali JK, 2003, J AM COLL CARDIOL, V42, P2128, DOI 10.1016/j.jacc.2003.05.012; Goldschlager N, 2001, ARCH INTERN MED, V161, P649, DOI 10.1001/archinte.161.5.649; Gregoratos Gabriel, 2002, Circulation, V106, P2145, DOI 10.1161/01.CIR.0000035996.46455.09; GRINES CL, 1989, CIRCULATION, V79, P845, DOI 10.1161/01.CIR.79.4.845; Higgins SL, 2003, J AM COLL CARDIOL, V42, P1454, DOI 10.1016/S0735-1097(03)01042-8; Iuliano S, 2002, AM HEART J, V143, P1085, DOI 10.1067/mhj.2002.122516; Kasravi B, 2005, PACE, V28, P51, DOI 10.1111/j.1540-8159.2005.09353.x; Kass DA, 1999, CIRCULATION, V99, P1567, DOI 10.1161/01.CIR.99.12.1567; Knight BP, 2004, J AM COLL CARDIOL, V44, P72, DOI 10.1016/j.jacc.2004.03.054; Leclercq C, 2000, AM J CARDIOL, V85, P1154, DOI 10.1016/S0002-9149(00)00716-5; Leclercq C, 2002, EUR HEART J, V23, P1780, DOI 10.1053/euhj.2002.3232; Leclercq C, 1998, J AM COLL CARDIOL, V32, P1825, DOI 10.1016/S0735-1097(98)00492-6; Leon AR, 2002, J AM COLL CARDIOL, V39, P1258, DOI 10.1016/S0735-1097(02)01779-5; McAlister FA, 2005, ANN INTERN MED, V142, P311; McAlister FA, 2004, ANN INTERN MED, V141, P381, DOI 10.7326/0003-4819-141-5-200409070-00101; Molhoek SG, 2004, AM J CARDIOL, V94, P1506, DOI 10.1016/j.amjcard.2004.08.028; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Navia JL, 2005, ANN THORAC SURG, V79, P1536, DOI 10.1016/j.athoracsur.2004.10.041; Nelson GS, 2000, CIRCULATION, V102, P3053; Penicka M, 2004, CIRCULATION, V109, P978, DOI 10.1161/01.CIR.0000116765.43251.D7; Pinski SL, 2002, PACE, V25, P1496, DOI 10.1046/j.1460-9592.2002.01496.x; Pinski SL, 2002, PACE, V25, P1367, DOI 10.1046/j.1460-9592.2002.01367.x; Pitzalis MV, 2005, J AM COLL CARDIOL, V45, P65, DOI 10.1016/j.jacc.2004.09.058; Ricci R, 2002, J INTERV CARD ELECTR, V6, P279, DOI 10.1023/A:1019570022647; Saxon LA, 2003, CIRCULATION, V108, P1044, DOI 10.1161/01.CIR.0000085656.57918.B1; Shamim W, 1999, INT J CARDIOL, V70, P171, DOI 10.1016/S0167-5273(99)00077-7; Strickberger SA, 2005, CIRCULATION, V111, P2146, DOI 10.1161/01.CIR.0000161276.09685.4A; Sundell J, 2004, J AM COLL CARDIOL, V43, P1027, DOI 10.1016/j.jacc.2003.10.044; Sutton MGS, 2003, CIRCULATION, V107, P1985, DOI 10.1161/01.CIR.0000065226.24159.E9; Swedberg K, 2005, EUR HEART J, V26, P1115, DOI 10.1093/eurheartj/ehi204; TANG AS, 2005, CAN J CARDIOL SA, V21; Turner MS, 2004, CIRCULATION, V109, P2544, DOI 10.1161/01.CIR.0000131184.40893.40; Tyers GFO, 2003, PACE, V26, P524; Wyman BT, 1999, AM J PHYSIOL-HEART C, V276, pH881, DOI 10.1152/ajpheart.1999.276.3.H881; WYNDHAM CRC, 1980, CIRCULATION, V61, P696, DOI 10.1161/01.CIR.61.4.696; Yong P, 2000, PACE, V23, P1735; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685; Zhang Q, 2006, EUR HEART J, V27, P1423, DOI 10.1093/eurheartj/ehi885	55	24	27	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 20	2006	355	3					288	294		10.1056/NEJMct055185	http://dx.doi.org/10.1056/NEJMct055185			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	064NY	16855269				2023-01-03	WOS:000239097600010
J	Steinbrook, R				Steinbrook, R			For sale: Physician's prescribing data	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material												rsteinbrook@attglobal.net						*AM MED ASS, 2004, US PHYS PAT PRESCR D; *AM MED ASS, 2005 ANN REP; *HLTH IMS, 2005 ANN REP; MUSACCHIO RJ, 2006, PHARM EXECUTIVE 0501; SAUL S, 2006, NY TIMES        0504	5	29	30	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	2006	354	26					2745	2747		10.1056/NEJMp068125	http://dx.doi.org/10.1056/NEJMp068125			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	057GQ	16807410				2023-01-03	WOS:000238584700001
J	Truog, RD; Christ, G; Browning, DM; Meyer, EC				Truog, Robert D.; Christ, Grace; Browning, David M.; Meyer, Elaine C.			Sudden traumatic death in children - "We did everything, but your child didn't survive"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE CARE; ORGAN DONATION; PARENTAL PERSPECTIVES; FAMILY PERSPECTIVES; HOSPITAL STAFF; BRAIN-DEATH; END; QUALITY; BEREAVEMENT; ETHICS	When caring for children who become suddenly and catastrophically ill, clinicians must simultaneously attend to a complex and rapidly evolving medical situation, as well as to the equally challenging demands of establishing compassionate relationships with family members and communicating well with colleagues. An 18-month-old toddler was brought to the hospital with severe head injury after being struck by a car. Over a period of hours, her condition evolved from prognostic uncertainty to the diagnosis of brain death and considerations of organ donation. Against this medical backdrop, the clinicians successfully established a trusting relationship with family members by careful attention to their emotional, informational, and care needs as they absorbed the devastating prognosis, took in the results of the brain death examination, and considered the option of organ donation. This case illustrates the importance of interdisciplinary communication, the vital role of social workers and other psychosocial providers with expertise in working with families, and the critical significance of mutual care and support for the clinicians who accompany families through these tragic life events.	Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; Childrens Hosp Boston, Div Crit Care Med, Boston, MA USA; Educ Dev Ctr Inc, Initiat Pediat Palliat Care, Boston, MA USA; Columbia Univ, Sch Social Work, New York, NY USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Columbia University	Truog, RD (corresponding author), Harvard Univ, Sch Med, Dept Social Med, 641 Huntington Ave, Boston, MA 02115 USA.	robert.truog@childrens.harvard.edu						Abbott KH, 2001, CRIT CARE MED, V29, P197, DOI 10.1097/00003246-200101000-00040; [Anonymous], 1998, Fed Regist, V63, P33856; Back AL, 2003, J CLIN ONCOL, V21, P2433, DOI 10.1200/JCO.2003.09.073; Back Anthony L, 2003, Ann Intern Med, V138, P439; Benight CC, 2004, BEHAV RES THER, V42, P1129, DOI 10.1016/j.brat.2003.08.008; BROWNING D, 2003, DIFFICULT CONVERSATI; Browning David, 2002, Bioethics Forum, V18, P23; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; Chambliss D.F, 1996, CARING HOSP NURSES S; CHRIST G, IN PRESS INNOVATIVE; Contro N, 2002, ARCH PEDIAT ADOL MED, V156, P14, DOI 10.1001/archpedi.156.1.14; Contro NA, 2004, PEDIATRICS, V114, P1248, DOI 10.1542/peds.2003-0857-L; Cook P, 2002, ARCH DIS CHILD, V87, P36, DOI 10.1136/adc.87.1.36; Curtis JR, 2002, J CRIT CARE, V17, P147, DOI 10.1053/jcrc.2002.35929; Davies B, 2002, J NURS ADMIN, V32, P5, DOI 10.1097/00005110-200201000-00001; Davis CG, 2000, DEATH STUD, V24, P497; Fallowfield L, 2004, LANCET, V363, P312, DOI 10.1016/S0140-6736(03)15392-5; FALLOWFIELD L, 1993, LANCET, V341, P476, DOI 10.1016/0140-6736(93)90219-7; FIELD MJ, 2003, I MED CHILDREN DIE I; FINLAY I, 1991, BRIT MED J, V302, P1524, DOI 10.1136/bmj.302.6791.1524; FLEISCHMAN AR, 1994, PEDIATRICS, V94, P433; Frank AW, 2004, INTERN MED J, V34, P355, DOI 10.1111/j.1445-5994.2004.00622.x; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Harbaugh Bonnie Lee, 2004, Issues Compr Pediatr Nurs, V27, P163, DOI 10.1080/01460860490497985; Hurwitz CA, 2004, JAMA-J AM MED ASSOC, V292, P2141, DOI 10.1001/jama.292.17.2141; *I MED, 2003, CHILDR DIE IMPR PALL; Janzen L, 2003, OMEGA-J DEATH DYING, V48, P149; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Kirschbaum MS, 1996, ADV NURS SCI, V19, P51, DOI 10.1097/00012272-199609000-00007; LEHMAN DR, 1987, J PERS SOC PSYCHOL, V52, P218, DOI 10.1037/0022-3514.52.1.218; Lipton H, 2000, Int J Emerg Ment Health, V2, P19; Lipton H, 2000, Int J Emerg Ment Health, V2, P181; Lock Margaret, 2002, TWICE DEAD ORGAN TRA, DOI DOI 10.1525/J.CTT1PN7PH; Macdonald ME, 2005, PEDIATRICS, V116, P884, DOI 10.1542/peds.2004-1980; Mack JW, 2005, J CLIN ONCOL, V23, P9155, DOI 10.1200/JCO.2005.04.010; Martinez R, 2002, THEOR MED BIOETH, V23, P185, DOI 10.1023/A:1020816824759; McDonagh JR, 2004, CRIT CARE MED, V32, P1484, DOI 10.1097/01.CCM.0000127262.16690.65; Meert K L, 2001, Pediatr Crit Care Med, V2, P324, DOI 10.1097/00130478-200110000-00007; Meert K L, 2000, Pediatr Crit Care Med, V1, P179, DOI 10.1097/00130478-200010000-00017; Meyer EC, 2006, PEDIATRICS, V117, P649, DOI 10.1542/peds.2005-0144; Meyer EC, 2002, CRIT CARE MED, V30, P226, DOI 10.1097/00003246-200201000-00032; Murphy SA, 2003, J TRAUMA STRESS, V16, P17, DOI 10.1023/A:1022003126168; Nolen-Hoeksema S., 1999, COPING LOSS; OLIVER RC, 1995, J TRAUMA, V39, P303, DOI 10.1097/00005373-199508000-00019; Plum F, 1999, DEFINITION OF DEATH, P34; Rabow MW, 1999, WESTERN J MED, V171, P260; Rachmani R, 1999, TRANSPLANT P, V31, P1912, DOI 10.1016/S0041-1345(99)00152-9; Roter DL, 2000, ARCH INTERN MED, V160, P3477, DOI 10.1001/archinte.160.22.3477; Seecharan GA, 2004, ARCH PEDIAT ADOL MED, V158, P515, DOI 10.1001/archpedi.158.6.515; Siminoff LA, 2001, JAMA-J AM MED ASSOC, V286, P71, DOI 10.1001/jama.286.1.71; Siminoff LA, 2001, CLIN TRANSPLANT, V15, P39, DOI 10.1034/j.1399-0012.2001.150107.x; Solomon MZ, 2005, PEDIATRICS, V116, P872, DOI 10.1542/peds.2004-0905; *SPEC TASK FORC, 1987, PEDIATRICS, V80, P298; Stack CG, 2003, PAEDIATR ANAESTH, V13, P651, DOI 10.1046/j.1460-9592.2003.01112.x; Truog R, 2003, J CLIN ETHIC, V14, P63; Truog RD, 2001, CRIT CARE MED, V29, P2332, DOI 10.1097/00003246-200112000-00017; Truog RD, 2003, CRIT CARE MED, V31, P2391, DOI 10.1097/01.CCM.0000090869.19410.3C; WALKER JA, 1990, CAN MED ASSOC J, V142, P1383; Wellesley A, 1997, J ACCID EMERG MED, V14, P24; Wheeler I, 2001, DEATH STUD, V25, P51, DOI 10.1080/07481180126147; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; WIJNGAARDSDEMEI.J, 2005, J CONSULT CLIN PSYCH, V73, P617; YOUNGNER SJ, 1989, JAMA-J AM MED ASSOC, V261, P2205, DOI 10.1001/jama.261.15.2205; 2003, J TRAUMA, V54, pS235	64	24	24	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	2006	295	22					2646	2654		10.1001/jama.295.22.2646	http://dx.doi.org/10.1001/jama.295.22.2646			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	052HI	16772628				2023-01-03	WOS:000238224000027
J	Abu-Laban, RB; McIntyre, CM; Christenson, JM; van Beek, CA; Innes, GD; O'Brien, RK; Wanger, KP; McKnight, RD; Gin, KG; Zed, PJ; Watts, J; Puskaric, J; MacPhail, IA; Berringer, RG; Milner, RA				Abu-Laban, RB; McIntyre, CM; Christenson, JM; van Beek, CA; Innes, GD; O'Brien, RK; Wanger, KP; McKnight, RD; Gin, KG; Zed, PJ; Watts, J; Puskaric, J; MacPhail, IA; Berringer, RG; Milner, RA			Aminophylline in bradyasystolic cardiac arrest: a randomised placebo-controlled trial	LANCET			English	Article							CARDIOPULMONARY-RESUSCITATION; VENTRICULAR-FIBRILLATION; ADENOSINE; ATROPINE; ANTAGONISM; CONDUCTION; ASYSTOLE	Background Endogenous adenosine might cause or perpetuate bradyasystole. Our aim was to determine whether aminophylline, an adenosine antagonist, increases the rate of return of spontaneous circulation (ROSC) after out-of-hospital cardiac arrest. Methods In a double-blind trial, we randomly assigned 971 patients older than 16 years with asystole or pulseless electrical activity at fewer than 60 beats per minute, and who were unresponsive to initial treatment with epinephrine and atropine, to receive intravenous aminophylline (250 mg, and an additional 250 mg if necessary) (n=486) or placebo (n=485). The patients were enrolled between January, 2001 and September, 2003, from 1886 people who had had cardiac arrests. Standard resuscitation measures were used for at least 10 mins after the study drug was administered. Analysis was by intention-to-treat. This trial is registered with the ClinicalTrials.gov registry with the number NCT00312273. Findings Baseline characteristics and survival predictors were similar in both groups. The median time from the arrival of the advanced life-support paramedic team to study drug administration was 13 min. The proportion of patients who had an ROSC was 24.5% in the aminophylline group and 23.7% in the placebo group (difference 0.8%; 95% CI -4.6% to 6.2%; p=0.778). The proportion of patients with non-sinus tachyarrhythmias after study drug administration was 34.6% in the aminophylline group and 26.2% in the placebo group (p=0.004). Survival to hospital admission and survival to hospital discharge were not significantly different between the groups. A multivariate logistic regression analysis showed no evidence of a significant subgroup or interactive effect from aminophylline. Interpretation Although aminophylline increases non-sinus tachyarrhythmias, we noted no evidence that it significantly increases the proportion of patients who achieve ROSC after bradyasystolic cardiac arrest.	Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; British Columbia Ambulance Serv, Victoria, BC, Canada; Ctr Clin Epidemiol & Evaluat, Vancouver, BC, Canada	University of British Columbia	Abu-Laban, RB (corresponding author), Vancouver Gen Hosp, Dept Emergency Med, Vancouver, BC V5Z 1M9, Canada.	abulaban@interchange.ubc.ca						Abu-Laban RB, 2002, NEW ENGL J MED, V346, P1522, DOI 10.1056/NEJMoa012885; AbuLaban RB, 2003, NEW ENGL J MED, V349, P1487; ABULABAN RB, 2004, ACAD EMERG MED, V11, P601; [Anonymous], 1986, Am J Emerg Med, V4, P72; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; BARDENHEUER H, 1986, AM J PHYSIOL, V250, pH173, DOI 10.1152/ajpheart.1986.250.2.H173; BERNE RM, 1963, AM J PHYSIOL, V204, P317, DOI 10.1152/ajplegacy.1963.204.2.317; Burton JH, 1997, ANN EMERG MED, V30, P154, DOI 10.1016/S0196-0644(97)70134-3; CUMMINS RO, 1993, ANN EMERG MED, V22, P37, DOI 10.1016/S0196-0644(05)80247-1; DIMARCO JP, 1985, J AM COLL CARDIOL, V6, P417, DOI 10.1016/S0735-1097(85)80181-9; DOBSON JG, 1983, AM J PHYSIOL, V245, pH468, DOI 10.1152/ajpheart.1983.245.3.H468; DOBSON JG, 1983, CIRC RES, V52, P151, DOI 10.1161/01.RES.52.2.151; FAVALE S, 1985, J AM COLL CARDIOL, V5, P1212, DOI 10.1016/S0735-1097(85)80027-9; Gray J D, 2001, CJEM, V3, P213; HERLITZ J, 1994, RESUSCITATION, V28, P27, DOI 10.1016/0300-9572(94)90051-5; JENNETT B, 1975, LANCET, V1, P480; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; Kaplan JL, 2003, ACAD EMERG MED, V10, P923, DOI 10.1197/S1069-6563(03)00309-9; Lee C C, 2001, Prehosp Emerg Care, V5, P304, DOI 10.1080/10903120190939878; Lee CC, 2000, AM J EMERG MED, V18, P350, DOI 10.1016/S0735-6757(00)90143-8; LEWIS RJ, 1993, ANN EMERG MED, V22, P1463, DOI 10.1016/S0196-0644(05)81997-3; LITTMANN L, 1994, J AM COLL CARDIOL, V23, P1708, DOI 10.1016/0735-1097(94)90679-3; Mader TJ, 1999, RESUSCITATION, V41, P39, DOI 10.1016/S0300-9572(99)00029-5; Mader TJ, 2000, RESUSCITATION, V47, P105, DOI 10.1016/S0300-9572(00)00234-3; Mader TJ, 1997, RESUSCITATION, V35, P3, DOI 10.1016/S0300-9572(97)01097-6; Mader TJ, 2003, ACAD EMERG MED, V10, P192, DOI 10.1111/j.1553-2712.2003.tb01989.x; MALCOLM AD, 1993, CARDIOVASC DRUG THER, V7, P139, DOI 10.1007/BF00878323; Ornato JP, 1996, ANN EMERG MED, V27, P576, DOI 10.1016/S0196-0644(96)70160-9; PELLEG A, 1990, AM J PHYSIOL, V258, pH1815, DOI 10.1152/ajpheart.1990.258.6.H1815; PEPE PE, 1993, CRIT CARE MED, V21, P1838, DOI 10.1097/00003246-199312000-00009; Perouansky M, 1998, RESUSCITATION, V38, P39, DOI 10.1016/S0300-9572(98)00079-3; Rea TD, 2004, RESUSCITATION, V63, P17, DOI 10.1016/j.resuscitation.2004.03.025; SCHRADER J, 1977, PFLUG ARCH EUR J PHY, V372, P29, DOI 10.1007/BF00582203; SEDGWICK ML, 1994, RESUSCITATION, V27, P55, DOI 10.1016/0300-9572(94)90022-1; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; URTHALER F, 1972, J LAB CLIN MED, V79, P96; VISKIN S, 1993, ANN INTERN MED, V118, P279, DOI 10.7326/0003-4819-118-4-199302150-00006; Wenzel V, 2004, NEW ENGL J MED, V350, P105, DOI 10.1056/NEJMoa025431; Willerson JT, 2000, CIRCULATION, V102, P1	41	25	28	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 13	2006	367	9522					1577	1584		10.1016/S0140-6736(06)68694-7	http://dx.doi.org/10.1016/S0140-6736(06)68694-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	043JT	16698410				2023-01-03	WOS:000237598000028
J	Yin, MB; Li, ZR; Toth, K; Cao, S; Durrani, FA; Hapke, G; Bhattacharya, A; Azrak, RG; Frank, C; Rustum, YM				Yin, MB; Li, ZR; Toth, K; Cao, S; Durrani, FA; Hapke, G; Bhattacharya, A; Azrak, RG; Frank, C; Rustum, YM			Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1 alpha expression, resulting in reduced angiogenesis	ONCOGENE			English	Article						MSC; irinotecan; COX-2; iNOS; HIF-1 alpha; angiogenesis	NF-KAPPA-B; SQUAMOUS-CELL CARCINOMA; COLON-CANCER CELLS; GENE-EXPRESSION; COLORECTAL-CANCER; ENDOTHELIAL-CELLS; MAMMARY-CANCER; NECK-CANCER; MOUSE SKIN; HUMAN HEAD	Until recently, the use of Se-methylselenocysteine ( MSC) as selective modulator of the antitumor activity and selectivity of anticancer drugs including irinotecan, a topoisomerase I poison, had not been evaluated. Therapeutic synergy between MSC and irinotecan was demonstrated by our laboratory in mice bearing human squamous cell carcinoma of the head and neck tumors. In FaDu xenografts, a poorly differentiated tumor-expressing mutant p53, the cure rate was increased from 30% with irinotecan alone to 100% with the combination of irinotecan and MSC. Cellular exposure to cytotoxic concentration of SN-38, the active metabolite of irinotecan (0.1 mu M) alone and in combination with noncytotoxic concentration of MSC (10 mu M) did not result in additional enhancement of chk2 phosphorylation and downregulation of specific DNA replication-associated proteins, cdc6, MCM2, cdc25A, nor increase in PARP cleavage, caspase activation and the 30-300 kb DNA fragmentation induced by SN-38 treatment. MSC did not alter significantly markers associated with apoptosis, nor potentiate irinotecan-induced apoptosis. These results indicate that apoptosis is unlikely to be one of the main mechanism associated with the observed in vivo therapeutic synergy. In contrast, significant downregulation of cyclooxygenase-2 (COX-2) expression and activity was observed in the cells exposed to SN-38 in combination with MSC compared to SN-38 alone. Moreover, the inhibition of PGE(2) production was also observed in the cells treated with the combination as compared with SN-38 alone. Analysis of tumor tissues at 24 h after treatment with synergistic modality of irinotecan and MSC revealed significant downregulation of COX-2, inducible nitric oxide synthase (iNOS) and hypoxia-induced factor-1 alpha expression (HIF 1 alpha). Moreover, decreased micro-vessel density was observed after irinotecan treatment with the addition of MSC. These results suggest that observed therapeutic synergy correlates with the inhibition of neoangiogenesis through the downregulation of COX-2, iNOS and HIF-1 alpha expression.	Roswell Pk Canc Inst, Dept Canc Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Rustum, YM (corresponding author), Roswell Pk Canc Inst, Dept Canc Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	youcef.rustum@roswellpark.org			NCI NIH HHS [CA16056, CA65761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA065761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn KS, 2005, LIFE SCI, V76, P2315, DOI 10.1016/j.lfs.2004.10.042; Apostolou S, 2004, ONCOGENE, V23, P5032, DOI 10.1038/sj.onc.1207683; Azrak RG, 2004, CLIN CANCER RES, V10, P1121, DOI 10.1158/1078-0432.CCR-0913-3; Bhattacharya A, 2004, CLIN CANCER RES, V10, P8005, DOI 10.1158/1078-0432.CCR-04-1306; Bing RJ, 2001, CLIN CANCER RES, V7, P3385; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Cao SS, 2004, CLIN CANCER RES, V10, P2561, DOI 10.1158/1078-0432.CCR-03-0268; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chapple KS, 2002, J PATHOL, V198, P435, DOI 10.1002/path.1223; Chen YC, 2000, BIOCHEM PHARMACOL, V59, P1445, DOI 10.1016/S0006-2952(00)00255-0; Cherukuri DR, 2005, CANCER BIOL THER, V4, P175; Chun KS, 2004, CARCINOGENESIS, V25, P445, DOI 10.1093/carcin/bgh021; Cianchi F, 2004, CLIN CANCER RES, V10, P2694, DOI 10.1158/1078-0432.CCR-03-0192; Cianchi F, 2001, GASTROENTEROLOGY, V121, P1339, DOI 10.1053/gast.2001.29691; Cianchi F, 2003, AM J PATHOL, V162, P793, DOI 10.1016/S0002-9440(10)63876-X; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gallo O, 2002, BIOCHEM BIOPH RES CO, V299, P517, DOI 10.1016/S0006-291X(02)02683-9; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; GIACCIA AJ, 1991, MUTAT RES, V263, P69, DOI 10.1016/0165-7992(91)90062-9; Guo B, 2000, CLIN CANCER RES, V6, P718; Hussain SP, 2004, CANCER RES, V64, P6849, DOI 10.1158/0008-5472.CAN-04-2201; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Ip C, 1999, ANTICANCER RES, V19, P2875; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Jiang C, 1999, MOL CARCINOGEN, V26, P213, DOI 10.1002/(SICI)1098-2744(199912)26:4<213::AID-MC1>3.0.CO;2-Z; Jones MK, 1999, NAT MED, V5, P1418; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kisley LR, 2002, CANCER RES, V62, P6850; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Lu JX, 2001, NUTR CANCER, V40, P64, DOI 10.1207/S15327914NC401_12; Lu JX, 2001, ADV EXP MED BIOL, V492, P131; Masferrer JL, 2000, CANCER RES, V60, P1306; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MEDINA D, 1988, PATHOL IMMUNOPATH R, V7, P187, DOI 10.1159/000157115; Merchan JR, 2005, INT J CANCER, V113, P490, DOI 10.1002/ijc.20595; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Park SW, 2003, INT J CANCER, V107, P729, DOI 10.1002/ijc.11498; Pichiule P, 2004, J BIOL CHEM, V279, P12171, DOI 10.1074/jbc.M305146200; Rajnakova A, 2001, CANCER LETT, V172, P177, DOI 10.1016/S0304-3835(01)00645-0; Rapisarda A, 2004, CANCER RES, V64, P6845, DOI 10.1158/0008-5472.CAN-04-2116; Reid ME, 2002, CANCER EPIDEM BIOMAR, V11, P1285; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Wei DY, 2004, CANCER RES, V64, P2030, DOI 10.1158/0008-5472.CAN-03-1945; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Yin MB, 2004, MOL PHARMACOL, V66, P153, DOI 10.1124/mol.66.1.153; Zhou N, 2003, J BIOL CHEM, V278, P29532, DOI 10.1074/jbc.M301877200; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; ZICHE M, 1993, BIOCHEM BIOPH RES CO, V192, P1198, DOI 10.1006/bbrc.1993.1543	57	32	35	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2509	2519		10.1038/sj.onc.1209073	http://dx.doi.org/10.1038/sj.onc.1209073			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16518418				2023-01-03	WOS:000236948000009
J	Noble, SIR; Nelson, A; Turner, C; Finlay, IG				Noble, SIR; Nelson, A; Turner, C; Finlay, IG			Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VENOUS THROMBOEMBOLISM; CANCER-PATIENTS	Objective To find out what inpatients with advanced cancer who are receiving palliative care think about the effect of thromboprophylaxis on overall quality of life. Design Qualitative study using audiotaping of semistructured interviews. Setting Regional cancer centre in Wales. Participants 28 inpatients with advanced metastatic cancer receiving palliative care and low molecular weight heparin. Main outcome measures Recurring themes on the effect of thromboprophylaxis on overall quality of life. Results Major emerging themes showed that patients knew about the risks of venous thromboembolism and die purpose of treatment with heparin. Media coverage had raised awareness about venous thromboembolism, and many had previous experience of thromboprophylaxis. All found low molecular weight heparin an acceptable intervention, and many said that it improved their quality of life by giving them a feeling of safety and reassurance. Antiembolic stockings were considered uncomfortable and had a negative impact on quality of life. Patients were concerned that because they had advanced disease they might not be eligible for thromboprophylaxis. Conclusion Low molecular weight heparin is acceptable to inpatients With advanced cancer receiving palliative care and has a positive impact on overall quality of life. Antiembolic stockings are an unacceptable intervention in this patient group. Guidelines on thromboprophylaxis are urgently needed for palliative care inpatient units and hospices.	Cardiff Univ, Cardiff CF10 3XQ, S Glam, Wales; Holme Tower Marie Curie Ctr, Penarth, S Glam, Wales; Velindre Hosp, Cardiff, S Glam, Wales	Cardiff University; Velindre Hospital	Noble, SIR (corresponding author), Gwent Hosp, Newport NP20 2UB, Gwent, Wales.	simon.noble@velindre-tr.wales.nhs.uk	Nelson, Annmarie/B-4893-2009; Nelson, Annmarie/AAD-2193-2020	Nelson, Annmarie/0000-0002-6075-8425; Nelson, Annmarie/0000-0002-6075-8425; Noble, Simon/0000-0001-5425-2383				AMBRUS JL, 1975, J MED, V6, P61; BICK RL, 1978, SEMIN THROMB HEMOST, V5, P1; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; *HOSP DIR, 2004, DIR HOSP CAR SERV UK; *HOUS COMM HLTH CO, 2004, 2 HOUS COMM HLTH COM; Johnson MJ, 1999, CLIN ONCOL-UK, V11, P105, DOI 10.1053/clon.1999.9023; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; MISHLER E, 1984, DISCOURSE MED DIELEC; Noble SIR, 2005, PALLIATIVE MED, V19, P197, DOI 10.1191/0269216305pm1008oa; NOBLE SIR, IN PRESS J PAIN SYMP; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; SHEN VS, 1980, SOUTHERN MED J, V73, P841, DOI 10.1097/00007611-198007000-00005; SHEN VS, 1980, SOUTH MED J, V73, P811; SPROUL E. E., 1938, AMER JOUR CANCER, V34, P566	14	77	79	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	2006	332	7541					577	580		10.1136/bmj.38733.616065.802	http://dx.doi.org/10.1136/bmj.38733.616065.802			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026CN	16459340	Green Published, Bronze			2023-01-03	WOS:000236314400015
J	Mitsuuchi, Y; Powell, DR; Gallo, JM				Mitsuuchi, Y; Powell, DR; Gallo, JM			Adenoviral modification of mouse brain derived endothelial cells, bEnd3, to induce apoptosis by vascular endothelial growth factor	ONCOGENE			English	Article						endothelial cells; drug delivery; adenovirus; VEGF; apoptosis	ANGIOGENESIS; MECHANISMS; VEHICLES; PROTEIN; CANCER; DELIVERY; RECEPTOR; SYSTEM; DRUGS; GENE	A second generation genetically-engineered cell-based drug delivery system, referred to as apoptotic-induced drug delivery (AIDD), was developed using endothelial cells (ECs) that undergo apoptosis upon binding of vascular endothelial growth factor (VEGF) to a Flk-1: Fas fusion protein (FF). This new AIDD was redesigned using mouse brain derived ECs, bEnd3cells, and an adenovirus vector in order to enhance and control the expression of FF. The FF was tagged with a HA epitope (FFHA) and designed to be coexpressed with green. fluorescence protein (GFP) by the regulation of cytomegalovirus promoters in the adenovirus vector. bEnd3 ce lls showed favorable coexpression of FFHA and GFP consistent with the multiplicity of infection of the adenovirus. Immunofluorescence analysis demonstrated that FFHA was localized at the plasma membrane, whereas GFP was predominantly located in the cytoplasm of ECs. Cell death was induced by VEGF, but not by platelet derived growth factor or. fibroblast growth factor in a dose-dependent manner (range 2 - 20 ng/ml), and revealed caspase-dependent apoptotic profiles. The FFHA expressing bEnd3cells underwent apoptosis when cocultured with a glioma cell (SF188V +) line able to overexpress VEGF. The combined data indicated that the FFHA adenovirus system can induce apoptotic signaling in ECs in response to VEGF, and thus, is an instrumental modi. cation to the development of AIDD.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Gallo, JM (corresponding author), Fox Chase Canc Ctr, Dept Pharmacol, 333 Cottham Ave, Philadelphia, PA 19111 USA.	jmgallo@temple.edu			NATIONAL CANCER INSTITUTE [R01CA085577] Funding Source: NIH RePORTER; NCI NIH HHS [CA 085577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; Carpenito C, 2002, INT J RADIAT ONCOL, V54, P1473, DOI 10.1016/S0360-3016(02)03921-4; CHINNAIYAN AM, 1995, CELL, V81, P512; Dass CR, 2002, J PHARM PHARMACOL, V54, P3, DOI 10.1211/0022357021771887; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Hallmann R, 2000, ENDOTHELIUM-J ENDOTH, V7, P135, DOI 10.3109/10623320009072208; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; ITOH N, 1993, J BIOL CHEM, V268, P10932; Le Ricousse-Roussanne S, 2004, CARDIOVASC RES, V62, P176, DOI 10.1016/j.cardiores.2004.01.017; Ma J, 1998, APOPTOSIS, V3, P195, DOI 10.1023/A:1009603023214; Ma JG, 1998, CLIN EXP METASTAS, V16, P559, DOI 10.1023/A:1006598419541; Ma JG, 2002, CANCER RES, V62, P1382; Mitsuuchi Y, 1998, J CELL BIOCHEM, V70, P433, DOI 10.1002/(SICI)1097-4644(19980915)70:4<433::AID-JCB1>3.0.CO;2-K; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Pereboeva L, 2003, STEM CELLS, V21, P389, DOI 10.1634/stemcells.21-4-389; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; Quinn TP, 2001, CANCER RES, V61, P8629; Scappaticci FA, 2002, J CLIN ONCOL, V20, P3906, DOI 10.1200/JCO.2002.01.033; Soga N, 2001, CELL COMMUN ADHES, V8, P1, DOI 10.3109/15419060109080703; ten Tije AJ, 2003, CLIN PHARMACOKINET, V42, P665, DOI 10.2165/00003088-200342070-00005; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wrede CE, 2002, J BIOL CHEM, V277, P49676, DOI 10.1074/jbc.M208756200	22	4	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					954	958		10.1038/sj.onc.1209142	http://dx.doi.org/10.1038/sj.onc.1209142			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247462				2023-01-03	WOS:000235212700014
J	Mathis, JM; Stoff-Khalili, MA; Curiel, DT				Mathis, JM; Stoff-Khalili, MA; Curiel, DT			Oncolytic adenoviruses - selective retargeting to tumor cells	ONCOGENE			English	Review						adenovirus; oncolytic; transduction; retargeting; virotherapy	REPLICATION-COMPETENT ADENOVIRUS; VESICULAR STOMATITIS-VIRUS; GROWTH-FACTOR RECEPTOR; CANCER GENE-THERAPY; PHASE-I TRIAL; 2 CANINE ADENOVIRUSES; PSEUDOTYPED RETROVIRAL VECTORS; MEDIATED TRANSGENE EXPRESSION; RECURRENT PROSTATE-CANCER; EPITHELIAL OVARIAN-CANCER	Virotherapy is an approach for the treatment of cancer, in which the replicating virus itself is the anticancer agent. Virotherapy exploits the lytic property of virus replication to kill tumor cells. As this approach relies on viral replication, the virus can self-amplify and spread in the tumor from an initial infection of only a few cells. The success of this approach is fundamentally based on the ability to deliver the replication-competent viral genome to target cells with a requisite level of efficiency. With virotherapy, while a number of transcriptional retargeting strategies have been utilized to restrict viral replication to tumor cells, this review will focus primarily on transductional retargeting strategies, whereby oncolytic viruses can be designed to selectively infect tumor cells. Using the adenoviral vector paradigm, there are three broad strategies useful for viral retargeting. One strategy uses heterologous retargeting ligands that are bispecific in that they bind both to the viral vector as well as to a cell surface target. A second strategy uses genetically modified viral vectors in which a cellular retargeting ligand is incorporated. A third strategy involves the construction of chimeric recombinant vectors, in which a capsid protein from one virus is exchanged for that of another. These transductional retargeting strategies have the potential for reducing deleterious side effects, and increasing the therapeutic index of virotherapeutic agents.	Univ Alabama, Dept Med, Div Human & Gene Therapy, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Div Human & Gene Therapy, Birmingham, AL 35294 USA; Univ Alabama, Dept Surg, Div Human & Gene Therapy, Birmingham, AL 35294 USA; Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Curiel, DT (corresponding author), Univ Alabama, Dept Med, Div Human & Gene Therapy, 901 19th St S,BMR2-508, Birmingham, AL 35294 USA.	david.curiel@ccc.uab.edu	Mathis, J. Michael/J-1379-2018	Mathis, J. Michael/0000-0001-5528-5195	NATIONAL CANCER INSTITUTE [P50CA086306] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA86306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 2001, CANCER RES, V61, P7882; Akalu A, 1999, J VIROL, V73, P6182, DOI 10.1128/JVI.73.7.6182-6187.1999; Alemany R, 2000, J GEN VIROL, V81, P2605, DOI 10.1099/0022-1317-81-11-2605; Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; Alemany R, 2001, GENE THER, V8, P1347, DOI 10.1038/sj.gt.3301515; Anderson BD, 2004, CANCER RES, V64, P4919, DOI 10.1158/0008-5472.CAN-04-0884; Arai T, 1998, J VIROL, V72, P1115, DOI 10.1128/JVI.72.2.1115-1121.1998; Arnberg N, 2000, J VIROL, V74, P42, DOI 10.1128/JVI.74.1.42-48.2000; Arnberg N, 2002, VIROLOGY, V302, P33, DOI 10.1006/viro.2002.1503; Asaoka K, 2000, J NEUROSURG, V92, P1002, DOI 10.3171/jns.2000.92.6.1002; Atkins GJ, 2004, CURR CANCER DRUG TAR, V4, P597, DOI 10.2174/1568009043332754; Banerjee NS, 2004, MOL CANCER THER, V3, P437; Barker SD, 2003, GENE THER, V10, P1198, DOI 10.1038/sj.gt.3301974; Baxi MK, 2000, VIROLOGY, V278, P234, DOI 10.1006/viro.2000.0661; Belousova N, 2003, J VIROL, V77, P11367, DOI 10.1128/JVI.77.21.11367-11377.2003; Belousova N, 2002, J VIROL, V76, P8621, DOI 10.1128/JVI.76.17.8621-8631.2002; Bennett JJ, 2001, NAT MED, V7, P859, DOI 10.1038/89991; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Blackwell JL, 1999, ARCH OTOLARYNGOL, V125, P856, DOI 10.1001/archotol.125.8.856; Blackwell JL, 2000, HUM GENE THER, V11, P1657, DOI 10.1089/10430340050111313; Borovjagin AV, 2005, CANCER GENE THER, V12, P475, DOI 10.1038/sj.cgt.7700806; Breidenbach M, 2004, HUM GENE THER, V15, P509, DOI 10.1089/10430340460745829; Brunetti-Pierri N, 2004, HUM GENE THER, V15, P35, DOI 10.1089/10430340460732445; Buller RE, 2002, CANCER GENE THER, V9, P553, DOI 10.1038/sj.cgt.7700472; Cashman SM, 2004, VIROLOGY, V324, P129, DOI 10.1016/j.virol.2004.04.001; Chen J, 2005, GENE THER, V12, P1079, DOI 10.1038/sj.gt.3302494; Chen J, 2001, HUM GENE THER, V12, P61, DOI 10.1089/104303401450979; Cherenova LV, 2004, VIRUS RES, V100, P257, DOI 10.1016/j.virusres.2003.11.018; Chiocca EA, 2004, MOL THER, V10, P958, DOI 10.1016/j.ymthe.2004.07.021; Cho JY, 2002, GENE THER, V9, P1139, DOI 10.1038/sj.gt.3301787; Christ M, 2000, HUM GENE THER, V11, P415, DOI 10.1089/10430340050015888; COLBY WW, 1981, J VIROL, V39, P977, DOI 10.1128/JVI.39.3.977-980.1981; Cosset FL, 1996, GENE THER, V3, P946; Cripe TP, 2001, CANCER RES, V61, P2953; Csatary LK, 2004, J NEURO-ONCOL, V67, P83, DOI 10.1023/B:NEON.0000021735.85511.05; Curiel D, 2002, ADENOVIRAL VECTORS G; CURTIS R, 1983, VET REC, V112, P347, DOI 10.1136/vr.112.15.347; Davydova J, 2004, CANCER RES, V64, P4319, DOI 10.1158/0008-5472.CAN-04-0064; Denby L, 2004, HUM GENE THER, V15, P1054, DOI 10.1089/1043034042431083; DEVAUX C, 1990, J MOL BIOL, V215, P567, DOI 10.1016/S0022-2836(05)80169-X; DeWeese TL, 2001, CANCER RES, V61, P7464; Dingli D, 2004, BLOOD, V103, P1641, DOI 10.1182/blood-2003-07-2233; Dirven CMF, 2002, J NEUROSURG, V97, P441, DOI 10.3171/jns.2002.97.2.0441; Dmitriev I, 2000, J VIROL, V74, P6875, DOI 10.1128/JVI.74.15.6875-6884.2000; Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706-9713.1998; Dmitriev IP, 2002, J VIROL, V76, P6893, DOI 10.1128/JVI.76.14.6893-6899.2002; Doronin K, 2000, J VIROL, V74, P6147, DOI 10.1128/JVI.74.13.6147-6155.2000; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Ebert O, 2005, CANCER GENE THER, V12, P350, DOI 10.1038/sj.cgt.7700794; Edwards BK, 2002, CANCER-AM CANCER SOC, V94, P2766, DOI 10.1002/cncr.10593; Einfeld DA, 1999, J VIROL, V73, P9130, DOI 10.1128/JVI.73.11.9130-9136.1999; Everett RS, 2003, HUM GENE THER, V14, P1715, DOI 10.1089/104303403322611737; Everts M, 2005, GENE THER, V12, P1042, DOI 10.1038/sj.gt.3302491; Farina SF, 2001, J VIROL, V75, P11603, DOI 10.1128/JVI.75.23.11603-11613.2001; Freytag SO, 2002, CANCER RES, V62, P4968; Freytag SO, 2003, CANCER RES, V63, P7497; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fuxe J, 2003, INT J CANCER, V103, P723, DOI 10.1002/ijc.10891; Galanis E, 2001, BRIT J CANCER, V85, P1432, DOI 10.1054/bjoc.2001.2129; Galanis E, 2005, GENE THER, V12, P437, DOI 10.1038/sj.gt.3302436; Gall J, 1996, J VIROL, V70, P2116, DOI 10.1128/JVI.70.4.2116-2123.1996; Ganly I, 2000, CLIN CANCER RES, V6, P798; Ganly I, 2001, GENE THER, V8, P369, DOI 10.1038/sj.gt.3301402; Geoerger B, 2003, BRIT J CANCER, V89, P577, DOI 10.1038/sj.bjc.6601102; Glasgow JN, 2004, VIROLOGY, V324, P103, DOI 10.1016/j.virol.2004.03.028; Glotzer JB, 2001, J VIROL, V75, P2421, DOI 10.1128/JVI.75.5.2421-2434.2001; Goldman CK, 1997, CANCER RES, V57, P1447; Goossens PH, 2001, ARTHRITIS RHEUM, V44, P570, DOI 10.1002/1529-0131(200103)44:3<570::AID-ANR105>3.3.CO;2-P; Grill J, 2001, CLIN CANCER RES, V7, P641; GRUBER WC, 1993, VIROLOGY, V196, P603, DOI 10.1006/viro.1993.1516; Habib N, 2002, CANCER GENE THER, V9, P254, DOI 10.1038/sj.cgt.7700431; Haisma HJ, 2000, CANCER GENE THER, V7, P901, DOI 10.1038/sj.cgt.7700198; Hallden G, 2003, MOL THER, V8, P412, DOI 10.1016/S1525-0016(03)00199-0; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Hammond JM, 2005, VET J, V169, P17, DOI 10.1016/j.tvjl.2003.09.007; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Harrow S, 2004, GENE THER, V11, P1648, DOI 10.1038/sj.gt.3302289; Haviv YS, 2002, CANCER RES, V62, P4273; Hay JG, 2004, TRENDS BIOTECHNOL, V22, P501, DOI 10.1016/j.tibtech.2004.08.002; Hay JG, 1999, HUM GENE THER, V10, P579, DOI 10.1089/10430349950018652; HEDLEY SJ, 2005, IN PRESS GENE THERAP; HEINZERLING L, 2005, BLOOD           0616; Hemmi S, 1998, HUM GENE THER, V9, P2363, DOI 10.1089/hum.1998.9.16-2363; Hemminki A, 2001, MOL THER, V4, P223, DOI 10.1006/mthe.2001.0446; Henning P, 2005, GENE THER, V12, P211, DOI 10.1038/sj.gt.3302408; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; HERRERO YC, 2004, INT J CANCER, V109, P76, DOI DOI 10.1002/IJC.11626; Herschman HR, 2004, ADV CANCER RES, V92, P29, DOI 10.1016/S0065-230X(04)92003-9; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294; Hu J, 2003, MOL THER, V8, P611, DOI 10.1016/S1525-0016(03)00239-9; Irving J, 2004, CANCER GENE THER, V11, P174, DOI 10.1038/sj.cgt.7700666; Itoh A, 2003, J GENE MED, V5, P929, DOI 10.1002/jgm.430; Joung I, 2005, BIOCHEM BIOPH RES CO, V328, P1182, DOI 10.1016/j.bbrc.2005.01.080; Kanerva A, 2002, CLIN CANCER RES, V8, P275; Kanerva A, 2005, GENE THER, V12, P87, DOI 10.1038/sj.gt.3302387; Kanerva A, 2004, GENE THER, V11, P552, DOI 10.1038/sj.gt.3302181; Kashentseva EA, 2002, CANCER RES, V62, P609; Kawakami Y, 2003, CANCER RES, V63, P1262; Kawashima H, 2003, CANCER SCI, V94, P70, DOI 10.1111/j.1349-7006.2003.tb01354.x; Kelly FJ, 2000, CLIN CANCER RES, V6, P4323; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kim J, 2002, J VIROL, V76, P1892, DOI 10.1128/JVI.76.4.1892-1903.2002; Kim M, 2003, BRIT J CANCER, V88, P1411, DOI 10.1038/sj.bjc.6600932; Kim M, 2002, EUR J CANCER, V38, P1917, DOI 10.1016/S0959-8049(02)00131-4; Kim SH, 2005, EUR J CANCER, V41, P313, DOI 10.1016/j.ejca.2004.10.018; Kirby TO, 2004, CLIN CANCER RES, V10, P8697, DOI 10.1158/1078-0432.CCR-04-1166; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Koizumi N, 2003, J GENE MED, V5, P267, DOI 10.1002/jgm.348; Korn T, 2004, J GENE MED, V6, P642, DOI 10.1002/jgm.555; Korokhov N, 2003, J VIROL, V77, P12931, DOI 10.1128/JVI.77.24.12931-12940.2003; Kraaij R, 2005, PROSTATE, V62, P253, DOI 10.1002/pros.20150; Krasnykh V, 1998, J VIROL, V72, P1844, DOI 10.1128/JVI.72.3.1844-1852.1998; Krasnykh V, 2001, J VIROL, V75, P4176, DOI 10.1128/JVI.75.9.4176-4183.2001; Krasnykh VN, 1996, J VIROL, V70, P6839, DOI 10.1128/JVI.70.10.6839-6846.1996; Kremer EJ, 2000, J VIROL, V74, P505, DOI 10.1128/JVI.74.1.505-512.2000; Kremer EJ, 2004, J GENE MED, V6, pS139, DOI 10.1002/jgm.497; Kruyt FAE, 2002, HUM GENE THER, V13, P485, DOI 10.1089/10430340252809784; Kurihara T, 2000, J CLIN INVEST, V106, P763, DOI 10.1172/JCI9180; Lam JT, 2004, J GENE MED, V6, P1333, DOI 10.1002/jgm.635; Lamont JP, 2000, ANN SURG ONCOL, V7, P588, DOI 10.1007/BF02725338; Lang FF, 2003, J CLIN ONCOL, V21, P2508, DOI 10.1200/JCO.2003.21.13.2508; Le LP, 2004, MOL IMAGING, V3, P105, DOI 10.1162/1535350041464874; Lee H, 2001, GENE THER, V8, P268, DOI 10.1038/sj.gt.3301390; Lehmberg E, 1999, J CHROMATOGR B, V732, P411, DOI 10.1016/S0378-4347(99)00316-3; Li DQ, 1999, CLIN CANCER RES, V5, P4175; Li J, 2005, VIROLOGY, V338, P247, DOI 10.1016/j.virol.2005.04.005; Liang Q, 2002, GENE THER, V9, P1659, DOI 10.1038/sj.gt.3301899; Lichty BD, 2004, HUM GENE THER, V15, P821, DOI 10.1089/1043034041839208; Liu R, 2005, GENE THER, V12, P647, DOI 10.1038/sj.gt.3302445; Liu RB, 2005, CANCER RES, V65, P1532, DOI 10.1158/0008-5472.CAN-04-3353; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; Lu W, 2004, WORLD J GASTROENTERO, V10, P3634, DOI 10.3748/wjg.v10.i24.3634; Lutz P, 1997, J VIROL, V71, P5102, DOI 10.1128/JVI.71.7.5102-5109.1997; Magnusson MK, 2002, J GENE MED, V4, P356, DOI 10.1002/jgm.285; Magnusson MK, 2001, J VIROL, V75, P7280, DOI 10.1128/JVI.75.16.7280-7289.2001; Makower D, 2003, CLIN CANCER RES, V9, P693; MARUSYK RG, 1972, MICROBIOS, V5, P259; MARUSYK RG, 1972, CAN J MICROBIOL, V18, P817, DOI 10.1139/m72-127; MARUSYK RG, 1970, J VIROL, V5, P507, DOI 10.1128/JVI.5.4.507-512.1970; MARUSYK RG, 1971, CAN J MICROBIOL, V17, P151, DOI 10.1139/m71-026; Mastrangeli A, 1996, HUM GENE THER, V7, P79, DOI 10.1089/hum.1996.7.1-79; McDonald D, 1999, GENE THER, V6, P1512, DOI 10.1038/sj.gt.3301006; Mercier GT, 2004, P NATL ACAD SCI USA, V101, P6188, DOI 10.1073/pnas.0400542101; Meulenbroek RA, 2004, MOL THER, V9, P617, DOI 10.1016/j.ymthe.2004.01.012; MICHAEL SI, 1995, GENE THER, V2, P660; Miller CR, 1998, CANCER RES, V58, P5738; Miyazawa N, 1999, J VIROL, V73, P6056, DOI 10.1128/JVI.73.7.6056-6065.1999; Mizuguchi H, 2001, GENE THER, V8, P730, DOI 10.1038/sj.gt.3301453; Mulvihlll S, 2001, GENE THER, V8, P308, DOI 10.1038/sj.gt.3301398; Muster T, 2004, INT J CANCER, V110, P15, DOI 10.1002/ijc.20078; Myers R, 2005, CANCER GENE THER, V12, P593, DOI 10.1038/sj.cgt.7700823; Nakamura T, 2003, J VIROL, V77, P2512, DOI 10.1128/JVI.77.4.2512-2521.2003; Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289; Nettelbeck DM, 2002, CANCER RES, V62, P4663; Nicklin SA, 2001, MOL THER, V4, P534, DOI 10.1006/mthe.2001.0489; Nicol CG, 2004, MOL THER, V10, P344, DOI 10.1016/j.ymthe.2004.05.020; Nilson BHK, 1996, GENE THER, V3, P280; Nilsson M, 2004, J GENE MED, V6, P631, DOI 10.1002/jgm.543; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; NOUREDDINI SC, 2005, IN PRESS J VIROL; Pagliaro LC, 2003, J CLIN ONCOL, V21, P2247, DOI 10.1200/JCO.2003.09.138; Parikh NS, 2005, PEDIATR BLOOD CANCER, V44, P469, DOI 10.1002/pbc.20268; Peng KW, 2002, NAT MED, V8, P527, DOI 10.1038/nm0502-527; Penuelas I, 2005, GASTROENTEROLOGY, V128, P1787, DOI 10.1053/j.gastro.2005.03.024; Portella G, 2002, J CLIN ENDOCR METAB, V87, P2525, DOI 10.1210/jc.87.6.2525; Qin M, 2003, CLIN CANCER RES, V9, P4992; Raki M, 2005, GENE THER, V12, P1198, DOI 10.1038/sj.gt.3302517; Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016; Raykov Z, 2004, INT J CANCER, V109, P742, DOI 10.1002/ijc.20013; Reddy PS, 2003, VIROLOGY, V311, P384, DOI 10.1016/S0042-6822(03)00161-2; Reid T, 2001, GENE THER, V8, P1618, DOI 10.1038/sj.gt.3301512; Rein DT, 2005, CLIN CANCER RES, V11, P1327; Reynolds PN, 2000, MOL THER, V2, P562, DOI 10.1006/mthe.2000.0205; Rivera AA, 2004, GENE THER, V11, P1694, DOI 10.1038/sj.gt.3302346; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; Sachs MD, 2002, UROLOGY, V60, P531, DOI 10.1016/S0090-4295(02)01748-X; Sauthoff H, 2002, HUM GENE THER, V13, P1859, DOI 10.1089/104303402760372954; Schaack J, 2005, VIRAL IMMUNOL, V18, P79, DOI 10.1089/vim.2005.18.79; Schuler M, 2001, J CLIN ONCOL, V19, P1750, DOI 10.1200/JCO.2001.19.6.1750; Segerman A, 2003, J VIROL, V77, P9183, DOI 10.1128/JVI.77.17.9183-9191.2003; Segerman A, 2003, J VIROL, V77, P1157, DOI 10.1128/JVI.77.2.1157-1162.2003; Shayakhmetov DM, 2000, J VIROL, V74, P2567, DOI 10.1128/JVI.74.6.2567-2583.2000; Shayakhmetov DM, 2005, J VIROL, V79, P7478, DOI 10.1128/JVI.79.12.7478-7491.2005; Shayakhmetov DM, 2005, J VIROL, V79, P1053, DOI 10.1128/JVI.79.2.1053-1061.2005; Shayakhmetov DM, 2004, J VIROL, V78, P5368, DOI 10.1128/JVI.78.10.5368-5381.2004; Shi J, 2005, CANCER RES, V65, P1687, DOI 10.1158/0008-5472.CAN-04-2749; Shillitoe EJ, 2005, CLIN CANCER RES, V11, P3109, DOI 10.1158/1078-0432.CCR-04-2302; Shinoura N, 2000, JPN J CANCER RES, V91, P1028, DOI 10.1111/j.1349-7006.2000.tb00881.x; Shinozaki K, 2004, MOL THER, V9, P368, DOI 10.1016/j.ymthe.2003.12.004; Short JJ, 2004, VIROLOGY, V322, P349, DOI 10.1016/j.virol.2004.02.016; Sinclair AM, 1997, GENE THER, V4, P918, DOI 10.1038/sj.gt.3300479; SINKOVICS J, 1993, INTERVIROLOGY, V36, P193, DOI 10.1159/000150339; Sirena D, 2004, J VIROL, V78, P4454, DOI 10.1128/JVI.78.9.4454-4462.2004; Soudais C, 2000, J VIROL, V74, P10639, DOI 10.1128/JVI.74.22.10639-10649.2000; STEVENSON SC, 1995, J VIROL, V69, P2850, DOI 10.1128/JVI.69.5.2850-2857.1995; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; STOFFKHALILI MA, 2005, GENE THERAPY    0721; Stone D, 2005, J VIROL, V79, P5090, DOI 10.1128/JVI.79.8.5090-5104.2005; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; Tekant Y, 2005, SURGERY, V137, P527, DOI 10.1016/j.surg.2004.12.014; Ternovoi VV, 2005, J VIROL, V79, P1308, DOI 10.1128/JVI.79.2.1308-1311.2005; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Toth K, 2005, HUM GENE THER, V16, P139, DOI 10.1089/hum.2005.16.139; Tseng JC, 2004, NAT BIOTECHNOL, V22, P70, DOI 10.1038/nbt917; Tseng JC, 2004, CANCER RES, V64, P6684, DOI 10.1158/0008-5472.CAN-04-1924; UCHINO J, 2005, CANC GENE THER  0429; Unno Y, 2005, CLIN CANCER RES, V11, P4553, DOI 10.1158/1078-0432.CCR-04-2610; van Beusechem VW, 2000, GENE THER, V7, P1940, DOI 10.1038/sj.gt.3301323; van der Poel HG, 2002, J UROLOGY, V168, P266, DOI 10.1016/S0022-5347(05)64905-1; Vanderkwaak TJ, 1999, GYNECOL ONCOL, V74, P227, DOI 10.1006/gyno.1999.5432; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; Vasey PA, 2002, J CLIN ONCOL, V20, P1562, DOI 10.1200/JCO.20.6.1562; Vellinga J, 2005, J GEN VIROL, V86, P1581, DOI 10.1099/vir.0.80877-0; Vellinga J, 2004, J VIROL, V78, P3470, DOI 10.1128/JVI.78.7.3470-3479.2004; Vigne E, 1999, J VIROL, V73, P5156, DOI 10.1128/JVI.73.6.5156-5161.1999; Voeks D, 2002, GENE THER, V9, P759, DOI 10.1038/sj.gt.3301698; Vollmer CM, 1999, CANCER RES, V59, P4369; Volpers C, 2003, J VIROL, V77, P2093, DOI 10.1128/JVI.77.3.2093-2104.2003; Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040; Wesseling JG, 2001, GENE THER, V8, P969, DOI 10.1038/sj.gt.3301473; Wickham TJ, 1996, NAT BIOTECHNOL, V14, P1570, DOI 10.1038/nbt1196-1570; Wickham TJ, 1997, J VIROL, V71, P8221, DOI 10.1128/JVI.71.11.8221-8229.1997; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Witlox AM, 2004, CLIN CANCER RES, V10, P61, DOI 10.1158/1078-0432.CCR-0609-03; Wolf JK, 2004, GYNECOL ONCOL, V94, P442, DOI 10.1016/j.ygyno.2004.05.041; Wu E, 2004, J VIROL, V78, P3897, DOI 10.1128/JVI.78.8.3897-3905.2004; Wu E, 2001, VIROLOGY, V279, P78, DOI 10.1006/viro.2000.0703; Wu H, 2004, GENE THER, V11, P874, DOI 10.1038/sj.gt.3302249; Wu HJ, 2005, J VIROL, V79, P3382, DOI 10.1128/JVI.79.6.3382-3390.2005; Wu HJ, 2002, HUM GENE THER, V13, P1647, DOI 10.1089/10430340260201734; Xia HB, 2000, J VIROL, V74, P11359, DOI 10.1128/JVI.74.23.11359-11366.2000; Yamamoto M, 2003, GASTROENTEROLOGY, V125, P1203, DOI 10.1016/S0016-5085(03)01196-X; Yang M, 2000, P NATL ACAD SCI USA, V97, P12278, DOI 10.1073/pnas.97.22.12278; Yoshida Y, 1998, HUM GENE THER, V9, P2503, DOI 10.1089/hum.1998.9.17-2503; You ZB, 2001, CANCER GENE THER, V8, P168, DOI 10.1038/sj.cgt.7700284; Yun CO, 2005, HUM GENE THER, V16, P248, DOI 10.1089/hum.2005.16.248; Zabner J, 1999, J VIROL, V73, P8689, DOI 10.1128/JVI.73.10.8689-8695.1999; Zakhartchouk A, 2003, VIROLOGY, V313, P377, DOI 10.1016/S0042-6822(03)00286-1; Zeimet AG, 2003, LANCET ONCOL, V4, P415, DOI 10.1016/S1470-2045(03)01139-2; Zhang J, 2004, J GENE MED, V6, P1082, DOI 10.1002/jgm.605; Zhang LN, 2005, VIRUS RES, V110, P169, DOI 10.1016/j.virusres.2005.02.008; Zhang LO, 2003, J GEN VIROL, V84, P687, DOI 10.1099/vir.0.18666-0; Zhu ZB, 2005, INT J ONCOL, V27, P237; Zhu ZB, 2004, VIROLOGY, V325, P116, DOI 10.1016/j.virol.2004.04.021; Zinn KR, 2000, J NUCL MED, V41, P887	250	99	109	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7775	7791		10.1038/sj.onc.1209044	http://dx.doi.org/10.1038/sj.onc.1209044			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299537				2023-01-03	WOS:000233372600013
J	Crotty, M; Whitehead, CH; Wundke, R; Giles, LC; Ben-Tovim, D; Phillips, PA				Crotty, M; Whitehead, CH; Wundke, R; Giles, LC; Ben-Tovim, D; Phillips, PA			Transitional care facility for elderly people in hospital awaiting a long term care bed: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTERMEDIATE CARE; OUTCOMES; DESIGNS; STROKE	Objective To assess the effectiveness of moving patients who are waiting in hospital for a lone term care bed to an off-site transitional care facility. Design Randomised controlled trial. Setting Three public hospitals in Southern Adelaide. Participants 320 elderly patients (mean age 83 years) in acute hospital beds (212 randomised to intervention, 108 to control). Interventions A transitional care facility where all patients received a single assessment from a specialist elder care team and appropriate ongoing therapy. Main outcome measures Length of stay in hospital, rates of readmission, deaths, and patient's functional level (modified Barthel index), quality of life (assessment of quality of life), and care needs (residential classification scale) at four months. Results From admission, those in the intervention group stayed a median of 32.5 days (95% confidence interval 29 to 36 days) in hospital. In the control group the median length of stay was 43.5 days (41 to 51 days) (95% confidence interval for difference 6 to 16 days). Patients in the intervention g roup took a median of 21 days (6 to 27 days) longer to be admitted to permanent care than those in the control group. In both groups few patients went home (14 (7%) in the intervention group v 9 (9%) in the control group). There were no significant differences in death rates (28% v 27%) or rates of transfer back to hospital (28% v 25%). Conclusions For frail elderly patients who are awaiting a residential care bed transfer out of hospital to an off-site transitional care unit with focus on aged care "unblocks beds" without adverse effects.	Flinders Univ S Australia, Repatriat Gen Hosp, Dept Rehabil & Aged Care, Daw Pk, SA 5041, Australia; Flinders Med Ctr, Clin Epidemiol & Hlth Outcomes Unit, Bedford Pk, SA 5042, Australia; Flinders Univ S Australia, Dept Med, Adelaide, SA 5001, Australia	Flinders University South Australia; Flinders Medical Centre; Flinders University South Australia	Crotty, M (corresponding author), Flinders Univ S Australia, Repatriat Gen Hosp, Dept Rehabil & Aged Care, Daw Pk, SA 5041, Australia.	maria.crotty@flinders.edu.au	Giles, Lynne/C-8789-2009	Giles, Lynne/0000-0001-9054-9088; Crotty, Maria/0000-0002-2996-5135				*BRIT GER SOC, 1998, INT CAR GUID COMM PR; Carpenter I, 2002, AGE AGEING, V31, P97, DOI 10.1093/ageing/31.2.97; CONOVER WJ, 1999, PRACTICAL NONPARAMET, P143; Ebrahim S, 2001, BMJ-BRIT MED J, V323, P337; ELLENBERG SS, 1984, NEW ENGL J MED, V310, P1404, DOI 10.1056/NEJM198405243102141; Evans JG, 2001, BRIT MED J, V322, P807, DOI 10.1136/bmj.322.7290.807; GRIFFITHS PD, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002214.PUB2; Hawthorne G, 1999, QUAL LIFE RES, V8, P209, DOI 10.1023/A:1008815005736; Kane RL, 1996, J AM GERIATR SOC, V44, P545, DOI 10.1111/j.1532-5415.1996.tb01440.x; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; Marshall Adele H, 2004, Health Care Manag Sci, V7, P27, DOI 10.1023/B:HCMS.0000005395.77308.d1; McClean S I, 1998, Health Care Manag Sci, V1, P159, DOI 10.1023/A:1019002804381; Pencheon D, 2002, BRIT MED J, V324, P1347, DOI 10.1136/bmj.324.7350.1347; SHAH S, 1989, STROKE, V20, P766, DOI 10.1161/01.STR.20.6.766; Steiner A, 2001, BRIT MED J, V322, P453, DOI 10.1136/bmj.322.7284.453; WARD D, 2004, COCHRANE DATABASE SY; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; ZELEN M, 1990, STAT MED, V9, P645, DOI 10.1002/sim.4780090611	18	29	29	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	2005	331	7525					1110	1113		10.1136/bmj.38638.441933.63	http://dx.doi.org/10.1136/bmj.38638.441933.63			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	985ZI	16267077	Green Published, Bronze			2023-01-03	WOS:000233417300013
J	Bangham, AD				Bangham, AD			Liposomes and the physico-chemical basis of unconsciousness	FASEB JOURNAL			English	Editorial Material							ANESTHETICS				Bangham, AD (corresponding author), 17 High Green, Cambridge CB2 5EG, England.	alecbangham@wwr.co.uk						Bangham A, 2000, BRIT J ANAESTH, V84, P820; BANGHAM AD, 1980, ANESTHESIOLOGY, V53, P135, DOI 10.1097/00000542-198008000-00007; BENNETT P. B., 1967, LIFE SCI, V6, P2527, DOI 10.1016/0024-3205(67)90317-7; BRYSON BA, 2003, SHORT HIST NEARLY EV, P102; HILL MW, 1981, J COMP PHYSIOL, V142, P61, DOI 10.1007/BF00605476; JOHNSON SM, 1969, BIOCHIM BIOPHYS ACTA, V193, P92, DOI 10.1016/0005-2736(69)90062-5; JOHNSON SM, 1970, NATURE, V288, P75; MILLER KW, 1983, LIPOSOME LETT, P251; NICHOLS JW, 1980, BIOCHIM BIOPHYS ACTA, V596, P393; WHITTAKER VP, 1965, J NEUROCHEM, V12, P363, DOI 10.1111/j.1471-4159.1965.tb04237.x	10	3	3	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1766	1768		10.1096/fj.05-1103ufm	http://dx.doi.org/10.1096/fj.05-1103ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260644				2023-01-03	WOS:000234053100027
J	Gebrekristos, HT; Mlisana, KP; Karim, QA				Gebrekristos, HT; Mlisana, KP; Karim, QA			Patients readiness to start highly active antiretroviral treatment for HIV	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HEALTH LITERACY; 21ST-CENTURY; MOTIVATION; CHALLENGE; INFECTION; THERAPY; SEARCH; SCALE		Nelson R Mandela Sch Med, CAPRISA, Durban, South Africa	University of Kwazulu Natal	Gebrekristos, HT (corresponding author), Nelson R Mandela Sch Med, CAPRISA, Durban, South Africa.	hgebrekr@jhsph.edu	Abdool Karim, Quarraisha/GVS-1160-2022; Mlisana, Koleka/N-6204-2013	Abdool Karim, Quarraisha/0000-0002-0985-477X; Mlisana, Koleka/0000-0002-8436-3268	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI051794, P30AI042853] Funding Source: NIH RePORTER; NIAID NIH HHS [1U19AI51794, P30 AI42853-05S1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Audrain J, 1997, Womens Health, V3, P139; *BHIVA WRIT COMM B, 2003, BRIT HIV ASS BHIVA G; BLUMENTHAL RN, 2001, DRUG ALCOHOL DEPEN, V62, P225; *BRIT HIV ASS, 2000, HIV MED, V1, P133; DELEON G, 1994, AM J DRUG ALCOHOL AB, V20, P495; Department of Health and Human Services, 2003, GUID US ANT AG HIV 1; Enriquez M, 2004, J ADV NURS, V45, P438, DOI 10.1046/j.1365-2648.2003.02928.x; Harrington M, 2000, LANCET, V355, P2147, DOI 10.1016/S0140-6736(00)02388-6; Lane HC, 2003, ANN INTERN MED, V138, P680, DOI 10.7326/0003-4819-138-8-200304150-00018; Miller WR, 1996, PSYCHOL ADDICT BEHAV, V10, P81, DOI 10.1037/0893-164X.10.2.81; *MIN HLTH REP UG, 2003, ANT TREATM POL; Neff JA, 2000, SUBST USE MISUSE, V35, P585, DOI 10.3109/10826080009147473; NT, 2003, MUN FIN MAN ACT, P19; Nutbeam D, 2000, HEALTH PROMOT INT, V15, P259, DOI 10.1093/heapro/15.3.259; Nutbeam D, 2000, HEALTH PROMOT INT, V15, P183, DOI 10.1093/heapro/15.3.183; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; ROHREN CL, 1994, PREV MED, V23, P335, DOI 10.1006/pmed.1994.1047; Skolnik PR, 2003, NEW ENGL J MED, V349, P2351, DOI 10.1056/NEJMe038173; Wagner Glenn, 2002, HIV Clin Trials, V3, P475; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	20	30	31	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2005	331	7519					772	775		10.1136/bmj.331.7519.772	http://dx.doi.org/10.1136/bmj.331.7519.772			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971XB	16195299	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000232417100029
J	Asplin, BR; Rhodes, KV; Levy, H; Lurie, N; Crain, AL; Carlin, BP; Kellermann, AL				Asplin, BR; Rhodes, KV; Levy, H; Lurie, N; Crain, AL; Carlin, BP; Kellermann, AL			Insurance status and access to urgent ambulatory care follow-up appointments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY; MEDICAID	Context There is growing pressure to avoid hospitalizing emergency department patients who can be treated safely as outpatients, but this strategy depends on timely access to follow-up care. Objective To determine the association between reported insurance status and access to follow-up appointments for serious conditions that are commonly identified during an emergency department visit. Design, Setting, and Participants Eight research assistants called 499 randomly selected ambulatory clinics in 9 US cities (May 2002-February 2003) and identified themselves as new patients who had been seen in an emergency department and needed an urgent follow-up appointment (within 1 week) for 1 of 3 clinical vignettes (pneumonia, hypertension, or possible ectopic pregnancy). The same person called each clinic twice using the same clinical vignette but different insurance status. Main Outcome Measure Proportion of callers who were offered an appointment within a week. Results Of 499 clinics contacted in the final sample, 430 completed the study protocol. Four hundred six (47.2%) of 860 total callers and 277 (64.4%) of 430 privately insured callers were offered appointments within a week. Callers who claimed to have private insurance were more likely to receive appointments than those who claimed to have Medicaid coverage (63.6% [147/231] vs 34.2% [79/231]; difference, 29.4 percentage points; 95% confidence interval, 21.2-37.6, P<.001). Callers reporting private insurance coverage had higher appointment rates than callers who reported that they were uninsured but offered to pay $20 and arrange payment of the balance (65.3% [130/199] vs 25.1% [50/199]; difference, 40.2; 95% confidence interval, 31.4-49.1; P<.001). There were no differences in appointment rates between callers who claimed to have private insurance coverage and those who reportedly were uninsured but willing to pay cash for the entire visit fee (66.3 % [132/199] vs 62.8% [125/199]; difference, 3.5; 95% confidence interval -3.7 to 10.8; P=.31). The median charge was $100 (range, $25-$600). Seventy-two percent of clinics did not attempt to determine the severity of the caller's condition. Conclusions Reported insurance status is associated with access to timely follow-up ambulatory care for potentially serious conditions. Having private insurance and being willing to pay cash may not eliminate the difficulty in obtaining urgent follow-up appointments.	Reg Hosp, Dept Emergency Med, St Paul, MN 55101 USA; HealthPartners Res Fdn, St Paul, MN USA; Univ Chicago Hosp, Dept Med, Sect Emergency Med, Chicago, IL 60637 USA; Univ Michigan, Inst Social Res, Survey Res Ctr, Ann Arbor, MI USA; Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; RAND Corp, Arlington, VA USA; HealthPartners Res Fdn, Minneapolis, MN USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA	University of Chicago; University of Illinois System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; RAND Corporation; HealthPartners Institute for Education & Research; University of Minnesota System; University of Minnesota Twin Cities; Emory University	Asplin, BR (corresponding author), Reg Hosp, Dept Emergency Med, 640 Jackson St, St Paul, MN 55101 USA.	Brent.R.Asplin@HealthPartners.com			AHRQ HHS [K08-HS13007] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS013007] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], ADV DATA; CURRIE J, 1995, AM ECON REV, V85, P106; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; *I MED COMM CONS U, 2002, CAR COV TO LITTL TOO; Institute of Medicine Committee on the Consequences of Uninsurance, 2002, HLTH INS IS FAM MATT; Institute of Medicine (US) Committee on the Consequences of Uninsurance, 2003, SHAR DEST COMM EFF U; Institute of Medicine (US) Committee on the Consequences of Uninsurance, 2001, COV MATT INS HLTH CA; Johnson LA, 2001, ANN EMERG MED, V37, P495, DOI 10.1067/mem.2001.115173; KELLERMANN AL, 1994, NEW ENGL J MED, V330, P1426; KNAPP RG, 1992, CLIN EPIDEMIOLOGY BI, P116; Murray M, 2003, JAMA-J AM MED ASSOC, V289, P1035, DOI 10.1001/jama.289.8.1035; Murray M, 2003, JAMA-J AM MED ASSOC, V289, P1042, DOI 10.1001/jama.289.8.1042; Sarver JH, 2002, ACAD EMERG MED, V9, P916, DOI 10.1197/aemj.9.9.916; Skaggs DL, 2001, PEDIATRICS, V107, P1405, DOI 10.1542/peds.107.6.1405; Solberg LI, 2004, AM J MANAG CARE, V10, P717; Weber EJ, 2005, ANN EMERG MED, V45, P4, DOI 10.1016/j.annemergmed.2004.06.023	16	203	203	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	2005	294	10					1248	1254		10.1001/jama.294.10.1248	http://dx.doi.org/10.1001/jama.294.10.1248			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	963UI	16160133	Bronze			2023-01-03	WOS:000231831200022
J	Doval, HC; Grancelli, HO; Nul, D; Varini, S; Soifer, S; Ferrante, DC; Villalba, E; Silva, C; Paiva, P; Zambrano, C; Schwartzman, RA; Christen, AI; Ramos, S; Cerezo, G; Fernandez, A				Doval, HC; Grancelli, HO; Nul, D; Varini, S; Soifer, S; Ferrante, DC; Villalba, E; Silva, C; Paiva, P; Zambrano, C; Schwartzman, RA; Christen, AI; Ramos, S; Cerezo, G; Fernandez, A		GESICA Investigators	Randomised trial of telephone intervention in chronic heart failure: DIAL trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DISEASE MANAGEMENT; ELDERLY-PATIENTS; READMISSION; PROGRAM; SUPPORT; DESIGN	Objective To determine whether a centralised telephone intervention reduces the incidence of death or admissions for worsening heart failure in outpatients with chronic heart failure. Design Multicentre randomised controlled trial. Setting 51 centres in Argentina (public and private hospitals and ambulatory settings). Participants 1518 outpatients with stable chronic heart failure and optimal drug treatment randomised, stratified by attending cardiologist, to telephone intervention or usual care. Intervention Education, counselling, and monitoring by nurses through frequent telephone follow-up in addition to usual care, delivered from a single centre. Main outcome measure All cause mortality or admission to hospital for worsening heart failure. Results Complete follow-up was available in 99.5% of patients. The 758 patients in the usual care group were more likely to be admitted for worsening heart failure or to dic (235 events, 31%) than the 760 patients who received the telephone intervention (200 events, 26.3%) (relative risk reduction = 20%, 95% confidence interval 3 to 34, P = 0.026). This benefit was mostly due to a significant reduction in admissions for heart failure (relative risk reduction = 29%, P = 0.005). Mortality was similar in both groups. At the end of the study the intervention group had a better quality of life than the usual care group (mean total score on Minnesota living with heart failure questionnaire 30.6 v 35, P = 0.001). Conclusions This simple, centralised heart failure programme was effective in reducing the primary end point through a significant reduction in admissions to hospital for heart failure.	Fdn GESICA, Buenos Aires, DF, Argentina		Grancelli, HO (corresponding author), Fdn GESICA, Av Rivadavia 2358,PB4,C1034ACP, Buenos Aires, DF, Argentina.	gesica@advancedsl.com.ar						Berry C, 2001, EUR J HEART FAIL, V3, P283, DOI 10.1016/S1388-9842(01)00123-4; BOURASSA MG, 1993, J AM COLL CARDIOL, V22, pA14, DOI 10.1016/0735-1097(93)90456-B; Capomolla S, 2002, J AM COLL CARDIOL, V40, P1259, DOI 10.1016/S0735-1097(02)02140-X; Cline CMJ, 1998, HEART, V80, P442, DOI 10.1136/hrt.80.5.442; Cohen-Solal A, 2000, EUR HEART J, V21, P763, DOI 10.1053/euhj.1999.1762; COX DR, 1972, J R STAT SOC B, V34, P187; Croft JB, 1997, J AM GERIATR SOC, V45, P270, DOI 10.1111/j.1532-5415.1997.tb00939.x; Grancelli H, 2003, J CARD FAIL, V9, P172, DOI 10.1054/jcaf.2003.33; Jaarsma T, 1999, EUR HEART J, V20, P673, DOI 10.1053/euhj.1998.1341; Krumholz HM, 2000, AM HEART J, V139, P72, DOI 10.1016/S0002-8703(00)90311-9; McAlister FA, 2001, AM J MED, V110, P378, DOI 10.1016/S0002-9343(00)00743-9; Philbin EF, 1999, AM J MED, V107, P549, DOI 10.1016/S0002-9343(99)00309-5; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rich MW, 1999, J CARD FAIL, V5, P64, DOI 10.1016/S1071-9164(99)90026-X; Stewart S, 2002, EUR HEART J, V23, P1369, DOI 10.1053/euhj.2001.3114; THOM TJ, 1997, DIS MANAG HEALTH OUT, V1, P75; VINSON JM, 1990, J AM GERIATR SOC, V38, P1290, DOI 10.1111/j.1532-5415.1990.tb03450.x; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; 1998, MMWR, V47, P633	20	135	148	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 20	2005	331	7514					425	427		10.1136/bmj.38516.398067.E0	http://dx.doi.org/10.1136/bmj.38516.398067.E0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958WB	16061499	Bronze, Green Published			2023-01-03	WOS:000231477800013
J	Mervis, J				Mervis, J			Inside the pipeline: Pharma goes to work - Introduction	SCIENCE			English	Editorial Material																			0	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 29	2005	309	5735					721	721		10.1126/science.309.5735.721	http://dx.doi.org/10.1126/science.309.5735.721			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	951NU	16051780				2023-01-03	WOS:000230938200032
J	Moore, A; McQuay, H				Moore, A; McQuay, H			Acupuncture: not just needles?	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; OSTEOARTHRITIS; KNEE; THERAPY		Churchill Hosp, Oxford OX3 7LJ, England	University of Oxford	Moore, A (corresponding author), Churchill Hosp, Oxford OX3 7LJ, England.	andrew.moore@pru.ox.ac.uk						Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006; Ezzo J, 2001, ARTHRITIS RHEUM, V44, P819, DOI 10.1002/1529-0131(200104)44:4<819::AID-ANR138>3.0.CO;2-P; Lee H, 2005, PAIN, V114, P511, DOI 10.1016/j.pain.2005.02.011; Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202; Vas J, 2004, BMJ-BRIT MED J, V329, P1216, DOI 10.1136/bmj.38238.601447.3A; Vickers AJ, 2004, HEALTH TECHNOL ASSES, V8, P1; Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7	7	14	14	1	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 9	2005	366	9480					100	101		10.1016/S0140-6736(05)66843-2	http://dx.doi.org/10.1016/S0140-6736(05)66843-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	943JH	16005314				2023-01-03	WOS:000230349200006
J	Hallenbeck, J				Hallenbeck, J			Palliative care in the final days of life - "They were expecting it at any time"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ILL CANCER-PATIENTS; LAST 48 HOURS; END-OF-LIFE; TERMINALLY-ILL; CULTURAL CONSIDERATIONS; HOSPITALIZED-PATIENTS; CONTROLLED-TRIAL; UNITED-STATES; DEATH RATTLE; BAD-NEWS	Providing care to actively dying patients presents unique challenges for the clinician. Patients, in their final days require careful symptom management. Families need support and coaching as death approaches. Care does not end with the death of the patient but continues through death pronouncement, family notification of the death, discussion of autopsy, and immediate bereavement support. Skills in these and related areas are discussed in the context of one man's death, as illuminated by comments made after death by his daughter and his physician. This case also highlights the often differing perspectives of families and clinicians as they work to deal with a patient's death. A goal of mastering the palliative skills necessary to competently care for an actively dying patient is to enable a patient to die peacefully and relatively free of discomfort. Achieving such competency should also help to relieve clinician stress attendant to caring for dying patients.	Stanford Univ, Sch Med, VA Palto Alto HCS, Palo Alto, CA 94304 USA	Stanford University	Hallenbeck, J (corresponding author), Stanford Univ, Sch Med, VA Palto Alto HCS, 1002C,3801 Miranda Ave, Palo Alto, CA 94304 USA.	james.hallenbeck@med.va.gov						Back IN, 2001, PALLIATIVE MED, V15, P329, DOI 10.1191/026921601678320313; Baile WF, 2002, J CLIN ONCOL, V20, P2189, DOI 10.1200/JCO.2002.08.004; Breitbart W, 2002, PSYCHOSOMATICS, V43, P183, DOI 10.1176/appi.psy.43.3.183; Breitbart W, 2000, CLIN GERIATR MED, V16, P357, DOI 10.1016/S0749-0690(05)70061-6; Bruera E, 1990, J Pain Symptom Manage, V5, P341, DOI 10.1016/0885-3924(90)90027-H; Byock I., 1997, DYING WELL; BYOCK IR, 2004, 4 THINS MATTER MOST; Campbell ML, 2004, CRIT CARE CLIN, V20, P403, DOI 10.1016/j.ccc.2004.03.015; Chandler S, 1999, Am J Hosp Palliat Care, V16, P418, DOI 10.1177/104990919901600113; CHERNY NJ, 1995, CANCER-AM CANCER SOC, V76, P1283, DOI 10.1002/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0; Christakis NA, 1999, DEATH FORETOLD PROPH; Conill C, 1997, J PAIN SYMPTOM MANAG, V14, P328, DOI 10.1016/S0885-3924(97)00263-7; COYLE N, 1990, J PAIN SYMPTOM MANAG, V5, P83; Dalal Shalini, 2004, J Support Oncol, V2, P467; Ellershaw J, 2001, J PAIN SYMPTOM MANAG, V21, P12, DOI 10.1016/S0885-3924(00)00240-2; Ellershaw J, 2003, BRIT MED J, V326, P30, DOI 10.1136/bmj.326.7379.30; FAINSINGER R, 1991, J PALLIATIVE CARE, V7, P5; FAINSINGER RL, 1998, TOPICS PALLIATIVE CA, V4, P261; Hall P, 2002, J AM GERIATR SOC, V50, P501, DOI 10.1046/j.1532-5415.2002.50117.x; Hallenbeck J, 1996, CLIN GERIATR MED, V12, P393; Hallenbeck J, 1999, GENERATIONS, V23, P24; HALLENBECK J, 2002, PRINCIPLES PRACTICE, P661; HALLENBECK J, END OF LIFE CARE CUR; Hallenbeck J. L., 2003, PALLIATIVE CARE PERS; Herndon CM, 2001, J PAIN SYMPTOM MANAG, V22, P1027, DOI 10.1016/S0885-3924(01)00365-7; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KOENIG BA, 1997, APPROACHING DEATH IM; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; Lichter I, 1990, J Palliat Care, V6, P7; Lo RSK, 2002, J PAIN SYMPTOM MANAG, V24, P388, DOI 10.1016/S0885-3924(02)00504-3; LYNN J, 1999, HDB MORTALS GUIDANCE; Marchand Lucille, 2004, J Palliat Med, V7, P80, DOI 10.1089/109662104322737322; Mazzocato C, 1999, ANN ONCOL, V10, P1511, DOI 10.1023/A:1008337624200; McPhee SJ, 1996, ARCH PATHOL LAB MED, V120, P743; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; MENKIN E, 2000, WRITING CONDOLENCE L; Morita T, 2004, ANN ONCOL, V15, P1551, DOI 10.1093/annonc/mdh386; Morita T, 2004, PSYCHOSOMATICS, V45, P107, DOI 10.1176/appi.psy.45.2.107; Morita T, 2002, J PAIN SYMPTOM MANAG, V24, P447, DOI 10.1016/S0885-3924(02)00499-2; Morita T, 2001, J PAIN SYMPTOM MANAG, V21, P282, DOI 10.1016/S0885-3924(01)00258-5; Morita T, 1998, Am J Hosp Palliat Care, V15, P217, DOI 10.1177/104990919801500407; ONeill B, 1997, BRIT MED J, V315, P801, DOI 10.1136/bmj.315.7111.801; Penson R T, 2000, Oncologist, V5, P425; PICKETT M, 1993, CANCER NURS, V16, P102; Prigerson HG, 2001, JAMA-J AM MED ASSOC, V286, P1369, DOI 10.1001/jama.286.11.1369; Puchalski Christina M, 2002, J Palliat Med, V5, P289, DOI 10.1089/109662102753641287; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; Rando T. A., 1993, TREATMENT COMPLICATE; ROUSSEAU P, 2003, J PALLIAT MED, V4, P255; SCHNEIDERMAN H, 1985, POSTGRAD MED, V77, P153, DOI 10.1080/00325481.1985.11698924; Sinard JH, 2001, EXP MOL PATHOL, V70, P333, DOI 10.1006/exmp.2001.2371; STEINHAUSER KE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI DOI 10.1001/JAMA.284.19.2476; STOREY P, 1998, PRINCIPLES PRACTICE, P741; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Vandekieft GK, 2001, AM FAM PHYSICIAN, V64, P1975; Ventafridda V, 1990, J Palliat Care, V6, P7; Wildiers H, 2002, J PAIN SYMPTOM MANAG, V23, P310, DOI 10.1016/S0885-3924(01)00421-3; Zeitlin SV, 2001, PRIMARY CARE, V28, P415, DOI 10.1016/S0095-4543(05)70031-2	60	28	29	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2005	293	18					2265	2271		10.1001/jama.293.18.2265	http://dx.doi.org/10.1001/jama.293.18.2265			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	924LU	15886382				2023-01-03	WOS:000228981100028
J	Oransky, I				Oransky, I			Wilfred Gordon Bigelow - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						BIGELOW WG, PUBLICATION LIST	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 7	2005	365	9471					1616	1616		10.1016/S0140-6736(05)66498-7	http://dx.doi.org/10.1016/S0140-6736(05)66498-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923UB	15898141				2023-01-03	WOS:000228933700014
J	Dobkin, BH				Dobkin, BH			Rehabilitation after stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; INDUCED MOVEMENT THERAPY; CONSTRAINT-INDUCED THERAPY; MOTOR RECOVERY; WALKING ABILITY; APHASIA THERAPY; LOWER-EXTREMITY; UPPER-LIMB; STIMULATION; METAANALYSIS		Univ Calif Los Angeles, Geffen Sch Med, Dept Neurol, Neurol Rehabil & Res Program, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Dobkin, BH (corresponding author), Univ Calif Los Angeles, Geffen Sch Med, Dept Neurol, Neurol Rehabil & Res Program, 710 Westwood Plaza, Los Angeles, CA 90095 USA.	bdobkin@mednet.ucla.edu			NICHD NIH HHS [HD07479, R24 HD039629, R01 HD046740, HD39629, HD046740] Funding Source: Medline; NINDS NIH HHS [T32 NS007479] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD046740, R24HD039629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007479] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baron JC, 2004, CEREBROVASC DIS, V18, P260, DOI 10.1159/000080293; Barreca S, 2003, NEUROREHAB NEURAL RE, V17, P220, DOI 10.1177/0888439003259415; Bhogal SK, 2003, STROKE, V34, P987, DOI 10.1161/01.STR.0000062343.64383.D0; Binkofski F, 2004, NEUROLOGY, V63, P1223, DOI 10.1212/01.WNL.0000140468.92212.BE; Bolton DAE, 2004, J NEUROL SCI, V223, P121, DOI 10.1016/j.jns.2004.05.005; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; Davis HF, 2003, JAMA-J AM MED ASSOC, V290, P1023; de Wit DCM, 2004, CLIN REHABIL, V18, P550, DOI 10.1191/0269215504cr770oa; Dobkin BH, 2004, LANCET NEUROL, V3, P528, DOI 10.1016/S1474-4422(04)00851-8; Dobkin BH, 2003, CURR OPIN NEUROL, V16, P685, DOI 10.1097/00019052-200312000-00007; Dobkin BH, 2004, NEUROIMAGE, V23, P370, DOI 10.1016/j.neuroimage.2004.06.008; Dobkin BH., 2003, CLIN SCI NEUROLOGIC; Doesborgh SJC, 2004, STROKE, V35, P141, DOI 10.1161/01.STR.0000105460.52928.A6; Donnelly M, 2004, STROKE, V35, P127, DOI 10.1161/01.STR.0000106911.96026.8F; Dromerick AW, 2000, STROKE, V31, P2984, DOI 10.1161/01.STR.31.12.2984; Eriksson M, 2004, STROKE, V35, P936, DOI 10.1161/01.STR.0000121643.86762.9a; Gordon NF, 2004, CIRCULATION, V109, P2031, DOI 10.1161/01.CIR.0000126280.65777.A4; Greener J, 2000, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000425; GRESHAM GE, 1995, DHHS PUBLICATION; Grotta JC, 2004, STROKE, V35, P2699, DOI 10.1161/01.STR.0000143320.64953.c4; Hendricks HT, 2002, ARCH PHYS MED REHAB, V83, P1629, DOI 10.1053/apmr.2002.35473; Hesse S, 2003, CURR OPIN NEUROL, V16, P705, DOI 10.1097/00019052-200312000-00010; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Johansson BB, 2001, STROKE, V32, P707, DOI 10.1161/01.STR.32.3.707; Kalra L, 2004, BMJ-BRIT MED J, V328, P1099, DOI 10.1136/bmj.328.7448.1099; Kondziolka D, 2002, J CLIN NEUROSCI, V9, P225, DOI 10.1054/jocn.2001.1043; Koski L, 2004, NEUROREHAB NEURAL RE, V18, P230, DOI 10.1177/1545968304269210; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Lai SM, 2002, STROKE, V33, P1840, DOI 10.1161/01.STR.0000019289.15440.F2; Langhorne P, 2001, STROKE, V32, P268, DOI 10.1161/01.STR.32.1.268; Lannin NA, 2003, ARCH PHYS MED REHAB, V84, P297, DOI 10.1053/apmr.2003.50031; Legg L, 2004, LANCET, V363, P352; Lieber RL, 2003, MUSCLE NERVE, V28, P464, DOI 10.1002/mus.10446; Lincoln NB, 1999, STROKE, V30, P573, DOI 10.1161/01.STR.30.3.573; Liu KP, 2004, ARCH PHYS MED REHAB, V85, P1403, DOI 10.1016/j.apmr.2003.12.035; Moseley AM, 2003, STROKE, V34, P3006, DOI 10.1161/01.STR.0000102415.43108.66; Musso M, 1999, BRAIN, V122, P1781, DOI 10.1093/brain/122.9.1781; Narushima K, 2003, AM J PSYCHIAT, V160, P1157, DOI 10.1176/appi.ajp.160.6.1157; Ottenbacher KJ, 2004, JAMA-J AM MED ASSOC, V292, P1687, DOI 10.1001/jama.292.14.1687; Patten C, 2004, J REHABIL RES DEV, V41, P293, DOI 10.1682/JRRD.2004.03.0293; Peck KK, 2004, STROKE, V35, P554, DOI 10.1161/01.STR.0000110983.50753.9D; Plewnia C, 2004, NEUROLOGY, V62, P2124, DOI 10.1212/01.WNL.0000128041.92710.17; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Robey RR, 1998, J SPEECH LANG HEAR R, V41, P172, DOI 10.1044/jslhr.4101.172; Samsa GP, 2004, J REHABIL RES DEV, V41, P279, DOI 10.1682/JRRD.2003.08.0117; Saunders DH, 2004, COCHRANE DB SYST REV, V1, DOI DOI 10.001002/14651858.CD14003316.PUB14651852; Sommerfeld DK, 2004, STROKE, V35, P134, DOI 10.1161/01.STR.0000105386.05173.5E; Steultjens EMJ, 2003, STROKE, V34, P676, DOI 10.1161/01.STR.0000057576.77308.30; van der Lee JH, 2001, CURR OPIN NEUROL, V14, P741, DOI 10.1097/00019052-200112000-00010; van Diepen PMJ, 2003, VIS COGN, V10, P79, DOI 10.1080/13506280143000023; WADE DT, 2002, INTERCOLLEGIATE WORK; Wellwood I, 2004, CLIN REHABIL, V18, P529, DOI 10.1191/0269215504cr768oa; Wolf SL, 2002, NEUROLOGIST, V8, P325, DOI 10.1097/00127893-200211000-00001; Yan TB, 2005, STROKE, V36, P80, DOI 10.1161/01.STR.0000149623.24906.63; 2000, COCHRANE DATABASE SY, V2	57	484	519	8	341	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 21	2005	352	16					1677	1684		10.1056/NEJMcp043511	http://dx.doi.org/10.1056/NEJMcp043511			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	918CE	15843670	Green Accepted			2023-01-03	WOS:000228515200009
J	Orchard, TJ; Temprosa, M; Goldberg, R; Haffner, S; Ratner, R; Marcovina, S; Fowler, S				Orchard, TJ; Temprosa, M; Goldberg, R; Haffner, S; Ratner, R; Marcovina, S; Fowler, S		Diabet Prevention Program Res Grp	The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The diabetes prevention program randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; PREVALENCE; MELLITUS; GLUCOSE; DIET; RISK	Background: The metabolic syndrome is a high-risk state for diabetes and cardiovascular disease. Little is known about its prevalence and prevention in those with impaired glucose tolerance. Objective: To determine the prevalence of the metabolic syndrome at baseline in the Diabetes Prevention Program and the effect of intensive lifestyle intervention and metformin therapy on the syndrome's incidence and resolution. Design: Randomized, controlled clinical trial. Setting: Research and community-based centers. Participants: Participants had impaired glucose tolerance (World Health Organization criteria plus fasting plasma glucose level >= 53 mmol/L [ >= 95 mg/dL]) and were followed for a mean of 3.2 years after random assignment to intensive lifestyle intervention, metformin therapy, or placebo. Interventions: Metformin, 850 ring twice daily, or intensive lifestyle intervention designed to achieve and maintain a 7% weight loss and 150 minutes of exercise per week. Measurements: The metabolic syndrome was defined as having 3 or more characteristics (waist circumference; blood pressure; and levels of high-density lipoprotein cholesterol, triglycerides, and fasting plasma glucose) that met criteria from the National Cholesterol Education Program Adult Treatment Panel III. Results: Fifty-three percent of participants (n = 1711) had the metabolic syndrome at baseline; incidence did not vary substantially by age. However, low levels of high-density lipoprotein cholesterol predominated in younger participants (age 25 to 44 years), and high blood pressure predominated in older participants (age 60 to 82 years). In life-table analyses (log-rank test), incidence of the metabolic syndrome was reduced by 41% in the lifestyle group (P < 0.001) and by 17% in the metformin group (P = 0.03) compared with placebo. Three-year cumulative incidences were 51%, 45%, and 34% in the placebo, metformin, and lifestyle groups, respectively. There was no significant heterogeneity by ethnic group. Limitations: The study involved a volunteer group with impaired glucose tolerance, which limits generalizability. Conclusions: The metabolic syndrome affected approximately half of the participants in the Diabetes Prevention Program at baseline. Both lifestyle intervention and metformin therapy reduced the development of the syndrome in the remaining participants.	George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, Rockville, MD 20852 USA	George Washington University	Orchard, TJ (corresponding author), George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, 6110 Execut Blvd,Suite 750, Rockville, MD 20852 USA.			orchard, trevor/0000-0001-9552-3215	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK048489] Funding Source: NIH RePORTER; NIDDK NIH HHS [U01 DK048489-06, U01 DK048489, 5U01DK048489] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Alexander CM, 2003, DIABETES, V52, P1210, DOI 10.2337/diabetes.52.5.1210; American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS11; Bonora E, 2003, DIABETES CARE, V26, P1251, DOI 10.2337/diacare.26.4.1251; Borch-Johnsen K, 1999, LANCET, V354, P617; Borch-Johnsen K, 2001, ARCH INTERN MED, V161, P397, DOI 10.1001/archinte.161.3.397; Bray GA, 1999, DIABETES CARE, V22, P623; Bureau of the Census, 1990, CENS POP 1990; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; CROUSE JR, 1989, LANCET, V1, P318, DOI 10.1016/S0140-6736(89)91320-2; Diggle PJ, 1994, ANAL LONGITUDINAL DA, V1st; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Han TS, 2002, DIABETES CARE, V25, P2016, DOI 10.2337/diacare.25.11.2016; HOKANSON JE, 1997, HDB LIPOPROTEIN TEST, P267; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lachin J. M., 2000, WILEY SER PROB STAT; Lindstrom J, 2003, DIABETES CARE, V26, P3230, DOI 10.2337/diacare.26.12.3230; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Ozata M, 2001, OBES RES, V9, P662, DOI 10.1038/oby.2001.90; Stern MP, 2002, ANN INTERN MED, V136, P575, DOI 10.7326/0003-4819-136-8-200204160-00006; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; Vrbikova J, 2001, EUR J ENDOCRINOL, V144, P619, DOI 10.1530/eje.0.1440619; Warnick G R, 1986, Methods Enzymol, V129, P101; WARNICK GR, 1982, CLIN CHEM, V28, P1379	24	653	672	2	53	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					611	619		10.7326/0003-4819-142-8-200504190-00009	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916TZ	15838067	Green Accepted			2023-01-03	WOS:000228410400003
J	Lo, B; Dornbrand, L; Dubler, NN				Lo, B; Dornbrand, L; Dubler, NN			HIPAA and patient care - The role for professional judgment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Federal health privacy regulations, commonly known as the Health Insurance Portability and Accountability Act (HIPAA) regulations, came into effect in April 2003. Many clinicians and institutions have relied on consultants and risk managers to tell them how to implement these regulations. Much of the controversy and confusion over the HIPAA regulations concern so-called incidental disclosures. Some interpretations of the privacy regulations would limit essential communication and compromise good patient care. This article analyzes misconceptions regarding what the regulations say about incidental disclosures and discusses the reasons for such misunderstandings. Many misconceptions arise from gaps in the regulations. These gaps are appropriately filled by professional judgment informed by ethical guidelines. The communication should be necessary and effective for good patient care, and the risks of a breach of confidentiality should be proportional to the likely benefit for the patient's care. The alternative for communication should be impractical. We offer specific recommendations to help physicians think through what incidental disclosures in patient care are ethically permissible and what safeguards ought to be taken. Physicians should work with risk managers and practice administrators to develop policies that promote good communication in patient care, while taking appropriate steps to protect patient privacy.	Univ Calif San Francisco, Program Med Eth, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA; Montefiore Med Ctr, Dept Epidemiol & Social Med, New York, NY USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Montefiore Medical Center	Lo, B (corresponding author), Univ Calif San Francisco, Program Med Eth, Room C 126,521 Parnassus Ave, San Francisco, CA 94143 USA.	bernie@medicine.ucsf.edu						BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P329; BEAUCHAMP TL, 2001, PRINCIPLES BIOMEDICA, P303; Beauchamp Tom L, 2001, PRINCIPLES BIOMEDICA, P165; Beauchamp Tom L., 2001, PRINCIPLES BIOMEDICA, P63; CALFEE JE, 1984, VA LAW REV, V70, P965, DOI 10.2307/1072946; Childress JF, 2002, J LAW MED ETHICS, V30, P170, DOI 10.1111/j.1748-720X.2002.tb00384.x; CLARK C, 2003, SAN DIEGO UNION 0609, pA1; *CTR MED MED SERV, 2003, IS MAND ENCR HIPAA S; *DEP HLTH HUM SERV, 2003, MAY DOCT FAX EMAIL D; *DEP HLTH HUM SERV, 2004, US OCR RES FIGHT MYT; *DEP HLTH HUM SERV, 2003, CAN HLTH CAR PROV CO; *DEP HLTH HUM SERV, 2001, HHS ISS 1 GUID NEW P; *DEP HLTH HUM SERV, 2003, CAN PAT HAV FRIEND F; *DEP HLTH HUM SERV, 2003, MUST FAC PRIV SOUNDP; *DEP HLTH HUM SERV, 2003, HLTH CAR PROV CONF C; *DEP HLTH HUM SERV, 2003, WHAT SAF NEED CONT C; *DEP HLTH HUM SERV, 2003, GEN WHAT DOES HIPAA; GOSTIN LO, 2000, PUBLIC HLTH LAW, P85; *HLTH PRIV PROJ, 2003, MYTHS FACTS HLPAA PR; *HLTH PRIV WORK GR, 1999, BEST PRINC HLTH PRIV; JONSEN AR, 1978, ANN INTERN MED, V88, P827, DOI 10.7326/0003-4819-88-6-827; KISSINGER M, 2003, MILWAUKEE J SEN 1109, pA1; Lo B, 2000, JAMA-J AM MED ASSOC, V283, P801, DOI 10.1001/jama.283.6.801; LO B, 2000, RESOLVING ETHICAL DI, P43; *LTH PRIV PROJ, 2003, MED PRIV STOR; *MARKL FDN, 2004, CONN HLTH PRIV SEC W; *OFF CIV RIGHTS HI, 2002, STAND PRIV IND ID HL; *OFF CIV RIGHTS HI, 2003, MED PRIV NAT STAND P; OSTROM CM, 2004, SEATTLE TIMES   0330, pA1; SORKIN MD, 2003, ST LOUIS POST D 0629, pA12; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; STEIN R, 2003, WASH POST       0330, pA1; SUNNSTEIN CR, 1996, LEGAL REASONING POLI; TARKAN L, 2003, NY TIMES        0603, pA1; UBEL PA, 1995, AM J MED, V99, P190, DOI 10.1016/S0002-9343(99)80139-9; *US ATT OFF W DIST, 2004, SEATTL AR MAN GETS P; WEISS BD, 1982, JAMA-J AM MED ASSOC, V247, P2695, DOI 10.1001/jama.247.19.2695; 2002, FED REG, V67, P14793; 2002, FED REG, V67, P55918	40	20	20	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2005	293	14					1766	1771		10.1001/jama.293.14.1766	http://dx.doi.org/10.1001/jama.293.14.1766			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915JS	15827316				2023-01-03	WOS:000228301100031
J	Vrakking, AM; van der Heide, A; Onwuteaka-Philipsen, BD; Keij-Deerenberg, IM; van der Maas, PJ; van der Wal, G				Vrakking, AM; van der Heide, A; Onwuteaka-Philipsen, BD; Keij-Deerenberg, IM; van der Maas, PJ; van der Wal, G			Medical end-of-life decisions made for neonates and infants in the Netherlands, 1995-2001	LANCET			English	Article							INTENSIVE-CARE	End-of-life decision-making for severely affected infants might be influenced by technical advances and societal debates. In 2001, we assessed the proportion of deaths of infants younger than 1 year that were preceded by end-of-life decisions, by replicating a questionnaire study from 1995. This proportion increased from 62% to 68% (weighted percentages), but the difference was not significant. Most of these decisions were to forgo life-sustaining treatment. Decisions to actively end the lives of infants not dependent on life-sustaining treatment remained stable at 1%. The practice of end-of-life decision-making in neonatology of 2001 has changed little since 1995.	Erasmus MC, Dept Publ Hlth, Univ Med Ctr Rotterdam, NL-3000 DR Rotterdam, Netherlands; VU Univ Med Ctr Amsterdam, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; VU Univ Med Ctr Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands; Stat Netherlands, Div Social & Spatial Stat, Voorburg, Netherlands	Erasmus University Rotterdam; Erasmus MC; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Vrakking, AM (corresponding author), Erasmus MC, Dept Publ Hlth, Univ Med Ctr Rotterdam, POB 1738, NL-3000 DR Rotterdam, Netherlands.	a.vrakking@erasmusmc.nl						Buitendijk S, 2003, EUR J OBSTET GYN R B, V111, pS66, DOI 10.1016/j.ejogrb.2003.09.007; Cuttini M, 2000, LANCET, V355, P2112, DOI 10.1016/S0140-6736(00)02378-3; Lemons JA, 2000, PEDIATRICS, V105, P454; vanderHeide A, 1997, LANCET, V350, P251, DOI 10.1016/S0140-6736(97)02315-5; Wall SN, 1997, PEDIATRICS, V99, P64, DOI 10.1542/peds.99.1.64	5	43	43	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1329	1331		10.1016/S0140-6736(05)61030-6	http://dx.doi.org/10.1016/S0140-6736(05)61030-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823383	Green Submitted			2023-01-03	WOS:000228219600028
J	Zhong, CB; Liljenquist, K				Zhong, Chen-Bo; Liljenquist, Katie			Washing away your sins: Threatened morality and physical cleansing	SCIENCE			English	Article								Physical cleansing has been a focal element in religious ceremonies for thousands of years. The prevalence of this practice suggests a psychological association between bodily purity and moral purity. In three studies, we explored what we call the "Macbeth effect'' - that is, a threat to one's moral purity induces the need to cleanse oneself. This effect revealed itself through an increased mental accessibility of cleansing-related concepts, a greater desire for cleansing products, and a greater likelihood of taking antiseptic wipes. Furthermore, we showed that physical cleansing alleviates the upsetting consequences of unethical behavior and reduces threats to one's moral self-image. Daily hygiene routines such as washing hands, as simple and benign as they might seem, can deliver a powerful antidote to threatened morality, enabling people to truly wash away their sins.	Univ Toronto, Joseph L Rotman Sch Management, Dept Org Behav & HR Management, Toronto, ON M5S 3E6, Canada; Northwestern Univ, JL Kellogg Grad Sch Management, Dept Management & Org, Evanston, IL 60208 USA	University of Toronto; Northwestern University	Zhong, CB (corresponding author), Univ Toronto, Joseph L Rotman Sch Management, Dept Org Behav & HR Management, Toronto, ON M5S 3E6, Canada.	chenbo.zhong@rotman.utoronto.ca						*BIBLE, ACTS, V22; Fuller C. J., 1992, CAMPHOR FLAME POPULA; Haidt J., 1997, PSYCHOL DEV SOC, V9, P107, DOI [10.1177/097133369700900105, DOI 10.1177/097133369700900105]; Haidt J., 2004, HDB EXPT EXISTENTIAL, P322; Lakoff G., 1987, WOMEN FIRE DANGEROUS, DOI DOI 10.7208/CHICAGO/9780226471013.001.0001; Moll J, 2005, COGN BEHAV NEUROL, V18, P68, DOI 10.1097/01.wnn.0000152236.46475.a7; ROZIN P, 1994, J PERS SOC PSYCHOL, V66, P870, DOI 10.1037//0022-3514.66.5.870; SHAKESPEARE W, 1998, MACBETH; Tetlock PE, 2000, J PERS SOC PSYCHOL, V78, P853, DOI 10.1037/0022-3514.78.5.853; Wicklund RA, 1981, BASIC APPL SOC PSYCH, V2, P89, DOI 10.1207/s15324834basp0202_2	10	651	687	11	250	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	2006	313	5792					1451	1452		10.1126/science.1130726	http://dx.doi.org/10.1126/science.1130726			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	081WQ	16960010				2023-01-03	WOS:000240348700047
J	Laing, C; Hamour, S; Sheaff, M; Miller, R; Woolfson, R				Laing, Chris; Hamour, Sally; Sheaff, Michael; Miller, Ron; Woolfson, Robin			Chinese herbal uropathy and nephropathy	LANCET			English	Editorial Material									Whittington Hosp, Dept Nephrol, London N19 5NF, England; Whittington Hosp, Dept Urol, London N19 5NF, England; Royal London Hosp, Barts & London NHS Trust, Dept Histopathol, London E1 1BB, England	University of London; University College London; University of London; University College London; Barts Health NHS Trust; Royal London Hospital	Hamour, S (corresponding author), Whittington Hosp, Dept Nephrol, London N19 5NF, England.	sallyhamour@hotmail.com						CHUNG O, 2004, STANDARD        0317; DEPIERREUX M, 1994, AM J KIDNEY DIS, V24, P172, DOI 10.1016/S0272-6386(12)80178-8; Gold LS, 2003, NEW ENGL J MED, V349, P1576, DOI 10.1056/NEJM200310163491619; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2	5	46	50	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 22	2006	368	9532					338	338		10.1016/S0140-6736(06)69079-X	http://dx.doi.org/10.1016/S0140-6736(06)69079-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	067PF	16860704				2023-01-03	WOS:000239314400032
J	Bardia, A; Williamson, EE; Bauer, BA				Bardia, Aditya; Williamson, Eric E.; Bauer, Brent A.			Scarring moxibustion and religious scarification resulting in hepatitis C and hepatocellular carcinoma	LANCET			English	Editorial Material							RISK-FACTORS; TRANSMISSION; INFECTION; VIRUS		Mayo Clin, Coll Med, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Radiol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Bauer, BA (corresponding author), Mayo Clin, Coll Med, Dept Internal Med, Rochester, MN 55905 USA.	bauer.brent@mayo.edu						Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7; KIYOSAWA K, 1994, GASTROENTEROLOGY, V106, P1596, DOI 10.1016/0016-5085(94)90416-2; Murphy EL, 2000, HEPATOLOGY, V31, P756, DOI 10.1002/hep.510310329; REFETOFF S, 1994, THYROID, V4, P249, DOI 10.1089/thy.1994.4.249; Zeuzem S, 1996, J HEPATOL, V24, P3	5	2	2	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 27	2006	367	9524					1790	1790		10.1016/S0140-6736(06)68775-8	http://dx.doi.org/10.1016/S0140-6736(06)68775-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	047BE	16731275				2023-01-03	WOS:000237854000035
J	Senecal, E; Thomas, SH; Lev, MH; Schwamm, LH; Milne, LW; Gordon, J; Harris, NL; Brown, DF				Senecal, Emily; Thomas, Stephen H.; Lev, Michael H.; Schwamm, Lee H.; Milne, Leslie W.; Gordon, James; Harris, Nancy Lee; Brown, David F.			A 72-year-old woman admitted to the emergency department because of a sudden change in mental status - Acute ischemic stroke.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TISSUE-PLASMINOGEN ACTIVATOR; INTRAARTERIAL THROMBOLYSIS; HYPERACUTE STROKE; CT ANGIOGRAPHY; PERFUSION; INTUBATION; PREDICTION; ACCURACY; EFFICACY; THERAPY		Massachusetts Gen Hosp, Emergency Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Telestroke & Acute Stroke Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Surg, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Thomas, SH (corresponding author), Massachusetts Gen Hosp, Emergency Serv, Boston, MA 02114 USA.			Thomas, Stephen/0000-0003-4153-3965				*2005 AM HEART ASS, 2005, CIRCULATION S, V112, P111; Adams H, 2005, STROKE, V36, P916, DOI 10.1161/01.STR.0000163257.66207.2d; Albers GW, 2004, CHEST, V126, p483S, DOI 10.1378/chest.126.3_suppl.483S; Alberts MJ, 2000, JAMA-J AM MED ASSOC, V283, P3102, DOI 10.1001/jama.283.23.3102; Arora S, 2005, STROKE, V36, P1232, DOI 10.1161/01.STR.0000165902.18021.5b; Becker KJ, 2005, STROKE, V36, P400, DOI 10.1161/01.STR.0000153056.25397.ff; Berzin TM, 2001, STROKE, V32, P317; Chalela JA, 1999, STROKE, V30, P2366, DOI 10.1161/01.STR.30.11.2366; *COMM MASS DEP HLT, 2004, ADV B PRIM STROK SER; *COMM MASS DEP HLT, AM HOSP LIC REG; Conroy MB, 1999, STROKE, V30, P2580, DOI 10.1161/01.STR.30.12.2580; *FOOD DRUG ADM, 2004, IND US CONC MERC RET; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P3204; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; Hacke W, 2004, LANCET, V363, P768; Harrison TH, 2004, PEDIATR EMERG CARE, V20, P101, DOI 10.1097/01.pec.0000113879.10140.7f; Hunter GJ, 1998, AM J NEURORADIOL, V19, P29; Ingall TJ, 2004, STROKE, V35, P2418, DOI 10.1161/01.STR.0000140891.70547.56; Kirchhof K, 2003, RADIOLOGY, V228, P126, DOI 10.1148/radiol.2273020530; Kothari RU, 1999, ANN EMERG MED, V33, P373, DOI 10.1016/S0196-0644(99)70299-4; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; Kwiatkowski T, 2005, ANN EMERG MED, V45, P377, DOI 10.1016/j.annemergmed.2004.06.021; Lev MH, 1999, RADIOLOGY, V213, P150, DOI 10.1148/radiology.213.1.r99oc10150; Lev MH, 2001, J COMPUT ASSIST TOMO, V25, P520, DOI 10.1097/00004728-200107000-00003; Lev MH, 2001, STROKE, V32, P2021, DOI 10.1161/hs0901.095680; Liferidge Aisha T, 2004, Prehosp Emerg Care, V8, P384; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Reeves MJ, 2005, STROKE, V36, P1820, DOI 10.1161/01.STR.0000178108.54612.9e; Rosamond Wayne D, 2005, Prehosp Emerg Care, V9, P19, DOI 10.1080/10903120590891985; Schramm P, 2002, STROKE, V33, P2426, DOI 10.1161/01.STR.0000032244.03134.37; Schwamm LH, 2005, STROKE, V36, P690, DOI 10.1161/01.STR.0000158165.42884.4F; Schwamm LH, 2004, ACAD EMERG MED, V11, P1193, DOI 10.1197/j.aem.2004.08.014; Silliman SL, 2003, STROKE, V34, P729, DOI 10.1161/01.STR.0000056529.29515.B2; Smith EE, 2005, STROKE, V36, P2497, DOI 10.1161/01.STR.0000185798.78817.f3; Smith WS, 2005, STROKE, V36, P1432, DOI 10.1161/01.STR.0000171066.25248.1d; Thomas S H, 1999, Prehosp Emerg Care, V3, P310, DOI 10.1080/10903129908958960; Thomas Stephen H, 2002, Prehosp Emerg Care, V6, P210, DOI 10.1080/10903120290938562; Thomson David P, 2003, Prehosp Emerg Care, V7, P265, DOI 10.1080/10903120390936923; TOMSICK TA, 1990, AM J NEURORADIOL, V11, P473; Wang H E, 2000, Prehosp Emerg Care, V4, P14, DOI 10.1080/10903120090941560; Wang Henry E, 2004, Prehosp Emerg Care, V8, P366; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Wintermark M, 2002, ANN NEUROL, V51, P417, DOI 10.1002/ana.10136	45	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	2006	354	21					2263	2271		10.1056/NEJMcpc069007	http://dx.doi.org/10.1056/NEJMcpc069007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	045RF	16723618				2023-01-03	WOS:000237758900010
J	Berry, DA; Cirrincione, C; Henderson, IC; Citron, ML; Budman, DR; Goldstein, LJ; Martino, S; Perez, EA; Muss, HB; Norton, L; Hudis, C; Winer, EP				Berry, DA; Cirrincione, C; Henderson, IC; Citron, ML; Budman, DR; Goldstein, LJ; Martino, S; Perez, EA; Muss, HB; Norton, L; Hudis, C; Winer, EP			Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADJUVANT CHEMOTHERAPY; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; TAMOXIFEN THERAPY; TRASTUZUMAB; RECURRENCE; COMBINATION; EXPRESSION; EFFICACY	Context Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy. Objective To compare differences in benefits from adjuvant chemotherapy achieved by patients with ER-negative vs ER-positive tumors. Design, Setting, and Patients Trial data from the Cancer and Leukemia Group B and US Breast Cancer Intergroup analyzed; patient outcomes by ER status compared using hazards over time and multivariate models. Randomized trials comparing (1): 3 regimens of cyclophosphamide, doxorubicin, and fluorouracil (January 1985 to April 1991); (2) 3 doses of doxorubicin concurrent with cyclophosphamide, with or without subsequent paclitaxel (May 1994 to April 1997); (3) sequential doxorubicin, paclitaxel, and cyclophosphamide with concurrent doxorubicin and cyclophosphamide followed by paclitaxel, and also 3-week vs 2-week cycles (September 1997 to March 1999). A total of 6644 node-positive breast cancer patients received adjuvant treatment. Main Outcome Measures Disease-free and overall survival. Results For ER-negative tumors, chemotherapy improvements reduced the relative risk of recurrence by 21%, 25%, and 23% in the 3 studies, respectively, and 55% comparing the lowest dose in the first study with biweekly cycles in the third study. Corresponding relative risk reductions for ER-positive tumors treated with tamoxifen were 9%, 12%, and 8% in the 3 studies, and 26% overall. The overall mortality rate reductions associated with chemotherapy improvements were 55% and 23% among ER-negative and ER-positive patients, respectively. All individual ER-negative comparisons and no ER-positive comparisons were statistically significant. Absolute benefits due to chemotherapy were greater for patients with ER-negative compared with ER-positive tumors: 22.8% more ER-negative patients survived to 5 years disease-free if receiving chemotherapy vs 7.0% for ER-positive patients; corresponding improvements for overall survival were 16.7% vs 4.0%. Conclusion Among patients with node-positive tumors, ER-negative breast cancer, biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death by more than 50% in comparison with low-dose cyclophosphamide, doxorubicin, and fluorouracil as used in the first study.	Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Canc & Leukemia Grp B Stat Ctr, Durham, NC USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Albert Einstein Coll Med, Lake Success, NY USA; N Shore Univ Hosp, Manhasset, NY USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Angeles Clin & Res Inst, Santa Monica, CA USA; Mayo Clin & Mayo Fdn, Jacksonville, FL USA; Univ Vermont, Vermont Reg Canc Ctr, Burlington, VT USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Francisco; Yeshiva University; Northwell Health; North Shore University Hospital; Fox Chase Cancer Center; Angeles Clinic & Research Institute; Mayo Clinic; University of Vermont; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute	Berry, DA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, 1515 Holcombe Blvd,Unit 447, Houston, TX 77030 USA.	dberry@mdanderson.org	Wardley, Andrew/N-8135-2015; Hudis, Clifford/AAW-9482-2021	Wardley, Andrew/0000-0002-9639-0888; Hudis, Clifford/0000-0001-7144-8791; Norton, Larry/0000-0003-3701-9250	NCI NIH HHS [U10 CA031946, U10 CA033601, CA31946, U01 CA088278] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA088278, U10CA033601, U10CA031946] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; ALBAIN K, 2004, BREAST CANC RES T S1, V88; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Ballesteros J, 2005, J CLIN PSYCHOPHARM, V25, P127, DOI 10.1097/01.jcp.0000155826.05327.c1; Baum M, 2002, LANCET, V359, P2131; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Berry DA, 2003, AM HEART J, V145, P1036, DOI 10.1016/S0002-8703(03)00106-6; BERRY DA, 1990, BIOMETRICS, V46, P1227; Budman DR, 1998, J NATL CANCER I, V90, P1205, DOI 10.1093/jnci/90.16.1205; BUZDAR AU, 2003, 26 ANN SAN ANT BREAS; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Colleoni M, 2004, CLIN CANCER RES, V10, P6622, DOI 10.1158/1078-0432.CCR-04-0380; Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331; DOMINICI F, 2000, METANALYSIS MED HLTH, P112; Emens LA, 2004, ONCOLOGY-NY, V18, P1117; GIANNI L, 2004, J CLIN ONCOL S14, V22; Goldhirsch A, 2002, JNCI-J NATL CANCER I, V94, P1054; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Joensuu H, 2004, JAMA-J AM MED ASSOC, V292, P1064, DOI 10.1001/jama.292.9.1064; Jones Robin L, 2004, Expert Opin Drug Saf, V3, P317, DOI 10.1517/14740338.3.4.317; Mann GB, 2005, J CLIN ONCOL, V23, P5148, DOI 10.1200/JCO.2005.02.076; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Paik S, 2004, BREAST CANCER RES TR, V88, pS15; Perez EA, 2005, J CLIN ONCOL, V23, p17S; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; ROBINSON A, 2005, J CLIN ONCOL, V23, P500; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Rueckert S, 2005, EXPERT OPIN BIOL TH, V5, P853, DOI 10.1517/14712598.5.6.853; Saphner T, 1996, J CLIN ONCOL, V14, P2738, DOI 10.1200/JCO.1996.14.10.2738; Shen Y, 2005, JNCI-J NATL CANCER I, V97, P1195, DOI 10.1093/jnci/dji239; Tan AR, 2003, SEMIN ONCOL, V30, P54, DOI 10.1053/j.seminoncol.2003.08.008; Thor AD, 1998, JNCI-J NATL CANCER I, V90, P1346, DOI 10.1093/jnci/90.18.1346	34	536	571	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2006	295	14					1658	1667		10.1001/jama.295.14.1658	http://dx.doi.org/10.1001/jama.295.14.1658			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	031LY	16609087	Green Accepted, Bronze			2023-01-03	WOS:000236707300021
J	Beresford, SAA; Johnson, KC; Ritenbaugh, C; Lasser, NL; Snetselaar, LG; Black, HR; Anderson, GL; Assaf, AR; Bassford, T; Bowen, D; Brunner, RL; Brzyski, RG; Caan, B; Chlebowski, RT; Gass, M; Harrigan, RC; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Howard, BV; Hsia, J; Hubbell, FA; Jackson, RD; Kotchen, JM; Kuller, LH; LaCroix, AZ; Lane, DS; Langer, RD; Lewis, CE; Manson, JE; Margolis, KL; Mossavar-Rahmani, Y; Ockene, JK; Parker, LM; Perri, MG; Phillips, L; Prentice, RL; Robbins, J; Rossouw, JE; Sarto, GE; Stefanick, ML; Van Horn, L; Vitolins, MZ; Wactawski-Wende, J; Wallace, RB; Whitlock, E				Beresford, SAA; Johnson, KC; Ritenbaugh, C; Lasser, NL; Snetselaar, LG; Black, HR; Anderson, GL; Assaf, AR; Bassford, T; Bowen, D; Brunner, RL; Brzyski, RG; Caan, B; Chlebowski, RT; Gass, M; Harrigan, RC; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Howard, BV; Hsia, J; Hubbell, FA; Jackson, RD; Kotchen, JM; Kuller, LH; LaCroix, AZ; Lane, DS; Langer, RD; Lewis, CE; Manson, JE; Margolis, KL; Mossavar-Rahmani, Y; Ockene, JK; Parker, LM; Perri, MG; Phillips, L; Prentice, RL; Robbins, J; Rossouw, JE; Sarto, GE; Stefanick, ML; Van Horn, L; Vitolins, MZ; Wactawski-Wende, J; Wallace, RB; Whitlock, E			Low-fat dietary pattern and risk of colorectal cancer - The Women's Health Initiative randomized controlled dietary modification trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-FIBER DIET; MEAT CONSUMPTION; COLON-CANCER; BETA-CAROTENE; RECURRENCE; VEGETABLES; INTERVENTION; PREVENTION; DISEASE; FRUIT	Context Observational studies and polyp recurrence trials are not conclusive regarding the effects of a low-fat dietary pattern on risk of colorectal cancer, necessitating a primary prevention trial. Objective To evaluate the effects of a low-fat eating pattern on risk of colorectal cancer in postmenopausal women. Design, Setting, and Participants The Women's Health Initiative Dietary Modification Trial, a randomized controlled trial conducted in 48 835 postmenopausal women aged 50 to 79 years recruited between 1993 and 1998 from 40 clinical centers throughout the United States. Interventions Participants were randomly assigned to the dietary modification intervention (n = 19 541; 40%) or the comparison group (n = 29 294; 60%). The intensive behavioral modification program aimed to motivate and support reductions in dietary fat, to increase consumption of vegetables and fruits, and to increase grain servings by using group sessions, self-monitoring techniques, and other tailored and targeted strategies. Women in the comparison group continued their usual eating pattern. Main Outcome Measure Invasive colorectal cancer incidence. Results A total of 480 incident cases of invasive colorectal cancer occurred during a mean follow-up of 8.1 (SD, 1.7) years. Intervention group participants significantly reduced their percentage of energy from fat by 10.7% more than did the comparison group at 1 year, and this difference between groups was mostly maintained (8.1% at year 6). Statistically significant increases in vegetable, fruit, and grain servings were also made. Despite these dietary changes, there was no evidence that the intervention reduced the risk of invasive colorectal cancer during the follow-up period. There were 201 women with invasive colorectal cancer (0.13% per year) in the intervention group and 279 (0.12% per year) in the comparison group (hazard ratio, 1.08; 95% confidence interval, 0.90-1.29). Secondary analyses suggested potential interactions with baseline aspirin use and combined estrogen-progestin use status (P=.01 for each). Colorectal examination rates, although not protocol defined, were comparable between the intervention and comparison groups. Similar results were seen in analyses adjusting for adherence to the intervention. Conclusion In this study, a low-fat dietary pattern intervention did not reduce the risk of colorectal cancer in postmenopausal women during 8.1 years of follow-up.	Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; Univ Arizona, Tucson, AZ USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Univ Iowa, Iowa City, IA USA; Rush Univ, Med Ctr, Chicago, IL 60612 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Brown Univ, Providence, RI 02912 USA; Univ Nevada, Reno, NV 89557 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Kaiser Permanente, Div Res, Oakland, CA USA; Harbor UCLA Res & Educ Inst, Torrance, CA USA; Univ Cincinnati, Cincinnati, OH USA; Univ Hawaii, Honolulu, HI 96822 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ N Carolina, Chapel Hill, NC USA; Wayne State Univ, Sch Med, Hutzel Hosp, Detroit, MI USA; Howard Univ, MedStar Res Inst, Washington, DC 20059 USA; George Washington Univ, Washington, DC USA; Univ Calif Irvine, Irvine, CA USA; Ohio State Univ, Columbus, OH 43210 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Univ Pittsburgh, Pittsburgh, PA USA; SUNY Stony Brook, Stony Brook, NY 11794 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Alabama Birmingham, Birmingham, AL USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; Univ Minnesota, Minneapolis, MN USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Univ Massachusetts, Fallon Clin, Worcester, MA 01605 USA; Univ Miami, Miami, FL 33152 USA; Univ Florida, Gainesville, FL USA; Emory Univ, Atlanta, GA 30322 USA; Univ Calif Davis, Sacramento, CA 95817 USA; NHLBI, Bethesda, MD 20892 USA; Univ Wisconsin, Madison, WI USA; Stanford Prevent Res Ctr, Stanford, CA USA; Northwestern Univ, Chicago, IL 60611 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; Univ Buffalo, Buffalo, NY USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA	University of Washington; University of Washington Seattle; University of Tennessee System; University of Tennessee Health Science Center; University of Arizona; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Iowa; Rush University; Fred Hutchinson Cancer Center; Brown University; Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Texas System; University of Texas Health San Antonio; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University System of Ohio; University of Cincinnati; University of Hawaii System; Baylor College of Medicine; University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University; Howard University; George Washington University; University of California System; University of California Irvine; University System of Ohio; Ohio State University; Medical College of Wisconsin; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities; Yeshiva University; Albert Einstein College of Medicine; University of Massachusetts System; University of Massachusetts Worcester; University of Miami; State University System of Florida; University of Florida; Emory University; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Wisconsin System; University of Wisconsin Madison; Stanford University; Northwestern University; Wake Forest University; Wake Forest Baptist Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Kaiser Permanente	Beresford, SAA (corresponding author), Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA.	beresfrd@u.washington.edu	Wactawski-Wende, Jean/AGH-5457-2022	Wactawski-Wende, Jean/0000-0003-3096-9595; Ritenbaugh, Cheryl/0000-0002-3307-2727; Caan, Bette/0000-0002-5803-310X; Margolis, Karen/0000-0003-1862-7402; Bowen, Deborah/0000-0002-5177-8520; Hays-Grudo, Jennifer/0000-0002-8107-1243; Perri, Michael/0000-0003-3651-1542; Mossavar-Rahmani, Yasmin/0000-0002-9214-6124				Albanes D, 2000, CANCER CAUSE CONTROL, V11, P197, DOI 10.1023/A:1008936214087; Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7; [Anonymous], [No title captured]; Bingham SA, 2003, LANCET, V361, P1496, DOI 10.1016/S0140-6736(03)13174-1; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; Bowen D, 2002, J AM DIET ASSOC, V102, P1631, DOI 10.1016/S0002-8223(02)90347-0; BURKITT DP, 1969, LANCET, V2, P1229, DOI 10.1016/S0140-6736(69)90757-0; Carroll K K, 1975, Prog Biochem Pharmacol, V10, P308; Chao A, 2005, JAMA-J AM MED ASSOC, V293, P172, DOI 10.1001/jama.293.2.172; Chin BCH, 2004, NUTR CANCER, V49, P49, DOI 10.1207/s15327914nc4901_7; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; Gifford KD, 2002, AM J MED, V113, P89, DOI 10.1016/S0002-9343(01)00996-2; Giovannucci E, 2003, J WOMEN HEALTH GEN-B, V12, P173, DOI 10.1089/154099903321576574; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; Harnack L, 2002, AM J CLIN NUTR, V76, P889, DOI 10.1093/ajcn/76.4.889; Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5; Heini AF, 1997, AM J MED, V102, P259, DOI 10.1016/S0002-9343(96)00456-1; Hofstad B, 1998, DIGESTION, V59, P148, DOI 10.1159/000007480; Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P655, DOI 10.1001/jama.295.6.655; Howe GR, 1997, CANCER CAUSE CONTROL, V8, P215, DOI 10.1023/A:1018476414781; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; Iacopetta B, 2002, INT J CANCER, V101, P403, DOI 10.1002/ijc.10635; INSULL W, 1990, ARCH INTERN MED, V150, P421, DOI 10.1001/archinte.150.2.421; Kim MK, 2005, INT J CANCER, V115, P790, DOI 10.1002/ijc.20943; Lanza E, 2001, AM J CLIN NUTR, V74, P387; Larsson SC, 2005, INT J CANCER, V113, P829, DOI 10.1002/ijc.20658; Law M, 2000, AM J CLIN NUTR, V72, p1291S, DOI 10.1093/ajcn/72.5.1291s; MACLENNAN R, 1995, J NATL CANCER I, V87, P1760, DOI 10.1093/jnci/87.23.1760; Mathew A, 2004, EUR J CANCER PREV, V13, P159, DOI 10.1097/01.cej.0000130022.23806.7b; MCKEOWNEYSSEN GE, 1994, J CLIN EPIDEMIOL, V47, P525, DOI 10.1016/0895-4356(94)90299-2; MCMICHAEL AJ, 1988, CANCER RES, V48, P751; Norat T, 2005, J NATL CANCER I, V97, P906, DOI 10.1093/jnci/dji164; Norat T, 2002, INT J CANCER, V98, P241, DOI 10.1002/ijc.10126; Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6; Patterson RE, 2004, J AM DIET ASSOC, V104, P654, DOI 10.1016/j.jada.2004.01.014; Peters U, 2003, LANCET, V361, P1491, DOI 10.1016/S0140-6736(03)13173-X; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; Prentice RL, 2006, JAMA-J AM MED ASSOC, V295, P629, DOI 10.1001/jama.295.6.629; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; Riboli E, 2003, AM J CLIN NUTR, V78, p559S, DOI 10.1093/ajcn/78.3.559S; Ries L., 2005, SEER CANC STAT REV 1; Ritenbaugh C, 2003, ANN EPIDEMIOL, V13, pS87, DOI 10.1016/S1047-2797(03)00044-9; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Smith-Warner SA, 2002, AM J EPIDEMIOL, V155, P1104, DOI 10.1093/aje/155.12.1104; STEINMETZ KA, 1993, INT J CANCER, V53, P711, DOI 10.1002/ijc.2910530502; STEINMETZ KA, 1994, AM J EPIDEMIOL, V139, P1; THOMAS DB, 1987, CANCER RES, V47, P5771; Tinker Lesley Fels, 1996, P510; TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650; US Department of Health and Human Services and US Department of Agriculture, 2005, DIET GUID AM; Winawer Sidney J., 1999, American Journal of Medicine, V106, p3S, DOI 10.1016/S0002-9343(98)00338-6; Wu XC, 2004, CANCER EPIDEM BIOMAR, V13, P1215; Yang QH, 1997, AM J EPIDEMIOL, V146, P713	56	282	288	1	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2006	295	6					643	654		10.1001/jama.295.6.643	http://dx.doi.org/10.1001/jama.295.6.643			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010DX	16467233				2023-01-03	WOS:000235168200024
J	Buytaert, E; Callewaert, G; Hendrickx, N; Scorrano, L; Hartmann, D; Missiaen, L; Vandenheede, JR; Heirman, I; Grooten, J; Agostinis, P				Buytaert, Esther; Callewaert, Geert; Hendrickx, Nico; Scorrano, Luca; Hartmann, Dieter; Missiaen, Ludwig; Vandenheede, Jackie R.; Heirman, Ingeborg; Grooten, Johan; Agostinis, Patrizia			Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy	FASEB JOURNAL			English	Article							THAPSIGARGIN-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; INTRACELLULAR CA2+; SIGNALING PATHWAYS; HELA-CELLS; BCL-2; CALCIUM; AUTOPHAGY; STORES; ACTIVATION	Both the commitment event and the modality of cell death in photodynamic therapy (PDT) remain poorly defined. We report that PDT with endoplasmic reticulum (ER)-associating hypericin leads to an immediate loss of SERCA2 protein levels, causing disruption of Ca2+ homeostasis and cell death. Protection of SERCA2 protein rescues ER-Ca2+ levels and prevents cell death, suggesting that SERCA2 photodestruction with consequent incapability of the ER to maintain intracellular Ca2+ homeostasis is causal to cell killing. Apoptosis is rapidly initiated after ER-Ca2+ depletion and strictly requires the BAX/BAK gateway at the mitochondria. Bax(-/-)Bak(-/-) double-knockout (DKO) cells are protected from apoptosis but undergo autophagy-associated cell death as revealed by electron microscopy and biochemical analysis. Autophagy inhibitors, but not caspase antagonists, significantly reduce death of DKO cells, suggesting that sustained autophagy is lethal. Thus, following ER photodamage and consequent disruption of Ca2+ homeostasis, BAX and BAK proteins model PDT-mediated cell killing, which is executed through apoptosis in their presence or via an autophagic pathway in their absence.	Catholic Univ Louvain, Dept Mol & Cell Biol, Fac Med, B-1348 Louvain, Belgium; Dulbecco Telethon Inst, Venetian Inst Mol Med, Padua, Italy; Univ Ghent, B-9000 Ghent, Belgium	Universite Catholique Louvain; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Veneto Institute Molecular Medicine; Ghent University	Agostinis, P (corresponding author), Div Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Patricia.Agostinis@med.kuleuven.ac.be	Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020; Scorrano, Luca/K-3967-2019; Scorrano, Luca/A-6652-2008	Agostinis, Patrizia/0000-0003-1314-2115; Scorrano, Luca/0000-0002-8515-8928; Scorrano, Luca/0000-0002-8515-8928				Agostinis P, 2004, PHOTOCH PHOTOBIO SCI, V3, P721, DOI 10.1039/b315237e; Agostinis P, 2002, INT J BIOCHEM CELL B, V34, P221, DOI 10.1016/S1357-2725(01)00126-1; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Chae HJ, 1999, BONE, V25, P453, DOI 10.1016/S8756-3282(99)00196-9; Chen B, 2002, INT J CANCER, V98, P284, DOI 10.1002/ijc.10175; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Chiu SM, 2003, BRIT J CANCER, V89, P1590, DOI 10.1038/sj.bjc.6601298; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Delaey EM, 1999, INT J ONCOL, V14, P759; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Granville DJ, 2001, CELL CALCIUM, V30, P343, DOI 10.1054/ceca.2001.0243; Inanami O, 1999, PHOTOCHEM PHOTOBIOL, V70, P650, DOI 10.1562/0031-8655(1999)070<0650:EOBAAF>2.3.CO;2; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaplan P, 2003, MOL CELL BIOCHEM, V248, P41, DOI 10.1023/A:1024145212616; Kuhn H, 2002, FREE RADICAL BIO MED, V33, P154, DOI 10.1016/S0891-5849(02)00855-9; Lemasters JJ, 2002, ANTIOXID REDOX SIGN, V4, P769, DOI 10.1089/152308602760598918; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; MISSIAEN L, 1994, J BIOL CHEM, V269, P5917; Nguyen HN, 2002, BRAIN RES, V924, P159, DOI 10.1016/S0006-8993(01)03229-2; Nilsson E, 1997, HISTOCHEM J, V29, P857, DOI 10.1023/A:1026441907803; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Oakes SA, 2003, BIOCHEM PHARMACOL, V66, P1335, DOI 10.1016/S0006-2952(03)00482-9; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; PENNING LC, 1992, BIOCHIM BIOPHYS ACTA, V1107, P255, DOI 10.1016/0005-2736(92)90412-F; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; RIZZUTO R, 2004, SCI STKE, V215, pRE1, DOI DOI 10.1126/STKE.2152004RE1; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Wei HF, 1998, J NEUROCHEM, V70, P2305; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitacre CM, 2002, CANCER LETT, V179, P43, DOI 10.1016/S0304-3835(01)00853-9; Yamaguchi H, 2003, CANCER RES, V63, P1483; ZDOLSEK JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P67, DOI 10.1111/j.1751-1097.1990.tb01685.x; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	51	189	196	0	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					756	+		10.1096/fj.05-4305fje	http://dx.doi.org/10.1096/fj.05-4305fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16455754	Green Published			2023-01-03	WOS:000237698700041
J	Voss, M; Ingram, JN; Haggard, P; Wolpert, DM				Voss, M; Ingram, JN; Haggard, P; Wolpert, DM			Sensorimotor attenuation by central motor command signals in the absence of movement	NATURE NEUROSCIENCE			English	Article							SOMATOSENSORY-EVOKED-POTENTIALS; VOLUNTARY MOVEMENT; HUMAN BRAIN; STIMULATION; PERCEPTION; SUPPRESSION; DELAY; TIME	Voluntary actions typically produce suppression of afferent sensation from the moving body part. We used transcranial magnetic stimulation to delay the output of motor commands from the motor cortex during voluntary movement. We show attenuation of sensation during this delay, in the absence of movement. We conclude that sensory suppression mainly relies on central signals related to the preparation for movement and that these signals are upstream of primary motor cortex.	Inst Neurol, Sobell Dept Motor Neurosci, London WC1N 3BG, England; Inst Cognit Neurosci, London WC1N 3AR, England; Dept Psychol, London WC1N 3AR, England	University of London; University College London; University of London; University College London	Voss, M (corresponding author), Inst Neurol, Sobell Dept Motor Neurosci, Queen Sq, London WC1N 3BG, England.	martin.voss@charite.de	Haggard, Patrick/A-5081-2010	Voss, Martin/0000-0002-5221-4647; Haggard, Patrick/0000-0001-7798-793X; Wolpert, Daniel/0000-0003-2011-2790	Wellcome Trust [077730] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Blakemore SJ, 1999, J COGNITIVE NEUROSCI, V11, P551, DOI 10.1162/089892999563607; CHAPMAN CE, 1987, EXP BRAIN RES, V68, P516; COHEN LG, 1987, BRAIN, V110, P451, DOI 10.1093/brain/110.2.451; DAY BL, 1989, BRAIN, V112, P649, DOI 10.1093/brain/112.3.649; Haggard P, 2004, COGNITIVE BRAIN RES, V19, P52, DOI 10.1016/j.cogbrainres.2003.10.018; PALMER E, 1994, J PHYSIOL-LONDON, V481, P509, DOI 10.1113/jphysiol.1994.sp020459; PASCUALLEONE A, 1994, ELECTROEN CLIN NEURO, V93, P230, DOI 10.1016/0168-5597(94)90045-0; Seki K, 2003, NAT NEUROSCI, V6, P1309, DOI 10.1038/nn1154; SEYAL M, 1992, ELECTROEN CLIN NEURO, V85, P397, DOI 10.1016/0168-5597(92)90053-E; Shergill SS, 2003, SCIENCE, V301, P187, DOI 10.1126/science.1085327; Shimazu H, 1999, NEUROREPORT, V10, P2457, DOI 10.1097/00001756-199908200-00004; VANHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464; Wasaka T, 2003, NEUROIMAGE, V20, P1830, DOI 10.1016/S1053-8119(03)00442-7; Williams SR, 2002, J NEUROPHYSIOL, V88, P1968, DOI 10.1152/jn.2002.88.4.1968; Ziemann U, 1997, BRAIN RES, V744, P32, DOI 10.1016/S0006-8993(96)01062-1	15	151	151	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1097-6256			NAT NEUROSCI	Nat. Neurosci.	JAN	2006	9	1					26	27		10.1038/nn1592	http://dx.doi.org/10.1038/nn1592			2	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	997ZQ	16311591	Green Accepted			2023-01-03	WOS:000234288000013
J	Chen, D; Steele, AD; Lindquist, S; Guarente, L				Chen, D; Steele, AD; Lindquist, S; Guarente, L			Increase in activity during calorie restriction requires Sirt1	SCIENCE			English	Article							LONGEVITY; RATS		MIT, Dept Biol, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	leng@mit.edu			NATIONAL INSTITUTE ON AGING [R01AG011119, R37AG011119] Funding Source: NIH RePORTER; NIA NIH HHS [AG11119] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		HOLLOSZY JO, 1991, J APPL PHYSIOL, V70, P1529, DOI 10.1152/jappl.1991.70.4.1529; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; McCarter RJM, 1997, AGING-CLIN EXP RES, V9, P73, DOI 10.1007/BF03340130; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Weed JL, 1997, PHYSIOL BEHAV, V62, P97, DOI 10.1016/S0031-9384(97)00147-9; Weindruch R., 1988, RETARDATION AGING DI	6	347	373	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	2005	310	5754					1641	1641		10.1126/science.1118357	http://dx.doi.org/10.1126/science.1118357			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	993NV	16339438				2023-01-03	WOS:000233961700034
J	Custer, B; Busch, MP; Marfin, AA; Petersen, LR				Custer, B; Busch, MP; Marfin, AA; Petersen, LR			The cost-effectiveness of screening the u.S. blood supply for West Nile virus	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; TRANSMISSION; TRANSFUSION; DONATION; HEALTH; RECOMMENDATIONS; MEDICINE; PANEL; HCV	Background: The spread of West Nile virus across North America and evidence of transmission by transfusion prompted the U.S. Food and Drug Administration to encourage the development of methods to screen the blood supply. Objective: To assess the cost-effectiveness of nucleic acid amplification testing for West Nile virus in the U.S. blood supply. Design: Markov cohort simulation. Data Sources: Outcome probabilities estimated from nucleic acid testing done for West Nile virus in 2003, data from the Centers for Disease Control and Prevention, and published literature. Costs were taken from an economic study of West Nile virus infection and from estimated test costs. Target Populations: Transfusion recipients, 60 years of age or older, with and without underlying immunocompromise. Time Horizon: Lifetime. Perspective: Societal. Interventions: The authors compared 6 strategies, taking into consideration minipool (pools of 6 to 16 donations) versus individual donation testing, and the geographic and seasonal nature of West Nile virus activity. Outcome Measures: Costs and effects of each strategy based on the prevention of transfusion-transmitted West Nile virus. Results of Base-Case Analysis: The cost-effectiveness of annual, national minipool testing was $483 000 per quality-adjusted life-year (QALY), whereas the cost-effectiveness of annual, national individual donation testing was $897 000/QALY. The cost-effectiveness of targeted individual donation testing in an area experiencing an outbreak coupled with minipool testing elsewhere was $520 000/QALY. Results of Sensitivity Analysis: in 1-way analyses, the most important influences were the prevalence of West Nile virus and the cost of minipool testing and individual donation testing. The 95% range of results from probabilistic sensitivity analysis for targeted individual donation testing was $256 000 to $1 044 000/ QALY. Limitations: The Outcomes of West Nile virus infection were based on data from the general population rather than from the population who received transfusions. The results are most useful in the context of geographically focused outbreaks of West Nile virus infection. Conclusions: Using targeted individual donation testing to interdict blood donations that are positive for the West Nile virus is relatively cost-effective but is highly dependent on West Nile virus prevalence.	Blood Syst Res Inst, San Francisco, CA 94118 USA	Vitalant; Vitalant Research Institute	Custer, B (corresponding author), Blood Syst Res Inst, 270 Mason Ave, San Francisco, CA 94118 USA.	bcuster@bloodsystems.org						AuBuchon JP, 1997, TRANSFUSION, V37, P45, DOI 10.1046/j.1537-2995.1997.37197176950.x; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; BUSCH MP, 2005, IN PRESS N ENGL J ME; Custer B, 2004, TRANSFUSION, V44, P1547, DOI 10.1111/j.0041-1132.2004.04227.x; Grosse S.D., 2003, PREVENTION EFFECTIVE, V2nd ed., P245; HOFFER S, 1998, PUBLICATION FEDERAL; Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987; Jackson BR, 2003, TRANSFUSION, V43, P721, DOI 10.1046/j.1537-2995.2003.00392.x; Jackson BR, 2000, TRANSFUSION, V40, P1063, DOI 10.1046/j.1537-2995.2000.40091063.x; Kleinman S, 2005, TRANSFUSION, V45, P469, DOI 10.1111/j.0041-1132.2005.04315.x; LLEWELYN C, 2004, EUR 19 OCT 2004 TRAN; Marshall DA, 2004, VOX SANG, V86, P28, DOI 10.1111/j.0042-9007.2004.00379.x; Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969; Petersen LR, 2004, NEW ENGL J MED, V351, P2257, DOI 10.1056/NEJMp048261; Siegel JE, 1997, PHARMACOECONOMICS, V11, P159, DOI 10.2165/00019053-199711020-00005; Stramer SL, 2004, NEW ENGL J MED, V351, P760, DOI 10.1056/NEJMoa040085; STRAMER SL, 2005, IN PRESS N ENGL J ME; *US DEP HHS FDA CT, 2002, WORKSH DEV DON SCREE; *US DEP HHS US FDA, 2005, DRAFT GUID IND ASS D; Wallace EL, 1998, TRANSFUSION, V38, P625, DOI 10.1046/j.1537-2995.1998.38798346630.x; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Weinstein MC, 1980, CLIN DECISION ANAL; Winkelmayer WC, 2002, MED DECIS MAKING, V22, P417, DOI 10.1177/027298902236927; Zohrabian A, 2004, EMERG INFECT DIS, V10, P1736, DOI 10.3201/eid1010.030925; 2003, MMWR MORB MORTAL WKL, V52, P769	26	58	61	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 4	2005	143	7					486	492		10.7326/0003-4819-143-7-200510040-00007	http://dx.doi.org/10.7326/0003-4819-143-7-200510040-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970FM	16204161				2023-01-03	WOS:000232290600003
J	Okie, S				Okie, S			Physician-assisted suicide - Oregon and beyond	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		COLBURN D, 2005, OREGONIAN       0304, pA1; Ganzini L, 2001, JAMA-J AM MED ASSOC, V285, P2363, DOI 10.1001/jama.285.18.2363; Tolle SW, 2004, J CLIN ETHIC, V15, P111	3	23	23	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 21	2005	352	16					1627	1630		10.1056/NEJMp058004	http://dx.doi.org/10.1056/NEJMp058004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	918CE	15843663				2023-01-03	WOS:000228515200001
J	Wilson, T; Buck, D; Ham, C				Wilson, T; Buck, D; Ham, C			Rising to the challenge: will the NHS support people with long term conditions?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE; MANAGEMENT	The NHS is waking to the challenge of chronic diseases. Three researchers who have worked in the Department of Health discuss how the NHS might rise to the challenge of better supporting people with long term conditions.	Mill Stream Surg, Wallingford OX10 6RL, Oxon, England; Dept Hlth, London SW1A 2NL, England; Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Wilson, T (corresponding author), Mill Stream Surg, Wallingford OX10 6RL, Oxon, England.	tim.wilson@gp-k84036.nhs.uk						Berwick DM, 2002, BRIT MED J, V324, P142; Caminal J, 2004, EUR J PUBLIC HEALTH, V14, P246, DOI 10.1093/eurpub/14.3.246; *CLIN SERV COMM CH, 2004, REP JOINT WORK PART; Grumbach Kevin, 2003, Ann Fam Med, V1, P4, DOI 10.1370/afm.47; *HM TREAS, 2005, PUBL SERV PERF; Hutt R, 2004, CASE MANAGING LONG T; Johri M, 2003, INT J GERIATR PSYCH, V18, P222, DOI 10.1002/gps.819; KENNEDY A, 2004, NAT EV EXP PAT PROGR; LAWRENCE S, 2004, E WEEK          0803; Maynard A, 2003, BRIT J GEN PRACT, V53, P754; MEADS G, 2003, PRIMARY CARE REPORT, V5, P10; *NAT PRIM CAR TRUS, CASTL HLTH CTR CHRON; Newman S, 2004, LANCET, V364, P1523, DOI 10.1016/S0140-6736(04)17277-2; Roland M, 2005, BRIT MED J, V330, P289, DOI 10.1136/bmj.330.7486.289; *SECR STAT HLTH, 2004, NHS IMPR PLAN 2004; Seddon ME, 2001, QUAL HEALTH CARE, V10, P152, DOI 10.1136/qhc.0100152..; Smith R, 2003, BRIT MED J, V327, P1239, DOI 10.1136/bmj.327.7426.1239; Stevens S, 2004, HEALTH AFFAIR, V23, P37, DOI 10.1377/hlthaff.23.3.37; Stuteley H, 2002, BRIT J GEN PRACT, V52, pS44; 2002, IMPROVING CHRONIC IL	20	61	61	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	2005	330	7492					657	661		10.1136/bmj.330.7492.657	http://dx.doi.org/10.1136/bmj.330.7492.657			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909LP	15775000	Green Published			2023-01-03	WOS:000227861700033
J	Levin, MH; Sullivan, S; Nielson, D; Yang, BX; Finkbeiner, WE; Verkman, AS				Levin, Marc H.; Sullivan, Shannon; Nielson, Dennis; Yang, Baoxue; Finkbeiner, Walter E.; Verkman, A. S.			Hypertonic saline therapy in cystic fibrosis - Evidence against the proposed mechanism involving aquaporins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG FLUID TRANSPORT; MUCOCILIARY CLEARANCE; WATER PERMEABILITY; INHALED MANNITOL; MUCUS CLEARANCE; SURFACE LIQUID; AMILORIDE; INHALATION; CHANNELS; SPUTUM	Recent data indicate the clinical benefit of nebulized hypertonic saline in cystic fibrosis lung disease, with a proposed mechanism involving sustained increase in airway surface liquid volume. To account for the paradoxical observation that amiloride suppresses the beneficial effect of hypertonic saline, it has been previously concluded (Donaldson, S. H., Bennett, W. D., Zeman, K. L., Knowles, M. R., Tarran, R., and Boucher, R. C. (2006) N. Engl. J. Med. 354, 241 - 250) that amiloride-inhibitable aquaporin (AQP) water channels in airway epithelia modulate airway surface liquid volume. Here, we have characterized water permeability and amiloride effects in well differentiated, primary cultures of human airway epithelial cells, stably transfected Fisher rat thyroid epithelial cells expressing individual airway/lung AQPs, and perfused mouse lung. We found high transepithelial water permeability (P-f, 54 +/- 5 mu m/s) in airway epithelial cells that was weakly temperature-dependent and inhibited by > 90% by reduced pH in the basal membrane-facing solution. Reverse transcription-PCR and immunofluorescence suggested the involvement of AQPs 3, 4, and 5 in high airway water permeability. Experiments using several sensitive measurement methods indicated that amiloride does not inhibit water permeability in non-cystic fibrosis (non-CF) or CF airway epithelia, AQP-transfected Fisher rat thyroid cells, or intact lung. Our data provide evidence against the mechanism proposed by Donaldson et al. to account for the effects of amiloride and hypertonic saline in CF lung disease, indicating the need to identify alternate mechanisms.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124, DK72517] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574, P30EY002162] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517, R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APP EM, 1990, AM REV RESPIR DIS, V141, P605, DOI 10.1164/ajrccm/141.3.605; Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; Borok Z, 2002, J APPL PHYSIOL, V93, P2199, DOI 10.1152/japplphysiol.01171.2001; Carter EP, 1996, J GEN PHYSIOL, V108, P133, DOI 10.1085/jgp.108.3.133; Daviskas E, 1997, EUR RESPIR J, V10, P2449, DOI 10.1183/09031936.97.10112449; Daviskas E, 2005, RESPIROLOGY, V10, P46, DOI 10.1111/j.1440-1843.2005.00659.x; Daviskas E, 1996, EUR RESPIR J, V9, P725, DOI 10.1183/09031936.96.09040725; Donaldson SH, 2006, NEW ENGL J MED, V354, P241, DOI 10.1056/NEJMoa043891; Durairaj L, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-13; Elkins MR, 2006, NEW ENGL J MED, V354, P229, DOI 10.1056/NEJMoa043900; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M; Fang X, 2002, J GEN PHYSIOL, V119, P199, DOI 10.1085/jgp.119.2.199; Feng W, 1998, AM J RESP CRIT CARE, V157, P710, DOI 10.1164/ajrccm.157.3.9703059; FOLKESSON HG, 1994, P NATL ACAD SCI USA, V91, P4970, DOI 10.1073/pnas.91.11.4970; Folkesson HG, 1996, J CLIN INVEST, V97, P664, DOI 10.1172/JCI118463; Fulcher M Leslie, 2005, Methods Mol Med, V107, P183; HASEGAWA H, 1994, AM J PHYSIOL, V266, pC893, DOI 10.1152/ajpcell.1994.266.4.C893; Hirsh AJ, 2004, J PHARMACOL EXP THER, V311, P929, DOI 10.1124/jpet.104.071886; King LS, 1997, AM J PHYSIOL-CELL PH, V273, pC1541, DOI 10.1152/ajpcell.1997.273.5.C1541; King M, 1997, AM J RESP CRIT CARE, V156, P173, DOI 10.1164/ajrccm.156.1.9512074; Kreda SM, 2001, AM J RESP CELL MOL, V24, P224, DOI 10.1165/ajrcmb.24.3.4367; Levin MH, 2004, INVEST OPHTH VIS SCI, V45, P4423, DOI 10.1167/iovs.04-0816; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Matthay MA, 1996, AM J PHYSIOL-LUNG C, V270, pL487, DOI 10.1152/ajplung.1996.270.4.L487; PAVIA D, 1978, AM REV RESPIR DIS, V117, P199; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Pedersen PS, 2005, PFLUG ARCH EUR J PHY, V451, P464, DOI 10.1007/s00424-005-1484-5; Robinson M, 1996, AM J RESP CRIT CARE, V153, P1503, DOI 10.1164/ajrccm.153.5.8630593; Robinson M, 1999, EUR RESPIR J, V14, P678, DOI 10.1034/j.1399-3003.1999.14c30.x; Robinson M, 1997, THORAX, V52, P900, DOI 10.1136/thx.52.10.900; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Sajjan U, 2004, J HEART LUNG TRANSPL, V23, P1382, DOI 10.1016/j.healun.2003.09.023; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573; Sood N, 2003, AM J RESP CRIT CARE, V167, P158, DOI 10.1164/rccm.200204-293OC; Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519; Wills PJ, 1997, J CLIN INVEST, V99, P9, DOI 10.1172/JCI119138; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; Zabner J, 2000, P NATL ACAD SCI USA, V97, P11614, DOI 10.1073/pnas.97.21.11614; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	42	43	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25803	25812		10.1074/jbc.M604332200	http://dx.doi.org/10.1074/jbc.M604332200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829520	hybrid			2023-01-03	WOS:000240031300082
J	Danel, C; Moh, R; Minga, A; Anzian, A; Ba-Gomis, O; Kanga, C; Nzunetu, G; Gabillard, D; Rouet, F; Sorho, S; Chaix, ML; Eholie, S; Menan, H; Sauvageot, D; Bissagnene, E; Salamon, R; Anglaret, X				Danel, Christine; Moh, Raoul; Minga, Albert; Anzian, Amani; Ba-Gomis, Olivier; Kanga, Constance; Nzunetu, Gustave; Gabillard, Delphine; Rouet, Francois; Sorho, Souleymane; Chaix, Marie-Laure; Eholie, Serge; Menan, Herve; Sauvageot, Delphine; Bissagnene, Emmanuel; Salamon, Roger; Anglaret, Xavier		Trivacan ANRS 1269 Trial Grp	CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial	LANCET			English	Article							T-CELLS; HIV-1-INFECTED PATIENTS; THERAPY; COHORT; COTRIMOXAZOLE; MUTATIONS; DYNAMICS; IMMUNITY; ABIDJAN; REGIMEN	Background Structured treatment interruptions of highly-active antiretroviral therapy (HAART) might be particularly relevant for sub-Saharan Africa, where cost-saving strategies could help to increase the number of patients on HAART. We did a randomised trial of structured treatment interruption in Abidjan, Cote d'Ivoire. Methods HIV-infected adults were randomised to receive continuous HAART (CT), CD4-guided HAART (CD4GT) with interruption and reintroduction thresholds at 350 and 250 cells per mm(3), respectively, or 2-months-off, 4-months-on HAART. Primary endpoints were death and severe morbidity (any WHO stage 3 or 4 events and any events leading to death) at month 24. We report data from the CT and CD4GT groups until Oct 31, 2005, when the data safety monitoring board recommended to prematurely stop the CD4GT arm. Analyses were intention-to-treat. This study is registered at ClinicalTrials.gov, number NCT00158405. Results 326 adults (median CD4 count nadir 272 per mm(3)) were randomised to the CT or CD4GT groups and followed up for median of 20 months. Incidence of mortality (per 100 person-years) was not different between groups (CT 0.6, CD4GT 1.2; p=0.57). Incidence of severe morbidity (per 100 person-years) was higher in the CDG4T group (17.6) than in the CT group (6.7; p=0.001). The most frequent severe events were invasive bacterial diseases. 79% of severe morbidity episodes occurred in patients with CD4 count 200-500 per mm(3). Conclusion Patients on CD4GT had severe morbidity rates 2.5-fold higher than those on CT This difference was mainly due to high rates of common diseases in patients with CD4 count 200-500 per mm(3). This CD4-guided structured treatment interruption strategy should not be recommended in Abidjan.	Univ Bordeaux 2, INSERM, U593, F-33076 Bordeaux, France; Programme PAC CI, Abidjan, Cote Ivoire; Ctr Hosp Univ Treichville, Serv Malad Infect & Trop, Abidjan, Cote Ivoire; Ctr Hosp Univ Treichville, Ctr Diagnost & Rech SIDA, Abidjan, Cote Ivoire; Ctr Hosp Univ Necker, Serv Virol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Anglaret, X (corresponding author), Univ Bordeaux 2, INSERM, U593, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	Xavier.Anglaret@isped.u-bordeaux2.fr	Anglaret, Xavier/T-2757-2019; Anglaret, Xavier/F-7333-2013; Eholie, Serge/T-6008-2019; Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427; Moh, Desmorys Raoul/0000-0002-1678-3340; Anglaret, Xavier/0000-0003-3319-8423				Ananworanich J, 2005, JAIDS-J ACQ IMM DEF, V39, P523; Ananworanich J, 2003, AIDS, V17, pF33, DOI 10.1097/00002030-200310170-00001; ANANWORANICH J, 2006, 13 C RETR OPP INF; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Anglaret X, 2003, AIDS, V17, P575, DOI 10.1097/00002030-200303070-00013; [Anonymous], 13 C RETR OPP INF DE; Arnedo-Valero M, 2005, CLIN INFECT DIS, V41, P883, DOI 10.1086/432881; Boschi A, 2004, AIDS, V18, P2381; D'Offizi G, 2002, AIDS, V16, P2431, DOI 10.1097/00002030-200212060-00008; Danel C, 2006, JAIDS-J ACQ IMM DEF, V42, P29, DOI 10.1097/01.qai.0000219777.04927.50; Dybul M, 2001, P NATL ACAD SCI USA, V98, P15161, DOI 10.1073/pnas.261568398; Dybul Mark, 2002, Curr Infect Dis Rep, V4, P175, DOI 10.1007/s11908-002-0059-2; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Fagard C, 2003, ARCH INTERN MED, V163, P1220, DOI 10.1001/archinte.163.10.1220; Fischer M, 2003, AIDS, V17, P195, DOI 10.1097/00002030-200301240-00009; Garcia F, 1999, AIDS, V13, pF79, DOI 10.1097/00002030-199907300-00002; Garcia F, 2001, AIDS, V15, pF29, DOI 10.1097/00002030-200106150-00002; Gilks CF, 1996, LANCET, V347, P718, DOI 10.1016/S0140-6736(96)90076-8; Hatano H, 2000, AIDS, V14, P1935, DOI 10.1097/00002030-200009080-00008; Hoen B, 2005, JAIDS-J ACQ IMM DEF, V40, P307, DOI 10.1097/01.qai.0000182628.66713.31; *INT AIDS SOC US, HIV DRUGS RES MUT; Lori F, 2001, JAMA-J AM MED ASSOC, V286, P2981, DOI 10.1001/jama.286.23.2981; Maggiolo F, 2004, AIDS, V18, P439, DOI 10.1097/00002030-200402200-00010; MARCHOU B, 2006, 13 C RETR OPP INF; Martinez-Picado J, 2002, AIDS, V16, P895, DOI 10.1097/00002030-200204120-00009; Martini F, 2002, J INFECT DIS, V186, P847, DOI 10.1086/342410; Metzner KJ, 2003, J INFECT DIS, V188, P1433, DOI 10.1086/379215; Moh R, 2005, ANTIVIR THER, V10, P615; Oxenius A, 2002, P NATL ACAD SCI USA, V99, P13747, DOI 10.1073/pnas.202372199; Pasquier C, 2001, J VIROL METHODS, V94, P45, DOI 10.1016/S0166-0934(01)00272-5; REID P, 2004, 15 INT AIDS C 11 16; Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005; Ruiz L, 2000, AIDS, V14, P397, DOI 10.1097/00002030-200003100-00013; Ruiz L, 2001, AIDS, V15, pF19, DOI 10.1097/00002030-200106150-00001; Sonnenberg P, 2005, J INFECT DIS, V191, P150, DOI 10.1086/426827; Tarwater PM, 2003, CLIN INFECT DIS, V37, P1541, DOI 10.1086/379514; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6; *WHO, 2003, WHO EXP CONS COTR PR; Wit FWNM, 2005, AIDS, V19, P345	39	174	177	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 17	2006	367	9527					1981	1989		10.1016/S0140-6736(06)68887-9	http://dx.doi.org/10.1016/S0140-6736(06)68887-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	055ZC	16782488				2023-01-03	WOS:000238488900032
J	Hsu, J; Price, M; Huang, J; Brand, R; Fung, V; Hui, R; Fireman, B; Newhouse, JP; Selby, JV				Hsu, John; Price, Mary; Huang, Jie; Brand, Richard; Fung, Vicki; Hui, Rita; Fireman, Bruce; Newhouse, Joseph P.; Selby, Joseph V.			Unintended consequences of caps on medicare drug benefits	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRESCRIPTION DRUGS; HEALTH-INSURANCE; CHRONICALLY ILL; COST; BENEFICIARIES; COVERAGE; ADMISSION; OUTCOMES; RISK	Background: Little information exists about the consequences of limits on prescription-drug benefits for Medicare beneficiaries. Methods: We compared the clinical and economic outcomes in 2003 among 157,275 Medicare+Choice beneficiaries whose annual drug benefits were capped at $1,000 and 41,904 beneficiaries whose drug benefits were unlimited because of employer supplements. Results: After adjusting for individual characteristics, we found that subjects whose benefits were capped had pharmacy costs for drugs applicable to the cap that were lower by 31 percent than subjects whose benefits were not capped (95 percent confidence interval, 29 to 33 percent) but had total medical costs that were only 1 percent lower (95 percent confidence interval, -4 to 6 percent). Subjects whose benefits were capped had higher relative rates of visits to the emergency department (relative rate, 1.09 [95 percent confidence interval, 1.04 to 1.14]), nonelective hospitalizations (relative rate, 1.13 [1.05 to 1.21]), and death (relative rate, 1.22 [1.07 to 1.38]; difference, 0.68 per 100 person-years [0.30 to 1.07]). Among subjects who used drugs for hypertension, hyperlipidemia, or diabetes in 2002, those whose benefits were capped were more likely to be nonadherent to long-term drug therapy in 2003; the respective odds ratios were 1.30 (95 percent confidence interval, 1.23 to 1.38), 1.27 (1.19 to 1.34), and 1.33 (1.18 to 1.48) for subjects using drugs for hypertension, hyperlipidemia, and diabetes. In each subgroup, the physiological outcomes were worse for subjects whose drug benefits were capped than for those whose benefits were not capped; the odds ratios were 1.05 (95 percent confidence interval, 1.00 to 1.09), 1.13 (1.03 to 1.25), and 1.23 (1.03 to 1.46), respectively, for subjects with a systolic blood pressure of 140 mm Hg or more, a serum low-density-lipoprotein cholesterol level of 130 mg per deciliter or more, and a glycated hemoglobin level of 8 percent or more. Conclusions: A cap on drug benefits was associated with lower drug consumption and unfavorable clinical outcomes. In patients with chronic disease, the cap was associated with poorer adherence to drug therapy and poorer control of blood pressure, lipid levels, and glucose levels. The savings in drug costs from the cap were offset by increases in the costs of hospitalization and emergency department care.	Kaiser Permanente, Div Res, Oakland, CA 94612 USA; Kaiser Permanente, Pharm Outcomes Res Grp, Oakland, CA 94612 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Kaiser Permanente; Kaiser Permanente; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Hsu, J (corresponding author), Kaiser Permanente, Div Res, 2000 Broadway,3rd Fl, Oakland, CA 94612 USA.	jth@dor.kaiser.org	Newhouse, Joseph/AGJ-5632-2022; Newhouse, Joseph/AAD-9763-2019		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS010803, R01HS013902] Funding Source: NIH RePORTER; AHRQ HHS [P01-HS-10803, R01-HS-013902] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ACHMAN L, 2004, COMMONWEALTH FUND PU, V795; Baker DW, 2001, NEW ENGL J MED, V345, P1106, DOI 10.1056/NEJMsa002887; Cox ER, 2001, MED CARE, V39, P296, DOI 10.1097/00005650-200103000-00009; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; Freemantle N, 1996, BRIT MED J, V312, P1469, DOI 10.1136/bmj.312.7044.1469; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; Joyce GF, 2002, JAMA-J AM MED ASSOC, V288, P2409; Joyce GF, 2002, JAMA-J AM MED ASSOC, V288, P1733, DOI 10.1001/jama.288.14.1733; *KAIS FAM FDN HEW, 2004, CURR TRENDS FUT OUTL; Krieger N, 1999, AM J EPIDEMIOL, V150, P892; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; Mayes R, 2004, HEALTH AFFAIR, V23, P282, DOI 10.1377/hlthaff.23.2.282; MCARDLE FB, 2004, HLTH AFF MILLWOOD S; Mojtabai R, 2003, HEALTH AFFAIR, V22, P220, DOI 10.1377/hlthaff.22.4.220; Morgan S, 2004, HEALTH AFFAIR, V23, P269, DOI 10.1377/hlthaff.23.3.269; Newhouse JP, 2004, HEALTH AFFAIR, V23, P89, DOI 10.1377/hlthaff.23.1.89; OEHLERT GW, 1992, AM STAT, V46, P27, DOI 10.2307/2684406; PHELPS CE, 1992, HLTH EC; Piette JD, 2004, AM J PUBLIC HEALTH, V94, P1782, DOI 10.2105/AJPH.94.10.1782; Rector TS, 2004, HEALTH AFFAIR, V23, P213, DOI 10.1377/hlthaff.23.4.213; Reed M, 2005, MED CARE, V43, P810, DOI 10.1097/01.mlr.0000170416.68260.78; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; RUBIN RJ, 1995, NEW ENGL J MED, V333, P733; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; Soumerai SB, 1999, NEW ENGL J MED, V340, P722, DOI 10.1056/NEJM199903043400909; Soumerai SB, 1999, NEW ENGL J MED, V340, P976; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; STEINER JF, 1988, MED CARE, V26, P814, DOI 10.1097/00005650-198808000-00007; Steinman MA, 2001, J GEN INTERN MED, V16, P793, DOI 10.1046/j.1525-1497.2001.10412.x; STUART B, 2005, HLTH AFF MILLWOOD S; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Tseng CW, 2004, JAMA-J AM MED ASSOC, V292, P952, DOI 10.1001/jama.292.8.952; Tseng CW, 2003, JAMA-J AM MED ASSOC, V290, P222, DOI 10.1001/jama.290.2.222; Valenstein M, 2002, MED CARE, V40, P630, DOI 10.1097/00005650-200208000-00002; Zhao Y, 2001, Health Serv Res, V36, P180; ZWEIFEL P, 2000, HDB HLTH EC, P409	37	287	287	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	2006	354	22					2349	2359		10.1056/NEJMsa054436	http://dx.doi.org/10.1056/NEJMsa054436			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	047ZZ	16738271				2023-01-03	WOS:000237918500007
J	Newman, TB; Liljestrand, P; Jeremy, RJ; Ferriero, DM; Wu, YW; Hudes, ES; Escobar, GJ				Newman, TB; Liljestrand, P; Jeremy, RJ; Ferriero, DM; Wu, YW; Hudes, ES; Escobar, GJ		Jaunde Infant Feeding Study	Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	56th Annual Meeting of the American-Academy-of-Pediatrics	OCT 08-10, 2004	San Francisco, CA	Amer Acad Pediat			NEONATAL HYPERBILIRUBINEMIA; CEREBRAL-PALSY; FOLLOW-UP; ERYTHROBLASTOSIS FETALIS; TERM; HEALTH; INTELLIGENCE; PERFORMANCE; CHILDREN; INFANTS	BACKGROUND: The neurodevelopmental risks associated with high total serum bilirubin levels in newborns are not well defined. METHODS: We identified 140 infants with neonatal total serum bilirubin levels of at least 25 mg per deciliter (428 micromol per liter) and 419 randomly selected controls from a cohort of 106,627 term and near-term infants born from 1995 through 1998 in Kaiser Permanente hospitals in northern California. Data on outcomes were obtained from electronic records, interviews, responses to questionnaires, and neurodevelopmental evaluations that had been performed in a blinded fashion. RESULTS: Peak bilirubin levels were between 25 and 29.9 mg per deciliter (511 micromol per liter) in 130 of the newborns with hyperbilirubinemia and 30 mg per deciliter (513 micromol per liter) or more in 10 newborns; treatment involved phototherapy in 136 cases and exchange transfusion in 5. Follow-up data to the age of at least two years were available for 132 of 140 children with a history of hyperbilirubinemia (94 percent) and 372 of 419 controls (89 percent) and included formal evaluation at a mean (+/-SD) age of 5.1+/-0.12 years for 82 children (59 percent) and 168 children (40 percent), respectively. There were no cases of kernicterus. Neither crude nor adjusted scores on cognitive tests differed significantly between the two groups; on most tests, 95 percent confidence intervals excluded a 3-point (0.2 SD) decrease in adjusted scores in the hyperbilirubinemia group. There was no significant difference between groups in the proportion of children with abnormal neurologic findings on physical examination or with documented diagnoses of neurologic abnormalities. Fourteen of the children with hyperbilirubinemia (17 percent) had ``questionable'' or abnormal findings on neurologic examination, as compared with 48 controls (29 percent; P=0.05; adjusted odds ratio, 0.47; 95 percent confidence interval, 0.23 to 0.98; P=0.04). The frequencies of parental concern and reported behavioral problems also were not significantly different between the two groups. Within the hyperbilirubinemia group, those with positive direct antiglobulin tests had lower scores on cognitive testing but not more neurologic or behavioral problems. CONCLUSIONS: When treated with phototherapy or exchange transfusion, total serum bilirubin levels in the range included in this study were not associated with adverse neurodevelopmental outcomes in infants born at or near term.	Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA; Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Kaiser Permanente Med Ctr, Dept Pediat, Walnut Creek, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente; Kaiser Permanente	Newman, TB (corresponding author), Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039683] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR01271] Funding Source: Medline; NINDS NIH HHS [R01 NS39683] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Achenbach T. M., 1991, CHILD BEHAV CHECKLIS; *AM AC PED SUBC HY, 2004, PEDIATRICS, V0114, P01138; Ashwal S, 2004, NEUROLOGY, V62, P851, DOI 10.1212/01.WNL.0000117981.35364.1B; Atkinson LR, 2003, PEDIATRICS, V111, pE555, DOI 10.1542/peds.111.5.e555; BEERY KE, 1997, BEERYBUKTENICA DEV T; Civic D, 2000, Matern Child Health J, V4, P215, DOI 10.1023/A:1026667720478; Colver AF, 2000, ARCH DIS CHILD-FETAL, V83, pF7, DOI 10.1136/fn.83.1.F7; DAY R, 1954, PEDIATRICS, V13, P333; Escobar GJ, 2002, ARCH PEDIAT ADOL MED, V156, P155, DOI 10.1001/archpedi.156.2.155; Glascoe FP, 1998, COLLABORATING PARENT; Grimmer I, 1999, ACTA PAEDIATR, V88, P661, DOI 10.1080/08035259950169341; Gwynne K, 2004, J PAEDIATR CHILD H, V40, P369, DOI 10.1111/j.1440-1754.2004.00404.x; HOLMES GE, 1968, AM J DIS CHILD, V116, P37, DOI 10.1001/archpedi.1968.02100020039005; HYMAN CB, 1969, AM J DIS CHILD, V117, P395, DOI 10.1001/archpedi.1969.02100030397002; Ip S, 2004, PEDIATRICS, V114, pE130, DOI 10.1542/peds.114.1.e130; JOHNSTON WH, 1967, PEDIATRICS, V39, P88; MADAN A, 2004, AVERYS DIS NEWBORN, P1247; Maisels MJ, 2004, PEDIATRICS, V114, P297; NEWMAN TB, 1993, PEDIATRICS, V92, P651; NEWMAN TB, 1990, CLIN PERINATOL, V17, P331, DOI 10.1016/S0095-5108(18)30571-2; Newman TB, 2003, PEDIATRICS, V111, P1303, DOI 10.1542/peds.111.6.1303; Newman TB, 2002, PEDIATRICS, V110, P1032, DOI 10.1542/peds.110.5.1032; Newman TB, 2000, ARCH PEDIAT ADOL MED, V154, P1140, DOI 10.1001/archpedi.154.11.1140; Newman TB, 1999, PEDIATRICS, V104, P1198; NILSEN ST, 1984, ACTA PAEDIATR SCAND, V73, P176, DOI 10.1111/j.1651-2227.1984.tb09924.x; Ozmert E, 1996, ACTA PAEDIATR, V85, P1440, DOI 10.1111/j.1651-2227.1996.tb13949.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SCHEIDT PC, 1991, PEDIATRICS, V87, P797; SEIDMAN DS, 1991, PEDIATRICS, V88, P828; Soorani-Lunsing I, 2001, PEDIATR RES, V50, P701, DOI 10.1203/00006450-200112000-00012; Watchko JF, 2005, PEDIATRICS, V115, P1747, DOI 10.1542/peds.2004-1748; Wechsler D., 2014, WECHSLER PRESCHOOL P; Winter S, 2002, PEDIATRICS, V110, P1220, DOI 10.1542/peds.110.6.1220; Wu YW, 2005, J PEDIATR NEUROL, V3, P141; Wu YW, 2003, JAMA-J AM MED ASSOC, V290, P2677, DOI 10.1001/jama.290.20.2677; Yilmaz Y, 2001, Indian Pediatr, V38, P165	36	126	140	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 4	2006	354	18					1889	1900		10.1056/NEJMoa054244	http://dx.doi.org/10.1056/NEJMoa054244			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	038RE	16672700				2023-01-03	WOS:000237239900005
J	Gattinoni, L; Caironi, P; Cressoni, M; Chiumello, D; Ranieri, VM; Quintel, M; Russo, S; Patroniti, N; Cornejo, R; Bugedo, G				Gattinoni, L; Caironi, P; Cressoni, M; Chiumello, D; Ranieri, VM; Quintel, M; Russo, S; Patroniti, N; Cornejo, R; Bugedo, G			Lung recruitment in patients with the acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							END-EXPIRATORY PRESSURES; MECHANICAL VENTILATION; PROTECTIVE-VENTILATION; FAILURE; MANEUVERS; MORTALITY; INJURY; ARDS	Background: In the acute respiratory distress syndrome (ARDS), positive end-expiratory pressure (PEEP) may decrease ventilator-induced lung injury by keeping lung regions open that otherwise would be collapsed. Since the effects of PEEP probably depend on the recruitability of lung tissue, we conducted a study to examine the relationship between the percentage of potentially recruitable lung, as indicated by computed tomography (CT), and the clinical and physiological effects of PEEP. Methods: Sixty-eight patients with acute lung injury or ARDS underwent whole-lung CT during breath-holding sessions at airway pressures of 5, 15, and 45 cm of water. The percentage of potentially recruitable lung was defined as the proportion of lung tissue in which aeration was restored at airway pressures between 5 and 45 cm of water. Results: The percentage of potentially recruitable lung varied widely in the population, accounting for a mean (+/-SD) of 13+/-11 percent of the lung weight, and was highly correlated with the percentage of lung tissue in which aeration was maintained after the application of PEEP (r(sup 2)=0.72, P < 0.001). On average, 24 percent of the lung could not be recruited. Patients with a higher percentage of potentially recruitable lung (greater than the median value of 9 percent) had greater total lung weights (P < 0.001), poorer oxygenation (defined as a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen) (P < 0.001) and respiratory-system compliance (P=0.002), higher levels of dead space (P=0.002), and higher rates of death (P=0.02) than patients with a lower percentage of potentially recruitable lung. The combined physiological variables predicted, with a sensitivity of 71 percent and a specificity of 59 percent, whether a patient's proportion of potentially recruitable lung was higher or lower than the median. Conclusions: In ARDS, the percentage of potentially recruitable lung is extremely variable and is strongly associated with the response to PEEP.	Univ Milan, Fdn IRCCS, Osped Maggiore Policlin, I-20122 Milan, Italy; Univ Turin, Azienda Osped San Giovanni Battista Molinette, Dipartimento Anestesia, Turin, Italy; Univ Klinikum Gottingen, Gottingen, Germany; Univ Studi Milano Bicocca, Azienda Osped San Gerardo Monza, Dipartimento Med Perioperat & Terapia Intens, Milan, Italy; Pontificia Univ Catolica Chile, Fac Med, Dept Anestesiol & Med Intens, Santiago, Chile	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin; University of Gottingen; University of Milano-Bicocca; Pontificia Universidad Catolica de Chile	Gattinoni, L (corresponding author), Univ Milan, Fdn IRCCS, Osped Maggiore Policlin, Via F Sforza 35, I-20122 Milan, Italy.	gattinon@policlinico.mi.it	Ranieri, Marco/AFX-8152-2022; Cressoni, Massimo/B-7315-2017; Patroniti, Nicolo/K-6347-2016	Gattinoni, Luciano/0000-0001-5380-2494; Caironi, Pietro/0000-0003-0490-0818; CHIUMELLO, DAVIDE ALBERTO/0000-0001-9260-3930; Patroniti, Nicolo/0000-0003-3600-193X; Cressoni, Massimo/0000-0002-0089-2905				*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; ASHBAUGH DG, 1967, LANCET, V2, P319; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2004, CRIT CARE MED, V32, P907; Crotti S, 2001, AM J RESP CRIT CARE, V164, P131, DOI 10.1164/ajrccm.164.1.2007011; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; GATTINONI L, 1980, LANCET, V2, P292; GATTINONI L, 1993, JAMA-J AM MED ASSOC, V269, P2122, DOI 10.1001/jama.269.16.2122; Gattinoni L, 2001, AM J RESP CRIT CARE, V164, P1701, DOI 10.1164/ajrccm.164.9.2103121; GATTINONI L, 1993, JAMA-J AM MED ASSOC, V270, P1814; Gattinoni L, 2003, EUR RESPIR J, V22, p15S, DOI 10.1183/09031936.03.00021303; Grasso S, 2005, AM J RESP CRIT CARE, V171, P1002, DOI 10.1164/rccm.200407-940OC; Grasso S, 2002, ANESTHESIOLOGY, V96, P795, DOI 10.1097/00000542-200204000-00005; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; KOLOBOW T, 1987, AM REV RESPIR DIS, V135, P312; LACHMANN B, 1992, INTENS CARE MED, V18, P319, DOI 10.1007/BF01694358; Lapinsky SE, 2005, CRIT CARE, V9, P60, DOI 10.1186/cc2934; LEGALL JR, 1994, JAMA-J AM MED ASSOC, V271, P1321; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Levy MM, 2004, NEW ENGL J MED, V351, P389, DOI 10.1056/NEJMe048103; Papadakos PJ, 2002, MT SINAI J MED, V69, P73; PELOSI P, 1994, AM J RESP CRIT CARE, V149, P8, DOI 10.1164/ajrccm.149.1.8111603; Piacentini E, 2004, CRIT CARE, V8, P115, DOI 10.1186/cc2364; PONTOPPIDAN H, 1972, NEW ENGL J MED, V287, P799, DOI 10.1056/NEJM197210192871605; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Terashima T, 1996, AM J RESP CRIT CARE, V153, P1600, DOI 10.1164/ajrccm.153.5.8630608; Villagra A, 2002, AM J RESP CRIT CARE, V165, P165, DOI 10.1164/ajrccm.165.2.2104092; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806	30	932	999	2	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 27	2006	354	17					1775	1786		10.1056/NEJMoa052052	http://dx.doi.org/10.1056/NEJMoa052052			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	036NF	16641394				2023-01-03	WOS:000237077100003
J	Sedlak, TW; Snyder, SH				Sedlak, TW; Snyder, SH			Messenger molecules and cell death - Therapeutic implications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NITRIC-OXIDE SYNTHASE; CULTURED CEREBELLAR NEURONS; HEME OXYGENASE-1 DEFICIENCY; IRON REGULATORY PROTEINS; PARKINSONS-DISEASE; SERUM BILIRUBIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; POLY(ADP-RIBOSE) POLYMERASE; MUTANT HUNTINGTIN; APOPTOTIC PATHWAYS	Programmed cell death, also called apoptosis, participates not only in normal physiologic processes such as development of the immune system, but also in many diseases. A loss of normal cell death may occur in cancer, and excessive cell death is found in a variety of neurodegenerative conditions. We describe 3 distinct pathways that regulate cell death. First, bilirubin, often thought to be a toxic end product of heme metabolism, serves as a physiologic cytoprotectant that may attenuate multiple forms of morbidity. In a second pathway, the glycolytic enzyme glyceraldehyde-3-phosphatedehydrogenase (GAPDH) mediates a novel cell death cascade. Cytotoxic stimuli, via nitric oxide generation, lead to the binding of GAPDH to the protein Siah1, translocation of GAPDH-Siah1 to the nucleus, and ultimately cell death. Third, cytochrome c, released from mitochondria early in apoptosis, synergizes with inositol-1,4,5-triphosphate (IP3) to elicit massive cellular calcium release, resulting in cell death. These pathways may regulate cell survival in a variety of pathologic states and represent fertile targets for novel therapies.	Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Snyder, SH (corresponding author), Johns Hopkins Sch Med, Dept Neurosci, Wood Basic Sci Bldg 813,725 N Wolfe St, Baltimore, MD 21205 USA.	ssnyder@bs.jhmi.edu			NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline; NIMH NIH HHS [MH68830] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH068830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Andringa G, 2000, EUR J NEUROSCI, V12, P3033, DOI 10.1046/j.1460-9568.2000.00181.x; Andringa G., 2000, Journal of Neural Transmission Supplement, V60, P215; BAE BI, 2004, SOC NEUR 34 ANN M OC; Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Berridge MJ, 2005, ANNU REV PHYSIOL, V67, P1, DOI 10.1146/annurev.physiol.67.040103.152647; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; BOYNTON BR, 1989, NEW ENGL J MED, V321, P193; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Cairo G, 2002, FREE RADICAL BIO MED, V32, P1237, DOI 10.1016/S0891-5849(02)00825-0; Carlile GW, 2000, MOL PHARMACOL, V57, P2; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chang EF, 2003, J NEUROSCI, V23, P3689; Cornett J, 2005, NAT GENET, V37, P198, DOI 10.1038/ng1503; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DeJonge MH, 1999, J PEDIATR-US, V135, P102, DOI 10.1016/S0022-3476(99)70336-7; Denicourt C, 2004, SCIENCE, V305, P1411, DOI 10.1126/science.1102974; DENNERY PA, 1995, FREE RADICAL BIO MED, V19, P395, DOI 10.1016/0891-5849(95)00032-S; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Djousse L, 2001, AM J CARDIOL, V87, P1196, DOI 10.1016/S0002-9149(01)01494-1; Djousse L, 2003, AM J CARDIOL, V91, P485, DOI 10.1016/S0002-9149(02)03256-3; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Dore S, 2000, NEUROSCIENCE, V99, P587, DOI 10.1016/S0306-4522(00)00216-5; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Exner M, 2004, FREE RADICAL BIO MED, V37, P1097, DOI 10.1016/j.freeradbiomed.2004.07.008; FAUCHERE JC, 1994, EUR J PEDIATR, V153, P358, DOI 10.1007/s004310050153; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; GATON DD, 1991, BRIT J OPHTHALMOL, V75, P532, DOI 10.1136/bjo.75.9.532; GOEHNING D, 2005, P NATL ACAD SCI USA, V102, P1466; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gulesserian T, 2005, CLIN CHEM, V51, P1661, DOI 10.1373/clinchem.2005.051581; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hammerman C, 2002, J PEDIATR GASTR NUTR, V35, P344, DOI 10.1097/00005176-200209000-00020; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; HARA MR, 2005, SOC NEUR 35 ANN M NO; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; HEYMAN E, 1989, NEW ENGL J MED, V320, P256; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250; Horn S, 2004, NEUROLOGY, V63, pS7, DOI 10.1212/WNL.63.7_suppl_2.S7; Hosono S, 2002, J PEDIAT OPHTH STRAB, V39, P151, DOI 10.3928/0191-3913-20020501-06; Ishitani R, 1996, P NATL ACAD SCI USA, V93, P9937, DOI 10.1073/pnas.93.18.9937; Ishitani R, 1998, MOL PHARMACOL, V53, P701, DOI 10.1124/mol.53.4.701; Ishizaka N, 2001, STROKE, V32, P581, DOI 10.1161/01.STR.32.2.580-b; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718; Jenner P, 2004, NEUROLOGY, V63, pS13, DOI 10.1212/WNL.63.7_suppl_2.S13; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kaplan M, 2003, PEDIATRICS, V111, P886, DOI 10.1542/peds.111.4.886; Kato Y, 2003, HEPATOLOGY, V38, P364, DOI 10.1053/jhep.2003.50300; Kawashima A, 2002, HUM PATHOL, V33, P125, DOI 10.1053/hupa.2002.30217; Kim HP, 2005, P NATL ACAD SCI USA, V102, P11319, DOI 10.1073/pnas.0501345102; Kragten E, 1998, J BIOL CHEM, V273, P5821, DOI 10.1074/jbc.273.10.5821; Kronenberg F, 2002, EUR J HUM GENET, V10, P539, DOI 10.1038/sj.ejhg.5200842; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LeWitt PA, 2004, NEUROLOGY, V63, pS23, DOI 10.1212/WNL.63.7_suppl_2.S23; Li H, 2000, NAT GENET, V25, P385, DOI 10.1038/78054; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; Li Y, 2004, P NATL ACAD SCI USA, V101, P15688, DOI 10.1073/pnas.0403535101; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; Margolis RL, 2001, TRENDS MOL MED, V7, P479, DOI 10.1016/S1471-4914(01)02179-7; Matarredona ER, 2003, RESTOR NEUROL NEUROS, V21, P29; Milner Joshua D, 2003, J Perinatol, V23, P208, DOI 10.1038/sj.jp.7210887; Mungrue IN, 2004, J CELL SCI, V117, P2627, DOI 10.1242/jcs.01187; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Novotny L, 2003, EXP BIOL MED, V228, P568, DOI 10.1177/15353702-0322805-29; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Ohta K, 2000, AM J KIDNEY DIS, V35, P863, DOI 10.1016/S0272-6386(00)70256-3; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Rieux-Laucat F, 2003, CURR OPIN IMMUNOL, V15, P325, DOI 10.1016/S0952-7915(03)00042-6; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; RYTER SW, 2004, SCI STKE, V230, pRE6; Sagot Y, 2000, BRIT J PHARMACOL, V131, P721, DOI 10.1038/sj.bjp.0703633; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Sawa A, 2005, NEUROBIOL DIS, V20, P267, DOI 10.1016/j.nbd.2005.02.013; Schilling G, 2004, HUM MOL GENET, V13, P1599, DOI 10.1093/hmg/ddh175; Sedlak TW, 2004, PEDIATRICS, V113, P1776, DOI 10.1542/peds.113.6.1776; SEDLAK TW, 2004, SOC NEUR 34 ANN M OC; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stocchi F, 2003, ANN NEUROL, V53, pS87, DOI 10.1002/ana.10488; Syntichaki P, 2003, NAT REV NEUROSCI, V4, P672, DOI 10.1038/nrn1174; Vitek L, 2005, PEDIATRICS, V115, P1411, DOI 10.1542/peds.2004-1796; Vitek L, 2002, ATHEROSCLEROSIS, V160, P449, DOI 10.1016/S0021-9150(01)00601-3; Waldmeier PC, 2000, ADV RES NEURODEGENER, V8, P197; Waldmeier PC, 2000, N-S ARCH PHARMACOL, V362, P526, DOI 10.1007/s002100000300; Wang HD, 2002, AM J RESP CRIT CARE, V165, P406, DOI 10.1164/ajrccm.165.3.2003149; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yeo KL, 1998, PEDIATRICS, V102, P1426, DOI 10.1542/peds.102.6.1426; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Youdim MBH, 2004, NEUROLOGY, V63, pS32, DOI 10.1212/WNL.63.7_suppl_2.S32; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	112	38	39	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	2006	295	1					81	89		10.1001/jama.295.1.81	http://dx.doi.org/10.1001/jama.295.1.81			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	999HT	16391220				2023-01-03	WOS:000234381100024
J	Walker, SP; Chang, SM; Powell, CA; Grantham-McGregor, SM				Walker, SP; Chang, SM; Powell, CA; Grantham-McGregor, SM			Effects of early childhood psychosocial stimulation and nutritional supplementation on cognition and education in growth-stunted Jamaican children: prospective cohort study	LANCET			English	Article							SCHOOL	Growth retardation affects about a third of children younger than age 5 years in developing countries and is associated with poor development. Previously, we did a trial of nutritional supplementation and psychosocial stimulation in stunted children aged 9-24 months. Non-stunted children were also assessed. Both types of intervention improved development. We now present the effects of early interventions on cognition and education in 103 of the 129 stunted children and compare them with 64 of the 84 non-stunted children now aged 17-18 years. We recorded no significant effects of nutritional supplementation. Compared with no intervention, stimulation resulted in higher full scale IQ scores (coefficient 0.38, 95% C1 0.06-0.71, p=0.02) and higher scores on the verbal subscale (0.3, 0.07-0.68, p=0.02), Peabody picture vocabulary test (7.84, 0.73-14.95, p=0.03), verbal analogies (0.26, 0.03-0.49, p=0.03), and reading tests (4.73, 1.31-8.14, p=0.007, and 2.7, 1.12.4.37, p=0.001). Overall, stunted non-stimulated participants had significantly poorer scores than the non-stunted group on 11 of 12 cognitive and educational tests. Stunting in early childhood is associated with cognitive and educational deficits in late adolescence, which are reduced by stimulation at a young age.	Univ W Indies, Res Inst Trop Med, Epidemiol Res Unit, Mona, Jamaica; Inst Child Hlth, London, England	University West Indies Mona Jamaica; University of London; University College London	Walker, SP (corresponding author), Univ W Indies, Res Inst Trop Med, Epidemiol Res Unit, Mona, Jamaica.	susan.walker@uwimona.edu.jm			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Chang SM, 2002, J CHILD PSYCHOL PSYC, V43, P775, DOI 10.1111/1469-7610.00088; Daniels MC, 2004, J NUTR, V134, P1439, DOI 10.1093/jn/134.6.1439; FRANCE N, 1997, GROUP READING TEST, V2; Gomby DS, 1999, FUTURE CHILD, V9, P4, DOI 10.2307/1602719; Grantham-McGregor S, 2002, LANCET, V359, P542, DOI 10.1016/S0140-6736(02)07719-X; GRANTHAMMCGREGOR SM, 1991, LANCET, V338, P1, DOI 10.1016/0140-6736(91)90001-6; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; POWELL C, 2004, BMJ             0624; Walker SP, 2000, J PEDIATR-US, V137, P36, DOI 10.1067/mpd.2000.106227	9	243	247	1	34	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 19	2005	366	9499					1804	1807		10.1016/S0140-6736(05)67574-5	http://dx.doi.org/10.1016/S0140-6736(05)67574-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	987KQ	16298218				2023-01-03	WOS:000233517200025
J	Feldmann, M; Steinman, L				Feldmann, M; Steinman, L			Design of effective immunotherapy for human autoimmunity	NATURE			English	Review							ANTITUMOR NECROSIS FACTOR; FACTOR MONOCLONAL-ANTIBODY; T-CELL-ACTIVATION; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; MULTIPLE-SCLEROSIS; ANIMAL-MODELS; FACTOR-ALPHA; THERAPY; METHOTREXATE	A better understanding of the molecules involved in immune responses has identified many potential targets for the treatment of autoimmune diseases. But although successful therapies have been found for immune disorders in animal studies, few have passed the much harder test of treating human diseases. So far, non-antigen-specific approaches, such as the blocking of tumour-necrosis factor, are achieving some success but the same is not true for antigen-specific approaches. Future therapies will probably include both non-antigen-specific strategies that target cytokines ( cell - cell signalling molecules) or block the molecules that stimulate immune responses, and antigen-specific therapies that induce tolerance to self antigens.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst Rheumatol, London W6 8LH, England; Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Imperial College London; University of Oxford; Stanford University	Feldmann, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst Rheumatol, ARC Bldg,1 Aspenlea Rd, London W6 8LH, England.	m.feldmann@imperial.ac.uk; Steinman@stanford.edu		Steinman, Lawrence/0000-0002-2437-2250				Adams G, 2003, NAT BIOTECHNOL, V21, P1314, DOI 10.1038/nbt888; Bach JF, 2002, ARTHRITIS RES THER, V4, DOI 10.1186/ar554; Baecklund E, 2004, CURR OPIN RHEUMATOL, V16, P254, DOI 10.1097/00002281-200405000-00014; Baggiolini M, 2000, IMMUNOL REV, V177, P5, DOI 10.1034/j.1600-065X.2000.17722.x; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Bluestone JA, 2004, P NATL ACAD SCI USA, V101, P14622, DOI 10.1073/pnas.0405234101; BOTTAZZO GF, 1983, LANCET, V2, P1115; Breedveld FC, 1998, RHEUM DIS CLIN N AM, V24, P567, DOI 10.1016/S0889-857X(05)70026-0; Brennan FM, 2002, ARTHRITIS RHEUM, V46, P31, DOI 10.1002/1529-0131(200201)46:1<31::AID-ART10029>3.0.CO;2-5; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; Butler DM, 1995, EUR CYTOKINE NETW, V6, P225; Charles PJ, 2000, ARTHRITIS RHEUM, V43, P2383, DOI 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.3.CO;2-4; CHARPENTIER B, 1992, TRANSPLANTATION, V54, P997, DOI 10.1097/00007890-199212000-00011; Chatenoud L, 2003, NAT REV IMMUNOL, V3, P123, DOI 10.1038/nri1000; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHILLER JM, 1970, P NATL ACAD SCI USA, V65, P551, DOI 10.1073/pnas.65.3.551; COPE AP, 1994, J CLIN INVEST, V94, P749, DOI 10.1172/JCI117394; Czura CJ, 2004, ADV IMMUNOL, V84, P181, DOI 10.1016/S0065-2776(04)84005-7; Dalbeth N, 2005, RHEUMATOLOGY, V44, P24, DOI 10.1093/rheumatology/keh398; Day R, 2002, LANCET, V359, P540, DOI 10.1016/S0140-6736(02)07718-8; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FELDMANN M, 2001, CYTOKINE REFERENCE, V1, P35; Garren H, 2001, IMMUNITY, V15, P15, DOI 10.1016/S1074-7613(01)00171-6; Genovese MC, 2004, ARTHRITIS RHEUM-US, V50, P1412, DOI 10.1002/art.20221; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; Gladwell M., 2000, TIPPING POINT LITTLE; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Humphreys IR, 2003, J EXP MED, V198, P1237, DOI 10.1084/jem.20030351; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Kazkaz H, 2004, CURR OPIN PHARMACOL, V4, P398, DOI 10.1016/j.coph.2004.03.006; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217; Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; LINDSEY JW, 1994, ANN NEUROL, V36, P183; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Lovett-Racke AE, 2004, J IMMUNOL, V172, P5790, DOI 10.4049/jimmunol.172.9.5790; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; Malfait AM, 2001, ARTHRITIS RHEUM, V44, P1215, DOI 10.1002/1529-0131(200105)44:5<1215::AID-ANR206>3.3.CO;2-R; McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0; MCDEVITT HO, 1987, CIBA F SYMP, V129, P184; McInnes IB, 2004, CURR OPIN PHARMACOL, V4, P392, DOI 10.1016/j.coph.2004.04.003; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Nishimoto N, 2004, CURR OPIN PHARMACOL, V4, P386, DOI 10.1016/j.coph.2004.03.005; Nishimoto N, 2004, ARTHRITIS RHEUM-US, V50, P1761, DOI 10.1002/art.20303; OPPENHEIM JJ, 2001, CYTOKINE REFERENCE, P3; Pisetsky DS, 2001, JAMA-J AM MED ASSOC, V286, P2787, DOI 10.1001/jama.286.22.2787; Quinn MA, 2005, ARTHRITIS RHEUM-US, V52, P27, DOI 10.1002/art.20712; Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5; Revel M, 2003, PHARMACOL THERAPEUT, V100, P49, DOI 10.1016/S0163-7258(03)00085-8; Robinson WH, 2003, NAT BIOTECHNOL, V21, P1033, DOI 10.1038/nbt859; Roep BO, 2004, NAT REV IMMUNOL, V4, P989, DOI 10.1038/nri1502; Ruiz PJ, 1999, J IMMUNOL, V162, P3336; Sayegh MH, 2004, NEW ENGL J MED, V351, P2761, DOI 10.1056/NEJMon043418; Sela M, 1999, Int Rev Immunol, V18, P201, DOI 10.3109/08830189909043025; Shevach EM, 2004, ARTHRITIS RHEUM, V50, P2721, DOI 10.1002/art.20500; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steed PM, 2003, SCIENCE, V301, P1895, DOI 10.1126/science.1081297; Steinman L, 2004, SCIENCE, V305, P212, DOI 10.1126/science.1099896; Steinman L, 2003, NAT BIOTECHNOL, V21, P1293, DOI 10.1038/nbt1103-1293; Toussirot Eric A., 2002, Current Drug Targets - Inflammation and Allergy, V1, P45, DOI 10.2174/1568010023344850; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Walmsley M, 1996, ARTHRITIS RHEUM-US, V39, P495, DOI 10.1002/art.1780390318; WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Yu M, 1996, J EXP MED, V183, P1777, DOI 10.1084/jem.183.4.1777	80	210	249	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					612	619		10.1038/nature03727	http://dx.doi.org/10.1038/nature03727			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931214				2023-01-03	WOS:000229476200039
J	Conigliaro, RL				Conigliaro, RL			Satisfaction?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												conigliarorl@upmc.edu							0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2005	293	18					2193	2193		10.1001/jama.293.18.2193	http://dx.doi.org/10.1001/jama.293.18.2193			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	924LU	15886362				2023-01-03	WOS:000228981100001
J	De Smet, PAGM				De Smet, PAGM			Herbal medicine in Europe - Relaxing regulatory standards	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Sci Inst Dutch Pharmacists, The Hague, Netherlands; Univ Med Ctr St Radboud, Dept Clin Pharm, Nijmegen, Netherlands	Radboud University Nijmegen	De Smet, PAGM (corresponding author), Sci Inst Dutch Pharmacists, The Hague, Netherlands.		Smet, P.A.G.M./L-4654-2015						0	74	74	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1176	1178		10.1056/NEJMp048083	http://dx.doi.org/10.1056/NEJMp048083			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788494				2023-01-03	WOS:000227832300003
J	Koppel, R; Metlay, JP; Cohen, A; Abaluck, B; Localio, AR; Kimmel, SE; Strom, BL				Koppel, R; Metlay, JP; Cohen, A; Abaluck, B; Localio, AR; Kimmel, SE; Strom, BL			Role of computerized physician order entry systems in facilitating medication errors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT SAFETY; PRESCRIBING ERRORS; INFORMATION-SYSTEM; HEALTH-CARE; HOSPITALS	Context Hospital computerized physician order entry (CPOE) systems are widely regarded as the technical solution to medication ordering errors, the largest identified source of preventable hospital medical error. Published studies report that CPOE reduces medication errors up to 81%. Few researchers, however, have focused on the existence or types of medication errors facilitated by CPOE. Objective To identify and quantify the role of CPOE in facilitating prescription error risks. Design, Setting, and Participants We performed a qualitative and quantitative study of house staff interaction with a CPOE system at a tertiary-care teaching hospital (2002-2004). We surveyed house staff (N=261; 88% of CPOE users); conducted 5 focus groups and 32 intensive one-on-one interviews with house staff, information technology leaders, pharmacy leaders, attending physicians, and nurses; shadowed house staff and nurses; and observed them using CPOE. Participants included house staff, nurses, and hospital leaders. Main Outcome Measure Examples of medication errors caused or exacerbated by the CPOE system. Results We found that a widely used CPOE system facilitated 22 types of medication error risks. Examples include fragmented CPOE displays that prevent a coherent view of patients' medications, pharmacy inventory displays mistaken for dosage guidelines, ignored antibiotic renewal notices placed on paper charts rather than in the CPOE system, separation of functions that facilitate double dosing and incompatible orders, and inflexible ordering formats generating wrong orders. Three quarters of the house staff reported observing each of these error risks, indicating that they occur weekly or more often. Use of multiple qualitative and survey methods identified and quantified error risks not previously considered, offering many opportunities for error reduction. Conclusions In this study, we found that a leading CPOE system often facilitated medication error risks, with many reported to occur frequently. As CPOE systems are implemented, clinicians and hospitals must attend to errors that these systems cause in addition to errors that they prevent.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Sociol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Gen Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA; Dept Vet Affairs, Ctr Hlth Equit Res & Promot, Philadelphia, PA USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Koppel, R (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Room 106,Blockley Hall, Philadelphia, PA 19104 USA.	rkoppel@sas.upenn.edu	Cohen, Abigail/K-9180-2013; Greiver, Michelle/N-8764-2015; Tao, Youyou/D-2367-2014	Cohen, Abigail/0000-0002-7425-7218; Greiver, Michelle/0000-0001-8957-0285; Koppel, Ross/0000-0002-8235-9900	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS011530] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AIKEN LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI [DOI 10.1001/JAMA.288.16.1987, 10.1001/jama.288.16.1987]; [Anonymous], 1999, 43 ANN M HUM FACT ER; ASH J, 2001, MEDINFO 2, V10, P1107; Ash JS, 2004, J AM MED INFORM ASSN, V11, P95, DOI 10.1197/jamia.M1427; Ash JS, 2000, J AM MED INFORM ASSN, P27; Ash JS, 2004, J AM MED INFORM ASSN, V11, P104, DOI 10.1197/jamia.M1471; ASH JS, 2004, J AM MED INFORM ASSN, V11, P207; Bates D W, 1994, Qual Manag Health Care, V2, P18; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bates DW, 2001, J AM MED INFORM ASSN, V8, P299, DOI 10.1136/jamia.2001.0080299; Berger RG, 2004, J AM MED INFORM ASSN, V11, P100, DOI 10.1197/jamia.M1411; BERNARD F, 2004, BMJ-BRIT MED J, V328, P1171; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; Bobb A, 2004, ARCH INTERN MED, V164, P785, DOI 10.1001/archinte.164.7.785; BRODER C, LAWMAKERS PUSH HLTH; Cook RI, 1996, J CLIN ANESTH, V8, pS29, DOI 10.1016/S0952-8180(96)90009-4; Cook RI, 2000, BRIT MED J, V320, P791, DOI 10.1136/bmj.320.7237.791; COOK RI, 1999, ENHANCING PATIENT SA; Cook Richard I, 2002, Nurs Econ, V20, P80; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Feied CF, 2004, ACAD EMERG MED, V11, P1162, DOI 10.1197/j.aem.2004.08.010; Ferner RE, 2004, BRIT MED J, V328, P1172, DOI 10.1136/bmj.328.7449.1172; *FROST SULL, 2002, US COMP PHYS ORD ENT; Giacomini MK, 2000, JAMA-J AM MED ASSOC, V284, P357, DOI 10.1001/jama.284.3.357; GORDON S, 1997, LIFE SUPPORT; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Kanjanarat P, 2003, AM J HEALTH-SYST PH, V60, P1750, DOI 10.1093/ajhp/60.17.1750; Kaushal R, 2003, ARCH INTERN MED, V163, P1409, DOI 10.1001/archinte.163.12.1409; KAUSHAL R, 2001, AHRQ PUBLICATION; Kohn LT, 2000, ERR IS HUMAN BUILDIN; KUPERMAN G, 1997, ASS HLTH SERV RES, V14, P224; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Lesar TS, 1997, ARCH INTERN MED, V157, P1569, DOI 10.1001/archinte.157.14.1569; McNutt RA, 2002, JAMA-J AM MED ASSOC, V287, P1997, DOI 10.1001/jama.287.15.1997; Nightingale PG, 2000, BMJ-BRIT MED J, V320, P750, DOI 10.1136/bmj.320.7237.750; Ottino JM, 2004, NATURE, V427, P399, DOI 10.1038/427399a; Patterson ES, 2002, J AM MED INFORM ASSN, V9, P540, DOI 10.1197/jamia.M1061; Perrow C., 1984, NORMAL ACCIDENTS LIV; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Ramsay J, 1997, BEHAV INFORM TECHNOL, V16, P17, DOI 10.1080/014492997119987; RASMUSSEN J, 1985, ERGONOMICS, V28, P1185, DOI 10.1080/00140138508963241; Sanders DL, 2001, J AM MED INFORM ASSN, P583; Sarter N. D., 1997, HDB HUMAN FACTORS ER; Schiff GD, 1998, JAMA-J AM MED ASSOC, V279, P1024, DOI 10.1001/jama.279.13.1024; Shane R, 2002, AM J HEALTH-SYST PH, V59, P286, DOI 10.1093/ajhp/59.3.286; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; Teich JM, 2000, ARCH INTERN MED, V160, P2741, DOI 10.1001/archinte.160.18.2741; Tucker AL, 2003, CALIF MANAGE REV, V45, P55, DOI 10.2307/41166165; *US PHARM, 2004, MEDMARX 5 ANN DAT RE; Woods D.D., 2002, COGN TECHNOL WORK, V4, P137, DOI DOI 10.1007/S101110200012; Woods D.D., 1994, HUMAN ERROR COGNITIV; WOODS DD, STEERING REVERBERATI	53	1340	1363	3	116	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	2005	293	10					1197	1203		10.1001/jama.293.10.1197	http://dx.doi.org/10.1001/jama.293.10.1197			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904LB	15755942	Bronze			2023-01-03	WOS:000227498400020
J	Rose, SH; Elliott, BA				Rose, Steven H.; Elliott, Beth A.			In only an instant	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												rose.steve@mayo.edu							0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2006	296	6					631	632		10.1001/jama.296.6.631	http://dx.doi.org/10.1001/jama.296.6.631			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071LN	16896094				2023-01-03	WOS:000239603800001
J	Mosoiu, D; Ryan, KM; Joranson, DE; Garthwaite, JP				Mosoiu, Daniela; Ryan, Karen M.; Joranson, David E.; Garthwaite, Jody P.			Reform of drug control policy for palliative care in Romania	LANCET			English	Article							CANCER PAIN; CURRENT PERSPECTIVES; AIDS; UNDERTREATMENT; MORPHINE; OPIOIDS	Unrelieved pain from cancer and HIV/AIDS is a substantial worldwide public-health problem. Inadequate pain relief is partly due to excessively strict national drug-control policies that constrain medical use of essential medicines such as morphine. Romania's drug-control policies are more than 35 years old and impose an antiquated regulatory system that is based on inpatient post-surgical management of acute pain that restricts prescription authority and makes access to opioid treatment difficult for outpatients with severe chronic pain due to cancer or HIV/AIDS. A Ministry of Health palliative-care commission used WHO guidelines to assess and recommend changes to Romania's national drug control law and regulations. The Romanian parliament has adopted a new law that will simplify prescribing requirements and allow modern pain management. Achievement of adequate pain relief is a vital part of worldwide health and will be dependent on reform of antidrug regulations in many countries.	Univ Wisconsin, Ctr Comprehens Canc, Pain & Policy Studies Grp, Madison, WI 53711 USA; Hospice Casa Sperantei, Brasov 500074, Romania	University of Wisconsin System; University of Wisconsin Madison	Ryan, KM (corresponding author), Univ Wisconsin, Ctr Comprehens Canc, Pain & Policy Studies Grp, Madison, WI 53711 USA.	kmryan2@wisc.edu	Mosoiu, Daniela/AAB-9021-2020; Mosoiu, Daniela/AAR-4779-2021					[Anonymous], 1961, SINGL CONV NARC DRUG; [Anonymous], 2000, ACH BAL NAT OP CONTR; Blengini C, 2003, EUR J CANCER CARE, V12, P28, DOI 10.1046/j.1365-2354.2003.00325.x; BRASSEUR L, 1993, J PAIN SYMPTOM MANAG, V8, P412, DOI 10.1016/0885-3924(93)90066-5; Breitbart W, 2002, ONCOLOGY-NY, V16, P818; Breitbart W, 2002, ONCOLOGY-NY, V16, P964; Breitbart W, 1996, PAIN, V65, P243, DOI 10.1016/0304-3959(95)00217-0; Clark D, 2002, TRANSITIONS END LIFE; *COMM SPEC PAIN TH, 2003, REC MIN HLTH BUCH; *COUNC EUR COMM MI, REC 24 COMM MIN MEMB; Dale A, 2005, PALLIATIVE MED, V19, P177, DOI 10.1191/0269216305pm1012ed; De Conno F, 2005, PALLIATIVE MED, V19, P179, DOI 10.1191/0269216305pm1002oa; Dobrossy L, 2002, LANCET ONCOL, V3, P374, DOI 10.1016/S1470-2045(02)00778-7; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; *I MED COMM CAR EN, 1997, APPR DEATH IMPR CAR; *INT NARC CONTR BO, 2003, EUR REG GLOB CONS MO; *INT NARC CONTR BO, 1989, REP INT NARC CONTR B; International Narcotics Control Board, 2002, REP INT NARC CONTR B; International Narcotics Control Board, 1996, REP INT NARC CONTR B; International Narcotics Control Board, 2005, REP INT NARC CONTR B; *JOINT UN PROGR HI, 2005, AIDS EP UPD; Krizanova K, 2002, J PAIN SYMPTOM MANAG, V24, P231, DOI 10.1016/S0885-3924(02)00439-6; Larue F, 1997, BRIT MED J, V314, P23, DOI 10.1136/bmj.314.7073.23; LARUE F, 1997, REV PRAT MED GEN, V11, P11; Luczak J, 2002, J PAIN SYMPTOM MANAG, V24, P215, DOI 10.1016/S0885-3924(02)00464-5; Mosoiu D, 2002, J PAIN SYMPTOM MANAG, V24, P225, DOI 10.1016/S0885-3924(02)00446-3; Muszbek K, 2002, J PAIN SYMPTOM MANAG, V24, P188, DOI 10.1016/S0885-3924(02)00457-8; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Seskevicius A, 2002, J PAIN SYMPTOM MANAG, V24, P205, DOI 10.1016/S0885-3924(02)00438-4; SOHN W, 1998, MORPHINVERSCHREIBUNG; STEWART BW, 2003, WHO WORLD CANC REPOR; *UN AIDS PROGR, 2004, EP FACT SHEETS HIV A; *WHO, HIGHL HLTH ROM; *WHO, HIV AIDS PALL CAR; *WHO, ESS MED WHO MOD LIST; *WHO, 1990, WHO TECHN REP SER, V804; WHO, ESS MED; *WHO, 1996, ESS MED; *WHO REG OFF EUR, 2002, ASS AV OP AN PALL CA; World Health Assembly, 2005, CANC PREV CONTR; World Health Organization, 1996, CANC PAIN REL GUID O; ZENZ M, 1993, J PAIN SYMPTOM MANAG, V8, P416, DOI 10.1016/0885-3924(93)90067-6	43	24	24	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	2006	367	9528					2110	2117		10.1016/S0140-6736(06)68482-1	http://dx.doi.org/10.1016/S0140-6736(06)68482-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	058HZ	16798394				2023-01-03	WOS:000238657400036
J	Salpeter, SR; Buckley, NS; Ormiston, TM; Salpeter, EE				Salpeter, Shelley R.; Buckley, Nicholas S.; Ormiston, Thomas M.; Salpeter, Edwin E.			Meta-analysis: Effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths	ANNALS OF INTERNAL MEDICINE			English	Review							FORMOTEROL DRY POWDER; QUALITY-OF-LIFE; METERED-DOSE INHALER; NEAR-FATAL ASTHMA; PERSISTENT ASTHMA; DOUBLE-BLIND; SALMETEROL XINAFOATE; TERM TREATMENT; BRONCHIAL RESPONSIVENESS; IPRATROPIUM BROMIDE	Background: Long-acting beta-agonists may increase the risk for fatal and nonfatal asthma exacerbations. Purpose: To assess the risk for severe, life-threatening, or fatal asthma exacerbations associated with long-acting beta-agonists. Data Sources: English- and non-English-language searches of MEDLINE, EMBASE, and Cochrane databases; the U.S. Food and Drug Administration Web site; and references of selected reviews through December 2005. Study Selection: Randomized, placebo-controlled trials that lasted at least 3 months and evaluated long-acting P-agonist use in patients with asthma. All trials allowed the use of as-needed short-acting beta-agonists. Data Extraction: outcomes measured were Peto odds ratio (OR) and risk difference of severe exacerbations requiring hospitalization, life-threatening exacerbations requiring intubation and ventilation, and asthma-related deaths. The OR for asthma-related deaths was obtained from the Salmeterol Multi-center Asthma Research Trial (SMART). Data Synthesis: Pooled results from 19 trials with 33 826 participants found that long-acting beta-agonists increased exacerbations requiring hospitalization (OR, 2.6 [95% Cl, 1.6 to 4.3]) and life-threatening exacerbations (OR, 1.8 [Cl, 1.1 to 2.9]) compared with placebo. Hospitalizations were statistically significantly increased with salmeterol (OR, 1.7 [Cl, 1.1 to 2.7]) and formoterol (OR, 3.2 [Cl, 1.7 to 6.0]) and in children (OR, 3.9 [Cl, 1.7 to 8.8]) and adults (OR, 2.0 [Cl, 1.1 to 3.9]). The absolute increase in hospitalization was 0.7% (Cl, 0.1% to 1.3%) over 6 months. The risk for asthma-related deaths was increased (OR, 3.5 [Cl, 1.3 to 9.3]), with a pooled risk difference of 0.07% (Cl, 0.01% to 0.1%). Limitations: The small number of deaths limited the reliability in assessing this risk, and 28 studies did not report information on the outcomes of interest. Conclusions: Long-acting beta-agonists have been shown to increase severe and life-threatening asthma exacerbations, as well as asthma-related deaths.	Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Cornell Univ, Ithaca, NY USA	Santa Clara Valley Medical Center; Cornell University	Salpeter, SR (corresponding author), Santa Clara Valley Med Ctr, 751 S Bascom Ave, San Jose, CA 95128 USA.	Salpeter@stanford.edu						Adams N, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002310.pub3; ALDREY OE, 1995, J ASTHMA, V32, P21, DOI 10.3109/02770909509089496; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Anis AH, 2001, CAN MED ASSOC J, V164, P625; Arledge TE, 1996, J ALLERGY CLIN IMMUN, V98, P1116, DOI 10.1016/S0091-6749(96)80200-4; BEASLEY R, 1995, INT ARCH ALLERGY IMM, V107, P325, DOI 10.1159/000237016; Bensch G, 2002, ANN ALLERG ASTHMA IM, V89, P180, DOI 10.1016/S1081-1206(10)61935-7; Bensch G, 2001, ANN ALLERG ASTHMA IM, V86, P19, DOI 10.1016/S1081-1206(10)62351-4; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; Bijl-Hofland ID, 2001, AM J RESP CRIT CARE, V164, P764, DOI 10.1164/ajrccm.164.5.9910103; BOYD G, 1995, EUR RESPIR J, V8, P1494; Busse W, 2004, CLIN THER, V26, P1587, DOI 10.1016/j.clinthera.2004.10.004; Busse WW, 1998, AM J MANAG CARE, V4, P1579; *CENTR INT AG, 2005, WORLD FACTB; CHERVINSKY P, 1977, J ALLERGY CLIN IMMUN, V59, P22, DOI 10.1016/0091-6749(77)90172-5; CLARKE PS, 1982, ANN ALLERGY, V48, P180; Cloosterman SGM, 2001, CHEST, V119, P1306, DOI 10.1378/chest.119.5.1306; Creticos PS, 1999, INT ARCH ALLERGY IMM, V118, P345, DOI 10.1159/000024129; CROMPTON GK, 1975, BRIT MED J, V4, P458, DOI 10.1136/bmj.4.5994.458; Cunningham S.J., 1997, EMERG PEDIAT, V10, P33; D'Urzo AD, 2001, CHEST, V119, P714, DOI 10.1378/chest.119.3.714; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; Deykin A, 2005, J ALLERGY CLIN IMMUN, V115, P720, DOI 10.1016/j.jaci.2004.12.1129; DODDS WN, 1975, BRIT MED J, V4, P345, DOI 10.1136/bmj.4.5992.345-b; Eisner MD, 2001, EUR RESPIR J, V17, P233, DOI 10.1183/09031936.01.17202330; Ekstrom T, 1998, RESP MED, V92, P1040, DOI 10.1016/S0954-6111(98)90352-3; Ekstrom T, 1998, ANN ALLERG ASTHMA IM, V81, P225, DOI 10.1016/S1081-1206(10)62816-5; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; FAHY JV, 1995, CLIN CHEST MED, V16, P715; FitzGerald JM, 1999, J ALLERGY CLIN IMMUN, V103, P427, DOI 10.1016/S0091-6749(99)70467-7; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Hancox RJ, 1999, EUR RESPIR J, V14, P283, DOI 10.1034/j.1399-3003.1999.14b08.x; Hancox RJ, 1999, THORAX, V54, P482, DOI 10.1136/thx.54.6.482; Hussey PS, 2004, HEALTH AFFAIR, V23, P89, DOI 10.1377/hlthaff.23.3.89; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; KELMAN GR, 1969, NATURE, V221, P1251, DOI 10.1038/2211251a0; Kemp JP, 1999, J ALLERGY CLIN IMMUN, V104, P1189, DOI 10.1016/S0091-6749(99)70012-6; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; Kips JC, 2001, AM J RESP CRIT CARE, V164, P923, DOI 10.1164/ajrccm.164.6.2010107; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LaForce C, 2005, J ASTHMA, V42, P101, DOI 10.1081/JAS-51334; Lanes SF, 2002, THORAX, V57, P683, DOI 10.1136/thorax.57.8.683; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Levy Robyn, 2005, Pediatric Asthma Allergy & Immunology, V18, P25, DOI 10.1089/pai.2005.18.25; Li X, 1999, AM J RESP CRIT CARE, V160, P1493, DOI 10.1164/ajrccm.160.5.9811052; LIPWORTH BJ, 1992, DRUG SAFETY, V7, P54, DOI 10.2165/00002018-199207010-00007; Lockey RF, 1999, CHEST, V115, P666, DOI 10.1378/chest.115.3.666; MANTEL N, 1959, J NATL CANCER I, V22, P719; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; MEIJER GG, 1995, AM J RESP CRIT CARE, V152, P1887, DOI 10.1164/ajrccm.152.6.8520751; *NAT HEART LUNG BL, 2005, PROGR DESCR; Nathan RA, 1999, ANN ALLERG ASTHMA IM, V82, P521, DOI 10.1016/S1081-1206(10)63159-6; NATHAN RA, 1995, ANN ALLERG ASTHMA IM, V75, P243; National Heart Lung and Blood Institute, 1997, GUID DIAGN MAN ASTHM; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; NEWCOMB R, 1985, AM REV RESPIR DIS, V132, P12; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; OConnor BJ, 1996, AM J RESP CRIT CARE, V154, P876, DOI 10.1164/ajrccm.154.4.8887578; Orsida BE, 2001, AM J RESP CRIT CARE, V164, P117, DOI 10.1164/ajrccm.164.1.2006003; Price D, 2002, THORAX, V57, P791, DOI 10.1136/thorax.57.9.791; Ramsey SD, 2000, CHEST, V117, P33; Rodrigo GJ, 2005, THORAX, V60, P740, DOI 10.1136/thx.2005.040444; Rosenthal RR, 1999, CHEST, V116, P595, DOI 10.1378/chest.116.3.595; RUSSELL G, 1995, ANN ALLERG ASTHMA IM, V75, P423; Salpeter SR, 2004, ANN INTERN MED, V140, P802, DOI 10.7326/0003-4819-140-10-200405180-00010; SALPETER SR, 2006, UNPUB J GEN INT MED; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Shapiro G, 2000, AM J RESP CRIT CARE, V161, P527, DOI 10.1164/ajrccm.161.2.9905091; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STEFFENSEN I, 1995, ALLERGY, V50, P657, DOI 10.1111/j.1398-9995.1995.tb02582.x; SUISSA S, 1994, EUR RESPIR J, V7, P1602, DOI 10.1183/09031936.94.07091602; Tashkin DP, 2005, CURR OPIN PULM MED, V11, P121, DOI 10.1097/00063198-200503000-00004; Taylor DR, 1996, MED CLIN N AM, V80, P719, DOI 10.1016/S0025-7125(05)70465-X; Taylor DR, 1998, THORAX, V53, P744, DOI 10.1136/thx.53.9.744; Taylor DR, 2000, THORAX, V55, P595, DOI 10.1136/thorax.55.7.595; Terzano C, 2004, Eur Rev Med Pharmacol Sci, V8, P259; *US FOOD DRUG ADM, 2001, SLD390 US FOOD DRUG; *US FOOD DRUG ADM, 020831 NDA US FOOD D; *US FOOD DRUG ADM, 2001, FOR FORM FUM INH A 5; *US FOOD DRUG ADM, 2005, SER ADV FO WITHD CON; *US FOOD DRUG ADM, FOR FORM FUM INH A 4; *US FOOD DRUG ADM, 2001, SERV SALM XIN INH 2; van Schayck CP, 2002, EUR RESPIR J, V19, P240, DOI 10.1183/09031936.02.00203602; van Schayck CP, 2002, RESP MED, V96, P155, DOI 10.1053/rmed.2001.1243; vanderMolen T, 1997, THORAX, V52, P535, DOI 10.1136/thx.52.6.535; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; von Berg A, 2003, INT J CLIN PRACT, V57, P852; von Berg A, 1998, RESP MED, V92, P292, DOI 10.1016/S0954-6111(98)90112-3; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; Weinstein SF, 1998, ANN ALLERG ASTHMA IM, V81, P51, DOI 10.1016/S1081-1206(10)63109-2; Westby M, 2004, Cochrane Database Syst Rev, pCD003269; Wilding P, 1997, BRIT MED J, V314, P1441, DOI 10.1136/bmj.314.7092.1441; Zimmerman B, 2004, PEDIATR PULM, V37, P122, DOI 10.1002/ppul.10404; 2004, PATTERNS MED USE US	102	375	389	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 20	2006	144	12					904	912		10.7326/0003-4819-144-12-200606200-00126	http://dx.doi.org/10.7326/0003-4819-144-12-200606200-00126			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	056WJ	16754916				2023-01-03	WOS:000238555500005
J	Samson, RA; Nadkarni, VM; Meaney, PA; Carey, SM; Berg, MD; Berg, RA				Samson, Ricardo A.; Nadkarni, Vinay M.; Meaney, Peter A.; Carey, Scott M.; Berg, Marc D.; Berg, Robert A.		Amer Heart Assoc Natl Registry CPR	Outcomes of in-hospital ventricular fibrillation in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC CARDIOPULMONARY-RESUSCITATION; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; CARDIAC-ARREST; INTENSIVE-CARE; UTSTEIN STYLE; RECOMMENDED GUIDELINES; ASSISTED VENTILATION; CHEST COMPRESSIONS; TASK-FORCE	Background: Ventricular fibrillation and ventricular tachycardia are less common causes of cardiac arrest in children than in adults. These tachyarrhythmias can also begin during cardiopulmonary resuscitation (CPR), presumably as reperfusion arrhythmias. We determined whether the outcome is better for initial than for subsequent ventricular fibrillation or tachycardia. Methods: All cardiac arrests in persons under 18 years of age were identified from a large, multicenter, in-hospital cardiac-arrest registry. The results from children with initial ventricular fibrillation or tachycardia, children in whom ventricular fibrillation or tachycardia developed during CPR, and children with no ventricular fibrillation or tachycardia were compared by chi-square and multivariable logistic-regression analysis. Results: Of 1005 index patients with in-hospital cardiac arrest, 272 (27 percent) had documented ventricular fibrillation or tachycardia during the arrest. In 104 patients (10 percent), ventricular fibrillation or tachycardia was the initial pulseless rhythm; in 149 patients (15 percent), it developed during the arrest. The time of initiation of ventricular fibrillation or tachycardia was not documented in 19 patients. Thirty-five percent of patients with initial ventricular fibrillation or tachycardia survived to hospital discharge, as compared with 11 percent of patients with subsequent ventricular fibrillation or tachycardia (odds ratio, 2.6; 95 percent confidence interval, 1.2 to 5.8). Twenty-seven percent of patients with no ventricular fibrillation or tachycardia survived to hospital discharge, as compared with 11 percent of patients with subsequent ventricular fibrillation or tachycardia (odds ratio, 3.8; 95 percent confidence interval, 1.8 to 7.6). Conclusions: In pediatric patients with in-hospital cardiac arrests, survival outcomes were highest among patients in whom ventricular fibrillation or tachycardia was present initially than among those in whom it developed subsequently. The outcomes for patients with subsequent ventricular fibrillation or tachycardia were substantially worse than those for patients with asystole or pulseless electrical activity.	Univ Arizona, Coll Med, Steele Childrens Res Ctr, Tucson, AZ 85724 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; Digital Innovat, Forest Hill, MD USA	University of Arizona; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Berg, RA (corresponding author), Univ Arizona, Coll Med, Steele Childrens Res Ctr, 1501 N Campbell Ave,POB 245073, Tucson, AZ 85724 USA.	rberg@peds.arizona.edu		Berg, Marc/0000-0001-8842-5369; Meaney, Peter/0000-0001-9898-6928				Berg RA, 1997, CIRCULATION, V95, P1635; Berg RA, 1999, CRIT CARE MED, V27, P1893, DOI 10.1097/00003246-199909000-00030; Berg RA, 2000, CIRCULATION, V101, P1743; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; EISENBERG MS, 1990, ANN EMERG MED, V19, P1249, DOI 10.1016/S0196-0644(05)82283-8; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Garrey WE, 1914, AM J PHYSIOL, V33, P397, DOI 10.1152/ajplegacy.1914.33.3.397; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Leng CT, 2001, CIRCULATION, V104, P723, DOI 10.1161/hc0701.092217; Lopez-Herce J, 2005, RESUSCITATION, V64, P79, DOI 10.1016/j.resuscitation.2004.07.010; MOGAYZEL C, 1995, ANN EMERG MED, V25, P484, DOI 10.1016/S0196-0644(95)70263-6; Nichols D G, 1986, Pediatr Emerg Care, V2, P1, DOI 10.1097/00006565-198603000-00001; PANIDIS IP, 1983, J AM COLL CARDIOL, V2, P798, DOI 10.1016/S0735-1097(83)80225-3; Parra DA, 2000, CRIT CARE MED, V28, P3296, DOI 10.1097/00003246-200009000-00030; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Reis AG, 2002, PEDIATRICS, V109, P200, DOI 10.1542/peds.109.2.200; Suominen P, 2000, RESUSCITATION, V45, P17, DOI 10.1016/S0300-9572(00)00167-2; Torres A, 1997, PEDIATR EMERG CARE, V13, P369, DOI 10.1097/00006565-199712000-00002; WALSH CK, 1983, AM J CARDIOL, V51, P557, DOI 10.1016/S0002-9149(83)80096-4; Young KD, 1999, ANN EMERG MED, V33, P195, DOI 10.1016/S0196-0644(99)70394-X; ZARITSKY A, 1987, ANN EMERG MED, V16, P1107, DOI 10.1016/S0196-0644(87)80465-1; ZARITSKY A, 1995, CIRCULATION, V92, P2006, DOI 10.1161/01.CIR.92.7.2006	23	170	171	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	2006	354	22					2328	2339		10.1056/NEJMoa052917	http://dx.doi.org/10.1056/NEJMoa052917			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	047ZZ	16738269				2023-01-03	WOS:000237918500005
J	Zaloga, GP				Zaloga, GP			Parenteral nutrition in adult inpatients with functioning gastrointestinal tracts: assessment of outcomes	LANCET			English	Review							CRITICALLY-ILL PATIENTS; BONE-MARROW TRANSPLANTATION; RANDOMIZED CLINICAL-TRIAL; TOTAL ENTERAL NUTRITION; CROHNS-DISEASE; DOUBLE-BLIND; HEAD-INJURY; BOWEL REST; GLUTAMINE SUPPLEMENTATION; INFECTIOUS COMPLICATIONS	Malnutrition is a common comorbidity that places inpatients at risk of complications, infections, long length of stay, higher costs, and increased mortality. Thus, nutrition support has become an important therapeutic adjunctive to the care of these patients. For patients unable to feed themselves, nutrition can be delivered via the parenteral or enteral routes. The formulations used to deliver nutrients and the route of nutrient delivery, absorption, and processing differ substantially between parenteral and enteral nutrition. Over the past two decades, many randomised clinical trials have assessed the effects of parenteral versus enteral nutrition on outcomes (ie, complications, infections, length of stay, costs, mortality) in diverse inpatient populations. From a search of medical publications, studies were selected that assessed important clinical outcomes of parenteral versus enteral feeding or intravenous fluids in patients with trauma/burn injuries, surgery, cancer, pancreatic disease, inflammatory bowel disease, critical illness, liver failure, acute renal failure, and organ transplantation. Our goal was to determine the optimum route of feeding in these patient groups. The available evidence lends support to the use of enteral over parenteral feeding in inpatients with functioning gastrointestinal tracts.	Methodist Res Inst, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University System; Indiana University-Purdue University Indianapolis	Zaloga, GP (corresponding author), Methodist Res Inst, 1812 N Capitol Ave, Indianapolis, IN 46202 USA.	gzaloga@clarian.org						ABADLACRUZ A, 1990, JPEN-PARENTER ENTER, V14, P618, DOI 10.1177/0148607190014006618; ADAMS S, 1986, J TRAUMA, V26, P882, DOI 10.1097/00005373-198610000-00004; ALVERDY J C, 1990, Journal of Parenteral and Enteral Nutrition, V14, p8S; ASPEN Board of Directors and the Clinical Guidelines Task Force, 2002, JPEN J PARENTER E S1, V26, p1SA; BASTTISTELLA FD, 1997, J TRAUMA, V43, P52; Bauer P, 2000, INTENS CARE MED, V26, P893, DOI 10.1007/s001340051278; Borzotta Anthony P., 1993, Surgical Forum, V44, P29; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; BOWER RH, 1986, ARCH SURG-CHICAGO, V121, P1040; Bozzetti F, 2001, LANCET, V358, P1487, DOI 10.1016/S0140-6736(01)06578-3; Braga M, 2001, CRIT CARE MED, V29, P242, DOI 10.1097/00003246-200102000-00003; Braunschweig CL, 2001, AM J CLIN NUTR, V74, P534; BRENNAN MF, 1994, ANN SURG, V220, P436, DOI 10.1097/00000658-199410000-00003; BUZBY GP, 1980, AM J SURG, V139, P160, DOI 10.1016/0002-9610(80)90246-9; CERRA FB, 1988, SURGERY, V104, P727; Cetin T, 2002, NUTRITION, V18, P599, DOI 10.1016/S0899-9007(02)00779-7; Chiarelli A G, 1996, Minerva Anestesiol, V62, P1; CRAVO M, 1991, AM J GASTROENTEROL, V86, P317; DELANY HM, 1994, AM J SURG, V167, P135, DOI 10.1016/0002-9610(94)90064-7; DETSKY AS, 1987, ANN INTERN MED, V107, P195, DOI 10.7326/0003-4819-107-2-195; DETSKY AS, 1987, JPEN-PARENTER ENTER, V11, P440, DOI 10.1177/0148607187011005440; DETSKY AS, 1987, ANN INTERN MED, V107, P252; Dhaliwal R, 2004, INTENS CARE MED, V30, P1666, DOI 10.1007/s00134-004-2345-y; DICKINSON RJ, 1980, GASTROENTEROLOGY, V79, P1199; DUNHAM CM, 1994, J TRAUMA, V37, P30, DOI 10.1097/00005373-199407000-00007; EISENBERG JM, 1993, JPEN-PARENTER ENTER, V17, P201, DOI 10.1177/0148607193017003201; FAN ST, 1994, NEW ENGL J MED, V331, P1547, DOI 10.1056/NEJM199412083312303; FELICIANO D V, 1991, Contemporary Surgery, V39, P30; Furst P, 1994, New Horiz, V2, P215; Gianotti L, 1997, ARCH SURG-CHICAGO, V132, P1222, DOI 10.1001/archsurg.1997.01430350072012; Goeters C, 2002, CRIT CARE MED, V30, P2032, DOI 10.1097/00003246-200209000-00013; GONZALEZHUIX F, 1993, AM J GASTROENTEROL, V88, P227; Gramlich L, 2004, NUTRITION, V20, P843, DOI 10.1016/j.nut.2004.06.003; GREENBERG GR, 1988, GUT, V29, P1309, DOI 10.1136/gut.29.10.1309; Griffiths RD, 1997, NUTRITION, V13, P295; HADLEY MN, 1986, NEUROSURGERY, V19, P367, DOI 10.1097/00006123-198609000-00006; Herndon D N, 1989, J Burn Care Rehabil, V10, P309, DOI 10.1097/00004630-198907000-00004; HERNDON DN, 1987, J TRAUMA, V27, P195, DOI 10.1097/00005373-198702000-00018; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Heyland DK, 1998, JAMA-J AM MED ASSOC, V280, P2013, DOI 10.1001/jama.280.23.2013; IOVINELLI G, 1993, JPEN-PARENTER ENTER, V17, P445, DOI 10.1177/0148607193017005445; JONES VA, 1987, DIGEST DIS SCI, V32, pS100, DOI 10.1007/BF01312473; Kaushik Neeraj, 2004, Nutr Clin Pract, V19, P25, DOI 10.1177/011542650401900125; KLEIN S, 1986, CANCER, V58, P1378, DOI 10.1002/1097-0142(19860915)58:6<1378::AID-CNCR2820580635>3.0.CO;2-S; KORETZ RL, 1984, J CLIN ONCOL, V2, P534, DOI 10.1200/JCO.1984.2.5.534; Koretz RL, 2001, GASTROENTEROLOGY, V121, P970, DOI [10.1053/gast.2001.28031, 10.1016/S0016-5085(01)92000-1]; Kotani J, 1999, ARCH SURG-CHICAGO, V134, P287, DOI 10.1001/archsurg.134.3.287; Krinsley JS, 2004, MAYO CLIN PROC, V79, P992, DOI 10.4065/79.8.992; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; KUDSK KA, 1981, J SURG RES, V31, P105, DOI 10.1016/0022-4804(81)90037-8; KUDSK KA, 1983, J TRAUMA, V23, P605, DOI 10.1097/00005373-198307000-00010; Kudsk KA, 2001, JPEN-PARENTER ENTER, V25, P174, DOI 10.1177/0148607101025004174; Lin MT, 1996, ANN SURG, V223, P84, DOI 10.1097/00000658-199601000-00012; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; Marik PE, 2004, BMJ-BRIT MED J, V328, P1407, DOI 10.1136/bmj.38118.593900.55; McClave Stephen A, 2004, Nutr Clin Pract, V19, P1, DOI 10.1177/011542650401900101; McCowen KC, 2000, CRIT CARE MED, V28, P3606, DOI 10.1097/00003246-200011000-00007; MCGEER AJ, 1990, NUTRITION, V6, P233; MCINTYRE PB, 1986, GUT, V27, P481, DOI 10.1136/gut.27.5.481; Middleton MH, 2001, INTERN MED J, V31, P455, DOI 10.1046/j.1445-5994.2001.00109.x; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; MULLER JM, 1982, LANCET, V1, P68; NAYLOR C D, 1987, Renal Failure, V10, P141, DOI 10.3109/08860228709047649; NAYLOR CD, 1989, GASTROENTEROLOGY, V97, P1033, DOI 10.1016/0016-5085(89)91517-5; Novak F, 2002, CRIT CARE MED, V30, P2022, DOI 10.1097/00003246-200209000-00011; Peter JV, 2005, CRIT CARE MED, V33, P213, DOI 10.1097/01.CCM.0000150960.36228.C0; PETERSEN SR, 1981, J TRAUMA, V21, P528, DOI 10.1097/00005373-198107000-00004; PETERSON VM, 1988, SURGERY, V104, P199; Powell-Tuck J, 1999, GUT, V45, P82, DOI 10.1136/gut.45.1.82; Reynolds JV, 1997, JPEN-PARENTER ENTER, V21, P196, DOI 10.1177/0148607197021004196; Roberts P R, 1994, New Horiz, V2, P237; ROBINSON G, 1987, JPEN-PARENTER ENTER, V11, P49, DOI 10.1177/014860718701100149; SAKO K, 1981, J SURG ONCOL, V16, P391, DOI 10.1002/jso.2930160413; Sand J, 1997, EUR J SURG, V163, P761; SANDSTROM R, 1993, ANN SURG, V217, P185, DOI 10.1097/00000658-199302000-00013; Shirabe K, 1997, HEPATO-GASTROENTEROL, V44, P205; SHOU J, 1994, ANN SURG, V219, P291, DOI 10.1097/00000658-199403000-00009; Simpson F, 2005, INTENS CARE MED, V31, P12, DOI 10.1007/s00134-004-2511-2; Suchner U, 1996, NUTRITION, V12, P13, DOI 10.1016/0899-9007(95)00016-X; SZELUGA DJ, 1987, CANCER RES, V47, P3309; TRICE S, 1997, NUTR CLIN PRACT, V12, P114; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WEISDORF SA, 1987, TRANSPLANTATION, V43, P833, DOI 10.1097/00007890-198743060-00012; WHITE LJ, 1989, ANN INTERN MED, V110, P734; WICKS C, 1994, LANCET, V344, P837, DOI 10.1016/S0140-6736(94)92824-X; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; Wischmeyer PE, 2001, CRIT CARE MED, V29, P2075, DOI 10.1097/00003246-200111000-00006; WRIGHT RA, 1990, J CLIN GASTROENTEROL, V12, P396, DOI 10.1097/00004836-199008000-00008; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668; Zaloga GP, 2004, MINI-REV MED CHEM, V4, P815, DOI 10.2174/1389557043403477; ZALOGA GP, 1991, CRIT CARE MED, V19, P54, DOI 10.1097/00003246-199101000-00015; ZALOGA GP, 1993, CIRC SHOCK, V39, P263; ZALOGA GP, 1994, NUTR CRITICAL CARE, P313; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	95	114	118	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 1	2006	367	9516					1101	1111		10.1016/S0140-6736(06)68307-4	http://dx.doi.org/10.1016/S0140-6736(06)68307-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	030ZF	16581410				2023-01-03	WOS:000236673200035
J	Browne, K; Hamilton-Giachritsis, C; Johnson, R; Ostergren, M				Browne, K; Hamilton-Giachritsis, C; Johnson, R; Ostergren, M			Child health - Overuse of institutional care for children in Europe	BRITISH MEDICAL JOURNAL			English	Editorial Material							MENTAL-HEALTH; ADOLESCENTS; PRIVATION; BRAIN		Univ Birmingham, Ctr Forens & Family Psychol, Birmingham B15 2TT, W Midlands, England; WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark	University of Birmingham; World Health Organization	Browne, K (corresponding author), Univ Birmingham, Ctr Forens & Family Psychol, Birmingham B15 2TT, W Midlands, England.	K.D.Browne@bham.ac.uk	Hamilton-Giachritsis, Catherine/B-7844-2013	Hamilton-Giachritsis, Catherine/0000-0001-9796-2107				Arie Sophie, 2005, BMJ, V331, P129, DOI 10.1136/bmj.331.7509.129; Bainham A, 2003, CHILD FAM LAW Q, V15, P233; Balbernie R., 2001, J CHILD PSYCH, V27, P237, DOI [10.1080/00754170110087531, DOI 10.1080/00754170110087531]; Bowlby John, 1952, MATERNAL CARE MENTAL; BROWNE KD, 2005, 2003046C WHO U BIRM; Browne K, 2005, ADOPT FOSTER, V29, P23, DOI 10.1177/030857590502900405; Fisher L, 1997, INT J BEHAV DEV, V20, P67, DOI 10.1080/016502597385441; Giese S, 1999, S AFR J PSYCHOL, V29, P17, DOI 10.1177/008124639902900103; Glaser D, 2000, J CHILD PSYCHOL PSYC, V41, P97, DOI 10.1017/S0021963099004990; HODGES J, 1989, J CHILD PSYCHOL PSYC, V30, P77, DOI 10.1111/j.1469-7610.1989.tb00770.x; HODGES J, 1989, J CHILD PSYCHOL PSYC, V30, P53, DOI 10.1111/j.1469-7610.1989.tb00769.x; *INT SOC PREV CHIL, 1998, WORLD PERSP CHILD AB; Jenkins R, 2005, BMJ-BRIT MED J, V331, P173, DOI 10.1136/bmj.331.7510.173; Marcovitch S, 1997, INT J BEHAV DEV, V20, P17, DOI 10.1080/016502597385414; O'Connor TG, 2000, CHILD DEV, V71, P376, DOI 10.1111/1467-8624.00151; Rushton A., 2002, CHILD ADOLESCENT PSY, P359; Rutter M, 1998, J CHILD PSYCHOL PSYC, V39, P465, DOI 10.1017/S0021963098002236; Schore AN, 2001, INFANT MENT HEALTH J, V22, P7, DOI 10.1002/1097-0355(200101/04)22:1<7::AID-IMHJ2>3.0.CO;2-N; Trevarthen C, 2001, J CHILD PSYCHOL PSYC, V42, P3, DOI 10.1017/S0021963001006552; *UNICEF, 2004, STAT WORLDS CHILDR; UNICEF, 2004, INN SOC MON EC GROWT	21	51	51	2	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 25	2006	332	7539					485	487		10.1136/bmj.332.7539.485	http://dx.doi.org/10.1136/bmj.332.7539.485			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	018VM	16497769	Green Published, Green Submitted			2023-01-03	WOS:000235792900025
J	Parfitt, A				Parfitt, A			Resuscitation guidelines	LANCET			English	Editorial Material							HOSPITAL CARDIAC-ARREST		St Thomas Hosp, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust	Parfitt, A (corresponding author), St Thomas Hosp, London SE1 7EH, England.	Andy.Parfitt@gstt.nhs.uk						Baren JM, 2005, ACAD EMERG MED, V12, P1027, DOI 10.1197/j.aem.2005.06.014; Chamberlain D, 2005, RESUSCITATION, V67, P157, DOI 10.1016/j.resuscitation.2005.05.011; HANDLEY AJ, 2005, RESUSCITATION GUIDEL; Hess EP, 2005, RESUSCITATION, V66, P7, DOI 10.1016/j.resuscitation.2005.01.011; Kause J, 2004, RESUSCITATION, V62, P275, DOI 10.1016/j.resuscitation.2004.05.016; Kern KB, 2005, RESUSCITATION, V64, P261, DOI 10.1016/j.resuscitation.2004.08.009; Langhelle A, 2003, RESUSCITATION, V56, P247, DOI 10.1016/S0300-9572(02)00409-4	7	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 28	2006	367	9507					283	284		10.1016/S0140-6736(06)68049-5	http://dx.doi.org/10.1016/S0140-6736(06)68049-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443024				2023-01-03	WOS:000235084600008
J	Platt, OS				Platt, OS			Preventing stroke in sickle cell anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ULTRASONOGRAPHY		Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, William B Castle Soc, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Platt, OS (corresponding author), Childrens Hosp, Dept Lab Med, 300 Longwood Ave, Boston, MA 02115 USA.							ADAMS R, 1992, NEW ENGL J MED, V326, P605, DOI 10.1056/NEJM199202273260905; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; HAM THOMAS H., 1940, TRANS ASSOC AMER PHYSICIANS, V55, P127; JANDL JH, 1996, BIOGRAPHICAL MEMOIRS, V67, P14	4	32	34	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	2005	353	26					2743	2745		10.1056/NEJMp058274	http://dx.doi.org/10.1056/NEJMp058274			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	997LK	16382060				2023-01-03	WOS:000234246700005
J	Ko, D; Hawkins, L; Yu, DC				Ko, D; Hawkins, L; Yu, DC			Development of transcriptionally regulated oncolytic adenoviruses	ONCOGENE			English	Review						cancer virotherapy; transcriptionally regulated; oncolytic adenovirus	REPLICATION-COMPETENT ADENOVIRUS; VESICULAR STOMATITIS-VIRUS; CANCER-SPECIFIC ADENOVIRUS; POLYMER-COATED ADENOVIRUS; RECURRENT PROSTATE-CANCER; TUMOR-NECROSIS-FACTOR; HERPES-SIMPLEX-VIRUS; SUICIDE GENE-THERAPY; IN-VIVO; TRANSGENE EXPRESSION	Changes initiated at the cellular and systemic levels as a result of viral infection or neoplastic transformation share significant overlap. Therefore, the use of replicating viruses to treat tumors has long been postulated as a promising avenue for oncolytic therapy. Over the last 10 years, transcriptionally regulated adenoviruses have become a popular platform for the development of such oncolytic viruses. Placement of heterologous promoters in front of key adenoviral transcription units to achieve tumor- or tissue-specific viral replication is well documented. Various derivatives of this general strategy have led to considerable insight into its limitations, pitfalls, and potential. Although a general process can be described by which to develop transcriptionally regulated adenoviruses, it is apparent that few set rules can yet be defined as to what constitutes a safe, stable, and therapeutically effective vector. Clinical experiences to date suggest the short-term potential for this class of therapeutics lies in combination therapy regimens. Such lessons from the clinic suggest the next generation of transcriptionally regulated oncolytic adenoviruses take advantage of the ability of the platform to carry transgenes in order to deliver a multimodal therapy from a single agent. Beyond this 'arming' of the vectors lies the detargeting, retargeting, and coating of adenoviruses to improve the delivery of the agent to the treatment site( s). As a therapeutic platform, transcriptionally regulated adenoviruses are at an early stage of development with considerable opportunities for advancement.	Cell Genesys Inc, San Francisco, CA 94080 USA	Cell Genesys Inc	Yu, DC (corresponding author), Cell Genesys Inc, San Francisco, CA 94080 USA.	mich204@yahoo.com						ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BELL JA, 1956, AM J PUBLIC HEALTH N, V46, P1130, DOI 10.2105/AJPH.46.9.1130; BERGET SM, 1977, P NATL ACAD SCI USA, V74, P3171, DOI 10.1073/pnas.74.8.3171; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BETT AJ, 1993, J VIROL, V67, P5911, DOI 10.1128/JVI.67.10.5911-5921.1993; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bristol JA, 2003, MOL THER, V7, P755, DOI 10.1016/S1525-0016(03)00103-5; Chen Y, 2001, CANCER RES, V61, P5453; Cripe TP, 2001, CANCER RES, V61, P2953; DEWEESE T, 2003, MOL THER S1, V7; DeWeese TL, 2001, CANCER RES, V61, P7464; Dilley J, 2005, CANCER GENE THER, V12, P715, DOI 10.1038/sj.cgt.7700835; Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706-9713.1998; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Douglas JT, 2001, CANCER RES, V61, P813; Fisher KD, 2001, GENE THER, V8, P341, DOI 10.1038/sj.gt.3301389; Freytag SO, 2002, CANCER RES, V62, P4968; Freytag SO, 2003, CANCER RES, V63, P7497; Giedlin MA, 2003, CANCER CELL, V4, P241, DOI 10.1016/S1535-6108(03)00251-4; GOODING LR, 1991, J VIROL, V65, P4114, DOI 10.1128/JVI.65.8.4114-4123.1991; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; Green NK, 2004, GENE THER, V11, P1256, DOI 10.1038/sj.gt.3302295; Han JH, 1998, ONCOGENE, V17, P2993, DOI 10.1038/sj.onc.1202215; Hemminki A, 2001, CANCER RES, V61, P6377; Henderson D.R., 2002, ADENOVIRAL VECTORS G, P287; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HERMISTON TW, 1993, J VIROL, V67, P5289, DOI 10.1128/JVI.67.9.5289-5298.1993; HITT MM, 1990, VIROLOGY, V179, P667, DOI 10.1016/0042-6822(90)90134-D; HOFFMANN D, 2005, J GENE MED      0609; HUNEYCUTT BS, 1993, J VIROL, V67, P6698, DOI 10.1128/JVI.67.11.6698-6706.1993; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; Ilan Y, 1997, P NATL ACAD SCI USA, V94, P2587, DOI 10.1073/pnas.94.6.2587; Jakubczak JL, 2003, CANCER RES, V63, P1490; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; KRAJCSI P, 1992, VIROLOGY, V187, P492, DOI 10.1016/0042-6822(92)90451-T; Li YH, 2001, CANCER RES, V61, P6428; Lichtenstein DL, 2004, J VIROL, V78, P12297, DOI 10.1128/JVI.78.22.12297-12307.2004; Lichtenstein DL, 2002, J VIROL, V76, P11329, DOI 10.1128/JVI.76.22.11329-11342.2002; Lipinski KS, 2001, MOL THER, V4, P365, DOI 10.1006/mthe.2001.0468; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MITSUI Y, 1957, AM J OPHTHALMOL, V43, P84, DOI 10.1016/0002-9394(57)91484-8; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; OSBORNE TF, 1983, J VIROL, V45, P594, DOI 10.1128/JVI.45.2.594-599.1983; Parr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145; Polakis P, 2000, GENE DEV, V14, P1837; RAMESH N, 2005, UNPUB CLIN CANC RES; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reid T, 2002, CANCER GENE THER, V9, P979, DOI 10.1038/sj.cgt.7700539; Rodriguez R, 1997, CANCER RES, V57, P2559; Rubinchik S, 2001, GENE THER, V8, P247, DOI 10.1038/sj.gt.3301364; Ryan PC, 2004, CANCER GENE THER, V11, P555, DOI 10.1038/sj.cgt.7700735; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shayakhmetov DM, 2005, J VIROL, V79, P1053, DOI 10.1128/JVI.79.2.1053-1061.2005; SHEN Y, 2003, 12 INT C GEN THER CA; SMALL EM, 2002, 5 ANN M AM SCOIET GE; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Toth K, 2004, CANCER RES, V64, P3638, DOI 10.1158/0008-5472.CAN-03-3882; Varghese S, 2002, CANCER GENE THER, V9, P967, DOI 10.1038/sj.cgt.7700537; Wakimoto H, 2003, GENE THER, V10, P983, DOI 10.1038/sj.gt.3302038; WARD TG, 1955, SCIENCE, V122, P1086, DOI 10.1126/science.122.3179.1086; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026; YOUNG CYF, 1991, CANCER RES, V51, P3748; Yu DC, 1999, CANCER RES, V59, P4200; Yu DC, 2001, CANCER RES, V61, P517; Yu DC, 1999, CANCER RES, V59, P1498; Zhu MZ, 2005, J VIROL, V79, P5455, DOI 10.1128/JVI.79.9.5455-5465.2005	82	65	72	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7763	7774		10.1038/sj.onc.1209048	http://dx.doi.org/10.1038/sj.onc.1209048			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299536				2023-01-03	WOS:000233372600012
J	O'Shea, CC				O'Shea, CC			Viruses - seeking and destroying the tumor program	ONCOGENE			English	Review						viruses; oncolytic viral therapy; cancer; transformation; systems biology; adenovirus	HUMAN-PAPILLOMAVIRUS TYPE-16; ADENOVIRUS-INFECTED CELLS; REVERSE-TRANSCRIPTASE PROMOTER; PROTEIN-INTERACTION NETWORKS; E1B 55-KILODALTON PROTEIN; CERVICAL-CARCINOMA CELLS; LATE GENE-EXPRESSION; E2F TARGET GENES; CANCER-THERAPY; MESSENGER-RNA	DNA viruses have enormous utility in cancer research, both as tools for tumor target discovery as well as agents for lytic cancer therapies. This is because there is a profound functional overlap between the DNA viral and tumor cell programs. DNA viruses encode proteins that elicit growth deregulation in infected cells similar to that engendered by mutations in tumor cells. Evolution has refined viral proteins to target the critical cellular hubs that regulate growth. Thus, viral proteins are discriminating biochemical probes that can be used to identify and characterize novel tumor targets. Moreover, the overlap between the DNA viral and tumor programs can also be exploited for the development of lytic cancer therapies. Discovering whether tumor cells selectively complement the replication of viral mutants can reveal novel oncolytic viral therapies, as well as unexpected tumor properties. For example, altered RNA export was recently uncovered as a novel tumor cell property that underlies ONYX-015 replication, a promising oncolytic adenoviral therapy. A perspective is provided on how adenovirus could be systematically exploited to map the requisite role, or indeed the redundancy, of cellular pathways that act in an integrated program to elicit pathological replication. This knowledge has important applications for the rational design of the next generation of oncolytic viruses, as well as the discovery of efficacious combination cancer therapies.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	O'Shea, CC (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St,N315, San Francisco, CA 94115 USA.	coshea@cc.ucsf.edu						Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Avruch J, 2005, CURR OPIN CLIN NUTR, V8, P67, DOI 10.1097/00075197-200501000-00010; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Barber GN, 2005, ONCOGENE, V24, P7710, DOI 10.1038/sj.onc.1209042; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Benedict CA, 2001, J BIOL CHEM, V276, P3270, DOI 10.1074/jbc.M008218200; Benedict CA, 2001, VIROLOGY, V289, P1, DOI 10.1006/viro.2001.1109; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Bischof O, 2005, MOL CELL BIOL, V25, P1013, DOI 10.1128/MCB.25.3.1013-1024.2005; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Branton PE, 2001, ONCOGENE, V20, P7855, DOI 10.1038/sj.onc.1204862; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Chiocca EA, 2002, NAT REV CANCER, V2, P938, DOI 10.1038/nrc948; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Cuesta R, 2004, J VIROL, V78, P7707, DOI 10.1128/JVI.78.14.7707-7716.2004; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dobbelstein M, 2004, CURR TOP MICROBIOL, V273, P291; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eisenberg E, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.138701; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; Freeman-Cook LL, 2005, ONCOGENE, V24, P7756, DOI 10.1038/sj.onc.1209039; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Gewin L, 2004, GENE DEV, V18, P2269, DOI 10.1101/gad.1214704; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Goodrum FD, 1999, J VIROL, V73, P7474, DOI 10.1128/JVI.73.9.7474-7488.1999; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hann B, 2003, J VIROL, V77, P11588, DOI 10.1128/JVI.77.21.11588-11595.2003; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Hart LS, 2005, J BIOL CHEM, V280, P1474, DOI 10.1074/jbc.M409934200; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HAYES BW, 1990, J VIROL, V64, P2732, DOI 10.1128/JVI.64.6.2732-2742.1990; HEGDE RS, 1995, J CELL PHYSIOL, V165, P186, DOI 10.1002/jcp.1041650122; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; HO YS, 1982, VIROLOGY, V122, P109, DOI 10.1016/0042-6822(82)90381-6; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; Huang SL, 2001, CANCER RES, V61, P3373; Huang W, 1998, J VIROL, V72, P225, DOI 10.1128/JVI.72.1.225-235.1998; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Ito A, 2003, HISTOL HISTOPATHOL, V18, P1313, DOI 10.14670/HH-18.1313; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 2001, EXPERT OPIN BIOL TH, V1, P525, DOI 10.1517/14712598.1.3.525; Ko D, 2005, ONCOGENE, V24, P7763, DOI 10.1038/sj.onc.1209048; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Kyo S, 2002, ONCOGENE, V21, P688, DOI 10.1038/sj.onc.1205163; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; Lichtenstein DL, 2004, INT REV IMMUNOL, V23, P75, DOI 10.1080/08830180490265556; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lu ZM, 2004, J BIOL CHEM, V279, P35664, DOI 10.1074/jbc.M403385200; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Mathis JM, 2005, ONCOGENE, V24, P7775, DOI 10.1038/sj.onc.1209044; McCormick F, 2005, ONCOGENE, V24, P7817, DOI 10.1038/sj.onc.1209064; McCormick F, 2003, CANCER BIOL THER, V2, pS157; McMurray HR, 2003, J VIROL, V77, P9852, DOI 10.1128/JVI.77.18.9852-9861.2003; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mohr I, 2005, ONCOGENE, V24, P7697, DOI 10.1038/sj.onc.1209053; Moule MG, 2004, P NATL ACAD SCI USA, V101, P14063, DOI 10.1073/pnas.0405533101; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; Nemunaitis J, 2000, CANCER RES, V60, P6359; Nilsson CE, 2001, EMBO J, V20, P864, DOI 10.1093/emboj/20.4.864; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; O'Connor RJ, 2000, J VIROL, V74, P5819, DOI 10.1128/JVI.74.13.5819-5824.2000; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2005, CELL CYCLE, V4, P449, DOI 10.4161/cc.4.3.1555; O'Shea CC, 2005, CELL CYCLE, V4, P883, DOI 10.4161/cc.4.7.1791; O'Shea CC, 2005, CANCER CELL, V8, P61, DOI 10.1016/j.ccr.2005.06.009; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Perez D, 2003, J VIROL, V77, P2651, DOI 10.1128/JVI.77.4.2651-2662.2003; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; Reid T, 2002, CANCER RES, V62, P6070; Ries S, 2002, BRIT J CANCER, V86, P5, DOI 10.1038/sj.bjc.6600006; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Rudin CM, 2003, J CLIN ONCOL, V21, P4546, DOI 10.1200/JCO.2003.03.544; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; Seidel ER, 1997, BRIT J PHARMACOL, V120, P571, DOI 10.1038/sj.bjp.0700936; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shmulevitz M, 2005, ONCOGENE, V24, P7720, DOI 10.1038/sj.onc.1209041; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Tarakanova VL, 2003, J VIROL, V77, P9324, DOI 10.1128/JVI.77.17.9324-9336.2003; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Thorne SH, 2005, J VIROL, V79, P581, DOI 10.1128/JVI.79.1.581-591.2005; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Tollefson AE, 2003, J VIROL, V77, P7764, DOI 10.1128/JVI.77.14.7764-7778.2003; Tollefson AE, 2001, J VIROL, V75, P8875, DOI 10.1128/JVI.75.19.8875-8887.2001; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Verma SC, 2004, J VIROL, V78, P10348, DOI 10.1128/JVI.78.19.10348-10359.2004; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wagner A, 2003, P ROY SOC B-BIOL SCI, V270, P457, DOI 10.1098/rspb.2002.2269; Walsh D, 2005, J VIROL, V79, P8057, DOI 10.1128/JVI.79.13.8057-8064.2005; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Weitzman MD, 2004, DNA REPAIR, V3, P1165, DOI 10.1016/j.dnarep.2004.03.018; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Working PK, 2005, ONCOGENE, V24, P7792, DOI 10.1038/sj.onc.1209045; YEN A, 1979, SCIENCE, V204, P1315, DOI 10.1126/science.451539; YODER SS, 1986, J VIROL, V60, P779, DOI 10.1128/JVI.60.2.779-781.1986; Yook SH, 2004, PROTEOMICS, V4, P928, DOI 10.1002/pmic.200300636; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yu YJ, 2002, J VIROL, V76, P3731, DOI 10.1128/JVI.76.8.3731-3738.2002; Yuan H, 2002, J VIROL, V76, P10685, DOI 10.1128/JVI.76.21.10685-10691.2002; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	180	49	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7640	7655		10.1038/sj.onc.1209047	http://dx.doi.org/10.1038/sj.onc.1209047			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299526	Green Submitted			2023-01-03	WOS:000233372600002
J	Perry, JE; Churchill, LR; Kirshner, HS				Perry, JE; Churchill, LR; Kirshner, HS			The Terri Schiavo case: Legal, ethical, and medical perspectives	ANNALS OF INTERNAL MEDICINE			English	Article							VEGETATIVE STATE	Although tragic, the plight of Terri Schiavo provides a valuable case study. The conflicts and misunderstandings surrounding her situation offer important lessons in medicine, law, and ethics. Despite media saturation and intense public interest, widespread confusion lingers regarding the diagnosis of persistent vegetative state, the judicial processes involved, and the appropriateness of the ethical framework used by those entrusted with Terri Schiavo's care. First, the authors review the current medical understanding of persistent vegetative state, including the requirements for patient examination, the differential diagnosis, and the practice guidelines of the American Academy of Neurology regarding artificial nutrition and hydration for patients with this diagnosis. Second, they examine the legal history, including the 2000 trial, the 2002 evidentiary hearing, and the subsequent appeals. The authors argue that the law did not fail Terri Schiavo, but produced the highest-quality evidence and provided the most judicial review of any end-of-life guardianship case in U.S. history. Third, they review alternative ethical frameworks for understanding the Terri Schiavo case and contend that the principle of respect for autonomy is paramount in this case and in similar cases. Far from being unusual, the manner in which Terri Schiavo's case was reviewed and the basis for the decision reflect a broad medical, legal, and ethical consensus. Greater clarity regarding the persistent vegetative state, less apprehension of the presumed mysteries of legal proceedings, and greater appreciation of the ethical principles at work are the chief benefits obtained from studying this provocative case.	Vanderbilt Univ, Med Ctr, Ctr Biomed Eth & Soc, Nashville, TN 37232 USA	Vanderbilt University	Perry, JE (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Biomed Eth & Soc, 507B Light Hall, Nashville, TN 37232 USA.							[Anonymous], 1989, NEUROLOGY, V39, P125; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Beauchamp T., 1994, PRINCIPLES BIOMEDICA, P120; Beuthien-Baumann B, 2003, NUCL MED COMMUN, V24, P643, DOI 10.1097/00006231-200306000-00005; BROOKS D, 2005, NY TIMES        0326, pA13; Els T, 2004, ACTA NEUROL SCAND, V110, P361, DOI 10.1111/j.1600-0404.2004.00342.x; FADEN RUTH R., 1986, HIST THEORY INFORM C, P3; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; LYTLE T, 2005, ORLANDO SENTINE 0420, pA18; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; Snyder L, 2005, ANN INTERN MED, V142, P560, DOI 10.7326/0003-4819-142-7-200504050-00014; THOGMARTIN JR, 2005, CHIEF MED EXAMINER R	14	42	42	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2005	143	10					744	748		10.7326/0003-4819-143-10-200511150-00012	http://dx.doi.org/10.7326/0003-4819-143-10-200511150-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	986YY	16287796				2023-01-03	WOS:000233486800007
J	Sommerville, A				Sommerville, A			Changes in BMA policy on assisted dying	BRITISH MEDICAL JOURNAL			English	Editorial Material									BMA, London WC1H 9JP, England		Sommerville, A (corresponding author), BMA, London WC1H 9JP, England.	asommerville@bma.org.uk						Dobscha Steven K, 2004, J Palliat Med, V7, P451, DOI 10.1089/1096621041349374; IDDON B, 2005, BRIT MED ASS VOTE EU; MEDIX UK, 2004, PHYS ASSISTED SUICID; Miller LL, 2004, PALLIATIVE MED, V18, P685, DOI 10.1191/0269216304pm961oa; *OR DEP HUM SERV, 2003, 5 OR DEP HUM SERV; Purvis J., DYING DIGNITY CONSUL; van der Maas P. J., 1992, EUTHANASIA OTHER MED; WINTERTON A, 2005, BRIT MED ASS DEBATE	8	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	SEP 24	2005	331	7518					686	688		10.1136/bmj.331.7518.686	http://dx.doi.org/10.1136/bmj.331.7518.686			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970HH	16179706	Green Published			2023-01-03	WOS:000232295400023
J	Abasolo, L; Blanco, M; Bachiller, J; Candelas, G; Collado, P; Lajas, C; Revenga, M; Ricci, P; Lazaro, P; Aguilar, D; Vargas, E; Fernandez-Gutierrez, B; Hernandez-Garcia, C; Carmona, L; Jover, JA				Abasolo, L; Blanco, M; Bachiller, J; Candelas, G; Collado, P; Lajas, C; Revenga, M; Ricci, P; Lazaro, P; Aguilar, D; Vargas, E; Fernandez-Gutierrez, B; Hernandez-Garcia, C; Carmona, L; Jover, JA			A health system program to reduce work disability related to musculoskeletal disorders	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-BACK-PAIN; RHEUMATIC-DISEASES; COST-EFFECTIVENESS; SICKNESS ABSENCE; CARE; PREVENTION; INTERVENTION; MANAGEMENT; ARTHRITIS; IMPACT	Background: Musculoskeletal disorders (MSDs) are a frequent cause of work disability, accounting for productivity losses in industrialized societies equivalent to 1.3% of the U.S. gross national product. Objective: To evaluate whether a population-based clinical program offered to patients with recent-inset work disability caused by MSDs is cost-effective. Design: Randomized controlled intervention study. The inclusion and follow-up periods each lasted 12 months. Setting: Three health districts in Madrid, Spain. Patients: All patients with MSD-related temporary work disability in 1998 and 1999. Intervention: The control group received standard primary care management, wit referral to specialized care if needed. The intervention group received a specific program, administered by rheumatologists, in which care was delivered during regular visits and included 3 main elements: education, protocol-based clinical management, and administrative duties. Measurements: Efficacy variables were 1) days of temporary work disability and 2) number of patients with permanent work disability. All analyses were done on an intention-to-treat basis. Results: 13 077 patients were included in the study, 7805 in the control group and 5272 in the intervention group, generating 16 297 episodes of MSD-related temporary work disability. These episodes were shorter in the intervention group than in the control group (man, 26 days compared with 41 days; P < 0.001), and the groups had similar numbers of episodes per patient. Fewer patients received long-term disability compensation in the intervention group (n = 38 [0.7%]) than in the control group (n = 99 [1.3%]) (P < 0.005). Direct and indirect costs were lower in the intervention group than in the control group. To save 1 day of temporary work disability, $6.00 had to be invested in the program. Each dollar invested generated a benefit of $11.00. The program's net benefit was in excess of $5 million. Limitations: The study was unblinded. Conclusions: Implementation of the program, offered to the general population, improves short- and long-term work disability outcomes and is cost-effective.	Hosp Clin San Carlos, Serv Reumatol, Madrid 28040, Spain; Hosp Ramon & Cajal, E-28034 Madrid, Spain; Hosp Severo Ochoa, Madrid, Spain	Hospital Clinico San Carlos; Hospital Universitario Ramon y Cajal; Severo Ochoa University Hospital	Jover, JA (corresponding author), Hosp Clin San Carlos, Serv Reumatol, Calle Prof Martin Lagos S-N, Madrid 28040, Spain.	jjover.hcsc@salud.madrid.org	Martínez, Marcelino Revenga/T-1168-2017; Vargas-Castrillón, Emilio/AAZ-7621-2021; Carmona, Loreto/A-2748-2014; Fernandez-Gutierrez, Benjamin/AAM-9063-2020; Bachiller Corral, Javier/AGX-7411-2022	Martínez, Marcelino Revenga/0000-0002-7350-8214; Vargas-Castrillón, Emilio/0000-0003-4828-6004; Carmona, Loreto/0000-0002-4401-2551; Bachiller Corral, Javier/0000-0001-8954-209X; Candelas, Gloria/0000-0001-7759-5127; Fernandez-Gutierrez, Benjamin/0000-0002-6126-8786				[Anonymous], 1996, JAMA, V276, P241; BADLEY EM, 1994, J RHEUMATOL, V21, P505; BADLEY EM, 1994, J RHEUMATOL, V21, P515; BADLEY EM, 1995, J RHEUMATOL, V22, P204; Borestein DG, 1995, LOW BACK PAIN MED DI; Buchbinder R, 2001, BRIT MED J, V322, P1516, DOI 10.1136/bmj.322.7301.1516; CANOSO J J, 1990, Current Opinion in Rheumatology, V2, P276; CANOSO JJ, 1997, RHEUMATOLOGY PRIMARY; DALTON SE, 1994, BRIT J RHEUMATOL, V33, P663; Daltroy LH, 1997, NEW ENGL J MED, V337, P322, DOI 10.1056/NEJM199707313370507; Fautrel B, 2002, CURR OPIN RHEUMATOL, V14, P121, DOI 10.1097/00002281-200203000-00008; FELTS W, 1989, J RHEUMATOL, V16, P867; FEUERSTEIN M, 1993, J OCCUP ENVIRON MED, V35, P396; Fitzpatrick R, 1998, Health Technol Assess, V2, P1; Frank J, 1998, CAN MED ASSOC J, V158, P1625; Frank JW, 1996, SPINE, V21, P2918, DOI 10.1097/00007632-199612150-00025; GLAZIER R, 1995, ARTHRITIS RHEUM, V38, P533, DOI 10.1002/art.1780380412; Hadler NM., 1999, OCCUPATIONAL MUSCULO; INDAHL A, 1995, SPINE, V20, P473, DOI 10.1097/00007632-199502001-00011; Kelly W, 1996, TXB RHEUMATOLOGY; Kivimaki M, 2003, BRIT MED J, V327, P364, DOI 10.1136/bmj.327.7411.364; Kivimaki M, 2004, J EPIDEMIOL COMMUN H, V58, P710, DOI 10.1136/jech.2003.015842; Korthals-de Bos IBC, 2003, BRIT MED J, V326, P911; LAHAD A, 1994, JAMA-J AM MED ASSOC, V272, P1286, DOI 10.1001/jama.272.16.1286; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; LEHMANN TR, 1993, SPINE, V18, P1103, DOI 10.1097/00007632-199306150-00023; Loisel P, 2002, OCCUP ENVIRON MED, V59, P807, DOI 10.1136/oem.59.12.807; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; McNeil JM, 2001, JAMA-J AM MED ASSOC, V285, P1571; MEENAN RF, 1988, J RHEUMATOL, V15, P1693; Meerding WJ, 1998, BRIT MED J, V317, P111, DOI 10.1136/bmj.317.7151.111; Mutchler JE, 1997, J GERONTOL B-PSYCHOL, V52, pS4, DOI 10.1093/geronb/52B.1.S4; *NIOSH, ERG MUSC DIS; Nordin M, 1997, MUSCULOSKELETAL DISO; PARISEK R, 1994, ARTHRITIS RHEUM S, V37, P356; REYNOLDS DL, 1992, J RHEUMATOL, V19, P1020; Robin MP., 1983, TREAT YOUR OWN NECK; Sheon RP, 1996, SOFT TISSUE RHEUMATI; Sinclair SJ, 1997, SPINE, V22, P2919, DOI 10.1097/00007632-199712150-00015; STROSBERG MA, 1980, J RHEUMATOL, V7, P923; *SUBD GEN COORD AD, 1997, MAN GEST INC TEMP; VANSCHAARDENBURG D, 1994, ANN RHEUM DIS, V53, P807, DOI 10.1136/ard.53.12.807; WARD MM, 1993, ARCH INTERN MED, V153, P2229, DOI 10.1001/archinte.153.19.2229; Warhold LG, 1993, J MUSCULOSKELETAL ME, V10, P55; World Health Organisation, 2001, ICF INT CLASFUNCT; YELIN E, 1987, ARTHRITIS RHEUM, V30, P507, DOI 10.1002/art.1780300504; YELIN EH, 1990, ARTHRITIS RHEUM, V33, P750, DOI 10.1002/art.1780330520; YELIN EH, 1986, ARTHRITIS RHEUM, V29, P1322, DOI 10.1002/art.1780291104; Young T, 2004, BRIT MED J, V328, P162, DOI 10.1136/bmj.328.7432.162	49	42	46	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 20	2005	143	6					404	414		10.7326/0003-4819-143-6-200509200-00005	http://dx.doi.org/10.7326/0003-4819-143-6-200509200-00005			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967OG	16172439				2023-01-03	WOS:000232099900002
J	Tappin, DM; Lumsden, MA; Gilmour, WH; Crawford, F; McIntyre, D; Stone, DH; Webber, R; MacIndoe, S; Mohammed, E				Tappin, DM; Lumsden, MA; Gilmour, WH; Crawford, F; McIntyre, D; Stone, DH; Webber, R; MacIndoe, S; Mohammed, E			Randomised controlled trial of home based motivational interviewing by midwives to help pregnant smokers quit or cut down	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NICOTINE; COTININE; SMOKING; ENGLAND; HEALTH	Objective To determine whether motivational interviewing-a behavioural therapy for addictions-provided at home by specially trained midwives helps pregnant smokers to quit. Design Randomised controlled non-blinded trial analysed by intention to treat. Setting Clinics attached to two maternity hospitals in Glasgow. Participants 762/1684 pregnant women who were regular smokers at antenatal booking: 351 in intervention group and 411 in control group. Interventions All women received standard health promotion information. Women in the intervention group were offered motivational interviewing at home. All interviews were recorded. Main outcome measures Self reported smoking cessation verified by plasma or salivary cotinine concentration. Results 17/351 (4.8%) women in the intervention group stopped smoking (according to self report and serum cotinine concentration < 13.7 ng/ml) compared with 19/411(4.6%) in the control group. Fifteen (4.2%) women in the intervention group cut down (self report and cotinine concentration less than half that at booking) compared with 26 (6.3%) in the control group. Fewer women in the intervention group reported smoking more (18 (5.1%) v 44 (10.7%); relative risk 0.48, 95% confidence interval 0.28 to 0.81). Birth weight did not differ significantly (mean 3078 g v 3048 g). Conclusion Good quality motivational interviewing did not significantly increase smoking cessation among pregnant women.	Univ Glasgow, Div Dev Med, Dept Child Hlth, Paediat Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland; Univ Glasgow, Div Dev Med, Sect Obstet & Gynaecol, Glasgow G31 2ER, Lanark, Scotland; Univ Glasgow, Div Community Based Sci, Sect Publ Hlth & Hlth Policy, Glasgow G12 8RZ, Lanark, Scotland; NHS Hlth Scotland, Publ Hlth Project, Glasgow G3 7LS, Lanark, Scotland; Int Non Govt Coalit Tobacco, London SW8 4WS, England; Yorkhill Hosp, Dept Haematol, Glasgow G3 8SJ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Tappin, DM (corresponding author), Univ Glasgow, Div Dev Med, Dept Child Hlth, Paediat Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland.	goda11@udcf.gla.ac.uk						Adams EK, 1997, JAMA-J AM MED ASSOC, V278, P2058; Bryant TN, 2000, STAT CONFIDENCE; CARSTAIRS V, 1989, BRIT MED J, V299, P886, DOI 10.1136/bmj.299.6704.886; Chandola T, 2004, ADDICTION, V99, P770, DOI 10.1111/j.1360-0443.2004.00756.x; Coleman T, 2004, BMJ-BRIT MED J, V328, P965, DOI 10.1136/bmj.328.7446.965; Cuzick J, 1997, STAT MED, V16, P1017, DOI 10.1002/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>3.0.CO;2-V; Dempsey D, 2002, J PHARMACOL EXP THER, V301, P594, DOI 10.1124/jpet.301.2.594; DiClemente C.C., 2002, MOTIVATIONAL INTERVI, V2nd ed., P201; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; Hegaard HK, 2003, ACTA OBSTET GYN SCAN, V82, P813, DOI 10.1034/j.1600-0412.2003.00221.x; Hughes EG, 2000, FERTIL STERIL, V74, P498, DOI 10.1016/S0015-0282(00)00687-7; Jarvis MJ, 2003, NICOTINE TOB RES, V5, P349, DOI 10.1080/1462220031000094213; LUMLEY J, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001055.PUB2; Moyers T, 2003, BEHAV COGN PSYCHOTH, V31, P177, DOI 10.1017/S1352465803002054; *NHS CTR REV DISS, 1998, EFFECTIVENESS MATTER, V3, P1; Owen L, 1998, BRIT MED J, V317, P728, DOI 10.1136/bmj.317.7160.728; *ROYAL COLL PHYS, 1992, SMOK YOUNG REP WORK, P103; *SCOTL HLTH, 1997, SCOTT HLTH SURV 1995; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stephenson J, 1998, BMJ-BRIT MED J, V316, P611, DOI 10.1136/bmj.316.7131.611; Tappin DM, 2000, HEALTH EDUC RES, V15, P491, DOI 10.1093/her/15.4.491; Townsend P., 1988, INEQUALITIES HLTH; WINDSOR RA, 1993, AM J PUBLIC HEALTH, V83, P201, DOI 10.2105/AJPH.83.2.201; Wisborg K, 2000, OBSTET GYNECOL, V96, P967, DOI 10.1016/S0029-7844(00)01071-1; Wright CM, 2001, BMJ-BRIT MED J, V323, P1280, DOI 10.1136/bmj.323.7324.1280	25	61	62	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 13	2005	331	7513					373	+		10.1136/bmj.331.7513.373	http://dx.doi.org/10.1136/bmj.331.7513.373			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	956SK	16096304	Green Published			2023-01-03	WOS:000231319900012
J	Decullier, E; Lheritier, V; Chapuis, F				Decullier, E; Lheritier, V; Chapuis, F			Fate of biomedical research protocols and publication bias in France: retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; FOLLOW-UP; REGISTRATION; COMMITTEE	Objectives To describe the fate of protocols approved by the French research ethics committees, a national system created by the French 1988 Huriet-Serusclat Act; to assess publication bias at a national level. Design Retrospective cohort study. Setting Representative sample of 25/48 French research ethics committees in 1994. Protocols 649 research protocols approved by committees, with follow-up information. Main outcome measures Protocols' initial characteristics (design, study size, investigator) abstracted from committees' archives; follow-up information (rates of initiation, completion, and publication) obtained from mailed questionnaire to principal investigators. Results Completed questionnaires were available for 649/976 (69%) protocols. Of these, 581 (90%) studies were initiated, 501/581 (86%) were completed, and 190/501 (38%) were published. Studies with confirmatory results were more likely to be published as scientific papers than were studies with inconclusive results (adjusted odds ratio 4.59, 95% confidence interval 2.21 to 9.54). Moreover, studies with confirmatory results were published more quickly than studies with inconclusive results (hazard ratio 2.48, 1.36 to 4.55). Conclusion At a national level, too many research studies are not completed, and among those completed too many are not published. We suggest capitalising on research ethics committees to register and follow all authorised research on human participants on a systematic and prospective basis.	Hop Hotel Dieu, French Natl Confederat Res Eth Comm, F-69002 Lyon, France; Hosp Civils Lyon, DIM, Clin Res Unit, F-69424 Lyon, France; Hop Hotel Dieu, CCPPRB Lyon B, F-69002 Lyon, France	CHU Lyon; CHU Lyon; CHU Lyon	Chapuis, F (corresponding author), Hop Hotel Dieu, French Natl Confederat Res Eth Comm, F-69002 Lyon, France.	francois.chapuis@chu-lyon.fr	decullier, evelyne/AAL-5861-2021					Abbasi K, 2004, BRIT MED J, V329, P637, DOI 10.1136/bmj.329.7467.637; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; De Angelis C, 2004, MED J AUSTRALIA, V181, P293, DOI 10.5694/j.1326-5377.2004.tb06290.x; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1992, CONTROL CLIN TRIALS, V13, P170, DOI 10.1016/0197-2456(92)90022-R; EASTERBROOK P, 1987, BRIT MED J, V295, P1347, DOI 10.1136/bmj.295.6609.1347-a; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; EASTERBROOK PJ, 1992, J ROY SOC MED, V85, P71; GREENWALD AG, 1975, PSYCHOL BULL, V82, P1, DOI 10.1037/h0076157; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Pich J, 2003, LANCET, V361, P1015, DOI 10.1016/S0140-6736(03)12799-7; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640	13	106	107	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	2005	331	7507					19	22		10.1136/bmj.38488.385995.8F	http://dx.doi.org/10.1136/bmj.38488.385995.8F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947TD	15967761	Green Published, Bronze			2023-01-03	WOS:000230668500016
J	Oliphant, T; Engle, M; Nybakken, GE; Doane, C; Johnson, S; Huang, L; Gorlatov, S; Mehlhop, E; Marri, A; Chung, KM; Ebel, GD; Kramer, LD; Fremont, DH; Diamond, MS				Oliphant, T; Engle, M; Nybakken, GE; Doane, C; Johnson, S; Huang, L; Gorlatov, S; Mehlhop, E; Marri, A; Chung, KM; Ebel, GD; Kramer, LD; Fremont, DH; Diamond, MS			Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus	NATURE MEDICINE			English	Article							JAPANESE ENCEPHALITIS-VIRUS; ENVELOPE PROTEIN; DENGUE VIRUS; DOMAIN-III; DISSEMINATED INFECTION; POLYPEPTIDE LIBRARIES; NUCLEOTIDE-SEQUENCE; IMMUNE-RESPONSE; NEW-YORK; IMMUNOGLOBULIN	Neutralization of West Nile virus (WNV) in vivo correlates with the development of an antibody response against the viral envelope ( E) protein. Using random mutagenesis and yeast surface display, we defined individual contact residues of 14 newly generated monoclonal antibodies against domain III of the WNV E protein. Monoclonal antibodies that strongly neutralized WNV localized to a surface patch on the lateral face of domain III. Convalescent antibodies from individuals who had recovered from WNV infection also detected this epitope. One monoclonal antibody, E16, neutralized 10 different strains in vitro, and showed therapeutic efficacy in mice, even when administered as a single dose 5 d after infection. A humanized version of E16 was generated that retained antigen specificity, avidity and neutralizing activity. In postexposure therapeutic trials in mice, a single dose of humanized E16 protected mice against WNV-induced mortality, and may therefore be a viable treatment option against WNV infection in humans.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; MacroGenics, Rockville, MD 20850 USA; New York State Dept Hlth, Wadsworth Ctr, Slingerlands, NY 12159 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Wadsworth Center	Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave,Box 8051, St Louis, MO 63110 USA.	diamond@borcim.wustl.edu	Diamond, Michael/AAH-1733-2019; Ebel, Gregory/D-8324-2017; Ebel, Gregory/ABG-1052-2021	Diamond, Michael/0000-0002-8791-3165; Fremont, Daved/0000-0002-8544-2689	NIAID NIH HHS [U54 AI057160, U01 AI061373] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057160, U01AI061373] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beasley DWC, 2002, J VIROL, V76, P13097, DOI 10.1128/JVI.76.24.13097-13100.2002; Beasley DWC, 2001, VIROLOGY, V279, P447, DOI 10.1006/viro.2000.0721; Ben-Nathan D, 2003, J INFECT DIS, V188, P5, DOI 10.1086/376870; Bhardwaj S, 2001, J VIROL, V75, P4002, DOI 10.1128/JVI.75.8.4002-4007.2001; Boder ET, 1998, BIOTECHNOL PROGR, V14, P55, DOI 10.1021/bp970144q; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; CECILIA D, 1991, VIROLOGY, V181, P70, DOI 10.1016/0042-6822(91)90471-M; Chambers TJ, 1998, J GEN VIROL, V79, P2375, DOI 10.1099/0022-1317-79-10-2375; Chu JJH, 2005, J GEN VIROL, V86, P405, DOI 10.1099/vir.0.80411-0; Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001; DELENDA C, 1994, J GEN VIROL, V75, P1569, DOI 10.1099/0022-1317-75-7-1569; Diamond MS, 2000, J VIROL, V74, P4957, DOI 10.1128/JVI.74.11.4957-4966.2000; Diamond MS, 2003, VIRAL IMMUNOL, V16, P259, DOI 10.1089/088282403322396082; Diamond MS, 2003, J VIROL, V77, P2578, DOI 10.1128/JVI.77.4.2578-2586.2003; Ebel GD, 2004, AM J TROP MED HYG, V71, P493, DOI 10.4269/ajtmh.2004.71.493; Engle MJ, 2003, J VIROL, V77, P12941, DOI 10.1128/JVI.77.24.12941-12949.2003; Granwehr BP, 2004, LANCET INFECT DIS, V4, P547, DOI 10.1016/S1473-3099(04)01128-4; HARLOW E, 1988, ANTIBODIES LAB MANUA, P714; HIETER PA, 1982, J BIOL CHEM, V257, P1516; KABAT E, 1991, SEEQUENCES PROTEINS, P3242; Karabatsos N., 1985, INT CATALOGUE ARBOVI; KIMURAKURODA J, 1988, J IMMUNOL, V141, P3606; KLOBECK HG, 1985, NUCLEIC ACIDS RES, V13, P6515, DOI 10.1093/nar/13.18.6515; KLOBECK HG, 1985, NUCLEIC ACIDS RES, V13, P6499, DOI 10.1093/nar/13.18.6499; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; LEVINE B, 1991, SCIENCE, V254, P856, DOI 10.1126/science.1658936; LIN B, 1994, VIROLOGY, V202, P885, DOI 10.1006/viro.1994.1410; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; Matsuda F, 1998, J EXP MED, V188, P2151, DOI 10.1084/jem.188.11.2151; MEREDITH RF, 1991, J NUCL MED, V32, P1162; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Mukhopadhyay S, 2003, SCIENCE, V302, P248, DOI 10.1126/science.1089316; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; Rey FA, 2003, P NATL ACAD SCI USA, V100, P6899, DOI 10.1073/pnas.1332695100; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Roehrig JT, 1998, VIROLOGY, V246, P317, DOI 10.1006/viro.1998.9200; Roehrig JT, 2001, ANN NY ACAD SCI, V951, P286; Shusta EV, 2000, NAT BIOTECHNOL, V18, P754, DOI 10.1038/77325; SMITHBURN K. C, 1940, AMER JOUR TROP MED, V20, P471; TAO MH, 1989, J IMMUNOL, V143, P2595; VIRGIN HW, 1988, J VIROL, V62, P4594, DOI 10.1128/JVI.62.12.4594-4604.1988; Volk DE, 2004, J BIOL CHEM, V279, P38755, DOI 10.1074/jbc.M402385200; Wang T, 2004, CURR OPIN IMMUNOL, V16, P519, DOI 10.1016/j.coi.2004.05.008; Wu KP, 2003, J BIOL CHEM, V278, P46007, DOI 10.1074/jbc.M307776200; Wu SC, 1997, VIRUS RES, V51, P173, DOI 10.1016/S0168-1702(97)00098-1; Zhang W, 2003, NAT STRUCT BIOL, V10, P907, DOI 10.1038/nsb990	47	408	443	2	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					522	530		10.1038/nm1240	http://dx.doi.org/10.1038/nm1240			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15852016	Green Accepted, Green Published			2023-01-03	WOS:000228915000024
J	Hammer, SM; Saag, MS; Schechter, M; Montaner, JSG; Schooley, RT; Jacobsen, DM; Thompson, MA; Carpenter, CCJ; Fischl, MA; Gazzard, BG; Gatell, JM; Hirsch, MS; Katzenstein, DA; Richman, DD; Vella, S; Yeni, PG; Volberding, PA				Hammer, Scott M.; Saag, Michael S.; Schechter, Mauro; Montaner, Julio S. G.; Schooley, Robert T.; Jacobsen, Donna M.; Thompson, Melanie A.; Carpenter, Charles C. J.; Fischl, Margaret A.; Gazzard, Brian G.; Gatell, Jose M.; Hirsch, Martin S.; Katzenstein, David A.; Richman, Douglas D.; Vella, Stefano; Yeni, Patrick G.; Volberding, Paul A.			Treatment for adult HIV infection - 2006 recommendations of the International AIDS Society-USA panel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; TENOFOVIR DISOPROXIL FUMARATE; ACTIVE ANTIRETROVIRAL THERAPY; EARLY VIROLOGICAL FAILURE; HEPATITIS-C VIRUS; DRUG-RESISTANCE; HIV-1-INFECTED PATIENTS; COMBINATION THERAPY; DISEASE PROGRESSION; INITIAL TREATMENT	Context Guidelines for antiretroviral therapy are important for clinicians worldwide given the complexity of the field and the varied clinical situations in which these agents are used. The International AIDS Society - USA panel has updated its recommendations as warranted by new developments in the field. Objective To provide physicians and other human immunodeficiency virus (HIV) clinicians with current recommendations for the use of antiretroviral therapy in HIV-infected adults in circumstances for which there is relatively unrestricted access to drugs and monitoring tools. The recommendations are centered on 4 key issues: when to start antiretroviral therapy; what to start; when to change; and what to change. Antiretroviral therapy in special circumstances is also described. Data Sources and Study Selection A 16-member noncompensated panel was appointed, based on expertise in HIV research and patient care internationally. Data published or presented at selected scientific conferences from mid 2004 through May 2006 were identified and reviewed by all members of the panel. Data Extraction and Synthesis Data that might change previous guidelines were identified and reviewed. New guidelines were drafted by a writing committee and reviewed by the entire panel. Conclusions Antiretroviral therapy in adults continues to evolve rapidly, making delivery of state-of-the-art care challenging. Initiation of therapy continues to be recommended in all symptomatic persons and in asymptomatic persons after the CD4 cell count falls below 350/mu L and before it declines to 200/mu L. A nonnucleoside reverse transcriptase inhibitor or a protease inhibitor boosted with low-dose ritonavir each combined with 2 nucleoside ( or nucleotide) reverse transcriptase inhibitors is recommended with choice being based on the individual patient profile. Therapy should be changed when toxicity or intolerance mandate it or when treatment failure is documented. The virologic target for patients with treatment failure is now a plasma HIV-1 RNA level below 50 copies/mL. Adherence to antiretroviral therapy in the short-term and the long-term is crucial for treatment success and must be continually reinforced.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Fed Rio de Janeiro, Dept Prevent Med, BR-21941 Rio De Janeiro, Brazil; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; Int AIDS Soc USA, San Francisco, CA USA; AIDS Res Consortium, Atlanta, GA USA; Brown Univ, Sch Med, Dept Biomed, Providence, RI 02912 USA; Univ Miami, Sch Med, Dept Med, Coral Gables, FL 33124 USA; Chelsea & Westminster Hosp, Dept HIV Med, London, England; Univ Barcelona, Hosp Clin, IDIBAPS, Dept Med, Barcelona, Spain; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; San Diego Vet Affairs Healthcare Syst, San Diego, CA USA; Ist Super Sanita, Dept Drug Discovery & Evaluat, I-00161 Rome, Italy; Hop Bichat Claude Bernard, X Bichat Med Sch, Dept Infect Dis, F-75877 Paris 18, France; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; San Francisco VA Med Ctr, San Francisco, CA USA	Columbia University; University of Alabama System; University of Alabama Birmingham; Universidade Federal do Rio de Janeiro; University of British Columbia; University of California System; University of California San Diego; Brown University; University of Miami; Imperial College London; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Harvard University; Harvard Medical School; Stanford University; University of California System; University of California San Diego; Istituto Superiore di Sanita (ISS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Hammer, SM (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St,Box 82, New York, NY 10032 USA.	smh48@columbia.edu	Gatell, Jose M/ABC-3607-2020; Schechter, Mauro/AAG-7445-2020; VELLA, STEFANO/V-8440-2019; Vella, Stefano/GZM-0519-2022; Montaner, Julio/K-7621-2012; VALLET, Yannick/F-9979-2011; VELLA, STEFANO/ABI-3368-2020	VELLA, STEFANO/0000-0003-2347-5984; katzenstein, david/0000-0002-8593-4560				Aberg JA, 2004, CLIN INFECT DIS, V39, P609, DOI 10.1086/423390; ANANWORANICH J, 2004, 15 INT AIDS C JUL 11; ANANWORANICH J, 2006, 13 C RETR OPP INF FE; Anastos K, 2005, JAIDS-J ACQ IMM DEF, V39, P537; Arribas JR, 2005, JAIDS-J ACQ IMM DEF, V40, P280, DOI 10.1097/01.qai.0000180077.59159.f4; Bani- Sadr F, 2005, CLIN INFECT DIS, V41, P1806, DOI 10.1086/498312; Bani-Sadr F, 2004, CLIN INFECT DIS, V39, P1062, DOI 10.1086/424012; BAYLOR MS, 2004, J ACQ IMMUN DEF SYND, V35, pS21; Benhamou Y, 2006, HEPATOLOGY, V43, P548, DOI 10.1002/hep.21055; Bessesen M, 1999, CLIN INFECT DIS, V28, P1032, DOI 10.1086/514750; Bonacini M, 2002, GASTROENTEROLOGY, V122, P244, DOI 10.1053/gast.2002.30901; BONNET F, 2006, ANTIVIR CHEM CHEMOTH, V16, P63; Breen RAM, 2004, THORAX, V59, P704, DOI 10.1136/thx.2003.019224; Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; *BRIST MYERS SQUIB, EF CAPS PACK INS; Burger D, 2006, BRIT J CLIN PHARMACO, V61, P148, DOI 10.1111/j.1365-2125.2005.02536.x; Burger DM, 2002, J ACQ IMMUN DEF SYND, V29, P101; Cahn P, 2004, 7 INT C DRUG THER HI; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; *CDCP, 1981, MMWR-MORBID MORTAL W, V30, P305; *CDCP, UPD GUID US RIF TREA; CHENG A, 2003, 9 EUR AIDS C OCT 25; Clark R, 2005, DRUG SAFETY, V28, P1075, DOI 10.2165/00002018-200528120-00003; Clark Rebecca A, 2005, Expert Rev Anti Infect Ther, V3, P213, DOI 10.1586/14787210.3.2.213; CRANE H, 2006, 13 C RETR OPP INF FE; Currier JS, 2000, J ACQ IMMUN DEF SYND, V24, P316; DANEL C, 2006, 13 C RETR OPP INF FE; De Santis M, 2002, ARCH INTERN MED, V162, P355, DOI 10.1001/archinte.162.3.355; Deeks SG, 2005, J INFECT DIS, V192, P1537, DOI 10.1086/496892; DEJESUS E, 2006, 13 C RETR OPP INF FE; Delaugerre C, 2002, ANTIMICROB AGENTS CH, V46, P1586, DOI 10.1128/AAC.46.5.1586-1588.2002; DEMEYER S, 13 C RETR OPP INF FE; Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205; Dore GJ, 2004, J INFECT DIS, V189, P1185, DOI 10.1086/380398; Dragsted UB, 2005, ANTIVIR THER, V10, P735; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; ELSADR W, 2006, 13 C RETR OPP INF FE; EMINI EA, 1996, 3 C RETR OPP INF JAN; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Fenton K. A., 2006, Morbidity and Mortality Weekly Report, V55, P585; Fundaro C, 2002, AIDS, V16, P299, DOI 10.1097/00002030-200201250-00025; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Gallant JE, 2005, CLIN INFECT DIS, V40, P1194, DOI 10.1086/428840; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Gandhi M, 2004, ANNU REV PHARMACOL, V44, P499, DOI [10.1146/annurev.pharmtox.44.101802.121453, 10.2165/00003088-200948030-00001]; GATELL JM, 2005, 10 EUR AIDS C NOV 17; GATELL JM, 2005, 3 IAS C HIV PATH TRE; Grabar S, 2005, JAIDS-J ACQ IMM DEF, V39, P284, DOI 10.1097/01.qai.0000160925.33935.72; GRINSZTEJN B, 2006, 13 C RETR OPP INF FE; GUEST J, 2006, 13 C RETR OPP INF FE; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; GULICK RM, 2003, 2 INT AIDS SOC C HIV; Gulick RM, 2006, JAMA-J AM MED ASSOC, V296, P769, DOI 10.1001/jama.296.7.769; Gupta SK, 2005, CLIN INFECT DIS, V40, P1559, DOI 10.1086/430257; Haas DW, 2004, AIDS, V18, P2391; Hammer SM, 2005, NEW ENGL J MED, V353, P1702, DOI 10.1056/NEJMcp051203; Haubrich RH, 2001, CLIN INFECT DIS, V33, P1060, DOI 10.1086/322636; Havlir DV, 2000, JAMA-J AM MED ASSOC, V283, P229, DOI 10.1001/jama.283.2.229; HEFFELFINGER J, 2006, 13 C RETR OPP INF FE; Hicks C, 2004, 44 INT C ANT AG CHEM; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; *INT AIDS SOC US R, UPD DRUG RES MUT HIV; JACOBSON J, 2005, 3 IAS C HIV PATH TRE; Johnson M, 2005, AIDS, V19, P685, DOI 10.1097/01.aids.0000166091.39317.99; Kaleebu P, 2006, AIDS, V20, P1391, DOI 10.1097/01.aids.0000233572.59522.45; KATLAMA C, 2006, 13 C RETR OPP INF FE; KATLAMA C, 2005, 3 IAS C HIV PATH TRE; KITCHEN C, 2006, 13 C RETR OPP INF FE; Kumar PN, 2006, HIV MED, V7, P85, DOI 10.1111/j.1468-1293.2006.00346.x; Leon A, 2005, AIDS, V19, P213, DOI 10.1097/00002030-200501280-00017; Lichtenstein K, 2006, 13 C RETR OPP INF FE; Linfante A, 2004, CIRCULATION, V110, P664; Lo JC, 2005, CLIN INFECT DIS, V41, P1335, DOI 10.1086/496981; Macias J, 2005, J INFECTION, V51, P195, DOI 10.1016/j.jinf.2004.11.010; MALAN N, 2006, 13 C RETR OPP INF FE; MARCHOU B, 2006, 13 C RETR OPP INF FE; Martin AM, 2004, P NATL ACAD SCI USA, V101, P4180, DOI 10.1073/pnas.0307067101; Martinez E, 2004, LANCET, V364, P65, DOI 10.1016/S0140-6736(04)16591-4; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; MEYER S, 2006, 13 C RETR OPP INF FE; Moore DM, 2006, AIDS, V20, P371, DOI 10.1097/01.aids.0000196180.11293.9a; Moyle G, 2006, ANTIVIR THER, V11, P73; Negredo E, 2005, CLIN INFECT DIS, V41, P901, DOI 10.1086/432879; Nelson M, 2005, JAIDS-J ACQ IMM DEF, V40, P404, DOI 10.1097/01.qai.0000185314.56556.c3; NELSON M, 2006, 13 C RETR OPP INF FE; Nettles RE, 2005, JAMA-J AM MED ASSOC, V293, P817, DOI 10.1001/jama.293.7.817; Nicastri E, 2005, J MED VIROL, V76, P153, DOI 10.1002/jmv.20352; *NIH, 7 JOINT NAT COMM PRE; Novoa SR, 2006, CLIN INFECT DIS, V42, P291, DOI 10.1086/499056; Pai MP, 2004, PHARMACOTHERAPY, V24, P592, DOI 10.1592/phco.24.6.592.34744; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PALMISANO L, 2006, 13 C RETR OPP INF FE; PARKIN NT, 2006, 13 C RETR OPP INF FE; Persico M, 2001, HEPATOLOGY, V33, P627, DOI 10.1053/jhep.2001.22499; PHANUPHAK N, 2006, 13 C RETR OPP INF FE; Podzomczer D, 2005, ANTIVIR THER, V10, P171; POZNIAK A, 2006, 12 ANN C BRIT HIV AS; Raboud JM, 1999, J INFECT DIS, V180, P1347, DOI 10.1086/314998; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; Rauch A, 2006, CLIN INFECT DIS, V43, P99, DOI 10.1086/504874; Ribaudo HJ, 2006, CLIN INFECT DIS, V42, P401, DOI 10.1086/499364; Rizzardi GP, 2000, J CLIN INVEST, V105, P777, DOI 10.1172/JCI9079; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Rockstroh JK, 2005, J INFECT DIS, V192, P992, DOI 10.1086/432762; Rotger M, 2005, J INFECT DIS, V192, P1381, DOI 10.1086/466531; Saag MS, 2004, JAMA-J AM MED ASSOC, V292, P180, DOI 10.1001/jama.292.2.180; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; Sanne I, 2005, J INFECT DIS, V191, P825, DOI 10.1086/428093; Santos J, 2005, INT J STD AIDS, V16, P677, DOI 10.1258/095646205774357398; Schluger NW, 2002, CHEST, V122, P597, DOI 10.1378/chest.122.2.597; SENSION M, 2005, 12 C RETR OPP INF FE; Sheran M, 2005, HIV CLIN TRIALS, V6, P158, DOI 10.1310/4KC0-56TM-VLBF-78BN; SKIEST D, 2006, 13 C RETR OPP INF FE; SMITH P, 2006, 13 C RETR OPP INF FE; Sterling TR, 1999, J INFECT DIS, V180, P666, DOI 10.1086/314967; Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119; Swindells S, 2006, JAMA-J AM MED ASSOC, V296, P806, DOI 10.1001/jama.296.7.806; Tavassoli N, 2006, PHARMACOTHERAPY, V26, P154, DOI 10.1592/phco.26.2.154; THOMPSON M, 2006, 13 C RETR OPP INF FE; *UNAIDS WHO, AIDS EP UPD DEC 2005; *US DEP HHS, US REC US ANT DRUGS; van Leth F, 2004, PLOS MED, V1, P64, DOI 10.1371/journal.pmed.0010019; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wensing AMJ, 2005, J INFECT DIS, V192, P958, DOI 10.1086/432916; WILKIN T, 2005, 45 INT C ANT AG CHEM; Wolters LMM, 2002, J CLIN VIROL, V24, P173, DOI 10.1016/S1386-6532(01)00245-1; World Health Organization, 2006, ANT THER HIV INF AD; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	133	655	691	0	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					827	843		10.1001/jama.296.7.827	http://dx.doi.org/10.1001/jama.296.7.827			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	073SR	17016878				2023-01-03	WOS:000239763400023
